PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22448169-4	2012	Troglitazone-induced increases in Erk phosphorylation were suppressed by the MEK inhibitor U0126 but not by the PPARgamma antagonist GW9662.	U 0126	91-96	mitogen-activated protein kinase 1	Homo sapiens	34-37
22448169-4	2012	Troglitazone-induced increases in Erk phosphorylation were suppressed by the MEK inhibitor U0126 but not by the PPARgamma antagonist GW9662.	U 0126	91-96	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
19457446-6	2009	Further, the treatment of inhibitors specific for PI3K (Wortmannin) or ERK (U0126) to A549 cells could cause reduced activities of MMP-2, MMP-9, and u-PA.	U 0126	76-81	mitogen-activated protein kinase 1	Homo sapiens	71-74
19457446-6	2009	Further, the treatment of inhibitors specific for PI3K (Wortmannin) or ERK (U0126) to A549 cells could cause reduced activities of MMP-2, MMP-9, and u-PA.	U 0126	76-81	matrix metallopeptidase 2	Homo sapiens	131-136
19457446-6	2009	Further, the treatment of inhibitors specific for PI3K (Wortmannin) or ERK (U0126) to A549 cells could cause reduced activities of MMP-2, MMP-9, and u-PA.	U 0126	76-81	matrix metallopeptidase 9	Homo sapiens	138-143
19457446-6	2009	Further, the treatment of inhibitors specific for PI3K (Wortmannin) or ERK (U0126) to A549 cells could cause reduced activities of MMP-2, MMP-9, and u-PA.	U 0126	76-81	plasminogen activator, urokinase	Homo sapiens	149-153
19477214-12	2009	In addition, hispolon-induced caspase-7 cleavage was inhibited by the ERK1/2 inhibitor, U0126.	U 0126	88-93	caspase 7	Homo sapiens	30-39
19477214-12	2009	In addition, hispolon-induced caspase-7 cleavage was inhibited by the ERK1/2 inhibitor, U0126.	U 0126	88-93	mitogen-activated protein kinase 3	Homo sapiens	70-76
19561517-9	2009	U0126, an inhibitor of mitogen-activated protein kinase signaling, and LY294002, a phosphatidylinositol-3 kinase inhibitor, reduced MMP-1 levels.	U 0126	0-5	matrix metallopeptidase 1	Homo sapiens	132-137
19561517-10	2009	U0126 also reduced TIMP-1 levels, but LY294002 increased TIMP-1.	U 0126	0-5	TIMP metallopeptidase inhibitor 1	Homo sapiens	19-25
12446683-5	2003	This PMA induction was blocked with the MEK inhibitor UO126, suggesting that the PMA-induced activation of the hTFPI-2 promoter is mediated through MEK.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
12446683-5	2003	This PMA induction was blocked with the MEK inhibitor UO126, suggesting that the PMA-induced activation of the hTFPI-2 promoter is mediated through MEK.	U 0126	54-59	tissue factor pathway inhibitor 2	Homo sapiens	111-118
12446683-5	2003	This PMA induction was blocked with the MEK inhibitor UO126, suggesting that the PMA-induced activation of the hTFPI-2 promoter is mediated through MEK.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	148-151
14980082-6	2004	Surprisingly, we found that inhibition of this surge of p44/p42 MAP kinase activation with MEK inhibitors (U0126 and PD98059) triggers earlier IFN-gamma mRNA and protein expression, correlated with earlier TER rising and restoration of epithelial phenotype.	U 0126	107-112	interferon gamma	Sus scrofa	143-152
34549851-7	2022	Notably, the beneficial effects of let-7b overexpression, including cell invasion and EMT, were largely reversed by treatment with U0126, an indirect ERK1/2 signaling inhibitor, in these cells.	U 0126	131-136	microRNA let-7b	Homo sapiens	35-41
34678088-8	2022	PI3K pathway inhibitor LY294002 or MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to carry out western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRbeta mainly activated the PI3K/AKT/mTOR/ c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
34678088-8	2022	PI3K pathway inhibitor LY294002 or MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to carry out western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRbeta mainly activated the PI3K/AKT/mTOR/ c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells.	U 0126	57-62	platelet derived growth factor receptor beta	Homo sapiens	202-211
34678088-8	2022	PI3K pathway inhibitor LY294002 or MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to carry out western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRbeta mainly activated the PI3K/AKT/mTOR/ c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells.	U 0126	57-62	AKT serine/threonine kinase 1	Homo sapiens	238-241
34678088-8	2022	PI3K pathway inhibitor LY294002 or MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to carry out western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRbeta mainly activated the PI3K/AKT/mTOR/ c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells.	U 0126	57-62	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	248-253
34480249-6	2022	Additionally, inhibition of ERK1/2 signaling pathway (by U0126 or GDC-0994) and NF-kappaB (by BAY) significantly reduced the LPS-induced SVIL expression.	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	28-34
34480249-6	2022	Additionally, inhibition of ERK1/2 signaling pathway (by U0126 or GDC-0994) and NF-kappaB (by BAY) significantly reduced the LPS-induced SVIL expression.	U 0126	57-62	supervillin	Homo sapiens	137-141
34954560-12	2022	Additionally, U0126, the inhibitor of MEK, abrogated the effects of PLAC8 on inflammation and cell mobility of LPS-PG-treated hPDLCs.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
34954560-12	2022	Additionally, U0126, the inhibitor of MEK, abrogated the effects of PLAC8 on inflammation and cell mobility of LPS-PG-treated hPDLCs.	U 0126	14-19	placenta associated 8	Homo sapiens	68-73
34826439-10	2022	Selective Erk1/2 inhibition by U0126 also reduced beta-hexosaminidase release and prevented mitochondrial fragmentation during FcepsilonRI-dependent degranulation of MC.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	10-16
34904400-7	2022	Additionally, using the inhibitor U0126, we verified that the ERK1/2 pathway is upstream of HIF-1alpha.	U 0126	34-39	mitogen-activated protein kinase 3	Mus musculus	62-68
34904400-7	2022	Additionally, using the inhibitor U0126, we verified that the ERK1/2 pathway is upstream of HIF-1alpha.	U 0126	34-39	hypoxia inducible factor 1, alpha subunit	Mus musculus	92-102
34157911-7	2022	Localized administration of the ERK phosphorylation inhibitor U0126 or the BMAL1 inhibitor GSK4112 suppressed ERK/AP1/BMAL1 signaling.	U 0126	62-67	Eph receptor B1	Rattus norvegicus	32-35
34157911-7	2022	Localized administration of the ERK phosphorylation inhibitor U0126 or the BMAL1 inhibitor GSK4112 suppressed ERK/AP1/BMAL1 signaling.	U 0126	62-67	Eph receptor B1	Rattus norvegicus	110-113
34157911-7	2022	Localized administration of the ERK phosphorylation inhibitor U0126 or the BMAL1 inhibitor GSK4112 suppressed ERK/AP1/BMAL1 signaling.	U 0126	62-67	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	114-117
34157911-7	2022	Localized administration of the ERK phosphorylation inhibitor U0126 or the BMAL1 inhibitor GSK4112 suppressed ERK/AP1/BMAL1 signaling.	U 0126	62-67	aryl hydrocarbon receptor nuclear translocator-like	Rattus norvegicus	118-123
34549851-7	2022	Notably, the beneficial effects of let-7b overexpression, including cell invasion and EMT, were largely reversed by treatment with U0126, an indirect ERK1/2 signaling inhibitor, in these cells.	U 0126	131-136	mitogen-activated protein kinase 3	Homo sapiens	150-156
34926455-7	2021	This regulating effect was discounted by TAZ knockdown or the use of MEK-ERK pathway inhibitor, UO126.	U 0126	96-101	midkine	Mus musculus	69-72
34959222-7	2021	FFAs significantly promoted ROS production and increased the expression of ERK, p38 and JNK, and treatment of the inhibitors of NAPDH oxidase (DPI), p38 (SB202190), ERK1/2 (U0126) and JNK (SP600125) inhibited FAAs-induced NETs production.	U 0126	173-178	mitogen-activated protein kinase 3	Homo sapiens	165-171
34971676-11	2022	Both extracellular signal-related kinase 1 and 2 (ERK1/2) inhibitors (U0126) and P38 inhibitors (SB203580) significantly inhibited HG-increased VSMC ETB receptors.	U 0126	70-75	mitogen activated protein kinase 3	Rattus norvegicus	50-56
34971676-11	2022	Both extracellular signal-related kinase 1 and 2 (ERK1/2) inhibitors (U0126) and P38 inhibitors (SB203580) significantly inhibited HG-increased VSMC ETB receptors.	U 0126	70-75	endothelin receptor type B	Rattus norvegicus	149-152
34977362-7	2021	AT-induced Bdnf mRNA expression was completely blocked by d-(-)-2-Amino-5-phosphonopentanoic acid but partially blocked by nicardipine, U0126, and FK506.	U 0126	136-141	brain-derived neurotrophic factor	Rattus norvegicus	11-15
34926455-7	2021	This regulating effect was discounted by TAZ knockdown or the use of MEK-ERK pathway inhibitor, UO126.	U 0126	96-101	mitogen-activated protein kinase 1	Mus musculus	73-76
34872456-10	2021	Finally, it showed that inhibiting signaling ERK1/2 pathway could aggravate the depressive behavior when treatment with ERK-specific inhibitor U0126, while the condition could be partially relieved when treated with paeoniflorin.	U 0126	143-148	mitogen-activated protein kinase 3	Mus musculus	45-51
34863716-11	2022	Irisin stimulated the phosphorylation of extracellular regulated protein kinases (ERK) 1/2 and nuclear factor erythroid-derived 2-like 2 (Nrf2) nuclear translocation, while U0126 (the inhibitor of ERK1/2) inhibited irisin-induced Nrf2 nuclear translocation and HO-1 expression.	U 0126	173-178	mitogen-activated protein kinase 3	Mus musculus	197-203
34863716-11	2022	Irisin stimulated the phosphorylation of extracellular regulated protein kinases (ERK) 1/2 and nuclear factor erythroid-derived 2-like 2 (Nrf2) nuclear translocation, while U0126 (the inhibitor of ERK1/2) inhibited irisin-induced Nrf2 nuclear translocation and HO-1 expression.	U 0126	173-178	nuclear factor, erythroid derived 2, like 2	Mus musculus	230-234
34863716-11	2022	Irisin stimulated the phosphorylation of extracellular regulated protein kinases (ERK) 1/2 and nuclear factor erythroid-derived 2-like 2 (Nrf2) nuclear translocation, while U0126 (the inhibitor of ERK1/2) inhibited irisin-induced Nrf2 nuclear translocation and HO-1 expression.	U 0126	173-178	heme oxygenase 1	Mus musculus	261-265
34872456-10	2021	Finally, it showed that inhibiting signaling ERK1/2 pathway could aggravate the depressive behavior when treatment with ERK-specific inhibitor U0126, while the condition could be partially relieved when treated with paeoniflorin.	U 0126	143-148	mitogen-activated protein kinase 1	Mus musculus	120-123
34571396-7	2021	Both AG1478 (EGFR inhibitor) and U0126 (ERK1/2 inhibitor) abolished the inhibitory effect of E2 on the protein expression of NPR2.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	40-46
34624416-8	2021	Honokiol restored GDNF levels following MEHP exposure by activating the ERK/c-fos signaling pathway, while the inhibitor U0126 further reduced the GDNF levels.	U 0126	121-126	glial cell derived neurotrophic factor	Rattus norvegicus	18-22
34624416-8	2021	Honokiol restored GDNF levels following MEHP exposure by activating the ERK/c-fos signaling pathway, while the inhibitor U0126 further reduced the GDNF levels.	U 0126	121-126	glial cell derived neurotrophic factor	Rattus norvegicus	147-151
34562585-10	2021	But the effect of LV-siDUSP1 can be reversed by the treatment with ERK1/2 pathway inhibitor U0126.	U 0126	92-97	mitogen activated protein kinase 3	Rattus norvegicus	67-73
34010584-11	2021	U0126, the inhibitor of ERK1/2 pathway, reversed the protective effects of myrtenol on brain tissue damage and angiogenesis in MCAO rats.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	24-30
34741867-7	2021	To dissect the signaling pathway leading to SGK1 upregulation, we pretreated THP-1-derived macrophages with specific inhibitors of Notch (DAPT), AKT (LY294002) or ERK (U0126).	U 0126	168-173	serum/glucocorticoid regulated kinase 1	Homo sapiens	44-48
34741867-7	2021	To dissect the signaling pathway leading to SGK1 upregulation, we pretreated THP-1-derived macrophages with specific inhibitors of Notch (DAPT), AKT (LY294002) or ERK (U0126).	U 0126	168-173	mitogen-activated protein kinase 1	Homo sapiens	163-166
34547509-7	2021	ERK and JAK-STAT signaling were blocked using the inhibitors U0126 and Tofacitinib, respectively.	U 0126	61-66	mitogen-activated protein kinase 1	Mus musculus	0-3
34547509-7	2021	ERK and JAK-STAT signaling were blocked using the inhibitors U0126 and Tofacitinib, respectively.	U 0126	61-66	signal transducer and activator of transcription 3	Mus musculus	12-16
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	44-47
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	U 0126	58-63	dicer 1, ribonuclease III	Homo sapiens	83-89
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	U 0126	58-63	dicer 1, ribonuclease III	Homo sapiens	174-180
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	U 0126	58-63	TARBP2 pseudogene 1	Homo sapiens	220-224
34571396-7	2021	Both AG1478 (EGFR inhibitor) and U0126 (ERK1/2 inhibitor) abolished the inhibitory effect of E2 on the protein expression of NPR2.	U 0126	33-38	natriuretic peptide receptor 2	Homo sapiens	125-129
34826251-5	2022	Besides, MEK1/2 inhibitor U0126, KV channel blocker XE-991, SKCa channel blocker apamin, and BKCa channel blocker tetraethylammonium (TEA) incubations significantly inhibited the irisin-induced relaxation responses.	U 0126	26-31	mitogen activated protein kinase kinase 1	Rattus norvegicus	9-15
34551066-8	2021	To explore this hypothesis, we treated sorted populations of human orthochromatic erythroblasts with MEK/ERK inhibitor U0126 and found that U0126 inhibited enucleation.	U 0126	119-124	mitogen-activated protein kinase kinase 7	Homo sapiens	101-104
34899191-9	2021	Meanwhile, the exogenous TNF-alpha increased the action potential frequency and reduced the BK Ca currents of TNC neurons significantly, which could be reversed by U0126 and SB203580, the inhibitors of MAPK.	U 0126	164-169	tumor necrosis factor	Rattus norvegicus	25-34
34899191-9	2021	Meanwhile, the exogenous TNF-alpha increased the action potential frequency and reduced the BK Ca currents of TNC neurons significantly, which could be reversed by U0126 and SB203580, the inhibitors of MAPK.	U 0126	164-169	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	92-97
34551066-8	2021	To explore this hypothesis, we treated sorted populations of human orthochromatic erythroblasts with MEK/ERK inhibitor U0126 and found that U0126 inhibited enucleation.	U 0126	119-124	mitogen-activated protein kinase 1	Homo sapiens	105-108
34551066-10	2021	Mechanistically, U0126 selectively inhibited formation/accumulation of cytoplasmic vesicles and endocytosis of the transferrin receptor without affecting chromatin condensation, nuclear polarization and enucleosome formation.	U 0126	17-22	transferrin receptor	Homo sapiens	115-135
34749347-11	2021	N-acetylcysteine and ERK1/2 inhibitor U0126 were found to significantly rescue the decreased cell viability, declined MMP and increased apoptosis induced by the combined treatment.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	21-27
34270681-9	2021	To provide insight into the molecular pathways implicated in the responses, experiments were carried out in the presence or absence of tamoxifen as estrogen receptors (ERs) blocker, and U0126 as ERK1/2 phosphorylation inhibitor.	U 0126	186-191	mitogen-activated protein kinase 3	Homo sapiens	195-201
34725674-3	2022	E17.5 ovaries were cultured for five days with a daily dose of media supplemented with either the PI3K inhibitor LY294002, the MEK inhibitor U0126, or a DMSO vehicle control.	U 0126	141-146	midkine	Mus musculus	127-130
34873481-5	2021	We find that APOBEC3B and polymerase iota are upregulated, and inhibition of MEK1/2 by U0126 leads to downregulation on the protein level.	U 0126	87-92	mitogen-activated protein kinase kinase 1	Homo sapiens	77-83
34210894-5	2021	AKNS-2-activated autophagy could be inhibited by the Erk inhibitor U0126 and by AMPK siRNA.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	53-56
34797522-6	2022	While intra-SC administration of U0126 (inhibitor of ERK 1/2 and long-term memory) impaired memory formation, lidocaine (local anaesthetic) hindered memory recall.	U 0126	33-38	mitogen activated protein kinase 3	Rattus norvegicus	53-60
34697270-10	2021	Treatment with U0126, an ERK inhibitor, delayed elongation of primary cilia and blocked the effect of NaHS-mediated primary cilia elongation and Sec10 and Arl13b upregulation.	U 0126	15-20	ADP ribosylation factor like GTPase 13B	Canis lupus familiaris	155-161
34686215-7	2021	Mechanically, phosphorylation of ERK1/2 was drastically enhanced in present with famotidine treatment, while inhibition of ERK1/2 activity by U0126 could reverse the promotion of famotidine in IL-18 secretion.	U 0126	142-147	mitogen-activated protein kinase 3	Homo sapiens	33-39
34539858-7	2021	Furthermore, the EGFR inhibitor, afatinib and the ERK inhibitor, U0126 blocked the increase of EGFR and ERK phosphorylation, and resulted in a notable enhancement of apoptosis and cell cycle arrest.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	50-53
34539858-7	2021	Furthermore, the EGFR inhibitor, afatinib and the ERK inhibitor, U0126 blocked the increase of EGFR and ERK phosphorylation, and resulted in a notable enhancement of apoptosis and cell cycle arrest.	U 0126	65-70	epidermal growth factor receptor	Homo sapiens	95-99
34539858-7	2021	Furthermore, the EGFR inhibitor, afatinib and the ERK inhibitor, U0126 blocked the increase of EGFR and ERK phosphorylation, and resulted in a notable enhancement of apoptosis and cell cycle arrest.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	104-107
34686215-7	2021	Mechanically, phosphorylation of ERK1/2 was drastically enhanced in present with famotidine treatment, while inhibition of ERK1/2 activity by U0126 could reverse the promotion of famotidine in IL-18 secretion.	U 0126	142-147	mitogen-activated protein kinase 3	Homo sapiens	123-129
34684771-12	2021	Attenuation of S1-induced transcription of IL-6 and IL-1beta by the MAPK kinase inhibitor U0126 was greater than that by the Akt inhibitor perifosine, and the effects were potentiated by simultaneous treatment with both inhibitors.	U 0126	90-95	interleukin 6	Homo sapiens	43-47
34676394-4	2022	We show here that both Mstn and GDF11 prevented skeletal myocyte differentiation but that the MEK inhibitor U0126 or trametinib restored differentiation in Mstn- or GDF11-treated myocytes.	U 0126	108-113	midkine	Mus musculus	94-97
34494081-5	2021	Moreover, we also found that MEK/ERK inhibitor U0126 could enhance the impact on cell proliferation, migration and invasion induced by silencing KIF2C in HCC.	U 0126	47-52	mitogen-activated protein kinase kinase 7	Homo sapiens	29-32
34494081-5	2021	Moreover, we also found that MEK/ERK inhibitor U0126 could enhance the impact on cell proliferation, migration and invasion induced by silencing KIF2C in HCC.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	33-36
34494081-5	2021	Moreover, we also found that MEK/ERK inhibitor U0126 could enhance the impact on cell proliferation, migration and invasion induced by silencing KIF2C in HCC.	U 0126	47-52	kinesin family member 2C	Homo sapiens	145-150
34331953-10	2021	We also found that Pref-1-stimulated fibrotic protein expressions were reduced by ATN-161, curcumin, U0126, and c-Jun siRNA in WI-38.	U 0126	101-106	delta like non-canonical Notch ligand 1	Homo sapiens	19-25
34684771-12	2021	Attenuation of S1-induced transcription of IL-6 and IL-1beta by the MAPK kinase inhibitor U0126 was greater than that by the Akt inhibitor perifosine, and the effects were potentiated by simultaneous treatment with both inhibitors.	U 0126	90-95	interleukin 1 alpha	Homo sapiens	52-60
34434266-11	2021	The results indicated that compared with the control group, IL-17F increased the protein expression of phosphorylated-ERK1/2, Runx2 and Osterix, whereas U0126 reversed IL-17F-mediated effects.	U 0126	153-158	Sp7 transcription factor	Rattus norvegicus	136-143
34607570-12	2021	Furthermore, inhibition of ERK1/2 using U0126 abolished the anti-arrhythmic action of empagliflozin and ERK1/2 phosphorylation.	U 0126	40-45	mitogen activated protein kinase 3	Rattus norvegicus	27-33
34607570-12	2021	Furthermore, inhibition of ERK1/2 using U0126 abolished the anti-arrhythmic action of empagliflozin and ERK1/2 phosphorylation.	U 0126	40-45	mitogen activated protein kinase 3	Rattus norvegicus	104-110
34790784-7	2021	Additionally, DDP treatment increased the protein phosphorylation expression of IKKbeta, JNK, ERK, and p38 in a dose-dependent manner, which was antagonized by the treatment of NF-kappaB-specific inhibitor BAY 11-7082 and pan-MAPK inhibitor U0126.	U 0126	241-246	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	80-87
34790784-7	2021	Additionally, DDP treatment increased the protein phosphorylation expression of IKKbeta, JNK, ERK, and p38 in a dose-dependent manner, which was antagonized by the treatment of NF-kappaB-specific inhibitor BAY 11-7082 and pan-MAPK inhibitor U0126.	U 0126	241-246	mitogen-activated protein kinase 8	Homo sapiens	89-92
34790784-7	2021	Additionally, DDP treatment increased the protein phosphorylation expression of IKKbeta, JNK, ERK, and p38 in a dose-dependent manner, which was antagonized by the treatment of NF-kappaB-specific inhibitor BAY 11-7082 and pan-MAPK inhibitor U0126.	U 0126	241-246	mitogen-activated protein kinase 1	Homo sapiens	94-97
34790784-7	2021	Additionally, DDP treatment increased the protein phosphorylation expression of IKKbeta, JNK, ERK, and p38 in a dose-dependent manner, which was antagonized by the treatment of NF-kappaB-specific inhibitor BAY 11-7082 and pan-MAPK inhibitor U0126.	U 0126	241-246	mitogen-activated protein kinase 14	Homo sapiens	103-106
34434266-11	2021	The results indicated that compared with the control group, IL-17F increased the protein expression of phosphorylated-ERK1/2, Runx2 and Osterix, whereas U0126 reversed IL-17F-mediated effects.	U 0126	153-158	mitogen activated protein kinase 3	Rattus norvegicus	118-124
34296452-6	2021	ERK signalling was activated in DRG neurons after treating with either CNTs-CaP/CS-AZ91D or CaP/CS-AZ91D extracts, and its inhibition with U0126 counteracted the beneficial effects of these extracts on DRG neuron.	U 0126	139-144	Eph receptor B1	Rattus norvegicus	0-3
34434266-11	2021	The results indicated that compared with the control group, IL-17F increased the protein expression of phosphorylated-ERK1/2, Runx2 and Osterix, whereas U0126 reversed IL-17F-mediated effects.	U 0126	153-158	interleukin 17F	Rattus norvegicus	168-174
34273373-6	2021	Gsk343 (methyltransferase EZH2 inhibitor) (1 mM) and U0126 (inhibitor of MEK1/2) (10 muM) were used to show the specific effect of PBDEs.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	73-79
34089554-10	2021	A mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, but not a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, decreased PTTH-stimulated RSK phosphorylation, indicating that ERK is an upstream signaling.	U 0126	70-75	extracellular regulated MAP kinase	Bombyx mori	42-45
34089554-10	2021	A mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, but not a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, decreased PTTH-stimulated RSK phosphorylation, indicating that ERK is an upstream signaling.	U 0126	70-75	MAP kinse-ERK kinase	Bombyx mori	54-57
34089554-10	2021	A mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, but not a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, decreased PTTH-stimulated RSK phosphorylation, indicating that ERK is an upstream signaling.	U 0126	70-75	prothoracicotropic hormone	Bombyx mori	155-159
34089554-10	2021	A mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, but not a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, decreased PTTH-stimulated RSK phosphorylation, indicating that ERK is an upstream signaling.	U 0126	70-75	extracellular regulated MAP kinase	Bombyx mori	208-211
34312179-6	2021	The mRNA levels of Cyp2b10 in primary hepatocytes from WT and D mice treated with PB alone or in combination with SKI-1 (a Src inhibitor), or U0126 (a MEK inhibitor), were evaluated.	U 0126	142-147	midkine	Mus musculus	151-154
34312179-7	2021	Treatment of hepatocytes from D mice with the combination of PB with U0126, but not SKI-1, significantly increased the mRNA levels of Cyp2b10 compared with those from the corresponding WT mice.	U 0126	69-74	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	134-141
34282280-8	2021	In addition, the activation of c-Raf and extracellular signal-regulated protein kinases (ERKs) signaling was blocked with PcTX-1 or ASIC1a-shRNA and the proliferation of RASFs was further inhibited by the ERK inhibitor (U0126), indicating that ERK/MAPK signaling contributes to the proliferation process of RASFs promoted by the activation of ASIC1a.	U 0126	220-225	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	31-36
34282280-8	2021	In addition, the activation of c-Raf and extracellular signal-regulated protein kinases (ERKs) signaling was blocked with PcTX-1 or ASIC1a-shRNA and the proliferation of RASFs was further inhibited by the ERK inhibitor (U0126), indicating that ERK/MAPK signaling contributes to the proliferation process of RASFs promoted by the activation of ASIC1a.	U 0126	220-225	mitogen-activated protein kinase 1	Homo sapiens	205-208
34282280-8	2021	In addition, the activation of c-Raf and extracellular signal-regulated protein kinases (ERKs) signaling was blocked with PcTX-1 or ASIC1a-shRNA and the proliferation of RASFs was further inhibited by the ERK inhibitor (U0126), indicating that ERK/MAPK signaling contributes to the proliferation process of RASFs promoted by the activation of ASIC1a.	U 0126	220-225	mitogen-activated protein kinase 1	Homo sapiens	244-247
34418751-7	2021	RESULTS: Three inhibitors of the EGFR pathway significantly increased PlGF secretion: gefitinib (p = 0.03), AG490 (p < 0.0001) and U0126 (p = 0.03) in primary cytotrophoblasts, while PD98059 reduced PlGF secretion (p = 0.002).	U 0126	131-136	epidermal growth factor receptor	Homo sapiens	33-37
34418751-7	2021	RESULTS: Three inhibitors of the EGFR pathway significantly increased PlGF secretion: gefitinib (p = 0.03), AG490 (p < 0.0001) and U0126 (p = 0.03) in primary cytotrophoblasts, while PD98059 reduced PlGF secretion (p = 0.002).	U 0126	131-136	placental growth factor	Homo sapiens	70-74
34418751-9	2021	Primary endothelial cell PlGF secretion was significantly reduced when treated with PD98059 and U0126 while ZM336372 had no effect.	U 0126	96-101	placental growth factor	Homo sapiens	25-29
34572149-7	2021	The synergistic catabolic effects of palmitate and IL-26 were attenuated by inhibitors of TLR4 (TAK242), ERK1/2 (U0126), or c-Jun (SP600125) in HACs and cartilage matrix.	U 0126	113-118	interleukin 26	Homo sapiens	51-56
34428599-8	2021	However, the levels of phosphorylated Cx43 decreased after pre-treatment with candesartan (AT1 receptor blocker), GF109203X (protein kinase C (PKC) blocker) and U0126 (mitogen-activated protein kinases/extracellular signal-regulated kinase1/2(MEK/ERK1/2)-specific blocker) in AngII-stimulated A7r5 cells.	U 0126	161-166	gap junction protein, alpha 1	Rattus norvegicus	38-42
34428599-8	2021	However, the levels of phosphorylated Cx43 decreased after pre-treatment with candesartan (AT1 receptor blocker), GF109203X (protein kinase C (PKC) blocker) and U0126 (mitogen-activated protein kinases/extracellular signal-regulated kinase1/2(MEK/ERK1/2)-specific blocker) in AngII-stimulated A7r5 cells.	U 0126	161-166	mitogen activated protein kinase 3	Rattus norvegicus	247-253
34428599-8	2021	However, the levels of phosphorylated Cx43 decreased after pre-treatment with candesartan (AT1 receptor blocker), GF109203X (protein kinase C (PKC) blocker) and U0126 (mitogen-activated protein kinases/extracellular signal-regulated kinase1/2(MEK/ERK1/2)-specific blocker) in AngII-stimulated A7r5 cells.	U 0126	161-166	angiotensinogen	Rattus norvegicus	276-281
34572149-7	2021	The synergistic catabolic effects of palmitate and IL-26 were attenuated by inhibitors of TLR4 (TAK242), ERK1/2 (U0126), or c-Jun (SP600125) in HACs and cartilage matrix.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	105-111
34572567-6	2021	Inhibition of JNK (SP600125) significantly suppressed the TNF-alpha-induced IP-10 in MCF-7 cells, while the inhibition of p38 MAPK (SB203580), MEK1/2 (U0126), and ERK1/2 (PD98059) had no significant effect.	U 0126	151-156	tumor necrosis factor	Homo sapiens	58-67
34594239-10	2021	The effect of T4 in endothelium-denuded arteries was abolished by inhibiting ERK1/2 activation with U0126 as well as by ILK inhibitor Cpd22 but persisted in the presence of Src- or Rho-kinase inhibitors (PP2 and Y27632, respectively).	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	77-83
34572567-6	2021	Inhibition of JNK (SP600125) significantly suppressed the TNF-alpha-induced IP-10 in MCF-7 cells, while the inhibition of p38 MAPK (SB203580), MEK1/2 (U0126), and ERK1/2 (PD98059) had no significant effect.	U 0126	151-156	C-X-C motif chemokine ligand 10	Homo sapiens	76-81
34278478-8	2021	An ERK inhibitor (U0126) and/or a histone acetylase inhibitor (anacardic acid; AA) attenuated the overexpression of phospho-ERK1/2 and H3K9ac hyperacetylation by inhibiting the expression of PCAF in PE-induced cardiomyocyte hypertrophy.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	3-6
34504181-5	2021	Inhibition of MAPK using UO126 in MDA231 cells reduced LDLR expression, and in MDA468 cells, UO126 impaired the LDLR increase in response to EGF.	U 0126	25-30	low density lipoprotein receptor	Homo sapiens	55-59
34504181-5	2021	Inhibition of MAPK using UO126 in MDA231 cells reduced LDLR expression, and in MDA468 cells, UO126 impaired the LDLR increase in response to EGF.	U 0126	93-98	low density lipoprotein receptor	Homo sapiens	112-116
34278478-8	2021	An ERK inhibitor (U0126) and/or a histone acetylase inhibitor (anacardic acid; AA) attenuated the overexpression of phospho-ERK1/2 and H3K9ac hyperacetylation by inhibiting the expression of PCAF in PE-induced cardiomyocyte hypertrophy.	U 0126	18-23	K(lysine) acetyltransferase 2B	Mus musculus	191-195
34278478-9	2021	Moreover, U0126 and/or AA could attenuate the overexpression of several biomarker genes related to cardiac hypertrophy (myocyte enhancer factor 2C, atrial natriuretic peptide, brain natriuretic peptide and beta-myosin heavy chain) and prevented cardiomyocyte hypertrophy.	U 0126	10-15	myocyte enhancer factor 2C	Mus musculus	120-146
34278478-9	2021	Moreover, U0126 and/or AA could attenuate the overexpression of several biomarker genes related to cardiac hypertrophy (myocyte enhancer factor 2C, atrial natriuretic peptide, brain natriuretic peptide and beta-myosin heavy chain) and prevented cardiomyocyte hypertrophy.	U 0126	10-15	natriuretic peptide type A	Mus musculus	148-174
34278478-9	2021	Moreover, U0126 and/or AA could attenuate the overexpression of several biomarker genes related to cardiac hypertrophy (myocyte enhancer factor 2C, atrial natriuretic peptide, brain natriuretic peptide and beta-myosin heavy chain) and prevented cardiomyocyte hypertrophy.	U 0126	10-15	natriuretic peptide type B	Mus musculus	176-201
34572303-8	2021	Aldosterone enhanced ERK1/2 phosphorylation and inhibition of ERK1/2-phosphorylation (10 micromol/L U0126) prevented aldosterone-induced alkalinization.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	62-68
34465552-10	2021	Baicalin also increases ERK phosphorylation, and the increased expression of UCP1 and PGC1a in adipocytes could be inhibited by an ERK inhibitor, U0126.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	24-27
34465552-10	2021	Baicalin also increases ERK phosphorylation, and the increased expression of UCP1 and PGC1a in adipocytes could be inhibited by an ERK inhibitor, U0126.	U 0126	146-151	uncoupling protein 1	Homo sapiens	77-81
34465552-10	2021	Baicalin also increases ERK phosphorylation, and the increased expression of UCP1 and PGC1a in adipocytes could be inhibited by an ERK inhibitor, U0126.	U 0126	146-151	PPARG coactivator 1 alpha	Homo sapiens	86-91
34465552-10	2021	Baicalin also increases ERK phosphorylation, and the increased expression of UCP1 and PGC1a in adipocytes could be inhibited by an ERK inhibitor, U0126.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	131-134
34396896-8	2021	Additionally, AURKB overexpression could potentiate the invasion and the expression of MRP1 and Ki67, while suppresses apoptosis in SK-N-AS-R and IMR-32-R, whereas ERK inhibitor U0126 could reverse the phenomenon caused by AURKB overexpression.Conclusion: AURKB overexpression was strongly associated with poor prognosis and carboplatin resistant acquisition.	U 0126	178-183	ATP binding cassette subfamily C member 1	Homo sapiens	87-91
34502346-8	2021	The ERK inhibitor (U0126) and Prdx1 siRNA affected TLR4/ERK1/2 expression.	U 0126	19-24	mitogen-activated protein kinase 1	Mus musculus	4-7
34502346-8	2021	The ERK inhibitor (U0126) and Prdx1 siRNA affected TLR4/ERK1/2 expression.	U 0126	19-24	toll-like receptor 4	Mus musculus	51-55
34502346-8	2021	The ERK inhibitor (U0126) and Prdx1 siRNA affected TLR4/ERK1/2 expression.	U 0126	19-24	mitogen-activated protein kinase 3	Mus musculus	56-62
34396896-8	2021	Additionally, AURKB overexpression could potentiate the invasion and the expression of MRP1 and Ki67, while suppresses apoptosis in SK-N-AS-R and IMR-32-R, whereas ERK inhibitor U0126 could reverse the phenomenon caused by AURKB overexpression.Conclusion: AURKB overexpression was strongly associated with poor prognosis and carboplatin resistant acquisition.	U 0126	178-183	mitogen-activated protein kinase 1	Homo sapiens	164-167
34396896-8	2021	Additionally, AURKB overexpression could potentiate the invasion and the expression of MRP1 and Ki67, while suppresses apoptosis in SK-N-AS-R and IMR-32-R, whereas ERK inhibitor U0126 could reverse the phenomenon caused by AURKB overexpression.Conclusion: AURKB overexpression was strongly associated with poor prognosis and carboplatin resistant acquisition.	U 0126	178-183	aurora kinase B	Homo sapiens	256-261
34396896-8	2021	Additionally, AURKB overexpression could potentiate the invasion and the expression of MRP1 and Ki67, while suppresses apoptosis in SK-N-AS-R and IMR-32-R, whereas ERK inhibitor U0126 could reverse the phenomenon caused by AURKB overexpression.Conclusion: AURKB overexpression was strongly associated with poor prognosis and carboplatin resistant acquisition.	U 0126	178-183	aurora kinase B	Homo sapiens	223-228
33433488-7	2021	Blocking ERK1/2 activation, using the ERK1/2 inhibitor U0126 (2 microg, intraventricular injection), reduced the level of NOX2-mediated oxidative stress induced by P2X7R activation after intracellular hemorrhage.	U 0126	55-60	mitogen-activated protein kinase 3	Mus musculus	9-15
34401470-8	2021	Results: IGF-1 dose-dependently stimulated NCM hypertrophy and NCF collagen synthesis.Treatment with IGFBP6 and the kinase inhibitors, Wortmannin, U0126, GSK576371, G2261818A and RWJ67657 significantly inhibited IGF-1 stimulated NCM hypertrophy and NCF collagen synthesis.	U 0126	147-152	insulin-like growth factor 1	Rattus norvegicus	9-14
34401470-8	2021	Results: IGF-1 dose-dependently stimulated NCM hypertrophy and NCF collagen synthesis.Treatment with IGFBP6 and the kinase inhibitors, Wortmannin, U0126, GSK576371, G2261818A and RWJ67657 significantly inhibited IGF-1 stimulated NCM hypertrophy and NCF collagen synthesis.	U 0126	147-152	neutrophil cytosolic factor 4	Homo sapiens	63-66
34401470-8	2021	Results: IGF-1 dose-dependently stimulated NCM hypertrophy and NCF collagen synthesis.Treatment with IGFBP6 and the kinase inhibitors, Wortmannin, U0126, GSK576371, G2261818A and RWJ67657 significantly inhibited IGF-1 stimulated NCM hypertrophy and NCF collagen synthesis.	U 0126	147-152	insulin like growth factor binding protein 6	Homo sapiens	101-107
34401470-8	2021	Results: IGF-1 dose-dependently stimulated NCM hypertrophy and NCF collagen synthesis.Treatment with IGFBP6 and the kinase inhibitors, Wortmannin, U0126, GSK576371, G2261818A and RWJ67657 significantly inhibited IGF-1 stimulated NCM hypertrophy and NCF collagen synthesis.	U 0126	147-152	insulin-like growth factor 1	Rattus norvegicus	212-217
34401470-8	2021	Results: IGF-1 dose-dependently stimulated NCM hypertrophy and NCF collagen synthesis.Treatment with IGFBP6 and the kinase inhibitors, Wortmannin, U0126, GSK576371, G2261818A and RWJ67657 significantly inhibited IGF-1 stimulated NCM hypertrophy and NCF collagen synthesis.	U 0126	147-152	neutrophil cytosolic factor 4	Homo sapiens	249-252
34169637-5	2021	In addition, blocking ERK1/2 expression with U0126 resulted in the down-regulated expression of CD147, which further led to the decreased expression of MMP-2 and MMP-9.	U 0126	45-50	mitogen-activated protein kinase 3	Mus musculus	22-28
34169637-5	2021	In addition, blocking ERK1/2 expression with U0126 resulted in the down-regulated expression of CD147, which further led to the decreased expression of MMP-2 and MMP-9.	U 0126	45-50	basigin	Mus musculus	96-101
34169637-5	2021	In addition, blocking ERK1/2 expression with U0126 resulted in the down-regulated expression of CD147, which further led to the decreased expression of MMP-2 and MMP-9.	U 0126	45-50	matrix metallopeptidase 2	Mus musculus	152-157
34169637-5	2021	In addition, blocking ERK1/2 expression with U0126 resulted in the down-regulated expression of CD147, which further led to the decreased expression of MMP-2 and MMP-9.	U 0126	45-50	matrix metallopeptidase 9	Mus musculus	162-167
33433488-7	2021	Blocking ERK1/2 activation, using the ERK1/2 inhibitor U0126 (2 microg, intraventricular injection), reduced the level of NOX2-mediated oxidative stress induced by P2X7R activation after intracellular hemorrhage.	U 0126	55-60	mitogen-activated protein kinase 3	Mus musculus	38-44
33433488-7	2021	Blocking ERK1/2 activation, using the ERK1/2 inhibitor U0126 (2 microg, intraventricular injection), reduced the level of NOX2-mediated oxidative stress induced by P2X7R activation after intracellular hemorrhage.	U 0126	55-60	cytochrome b-245, beta polypeptide	Mus musculus	122-126
34165177-9	2021	Notably, DC induced apoptosis by affecting the phosphorylation of JNK and ERK, and DC and inhibitors (SP600125 and U0126) in combination restored the overexpression of p-JNK and p-ERK.	U 0126	115-120	mitogen-activated protein kinase 8	Homo sapiens	170-173
33433488-7	2021	Blocking ERK1/2 activation, using the ERK1/2 inhibitor U0126 (2 microg, intraventricular injection), reduced the level of NOX2-mediated oxidative stress induced by P2X7R activation after intracellular hemorrhage.	U 0126	55-60	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	164-169
34165177-9	2021	Notably, DC induced apoptosis by affecting the phosphorylation of JNK and ERK, and DC and inhibitors (SP600125 and U0126) in combination restored the overexpression of p-JNK and p-ERK.	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	180-183
34693427-12	2021	Western blot assay confirmed that fluoride induced up-regulation of p-ERK, but not that of p-JNK and p-p38, and specifically blocking ERK pathway with U0126 could partially rescue the fluoride-induced cell apoptosis.	U 0126	151-156	mitogen-activated protein kinase 1	Homo sapiens	70-73
34693427-12	2021	Western blot assay confirmed that fluoride induced up-regulation of p-ERK, but not that of p-JNK and p-p38, and specifically blocking ERK pathway with U0126 could partially rescue the fluoride-induced cell apoptosis.	U 0126	151-156	mitogen-activated protein kinase 1	Homo sapiens	134-137
34421344-0	2021	The MEK inhibitor U0126 ameliorates diabetic cardiomyopathy by restricting XBP1"s phosphorylation dependent SUMOylation.	U 0126	18-23	midkine	Mus musculus	4-7
34330273-11	2021	Inhibition of the MEK/ERK pathway or of GSK3beta by the U0126 or azakenpaullone compounds respectively significantly restores the impaired differentiation observed in Hrs-depleted cells.	U 0126	56-61	midkine	Mus musculus	18-21
34330273-11	2021	Inhibition of the MEK/ERK pathway or of GSK3beta by the U0126 or azakenpaullone compounds respectively significantly restores the impaired differentiation observed in Hrs-depleted cells.	U 0126	56-61	mitogen-activated protein kinase 1	Mus musculus	22-25
34330273-11	2021	Inhibition of the MEK/ERK pathway or of GSK3beta by the U0126 or azakenpaullone compounds respectively significantly restores the impaired differentiation observed in Hrs-depleted cells.	U 0126	56-61	glycogen synthase kinase 3 alpha	Mus musculus	40-48
34326272-6	2021	Administration of U0126 could partially elevate the PWMT and reduce the protein expression of NOX4 and the above pathological changes in obese CCD rats.	U 0126	18-23	NADPH oxidase 4	Rattus norvegicus	94-98
34326272-7	2021	In vitro, ERK phosphorylation, NOX4 protein expression increased significantly in DRG neurons under the stimulation of palmitic acid (PA), accompanied with increased secretion of inflammatory factors, oxidative stress and apoptosis level, while U0126 partially attenuated the PA-induced upregulation of NOX4 and other pathological changes.	U 0126	245-250	Eph receptor B1	Rattus norvegicus	10-13
34326272-7	2021	In vitro, ERK phosphorylation, NOX4 protein expression increased significantly in DRG neurons under the stimulation of palmitic acid (PA), accompanied with increased secretion of inflammatory factors, oxidative stress and apoptosis level, while U0126 partially attenuated the PA-induced upregulation of NOX4 and other pathological changes.	U 0126	245-250	NADPH oxidase 4	Rattus norvegicus	31-35
34326272-7	2021	In vitro, ERK phosphorylation, NOX4 protein expression increased significantly in DRG neurons under the stimulation of palmitic acid (PA), accompanied with increased secretion of inflammatory factors, oxidative stress and apoptosis level, while U0126 partially attenuated the PA-induced upregulation of NOX4 and other pathological changes.	U 0126	245-250	NADPH oxidase 4	Rattus norvegicus	303-307
34326272-8	2021	In the rescue experiment, overexpression of NOX4 abolished the above protective effect of U0126 on DRG neurons in high-fat environment.	U 0126	90-95	NADPH oxidase 4	Rattus norvegicus	44-48
34316004-3	2021	The microinfusion of ERK1/2 inhibitor (FR180204, n = 8-13/group) or MEK inhibitor (U0126, n = 8-9/group) into the basolateral amygdala did not affect anxiety-related behavior but impaired the evocation (anticipation) of conditioned-defensive behavior (n = 9-11/group).	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	68-71
34326272-3	2021	U0126 was applied to inhibit ERK, and metformin or 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) was applied to cause AMP-activated protein kinase (AMPK) activation.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	29-32
34451823-7	2021	Mevalonic acid, cholesterol and the MEK1/2 inhibitor U0126 reversed this Pitavastatin-mediated ERK1/2 activation and apoptosis of T cells.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	36-42
34451823-7	2021	Mevalonic acid, cholesterol and the MEK1/2 inhibitor U0126 reversed this Pitavastatin-mediated ERK1/2 activation and apoptosis of T cells.	U 0126	53-58	mitogen-activated protein kinase 3	Homo sapiens	95-101
34195782-11	2021	Additionally, suppression of ERK1/2 with U0126 incubation could significantly reverse NELL2 deficiency triggered cell apoptosis.	U 0126	41-46	mitogen-activated protein kinase 3	Homo sapiens	29-35
34195782-11	2021	Additionally, suppression of ERK1/2 with U0126 incubation could significantly reverse NELL2 deficiency triggered cell apoptosis.	U 0126	41-46	neural EGFL like 2	Homo sapiens	86-91
34358110-5	2021	The inhibitor of Src-family tyrosine kinases PP2 eliminated the effects of PRL and GH on meiotic arrest in DOs, whereas the MEK inhibitor U0126 only abolished the PRL effect.	U 0126	138-143	prolactin	Bos taurus	163-166
34421344-0	2021	The MEK inhibitor U0126 ameliorates diabetic cardiomyopathy by restricting XBP1"s phosphorylation dependent SUMOylation.	U 0126	18-23	X-box binding protein 1	Mus musculus	75-79
34421344-3	2021	In the present study, we determined whether targeting MAPK/ERK pathway using MEK inhibitor U0126 could ameliorate DCM by regulating IRE1alpha-XBP1s pathway.	U 0126	91-96	mitogen-activated protein kinase 1	Mus musculus	59-62
34421344-3	2021	In the present study, we determined whether targeting MAPK/ERK pathway using MEK inhibitor U0126 could ameliorate DCM by regulating IRE1alpha-XBP1s pathway.	U 0126	91-96	midkine	Mus musculus	77-80
34421344-3	2021	In the present study, we determined whether targeting MAPK/ERK pathway using MEK inhibitor U0126 could ameliorate DCM by regulating IRE1alpha-XBP1s pathway.	U 0126	91-96	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	132-141
34421344-10	2021	Intriguingly, U0126 treatment significantly ameliorated progression of DCM, and this protective effect was achieved through enriching XBP1s" nuclear accumulation.	U 0126	14-19	X-box binding protein 1	Mus musculus	134-138
34421344-11	2021	Mechanistically, U0126 inhibited XBP1s" phosphorylation on S348 and SUMOylation on K276 promoting XBP1s" nuclear translocation.	U 0126	17-22	X-box binding protein 1	Mus musculus	33-37
34244422-5	2021	Furthermore, using an MEK inhibitor (U0126), we found that mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling, which is downstream of EphB/ephrin-B signaling, is activated in M3-deficient crypts.	U 0126	37-42	midkine	Mus musculus	22-25
34244422-5	2021	Furthermore, using an MEK inhibitor (U0126), we found that mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling, which is downstream of EphB/ephrin-B signaling, is activated in M3-deficient crypts.	U 0126	37-42	mitogen-activated protein kinase 1	Mus musculus	136-139
34211022-4	2021	We show that the small molecule inhibitors MG132 (a 26S proteasome inhibitor used to block NF-kappaB signaling) and U0126 (a MAPK Kinase inhibitor used to block CCAAT-enhancer-binding proteins C/EBP) successfully block IL-1beta and TNF-alpha mRNA expression.	U 0126	116-121	CCAAT enhancer binding protein alpha	Homo sapiens	193-198
34229599-21	2021	U0126 (an ERK inhibitor), curcumin (an AP-1 inhibitor) or c-Jun siRNA downregulated hypoxia-induced Pref-1 expression.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
34229599-21	2021	U0126 (an ERK inhibitor), curcumin (an AP-1 inhibitor) or c-Jun siRNA downregulated hypoxia-induced Pref-1 expression.	U 0126	0-5	delta like non-canonical Notch ligand 1	Homo sapiens	100-106
34114637-8	2021	Using the PMT1F-EGFP reporter, we found that MEK inhibitors (U0126) and Astragaloside IV could significantly increase intracellular copper ions.	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	45-48
34211022-4	2021	We show that the small molecule inhibitors MG132 (a 26S proteasome inhibitor used to block NF-kappaB signaling) and U0126 (a MAPK Kinase inhibitor used to block CCAAT-enhancer-binding proteins C/EBP) successfully block IL-1beta and TNF-alpha mRNA expression.	U 0126	116-121	interleukin 1 alpha	Homo sapiens	219-227
34211022-4	2021	We show that the small molecule inhibitors MG132 (a 26S proteasome inhibitor used to block NF-kappaB signaling) and U0126 (a MAPK Kinase inhibitor used to block CCAAT-enhancer-binding proteins C/EBP) successfully block IL-1beta and TNF-alpha mRNA expression.	U 0126	116-121	tumor necrosis factor	Homo sapiens	232-241
34199278-5	2021	Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	106-109
34182538-6	2021	MEK/ERK signaling blockage by U0126 decreased the autophagic behavior and resistance ability of cancer cells to TAM.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
34182538-6	2021	MEK/ERK signaling blockage by U0126 decreased the autophagic behavior and resistance ability of cancer cells to TAM.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	4-7
34202288-6	2021	Furthermore, the use of ERK inhibitor (U0126) and activator (tBHQ) confirmed that the pharmaceutic inhibition of MEK-ERK augmented the LCN2-mediated MET suppression and migration of U2OS and HOS cells.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	24-27
34202288-6	2021	Furthermore, the use of ERK inhibitor (U0126) and activator (tBHQ) confirmed that the pharmaceutic inhibition of MEK-ERK augmented the LCN2-mediated MET suppression and migration of U2OS and HOS cells.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	113-116
34202288-6	2021	Furthermore, the use of ERK inhibitor (U0126) and activator (tBHQ) confirmed that the pharmaceutic inhibition of MEK-ERK augmented the LCN2-mediated MET suppression and migration of U2OS and HOS cells.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	117-120
34202288-6	2021	Furthermore, the use of ERK inhibitor (U0126) and activator (tBHQ) confirmed that the pharmaceutic inhibition of MEK-ERK augmented the LCN2-mediated MET suppression and migration of U2OS and HOS cells.	U 0126	39-44	lipocalin 2	Homo sapiens	135-139
34202288-6	2021	Furthermore, the use of ERK inhibitor (U0126) and activator (tBHQ) confirmed that the pharmaceutic inhibition of MEK-ERK augmented the LCN2-mediated MET suppression and migration of U2OS and HOS cells.	U 0126	39-44	SAFB like transcription modulator	Homo sapiens	149-152
34203721-8	2021	IL1A expression was reduced by UO126.	U 0126	31-36	interleukin 1 alpha	Homo sapiens	0-4
34199278-5	2021	Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively.	U 0126	37-42	mitogen-activated protein kinase 8	Homo sapiens	111-114
34199278-5	2021	Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively.	U 0126	37-42	mitogen-activated protein kinase 14	Homo sapiens	119-122
34140895-4	2021	The expression of HSP32 in spinal cord tissue was measured at 6, 12, 18, and 24 h following NBO and MEK1/2 inhibitor U0126 pretreatment.	U 0126	117-122	mitogen activated protein kinase kinase 1	Rattus norvegicus	100-106
34099834-4	2021	Thromboembolic stroke was induced in C57 black/6J mice and the MEK1/2 inhibitor U0126 was administrated 3.5 h and rt-PA 4 h post stroke-onset.	U 0126	80-85	mitogen-activated protein kinase kinase 1	Mus musculus	63-69
34099834-5	2021	Treatment with rt-PA demonstrated enhanced MMP-9 protein levels and hemorrhagic transformation which was prevented when U0126 was given in conjunction with rt-PA. By blocking the MMP-9 with U0126 the safety of rt-PA administration was improved and demonstrates a promising adjuvant strategy to reduce the harmful effects of delayed rt-PA treatment in acute ischemic stroke.	U 0126	120-125	matrix metallopeptidase 9	Mus musculus	43-48
34099834-5	2021	Treatment with rt-PA demonstrated enhanced MMP-9 protein levels and hemorrhagic transformation which was prevented when U0126 was given in conjunction with rt-PA. By blocking the MMP-9 with U0126 the safety of rt-PA administration was improved and demonstrates a promising adjuvant strategy to reduce the harmful effects of delayed rt-PA treatment in acute ischemic stroke.	U 0126	190-195	matrix metallopeptidase 9	Mus musculus	43-48
34099834-5	2021	Treatment with rt-PA demonstrated enhanced MMP-9 protein levels and hemorrhagic transformation which was prevented when U0126 was given in conjunction with rt-PA. By blocking the MMP-9 with U0126 the safety of rt-PA administration was improved and demonstrates a promising adjuvant strategy to reduce the harmful effects of delayed rt-PA treatment in acute ischemic stroke.	U 0126	190-195	matrix metallopeptidase 9	Mus musculus	179-184
34140895-8	2021	These results suggest that pretreatment with NBO and U0126 combined can effectively alleviate DCS spinal cord injury in rats by upregulating HSP32.	U 0126	53-58	heme oxygenase 1	Rattus norvegicus	141-146
34113239-11	2021	After capsaicin injection, GF109203X inhibited the protein expression of NKCC1 and p-ERK, while U0126 inhibited the protein expression of NKCC1.	U 0126	96-101	solute carrier family 12 member 2	Rattus norvegicus	138-143
35312883-4	2022	Then, through transfection of lentivirus vector expressing B7-H3-shRNA, overexpression vector of B7-H3 (B7-H3-LV), U0126 (small molecule inhibitor of MEK), or PD98059 (small molecule inhibitor of ERK), the in vitro and in vivo effects of B7-H3 in breast cancer cell biological processes, and lung metastasis were analyzed in relation to the Raf/MEK/ERK axis.	U 0126	115-120	midkine	Mus musculus	150-153
34113239-7	2021	After intrathecal injection of protein kinase C (PKC) inhibitor (GF109203X) or MEK/extracellular signal-regulated kinase (ERK) inhibitor (U0126), the behavioral changes and the expression of NKCC1 and p-ERK protein in L4 - 6 DRG were observed.	U 0126	138-143	Eph receptor B1	Rattus norvegicus	122-125
34073773-7	2021	Using inhibitors of JNK (JNK-in-8) and p38 (SB203580), GO-Y078"s increases in cleaved caspases 8, 9, and 3 could be expectedly suppressed, but they could not be affected by co-treatment with the ERK inhibitor (U0126).	U 0126	210-215	caspase 8	Homo sapiens	86-106
34073773-7	2021	Using inhibitors of JNK (JNK-in-8) and p38 (SB203580), GO-Y078"s increases in cleaved caspases 8, 9, and 3 could be expectedly suppressed, but they could not be affected by co-treatment with the ERK inhibitor (U0126).	U 0126	210-215	mitogen-activated protein kinase 1	Homo sapiens	195-198
34093234-9	2021	Pretreatment with either U0126, a specific ERK1/2 phosphorylation inhibitor, or EGFR kinase inhibitor, AG1478, blocked the PG-1 induced proliferation.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	43-49
34093234-9	2021	Pretreatment with either U0126, a specific ERK1/2 phosphorylation inhibitor, or EGFR kinase inhibitor, AG1478, blocked the PG-1 induced proliferation.	U 0126	25-30	protegrin-1	Sus scrofa	123-127
35398541-9	2022	Furthermore, the expression of NR2B and phosphorylated ERK (pERK)/phosphorylated CREB (pCREB) were up-regulated with the development of pain aversion, whereas the use of NR2B blocker Ro25-6981, or ERK inhibitor U0126 could reduce the pain aversion.	U 0126	211-216	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	31-35
35398541-9	2022	Furthermore, the expression of NR2B and phosphorylated ERK (pERK)/phosphorylated CREB (pCREB) were up-regulated with the development of pain aversion, whereas the use of NR2B blocker Ro25-6981, or ERK inhibitor U0126 could reduce the pain aversion.	U 0126	211-216	Eph receptor B1	Rattus norvegicus	55-58
35398541-9	2022	Furthermore, the expression of NR2B and phosphorylated ERK (pERK)/phosphorylated CREB (pCREB) were up-regulated with the development of pain aversion, whereas the use of NR2B blocker Ro25-6981, or ERK inhibitor U0126 could reduce the pain aversion.	U 0126	211-216	cAMP responsive element binding protein 1	Rattus norvegicus	81-85
35398541-9	2022	Furthermore, the expression of NR2B and phosphorylated ERK (pERK)/phosphorylated CREB (pCREB) were up-regulated with the development of pain aversion, whereas the use of NR2B blocker Ro25-6981, or ERK inhibitor U0126 could reduce the pain aversion.	U 0126	211-216	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	170-174
34062746-8	2021	Treatment of these cells with a MEK inhibitor (U0126) restored CTSD expression, cell migration, and cell invasiveness.	U 0126	47-52	mitogen-activated protein kinase kinase 7	Homo sapiens	32-35
34062746-8	2021	Treatment of these cells with a MEK inhibitor (U0126) restored CTSD expression, cell migration, and cell invasiveness.	U 0126	47-52	cathepsin D	Homo sapiens	63-67
35504090-4	2022	Treatment with U0126, an inhibitor of MEK1/2 that phosphorylates and activates ERK1/2, during the differentiation, increased the mRNA levels of Myod and Myog with an increase in the protein level of myosin heavy chain (MYH)1/2.	U 0126	15-20	mitogen-activated protein kinase kinase 1	Mus musculus	38-44
35504090-4	2022	Treatment with U0126, an inhibitor of MEK1/2 that phosphorylates and activates ERK1/2, during the differentiation, increased the mRNA levels of Myod and Myog with an increase in the protein level of myosin heavy chain (MYH)1/2.	U 0126	15-20	mitogen-activated protein kinase 3	Mus musculus	79-85
35504090-4	2022	Treatment with U0126, an inhibitor of MEK1/2 that phosphorylates and activates ERK1/2, during the differentiation, increased the mRNA levels of Myod and Myog with an increase in the protein level of myosin heavy chain (MYH)1/2.	U 0126	15-20	myogenic differentiation 1	Mus musculus	144-148
35504090-4	2022	Treatment with U0126, an inhibitor of MEK1/2 that phosphorylates and activates ERK1/2, during the differentiation, increased the mRNA levels of Myod and Myog with an increase in the protein level of myosin heavy chain (MYH)1/2.	U 0126	15-20	myogenin	Mus musculus	153-157
35504090-4	2022	Treatment with U0126, an inhibitor of MEK1/2 that phosphorylates and activates ERK1/2, during the differentiation, increased the mRNA levels of Myod and Myog with an increase in the protein level of myosin heavy chain (MYH)1/2.	U 0126	15-20	myosin, heavy polypeptide 1, skeletal muscle, adult	Mus musculus	219-226
35504090-6	2022	However, combination treatment with vitamin C and U0126 greatly enhanced myogenesis; the number of thick and long myotubes was increased, and the expression of MYH1/2 was also increased.	U 0126	50-55	myosin, heavy polypeptide 1, skeletal muscle, adult	Mus musculus	160-166
35439615-7	2022	More importantly, ERK inhibitor (U0126) or NF-kappaB inhibitor (Bay11-7082) could partially reverse GSK101-induced NLRP3-inflammasome up-regulation.	U 0126	33-38	mitogen-activated protein kinase 1	Mus musculus	18-21
35439615-7	2022	More importantly, ERK inhibitor (U0126) or NF-kappaB inhibitor (Bay11-7082) could partially reverse GSK101-induced NLRP3-inflammasome up-regulation.	U 0126	33-38	NLR family, pyrin domain containing 3	Mus musculus	115-120
35439615-8	2022	Interestingly, U0126 can reversed GSK101-induced NF-kappaB phosphorylation, but Bay11-7082 cannot change GSK101-induced ERK phosphorylation.	U 0126	15-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	49-58
35429799-5	2022	Increased relative mRNA and protein expressions of ERK and CDKN3, and proportion of S phase, as well as decreased proportion of G0/G1 phase were observed with increasing BPA concentrations, which could be partially inhibited by ERK inhibitor U0126.	U 0126	242-247	mitogen-activated protein kinase 1	Homo sapiens	51-54
35429799-5	2022	Increased relative mRNA and protein expressions of ERK and CDKN3, and proportion of S phase, as well as decreased proportion of G0/G1 phase were observed with increasing BPA concentrations, which could be partially inhibited by ERK inhibitor U0126.	U 0126	242-247	cyclin dependent kinase inhibitor 3	Homo sapiens	59-64
35429799-5	2022	Increased relative mRNA and protein expressions of ERK and CDKN3, and proportion of S phase, as well as decreased proportion of G0/G1 phase were observed with increasing BPA concentrations, which could be partially inhibited by ERK inhibitor U0126.	U 0126	242-247	mitogen-activated protein kinase 1	Homo sapiens	228-231
35001858-9	2022	However, U0126, a kind of inhibitor of MEK, lowered the quantities of phospho-ERK and MMP-9, raised the expression of ZO-1, and suppressed apoptosis.	U 0126	9-14	matrix metallopeptidase 9	Rattus norvegicus	86-91
35001858-9	2022	However, U0126, a kind of inhibitor of MEK, lowered the quantities of phospho-ERK and MMP-9, raised the expression of ZO-1, and suppressed apoptosis.	U 0126	9-14	tight junction protein 1	Rattus norvegicus	118-122
35001858-10	2022	U0126 also ameliorated the neurobehavioral impairments and brain edema induced by R-periostin.	U 0126	0-5	periostin	Rattus norvegicus	84-93
35397284-10	2022	U0126 was used to block ERK phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	24-27
35397284-16	2022	The expression of alpha7nAChR was suppressed by U0126, which lessened the expression of p-ERK1/2 and Egr-1.	U 0126	48-53	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	18-29
35397284-16	2022	The expression of alpha7nAChR was suppressed by U0126, which lessened the expression of p-ERK1/2 and Egr-1.	U 0126	48-53	early growth response 1	Mus musculus	101-106
35574901-10	2022	The ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and PI3K-Akt, respectively, which in turn reduced the LIPUS-induced viability of H9C2s in 3D bio-printed cell-laden GelMA scaffolds.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	4-10
35587097-6	2022	Treatment with Sorafenib and UO126 inhibited proliferation of Ba/F3-SOX5-RAF1 cells in the absence of IL3 but not the PLX 4720, a specific inhibitor of BRAF.	U 0126	29-34	SRY (sex determining region Y)-box 5	Mus musculus	68-72
35587097-6	2022	Treatment with Sorafenib and UO126 inhibited proliferation of Ba/F3-SOX5-RAF1 cells in the absence of IL3 but not the PLX 4720, a specific inhibitor of BRAF.	U 0126	29-34	v-raf-leukemia viral oncogene 1	Mus musculus	73-77
35587097-6	2022	Treatment with Sorafenib and UO126 inhibited proliferation of Ba/F3-SOX5-RAF1 cells in the absence of IL3 but not the PLX 4720, a specific inhibitor of BRAF.	U 0126	29-34	interleukin 3	Mus musculus	102-105
35581378-7	2022	Pharmacological kinase inhibition with LY294002 (a PI3K inhibitor), U0126 (a MEK/ERK inhibitor), or PP2 (a Src family kinase inhibitor) resulted in impaired ZO-1 expression at both transcript and protein levels.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
35581378-7	2022	Pharmacological kinase inhibition with LY294002 (a PI3K inhibitor), U0126 (a MEK/ERK inhibitor), or PP2 (a Src family kinase inhibitor) resulted in impaired ZO-1 expression at both transcript and protein levels.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	81-84
35581378-7	2022	Pharmacological kinase inhibition with LY294002 (a PI3K inhibitor), U0126 (a MEK/ERK inhibitor), or PP2 (a Src family kinase inhibitor) resulted in impaired ZO-1 expression at both transcript and protein levels.	U 0126	68-73	tight junction protein 1	Homo sapiens	157-161
35574901-10	2022	The ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and PI3K-Akt, respectively, which in turn reduced the LIPUS-induced viability of H9C2s in 3D bio-printed cell-laden GelMA scaffolds.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	114-120
35574901-10	2022	The ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and PI3K-Akt, respectively, which in turn reduced the LIPUS-induced viability of H9C2s in 3D bio-printed cell-laden GelMA scaffolds.	U 0126	22-27	AKT serine/threonine kinase 1	Rattus norvegicus	130-133
35293250-5	2022	In vitro Lep treatment reversed ovine GH (oGH)-stimulated expression of igf1 and igf2 in hepatocytes isolated from fasted fish, similar to the inhibitory effects of the MEK1/2 inhibitor U0126 treatment.	U 0126	186-191	leptin	Oncorhynchus mykiss	9-12
35499276-14	2022	Interestingly, while the MEK inhibitor U0126 (10 muM) enhanced NiSO4 -induced apoptosis in HUVECs, it reduced cell inflammation.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
35293250-5	2022	In vitro Lep treatment reversed ovine GH (oGH)-stimulated expression of igf1 and igf2 in hepatocytes isolated from fasted fish, similar to the inhibitory effects of the MEK1/2 inhibitor U0126 treatment.	U 0126	186-191	insulin-like growth factor II	Oncorhynchus mykiss	81-85
35490780-7	2022	We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts.	U 0126	40-45	Y box protein 1	Mus musculus	162-166
35385768-10	2022	Treatment with the ERK 1/2 inhibitor U0126 partially prevented the induction of fibronectin in response to LPA, suggesting that this pathway is involved in LPA-induced fibrosis.	U 0126	37-42	mitogen-activated protein kinase 3	Mus musculus	19-26
35385768-10	2022	Treatment with the ERK 1/2 inhibitor U0126 partially prevented the induction of fibronectin in response to LPA, suggesting that this pathway is involved in LPA-induced fibrosis.	U 0126	37-42	fibronectin 1	Mus musculus	80-91
35490780-6	2022	Accordingly, pharmacological inhibition of the ERK pathway using the upstream kinase inhibitor U0126 ameliorated features of DCM compared to vehicle-treated diabetic mice.	U 0126	95-100	mitogen-activated protein kinase 1	Mus musculus	47-50
35355356-11	2022	This was largely counteracted by treatment with extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	48-89
35355356-11	2022	This was largely counteracted by treatment with extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126.	U 0126	109-114	mitogen-activated protein kinase 3	Homo sapiens	91-97
35485293-8	2022	In addition, ERK inhibitor U0126 attenuated the promotion effect of miR-497-5p inhibitor on activation of ERK/AKT and cell proliferation and migration.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	13-16
35485293-8	2022	In addition, ERK inhibitor U0126 attenuated the promotion effect of miR-497-5p inhibitor on activation of ERK/AKT and cell proliferation and migration.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	106-109
35485293-8	2022	In addition, ERK inhibitor U0126 attenuated the promotion effect of miR-497-5p inhibitor on activation of ERK/AKT and cell proliferation and migration.	U 0126	27-32	AKT serine/threonine kinase 1	Homo sapiens	110-113
35490780-7	2022	We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts.	U 0126	40-45	mitogen-activated protein kinase 1	Mus musculus	20-23
35490780-7	2022	We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts.	U 0126	40-45	OTU domain, ubiquitin aldehyde binding 1	Mus musculus	171-176
35490780-7	2022	We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts.	U 0126	40-45	ribosomal protein S6 kinase polypeptide 1	Mus musculus	100-103
35490780-7	2022	We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts.	U 0126	40-45	Y box protein 1	Mus musculus	199-203
35487301-2	2022	Sprague-Dawley male rat model of SNL-stimulated NP was established, which were pre-treated with different doses of RvD1, WRW4 (ALX/FPR2 inhibitor) or U0126 (ERK inhibitor) for three successive days following the operation.	U 0126	150-155	Eph receptor B1	Rattus norvegicus	157-160
35490780-7	2022	We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts.	U 0126	40-45	Y box protein 1	Mus musculus	108-112
35485167-8	2022	RGS16 was inhibited while CXCR4 and CXCL12 was increased by U0126 in neointimal areas, especially in the endothelium.	U 0126	60-65	regulator of G-protein signaling 16	Mus musculus	0-5
35546898-11	2022	Both the PKA inhibitor K5720 and MEK inhibitor U0126 in artificial cerebrospinal fluid (ACSF) prevented the inhibitory effects of DAMGO on PF-PC mEPSCs.	U 0126	47-52	midkine	Mus musculus	33-36
35497094-10	2022	Thrombin promoted phosphorylation of NF-kappaB p65, leading to nuclear translocation and binding to the COX-2 promoter element to enhance promoter activity, which was reduced by Go6976, SP600125, SB202190, or U0126.	U 0126	209-214	coagulation factor II, thrombin	Homo sapiens	0-8
35497094-10	2022	Thrombin promoted phosphorylation of NF-kappaB p65, leading to nuclear translocation and binding to the COX-2 promoter element to enhance promoter activity, which was reduced by Go6976, SP600125, SB202190, or U0126.	U 0126	209-214	RELA proto-oncogene, NF-kB subunit	Homo sapiens	37-50
35497094-10	2022	Thrombin promoted phosphorylation of NF-kappaB p65, leading to nuclear translocation and binding to the COX-2 promoter element to enhance promoter activity, which was reduced by Go6976, SP600125, SB202190, or U0126.	U 0126	209-214	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	104-109
35420711-8	2022	While Insulin/MAPK/Erk signaling pathway plays a negative regulatory role, inhibiting its activity with U0126 can markedly promote the discharge of plasmatocytes from HPOs.	U 0126	104-109	extracellular regulated MAP kinase	Bombyx mori	19-22
35437455-8	2022	Furthermore, we found that the inhibitor U0126 could partly aggravate apoptosis of the AQP-3-overexpressed NP cells.	U 0126	41-46	aquaporin 3 (Gill blood group)	Homo sapiens	87-92
35151202-6	2022	Moreover, apoptosis induced by CdtB was inhibited due to Erk/p38 MAPK signaling pathway suppression performed with SB203580 or U0126.	U 0126	127-132	mitogen-activated protein kinase 1	Mus musculus	57-60
35485167-3	2022	We previously reported that MEK1/2 inhibitor, U0126, has a protective effect on the development of atherosclerosis and vascular calcification.	U 0126	46-51	mitogen-activated protein kinase kinase 1	Mus musculus	28-34
35485167-8	2022	RGS16 was inhibited while CXCR4 and CXCL12 was increased by U0126 in neointimal areas, especially in the endothelium.	U 0126	60-65	chemokine (C-X-C motif) receptor 4	Mus musculus	26-31
35485167-8	2022	RGS16 was inhibited while CXCR4 and CXCL12 was increased by U0126 in neointimal areas, especially in the endothelium.	U 0126	60-65	chemokine (C-X-C motif) ligand 12	Mus musculus	36-42
35485167-10	2022	In addition, vascular cell adhesion molecule 1 (VCAM-1), another miR-126-3p target gene, was reduced by U0126 in the neointimal areas, resulting reduced monocytes/macrophages accumulation.	U 0126	104-109	vascular cell adhesion molecule 1	Mus musculus	13-46
35479117-3	2022	This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling.	U 0126	79-84	mitogen-activated protein kinase 1	Mus musculus	102-106
35479117-3	2022	This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling.	U 0126	79-84	mitogen-activated protein kinase 1	Mus musculus	107-110
35479117-4	2022	We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot.	U 0126	55-60	fibroblast growth factor 1	Mus musculus	75-79
35479117-4	2022	We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot.	U 0126	55-60	mitogen-activated protein kinase 1	Mus musculus	104-108
35479117-4	2022	We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot.	U 0126	55-60	mitogen-activated protein kinase 1	Mus musculus	109-112
35444406-10	2022	In vitro, suramin or P2Y2R silencing effectively inhibited the phosphorylation of EGFR and ERK1/2, similar to the down-regulated effects of their corresponding inhibitors (EGFR inhibitor AG1478 and ERK1/2 inhibitor U0126) accompanied by reduced levels of TNF-alpha and IL-1beta compared to alcohol-induced AML-12 cell.	U 0126	215-220	epidermal growth factor receptor	Mus musculus	82-86
35444406-10	2022	In vitro, suramin or P2Y2R silencing effectively inhibited the phosphorylation of EGFR and ERK1/2, similar to the down-regulated effects of their corresponding inhibitors (EGFR inhibitor AG1478 and ERK1/2 inhibitor U0126) accompanied by reduced levels of TNF-alpha and IL-1beta compared to alcohol-induced AML-12 cell.	U 0126	215-220	mitogen-activated protein kinase 3	Mus musculus	91-97
35485167-10	2022	In addition, vascular cell adhesion molecule 1 (VCAM-1), another miR-126-3p target gene, was reduced by U0126 in the neointimal areas, resulting reduced monocytes/macrophages accumulation.	U 0126	104-109	vascular cell adhesion molecule 1	Mus musculus	48-54
35257817-6	2022	In addition, NMDA induced Cav-1 and ERK1/2 sequential phosphorylation,but these effects were attenuated by silencing the Cav-1 gene with shRNA and ERK1/2 inhibitor U0126, respectively.	U 0126	164-169	caveolin 1, caveolae protein	Mus musculus	26-31
35091962-6	2022	Further study suggested that the protective role of GSK-126 in ischemic rats was antagonized by U0126, an inhibitor of ERK1/2.	U 0126	96-101	mitogen activated protein kinase 3	Rattus norvegicus	119-125
35395977-2	2022	METHODS: Myeloma cell line H929 was treated with DOX, MEK inhibitor U0126 or RAS agonist ML-098, either alone or in combination.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
35395977-5	2022	MEK antagonist U0126 significantly increased the levels of cleaved caspase-3 and caspase-9, and down-regulated the level of p-MEK (P<0.05).	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
35395977-5	2022	MEK antagonist U0126 significantly increased the levels of cleaved caspase-3 and caspase-9, and down-regulated the level of p-MEK (P<0.05).	U 0126	15-20	caspase 3	Homo sapiens	67-76
35395977-5	2022	MEK antagonist U0126 significantly increased the levels of cleaved caspase-3 and caspase-9, and down-regulated the level of p-MEK (P<0.05).	U 0126	15-20	caspase 9	Homo sapiens	81-90
35395977-5	2022	MEK antagonist U0126 significantly increased the levels of cleaved caspase-3 and caspase-9, and down-regulated the level of p-MEK (P<0.05).	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
35347804-9	2022	Moreover, TOX3 overexpression upregulated MAPK signaling, while MAPK signaling inhibitor U0126 induced CRC cell proliferation arrest or apoptosis, and attenuated the inhibition of RhoB in TOX3 overexpression cells.	U 0126	89-94	TOX high mobility group box family member 3	Homo sapiens	10-14
35347804-9	2022	Moreover, TOX3 overexpression upregulated MAPK signaling, while MAPK signaling inhibitor U0126 induced CRC cell proliferation arrest or apoptosis, and attenuated the inhibition of RhoB in TOX3 overexpression cells.	U 0126	89-94	ras homolog family member B	Homo sapiens	180-184
35347804-9	2022	Moreover, TOX3 overexpression upregulated MAPK signaling, while MAPK signaling inhibitor U0126 induced CRC cell proliferation arrest or apoptosis, and attenuated the inhibition of RhoB in TOX3 overexpression cells.	U 0126	89-94	TOX high mobility group box family member 3	Homo sapiens	188-192
35257817-6	2022	In addition, NMDA induced Cav-1 and ERK1/2 sequential phosphorylation,but these effects were attenuated by silencing the Cav-1 gene with shRNA and ERK1/2 inhibitor U0126, respectively.	U 0126	164-169	mitogen-activated protein kinase 3	Homo sapiens	36-42
35257817-6	2022	In addition, NMDA induced Cav-1 and ERK1/2 sequential phosphorylation,but these effects were attenuated by silencing the Cav-1 gene with shRNA and ERK1/2 inhibitor U0126, respectively.	U 0126	164-169	caveolin 1, caveolae protein	Mus musculus	121-126
35257817-6	2022	In addition, NMDA induced Cav-1 and ERK1/2 sequential phosphorylation,but these effects were attenuated by silencing the Cav-1 gene with shRNA and ERK1/2 inhibitor U0126, respectively.	U 0126	164-169	mitogen-activated protein kinase 3	Homo sapiens	147-153
35346134-16	2022	However, inhibition of ERK activity by U0126 resulted in partial reversal of this effect and did not influence an increase in AKT phosphorylation induced by ZIP12 overexpression.	U 0126	39-44	Eph receptor B1	Rattus norvegicus	23-26
35378949-10	2022	Inversely, P38 inhibitor (SB203580) and ERK inhibitor (U0126) could reverse the cardioprotective effects induced by si-MLCK.	U 0126	55-60	Eph receptor B1	Rattus norvegicus	40-43
35378949-10	2022	Inversely, P38 inhibitor (SB203580) and ERK inhibitor (U0126) could reverse the cardioprotective effects induced by si-MLCK.	U 0126	55-60	myosin light chain kinase	Rattus norvegicus	119-123
35355588-12	2022	Mechanistically, Apelin-13 pretreatment inhibited SD/H-induced MSC apoptosis by downregulating mitochondrial fission via activation of the ERK pathway, and these effects were partially abrogated by ERK inhibitor U0126.	U 0126	212-217	mitogen-activated protein kinase 1	Mus musculus	139-142
35431500-15	2022	Quercetin, TNF-alpha antagonist, PP1, U0126, and tanshinone IIA (TSIIA) reduced TNF-alpha-induced c-Fos phosphorylation and AP-1-Luciferase (Luc) activity in a dose- and time-dependent manner.	U 0126	38-43	tumor necrosis factor	Homo sapiens	80-89
35431500-15	2022	Quercetin, TNF-alpha antagonist, PP1, U0126, and tanshinone IIA (TSIIA) reduced TNF-alpha-induced c-Fos phosphorylation and AP-1-Luciferase (Luc) activity in a dose- and time-dependent manner.	U 0126	38-43	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-103
35431500-16	2022	Pretreatment with quercetin, TNF-alpha antagonist, PP1, U0126, or Bay 11-7082 reduced TNF-alpha-induced p65 phosphorylation and translocation and p65-Luc activity in a dose- and time-dependent manner.	U 0126	56-61	tumor necrosis factor	Homo sapiens	86-95
35431500-16	2022	Pretreatment with quercetin, TNF-alpha antagonist, PP1, U0126, or Bay 11-7082 reduced TNF-alpha-induced p65 phosphorylation and translocation and p65-Luc activity in a dose- and time-dependent manner.	U 0126	56-61	RELA proto-oncogene, NF-kB subunit	Homo sapiens	104-107
35355588-12	2022	Mechanistically, Apelin-13 pretreatment inhibited SD/H-induced MSC apoptosis by downregulating mitochondrial fission via activation of the ERK pathway, and these effects were partially abrogated by ERK inhibitor U0126.	U 0126	212-217	mitogen-activated protein kinase 1	Mus musculus	198-201
35360251-8	2022	Mechanistically, we found that GDL treatment was strongly associated with activation of pro-survival extracellular signal-regulated kinase (ERK) signaling both in vivo and in vitro, and pharmacological inhibition of ERK signaling via U0126 attenuated GDL-induced cardioprotection against H/R injury in NRCM cells.	U 0126	234-239	Eph receptor B1	Rattus norvegicus	216-219
35159398-5	2022	Also, we report here that decreased OXPHOS activity following ERK1/2 inhibition (U0126 treatment) during IgE-Ag activation was mediated by the dephosphorylation of Serine 73 mitochondrial MITF, which inhibited its association with PDH.	U 0126	81-86	mitogen activated protein kinase 3	Rattus norvegicus	62-68
35078034-3	2022	Nuclear oocyte maturation stimulated by leptin was significantly impaired when we added the specific inhibitors of MAPK (U0126) and JAK2/STAT3 (AG490) to the maturation medium.	U 0126	121-126	leptin	Homo sapiens	40-46
35220404-8	2022	Further, we proved that neuroblast proliferation and differentiation in the dentate gyrus and cognitive function were significantly reversed in young cerebral ischemic gerbils by administering the ERK inhibitor (U0126) and autophagy inhibitor (3MA).	U 0126	212-217	mitogen-activated protein kinase 1	Homo sapiens	197-200
35173145-11	2022	U0126, a specific MEK/ERK inhibitor, significantly inhibited either high glucose or rmHPSE-induced EndMT of GEnCs.	U 0126	0-5	midkine	Mus musculus	18-21
35173145-11	2022	U0126, a specific MEK/ERK inhibitor, significantly inhibited either high glucose or rmHPSE-induced EndMT of GEnCs.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	22-25
35159398-5	2022	Also, we report here that decreased OXPHOS activity following ERK1/2 inhibition (U0126 treatment) during IgE-Ag activation was mediated by the dephosphorylation of Serine 73 mitochondrial MITF, which inhibited its association with PDH.	U 0126	81-86	melanogenesis associated transcription factor	Mus musculus	188-192
35106811-3	2022	Inflammatory human nucleus pulposus (NP) cells (NPCs) were induced using tumor necrosis factor-alpha and the ERK pathway was blocked using a selective molecule-based inhibitor U0126.	U 0126	176-181	mitogen-activated protein kinase 1	Homo sapiens	109-112
35132190-9	2022	Using ERK1/2 inhibitor U0126 and PI3K/AKT inhibitor LY294002, we revealed that the amount of Nurr1 in the nucleus was upregulated through beta-arrestin2/ERK1/2 and PI3K/AKT/GSK-3beta signaling pathways.	U 0126	23-28	mitogen-activated protein kinase 3	Mus musculus	6-12
35132190-9	2022	Using ERK1/2 inhibitor U0126 and PI3K/AKT inhibitor LY294002, we revealed that the amount of Nurr1 in the nucleus was upregulated through beta-arrestin2/ERK1/2 and PI3K/AKT/GSK-3beta signaling pathways.	U 0126	23-28	nuclear receptor subfamily 4, group A, member 2	Mus musculus	93-98
35132190-9	2022	Using ERK1/2 inhibitor U0126 and PI3K/AKT inhibitor LY294002, we revealed that the amount of Nurr1 in the nucleus was upregulated through beta-arrestin2/ERK1/2 and PI3K/AKT/GSK-3beta signaling pathways.	U 0126	23-28	arrestin, beta 2	Mus musculus	138-152
35132190-9	2022	Using ERK1/2 inhibitor U0126 and PI3K/AKT inhibitor LY294002, we revealed that the amount of Nurr1 in the nucleus was upregulated through beta-arrestin2/ERK1/2 and PI3K/AKT/GSK-3beta signaling pathways.	U 0126	23-28	mitogen-activated protein kinase 3	Mus musculus	153-159
35132190-9	2022	Using ERK1/2 inhibitor U0126 and PI3K/AKT inhibitor LY294002, we revealed that the amount of Nurr1 in the nucleus was upregulated through beta-arrestin2/ERK1/2 and PI3K/AKT/GSK-3beta signaling pathways.	U 0126	23-28	thymoma viral proto-oncogene 1	Mus musculus	169-172
35132190-9	2022	Using ERK1/2 inhibitor U0126 and PI3K/AKT inhibitor LY294002, we revealed that the amount of Nurr1 in the nucleus was upregulated through beta-arrestin2/ERK1/2 and PI3K/AKT/GSK-3beta signaling pathways.	U 0126	23-28	glycogen synthase kinase 3 alpha	Mus musculus	173-182
35132190-12	2022	Pretreatment with the signaling pathway inhibitors, especially U0126, reversed the inhibitory effect of 2-AG on phagocytosis, suggesting that CB2 receptor may regulate the phagocytic function of microglia by activating Nurr1.	U 0126	63-68	nuclear receptor subfamily 4, group A, member 2	Mus musculus	219-224
35112334-9	2022	What"s more, ERK1/2 signaling pathway inhibitor U0126 also could inhibit the expression of VEGF.	U 0126	48-53	mitogen activated protein kinase 3	Rattus norvegicus	13-19
35112334-9	2022	What"s more, ERK1/2 signaling pathway inhibitor U0126 also could inhibit the expression of VEGF.	U 0126	48-53	vascular endothelial growth factor A	Rattus norvegicus	91-95
34974790-12	2022	MEK1/2 inhibitor U0126 blocked the increase of cell proliferation regulated by NCAPH overexpression.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
34974790-12	2022	MEK1/2 inhibitor U0126 blocked the increase of cell proliferation regulated by NCAPH overexpression.	U 0126	17-22	non-SMC condensin I complex subunit H	Homo sapiens	79-84
35106811-6	2022	The NPC metabolic activity and viability were assessed using resazurin sodium-salt and live/dead assays, and subsequently, the specificity of U0126 on ERK1/2 signaling was determined.	U 0126	142-147	mitogen-activated protein kinase 3	Homo sapiens	151-157
35106811-7	2022	The catabolic enzyme MMP3 (p = 0.0001) and proinflammatory cytokine interleukin 6 (p = 0.036) were downregulated by U0126 in NPCs under inflammatory conditions.	U 0126	116-121	matrix metallopeptidase 3	Homo sapiens	21-25
35106811-7	2022	The catabolic enzyme MMP3 (p = 0.0001) and proinflammatory cytokine interleukin 6 (p = 0.036) were downregulated by U0126 in NPCs under inflammatory conditions.	U 0126	116-121	interleukin 6	Homo sapiens	68-81
35106811-10	2022	We confirmed that U0126 selectively blocks the ERK phosphorylation and only affects the cell metabolic activity without the reduction of viable cells.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	47-50
34987108-4	2022	We have previously confirmed that the mitogen-activated protein (MAP) kinase kinase (MEK) inhibitor U0126 inhibits persistent ERK1/2 phosphorylation and ferroptosis.	U 0126	100-105	mitogen-activated protein kinase 3	Mus musculus	126-132
35145518-10	2022	Administration of U0126, a MEK/ERK inhibitor, confirmed this phenomenon, since bigger lesions and higher parasite loads were seen in infected mice that received U0126.	U 0126	18-23	midkine	Mus musculus	27-30
35145518-10	2022	Administration of U0126, a MEK/ERK inhibitor, confirmed this phenomenon, since bigger lesions and higher parasite loads were seen in infected mice that received U0126.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	31-34
35145518-10	2022	Administration of U0126, a MEK/ERK inhibitor, confirmed this phenomenon, since bigger lesions and higher parasite loads were seen in infected mice that received U0126.	U 0126	161-166	midkine	Mus musculus	27-30
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	U 0126	142-147	mitogen-activated protein kinase 3	Homo sapiens	69-75
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	U 0126	142-147	mitogen-activated protein kinase kinase 7	Homo sapiens	127-130
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	U 0126	142-147	transforming growth factor beta induced	Homo sapiens	209-214
35003795-6	2022	Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production.	U 0126	123-128	mitogen-activated protein kinase 1	Mus musculus	8-11
35003795-6	2022	Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production.	U 0126	123-128	sprouty-related EVH1 domain containing 2	Mus musculus	44-50
35003795-6	2022	Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production.	U 0126	123-128	sprouty-related EVH1 domain containing 2	Mus musculus	80-86
35003795-6	2022	Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production.	U 0126	123-128	mitogen-activated protein kinase 1	Mus musculus	109-112
35003795-6	2022	Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production.	U 0126	123-128	interferon gamma	Mus musculus	177-185
35145518-10	2022	Administration of U0126, a MEK/ERK inhibitor, confirmed this phenomenon, since bigger lesions and higher parasite loads were seen in infected mice that received U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Mus musculus	31-34
35022331-8	2022	Inhibition of TIMP-2 using an anti-TIMP-2 antibody or ERK/MAPK inhibition by U0126 suppressed TIMP-2 mediated 5-Fu-resistance in CRC patients.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	54-57
35022331-8	2022	Inhibition of TIMP-2 using an anti-TIMP-2 antibody or ERK/MAPK inhibition by U0126 suppressed TIMP-2 mediated 5-Fu-resistance in CRC patients.	U 0126	77-82	TIMP metallopeptidase inhibitor 2	Homo sapiens	94-100
35012661-0	2022	Nonwoven-based gelatin/polycaprolactone membrane loaded with ERK inhibitor U0126 for treatment of tendon defects.	U 0126	75-80	Eph receptor B1	Rattus norvegicus	61-64
35012661-10	2022	RESULTS: In this study, we have shown that ERK inhibitor U0126 rather PD98059 could effectively increase the expression of tendon-related genes and promote the tenogenesis of TSPCs in vitro.	U 0126	57-62	Eph receptor B1	Rattus norvegicus	43-46
35012661-12	2022	The result showed that GDF6 was significantly increased by U0126, which is an important factor of the TGFbeta superfamily regulating tendon development and tenogenesis.	U 0126	59-64	growth differentiation factor 6	Rattus norvegicus	23-27
35012661-15	2022	CONCLUSION: Taken together, we have found U0126 promoted tenogenesis in TSPCs through activating GDF6, and NBM loaded with U0126 significantly promoted tendon defect healing, which provides a new treatment for tendon injury.	U 0126	42-47	growth differentiation factor 6	Rattus norvegicus	97-101
35053304-8	2022	U0126 pre-treatment suppressed NE-induced ERK1/2 phosphorylation but failed to attenuate hypertrophy.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	42-48
35053304-9	2022	U0126 inhibition of ERK1/2 phosphorylation prevented NE-mediated upregulation of CaValpha2delta1, whereas CaVbeta3 protein levels remained elevated.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	20-26
33880577-10	2021	Notably, U0126, a specific MEK inhibitor, decreased MEK and ERK expression, and blocked the promotive effects of BANCR overexpression on the proliferation, migration and invasion of ESCC cells.	U 0126	9-14	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
33895548-9	2021	On the contrary, it was inhibited by the pre-treatment of U0126 or SB203580, an ERK or a p38 inhibitor, respectively, suggesting that E2-induced endothelial exocytosis is non-genomically mediated by the MAP kinase pathway.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	80-83
33895548-9	2021	On the contrary, it was inhibited by the pre-treatment of U0126 or SB203580, an ERK or a p38 inhibitor, respectively, suggesting that E2-induced endothelial exocytosis is non-genomically mediated by the MAP kinase pathway.	U 0126	58-63	mitogen-activated protein kinase 14	Homo sapiens	89-92
33880577-10	2021	Notably, U0126, a specific MEK inhibitor, decreased MEK and ERK expression, and blocked the promotive effects of BANCR overexpression on the proliferation, migration and invasion of ESCC cells.	U 0126	9-14	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
33880577-10	2021	Notably, U0126, a specific MEK inhibitor, decreased MEK and ERK expression, and blocked the promotive effects of BANCR overexpression on the proliferation, migration and invasion of ESCC cells.	U 0126	9-14	mitogen-activated protein kinase 1	Homo sapiens	60-63
33880577-10	2021	Notably, U0126, a specific MEK inhibitor, decreased MEK and ERK expression, and blocked the promotive effects of BANCR overexpression on the proliferation, migration and invasion of ESCC cells.	U 0126	9-14	BRAF-activated non-protein coding RNA	Homo sapiens	113-118
33349854-10	2021	These changes by lower dose combination, except in p-IkappaB expression and NF-kappaB activity, were significantly inhibited by pretreatment with U0126 (ERK inhibitor).	U 0126	146-151	mitogen-activated protein kinase 1	Mus musculus	153-156
34052676-8	2021	As compared to the Control group, CAL27 and SCC-15 cells in the RN181 group and U0126 group presented with decreases in the proliferation, invasion and migration, but increases in the cell ratio at the G0/G1 phase and apoptosis, while the p-ERK 1/2/ERK 1/2 was down-regulated.	U 0126	80-85	mitogen-activated protein kinase 3	Homo sapiens	241-248
34052676-8	2021	As compared to the Control group, CAL27 and SCC-15 cells in the RN181 group and U0126 group presented with decreases in the proliferation, invasion and migration, but increases in the cell ratio at the G0/G1 phase and apoptosis, while the p-ERK 1/2/ERK 1/2 was down-regulated.	U 0126	80-85	mitogen-activated protein kinase 3	Homo sapiens	249-256
34034470-3	2021	The effects of Fat1 and extracellular regulated protein kinase (ERK) pathway inhibitor U0126 on the proliferation of ESCC cells were detected by methyl thiazolyl tetrazolium (MTT).	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	64-67
33744198-9	2021	Overexpression of C/EBPbeta in MEK/ERK pathway inhibited by U0126 did not promote MKs differentiation.	U 0126	60-65	CCAAT enhancer binding protein alpha	Homo sapiens	18-27
33744198-9	2021	Overexpression of C/EBPbeta in MEK/ERK pathway inhibited by U0126 did not promote MKs differentiation.	U 0126	60-65	midkine	Mus musculus	31-34
33744198-9	2021	Overexpression of C/EBPbeta in MEK/ERK pathway inhibited by U0126 did not promote MKs differentiation.	U 0126	60-65	mitogen-activated protein kinase 1	Mus musculus	35-38
33716118-5	2021	The results obtained demonstrated that GLP-2 restored impairments in spatial working memory and hippocampal long-term depression (LTD) in JDM rats, and that the MEK1/2 inhibitor, U0126, inhibited this recovery.	U 0126	179-184	mitogen activated protein kinase kinase 1	Rattus norvegicus	161-167
34003249-7	2021	SGLT2 and ERK inhibition on D-glucose, 25mM, and TGF-beta1, 0.75ng/ml, treated cells was explored using dapagliflozin and U0126, respectively.	U 0126	122-127	transforming growth factor beta 1	Homo sapiens	49-58
34019587-9	2021	Moreover, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) inhibitor U0126, p38 inhibitor SB205380, JNK inhibitor SP600125 and Akt inhibitor GSK 690693 decreased IL-1beta-induced MMP-3 mRNA and protein expression.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	66-72
34019587-9	2021	Moreover, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) inhibitor U0126, p38 inhibitor SB205380, JNK inhibitor SP600125 and Akt inhibitor GSK 690693 decreased IL-1beta-induced MMP-3 mRNA and protein expression.	U 0126	84-89	interleukin 1 alpha	Homo sapiens	177-185
34034470-11	2021	After U0126 treatment, the effect of Fat1 knockdown on the proliferation of KYSE450 cells disappeared, and the expression of p-ERK1/2 in KYSE450 cells decreased to a level similar to that in the control group.	U 0126	6-11	FAT atypical cadherin 1	Homo sapiens	37-41
34034470-11	2021	After U0126 treatment, the effect of Fat1 knockdown on the proliferation of KYSE450 cells disappeared, and the expression of p-ERK1/2 in KYSE450 cells decreased to a level similar to that in the control group.	U 0126	6-11	mitogen-activated protein kinase 3	Homo sapiens	127-133
33960038-5	2021	Exendin-4/GLP1R-stimulated neuritogenesis was MEK-ERK-dependent (blocked by U0126), indicating its use of the cAMP RapGEF2 ERK neuritogenic signalling pathway previously identified for PACAP/PAC1 signalling in NS-1 cells.	U 0126	76-81	glucagon like peptide 1 receptor	Homo sapiens	10-15
34054526-12	2021	Moreover, it was observed that the IL-11/ERK1/2 inhibitor, U0126, partly blocked the antifibrogenic effects of osthole.	U 0126	59-64	interleukin 11	Homo sapiens	35-40
34054526-12	2021	Moreover, it was observed that the IL-11/ERK1/2 inhibitor, U0126, partly blocked the antifibrogenic effects of osthole.	U 0126	59-64	mitogen-activated protein kinase 3	Homo sapiens	41-47
33960038-5	2021	Exendin-4/GLP1R-stimulated neuritogenesis was MEK-ERK-dependent (blocked by U0126), indicating its use of the cAMP RapGEF2 ERK neuritogenic signalling pathway previously identified for PACAP/PAC1 signalling in NS-1 cells.	U 0126	76-81	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
33960038-5	2021	Exendin-4/GLP1R-stimulated neuritogenesis was MEK-ERK-dependent (blocked by U0126), indicating its use of the cAMP RapGEF2 ERK neuritogenic signalling pathway previously identified for PACAP/PAC1 signalling in NS-1 cells.	U 0126	76-81	mitogen-activated protein kinase 1	Homo sapiens	50-53
33571699-6	2021	More importantly, the promotive effects of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis were significantly reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC functions through ERK1/2 signaling.	U 0126	184-189	A-kinase anchoring protein 2	Homo sapiens	43-48
33939302-8	2021	U0126 was added as an ERK inhibitor.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	22-25
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	Eph receptor B1	Rattus norvegicus	13-16
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	tumor necrosis factor	Rattus norvegicus	62-71
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	interleukin 6	Rattus norvegicus	73-77
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	matrix metallopeptidase 3	Rattus norvegicus	102-107
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	matrix metallopeptidase 13	Rattus norvegicus	109-115
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	ADAM metallopeptidase with thrombospondin type 1 motif, 5	Rattus norvegicus	117-125
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	intercellular adhesion molecule 1	Rattus norvegicus	127-133
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	Eph receptor B1	Rattus norvegicus	135-138
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	Eph receptor B1	Rattus norvegicus	135-138
33939302-21	2021	In addition, ERK inhibitor U0126 treatment also decreased the TNF-alpha, IL-6, and IL-1betalevels and MMP-3, MMP-13, ADAMTS-5, ICAM-1, ERK and p-ERK expression in HG + IL-1beta treated rat synovial fibroblasts.	U 0126	27-32	interleukin 1 alpha	Rattus norvegicus	83-91
33550048-11	2021	Pretreatment with P38/ERK inhibitors, SB203580, and U0126, decreased L20-induced apoptosis.	U 0126	52-57	mitogen-activated protein kinase 14	Homo sapiens	18-21
33550048-11	2021	Pretreatment with P38/ERK inhibitors, SB203580, and U0126, decreased L20-induced apoptosis.	U 0126	52-57	immunoglobulin kappa variable 3D-11	Homo sapiens	69-72
33571699-6	2021	More importantly, the promotive effects of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis were significantly reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC functions through ERK1/2 signaling.	U 0126	184-189	glycophorin C (Gerbich blood group)	Homo sapiens	67-70
33571699-6	2021	More importantly, the promotive effects of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis were significantly reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC functions through ERK1/2 signaling.	U 0126	184-189	mitogen-activated protein kinase 3	Homo sapiens	156-162
33571699-6	2021	More importantly, the promotive effects of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis were significantly reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC functions through ERK1/2 signaling.	U 0126	184-189	A-kinase anchoring protein 2	Homo sapiens	207-212
33571699-6	2021	More importantly, the promotive effects of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis were significantly reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC functions through ERK1/2 signaling.	U 0126	184-189	glycophorin C (Gerbich blood group)	Homo sapiens	222-225
33571699-6	2021	More importantly, the promotive effects of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis were significantly reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC functions through ERK1/2 signaling.	U 0126	184-189	mitogen-activated protein kinase 3	Homo sapiens	244-250
33788814-6	2021	When DRGs were cultured in the presence of U0126, a pharmacological inhibitor of Erk, the HGF-mediated increase in neurite outgrowth and the level of pSTAT3 (Ser 727) were both suppressed.	U 0126	43-48	mitogen-activated protein kinase 1	Mus musculus	81-84
33621689-4	2021	Additionally, sodium arsenite increased levels of active phosphorylation of ERK1/2, and inhibition of ERK1/2 by U0126 partially improved the Tau1 reduction.	U 0126	112-117	mitogen-activated protein kinase 3	Homo sapiens	102-108
33747186-8	2021	FK18 also increased the Bcl-2/Bax ratio and decreased the level of cleaved-caspase-3 in SY5Y cells, which was reversed by the Akt pathway inhibitor LY294002, but not by the Erk pathway inhibitor U0126.	U 0126	195-200	AKT serine/threonine kinase 1	Homo sapiens	126-129
33735723-6	2021	Furthermore, to further clarify the relevant mechanism of HSYA"s effects on mPTP, inhibition of extracellular regulated protein kinases (ERK) with U0126 and transfect with Cyclophilin D (CypD) SiRNA to reversely verified whether the protective effects of HSYA were exerted by regulating the Mitogen-activated protein kinase kinase (MEK)/ERK/CypD pathway.	U 0126	147-152	Eph receptor B1	Rattus norvegicus	137-140
33922757-8	2021	The MEK1/2 inhibitor, U0126, reduced the neuroprotective effect of metformin.	U 0126	22-27	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-10
33874992-6	2021	We further reduced ERK1/2 phosphorylation by administering MEK inhibitor, U0126, into Prdx6-/- mice before the probe test, which reversed their spatial memory deficit.	U 0126	74-79	mitogen-activated protein kinase 3	Mus musculus	19-25
33874992-6	2021	We further reduced ERK1/2 phosphorylation by administering MEK inhibitor, U0126, into Prdx6-/- mice before the probe test, which reversed their spatial memory deficit.	U 0126	74-79	midkine	Mus musculus	59-62
33874992-6	2021	We further reduced ERK1/2 phosphorylation by administering MEK inhibitor, U0126, into Prdx6-/- mice before the probe test, which reversed their spatial memory deficit.	U 0126	74-79	peroxiredoxin 6	Mus musculus	86-91
33755094-7	2021	Furthermore, U0126, a specific ERK inhibitor, could effectively inhibit EB2-mediated HCC proliferation and metastasis in vitro and in vivo.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	31-34
33755094-7	2021	Furthermore, U0126, a specific ERK inhibitor, could effectively inhibit EB2-mediated HCC proliferation and metastasis in vitro and in vivo.	U 0126	13-18	microtubule associated protein RP/EB family member 2	Homo sapiens	72-75
33495943-8	2021	The mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 reduced CYP3A4 mRNA levels of THLE-5b cells.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	4-43
33495943-8	2021	The mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 reduced CYP3A4 mRNA levels of THLE-5b cells.	U 0126	104-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-187
33844290-8	2021	TGF-beta1 phosphorylated ERK1/2 and Smad2/3 to induce AmeloD expression, whereas treatment with the MEK inhibitor, U0126, inhibited AmeloD induction.	U 0126	115-120	mitogen-activated protein kinase kinase 7	Homo sapiens	100-103
33788814-6	2021	When DRGs were cultured in the presence of U0126, a pharmacological inhibitor of Erk, the HGF-mediated increase in neurite outgrowth and the level of pSTAT3 (Ser 727) were both suppressed.	U 0126	43-48	hepatocyte growth factor	Mus musculus	90-93
33607589-4	2021	A pharmacological inhibitor of ERK, U0126 was used while PELP1 was overexpressed, and the expression of RUNX2 was monitored by qRT-PCR.	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	31-34
33607589-7	2021	Moreover, PELP1 knockdown resulted in reduced ERK phosphorylation and RUNX2 expression, and PELP1 overexpression induced RUNX2 expression was inhibited by U0126 in the hPDLSCs.	U 0126	155-160	proline, glutamate and leucine rich protein 1	Homo sapiens	92-97
33607589-7	2021	Moreover, PELP1 knockdown resulted in reduced ERK phosphorylation and RUNX2 expression, and PELP1 overexpression induced RUNX2 expression was inhibited by U0126 in the hPDLSCs.	U 0126	155-160	RUNX family transcription factor 2	Homo sapiens	121-126
33393692-5	2021	Furthermore, U0126, an ERK inhibitor, inhibited SREBP1 and decreased cellular cholesterol level, unwinding the molecular mechanism behind AA-DA-mediated anticancer activity.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	23-26
33393692-5	2021	Furthermore, U0126, an ERK inhibitor, inhibited SREBP1 and decreased cellular cholesterol level, unwinding the molecular mechanism behind AA-DA-mediated anticancer activity.	U 0126	13-18	sterol regulatory element binding transcription factor 1	Homo sapiens	48-54
33184870-10	2021	Furthermore, inhibition of the ERK signal pathway by U0126 reversed the increased proliferation and metastasis induced by overexpression of PBK.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	31-34
33184870-10	2021	Furthermore, inhibition of the ERK signal pathway by U0126 reversed the increased proliferation and metastasis induced by overexpression of PBK.	U 0126	53-58	PDZ binding kinase	Homo sapiens	140-143
33511708-9	2021	Pretreatment with ERK inhibitor U0126 blocked SDF-1/EX-4 cotherapy induced ERK signal activation and PDLSC proliferation.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	18-21
33577918-5	2021	U0126 is a specific inhibitor of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) signaling pathway and has neuroprotective effects.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	93-99
33707758-9	2021	The expression of p-Connexin 43 was significantly decreased in the presence of the ERK1/2 inhibitor U0126 but not the p38 inhibitor SB203580.	U 0126	100-105	gap junction protein, alpha 1	Rattus norvegicus	20-31
33707758-9	2021	The expression of p-Connexin 43 was significantly decreased in the presence of the ERK1/2 inhibitor U0126 but not the p38 inhibitor SB203580.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	83-89
32665706-12	2021	Moreover, the ERK1/2 inhibitor U0126 (10 muM) had the similar effects as MB.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	14-20
33078208-6	2021	We demonstrated a molecular mechanism whereby WNT5A be negatively regulated by transcription factor E2F1, and ERK1/2 inhibitor (U0126) suppressed E2F1"s regulation of WNT5A expression in EGFR-mutant cells.	U 0126	128-133	E2F transcription factor 1	Homo sapiens	146-150
33078208-6	2021	We demonstrated a molecular mechanism whereby WNT5A be negatively regulated by transcription factor E2F1, and ERK1/2 inhibitor (U0126) suppressed E2F1"s regulation of WNT5A expression in EGFR-mutant cells.	U 0126	128-133	Wnt family member 5A	Homo sapiens	167-172
33078208-6	2021	We demonstrated a molecular mechanism whereby WNT5A be negatively regulated by transcription factor E2F1, and ERK1/2 inhibitor (U0126) suppressed E2F1"s regulation of WNT5A expression in EGFR-mutant cells.	U 0126	128-133	epidermal growth factor receptor	Homo sapiens	187-191
33420899-4	2021	However, U0126 (a MEK inhibitor) strengthened the cell apoptosis and the expressions of cleaved-caspase-3 and cleaved PARP.	U 0126	9-14	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
33420899-4	2021	However, U0126 (a MEK inhibitor) strengthened the cell apoptosis and the expressions of cleaved-caspase-3 and cleaved PARP.	U 0126	9-14	collagen type XI alpha 2 chain	Homo sapiens	118-122
33420899-11	2021	U0126 potentiated JS-K-induced inhibitory effect of Raf/MEK/ERK pathway.	U 0126	0-5	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	52-55
33420899-11	2021	U0126 potentiated JS-K-induced inhibitory effect of Raf/MEK/ERK pathway.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
33420899-11	2021	U0126 potentiated JS-K-induced inhibitory effect of Raf/MEK/ERK pathway.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	60-63
33078208-6	2021	We demonstrated a molecular mechanism whereby WNT5A be negatively regulated by transcription factor E2F1, and ERK1/2 inhibitor (U0126) suppressed E2F1"s regulation of WNT5A expression in EGFR-mutant cells.	U 0126	128-133	Wnt family member 5A	Homo sapiens	46-51
33078208-6	2021	We demonstrated a molecular mechanism whereby WNT5A be negatively regulated by transcription factor E2F1, and ERK1/2 inhibitor (U0126) suppressed E2F1"s regulation of WNT5A expression in EGFR-mutant cells.	U 0126	128-133	mitogen-activated protein kinase 3	Homo sapiens	110-116
33511708-9	2021	Pretreatment with ERK inhibitor U0126 blocked SDF-1/EX-4 cotherapy induced ERK signal activation and PDLSC proliferation.	U 0126	32-37	C-X-C motif chemokine ligand 12	Rattus norvegicus	46-51
33511708-9	2021	Pretreatment with ERK inhibitor U0126 blocked SDF-1/EX-4 cotherapy induced ERK signal activation and PDLSC proliferation.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	75-78
33421718-11	2021	Suppressing ERK with U0126 (an ERK inhibitor) or knocking down ERK with siRNA decreased BaP-induced MUC5AC expression.	U 0126	21-26	erk	None	12-15
33748286-4	2021	What is more, ERK inhibitor U0126 could decrease the release of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the number of apoptotic cells induced by urinary proteins, indicating the damaging effects of ERK pathway in mediating cellular injury and apoptosis in HK-2 cells.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	14-17
33748286-4	2021	What is more, ERK inhibitor U0126 could decrease the release of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the number of apoptotic cells induced by urinary proteins, indicating the damaging effects of ERK pathway in mediating cellular injury and apoptosis in HK-2 cells.	U 0126	28-33	lipocalin 2	Homo sapiens	64-106
33748286-4	2021	What is more, ERK inhibitor U0126 could decrease the release of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the number of apoptotic cells induced by urinary proteins, indicating the damaging effects of ERK pathway in mediating cellular injury and apoptosis in HK-2 cells.	U 0126	28-33	lipocalin 2	Homo sapiens	108-112
33748286-4	2021	What is more, ERK inhibitor U0126 could decrease the release of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the number of apoptotic cells induced by urinary proteins, indicating the damaging effects of ERK pathway in mediating cellular injury and apoptosis in HK-2 cells.	U 0126	28-33	hepatitis A virus cellular receptor 1	Homo sapiens	115-139
33748286-4	2021	What is more, ERK inhibitor U0126 could decrease the release of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the number of apoptotic cells induced by urinary proteins, indicating the damaging effects of ERK pathway in mediating cellular injury and apoptosis in HK-2 cells.	U 0126	28-33	hepatitis A virus cellular receptor 1	Homo sapiens	141-146
33748286-4	2021	What is more, ERK inhibitor U0126 could decrease the release of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the number of apoptotic cells induced by urinary proteins, indicating the damaging effects of ERK pathway in mediating cellular injury and apoptosis in HK-2 cells.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	247-250
33748286-5	2021	Interestingly, we also found that the increased expression of microtubule-associated protein 1 light chain 3 (LC3)-II (a key marker of autophagy) and the decreased expression of p62 (autophagic substrate) induced by urinary proteins were reversed by U0126, suggesting autophagy was activated by ERK pathway.	U 0126	250-255	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	110-113
33748286-5	2021	Interestingly, we also found that the increased expression of microtubule-associated protein 1 light chain 3 (LC3)-II (a key marker of autophagy) and the decreased expression of p62 (autophagic substrate) induced by urinary proteins were reversed by U0126, suggesting autophagy was activated by ERK pathway.	U 0126	250-255	nucleoporin 62	Homo sapiens	178-181
33748286-5	2021	Interestingly, we also found that the increased expression of microtubule-associated protein 1 light chain 3 (LC3)-II (a key marker of autophagy) and the decreased expression of p62 (autophagic substrate) induced by urinary proteins were reversed by U0126, suggesting autophagy was activated by ERK pathway.	U 0126	250-255	mitogen-activated protein kinase 1	Homo sapiens	295-298
32253606-7	2021	ERK inhibitor U0126 could abolish the protective effect of hesperein in DEX-treated BMSCs.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	0-3
33275121-5	2021	Moreover, PGE2-stimulated CITED4 mRNA expression was blocked by ERK1/2 inhibition (U0126), suggesting that CITED4 is a downstream target of the ERK1/2 pathway in sheep GCs.	U 0126	83-88	cbp/p300-interacting transactivator 4	Ovis aries	26-32
32927466-57	2021	h MEK inhibition with U0126 (1 microM) prevents DA-induced increases in Gadd45b mRNA.	U 0126	22-27	growth arrest and DNA-damage-inducible, beta	Rattus norvegicus	72-79
33275121-5	2021	Moreover, PGE2-stimulated CITED4 mRNA expression was blocked by ERK1/2 inhibition (U0126), suggesting that CITED4 is a downstream target of the ERK1/2 pathway in sheep GCs.	U 0126	83-88	cbp/p300-interacting transactivator 4	Ovis aries	107-113
33708336-12	2021	U0126 and ML385 abolished the treatment effects of albumin on behavior and protein levels after ICH.	U 0126	0-5	albumin	Rattus norvegicus	51-58
33637715-8	2021	In addition, the CnA inhibitor cyclosporin A and p-ERK1/2 inhibitor U0126 improved HG-induced cardiomyocyte hypertrophy by promoting and inhibiting phosphorylation of Drp1 at S637 and S616, respectively.	U 0126	68-73	mitogen activated protein kinase 3	Rattus norvegicus	51-57
33637715-8	2021	In addition, the CnA inhibitor cyclosporin A and p-ERK1/2 inhibitor U0126 improved HG-induced cardiomyocyte hypertrophy by promoting and inhibiting phosphorylation of Drp1 at S637 and S616, respectively.	U 0126	68-73	collapsin response mediator protein 1	Rattus norvegicus	167-171
33658828-13	2021	U0126, an ERK1/2 inhibitor, reduced the effect of Hyp on Crm1 expression and the Bach1 redistribution.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	10-16
33658828-13	2021	U0126, an ERK1/2 inhibitor, reduced the effect of Hyp on Crm1 expression and the Bach1 redistribution.	U 0126	0-5	exportin 1	Homo sapiens	57-61
33658828-13	2021	U0126, an ERK1/2 inhibitor, reduced the effect of Hyp on Crm1 expression and the Bach1 redistribution.	U 0126	0-5	BTB domain and CNC homolog 1	Homo sapiens	81-86
33422538-5	2021	Roscovitine (a CDK5 inhibitor) suppressed the effect of tunicamycin in the molecular layer of the dentate gyrus and the CA1 region, while U0126 (an ERK1/2 inhibitor) reversed it in the CA1 region.	U 0126	138-143	mitogen activated protein kinase 3	Rattus norvegicus	148-154
33692666-9	2021	As cotreatment with the ERK-specific inhibitor U0126 and ICT abolishes the beneficial effects of ITC on the ERK/DAPK1 pathway, NMDAR subtypes and neuronal cell survival, ERK is recognized as a crucial mediator in the protective mechanism of ICT.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	24-27
33692666-9	2021	As cotreatment with the ERK-specific inhibitor U0126 and ICT abolishes the beneficial effects of ITC on the ERK/DAPK1 pathway, NMDAR subtypes and neuronal cell survival, ERK is recognized as a crucial mediator in the protective mechanism of ICT.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	108-111
33692666-9	2021	As cotreatment with the ERK-specific inhibitor U0126 and ICT abolishes the beneficial effects of ITC on the ERK/DAPK1 pathway, NMDAR subtypes and neuronal cell survival, ERK is recognized as a crucial mediator in the protective mechanism of ICT.	U 0126	47-52	death associated protein kinase 1	Rattus norvegicus	112-117
33692666-9	2021	As cotreatment with the ERK-specific inhibitor U0126 and ICT abolishes the beneficial effects of ITC on the ERK/DAPK1 pathway, NMDAR subtypes and neuronal cell survival, ERK is recognized as a crucial mediator in the protective mechanism of ICT.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	108-111
33450374-10	2021	Impairment of autophagy by U0126 or Olaparib results in lysosomal iron accumulation and decrease of the cytosolic labile iron pool, leading to reduction of SCD1, lipid level and cell viability.	U 0126	27-32	stearoyl-CoA desaturase	Homo sapiens	156-160
33670725-4	2021	To test this hypothesis, we tested the effects of lenvatinib with the MEK inhibitor U0126 in vitro using two human anaplastic thyroid cancer (ATC) cell lines, 8505C and TCO1, and with another MEK inhibitor, selumetinib (AZD6244), in an ATC mouse model.	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
33422538-5	2021	Roscovitine (a CDK5 inhibitor) suppressed the effect of tunicamycin in the molecular layer of the dentate gyrus and the CA1 region, while U0126 (an ERK1/2 inhibitor) reversed it in the CA1 region.	U 0126	138-143	carbonic anhydrase 1	Rattus norvegicus	185-188
33574243-7	2021	Through loss-of function and gain-of function experiments, we found that PLAU promoted ESCC proliferation and clone formation via MAPK pathway, and promotes migration by upregulating Slug and MMP9, which can be reversed by the MEK 1/2 inhibitor U0126.	U 0126	245-250	plasminogen activator, urokinase	Homo sapiens	73-77
33681255-10	2021	Additionally, 0.3% formalin-induced up-regulation of phosphorylation of extracellular regulated protein kinases (p-ERK) in the dorsal root ganglion (DRG) and scratching were suppressed by intrathecal injection of MEK inhibitor U0126 in mice.	U 0126	227-232	mitogen-activated protein kinase 1	Mus musculus	115-118
33681255-10	2021	Additionally, 0.3% formalin-induced up-regulation of phosphorylation of extracellular regulated protein kinases (p-ERK) in the dorsal root ganglion (DRG) and scratching were suppressed by intrathecal injection of MEK inhibitor U0126 in mice.	U 0126	227-232	midkine	Mus musculus	213-216
33412209-6	2021	However, U0126, a potent extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, decreased PDGF-BB-induced LC3 expression, while rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), increased it.	U 0126	9-14	mitogen-activated protein kinase 1	Homo sapiens	25-66
33412209-6	2021	However, U0126, a potent extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, decreased PDGF-BB-induced LC3 expression, while rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), increased it.	U 0126	9-14	mitogen-activated protein kinase 3	Homo sapiens	68-74
33412209-6	2021	However, U0126, a potent extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, decreased PDGF-BB-induced LC3 expression, while rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), increased it.	U 0126	9-14	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	113-116
33412209-6	2021	However, U0126, a potent extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, decreased PDGF-BB-induced LC3 expression, while rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), increased it.	U 0126	9-14	mechanistic target of rapamycin kinase	Homo sapiens	197-201
33412209-7	2021	Furthermore, U0126 decreased the expresseion of autophagy-related genes (Atgs) such as beclin-1, Atg7, Atg5, and Atg12-Atg5 complex, indicating that Erk1/2 is a regulator of PDGF-BB-induced VSMC autophagy.	U 0126	13-18	beclin 1	Homo sapiens	87-95
33412209-7	2021	Furthermore, U0126 decreased the expresseion of autophagy-related genes (Atgs) such as beclin-1, Atg7, Atg5, and Atg12-Atg5 complex, indicating that Erk1/2 is a regulator of PDGF-BB-induced VSMC autophagy.	U 0126	13-18	autophagy related 7	Homo sapiens	97-101
33412209-7	2021	Furthermore, U0126 decreased the expresseion of autophagy-related genes (Atgs) such as beclin-1, Atg7, Atg5, and Atg12-Atg5 complex, indicating that Erk1/2 is a regulator of PDGF-BB-induced VSMC autophagy.	U 0126	13-18	autophagy related 5	Homo sapiens	103-107
33412209-7	2021	Furthermore, U0126 decreased the expresseion of autophagy-related genes (Atgs) such as beclin-1, Atg7, Atg5, and Atg12-Atg5 complex, indicating that Erk1/2 is a regulator of PDGF-BB-induced VSMC autophagy.	U 0126	13-18	autophagy related 12	Homo sapiens	113-118
33412209-7	2021	Furthermore, U0126 decreased the expresseion of autophagy-related genes (Atgs) such as beclin-1, Atg7, Atg5, and Atg12-Atg5 complex, indicating that Erk1/2 is a regulator of PDGF-BB-induced VSMC autophagy.	U 0126	13-18	autophagy related 5	Homo sapiens	119-123
33412209-7	2021	Furthermore, U0126 decreased the expresseion of autophagy-related genes (Atgs) such as beclin-1, Atg7, Atg5, and Atg12-Atg5 complex, indicating that Erk1/2 is a regulator of PDGF-BB-induced VSMC autophagy.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	149-155
33412209-9	2021	Furthermore, PDGF-BB-stimulated VSMC proliferation, migration and proliferating cell nuclear antigen (PCNA) expression were inhibited by U0126 and rapamycin.	U 0126	137-142	proliferating cell nuclear antigen	Homo sapiens	66-100
33412209-9	2021	Furthermore, PDGF-BB-stimulated VSMC proliferation, migration and proliferating cell nuclear antigen (PCNA) expression were inhibited by U0126 and rapamycin.	U 0126	137-142	proliferating cell nuclear antigen	Homo sapiens	102-106
33383048-4	2021	MATERIALS AND METHODS: FGF9 was treated with ERK (U0126) or NF-kB (BAY11-7082) inhibitors in STHdhQ7/Q7 and STHdhQ111/Q111 striatal knock-in cell lines to examine neurite outgrowth, cytoskeletal markers, and synaptic proteins via immunofluorescence staining and Western blotting.	U 0126	50-55	fibroblast growth factor 9	Mus musculus	23-27
33574243-7	2021	Through loss-of function and gain-of function experiments, we found that PLAU promoted ESCC proliferation and clone formation via MAPK pathway, and promotes migration by upregulating Slug and MMP9, which can be reversed by the MEK 1/2 inhibitor U0126.	U 0126	245-250	mitogen-activated protein kinase kinase 1	Homo sapiens	227-234
33633581-12	2021	Though FSS did not alter alpha- or gamma-ENaC expression in mpkCCD cells, gamma-ENaC was reduced in U0126 treated cells.	U 0126	100-105	sodium channel, nonvoltage-gated 1 gamma	Mus musculus	74-84
33558461-5	2021	This increased flux at early stages of resistance was found to be dictated by a hyperactive ERK1/2 signaling, which when inhibited either pharmacologically (U0126/Trametinib) or genetically, reduced p62 degradation, number of LC3+veLAMP1+ve puncta, autophagolysosome formation, and led to chemo-sensitization and apoptosis.	U 0126	157-162	mitogen-activated protein kinase 3	Mus musculus	92-98
33558461-5	2021	This increased flux at early stages of resistance was found to be dictated by a hyperactive ERK1/2 signaling, which when inhibited either pharmacologically (U0126/Trametinib) or genetically, reduced p62 degradation, number of LC3+veLAMP1+ve puncta, autophagolysosome formation, and led to chemo-sensitization and apoptosis.	U 0126	157-162	nucleoporin 62	Mus musculus	199-202
33280973-9	2021	On treatment with the Erk1/2 inhibitor U0126, the expression of Col1, Alp, and p-Erk1/2 mRNA and protein was significantly downregulated.	U 0126	39-44	mitogen-activated protein kinase 3	Mus musculus	22-28
33540617-7	2021	We confirmed the functional relevance for mPFC ERK activation for MA-induced place-preference via site-directed infusion of the MEK inhibitor U0126.	U 0126	142-147	mitogen-activated protein kinase 1	Mus musculus	47-50
33540617-7	2021	We confirmed the functional relevance for mPFC ERK activation for MA-induced place-preference via site-directed infusion of the MEK inhibitor U0126.	U 0126	142-147	midkine	Mus musculus	128-131
33280973-9	2021	On treatment with the Erk1/2 inhibitor U0126, the expression of Col1, Alp, and p-Erk1/2 mRNA and protein was significantly downregulated.	U 0126	39-44	alopecia, recessive	Mus musculus	70-73
33280973-9	2021	On treatment with the Erk1/2 inhibitor U0126, the expression of Col1, Alp, and p-Erk1/2 mRNA and protein was significantly downregulated.	U 0126	39-44	mitogen-activated protein kinase 3	Mus musculus	81-87
33250417-7	2021	Whereas, the addition of inhibitor U0126 down-regulated sharply the expression level of p-ERK, which indicated that cellular osteogenic differentiation of MC3T3-E1 cells was governed through alpha2beta1 integrin-mediated MEK/ERK signaling pathways during CoFe2O4/P(VDF-TrFE) nanocomposite coatings were combined with SMF.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	90-93
33247506-9	2021	Blocking c-KIT signaling using Imatinib or ISCK03 reduced p-ELK1 expression and consequently decreased CEA levels in CRC cells, as did blocking the ERK1/2 pathway by U0126.	U 0126	166-171	mitogen-activated protein kinase 3	Homo sapiens	148-154
33250417-7	2021	Whereas, the addition of inhibitor U0126 down-regulated sharply the expression level of p-ERK, which indicated that cellular osteogenic differentiation of MC3T3-E1 cells was governed through alpha2beta1 integrin-mediated MEK/ERK signaling pathways during CoFe2O4/P(VDF-TrFE) nanocomposite coatings were combined with SMF.	U 0126	35-40	midkine	Mus musculus	221-224
33250417-7	2021	Whereas, the addition of inhibitor U0126 down-regulated sharply the expression level of p-ERK, which indicated that cellular osteogenic differentiation of MC3T3-E1 cells was governed through alpha2beta1 integrin-mediated MEK/ERK signaling pathways during CoFe2O4/P(VDF-TrFE) nanocomposite coatings were combined with SMF.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	225-228
32918333-7	2021	In contrast, when U0126 was used to block the ERK1/2 pathway, ERK1/2 and Elk1 phosphorylation levels were downregulated, ERK1/2 nuclear translocation and SOD content were significantly reduced, and PARK7-overexperssion-induced antioxidative activity was completely blocked.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	46-52
33238752-10	2021	Further experiments revealed that Bach1 knockdown repressed cell viability, alpha-SMA, Fn1, IL-6 and COL1A1 expressions in PF cell model, then ERK inhibition by U0126 enhanced these effects.	U 0126	161-166	BTB and CNC homology 1, basic leucine zipper transcription factor 1	Mus musculus	34-39
33238752-10	2021	Further experiments revealed that Bach1 knockdown repressed cell viability, alpha-SMA, Fn1, IL-6 and COL1A1 expressions in PF cell model, then ERK inhibition by U0126 enhanced these effects.	U 0126	161-166	mitogen-activated protein kinase 1	Mus musculus	143-146
33522294-12	2021	Notably, Alendronate increased the phosphorylation of ERK1/2 and inhibition of ERK1/2 using its specific inhibitor U0126 blocked the expression of SP-1.	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	79-85
32914311-11	2021	CuD-induced cell death was enhanced by the mitogen-activated protein kinase kinase (MEK)1/2 inhibitor U0126.	U 0126	102-107	mitogen-activated protein kinase kinase 1	Homo sapiens	43-91
32914311-14	2021	MEK1/2 and p38 inhibitors enhanced CuD-induced cell death, and U0126 enhanced the CuD-induced de-phosphorylation of ERK in MT-1 and MT-4 cells.	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	116-119
32918333-7	2021	In contrast, when U0126 was used to block the ERK1/2 pathway, ERK1/2 and Elk1 phosphorylation levels were downregulated, ERK1/2 nuclear translocation and SOD content were significantly reduced, and PARK7-overexperssion-induced antioxidative activity was completely blocked.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	62-68
32918333-7	2021	In contrast, when U0126 was used to block the ERK1/2 pathway, ERK1/2 and Elk1 phosphorylation levels were downregulated, ERK1/2 nuclear translocation and SOD content were significantly reduced, and PARK7-overexperssion-induced antioxidative activity was completely blocked.	U 0126	18-23	ETS transcription factor ELK1	Homo sapiens	73-77
32918333-7	2021	In contrast, when U0126 was used to block the ERK1/2 pathway, ERK1/2 and Elk1 phosphorylation levels were downregulated, ERK1/2 nuclear translocation and SOD content were significantly reduced, and PARK7-overexperssion-induced antioxidative activity was completely blocked.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	62-68
32918333-7	2021	In contrast, when U0126 was used to block the ERK1/2 pathway, ERK1/2 and Elk1 phosphorylation levels were downregulated, ERK1/2 nuclear translocation and SOD content were significantly reduced, and PARK7-overexperssion-induced antioxidative activity was completely blocked.	U 0126	18-23	Parkinsonism associated deglycase	Homo sapiens	198-203
32667711-6	2021	Using the extracellular signal-regulated kinase pathway inhibitor U0126 and activator tumor growth factor-beta, we investigated the mechanism of epithelial-mesenchymal transition induced by 5-lipoxygenase in gastric cancer cells.	U 0126	66-71	arachidonate 5-lipoxygenase	Mus musculus	190-204
32667711-10	2021	Inhibition of extracellular signal-regulated kinase signaling by U0126 or activation by tumor growth factor-beta neutralized the effect of 5-LOX overexpression or silencing on epithelial-mesenchymal transition.	U 0126	65-70	arachidonate 5-lipoxygenase	Mus musculus	139-144
32400208-6	2021	Results: The results showed that SHS in vivo caused increased expression of ET receptors ETA and ETB, and that the MEK1/2 blocker U0126 significantly reversed SHS exposure-increased ETA-mediated contractile responses and protein levels.	U 0126	130-135	endothelin receptor type B	Rattus norvegicus	97-100
33169491-10	2021	After U0126 pretreatment, the inhibition effect of silencing RHPN1-AS1 on the phosphorylation of MEK and ERK was strengthened.	U 0126	6-11	rhophilin Rho GTPase binding protein 1	Homo sapiens	61-66
33169491-10	2021	After U0126 pretreatment, the inhibition effect of silencing RHPN1-AS1 on the phosphorylation of MEK and ERK was strengthened.	U 0126	6-11	prostaglandin D2 receptor	Homo sapiens	67-70
33169491-10	2021	After U0126 pretreatment, the inhibition effect of silencing RHPN1-AS1 on the phosphorylation of MEK and ERK was strengthened.	U 0126	6-11	mitogen-activated protein kinase kinase 7	Homo sapiens	97-100
33169491-10	2021	After U0126 pretreatment, the inhibition effect of silencing RHPN1-AS1 on the phosphorylation of MEK and ERK was strengthened.	U 0126	6-11	mitogen-activated protein kinase 1	Homo sapiens	105-108
33166587-0	2021	BLOCKADE OF ERK1/2 ACTIVATION WITH U0126 OR PEP7 REDUCES SODIUM APPETITE AND ANGIOTENSIN II-INDUCED PRESSOR RESPONSES IN SPONTANEOUSLY HYPERTENSIVE RATS.	U 0126	35-40	mitogen activated protein kinase 3	Rattus norvegicus	12-18
33166587-6	2021	The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min).	U 0126	57-62	mitogen activated protein kinase 3	Rattus norvegicus	16-22
33166587-6	2021	The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min).	U 0126	57-62	mitogen activated protein kinase kinase 1	Rattus norvegicus	64-70
33166587-9	2021	In addition, U0126 or PEP7 icv reduced the pressor response to icv ANG II.	U 0126	13-18	angiotensinogen	Rattus norvegicus	67-73
32400208-6	2021	Results: The results showed that SHS in vivo caused increased expression of ET receptors ETA and ETB, and that the MEK1/2 blocker U0126 significantly reversed SHS exposure-increased ETA-mediated contractile responses and protein levels.	U 0126	130-135	mitogen activated protein kinase kinase 1	Rattus norvegicus	115-121
32400208-6	2021	Results: The results showed that SHS in vivo caused increased expression of ET receptors ETA and ETB, and that the MEK1/2 blocker U0126 significantly reversed SHS exposure-increased ETA-mediated contractile responses and protein levels.	U 0126	130-135	endothelin receptor type A	Rattus norvegicus	182-185
32400208-9	2021	However, only the higher dose U0126 (15 mg/kg) had inhibitory effects on the ETA receptor.	U 0126	30-35	endothelin receptor type A	Rattus norvegicus	77-80
33479915-5	2021	We found that inhibiting ERK by microinjection of U0126 into the NAc at 1 or 6 days following withdrawal from BS did not affect the expression of BS when challenged with cocaine at 14 days.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	25-28
33504418-4	2021	After treated with 1 mug/mL PGRN and ERK1/2 signaling pathway inhibitor U0126 (10 mumol/L) simultaneously, the migration and invasion ability of 4T1 cells and the changes in the expression of E-cadherin, vimentin and p-ERK proteins were detected again.	U 0126	72-77	mitogen-activated protein kinase 3	Mus musculus	37-43
33504418-4	2021	After treated with 1 mug/mL PGRN and ERK1/2 signaling pathway inhibitor U0126 (10 mumol/L) simultaneously, the migration and invasion ability of 4T1 cells and the changes in the expression of E-cadherin, vimentin and p-ERK proteins were detected again.	U 0126	72-77	mitogen-activated protein kinase 1	Mus musculus	37-40
32776778-3	2021	This study aims to investigate whether inhibition of ERK signaling with U0126 can prevent prolonged cold IRI in heart transplantation.	U 0126	72-77	Eph receptor B1	Rattus norvegicus	53-56
32776778-5	2021	The effect of U0126 on H9c2 cells in response to H/R stress was determined by measuring cell death, reactive oxygen species production, mitochondrial membrane potential, and ERK signaling activation.	U 0126	14-19	Eph receptor B1	Rattus norvegicus	174-177
32776778-9	2021	Pretreatment with U0126 inhibited ERK phosphorylation and prevented H9c2 cells from cell death, reactive oxygen species generation, and mitochondrial membrane potential loss in response to H/R.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	34-37
32776778-11	2021	CONCLUSIONS: Addition of U0126 to UW solution reduces ERK signal activation and attenuates prolonged cold IRI in a heart transplantation model.	U 0126	25-30	Eph receptor B1	Rattus norvegicus	54-57
32776778-12	2021	ERK inhibition with U0126 may be a useful strategy to minimize IRI in organ transplantation.	U 0126	20-25	Eph receptor B1	Rattus norvegicus	0-3
33465083-4	2021	Here we exploit the ability to finely titrate FGF signaling activity via the MAPK pathway using the MEK inhibitor U0126 to quantify the dependence of transcription driven by different Brachyury reporter constructs on this direct upstream regulator.	U 0126	114-119	mitogen-activated protein kinase kinase 7	Homo sapiens	100-103
33584253-11	2020	The mitogen-activated kinase kinase 1/2 inhibitor U0126 inhibited PKC agonist-induced hypertrophy fully and ET-1-induced hypertrophy partially.	U 0126	50-55	proline rich transmembrane protein 2	Homo sapiens	66-69
33505496-9	2021	Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively.	U 0126	318-323	C-X-C motif chemokine ligand 8	Homo sapiens	17-21
33189864-9	2021	Moreover, S1P-dependent CREB phosphorylation was dampened by the mitogen-activate protein kinase (MEK) inhibitor U0126 and by the L-type Ca2+ channel blocker verapamil.	U 0126	113-118	cAMP responsive element binding protein 1	Homo sapiens	24-28
33189864-9	2021	Moreover, S1P-dependent CREB phosphorylation was dampened by the mitogen-activate protein kinase (MEK) inhibitor U0126 and by the L-type Ca2+ channel blocker verapamil.	U 0126	113-118	mitogen-activated protein kinase kinase 7	Homo sapiens	65-96
33189864-9	2021	Moreover, S1P-dependent CREB phosphorylation was dampened by the mitogen-activate protein kinase (MEK) inhibitor U0126 and by the L-type Ca2+ channel blocker verapamil.	U 0126	113-118	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
33505496-9	2021	Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively.	U 0126	318-323	C-X-C motif chemokine ligand 8	Homo sapiens	100-104
33271127-6	2021	The effects of oestrogen on SOX9 and tubulin were blocked by the ERK1/2 inhibitor U0126, demonstrating that ERK1/2 mediates the stabilisation of microtubules and cytoplasmic retention of SOX9 by oestrogen.	U 0126	82-87	SRY-box transcription factor 9	Homo sapiens	28-32
33271127-6	2021	The effects of oestrogen on SOX9 and tubulin were blocked by the ERK1/2 inhibitor U0126, demonstrating that ERK1/2 mediates the stabilisation of microtubules and cytoplasmic retention of SOX9 by oestrogen.	U 0126	82-87	mitogen-activated protein kinase 3	Homo sapiens	65-71
33271127-6	2021	The effects of oestrogen on SOX9 and tubulin were blocked by the ERK1/2 inhibitor U0126, demonstrating that ERK1/2 mediates the stabilisation of microtubules and cytoplasmic retention of SOX9 by oestrogen.	U 0126	82-87	mitogen-activated protein kinase 3	Homo sapiens	108-114
33271127-6	2021	The effects of oestrogen on SOX9 and tubulin were blocked by the ERK1/2 inhibitor U0126, demonstrating that ERK1/2 mediates the stabilisation of microtubules and cytoplasmic retention of SOX9 by oestrogen.	U 0126	82-87	SRY-box transcription factor 9	Homo sapiens	187-191
33505496-9	2021	Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively.	U 0126	318-323	AKT serine/threonine kinase 1	Homo sapiens	270-273
33505496-9	2021	Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively.	U 0126	318-323	mitogen-activated protein kinase 1	Homo sapiens	280-283
33505496-9	2021	Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively.	U 0126	318-323	C-X-C motif chemokine ligand 8	Homo sapiens	100-104
33505496-9	2021	Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively.	U 0126	318-323	AKT serine/threonine kinase 1	Homo sapiens	154-157
33108571-6	2021	Moreover, Curcusone C activated mitogen-activated protein kinases, and the ERK inhibitor U0126 significantly attenuated the growth-inhibitory and apoptotic effects of Curcusone C in Ishikawa cells.	U 0126	89-94	mitogen-activated protein kinase 1	Homo sapiens	75-78
33435161-9	2021	U0126, an extracellular signal-regulated kinase (ERK) inhibitor, regulated the expression of LAMB1 in gastric cancer cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-47
33435161-9	2021	U0126, an extracellular signal-regulated kinase (ERK) inhibitor, regulated the expression of LAMB1 in gastric cancer cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	49-52
33435161-9	2021	U0126, an extracellular signal-regulated kinase (ERK) inhibitor, regulated the expression of LAMB1 in gastric cancer cells.	U 0126	0-5	laminin subunit beta 1	Homo sapiens	93-98
33407520-9	2021	Transfection with miR-29b mimic, siRNA-ETV4, or ERK signaling pathway inhibitor U0126 increased expression of E-cadherin and TSP-1, and CRC cell apoptosis, yet reduced expression of ERK1/2, MMP-2, MMP-9, Vimentin, and VEGF, as well as inhibiting EMT, angiogenesis, and CRC cell migration and invasion.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	48-51
33407520-9	2021	Transfection with miR-29b mimic, siRNA-ETV4, or ERK signaling pathway inhibitor U0126 increased expression of E-cadherin and TSP-1, and CRC cell apoptosis, yet reduced expression of ERK1/2, MMP-2, MMP-9, Vimentin, and VEGF, as well as inhibiting EMT, angiogenesis, and CRC cell migration and invasion.	U 0126	80-85	cadherin 1	Homo sapiens	110-120
33407520-9	2021	Transfection with miR-29b mimic, siRNA-ETV4, or ERK signaling pathway inhibitor U0126 increased expression of E-cadherin and TSP-1, and CRC cell apoptosis, yet reduced expression of ERK1/2, MMP-2, MMP-9, Vimentin, and VEGF, as well as inhibiting EMT, angiogenesis, and CRC cell migration and invasion.	U 0126	80-85	thrombospondin 1	Homo sapiens	125-130
33407520-9	2021	Transfection with miR-29b mimic, siRNA-ETV4, or ERK signaling pathway inhibitor U0126 increased expression of E-cadherin and TSP-1, and CRC cell apoptosis, yet reduced expression of ERK1/2, MMP-2, MMP-9, Vimentin, and VEGF, as well as inhibiting EMT, angiogenesis, and CRC cell migration and invasion.	U 0126	80-85	mitogen-activated protein kinase 3	Homo sapiens	182-188
32961216-6	2021	Furthermore, immunoblotting and treatment with U0126, an ERK (extracellular signal-regulated kinase) antagonist, showed that the ICSS-induced neurite outgrowth was related to neuronal ERK activity.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	57-60
32961216-6	2021	Furthermore, immunoblotting and treatment with U0126, an ERK (extracellular signal-regulated kinase) antagonist, showed that the ICSS-induced neurite outgrowth was related to neuronal ERK activity.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	62-99
32961216-6	2021	Furthermore, immunoblotting and treatment with U0126, an ERK (extracellular signal-regulated kinase) antagonist, showed that the ICSS-induced neurite outgrowth was related to neuronal ERK activity.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	184-187
33296781-10	2021	Moreover, inhibition of pERK1/2 signaling using U0126 decreased the expression of MMP-10 in ethanol-induced gastritis.	U 0126	48-53	matrix metallopeptidase 10	Mus musculus	82-88
33296781-11	2021	U0126 treatment also suppressed the expression of TNF-alpha, IL-1beta, and IL-8, and enhanced IL-10 expression in mice gastric mucosa.	U 0126	0-5	tumor necrosis factor	Mus musculus	50-59
33296781-11	2021	U0126 treatment also suppressed the expression of TNF-alpha, IL-1beta, and IL-8, and enhanced IL-10 expression in mice gastric mucosa.	U 0126	0-5	interleukin 1 alpha	Mus musculus	61-69
33296781-11	2021	U0126 treatment also suppressed the expression of TNF-alpha, IL-1beta, and IL-8, and enhanced IL-10 expression in mice gastric mucosa.	U 0126	0-5	chemokine (C-X-C motif) ligand 15	Mus musculus	75-79
33296781-11	2021	U0126 treatment also suppressed the expression of TNF-alpha, IL-1beta, and IL-8, and enhanced IL-10 expression in mice gastric mucosa.	U 0126	0-5	interleukin 10	Mus musculus	94-99
33277533-6	2020	P-ERK1/2 inhibition by U0126 in kidney epithelial cells resulted in decreased expression of LCN2.	U 0126	23-28	mitogen-activated protein kinase 3	Homo sapiens	2-8
33374849-8	2020	Treating MDA-MB-231 cells with U0126, a specific mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, blocked XCL1-induced HIF-1alpha accumulation and cell migration.	U 0126	31-36	mitogen-activated protein kinase kinase 1	Homo sapiens	90-98
33374849-8	2020	Treating MDA-MB-231 cells with U0126, a specific mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, blocked XCL1-induced HIF-1alpha accumulation and cell migration.	U 0126	31-36	X-C motif chemokine ligand 1	Homo sapiens	118-122
33374849-8	2020	Treating MDA-MB-231 cells with U0126, a specific mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, blocked XCL1-induced HIF-1alpha accumulation and cell migration.	U 0126	31-36	hypoxia inducible factor 1 subunit alpha	Homo sapiens	131-141
33320603-7	2020	However, the addition of the inhibitor U0126 sharply reduced the expression level of p-ERK, which indicated that alpha2beta1 integrin-mediated MEK/ERK signaling pathways play a key role in SMF-assisted cellular osteogenic differentiation over ZnFe2O4 coatings.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	87-90
33320603-7	2020	However, the addition of the inhibitor U0126 sharply reduced the expression level of p-ERK, which indicated that alpha2beta1 integrin-mediated MEK/ERK signaling pathways play a key role in SMF-assisted cellular osteogenic differentiation over ZnFe2O4 coatings.	U 0126	39-44	midkine	Mus musculus	143-146
33320603-7	2020	However, the addition of the inhibitor U0126 sharply reduced the expression level of p-ERK, which indicated that alpha2beta1 integrin-mediated MEK/ERK signaling pathways play a key role in SMF-assisted cellular osteogenic differentiation over ZnFe2O4 coatings.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	147-150
33391525-4	2021	ApoE deficient mice received ERK1/2 inhibitor (U0126) treatment, followed by determination of atherosclerosis, calcification and miR-126-3p production.	U 0126	47-52	apolipoprotein E	Mus musculus	0-4
33391525-8	2021	At cellular and animal levels, U0126 reduced intimal calcification in atherosclerotic lesions of high-fat diet-fed apoE deficient mice, medial arterial calcification in VD3-treated C57BL/6J mice, and calcification in cultured SMCs and arterial rings.	U 0126	31-36	apolipoprotein E	Mus musculus	115-119
33317626-15	2020	Additionally, ELA treatment induced the phosphorylation of AKT and ERK, while the blockade of PI3K/AKT and ERK1/2 pathways with respective inhibitors, LY294002 and U0126, suppressed the action of ELA.	U 0126	164-169	AKT serine/threonine kinase 1	Homo sapiens	99-102
33317626-15	2020	Additionally, ELA treatment induced the phosphorylation of AKT and ERK, while the blockade of PI3K/AKT and ERK1/2 pathways with respective inhibitors, LY294002 and U0126, suppressed the action of ELA.	U 0126	164-169	mitogen-activated protein kinase 3	Homo sapiens	107-113
33277533-6	2020	P-ERK1/2 inhibition by U0126 in kidney epithelial cells resulted in decreased expression of LCN2.	U 0126	23-28	lipocalin 2	Homo sapiens	92-96
32976922-11	2020	Meanwhile, U0126, an ERK1/2 inhibitor, further repressed ERK1/2-LKB1-AMPK pathway phosphorylation.	U 0126	11-16	mitogen-activated protein kinase 3	Mus musculus	21-27
32950025-8	2020	TSH-stimulated TSLP secretion from subcutaneous adipocytes was enhanced by IBMX (raises cAMP levels) and was blocked by UO126 (inhibitor of MEK1/2-ERK1/2).	U 0126	120-125	thymic stromal lymphopoietin	Homo sapiens	15-19
32950025-8	2020	TSH-stimulated TSLP secretion from subcutaneous adipocytes was enhanced by IBMX (raises cAMP levels) and was blocked by UO126 (inhibitor of MEK1/2-ERK1/2).	U 0126	120-125	mitogen-activated protein kinase kinase 1	Homo sapiens	140-146
32950025-8	2020	TSH-stimulated TSLP secretion from subcutaneous adipocytes was enhanced by IBMX (raises cAMP levels) and was blocked by UO126 (inhibitor of MEK1/2-ERK1/2).	U 0126	120-125	mitogen-activated protein kinase 3	Homo sapiens	147-153
33112787-6	2020	Further treatment with U0126, a specific ERK1/2 phosphorylation inhibitor, markedly suppressed PLAU/PLAUR-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	23-28	mitogen-activated protein kinase 3	Bos taurus	41-47
33112787-6	2020	Further treatment with U0126, a specific ERK1/2 phosphorylation inhibitor, markedly suppressed PLAU/PLAUR-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	23-28	plasminogen activator, urokinase	Bos taurus	95-99
33112787-6	2020	Further treatment with U0126, a specific ERK1/2 phosphorylation inhibitor, markedly suppressed PLAU/PLAUR-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	23-28	plasminogen activator, urokinase receptor	Bos taurus	100-105
33112787-6	2020	Further treatment with U0126, a specific ERK1/2 phosphorylation inhibitor, markedly suppressed PLAU/PLAUR-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	23-28	mitogen-activated protein kinase 3	Bos taurus	114-120
32976922-11	2020	Meanwhile, U0126, an ERK1/2 inhibitor, further repressed ERK1/2-LKB1-AMPK pathway phosphorylation.	U 0126	11-16	mitogen-activated protein kinase 3	Mus musculus	57-63
32976922-11	2020	Meanwhile, U0126, an ERK1/2 inhibitor, further repressed ERK1/2-LKB1-AMPK pathway phosphorylation.	U 0126	11-16	serine/threonine kinase 11	Mus musculus	64-68
33247374-6	2022	In addition, we showed that the phosphorylation levels of ERK1/2, JNK, and P38 were upregulated in apoptotic hUC-MSCs, while curcumin increased the phosphorylation of ERK1/2 but did not activate JNK or P38, and these effects were reversed by the p42/44 antagonist U0126.	U 0126	264-269	mitogen activated protein kinase 3	Rattus norvegicus	58-64
33260349-5	2020	The TGF-beta-induced increase in RSK1 phosphorylation was inhibited by TAPI-0 and U0126.	U 0126	82-87	transforming growth factor alpha	Homo sapiens	4-12
33260349-5	2020	The TGF-beta-induced increase in RSK1 phosphorylation was inhibited by TAPI-0 and U0126.	U 0126	82-87	ribosomal protein S6 kinase A1	Homo sapiens	33-37
33260349-6	2020	TGF-beta-induced C/EBPbeta phosphorylation was weakened by U0126, ADAM17 siRNA, and RSK1 siRNA.	U 0126	59-64	transforming growth factor alpha	Homo sapiens	0-8
33260349-6	2020	TGF-beta-induced C/EBPbeta phosphorylation was weakened by U0126, ADAM17 siRNA, and RSK1 siRNA.	U 0126	59-64	CCAAT enhancer binding protein alpha	Homo sapiens	17-26
33260349-3	2020	RESULTS: Our results revealed that TGF-beta-induced CTGF expression was weakened by ADAM17 small interfering RNA (ADAM17 siRNA), TNF-alpha processing inhibitor-0 (TAPI-0, an ADAM17 inhibitor), U0126 (an ERK inhibitor), RSK1 siRNA, and C/EBPbeta siRNA.	U 0126	193-198	transforming growth factor alpha	Homo sapiens	35-43
33260349-3	2020	RESULTS: Our results revealed that TGF-beta-induced CTGF expression was weakened by ADAM17 small interfering RNA (ADAM17 siRNA), TNF-alpha processing inhibitor-0 (TAPI-0, an ADAM17 inhibitor), U0126 (an ERK inhibitor), RSK1 siRNA, and C/EBPbeta siRNA.	U 0126	193-198	cellular communication network factor 2	Homo sapiens	52-56
33260349-3	2020	RESULTS: Our results revealed that TGF-beta-induced CTGF expression was weakened by ADAM17 small interfering RNA (ADAM17 siRNA), TNF-alpha processing inhibitor-0 (TAPI-0, an ADAM17 inhibitor), U0126 (an ERK inhibitor), RSK1 siRNA, and C/EBPbeta siRNA.	U 0126	193-198	ADAM metallopeptidase domain 17	Homo sapiens	84-90
33260349-4	2020	TGF-beta-induced ERK phosphorylation as well as ADAM17 phosphorylation was attenuated by U0126.	U 0126	89-94	transforming growth factor alpha	Homo sapiens	0-8
33260349-4	2020	TGF-beta-induced ERK phosphorylation as well as ADAM17 phosphorylation was attenuated by U0126.	U 0126	89-94	ADAM metallopeptidase domain 17	Homo sapiens	48-54
33247374-6	2022	In addition, we showed that the phosphorylation levels of ERK1/2, JNK, and P38 were upregulated in apoptotic hUC-MSCs, while curcumin increased the phosphorylation of ERK1/2 but did not activate JNK or P38, and these effects were reversed by the p42/44 antagonist U0126.	U 0126	264-269	mitogen activated protein kinase 3	Rattus norvegicus	167-173
33160389-6	2020	To identify the role of ERK1/2 in HMGB1-induced colon cancer cell proliferation, we performed western blotting and CCK8 assays using the ERK1/2-specific inhibitor U0126 in CT26 colon cancer cells.	U 0126	163-168	high mobility group box 1	Mus musculus	34-39
33293964-8	2020	The activation in ERK and p38 signals was detected in DIM-treated BMMSCs, and both pathways and osteogenic process were suppressed while using ERK inhibitor U0126 and p38 inhibitor SB203580, respectively.	U 0126	157-162	Eph receptor B1	Rattus norvegicus	18-21
33293964-8	2020	The activation in ERK and p38 signals was detected in DIM-treated BMMSCs, and both pathways and osteogenic process were suppressed while using ERK inhibitor U0126 and p38 inhibitor SB203580, respectively.	U 0126	157-162	mitogen activated protein kinase 14	Rattus norvegicus	26-29
33293964-8	2020	The activation in ERK and p38 signals was detected in DIM-treated BMMSCs, and both pathways and osteogenic process were suppressed while using ERK inhibitor U0126 and p38 inhibitor SB203580, respectively.	U 0126	157-162	Eph receptor B1	Rattus norvegicus	143-146
33160389-6	2020	To identify the role of ERK1/2 in HMGB1-induced colon cancer cell proliferation, we performed western blotting and CCK8 assays using the ERK1/2-specific inhibitor U0126 in CT26 colon cancer cells.	U 0126	163-168	mitogen-activated protein kinase 3	Mus musculus	137-143
32996643-6	2020	Using inhibition approaches, including pharmacological inhibition (a specific p38 inhibitor, SB203580, and a specific ERK1/2 inhibitor, U0126) and specific siRNA-mediated knockdown inhibition, we demonstrated that TGF-beta1 promoted the expression and production of COL1A1 in hGL cells, most likely via the ALK5-mediated p38 signaling pathway.	U 0126	136-141	transforming growth factor, beta 1	Mus musculus	214-223
33148869-11	2020	However, 5Z-7-oxozeaenol, SB203580 and U0126 only reversed the stimulatory effect of TGF-beta1 on ALP.	U 0126	39-44	transforming growth factor beta 1	Homo sapiens	85-94
33148869-11	2020	However, 5Z-7-oxozeaenol, SB203580 and U0126 only reversed the stimulatory effect of TGF-beta1 on ALP.	U 0126	39-44	alkaline phosphatase, placental	Homo sapiens	98-101
33334784-7	2020	Contrary to this, treatment of cells with U0126, a MAPK kinase inhibitor, significantly abrogated Btg2 expression.	U 0126	42-47	BTG anti-proliferation factor 2	Homo sapiens	98-102
32822804-7	2020	BD1047, a sigma-1 receptor antagonist, and U0126, an ERK inhibitor significantly induced the Nrf2-related antioxidant potential against behavioral sensitization.	U 0126	43-48	mitogen-activated protein kinase 1	Mus musculus	53-56
32822804-7	2020	BD1047, a sigma-1 receptor antagonist, and U0126, an ERK inhibitor significantly induced the Nrf2-related antioxidant potential against behavioral sensitization.	U 0126	43-48	nuclear factor, erythroid derived 2, like 2	Mus musculus	93-97
32716065-13	2020	SB203580 and U0126 blocked the effects of IL-25 through the inhibition of ERK, P38MAPK, P-ERK, P-P38MAPK.	U 0126	13-18	interleukin 25	Homo sapiens	42-47
32716065-13	2020	SB203580 and U0126 blocked the effects of IL-25 through the inhibition of ERK, P38MAPK, P-ERK, P-P38MAPK.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	74-77
32716065-13	2020	SB203580 and U0126 blocked the effects of IL-25 through the inhibition of ERK, P38MAPK, P-ERK, P-P38MAPK.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	90-93
32871684-7	2020	RESULT: Our results showed that the decreasing effects of CUMS and CSDS on the mTORC1 signaling cascade in the hippocampus and mPFC were restored by venlafaxine, and the use of rapamycin, LY294002, U0126 and mTORC1-shRNA fully abolished the anti-stress actions of venlafaxine in mice.	U 0126	198-203	CREB regulated transcription coactivator 1	Mus musculus	79-85
31729901-7	2020	Moreover, p38/MAPK inhibitor SB203580 and NF-kappaB inhibitor BAY11-7082 could block the IL-8 up-regulated by X-rays but JNK inhibitor SP600125, ERK inhibitor U0126, ROS Scavenger NAC could not inhibit this phenomenon.Conclusions: X-rays could induce IL-8 production in lung cancer cells, which may be related to the activation of p38/MAPK and NF-kappaB signaling pathway, providing a new point for elucidating the mechanism of radiation pneumonitis.	U 0126	159-164	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
33105690-7	2020	PI3K inhibitor (LY294002) and MEK inhibitor (U0126) were used to determine the signaling pathway in regulation of neuronal differentiation.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	30-33
32939933-8	2020	We also assessed that the adipogenic differentiation of hMSCs in which tsRNA-06018 was knocked down was further enhanced upon the addition of the ERK1/2 inhibitor U0126 as compared tsRNA-06018 knockdown alone.	U 0126	163-168	mitogen-activated protein kinase 3	Homo sapiens	146-152
31932202-4	2020	METHODS: SCAP cells were treated under different concentrations of bFGF with or without U0126 (an inhibitor of MEK/ERK).	U 0126	88-93	SREBF chaperone	Homo sapiens	9-13
31932202-4	2020	METHODS: SCAP cells were treated under different concentrations of bFGF with or without U0126 (an inhibitor of MEK/ERK).	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
31932202-4	2020	METHODS: SCAP cells were treated under different concentrations of bFGF with or without U0126 (an inhibitor of MEK/ERK).	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	115-118
31932202-10	2020	U0126 pretreatment and co-incubation attenuated the bFGF-induced proliferation, cdc2, cyclin B1 and TIMP-1 proteins" expression, but not type I collagen in SCAP.	U 0126	0-5	fibroblast growth factor 2	Homo sapiens	52-56
31932202-10	2020	U0126 pretreatment and co-incubation attenuated the bFGF-induced proliferation, cdc2, cyclin B1 and TIMP-1 proteins" expression, but not type I collagen in SCAP.	U 0126	0-5	cyclin dependent kinase 1	Homo sapiens	80-84
31932202-10	2020	U0126 pretreatment and co-incubation attenuated the bFGF-induced proliferation, cdc2, cyclin B1 and TIMP-1 proteins" expression, but not type I collagen in SCAP.	U 0126	0-5	cyclin B1	Homo sapiens	86-95
31932202-10	2020	U0126 pretreatment and co-incubation attenuated the bFGF-induced proliferation, cdc2, cyclin B1 and TIMP-1 proteins" expression, but not type I collagen in SCAP.	U 0126	0-5	TIMP metallopeptidase inhibitor 1	Homo sapiens	100-106
31932202-10	2020	U0126 pretreatment and co-incubation attenuated the bFGF-induced proliferation, cdc2, cyclin B1 and TIMP-1 proteins" expression, but not type I collagen in SCAP.	U 0126	0-5	SREBF chaperone	Homo sapiens	156-160
33118159-8	2021	LPA-induced TSP-1 mRNA expression was inhibited by U0126, MAPK/ERK kinase (MEK) inhibitor, but not SB202190, p38 MAPK inhibitor, or SP600125, JNK inhibitor.	U 0126	51-56	thrombospondin 1	Rattus norvegicus	12-17
33195147-10	2020	U0126 and SB2030580, but not PTx, inhibited the effect of Hst1.	U 0126	0-5	fibroblast growth factor 4	Homo sapiens	58-62
33000231-9	2020	Proliferation, invasion and EMT of OC cells were enhanced following overexpression of HOTTIP; however, these effects were reversed by the MEK/ERK pathway inhibitor U0126.	U 0126	164-169	HOXA distal transcript antisense RNA	Homo sapiens	86-92
33000231-9	2020	Proliferation, invasion and EMT of OC cells were enhanced following overexpression of HOTTIP; however, these effects were reversed by the MEK/ERK pathway inhibitor U0126.	U 0126	164-169	mitogen-activated protein kinase kinase 7	Homo sapiens	138-141
33000231-9	2020	Proliferation, invasion and EMT of OC cells were enhanced following overexpression of HOTTIP; however, these effects were reversed by the MEK/ERK pathway inhibitor U0126.	U 0126	164-169	mitogen-activated protein kinase 1	Homo sapiens	142-145
33097082-10	2020	Inhibition of ERK signaling pathway with U0126 or silencing ERK1/2 effectively blocked the stimulation of osteogenic differentiation induced by HSPB7 knockdown.	U 0126	41-46	mitogen-activated protein kinase 1	Mus musculus	14-17
33097082-10	2020	Inhibition of ERK signaling pathway with U0126 or silencing ERK1/2 effectively blocked the stimulation of osteogenic differentiation induced by HSPB7 knockdown.	U 0126	41-46	heat shock protein family, member 7 (cardiovascular)	Mus musculus	144-149
32659472-8	2020	Pretreatment of neutrophils with DPI, U0126 and SB202190 significantly reduced ROS generation, and prevented NET formation, further suggesting that ROS dependent activation of ERK 1/2 and p38 pathways, which possibly mediate FB1-induced NET release in neutrophils.	U 0126	38-43	mitogen-activated protein kinase 3	Bos taurus	176-183
32418930-3	2020	In vitro culture experiments showed that inhibiting activation of ERK1-2 with the MEK-specific inhibitor U0126 significantly reduced the growth of 8.5 dpc PGCs in culture but had little effect on 11.5-12.5 dpc PGCs.	U 0126	105-110	mitogen-activated protein kinase 3	Mus musculus	66-72
32418930-3	2020	In vitro culture experiments showed that inhibiting activation of ERK1-2 with the MEK-specific inhibitor U0126 significantly reduced the growth of 8.5 dpc PGCs in culture but had little effect on 11.5-12.5 dpc PGCs.	U 0126	105-110	midkine	Mus musculus	82-85
32659472-8	2020	Pretreatment of neutrophils with DPI, U0126 and SB202190 significantly reduced ROS generation, and prevented NET formation, further suggesting that ROS dependent activation of ERK 1/2 and p38 pathways, which possibly mediate FB1-induced NET release in neutrophils.	U 0126	38-43	mitogen-activated protein kinase 14	Bos taurus	188-191
33037575-8	2021	Conversely, U0126 and LY294002, which respectively inhibited phosphorylation of ERK1/2 and Akt, partially prevented S727 phosphorylation, but had limited effects on the level of pY705, suggesting that phosphorylation of Y705 and S727 is regulated via independent mechanisms in FD-treated brains.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	80-86
33037575-8	2021	Conversely, U0126 and LY294002, which respectively inhibited phosphorylation of ERK1/2 and Akt, partially prevented S727 phosphorylation, but had limited effects on the level of pY705, suggesting that phosphorylation of Y705 and S727 is regulated via independent mechanisms in FD-treated brains.	U 0126	12-17	AKT serine/threonine kinase 1	Homo sapiens	91-94
32180468-8	2020	Moreover, the expression of p-Erk/Nrf2/Trx-signaling pathway proteins was also up-regulated and the generation of ROS was decreased after LIRA treatment which was inhibited after treatment with U0126 (Erk inhibitor).	U 0126	194-199	mitogen-activated protein kinase 1	Homo sapiens	30-33
33036162-7	2020	Coadministration of PI3K class III inhibitor 3-methyladenine or MEK inhibitor U0126 suppressed pterostilbene-induced autophagy and reversed pterostilbene-enhanced cytotoxicity, but did not affect pterostilbene-elevated cell senescence in T24 cells.	U 0126	78-83	mitogen-activated protein kinase kinase 7	Homo sapiens	64-67
33209885-5	2020	Studies have shown that MAPK may be related to MGMT expression, U0126 is a highly selective inhibitor of MEK1 and MEK2, which were crucial molecule in cascade of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway.	U 0126	64-69	O-6-methylguanine-DNA methyltransferase	Homo sapiens	47-51
33209885-5	2020	Studies have shown that MAPK may be related to MGMT expression, U0126 is a highly selective inhibitor of MEK1 and MEK2, which were crucial molecule in cascade of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway.	U 0126	64-69	mitogen-activated protein kinase kinase 1	Homo sapiens	105-109
33209885-5	2020	Studies have shown that MAPK may be related to MGMT expression, U0126 is a highly selective inhibitor of MEK1 and MEK2, which were crucial molecule in cascade of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway.	U 0126	64-69	mitogen-activated protein kinase kinase 2	Homo sapiens	114-118
33209885-5	2020	Studies have shown that MAPK may be related to MGMT expression, U0126 is a highly selective inhibitor of MEK1 and MEK2, which were crucial molecule in cascade of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway.	U 0126	64-69	mitogen-activated protein kinase 1	Homo sapiens	239-242
33209885-7	2020	This research was aimed to investigate the efficacy of MAPK/ERK inhibitor U0126 and sorafenib combine with TMZ in the treatment of HCC.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	60-63
33209885-8	2020	Methods: In HCC cells, MAPK/ERK signaling pathway was blocked by U0126 and sorafenib.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	28-31
33209885-17	2020	Moreover, the results from RT-qPCR and Western blot showed that U0126 downregulated MGMT mRNA and MGMT protein expression via blocking MAPK/ERK pathway.	U 0126	64-69	O-6-methylguanine-DNA methyltransferase	Homo sapiens	84-88
33209885-17	2020	Moreover, the results from RT-qPCR and Western blot showed that U0126 downregulated MGMT mRNA and MGMT protein expression via blocking MAPK/ERK pathway.	U 0126	64-69	O-6-methylguanine-DNA methyltransferase	Homo sapiens	98-102
33209885-17	2020	Moreover, the results from RT-qPCR and Western blot showed that U0126 downregulated MGMT mRNA and MGMT protein expression via blocking MAPK/ERK pathway.	U 0126	64-69	mitogen-activated protein kinase 1	Homo sapiens	140-143
33209885-18	2020	Furthermore, after transfection with an MGMT expression plasmid, overexpression of MGMT restored U0126-induced chemosensitivity to TMZ in HCC cells.	U 0126	97-102	O-6-methylguanine-DNA methyltransferase	Homo sapiens	40-44
33209885-18	2020	Furthermore, after transfection with an MGMT expression plasmid, overexpression of MGMT restored U0126-induced chemosensitivity to TMZ in HCC cells.	U 0126	97-102	O-6-methylguanine-DNA methyltransferase	Homo sapiens	83-87
33116499-7	2020	Finally, the ERK phosphorylation is selectively upregulated on MNT surface and the AVs number and Arg1 expression are significantly suppressed by U0126 treatment.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	13-16
33116499-7	2020	Finally, the ERK phosphorylation is selectively upregulated on MNT surface and the AVs number and Arg1 expression are significantly suppressed by U0126 treatment.	U 0126	146-151	arginase 1	Homo sapiens	98-102
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	insulin like growth factor 1	Homo sapiens	77-82
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	microRNA 4286	Homo sapiens	91-99
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	insulin like growth factor 1	Homo sapiens	104-109
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	transforming growth factor beta 1	Homo sapiens	118-123
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	transforming growth factor beta receptor 2	Homo sapiens	124-130
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	160-163
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	164-167
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	insulin like growth factor 1	Homo sapiens	104-109
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	microRNA 4286	Homo sapiens	203-211
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	transforming growth factor alpha	Homo sapiens	212-220
32180468-8	2020	Moreover, the expression of p-Erk/Nrf2/Trx-signaling pathway proteins was also up-regulated and the generation of ROS was decreased after LIRA treatment which was inhibited after treatment with U0126 (Erk inhibitor).	U 0126	194-199	NFE2 like bZIP transcription factor 2	Homo sapiens	34-38
32180468-8	2020	Moreover, the expression of p-Erk/Nrf2/Trx-signaling pathway proteins was also up-regulated and the generation of ROS was decreased after LIRA treatment which was inhibited after treatment with U0126 (Erk inhibitor).	U 0126	194-199	thioredoxin	Homo sapiens	39-42
32180468-8	2020	Moreover, the expression of p-Erk/Nrf2/Trx-signaling pathway proteins was also up-regulated and the generation of ROS was decreased after LIRA treatment which was inhibited after treatment with U0126 (Erk inhibitor).	U 0126	194-199	mitogen-activated protein kinase 1	Homo sapiens	201-204
32602013-9	2020	Afterward, MEK1/2 was inhibited using a specific inhibitor U0126.	U 0126	59-64	mitogen-activated protein kinase kinase 1	Homo sapiens	11-17
32851798-8	2020	The ERK and P38 MAPK which activated by KLHDC8A overexpression could be reversed by U0126 and SB203580, respectively.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	4-7
32851798-8	2020	The ERK and P38 MAPK which activated by KLHDC8A overexpression could be reversed by U0126 and SB203580, respectively.	U 0126	84-89	kelch domain containing 8A	Homo sapiens	40-47
32865871-10	2020	Using a MAPK signaling-specific inhibitor, U0126, we could rescue the promotion of proliferation and viability in LMTK3 overexpressing cells.	U 0126	43-48	lemur tyrosine kinase 3	Homo sapiens	114-119
33041790-7	2020	Bmal1 overexpression relieved the alterations induced by IL-6, which was consistent with the effect of U0126 (an ERK inhibitor).	U 0126	103-108	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	0-5
32692865-14	2020	In contrast, PD98059 and U0126, inhibitors of the upstream activator of ERK-1/2 (ie, MEK-1/2) restored claudin-1 expression level as well as the epithelial barrier.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	72-79
32692865-14	2020	In contrast, PD98059 and U0126, inhibitors of the upstream activator of ERK-1/2 (ie, MEK-1/2) restored claudin-1 expression level as well as the epithelial barrier.	U 0126	25-30	mitogen-activated protein kinase kinase 1	Homo sapiens	85-92
32692865-14	2020	In contrast, PD98059 and U0126, inhibitors of the upstream activator of ERK-1/2 (ie, MEK-1/2) restored claudin-1 expression level as well as the epithelial barrier.	U 0126	25-30	claudin 1	Homo sapiens	103-112
33041790-7	2020	Bmal1 overexpression relieved the alterations induced by IL-6, which was consistent with the effect of U0126 (an ERK inhibitor).	U 0126	103-108	mitogen-activated protein kinase 1	Homo sapiens	113-116
32942306-8	2020	This signaling pathway contributed to cytoplasmic irradiation-induced adaptive response as supported by the observations that treatment with the mitochondrial superoxide scavenger mito-tempol, ERK 1/2 inhibitor U0126 or NRF2 inhibitor ML385 could repress the adaptive response.	U 0126	211-216	mitogen-activated protein kinase 3	Homo sapiens	193-200
32710959-3	2020	Rats were exposed to PM10 or filtered air for 2 to 4 months using a whole body exposure system, and intraperitoneally injected with the MEK1/2 inhibitor U0126.	U 0126	153-158	mitogen activated protein kinase kinase 1	Rattus norvegicus	136-142
32924599-6	2021	Furthermore, sustained activation of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 was observed wherein ERK1/2 (U0126) and p38 (SB203580) inhibitors confirmed crosstalk ERK1/2-Akt and MAPK intrinsic mitochondrial pathways.	U 0126	123-128	mitogen-activated protein kinase 3	Homo sapiens	115-121
32710959-10	2020	U0126 inhibited the PM10 exposure-induced upregulation of ETBR in pulmonary arteriole, ETBR-mediated pulmonary arterial hyperresponsiveness and vascular remodeling.	U 0126	0-5	endothelin receptor type B	Rattus norvegicus	58-62
32710959-10	2020	U0126 inhibited the PM10 exposure-induced upregulation of ETBR in pulmonary arteriole, ETBR-mediated pulmonary arterial hyperresponsiveness and vascular remodeling.	U 0126	0-5	endothelin receptor type B	Rattus norvegicus	87-91
32924599-6	2021	Furthermore, sustained activation of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 was observed wherein ERK1/2 (U0126) and p38 (SB203580) inhibitors confirmed crosstalk ERK1/2-Akt and MAPK intrinsic mitochondrial pathways.	U 0126	123-128	mitogen-activated protein kinase 3	Homo sapiens	115-121
32924599-6	2021	Furthermore, sustained activation of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 was observed wherein ERK1/2 (U0126) and p38 (SB203580) inhibitors confirmed crosstalk ERK1/2-Akt and MAPK intrinsic mitochondrial pathways.	U 0126	123-128	mitogen-activated protein kinase 3	Homo sapiens	79-85
32924599-6	2021	Furthermore, sustained activation of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 was observed wherein ERK1/2 (U0126) and p38 (SB203580) inhibitors confirmed crosstalk ERK1/2-Akt and MAPK intrinsic mitochondrial pathways.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	90-93
32924599-6	2021	Furthermore, sustained activation of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 was observed wherein ERK1/2 (U0126) and p38 (SB203580) inhibitors confirmed crosstalk ERK1/2-Akt and MAPK intrinsic mitochondrial pathways.	U 0126	123-128	AKT serine/threonine kinase 1	Homo sapiens	187-190
32407761-5	2020	Furthermore, the increase of NOS and extracellular signal regulated kinases1/2 (ERK1/2) phosphorylation mediated by APJ/B2R dimer can be inhibited by U0126 and U73122, respectively, suggesting that the heterodimer might activate the PLC/ERK1/2/eNOS signaling pathway, and finally leading to a significant increase in cell proliferation.	U 0126	150-155	mitogen-activated protein kinase 1	Homo sapiens	37-78
32747927-8	2020	These tumor promoting effects were mediated by GNB4 which activates the Erk1/2 pathway through upregulating Erk1/2 phosphorylation, as U0126, an Erk1/2 phosphorylation inhibitor, could significantly inhibit GNB4-mediated cell proliferation, migration and invasion.	U 0126	135-140	G protein subunit beta 4	Homo sapiens	47-51
32747927-8	2020	These tumor promoting effects were mediated by GNB4 which activates the Erk1/2 pathway through upregulating Erk1/2 phosphorylation, as U0126, an Erk1/2 phosphorylation inhibitor, could significantly inhibit GNB4-mediated cell proliferation, migration and invasion.	U 0126	135-140	mitogen-activated protein kinase 3	Homo sapiens	72-78
32747927-8	2020	These tumor promoting effects were mediated by GNB4 which activates the Erk1/2 pathway through upregulating Erk1/2 phosphorylation, as U0126, an Erk1/2 phosphorylation inhibitor, could significantly inhibit GNB4-mediated cell proliferation, migration and invasion.	U 0126	135-140	mitogen-activated protein kinase 3	Homo sapiens	108-114
32747927-8	2020	These tumor promoting effects were mediated by GNB4 which activates the Erk1/2 pathway through upregulating Erk1/2 phosphorylation, as U0126, an Erk1/2 phosphorylation inhibitor, could significantly inhibit GNB4-mediated cell proliferation, migration and invasion.	U 0126	135-140	mitogen-activated protein kinase 3	Homo sapiens	108-114
32747927-8	2020	These tumor promoting effects were mediated by GNB4 which activates the Erk1/2 pathway through upregulating Erk1/2 phosphorylation, as U0126, an Erk1/2 phosphorylation inhibitor, could significantly inhibit GNB4-mediated cell proliferation, migration and invasion.	U 0126	135-140	G protein subunit beta 4	Homo sapiens	207-211
32954764-4	2020	METHODS: We established a D-galactose-induced MCI rat model and evaluated the role of extracellularregulated kinase (ERK) signaling in HBO therapy for cognitive function using a specific inhibitor, U0126.	U 0126	198-203	Eph receptor B1	Rattus norvegicus	86-115
32954764-4	2020	METHODS: We established a D-galactose-induced MCI rat model and evaluated the role of extracellularregulated kinase (ERK) signaling in HBO therapy for cognitive function using a specific inhibitor, U0126.	U 0126	198-203	Eph receptor B1	Rattus norvegicus	117-120
32954764-11	2020	Caspase 3 levels also differed significantly, with lowest expression in the HBO group as compared to the MCI and U0126 groups.	U 0126	113-118	caspase 3	Rattus norvegicus	0-9
32963697-9	2020	Correspondingly, both the ERK1/2 inhibitor (U0126) and pan-caspase inhibitor (Z-VAD-FMK) could at least partially abolish the ADR-associated cytotoxicity in H9c2 cells.	U 0126	44-49	mitogen activated protein kinase 3	Rattus norvegicus	26-32
32407761-5	2020	Furthermore, the increase of NOS and extracellular signal regulated kinases1/2 (ERK1/2) phosphorylation mediated by APJ/B2R dimer can be inhibited by U0126 and U73122, respectively, suggesting that the heterodimer might activate the PLC/ERK1/2/eNOS signaling pathway, and finally leading to a significant increase in cell proliferation.	U 0126	150-155	mitogen-activated protein kinase 3	Homo sapiens	80-86
32407761-5	2020	Furthermore, the increase of NOS and extracellular signal regulated kinases1/2 (ERK1/2) phosphorylation mediated by APJ/B2R dimer can be inhibited by U0126 and U73122, respectively, suggesting that the heterodimer might activate the PLC/ERK1/2/eNOS signaling pathway, and finally leading to a significant increase in cell proliferation.	U 0126	150-155	mitogen-activated protein kinase 3	Homo sapiens	237-243
32407761-5	2020	Furthermore, the increase of NOS and extracellular signal regulated kinases1/2 (ERK1/2) phosphorylation mediated by APJ/B2R dimer can be inhibited by U0126 and U73122, respectively, suggesting that the heterodimer might activate the PLC/ERK1/2/eNOS signaling pathway, and finally leading to a significant increase in cell proliferation.	U 0126	150-155	nitric oxide synthase 3	Homo sapiens	244-248
32782506-6	2020	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 abrogated the FGF-1- and EGF-mediated suppression of MF marker expression.	U 0126	84-89	mitogen-activated protein kinase 1	Mus musculus	57-60
32782506-6	2020	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 abrogated the FGF-1- and EGF-mediated suppression of MF marker expression.	U 0126	84-89	midkine	Mus musculus	69-72
32782506-6	2020	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 abrogated the FGF-1- and EGF-mediated suppression of MF marker expression.	U 0126	84-89	fibroblast growth factor 1	Mus musculus	104-109
32782506-6	2020	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 abrogated the FGF-1- and EGF-mediated suppression of MF marker expression.	U 0126	84-89	epidermal growth factor	Mus musculus	115-118
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	U 0126	70-75	mitogen-activated protein kinase 3	Mus musculus	52-59
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	U 0126	70-75	cAMP responsive element binding protein 1	Mus musculus	160-164
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	U 0126	70-75	mitogen-activated protein kinase 3	Homo sapiens	52-57
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	U 0126	70-75	CREB regulated transcription coactivator 1	Mus musculus	190-196
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	U 0126	70-75	cAMP responsive element binding protein 1	Mus musculus	223-227
32582994-7	2020	The promoting effects of miR-143 knockdown on the osteogenic differentiation of hADSCs were partly diminished by the mitogen-activated protein kinase (MEK) inhibitors U0126 and PD98059.	U 0126	167-172	mitogen-activated protein kinase kinase 7	Homo sapiens	117-149
32582994-7	2020	The promoting effects of miR-143 knockdown on the osteogenic differentiation of hADSCs were partly diminished by the mitogen-activated protein kinase (MEK) inhibitors U0126 and PD98059.	U 0126	167-172	mitogen-activated protein kinase kinase 7	Homo sapiens	151-154
32843616-8	2020	Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK.	U 0126	54-59	mitogen-activated protein kinase kinase 1	Homo sapiens	26-32
32582994-7	2020	The promoting effects of miR-143 knockdown on the osteogenic differentiation of hADSCs were partly diminished by the mitogen-activated protein kinase (MEK) inhibitors U0126 and PD98059.	U 0126	167-172	microRNA 143	Homo sapiens	25-32
32794652-4	2020	U0126 (10 muM) inhibited JC105-mediated phosphorylation of ERK1/2 and DRP1 without affecting AKT or AMPK, which were also not regulated by JC105.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	59-65
32794652-4	2020	U0126 (10 muM) inhibited JC105-mediated phosphorylation of ERK1/2 and DRP1 without affecting AKT or AMPK, which were also not regulated by JC105.	U 0126	0-5	collapsin response mediator protein 1	Rattus norvegicus	70-74
32558188-10	2020	Stimulation of cultured rat cortical neurons, but not astrocyte, with BDNF, led to marked elevations in the mRNA levels of Vexin, which was inhibited in the presence of K252a and U0126.	U 0126	179-184	brain-derived neurotrophic factor	Rattus norvegicus	70-74
32843616-8	2020	Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK.	U 0126	54-59	mitogen-activated protein kinase kinase 1	Homo sapiens	26-30
32843616-8	2020	Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK.	U 0126	54-59	AKT serine/threonine kinase 1	Homo sapiens	137-140
32843616-8	2020	Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	26-29
32843616-9	2020	Furthermore, the combination of BMS-754807 and U0126 efficiently decreased the cell viability and increased cleaved caspase 3 and apoptosis in vitro and in vivo.	U 0126	47-52	caspase 3	Homo sapiens	116-125
32908568-13	2020	AD and the ERK1/2 inhibitor U0126 (10 mumol/L) inhibited VSMC proliferation and reduced the overexpression of miR-17~92a.	U 0126	28-33	mitogen activated protein kinase 3	Rattus norvegicus	11-17
33747277-9	2021	The cells were incubated with kaempferol alone or in combination with fulvestrant (an antagonist of ER) and U0126 (an inhibitor of ERK) in Abeta25-35 culture.	U 0126	108-113	Eph receptor B1	Rattus norvegicus	131-134
33747277-14	2021	Treatment with fulvestrant (an antagonist of ER) and U0126 (an inhibitor of ERK) significantly increased the apoptosis of PC-12 cells.	U 0126	53-58	Eph receptor B1	Rattus norvegicus	76-79
32908568-13	2020	AD and the ERK1/2 inhibitor U0126 (10 mumol/L) inhibited VSMC proliferation and reduced the overexpression of miR-17~92a.	U 0126	28-33	microRNA 17	Rattus norvegicus	110-116
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	secreted phosphoprotein 1	Homo sapiens	186-190
32512068-8	2020	Dasatinib, an inhibitor of p-Src, and U0126, an inhibitor of p-Erk1/2, down-regulated invasion and expression of CTSB by HCC70 and SUM149 cells, a mechanism that is reversed by IL-8 and MCP-1/CCL2.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	63-69
32512068-8	2020	Dasatinib, an inhibitor of p-Src, and U0126, an inhibitor of p-Erk1/2, down-regulated invasion and expression of CTSB by HCC70 and SUM149 cells, a mechanism that is reversed by IL-8 and MCP-1/CCL2.	U 0126	38-43	cathepsin B	Homo sapiens	113-117
32512068-8	2020	Dasatinib, an inhibitor of p-Src, and U0126, an inhibitor of p-Erk1/2, down-regulated invasion and expression of CTSB by HCC70 and SUM149 cells, a mechanism that is reversed by IL-8 and MCP-1/CCL2.	U 0126	38-43	C-X-C motif chemokine ligand 8	Homo sapiens	177-181
32512068-8	2020	Dasatinib, an inhibitor of p-Src, and U0126, an inhibitor of p-Erk1/2, down-regulated invasion and expression of CTSB by HCC70 and SUM149 cells, a mechanism that is reversed by IL-8 and MCP-1/CCL2.	U 0126	38-43	C-C motif chemokine ligand 2	Homo sapiens	186-191
32512068-8	2020	Dasatinib, an inhibitor of p-Src, and U0126, an inhibitor of p-Erk1/2, down-regulated invasion and expression of CTSB by HCC70 and SUM149 cells, a mechanism that is reversed by IL-8 and MCP-1/CCL2.	U 0126	38-43	C-C motif chemokine ligand 2	Homo sapiens	192-196
32450527-9	2020	Inhibition of ERK by inhibitor (U0126) significantly blocked high glucose-induced calcification, which further confirmed the significance of MAPKs.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	14-17
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	alkaline phosphatase, placental	Homo sapiens	118-121
32817784-7	2020	Finally, the MAPK pathway inhibitor UO126 attenuated diazoxide-induced upregulation of STIM1 and Orai1 expression.	U 0126	36-41	stromal interaction molecule 1	Rattus norvegicus	87-92
32817784-7	2020	Finally, the MAPK pathway inhibitor UO126 attenuated diazoxide-induced upregulation of STIM1 and Orai1 expression.	U 0126	36-41	ORAI calcium release-activated calcium modulator 1	Rattus norvegicus	97-102
32468069-7	2020	The current density of Nav1.7 was significantly increased in the SNI model and administration of AOAA and U0126 both significantly decreased the density.	U 0126	106-111	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	23-29
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	bone gamma-carboxyglutamate protein	Homo sapiens	179-184
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	collagen type I alpha 1 chain	Homo sapiens	192-198
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	200-205
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	AKT serine/threonine kinase 1	Homo sapiens	207-211
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	RUNX family transcription factor 2	Homo sapiens	213-218
32751124-8	2020	3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genes BGLAP, SPP1, COL1A1, MAPK1, AKT1, RUNX2, and GLI1 relative to untreated.	U 0126	79-84	GLI family zinc finger 1	Homo sapiens	224-228
32339486-9	2020	The PKA inhibitor H-89 (10 muM), and the MEK1/2 inhibitor U0126 (10 muM), also produced a significant reduction in the TPA response (~50%).	U 0126	58-63	mitogen-activated protein kinase kinase 1	Homo sapiens	41-47
32339486-12	2020	In conclusion, RAIG1/RAI3/GPRC5A corresponds to the originally reported PEIG-1/TIG1; the inhibition observed in the presence of Go 6983, BAPTA and U0126, suggests that its TPA-induced upregulation is mediated through a PKC/Ca2+  MEK1/2 signalling axis.	U 0126	147-152	G protein-coupled receptor class C group 5 member A	Homo sapiens	15-20
32339486-12	2020	In conclusion, RAIG1/RAI3/GPRC5A corresponds to the originally reported PEIG-1/TIG1; the inhibition observed in the presence of Go 6983, BAPTA and U0126, suggests that its TPA-induced upregulation is mediated through a PKC/Ca2+  MEK1/2 signalling axis.	U 0126	147-152	G protein-coupled receptor class C group 5 member A	Homo sapiens	21-25
32339486-12	2020	In conclusion, RAIG1/RAI3/GPRC5A corresponds to the originally reported PEIG-1/TIG1; the inhibition observed in the presence of Go 6983, BAPTA and U0126, suggests that its TPA-induced upregulation is mediated through a PKC/Ca2+  MEK1/2 signalling axis.	U 0126	147-152	G protein-coupled receptor class C group 5 member A	Homo sapiens	26-32
32339486-12	2020	In conclusion, RAIG1/RAI3/GPRC5A corresponds to the originally reported PEIG-1/TIG1; the inhibition observed in the presence of Go 6983, BAPTA and U0126, suggests that its TPA-induced upregulation is mediated through a PKC/Ca2+  MEK1/2 signalling axis.	U 0126	147-152	G protein-coupled receptor class C group 5 member A	Homo sapiens	72-78
32339486-12	2020	In conclusion, RAIG1/RAI3/GPRC5A corresponds to the originally reported PEIG-1/TIG1; the inhibition observed in the presence of Go 6983, BAPTA and U0126, suggests that its TPA-induced upregulation is mediated through a PKC/Ca2+  MEK1/2 signalling axis.	U 0126	147-152	G protein-coupled receptor class C group 5 member A	Homo sapiens	79-83
32339486-12	2020	In conclusion, RAIG1/RAI3/GPRC5A corresponds to the originally reported PEIG-1/TIG1; the inhibition observed in the presence of Go 6983, BAPTA and U0126, suggests that its TPA-induced upregulation is mediated through a PKC/Ca2+  MEK1/2 signalling axis.	U 0126	147-152	mitogen-activated protein kinase kinase 1	Homo sapiens	229-235
32482389-7	2020	Furthermore, the treatment with the ERK inhibitor U0126 and selective Ca2+-permeable AMPA receptor antagonist NASPM completely antagonized the effects of oxytocin.	U 0126	50-55	mitogen-activated protein kinase 1	Mus musculus	36-39
32456793-4	2020	Reverse phase protein array (RPPA) revealed that SNAIL (SNAI1) was upregulated in U0126 (MEK inhibitor)-treated LM2 cells.	U 0126	82-87	snail family zinc finger 1	Mus musculus	49-54
32456793-4	2020	Reverse phase protein array (RPPA) revealed that SNAIL (SNAI1) was upregulated in U0126 (MEK inhibitor)-treated LM2 cells.	U 0126	82-87	snail family zinc finger 1	Mus musculus	56-61
32456793-4	2020	Reverse phase protein array (RPPA) revealed that SNAIL (SNAI1) was upregulated in U0126 (MEK inhibitor)-treated LM2 cells.	U 0126	82-87	midkine	Mus musculus	89-92
32456793-6	2020	Furthermore, depletion of SNAIL led to reduced cell motility in U0126-treated LM2 cells.	U 0126	64-69	snail family zinc finger 1	Mus musculus	26-31
32463725-9	2020	Blockade of the ERK1/2 pathway by incubation with the MEK-specific inhibitor U0126 partially abolished 14-3-3gamma-mediated inhibition of BK protein expression.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	16-22
32733640-7	2020	UO126 and wortmannin, inhibitors of ERK1/2 and PI3K/Akt signalling pathways, respectively, prevented neuroprotective effects of quercetin.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	36-42
32733640-7	2020	UO126 and wortmannin, inhibitors of ERK1/2 and PI3K/Akt signalling pathways, respectively, prevented neuroprotective effects of quercetin.	U 0126	0-5	AKT serine/threonine kinase 1	Homo sapiens	52-55
32456793-5	2020	Importantly, LM2 cells simultaneously treated with U0126 and PI3K inhibitor LY294002 exhibited reduced expression of SNAIL.	U 0126	51-56	snail family zinc finger 1	Mus musculus	117-122
32660129-8	2020	We showed that the inhibition of MEK by the U0126 inhibitor rescued the osteoclast development of RAW264.7 induced by RANKL in a co-culture system with CK2.3.	U 0126	44-49	mitogen-activated protein kinase kinase 7	Homo sapiens	33-36
32660129-8	2020	We showed that the inhibition of MEK by the U0126 inhibitor rescued the osteoclast development of RAW264.7 induced by RANKL in a co-culture system with CK2.3.	U 0126	44-49	TNF superfamily member 11	Homo sapiens	118-123
32660129-8	2020	We showed that the inhibition of MEK by the U0126 inhibitor rescued the osteoclast development of RAW264.7 induced by RANKL in a co-culture system with CK2.3.	U 0126	44-49	keratin 23	Homo sapiens	152-157
32463725-9	2020	Blockade of the ERK1/2 pathway by incubation with the MEK-specific inhibitor U0126 partially abolished 14-3-3gamma-mediated inhibition of BK protein expression.	U 0126	77-82	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
32463725-9	2020	Blockade of the ERK1/2 pathway by incubation with the MEK-specific inhibitor U0126 partially abolished 14-3-3gamma-mediated inhibition of BK protein expression.	U 0126	77-82	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	Homo sapiens	103-114
31713744-5	2020	The MEK inhibitor U0126 was used to inhibit phosphorylation of ERK1/2 in the in vitro and in vivo models.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
32194168-2	2020	Phospho extracellular signal-regulated kinase1/2 (pERK1/2) expression in kidney and tumors was decreased by the MEK1/2 inhibitors, U0126 and trametinib, that potently inhibit pERK1/2.	U 0126	131-136	mitogen-activated protein kinase 3	Mus musculus	8-48
32194168-2	2020	Phospho extracellular signal-regulated kinase1/2 (pERK1/2) expression in kidney and tumors was decreased by the MEK1/2 inhibitors, U0126 and trametinib, that potently inhibit pERK1/2.	U 0126	131-136	mitogen activated protein kinase kinase 1	Rattus norvegicus	112-118
32194168-4	2020	Genes that were significantly decreased by U0126 were heat shock protein 1, cyclin-dependent kinase 4 (CDK4) and stratifin (14-3-3sigma).	U 0126	43-48	heat shock protein 1	Mus musculus	54-74
32194168-4	2020	Genes that were significantly decreased by U0126 were heat shock protein 1, cyclin-dependent kinase 4 (CDK4) and stratifin (14-3-3sigma).	U 0126	43-48	cyclin-dependent kinase 4	Mus musculus	76-101
32194168-4	2020	Genes that were significantly decreased by U0126 were heat shock protein 1, cyclin-dependent kinase 4 (CDK4) and stratifin (14-3-3sigma).	U 0126	43-48	cyclin-dependent kinase 4	Mus musculus	103-107
32194168-9	2020	The effect of U0126 to decrease AKI may be mediated by inhibition of heat shock protein 1, CDK4 or stratifin (14-3-3sigma).	U 0126	14-19	heat shock protein 1	Mus musculus	69-89
32194168-9	2020	The effect of U0126 to decrease AKI may be mediated by inhibition of heat shock protein 1, CDK4 or stratifin (14-3-3sigma).	U 0126	14-19	cyclin-dependent kinase 4	Mus musculus	91-95
31713744-5	2020	The MEK inhibitor U0126 was used to inhibit phosphorylation of ERK1/2 in the in vitro and in vivo models.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	63-69
31713744-7	2020	Treatment of the 3D culture with U0126 resulted in a reduced pERK1/2/ERK1/2 ratio.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	62-68
32339784-8	2020	In DOX-challenged neonatal mouse ventricular myocytes (NMVMs), LIEN-suppressed Drp1 phosphorylation, mitochondrial fragmentation, and apoptosis were blunted by Rab7 overexpression, the effect of which was reversed by the ERK inhibitor U0126.	U 0126	235-240	dynamin 1-like	Mus musculus	79-83
32377716-9	2020	Furthermore, the phosphorylation was sustained in HIKESHI-KD cells under MHT conditions, and this sustained phosphorylation was abolished by pretreatment with U0126, an inhibitor of mitogen-activated protein kinase/ERK.	U 0126	159-164	heat shock protein nuclear import factor hikeshi	Homo sapiens	50-57
32377716-9	2020	Furthermore, the phosphorylation was sustained in HIKESHI-KD cells under MHT conditions, and this sustained phosphorylation was abolished by pretreatment with U0126, an inhibitor of mitogen-activated protein kinase/ERK.	U 0126	159-164	mitogen-activated protein kinase 1	Homo sapiens	215-218
32377716-10	2020	In addition, U0126 significantly decreased the viability of cells treated with the combination of HIKESHI-KD and MHT.	U 0126	13-18	heat shock protein nuclear import factor hikeshi	Homo sapiens	98-105
32433749-7	2020	When HDAC8-knockdown cells were pretreated with the ERK inhibitor U0126, expression levels of CD163, activated caspases 3, 7 and 9, and the apoptosis rate, were rescued.	U 0126	66-71	histone deacetylase 8	Homo sapiens	5-10
32433749-7	2020	When HDAC8-knockdown cells were pretreated with the ERK inhibitor U0126, expression levels of CD163, activated caspases 3, 7 and 9, and the apoptosis rate, were rescued.	U 0126	66-71	mitogen-activated protein kinase 1	Homo sapiens	52-55
32433749-7	2020	When HDAC8-knockdown cells were pretreated with the ERK inhibitor U0126, expression levels of CD163, activated caspases 3, 7 and 9, and the apoptosis rate, were rescued.	U 0126	66-71	CD163 molecule	Homo sapiens	94-99
32433749-7	2020	When HDAC8-knockdown cells were pretreated with the ERK inhibitor U0126, expression levels of CD163, activated caspases 3, 7 and 9, and the apoptosis rate, were rescued.	U 0126	66-71	caspase 3	Homo sapiens	111-130
32339784-8	2020	In DOX-challenged neonatal mouse ventricular myocytes (NMVMs), LIEN-suppressed Drp1 phosphorylation, mitochondrial fragmentation, and apoptosis were blunted by Rab7 overexpression, the effect of which was reversed by the ERK inhibitor U0126.	U 0126	235-240	RAB7, member RAS oncogene family	Mus musculus	160-164
32553076-5	2020	PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	32-35
32596036-9	2020	Finally, we demonstrated that DAXX overexpression induced HUVECs apoptosis in the presence of normal Pi, whereas additional treatment with U0126 (a specific ERK inhibitor) reversed that effect.	U 0126	139-144	mitogen-activated protein kinase 1	Homo sapiens	157-160
32606741-8	2020	The PI3K inhibitor LY294002 or RAF-MEK-ERK inhibitor U0126 in combination with ELE and 5-FU decreased cell viability in both cell lines significantly, thereby showing the involvement of these pathways in cell apoptosis.	U 0126	53-58	zinc fingers and homeoboxes 2	Homo sapiens	31-34
32606741-8	2020	The PI3K inhibitor LY294002 or RAF-MEK-ERK inhibitor U0126 in combination with ELE and 5-FU decreased cell viability in both cell lines significantly, thereby showing the involvement of these pathways in cell apoptosis.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
32606741-8	2020	The PI3K inhibitor LY294002 or RAF-MEK-ERK inhibitor U0126 in combination with ELE and 5-FU decreased cell viability in both cell lines significantly, thereby showing the involvement of these pathways in cell apoptosis.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	39-42
31925325-5	2020	Cotreatment with IL-17 and specific TGFbeta receptor type I kinase inhibitor SB431542, or Erk 1/2 inhibitor U0126, abrogates the corresponding morphological changes and EMT phenotypic markers expression in healthy SGEC.	U 0126	108-113	mitogen-activated protein kinase 3	Homo sapiens	90-97
32398865-6	2020	Both the BET inhibitor JQ1 and the MEK inhibitor U0126 decreased the mRNA level of LAMB3 in multiple CRC cells.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
32398865-6	2020	Both the BET inhibitor JQ1 and the MEK inhibitor U0126 decreased the mRNA level of LAMB3 in multiple CRC cells.	U 0126	49-54	laminin subunit beta 3	Homo sapiens	83-88
32606806-11	2020	Additionally, we found that SSPH I could mediate the activation of MAPK/ERK1/2 signaling pathway, and the use of NAC (ROS inhibitor) and U0126 (MEK1/2 inhibitor) converted the effect of SSPH I on apoptosis and autophagy in HepG2 cells.	U 0126	137-142	mitogen-activated protein kinase 3	Homo sapiens	72-78
32606806-11	2020	Additionally, we found that SSPH I could mediate the activation of MAPK/ERK1/2 signaling pathway, and the use of NAC (ROS inhibitor) and U0126 (MEK1/2 inhibitor) converted the effect of SSPH I on apoptosis and autophagy in HepG2 cells.	U 0126	137-142	mitogen-activated protein kinase kinase 1	Homo sapiens	144-150
32187723-5	2020	Moreover, pre-treatment with the ERK inhibitor U0126 significantly and dose-dependently suppressed PAF-induced acrosome reaction.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	33-36
32187723-5	2020	Moreover, pre-treatment with the ERK inhibitor U0126 significantly and dose-dependently suppressed PAF-induced acrosome reaction.	U 0126	47-52	PCNA clamp associated factor	Homo sapiens	99-102
32553076-5	2020	PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1.	U 0126	46-51	AKT serine/threonine kinase 1	Homo sapiens	82-85
32553076-5	2020	PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	89-92
32553076-5	2020	PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1.	U 0126	46-51	actin alpha 1, skeletal muscle	Homo sapiens	97-106
32553076-5	2020	PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1.	U 0126	46-51	cadherin 1	Homo sapiens	140-150
32553076-5	2020	PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1.	U 0126	46-51	claudin 1	Homo sapiens	155-164
32489459-7	2020	Pretreatment of cells with U0126 could reverse the nuclear translocation of NF-kappaB/p50 and p65 and EMT induced by IL-17A.	U 0126	27-32	nuclear factor kappa B subunit 1	Homo sapiens	76-86
32489459-7	2020	Pretreatment of cells with U0126 could reverse the nuclear translocation of NF-kappaB/p50 and p65 and EMT induced by IL-17A.	U 0126	27-32	nuclear factor kappa B subunit 1	Homo sapiens	86-89
32489459-7	2020	Pretreatment of cells with U0126 could reverse the nuclear translocation of NF-kappaB/p50 and p65 and EMT induced by IL-17A.	U 0126	27-32	RELA proto-oncogene, NF-kB subunit	Homo sapiens	94-97
32489459-7	2020	Pretreatment of cells with U0126 could reverse the nuclear translocation of NF-kappaB/p50 and p65 and EMT induced by IL-17A.	U 0126	27-32	interleukin 17A	Homo sapiens	117-123
32398643-5	2020	Recordings from LC neurons in brain slices showed that the inhibition of ERK1/2 with U0126 and FR180204 accelerated the decay of whole-cell membrane current induced by prolonged baclofen application.	U 0126	85-90	mitogen-activated protein kinase 3	Homo sapiens	73-79
32414345-13	2020	This activation is essential for the apoptotic affect by GT3 as demonstrated the complete inhibition of apoptosis by MEK1 inhibitor U0126.	U 0126	132-137	mitogen-activated protein kinase kinase 1	Homo sapiens	117-121
32395078-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	U 0126	101-106	mitogen-activated protein kinase 1	Mus musculus	75-78
31955434-9	2020	U0126 attenuated the TGF-beta1-induced expression/secretion of uPAR, but not PAI-1 in SCAP.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	21-30
31955434-9	2020	U0126 attenuated the TGF-beta1-induced expression/secretion of uPAR, but not PAI-1 in SCAP.	U 0126	0-5	plasminogen activator, urokinase receptor	Homo sapiens	63-67
31943528-7	2020	Eotaxin-1 expression was inhibited in cells treated with the FGFR tyrosine kinase inhibitor and extracellular signal-regulated kinase (ERK) inhibitor U0126, even in the presence of FGF-2.	U 0126	150-155	C-C motif chemokine ligand 11	Homo sapiens	0-9
31943528-7	2020	Eotaxin-1 expression was inhibited in cells treated with the FGFR tyrosine kinase inhibitor and extracellular signal-regulated kinase (ERK) inhibitor U0126, even in the presence of FGF-2.	U 0126	150-155	mitogen-activated protein kinase 1	Homo sapiens	96-133
31943528-7	2020	Eotaxin-1 expression was inhibited in cells treated with the FGFR tyrosine kinase inhibitor and extracellular signal-regulated kinase (ERK) inhibitor U0126, even in the presence of FGF-2.	U 0126	150-155	mitogen-activated protein kinase 1	Homo sapiens	135-138
31943528-8	2020	Moreover, eotaxin-1 expression was synergistically enhanced by combined treatment with FGF-2 and IL-4 and inhibited in the presence of U0126.	U 0126	135-140	C-C motif chemokine ligand 11	Homo sapiens	10-19
32392918-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	U 0126	101-106	mitogen-activated protein kinase 1	Mus musculus	75-78
32392918-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	U 0126	101-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
32395078-7	2020	Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis.	U 0126	101-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
32145408-7	2020	Correspondingly, the disruption of the epigenetic regulation induced by ERK1/2 signaling through an intra-hippocampal injection of the MEK antagonist U0126 or GluN2A-selective pharmacological antagonist NVP-AAM077 blocked context-dependent memory formation, while no changes were observed after treatment with the GluN2B-selective antagonist Ro25-6981.	U 0126	150-155	mitogen-activated protein kinase 3	Mus musculus	72-78
31907582-7	2020	In addition, CsA-induced ERK phosphorylation was highly reduced in the presence of either neutralizing anti-heparin-binding-epidermal growth factor (HB-EGF) antibody or UO126 (MEK inhibitor).	U 0126	169-174	chorionic somatomammotropin hormone 1	Homo sapiens	13-16
31907582-7	2020	In addition, CsA-induced ERK phosphorylation was highly reduced in the presence of either neutralizing anti-heparin-binding-epidermal growth factor (HB-EGF) antibody or UO126 (MEK inhibitor).	U 0126	169-174	mitogen-activated protein kinase 1	Homo sapiens	25-28
31907582-9	2020	Furthermore, CsA-induced cell proliferation was strongly reduced in the presence of either PEG-SOD or TAPI-2 or neutralizing anti-ADAM17 antibody or neutralizing anti-HB-EGF antibody or AG1478 or UO126.	U 0126	196-201	chorionic somatomammotropin hormone 1	Homo sapiens	13-16
32145408-7	2020	Correspondingly, the disruption of the epigenetic regulation induced by ERK1/2 signaling through an intra-hippocampal injection of the MEK antagonist U0126 or GluN2A-selective pharmacological antagonist NVP-AAM077 blocked context-dependent memory formation, while no changes were observed after treatment with the GluN2B-selective antagonist Ro25-6981.	U 0126	150-155	midkine	Mus musculus	135-138
31958455-5	2020	Pretreatment with diphenyleneiodonium (an NADPH oxidase inhibitor) and U0126 or PD98059 (MEK Inhibitors) inhibited PDGF-BB-induced BMAL1 expression in a dose-dependent manner in VSMCs.	U 0126	71-76	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	131-136
32354204-6	2020	We showed that GLI transcript levels were down-regulated by the MEK inhibitor U0126 and the Raf inhibitor sorafenib, suggesting that non-canonical signaling including the Ras-Raf-MEK-ERK pathway is involved.	U 0126	78-83	GLI family zinc finger 1	Homo sapiens	15-18
32354204-6	2020	We showed that GLI transcript levels were down-regulated by the MEK inhibitor U0126 and the Raf inhibitor sorafenib, suggesting that non-canonical signaling including the Ras-Raf-MEK-ERK pathway is involved.	U 0126	78-83	mitogen-activated protein kinase kinase 7	Homo sapiens	64-67
32354204-6	2020	We showed that GLI transcript levels were down-regulated by the MEK inhibitor U0126 and the Raf inhibitor sorafenib, suggesting that non-canonical signaling including the Ras-Raf-MEK-ERK pathway is involved.	U 0126	78-83	mitogen-activated protein kinase kinase 7	Homo sapiens	179-182
32354204-6	2020	We showed that GLI transcript levels were down-regulated by the MEK inhibitor U0126 and the Raf inhibitor sorafenib, suggesting that non-canonical signaling including the Ras-Raf-MEK-ERK pathway is involved.	U 0126	78-83	mitogen-activated protein kinase 1	Homo sapiens	183-186
32276610-10	2020	However, an AKT inhibitor (LY294002), an ERK inhibitor (U0126), a JNK inhibitor (SP600125), and a p38 inhibitor (SB203580) inhibited the increase of mineralization induced by PTHrP.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	41-44
32299362-9	2020	In addition, the ERK pathway inhibitor, U0126 (10 muM), significantly reversed the positive effect of TNF-alpha on the protein levels of RUNX2 and BSP.	U 0126	40-45	mitogen-activated protein kinase 1	Mus musculus	17-20
32299362-9	2020	In addition, the ERK pathway inhibitor, U0126 (10 muM), significantly reversed the positive effect of TNF-alpha on the protein levels of RUNX2 and BSP.	U 0126	40-45	tumor necrosis factor	Mus musculus	102-111
32299362-9	2020	In addition, the ERK pathway inhibitor, U0126 (10 muM), significantly reversed the positive effect of TNF-alpha on the protein levels of RUNX2 and BSP.	U 0126	40-45	runt related transcription factor 2	Mus musculus	137-142
32299362-9	2020	In addition, the ERK pathway inhibitor, U0126 (10 muM), significantly reversed the positive effect of TNF-alpha on the protein levels of RUNX2 and BSP.	U 0126	40-45	black spleen	Mus musculus	147-150
32341653-11	2020	Western blotting analysis revealed that Rap2c overexpression increased the phosphorylation level of extracellular signal-related kinase1/2 (ERK1/2), and this effect was abolished with U0126, a selective MEK inhibitor.	U 0126	184-189	RAP2C, member of RAS oncogene family	Homo sapiens	40-45
32341653-11	2020	Western blotting analysis revealed that Rap2c overexpression increased the phosphorylation level of extracellular signal-related kinase1/2 (ERK1/2), and this effect was abolished with U0126, a selective MEK inhibitor.	U 0126	184-189	mitogen-activated protein kinase 3	Homo sapiens	100-138
32341653-11	2020	Western blotting analysis revealed that Rap2c overexpression increased the phosphorylation level of extracellular signal-related kinase1/2 (ERK1/2), and this effect was abolished with U0126, a selective MEK inhibitor.	U 0126	184-189	mitogen-activated protein kinase 3	Homo sapiens	140-146
32341653-11	2020	Western blotting analysis revealed that Rap2c overexpression increased the phosphorylation level of extracellular signal-related kinase1/2 (ERK1/2), and this effect was abolished with U0126, a selective MEK inhibitor.	U 0126	184-189	mitogen-activated protein kinase kinase 7	Homo sapiens	203-206
32112164-9	2020	What"s more, similar effects of ERK1/2 inhibitor U0126 with Xuefu Zhuyu decoction proved the involvement of ERK1/2 signaling pathway.	U 0126	49-54	mitogen activated protein kinase 3	Rattus norvegicus	32-38
31986415-11	2020	ERK inhibitor U0126 reduced MIF-induced the increase in integrin-beta1 mRNA and protein expression following MIF stimulation.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	0-3
31986415-11	2020	ERK inhibitor U0126 reduced MIF-induced the increase in integrin-beta1 mRNA and protein expression following MIF stimulation.	U 0126	14-19	macrophage migration inhibitory factor	Homo sapiens	28-31
31986415-11	2020	ERK inhibitor U0126 reduced MIF-induced the increase in integrin-beta1 mRNA and protein expression following MIF stimulation.	U 0126	14-19	integrin subunit beta 1	Homo sapiens	56-70
31986415-11	2020	ERK inhibitor U0126 reduced MIF-induced the increase in integrin-beta1 mRNA and protein expression following MIF stimulation.	U 0126	14-19	macrophage migration inhibitory factor	Homo sapiens	109-112
31986415-13	2020	MIF-induced increase in cyclin D1 mRNA level also was inhibited only by U0126 following MIF stimulation.	U 0126	72-77	macrophage migration inhibitory factor	Homo sapiens	0-3
31986415-13	2020	MIF-induced increase in cyclin D1 mRNA level also was inhibited only by U0126 following MIF stimulation.	U 0126	72-77	cyclin D1	Homo sapiens	24-33
31986415-13	2020	MIF-induced increase in cyclin D1 mRNA level also was inhibited only by U0126 following MIF stimulation.	U 0126	72-77	macrophage migration inhibitory factor	Homo sapiens	88-91
32112164-9	2020	What"s more, similar effects of ERK1/2 inhibitor U0126 with Xuefu Zhuyu decoction proved the involvement of ERK1/2 signaling pathway.	U 0126	49-54	mitogen activated protein kinase 3	Rattus norvegicus	108-114
32329847-5	2020	RESULTS: Compared with Control group, miR-214 mimics group exhibited increased expression of miR-214 in oral cancer cells (p<0.01), extremely raised expression levels of p-ERK and PCNA, but an extremely decreased protein expression level of p21 (p<0.01), whereas miR-214 mimics + U0126 group had remarkably lower levels of p-ERK and PCNA, and a considerably higher protein level of p21 than miR-214 mimics group (p<0.05).	U 0126	280-285	microRNA 214	Homo sapiens	38-45
32329847-8	2020	Finally, it was found through the Hoechst apoptosis assay that compared with that in Control group, the cell apoptosis was notably inhibited in miR-214 mimics group, and it was greatly increased in miR-214 mimics + U0126 group.	U 0126	215-220	microRNA 214	Homo sapiens	198-205
31982135-5	2020	Treatment of cells using the ERK inhibitor U0126 disrupted this ERK1/2 phosphorylation and restored the adipogenic differentiation of these hMSCs.	U 0126	43-48	mitogen-activated protein kinase 1	Homo sapiens	29-32
32026128-5	2020	U0126, an inhibitor of MAPK/ERK, significantly prevented LIPUS-induced expression of Fos and Egr1, but not that of Jun and Ptgs2.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	23-27
32026128-5	2020	U0126, an inhibitor of MAPK/ERK, significantly prevented LIPUS-induced expression of Fos and Egr1, but not that of Jun and Ptgs2.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	28-31
32026128-5	2020	U0126, an inhibitor of MAPK/ERK, significantly prevented LIPUS-induced expression of Fos and Egr1, but not that of Jun and Ptgs2.	U 0126	0-5	early growth response 1	Mus musculus	93-97
32244796-7	2020	Cotreatment with PC and U0126 synergistically inhibited CTSD expression, cell migration, and cell invasion, which suggests that the ERK1/2 signalling pathway is involved in the downregulation of CTSD expression and invasion activity of NSCLC cells by PC.	U 0126	24-29	cathepsin D	Homo sapiens	56-60
32244796-7	2020	Cotreatment with PC and U0126 synergistically inhibited CTSD expression, cell migration, and cell invasion, which suggests that the ERK1/2 signalling pathway is involved in the downregulation of CTSD expression and invasion activity of NSCLC cells by PC.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	132-138
32244796-7	2020	Cotreatment with PC and U0126 synergistically inhibited CTSD expression, cell migration, and cell invasion, which suggests that the ERK1/2 signalling pathway is involved in the downregulation of CTSD expression and invasion activity of NSCLC cells by PC.	U 0126	24-29	cathepsin D	Homo sapiens	195-199
32230861-7	2020	The specific MAPK inhibitors, U0126, SP600125, and SB203580, suppressed LPS-stimulated pro-inflammatory mediators, cell migration, and NF-kappaB nuclear translocation, indicating that MAPKs may be the upstream kinase of NF-kappaB signaling.	U 0126	30-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	135-144
32230861-7	2020	The specific MAPK inhibitors, U0126, SP600125, and SB203580, suppressed LPS-stimulated pro-inflammatory mediators, cell migration, and NF-kappaB nuclear translocation, indicating that MAPKs may be the upstream kinase of NF-kappaB signaling.	U 0126	30-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	220-229
31982135-5	2020	Treatment of cells using the ERK inhibitor U0126 disrupted this ERK1/2 phosphorylation and restored the adipogenic differentiation of these hMSCs.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	64-70
32266254-9	2020	Our in vitro experimental results confirmed that both LY294002 and U0126 largely abolished the protective effect of FGF2.	U 0126	67-72	fibroblast growth factor 2	Rattus norvegicus	116-120
31942645-5	2020	We have previously shown that the MEK/ERK inhibitor U0126 inhibits the replication of the flavivirus yellow fever virus.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
31968212-7	2020	Inhibitors of the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) pathway (U0126 and PD0325901) suppressed the uptake of acetylated-LDL (Ac-LDL) and the expression of CD204 but not CD36 in LPS-activated macrophages.	U 0126	84-89	mitogen-activated protein kinase 1	Mus musculus	58-61
31881249-5	2020	Decreasing of DKK1 expression reduces the phosphorylation of ERK1/2 and MEK1/2 increased by A1CF overexpression; further, inhibiting of the phosphorylation of MEK1/2 by U0126 also decreases the ERK activation upregulated by A1CF overexpression.	U 0126	169-174	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	14-18
31881249-5	2020	Decreasing of DKK1 expression reduces the phosphorylation of ERK1/2 and MEK1/2 increased by A1CF overexpression; further, inhibiting of the phosphorylation of MEK1/2 by U0126 also decreases the ERK activation upregulated by A1CF overexpression.	U 0126	169-174	mitogen-activated protein kinase kinase 1	Homo sapiens	159-165
31881249-6	2020	Deficiency of DKK1 or U0126 treatment suppresses the cell proliferation promoted by A1CF overexpression in 786-O cells; furthermore, U0126 treatment inhibits DKK1-increased cell proliferation in 786-O cells.	U 0126	22-27	APOBEC1 complementation factor	Homo sapiens	84-88
31881249-6	2020	Deficiency of DKK1 or U0126 treatment suppresses the cell proliferation promoted by A1CF overexpression in 786-O cells; furthermore, U0126 treatment inhibits DKK1-increased cell proliferation in 786-O cells.	U 0126	133-138	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	14-18
31881249-6	2020	Deficiency of DKK1 or U0126 treatment suppresses the cell proliferation promoted by A1CF overexpression in 786-O cells; furthermore, U0126 treatment inhibits DKK1-increased cell proliferation in 786-O cells.	U 0126	133-138	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	158-162
32143008-9	2020	While treatment with 5-HT1AR agonist 8-OH-DPAT or ERK inhibitor U0126 exerted no effects or even aggravated Abeta-induced learning and memory decline.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	50-53
31770110-7	2020	Stress-induced up regulation of ABCB1 was mitigated by combined use of pharmacologic inhibitors U0126 and ISRIB, which inhibit stress signalling and have potential for use as adjuvants to enhance the activity of ABCB1 inhibitors.	U 0126	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	32-37
31770110-7	2020	Stress-induced up regulation of ABCB1 was mitigated by combined use of pharmacologic inhibitors U0126 and ISRIB, which inhibit stress signalling and have potential for use as adjuvants to enhance the activity of ABCB1 inhibitors.	U 0126	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	212-217
31942645-5	2020	We have previously shown that the MEK/ERK inhibitor U0126 inhibits the replication of the flavivirus yellow fever virus.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	38-41
31805308-5	2020	U0126 significantly reversed the testosterone-mediated phosphorylation of CREB.	U 0126	0-5	cAMP responsive element binding protein 1	Rattus norvegicus	74-78
31901549-5	2020	The addition of IL-17A (25-100 mug) to human renal proximal tubular cells or renal fibroblasts caused an increase in fibronectin production and extracellular signal-regulated kinase (ERK)1/2 activation, which were reduced upon pretreatment with the ERK inhibitor U0126.	U 0126	263-268	interleukin 17A	Homo sapiens	16-22
31901549-5	2020	The addition of IL-17A (25-100 mug) to human renal proximal tubular cells or renal fibroblasts caused an increase in fibronectin production and extracellular signal-regulated kinase (ERK)1/2 activation, which were reduced upon pretreatment with the ERK inhibitor U0126.	U 0126	263-268	mitogen-activated protein kinase 3	Homo sapiens	144-190
32104150-10	2020	U0126 (inhibiting p-ERK1/2) and SB202190 (inhibiting p38) decreased the contents of MCP-1, sICAM-1, and sVCAM-1, but SP600125 (inhibiting p-JNK1/2) had none of these effects.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	20-26
32392192-12	2020	These effects were attenuated by luzindole, a melatonin receptor antagonist and U0126, an inhibitor of p-ERK activation.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	105-108
31746084-6	2020	Furthermore, stimulation of MSC migration induced by Yoda1 as well as ATP was suppressed by PF431396, a PYK2 kinase inhibitor, or U0126, an inhibitor of the mitogen-activated protein kinase MEK/ERK signaling pathway.	U 0126	130-135	mitogen-activated protein kinase kinase 7	Homo sapiens	190-193
32104150-10	2020	U0126 (inhibiting p-ERK1/2) and SB202190 (inhibiting p38) decreased the contents of MCP-1, sICAM-1, and sVCAM-1, but SP600125 (inhibiting p-JNK1/2) had none of these effects.	U 0126	0-5	mitogen-activated protein kinase 8	Homo sapiens	140-146
32049100-9	2020	The results in the SULF2 group were quite the opposite in which SULF2 facilitated the growth of cervical cancer cells, which was reversed by LY294002 or U0126.	U 0126	153-158	sulfatase 2	Mus musculus	19-24
32049100-9	2020	The results in the SULF2 group were quite the opposite in which SULF2 facilitated the growth of cervical cancer cells, which was reversed by LY294002 or U0126.	U 0126	153-158	sulfatase 2	Mus musculus	64-69
31894254-8	2020	In addition, LY294002, an Akt inhibitor, inhibited the phosphorylation of ERK, and U0126, an ERK inhibitor, inhibited the phosphorylation of Akt.	U 0126	83-88	mitogen-activated protein kinase 1	Homo sapiens	93-96
31784089-1	2020	Combined LXR ligand (T0901317) and MEK1/2 inhibitor (U0126) not only reduces atherosclerosis in apoE deficient mice, but also blocks LXR ligand-induced fatty liver and hypertriglyceridemia.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Mus musculus	35-41
31784089-1	2020	Combined LXR ligand (T0901317) and MEK1/2 inhibitor (U0126) not only reduces atherosclerosis in apoE deficient mice, but also blocks LXR ligand-induced fatty liver and hypertriglyceridemia.	U 0126	53-58	apolipoprotein E	Mus musculus	96-100
31784089-1	2020	Combined LXR ligand (T0901317) and MEK1/2 inhibitor (U0126) not only reduces atherosclerosis in apoE deficient mice, but also blocks LXR ligand-induced fatty liver and hypertriglyceridemia.	U 0126	53-58	nuclear receptor subfamily 1, group H, member 3	Mus musculus	133-136
32116715-6	2020	Significantly, U0126, a selective noncompetitive inhibitor of MAP kinase kinases (MKK), largely abolished the protective role of FGF10.	U 0126	15-20	fibroblast growth factor 10	Rattus norvegicus	129-134
31784089-8	2020	Mechanistically, U0126 reduced fatty acid de novo synthesis by inhibiting hepatic fatty acid synthase (FASN) expression, thereby correcting T0901317-induced triglyceride overproduction.	U 0126	17-22	fatty acid synthase	Mus musculus	82-101
31784089-8	2020	Mechanistically, U0126 reduced fatty acid de novo synthesis by inhibiting hepatic fatty acid synthase (FASN) expression, thereby correcting T0901317-induced triglyceride overproduction.	U 0126	17-22	fatty acid synthase	Mus musculus	103-107
31812679-5	2020	Only the ERK1/2 inhibitor U0126 but not the other inhibitors examined (including those inhibiting the unconventional secretion of FGF2) was able to reduce ouabain-induced FGF2 secretion and FGFR1 activation.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	9-15
31812679-5	2020	Only the ERK1/2 inhibitor U0126 but not the other inhibitors examined (including those inhibiting the unconventional secretion of FGF2) was able to reduce ouabain-induced FGF2 secretion and FGFR1 activation.	U 0126	26-31	fibroblast growth factor 2	Homo sapiens	130-134
31812679-5	2020	Only the ERK1/2 inhibitor U0126 but not the other inhibitors examined (including those inhibiting the unconventional secretion of FGF2) was able to reduce ouabain-induced FGF2 secretion and FGFR1 activation.	U 0126	26-31	fibroblast growth factor 2	Homo sapiens	171-175
31812679-5	2020	Only the ERK1/2 inhibitor U0126 but not the other inhibitors examined (including those inhibiting the unconventional secretion of FGF2) was able to reduce ouabain-induced FGF2 secretion and FGFR1 activation.	U 0126	26-31	fibroblast growth factor receptor 1	Homo sapiens	190-195
31907536-11	2020	Prostaglandin production was inhibited by rofecoxib, pertussin toxin, and ERK inhibitor U0126.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	74-77
31894254-8	2020	In addition, LY294002, an Akt inhibitor, inhibited the phosphorylation of ERK, and U0126, an ERK inhibitor, inhibited the phosphorylation of Akt.	U 0126	83-88	AKT serine/threonine kinase 1	Homo sapiens	141-144
31509344-9	2020	Furthermore, HAMSC effects were markedly blunted by pretreatment with APPL1 siRNA and U0126, an ERK1/2 signaling inhibitor with high selectivity.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	96-102
31770525-5	2020	The presence of PI3K inhibitor (LY294002) or MEK inhibitor (U0126) or prior silencing of beta-catenin with siRNA suppressed LTB4-induced cyclin D1 up-regulation and PASMCs proliferation.	U 0126	60-65	cyclin D1	Rattus norvegicus	137-146
31974343-3	2020	TFPT-BTAN-AO shows an exceptional UO22+ adsorption capacity of 427 mg g-1 attributable to the abundant selective uranium-binding groups on the highly accessible pore walls of open 1D channels.	U 0126	34-38	TCF3 fusion partner	Homo sapiens	0-4
32330731-8	2020	Gastrin activates ERK pathway in vivo and in vitro, and treatment with the MEK1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and CgA expression in vitro.	U 0126	90-95	mitogen-activated protein kinase 1	Mus musculus	18-21
32522929-4	2020	It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	65-104
32522929-4	2020	It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	106-110
32522929-4	2020	It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4.	U 0126	24-29	mitogen activated protein kinase 1	Rattus norvegicus	113-117
32522929-4	2020	It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4.	U 0126	24-29	mitogen-activated protein kinase 7	Rattus norvegicus	123-127
32522929-4	2020	It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4.	U 0126	24-29	early growth response 1	Rattus norvegicus	176-180
32522929-4	2020	It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4.	U 0126	24-29	Kruppel like factor 4	Rattus norvegicus	185-189
32522929-9	2020	The gel-shift of ERK5 was inhibited completely by both U0126 and ERK5-IN-1, a specific inhibitor of ERK5.	U 0126	55-60	mitogen-activated protein kinase 7	Rattus norvegicus	17-21
32009900-5	2019	We found that astrocytes and microglia strongly upregulate cell surface levels of ARTC2.1 and ADP-ribosylation of cell surface proteins in response to treatment with lipopolysaccharide (LPS) and the mitogen-activated protein kinase kinase (MEK) 1 and 2 inhibitor U0126, but do not respond to extracellular NAD+ with P2X7 activation and induction of cell death.	U 0126	263-268	mitogen-activated protein kinase kinase 1	Mus musculus	199-252
31924228-7	2020	However, the downstream effects of isotalatizidine were abrogated by the selective ERK1/2 inhibitor U0126-EtOH or CREB inhibitor of KG-501, but not by the p38 inhibitor SB203580.	U 0126	100-110	mitogen-activated protein kinase 3	Mus musculus	83-89
31654720-8	2020	Moreover, betacellulin induced the activation of MEK-ERK signaling, and its effects on Connexin43 were inhibited by pre-treatment with U0126.	U 0126	135-140	betacellulin	Homo sapiens	10-22
31654720-8	2020	Moreover, betacellulin induced the activation of MEK-ERK signaling, and its effects on Connexin43 were inhibited by pre-treatment with U0126.	U 0126	135-140	gap junction protein alpha 1	Homo sapiens	87-97
32330731-8	2020	Gastrin activates ERK pathway in vivo and in vitro, and treatment with the MEK1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and CgA expression in vitro.	U 0126	90-95	mitogen-activated protein kinase kinase 1	Mus musculus	75-79
32330731-8	2020	Gastrin activates ERK pathway in vivo and in vitro, and treatment with the MEK1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and CgA expression in vitro.	U 0126	90-95	cholecystokinin B receptor	Mus musculus	149-154
32330731-8	2020	Gastrin activates ERK pathway in vivo and in vitro, and treatment with the MEK1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and CgA expression in vitro.	U 0126	90-95	chromogranin A	Mus musculus	224-227
31882478-3	2020	MATERIALS AND METHODS: TPC1, 8505C and HTori-3 cells were treated with U0126 (MEK-ERK inhibitor) and cell viability was counted in the Neubauer chamber.	U 0126	71-76	mitogen-activated protein kinase kinase 7	Homo sapiens	78-81
33081508-7	2020	After intramuscular injection of U0126 (ERK inhibitor), the mechanical pain threshold significantly increased.	U 0126	33-38	Eph receptor B1	Rattus norvegicus	40-43
32407275-8	2020	Intrathecal injection of U0126 (a MEK inhibitor) blocking ERK1/2 phosphorylation blunted up-regulation of Nav1.7 in the DRG and correspondingly attenuated hyperalgesia.	U 0126	25-30	mitogen activated protein kinase 3	Rattus norvegicus	58-64
32407275-8	2020	Intrathecal injection of U0126 (a MEK inhibitor) blocking ERK1/2 phosphorylation blunted up-regulation of Nav1.7 in the DRG and correspondingly attenuated hyperalgesia.	U 0126	25-30	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	106-112
31587482-11	2020	Finally, pretreatment with the ERK inhibitor U0126 diminished c-Jun phosphorylation and transcriptional activation, suggesting that BITC elicits ERK/c-Jun signal transduction, which is responsible for miR-99a expression in bladder cancer.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	31-34
31587482-11	2020	Finally, pretreatment with the ERK inhibitor U0126 diminished c-Jun phosphorylation and transcriptional activation, suggesting that BITC elicits ERK/c-Jun signal transduction, which is responsible for miR-99a expression in bladder cancer.	U 0126	45-50	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	62-67
31587482-11	2020	Finally, pretreatment with the ERK inhibitor U0126 diminished c-Jun phosphorylation and transcriptional activation, suggesting that BITC elicits ERK/c-Jun signal transduction, which is responsible for miR-99a expression in bladder cancer.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	145-148
31587482-11	2020	Finally, pretreatment with the ERK inhibitor U0126 diminished c-Jun phosphorylation and transcriptional activation, suggesting that BITC elicits ERK/c-Jun signal transduction, which is responsible for miR-99a expression in bladder cancer.	U 0126	45-50	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	149-154
31587482-11	2020	Finally, pretreatment with the ERK inhibitor U0126 diminished c-Jun phosphorylation and transcriptional activation, suggesting that BITC elicits ERK/c-Jun signal transduction, which is responsible for miR-99a expression in bladder cancer.	U 0126	45-50	microRNA 99a	Homo sapiens	201-208
31586300-3	2020	The object of this study is recognition of the possible role of mTOR kinase inhibitors-everolimus single and in combination with selected downstream protein kinases inhibitors: LY294002 (PI3 K), U0126 (ERK1/2), GDC-0879 (B-RAF), AS-703026 (MEK), MK-2206 (AKT), PLX-4032 (B-RRAF) in cell invasion in malignant melanoma.	U 0126	195-200	mechanistic target of rapamycin kinase	Homo sapiens	64-68
31882478-3	2020	MATERIALS AND METHODS: TPC1, 8505C and HTori-3 cells were treated with U0126 (MEK-ERK inhibitor) and cell viability was counted in the Neubauer chamber.	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	82-85
31882478-6	2020	RESULTS: Treatment with U0126 inhibited proliferation of TPC1 and 8505C cells in a dose-dependent manner.	U 0126	24-29	two pore segment channel 1	Homo sapiens	57-61
31882478-9	2020	CONCLUSION: The combination of U0126 and sodium selenite inhibited proliferation of thyroid cancer cells through ERK inhibition.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	113-116
31256425-9	2020	TRB3 overexpression enhances the malignant transformation abilities of HBEpC such as cell proliferation, migration and colony formation, which could be reversed by U0126 and SP600125.	U 0126	164-169	tribbles pseudokinase 3	Homo sapiens	0-4
31668507-8	2020	Further treatment with the ERK phosphorylation inhibitor U0126 also blocked angiotensin II-induced HASMCs proliferation.	U 0126	57-62	mitogen-activated protein kinase 1	Homo sapiens	27-30
31668507-8	2020	Further treatment with the ERK phosphorylation inhibitor U0126 also blocked angiotensin II-induced HASMCs proliferation.	U 0126	57-62	angiotensinogen	Homo sapiens	76-90
31866376-8	2020	These alterations were all reduced by MnTMPyP, ML171 (a NOX1 inhibitor), and U0126 (an inhibitor of Erk signaling).	U 0126	77-82	Eph receptor B1	Rattus norvegicus	100-103
30843033-7	2020	Furthermore, the combination treatment of OTA and signaling inhibitors (LY294002, U0126, or SP600125) exerted synergistic antiproliferative effects in TM3 and TM4 cells.	U 0126	82-87	tropomyosin 1, alpha	Mus musculus	151-154
33000678-9	2020	U0126, a MEK inhibitor, showed the similar effects on MAPK-related protein levels with si-AHNAK2.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
31677553-7	2020	Prevention of DCA-induced ERK1/2 activation with EC, VAS-2870, apocynin and the MEK inhibitor U0126, also prevented monolayer permeabilization, stressing the key involvement of ERK1/2 in this process and its redox regulation.	U 0126	94-99	mitogen-activated protein kinase 3	Homo sapiens	26-32
31677553-7	2020	Prevention of DCA-induced ERK1/2 activation with EC, VAS-2870, apocynin and the MEK inhibitor U0126, also prevented monolayer permeabilization, stressing the key involvement of ERK1/2 in this process and its redox regulation.	U 0126	94-99	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
31677553-7	2020	Prevention of DCA-induced ERK1/2 activation with EC, VAS-2870, apocynin and the MEK inhibitor U0126, also prevented monolayer permeabilization, stressing the key involvement of ERK1/2 in this process and its redox regulation.	U 0126	94-99	mitogen-activated protein kinase 3	Homo sapiens	177-183
32046373-10	2020	Denuded oocytes treated with 20 muM U0126 mainly blocked MAPK phosphorylation and affected oocyte maturation.	U 0126	36-41	mitogen-activated protein kinase 1	Mus musculus	57-61
32046373-12	2020	Furthermore, Mat2b knockdown or U0126 treatment resulted in the aberrant expression of six maternal transcripts, namely, Fgf8, Cdc2, Gdf9, Padi6, Polr2d, and Tecb2.	U 0126	32-37	fibroblast growth factor 8	Mus musculus	121-125
32046373-12	2020	Furthermore, Mat2b knockdown or U0126 treatment resulted in the aberrant expression of six maternal transcripts, namely, Fgf8, Cdc2, Gdf9, Padi6, Polr2d, and Tecb2.	U 0126	32-37	cyclin-dependent kinase 1	Mus musculus	127-131
32046373-12	2020	Furthermore, Mat2b knockdown or U0126 treatment resulted in the aberrant expression of six maternal transcripts, namely, Fgf8, Cdc2, Gdf9, Padi6, Polr2d, and Tecb2.	U 0126	32-37	growth differentiation factor 9	Mus musculus	133-137
32046373-12	2020	Furthermore, Mat2b knockdown or U0126 treatment resulted in the aberrant expression of six maternal transcripts, namely, Fgf8, Cdc2, Gdf9, Padi6, Polr2d, and Tecb2.	U 0126	32-37	peptidyl arginine deiminase, type VI	Mus musculus	139-144
32046373-12	2020	Furthermore, Mat2b knockdown or U0126 treatment resulted in the aberrant expression of six maternal transcripts, namely, Fgf8, Cdc2, Gdf9, Padi6, Polr2d, and Tecb2.	U 0126	32-37	polymerase (RNA) II (DNA directed) polypeptide D	Mus musculus	146-152
33000678-9	2020	U0126, a MEK inhibitor, showed the similar effects on MAPK-related protein levels with si-AHNAK2.	U 0126	0-5	AHNAK nucleoprotein 2	Homo sapiens	90-96
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	AKT serine/threonine kinase 1	Homo sapiens	80-83
31905925-4	2019	We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus.	U 0126	73-78	glial cell derived neurotrophic factor	Rattus norvegicus	40-44
31905925-4	2019	We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus.	U 0126	73-78	mitogen activated protein kinase 3	Rattus norvegicus	137-184
31905925-4	2019	We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus.	U 0126	73-78	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	222-238
31905925-4	2019	We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus.	U 0126	73-78	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	240-243
31905925-4	2019	We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus.	U 0126	73-78	cAMP responsive element binding protein 1	Rattus norvegicus	289-326
31905925-4	2019	We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus.	U 0126	73-78	cAMP responsive element binding protein 1	Rattus norvegicus	328-332
31874951-15	2019	Further inhibition of ERK1/2 signaling by a MEK1/2 inhibitor U0126 reduced the proliferation of AGS cells, which aggravated the inhibition effect of NOTCH1 knock-down on cell proliferation.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	22-28
31874951-15	2019	Further inhibition of ERK1/2 signaling by a MEK1/2 inhibitor U0126 reduced the proliferation of AGS cells, which aggravated the inhibition effect of NOTCH1 knock-down on cell proliferation.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Homo sapiens	44-50
31874951-15	2019	Further inhibition of ERK1/2 signaling by a MEK1/2 inhibitor U0126 reduced the proliferation of AGS cells, which aggravated the inhibition effect of NOTCH1 knock-down on cell proliferation.	U 0126	61-66	notch receptor 1	Homo sapiens	149-155
31831023-12	2019	And blocking ERK1/2 pathway by U0126 or blocking p38 pathway by PD98059, proliferation and migration of ECs co-cultured with VSMCs were further suppressed, while cell apoptosis was further promoted.	U 0126	31-36	rolled	Drosophila melanogaster	13-19
31468983-12	2019	FAK inhibitor (PF-573228) and ERK1/2 inhibitor (U0126) were proved, in turn, decreased the BMSCs migration induced using LIPUS (p &lt; .05).	U 0126	48-53	mitogen activated protein kinase 3	Rattus norvegicus	30-36
31555866-4	2019	LY294002 (a PI3K inhibitor) and U0126 (an ERK inhibitor) prior to PABA/NO were found to synergistically enhance PABA/NO-induced apoptosis.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	42-45
31274009-9	2019	When cremophor EL was chosen for drug delivery, it had an inhibitory and additive effect (combined with U0126) on the ETB receptor contractility.	U 0126	104-109	endothelin receptor type B	Homo sapiens	118-121
31274009-11	2019	U0126 and cremophor EL are well tolerated at doses that have effect on ETB receptor upregulation.	U 0126	0-5	endothelin receptor type B	Homo sapiens	71-74
31655042-8	2019	U0126, a MEK1/2 inhibitor, down regulated the expression of these inflammation factors.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	9-15
31218464-9	2019	The AQP9 gene knock-down or exogenous administration of the ERK1/2 inhibitor U0126 could improve the above indexes.	U 0126	77-82	aquaporin 9	Rattus norvegicus	4-8
31218464-9	2019	The AQP9 gene knock-down or exogenous administration of the ERK1/2 inhibitor U0126 could improve the above indexes.	U 0126	77-82	mitogen activated protein kinase 3	Rattus norvegicus	60-66
31675556-6	2019	Mechanistically, curcumin behaved like MEK-specific inhibitor (U0126) to enhance regorafenib-induced growth inhibition, apoptosis and autophagy in HCT 116 cells.	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
31638299-5	2019	EGF-stimulated phosphorylation of CREB was completely inhibited by MAPK3/1 inhibitor U0126, suggesting that EGF-activated MAPK3/1 results in the activation of CREB for cumulus expansion.	U 0126	85-90	mitogen-activated protein kinase 3	Mus musculus	67-74
31638299-5	2019	EGF-stimulated phosphorylation of CREB was completely inhibited by MAPK3/1 inhibitor U0126, suggesting that EGF-activated MAPK3/1 results in the activation of CREB for cumulus expansion.	U 0126	85-90	epidermal growth factor	Mus musculus	108-111
31638299-5	2019	EGF-stimulated phosphorylation of CREB was completely inhibited by MAPK3/1 inhibitor U0126, suggesting that EGF-activated MAPK3/1 results in the activation of CREB for cumulus expansion.	U 0126	85-90	mitogen-activated protein kinase 3	Mus musculus	122-129
31638299-5	2019	EGF-stimulated phosphorylation of CREB was completely inhibited by MAPK3/1 inhibitor U0126, suggesting that EGF-activated MAPK3/1 results in the activation of CREB for cumulus expansion.	U 0126	85-90	cAMP responsive element binding protein 1	Mus musculus	159-163
31614166-7	2019	We then have identified that, coniferaldehyde activates the extracellular signals-regulated Kinase 1 and 2 (ERK1/2), and further noted that, U0126, an ERK1/2 inhibitor, blocks coniferaldehyde-facilitated neurite outgrowth.	U 0126	141-146	mitogen-activated protein kinase 3	Mus musculus	60-106
31614166-7	2019	We then have identified that, coniferaldehyde activates the extracellular signals-regulated Kinase 1 and 2 (ERK1/2), and further noted that, U0126, an ERK1/2 inhibitor, blocks coniferaldehyde-facilitated neurite outgrowth.	U 0126	141-146	mitogen-activated protein kinase 3	Mus musculus	108-114
31614166-7	2019	We then have identified that, coniferaldehyde activates the extracellular signals-regulated Kinase 1 and 2 (ERK1/2), and further noted that, U0126, an ERK1/2 inhibitor, blocks coniferaldehyde-facilitated neurite outgrowth.	U 0126	141-146	mitogen-activated protein kinase 3	Mus musculus	151-157
31768875-10	2019	was completely prevented by the treatment with MEK1/2 inhibitors U0126 (5 mug/site, i.c.v.	U 0126	65-70	mitogen-activated protein kinase kinase 1	Mus musculus	47-53
31769424-7	2019	Mechanistically, IL-8-induced myotube atrophy is inhibited by treatment with the CXCR2 antagonist, SB225002, or by treatment with the ERK1/2 inhibitor, U0126.	U 0126	152-157	C-X-C motif chemokine ligand 8	Homo sapiens	17-21
31769424-7	2019	Mechanistically, IL-8-induced myotube atrophy is inhibited by treatment with the CXCR2 antagonist, SB225002, or by treatment with the ERK1/2 inhibitor, U0126.	U 0126	152-157	mitogen-activated protein kinase 3	Homo sapiens	134-140
31807022-7	2019	Finally, ERK was inhibited using a mitogen-activated protein kinase/ERK kinase inhibitor (U0126) to further explore the molecular mechanism of GOF-mutant SHP2 affecting GBM cells.	U 0126	90-95	mitogen-activated protein kinase 1	Homo sapiens	9-12
31682623-5	2019	MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Mus musculus	0-6
31682623-5	2019	MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells.	U 0126	18-23	stimulated by retinoic acid gene 8	Mus musculus	81-86
31682623-5	2019	MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells.	U 0126	18-23	REC8 meiotic recombination protein	Mus musculus	113-117
31682623-5	2019	MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells.	U 0126	18-23	SPO11 initiator of meiotic double stranded breaks	Mus musculus	119-124
31682623-5	2019	MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells.	U 0126	18-23	DNA meiotic recombinase 1	Mus musculus	126-130
31682623-5	2019	MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells.	U 0126	18-23	synaptonemal complex protein 3	Mus musculus	136-141
31682623-6	2019	Furthermore, U0126 treatment dramatically reduced STRA8 protein levels and numbers of meiotic cells among cultured XX and XY fetal germ cells even in the presence of RA.	U 0126	13-18	stimulated by retinoic acid gene 8	Mus musculus	50-55
31865729-10	2019	Moreover, we found that the overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126.	U 0126	169-174	microRNA 155	Mus musculus	46-53
31865729-10	2019	Moreover, we found that the overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126.	U 0126	169-174	NLR family, pyrin domain containing 3	Mus musculus	100-105
31865729-10	2019	Moreover, we found that the overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126.	U 0126	169-174	mitogen-activated protein kinase 1	Mus musculus	155-158
31683954-4	2019	In the present study, hyperforin (a TRPC6 activator) facilitated mitochondrial fission in DGC concomitant with increases in Lon protease-1 (LONP1, a mitochondrial protease) expression and extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation under physiological conditions, which were abrogated by U0126 (an ERK1/2 inhibitor) co-treatment.	U 0126	311-316	transient receptor potential cation channel subfamily C member 6	Homo sapiens	36-41
31365278-5	2019	ERK1/2 inhibitor U0126 abrogated NF-kappaB activation in d-glucose-treated BV2 cells.	U 0126	17-22	mitogen-activated protein kinase 3	Mus musculus	0-6
30993729-8	2019	Further investigation demonstrated that an Erk inhibitor (U0126) reversed the AlCl3 -induced decrease in apoptosis, enhancement of cell cycle progression, promotion of cell migration, and attenuation of oxidative stress.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	43-46
31264250-8	2019	Inactivation of the ERK pathway by U0126 suppressed the phosphorylation of GRASP65, GA fragmentation, and endothelial cell injury induced by ox-LDL.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	20-23
31264250-8	2019	Inactivation of the ERK pathway by U0126 suppressed the phosphorylation of GRASP65, GA fragmentation, and endothelial cell injury induced by ox-LDL.	U 0126	35-40	golgi reassembly stacking protein 1	Homo sapiens	75-82
31718896-7	2019	The AKT inhibitor MK-2206 blocked the epidermal preservation effect of Y-27632, while the MEK/ERK inhibitor U0126 enhanced the preservation of epidermal structure in the hSOC.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
31718896-7	2019	The AKT inhibitor MK-2206 blocked the epidermal preservation effect of Y-27632, while the MEK/ERK inhibitor U0126 enhanced the preservation of epidermal structure in the hSOC.	U 0126	108-113	mitogen-activated protein kinase 1	Homo sapiens	94-97
31718896-7	2019	The AKT inhibitor MK-2206 blocked the epidermal preservation effect of Y-27632, while the MEK/ERK inhibitor U0126 enhanced the preservation of epidermal structure in the hSOC.	U 0126	108-113	UBX domain protein 11	Homo sapiens	170-174
31562895-6	2019	U0126 and SL327, which are known to inhibit MEK1 and MEK2, induced neuronal differentiation, whereas PD98059, which is reported to preferentially inhibit MEK1 at higher concentrations, increased astrocytogenesis.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	44-48
31562895-6	2019	U0126 and SL327, which are known to inhibit MEK1 and MEK2, induced neuronal differentiation, whereas PD98059, which is reported to preferentially inhibit MEK1 at higher concentrations, increased astrocytogenesis.	U 0126	0-5	mitogen activated protein kinase kinase 2	Rattus norvegicus	53-57
31562895-11	2019	U0126 and SL327 increase neurogenesis through MEK2 inhibition, whereas PD98059 induced astrocytogenesis in NSCs, which is mediated by the chemical structure, particularly the 3"-methoxy group rather than its renowned MEK1 inhibition.	U 0126	0-5	mitogen activated protein kinase kinase 2	Rattus norvegicus	46-50
31878993-12	2019	Compared with PBS group, the phosphorylation of ERK protein on DC was enhanced significantly, and then reduced significantly after U0126 treatment.	U 0126	131-136	mitogen-activated protein kinase 1	Mus musculus	48-51
32083234-10	2020	All changes caused by prolactin were inhibited in Ishikawa cells pretreated with U0126.	U 0126	81-86	prolactin	Homo sapiens	22-31
31823825-14	2019	In agreement, ERK signaling inhibition by U0126 blunted the effect of high extracellular Mg2+ on mineralization and odontogenic differentiation in DPSCs.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	14-17
31823825-15	2019	Interestingly, BMP2, BMPR1, and phosphorylated Smad1/5/9 were significantly decreased by U0126, indicating that BMP2/Smads acted as downstream of ERK.	U 0126	89-94	bone morphogenetic protein 2	Homo sapiens	15-19
31823825-15	2019	Interestingly, BMP2, BMPR1, and phosphorylated Smad1/5/9 were significantly decreased by U0126, indicating that BMP2/Smads acted as downstream of ERK.	U 0126	89-94	SMAD family member 1	Homo sapiens	47-56
31823825-15	2019	Interestingly, BMP2, BMPR1, and phosphorylated Smad1/5/9 were significantly decreased by U0126, indicating that BMP2/Smads acted as downstream of ERK.	U 0126	89-94	bone morphogenetic protein 2	Homo sapiens	112-116
31823825-15	2019	Interestingly, BMP2, BMPR1, and phosphorylated Smad1/5/9 were significantly decreased by U0126, indicating that BMP2/Smads acted as downstream of ERK.	U 0126	89-94	mitogen-activated protein kinase 1	Homo sapiens	146-149
31850235-9	2019	Furthermore, combined treatment of PSH with ERK1/2 inhibitor (U0126) caused significant elevation of the activity and the expression of MMP-2.	U 0126	62-67	mitogen-activated protein kinase 3	Homo sapiens	44-50
31850235-9	2019	Furthermore, combined treatment of PSH with ERK1/2 inhibitor (U0126) caused significant elevation of the activity and the expression of MMP-2.	U 0126	62-67	matrix metallopeptidase 2	Homo sapiens	136-141
31274009-3	2019	U0126 is a potent inhibitor of vascular phenotypical changes, exemplified by functional endothelin B (ETB) receptor upregulation.	U 0126	0-5	endothelin receptor type B	Homo sapiens	88-100
31274009-3	2019	U0126 is a potent inhibitor of vascular phenotypical changes, exemplified by functional endothelin B (ETB) receptor upregulation.	U 0126	0-5	endothelin receptor type B	Homo sapiens	102-105
31274009-8	2019	U0126 (10 microM) had a strong effect on the prevention of functional ETB receptor contractility, combined with minimal effect on the depolarization-induced contractility.	U 0126	0-5	endothelin receptor type B	Homo sapiens	70-73
30684191-8	2019	Inhibition of MAPK by U0126 and PI3K by LY294002 led to concomitant decrease in the HGF-mediated migration/invasion of HTR-8/SVneo cells.	U 0126	22-27	hepatocyte growth factor	Homo sapiens	84-87
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	chemokine (C-C motif) ligand 2	Mus musculus	148-153
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	chemokine (C-C motif) ligand 2	Mus musculus	155-160
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	mitogen-activated protein kinase kinase 1	Mus musculus	167-173
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	tumor necrosis factor	Mus musculus	217-226
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	chemokine (C-C motif) ligand 2	Mus musculus	231-236
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	chemokine (C-C motif) ligand 2	Mus musculus	238-243
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	mitogen-activated protein kinase 8	Mus musculus	254-262
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	U 0126	184-189	nitric oxide synthase 2, inducible	Mus musculus	312-343
31638299-5	2019	EGF-stimulated phosphorylation of CREB was completely inhibited by MAPK3/1 inhibitor U0126, suggesting that EGF-activated MAPK3/1 results in the activation of CREB for cumulus expansion.	U 0126	85-90	epidermal growth factor	Mus musculus	0-3
31638299-5	2019	EGF-stimulated phosphorylation of CREB was completely inhibited by MAPK3/1 inhibitor U0126, suggesting that EGF-activated MAPK3/1 results in the activation of CREB for cumulus expansion.	U 0126	85-90	cAMP responsive element binding protein 1	Mus musculus	34-38
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	epidermal growth factor	Homo sapiens	222-225
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	transforming growth factor beta 1	Homo sapiens	231-240
31795399-10	2019	Co-treatment of U0126 (an ERK1/2 inhibitor) alleviated vasogenic edema formation and the reduced dystrophin-AQP4 expressions induced by 67-kDa LR neutralization.	U 0126	16-21	mitogen activated protein kinase 3	Rattus norvegicus	26-32
31795399-10	2019	Co-treatment of U0126 (an ERK1/2 inhibitor) alleviated vasogenic edema formation and the reduced dystrophin-AQP4 expressions induced by 67-kDa LR neutralization.	U 0126	16-21	aquaporin 4	Rattus norvegicus	108-112
30839135-5	2019	U0126 and PD98059 were used to inhibit the MEK-ERK1/2 pathway.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
30839135-5	2019	U0126 and PD98059 were used to inhibit the MEK-ERK1/2 pathway.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	47-53
31032956-11	2019	Furthermore, quantitative reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay demonstrated that extracellular UDP-glucose significantly enhanced interleukin-1beta (IL-1beta) and chemokine CCL2 (CCL2) release, which was abolished by PPTN and significantly decreased by inhibitors of MEK/ERK (U0126) and p38 (SB202190).	U 0126	325-330	interleukin 1 beta	Rattus norvegicus	179-196
31461632-12	2019	TNF-alpha increased the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and inhibition of ERK1/2 by U0126 reversed TNF-alpha-induced TFEB redistribution, lysosomal dysfunction, and autophagic flux suppression.	U 0126	120-125	mitogen-activated protein kinase 3	Homo sapiens	110-116
31461632-12	2019	TNF-alpha increased the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and inhibition of ERK1/2 by U0126 reversed TNF-alpha-induced TFEB redistribution, lysosomal dysfunction, and autophagic flux suppression.	U 0126	120-125	tumor necrosis factor	Homo sapiens	135-144
31461632-12	2019	TNF-alpha increased the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and inhibition of ERK1/2 by U0126 reversed TNF-alpha-induced TFEB redistribution, lysosomal dysfunction, and autophagic flux suppression.	U 0126	120-125	transcription factor EB	Homo sapiens	153-157
31487015-8	2019	The ERK inhibitor U0126 showed similar inhibition of cell apoptosis, tube formation and HIF-1alpha/VEGF expression as that exhibited by lenti-CGRP.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	4-7
31487015-8	2019	The ERK inhibitor U0126 showed similar inhibition of cell apoptosis, tube formation and HIF-1alpha/VEGF expression as that exhibited by lenti-CGRP.	U 0126	18-23	hypoxia inducible factor 1, alpha subunit	Mus musculus	88-98
31487015-8	2019	The ERK inhibitor U0126 showed similar inhibition of cell apoptosis, tube formation and HIF-1alpha/VEGF expression as that exhibited by lenti-CGRP.	U 0126	18-23	vascular endothelial growth factor A	Mus musculus	99-103
31487015-8	2019	The ERK inhibitor U0126 showed similar inhibition of cell apoptosis, tube formation and HIF-1alpha/VEGF expression as that exhibited by lenti-CGRP.	U 0126	18-23	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	142-146
31620204-7	2019	Inhibition of the ERK signaling pathway with U0126 reversed the effects induced by inhibiting or overexpressing PLAC8 on cell proliferation.	U 0126	45-50	placenta associated 8	Homo sapiens	112-117
31620204-8	2019	In addition, overexpression of PLAC8 significantly decreased the sensitivity of PC-9 cells to gefitinib, and this effect was reversed by U0126.	U 0126	137-142	placenta associated 8	Homo sapiens	31-36
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	88-91
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	cadherin 1	Homo sapiens	144-154
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	vimentin	Homo sapiens	189-197
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	snail family transcriptional repressor 1	Homo sapiens	202-207
31619255-10	2019	Inhibition of ERK activity (U0126) remarkably enhanced Cav1 and AQP1 expression in bEnd.3 cells.	U 0126	28-33	mitogen-activated protein kinase 1	Mus musculus	14-17
31619255-10	2019	Inhibition of ERK activity (U0126) remarkably enhanced Cav1 and AQP1 expression in bEnd.3 cells.	U 0126	28-33	caveolin 1, caveolae protein	Mus musculus	55-59
31619255-10	2019	Inhibition of ERK activity (U0126) remarkably enhanced Cav1 and AQP1 expression in bEnd.3 cells.	U 0126	28-33	aquaporin 1	Mus musculus	64-68
31306636-7	2019	Mirtazapine treatment increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and the mirtazapine-induced GDNF and BDNF expression were blocked by MAPK/ERK kinase (MEK) inhibitor (U0126).	U 0126	202-207	mitogen activated protein kinase 3	Rattus norvegicus	51-98
31421834-10	2019	And after U0126 (an inhibitor of ERK1/2 phosphorylation) treatment, ERK1/2 and STAT3 (Ser727) phosphorylation was simultaneously suppressed indicating that ERK1/2 is an upstream pathway protein of STAT3 (Ser727).	U 0126	10-15	mitogen-activated protein kinase 3	Homo sapiens	33-39
31421834-10	2019	And after U0126 (an inhibitor of ERK1/2 phosphorylation) treatment, ERK1/2 and STAT3 (Ser727) phosphorylation was simultaneously suppressed indicating that ERK1/2 is an upstream pathway protein of STAT3 (Ser727).	U 0126	10-15	mitogen-activated protein kinase 3	Homo sapiens	68-74
31421834-10	2019	And after U0126 (an inhibitor of ERK1/2 phosphorylation) treatment, ERK1/2 and STAT3 (Ser727) phosphorylation was simultaneously suppressed indicating that ERK1/2 is an upstream pathway protein of STAT3 (Ser727).	U 0126	10-15	signal transducer and activator of transcription 3	Homo sapiens	79-84
31421834-10	2019	And after U0126 (an inhibitor of ERK1/2 phosphorylation) treatment, ERK1/2 and STAT3 (Ser727) phosphorylation was simultaneously suppressed indicating that ERK1/2 is an upstream pathway protein of STAT3 (Ser727).	U 0126	10-15	mitogen-activated protein kinase 3	Homo sapiens	68-74
31421834-10	2019	And after U0126 (an inhibitor of ERK1/2 phosphorylation) treatment, ERK1/2 and STAT3 (Ser727) phosphorylation was simultaneously suppressed indicating that ERK1/2 is an upstream pathway protein of STAT3 (Ser727).	U 0126	10-15	signal transducer and activator of transcription 3	Homo sapiens	197-202
31306636-7	2019	Mirtazapine treatment increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and the mirtazapine-induced GDNF and BDNF expression were blocked by MAPK/ERK kinase (MEK) inhibitor (U0126).	U 0126	202-207	glial cell derived neurotrophic factor	Rattus norvegicus	128-132
31306636-7	2019	Mirtazapine treatment increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and the mirtazapine-induced GDNF and BDNF expression were blocked by MAPK/ERK kinase (MEK) inhibitor (U0126).	U 0126	202-207	brain-derived neurotrophic factor	Rattus norvegicus	137-141
31306636-7	2019	Mirtazapine treatment increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and the mirtazapine-induced GDNF and BDNF expression were blocked by MAPK/ERK kinase (MEK) inhibitor (U0126).	U 0126	202-207	mitogen activated protein kinase 3	Rattus norvegicus	169-173
31061533-11	2019	The effects of irisin were blocked by the ERK inhibitor U0126.	U 0126	56-61	fibronectin type III domain containing 5	Homo sapiens	15-21
31061533-11	2019	The effects of irisin were blocked by the ERK inhibitor U0126.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	42-45
30941654-6	2019	Exposure to 17beta-estradiol (E2) upregulated EZH2 via ERalpha signaling, and this effect was blocked by U0126, a MEK inhibiter.	U 0126	105-110	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	46-50
31301277-12	2019	The inhibition of ERK inhibitor U0126 or knockdown of ERK by siRNA clearly restored Rg5-induced apoptosis and autophagy.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	18-21
31310799-7	2019	Inhibition of the ERK pathway with U0126 induced p27KIP1 expression in the pancreatic cancer cells, confirming that the cell cycle retardation was the result of inhibition of the ERK pathway.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	18-21
30941654-6	2019	Exposure to 17beta-estradiol (E2) upregulated EZH2 via ERalpha signaling, and this effect was blocked by U0126, a MEK inhibiter.	U 0126	105-110	estrogen receptor 1	Homo sapiens	55-62
30941654-6	2019	Exposure to 17beta-estradiol (E2) upregulated EZH2 via ERalpha signaling, and this effect was blocked by U0126, a MEK inhibiter.	U 0126	105-110	mitogen-activated protein kinase kinase 7	Homo sapiens	114-117
31310799-7	2019	Inhibition of the ERK pathway with U0126 induced p27KIP1 expression in the pancreatic cancer cells, confirming that the cell cycle retardation was the result of inhibition of the ERK pathway.	U 0126	35-40	cyclin dependent kinase inhibitor 1B	Homo sapiens	49-56
31310799-7	2019	Inhibition of the ERK pathway with U0126 induced p27KIP1 expression in the pancreatic cancer cells, confirming that the cell cycle retardation was the result of inhibition of the ERK pathway.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	179-182
31199065-9	2019	SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor) significantly decreased PM2.5 -induced elevated contraction and mRNA and protein expression of 5-HT2A receptor.	U 0126	29-34	mitogen activated protein kinase 3	Rattus norvegicus	36-42
31199065-13	2019	SB203580 and U0126 inhibited the PM2.5 caused increased phosphorylation protein of p38 and ERK1/2.	U 0126	13-18	mitogen activated protein kinase 14	Rattus norvegicus	83-86
31199065-13	2019	SB203580 and U0126 inhibited the PM2.5 caused increased phosphorylation protein of p38 and ERK1/2.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	91-97
31062874-11	2019	Chemical inhibitors of NF-kappaB (Bay11-7082), p38 (SB202190) or ERK (U0126) decreased the FlaB induction of uPA expression.	U 0126	70-75	mitogen-activated protein kinase 1	Homo sapiens	65-68
31555361-7	2019	Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P&lt;0.01).	U 0126	128-133	kit ligand	Mus musculus	18-21
31555361-7	2019	Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P&lt;0.01).	U 0126	128-133	interleukin 13	Mus musculus	66-71
31555361-7	2019	Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P&lt;0.01).	U 0126	128-133	mitogen-activated protein kinase 1	Mus musculus	135-138
31555361-7	2019	Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P&lt;0.01).	U 0126	128-133	midkine	Mus musculus	139-142
31062874-11	2019	Chemical inhibitors of NF-kappaB (Bay11-7082), p38 (SB202190) or ERK (U0126) decreased the FlaB induction of uPA expression.	U 0126	70-75	plasminogen activator, urokinase	Homo sapiens	109-112
31233701-5	2019	Addition of ERK1/2 (U0126), EGFR (AG1478) and PPARgamma (GW9662) inhibitors prevented the ROSI-induced STAR mRNA expression and progesterone production after 48h.	U 0126	20-25	mitogen-activated protein kinase 3	Homo sapiens	12-18
31314915-7	2019	Meanwhile, intrathecal injection of the Cdk5 inhibitor roscovitine, the mitogen-activated ERK kinase (MEK) inhibitor U0126 and the PPARgamma agonist pioglitazone prevented or reversed behavioural allodynia, increased pPPARgamma expression, inhibited astrocyte activation and alleviated proinflammatory cytokine (tumour necrosis factor-alpha, IL-1beta, and IL-6) release from activated astrocytes.	U 0126	117-122	interleukin 1 alpha	Rattus norvegicus	342-350
31314915-7	2019	Meanwhile, intrathecal injection of the Cdk5 inhibitor roscovitine, the mitogen-activated ERK kinase (MEK) inhibitor U0126 and the PPARgamma agonist pioglitazone prevented or reversed behavioural allodynia, increased pPPARgamma expression, inhibited astrocyte activation and alleviated proinflammatory cytokine (tumour necrosis factor-alpha, IL-1beta, and IL-6) release from activated astrocytes.	U 0126	117-122	interleukin 6	Rattus norvegicus	356-360
31233701-5	2019	Addition of ERK1/2 (U0126), EGFR (AG1478) and PPARgamma (GW9662) inhibitors prevented the ROSI-induced STAR mRNA expression and progesterone production after 48h.	U 0126	20-25	steroidogenic acute regulatory protein	Homo sapiens	103-107
31233701-7	2019	On the other hand, U0126 and GW9662 prevented the ROSI-induced increase in PPARgamma transcripts after 6h.	U 0126	19-24	peroxisome proliferator activated receptor gamma	Homo sapiens	75-84
31880530-21	2019	However, the caspase-3 activity of nerve cells treated with ODR after U0126 intervention was significantly decreased, when compared with single OGD treatment group.	U 0126	70-75	caspase 3	Rattus norvegicus	13-22
31880530-10	2019	In in vivo trial, it was found that the protein expression level of p-ERK1/2 in cerebral tissue in the MCAO group was significantly increased, when compared with that of the sham-operated group, while the protein expression level of p-Erk1/2 in the U0126 group was significantly lower than that in the MCAO group.	U 0126	249-254	mitogen activated protein kinase 3	Rattus norvegicus	235-241
31880530-11	2019	The expression levels of Bcl-2 and Bcl-xl in the MCAO group were significantly lower than the corresponding expression levels in the sham-operated group, while the expressions of Bcl-2 and Bcl-xl in the U0126 group were significantly lower than those in MCAO group.	U 0126	203-208	BCL2, apoptosis regulator	Rattus norvegicus	25-30
31880530-11	2019	The expression levels of Bcl-2 and Bcl-xl in the MCAO group were significantly lower than the corresponding expression levels in the sham-operated group, while the expressions of Bcl-2 and Bcl-xl in the U0126 group were significantly lower than those in MCAO group.	U 0126	203-208	Bcl2-like 1	Rattus norvegicus	35-41
31880530-11	2019	The expression levels of Bcl-2 and Bcl-xl in the MCAO group were significantly lower than the corresponding expression levels in the sham-operated group, while the expressions of Bcl-2 and Bcl-xl in the U0126 group were significantly lower than those in MCAO group.	U 0126	203-208	BCL2, apoptosis regulator	Rattus norvegicus	179-184
31880530-11	2019	The expression levels of Bcl-2 and Bcl-xl in the MCAO group were significantly lower than the corresponding expression levels in the sham-operated group, while the expressions of Bcl-2 and Bcl-xl in the U0126 group were significantly lower than those in MCAO group.	U 0126	203-208	Bcl2-like 1	Rattus norvegicus	189-195
31880530-12	2019	In MCAO group, the expression of Bax was significantly higher than that in the sham-operated group, while Bax expression was higher in U0126 than in MCAO group.	U 0126	135-140	BCL2 associated X, apoptosis regulator	Rattus norvegicus	106-109
31673231-10	2019	Treatment with either an ERK1/2 inhibitor U0126 or a JNK inhibitor SP600125 rescued SNU-216 from dying of bortezomib or combined treatment.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	25-31
31514417-11	2019	The inhibition of ODN-induced N2a differentiation with H89, U73122, chelerythrine and U0126 supports the activation of a PKA/PLC/PKC/MEK/ERK-dependent signaling pathway.	U 0126	86-91	perlecan (heparan sulfate proteoglycan 2)	Mus musculus	125-128
31514417-11	2019	The inhibition of ODN-induced N2a differentiation with H89, U73122, chelerythrine and U0126 supports the activation of a PKA/PLC/PKC/MEK/ERK-dependent signaling pathway.	U 0126	86-91	midkine	Mus musculus	133-136
31514417-11	2019	The inhibition of ODN-induced N2a differentiation with H89, U73122, chelerythrine and U0126 supports the activation of a PKA/PLC/PKC/MEK/ERK-dependent signaling pathway.	U 0126	86-91	mitogen-activated protein kinase 1	Mus musculus	137-140
31293025-8	2019	Moreover, the inhibitory effect of U0126 (a specific ERK1/2 inhibitor) on the ERK1/2 activities was partially recovered by overexpression of MAT2A and MAT2B in porcine intramuscular preadipocytes.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	53-59
31293025-8	2019	Moreover, the inhibitory effect of U0126 (a specific ERK1/2 inhibitor) on the ERK1/2 activities was partially recovered by overexpression of MAT2A and MAT2B in porcine intramuscular preadipocytes.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	78-84
31293025-8	2019	Moreover, the inhibitory effect of U0126 (a specific ERK1/2 inhibitor) on the ERK1/2 activities was partially recovered by overexpression of MAT2A and MAT2B in porcine intramuscular preadipocytes.	U 0126	35-40	methionine adenosyltransferase 2A	Homo sapiens	141-146
31293025-8	2019	Moreover, the inhibitory effect of U0126 (a specific ERK1/2 inhibitor) on the ERK1/2 activities was partially recovered by overexpression of MAT2A and MAT2B in porcine intramuscular preadipocytes.	U 0126	35-40	methionine adenosyltransferase 2B	Homo sapiens	151-156
31666990-9	2019	The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling.	U 0126	104-109	transforming growth factor beta 1	Homo sapiens	4-13
31666990-9	2019	The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling.	U 0126	104-109	gap junction protein alpha 1	Homo sapiens	38-42
31666990-9	2019	The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling.	U 0126	104-109	pannexin 1	Homo sapiens	47-52
31666990-9	2019	The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	89-92
31666990-9	2019	The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling.	U 0126	104-109	SMAD family member 3	Homo sapiens	160-165
31695767-14	2019	Moreover, ERK1/2 was identified as a regulator of RNA pol III, and ERK1/2 inhibition by U0126 significantly repressed Maf1 knockdown-promoted cardiac hypertrophy accompanied by suppressed RNA pol III transcription.	U 0126	88-93	mitogen-activated protein kinase 3	Mus musculus	67-73
31695767-14	2019	Moreover, ERK1/2 was identified as a regulator of RNA pol III, and ERK1/2 inhibition by U0126 significantly repressed Maf1 knockdown-promoted cardiac hypertrophy accompanied by suppressed RNA pol III transcription.	U 0126	88-93	MAF1 homolog, negative regulator of RNA polymerase III	Mus musculus	118-122
31518371-6	2019	Irisin increased extracellular signal-regulated kinase (ERK) phosphorylation, and U0126, an ERK pathway inhibitor, suppressed irisin-induced C2C12 cell proliferation.	U 0126	82-87	mitogen-activated protein kinase 1	Mus musculus	92-95
31501412-9	2019	Moreover, the increase in IL-1beta and TNF-alpha was suppressed by L703, 606, U0126 and SB203580 in vivo and in vitro.	U 0126	78-83	interleukin 1 alpha	Rattus norvegicus	26-34
31501412-9	2019	Moreover, the increase in IL-1beta and TNF-alpha was suppressed by L703, 606, U0126 and SB203580 in vivo and in vitro.	U 0126	78-83	tumor necrosis factor	Rattus norvegicus	39-48
31505816-7	2019	Using inhibitors of JNK (JNK-in-8) and p38 (SB203580), CLEFMA"s increases of cleaved caspases 3, 8, and 9 could be expectedly suppressed, but they could not be affected by co-treatment with the ERK inhibitor (U0126).	U 0126	209-214	mitogen-activated protein kinase 8	Homo sapiens	20-23
31202174-8	2019	Moreover, we found that in mPanx-1-transfected cells treated with U0126 (inhibitor of p-ERK1/2), the migration and invasion of I-10 cells were remarkably attenuated.	U 0126	66-71	pannexin 1	Mus musculus	27-34
31202174-8	2019	Moreover, we found that in mPanx-1-transfected cells treated with U0126 (inhibitor of p-ERK1/2), the migration and invasion of I-10 cells were remarkably attenuated.	U 0126	66-71	mitogen-activated protein kinase 3	Mus musculus	88-94
31348616-12	2019	The phosphorylation of AKT and ERK, as well as the expression of the vascular endothelial growth factor, can be inhibited using the LY294002 and U0126 inhibitors.	U 0126	145-150	AKT serine/threonine kinase 1	Homo sapiens	23-26
31348616-12	2019	The phosphorylation of AKT and ERK, as well as the expression of the vascular endothelial growth factor, can be inhibited using the LY294002 and U0126 inhibitors.	U 0126	145-150	mitogen-activated protein kinase 1	Homo sapiens	31-34
31348616-12	2019	The phosphorylation of AKT and ERK, as well as the expression of the vascular endothelial growth factor, can be inhibited using the LY294002 and U0126 inhibitors.	U 0126	145-150	vascular endothelial growth factor A	Homo sapiens	69-103
31100371-7	2019	If spinal giving U0126 (a selective MEK inhibitor) or AG490 (a Janus kinase (JAK)-STAT inhibitor) to db/db mice, both of them can decrease the mechanical allodynia, but only inhibit pERK (by U0126) or pSTAT3 (by AG490) respectively.	U 0126	17-22	midkine	Mus musculus	36-39
31501803-11	2019	Mechanistically, the phosphorylation of extracellular signal-regulated kinase (ERK) was associated with the invasive activity of BC cells, while U0126 (an ERK inhibitor) reduced the invasive activity of CD81-knockdown BC cells.	U 0126	145-150	mitogen-activated protein kinase 1	Homo sapiens	155-158
31501803-11	2019	Mechanistically, the phosphorylation of extracellular signal-regulated kinase (ERK) was associated with the invasive activity of BC cells, while U0126 (an ERK inhibitor) reduced the invasive activity of CD81-knockdown BC cells.	U 0126	145-150	CD81 molecule	Homo sapiens	203-207
31026057-12	2019	The promoting effects of intermittent PTH on cementogenesis and osteogenic differentiation were abrogated by H89 and U0126 in vitro, respectively.	U 0126	117-122	parathyroid hormone	Rattus norvegicus	38-41
31019292-9	2019	Treatment with the MEK inhibitor U0126 decreased the LSCC cells" proliferation capability.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
31534465-10	2019	When U0126 or LY294002 pretreated cells alone, DP-induced p-ERK or p-PI3K downstream proteins and cell proliferation were suppressed compared to those of the control group, but EGFR was not affected.	U 0126	5-10	mitogen-activated protein kinase 1	Homo sapiens	60-63
31438640-9	2019	Furthermore, treatment with a MEK inhibitor (UO126) reduced the inhibitory effects of fisetin on the metastasis of RCC cells through the ERK/CTSS/ADAM9 pathway.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	30-33
31438640-9	2019	Furthermore, treatment with a MEK inhibitor (UO126) reduced the inhibitory effects of fisetin on the metastasis of RCC cells through the ERK/CTSS/ADAM9 pathway.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	137-140
31438640-9	2019	Furthermore, treatment with a MEK inhibitor (UO126) reduced the inhibitory effects of fisetin on the metastasis of RCC cells through the ERK/CTSS/ADAM9 pathway.	U 0126	45-50	cathepsin S	Homo sapiens	141-145
31438640-9	2019	Furthermore, treatment with a MEK inhibitor (UO126) reduced the inhibitory effects of fisetin on the metastasis of RCC cells through the ERK/CTSS/ADAM9 pathway.	U 0126	45-50	ADAM metallopeptidase domain 9	Homo sapiens	146-151
31387935-3	2019	We have previously shown that the MEK1/2 inhibitor U0126 improves neurological assessment after SAH in rats.	U 0126	51-56	mitogen activated protein kinase kinase 1	Rattus norvegicus	34-40
31387634-10	2019	p-JNK was not significantly decreased in SP600125 + DBP group, while p-ERK1/2 was significantly decreased in U0126 + DBP group.	U 0126	109-114	mitogen activated protein kinase 3	Rattus norvegicus	71-77
31322183-6	2019	Inhibition of MEK1/2 by its antagonist U0126 reversed the effects of CXCL1 on MMP2/9 expression.	U 0126	39-44	mitogen-activated protein kinase kinase 1	Homo sapiens	14-20
31322183-6	2019	Inhibition of MEK1/2 by its antagonist U0126 reversed the effects of CXCL1 on MMP2/9 expression.	U 0126	39-44	C-X-C motif chemokine ligand 1	Homo sapiens	69-74
31322183-6	2019	Inhibition of MEK1/2 by its antagonist U0126 reversed the effects of CXCL1 on MMP2/9 expression.	U 0126	39-44	matrix metallopeptidase 2	Homo sapiens	78-84
31466304-10	2019	ERK activation inhibitor U0126 in the PVN reversed Ang II-induced enhancement of SNA, and Apo and IMD pretreatment in the PVN decreased Ang II-induced ERK activation.	U 0126	25-30	Eph receptor B1	Rattus norvegicus	0-3
31466304-10	2019	ERK activation inhibitor U0126 in the PVN reversed Ang II-induced enhancement of SNA, and Apo and IMD pretreatment in the PVN decreased Ang II-induced ERK activation.	U 0126	25-30	angiotensinogen	Rattus norvegicus	51-57
31227218-7	2019	Treating cells with U0126, a potent MEK1/2 inhibitor, decreased carbachol-stimulated eEF2 dephosphorylation.	U 0126	20-25	mitogen-activated protein kinase kinase 1	Homo sapiens	36-42
31227218-7	2019	Treating cells with U0126, a potent MEK1/2 inhibitor, decreased carbachol-stimulated eEF2 dephosphorylation.	U 0126	20-25	eukaryotic translation elongation factor 2	Homo sapiens	85-89
31429423-12	2019	CORM3 administration attenuated LPS induced activation of extracellular-signal-regulated kinase (ERK) and its protection against necroptosis was abolished by ERK inhibitor U0126.	U 0126	172-177	Eph receptor B1	Rattus norvegicus	58-95
31429423-12	2019	CORM3 administration attenuated LPS induced activation of extracellular-signal-regulated kinase (ERK) and its protection against necroptosis was abolished by ERK inhibitor U0126.	U 0126	172-177	Eph receptor B1	Rattus norvegicus	97-100
31429423-12	2019	CORM3 administration attenuated LPS induced activation of extracellular-signal-regulated kinase (ERK) and its protection against necroptosis was abolished by ERK inhibitor U0126.	U 0126	172-177	Eph receptor B1	Rattus norvegicus	158-161
31496741-8	2019	Incorporation with U0126 reversed the effects of FAM163A overexpression.	U 0126	19-24	family with sequence similarity 163 member A	Homo sapiens	49-56
31075703-5	2019	Addition of ERK1/2 (U0126), EGFR (AG1478) and PPARgamma (GW9662) inhibitors prevented the BPA-induced STAR and PPARgamma mRNA expression.	U 0126	20-25	steroidogenic acute regulatory protein	Homo sapiens	102-106
31100371-7	2019	If spinal giving U0126 (a selective MEK inhibitor) or AG490 (a Janus kinase (JAK)-STAT inhibitor) to db/db mice, both of them can decrease the mechanical allodynia, but only inhibit pERK (by U0126) or pSTAT3 (by AG490) respectively.	U 0126	17-22	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	182-186
30859584-3	2019	Moreover, flow cytometry results revealed that the proliferation promoting effect of RA was attenuated by U0126, a specific inhibitor of extracellular signal-regulated kinase (ERK).	U 0126	106-111	mitogen-activated protein kinase 1	Homo sapiens	137-174
30712236-12	2019	Testosterone up-regulated the promotor activity, protein expression of FEN1, and phosphorylation of ERK/Elk-1, which could be eliminated by both letrozole and MEK1/2 inhibitor U0126.	U 0126	176-181	flap structure-specific endonuclease 1	Homo sapiens	71-75
30712236-12	2019	Testosterone up-regulated the promotor activity, protein expression of FEN1, and phosphorylation of ERK/Elk-1, which could be eliminated by both letrozole and MEK1/2 inhibitor U0126.	U 0126	176-181	mitogen-activated protein kinase 1	Homo sapiens	100-103
30712236-12	2019	Testosterone up-regulated the promotor activity, protein expression of FEN1, and phosphorylation of ERK/Elk-1, which could be eliminated by both letrozole and MEK1/2 inhibitor U0126.	U 0126	176-181	ETS transcription factor ELK1	Homo sapiens	104-109
30712236-12	2019	Testosterone up-regulated the promotor activity, protein expression of FEN1, and phosphorylation of ERK/Elk-1, which could be eliminated by both letrozole and MEK1/2 inhibitor U0126.	U 0126	176-181	mitogen-activated protein kinase kinase 1	Homo sapiens	159-165
31329883-4	2019	Of these stimuli, Toll-like receptor ligands most strongly induce TMEM55B phosphorylation, and this is blocked by the MEK1/2 inhibitor U0126.	U 0126	135-140	phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1	Homo sapiens	66-73
31329883-4	2019	Of these stimuli, Toll-like receptor ligands most strongly induce TMEM55B phosphorylation, and this is blocked by the MEK1/2 inhibitor U0126.	U 0126	135-140	mitogen-activated protein kinase kinase 1	Homo sapiens	118-124
31329883-8	2019	Cells exposed to U0126 also exhibit attenuated lamp1 clustering.	U 0126	17-22	lysosomal associated membrane protein 1	Homo sapiens	47-52
30859584-3	2019	Moreover, flow cytometry results revealed that the proliferation promoting effect of RA was attenuated by U0126, a specific inhibitor of extracellular signal-regulated kinase (ERK).	U 0126	106-111	mitogen-activated protein kinase 1	Homo sapiens	176-179
31257493-12	2019	The proliferation of Huh-7 cells was decreased using the ERK1/2 inhibitor U0126.	U 0126	74-79	MIR7-3 host gene	Homo sapiens	21-26
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	midkine	Mus musculus	152-155
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	mitogen-activated protein kinase 1	Mus musculus	156-159
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	160-169
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	NLR family, pyrin domain containing 3	Mus musculus	198-203
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	NLR family, pyrin domain containing 3	Mus musculus	235-240
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	caspase 1	Mus musculus	242-251
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	interleukin 18	Mus musculus	253-258
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	interleukin 1 alpha	Mus musculus	260-268
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	58-63	microRNA 181a-2	Mus musculus	289-297
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	microRNA 181a-2	Mus musculus	21-29
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	midkine	Mus musculus	152-155
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	mitogen-activated protein kinase 1	Mus musculus	156-159
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	160-169
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	NLR family, pyrin domain containing 3	Mus musculus	198-203
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	NLR family, pyrin domain containing 3	Mus musculus	235-240
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	caspase 1	Mus musculus	242-251
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	interleukin 18	Mus musculus	253-258
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	interleukin 1 alpha	Mus musculus	260-268
30938884-10	2019	When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown.	U 0126	105-110	microRNA 181a-2	Mus musculus	289-297
31257493-12	2019	The proliferation of Huh-7 cells was decreased using the ERK1/2 inhibitor U0126.	U 0126	74-79	mitogen-activated protein kinase 3	Homo sapiens	57-63
31187398-8	2019	In cultured hypoxic hippocampal neurons, individual blockage of MAPK signaling by the MEK1/2 inhibitor (U0126), but not by the P38 inhibitor (SB203580) or JNK inhibitor (SP600125), completely prevented the upregulation of all three kinds of SK channels.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	64-68
31187398-8	2019	In cultured hypoxic hippocampal neurons, individual blockage of MAPK signaling by the MEK1/2 inhibitor (U0126), but not by the P38 inhibitor (SB203580) or JNK inhibitor (SP600125), completely prevented the upregulation of all three kinds of SK channels.	U 0126	104-109	mitogen activated protein kinase kinase 1	Rattus norvegicus	86-92
31383289-7	2019	Using the Erk pathway inhibitor U0126, we showed that p-Erk was downregulated and the proliferation and migration of K7M2 decreased along with it.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	10-13
31332289-6	2019	Treatment of either a proteasome inhibitor MG132 or bortezomib, or with a p-ERK/MEK inhibitor U0126 attenuate the SOX7 promoted BIM degradation.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	76-79
31332289-6	2019	Treatment of either a proteasome inhibitor MG132 or bortezomib, or with a p-ERK/MEK inhibitor U0126 attenuate the SOX7 promoted BIM degradation.	U 0126	94-99	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
31332289-6	2019	Treatment of either a proteasome inhibitor MG132 or bortezomib, or with a p-ERK/MEK inhibitor U0126 attenuate the SOX7 promoted BIM degradation.	U 0126	94-99	SRY-box transcription factor 7	Homo sapiens	114-118
31332289-6	2019	Treatment of either a proteasome inhibitor MG132 or bortezomib, or with a p-ERK/MEK inhibitor U0126 attenuate the SOX7 promoted BIM degradation.	U 0126	94-99	BCL2 like 11	Homo sapiens	128-131
31195342-6	2019	RESULTS: Our findings revealed that the m-BDNF-inducing activity of HMF was abolished by U0126 but not by H89 or K252a.	U 0126	89-94	brain-derived neurotrophic factor	Rattus norvegicus	42-46
31383289-7	2019	Using the Erk pathway inhibitor U0126, we showed that p-Erk was downregulated and the proliferation and migration of K7M2 decreased along with it.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	56-59
31344106-5	2019	In cells treated with U0126, an inhibitor of MAPK/ERK kinase (MEK), which activates ERK, IL-1beta-induced IL-6 mRNA expression was also inhibited.	U 0126	22-27	mitogen-activated protein kinase 1	Canis lupus familiaris	45-49
31344106-5	2019	In cells treated with U0126, an inhibitor of MAPK/ERK kinase (MEK), which activates ERK, IL-1beta-induced IL-6 mRNA expression was also inhibited.	U 0126	22-27	interleukin 1 beta	Canis lupus familiaris	89-97
31344106-5	2019	In cells treated with U0126, an inhibitor of MAPK/ERK kinase (MEK), which activates ERK, IL-1beta-induced IL-6 mRNA expression was also inhibited.	U 0126	22-27	interleukin 6	Canis lupus familiaris	106-110
30946562-5	2019	Inhibition of Galphai/o signaling with pertussis toxin, as well as MEK1/2 inhibition with U0126, also reduced 5-HT1B-mediated ERK1/2 phosphorylation.	U 0126	90-95	mitogen-activated protein kinase kinase 1	Mus musculus	67-73
31336670-8	2019	Blocking A2A adenosine receptors by ZM241385 abolished the effect of BDNF, whereas additional stimulation of A2A receptors by CGS21680 increased MEPP amplitudes, which was prevented by MEK1/2 inhibitor U0126.	U 0126	202-207	brain derived neurotrophic factor	Mus musculus	69-73
31336670-8	2019	Blocking A2A adenosine receptors by ZM241385 abolished the effect of BDNF, whereas additional stimulation of A2A receptors by CGS21680 increased MEPP amplitudes, which was prevented by MEK1/2 inhibitor U0126.	U 0126	202-207	mitogen-activated protein kinase kinase 1	Mus musculus	185-191
31322778-6	2019	The inhibitory effect of LPS on GPR120 expression was blocked by Toll-like receptor 4 (TLR4) inhibitor TAK242 and p38 mitogen-activated protein kinase inhibitor LY222820, but not by ERK1/2 inhibitor U0126 and c-Jun N-terminal kinase inhibitor SP600125.	U 0126	199-204	mitogen-activated protein kinase 14	Mus musculus	114-117
30946562-5	2019	Inhibition of Galphai/o signaling with pertussis toxin, as well as MEK1/2 inhibition with U0126, also reduced 5-HT1B-mediated ERK1/2 phosphorylation.	U 0126	90-95	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	110-116
30946562-5	2019	Inhibition of Galphai/o signaling with pertussis toxin, as well as MEK1/2 inhibition with U0126, also reduced 5-HT1B-mediated ERK1/2 phosphorylation.	U 0126	90-95	mitogen-activated protein kinase 3	Mus musculus	126-132
31379571-8	2019	The addition of U0126 and U73122, antagonists of the ERK and PLCgamma pathway, respectively, significantly inhibited cell viability and GAP-43 protein expression.	U 0126	16-21	mitogen-activated protein kinase 1	Mus musculus	53-56
31379571-8	2019	The addition of U0126 and U73122, antagonists of the ERK and PLCgamma pathway, respectively, significantly inhibited cell viability and GAP-43 protein expression.	U 0126	16-21	growth associated protein 43	Mus musculus	136-142
31373312-8	2019	In cultured primary renal tubular epithelial cells (TECs), administration of saturated fatty acid palmitate resulted in an upregulation of KIM-1, osteopontin, and CD44, which was greatly attenuated by U0126, an inhibitor of extracellular signal-regulated kinase (ERK)1/2.	U 0126	201-206	hepatitis A virus cellular receptor 1	Rattus norvegicus	139-144
31296837-13	2019	CTRP3 protein alone promoted MSCs proliferation and migration by upregulating matrix metalloproteinase 9 (MMP9) and protecting against oxidation by increasing superoxide dismutase 2 (SOD2) and metallothionein 1/2 (MT1/2) expression; and these effects were blocked by pretreatment with the extracellular signal-regulated kinase (ERK1/2) inhibitor U0126.	U 0126	346-351	C1q and tumor necrosis factor related protein 3	Mus musculus	0-5
31373312-8	2019	In cultured primary renal tubular epithelial cells (TECs), administration of saturated fatty acid palmitate resulted in an upregulation of KIM-1, osteopontin, and CD44, which was greatly attenuated by U0126, an inhibitor of extracellular signal-regulated kinase (ERK)1/2.	U 0126	201-206	secreted phosphoprotein 1	Rattus norvegicus	146-157
31373312-8	2019	In cultured primary renal tubular epithelial cells (TECs), administration of saturated fatty acid palmitate resulted in an upregulation of KIM-1, osteopontin, and CD44, which was greatly attenuated by U0126, an inhibitor of extracellular signal-regulated kinase (ERK)1/2.	U 0126	201-206	CD44 molecule (Indian blood group)	Rattus norvegicus	163-167
31373312-8	2019	In cultured primary renal tubular epithelial cells (TECs), administration of saturated fatty acid palmitate resulted in an upregulation of KIM-1, osteopontin, and CD44, which was greatly attenuated by U0126, an inhibitor of extracellular signal-regulated kinase (ERK)1/2.	U 0126	201-206	mitogen activated protein kinase 3	Rattus norvegicus	224-270
31338323-6	2019	Moreover, these complexes also induced the phosphorylation of ERK1/2, and coincubation with an MEK inhibitor (U0126), which is known to inhibit the activation of ERK1/2, but not JNK/SAPK and p38 MAPK inhibitors, reduced the complexes-induced apoptosis compared to that in the negative controls, indicating that the induction of apoptotic cell death occurred through ERK1/2 signaling in HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	162-168
31338323-6	2019	Moreover, these complexes also induced the phosphorylation of ERK1/2, and coincubation with an MEK inhibitor (U0126), which is known to inhibit the activation of ERK1/2, but not JNK/SAPK and p38 MAPK inhibitors, reduced the complexes-induced apoptosis compared to that in the negative controls, indicating that the induction of apoptotic cell death occurred through ERK1/2 signaling in HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	191-194
31286589-7	2019	FGL2 was confirmed to be downregulated by MAPK signaling inhibitor U0126.	U 0126	67-72	fibrinogen like 2	Homo sapiens	0-4
31286589-10	2019	However, these changes initiated by U0126 were abolished by FGL2 overexpression.	U 0126	36-41	fibrinogen like 2	Homo sapiens	60-64
31312250-8	2019	The ERK-specific inhibitor U0126 and agonist TPA was used to explore the role of ERK.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	4-7
31338323-6	2019	Moreover, these complexes also induced the phosphorylation of ERK1/2, and coincubation with an MEK inhibitor (U0126), which is known to inhibit the activation of ERK1/2, but not JNK/SAPK and p38 MAPK inhibitors, reduced the complexes-induced apoptosis compared to that in the negative controls, indicating that the induction of apoptotic cell death occurred through ERK1/2 signaling in HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	62-68
31338323-6	2019	Moreover, these complexes also induced the phosphorylation of ERK1/2, and coincubation with an MEK inhibitor (U0126), which is known to inhibit the activation of ERK1/2, but not JNK/SAPK and p38 MAPK inhibitors, reduced the complexes-induced apoptosis compared to that in the negative controls, indicating that the induction of apoptotic cell death occurred through ERK1/2 signaling in HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
31338323-6	2019	Moreover, these complexes also induced the phosphorylation of ERK1/2, and coincubation with an MEK inhibitor (U0126), which is known to inhibit the activation of ERK1/2, but not JNK/SAPK and p38 MAPK inhibitors, reduced the complexes-induced apoptosis compared to that in the negative controls, indicating that the induction of apoptotic cell death occurred through ERK1/2 signaling in HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	195-199
31338323-6	2019	Moreover, these complexes also induced the phosphorylation of ERK1/2, and coincubation with an MEK inhibitor (U0126), which is known to inhibit the activation of ERK1/2, but not JNK/SAPK and p38 MAPK inhibitors, reduced the complexes-induced apoptosis compared to that in the negative controls, indicating that the induction of apoptotic cell death occurred through ERK1/2 signaling in HepG2 cells.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	162-168
31312250-13	2019	Treatment of HeLa/DDP cells transfected with P16 plasmid with ERK-specific inhibitor U0126 significantly decreased the expression of pERK1/2 and increased the expression of P-gp from 6 h to 48 h. Moreover, after 72 h, the expression of pERK1/2 was up-regulated and the expression of P-gp was inhibited.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	62-65
31312250-13	2019	Treatment of HeLa/DDP cells transfected with P16 plasmid with ERK-specific inhibitor U0126 significantly decreased the expression of pERK1/2 and increased the expression of P-gp from 6 h to 48 h. Moreover, after 72 h, the expression of pERK1/2 was up-regulated and the expression of P-gp was inhibited.	U 0126	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	173-177
31312250-13	2019	Treatment of HeLa/DDP cells transfected with P16 plasmid with ERK-specific inhibitor U0126 significantly decreased the expression of pERK1/2 and increased the expression of P-gp from 6 h to 48 h. Moreover, after 72 h, the expression of pERK1/2 was up-regulated and the expression of P-gp was inhibited.	U 0126	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	283-287
31312250-13	2019	Treatment of HeLa/DDP cells transfected with P16 plasmid with ERK-specific inhibitor U0126 significantly decreased the expression of pERK1/2 and increased the expression of P-gp from 6 h to 48 h. Moreover, after 72 h, the expression of pERK1/2 was up-regulated and the expression of P-gp was inhibited.	U 0126	85-90	cyclin dependent kinase inhibitor 2A	Homo sapiens	45-48
30822571-8	2019	Meanwhile, these effects were blocked by the MEK inhibitor U0126.	U 0126	59-64	midkine	Mus musculus	45-48
31360172-10	2019	The increase in ALP, mineral deposition, and osteoblastic genes induced by the mechanical stretch-EPO combination was inhibited by U0126, an ERK1/2 inhibitor.	U 0126	131-136	erythropoietin	Rattus norvegicus	98-101
31360172-10	2019	The increase in ALP, mineral deposition, and osteoblastic genes induced by the mechanical stretch-EPO combination was inhibited by U0126, an ERK1/2 inhibitor.	U 0126	131-136	mitogen activated protein kinase 3	Rattus norvegicus	141-147
31034822-12	2019	U0126 and LY294002, inhibitors of Erk and Akt respectively, block SNP-enhanced KDFs proliferation effectively.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	34-37
31034822-12	2019	U0126 and LY294002, inhibitors of Erk and Akt respectively, block SNP-enhanced KDFs proliferation effectively.	U 0126	0-5	AKT serine/threonine kinase 1	Homo sapiens	42-45
31269957-10	2019	The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 and PD98059 suggesting downstream activation of this pathway.	U 0126	66-71	mitogen-activated protein kinase kinase 7	Homo sapiens	44-47
31269957-10	2019	The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 and PD98059 suggesting downstream activation of this pathway.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	48-54
31121283-8	2019	A MEK inhibitor (U0126) enhanced the interaction between ShcD and unphosphorylated ERK under oxidative stress conditions.	U 0126	17-22	mitogen-activated protein kinase kinase 7	Homo sapiens	2-5
31121283-8	2019	A MEK inhibitor (U0126) enhanced the interaction between ShcD and unphosphorylated ERK under oxidative stress conditions.	U 0126	17-22	SHC adaptor protein 4	Homo sapiens	57-61
31121283-8	2019	A MEK inhibitor (U0126) enhanced the interaction between ShcD and unphosphorylated ERK under oxidative stress conditions.	U 0126	17-22	mitogen-activated protein kinase 1	Homo sapiens	83-86
31112365-8	2019	U0126, a selective inhibitor of ERK1/2 MAPK signaling, significantly suppressed maintaining of the stemness-based effects on transwell coculture system.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	32-38
29889817-8	2019	Treatment with U0126 (a specific ERK1/2 inhibitor) reversed the effects of PE on IkappaBalpha, p38MAPK and JNK phosphorylation as well as caspase-3/-8/-9 activation in LPS-treated ARVMs.	U 0126	15-20	mitogen activated protein kinase 3	Rattus norvegicus	33-39
29889817-8	2019	Treatment with U0126 (a specific ERK1/2 inhibitor) reversed the effects of PE on IkappaBalpha, p38MAPK and JNK phosphorylation as well as caspase-3/-8/-9 activation in LPS-treated ARVMs.	U 0126	15-20	NFKB inhibitor alpha	Rattus norvegicus	81-93
29889817-8	2019	Treatment with U0126 (a specific ERK1/2 inhibitor) reversed the effects of PE on IkappaBalpha, p38MAPK and JNK phosphorylation as well as caspase-3/-8/-9 activation in LPS-treated ARVMs.	U 0126	15-20	mitogen-activated protein kinase 8	Rattus norvegicus	107-110
31219801-9	2019	Furthermore, TRPM7 inhibition activated MEK/ERK pathway, and the effects of TRPM7 inhibition were drastically attenuated by pathway specific inhibitor U0126, thus suggesting that activating MEK/ERK pathway is a predominant mechanism through which TRPM7 inhibition exacerbates PAH.	U 0126	151-156	transient receptor potential cation channel, subfamily M, member 7	Rattus norvegicus	13-18
31219801-9	2019	Furthermore, TRPM7 inhibition activated MEK/ERK pathway, and the effects of TRPM7 inhibition were drastically attenuated by pathway specific inhibitor U0126, thus suggesting that activating MEK/ERK pathway is a predominant mechanism through which TRPM7 inhibition exacerbates PAH.	U 0126	151-156	Eph receptor B1	Rattus norvegicus	44-47
31219801-9	2019	Furthermore, TRPM7 inhibition activated MEK/ERK pathway, and the effects of TRPM7 inhibition were drastically attenuated by pathway specific inhibitor U0126, thus suggesting that activating MEK/ERK pathway is a predominant mechanism through which TRPM7 inhibition exacerbates PAH.	U 0126	151-156	transient receptor potential cation channel, subfamily M, member 7	Rattus norvegicus	76-81
31219801-9	2019	Furthermore, TRPM7 inhibition activated MEK/ERK pathway, and the effects of TRPM7 inhibition were drastically attenuated by pathway specific inhibitor U0126, thus suggesting that activating MEK/ERK pathway is a predominant mechanism through which TRPM7 inhibition exacerbates PAH.	U 0126	151-156	Eph receptor B1	Rattus norvegicus	194-197
31212975-8	2019	Furthermore, MAPK inhibitors including an extracellular signal-regulated kinase (ERK) 1/2 inhibitor (U0126), a p38 inhibitor (SB202190) and a c-Jun N-terminal kinase (JNK) inhibitor (SP600125) decreased the expression of soluble ICAM-1 (sICAM-1), but not ICAM-1.	U 0126	101-106	mitogen-activated protein kinase 3	Homo sapiens	42-89
31212975-9	2019	U0126 and SB202190 could inhibit the expression of IL-6, IL-8 and MCP-1, but SP600125 could not.	U 0126	0-5	interleukin 6	Homo sapiens	51-55
31212975-9	2019	U0126 and SB202190 could inhibit the expression of IL-6, IL-8 and MCP-1, but SP600125 could not.	U 0126	0-5	C-X-C motif chemokine ligand 8	Homo sapiens	57-61
31212975-9	2019	U0126 and SB202190 could inhibit the expression of IL-6, IL-8 and MCP-1, but SP600125 could not.	U 0126	0-5	C-C motif chemokine ligand 2	Homo sapiens	66-71
31005550-7	2019	KEY FINDINGS: U-0126 administration reversed the neuroprotective effect induced by zeranol through decreasing ratio of p-ERK1/2:ERK1/2 and Bcl-2/Bax in brain tissue.	U 0126	14-20	mitogen activated protein kinase 3	Rattus norvegicus	121-127
31005550-7	2019	KEY FINDINGS: U-0126 administration reversed the neuroprotective effect induced by zeranol through decreasing ratio of p-ERK1/2:ERK1/2 and Bcl-2/Bax in brain tissue.	U 0126	14-20	mitogen activated protein kinase 3	Rattus norvegicus	128-134
31005550-7	2019	KEY FINDINGS: U-0126 administration reversed the neuroprotective effect induced by zeranol through decreasing ratio of p-ERK1/2:ERK1/2 and Bcl-2/Bax in brain tissue.	U 0126	14-20	BCL2, apoptosis regulator	Rattus norvegicus	139-144
31005550-7	2019	KEY FINDINGS: U-0126 administration reversed the neuroprotective effect induced by zeranol through decreasing ratio of p-ERK1/2:ERK1/2 and Bcl-2/Bax in brain tissue.	U 0126	14-20	BCL2 associated X, apoptosis regulator	Rattus norvegicus	145-148
31005550-9	2019	SIGNIFICANCE: Zeranol showed protective effect in OVX rats that were exposed to cerebral I/R by activation of ERK signaling pathway which was blocked by U0126.	U 0126	153-158	Eph receptor B1	Rattus norvegicus	110-113
30920400-8	2019	Moreover, the ERK-specific inhibitor U0126 suppressed the expression of the epithelial-mesenchymal transition of lung cancer cells.	U 0126	37-42	mitogen-activated protein kinase 1	Mus musculus	14-17
30954555-8	2019	Treatment of cells with U0126 (inhibitor of ERK) reduced the expression of DNMT1, Snail and Slug, increased CDH1.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	44-47
30954555-8	2019	Treatment of cells with U0126 (inhibitor of ERK) reduced the expression of DNMT1, Snail and Slug, increased CDH1.	U 0126	24-29	DNA methyltransferase 1	Homo sapiens	75-80
30954555-8	2019	Treatment of cells with U0126 (inhibitor of ERK) reduced the expression of DNMT1, Snail and Slug, increased CDH1.	U 0126	24-29	snail family transcriptional repressor 1	Homo sapiens	82-87
30624774-7	2019	In addition, both the cell proliferative response and the ERK1/2 activation induced by MF exposure were blocked completely by U0126, a specific inhibitor of MEK (ERK kinases 1 and 2).	U 0126	126-131	mitogen-activated protein kinase 3	Homo sapiens	58-64
31147562-7	2019	When pHCE were treated with EGF for 6 hours, the cells produced enhanced levels of TGF-betaRII, which was blocked by U0126.	U 0126	117-122	epidermal growth factor	Homo sapiens	28-31
31147562-7	2019	When pHCE were treated with EGF for 6 hours, the cells produced enhanced levels of TGF-betaRII, which was blocked by U0126.	U 0126	117-122	transforming growth factor beta receptor 2	Homo sapiens	83-94
30575440-5	2019	Both the phosphatidylinositol 3-kinase/AKT inhibitor LY49002 and MEK/ERK inhibitor U0126 could inhibit the permeability of HUVECs, but with different effects on tyrosine phosphorylation of VE-cadherin.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	65-68
30575440-5	2019	Both the phosphatidylinositol 3-kinase/AKT inhibitor LY49002 and MEK/ERK inhibitor U0126 could inhibit the permeability of HUVECs, but with different effects on tyrosine phosphorylation of VE-cadherin.	U 0126	83-88	mitogen-activated protein kinase 1	Homo sapiens	69-72
30575440-5	2019	Both the phosphatidylinositol 3-kinase/AKT inhibitor LY49002 and MEK/ERK inhibitor U0126 could inhibit the permeability of HUVECs, but with different effects on tyrosine phosphorylation of VE-cadherin.	U 0126	83-88	cadherin 5	Homo sapiens	189-200
30730256-7	2019	The MEK1/2 inhibitor U0126 blocked all of these molecular events induced by 6-MSITC, and enhanced the cell viability in both types of cells in the same manner.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
31118804-5	2019	The ERK-pathway inhibitor U0126 was used to confirm TGFbeta-ERK-Snail pathway-mediated cell behavior.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	4-7
31118804-5	2019	The ERK-pathway inhibitor U0126 was used to confirm TGFbeta-ERK-Snail pathway-mediated cell behavior.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	60-63
31118804-5	2019	The ERK-pathway inhibitor U0126 was used to confirm TGFbeta-ERK-Snail pathway-mediated cell behavior.	U 0126	26-31	snail family transcriptional repressor 1	Homo sapiens	64-69
30972974-9	2019	Treatment with the specific MEK inhibitor U0126 diminished KLB deficiency-induced EndMT.	U 0126	42-47	mitogen-activated protein kinase kinase 7	Homo sapiens	28-31
30864686-5	2019	To gain insight into the potential mechanism, an Erk1/2 inhibitor (U0126) was applied.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	49-55
30246250-7	2019	Cell viability was further inhibited by the combination of EB30 with LY294002 (a specific PI3K inhibitor) or U0126 (a MEK inhibitor).	U 0126	109-114	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
30907511-7	2019	Notably, the Sal B induced up-expression of TAZ was blocked by U0126 (the MEK-ERK inhibitor), rather than LY294002 (the PI3K-Akt inhibitor).	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
30907511-7	2019	Notably, the Sal B induced up-expression of TAZ was blocked by U0126 (the MEK-ERK inhibitor), rather than LY294002 (the PI3K-Akt inhibitor).	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	78-81
30852743-6	2019	It was found that the level of MEK phosphorylation was upregulated after LPS stimulation, which was blocked by 10 mug/ml of papaverine.10muM U0126 significantly inhibited TNF-alpha and IL-1beta and increased IL-10 transcription and expression in retinal microglia (P &lt; 0.01).	U 0126	141-146	tumor necrosis factor	Rattus norvegicus	171-180
30852743-6	2019	It was found that the level of MEK phosphorylation was upregulated after LPS stimulation, which was blocked by 10 mug/ml of papaverine.10muM U0126 significantly inhibited TNF-alpha and IL-1beta and increased IL-10 transcription and expression in retinal microglia (P &lt; 0.01).	U 0126	141-146	interleukin 1 beta	Rattus norvegicus	185-193
30852743-6	2019	It was found that the level of MEK phosphorylation was upregulated after LPS stimulation, which was blocked by 10 mug/ml of papaverine.10muM U0126 significantly inhibited TNF-alpha and IL-1beta and increased IL-10 transcription and expression in retinal microglia (P &lt; 0.01).	U 0126	141-146	interleukin 10	Rattus norvegicus	208-213
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	mitogen-activated protein kinase 1	Homo sapiens	50-53
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	cyclin D1	Homo sapiens	75-84
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	cyclin D1	Homo sapiens	86-91
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	cyclin dependent kinase 2	Homo sapiens	98-123
30859584-4	2019	Western blot analysis showed the protein level of ERK, phosphorylated ERK, cyclin D1 (CCND1), and cyclin-dependent kinase 2 (CDK2) increased after stimulation with RA, and this effect could also be abolished by U0126.	U 0126	211-216	cyclin dependent kinase 2	Homo sapiens	125-129
30859584-5	2019	Our data revealed that ablation of ERK expression by U0126 should significantly decrease proliferation of pPGCLCS.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	35-38
31234488-12	2019	Furthermore, LQ- or LQG-mediated melanin synthesis was partially blocked by p38 inhibitor (SB203580) and protein kinase A (PKA) inhibitor (H-89); however, ERK kinase (MEK) inhibitor (U0126) and phosphatidylinositol-3-kinase (PI3K) inhibitor (LY294002) had no effect.	U 0126	183-188	mitogen-activated protein kinase 1	Homo sapiens	155-158
31219801-9	2019	Furthermore, TRPM7 inhibition activated MEK/ERK pathway, and the effects of TRPM7 inhibition were drastically attenuated by pathway specific inhibitor U0126, thus suggesting that activating MEK/ERK pathway is a predominant mechanism through which TRPM7 inhibition exacerbates PAH.	U 0126	151-156	transient receptor potential cation channel, subfamily M, member 7	Rattus norvegicus	76-81
31200778-10	2019	However, the abovementioned NE-induced changes could be suppressed by the specific ERK-1/2 inhibitor U0126.	U 0126	101-106	mitogen activated protein kinase 3	Rattus norvegicus	83-90
30706522-9	2019	After additional treatment with U0126, a specific noncompetitive inhibitor of mitogen-activated protein kinase kinase (MAPKK), the upregulation of claudin-11 mRNA induced by mirabegron was reduced.	U 0126	32-37	claudin 11	Rattus norvegicus	147-157
30706522-10	2019	At the same time, immunocytochemistry showed mirabegron treatment disturbed claudin-11 localisation to tight junction, which was recovered when treated with mirabegron in the presence of U0126.	U 0126	187-192	claudin 11	Rattus norvegicus	76-86
30954555-8	2019	Treatment of cells with U0126 (inhibitor of ERK) reduced the expression of DNMT1, Snail and Slug, increased CDH1.	U 0126	24-29	snail family transcriptional repressor 2	Homo sapiens	92-96
30954555-8	2019	Treatment of cells with U0126 (inhibitor of ERK) reduced the expression of DNMT1, Snail and Slug, increased CDH1.	U 0126	24-29	cadherin 1	Homo sapiens	108-112
30707290-7	2019	DNMT1 knockdown increased the phosphorylation of IKKalpha/beta, IkappaBalpha, and p65 in the NF-kappaB pathway and the phosphorylation of p38 and ERK in the MAPK pathway; however, only the NF-kappaB pathway inhibitor PDTC suppressed both IL-6 and IL-8 expression, whereas inhibitors of the MAPK pathway (U0126, SB2035580, and SP600125) did not.	U 0126	304-309	DNA methyltransferase 1	Homo sapiens	0-5
30822534-6	2019	Pre-treatment with a PI3K/AKT inhibitor (Wortmannin), ERK1/2 inhibitor (U0126), and JNK inhibitor (SP600125) induced the signaling interactions of these molecules, and oxibendazole co-treatment with each inhibitor resulted in even greater decreases in cell proliferation.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	54-60
30609134-9	2019	The regulatory effects of CASC2 on PTC cell biological behavior were further enhanced by mitogen-activated protein kinase kinase (MEK) inhibitor U0126 or AKT1/2/3 inhibitor MK-2206 2HCl.	U 0126	145-150	cancer susceptibility 2	Homo sapiens	26-31
31360690-15	2019	Inhibition of ERK activation by U0126 abrogated ability of Z-ajoene to activate Nrf2 and to induce NQO1 expression.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	14-17
31360690-15	2019	Inhibition of ERK activation by U0126 abrogated ability of Z-ajoene to activate Nrf2 and to induce NQO1 expression.	U 0126	32-37	NFE2 like bZIP transcription factor 2	Homo sapiens	80-84
31360690-15	2019	Inhibition of ERK activation by U0126 abrogated ability of Z-ajoene to activate Nrf2 and to induce NQO1 expression.	U 0126	32-37	NAD(P)H quinone dehydrogenase 1	Homo sapiens	99-103
30990944-10	2019	We found that U0126-EtOH decreased progesterone production and the expression of steroidogenic enzymes and SF1.	U 0126	14-19	nuclear receptor subfamily 5, group A, member 1	Mus musculus	107-110
31292053-4	2019	Reverse transcription PCR was used to test the effect of U0126 at different concentrations (0, 1, 5, 10 mumol/L) on the mRNA expression of IL-8 induced by Stattic in THP-1 cells.	U 0126	57-62	C-X-C motif chemokine ligand 8	Homo sapiens	139-143
31292053-9	2019	In addition, U0126, a selective inhibitor of ERK pathway, inhibited Stattic-induced IL-8 expression in a concentration-dependent manner.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	45-48
31292053-9	2019	In addition, U0126, a selective inhibitor of ERK pathway, inhibited Stattic-induced IL-8 expression in a concentration-dependent manner.	U 0126	13-18	C-X-C motif chemokine ligand 8	Homo sapiens	84-88
31138786-6	2019	Intriguingly, co-treatment of Sprouty1 KD ASCs with differentiation medium and the pharmacological MEK inhibitor U0126 blunted ERK phosphorylation; however, failed to rescue adipogenic differentiation.	U 0126	113-118	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
31138786-6	2019	Intriguingly, co-treatment of Sprouty1 KD ASCs with differentiation medium and the pharmacological MEK inhibitor U0126 blunted ERK phosphorylation; however, failed to rescue adipogenic differentiation.	U 0126	113-118	mitogen-activated protein kinase 1	Homo sapiens	127-130
31807353-3	2019	Treatments with MTA, propolis or combined increased the phosphorylation of extracellular signal-regulated kinases (ERK), one of mitogen-activated protein kinases signaling cascades during odontogenic differentiation of DPSCs (p &lt; 0.05), and U0126, an inhibitor of ERK, decreased calcium deposits (p &lt; 0.05).	U 0126	244-249	mitogen-activated protein kinase 1	Homo sapiens	75-113
31807353-3	2019	Treatments with MTA, propolis or combined increased the phosphorylation of extracellular signal-regulated kinases (ERK), one of mitogen-activated protein kinases signaling cascades during odontogenic differentiation of DPSCs (p &lt; 0.05), and U0126, an inhibitor of ERK, decreased calcium deposits (p &lt; 0.05).	U 0126	244-249	mitogen-activated protein kinase 1	Homo sapiens	115-118
30753865-5	2019	The effects of BDNF in combination with AS1949490 on the Bdnf mRNA levels were blocked by inhibitors of mitogen-activated protein kinase kinase (U0126), PI3-kinase (LY294002), phospholipase Cgamma (U73122), and protein kinase C (bisindolylmaleimide I), whereas the effect of BDNF alone was inhibited only by U0126.	U 0126	145-150	brain derived neurotrophic factor	Homo sapiens	15-19
30753865-5	2019	The effects of BDNF in combination with AS1949490 on the Bdnf mRNA levels were blocked by inhibitors of mitogen-activated protein kinase kinase (U0126), PI3-kinase (LY294002), phospholipase Cgamma (U73122), and protein kinase C (bisindolylmaleimide I), whereas the effect of BDNF alone was inhibited only by U0126.	U 0126	145-150	brain derived neurotrophic factor	Homo sapiens	57-61
30753865-5	2019	The effects of BDNF in combination with AS1949490 on the Bdnf mRNA levels were blocked by inhibitors of mitogen-activated protein kinase kinase (U0126), PI3-kinase (LY294002), phospholipase Cgamma (U73122), and protein kinase C (bisindolylmaleimide I), whereas the effect of BDNF alone was inhibited only by U0126.	U 0126	308-313	brain derived neurotrophic factor	Homo sapiens	15-19
30753865-5	2019	The effects of BDNF in combination with AS1949490 on the Bdnf mRNA levels were blocked by inhibitors of mitogen-activated protein kinase kinase (U0126), PI3-kinase (LY294002), phospholipase Cgamma (U73122), and protein kinase C (bisindolylmaleimide I), whereas the effect of BDNF alone was inhibited only by U0126.	U 0126	308-313	brain derived neurotrophic factor	Homo sapiens	57-61
30779937-3	2019	Here we show TNF-alpha, commonly increased in PE subjects, inhibits Cx43 function and Ca2+ bursts in pregnancy-derived ovine uterine artery endothelial cells (P-UAEC) via Src and MEK/ERK phosphorylation of Cx43, and this can be reversed by PP2 or U0126.	U 0126	247-252	tumor necrosis factor	Homo sapiens	13-22
31118889-6	2019	U0126 (an ERK1/2 inhibitor) elongated mitochondrial length, accompanied by the reduced DRP1-S616 phosphorylation.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	10-16
31118889-6	2019	U0126 (an ERK1/2 inhibitor) elongated mitochondrial length, accompanied by the reduced DRP1-S616 phosphorylation.	U 0126	0-5	dynamin 1-like	Rattus norvegicus	87-91
30362534-9	2019	Albumin-induced CD44 and claudin-1 expression were greatly suppressed in the presence of the ERK1/2 inhibitor, U0126.	U 0126	111-116	albumin	Rattus norvegicus	0-7
30362534-9	2019	Albumin-induced CD44 and claudin-1 expression were greatly suppressed in the presence of the ERK1/2 inhibitor, U0126.	U 0126	111-116	claudin 1	Rattus norvegicus	25-34
30362534-9	2019	Albumin-induced CD44 and claudin-1 expression were greatly suppressed in the presence of the ERK1/2 inhibitor, U0126.	U 0126	111-116	mitogen activated protein kinase 3	Rattus norvegicus	93-99
31057410-7	2019	The ERK activation inhibitor U0126 and glucagon-like peptide-1 (GLP-1) receptor antagonist exendin 9-39 abolished the geniposide-induced activation of ERK and inhibited the protective effect of geniposide.	U 0126	29-34	mitogen-activated protein kinase 1	Mus musculus	4-7
31844611-18	2019	U0126, an inhibitor of ERK activation, significantly abrogated the protective effects of CoPP.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	23-26
31080405-7	2019	The NAD+-induced changes can also be blocked by the ERK signaling inhibitor U0126.	U 0126	76-81	Eph receptor B1	Rattus norvegicus	52-55
31118775-16	2019	U0126 significantly inhibited the SMARCE1-induced proliferation and mobility of GC cells.	U 0126	0-5	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1	Homo sapiens	34-41
31018569-5	2019	Notably, chemical inhibition of RSK2 signaling using kaempferol (a RSK2 inhibitor) or U0126 (a selective MEK inhibitor) suppressed EGF-induced c-fos promoter activity.	U 0126	86-91	ribosomal protein S6 kinase A3	Homo sapiens	32-36
31018569-5	2019	Notably, chemical inhibition of RSK2 signaling using kaempferol (a RSK2 inhibitor) or U0126 (a selective MEK inhibitor) suppressed EGF-induced c-fos promoter activity.	U 0126	86-91	mitogen-activated protein kinase kinase 7	Homo sapiens	105-108
31018569-5	2019	Notably, chemical inhibition of RSK2 signaling using kaempferol (a RSK2 inhibitor) or U0126 (a selective MEK inhibitor) suppressed EGF-induced c-fos promoter activity.	U 0126	86-91	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	143-148
31139644-7	2019	ERK inhibitor U0126 reversed the protective effect of chlorogenic acid on colon tissue.	U 0126	14-19	mitogen-activated protein kinase 1	Mus musculus	0-3
31057410-7	2019	The ERK activation inhibitor U0126 and glucagon-like peptide-1 (GLP-1) receptor antagonist exendin 9-39 abolished the geniposide-induced activation of ERK and inhibited the protective effect of geniposide.	U 0126	29-34	mitogen-activated protein kinase 1	Mus musculus	151-154
31057535-11	2019	Because inhibition of ERK by U0126 abolished PV-IgG- and AK23-induced loss of cell cohesion in ST18-expressing cells, we conclude that autoantibody-induced ERK activation was relevant in this scenario.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	22-25
31057535-11	2019	Because inhibition of ERK by U0126 abolished PV-IgG- and AK23-induced loss of cell cohesion in ST18-expressing cells, we conclude that autoantibody-induced ERK activation was relevant in this scenario.	U 0126	29-34	ST18 C2H2C-type zinc finger transcription factor	Homo sapiens	95-99
30716312-8	2019	Furthermore, both LY294002 (the PI3K-Akt inhibitor) and U0126 (the MEK-ERK inhibitor) blocked the regulation of IRS-1 on TAZ during adipogenesis.	U 0126	56-61	Eph receptor B1	Rattus norvegicus	71-74
30716312-8	2019	Furthermore, both LY294002 (the PI3K-Akt inhibitor) and U0126 (the MEK-ERK inhibitor) blocked the regulation of IRS-1 on TAZ during adipogenesis.	U 0126	56-61	insulin receptor substrate 1	Rattus norvegicus	112-117
30971268-13	2019	Whereas blocking of Raf1 by shRNA or specific inhibition of MEK1 by U0126 antagonized the oncogenetic effect of PAK1 on ESCC cells.	U 0126	68-73	mitogen-activated protein kinase kinase 1	Homo sapiens	60-64
31844616-7	2019	Subsequently, the two groups were treated with the MAPK/ERK-specific inhibitor U0126, and then, the mRNA expression levels of osteogenic genes and protein expression levels of p-ERK in the cultures were determined by Q-PCR and Western blotting, respectively.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	56-59
31844616-10	2019	Subsequently, using the MAPK/ERK-specific inhibitor U0126, Western blotting showed that the expression of p-ERK protein was significantly inhibited and that there was no difference between the two groups.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	24-28
31844616-10	2019	Subsequently, using the MAPK/ERK-specific inhibitor U0126, Western blotting showed that the expression of p-ERK protein was significantly inhibited and that there was no difference between the two groups.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	29-32
31844616-10	2019	Subsequently, using the MAPK/ERK-specific inhibitor U0126, Western blotting showed that the expression of p-ERK protein was significantly inhibited and that there was no difference between the two groups.	U 0126	52-57	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	106-111
30978262-0	2019	MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats.	U 0126	17-22	mitogen activated protein kinase kinase 1	Rattus norvegicus	0-6
30978262-4	2019	The aim of the study was to compare intrathecal and subcutaneous treatment regimens of nimodipine and intrathecal treatment regimens of U0126, a MEK1/2 inhibitor, in a single injection experimental rat SAH model with post 48 h endpoints consisting of wire myography of cerebral arteries, flow cytometry of cerebral arterial tissue and behavioural evaluation.	U 0126	136-141	mitogen activated protein kinase kinase 1	Rattus norvegicus	145-151
30971268-13	2019	Whereas blocking of Raf1 by shRNA or specific inhibition of MEK1 by U0126 antagonized the oncogenetic effect of PAK1 on ESCC cells.	U 0126	68-73	p21 (RAC1) activated kinase 1	Homo sapiens	112-116
30978262-5	2019	Following ET-1 concentration-response curves, U0126 exposed arteries had a significantly lower ET-1max than vehicle arteries.	U 0126	46-51	endothelin 1	Rattus norvegicus	10-14
30557604-10	2019	Treatment with the MEK inhibitor U0126 inhibited the activation by TCF7L2 or EGR1 overexpression.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
30969964-10	2019	Both were attenuated by the ERK1/2 signaling inhibitors, U0126 and AZD6244.	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	28-34
30863710-9	2019	Interestingly, LY294002 decreased the expression of p-AKT and attenuated the neuroprotective effect of EPO; while, U0126 decreased the expression of p-Erk1/2 and enhanced the neuroprotective effect of EPO.	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	151-157
30863710-9	2019	Interestingly, LY294002 decreased the expression of p-AKT and attenuated the neuroprotective effect of EPO; while, U0126 decreased the expression of p-Erk1/2 and enhanced the neuroprotective effect of EPO.	U 0126	115-120	erythropoietin	Homo sapiens	201-204
30648910-0	2019	Blockade of ERK1/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	12-18
30648910-6	2019	Administration of U0126, a selective inhibitor of ERK1/2, blocked all these responses.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	50-56
30648910-7	2019	U0126 was also effective in inhibiting renal tubular cell injury, as shown by decreased expression of lipocalin-2 and kidney injury molecule-1 and active forms of caspase-3.	U 0126	0-5	lipocalin 2	Rattus norvegicus	102-113
30648910-7	2019	U0126 was also effective in inhibiting renal tubular cell injury, as shown by decreased expression of lipocalin-2 and kidney injury molecule-1 and active forms of caspase-3.	U 0126	0-5	hepatitis A virus cellular receptor 1	Rattus norvegicus	118-142
30648910-7	2019	U0126 was also effective in inhibiting renal tubular cell injury, as shown by decreased expression of lipocalin-2 and kidney injury molecule-1 and active forms of caspase-3.	U 0126	0-5	caspase 3	Rattus norvegicus	163-172
30648910-8	2019	U0126 or ERK1/2 siRNA can inhibit tubular cell EMT and cell apoptosis as characterized with decreased expression of cleaved caspase-3.	U 0126	0-5	caspase 3	Rattus norvegicus	124-133
31975773-4	2019	Purposes: The current study was designed to investigate the effect of inhibition of MEK-ERK1/2 signaling by PD98059 and U0126 on the growth and migration of glioma cells as well as their adhesion to extracellular matrix.	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
31975773-4	2019	Purposes: The current study was designed to investigate the effect of inhibition of MEK-ERK1/2 signaling by PD98059 and U0126 on the growth and migration of glioma cells as well as their adhesion to extracellular matrix.	U 0126	120-125	mitogen-activated protein kinase 3	Homo sapiens	88-94
31975773-5	2019	Methods: MEK-ERK1/2 signaling in U87-MG cells was inhibited by PD98059 and U0126.	U 0126	75-80	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
31975773-5	2019	Methods: MEK-ERK1/2 signaling in U87-MG cells was inhibited by PD98059 and U0126.	U 0126	75-80	mitogen-activated protein kinase 3	Homo sapiens	13-19
30445521-11	2019	Moreover, pretreatment with the U0126, a specific ERK1/2 phosphorylation inhibitor, suppressed PDEFB103A inducing GCs ERK1/2 phosphorylation, as well as proliferation and migration, suggesting that PDEFB103A may act via activating the ERK1/2 pathway.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	50-56
30445521-11	2019	Moreover, pretreatment with the U0126, a specific ERK1/2 phosphorylation inhibitor, suppressed PDEFB103A inducing GCs ERK1/2 phosphorylation, as well as proliferation and migration, suggesting that PDEFB103A may act via activating the ERK1/2 pathway.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	118-124
30445521-11	2019	Moreover, pretreatment with the U0126, a specific ERK1/2 phosphorylation inhibitor, suppressed PDEFB103A inducing GCs ERK1/2 phosphorylation, as well as proliferation and migration, suggesting that PDEFB103A may act via activating the ERK1/2 pathway.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	118-124
30920672-4	2019	Also, treatment with U0126, an inhibitor of ERK, could block MF-induced SK1 phosphorylation, but had no effect on PKCalpha phosphorylation.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	44-47
30920672-4	2019	Also, treatment with U0126, an inhibitor of ERK, could block MF-induced SK1 phosphorylation, but had no effect on PKCalpha phosphorylation.	U 0126	21-26	sphingosine kinase 1	Homo sapiens	72-75
30685603-6	2019	Quercetin, rottlerin, SP600125 and U0126 attenuated TNF-alpha-stimulated c-Jun phosphorylation and AP-1-Luc activity.	U 0126	35-40	tumor necrosis factor	Homo sapiens	52-61
30685603-6	2019	Quercetin, rottlerin, SP600125 and U0126 attenuated TNF-alpha-stimulated c-Jun phosphorylation and AP-1-Luc activity.	U 0126	35-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	73-78
30685603-8	2019	TNF-alpha significantly increased MMP-9 promoter activity and THP-1 cell adherence, and these effects were attenuated by pretreatment with quercetin, rottlerin, SP600125, U0126, tanshinone IIA or Bay 11-7082.	U 0126	171-176	tumor necrosis factor	Homo sapiens	0-9
30685603-8	2019	TNF-alpha significantly increased MMP-9 promoter activity and THP-1 cell adherence, and these effects were attenuated by pretreatment with quercetin, rottlerin, SP600125, U0126, tanshinone IIA or Bay 11-7082.	U 0126	171-176	matrix metallopeptidase 9	Homo sapiens	34-39
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	U 0126	49-54	interleukin 1 beta	Homo sapiens	110-118
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	U 0126	49-54	matrix metallopeptidase 9	Homo sapiens	127-132
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	27-33
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	U 0126	35-40	interleukin 1 beta	Homo sapiens	72-80
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	U 0126	35-40	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-94
30320903-6	2019	Cotreatment of either purvalanol or roscovitine with ERK1/2 inhibitor, U0126, synergistically suppressed cell proliferation, and induced apoptotic action.	U 0126	71-76	mitogen-activated protein kinase 3	Homo sapiens	53-59
30238980-6	2019	Ephrin A1 dose-dependently increased phosphorylation of extracellular signal-regulated kinases (ERK)1/2, c-Jun N-terminal kinases (JNK), P38, protein kinase B (AKT), P70S6K, S6, and cyclin D1, and the activated proteins were suppressed by pharmacological inhibitors including wortmannin (a PI3K inhibitor), U0126 (an ERK1/2 inhibitor), and SP600125 (a JNK inhibitor).	U 0126	307-312	ephrin A1	Bos taurus	0-9
30685085-9	2019	Under LSS, ERK inhibitor U0126 decreased both active YAP and ERK expressions, while YAP inhibitor verteporfin failed to decrease ERK phosphorylation.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	11-14
30685085-9	2019	Under LSS, ERK inhibitor U0126 decreased both active YAP and ERK expressions, while YAP inhibitor verteporfin failed to decrease ERK phosphorylation.	U 0126	25-30	Yes1 associated transcriptional regulator	Homo sapiens	53-56
30685085-9	2019	Under LSS, ERK inhibitor U0126 decreased both active YAP and ERK expressions, while YAP inhibitor verteporfin failed to decrease ERK phosphorylation.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	61-64
30685085-9	2019	Under LSS, ERK inhibitor U0126 decreased both active YAP and ERK expressions, while YAP inhibitor verteporfin failed to decrease ERK phosphorylation.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	61-64
30840849-6	2019	U0126 (MEK specific inhibitor) not only suppressed the combination-induced differentiation but also restored the protein level of CCAAT/enhancer binding protein beta and/or PU.1.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	7-10
30840849-6	2019	U0126 (MEK specific inhibitor) not only suppressed the combination-induced differentiation but also restored the protein level of CCAAT/enhancer binding protein beta and/or PU.1.	U 0126	0-5	CCAAT enhancer binding protein beta	Homo sapiens	130-165
30840849-6	2019	U0126 (MEK specific inhibitor) not only suppressed the combination-induced differentiation but also restored the protein level of CCAAT/enhancer binding protein beta and/or PU.1.	U 0126	0-5	Spi-1 proto-oncogene	Homo sapiens	173-177
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	U 0126	49-54	mitogen-activated protein kinase 3	Homo sapiens	41-47
30132884-7	2019	Inactivation of ERK1/2 and p38 MAPK pathways using selective inhibitors (U0126 and SB203580) abrogated PXR-induced SMC proliferation and migration.	U 0126	73-78	mitogen activated protein kinase 3	Rattus norvegicus	16-22
30132884-7	2019	Inactivation of ERK1/2 and p38 MAPK pathways using selective inhibitors (U0126 and SB203580) abrogated PXR-induced SMC proliferation and migration.	U 0126	73-78	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	103-106
30649683-8	2019	First, we confirmed the role of PDGF-A-activated ERK signaling in OPC migration using the pharmacological inhibitor U0126, or siRNA-mediated suppression of ERK expression.	U 0126	116-121	platelet derived growth factor subunit A	Homo sapiens	32-38
30649683-8	2019	First, we confirmed the role of PDGF-A-activated ERK signaling in OPC migration using the pharmacological inhibitor U0126, or siRNA-mediated suppression of ERK expression.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	49-52
30649683-9	2019	Then, we demonstrated that PDGF-A-induced actin reorganization and interaction of focal adhesion kinase (FAK), Paxillin, and pERK signals are impaired in OPCs treated with the MEK inhibitor U0126.	U 0126	190-195	platelet derived growth factor subunit A	Homo sapiens	27-33
30649683-9	2019	Then, we demonstrated that PDGF-A-induced actin reorganization and interaction of focal adhesion kinase (FAK), Paxillin, and pERK signals are impaired in OPCs treated with the MEK inhibitor U0126.	U 0126	190-195	protein tyrosine kinase 2	Homo sapiens	82-103
30649683-9	2019	Then, we demonstrated that PDGF-A-induced actin reorganization and interaction of focal adhesion kinase (FAK), Paxillin, and pERK signals are impaired in OPCs treated with the MEK inhibitor U0126.	U 0126	190-195	protein tyrosine kinase 2	Homo sapiens	105-108
30649683-9	2019	Then, we demonstrated that PDGF-A-induced actin reorganization and interaction of focal adhesion kinase (FAK), Paxillin, and pERK signals are impaired in OPCs treated with the MEK inhibitor U0126.	U 0126	190-195	paxillin	Homo sapiens	111-119
30649683-9	2019	Then, we demonstrated that PDGF-A-induced actin reorganization and interaction of focal adhesion kinase (FAK), Paxillin, and pERK signals are impaired in OPCs treated with the MEK inhibitor U0126.	U 0126	190-195	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	125-129
30649683-9	2019	Then, we demonstrated that PDGF-A-induced actin reorganization and interaction of focal adhesion kinase (FAK), Paxillin, and pERK signals are impaired in OPCs treated with the MEK inhibitor U0126.	U 0126	190-195	mitogen-activated protein kinase kinase 7	Homo sapiens	176-179
29934960-14	2019	U0126, a specific inhibitor for mitogen-activated and extracellular signal-regulated kinase kinases 1/2 (MEK-1/2), completely blocked TGF-beta1-induced MCP-1 expression.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	105-112
29934960-14	2019	U0126, a specific inhibitor for mitogen-activated and extracellular signal-regulated kinase kinases 1/2 (MEK-1/2), completely blocked TGF-beta1-induced MCP-1 expression.	U 0126	0-5	transforming growth factor, beta 1	Rattus norvegicus	134-143
29934960-14	2019	U0126, a specific inhibitor for mitogen-activated and extracellular signal-regulated kinase kinases 1/2 (MEK-1/2), completely blocked TGF-beta1-induced MCP-1 expression.	U 0126	0-5	C-C motif chemokine ligand 2	Rattus norvegicus	152-157
30641047-8	2019	Luteolin increased phosphorylation of Nrf2 at Ser40, and MEK inhibitors (U0126 and PD98059) canceled luteolin-induced phosphorylation of Nrf2.	U 0126	73-78	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
30641047-8	2019	Luteolin increased phosphorylation of Nrf2 at Ser40, and MEK inhibitors (U0126 and PD98059) canceled luteolin-induced phosphorylation of Nrf2.	U 0126	73-78	NFE2 like bZIP transcription factor 2	Homo sapiens	137-141
30993112-6	2019	Pretreatment with the ERK inhibitor (U0126 or PD98059) suppressed the release of ET-1 and EMT induced by uric acid.	U 0126	37-42	Eph receptor B1	Rattus norvegicus	22-25
30993112-6	2019	Pretreatment with the ERK inhibitor (U0126 or PD98059) suppressed the release of ET-1 and EMT induced by uric acid.	U 0126	37-42	endothelin 1	Rattus norvegicus	81-85
30639310-11	2019	The NH4Cl-induced alterations were reversed by reactive oxygen species scavenger N-acetylcysteine and ERK1/2 inhibitor U0126.	U 0126	119-124	mitogen activated protein kinase 3	Rattus norvegicus	102-108
30557604-10	2019	Treatment with the MEK inhibitor U0126 inhibited the activation by TCF7L2 or EGR1 overexpression.	U 0126	33-38	transcription factor 7 like 2	Homo sapiens	67-73
30557604-10	2019	Treatment with the MEK inhibitor U0126 inhibited the activation by TCF7L2 or EGR1 overexpression.	U 0126	33-38	early growth response 1	Homo sapiens	77-81
30816240-8	2019	The ERK inhibitor U0126 alleviated mechanical allodynia with lower p-ERK expression in the sham females but did not affect the OVX rats.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	4-7
30908581-7	2019	PI3K/AKT inhibitor (wortmannin) and MEK/ERK inhibitor (U0126) reduced the TGF-beta1-induced synthesis of FN, COL3, and alpha-SMA in HPFs.	U 0126	55-60	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
30908581-7	2019	PI3K/AKT inhibitor (wortmannin) and MEK/ERK inhibitor (U0126) reduced the TGF-beta1-induced synthesis of FN, COL3, and alpha-SMA in HPFs.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	40-43
30908581-7	2019	PI3K/AKT inhibitor (wortmannin) and MEK/ERK inhibitor (U0126) reduced the TGF-beta1-induced synthesis of FN, COL3, and alpha-SMA in HPFs.	U 0126	55-60	transforming growth factor beta 1	Homo sapiens	74-83
30474276-7	2019	To elucidate whether the observed downregulation of beta1 is EGF-RT845 -dependent or emerging from ERK1/2 signaling, we exposed epithelia, grown on the NWMs, with the ERK1/2-directed inhibitor U0126.	U 0126	193-198	mitogen-activated protein kinase 3	Homo sapiens	167-173
30066962-4	2019	Inhibition of Erk1/2 with U0126, knockdown of Erk1/2, or overexpression of dominant-negative mitogen-activated protein kinase kinase 1 (MKK1) strengthened resveratrol"s inhibition of the basal or IGF-1-stimulated of Erk1/2 phosphorylation and cell adhesion, whereas ectopic expression of constitutively active MKK1 attenuated the inhibitory effects of resveratrol.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	14-20
30597356-7	2019	ERK1/2 inhibitor U0126 reduced ROS formation, the activation of NFkappaB and Egr1, and the elevated TNFalpha expression in D-glucose-stimulated BV2 cells.	U 0126	17-22	mitogen-activated protein kinase 3	Mus musculus	0-6
30597356-7	2019	ERK1/2 inhibitor U0126 reduced ROS formation, the activation of NFkappaB and Egr1, and the elevated TNFalpha expression in D-glucose-stimulated BV2 cells.	U 0126	17-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	64-72
30597356-7	2019	ERK1/2 inhibitor U0126 reduced ROS formation, the activation of NFkappaB and Egr1, and the elevated TNFalpha expression in D-glucose-stimulated BV2 cells.	U 0126	17-22	early growth response 1	Mus musculus	77-81
30597356-7	2019	ERK1/2 inhibitor U0126 reduced ROS formation, the activation of NFkappaB and Egr1, and the elevated TNFalpha expression in D-glucose-stimulated BV2 cells.	U 0126	17-22	tumor necrosis factor	Mus musculus	100-108
30684529-9	2019	Inhibition of hinokitiol-induced ERK activation by MEK inhibitor U0126 completely blocked expression of MKP-3.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	33-36
30684529-9	2019	Inhibition of hinokitiol-induced ERK activation by MEK inhibitor U0126 completely blocked expression of MKP-3.	U 0126	65-70	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
30684529-9	2019	Inhibition of hinokitiol-induced ERK activation by MEK inhibitor U0126 completely blocked expression of MKP-3.	U 0126	65-70	dual specificity phosphatase 6	Homo sapiens	104-109
30923636-8	2019	As expected, after pretreatment with a MEK inhibitor (U0126), ADH-induced THP-1 cells exhibited unaltered morphological features, eliminated ERK1/2 phosphorylation, prevented CD86/CD11b upregulation and inhibited pro-inflammatory cytokine increase.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
30923636-8	2019	As expected, after pretreatment with a MEK inhibitor (U0126), ADH-induced THP-1 cells exhibited unaltered morphological features, eliminated ERK1/2 phosphorylation, prevented CD86/CD11b upregulation and inhibited pro-inflammatory cytokine increase.	U 0126	54-59	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	62-65
30923636-8	2019	As expected, after pretreatment with a MEK inhibitor (U0126), ADH-induced THP-1 cells exhibited unaltered morphological features, eliminated ERK1/2 phosphorylation, prevented CD86/CD11b upregulation and inhibited pro-inflammatory cytokine increase.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	141-147
30923636-8	2019	As expected, after pretreatment with a MEK inhibitor (U0126), ADH-induced THP-1 cells exhibited unaltered morphological features, eliminated ERK1/2 phosphorylation, prevented CD86/CD11b upregulation and inhibited pro-inflammatory cytokine increase.	U 0126	54-59	CD86 molecule	Homo sapiens	175-179
30923636-8	2019	As expected, after pretreatment with a MEK inhibitor (U0126), ADH-induced THP-1 cells exhibited unaltered morphological features, eliminated ERK1/2 phosphorylation, prevented CD86/CD11b upregulation and inhibited pro-inflammatory cytokine increase.	U 0126	54-59	integrin subunit alpha M	Homo sapiens	180-185
30816240-8	2019	The ERK inhibitor U0126 alleviated mechanical allodynia with lower p-ERK expression in the sham females but did not affect the OVX rats.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	69-72
30781697-6	2019	Inhibiting either Phosphatidyl inositol (3) kinase (PI3K) with Wortmannin or the mitogen-activated protein kinase extracellular-regulated kinase (MAPK ERK) with U0126 leads to the inhibition of tube formation.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	146-150
30818884-14	2019	Similarly, the ERK inhibitor U0126 inhibited HAS-2 in Pm-ME/H2O2-treated HaCaT cells.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	15-18
30818884-14	2019	Similarly, the ERK inhibitor U0126 inhibited HAS-2 in Pm-ME/H2O2-treated HaCaT cells.	U 0126	29-34	hyaluronan synthase 2	Homo sapiens	45-50
30838176-8	2019	In line with these results, ERK (U0126) and p38 MAPK (SB203580) specific signaling inhibitors suppressed hIL-6 expression and attenuated cell growth in PEL cells.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	28-31
30838176-8	2019	In line with these results, ERK (U0126) and p38 MAPK (SB203580) specific signaling inhibitors suppressed hIL-6 expression and attenuated cell growth in PEL cells.	U 0126	33-38	interleukin 6	Homo sapiens	105-110
30781697-6	2019	Inhibiting either Phosphatidyl inositol (3) kinase (PI3K) with Wortmannin or the mitogen-activated protein kinase extracellular-regulated kinase (MAPK ERK) with U0126 leads to the inhibition of tube formation.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	151-154
30365943-6	2019	UV irradiation of HCE-S cells resulted in an increase in ERK phosphorylation and CRIM1 expression, the latter further elevated by the addition of the MEK1/2 inhibitor, U0126.	U 0126	168-173	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	18-21
30899375-9	2019	Moreover, CCR4 knockdown, U0126 (a MEK/ERK inhibitor) or ophiopogonin B also partially blocked the EMT promoting effects of CCL2 and CCL5.	U 0126	26-31	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
30899375-9	2019	Moreover, CCR4 knockdown, U0126 (a MEK/ERK inhibitor) or ophiopogonin B also partially blocked the EMT promoting effects of CCL2 and CCL5.	U 0126	26-31	EPH receptor B2	Homo sapiens	39-42
30899375-9	2019	Moreover, CCR4 knockdown, U0126 (a MEK/ERK inhibitor) or ophiopogonin B also partially blocked the EMT promoting effects of CCL2 and CCL5.	U 0126	26-31	C-C motif chemokine ligand 2	Homo sapiens	124-128
30899375-9	2019	Moreover, CCR4 knockdown, U0126 (a MEK/ERK inhibitor) or ophiopogonin B also partially blocked the EMT promoting effects of CCL2 and CCL5.	U 0126	26-31	C-C motif chemokine ligand 5	Homo sapiens	133-137
30579831-14	2019	Pre-administration of wortmannin or U0126 blocked the protective effects of KY-226 on ZO-1 protein and mRNA reduction in tMCAO mice.	U 0126	36-41	tight junction protein 1	Mus musculus	86-90
30709842-6	2019	The transient increase in Adam17 mRNA in response to PMA was strongly reduced by an inhibitor of ERK1/2 phosphorylation, U0126.	U 0126	121-126	a disintegrin and metallopeptidase domain 17	Mus musculus	26-32
30709842-6	2019	The transient increase in Adam17 mRNA in response to PMA was strongly reduced by an inhibitor of ERK1/2 phosphorylation, U0126.	U 0126	121-126	mitogen-activated protein kinase 3	Mus musculus	97-103
30365943-6	2019	UV irradiation of HCE-S cells resulted in an increase in ERK phosphorylation and CRIM1 expression, the latter further elevated by the addition of the MEK1/2 inhibitor, U0126.	U 0126	168-173	mitogen-activated protein kinase 1	Homo sapiens	57-60
30365943-6	2019	UV irradiation of HCE-S cells resulted in an increase in ERK phosphorylation and CRIM1 expression, the latter further elevated by the addition of the MEK1/2 inhibitor, U0126.	U 0126	168-173	cysteine rich transmembrane BMP regulator 1	Homo sapiens	81-86
30680029-7	2019	VPC23019 and U0126 eliminated the neuroprotective effects of metformin on neuronal apoptosis, which suggests that metformin is able to protect against sevoflurane-induced neurotoxicity via activation of the S1P1-dependent ERK1/2 signaling pathway.	U 0126	13-18	sphingosine-1-phosphate receptor 1	Homo sapiens	207-211
30680029-7	2019	VPC23019 and U0126 eliminated the neuroprotective effects of metformin on neuronal apoptosis, which suggests that metformin is able to protect against sevoflurane-induced neurotoxicity via activation of the S1P1-dependent ERK1/2 signaling pathway.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	222-226
30365943-6	2019	UV irradiation of HCE-S cells resulted in an increase in ERK phosphorylation and CRIM1 expression, the latter further elevated by the addition of the MEK1/2 inhibitor, U0126.	U 0126	168-173	mitogen-activated protein kinase kinase 1	Homo sapiens	150-156
30439349-5	2019	MEK/ERK1/2 inhibitor U0126 was administered at 0, 6, and 24 h following reperfusion and the functional properties of the ophthalmic artery were evaluated at 48 h post reperfusion.	U 0126	21-26	mitogen activated protein kinase 3	Rattus norvegicus	4-10
30439349-7	2019	Occlusion of the ophthalmic artery led to a significant increase of endothelin-1 mediated vasoconstriction which can be attenuated by U0126 treatment, most evident at higher ET-1 concentrations of 10-7 M (Emax151.0 +- 22.0% of 60 mM K+), vs non-treated ischemic arteries Emax 212.1 +- 14.7% of 60 mM K+).	U 0126	134-139	endothelin 1	Rattus norvegicus	68-80
30439349-7	2019	Occlusion of the ophthalmic artery led to a significant increase of endothelin-1 mediated vasoconstriction which can be attenuated by U0126 treatment, most evident at higher ET-1 concentrations of 10-7 M (Emax151.0 +- 22.0% of 60 mM K+), vs non-treated ischemic arteries Emax 212.1 +- 14.7% of 60 mM K+).	U 0126	134-139	endothelin 1	Rattus norvegicus	174-178
29873042-6	2019	Using ERK1/2 inhibitor U0126, JNK inhibitor SP600125, and p38 inhibitor SB203580, we validated the role of MAP kinase proteins in the activation of NF-kB and caspase-3.	U 0126	23-28	nuclear factor kappa B subunit 1	Rattus norvegicus	148-153
30515965-9	2019	Moreover, the expression of CDK6 was also inhibited by the ERK signalling inhibitor, U0126.	U 0126	85-90	cyclin dependent kinase 6	Homo sapiens	28-32
30515965-9	2019	Moreover, the expression of CDK6 was also inhibited by the ERK signalling inhibitor, U0126.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	59-62
30276527-10	2019	The mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) inhibitor U0126 in the PVN partially reversed the LPS-induced enhancement of SNA.	U 0126	91-96	Eph receptor B1	Rattus norvegicus	76-79
30535504-3	2019	MEK inhibition by U0126 significantly decreased the growth of SW48 cells that harbored the MEK1 Q56P mutation, although it did not evidently affect the growth of NCI-H508 cells with MEK1 wild-type.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
30535504-3	2019	MEK inhibition by U0126 significantly decreased the growth of SW48 cells that harbored the MEK1 Q56P mutation, although it did not evidently affect the growth of NCI-H508 cells with MEK1 wild-type.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	91-95
30535504-4	2019	In addition, U0126 increased the sensitivity of SW48 cells to 5-fluorouracil (5-FU) and oxaliplatin by producing more gammaH2AX foci and decreasing the expression of excision repair cross-complementation group 1 and thymidylate synthase.	U 0126	13-18	thymidylate synthetase	Homo sapiens	216-236
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	phosphatidylethanolamine binding protein 4	Homo sapiens	17-22
32542095-8	2020	U0126 inhibited semen-induced ERK1/2 phosphorylation, c-myc upregulation and cell proliferation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	30-36
32542095-8	2020	U0126 inhibited semen-induced ERK1/2 phosphorylation, c-myc upregulation and cell proliferation.	U 0126	0-5	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
30723473-9	2019	U0126, a MEK inhibitor, reduced the PA-induced cytokine response.	U 0126	0-5	midkine	Mus musculus	9-12
29246772-3	2019	By using 8-OH-DPAT, a selective 5-HT1aR agonist, NAN-190, a selective 5-HT1aR antagonist, and U0126, an Extracellular Regulated Protein Kinases (ERK) phosphorylation inhibitor, we investigated the role of ERK in 5-HT1aR-nNOS pathway.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	205-208
29246772-3	2019	By using 8-OH-DPAT, a selective 5-HT1aR agonist, NAN-190, a selective 5-HT1aR antagonist, and U0126, an Extracellular Regulated Protein Kinases (ERK) phosphorylation inhibitor, we investigated the role of ERK in 5-HT1aR-nNOS pathway.	U 0126	94-99	nitric oxide synthase 1	Homo sapiens	220-224
30728885-11	2019	In H9c2 cells, hypoxia-induced TXNIP and NLRP3 expressions were inhibited by EP and to a lesser degree by U0126 (MEK inhibitor) and SB203580 (p38 inhibitor) as well.	U 0126	106-111	thioredoxin interacting protein	Rattus norvegicus	31-36
30728885-11	2019	In H9c2 cells, hypoxia-induced TXNIP and NLRP3 expressions were inhibited by EP and to a lesser degree by U0126 (MEK inhibitor) and SB203580 (p38 inhibitor) as well.	U 0126	106-111	NLR family, pyrin domain containing 3	Rattus norvegicus	41-46
30792807-5	2019	Moreover, TTM protected both melanoma types from toxicity induced by DSF, NC and co-treatment with sub-lethal levels of DSF and the MEK inhibitor, UO126.	U 0126	147-152	mitogen-activated protein kinase kinase 7	Homo sapiens	132-135
30621146-8	2019	Using the inhibitors of MAPK/ERK, U0126, we found that the crosstalk among the signaling pathways of MAPK/ERK, Akt-mTOR, and the inflammatory adipogenesis can be the possible mechanism of salt-linked obesity.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	101-105
30621146-8	2019	Using the inhibitors of MAPK/ERK, U0126, we found that the crosstalk among the signaling pathways of MAPK/ERK, Akt-mTOR, and the inflammatory adipogenesis can be the possible mechanism of salt-linked obesity.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	106-109
30621146-8	2019	Using the inhibitors of MAPK/ERK, U0126, we found that the crosstalk among the signaling pathways of MAPK/ERK, Akt-mTOR, and the inflammatory adipogenesis can be the possible mechanism of salt-linked obesity.	U 0126	34-39	AKT serine/threonine kinase 1	Homo sapiens	111-114
30621146-8	2019	Using the inhibitors of MAPK/ERK, U0126, we found that the crosstalk among the signaling pathways of MAPK/ERK, Akt-mTOR, and the inflammatory adipogenesis can be the possible mechanism of salt-linked obesity.	U 0126	34-39	mechanistic target of rapamycin kinase	Homo sapiens	115-119
30447218-9	2019	MEK1/2 inhibitor U0126 reduced the d-glucose-induced NFkappaB nuclear accumulation and TNFalpha expression in BV2 cells.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Mus musculus	0-6
30447218-9	2019	MEK1/2 inhibitor U0126 reduced the d-glucose-induced NFkappaB nuclear accumulation and TNFalpha expression in BV2 cells.	U 0126	17-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	53-61
30447218-9	2019	MEK1/2 inhibitor U0126 reduced the d-glucose-induced NFkappaB nuclear accumulation and TNFalpha expression in BV2 cells.	U 0126	17-22	tumor necrosis factor	Mus musculus	87-95
30603049-10	2019	Furthermore, pretreatment with Y-27632 or U0126 was found to restore the nuclear translocation of Smad1 suppressed by PDGF-BB and decrease the proliferation of PASMCs.	U 0126	42-47	SMAD family member 1	Rattus norvegicus	98-103
30719147-9	2019	Moreover, JNK inhibitor (SP600125) and MEK inhibitor (U0126) treatment abolished the increase in phosphorylated MTOR and ribosomal protein S6 as well as the increase in ZO-1 and the decrease in claudin-1 in lycopene-treated COLO-16 cells.	U 0126	54-59	tight junction protein 1	Homo sapiens	169-173
30719147-9	2019	Moreover, JNK inhibitor (SP600125) and MEK inhibitor (U0126) treatment abolished the increase in phosphorylated MTOR and ribosomal protein S6 as well as the increase in ZO-1 and the decrease in claudin-1 in lycopene-treated COLO-16 cells.	U 0126	54-59	claudin 1	Homo sapiens	194-203
30145138-8	2019	The HSP27 phosphorylation induced by visfatin was also blocked by the specific PI3K/Akt inhibitor LY294002 and ERK 1/2 inhibitor U0126.	U 0126	129-134	heat shock protein family B (small) member 1	Homo sapiens	4-9
30145138-8	2019	The HSP27 phosphorylation induced by visfatin was also blocked by the specific PI3K/Akt inhibitor LY294002 and ERK 1/2 inhibitor U0126.	U 0126	129-134	nicotinamide phosphoribosyltransferase	Homo sapiens	37-45
30145138-8	2019	The HSP27 phosphorylation induced by visfatin was also blocked by the specific PI3K/Akt inhibitor LY294002 and ERK 1/2 inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	111-118
30145138-9	2019	Furthermore, the visfatin impact on HUVECs as above were also blocked by LY294002 and U0126.	U 0126	86-91	nicotinamide phosphoribosyltransferase	Homo sapiens	17-25
30675292-2	2019	The transduction process of ERK/MAPK signaling pathway was inhibited using methyl ethyl ketone (MEK) inhibitor U0126.	U 0126	111-116	mitogen-activated protein kinase 1	Homo sapiens	28-31
31080992-2	2019	METHODS: HPDLCs were isolated and transfected with si-MGF, or stimulated with MGF or MEK/ERK pathway inhibitor U0126.	U 0126	111-116	mitogen-activated protein kinase kinase 7	Homo sapiens	85-88
31080992-2	2019	METHODS: HPDLCs were isolated and transfected with si-MGF, or stimulated with MGF or MEK/ERK pathway inhibitor U0126.	U 0126	111-116	mitogen-activated protein kinase 1	Homo sapiens	89-92
31080992-14	2019	Simultaneously, precondition with U0126 antagonized MGF-enhanced effects on CS-triggered osteogenic differentiation and MMP-1, MMP-2 expression (P&lt;0.05).	U 0126	34-39	insulin like growth factor 1	Homo sapiens	52-55
31080992-14	2019	Simultaneously, precondition with U0126 antagonized MGF-enhanced effects on CS-triggered osteogenic differentiation and MMP-1, MMP-2 expression (P&lt;0.05).	U 0126	34-39	matrix metallopeptidase 1	Homo sapiens	120-125
31080992-14	2019	Simultaneously, precondition with U0126 antagonized MGF-enhanced effects on CS-triggered osteogenic differentiation and MMP-1, MMP-2 expression (P&lt;0.05).	U 0126	34-39	matrix metallopeptidase 2	Homo sapiens	127-132
30700692-7	2019	Our results also indicated that there was significantly lower expression of D1R, p-ERK1/2, and c-Fos in the IC of the U0126+Ket group, SCH23390+Ket group, and Ket+EA1 group as compared with that of the Ket group.	U 0126	118-123	mitogen activated protein kinase 3	Rattus norvegicus	83-89
30700692-7	2019	Our results also indicated that there was significantly lower expression of D1R, p-ERK1/2, and c-Fos in the IC of the U0126+Ket group, SCH23390+Ket group, and Ket+EA1 group as compared with that of the Ket group.	U 0126	118-123	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	95-100
30399361-13	2019	Pretreatment with 1  muM MEK inhibitor U0126 reversed the effects of Abeta1-42 on GRK2 expression of and NSPC migration.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
30399361-13	2019	Pretreatment with 1  muM MEK inhibitor U0126 reversed the effects of Abeta1-42 on GRK2 expression of and NSPC migration.	U 0126	39-44	G protein-coupled receptor kinase 2	Homo sapiens	82-86
30574980-5	2019	Consistently, AG490, a JAK2/STAT3 inhibitor, dicyclomine, an M1 mAChR antagonist, or U0126, an ERK1/2 inhibitor, significantly counteracted theanine-induced attenuation of memory impairment induced by klotho gene depletion in mice.	U 0126	85-90	mitogen-activated protein kinase 3	Mus musculus	95-101
30666499-7	2019	Moreover, the inhibition of ERK pathway by U0126 not only reduces the CREB activation but also the CUL4A levels suggesting that CREB is the upstream activator of CUL4A transcription.	U 0126	43-48	mitogen-activated protein kinase 1	Homo sapiens	28-31
30666499-7	2019	Moreover, the inhibition of ERK pathway by U0126 not only reduces the CREB activation but also the CUL4A levels suggesting that CREB is the upstream activator of CUL4A transcription.	U 0126	43-48	cAMP responsive element binding protein 1	Homo sapiens	70-74
30666499-7	2019	Moreover, the inhibition of ERK pathway by U0126 not only reduces the CREB activation but also the CUL4A levels suggesting that CREB is the upstream activator of CUL4A transcription.	U 0126	43-48	cullin 4A	Homo sapiens	99-104
30666499-7	2019	Moreover, the inhibition of ERK pathway by U0126 not only reduces the CREB activation but also the CUL4A levels suggesting that CREB is the upstream activator of CUL4A transcription.	U 0126	43-48	cAMP responsive element binding protein 1	Homo sapiens	128-132
30666499-7	2019	Moreover, the inhibition of ERK pathway by U0126 not only reduces the CREB activation but also the CUL4A levels suggesting that CREB is the upstream activator of CUL4A transcription.	U 0126	43-48	cullin 4A	Homo sapiens	162-167
30666499-8	2019	The reduction of CUL4A levels upon the knocking down of CREB or by U0126 treatment increases the protein levels of CUL4A substrates such as p21 and p27.	U 0126	67-72	cullin 4A	Homo sapiens	17-22
30666499-8	2019	The reduction of CUL4A levels upon the knocking down of CREB or by U0126 treatment increases the protein levels of CUL4A substrates such as p21 and p27.	U 0126	67-72	cullin 4A	Homo sapiens	115-120
30666499-8	2019	The reduction of CUL4A levels upon the knocking down of CREB or by U0126 treatment increases the protein levels of CUL4A substrates such as p21 and p27.	U 0126	67-72	H3 histone pseudogene 16	Homo sapiens	140-143
30666499-8	2019	The reduction of CUL4A levels upon the knocking down of CREB or by U0126 treatment increases the protein levels of CUL4A substrates such as p21 and p27.	U 0126	67-72	interferon alpha inducible protein 27	Homo sapiens	148-151
30654768-13	2019	Additionally, PDPN depleted BcPAP cells treated with inhibitors of MEK1/2 kinases (U0126) or of the BRAF V600E protein (PLX4720) had reduced motility, similar to that previously observed in TPC1 cells after PDPN knock-down.	U 0126	83-88	podoplanin	Homo sapiens	14-18
30654768-13	2019	Additionally, PDPN depleted BcPAP cells treated with inhibitors of MEK1/2 kinases (U0126) or of the BRAF V600E protein (PLX4720) had reduced motility, similar to that previously observed in TPC1 cells after PDPN knock-down.	U 0126	83-88	mitogen-activated protein kinase kinase 1	Homo sapiens	67-73
30692946-7	2018	Blockade of the ERK-CREB axis with the ERK-specific inhibitor U0126 repressed the neuroprotective and antidepressant-like effects of paeoniflorin on rats in the setting of chronic-mild-stress and abolished the recoveries of p-ERK mediated by paeoniflorin treatment.	U 0126	62-67	Eph receptor B1	Rattus norvegicus	16-19
30692946-7	2018	Blockade of the ERK-CREB axis with the ERK-specific inhibitor U0126 repressed the neuroprotective and antidepressant-like effects of paeoniflorin on rats in the setting of chronic-mild-stress and abolished the recoveries of p-ERK mediated by paeoniflorin treatment.	U 0126	62-67	cAMP responsive element binding protein 1	Rattus norvegicus	20-24
30692946-7	2018	Blockade of the ERK-CREB axis with the ERK-specific inhibitor U0126 repressed the neuroprotective and antidepressant-like effects of paeoniflorin on rats in the setting of chronic-mild-stress and abolished the recoveries of p-ERK mediated by paeoniflorin treatment.	U 0126	62-67	Eph receptor B1	Rattus norvegicus	39-42
30692946-7	2018	Blockade of the ERK-CREB axis with the ERK-specific inhibitor U0126 repressed the neuroprotective and antidepressant-like effects of paeoniflorin on rats in the setting of chronic-mild-stress and abolished the recoveries of p-ERK mediated by paeoniflorin treatment.	U 0126	62-67	Eph receptor B1	Rattus norvegicus	39-42
30606985-5	2019	Furthermore, the increases in norgalanthamine-induced ERK 1/2 activation and subsequent DPC proliferation were suppressed by the mitogen-activated protein kinase/ERK kinase (MEK) 1/2 inhibitor, U0126.	U 0126	194-199	mitogen activated protein kinase 3	Rattus norvegicus	54-61
30606985-5	2019	Furthermore, the increases in norgalanthamine-induced ERK 1/2 activation and subsequent DPC proliferation were suppressed by the mitogen-activated protein kinase/ERK kinase (MEK) 1/2 inhibitor, U0126.	U 0126	194-199	mitogen activated protein kinase kinase 1	Rattus norvegicus	129-182
31237214-10	2019	Nevertheless, U0126 (an inhibitor of MEK1/2) pre-treatment reduced the p-ERK1/2 level in both the tGCI+ U0126 group and the tGCI+ U0126+ NaHS group.	U 0126	14-19	mitogen activated protein kinase kinase 1	Rattus norvegicus	37-43
31237214-10	2019	Nevertheless, U0126 (an inhibitor of MEK1/2) pre-treatment reduced the p-ERK1/2 level in both the tGCI+ U0126 group and the tGCI+ U0126+ NaHS group.	U 0126	14-19	mitogen activated protein kinase 3	Rattus norvegicus	73-79
31237214-10	2019	Nevertheless, U0126 (an inhibitor of MEK1/2) pre-treatment reduced the p-ERK1/2 level in both the tGCI+ U0126 group and the tGCI+ U0126+ NaHS group.	U 0126	104-109	mitogen activated protein kinase kinase 1	Rattus norvegicus	37-43
31237214-10	2019	Nevertheless, U0126 (an inhibitor of MEK1/2) pre-treatment reduced the p-ERK1/2 level in both the tGCI+ U0126 group and the tGCI+ U0126+ NaHS group.	U 0126	104-109	mitogen activated protein kinase kinase 1	Rattus norvegicus	37-43
31237214-13	2019	Furthermore, U0126 pre-treatment significantly attenuated the protective effect of NaHS post-conditioning on the neurons survival and NeuNpositive neurons in CA1 subregion.	U 0126	13-18	carbonic anhydrase 1	Rattus norvegicus	158-161
30412649-12	2019	The phosphoinositide-3 kinase (PI3K) inhibitor wortmannin and MEK1/2 inhibitor U0126 had no effect on BM-MSC differentiation into keratinocytes.	U 0126	79-84	mitogen activated protein kinase kinase 1	Rattus norvegicus	62-68
31933752-7	2019	MEK inhibitor U0126 was used to confirm the effects of BPIFB1 on the MEK/ERK pathway, and U0126 can inverse the effects of siBPIFB1.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
31933752-7	2019	MEK inhibitor U0126 was used to confirm the effects of BPIFB1 on the MEK/ERK pathway, and U0126 can inverse the effects of siBPIFB1.	U 0126	14-19	BPI fold containing family B member 1	Homo sapiens	55-61
30450828-7	2019	Additionally, treatment with the ERK inhibitor U0126 or autophagy inhibitor 3-MA partially abolishes anti-oxidant effect and reduces SCs death.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	33-36
31068539-7	2019	Treatment of PDL cells with both the MEK1/2 inhibitor U0126 and the PI3K inhibitor LY294002 strongly attenuated TiO2-NPs-induced activation of NF-kappaB, and also the expression of COX-2.	U 0126	54-59	mitogen-activated protein kinase kinase 1	Homo sapiens	37-43
31068539-7	2019	Treatment of PDL cells with both the MEK1/2 inhibitor U0126 and the PI3K inhibitor LY294002 strongly attenuated TiO2-NPs-induced activation of NF-kappaB, and also the expression of COX-2.	U 0126	54-59	nuclear factor kappa B subunit 1	Homo sapiens	143-152
31068539-7	2019	Treatment of PDL cells with both the MEK1/2 inhibitor U0126 and the PI3K inhibitor LY294002 strongly attenuated TiO2-NPs-induced activation of NF-kappaB, and also the expression of COX-2.	U 0126	54-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	181-186
30371869-21	2019	Furthermore, inhibition of the ERK/MAPK pathway with U0126, the up-regulation of p-ERK1/2, P21 and P53, and the down-regulation of CDK2 and cyclin D1 by the knockdown of MALAT1 were all attenuated by MALAT1 knockdown.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	31-34
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	mitogen-activated protein kinase 1	Homo sapiens	58-100
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	mitogen-activated protein kinase 3	Homo sapiens	102-108
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	mitogen-activated protein kinase kinase 1	Homo sapiens	187-193
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	mitogen-activated protein kinase 3	Homo sapiens	207-213
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	mitogen-activated protein kinase 3	Homo sapiens	207-213
30255656-8	2019	Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4.	U 0126	155-160	phosphatidylethanolamine binding protein 4	Homo sapiens	318-323
30951887-7	2019	Furthermore, the effects of IL-17A and IL-17F were reduced by downregulation of Act1 with siRNA and inhibition of NF-kappaB and MAPK pathways with BAY11-7082 and U0126, respectively.	U 0126	162-167	interleukin 17A	Homo sapiens	28-34
30483803-2	2019	The present study aimed to investigate the effect of the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 on human tenon fibroblast (HTF) myofibrosis transdifferentiation, and to illuminate the underlying molecular mechanisms involved.	U 0126	113-118	mitogen-activated protein kinase kinase 7	Homo sapiens	57-96
30951887-7	2019	Furthermore, the effects of IL-17A and IL-17F were reduced by downregulation of Act1 with siRNA and inhibition of NF-kappaB and MAPK pathways with BAY11-7082 and U0126, respectively.	U 0126	162-167	interleukin 17F	Homo sapiens	39-45
30483803-2	2019	The present study aimed to investigate the effect of the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 on human tenon fibroblast (HTF) myofibrosis transdifferentiation, and to illuminate the underlying molecular mechanisms involved.	U 0126	113-118	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
30483803-3	2019	It was demonstrated that U0126 significantly inhibited the proliferation, migration and collagen contraction of HTFs stimulated with TGF-beta1.	U 0126	25-30	transforming growth factor beta 1	Homo sapiens	133-142
30483803-4	2019	In addition, U0126 largely attenuated the TGF-beta1-induced conversion of HTFs into myofibroblasts, as indicated by a downregulation of the mRNA and protein expression of alpha-smooth muscle actin and zinc finger protein SNAI1, and by ameliorating the 3D-collagen contraction response.	U 0126	13-18	transforming growth factor beta 1	Homo sapiens	42-51
30483803-4	2019	In addition, U0126 largely attenuated the TGF-beta1-induced conversion of HTFs into myofibroblasts, as indicated by a downregulation of the mRNA and protein expression of alpha-smooth muscle actin and zinc finger protein SNAI1, and by ameliorating the 3D-collagen contraction response.	U 0126	13-18	snail family transcriptional repressor 1	Homo sapiens	221-226
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	17-22	transforming growth factor beta 1	Homo sapiens	38-47
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	164-205
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	17-22	transforming growth factor beta 1	Homo sapiens	318-327
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	223-228	transforming growth factor beta 1	Homo sapiens	38-47
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	223-228	transforming growth factor beta 1	Homo sapiens	318-327
30496978-7	2019	Pretreatment with ERK inhibitor (UO126) antagonized PAMPs mediated TLR stimulation, leading to sequential downregulation of MyD88/NF-kappaB/cytokines via interrupting ERK/NF-kappaB signaling axis.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	18-21
30496978-7	2019	Pretreatment with ERK inhibitor (UO126) antagonized PAMPs mediated TLR stimulation, leading to sequential downregulation of MyD88/NF-kappaB/cytokines via interrupting ERK/NF-kappaB signaling axis.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	167-170
31061345-9	2019	Notably, the ACA-28-induced apoptosis was abrogated when ERK activation was blocked with the specific MEK inhibitor U0126.	U 0126	116-121	small nucleolar RNA, H/ACA box 28	Homo sapiens	13-19
30359932-7	2019	Important, pretreatment with a p38 MAPK inhibitor (PD 169316) and MEK inhibitor (U-0126), known to inhibit ERK1/2 activation, also prevented the complex-induced apoptosis.	U 0126	81-87	mitogen-activated protein kinase kinase 7	Homo sapiens	66-69
30359932-7	2019	Important, pretreatment with a p38 MAPK inhibitor (PD 169316) and MEK inhibitor (U-0126), known to inhibit ERK1/2 activation, also prevented the complex-induced apoptosis.	U 0126	81-87	mitogen-activated protein kinase 3	Homo sapiens	107-113
31061345-9	2019	Notably, the ACA-28-induced apoptosis was abrogated when ERK activation was blocked with the specific MEK inhibitor U0126.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	57-60
31061345-9	2019	Notably, the ACA-28-induced apoptosis was abrogated when ERK activation was blocked with the specific MEK inhibitor U0126.	U 0126	116-121	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
30584711-7	2018	The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490.	U 0126	142-147	mitogen-activated protein kinase 1	Homo sapiens	25-28
30584711-7	2018	The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490.	U 0126	142-147	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	30-35
30584711-7	2018	The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490.	U 0126	142-147	Janus kinase 2	Homo sapiens	37-41
30584711-7	2018	The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490.	U 0126	142-147	Janus kinase 2	Homo sapiens	48-52
30584711-7	2018	The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490.	U 0126	142-147	mitogen-activated protein kinase 1	Homo sapiens	32-35
30584711-7	2018	The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490.	U 0126	142-147	Janus kinase 2	Homo sapiens	48-52
30573978-10	2018	And those phenomena could be blocked by U0126, which is an ERK1/2 inhibitor.	U 0126	40-45	mitogen-activated protein kinase 3	Mus musculus	59-65
29928931-8	2018	This dephosphorylation is under the control of the OTR-coupled MAPK pathway, as blocking MEK1/2 by U0126 inhibited MEF-2A activation and subsequent neurite retraction.	U 0126	99-104	oxytocin receptor	Homo sapiens	51-54
29928931-8	2018	This dephosphorylation is under the control of the OTR-coupled MAPK pathway, as blocking MEK1/2 by U0126 inhibited MEF-2A activation and subsequent neurite retraction.	U 0126	99-104	mitogen-activated protein kinase kinase 1	Homo sapiens	89-95
29928931-8	2018	This dephosphorylation is under the control of the OTR-coupled MAPK pathway, as blocking MEK1/2 by U0126 inhibited MEF-2A activation and subsequent neurite retraction.	U 0126	99-104	myocyte enhancer factor 2A	Homo sapiens	115-121
30207782-6	2018	Exposing lenses to hyperosmotic solution in the presence of MEK/ERK inhibitor U0126 (10 microM) or the with-no-lysine kinase (WNK) inhibitor WNK463 (1 microM) also prevented NKCC1 phosphorylation and the Rb uptake responses to hyperosmotic solution.	U 0126	78-83	solute carrier family 12 member 2	Homo sapiens	174-179
30568656-5	2018	U0126-EtOH was used to inhibit the MAPK/ERK signaling pathway.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	35-39
30568656-5	2018	U0126-EtOH was used to inhibit the MAPK/ERK signaling pathway.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	40-43
30568656-10	2018	Co-treated with Purmorphamine and U0126-EtOH or Cyclopamine both decreased the levels of p-ERK1/2 (P &lt; 0.05).	U 0126	34-39	mitogen-activated protein kinase 3	Homo sapiens	91-97
30534001-5	2018	Treatment with the ERK inhibitor, U0126, was used to determine whether autophagy and apoptosis are mediated by the ERK pathway.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	19-22
30556844-17	2018	By contrast, U0126 pretreatment markedly inhibited the OPA expression, restrained the P38 signaling pathway, enhanced mitochondrial ATP production and suppressed the bone marrow cell apoptosis in mouse osteoporosis model.	U 0126	13-18	mitogen-activated protein kinase 14	Mus musculus	86-89
30251772-6	2018	SB203580 and U0126 upregulated CytC expression treated by V100 (P &lt; .05), except SP600125, while SB203580 administration resulted in a similar upregulation of PARP1 expression (P &lt; .05).	U 0126	13-18	cytochrome c, somatic	Homo sapiens	31-35
30693838-9	2018	The mitogen-activated protein kinase (MEK) inhibitor, U0126, abolished the rescuing effect of resveratrol on rotenone treated neurons through the inhibition of autophagy flux.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	4-36
30693838-9	2018	The mitogen-activated protein kinase (MEK) inhibitor, U0126, abolished the rescuing effect of resveratrol on rotenone treated neurons through the inhibition of autophagy flux.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
30288546-7	2018	Combination of ERK siRNA knockdown and treatment with the specific MEK inhibitor (U0126) enhanced the cytotoxic effects of the chemotherapy on UC cells.	U 0126	82-87	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
30316871-5	2018	Using the rabbit polyclonal antibody against phospho-S299 of HSF4, we found that EGF and ectopic expression of MEK1 can increase the phosphorylation of HSF4/S299 and induce HSF4 sumoylation, and these effects are inhibited by U0126.	U 0126	226-231	heat shock transcription factor 4	Mus musculus	61-65
30316871-5	2018	Using the rabbit polyclonal antibody against phospho-S299 of HSF4, we found that EGF and ectopic expression of MEK1 can increase the phosphorylation of HSF4/S299 and induce HSF4 sumoylation, and these effects are inhibited by U0126.	U 0126	226-231	mitogen-activated protein kinase kinase 1	Mus musculus	111-115
30316871-5	2018	Using the rabbit polyclonal antibody against phospho-S299 of HSF4, we found that EGF and ectopic expression of MEK1 can increase the phosphorylation of HSF4/S299 and induce HSF4 sumoylation, and these effects are inhibited by U0126.	U 0126	226-231	heat shock transcription factor 4	Mus musculus	152-156
30316871-5	2018	Using the rabbit polyclonal antibody against phospho-S299 of HSF4, we found that EGF and ectopic expression of MEK1 can increase the phosphorylation of HSF4/S299 and induce HSF4 sumoylation, and these effects are inhibited by U0126.	U 0126	226-231	heat shock transcription factor 4	Mus musculus	152-156
30316871-8	2018	EGF can upregulate phospho-HSF4/S299 and downregulate alpha B-crystallin expression in P3 mouse lens, and this downregulation is suppressed by U0126.	U 0126	143-148	heat shock transcription factor 4	Mus musculus	27-31
30316871-8	2018	EGF can upregulate phospho-HSF4/S299 and downregulate alpha B-crystallin expression in P3 mouse lens, and this downregulation is suppressed by U0126.	U 0126	143-148	crystallin, alpha B	Mus musculus	54-72
30430306-8	2018	In functional studies, we found that pharmacological inhibition of ERK with an inhibitor U0126 reduced the efficacy of mGlu5 receptors in stimulating production of cytoplasmic inositol-1,4,5-triphosphate, a major downstream conventional signaling event, in striatal neurons under normal conditions.	U 0126	89-94	mitogen-activated protein kinase 1	Homo sapiens	67-70
30015410-5	2018	Adiponectin-stimulated nuclear oocyte maturation was significantly impaired by a mitogen-activated protein kinase MEK 1/2 inhibitor, U0126 (p &lt; 0.05).	U 0126	133-138	adiponectin	Capra hircus	0-11
30022248-6	2018	U0126, an ERK1/2 inhibitor, was administered to Spred2-/- mice with reperfused lungs.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	10-16
30022248-6	2018	U0126, an ERK1/2 inhibitor, was administered to Spred2-/- mice with reperfused lungs.	U 0126	0-5	sprouty-related EVH1 domain containing 2	Mus musculus	48-54
30290166-9	2018	However, pre-incubation with the inhibitor of ERK (U0126), significantly increased the BAX/BCL2 ratio.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	46-49
30248419-6	2018	Hoechst 33258 staining and Annexin V/PI analysis exhibited that U0126, the ERK1/2 inhibitor, aggravated OTA-induced apoptosis.	U 0126	64-69	mitogen-activated protein kinase 3	Sus scrofa	75-81
30300626-12	2018	Additionally, co-treatment with ERK1/2 (U0126) or an AKT inhibitor (LY294002) plus chrysophanol reduced cell proliferation, whereas P38 (SB203580) and a JNK inhibitor (SP600125) showed synergic effects only in BT-474 cell lines.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	32-38
30485526-5	2018	Most interestingly, extracellular signal-regulated kinase (ERK) demonstrated a highly sustained phosphorylation and activation in the BMP2/7 heterodimer treatment groups, and inhibition of ERK cascades using U0126 special inhibitor that significantly reduced the activity of ALP and calcium mineralization to a substantial degree in rat BMSCs treated with BMP2/7 heterodimers.	U 0126	208-213	Eph receptor B1	Rattus norvegicus	20-57
30485526-5	2018	Most interestingly, extracellular signal-regulated kinase (ERK) demonstrated a highly sustained phosphorylation and activation in the BMP2/7 heterodimer treatment groups, and inhibition of ERK cascades using U0126 special inhibitor that significantly reduced the activity of ALP and calcium mineralization to a substantial degree in rat BMSCs treated with BMP2/7 heterodimers.	U 0126	208-213	Eph receptor B1	Rattus norvegicus	59-62
30485526-5	2018	Most interestingly, extracellular signal-regulated kinase (ERK) demonstrated a highly sustained phosphorylation and activation in the BMP2/7 heterodimer treatment groups, and inhibition of ERK cascades using U0126 special inhibitor that significantly reduced the activity of ALP and calcium mineralization to a substantial degree in rat BMSCs treated with BMP2/7 heterodimers.	U 0126	208-213	bone morphogenetic protein 2	Rattus norvegicus	134-138
30485526-5	2018	Most interestingly, extracellular signal-regulated kinase (ERK) demonstrated a highly sustained phosphorylation and activation in the BMP2/7 heterodimer treatment groups, and inhibition of ERK cascades using U0126 special inhibitor that significantly reduced the activity of ALP and calcium mineralization to a substantial degree in rat BMSCs treated with BMP2/7 heterodimers.	U 0126	208-213	Eph receptor B1	Rattus norvegicus	189-192
30485526-5	2018	Most interestingly, extracellular signal-regulated kinase (ERK) demonstrated a highly sustained phosphorylation and activation in the BMP2/7 heterodimer treatment groups, and inhibition of ERK cascades using U0126 special inhibitor that significantly reduced the activity of ALP and calcium mineralization to a substantial degree in rat BMSCs treated with BMP2/7 heterodimers.	U 0126	208-213	PDZ and LIM domain 3	Rattus norvegicus	275-278
30485526-5	2018	Most interestingly, extracellular signal-regulated kinase (ERK) demonstrated a highly sustained phosphorylation and activation in the BMP2/7 heterodimer treatment groups, and inhibition of ERK cascades using U0126 special inhibitor that significantly reduced the activity of ALP and calcium mineralization to a substantial degree in rat BMSCs treated with BMP2/7 heterodimers.	U 0126	208-213	bone morphogenetic protein 2	Rattus norvegicus	356-360
30290166-9	2018	However, pre-incubation with the inhibitor of ERK (U0126), significantly increased the BAX/BCL2 ratio.	U 0126	51-56	BCL2 associated X, apoptosis regulator	Homo sapiens	87-90
30290166-9	2018	However, pre-incubation with the inhibitor of ERK (U0126), significantly increased the BAX/BCL2 ratio.	U 0126	51-56	BCL2 apoptosis regulator	Homo sapiens	91-95
29943101-9	2018	Pretreatment with U0126 (1 x 10-6 mol/L), a highly selective inhibitor of ERK1/2 phosphorylation, reduced HSP70, GLUT3, and LDHA expressions and decreased LDH activity and lactate production.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	74-80
30464524-6	2018	Moreover, a specific ERK1/2 inhibitor, U0126, suppressed the function of TMEM176A in GBM cells.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	21-27
30464524-6	2018	Moreover, a specific ERK1/2 inhibitor, U0126, suppressed the function of TMEM176A in GBM cells.	U 0126	39-44	transmembrane protein 176A	Homo sapiens	73-81
29943101-9	2018	Pretreatment with U0126 (1 x 10-6 mol/L), a highly selective inhibitor of ERK1/2 phosphorylation, reduced HSP70, GLUT3, and LDHA expressions and decreased LDH activity and lactate production.	U 0126	18-23	heat shock protein family A (Hsp70) member 4	Homo sapiens	106-111
29943101-9	2018	Pretreatment with U0126 (1 x 10-6 mol/L), a highly selective inhibitor of ERK1/2 phosphorylation, reduced HSP70, GLUT3, and LDHA expressions and decreased LDH activity and lactate production.	U 0126	18-23	solute carrier family 2 member 3	Homo sapiens	113-118
29943101-9	2018	Pretreatment with U0126 (1 x 10-6 mol/L), a highly selective inhibitor of ERK1/2 phosphorylation, reduced HSP70, GLUT3, and LDHA expressions and decreased LDH activity and lactate production.	U 0126	18-23	lactate dehydrogenase A	Homo sapiens	124-128
29935949-9	2018	ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors significantly blocked TNF-alpha-induced and constitutive expression of MMP-8 in UM.	U 0126	8-13	mitogen-activated protein kinase 3	Homo sapiens	0-6
29457525-8	2018	In in vitro tests, both apoptosis and phosphorylated ERK expression in rat AFCs decreased in the IL-1beta+U0126 group compared with the IL-1beta group.	U 0126	106-111	Eph receptor B1	Rattus norvegicus	53-56
29457525-8	2018	In in vitro tests, both apoptosis and phosphorylated ERK expression in rat AFCs decreased in the IL-1beta+U0126 group compared with the IL-1beta group.	U 0126	106-111	interleukin 1 beta	Rattus norvegicus	97-105
29457525-8	2018	In in vitro tests, both apoptosis and phosphorylated ERK expression in rat AFCs decreased in the IL-1beta+U0126 group compared with the IL-1beta group.	U 0126	106-111	interleukin 1 beta	Rattus norvegicus	136-144
29457525-9	2018	The expression levels of Bax, caspase-3, and caspase-9 in AFCs decreased significantly in the IL-1beta+U0126 group compared with those in the IL-1beta group.	U 0126	103-108	BCL2 associated X, apoptosis regulator	Homo sapiens	25-28
29457525-9	2018	The expression levels of Bax, caspase-3, and caspase-9 in AFCs decreased significantly in the IL-1beta+U0126 group compared with those in the IL-1beta group.	U 0126	103-108	caspase 3	Homo sapiens	30-39
29457525-9	2018	The expression levels of Bax, caspase-3, and caspase-9 in AFCs decreased significantly in the IL-1beta+U0126 group compared with those in the IL-1beta group.	U 0126	103-108	caspase 9	Homo sapiens	45-54
29457525-9	2018	The expression levels of Bax, caspase-3, and caspase-9 in AFCs decreased significantly in the IL-1beta+U0126 group compared with those in the IL-1beta group.	U 0126	103-108	interleukin 1 beta	Homo sapiens	94-102
31949596-9	2018	MSC-EV treatment significantly inhibited RSC96 cell proliferation and migration, promoted their apoptosis, and activated the ERK pathway, while ERK signal repression using U0126 exhibited the opposite effects.	U 0126	172-177	Eph receptor B1	Rattus norvegicus	144-147
30403388-9	2018	Phosphorylation of CREB by ISO was prevented by U0126, an inhibitor of mitogen-activated protein kinase.	U 0126	48-53	cAMP responsive element binding protein 1	Rattus norvegicus	19-23
30233066-4	2018	Indeed, although alkynol compounds such as panaxydol can increase intracellular cyclic adenosine 3",5"-monophosphate (cAMP) levels and the ERK inhibitor U0126 inhibits alkynol-induced axonal growth, how pathways downstream of cAMP activate ERK have not been investigated.	U 0126	153-158	Eph receptor B1	Rattus norvegicus	139-142
30233066-4	2018	Indeed, although alkynol compounds such as panaxydol can increase intracellular cyclic adenosine 3",5"-monophosphate (cAMP) levels and the ERK inhibitor U0126 inhibits alkynol-induced axonal growth, how pathways downstream of cAMP activate ERK have not been investigated.	U 0126	153-158	Eph receptor B1	Rattus norvegicus	240-243
30233066-8	2018	The ERK inhibitor U0126 inhibited axonal growth induced by all three factors.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	4-7
30367147-7	2018	This protection required ERK1/2 activity as it was prevented by inhibitors PD98059 and U0126.	U 0126	87-92	mitogen activated protein kinase 3	Rattus norvegicus	25-31
30377685-6	2018	The effect of icaritin on the proliferation of MG63 cells was significantly decreased by pretreating the cells with U0126 (an ERK signaling pathway blocker) and LY294002 (an AKT signaling pathway blocker), respectively.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	126-129
30308003-11	2018	However, transient treatment with U0126 in class II COCs increased oocyte maturation and AKT activity, improving embryonic development.	U 0126	34-39	AKT serine/threonine kinase 1	Sus scrofa	89-92
30096296-8	2018	Mechanism studies showed that 25-OCH3-PPD significantly activated ERK/MAPK signaling pathway, and the inhibition of ERK/MAPK by U0126 dramatically abolished the inhibitory effect of 25-OCH3-PPD on ER stress, suggesting that 25-OCH3-PPD attenuated ER stress at least partially through activation of ERK/MAPK signaling pathway.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	66-69
30096296-8	2018	Mechanism studies showed that 25-OCH3-PPD significantly activated ERK/MAPK signaling pathway, and the inhibition of ERK/MAPK by U0126 dramatically abolished the inhibitory effect of 25-OCH3-PPD on ER stress, suggesting that 25-OCH3-PPD attenuated ER stress at least partially through activation of ERK/MAPK signaling pathway.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	116-119
30096296-8	2018	Mechanism studies showed that 25-OCH3-PPD significantly activated ERK/MAPK signaling pathway, and the inhibition of ERK/MAPK by U0126 dramatically abolished the inhibitory effect of 25-OCH3-PPD on ER stress, suggesting that 25-OCH3-PPD attenuated ER stress at least partially through activation of ERK/MAPK signaling pathway.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	120-124
30096296-8	2018	Mechanism studies showed that 25-OCH3-PPD significantly activated ERK/MAPK signaling pathway, and the inhibition of ERK/MAPK by U0126 dramatically abolished the inhibitory effect of 25-OCH3-PPD on ER stress, suggesting that 25-OCH3-PPD attenuated ER stress at least partially through activation of ERK/MAPK signaling pathway.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	116-119
30096296-8	2018	Mechanism studies showed that 25-OCH3-PPD significantly activated ERK/MAPK signaling pathway, and the inhibition of ERK/MAPK by U0126 dramatically abolished the inhibitory effect of 25-OCH3-PPD on ER stress, suggesting that 25-OCH3-PPD attenuated ER stress at least partially through activation of ERK/MAPK signaling pathway.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	120-124
29935949-9	2018	ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors significantly blocked TNF-alpha-induced and constitutive expression of MMP-8 in UM.	U 0126	8-13	tumor necrosis factor	Homo sapiens	70-79
29935949-9	2018	ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors significantly blocked TNF-alpha-induced and constitutive expression of MMP-8 in UM.	U 0126	8-13	matrix metallopeptidase 8	Homo sapiens	119-124
30271483-6	2018	Further study demonstrated that scutellarin stimulated phosphorylation of ERK1/2, and inhibition of ERK1/2 with inhibitor U0126 markedly attenuated scutellarin-induced autophagy.	U 0126	122-127	mitogen-activated protein kinase 3	Mus musculus	100-106
30031040-8	2018	PFBS significantly activated the phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) after 4-h treatment, and PFBS" effect on triglyceride was abolished by U0126, a specific MAPK/ERK kinase (MEK) inhibitor.	U 0126	173-178	mitogen-activated protein kinase 1	Homo sapiens	52-92
30031040-8	2018	PFBS significantly activated the phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) after 4-h treatment, and PFBS" effect on triglyceride was abolished by U0126, a specific MAPK/ERK kinase (MEK) inhibitor.	U 0126	173-178	mitogen-activated protein kinase 3	Homo sapiens	94-100
30031040-8	2018	PFBS significantly activated the phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) after 4-h treatment, and PFBS" effect on triglyceride was abolished by U0126, a specific MAPK/ERK kinase (MEK) inhibitor.	U 0126	173-178	mitogen-activated protein kinase 3	Homo sapiens	191-195
30031040-8	2018	PFBS significantly activated the phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) after 4-h treatment, and PFBS" effect on triglyceride was abolished by U0126, a specific MAPK/ERK kinase (MEK) inhibitor.	U 0126	173-178	mitogen-activated protein kinase kinase 7	Homo sapiens	208-211
30085340-7	2018	Meanwhile, the NF-kappabeta p65 inhibitor ammonium pyrrolidinedithiocarbamate and the ERK1/2 inhibitor U0126, but not the p38 inhibitor SB203580, were able to block oxLDL/beta2GPI/anti-beta2GPI complex-induced foam cell formation and migration in A7r5 cells.	U 0126	103-108	synaptotagmin 1	Rattus norvegicus	28-31
30085340-7	2018	Meanwhile, the NF-kappabeta p65 inhibitor ammonium pyrrolidinedithiocarbamate and the ERK1/2 inhibitor U0126, but not the p38 inhibitor SB203580, were able to block oxLDL/beta2GPI/anti-beta2GPI complex-induced foam cell formation and migration in A7r5 cells.	U 0126	103-108	mitogen activated protein kinase 3	Rattus norvegicus	86-92
30085340-7	2018	Meanwhile, the NF-kappabeta p65 inhibitor ammonium pyrrolidinedithiocarbamate and the ERK1/2 inhibitor U0126, but not the p38 inhibitor SB203580, were able to block oxLDL/beta2GPI/anti-beta2GPI complex-induced foam cell formation and migration in A7r5 cells.	U 0126	103-108	apolipoprotein H	Rattus norvegicus	171-179
30085340-7	2018	Meanwhile, the NF-kappabeta p65 inhibitor ammonium pyrrolidinedithiocarbamate and the ERK1/2 inhibitor U0126, but not the p38 inhibitor SB203580, were able to block oxLDL/beta2GPI/anti-beta2GPI complex-induced foam cell formation and migration in A7r5 cells.	U 0126	103-108	apolipoprotein H	Rattus norvegicus	185-193
30184235-5	2018	Treatment of WT-TE671 cells with vitamin D3 alone and cotreatment with U0126 also promoted dysferlin expression.	U 0126	71-76	dysferlin	Homo sapiens	91-100
29846015-9	2018	In these cells, phospho-p90RSK, phospho-MSK, and Cyclin D1 expression was increased by AKR1B10, and pharmacological inhibition of the ERK signaling cascade with MEK1/2 inhibitors U0126 and PD98059 eradicated induction of phospho-p90RSK, phospho-MSK, and Cyclin D1.	U 0126	179-184	aldo-keto reductase family 1, member B10 (aldose reductase)	Mus musculus	87-94
29846015-9	2018	In these cells, phospho-p90RSK, phospho-MSK, and Cyclin D1 expression was increased by AKR1B10, and pharmacological inhibition of the ERK signaling cascade with MEK1/2 inhibitors U0126 and PD98059 eradicated induction of phospho-p90RSK, phospho-MSK, and Cyclin D1.	U 0126	179-184	mitogen-activated protein kinase 1	Mus musculus	134-137
29952428-12	2018	PD98059 and U0126, inhibitors of ERK1/2, showed similar inhibitory effect to that of TSN.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	33-39
29981360-5	2018	When LY294002 (AKT inhibitor) and U0126 (ERK1/2 inhibitor) were treated with avobenzone, the anti-proliferative effect of avobenzone was alleviated.	U 0126	34-39	mitogen-activated protein kinase 3	Homo sapiens	41-47
30177390-8	2018	Both wild-type and truncated HMGA2 increased levels of phospho-ERK, and interestingly, treatment with U0126, MAPK inhibitor, antagonized wild-type HMGA2-mediated EMT and cell migration, but did not affect truncated HMGA2-mediated cell proliferation or migration.	U 0126	102-107	high mobility group AT-hook 2	Homo sapiens	29-34
30177390-8	2018	Both wild-type and truncated HMGA2 increased levels of phospho-ERK, and interestingly, treatment with U0126, MAPK inhibitor, antagonized wild-type HMGA2-mediated EMT and cell migration, but did not affect truncated HMGA2-mediated cell proliferation or migration.	U 0126	102-107	high mobility group AT-hook 2	Homo sapiens	147-152
30177390-8	2018	Both wild-type and truncated HMGA2 increased levels of phospho-ERK, and interestingly, treatment with U0126, MAPK inhibitor, antagonized wild-type HMGA2-mediated EMT and cell migration, but did not affect truncated HMGA2-mediated cell proliferation or migration.	U 0126	102-107	high mobility group AT-hook 2	Homo sapiens	147-152
30262819-12	2018	Treatment of cells with U0126, an ERK kinase inhibitor, potently inhibited viral replication.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	34-37
30258088-6	2018	The migration of keratinocytes effected by AES16-2M was promoted through ERK phosphorylation and blocked with U0126, an ERK inhibitor.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	120-123
30232195-6	2018	The tyrosine kinase inhibitor SU1498 that blocks VEGFR2 activity exhibited a potent inhibition of tube growth, and the Akt inhibitor MK-2206 2HCl, the Erk1/2 inhibitor U0126 and the JNK inhibitor SB203580 significantly reduced EF-stimulated tubulogenesis.	U 0126	168-173	mitogen-activated protein kinase 3	Homo sapiens	151-157
30241394-5	2018	The SC-induced elevation of TRPM6 was inhibited by U0126, a mitogen-activated protein kinase kinase (MEK) inhibitor, but the CNNM2 was not.	U 0126	51-56	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	28-33
30241394-6	2018	SC increased the levels of p-ERK1/2 and p-c-Fos, which were inhibited by U0126.	U 0126	73-78	mitogen activated protein kinase 3	Rattus norvegicus	29-35
30241394-6	2018	SC increased the levels of p-ERK1/2 and p-c-Fos, which were inhibited by U0126.	U 0126	73-78	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	42-47
30059670-11	2018	SIS3, U0126 and SB203580 all partly attenuated alpha-SMA mRNA expression under TGF-beta1 treatment.	U 0126	6-11	transforming growth factor beta 1	Homo sapiens	79-88
29753068-5	2018	Pre-treatment with U0126, an ERK1/2inhibitor;or JSH-23, a NF-kB inhibitor, can reverse the PFOA-induced cell migration and invasion.	U 0126	19-24	mitogen-activated protein kinase 3	Homo sapiens	29-35
30228782-9	2018	The results of TAE226, U0126 or Ly294002 treatment confirmed an essential role of FMNL3 in activation of the RhoC/FAK pathway and the subsequent promotion of CRC invasion.	U 0126	23-28	formin like 3	Homo sapiens	82-87
30213106-6	2018	The pharmacological inhibition of ERK1/2 phosphorylation using the highly selective inhibitors U0126 and SCH772984 resulted in the reduced levels of NDV RNA in cells and virus titers in the cell supernatant, which established an important role for the MEK/ERK signaling pathway in NDV replication.	U 0126	95-100	mitogen-activated protein kinase 3	Homo sapiens	34-40
30213106-6	2018	The pharmacological inhibition of ERK1/2 phosphorylation using the highly selective inhibitors U0126 and SCH772984 resulted in the reduced levels of NDV RNA in cells and virus titers in the cell supernatant, which established an important role for the MEK/ERK signaling pathway in NDV replication.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	252-255
30213106-6	2018	The pharmacological inhibition of ERK1/2 phosphorylation using the highly selective inhibitors U0126 and SCH772984 resulted in the reduced levels of NDV RNA in cells and virus titers in the cell supernatant, which established an important role for the MEK/ERK signaling pathway in NDV replication.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	34-37
30271499-4	2018	MEK inhibitor U0126 can lead to dephosphorylation of MTOR and Rictor in COLO-16 cells; however, c-Raf was not yet down-regulated after salirasib treatment in the presence of U0126.	U 0126	14-19	mechanistic target of rapamycin kinase	Homo sapiens	53-57
30256444-3	2018	Intramuscular mature adipocytes of dairy bull calves were cultured in vitro and were treated with Chemerin or U0126, which is an inhibitor of ERK1/2 pathway.	U 0126	110-115	mitogen-activated protein kinase 3	Bos taurus	142-148
30371171-10	2018	Pretreatment with U0126 (a specific inhibitor of ERK 1/2) significantly attenuates HOC l-induced VSMC phenotypic switch.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	49-56
30256444-6	2018	Interestingly, all the effects of Chemerin on genes expression in intramuscular mature adipocytes or fat tissue were inhibited by U0126, showed that the function of Chemerin to promote adipose decomposition will be significantly weakened if the ERK1/2 pathway is suppressed, and confirmed that ERK1/2 pathway is involved in mediate Chemerin-enhanced lipolysis.	U 0126	130-135	retinoic acid receptor responder 2	Bos taurus	34-42
30256444-6	2018	Interestingly, all the effects of Chemerin on genes expression in intramuscular mature adipocytes or fat tissue were inhibited by U0126, showed that the function of Chemerin to promote adipose decomposition will be significantly weakened if the ERK1/2 pathway is suppressed, and confirmed that ERK1/2 pathway is involved in mediate Chemerin-enhanced lipolysis.	U 0126	130-135	retinoic acid receptor responder 2	Bos taurus	165-173
30256444-6	2018	Interestingly, all the effects of Chemerin on genes expression in intramuscular mature adipocytes or fat tissue were inhibited by U0126, showed that the function of Chemerin to promote adipose decomposition will be significantly weakened if the ERK1/2 pathway is suppressed, and confirmed that ERK1/2 pathway is involved in mediate Chemerin-enhanced lipolysis.	U 0126	130-135	mitogen-activated protein kinase 3	Bos taurus	245-251
30256444-6	2018	Interestingly, all the effects of Chemerin on genes expression in intramuscular mature adipocytes or fat tissue were inhibited by U0126, showed that the function of Chemerin to promote adipose decomposition will be significantly weakened if the ERK1/2 pathway is suppressed, and confirmed that ERK1/2 pathway is involved in mediate Chemerin-enhanced lipolysis.	U 0126	130-135	mitogen-activated protein kinase 3	Bos taurus	294-300
30256444-6	2018	Interestingly, all the effects of Chemerin on genes expression in intramuscular mature adipocytes or fat tissue were inhibited by U0126, showed that the function of Chemerin to promote adipose decomposition will be significantly weakened if the ERK1/2 pathway is suppressed, and confirmed that ERK1/2 pathway is involved in mediate Chemerin-enhanced lipolysis.	U 0126	130-135	retinoic acid receptor responder 2	Bos taurus	165-173
30214308-12	2018	Furthermore, the ERK inhibitor U0126 could reverse all these effects induced by ZNF259 transfection.	U 0126	31-36	EPH receptor B2	Homo sapiens	17-20
30214308-12	2018	Furthermore, the ERK inhibitor U0126 could reverse all these effects induced by ZNF259 transfection.	U 0126	31-36	ZPR1 zinc finger	Homo sapiens	80-86
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	129-132
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	caspase 9	Homo sapiens	158-167
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	caspase 3	Homo sapiens	169-178
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	collagen type XI alpha 2 chain	Homo sapiens	188-192
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	baculoviral IAP repeat containing 2	Homo sapiens	219-225
29962003-7	2018	Moreover, pretreatment with U0126 (MEK inhibitor) markedly abolished nimbolide-inhibited cell viability, induced cell apoptosis, ERK phosphorylation, cleaved caspase-9, caspase-3, cleaved-PARP activation, and increased c-IAP1 expression in Huh-7 cells.	U 0126	28-33	MIR7-3 host gene	Homo sapiens	240-245
29902535-6	2018	Moreover, U0126 (an ERK inhibitor) inhibited thrombin-stimulated CTGF expression and c-Jun phosphorylation.	U 0126	10-15	coagulation factor II, thrombin	Homo sapiens	45-53
29902535-6	2018	Moreover, U0126 (an ERK inhibitor) inhibited thrombin-stimulated CTGF expression and c-Jun phosphorylation.	U 0126	10-15	cellular communication network factor 2	Homo sapiens	65-69
29902535-6	2018	Moreover, U0126 (an ERK inhibitor) inhibited thrombin-stimulated CTGF expression and c-Jun phosphorylation.	U 0126	10-15	mitogen-activated protein kinase 1	Homo sapiens	20-23
29902535-6	2018	Moreover, U0126 (an ERK inhibitor) inhibited thrombin-stimulated CTGF expression and c-Jun phosphorylation.	U 0126	10-15	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	85-90
29959569-11	2018	Notably, U0126 and trametinib induced a drastic down-regulation of BMX, which is known to prevent apoptosis in cancer cells.	U 0126	9-14	BMX non-receptor tyrosine kinase	Homo sapiens	67-70
29663365-8	2018	Moreover, inhibition of PI3K and MAPK using LY294002, U0126, or SP600125, in addition to myricetin treatment, effectively suppressed cell proliferation compared to treatment with myricetin or each inhibitor alone.	U 0126	54-59	mitogen-activated protein kinase 1	Canis lupus familiaris	33-37
30088173-7	2018	Furthermore, inhibiting Erk1/2 by U0126 or p38 by SB203580 partially protected against NO-induced cell death.	U 0126	34-39	mitogen-activated protein kinase 3	Homo sapiens	24-30
30116193-10	2018	U0126, an inhibitor of ERK signaling pathway reversed the oncogenic phenotypes caused by UBE2C.	U 0126	0-5	ubiquitin conjugating enzyme E2 C	Homo sapiens	89-94
30134957-9	2018	Furthermore, we inhibited the ERK pathway using ERK inhibitor (U0126) treatment in control MSX1-transfected DPSCs which could downregulate mineralized nodule formation and the expression of odontogenic genes.	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	30-33
30134957-9	2018	Furthermore, we inhibited the ERK pathway using ERK inhibitor (U0126) treatment in control MSX1-transfected DPSCs which could downregulate mineralized nodule formation and the expression of odontogenic genes.	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	48-51
30134957-9	2018	Furthermore, we inhibited the ERK pathway using ERK inhibitor (U0126) treatment in control MSX1-transfected DPSCs which could downregulate mineralized nodule formation and the expression of odontogenic genes.	U 0126	63-68	msh homeobox 1	Homo sapiens	91-95
30111352-7	2018	The ERK1/2 pathway inhibitor U0126 and AKT pathway agonist SC-79 were used to treat HCC cell lines for further mechanistic investigations.	U 0126	29-34	mitogen-activated protein kinase 3	Homo sapiens	4-10
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	54-59	tumor necrosis factor	Rattus norvegicus	114-123
29369532-2	2018	The aim of this study was to investigate whether or not the MEK/ERK1/2 pathway is involved in the observed upregulation and whether specific MEK/ERK1/2 inhibitors U0126 and trametinib can prevent it.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	145-151
29369532-7	2018	U0126 and trametinib were successful in attenuating the functional vasoconstriction in both rat and pig, as well as restoring immunofluorescence of pERK to fresh levels and counteracting ETB expression in the smooth muscle cells of the rat ophthalmic artery.	U 0126	0-5	endothelin receptor type B	Sus scrofa	187-190
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	54-59	interleukin 6	Rattus norvegicus	125-129
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	54-59	interleukin 1 beta	Rattus norvegicus	131-139
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	54-59	NRAS proto-oncogene, GTPase	Rattus norvegicus	148-153
29580892-4	2018	Intracerebroventricular (icv) administration of CART (55-102) dose-dependently lowered ICSS threshold suggesting reward promoting action, however, pretreatment with subeffective doses of Gi/o inhibitor (pertussis toxin, PTX) or PKA inhibitor (Rp-cAMPS) or ERK inhibitor (U0126) via icv route, attenuated CART mediated reward experience.	U 0126	271-276	CART prepropeptide	Rattus norvegicus	48-52
29580892-7	2018	Pretreatment with U0126 significantly decreased CART induced pCREB activation in the AcbSh and VTA, but not in PVN and ARC.	U 0126	18-23	CART prepropeptide	Rattus norvegicus	48-52
29580892-8	2018	ICSS or CART induced CREB mRNA expression in Acb and VTA was attenuated by U0126.	U 0126	75-80	CART prepropeptide	Rattus norvegicus	8-12
29580892-8	2018	ICSS or CART induced CREB mRNA expression in Acb and VTA was attenuated by U0126.	U 0126	75-80	cAMP responsive element binding protein 1	Rattus norvegicus	21-25
29594759-9	2018	Small molecule antagonists against Chemokine Receptor 2 (CCR2), cognate receptor for MCP-1 as well as the MAP kinase pathway inhibitor U0126 negatively affected MCP-1 induced MCF-7 cell invasion.	U 0126	135-140	chemokine (C-C motif) ligand 2	Mus musculus	161-166
29652528-5	2018	TGFbeta signaling was evident by nuclear localization of Smad2/3 and this was effectively blocked by pre-treatment with UO126, but not by post-treatment with this ERK1/2 signaling inhibitor.	U 0126	120-125	transforming growth factor, beta 1	Rattus norvegicus	0-7
29652528-5	2018	TGFbeta signaling was evident by nuclear localization of Smad2/3 and this was effectively blocked by pre-treatment with UO126, but not by post-treatment with this ERK1/2 signaling inhibitor.	U 0126	120-125	SMAD family member 2	Rattus norvegicus	57-64
29890199-11	2018	These effects of glyphosate and E2 were abolished by the ER antagonist, 4-hydroxytamoxifen and U0126, a MEK inhibitor.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	U 0126	83-88	latexin	Homo sapiens	100-103
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	U 0126	83-88	interleukin 1 beta	Homo sapiens	119-127
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	U 0126	83-88	C-X-C motif chemokine ligand 8	Homo sapiens	136-140
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	U 0126	83-88	plasminogen activator, urokinase	Homo sapiens	145-148
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	U 0126	19-24	interleukin 1 beta	Homo sapiens	45-53
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	U 0126	19-24	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	U 0126	19-24	plasminogen activator, urokinase	Homo sapiens	71-74
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	74-79	tumor necrosis factor	Rattus norvegicus	114-123
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	74-79	interleukin 6	Rattus norvegicus	125-129
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	74-79	interleukin 1 beta	Rattus norvegicus	131-139
30020400-6	2018	As compared with the blank and NC groups, the siKSR1, U0126, and siKSR1 + U0126 groups showed decreased levels of TNF-alpha, IL-6, IL-1beta, HSP47, N-ras, Raf-1, c-fos, TNF-alpha, IL-6, p38 MAPK, cleaved caspase-3, cleaved caspase-9, p53, and cell apoptosis, accompanied by an increased mRNA and protein level of Bcl-2.	U 0126	74-79	NRAS proto-oncogene, GTPase	Rattus norvegicus	148-153
29917164-12	2018	Inhibition of c-Raf via U0126 decreased the expression of LGR5 and EpCAM, as well as phosphorylated levels of c-Raf, MEK1/2 and ERK1/2 in the BCPAP cells, compared to levels in the DMSO controls.	U 0126	24-29	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	14-19
29901080-8	2018	U0126, an inhibitor of ERK signaling, reversed the beneficial effects of exercise.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	23-26
29917164-12	2018	Inhibition of c-Raf via U0126 decreased the expression of LGR5 and EpCAM, as well as phosphorylated levels of c-Raf, MEK1/2 and ERK1/2 in the BCPAP cells, compared to levels in the DMSO controls.	U 0126	24-29	epithelial cell adhesion molecule	Homo sapiens	67-72
29917165-7	2018	Both AKT inhibitor LY294002 and ERK1/2 inhibitor U0126 reduced the ability of angiogenesis and VM formation, as well as mosaic vessel formation induced by HGF.	U 0126	49-54	mitogen-activated protein kinase 3	Homo sapiens	32-38
29917165-7	2018	Both AKT inhibitor LY294002 and ERK1/2 inhibitor U0126 reduced the ability of angiogenesis and VM formation, as well as mosaic vessel formation induced by HGF.	U 0126	49-54	hepatocyte growth factor	Homo sapiens	155-158
30013654-5	2018	To characterize the receptor-mediated pathway, a specific ERK inhibitor, U0126, was used, which reduced BxPC-3 cell migration and the expression of ANO6.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	58-61
30042437-7	2018	Introducing of Mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, was not only dropping the average of basal activity for 7.5%, but also diminishing oscillatory behavior.	U 0126	72-77	mitogen-activated protein kinase kinase 7	Homo sapiens	15-54
30042437-7	2018	Introducing of Mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, was not only dropping the average of basal activity for 7.5%, but also diminishing oscillatory behavior.	U 0126	72-77	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
29802848-6	2018	The level of neuronal autophagy was down-regulated significantly by using U0126, an ERK signaling pathway inhibitor.	U 0126	74-79	Eph receptor B1	Rattus norvegicus	84-87
30072893-10	2018	The effects of the mTOR inhibitor (rapamycin), the PI3K inhibitor (LY294002) and the p-ERK1/2 inhibitor (U0126) suggesting that the ERK/mTOR or PI3K/Akt/mTOR signaling pathway is not involved in the antidepressant effects of CST-14.	U 0126	105-110	mitogen-activated protein kinase 1	Mus musculus	87-90
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	CREB regulated transcription coactivator 1	Mus musculus	18-24
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	ribosomal protein S6 kinase B1	Homo sapiens	25-28
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	76-79
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	153-156
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	157-160
30073169-9	2018	Activation of the mTORC1/S6K pathway was attenuated by 10-6 M U0126, an MEK/ERK inhibitor, and 10-6 M calphostin C, a PKC inhibitor, indicating that the MEK/ERK/TSC2 axis acts as a mediator.	U 0126	62-67	TSC complex subunit 2	Homo sapiens	161-165
30061836-13	2018	Furthermore, these proliferative effects in RWPE-1cells were attenuated by treatment with U0126, an ERK inhibitor, confirming BBR can relieve overgrowth of prostate via ERK-dependent signaling.	U 0126	90-95	mitogen-activated protein kinase 1	Homo sapiens	100-103
30061836-13	2018	Furthermore, these proliferative effects in RWPE-1cells were attenuated by treatment with U0126, an ERK inhibitor, confirming BBR can relieve overgrowth of prostate via ERK-dependent signaling.	U 0126	90-95	mitogen-activated protein kinase 1	Homo sapiens	169-172
28736254-5	2018	U0126, an inhibitor of ERK activation, remarkably rescued trophoblast invasion and the inhibition of CXCL8 expression caused by BPA treatment.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	23-26
28736254-5	2018	U0126, an inhibitor of ERK activation, remarkably rescued trophoblast invasion and the inhibition of CXCL8 expression caused by BPA treatment.	U 0126	0-5	C-X-C motif chemokine ligand 8	Homo sapiens	101-106
29917164-12	2018	Inhibition of c-Raf via U0126 decreased the expression of LGR5 and EpCAM, as well as phosphorylated levels of c-Raf, MEK1/2 and ERK1/2 in the BCPAP cells, compared to levels in the DMSO controls.	U 0126	24-29	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	58-62
30073206-7	2018	NphA2/STIR but not NphA2 was moderately sensitive to U0126, an ERK inhibitor.	U 0126	53-58	EPH receptor B2	Homo sapiens	63-66
29997437-8	2018	Experiments in vitro revealed that treatment with 8-Br-cAMP and U0126 decreased VEGF expression through PKA-ERK in CT26 cells by qRT-PCR.	U 0126	64-69	vascular endothelial growth factor A	Mus musculus	80-84
29980681-4	2018	Blocking ERK activation using a MEK inhibitor (U0126) suppressed NE-induced IL-8 secretion and knockdown of proteinase-activated receptor 2 (PAR2) using siRNAs inhibited both NE-induced ERK activation and subsequent IL-8 release, suggesting that NE-induced IL-8 production is dependent on PAR2-mediated ERK activation.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	9-12
29980681-4	2018	Blocking ERK activation using a MEK inhibitor (U0126) suppressed NE-induced IL-8 secretion and knockdown of proteinase-activated receptor 2 (PAR2) using siRNAs inhibited both NE-induced ERK activation and subsequent IL-8 release, suggesting that NE-induced IL-8 production is dependent on PAR2-mediated ERK activation.	U 0126	47-52	mitogen-activated protein kinase kinase 7	Homo sapiens	32-35
29980681-4	2018	Blocking ERK activation using a MEK inhibitor (U0126) suppressed NE-induced IL-8 secretion and knockdown of proteinase-activated receptor 2 (PAR2) using siRNAs inhibited both NE-induced ERK activation and subsequent IL-8 release, suggesting that NE-induced IL-8 production is dependent on PAR2-mediated ERK activation.	U 0126	47-52	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
29673908-8	2018	U0126, a MEK 1/2- signal cascade inhibitor, attenuated this phosphorylation and the positive inotropic effects of UTP in murine and human atrial preparations.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	9-16
29997437-8	2018	Experiments in vitro revealed that treatment with 8-Br-cAMP and U0126 decreased VEGF expression through PKA-ERK in CT26 cells by qRT-PCR.	U 0126	64-69	Eph receptor B2	Mus musculus	108-111
29656114-2	2018	Here, we show that the dual combination of insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1/R) and mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibition using AG1024 + U0126 can sensitize apoptosis-resistant ALL cells to ionizing radiation-induced DNA damage irrespective of effect of single pathway inhibition in vitro.	U 0126	222-227	mitogen-activated protein kinase kinase 7	Homo sapiens	191-194
29577978-10	2018	ERK1/2 inhibition by UO126 caused a decrease in Smad2L phosphorylation while the p38 inhibitor SB202190 and JNK inhibitor SP600125 did not.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	0-6
29577978-10	2018	ERK1/2 inhibition by UO126 caused a decrease in Smad2L phosphorylation while the p38 inhibitor SB202190 and JNK inhibitor SP600125 did not.	U 0126	21-26	SMAD family member 2	Homo sapiens	48-53
29656114-4	2018	Evidence of the synergistic action of AG1024 + U0126 in samples with variable basal levels of phosphorylated IGF1/Rbeta and ERK1/2 suggested additional targets of this drug combination.	U 0126	47-52	insulin like growth factor 1	Homo sapiens	109-113
29656114-4	2018	Evidence of the synergistic action of AG1024 + U0126 in samples with variable basal levels of phosphorylated IGF1/Rbeta and ERK1/2 suggested additional targets of this drug combination.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	124-130
29659837-7	2018	In contrast, we documented a role of RAS/ERK hyperactivation at the growth plate level since 1) NS-causing SHP2 mutants enhance RAS/ERK activation in chondrocytes in vivo (NS mice) and in vitro (ATDC5 cells) and 2) inhibition of RAS/ERK hyperactivation by U0126 treatment alleviated growth plate abnormalities and enhanced chondrocyte differentiation.	U 0126	256-261	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	107-111
29845241-9	2018	Treatment with the MEK inhibitor U0126 significantly inhibited the protein expression levels of WSNNP-induced differentiation markers, including collagen I, RUNX2, SPP1 and ALP, and autophagy markers, including LC3II/I, Beclin1 and ATG7.	U 0126	33-38	midkine	Mus musculus	19-22
29775175-5	2018	Inhibition of HIV-associated MAPK activation by U0126 abolishes NF-kappaB and MMP-9 upregulation and reduces HSV-1 spread.	U 0126	48-53	nuclear factor kappa B subunit 1	Homo sapiens	64-73
29775175-5	2018	Inhibition of HIV-associated MAPK activation by U0126 abolishes NF-kappaB and MMP-9 upregulation and reduces HSV-1 spread.	U 0126	48-53	matrix metallopeptidase 9	Homo sapiens	78-83
29119536-8	2018	MEK specific inhibitors (PD98059 and U0126) blocked the SCF + G-CSF-increased ERK phosphorylation and p53 gene and protein expression, and the MEK specific inhibitors also eliminated the SCF + G-CSF-promoted neurite outgrowth.	U 0126	37-42	KIT ligand	Rattus norvegicus	56-59
29119536-8	2018	MEK specific inhibitors (PD98059 and U0126) blocked the SCF + G-CSF-increased ERK phosphorylation and p53 gene and protein expression, and the MEK specific inhibitors also eliminated the SCF + G-CSF-promoted neurite outgrowth.	U 0126	37-42	colony stimulating factor 3	Rattus norvegicus	62-67
29119536-8	2018	MEK specific inhibitors (PD98059 and U0126) blocked the SCF + G-CSF-increased ERK phosphorylation and p53 gene and protein expression, and the MEK specific inhibitors also eliminated the SCF + G-CSF-promoted neurite outgrowth.	U 0126	37-42	Eph receptor B1	Rattus norvegicus	78-81
29119536-8	2018	MEK specific inhibitors (PD98059 and U0126) blocked the SCF + G-CSF-increased ERK phosphorylation and p53 gene and protein expression, and the MEK specific inhibitors also eliminated the SCF + G-CSF-promoted neurite outgrowth.	U 0126	37-42	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	102-105
29845241-9	2018	Treatment with the MEK inhibitor U0126 significantly inhibited the protein expression levels of WSNNP-induced differentiation markers, including collagen I, RUNX2, SPP1 and ALP, and autophagy markers, including LC3II/I, Beclin1 and ATG7.	U 0126	33-38	runt related transcription factor 2	Mus musculus	157-162
29845241-9	2018	Treatment with the MEK inhibitor U0126 significantly inhibited the protein expression levels of WSNNP-induced differentiation markers, including collagen I, RUNX2, SPP1 and ALP, and autophagy markers, including LC3II/I, Beclin1 and ATG7.	U 0126	33-38	secreted phosphoprotein 1	Mus musculus	164-168
29845241-9	2018	Treatment with the MEK inhibitor U0126 significantly inhibited the protein expression levels of WSNNP-induced differentiation markers, including collagen I, RUNX2, SPP1 and ALP, and autophagy markers, including LC3II/I, Beclin1 and ATG7.	U 0126	33-38	liver cell immortalization	Mus musculus	211-218
29845241-9	2018	Treatment with the MEK inhibitor U0126 significantly inhibited the protein expression levels of WSNNP-induced differentiation markers, including collagen I, RUNX2, SPP1 and ALP, and autophagy markers, including LC3II/I, Beclin1 and ATG7.	U 0126	33-38	beclin 1, autophagy related	Mus musculus	220-227
29845241-9	2018	Treatment with the MEK inhibitor U0126 significantly inhibited the protein expression levels of WSNNP-induced differentiation markers, including collagen I, RUNX2, SPP1 and ALP, and autophagy markers, including LC3II/I, Beclin1 and ATG7.	U 0126	33-38	autophagy related 7	Mus musculus	232-236
29954440-11	2018	The ERK1/2 phosphorylation induced by intrathecal morphine was inhibited by ketamine, ifenprodil and U0126 as well.	U 0126	101-106	mitogen-activated protein kinase 3	Mus musculus	4-10
29567110-8	2018	Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells.	U 0126	162-167	mitogen activated protein kinase 3	Rattus norvegicus	136-140
29864778-9	2018	U0126 (Erk1/2 inhibitor), SB203580 (p38 MAPK inhibitor) and 740 Y-P (PI3K agonist) significantly reversed Cy-3-g-reduced phosphorylation of p65.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	7-13
29864778-9	2018	U0126 (Erk1/2 inhibitor), SB203580 (p38 MAPK inhibitor) and 740 Y-P (PI3K agonist) significantly reversed Cy-3-g-reduced phosphorylation of p65.	U 0126	0-5	RELA proto-oncogene, NF-kB subunit	Homo sapiens	140-143
29567110-8	2018	Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells.	U 0126	162-167	mitogen activated protein kinase 3	Rattus norvegicus	266-272
29567110-8	2018	Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells.	U 0126	162-167	mitogen activated protein kinase 14	Rattus norvegicus	277-280
29567110-8	2018	Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells.	U 0126	162-167	mitogen activated protein kinase 3	Rattus norvegicus	281-285
29892075-0	2018	Potent block of potassium channels by MEK inhibitor U0126 in primary cultures and brain slices.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
29892075-1	2018	U0126 (1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene), a widely used mitogen-activated protein kinase kinase (MEK) inhibitor, was found to accelerate voltage-gated K+ channel (KV) inactivation in heterologous cells expressing several types of KV.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	85-124
29892075-1	2018	U0126 (1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene), a widely used mitogen-activated protein kinase kinase (MEK) inhibitor, was found to accelerate voltage-gated K+ channel (KV) inactivation in heterologous cells expressing several types of KV.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
29892075-1	2018	U0126 (1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene), a widely used mitogen-activated protein kinase kinase (MEK) inhibitor, was found to accelerate voltage-gated K+ channel (KV) inactivation in heterologous cells expressing several types of KV.	U 0126	7-68	mitogen-activated protein kinase kinase 7	Homo sapiens	85-124
29892075-1	2018	U0126 (1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene), a widely used mitogen-activated protein kinase kinase (MEK) inhibitor, was found to accelerate voltage-gated K+ channel (KV) inactivation in heterologous cells expressing several types of KV.	U 0126	7-68	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
29892075-2	2018	The goal of this study was to examine whether U0126 at a concentration thought to specifically inhibit MEK signaling also inhibits KV in native neurons of primary cultures or brain slices.	U 0126	46-51	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
29930499-5	2018	U0126, an ERK1/2 inhibitor, showed opposite effects.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	10-16
31032589-4	2018	The regulatory effect of MEK inhibitor(U0126) on Baicalein was tested by Western blot assay.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
29377587-10	2018	MEK inhibitor U0126 depressed the phosphorylation of ERK-p90RSK and increase in myotube diameter induced by lactate.	U 0126	14-19	midkine	Mus musculus	0-3
29377587-10	2018	MEK inhibitor U0126 depressed the phosphorylation of ERK-p90RSK and increase in myotube diameter induced by lactate.	U 0126	14-19	mitogen-activated protein kinase 1	Mus musculus	53-56
29377587-10	2018	MEK inhibitor U0126 depressed the phosphorylation of ERK-p90RSK and increase in myotube diameter induced by lactate.	U 0126	14-19	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	57-63
29505932-5	2018	Furthermore, as the focal adhesion biomarker, hyperphosphorylation of paxillin (ser83) was induced by MC-LR, which can be blocked by ERK1/2 pathway inhibitor (U0126) and was enhanced after hepatocytes transfected with pCMV6-MAPK plasmid.	U 0126	159-164	mitogen-activated protein kinase 3	Homo sapiens	133-139
29505932-6	2018	E-cadherin, as a biomarker which reflects the dynamic of cell-cell adhesion, its redistribution in hepatocytes was induced by MC-LR, and these redistribution and colocalization can be attenuated by U0126.	U 0126	198-203	cadherin 1	Homo sapiens	0-10
29656209-9	2018	Pretreatment with the extracellular signal-regulated kinase (ERK)1/2 inhibitor U0126 suppressed TDI-induced Lrp6 phosphorylation.	U 0126	79-84	mitogen-activated protein kinase 3	Mus musculus	22-68
29656209-9	2018	Pretreatment with the extracellular signal-regulated kinase (ERK)1/2 inhibitor U0126 suppressed TDI-induced Lrp6 phosphorylation.	U 0126	79-84	low density lipoprotein receptor-related protein 6	Mus musculus	108-112
29805565-9	2018	The ERK inhibitor, U0126, was able to block the migration and invasion abilities of Hep-G2 cells induced by BaP.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	4-7
29805565-9	2018	The ERK inhibitor, U0126, was able to block the migration and invasion abilities of Hep-G2 cells induced by BaP.	U 0126	19-24	DNL-type zinc finger	Homo sapiens	84-87
29857489-6	2018	Besides, by using mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126, we provided mechanistic evidence that the antineoplastic effects of NSC 95397 were achieved via inhibiting MKP-1 activity followed by ERK1/2 phosphorylation.	U 0126	118-123	mitogen-activated protein kinase 3	Homo sapiens	103-106
29518531-9	2018	Pretreatment with the MEK1/2 inhibitor U0126 significantly suppressed the acute induction of Per2, Dec1, and Noct by EGF and also abolished the EGF-induced phase shift of the PER2::LUCIFERASE rhythm in NSCs.	U 0126	39-44	mitogen-activated protein kinase kinase 1	Mus musculus	22-28
29518531-9	2018	Pretreatment with the MEK1/2 inhibitor U0126 significantly suppressed the acute induction of Per2, Dec1, and Noct by EGF and also abolished the EGF-induced phase shift of the PER2::LUCIFERASE rhythm in NSCs.	U 0126	39-44	period circadian clock 2	Mus musculus	93-97
29518531-9	2018	Pretreatment with the MEK1/2 inhibitor U0126 significantly suppressed the acute induction of Per2, Dec1, and Noct by EGF and also abolished the EGF-induced phase shift of the PER2::LUCIFERASE rhythm in NSCs.	U 0126	39-44	basic helix-loop-helix family, member e40	Mus musculus	99-103
29518531-9	2018	Pretreatment with the MEK1/2 inhibitor U0126 significantly suppressed the acute induction of Per2, Dec1, and Noct by EGF and also abolished the EGF-induced phase shift of the PER2::LUCIFERASE rhythm in NSCs.	U 0126	39-44	period circadian clock 2	Mus musculus	175-179
29887965-6	2018	These effects were mediated by activation of the ERK 1/2 signaling pathway, and inhibition of this pathway with a specific ERK 1/2 inhibitor (U0126) could impair the tumor-promoting effects induced by overexpression of FOXD1.	U 0126	142-147	mitogen-activated protein kinase 3	Homo sapiens	49-56
29887965-6	2018	These effects were mediated by activation of the ERK 1/2 signaling pathway, and inhibition of this pathway with a specific ERK 1/2 inhibitor (U0126) could impair the tumor-promoting effects induced by overexpression of FOXD1.	U 0126	142-147	mitogen-activated protein kinase 3	Homo sapiens	123-130
29887965-6	2018	These effects were mediated by activation of the ERK 1/2 signaling pathway, and inhibition of this pathway with a specific ERK 1/2 inhibitor (U0126) could impair the tumor-promoting effects induced by overexpression of FOXD1.	U 0126	142-147	forkhead box D1	Homo sapiens	219-224
29571732-8	2018	Furthermore, combination of AZD8055 and MEK inhibitor U0126 enhanced the growth inhibition of resistant cells significantly in vitro and in vivo.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
30034315-7	2018	Visfatin-induced Ser118 phosphorylation was diminished after treatment of cells with U0126 (MEK1/2 inhibitor).	U 0126	85-90	nicotinamide phosphoribosyltransferase	Homo sapiens	0-8
30034315-7	2018	Visfatin-induced Ser118 phosphorylation was diminished after treatment of cells with U0126 (MEK1/2 inhibitor).	U 0126	85-90	mitogen-activated protein kinase kinase 1	Homo sapiens	92-98
29739041-8	2018	Phosphorylation of ERK1/2 was inhibited, not only by U0126 but also by PP2 (a Src specific inhibitor) which led to the promotion of differentiation of C2C12 cells; however, U0126 did not inhibit Src phosphorylation.	U 0126	53-58	mitogen-activated protein kinase 3	Mus musculus	19-25
29055086-3	2018	The specific MEK1/2 inhibitor U0126 was administered ip at 6 and 24 hours post-reperfusion.	U 0126	30-35	mitogen activated protein kinase kinase 1	Rattus norvegicus	13-19
29635900-6	2018	The p-ERK expression was apparently repressed after treatment with the TRPV4 antagonist, further blockade of the ERK pathway with U0126 could significantly aggravate HCC cells apoptosis.	U 0126	130-135	mitogen-activated protein kinase 1	Homo sapiens	6-9
29635900-6	2018	The p-ERK expression was apparently repressed after treatment with the TRPV4 antagonist, further blockade of the ERK pathway with U0126 could significantly aggravate HCC cells apoptosis.	U 0126	130-135	transient receptor potential cation channel subfamily V member 4	Homo sapiens	71-76
29635900-6	2018	The p-ERK expression was apparently repressed after treatment with the TRPV4 antagonist, further blockade of the ERK pathway with U0126 could significantly aggravate HCC cells apoptosis.	U 0126	130-135	mitogen-activated protein kinase 1	Homo sapiens	113-116
29739041-8	2018	Phosphorylation of ERK1/2 was inhibited, not only by U0126 but also by PP2 (a Src specific inhibitor) which led to the promotion of differentiation of C2C12 cells; however, U0126 did not inhibit Src phosphorylation.	U 0126	173-178	neuropeptide Y receptor Y6	Mus musculus	71-74
29536419-12	2018	The U0126 (MEK/ERK1/2 inhibitor) and SB203580 (p38 inhibitor) significantly attenuated both organ cultured-induced and PM2.5-induced up-regulation of ETB receptor.	U 0126	4-9	mitogen activated protein kinase 3	Rattus norvegicus	15-21
29385302-8	2018	In addition, treating SCC-9 cells with U0126, a MEK-specific inhibitor, decreased MMP-2 expression and concomitantly inhibited cell migration.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
29385302-8	2018	In addition, treating SCC-9 cells with U0126, a MEK-specific inhibitor, decreased MMP-2 expression and concomitantly inhibited cell migration.	U 0126	39-44	matrix metallopeptidase 2	Homo sapiens	82-87
29536419-12	2018	The U0126 (MEK/ERK1/2 inhibitor) and SB203580 (p38 inhibitor) significantly attenuated both organ cultured-induced and PM2.5-induced up-regulation of ETB receptor.	U 0126	4-9	endothelin receptor type B	Rattus norvegicus	150-153
29536419-13	2018	U0126 also suppressed organ culture-increased and PM2.5-increased expressions of ETA receptor.	U 0126	0-5	endothelin receptor type A	Rattus norvegicus	81-84
29485707-7	2018	Dasatinib (SFK inhibitor), U0126 (MEK inhibitor), and PS-1145 (IkappaB kinase (IKK) inhibitor) used in combination resulted in elimination of 65% of IM-resistant cells and reduction in the colony-forming capacity of CML CD34+ cells in methylcellulose assays by 80%.	U 0126	27-32	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
29648633-9	2018	Inhibition of mitogen-activated protein kinase/ERK signaling by the kinase antagonist U0126 and PD98059 completely abolished the UT-R-mediated IA decrease.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	47-50
29648633-9	2018	Inhibition of mitogen-activated protein kinase/ERK signaling by the kinase antagonist U0126 and PD98059 completely abolished the UT-R-mediated IA decrease.	U 0126	86-91	urotensin 2 receptor	Homo sapiens	129-133
29330129-7	2018	Enhanced ICa,L and Cav1.2alpha1C expression by E2 was suppressed by inhibitors of phosphoinositide-3-kinase (Pi3K) (30 muM LY294002; P &lt;.05) and Akt (5 muM MK2206) but not of mitogen-activated protein kinase (5 muM U0126) or protein kinase A (1 muM KT5720).	U 0126	218-223	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	82-107
29330129-7	2018	Enhanced ICa,L and Cav1.2alpha1C expression by E2 was suppressed by inhibitors of phosphoinositide-3-kinase (Pi3K) (30 muM LY294002; P &lt;.05) and Akt (5 muM MK2206) but not of mitogen-activated protein kinase (5 muM U0126) or protein kinase A (1 muM KT5720).	U 0126	218-223	latexin	Homo sapiens	119-122
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	U 0126	208-213	sarcoglycan beta	Homo sapiens	139-142
29138938-3	2018	Above increases except for gamma-ECS activity and NO production were all suppressed by pre-treatments with MEK1/2 inhibitors PD98059 and U0126.	U 0126	137-142	MEK homolog 1	Zea mays	107-113
29425910-9	2018	However, these benefits were diminished when the MEK1/2/ERK1/2/p90RSK pathway was inhibited by U0126.	U 0126	95-100	mitogen activated protein kinase kinase 1	Rattus norvegicus	49-55
29605806-9	2018	On the other hand, Phalloidin enhanced ERK and Smad2 signaling, but inhibited adipocyte differentiation which was rescued by ERK specific chemical inhibitor U0126.	U 0126	157-162	mitogen-activated protein kinase 1	Homo sapiens	125-128
29747318-8	2018	The protein expressions of p-ERK1/2 were lower in GA at a dose of 100 mg/kg (0.090+-0.022) and U0126 group (0.072+-0.017) than those in asthmatic group (0.143+-0.022) (all P&lt;0.05).	U 0126	95-100	mitogen-activated protein kinase 3	Mus musculus	29-35
29747318-10	2018	Compared with asthmatic group (0.783+-0.133, 0.649+-0.095), the protein expressions of p-ERK1/2 and p-p38 MAPK in GA at a high dose group (0.385+-0.186, 0.275+-0.089) and in U0126 group (0.117+-0.051) or in SB203580 group (0.108+-0.043) were decreased by Western blotting (all P&lt;0.05).	U 0126	174-179	mitogen-activated protein kinase 3	Mus musculus	89-95
29425910-9	2018	However, these benefits were diminished when the MEK1/2/ERK1/2/p90RSK pathway was inhibited by U0126.	U 0126	95-100	mitogen activated protein kinase 3	Rattus norvegicus	56-62
29425910-10	2018	We also found that TXL upregulated the expression levels of p-MEK1/2, p-ERK1/2, p-p90RSK and p-bad, which were all significantly reversed by U0126.	U 0126	141-146	mitogen activated protein kinase kinase 1	Rattus norvegicus	62-68
29425910-10	2018	We also found that TXL upregulated the expression levels of p-MEK1/2, p-ERK1/2, p-p90RSK and p-bad, which were all significantly reversed by U0126.	U 0126	141-146	mitogen activated protein kinase 3	Rattus norvegicus	72-78
29276208-8	2018	In addition, 3 muM H-89 (a PKA inhibitor) and 3 muM U0126 (an ERK inhibitor) effectively inhibited PGE2-induced upregulation of OVGP1, and 5 muM chelerythrine chloride (a PKC inhibitor) and 3 muM U0126 negated OVGP1 downregulation by PGF2alpha.	U 0126	52-57	oviduct-specific glycoprotein	Bos taurus	128-133
29736214-6	2018	After the combined treatment of the IM and LDN-193189 as well as U0126, the IM-induced increase in Runx2, Col I, and OCN expression was significantly inhibited.	U 0126	65-70	RUNX family transcription factor 2	Rattus norvegicus	99-104
29736214-6	2018	After the combined treatment of the IM and LDN-193189 as well as U0126, the IM-induced increase in Runx2, Col I, and OCN expression was significantly inhibited.	U 0126	65-70	bone gamma-carboxyglutamate protein	Rattus norvegicus	117-120
29276208-8	2018	In addition, 3 muM H-89 (a PKA inhibitor) and 3 muM U0126 (an ERK inhibitor) effectively inhibited PGE2-induced upregulation of OVGP1, and 5 muM chelerythrine chloride (a PKC inhibitor) and 3 muM U0126 negated OVGP1 downregulation by PGF2alpha.	U 0126	52-57	oviduct-specific glycoprotein	Bos taurus	210-215
29276208-8	2018	In addition, 3 muM H-89 (a PKA inhibitor) and 3 muM U0126 (an ERK inhibitor) effectively inhibited PGE2-induced upregulation of OVGP1, and 5 muM chelerythrine chloride (a PKC inhibitor) and 3 muM U0126 negated OVGP1 downregulation by PGF2alpha.	U 0126	196-201	oviduct-specific glycoprotein	Bos taurus	128-133
29642540-7	2018	On the other hand, both of an ERK inhibitor U0126 (non-specific specific inhibitor) and SCH772984 (specific inhibitor) attenuated the enhanced cell growth by sericin, and the growth level in the case of co-treatment with sericin and ERK1/2 inhibitor was similar to that of cells treated with ERK1/2 inhibitor alone.	U 0126	44-49	Eph receptor B1	Rattus norvegicus	30-33
29642540-7	2018	On the other hand, both of an ERK inhibitor U0126 (non-specific specific inhibitor) and SCH772984 (specific inhibitor) attenuated the enhanced cell growth by sericin, and the growth level in the case of co-treatment with sericin and ERK1/2 inhibitor was similar to that of cells treated with ERK1/2 inhibitor alone.	U 0126	44-49	mitogen activated protein kinase 3	Rattus norvegicus	233-239
29662304-14	2018	However, the downregulated level of Nrf2 and the antitumor effect of chrysin in glioblastoma cell lines were partially abrogated by the ERK1/2 signaling inhibitor (U0126).	U 0126	164-169	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
29662304-14	2018	However, the downregulated level of Nrf2 and the antitumor effect of chrysin in glioblastoma cell lines were partially abrogated by the ERK1/2 signaling inhibitor (U0126).	U 0126	164-169	mitogen-activated protein kinase 3	Mus musculus	136-142
29341888-4	2018	Interestingly, methyllycaconitine, an antagonist of alpha7 nAChR, attenuated this effect on alphaAPP, but not on phospho-ERK1/2; whereas U0126, an inhibitor of MAPK/ERK kinase/ERK, blocked both the elevated expression of alpha7 nAChR and enhanced secretion of alphaAPP.	U 0126	137-142	mitogen-activated protein kinase 3	Homo sapiens	160-164
29377347-11	2018	The MEK/ERK inhibitor U0126 and TM inhibited hyaluronic acid-induced cell migration in HCC cells.	U 0126	22-27	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
29429450-6	2018	Moreover, the positive effect of HAMSCs was significantly inhibited by U0126, a highly selective inhibitor of extracellular signaling-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway.	U 0126	71-76	mitogen-activated protein kinase 3	Homo sapiens	156-162
29429450-6	2018	Moreover, the positive effect of HAMSCs was significantly inhibited by U0126, a highly selective inhibitor of extracellular signaling-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway.	U 0126	71-76	mitogen-activated protein kinase 3	Homo sapiens	198-202
29377347-11	2018	The MEK/ERK inhibitor U0126 and TM inhibited hyaluronic acid-induced cell migration in HCC cells.	U 0126	22-27	mitogen-activated protein kinase 1	Homo sapiens	8-11
28749049-8	2018	When hPDLSCs were treated with the inhibitors of NF-kappaB and MAPK pathways (U0126, SP600125, SB203580, and BMS345541), the effects of MTA on the differentiation of hPDLSCs were suppressed.	U 0126	78-83	nuclear factor kappa B subunit 1	Homo sapiens	49-58
29319206-8	2018	Furthermore, pretreatment of cells with LY294002 (an AKT inhibitor) and U0126 (ERK1/2 inhibitor) revealed that ERK1/2 activity is also involved in BP-mediated signal transduction in HTR8/SVneo cells.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	79-85
29319206-8	2018	Furthermore, pretreatment of cells with LY294002 (an AKT inhibitor) and U0126 (ERK1/2 inhibitor) revealed that ERK1/2 activity is also involved in BP-mediated signal transduction in HTR8/SVneo cells.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	111-117
29545863-6	2018	When cells were treated with a combination of TPI and the Erk1/2 inhibitor U0126, the downregulation of P62 and upregulation of Bax were inhibited, which demonstrated that the inhibition of Erk1/2 reversed the autophagy changes induced by TPI.	U 0126	75-80	mitogen-activated protein kinase 3	Homo sapiens	58-64
29545863-6	2018	When cells were treated with a combination of TPI and the Erk1/2 inhibitor U0126, the downregulation of P62 and upregulation of Bax were inhibited, which demonstrated that the inhibition of Erk1/2 reversed the autophagy changes induced by TPI.	U 0126	75-80	nucleoporin 62	Homo sapiens	104-107
29545863-6	2018	When cells were treated with a combination of TPI and the Erk1/2 inhibitor U0126, the downregulation of P62 and upregulation of Bax were inhibited, which demonstrated that the inhibition of Erk1/2 reversed the autophagy changes induced by TPI.	U 0126	75-80	BCL2 associated X, apoptosis regulator	Homo sapiens	128-131
29545863-6	2018	When cells were treated with a combination of TPI and the Erk1/2 inhibitor U0126, the downregulation of P62 and upregulation of Bax were inhibited, which demonstrated that the inhibition of Erk1/2 reversed the autophagy changes induced by TPI.	U 0126	75-80	mitogen-activated protein kinase 3	Homo sapiens	190-196
29393335-7	2018	The inhibition of ERK and NF-kappaB signaling using U0126 and pyrollidine dithiocarbamate, respectively, inhibited the expression of survivin, whereas blocking the expression of survivin using small interfering RNA inhibited the alleviating effect of SchB on cis-DDP-induced apoptosis as indicated by a reduction in cleaved caspase-3 expression.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	18-21
29393335-7	2018	The inhibition of ERK and NF-kappaB signaling using U0126 and pyrollidine dithiocarbamate, respectively, inhibited the expression of survivin, whereas blocking the expression of survivin using small interfering RNA inhibited the alleviating effect of SchB on cis-DDP-induced apoptosis as indicated by a reduction in cleaved caspase-3 expression.	U 0126	52-57	nuclear factor kappa B subunit 1	Homo sapiens	26-35
28885691-5	2018	FGF2 also increased phosphorylation of AKT, P70S6K, S6, ERK1/2, JNK, and P38 in BEND cells in a dose-dependent manner, and expression of each of those transcription factors was inhibited by their respective pharmacological inhibitor including Wormannin, U0126, and SP600125.	U 0126	254-259	fibroblast growth factor 2	Bos taurus	0-4
29683502-11	2018	Increased phosphorylated ERK1/2 was observed in the presence of AMG-CP, and decreased phosphorylated ERK1/2 was seen in the presence of anti-LAMP1 antibody or U0126.	U 0126	159-164	mitogen-activated protein kinase 3	Homo sapiens	101-107
27723266-12	2018	In addition, SB431542, 5z-7-oxozeaenol and U0126 attenuated the TGF-beta1-induced secretion of PAI-1 and suPAR.	U 0126	43-48	transforming growth factor beta 1	Homo sapiens	64-73
27723266-12	2018	In addition, SB431542, 5z-7-oxozeaenol and U0126 attenuated the TGF-beta1-induced secretion of PAI-1 and suPAR.	U 0126	43-48	serpin family E member 1	Homo sapiens	95-100
29393450-10	2018	Inhibiting ERK through treatment with U0126 significantly abrogated CUL7-induced alterations in Vimentin, SNAI2 and E-cadherin expression levels.	U 0126	38-43	mitogen-activated protein kinase 1	Homo sapiens	11-14
29393450-10	2018	Inhibiting ERK through treatment with U0126 significantly abrogated CUL7-induced alterations in Vimentin, SNAI2 and E-cadherin expression levels.	U 0126	38-43	cullin 7	Homo sapiens	68-72
29393450-10	2018	Inhibiting ERK through treatment with U0126 significantly abrogated CUL7-induced alterations in Vimentin, SNAI2 and E-cadherin expression levels.	U 0126	38-43	vimentin	Homo sapiens	96-104
29393450-10	2018	Inhibiting ERK through treatment with U0126 significantly abrogated CUL7-induced alterations in Vimentin, SNAI2 and E-cadherin expression levels.	U 0126	38-43	snail family transcriptional repressor 2	Homo sapiens	106-111
29393450-10	2018	Inhibiting ERK through treatment with U0126 significantly abrogated CUL7-induced alterations in Vimentin, SNAI2 and E-cadherin expression levels.	U 0126	38-43	cadherin 1	Homo sapiens	116-126
29436684-6	2018	The mitogen-activated protein kinase kinase 1/2 inhibitor U0126 inhibited Lf-induced ERK1/2 phosphorylation and repressed Lf-promoted myoblast proliferation.	U 0126	58-63	mitogen-activated protein kinase kinase 1	Mus musculus	4-45
29436684-6	2018	The mitogen-activated protein kinase kinase 1/2 inhibitor U0126 inhibited Lf-induced ERK1/2 phosphorylation and repressed Lf-promoted myoblast proliferation.	U 0126	58-63	lactotransferrin	Mus musculus	74-76
29436684-6	2018	The mitogen-activated protein kinase kinase 1/2 inhibitor U0126 inhibited Lf-induced ERK1/2 phosphorylation and repressed Lf-promoted myoblast proliferation.	U 0126	58-63	mitogen-activated protein kinase 3	Mus musculus	85-91
29436684-6	2018	The mitogen-activated protein kinase kinase 1/2 inhibitor U0126 inhibited Lf-induced ERK1/2 phosphorylation and repressed Lf-promoted myoblast proliferation.	U 0126	58-63	lactotransferrin	Mus musculus	122-124
28497199-9	2018	Moreover, AA-induced HO-1 expression was mediated through phosphorylation of Src, Pyk2, platelet-derived growth factor, PI3K/Akt, and ERK1/2 which were inhibited by the pharmacological inhibitors including PP1, PF431396, AG1296, LY294002, and U0126 or by transfection with respective siRNAs.	U 0126	243-248	heme oxygenase 1	Rattus norvegicus	21-25
29473447-0	2018	U0126 protects hippocampal CA1 neurons against forebrain ischemia-induced apoptosis via the ERK1/2 signaling pathway and NMDA receptors.	U 0126	0-5	carbonic anhydrase 1	Rattus norvegicus	27-30
29473447-0	2018	U0126 protects hippocampal CA1 neurons against forebrain ischemia-induced apoptosis via the ERK1/2 signaling pathway and NMDA receptors.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	92-98
29473447-9	2018	Blocking the ERK1/2 signaling pathway by administration U0126 attenuated apoptotic neuronal cell death via inhibition of NMDA receptors.	U 0126	56-61	mitogen activated protein kinase 3	Rattus norvegicus	13-19
29722320-4	2018	The microglia were treated with Y27632, fasudil and/or the ERK inhibitor U0126.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	59-62
29722320-10	2018	The ERK inhibitor U0126 suppressed these effects of Y27632 and fasudil.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
29526395-8	2018	However, the ERK inhibitor U0126 not only reversed the activating effect of PA on the ERK-Nrf2-HO-1 pathway but also aggravated PA-induced ROS.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	13-16
29526395-8	2018	However, the ERK inhibitor U0126 not only reversed the activating effect of PA on the ERK-Nrf2-HO-1 pathway but also aggravated PA-induced ROS.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	86-89
29526395-8	2018	However, the ERK inhibitor U0126 not only reversed the activating effect of PA on the ERK-Nrf2-HO-1 pathway but also aggravated PA-induced ROS.	U 0126	27-32	NFE2 like bZIP transcription factor 2	Homo sapiens	90-94
29526395-8	2018	However, the ERK inhibitor U0126 not only reversed the activating effect of PA on the ERK-Nrf2-HO-1 pathway but also aggravated PA-induced ROS.	U 0126	27-32	heme oxygenase 1	Homo sapiens	95-99
29436678-12	2018	Furthermore, we used the ERK-specific blocker U0126 to demonstrate this phenomenon.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	25-28
29552216-11	2018	Administration of U0126 inhibitor inhibited the regulation of phosphorylation levels by MEK1/2 and ERK1/2.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	88-94
29552216-11	2018	Administration of U0126 inhibitor inhibited the regulation of phosphorylation levels by MEK1/2 and ERK1/2.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	99-105
29552216-12	2018	Additionally, U0126 upregulated the expression of E-cadherin and downregulated the expression of vimentin.	U 0126	14-19	cadherin 1	Homo sapiens	50-60
29552216-12	2018	Additionally, U0126 upregulated the expression of E-cadherin and downregulated the expression of vimentin.	U 0126	14-19	vimentin	Homo sapiens	97-105
29552230-9	2018	Furthermore, treatment with the AKT inhibitor LY294002 or the ERK inhibitor U0126 inhibited the upregulation of VEGF-A induced by FAP expression.	U 0126	76-81	mitogen-activated protein kinase 1	Homo sapiens	62-65
29552230-9	2018	Furthermore, treatment with the AKT inhibitor LY294002 or the ERK inhibitor U0126 inhibited the upregulation of VEGF-A induced by FAP expression.	U 0126	76-81	vascular endothelial growth factor A	Homo sapiens	112-118
29552230-9	2018	Furthermore, treatment with the AKT inhibitor LY294002 or the ERK inhibitor U0126 inhibited the upregulation of VEGF-A induced by FAP expression.	U 0126	76-81	fibroblast activation protein alpha	Homo sapiens	130-133
29300860-6	2018	However, transfection with the nonphosphorylatable hRXRalpha (S260A) mutant or treatment with the mitogen-activated protein kinase (MAPK) inhibitor UO126 rescued their nuclear localization, interaction, and binding of the complex to chromatin in the HPK1Aras cells.	U 0126	148-153	retinoid X receptor alpha	Homo sapiens	51-60
29300860-6	2018	However, transfection with the nonphosphorylatable hRXRalpha (S260A) mutant or treatment with the mitogen-activated protein kinase (MAPK) inhibitor UO126 rescued their nuclear localization, interaction, and binding of the complex to chromatin in the HPK1Aras cells.	U 0126	148-153	mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens	250-254
29642540-7	2018	On the other hand, both of an ERK inhibitor U0126 (non-specific specific inhibitor) and SCH772984 (specific inhibitor) attenuated the enhanced cell growth by sericin, and the growth level in the case of co-treatment with sericin and ERK1/2 inhibitor was similar to that of cells treated with ERK1/2 inhibitor alone.	U 0126	44-49	mitogen activated protein kinase 3	Rattus norvegicus	292-298
29721041-5	2018	We further illustrate that exposure to MEK inhibitor U0126 inactivates phosphorylation of ERK1/2 and MEK in verteporfin-treated PTC cells.	U 0126	53-58	midkine	Mus musculus	39-42
29721041-5	2018	We further illustrate that exposure to MEK inhibitor U0126 inactivates phosphorylation of ERK1/2 and MEK in verteporfin-treated PTC cells.	U 0126	53-58	mitogen-activated protein kinase 3	Mus musculus	90-96
29721041-5	2018	We further illustrate that exposure to MEK inhibitor U0126 inactivates phosphorylation of ERK1/2 and MEK in verteporfin-treated PTC cells.	U 0126	53-58	midkine	Mus musculus	101-104
29765986-8	2018	Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF).	U 0126	57-62	mitogen-activated protein kinase 1	Mus musculus	52-55
29765986-8	2018	Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF).	U 0126	57-62	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	136-142
29765986-8	2018	Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF).	U 0126	57-62	antigen identified by monoclonal antibody Ki 67	Mus musculus	193-197
29743885-8	2018	Silencing DAB2IP activated extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, and the enhanced proliferation and migration ability induced by DAB2IP knockdown were reduced after incubation with U0126 in SGC7901 gastric cancer cells.	U 0126	203-208	DAB2 interacting protein	Homo sapiens	10-16
29743885-8	2018	Silencing DAB2IP activated extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, and the enhanced proliferation and migration ability induced by DAB2IP knockdown were reduced after incubation with U0126 in SGC7901 gastric cancer cells.	U 0126	203-208	mitogen-activated protein kinase 1	Homo sapiens	27-68
29743885-8	2018	Silencing DAB2IP activated extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, and the enhanced proliferation and migration ability induced by DAB2IP knockdown were reduced after incubation with U0126 in SGC7901 gastric cancer cells.	U 0126	203-208	mitogen-activated protein kinase 3	Homo sapiens	70-76
29743885-8	2018	Silencing DAB2IP activated extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, and the enhanced proliferation and migration ability induced by DAB2IP knockdown were reduced after incubation with U0126 in SGC7901 gastric cancer cells.	U 0126	203-208	DAB2 interacting protein	Homo sapiens	151-157
29543778-9	2018	The inhibition of NMDA toxicity by BL-M was dramatically reversed by U0126, a well-known MEK inhibitor, suggesting that ERK1/2-mediated CREB phosphorylation is required for the neuroprotective action.	U 0126	69-74	mitogen activated protein kinase 3	Rattus norvegicus	120-126
29543778-9	2018	The inhibition of NMDA toxicity by BL-M was dramatically reversed by U0126, a well-known MEK inhibitor, suggesting that ERK1/2-mediated CREB phosphorylation is required for the neuroprotective action.	U 0126	69-74	cAMP responsive element binding protein 1	Rattus norvegicus	136-140
29713651-8	2018	In contrast, MCP-1 release suppression was abolished by the AMPK inhibitor compound C and the MEK inhibitor U0126.	U 0126	108-113	C-C motif chemokine ligand 2	Homo sapiens	13-18
29713651-8	2018	In contrast, MCP-1 release suppression was abolished by the AMPK inhibitor compound C and the MEK inhibitor U0126.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	94-97
29725265-4	2018	MEK inhibitor U0126 effectively restrained the CTGF-induced expression of alpha-smooth muscle actin (alpha-SMA), fibronectin (Fn) and type I collagen (COL-1) in HLECs.	U 0126	14-19	cellular communication network factor 2	Rattus norvegicus	47-51
29725265-4	2018	MEK inhibitor U0126 effectively restrained the CTGF-induced expression of alpha-smooth muscle actin (alpha-SMA), fibronectin (Fn) and type I collagen (COL-1) in HLECs.	U 0126	14-19	actin gamma 2, smooth muscle	Rattus norvegicus	74-99
29725265-4	2018	MEK inhibitor U0126 effectively restrained the CTGF-induced expression of alpha-smooth muscle actin (alpha-SMA), fibronectin (Fn) and type I collagen (COL-1) in HLECs.	U 0126	14-19	actin gamma 2, smooth muscle	Rattus norvegicus	101-110
29725265-4	2018	MEK inhibitor U0126 effectively restrained the CTGF-induced expression of alpha-smooth muscle actin (alpha-SMA), fibronectin (Fn) and type I collagen (COL-1) in HLECs.	U 0126	14-19	fibronectin 1	Rattus norvegicus	113-124
29725265-4	2018	MEK inhibitor U0126 effectively restrained the CTGF-induced expression of alpha-smooth muscle actin (alpha-SMA), fibronectin (Fn) and type I collagen (COL-1) in HLECs.	U 0126	14-19	fibronectin 1	Rattus norvegicus	126-128
29515111-10	2018	The oncogenic effects induced by CRLF1 were suppressed by treating the cells with the MEK inhibitor U0126 or the AKT inhibitor MK-2206.	U 0126	100-105	cytokine receptor like factor 1	Homo sapiens	33-38
29515111-10	2018	The oncogenic effects induced by CRLF1 were suppressed by treating the cells with the MEK inhibitor U0126 or the AKT inhibitor MK-2206.	U 0126	100-105	mitogen-activated protein kinase kinase 7	Homo sapiens	86-89
29278848-6	2018	Furthermore, pretreatment of ERK1/2 inhibitor U0126 or p38 inhibitor SB203580 entirely eliminated BPA-induced increases in the densities of the dendritic spine and synapse.	U 0126	46-51	mitogen activated protein kinase 3	Rattus norvegicus	29-35
29367088-10	2018	U0126, the inhibitor of ERK1/2 inhibited alpha7nAChR expression and FLS proliferation significantly (P &lt; .05 or P &lt; .01).	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	24-30
29279286-10	2018	While TSLP expression was induced by EGF, it was inhibited by the MEK inhibitor, U0126.	U 0126	81-86	thymic stromal lymphopoietin	Homo sapiens	6-10
29279286-10	2018	While TSLP expression was induced by EGF, it was inhibited by the MEK inhibitor, U0126.	U 0126	81-86	mitogen-activated protein kinase kinase 7	Homo sapiens	66-69
29528074-4	2018	Furthermore, an ERK inhibitor (U0126) significantly reduced the expression of NFAT2 nuclear protein, and an ERK and JNK inhibitor decreased the levels of p65 and p50 nuclear protein.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	16-19
29528074-4	2018	Furthermore, an ERK inhibitor (U0126) significantly reduced the expression of NFAT2 nuclear protein, and an ERK and JNK inhibitor decreased the levels of p65 and p50 nuclear protein.	U 0126	31-36	nuclear factor of activated T cells 2	Homo sapiens	78-83
29328481-8	2018	Treating cells with insulin, SP600125 and U0126 indicated that the Akt/mTOR pathway and JNK were involved in TTF1-NP-induced autophagy.	U 0126	42-47	AKT serine/threonine kinase 1	Homo sapiens	67-70
29328481-8	2018	Treating cells with insulin, SP600125 and U0126 indicated that the Akt/mTOR pathway and JNK were involved in TTF1-NP-induced autophagy.	U 0126	42-47	transcription termination factor 1	Homo sapiens	109-113
29136249-9	2018	Moreover, ERK1/2 inhibitors (U0126 and PD98059) and ERK2 siRNA abrogated CGA-induced Nrf2 phosphorylation and its subsequent transcriptional activation, and also reduced the protection provided by CGA against APAP-induced cytotoxicity in hepatocytes.	U 0126	29-34	mitogen-activated protein kinase 3	Mus musculus	10-16
29136249-9	2018	Moreover, ERK1/2 inhibitors (U0126 and PD98059) and ERK2 siRNA abrogated CGA-induced Nrf2 phosphorylation and its subsequent transcriptional activation, and also reduced the protection provided by CGA against APAP-induced cytotoxicity in hepatocytes.	U 0126	29-34	nuclear factor, erythroid derived 2, like 2	Mus musculus	85-89
29535732-6	2018	We found that MEK1/2 inhibitors, PD0325901 and U0126 potentiated TLR9-mediated production of IFN-I in GEN2.2 cells.	U 0126	47-52	toll like receptor 9	Homo sapiens	65-69
29155130-8	2018	Pre-treatment with specific p38, ERK1/2, and JNK1/2 inhibitors (SB203580, U0126, SP600125, respectively) attenuated the inducible phosphorylation events.	U 0126	74-79	mitogen-activated protein kinase 14	Mus musculus	28-31
29155130-8	2018	Pre-treatment with specific p38, ERK1/2, and JNK1/2 inhibitors (SB203580, U0126, SP600125, respectively) attenuated the inducible phosphorylation events.	U 0126	74-79	mitogen-activated protein kinase 8	Mus musculus	45-49
29483719-11	2018	The inhibitors of MAPK (U0126, SP600125,SB203580) and inhibitor of AKT (perifosine) could also inhibit Runx2 expression.	U 0126	24-29	RUNX family transcription factor 2	Homo sapiens	103-108
29084209-6	2018	Pretreatment with the ROS scavenger N-acetyl-L-cysteine, the ERK1/2 inhibitor UO126, or ERK1/2 siRNA knockdown blocked the H2O2-induced shift of MLK3, while MLK3 inhibition with Cep1347 did not.	U 0126	78-83	mitogen-activated protein kinase 3	Homo sapiens	61-67
29084209-6	2018	Pretreatment with the ROS scavenger N-acetyl-L-cysteine, the ERK1/2 inhibitor UO126, or ERK1/2 siRNA knockdown blocked the H2O2-induced shift of MLK3, while MLK3 inhibition with Cep1347 did not.	U 0126	78-83	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	145-149
29467389-9	2018	The cells were treated with the BRAF-specific drug vemurafenib (PLX4032) or the MEK1/2 inhibitor, U0126, respectively.	U 0126	98-103	mitogen-activated protein kinase kinase 1	Homo sapiens	80-86
29497296-6	2018	Thirty minutes prior to SAH, anti-TNF-alpha antibody or U0126, an extracellular signal-regulated kinase (Erk) inhibitor, was microinjected into the left lateral cerebral ventricle.	U 0126	56-61	Eph receptor B1	Rattus norvegicus	66-103
29397067-5	2018	Drp1 phosphorylation at serine 616 is increased in HD knock-in mouse derived striatal cells, which is abolished by treatment with U0126, a potent inhibitor of MEK1/2.	U 0126	130-135	dynamin 1-like	Mus musculus	0-4
29397067-5	2018	Drp1 phosphorylation at serine 616 is increased in HD knock-in mouse derived striatal cells, which is abolished by treatment with U0126, a potent inhibitor of MEK1/2.	U 0126	130-135	mitogen-activated protein kinase kinase 1	Mus musculus	159-165
29234153-9	2018	More importantly, blocking these pathways with their antagonists LY294002 or U0126 reversed the effects of netrin-1 overexpression on cell invasion, migration, EMT, and VM formation.	U 0126	77-82	netrin 1	Homo sapiens	107-115
29459829-5	2018	Pretreatment with an inhibitor (U0126) of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) and an inhibitor (LY294002) of phosphoinositide 3-kinase (PI3K) failed to significantly inhibit PTTH-stimulated JNK phosphorylation, indicating that ERK and PI3K were not related to JNK.	U 0126	32-37	extracellular regulated MAP kinase	Bombyx mori	121-124
29459829-5	2018	Pretreatment with an inhibitor (U0126) of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) and an inhibitor (LY294002) of phosphoinositide 3-kinase (PI3K) failed to significantly inhibit PTTH-stimulated JNK phosphorylation, indicating that ERK and PI3K were not related to JNK.	U 0126	32-37	MAP kinse-ERK kinase	Bombyx mori	134-137
29207179-9	2018	We confirmed that an inhibitor of ERK (U0126) or p38 MAPK (SB202190 and SB203580) suppressed the proliferation of the BC3 PEL cells compared with the KSHV-negative DG75 cells.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	34-37
29247711-14	2018	Blocking the MEK/ERK pathway using the MEK inhibitor U0126 prevented cisplatin-induced autophagy enhanced by HK2 overexpression.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
29247711-14	2018	Blocking the MEK/ERK pathway using the MEK inhibitor U0126 prevented cisplatin-induced autophagy enhanced by HK2 overexpression.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	17-20
29247711-14	2018	Blocking the MEK/ERK pathway using the MEK inhibitor U0126 prevented cisplatin-induced autophagy enhanced by HK2 overexpression.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
29247711-14	2018	Blocking the MEK/ERK pathway using the MEK inhibitor U0126 prevented cisplatin-induced autophagy enhanced by HK2 overexpression.	U 0126	53-58	hexokinase 2	Homo sapiens	109-112
29207116-12	2018	Additionally, the inductive effect of melatonin on the expression of insulin mRNA was attenuated when the activities of Raf-1 or ERK were blocked using the chemical inhibitors GW5074 and U0126, respectively.	U 0126	187-192	v-raf-leukemia viral oncogene 1	Mus musculus	120-125
29207116-12	2018	Additionally, the inductive effect of melatonin on the expression of insulin mRNA was attenuated when the activities of Raf-1 or ERK were blocked using the chemical inhibitors GW5074 and U0126, respectively.	U 0126	187-192	mitogen-activated protein kinase 1	Mus musculus	129-132
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	25-28
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	U 0126	18-23	hypoxia inducible factor 1 subunit alpha	Homo sapiens	121-131
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	U 0126	18-23	vascular endothelial growth factor A	Homo sapiens	136-140
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	U 0126	18-23	high mobility group box 1	Homo sapiens	152-157
29199516-4	2018	The protein of arginase-1 was significantly overexpressed in RAW264.7 cells stimulated by TGF-beta1 and high-ambient glucose, which can be partially blocked by not only U0126 (ERK inhibitor) but also SB431542 (Smad2 inhibitor).	U 0126	169-174	arginase, liver	Mus musculus	15-25
29528074-7	2018	Treatment with U0126 also significantly decreased Cyclin D1 protein expression while JNK and p38 inhibitors did not attenuate the arsenite-associated increase in Cyclin D1 protein expression.	U 0126	15-20	cyclin D1	Homo sapiens	50-59
29388547-8	2018	RESULTS: Both mRNA and protein levels of IL-10 were up-regulated in stimulated cells, and the production of IL-10 was reduced when cells were treated with U0126 or SB203580.	U 0126	155-160	interleukin 10	Homo sapiens	41-46
29388547-8	2018	RESULTS: Both mRNA and protein levels of IL-10 were up-regulated in stimulated cells, and the production of IL-10 was reduced when cells were treated with U0126 or SB203580.	U 0126	155-160	interleukin 10	Homo sapiens	108-113
29199516-4	2018	The protein of arginase-1 was significantly overexpressed in RAW264.7 cells stimulated by TGF-beta1 and high-ambient glucose, which can be partially blocked by not only U0126 (ERK inhibitor) but also SB431542 (Smad2 inhibitor).	U 0126	169-174	transforming growth factor, beta 1	Mus musculus	90-99
29199516-4	2018	The protein of arginase-1 was significantly overexpressed in RAW264.7 cells stimulated by TGF-beta1 and high-ambient glucose, which can be partially blocked by not only U0126 (ERK inhibitor) but also SB431542 (Smad2 inhibitor).	U 0126	169-174	mitogen-activated protein kinase 1	Mus musculus	176-179
29207091-9	2018	Molecular mechanism analysis demonstrated that p-ERK and p-Akt in SW1116 and HT29 cells were affected by alterations in FAP-alpha expression, and treatment with a p-ERK inhibitor (U0126) and p-Akt inhibitor (LY294002) ameliorated VEGF-A upregulation induced by FAP-alpha overexpression.	U 0126	180-185	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	47-52
29207091-9	2018	Molecular mechanism analysis demonstrated that p-ERK and p-Akt in SW1116 and HT29 cells were affected by alterations in FAP-alpha expression, and treatment with a p-ERK inhibitor (U0126) and p-Akt inhibitor (LY294002) ameliorated VEGF-A upregulation induced by FAP-alpha overexpression.	U 0126	180-185	AKT serine/threonine kinase 1	Homo sapiens	59-62
29207091-9	2018	Molecular mechanism analysis demonstrated that p-ERK and p-Akt in SW1116 and HT29 cells were affected by alterations in FAP-alpha expression, and treatment with a p-ERK inhibitor (U0126) and p-Akt inhibitor (LY294002) ameliorated VEGF-A upregulation induced by FAP-alpha overexpression.	U 0126	180-185	mitogen-activated protein kinase 1	Homo sapiens	49-52
29063347-8	2018	Furthermore, administration of the ERK inhibitor U0126 or transient (siRNA) silencing of Nrf2 blocked the protective effects of taurine on cell viability and expression levels of Nrf2 and heme oxygenase-1 (HO-1) in the CORT model of neuronal damage.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	35-38
29212876-4	2018	The presence of MEK inhibitors U0126 or PD98059, or prior silencing Egr-1 with small interfering RNA suppressed leptin-induced PPARgamma reduction.	U 0126	31-36	leptin	Rattus norvegicus	112-118
29212876-4	2018	The presence of MEK inhibitors U0126 or PD98059, or prior silencing Egr-1 with small interfering RNA suppressed leptin-induced PPARgamma reduction.	U 0126	31-36	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	127-136
29063347-8	2018	Furthermore, administration of the ERK inhibitor U0126 or transient (siRNA) silencing of Nrf2 blocked the protective effects of taurine on cell viability and expression levels of Nrf2 and heme oxygenase-1 (HO-1) in the CORT model of neuronal damage.	U 0126	49-54	NFE2 like bZIP transcription factor 2	Homo sapiens	179-183
29063347-8	2018	Furthermore, administration of the ERK inhibitor U0126 or transient (siRNA) silencing of Nrf2 blocked the protective effects of taurine on cell viability and expression levels of Nrf2 and heme oxygenase-1 (HO-1) in the CORT model of neuronal damage.	U 0126	49-54	heme oxygenase 1	Homo sapiens	188-204
28468567-11	2018	UO126 prevented the increase in CYP11A1 and CYP17 in control FACs.	U 0126	0-5	cholesterol side-chain cleavage enzyme, mitochondrial	Ovis aries	32-39
28468567-11	2018	UO126 prevented the increase in CYP11A1 and CYP17 in control FACs.	U 0126	0-5	steroid 17-alpha-hydroxylase/17,20 lyase	Ovis aries	44-49
29373584-4	2018	Pre-treatment with EGCG ameliorated the corticosterone-induced neuronal injuries; however, it was blocked by pharmacological inhibitors for ERK1/2 (U0126) and PI3K/AKT (LY294002).	U 0126	148-153	mitogen-activated protein kinase 3	Homo sapiens	140-146
29110347-3	2018	Breakdown of the GAPJs was delayed in the group treated with 5 muM U0126 when compared to controls, as estimated by immunohistochemical examination of connexin 43, which is a primary constituent of the GAPJs.	U 0126	67-72	gap junction protein alpha 1	Bos taurus	151-162
29248464-10	2018	Pre-treatment of cells with selective inhibitors of AKT (LY294002) and ERK1/2 (U0126) revealed that the AKT and ERK1/2 signaling pathways regulated by DA displayed cross-talk in HTR8/SVneo cells.	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	71-77
29362398-6	2018	In addition, RCX induced the phosphorylation of ERK1/2, and pretreatment with U-0126, an MEK inhibitor known to inhibit the activation of ERK1/2, prevented RCX-induced apoptosis.	U 0126	78-84	mitogen-activated protein kinase 3	Homo sapiens	48-54
29362398-6	2018	In addition, RCX induced the phosphorylation of ERK1/2, and pretreatment with U-0126, an MEK inhibitor known to inhibit the activation of ERK1/2, prevented RCX-induced apoptosis.	U 0126	78-84	mitogen-activated protein kinase kinase 7	Homo sapiens	89-92
29362398-6	2018	In addition, RCX induced the phosphorylation of ERK1/2, and pretreatment with U-0126, an MEK inhibitor known to inhibit the activation of ERK1/2, prevented RCX-induced apoptosis.	U 0126	78-84	mitogen-activated protein kinase 3	Homo sapiens	138-144
29348467-5	2018	Treatment with U0126, PD901, and Selumetinib MEK inhibitors triggered growth restraint in all CCA cell lines tested, with the most pronounced growth suppressive effects being observed in K-Ras mutant cells.	U 0126	15-20	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	187-192
29248464-10	2018	Pre-treatment of cells with selective inhibitors of AKT (LY294002) and ERK1/2 (U0126) revealed that the AKT and ERK1/2 signaling pathways regulated by DA displayed cross-talk in HTR8/SVneo cells.	U 0126	79-84	AKT serine/threonine kinase 1	Homo sapiens	104-107
29248464-10	2018	Pre-treatment of cells with selective inhibitors of AKT (LY294002) and ERK1/2 (U0126) revealed that the AKT and ERK1/2 signaling pathways regulated by DA displayed cross-talk in HTR8/SVneo cells.	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	112-118
29317674-4	2018	Enhanced ERK activation was observed in Spred2-/--livers, and the MEK/ERK inhibitor U0126 ameliorated ALI.	U 0126	84-89	midkine	Mus musculus	66-69
29317674-7	2018	Immunohistochemically, Kupffer cells were found to produce TNFalpha, and isolated Kupffer cells from Spred2-/- mice produced significantly higher levels of TNFalpha than those from wild-type mice after LPS stimulation, which was significantly decreased by U0126.	U 0126	256-261	sprouty-related EVH1 domain containing 2	Mus musculus	101-107
29317674-7	2018	Immunohistochemically, Kupffer cells were found to produce TNFalpha, and isolated Kupffer cells from Spred2-/- mice produced significantly higher levels of TNFalpha than those from wild-type mice after LPS stimulation, which was significantly decreased by U0126.	U 0126	256-261	tumor necrosis factor	Mus musculus	156-164
29637869-11	2018	In addition, MAPKs inhibitors (SP600125, U0126, and SB203580) reversed MAM-induced cell death and ATM/Chk2 activation.	U 0126	41-46	ATM serine/threonine kinase	Homo sapiens	98-101
29637869-11	2018	In addition, MAPKs inhibitors (SP600125, U0126, and SB203580) reversed MAM-induced cell death and ATM/Chk2 activation.	U 0126	41-46	checkpoint kinase 2	Homo sapiens	102-106
29091876-7	2018	The ERK1/2 inhibitor U0126 enhanced the inhibitory effects of CTRP6 overexpression on cell proliferation, migration and ECM expression in TGF-beta1-stimulated NRK-49F cells.	U 0126	21-26	mitogen activated protein kinase 3	Rattus norvegicus	4-10
29091876-7	2018	The ERK1/2 inhibitor U0126 enhanced the inhibitory effects of CTRP6 overexpression on cell proliferation, migration and ECM expression in TGF-beta1-stimulated NRK-49F cells.	U 0126	21-26	C1q and TNF related 6	Rattus norvegicus	62-67
29091876-7	2018	The ERK1/2 inhibitor U0126 enhanced the inhibitory effects of CTRP6 overexpression on cell proliferation, migration and ECM expression in TGF-beta1-stimulated NRK-49F cells.	U 0126	21-26	transforming growth factor, beta 1	Rattus norvegicus	138-147
29899190-8	2018	U0126, an inhibitor of ERK activation, completely inhibited the increases in the mRNA levels of DUSP5 and DUSP6.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	23-26
29899190-8	2018	U0126, an inhibitor of ERK activation, completely inhibited the increases in the mRNA levels of DUSP5 and DUSP6.	U 0126	0-5	dual specificity phosphatase 5	Mus musculus	96-101
29899190-8	2018	U0126, an inhibitor of ERK activation, completely inhibited the increases in the mRNA levels of DUSP5 and DUSP6.	U 0126	0-5	dual specificity phosphatase 6	Mus musculus	106-111
29074343-2	2018	METHODS: We used an intra-hippocampal microinfusion of U0126 to suppress ERK activation.	U 0126	55-60	Eph receptor B1	Rattus norvegicus	73-76
29074343-8	2018	RESULTS: Treatment with 0.11%SEV led to rapid phosphorylation of ERK, while 0.3%SEV inhibited phosphorylation; the latter change was reversed by the microinfusion of U0126 in the hippocampus.	U 0126	166-171	Eph receptor B1	Rattus norvegicus	65-68
29074343-10	2018	The local infusion of U0126 abolished the 0.3%SEV-induced memory impairment and ERK inhibition.	U 0126	22-27	Eph receptor B1	Rattus norvegicus	80-83
29950141-10	2018	Results also showed that inhibition of ERK1/2 pathway using U0126 significantly inhibited TNF-alpha-induced autophagy.	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	39-45
29950141-10	2018	Results also showed that inhibition of ERK1/2 pathway using U0126 significantly inhibited TNF-alpha-induced autophagy.	U 0126	60-65	tumor necrosis factor	Rattus norvegicus	90-99
29950141-11	2018	Furthermore, the TNF-alpha-mediated inhibition of IEC-6 proliferation and promotion of IEC-6 apoptosis was abolished by U0126.	U 0126	120-125	tumor necrosis factor	Rattus norvegicus	17-26
27867196-10	2018	Accordingly, ADP-induced MCP-1 production and protection against bacterial infection could also be reduced by U0126, forskolin and 8-bromo-cAMP.	U 0126	110-115	mast cell protease 1	Mus musculus	25-30
30032146-16	2018	Compared with the control2 group, UO126 increased galectin-1 expressions, IL-10 and TGF-beta levels and reduced IL-2 levels with inactivated HSCs.	U 0126	34-39	lectin, galactose binding, soluble 1	Mus musculus	50-60
30032146-16	2018	Compared with the control2 group, UO126 increased galectin-1 expressions, IL-10 and TGF-beta levels and reduced IL-2 levels with inactivated HSCs.	U 0126	34-39	interleukin 10	Mus musculus	74-79
30032146-16	2018	Compared with the control2 group, UO126 increased galectin-1 expressions, IL-10 and TGF-beta levels and reduced IL-2 levels with inactivated HSCs.	U 0126	34-39	transforming growth factor, beta 1	Mus musculus	84-92
30032146-16	2018	Compared with the control2 group, UO126 increased galectin-1 expressions, IL-10 and TGF-beta levels and reduced IL-2 levels with inactivated HSCs.	U 0126	34-39	interleukin 2	Mus musculus	112-116
30458456-5	2018	Moreover, the role of the integrin alpha5beta1/ERK1/2 pathway on the osteoinductive performance of Ta and Ti was assessed by up- and down-regulation of integrin alpha5 and beta1 with RNA interference, as well as through ERK1/2 inhibition with U0126.	U 0126	243-248	integrin subunit alpha 5	Rattus norvegicus	26-41
29554648-11	2018	Moreover, the Erk inhibitor U0126 prevented HG-induced mTOR activation.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	14-17
29554648-11	2018	Moreover, the Erk inhibitor U0126 prevented HG-induced mTOR activation.	U 0126	28-33	mechanistic target of rapamycin kinase	Homo sapiens	55-59
30112985-9	2018	A specific MAPK inhibitor, U0126, was used to block ERK activity.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	11-15
30112985-9	2018	A specific MAPK inhibitor, U0126, was used to block ERK activity.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	52-55
30112985-12	2018	The pERK/tERK ratio was significantly (P &lt; 0.05) increased upon treatment with rh174 or amgCP compared to non-treated ADSCs, while this increase was significantly (P &lt; 0.05) suppressed by the addition of U0126.	U 0126	210-215	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	4-8
29208568-7	2018	Furthermore, the promotive effects of ELF3 on cellular proliferation and metastasis could be rescued by Ly294002 (inhibitor of PI3K) and U0126 (inhibitor of MEK1/2).	U 0126	137-142	E74 like ETS transcription factor 3	Homo sapiens	38-42
29208568-7	2018	Furthermore, the promotive effects of ELF3 on cellular proliferation and metastasis could be rescued by Ly294002 (inhibitor of PI3K) and U0126 (inhibitor of MEK1/2).	U 0126	137-142	mitogen-activated protein kinase kinase 1	Homo sapiens	157-163
29578162-11	2018	MEK specific inhibitor U0126 inhibited the occurrence of autophagy, and then blocked curcumin-induced cytotoxicity at 4 h and 8 h. Conclusions: Curcumin induce autophagic cell death in SUP-B15 cells via activating RAF/MEK/ERK pathway.	U 0126	23-28	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
29578162-11	2018	MEK specific inhibitor U0126 inhibited the occurrence of autophagy, and then blocked curcumin-induced cytotoxicity at 4 h and 8 h. Conclusions: Curcumin induce autophagic cell death in SUP-B15 cells via activating RAF/MEK/ERK pathway.	U 0126	23-28	zinc fingers and homeoboxes 2	Homo sapiens	214-217
29578162-11	2018	MEK specific inhibitor U0126 inhibited the occurrence of autophagy, and then blocked curcumin-induced cytotoxicity at 4 h and 8 h. Conclusions: Curcumin induce autophagic cell death in SUP-B15 cells via activating RAF/MEK/ERK pathway.	U 0126	23-28	mitogen-activated protein kinase kinase 7	Homo sapiens	218-221
29578162-11	2018	MEK specific inhibitor U0126 inhibited the occurrence of autophagy, and then blocked curcumin-induced cytotoxicity at 4 h and 8 h. Conclusions: Curcumin induce autophagic cell death in SUP-B15 cells via activating RAF/MEK/ERK pathway.	U 0126	23-28	EPH receptor B2	Homo sapiens	222-225
28218391-5	2018	Culture of 3 days post-parturition (dpp) ovaries with the MAPK3/1 signaling inhibitor U0126 significantly reduced the number of activated follicles and was accompanied by dramatically reduced granulosa cell proliferation and increased oocyte apoptosis.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	58-63
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	TSC complex subunit 2	Homo sapiens	117-121
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	ribosomal protein S6 kinase B1	Homo sapiens	123-127
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	ribosomal protein S6	Homo sapiens	133-137
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	KIT ligand	Homo sapiens	160-164
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	CREB regulated transcription coactivator 1	Mus musculus	197-203
29317674-4	2018	Enhanced ERK activation was observed in Spred2-/--livers, and the MEK/ERK inhibitor U0126 ameliorated ALI.	U 0126	84-89	mitogen-activated protein kinase 1	Mus musculus	70-73
28322449-4	2018	And the downregulation of MAPK-ERK signaling using pharmacological inhibitor U0126 and RNA interference rescued osteoblast differentiation suppressed by TGF-beta, which was confirmed by Alkaline phosphatase (ALP) staining and alizarrn red staining, and the enhanced expression of osteogenesic markers.	U 0126	77-82	mitogen-activated protein kinase 1	Mus musculus	31-34
30359975-10	2018	Except for ALP and Col-I, the promotive effects of Nell-1 on the expression of osteogenic markers were suppressed by ERK inhibitor U0126.	U 0126	131-136	NEL-like 1	Mus musculus	51-57
30359975-10	2018	Except for ALP and Col-I, the promotive effects of Nell-1 on the expression of osteogenic markers were suppressed by ERK inhibitor U0126.	U 0126	131-136	mitogen-activated protein kinase 1	Mus musculus	117-120
28322449-4	2018	And the downregulation of MAPK-ERK signaling using pharmacological inhibitor U0126 and RNA interference rescued osteoblast differentiation suppressed by TGF-beta, which was confirmed by Alkaline phosphatase (ALP) staining and alizarrn red staining, and the enhanced expression of osteogenesic markers.	U 0126	77-82	transforming growth factor, beta 1	Mus musculus	153-161
28322449-6	2018	Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes.	U 0126	129-134	SMAD specific E3 ubiquitin protein ligase 1	Mus musculus	45-51
28322449-6	2018	Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes.	U 0126	129-134	SMAD family member 1	Mus musculus	81-86
28322449-6	2018	Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes.	U 0126	129-134	runt related transcription factor 2	Mus musculus	91-96
28322449-6	2018	Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes.	U 0126	129-134	mitogen-activated protein kinase 1	Mus musculus	115-118
28322449-6	2018	Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes.	U 0126	129-134	transforming growth factor, beta 1	Mus musculus	138-146
28322449-6	2018	Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes.	U 0126	129-134	mitogen-activated protein kinase 1	Mus musculus	208-211
28322449-9	2018	In addition, the potentiation of BMP-2 on osteogenic activity by ERK1/2 inhibitor U0126 suggests that it may have potential clinical utility for promoting osteogenesis in bone fracture repair.	U 0126	82-87	bone morphogenetic protein 2	Mus musculus	33-38
28322449-9	2018	In addition, the potentiation of BMP-2 on osteogenic activity by ERK1/2 inhibitor U0126 suggests that it may have potential clinical utility for promoting osteogenesis in bone fracture repair.	U 0126	82-87	mitogen-activated protein kinase 3	Mus musculus	65-71
29454612-5	2018	Using western blots, we measured the phosphorylation of 4E-BP and S6K proteins, the main targets of TOR, following the in vitro exposure of PGs to brain extract containing PTTH (hereafter referred to as PTTH) and/or the inhibitors of MAPK (U0126), PI3K (LY294002) or TOR (rapamycin).	U 0126	240-245	prothoracicotropic hormone	Bombyx mori	172-176
28833753-7	2017	As expected, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the MAPK inhibitor U0126 inhibited Lf-induced phosphorylation of Akt1 and ERK1/2, respectively.	U 0126	96-101	mitogen-activated protein kinase 3	Homo sapiens	81-85
29115504-4	2018	A MAPK inhibitor and U0126, an ERK inhibitor, abolished the effects of GD on Cx43 expression levels.	U 0126	21-26	Eph receptor B1	Rattus norvegicus	31-34
29115504-4	2018	A MAPK inhibitor and U0126, an ERK inhibitor, abolished the effects of GD on Cx43 expression levels.	U 0126	21-26	gap junction protein, alpha 1	Rattus norvegicus	77-81
29299041-9	2017	In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors.	U 0126	57-62	mitogen-activated protein kinase 3	Mus musculus	31-37
29299041-9	2017	In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors.	U 0126	57-62	mitogen-activated protein kinase kinase 1	Mus musculus	101-105
29299041-9	2017	In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors.	U 0126	57-62	mitogen-activated protein kinase kinase 2	Mus musculus	110-114
29299041-9	2017	In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors.	U 0126	57-62	mitogen-activated protein kinase 1	Mus musculus	129-133
29299041-9	2017	In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors.	U 0126	57-62	mitogen-activated protein kinase 1	Mus musculus	31-34
29268768-17	2017	CX3CL1-mediated MMP-3 production was attenuated by c-Raf inhibitors (GW5074) and MEK/ERK inhibitors (PD98059 and U0126).	U 0126	113-118	C-X3-C motif chemokine ligand 1	Homo sapiens	0-6
29268768-17	2017	CX3CL1-mediated MMP-3 production was attenuated by c-Raf inhibitors (GW5074) and MEK/ERK inhibitors (PD98059 and U0126).	U 0126	113-118	matrix metallopeptidase 3	Homo sapiens	16-21
29261154-4	2017	RESULTS: Inhibition of ERK signaling with the MEK inhibitor U0126 blunted the ability of TGF-beta1 to induce migration in pancreatic cancer Panc1 cells.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	23-26
29261154-4	2017	RESULTS: Inhibition of ERK signaling with the MEK inhibitor U0126 blunted the ability of TGF-beta1 to induce migration in pancreatic cancer Panc1 cells.	U 0126	60-65	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
29261154-4	2017	RESULTS: Inhibition of ERK signaling with the MEK inhibitor U0126 blunted the ability of TGF-beta1 to induce migration in pancreatic cancer Panc1 cells.	U 0126	60-65	transforming growth factor beta 1	Homo sapiens	89-98
29261154-6	2017	Basal and TGF-beta1-dependent ERK, but not SMAD activation, was blocked by U0126 in Panc1 and other cell types indicating that ERK activation is downstream or independent of SMAD signaling.	U 0126	75-80	transforming growth factor beta 1	Homo sapiens	10-19
29261154-6	2017	Basal and TGF-beta1-dependent ERK, but not SMAD activation, was blocked by U0126 in Panc1 and other cell types indicating that ERK activation is downstream or independent of SMAD signaling.	U 0126	75-80	mitogen-activated protein kinase 1	Homo sapiens	30-33
29261154-6	2017	Basal and TGF-beta1-dependent ERK, but not SMAD activation, was blocked by U0126 in Panc1 and other cell types indicating that ERK activation is downstream or independent of SMAD signaling.	U 0126	75-80	mitogen-activated protein kinase 1	Homo sapiens	127-130
29435145-4	2018	Upon TNF-alpha treatment, the activity of smad1/5/8 was inhibited, by contrast, extracellular signal-regulated kinase-1/2 (ERK1/2) and P38 was increased in C2C12 cells, the inhibitor of ERK1/2 (U0126) was found to abrogate the TNF-alpha inhibition of SATB2 expression.	U 0126	194-199	tumor necrosis factor	Mus musculus	5-14
29435145-4	2018	Upon TNF-alpha treatment, the activity of smad1/5/8 was inhibited, by contrast, extracellular signal-regulated kinase-1/2 (ERK1/2) and P38 was increased in C2C12 cells, the inhibitor of ERK1/2 (U0126) was found to abrogate the TNF-alpha inhibition of SATB2 expression.	U 0126	194-199	SMAD family member 1	Mus musculus	42-51
29435145-4	2018	Upon TNF-alpha treatment, the activity of smad1/5/8 was inhibited, by contrast, extracellular signal-regulated kinase-1/2 (ERK1/2) and P38 was increased in C2C12 cells, the inhibitor of ERK1/2 (U0126) was found to abrogate the TNF-alpha inhibition of SATB2 expression.	U 0126	194-199	mitogen-activated protein kinase 3	Mus musculus	80-121
29435145-4	2018	Upon TNF-alpha treatment, the activity of smad1/5/8 was inhibited, by contrast, extracellular signal-regulated kinase-1/2 (ERK1/2) and P38 was increased in C2C12 cells, the inhibitor of ERK1/2 (U0126) was found to abrogate the TNF-alpha inhibition of SATB2 expression.	U 0126	194-199	mitogen-activated protein kinase 3	Mus musculus	123-129
29435145-4	2018	Upon TNF-alpha treatment, the activity of smad1/5/8 was inhibited, by contrast, extracellular signal-regulated kinase-1/2 (ERK1/2) and P38 was increased in C2C12 cells, the inhibitor of ERK1/2 (U0126) was found to abrogate the TNF-alpha inhibition of SATB2 expression.	U 0126	194-199	mitogen-activated protein kinase 14	Mus musculus	135-138
29435145-4	2018	Upon TNF-alpha treatment, the activity of smad1/5/8 was inhibited, by contrast, extracellular signal-regulated kinase-1/2 (ERK1/2) and P38 was increased in C2C12 cells, the inhibitor of ERK1/2 (U0126) was found to abrogate the TNF-alpha inhibition of SATB2 expression.	U 0126	194-199	mitogen-activated protein kinase 3	Mus musculus	186-192
29321724-6	2017	These effects were partly abolished by blocking its receptor deleted in colorectal cancer (DCC) or U0126, an inhibitor of the ERK signaling pathway.	U 0126	99-104	Eph receptor B1	Rattus norvegicus	126-129
29358904-8	2017	The BDNF induction by Kir4.1 siRNA transfection was suppressed by the MEK1/2 inhibitor U0126, but not by the p38 MAPK inhibitor SB202190 or the JNK inhibitor SP600125.	U 0126	87-92	brain derived neurotrophic factor	Mus musculus	4-8
29358904-8	2017	The BDNF induction by Kir4.1 siRNA transfection was suppressed by the MEK1/2 inhibitor U0126, but not by the p38 MAPK inhibitor SB202190 or the JNK inhibitor SP600125.	U 0126	87-92	potassium inwardly-rectifying channel, subfamily J, member 10	Mus musculus	22-28
29358904-8	2017	The BDNF induction by Kir4.1 siRNA transfection was suppressed by the MEK1/2 inhibitor U0126, but not by the p38 MAPK inhibitor SB202190 or the JNK inhibitor SP600125.	U 0126	87-92	mitogen-activated protein kinase kinase 1	Mus musculus	70-76
29206176-8	2017	Moreover, inhibiting ERK1/2, AKT, mTOR and STAT5 with U0126, MK2206, Rapamycin and AG490 could block the effects of Kp-10.	U 0126	54-59	mitogen-activated protein kinase 3	Bos taurus	21-27
29206176-8	2017	Moreover, inhibiting ERK1/2, AKT, mTOR and STAT5 with U0126, MK2206, Rapamycin and AG490 could block the effects of Kp-10.	U 0126	54-59	mechanistic target of rapamycin kinase	Bos taurus	34-38
28940899-9	2017	ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and Akt, respectively, which in turn reduced the LIPUS-induced proliferation of hAD-MSCs.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	0-6
28940899-9	2017	ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and Akt, respectively, which in turn reduced the LIPUS-induced proliferation of hAD-MSCs.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	110-116
28940899-9	2017	ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and Akt, respectively, which in turn reduced the LIPUS-induced proliferation of hAD-MSCs.	U 0126	18-23	AKT serine/threonine kinase 1	Homo sapiens	121-124
28833753-7	2017	As expected, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the MAPK inhibitor U0126 inhibited Lf-induced phosphorylation of Akt1 and ERK1/2, respectively.	U 0126	96-101	AKT serine/threonine kinase 1	Homo sapiens	142-146
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	57-62	KIT ligand	Homo sapiens	204-208
28833753-7	2017	As expected, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the MAPK inhibitor U0126 inhibited Lf-induced phosphorylation of Akt1 and ERK1/2, respectively.	U 0126	96-101	mitogen-activated protein kinase 3	Homo sapiens	151-157
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	TSC complex subunit 2	Homo sapiens	117-121
29017756-7	2017	The inhibition of the ERK1/2 activity via U0126 yielded an unchanged strain-related modulation of nuclear YAP localization, while YAP amount in whole cell extracts of strained cells was decreased.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	22-28
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	ribosomal protein S6 kinase B1	Homo sapiens	123-127
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	ribosomal protein S6	Homo sapiens	133-137
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	KIT ligand	Homo sapiens	160-164
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	CREB regulated transcription coactivator 1	Mus musculus	197-203
28218391-6	2018	Western blot and immunofluorescence analyses showed that U0126 significantly decreased the phosphorylation levels of Tsc2, S6K1, and rpS6 and the expression of KITL, indicating that U0126 inhibits mTORC1-KITL signaling.	U 0126	182-187	KIT ligand	Homo sapiens	204-208
28218391-7	2018	Furthermore, U0126 decreased the phosphorylation levels of Akt, resulting in a decreased number of oocytes with Foxo3 nuclear export.	U 0126	13-18	AKT serine/threonine kinase 1	Homo sapiens	59-62
28218391-7	2018	Furthermore, U0126 decreased the phosphorylation levels of Akt, resulting in a decreased number of oocytes with Foxo3 nuclear export.	U 0126	13-18	forkhead box O3	Homo sapiens	112-117
28218391-9	2018	In this model, U0126 also inhibited the activation of primordial follicles and mTORC1 signaling.	U 0126	15-20	CREB regulated transcription coactivator 1	Mus musculus	79-85
29061354-12	2017	However, ERK inhibitor (U0126) inhibited the increase in dentin sialophosphoprotein and dentin matrix protein-1 expression and mineralization induced by OST.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	9-12
29061354-12	2017	However, ERK inhibitor (U0126) inhibited the increase in dentin sialophosphoprotein and dentin matrix protein-1 expression and mineralization induced by OST.	U 0126	24-29	dentin matrix acidic phosphoprotein 1	Homo sapiens	88-111
29061354-12	2017	However, ERK inhibitor (U0126) inhibited the increase in dentin sialophosphoprotein and dentin matrix protein-1 expression and mineralization induced by OST.	U 0126	24-29	parathyroid hormone like hormone	Homo sapiens	153-156
30053080-11	2017	Treatment with the MEK inhibitors U0126 and PD302 rescued PIGU expression.	U 0126	34-39	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
30053080-11	2017	Treatment with the MEK inhibitors U0126 and PD302 rescued PIGU expression.	U 0126	34-39	phosphatidylinositol glycan anchor biosynthesis class U	Homo sapiens	58-62
29344155-11	2017	Furthermore, SGC7901 GC cells were treated with U0126, an inhibitor of the ERK signaling pathway, to assess whether CD133 is upstream of ERK/P70S6K.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	75-78
29344155-12	2017	The results showed that the expression of p-ERK and p-P70S6K was downregulated in the cells treated with U0126, while the expression of CD133 remained unaltered.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	44-47
29344155-12	2017	The results showed that the expression of p-ERK and p-P70S6K was downregulated in the cells treated with U0126, while the expression of CD133 remained unaltered.	U 0126	105-110	ribosomal protein S6 kinase B1	Homo sapiens	54-60
29344155-12	2017	The results showed that the expression of p-ERK and p-P70S6K was downregulated in the cells treated with U0126, while the expression of CD133 remained unaltered.	U 0126	105-110	prominin 1	Homo sapiens	136-141
28726167-8	2017	Furthermore, B1R activation facilitated the mRNA and protein expressions of MMP-9 in the hemorrhagic tissues, and these increases were blocked by both ERK inhibitor U0126 and NF-kappaB inhibitor PDTC.	U 0126	165-170	bradykinin receptor B1	Rattus norvegicus	13-16
28990082-6	2017	The increase in Runx2 and ALP activity was accompanied by the activation of calcium/calmodulin-dependent protein kinase type II (CaMK II) and extracellular signal-regulated kinases 1/2 (ERK1/2), which was completely abolished by treatment with KN93 and U0126, respectively.	U 0126	253-258	runt related transcription factor 2	Mus musculus	16-21
28990082-6	2017	The increase in Runx2 and ALP activity was accompanied by the activation of calcium/calmodulin-dependent protein kinase type II (CaMK II) and extracellular signal-regulated kinases 1/2 (ERK1/2), which was completely abolished by treatment with KN93 and U0126, respectively.	U 0126	253-258	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	76-127
28990082-6	2017	The increase in Runx2 and ALP activity was accompanied by the activation of calcium/calmodulin-dependent protein kinase type II (CaMK II) and extracellular signal-regulated kinases 1/2 (ERK1/2), which was completely abolished by treatment with KN93 and U0126, respectively.	U 0126	253-258	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	129-136
28990082-6	2017	The increase in Runx2 and ALP activity was accompanied by the activation of calcium/calmodulin-dependent protein kinase type II (CaMK II) and extracellular signal-regulated kinases 1/2 (ERK1/2), which was completely abolished by treatment with KN93 and U0126, respectively.	U 0126	253-258	mitogen-activated protein kinase 3	Mus musculus	142-184
28990082-6	2017	The increase in Runx2 and ALP activity was accompanied by the activation of calcium/calmodulin-dependent protein kinase type II (CaMK II) and extracellular signal-regulated kinases 1/2 (ERK1/2), which was completely abolished by treatment with KN93 and U0126, respectively.	U 0126	253-258	mitogen-activated protein kinase 3	Mus musculus	186-192
28726167-8	2017	Furthermore, B1R activation facilitated the mRNA and protein expressions of MMP-9 in the hemorrhagic tissues, and these increases were blocked by both ERK inhibitor U0126 and NF-kappaB inhibitor PDTC.	U 0126	165-170	matrix metallopeptidase 9	Rattus norvegicus	76-81
28726167-8	2017	Furthermore, B1R activation facilitated the mRNA and protein expressions of MMP-9 in the hemorrhagic tissues, and these increases were blocked by both ERK inhibitor U0126 and NF-kappaB inhibitor PDTC.	U 0126	165-170	Eph receptor B1	Rattus norvegicus	151-154
28726167-9	2017	U0126 also remarkably decreased the B1R-induced NF-kappaB/p65 activation.	U 0126	0-5	bradykinin receptor B1	Rattus norvegicus	36-40
28726167-9	2017	U0126 also remarkably decreased the B1R-induced NF-kappaB/p65 activation.	U 0126	0-5	synaptotagmin 1	Rattus norvegicus	58-61
29204135-4	2017	Extensor digitorum longus (EDL) and soleus muscles from male C57BL/6 mice were isolated, divided into halves, and then incubated with ucOC with or without the pretreatment of ERK inhibitor U0126.	U 0126	189-194	mitogen-activated protein kinase 1	Mus musculus	175-178
29182679-10	2017	Treatment with a neutralizing antibody against alpha5beta1 and MEK inhibitor U0126 inhibited Edil3-enhanced osteogenic marker gene expression and mineral deposition.	U 0126	77-82	midkine	Mus musculus	63-66
29182679-10	2017	Treatment with a neutralizing antibody against alpha5beta1 and MEK inhibitor U0126 inhibited Edil3-enhanced osteogenic marker gene expression and mineral deposition.	U 0126	77-82	EGF-like repeats and discoidin I-like domains 3	Mus musculus	93-98
29182679-12	2017	Edil3-induced Runx2 protein expression was suppressed by pretreatment with U0126.	U 0126	75-80	EGF-like repeats and discoidin I-like domains 3	Mus musculus	0-5
29182679-12	2017	Edil3-induced Runx2 protein expression was suppressed by pretreatment with U0126.	U 0126	75-80	runt related transcription factor 2	Mus musculus	14-19
28063235-9	2017	Moreover, the abundance of adiponectin-activated signaling molecules were suppressed by pharmacological inhibitors including wortmannin, U0126, SP600125, and SB203580, respectively, in pLE cells.	U 0126	137-142	adiponectin, C1Q and collagen domain containing	Homo sapiens	27-38
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	tyrosinase	Homo sapiens	157-160
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	tyrosinase related protein 1	Homo sapiens	162-167
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	dopachrome tautomerase	Homo sapiens	169-174
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	176-181
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	183-188
29104663-8	2017	The estrogen receptor inhibitor, ICI182780, and MEK inhibitor, U0126, significantly reversed the effects of wogonin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK-1, ERK-2 and JNK-2 (all P&lt;0.01).	U 0126	63-68	mitogen-activated protein kinase 9	Homo sapiens	193-198
29131833-13	2017	These data point to a potentially successful treatment of MPNST by combined application of ATRA and MEK inhibitors such as U0126 or PD0325901.	U 0126	123-128	mitogen-activated protein kinase kinase 7	Homo sapiens	100-103
28882596-5	2017	Inhibitors of PI3K, wortmannin and LY294002, and a MEK inhibitor, U0126, abolished the potentiating effect of long-term insulin treatment.	U 0126	66-71	insulin S homeolog	Xenopus laevis	120-127
28492136-5	2017	Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
28492136-5	2017	Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation.	U 0126	47-52	transforming growth factor beta 1	Homo sapiens	65-74
28492136-5	2017	Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation.	U 0126	47-52	vimentin	Homo sapiens	96-104
28492136-5	2017	Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation.	U 0126	47-52	matrix metallopeptidase 9	Homo sapiens	109-113
29061787-9	2017	The DOX-induced P-gp overexpression was partially suppressed by an inhibitor of MEK1/2 (U0126), but not by a PI3K inhibitor (LY294002).	U 0126	88-93	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
29061787-9	2017	The DOX-induced P-gp overexpression was partially suppressed by an inhibitor of MEK1/2 (U0126), but not by a PI3K inhibitor (LY294002).	U 0126	88-93	mitogen-activated protein kinase kinase 1	Homo sapiens	80-86
29061787-10	2017	Interestingly, the expression of P-gp was synergistically inhibited by combined treatment of U0126 with LY294002 and also inhibited by an mTORC1 inhibitor, rapamycin.	U 0126	93-98	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
28835988-5	2017	The changes caused by VLDL were dependent on extracellular signal-regulated kinase (ERK) 1/2 since they were prevented by the ERK1/2 inhibitor U0126 or by knockdown of this kinase by siRNA transfection.	U 0126	143-148	CD320 antigen	Mus musculus	22-26
28835988-5	2017	The changes caused by VLDL were dependent on extracellular signal-regulated kinase (ERK) 1/2 since they were prevented by the ERK1/2 inhibitor U0126 or by knockdown of this kinase by siRNA transfection.	U 0126	143-148	mitogen-activated protein kinase 3	Mus musculus	45-92
28835988-5	2017	The changes caused by VLDL were dependent on extracellular signal-regulated kinase (ERK) 1/2 since they were prevented by the ERK1/2 inhibitor U0126 or by knockdown of this kinase by siRNA transfection.	U 0126	143-148	mitogen-activated protein kinase 3	Mus musculus	126-132
28866332-6	2017	ERK inactivation by U0126, however, restored insulin-stimulated AKT phosphorylation, which was decreased by permethrin treatment.	U 0126	20-25	mitogen-activated protein kinase 3	Mus musculus	0-3
28866332-6	2017	ERK inactivation by U0126, however, restored insulin-stimulated AKT phosphorylation, which was decreased by permethrin treatment.	U 0126	20-25	thymoma viral proto-oncogene 1	Mus musculus	64-67
28939254-9	2017	Also CVS-infected/U0126-treated mice revealed significant decrease in caspase 3 but increase in Bcl-2 mRNA levels and less TUNEL positive apoptotic cells.	U 0126	18-23	caspase 3	Mus musculus	70-79
28939254-9	2017	Also CVS-infected/U0126-treated mice revealed significant decrease in caspase 3 but increase in Bcl-2 mRNA levels and less TUNEL positive apoptotic cells.	U 0126	18-23	B cell leukemia/lymphoma 2	Mus musculus	96-101
28944838-12	2017	Additionally, the ERK pathway inhibitor U0126 and Wnt pathway inhibitor dickkopf-related protein 1 markedly suppressed the expression of the above genes (P&lt;0.01).	U 0126	40-45	mitogen-activated protein kinase 1	Mus musculus	18-21
28944867-7	2017	Notably, the Erk antagonist (U0126) or mTOR inhibitor (rapamycin) abolished the effect of succinate on protein synthesis.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	13-16
28762104-9	2017	Co-treatment with the PI3K inhibitor LY294002 or ERK1/2 inhibitor U0126 significantly reverses the protective role of NGF on HG-induced excessive ER stress and subsequent apoptosis.	U 0126	66-71	mitogen activated protein kinase 3	Rattus norvegicus	49-55
28762104-9	2017	Co-treatment with the PI3K inhibitor LY294002 or ERK1/2 inhibitor U0126 significantly reverses the protective role of NGF on HG-induced excessive ER stress and subsequent apoptosis.	U 0126	66-71	nerve growth factor	Rattus norvegicus	118-121
28972999-7	2017	Their effects on pax3 and MyoD expression were blocked by inhibitors of both the IGF type I receptor (picropodophyllotoxin, PPP) and MEK (U0126).	U 0126	138-143	paired box 3	Gallus gallus	17-21
29111814-5	2017	However, both the redox inhibitor glutathione (GSH) and ERK inhibitor U0126 antagonized SW-induced phosphorylations of ATM, ATR, and CHK1 in AGS cells.	U 0126	70-75	ATM serine/threonine kinase	Homo sapiens	119-122
29111814-5	2017	However, both the redox inhibitor glutathione (GSH) and ERK inhibitor U0126 antagonized SW-induced phosphorylations of ATM, ATR, and CHK1 in AGS cells.	U 0126	70-75	ATR serine/threonine kinase	Homo sapiens	124-127
29111814-5	2017	However, both the redox inhibitor glutathione (GSH) and ERK inhibitor U0126 antagonized SW-induced phosphorylations of ATM, ATR, and CHK1 in AGS cells.	U 0126	70-75	checkpoint kinase 1	Homo sapiens	133-137
28943602-9	2017	DM-induced neurite outgrowth was abolished by U0126 and rapamycin, indicating the involvement of the mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathways.	U 0126	46-51	mechanistic target of rapamycin kinase	Homo sapiens	145-174
28943602-9	2017	DM-induced neurite outgrowth was abolished by U0126 and rapamycin, indicating the involvement of the mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathways.	U 0126	46-51	mechanistic target of rapamycin kinase	Homo sapiens	176-180
29070458-5	2017	The effect of ERK inhibitor U0126 pretreatment on MUC5AC mRNA expression was also analyzed in the cells.	U 0126	28-33	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	50-56
29070458-9	2017	Treatment with the ERK inhibitor U0126 also lowered TDI?HSA?induced up?regulation of MUC5AC mRNA in the cells (P&lt;0.05).	U 0126	33-38	mitogen-activated protein kinase 1	Mus musculus	19-22
29070458-9	2017	Treatment with the ERK inhibitor U0126 also lowered TDI?HSA?induced up?regulation of MUC5AC mRNA in the cells (P&lt;0.05).	U 0126	33-38	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	85-91
28993690-4	2017	The MEK inhibitor U0126 significantly reduced LPS-induced chemokine production by Spred2-/- resident macrophages in vitro, and decreased CLP-induced leukocyte infiltration in vivo.	U 0126	18-23	midkine	Mus musculus	4-7
28993690-4	2017	The MEK inhibitor U0126 significantly reduced LPS-induced chemokine production by Spred2-/- resident macrophages in vitro, and decreased CLP-induced leukocyte infiltration in vivo.	U 0126	18-23	sprouty-related EVH1 domain containing 2	Mus musculus	82-88
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 1	Homo sapiens	15-59
28910744-8	2017	The ERK1/2 inhibitor U0126, the P38 inhibitor SB239063 and the STAT3 inhibitor S3I-201 all attenuated the effects of AGEs on MLO-Y4 cell apoptosis and IL-6 and VEGF-A secretion.	U 0126	21-26	mitogen-activated protein kinase 3	Mus musculus	4-10
28910744-8	2017	The ERK1/2 inhibitor U0126, the P38 inhibitor SB239063 and the STAT3 inhibitor S3I-201 all attenuated the effects of AGEs on MLO-Y4 cell apoptosis and IL-6 and VEGF-A secretion.	U 0126	21-26	interleukin 6	Mus musculus	151-155
28910744-8	2017	The ERK1/2 inhibitor U0126, the P38 inhibitor SB239063 and the STAT3 inhibitor S3I-201 all attenuated the effects of AGEs on MLO-Y4 cell apoptosis and IL-6 and VEGF-A secretion.	U 0126	21-26	vascular endothelial growth factor A	Mus musculus	160-166
28822602-12	2017	The MEK1/2 inhibitor U0126 prevented ARI from improving the behavioral impairment as well as enhancing NGF levels in OBX mice.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Mus musculus	4-10
28822602-12	2017	The MEK1/2 inhibitor U0126 prevented ARI from improving the behavioral impairment as well as enhancing NGF levels in OBX mice.	U 0126	21-26	nerve growth factor	Mus musculus	103-106
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 8	Homo sapiens	64-87
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 8	Homo sapiens	89-92
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	NFKB inhibitor alpha	Homo sapiens	173-186
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 1	Homo sapiens	54-57
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 8	Homo sapiens	277-280
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 1	Homo sapiens	269-272
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	mitogen-activated protein kinase 8	Homo sapiens	277-280
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	U 0126	114-119	nuclear factor kappa B subunit 1	Homo sapiens	344-353
28697633-7	2017	Treatment of cells with p38 inhibitor (SB203580), c-Jun N-terminal kinase inhibitor (SP600125), and MEK 1/2 inhibitor (U0126) did not significantly suppress the induction of HO-1 by ZnC.	U 0126	119-124	mitogen-activated protein kinase kinase 1	Mus musculus	100-107
28779848-12	2017	Similarly, U0126 also partly inhibited the TGF-beta1-induced COX-2 expression.	U 0126	11-16	transforming growth factor beta 1	Homo sapiens	43-52
29188650-5	2017	ERK1/2 activation was blocked by U0126, a specific ERK1/2 pathway inhibitor.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	0-6
29188650-5	2017	ERK1/2 activation was blocked by U0126, a specific ERK1/2 pathway inhibitor.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	51-57
29188650-10	2017	The inhibition of ERK1/2 by U0126 and DN-ERK1/2 suppressed the expressionof Runx2 mRNA, OCN mRNA, BSP mRNA, Runx 2 protein, and p-ERK1/2 protein relative to that in stretched cells without the ERK1/2 inhibitor.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	18-24
29188650-10	2017	The inhibition of ERK1/2 by U0126 and DN-ERK1/2 suppressed the expressionof Runx2 mRNA, OCN mRNA, BSP mRNA, Runx 2 protein, and p-ERK1/2 protein relative to that in stretched cells without the ERK1/2 inhibitor.	U 0126	28-33	RUNX family transcription factor 2	Homo sapiens	76-81
29188650-10	2017	The inhibition of ERK1/2 by U0126 and DN-ERK1/2 suppressed the expressionof Runx2 mRNA, OCN mRNA, BSP mRNA, Runx 2 protein, and p-ERK1/2 protein relative to that in stretched cells without the ERK1/2 inhibitor.	U 0126	28-33	bone gamma-carboxyglutamate protein	Homo sapiens	88-91
29188650-10	2017	The inhibition of ERK1/2 by U0126 and DN-ERK1/2 suppressed the expressionof Runx2 mRNA, OCN mRNA, BSP mRNA, Runx 2 protein, and p-ERK1/2 protein relative to that in stretched cells without the ERK1/2 inhibitor.	U 0126	28-33	integrin binding sialoprotein	Homo sapiens	98-101
29188650-10	2017	The inhibition of ERK1/2 by U0126 and DN-ERK1/2 suppressed the expressionof Runx2 mRNA, OCN mRNA, BSP mRNA, Runx 2 protein, and p-ERK1/2 protein relative to that in stretched cells without the ERK1/2 inhibitor.	U 0126	28-33	RUNX family transcription factor 2	Homo sapiens	108-114
28295583-9	2017	An ERK1/2-selective inhibitor, U0126, suppressed expression of the IL-1beta gene as well as its protein expression in U937 cells treated with LPS and AMBN.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	3-9
28295583-9	2017	An ERK1/2-selective inhibitor, U0126, suppressed expression of the IL-1beta gene as well as its protein expression in U937 cells treated with LPS and AMBN.	U 0126	31-36	interleukin 1 beta	Homo sapiens	67-75
28295583-9	2017	An ERK1/2-selective inhibitor, U0126, suppressed expression of the IL-1beta gene as well as its protein expression in U937 cells treated with LPS and AMBN.	U 0126	31-36	ameloblastin	Homo sapiens	150-154
28779848-12	2017	Similarly, U0126 also partly inhibited the TGF-beta1-induced COX-2 expression.	U 0126	11-16	prostaglandin-endoperoxide synthase 2	Homo sapiens	61-66
28470343-5	2017	Furthermore, SEA was found in PBMCs to induce a rapid and long-lasting phosphorylation of extracellular signal-regulated kinases (ERKs) which was significantly inhibited by MEK/ERK pathway inhibitors U0126 and PD0325901, and a late onset of phosphorylation of signal transducers and activators of transcription (STATs) which was significantly inhibited by a pan-JAK inhibitor Pyridone 6 (P6).	U 0126	200-205	mitogen-activated protein kinase 1	Homo sapiens	130-134
28470343-5	2017	Furthermore, SEA was found in PBMCs to induce a rapid and long-lasting phosphorylation of extracellular signal-regulated kinases (ERKs) which was significantly inhibited by MEK/ERK pathway inhibitors U0126 and PD0325901, and a late onset of phosphorylation of signal transducers and activators of transcription (STATs) which was significantly inhibited by a pan-JAK inhibitor Pyridone 6 (P6).	U 0126	200-205	mitogen-activated protein kinase kinase 7	Homo sapiens	173-176
28470343-5	2017	Furthermore, SEA was found in PBMCs to induce a rapid and long-lasting phosphorylation of extracellular signal-regulated kinases (ERKs) which was significantly inhibited by MEK/ERK pathway inhibitors U0126 and PD0325901, and a late onset of phosphorylation of signal transducers and activators of transcription (STATs) which was significantly inhibited by a pan-JAK inhibitor Pyridone 6 (P6).	U 0126	200-205	mitogen-activated protein kinase 1	Homo sapiens	130-133
28470343-6	2017	Unexpectedly constitutive ERK or STATs phosphorylation was also significantly inhibited by P6 or U0126 in a dose-dependent manner, respectively.	U 0126	97-102	mitogen-activated protein kinase 1	Homo sapiens	26-29
27660267-7	2017	Finally, GSK1016790A-enhanced proliferation was markedly blocked by a MAPK/ERK kinase or p38 MAPK antagonist (U0126 or SB203580, respectively).	U 0126	110-115	mitogen-activated protein kinase 1	Mus musculus	70-74
28802646-6	2017	In contrast to Zn, the long acting NMDAR antagonist Ro 25-6981 produces persistent ERK activation lasting up to 24 h. Pretreatment with the MAPK/ERK inhibitor (U0126) totally abolished Zn and Ro 25-6981 antidepressant-like activities in the forced swim test in rats.	U 0126	160-165	Eph receptor B1	Rattus norvegicus	83-86
27660267-7	2017	Finally, GSK1016790A-enhanced proliferation was markedly blocked by a MAPK/ERK kinase or p38 MAPK antagonist (U0126 or SB203580, respectively).	U 0126	110-115	mitogen-activated protein kinase 14	Mus musculus	89-97
27660267-8	2017	The increased protein levels of CDK2 and CDK6, as well as those of cyclin E1 and cyclin A2, in GSK1016790A-injected mice were substantially reduced by co-injection of U0126 or SB203580.	U 0126	167-172	cyclin-dependent kinase 2	Mus musculus	32-36
27660267-8	2017	The increased protein levels of CDK2 and CDK6, as well as those of cyclin E1 and cyclin A2, in GSK1016790A-injected mice were substantially reduced by co-injection of U0126 or SB203580.	U 0126	167-172	cyclin-dependent kinase 6	Mus musculus	41-45
27660267-8	2017	The increased protein levels of CDK2 and CDK6, as well as those of cyclin E1 and cyclin A2, in GSK1016790A-injected mice were substantially reduced by co-injection of U0126 or SB203580.	U 0126	167-172	cyclin E1	Mus musculus	67-76
27660267-8	2017	The increased protein levels of CDK2 and CDK6, as well as those of cyclin E1 and cyclin A2, in GSK1016790A-injected mice were substantially reduced by co-injection of U0126 or SB203580.	U 0126	167-172	cyclin A2	Mus musculus	81-90
28802646-6	2017	In contrast to Zn, the long acting NMDAR antagonist Ro 25-6981 produces persistent ERK activation lasting up to 24 h. Pretreatment with the MAPK/ERK inhibitor (U0126) totally abolished Zn and Ro 25-6981 antidepressant-like activities in the forced swim test in rats.	U 0126	160-165	Eph receptor B1	Rattus norvegicus	145-148
28849196-7	2017	Furthermore, EGF increased ERK1/2 activity and blocking ERK1/2 signaling with its inhibitor, U0126, markedly inhibited EGF-induced uPAR expression and consequently EMT.	U 0126	93-98	mitogen-activated protein kinase 3	Homo sapiens	56-62
28765903-9	2017	Furthermore, the alterations in FN and p53 expression in response to TPA were prevented by a specific MEK inhibitor, UO126.	U 0126	117-122	fibronectin 1	Homo sapiens	32-34
28765903-9	2017	Furthermore, the alterations in FN and p53 expression in response to TPA were prevented by a specific MEK inhibitor, UO126.	U 0126	117-122	tumor protein p53	Homo sapiens	39-42
28849196-7	2017	Furthermore, EGF increased ERK1/2 activity and blocking ERK1/2 signaling with its inhibitor, U0126, markedly inhibited EGF-induced uPAR expression and consequently EMT.	U 0126	93-98	epidermal growth factor	Homo sapiens	119-122
28849196-7	2017	Furthermore, EGF increased ERK1/2 activity and blocking ERK1/2 signaling with its inhibitor, U0126, markedly inhibited EGF-induced uPAR expression and consequently EMT.	U 0126	93-98	plasminogen activator, urokinase receptor	Homo sapiens	131-135
28962206-7	2017	Extracellular signal-regulated kinase (ERK) inhibitor UO126 was applied to study the role of the ERK pathway in cell migration.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	0-37
28522271-12	2017	Finally, we found the level of phosphorylated ERK in the MPA-pTHP-1 cells was increased, but its IL-10 production was suppressed by either the progesterone/glucocorticoid antagonist (Mifepristone) or MEK inhibitor (U0126).	U 0126	215-220	mitogen-activated protein kinase 1	Homo sapiens	46-49
28522271-12	2017	Finally, we found the level of phosphorylated ERK in the MPA-pTHP-1 cells was increased, but its IL-10 production was suppressed by either the progesterone/glucocorticoid antagonist (Mifepristone) or MEK inhibitor (U0126).	U 0126	215-220	interleukin 10	Homo sapiens	97-102
28522271-12	2017	Finally, we found the level of phosphorylated ERK in the MPA-pTHP-1 cells was increased, but its IL-10 production was suppressed by either the progesterone/glucocorticoid antagonist (Mifepristone) or MEK inhibitor (U0126).	U 0126	215-220	mitogen-activated protein kinase kinase 7	Homo sapiens	200-203
28873461-11	2017	SB431542 or U0126 treated cells showed inhibited morphological changes and phenotypic markers expression, such as up-regulated E-cad expression and down-regulated alpha-SMA expression.	U 0126	12-17	cadherin 1	Homo sapiens	127-132
28647405-7	2017	ERK1/2 activity is known to regulate the transition from OPs to immature oligodendrocytes and the presence of specific inhibitors of ERK1/2 phosphorylation (U0126 or PD98059) prevented the differentiating effects of both DHA and PGZ.	U 0126	157-162	mitogen-activated protein kinase 3	Homo sapiens	0-6
28647405-7	2017	ERK1/2 activity is known to regulate the transition from OPs to immature oligodendrocytes and the presence of specific inhibitors of ERK1/2 phosphorylation (U0126 or PD98059) prevented the differentiating effects of both DHA and PGZ.	U 0126	157-162	mitogen-activated protein kinase 3	Homo sapiens	133-139
28990465-6	2017	Moreover, combined treatment of U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, and rapamycin, a mammalian target of rapamycin inhibitor, induced Bim and p27 expressions.	U 0126	32-37	mechanistic target of rapamycin kinase	Homo sapiens	113-142
28990465-6	2017	Moreover, combined treatment of U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, and rapamycin, a mammalian target of rapamycin inhibitor, induced Bim and p27 expressions.	U 0126	32-37	BCL2 like 11	Homo sapiens	162-165
28990465-6	2017	Moreover, combined treatment of U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, and rapamycin, a mammalian target of rapamycin inhibitor, induced Bim and p27 expressions.	U 0126	32-37	interferon alpha inducible protein 27	Homo sapiens	170-173
28959141-9	2017	h-TGF-beta1 stimulated Smad2/3 and ERK1/2 phosphorylation, and the MEK1/2 inhibitor U0126 attenuated TGF-beta1-induced KKU-M213 cell invasion and MMP-9 production but moderately enhanced the cytokine growth inhibitory activity.	U 0126	84-89	mitogen-activated protein kinase kinase 1	Homo sapiens	67-73
28959141-9	2017	h-TGF-beta1 stimulated Smad2/3 and ERK1/2 phosphorylation, and the MEK1/2 inhibitor U0126 attenuated TGF-beta1-induced KKU-M213 cell invasion and MMP-9 production but moderately enhanced the cytokine growth inhibitory activity.	U 0126	84-89	transforming growth factor beta 1	Homo sapiens	101-110
28959141-9	2017	h-TGF-beta1 stimulated Smad2/3 and ERK1/2 phosphorylation, and the MEK1/2 inhibitor U0126 attenuated TGF-beta1-induced KKU-M213 cell invasion and MMP-9 production but moderately enhanced the cytokine growth inhibitory activity.	U 0126	84-89	matrix metallopeptidase 9	Homo sapiens	146-151
28732667-7	2017	Importantly, we found that administration of exogenous BDNF into the rACC of intact rats was sufficient to produce CPA, while selectively blocking phosphorylated extracellular signal regulated kinase (p-ERK) with a mitogen-activated protein kinase (MAPK) inhibitor U0126 completely abolished the acquisition of BDNF-induced CPA.	U 0126	265-270	brain-derived neurotrophic factor	Rattus norvegicus	55-59
28732667-7	2017	Importantly, we found that administration of exogenous BDNF into the rACC of intact rats was sufficient to produce CPA, while selectively blocking phosphorylated extracellular signal regulated kinase (p-ERK) with a mitogen-activated protein kinase (MAPK) inhibitor U0126 completely abolished the acquisition of BDNF-induced CPA.	U 0126	265-270	Eph receptor B1	Rattus norvegicus	203-206
28501331-6	2017	Inhibition of the extracellular-signal regulated kinases (ERK1/2) pathway by the addition of the mitogen-activated protein kinase kinase 1 (MEK1) and MEK2 kinase inhibitor U0126 resulted in a decrease in the phosphorylation of ERK1/2 and a reduced expression of KRT6.	U 0126	172-177	mitogen-activated protein kinase 3	Homo sapiens	58-64
28501331-6	2017	Inhibition of the extracellular-signal regulated kinases (ERK1/2) pathway by the addition of the mitogen-activated protein kinase kinase 1 (MEK1) and MEK2 kinase inhibitor U0126 resulted in a decrease in the phosphorylation of ERK1/2 and a reduced expression of KRT6.	U 0126	172-177	mitogen-activated protein kinase kinase 1	Homo sapiens	97-138
28501331-6	2017	Inhibition of the extracellular-signal regulated kinases (ERK1/2) pathway by the addition of the mitogen-activated protein kinase kinase 1 (MEK1) and MEK2 kinase inhibitor U0126 resulted in a decrease in the phosphorylation of ERK1/2 and a reduced expression of KRT6.	U 0126	172-177	mitogen-activated protein kinase kinase 2	Homo sapiens	150-154
28501331-6	2017	Inhibition of the extracellular-signal regulated kinases (ERK1/2) pathway by the addition of the mitogen-activated protein kinase kinase 1 (MEK1) and MEK2 kinase inhibitor U0126 resulted in a decrease in the phosphorylation of ERK1/2 and a reduced expression of KRT6.	U 0126	172-177	mitogen-activated protein kinase 3	Homo sapiens	227-233
28501331-6	2017	Inhibition of the extracellular-signal regulated kinases (ERK1/2) pathway by the addition of the mitogen-activated protein kinase kinase 1 (MEK1) and MEK2 kinase inhibitor U0126 resulted in a decrease in the phosphorylation of ERK1/2 and a reduced expression of KRT6.	U 0126	172-177	keratin 72	Homo sapiens	262-266
28959190-7	2017	Additionally, pharmacological results demonstrated that the application of the ERK1/2 activation inhibitor U0126 into the PPT prevented RSHD and suppressed BDNF expression in the PPT.	U 0126	107-112	mitogen activated protein kinase 3	Rattus norvegicus	79-85
28959190-7	2017	Additionally, pharmacological results demonstrated that the application of the ERK1/2 activation inhibitor U0126 into the PPT prevented RSHD and suppressed BDNF expression in the PPT.	U 0126	107-112	brain-derived neurotrophic factor	Rattus norvegicus	156-160
28451751-6	2017	The effect of CNP on P-ERK1/2 was sensitive to pharmacological blockade of MEK (U0126) and Src kinases (PP2).	U 0126	80-85	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	14-17
28451751-6	2017	The effect of CNP on P-ERK1/2 was sensitive to pharmacological blockade of MEK (U0126) and Src kinases (PP2).	U 0126	80-85	mitogen activated protein kinase 3	Rattus norvegicus	23-29
28451751-6	2017	The effect of CNP on P-ERK1/2 was sensitive to pharmacological blockade of MEK (U0126) and Src kinases (PP2).	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	75-78
28962206-7	2017	Extracellular signal-regulated kinase (ERK) inhibitor UO126 was applied to study the role of the ERK pathway in cell migration.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	39-42
28277616-6	2017	Moreover, combination treatment of MMPP with ERK inhibitor U0126 (10 microM) augmented MMPP-induced inhibitory effect on cell growth and DNA binding activity of STAT3, and enhanced expression of cleaved caspase-3 and cleaved caspase-9.	U 0126	59-64	mitogen-activated protein kinase 1	Homo sapiens	45-48
28277616-6	2017	Moreover, combination treatment of MMPP with ERK inhibitor U0126 (10 microM) augmented MMPP-induced inhibitory effect on cell growth and DNA binding activity of STAT3, and enhanced expression of cleaved caspase-3 and cleaved caspase-9.	U 0126	59-64	signal transducer and activator of transcription 3	Homo sapiens	161-166
28927059-6	2017	In addition, the apoptotic effects of matrine in RMS cells were partially inhibited upon MEK1 overexpression and enhanced upon combined treatment with an ERK inhibitor (U0126).	U 0126	169-174	mitogen-activated protein kinase 1	Homo sapiens	154-157
28927156-5	2017	It was also demonstrated that ISO transiently induced extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation, and that blocking the mitogen-activated protein kinase pathway by U0126 inhibited ERK1/2 phosphorylation and suppressed U251 cell proliferation.	U 0126	186-191	mitogen-activated protein kinase 3	Homo sapiens	202-208
28928846-2	2017	A Cell Counting Kit-8 assay was used to determine the drug sensitivity of HepG2 and HepG2/ADM hepatocellular carcinoma cell lines in combination with the MAPK/extracellular-signal-regulated kinase kinase (MEK) inhibitor U0126.	U 0126	220-225	mitogen-activated protein kinase kinase 7	Homo sapiens	154-203
28928846-4	2017	The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126.	U 0126	239-244	ATP binding cassette subfamily B member 1	Homo sapiens	97-111
28928846-4	2017	The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126.	U 0126	239-244	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
28928846-4	2017	The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126.	U 0126	239-244	ATP binding cassette subfamily C member 1	Homo sapiens	123-164
28928846-4	2017	The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126.	U 0126	239-244	ATP binding cassette subfamily C member 1	Homo sapiens	166-170
28928846-11	2017	The results of the present study indicate that the MEK inhibitor U0126 enhances sensitivity to chemotherapeutic drugs by downregulating P-gp and MRP1 expression in resistant hepatocellular carcinoma cells.	U 0126	65-70	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
28928846-11	2017	The results of the present study indicate that the MEK inhibitor U0126 enhances sensitivity to chemotherapeutic drugs by downregulating P-gp and MRP1 expression in resistant hepatocellular carcinoma cells.	U 0126	65-70	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
28928846-11	2017	The results of the present study indicate that the MEK inhibitor U0126 enhances sensitivity to chemotherapeutic drugs by downregulating P-gp and MRP1 expression in resistant hepatocellular carcinoma cells.	U 0126	65-70	ATP binding cassette subfamily C member 1	Homo sapiens	145-149
28709835-9	2017	A significant and further increase in transient phosphorylation of the p44/42 MAPKs was demonstrated by hBD-1 co-treatment (p&lt;0.05), consistent with the inhibitory effect by pretreatment with U0126 or PD98059 on hBD-1-enhanced osteoclastogenesis.	U 0126	195-200	interferon induced protein 44	Homo sapiens	71-74
28709835-9	2017	A significant and further increase in transient phosphorylation of the p44/42 MAPKs was demonstrated by hBD-1 co-treatment (p&lt;0.05), consistent with the inhibitory effect by pretreatment with U0126 or PD98059 on hBD-1-enhanced osteoclastogenesis.	U 0126	195-200	defensin beta 1	Homo sapiens	104-109
28709835-9	2017	A significant and further increase in transient phosphorylation of the p44/42 MAPKs was demonstrated by hBD-1 co-treatment (p&lt;0.05), consistent with the inhibitory effect by pretreatment with U0126 or PD98059 on hBD-1-enhanced osteoclastogenesis.	U 0126	195-200	defensin beta 1	Homo sapiens	215-220
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	U 0126	189-194	apolipoprotein H	Homo sapiens	19-27
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	U 0126	189-194	apolipoprotein H	Homo sapiens	28-36
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	U 0126	189-194	apolipoprotein H	Homo sapiens	28-36
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	U 0126	189-194	mechanistic target of rapamycin kinase	Homo sapiens	92-96
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	U 0126	189-194	mitogen-activated protein kinase 1	Homo sapiens	153-156
28797761-3	2017	Mice were injected with normal saline (NS group), mmLDL in the tail vein (mmLDL group), or with both mmLDL and an intraperitoneal injection of the ERK1/2 pathway-specific inhibitor U0126 (mmLDL+U0126 group).	U 0126	181-186	mitogen-activated protein kinase 3	Mus musculus	147-153
28797761-7	2017	The serum concentration and expression of ICAM-1 and VCAM-1 were also increased by mmLDL treatment, but intraperitoneal injection of U0126 inhibited these changes as well as the increase in p-ERK1/2 protein in the vessel wall caused by mmLDL.	U 0126	133-138	intercellular adhesion molecule 1	Mus musculus	42-48
28797761-7	2017	The serum concentration and expression of ICAM-1 and VCAM-1 were also increased by mmLDL treatment, but intraperitoneal injection of U0126 inhibited these changes as well as the increase in p-ERK1/2 protein in the vessel wall caused by mmLDL.	U 0126	133-138	vascular cell adhesion molecule 1	Mus musculus	53-59
28797761-7	2017	The serum concentration and expression of ICAM-1 and VCAM-1 were also increased by mmLDL treatment, but intraperitoneal injection of U0126 inhibited these changes as well as the increase in p-ERK1/2 protein in the vessel wall caused by mmLDL.	U 0126	133-138	mitogen-activated protein kinase 3	Mus musculus	192-198
28659476-10	2017	Finally, when polarized cells were treated with oleic acid and U0126, a MEK inhibitor, to promote lipoprotein secretion, a higher proportion of infectious viral particles of lower density were secreted.	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
29113345-4	2017	The Raf inhibitor sorafenib (SFN) or the Mek inhibitor U0126 suppressed MAPK signaling to a greater extent than LPN; which correlated with greater cytotoxic potency of SFN, but not U0126.	U 0126	55-60	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
29113345-4	2017	The Raf inhibitor sorafenib (SFN) or the Mek inhibitor U0126 suppressed MAPK signaling to a greater extent than LPN; which correlated with greater cytotoxic potency of SFN, but not U0126.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	72-76
28835716-7	2017	According with this data, using chemical inhibitor U0126 and ERK dominant negative cells we found that the lack of ERK1 activity affects cyclin E protein accumulation, viral gene transcription and percentage of the cells in S phase, during the viral replication.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	115-119
28602697-5	2017	Administration of ERK inhibitor U0126 or knockdown of RICTOR by siRNA attenuated AR-A014418 induced osteogenic differentiation of hASCs.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	18-21
28602697-5	2017	Administration of ERK inhibitor U0126 or knockdown of RICTOR by siRNA attenuated AR-A014418 induced osteogenic differentiation of hASCs.	U 0126	32-37	p21 (RAC1) activated kinase 3	Homo sapiens	81-85
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	79-120
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	122-128
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	152-156
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	cadherin 1	Homo sapiens	167-177
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	fibronectin 1	Homo sapiens	220-231
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	236-241
29207630-5	2017	Moreover, by overexpressing Shp2 or using U0126, a small-molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), we demonstrated that Shp2 inhibited E-cadherin expression and enhanced the expression of fibronectin and c-Myc through activation of the ERK1/2 pathway.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	268-274
28805677-8	2017	In contrast, administration of rat serum albumin (RSA, 0.1-0.5 mg/mL) resulted in a dose-dependent increase in MMP-9 expression and secretion by TECs, which was abolished in the presence of an ERK1/2-specific inhibitor, U0126.	U 0126	220-225	matrix metallopeptidase 9	Rattus norvegicus	111-116
28805677-8	2017	In contrast, administration of rat serum albumin (RSA, 0.1-0.5 mg/mL) resulted in a dose-dependent increase in MMP-9 expression and secretion by TECs, which was abolished in the presence of an ERK1/2-specific inhibitor, U0126.	U 0126	220-225	mitogen activated protein kinase 3	Rattus norvegicus	193-199
29137326-8	2017	In addition, treatment with MMP-9 short hairpin RNA, an MMP inhibitor (GM6001), an FAK mutant, or an MEK inhibitor (U0126) inhibited CAIX-induced cell motility in SCC-9 cells.	U 0126	116-121	mitogen-activated protein kinase kinase 7	Homo sapiens	101-104
29137326-8	2017	In addition, treatment with MMP-9 short hairpin RNA, an MMP inhibitor (GM6001), an FAK mutant, or an MEK inhibitor (U0126) inhibited CAIX-induced cell motility in SCC-9 cells.	U 0126	116-121	carbonic anhydrase 9	Homo sapiens	133-137
28798340-6	2017	Intra-IL infusion of BDNF antibody and the ERK1/2 inhibitor U0126 reversed PCMS-induced enhancement of fear extinction.	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	43-49
28601633-8	2017	U0126 (an ERK1/2 inhibitor) co-treatment abolished the protective effect of LMB on SE-induced neuronal death without alterations in PKA and PP2B phosphorylations.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	10-16
28506883-9	2017	Finally, a downstream step, MEK1/2-ERK1/2 was also investigated, and, similar to Src inhibition, the MEK1/2 inhibitor (U0126) suppressed the BUF effect.	U 0126	119-124	mitogen activated protein kinase kinase 1	Rattus norvegicus	28-34
28506883-9	2017	Finally, a downstream step, MEK1/2-ERK1/2 was also investigated, and, similar to Src inhibition, the MEK1/2 inhibitor (U0126) suppressed the BUF effect.	U 0126	119-124	mitogen activated protein kinase 3	Rattus norvegicus	35-41
28506883-9	2017	Finally, a downstream step, MEK1/2-ERK1/2 was also investigated, and, similar to Src inhibition, the MEK1/2 inhibitor (U0126) suppressed the BUF effect.	U 0126	119-124	mitogen activated protein kinase kinase 1	Rattus norvegicus	101-107
28277616-6	2017	Moreover, combination treatment of MMPP with ERK inhibitor U0126 (10 microM) augmented MMPP-induced inhibitory effect on cell growth and DNA binding activity of STAT3, and enhanced expression of cleaved caspase-3 and cleaved caspase-9.	U 0126	59-64	caspase 3	Homo sapiens	203-212
28277616-6	2017	Moreover, combination treatment of MMPP with ERK inhibitor U0126 (10 microM) augmented MMPP-induced inhibitory effect on cell growth and DNA binding activity of STAT3, and enhanced expression of cleaved caspase-3 and cleaved caspase-9.	U 0126	59-64	caspase 9	Homo sapiens	225-234
28405735-8	2017	The ERK activation inhibitor U0126 or curcumin was applied 30 min before each TNCB challenge.	U 0126	29-34	mitogen-activated protein kinase 1	Mus musculus	4-7
28741142-4	2017	SAH was induced in rats that were treated with the MEK1/2 inhibitor U0126 or vehicle.	U 0126	68-73	mitogen activated protein kinase kinase 1	Rattus norvegicus	51-57
28272757-7	2017	The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	19-25
28272757-7	2017	The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation.	U 0126	104-109	signal transducer and activator of transcription 3	Rattus norvegicus	47-52
28272757-7	2017	The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	134-140
28272757-7	2017	The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation.	U 0126	104-109	signal transducer and activator of transcription 3	Rattus norvegicus	145-150
29256223-7	2017	The proportion of cells in G0/G1 phase increased and that in S phase declined in CXCR4-downregulated cell, and the effect was more significant when combined with the use of LY294002 or U0126.	U 0126	185-190	C-X-C motif chemokine receptor 4	Homo sapiens	81-86
28925474-10	2017	ERK signaling pathway inhibitor, U0126, was used to pre-treat mice.	U 0126	33-38	mitogen-activated protein kinase 1	Mus musculus	0-3
28925474-13	2017	U0126 intervention significantly suppressed UCP1 expression, inhibited ERK signaling pathway, enhanced ATP production, and restrained liver cell apoptosis in mice liver injury model.	U 0126	0-5	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	44-48
28925474-13	2017	U0126 intervention significantly suppressed UCP1 expression, inhibited ERK signaling pathway, enhanced ATP production, and restrained liver cell apoptosis in mice liver injury model.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	71-74
28716954-4	2017	In contrast, delivery of U0126, an MEK inhibitor, attenuated rpS6 phosphorylation specifically in the dendritic laminae leaving phosphorylation in the granule cell bodies intact.	U 0126	25-30	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
28716954-4	2017	In contrast, delivery of U0126, an MEK inhibitor, attenuated rpS6 phosphorylation specifically in the dendritic laminae leaving phosphorylation in the granule cell bodies intact.	U 0126	25-30	ribosomal protein S6	Homo sapiens	61-65
28479396-7	2017	Similar to TRPC6 knockdown, ERK1/2 inhibition by U0126 evoked mitochondrial elongation with diminished DRP1-S616 phosphorylation, and facilitated SE-induced DGC degeneration independent of seizure severity.	U 0126	49-54	mitogen activated protein kinase 3	Rattus norvegicus	28-34
28479396-7	2017	Similar to TRPC6 knockdown, ERK1/2 inhibition by U0126 evoked mitochondrial elongation with diminished DRP1-S616 phosphorylation, and facilitated SE-induced DGC degeneration independent of seizure severity.	U 0126	49-54	dynamin 1-like	Rattus norvegicus	103-107
28535682-8	2017	Interestingly, the effect of CTRP6 shRNA or CTRP6 recombinant protein was attenuated by U0126 (a special p-Erk inhibitor) or SB203580 (a special p-p38 inhibitor) in adipocytes.	U 0126	88-93	C1q and tumor necrosis factor related protein 6	Mus musculus	29-34
28535682-8	2017	Interestingly, the effect of CTRP6 shRNA or CTRP6 recombinant protein was attenuated by U0126 (a special p-Erk inhibitor) or SB203580 (a special p-p38 inhibitor) in adipocytes.	U 0126	88-93	C1q and tumor necrosis factor related protein 6	Mus musculus	44-49
28535682-8	2017	Interestingly, the effect of CTRP6 shRNA or CTRP6 recombinant protein was attenuated by U0126 (a special p-Erk inhibitor) or SB203580 (a special p-p38 inhibitor) in adipocytes.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	107-110
28431406-4	2017	RESULTS: The activated ERK downregulates STAT1 expression in ESCC cell lines and U0126 increases expression of STAT1.	U 0126	81-86	signal transducer and activator of transcription 1	Homo sapiens	111-116
28431406-9	2017	MATERIALS AND METHODS: To investigate whether ERK can mediated STAT1 expression in ESCC, we used the MEK plasmid and U0126, a MEK inhibitor, to treat the cell.	U 0126	117-122	mitogen-activated protein kinase 1	Homo sapiens	46-49
28431406-9	2017	MATERIALS AND METHODS: To investigate whether ERK can mediated STAT1 expression in ESCC, we used the MEK plasmid and U0126, a MEK inhibitor, to treat the cell.	U 0126	117-122	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
28781955-3	2017	In ErbB2-overexpressing breast epithelial cells, miR-205 expression was significantly increased by treatment with MEK inhibitor U0126 or PD98059, Raf-1 inhibitor ZM-336372, and ERK inhibitor SCH772984, but PI3K inhibitor LY294002 and p38 MAPK inhibitor SB203580 had no effect.	U 0126	128-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-8
28781955-3	2017	In ErbB2-overexpressing breast epithelial cells, miR-205 expression was significantly increased by treatment with MEK inhibitor U0126 or PD98059, Raf-1 inhibitor ZM-336372, and ERK inhibitor SCH772984, but PI3K inhibitor LY294002 and p38 MAPK inhibitor SB203580 had no effect.	U 0126	128-133	microRNA 205	Homo sapiens	49-56
28781955-3	2017	In ErbB2-overexpressing breast epithelial cells, miR-205 expression was significantly increased by treatment with MEK inhibitor U0126 or PD98059, Raf-1 inhibitor ZM-336372, and ERK inhibitor SCH772984, but PI3K inhibitor LY294002 and p38 MAPK inhibitor SB203580 had no effect.	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	114-117
28915658-10	2017	Interventions by Cyp1A2 and Mek2siRNA, MEK inhibitor UO126, diphenylene iodonium, as well as a combination of N-acetylcysteine with selenium all inhibited VEGF upregulation caused by erlotinib.	U 0126	53-58	vascular endothelial growth factor A	Homo sapiens	155-159
28513279-5	2017	Inhibition of the MAPK1/3 pathway with U0126 or blockade of autophagy by specific chemical inhibitors markedly attenuated the effect of w09-mediated growth inhibition and caspase-dependent apoptosis.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	18-23
28756806-9	2017	Both ERK1/2 signaling inhibitor U0126 and ERK-phosphoacceptor-site mutant (GFP-hnRNPK S284/353A) diminish cytoplasmic accumulation of hnRNPK induced by TRAIL.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	5-11
28554198-5	2017	Although TAZ knockdown or knockout did not reduce LPA-induced phosphorylation of ERK and AKT, the MEK inhibitor U0126 or the ROCK inhibitor Y27632 blocked LPA-induced TAZ expression along with the reduction in the proliferation and migration of MSCs.	U 0126	112-117	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
28756806-9	2017	Both ERK1/2 signaling inhibitor U0126 and ERK-phosphoacceptor-site mutant (GFP-hnRNPK S284/353A) diminish cytoplasmic accumulation of hnRNPK induced by TRAIL.	U 0126	32-37	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	134-140
28554198-5	2017	Although TAZ knockdown or knockout did not reduce LPA-induced phosphorylation of ERK and AKT, the MEK inhibitor U0126 or the ROCK inhibitor Y27632 blocked LPA-induced TAZ expression along with the reduction in the proliferation and migration of MSCs.	U 0126	112-117	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	167-170
28756806-9	2017	Both ERK1/2 signaling inhibitor U0126 and ERK-phosphoacceptor-site mutant (GFP-hnRNPK S284/353A) diminish cytoplasmic accumulation of hnRNPK induced by TRAIL.	U 0126	32-37	TNF superfamily member 10	Homo sapiens	152-157
26996066-5	2017	The inhibition of MEK/ERK by U0126 attenuated the MCP-1-induced phosphorylation of GSK-3beta and decreased the expression of Snail, an EMT-related transcription factor, leading to the inhibition of MCF-7 cell migration and invasion.	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
26996066-5	2017	The inhibition of MEK/ERK by U0126 attenuated the MCP-1-induced phosphorylation of GSK-3beta and decreased the expression of Snail, an EMT-related transcription factor, leading to the inhibition of MCF-7 cell migration and invasion.	U 0126	29-34	EPH receptor B2	Homo sapiens	22-25
26996066-5	2017	The inhibition of MEK/ERK by U0126 attenuated the MCP-1-induced phosphorylation of GSK-3beta and decreased the expression of Snail, an EMT-related transcription factor, leading to the inhibition of MCF-7 cell migration and invasion.	U 0126	29-34	C-C motif chemokine ligand 2	Homo sapiens	50-55
26996066-5	2017	The inhibition of MEK/ERK by U0126 attenuated the MCP-1-induced phosphorylation of GSK-3beta and decreased the expression of Snail, an EMT-related transcription factor, leading to the inhibition of MCF-7 cell migration and invasion.	U 0126	29-34	glycogen synthase kinase 3 beta	Homo sapiens	83-92
26996066-5	2017	The inhibition of MEK/ERK by U0126 attenuated the MCP-1-induced phosphorylation of GSK-3beta and decreased the expression of Snail, an EMT-related transcription factor, leading to the inhibition of MCF-7 cell migration and invasion.	U 0126	29-34	snail family transcriptional repressor 1	Homo sapiens	125-130
28376659-11	2017	Both stress and U69,593-induced allodynia were prevented by right CeA U0126, a mitogen-activated protein kinase inhibitor, presumably acting downstream of KOR.	U 0126	70-75	carcinoembryonic antigen gene family 4	Rattus norvegicus	66-69
28392425-7	2017	T-cadherin upregulation on SMCs conferred a survival advantage during prolonged serum-starvation which was sensitive to inhibition of MEK1/2/Erk1/2 by PD98059 or UO126 and to blockade of autophagy by chloroquine.	U 0126	162-167	cadherin 13	Rattus norvegicus	0-10
28392425-7	2017	T-cadherin upregulation on SMCs conferred a survival advantage during prolonged serum-starvation which was sensitive to inhibition of MEK1/2/Erk1/2 by PD98059 or UO126 and to blockade of autophagy by chloroquine.	U 0126	162-167	mitogen activated protein kinase kinase 1	Rattus norvegicus	134-140
28429502-6	2017	U0126, a specific inhibitor of mitogen-activated protein kinase kinase (MAPKK) could reverse the decrease in expression of Cx43 protein induced by rMIF.	U 0126	0-5	gap junction protein alpha 1	Homo sapiens	123-127
28429502-6	2017	U0126, a specific inhibitor of mitogen-activated protein kinase kinase (MAPKK) could reverse the decrease in expression of Cx43 protein induced by rMIF.	U 0126	0-5	macrophage migration inhibitory factor	Rattus norvegicus	147-151
28476501-12	2017	U0126, a specific inhibitor for ERK-1/2, attenuated the NE-induced proliferation of PASMCs under normoxia and hypoxia.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	32-39
28158928-6	2017	The baicalin-induced effect on osteoclast differentiation can be mimicked by specific inhibitors of p-ERK (U0126) and the Mitf-specific siRNA, respectively.	U 0126	107-112	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	100-105
27181591-7	2017	Moreover, thrombin-stimulated c-Src, Pyk2, EGFR, Akt, p42/p44 MAPK, or c-Jun phosphorylation was attenuated by their respective inhibitor of PP1, PF431396, AG1478, SH-5, U0126, or TanshinoneIIA.	U 0126	170-175	coagulation factor II, thrombin	Homo sapiens	10-18
27181591-7	2017	Moreover, thrombin-stimulated c-Src, Pyk2, EGFR, Akt, p42/p44 MAPK, or c-Jun phosphorylation was attenuated by their respective inhibitor of PP1, PF431396, AG1478, SH-5, U0126, or TanshinoneIIA.	U 0126	170-175	neuropeptide Y receptor Y4	Homo sapiens	141-144
28560420-9	2017	TUNEL, Annexin V-fluorescein isothiocyanate/propidium iodide, and ratio of Bcl-2-associated X protein and B cell lymphoma 2 indicated that baicalein and U0126 induced HeLa cell apoptosis.	U 0126	153-158	BCL2 apoptosis regulator	Homo sapiens	75-80
28560420-12	2017	Baicalein and U0126 markedly downregulated extracellular signal-regulated kinase 1/2, matrix metalloproteinase (MMP) 2 and MMP9 levels both in mRNA and protein.	U 0126	14-19	mitogen-activated protein kinase 3	Homo sapiens	43-84
28560420-12	2017	Baicalein and U0126 markedly downregulated extracellular signal-regulated kinase 1/2, matrix metalloproteinase (MMP) 2 and MMP9 levels both in mRNA and protein.	U 0126	14-19	matrix metallopeptidase 2	Homo sapiens	86-118
28560420-12	2017	Baicalein and U0126 markedly downregulated extracellular signal-regulated kinase 1/2, matrix metalloproteinase (MMP) 2 and MMP9 levels both in mRNA and protein.	U 0126	14-19	matrix metallopeptidase 9	Homo sapiens	123-127
28693200-9	2017	There was a reduction in the expression of Ets-1 and ERK phosphorylation in sorafenib or 1,4-Diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene treated cells suggesting that sorafenib may reduce the expression levels of Ets-1 by blocking the Ras/Raf/mitogen activated protein kinase signaling pathway.	U 0126	89-150	ETS proto-oncogene 1, transcription factor	Homo sapiens	43-48
28693200-9	2017	There was a reduction in the expression of Ets-1 and ERK phosphorylation in sorafenib or 1,4-Diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene treated cells suggesting that sorafenib may reduce the expression levels of Ets-1 by blocking the Ras/Raf/mitogen activated protein kinase signaling pathway.	U 0126	89-150	mitogen-activated protein kinase 1	Homo sapiens	53-56
28693237-6	2017	Furthermore, the combination of certain pharmacological inhibitors, including phosphoinositide 3-kinase (PI3K; LY294002), ERK1/2 (U0126) and delphinidin significantly reduced the proliferation of SKOV3 cells and the phosphorylation of each of those target proteins.	U 0126	130-135	mitogen-activated protein kinase 3	Homo sapiens	122-128
28646880-10	2017	The inhibitors of Trk receptor (K252a), MEK/ERK1/2 (U0126 and PD98059) and PI3K/AKT (LY294002) attenuated the neuritogenic activity of both NGF and 6-shogaol, respectively.	U 0126	52-57	mitogen activated protein kinase 3	Rattus norvegicus	44-50
28670382-5	2017	Furthermore, the Piezo1 expression was attenuated by Erk1/2 chemical inhibitor (U0126) only, but not by p38 MAPK inhibitor (SB203580), or JNK inhibitor (SP600125).	U 0126	80-85	piezo type mechanosensitive ion channel component 1	Homo sapiens	17-23
28670382-5	2017	Furthermore, the Piezo1 expression was attenuated by Erk1/2 chemical inhibitor (U0126) only, but not by p38 MAPK inhibitor (SB203580), or JNK inhibitor (SP600125).	U 0126	80-85	mitogen-activated protein kinase 3	Homo sapiens	53-59
28620185-7	2017	Administration of ERK inhibitor U0126 impeded the development of rectal prolapse in c-Abl deficient mice.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	18-21
28620185-7	2017	Administration of ERK inhibitor U0126 impeded the development of rectal prolapse in c-Abl deficient mice.	U 0126	32-37	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	84-89
28450277-5	2017	Increased intracellular bacteria in wild-type (WT) and NOD2 knockdown (KD) cells and colonoids from NOD2-/- mice were mediated by reactive oxygen species (ROS) and the MAPK ERK1/2 pathways as determined by cotreatment with the antioxidant mitoTEMPO and the ERK inhibitor U0126: ROS was upstream of ERK1/2 activation.	U 0126	271-276	nucleotide-binding oligomerization domain containing 2	Mus musculus	55-59
28450279-11	2017	ERK1/2 inhibitor U0126 significantly attenuated mRNA and protein expressions of PRR in podocytes treated with rapamycin.	U 0126	17-22	mitogen-activated protein kinase 3	Mus musculus	0-6
28450279-11	2017	ERK1/2 inhibitor U0126 significantly attenuated mRNA and protein expressions of PRR in podocytes treated with rapamycin.	U 0126	17-22	ATPase, H+ transporting, lysosomal accessory protein 2	Mus musculus	80-83
28485554-7	2017	Notably, the ACA-28-induced apoptosis in melanoma and HER2-transformed cells was abrogated when ERK activation was blocked with a specific MEK inhibitor U0126.	U 0126	153-158	small nucleolar RNA, H/ACA box 28	Homo sapiens	13-19
28485554-7	2017	Notably, the ACA-28-induced apoptosis in melanoma and HER2-transformed cells was abrogated when ERK activation was blocked with a specific MEK inhibitor U0126.	U 0126	153-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
28485554-7	2017	Notably, the ACA-28-induced apoptosis in melanoma and HER2-transformed cells was abrogated when ERK activation was blocked with a specific MEK inhibitor U0126.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	96-99
28193531-6	2017	Consistently, NCAM140 endocytosis was inhibited by the MEK inhibitor U0126 in contrast to NCAM140-T803D or NCAM140-T803A endocytosis supporting a role of a potential ERK2 mediated phosphorylation at this site in endocytosis.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
28193531-6	2017	Consistently, NCAM140 endocytosis was inhibited by the MEK inhibitor U0126 in contrast to NCAM140-T803D or NCAM140-T803A endocytosis supporting a role of a potential ERK2 mediated phosphorylation at this site in endocytosis.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	166-170
28693200-9	2017	There was a reduction in the expression of Ets-1 and ERK phosphorylation in sorafenib or 1,4-Diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene treated cells suggesting that sorafenib may reduce the expression levels of Ets-1 by blocking the Ras/Raf/mitogen activated protein kinase signaling pathway.	U 0126	89-150	ETS proto-oncogene 1, transcription factor	Homo sapiens	227-232
28385499-6	2017	Pretreatment with p38 inhibitor (SB202190) and ERK1/2 inhibitor (U0126) attenuated the induction of CYP2E1 mRNA and protein levels by ethanol; however, no change was observed with JNK inhibitor pretreatment.	U 0126	65-70	mitogen activated protein kinase 3	Rattus norvegicus	47-53
28385499-6	2017	Pretreatment with p38 inhibitor (SB202190) and ERK1/2 inhibitor (U0126) attenuated the induction of CYP2E1 mRNA and protein levels by ethanol; however, no change was observed with JNK inhibitor pretreatment.	U 0126	65-70	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	100-106
28408625-10	2017	MAPK inhibitor U0126 treatment decreased TAZ expression in RWPE1 cells, and ETV4 overexpression rescued TAZ expression in RWPE1 cells with U0126 treatment.	U 0126	139-144	ETS variant transcription factor 4	Homo sapiens	76-80
28575129-15	2017	Interestingly, a specific mitogen-activated protein kinase ERK inhibitor U0126, but not JNK kinase inhibitor SP600125, abrogated TNF-alpha activation of Osx expression.	U 0126	73-78	tumor necrosis factor	Homo sapiens	129-138
28575129-15	2017	Interestingly, a specific mitogen-activated protein kinase ERK inhibitor U0126, but not JNK kinase inhibitor SP600125, abrogated TNF-alpha activation of Osx expression.	U 0126	73-78	Sp7 transcription factor	Homo sapiens	153-156
28268166-6	2017	Consistent with this, the p-ERK inhibitors U0126 and PD98059 both effectively blocked GC cell VM.	U 0126	43-48	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	26-31
28375585-8	2017	The promoting effects of Talin1 knockdown on epithelial-mesenchymal transition, migration, and invasion were reversed by U0126, a specific ERK1/2 inhibitor.	U 0126	121-126	talin 1	Homo sapiens	25-31
28375585-8	2017	The promoting effects of Talin1 knockdown on epithelial-mesenchymal transition, migration, and invasion were reversed by U0126, a specific ERK1/2 inhibitor.	U 0126	121-126	mitogen-activated protein kinase 3	Homo sapiens	139-145
28587345-6	2017	However, the inhibitory effects were reversed with the addition of U0126, suggesting that the ERK1/2-mediated pathway may be the underlying mechanism responsible for palmitoleate-induced downregulation of insulin mRNA.	U 0126	67-72	mitogen activated protein kinase 3	Rattus norvegicus	94-100
27775163-8	2017	Moreover, phosphorylation of AKT, ERK1/2, P38, and JNK proteins were suppressed by their inhibitors wortmannin, U0126, SB203580, and SP600125, respectively.	U 0126	112-117	AKT serine/threonine kinase 1	Sus scrofa	29-32
27775163-8	2017	Moreover, phosphorylation of AKT, ERK1/2, P38, and JNK proteins were suppressed by their inhibitors wortmannin, U0126, SB203580, and SP600125, respectively.	U 0126	112-117	mitogen-activated protein kinase 3	Sus scrofa	34-40
28416318-11	2017	U0126 was used to clarify the role of MEK/ERK signaling.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
28416318-11	2017	U0126 was used to clarify the role of MEK/ERK signaling.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	42-45
28416318-17	2017	U0126 (a MEK/ERK inhibitor) attenuated the bFGF-induced increase of cyclin B1, cdc2, and TIMP-1.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
28416318-17	2017	U0126 (a MEK/ERK inhibitor) attenuated the bFGF-induced increase of cyclin B1, cdc2, and TIMP-1.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	13-16
28416318-17	2017	U0126 (a MEK/ERK inhibitor) attenuated the bFGF-induced increase of cyclin B1, cdc2, and TIMP-1.	U 0126	0-5	fibroblast growth factor 2	Homo sapiens	43-47
28416318-17	2017	U0126 (a MEK/ERK inhibitor) attenuated the bFGF-induced increase of cyclin B1, cdc2, and TIMP-1.	U 0126	0-5	cyclin B1	Homo sapiens	68-77
28416318-17	2017	U0126 (a MEK/ERK inhibitor) attenuated the bFGF-induced increase of cyclin B1, cdc2, and TIMP-1.	U 0126	0-5	cyclin dependent kinase 1	Homo sapiens	79-83
28416318-17	2017	U0126 (a MEK/ERK inhibitor) attenuated the bFGF-induced increase of cyclin B1, cdc2, and TIMP-1.	U 0126	0-5	TIMP metallopeptidase inhibitor 1	Homo sapiens	89-95
28365254-5	2017	Moreover, arecoline-induced HIF-1alpha expression was downregulated by mitogen-activated protein kinase inhibitor U0126, phosphatidylinositol 3-kinase inhibitor LY294002, p38 inhibitor SB203580, cyclooxygenase-2 inhibitor NS-398, and glutathione precursor N-acetyl-L-cysteine (p&lt;0.05).	U 0126	114-119	hypoxia inducible factor 1 subunit alpha	Homo sapiens	28-38
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	U 0126	83-88	cyclin dependent kinase 2	Homo sapiens	18-22
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	U 0126	83-88	cyclin dependent kinase 6	Homo sapiens	24-28
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	U 0126	83-88	cyclin D1	Homo sapiens	30-39
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	U 0126	83-88	cyclin D3	Homo sapiens	45-54
28333280-19	2017	ESCs stimulated with hCG for up to 72 h showed a significant increase in PR mRNA and immunofluorescent label at 48 h only; an effect that was abrogated with the mitogen-activated protein kinase kinase inhibitor UO126.	U 0126	211-216	hypertrichosis 2 (generalised, congenital)	Homo sapiens	21-24
28333280-19	2017	ESCs stimulated with hCG for up to 72 h showed a significant increase in PR mRNA and immunofluorescent label at 48 h only; an effect that was abrogated with the mitogen-activated protein kinase kinase inhibitor UO126.	U 0126	211-216	progesterone receptor	Homo sapiens	73-75
28440453-6	2017	SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production.	U 0126	186-191	scrapie responsive gene 1	Mus musculus	0-5
28440453-6	2017	SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production.	U 0126	186-191	mitogen-activated protein kinase 3	Mus musculus	42-83
28440453-6	2017	SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production.	U 0126	186-191	mitogen-activated protein kinase 1	Mus musculus	159-163
28440453-6	2017	SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production.	U 0126	186-191	scrapie responsive gene 1	Mus musculus	231-236
28440453-6	2017	SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production.	U 0126	186-191	chemokine (C-C motif) ligand 22	Mus musculus	262-267
28215740-9	2017	Significantly diminished ERK phosphorylation and hTERT mRNA expression concomitantly reduced telomerase activity that was observed after U0126 treatment.	U 0126	137-142	mitogen-activated protein kinase 1	Homo sapiens	25-28
28575053-8	2017	Treatment of HUVECs with U0126, an ERK1/2 signaling inhibitor, attenuated autocrine production of IL-8 induced by Mxi1-0 overexpression.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	35-41
28575053-8	2017	Treatment of HUVECs with U0126, an ERK1/2 signaling inhibitor, attenuated autocrine production of IL-8 induced by Mxi1-0 overexpression.	U 0126	25-30	C-X-C motif chemokine ligand 8	Homo sapiens	98-102
28575053-8	2017	Treatment of HUVECs with U0126, an ERK1/2 signaling inhibitor, attenuated autocrine production of IL-8 induced by Mxi1-0 overexpression.	U 0126	25-30	MAX interactor 1, dimerization protein	Homo sapiens	114-118
28215740-9	2017	Significantly diminished ERK phosphorylation and hTERT mRNA expression concomitantly reduced telomerase activity that was observed after U0126 treatment.	U 0126	137-142	telomerase reverse transcriptase	Homo sapiens	49-54
28549486-10	2017	In addition, CMA stimulation resulted in phosphorylation of ERK and resulted in inhibition of downstream molecules by the ERK inhibitor U0126.	U 0126	136-141	mitogen-activated protein kinase 1	Homo sapiens	122-125
28618937-3	2017	In addition, we further demonstrated that the c-Jun N-terminal kinase inhibitor SP600125 and extracellular signal-regulated protein kinase inhibitor U0126 blocked the c-Jun activity and abolished hypoxia-induced 37-kDa laminin receptor precursor expression and promoter activity in a concentration-dependent manner.	U 0126	149-154	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
28618937-3	2017	In addition, we further demonstrated that the c-Jun N-terminal kinase inhibitor SP600125 and extracellular signal-regulated protein kinase inhibitor U0126 blocked the c-Jun activity and abolished hypoxia-induced 37-kDa laminin receptor precursor expression and promoter activity in a concentration-dependent manner.	U 0126	149-154	ribosomal protein SA	Homo sapiens	212-235
28618937-6	2017	The inhibition of 37-kDa laminin receptor precursor expression by SP600125 and U0126 could be rescued by c-Jun overexpression.	U 0126	79-84	ribosomal protein SA	Homo sapiens	18-41
28618937-6	2017	The inhibition of 37-kDa laminin receptor precursor expression by SP600125 and U0126 could be rescued by c-Jun overexpression.	U 0126	79-84	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	105-110
29137241-7	2017	ERK inhibition (by MEK162/U0126) or knockdown (by targeted ERK1/2 shRNAs) dramatically sensitized CZ415-induced osteosarcoma cell apoptosis.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	0-3
28542135-6	2017	The specific inhibitors U0126, SP600125 and SB202190 attenuated the expression of MAPKs, and regulated the expression of cleaved caspase-8, -9 and -3.	U 0126	24-29	caspase 8	Homo sapiens	129-149
28542650-7	2017	Inhibition of ERK1/2 phosphorylation by U0126 (10 muM) led to a significant decrease in EGF-mediated invasion with simultaneous decrease in the phosphorylated forms of STAT3 and STAT1.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	14-20
28542650-7	2017	Inhibition of ERK1/2 phosphorylation by U0126 (10 muM) led to a significant decrease in EGF-mediated invasion with simultaneous decrease in the phosphorylated forms of STAT3 and STAT1.	U 0126	40-45	latexin	Homo sapiens	50-53
28542650-7	2017	Inhibition of ERK1/2 phosphorylation by U0126 (10 muM) led to a significant decrease in EGF-mediated invasion with simultaneous decrease in the phosphorylated forms of STAT3 and STAT1.	U 0126	40-45	signal transducer and activator of transcription 3	Homo sapiens	168-173
28542650-7	2017	Inhibition of ERK1/2 phosphorylation by U0126 (10 muM) led to a significant decrease in EGF-mediated invasion with simultaneous decrease in the phosphorylated forms of STAT3 and STAT1.	U 0126	40-45	signal transducer and activator of transcription 1	Homo sapiens	178-183
28524180-5	2017	Moreover, treatment with the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 similarly suppressed the migration and invasion of SK-OV-3 cells, implying that GABRP promotes these cellular behaviors by activating the MAPK/ERK pathway.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	63-67
28524180-5	2017	Moreover, treatment with the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 similarly suppressed the migration and invasion of SK-OV-3 cells, implying that GABRP promotes these cellular behaviors by activating the MAPK/ERK pathway.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	69-72
28524180-5	2017	Moreover, treatment with the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 similarly suppressed the migration and invasion of SK-OV-3 cells, implying that GABRP promotes these cellular behaviors by activating the MAPK/ERK pathway.	U 0126	96-101	gamma-aminobutyric acid type A receptor subunit pi	Homo sapiens	182-187
28524180-5	2017	Moreover, treatment with the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 similarly suppressed the migration and invasion of SK-OV-3 cells, implying that GABRP promotes these cellular behaviors by activating the MAPK/ERK pathway.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	240-244
28524180-5	2017	Moreover, treatment with the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 similarly suppressed the migration and invasion of SK-OV-3 cells, implying that GABRP promotes these cellular behaviors by activating the MAPK/ERK pathway.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	245-248
28881663-5	2017	Inhibitors of mitogen-activated protein kinase (MAPK) U0126 and phosphatidylinositol-3-kinases (PI3K) LY294002 reversed the protein levels of integrin-beta1 and MMP-9 as well as the migratory ability induced by BPA.	U 0126	54-59	integrin beta 1 (fibronectin receptor beta)	Mus musculus	142-156
28385507-3	2017	Importantly, 2 exhibited MEK1 binding affinity with IC5071nM, which is so far the best result for metal complexes and more potent than U0126 (7.02muM) and AZD6244 (2.20muM).	U 0126	135-140	mitogen-activated protein kinase kinase 1	Homo sapiens	25-29
28344073-7	2017	The thrombin-induced MMP-9 release was inhibited by U0126, LY294002, Go6976, and Go6983.	U 0126	52-57	coagulation factor II, thrombin	Homo sapiens	4-12
28344073-7	2017	The thrombin-induced MMP-9 release was inhibited by U0126, LY294002, Go6976, and Go6983.	U 0126	52-57	matrix metallopeptidase 9	Homo sapiens	21-26
29029396-9	2017	Moreover, the administration of AM630, LY294002, U0126 and AG490 (inhibitors for CB2, Akt, ERK1/2 and Stat3, respectively) could abolish the beneficial actions of AM1241.	U 0126	49-54	cannabinoid receptor 2 (macrophage)	Mus musculus	81-84
28442634-4	2017	Administration of U0126, which is a selective inhibitor of the ERK1/2 pathway, improved renal function, decreased urine microalbumin and inhibited activation of renal interstitial fibroblasts as well as accumulation of extracellular proteins.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	63-69
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	SMAD family member 2	Homo sapiens	14-19
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	mitogen-activated protein kinase 3	Homo sapiens	33-39
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	transforming growth factor beta 1	Homo sapiens	156-163
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	mitogen-activated protein kinase 3	Homo sapiens	172-178
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	transforming growth factor beta 1	Homo sapiens	306-313
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	cadherin 1	Homo sapiens	418-428
28365272-7	2017	Pre-treatment with UO126 was effective at blocking the TGFbeta-induced EMT, as evidenced by a reduction of alpha-SMA expression and protein labeling, E-cadherin labeling at cell borders, and a reduction of cell loss, cell elongation and capsular wrinkling.	U 0126	19-24	transforming growth factor beta 1	Homo sapiens	55-62
28365272-7	2017	Pre-treatment with UO126 was effective at blocking the TGFbeta-induced EMT, as evidenced by a reduction of alpha-SMA expression and protein labeling, E-cadherin labeling at cell borders, and a reduction of cell loss, cell elongation and capsular wrinkling.	U 0126	19-24	cadherin 1	Homo sapiens	150-160
28365272-8	2017	Post-treatment with UO126 at 2 and 6 h after TGFbeta addition was also effective at blocking EMT while post-treatment with UO126 at 24 and 48 h was not sufficient in hampering TGFbeta-induced EMT.	U 0126	20-25	transforming growth factor beta 1	Homo sapiens	45-52
29029396-9	2017	Moreover, the administration of AM630, LY294002, U0126 and AG490 (inhibitors for CB2, Akt, ERK1/2 and Stat3, respectively) could abolish the beneficial actions of AM1241.	U 0126	49-54	thymoma viral proto-oncogene 1	Mus musculus	86-89
29029396-9	2017	Moreover, the administration of AM630, LY294002, U0126 and AG490 (inhibitors for CB2, Akt, ERK1/2 and Stat3, respectively) could abolish the beneficial actions of AM1241.	U 0126	49-54	mitogen-activated protein kinase 3	Mus musculus	91-97
29029396-9	2017	Moreover, the administration of AM630, LY294002, U0126 and AG490 (inhibitors for CB2, Akt, ERK1/2 and Stat3, respectively) could abolish the beneficial actions of AM1241.	U 0126	49-54	signal transducer and activator of transcription 3	Mus musculus	102-107
28469203-7	2017	Moreover, intravitreal injection of U0126 eliminated the upregulated GFAP expression in COH retinas.	U 0126	36-41	glial fibrillary acidic protein	Rattus norvegicus	69-73
28469203-3	2017	In normal retinas, intravitreal injection of BaCl2 significantly increased GFAP expression in Muller cells, which was eliminated by co-injecting mitogen-activated protein kinase (MAPK) inhibitor U0126.	U 0126	195-200	glial fibrillary acidic protein	Rattus norvegicus	75-79
28469203-3	2017	In normal retinas, intravitreal injection of BaCl2 significantly increased GFAP expression in Muller cells, which was eliminated by co-injecting mitogen-activated protein kinase (MAPK) inhibitor U0126.	U 0126	195-200	mitogen activated protein kinase 3	Rattus norvegicus	179-183
28283475-10	2017	Among MAPK inhibitors studied, neither SB203580 nor PD98059 had any effect on synergy, whereas U0126 prevented synergistic induction of CCL20 by HRV and bacteria, apparently via "off-target" effects.	U 0126	95-100	C-C motif chemokine ligand 20	Homo sapiens	136-141
28298334-8	2017	The MEK inhibitor U0126 significantly inhibited EPO-induced Sox17 expression.	U 0126	18-23	midkine	Mus musculus	4-7
28298334-8	2017	The MEK inhibitor U0126 significantly inhibited EPO-induced Sox17 expression.	U 0126	18-23	erythropoietin	Mus musculus	48-51
28298334-8	2017	The MEK inhibitor U0126 significantly inhibited EPO-induced Sox17 expression.	U 0126	18-23	SRY (sex determining region Y)-box 17	Mus musculus	60-65
28173642-6	2017	UII-induced proliferation of HASMC cells was inhibited by U0126, an ERK1/2 inhibitor, but not by SP600125 (inhibitor of JNK) or SB202190 (inhibitor of p38 MAPK).	U 0126	58-63	urotensin 2	Homo sapiens	0-3
28173642-6	2017	UII-induced proliferation of HASMC cells was inhibited by U0126, an ERK1/2 inhibitor, but not by SP600125 (inhibitor of JNK) or SB202190 (inhibitor of p38 MAPK).	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	68-74
28549488-6	2017	Moreover, microwave-induced cellular apoptosis and cell cycle regulation were analyzed after blockade of ERK signaling by using U0126.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	105-108
28181145-10	2017	U0126 inhibited ERK activation and decreased autophagy proteins expression but increased connexin43 expression.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	16-19
28181145-10	2017	U0126 inhibited ERK activation and decreased autophagy proteins expression but increased connexin43 expression.	U 0126	0-5	gap junction protein, alpha 1	Rattus norvegicus	89-99
27639037-5	2017	A co-treatment with the MEK inhibitor U0126 abolished the increase in the expression of Dmp1 and Fgfr1 by elevated Pi, suggesting the involvement of the MEK/ERK pathway in this up-regulation.	U 0126	38-43	midkine	Mus musculus	24-27
27639037-5	2017	A co-treatment with the MEK inhibitor U0126 abolished the increase in the expression of Dmp1 and Fgfr1 by elevated Pi, suggesting the involvement of the MEK/ERK pathway in this up-regulation.	U 0126	38-43	dentin matrix protein 1	Mus musculus	88-92
27639037-5	2017	A co-treatment with the MEK inhibitor U0126 abolished the increase in the expression of Dmp1 and Fgfr1 by elevated Pi, suggesting the involvement of the MEK/ERK pathway in this up-regulation.	U 0126	38-43	fibroblast growth factor receptor 1	Mus musculus	97-102
27639037-5	2017	A co-treatment with the MEK inhibitor U0126 abolished the increase in the expression of Dmp1 and Fgfr1 by elevated Pi, suggesting the involvement of the MEK/ERK pathway in this up-regulation.	U 0126	38-43	midkine	Mus musculus	153-156
27639037-5	2017	A co-treatment with the MEK inhibitor U0126 abolished the increase in the expression of Dmp1 and Fgfr1 by elevated Pi, suggesting the involvement of the MEK/ERK pathway in this up-regulation.	U 0126	38-43	mitogen-activated protein kinase 1	Mus musculus	157-160
27720345-6	2017	SB431542 and U0126 prevented the TGF-beta1-induced increase of collagen content and TIMP-1 production of dental pulp cells.	U 0126	13-18	transforming growth factor beta 1	Homo sapiens	33-42
27720345-6	2017	SB431542 and U0126 prevented the TGF-beta1-induced increase of collagen content and TIMP-1 production of dental pulp cells.	U 0126	13-18	TIMP metallopeptidase inhibitor 1	Homo sapiens	84-90
28083623-9	2017	SFN was found to promote MAPK signaling, and inhibition of ERK activation using U0126 prevented SFN-induced LC3-II elevation and vesicle formation.	U 0126	80-85	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	108-111
28461772-3	2017	Up-regulation of mDC-specific markers like CD80, CD83 and CD88 induced by stimulation with 27OHChol was significantly reduced in the presence of LY294002, an inhibitor of PI3K, and U0126, an inhibitor of ERK.	U 0126	181-186	CD80 molecule	Homo sapiens	43-47
28461772-3	2017	Up-regulation of mDC-specific markers like CD80, CD83 and CD88 induced by stimulation with 27OHChol was significantly reduced in the presence of LY294002, an inhibitor of PI3K, and U0126, an inhibitor of ERK.	U 0126	181-186	CD83 molecule	Homo sapiens	49-53
28461772-3	2017	Up-regulation of mDC-specific markers like CD80, CD83 and CD88 induced by stimulation with 27OHChol was significantly reduced in the presence of LY294002, an inhibitor of PI3K, and U0126, an inhibitor of ERK.	U 0126	181-186	complement C5a receptor 1	Homo sapiens	58-62
28461772-3	2017	Up-regulation of mDC-specific markers like CD80, CD83 and CD88 induced by stimulation with 27OHChol was significantly reduced in the presence of LY294002, an inhibitor of PI3K, and U0126, an inhibitor of ERK.	U 0126	181-186	mitogen-activated protein kinase 1	Homo sapiens	204-207
28461772-7	2017	Transcription and surface expression of CD molecules involved in atherosclerosis such as CD105, CD137 and CD166 were also significantly decreased by treatment with LY294002 and U0126.	U 0126	177-182	TNF receptor superfamily member 9	Homo sapiens	96-101
28461772-7	2017	Transcription and surface expression of CD molecules involved in atherosclerosis such as CD105, CD137 and CD166 were also significantly decreased by treatment with LY294002 and U0126.	U 0126	177-182	activated leukocyte cell adhesion molecule	Homo sapiens	106-111
27011380-6	2017	Intraplantar coinjection of ERK inhibitor, U0126, and PI3K inhibitor, LY294002, as well as two protein translation inhibitors, temsirolimus and cordycepin, prevented the development of SDF1-induced acute mechanical hyperalgesia and hyperalgesic priming.	U 0126	43-48	C-X-C motif chemokine ligand 12	Homo sapiens	185-189
28442634-8	2017	Finally, U0126 inhibited phosphorylation of Smad3, a key mediator in transforming growth factor (TGF-beta) signaling.	U 0126	9-14	SMAD family member 3	Rattus norvegicus	44-49
28442634-8	2017	Finally, U0126 inhibited phosphorylation of Smad3, a key mediator in transforming growth factor (TGF-beta) signaling.	U 0126	9-14	transforming growth factor, beta 1	Rattus norvegicus	97-105
28430129-10	2017	The expression of autophagy markers could be decreased when the chondrocytes were incubated with ERK1/2 inhibitor U0126.	U 0126	114-119	mitogen-activated protein kinase 3	Homo sapiens	97-103
28288823-12	2017	Pretreatment with U0126-an inhibitor of MEK1 and MEK2 kinases-SB203580-a p38 MAPK inhibitor-and SC-514-an IKKbeta inhibitor-suppressed cadmium-induced IL-8 expression and release.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	40-44
28288823-12	2017	Pretreatment with U0126-an inhibitor of MEK1 and MEK2 kinases-SB203580-a p38 MAPK inhibitor-and SC-514-an IKKbeta inhibitor-suppressed cadmium-induced IL-8 expression and release.	U 0126	18-23	mitogen-activated protein kinase kinase 2	Homo sapiens	49-53
28288823-12	2017	Pretreatment with U0126-an inhibitor of MEK1 and MEK2 kinases-SB203580-a p38 MAPK inhibitor-and SC-514-an IKKbeta inhibitor-suppressed cadmium-induced IL-8 expression and release.	U 0126	18-23	C-X-C motif chemokine ligand 8	Homo sapiens	151-155
28315333-7	2017	The mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway inhibitor U0126 (10 mumol/L) significantly inhibited the ability of T3 to promote the proliferation of EPCs and to alter cell cycle progression.	U 0126	114-119	mitogen-activated protein kinase 1	Homo sapiens	81-84
28418405-5	2017	Remarkably, inhibition of ERK1 and ERK2 phosphorylation by U0126 in the dHip prior to Pavlovian-conditioning exacerbated impulsive reward seeking.	U 0126	59-64	mitogen-activated protein kinase 3	Mus musculus	26-30
28288823-13	2017	Upregulation of cadmium-induced IL-6 was inhibited by U0126 and SC-514, but not SB203580.	U 0126	54-59	interleukin 6	Homo sapiens	32-36
28130187-13	2017	Treatment with U0126, an ERK inhibitor, exerted the same effect as treatment with miR-206 mimics.	U 0126	15-20	Eph receptor B1	Rattus norvegicus	25-28
28206960-8	2017	Treatment with U0126, an inhibitor of the MEK-ERK1/2 signaling, greatly inhibited the GDF15-induced tumor sphere formation.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
28206960-8	2017	Treatment with U0126, an inhibitor of the MEK-ERK1/2 signaling, greatly inhibited the GDF15-induced tumor sphere formation.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	46-52
28206960-8	2017	Treatment with U0126, an inhibitor of the MEK-ERK1/2 signaling, greatly inhibited the GDF15-induced tumor sphere formation.	U 0126	15-20	growth differentiation factor 15	Homo sapiens	86-91
28374767-7	2017	GPR91 siRNA transduction and the ERK1/2 inhibitor U0126 inhibited the increases in C/EBP beta, C/EBP delta, c-Fos and HIF-1alpha.	U 0126	50-55	mitogen activated protein kinase 3	Rattus norvegicus	33-39
28374767-7	2017	GPR91 siRNA transduction and the ERK1/2 inhibitor U0126 inhibited the increases in C/EBP beta, C/EBP delta, c-Fos and HIF-1alpha.	U 0126	50-55	CCAAT/enhancer binding protein beta	Rattus norvegicus	83-93
28374767-7	2017	GPR91 siRNA transduction and the ERK1/2 inhibitor U0126 inhibited the increases in C/EBP beta, C/EBP delta, c-Fos and HIF-1alpha.	U 0126	50-55	CCAAT/enhancer binding protein delta	Rattus norvegicus	95-106
28374767-7	2017	GPR91 siRNA transduction and the ERK1/2 inhibitor U0126 inhibited the increases in C/EBP beta, C/EBP delta, c-Fos and HIF-1alpha.	U 0126	50-55	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	108-113
28374767-7	2017	GPR91 siRNA transduction and the ERK1/2 inhibitor U0126 inhibited the increases in C/EBP beta, C/EBP delta, c-Fos and HIF-1alpha.	U 0126	50-55	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	118-128
26595054-4	2017	Therefore, the aim of this study was to assess neurological function, infarct size and recovery processes 14 days after stroke in male rats to determine long-term outcome following acute treatment with the MEK1/2 inhibitor U0126.	U 0126	223-228	mitogen activated protein kinase kinase 1	Rattus norvegicus	206-212
28314481-11	2017	Moreover, MAPK inhibitors including U0126 (an ERK1/2/MAPK inhibitor) and SB202190 (p38/MAPK inhibitor) suppressed an increase of MDR1 mRNA levels in the cells treated with benzophenones (GK, OC) and xanthone ISO, respectively.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	46-52
28314481-11	2017	Moreover, MAPK inhibitors including U0126 (an ERK1/2/MAPK inhibitor) and SB202190 (p38/MAPK inhibitor) suppressed an increase of MDR1 mRNA levels in the cells treated with benzophenones (GK, OC) and xanthone ISO, respectively.	U 0126	36-41	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
26595054-10	2017	RESULTS: Acute treatment with U0126 significantly improved long-term functional recovery, reduced infarct size, and enhanced Tie-2 and nestin protein expression at 14 days post-stroke.	U 0126	30-35	TEK receptor tyrosine kinase	Rattus norvegicus	125-130
28197636-7	2017	Inhibitors of the PI3K-Akt and ERK1/2 pathways, LY294002 and U0126, significantly suppressed the EMT phenotype.	U 0126	61-66	AKT serine/threonine kinase 1	Homo sapiens	23-26
28418405-5	2017	Remarkably, inhibition of ERK1 and ERK2 phosphorylation by U0126 in the dHip prior to Pavlovian-conditioning exacerbated impulsive reward seeking.	U 0126	59-64	mitogen-activated protein kinase 1	Mus musculus	35-39
28413468-7	2017	Sunitinib-induced autophagy was notably reversed by ERK1/2 kinase inhibitor, U0126.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	52-58
28003340-7	2017	We further found that apicidin did not affect the phosphorylation of ERK or USF1; however, ERK inhibitor U0126 blocked the effect of apicidin on ADAM10.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	91-94
28003340-7	2017	We further found that apicidin did not affect the phosphorylation of ERK or USF1; however, ERK inhibitor U0126 blocked the effect of apicidin on ADAM10.	U 0126	105-110	ADAM metallopeptidase domain 10	Homo sapiens	145-151
28197636-7	2017	Inhibitors of the PI3K-Akt and ERK1/2 pathways, LY294002 and U0126, significantly suppressed the EMT phenotype.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	31-37
27463736-10	2017	In addition, U0126, a MEK inhibitor, inhibited GDNF-induced neurite outgrowth of PC12 cells.	U 0126	13-18	glial cell derived neurotrophic factor	Rattus norvegicus	47-51
28804610-9	2017	More importantly, both the enhancing effect of naringin on osteogenic differentiation and the activity effect of naringin on ERK signaling pathway were reversed by U0126 addition.	U 0126	164-169	mitogen-activated protein kinase 1	Homo sapiens	125-128
27998643-9	2017	Second, in CD44-overexpressing parietal epithelial cells, decreasing pERK with U0126 was accompanied by reduced CD44.	U 0126	79-84	CD44 antigen	Mus musculus	11-15
27998643-9	2017	Second, in CD44-overexpressing parietal epithelial cells, decreasing pERK with U0126 was accompanied by reduced CD44.	U 0126	79-84	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	69-73
27998643-9	2017	Second, in CD44-overexpressing parietal epithelial cells, decreasing pERK with U0126 was accompanied by reduced CD44.	U 0126	79-84	CD44 antigen	Mus musculus	112-116
28259937-8	2017	Combined treatment with an ERK inhibitor (U0126) and baicalein led to the synergistic reduction of MMP-2/9 expression; and the invasive capabilities of DLD1 cells were also inhibited markedy.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	27-30
28259937-8	2017	Combined treatment with an ERK inhibitor (U0126) and baicalein led to the synergistic reduction of MMP-2/9 expression; and the invasive capabilities of DLD1 cells were also inhibited markedy.	U 0126	42-47	matrix metallopeptidase 2	Homo sapiens	99-106
28322340-6	2017	Furthermore, Zn2+-induced PARP-1 stimulation, increase in the [Ca2+]c and cell death were inhibited by PF431396, a Ca2+-sensitive PYK2 inhibitor, and U0126, a MEK/ERK inhibitor.	U 0126	150-155	poly(ADP-ribose) polymerase 1	Homo sapiens	26-32
27617337-3	2017	Moreover, AAT abrogated cytotoxicity of MEK inhibitor U0126 in PC3 cell line.	U 0126	54-59	serpin family A member 1	Homo sapiens	10-13
27617337-3	2017	Moreover, AAT abrogated cytotoxicity of MEK inhibitor U0126 in PC3 cell line.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
27617337-3	2017	Moreover, AAT abrogated cytotoxicity of MEK inhibitor U0126 in PC3 cell line.	U 0126	54-59	proprotein convertase subtilisin/kexin type 1	Homo sapiens	63-66
28087840-6	2017	MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-alpha/Cholix.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	0-4
28087840-6	2017	MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-alpha/Cholix.	U 0126	40-45	poly(ADP-ribose) polymerase 1	Homo sapiens	58-62
28087840-6	2017	MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-alpha/Cholix.	U 0126	40-45	tumor necrosis factor	Homo sapiens	83-99
27694893-7	2017	These effects are mediated by activation of the ERK1/2 signalling pathway, and inhibition of this pathway with a specific ERK1/2 inhibitor (U0126) significantly impairs the tumour-promoting effects induced by TBL1XR1.	U 0126	140-145	mitogen-activated protein kinase 3	Homo sapiens	48-54
27694893-7	2017	These effects are mediated by activation of the ERK1/2 signalling pathway, and inhibition of this pathway with a specific ERK1/2 inhibitor (U0126) significantly impairs the tumour-promoting effects induced by TBL1XR1.	U 0126	140-145	mitogen-activated protein kinase 3	Homo sapiens	122-128
27694893-7	2017	These effects are mediated by activation of the ERK1/2 signalling pathway, and inhibition of this pathway with a specific ERK1/2 inhibitor (U0126) significantly impairs the tumour-promoting effects induced by TBL1XR1.	U 0126	140-145	TBL1X/Y related 1	Homo sapiens	209-216
28322340-6	2017	Furthermore, Zn2+-induced PARP-1 stimulation, increase in the [Ca2+]c and cell death were inhibited by PF431396, a Ca2+-sensitive PYK2 inhibitor, and U0126, a MEK/ERK inhibitor.	U 0126	150-155	protein tyrosine kinase 2 beta	Homo sapiens	130-134
28322340-6	2017	Furthermore, Zn2+-induced PARP-1 stimulation, increase in the [Ca2+]c and cell death were inhibited by PF431396, a Ca2+-sensitive PYK2 inhibitor, and U0126, a MEK/ERK inhibitor.	U 0126	150-155	mitogen-activated protein kinase kinase 7	Homo sapiens	159-162
28322340-6	2017	Furthermore, Zn2+-induced PARP-1 stimulation, increase in the [Ca2+]c and cell death were inhibited by PF431396, a Ca2+-sensitive PYK2 inhibitor, and U0126, a MEK/ERK inhibitor.	U 0126	150-155	mitogen-activated protein kinase 1	Homo sapiens	163-166
28377346-9	2017	The specific inhibitors of ERK signal pathway (U0126) and JNK signal pathway (SP600125) significantly decreased the percentage of BrdU+ cells in RSC96-CM-induced OPCs (P&lt;0.01).	U 0126	47-52	mitogen activated protein kinase 3	Rattus norvegicus	27-30
27864692-9	2017	The inactivation of ERK1/2 signalling pathway, but not JNK, by either genistein or U0126, a MEK1/2 inhibitor, was not able to blunt Abeta1-42-induced TG2 up-regulation, that, instead, was significantly reduced by R283.	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	20-26
28323857-4	2017	Furthermore, we evaluated whether treatment with a specific MEK1/2 inhibitor, U0126, modified the expression and function of these proteins.	U 0126	78-83	mitogen activated protein kinase kinase 1	Rattus norvegicus	60-66
28323857-13	2017	Treatment with U0126 reduced pERK1/2, expression of ET-1 and ETB receptor, and ETB receptor-mediated vasoconstriction.	U 0126	15-20	endothelin 1	Rattus norvegicus	52-73
28323857-13	2017	Treatment with U0126 reduced pERK1/2, expression of ET-1 and ETB receptor, and ETB receptor-mediated vasoconstriction.	U 0126	15-20	endothelin receptor type B	Rattus norvegicus	61-64
27933490-2	2017	GCI was induced in male Wistar rats followed by treatment with either vehicle or the MEK1/2 inhibitor U0126 every 12 h post-GCI.	U 0126	102-107	mitogen activated protein kinase kinase 1	Rattus norvegicus	85-91
26993510-11	2017	These findings were further confirmed by ERK1/2 inhibition studies, using the pharmacological inhibitor U0126.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	41-47
27817132-10	2017	The ERK antagonist U0126 significantly reversed mechanical hyperalgesia in the OVX rats.	U 0126	19-24	Eph receptor B1	Rattus norvegicus	4-7
27436370-7	2017	PD153035 (EGFR inhibitor) and U0126 (ERK inhibitor) inhibited AQP3 expression and also the attachment and outgrowth of blastocysts.	U 0126	30-35	aquaporin 3	Mus musculus	62-66
28345466-7	2017	By screening the trop2-related signaling pathways, we observed that excessive angiogenesis was correlated with activation of ERK1/2 signaling pathway, and ERK1/2 inhibitor (U0126) could suppress the tubular formation ability induced by trop2 expression.	U 0126	173-178	tumor associated calcium signal transducer 2	Homo sapiens	17-22
28345466-7	2017	By screening the trop2-related signaling pathways, we observed that excessive angiogenesis was correlated with activation of ERK1/2 signaling pathway, and ERK1/2 inhibitor (U0126) could suppress the tubular formation ability induced by trop2 expression.	U 0126	173-178	mitogen-activated protein kinase 3	Homo sapiens	125-131
28345466-7	2017	By screening the trop2-related signaling pathways, we observed that excessive angiogenesis was correlated with activation of ERK1/2 signaling pathway, and ERK1/2 inhibitor (U0126) could suppress the tubular formation ability induced by trop2 expression.	U 0126	173-178	mitogen-activated protein kinase 3	Homo sapiens	155-161
28345466-7	2017	By screening the trop2-related signaling pathways, we observed that excessive angiogenesis was correlated with activation of ERK1/2 signaling pathway, and ERK1/2 inhibitor (U0126) could suppress the tubular formation ability induced by trop2 expression.	U 0126	173-178	tumor associated calcium signal transducer 2	Homo sapiens	236-241
28240737-6	2017	Thus, treatment with the pure antiestrogen ICI 182 780 or the potent and specific inhibitor of MEK/ERK, U0126, was sufficient to abolish the synergistic nature of the interaction between FASN blockade and E2-stimulated ERalpha transactivation.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
28240737-6	2017	Thus, treatment with the pure antiestrogen ICI 182 780 or the potent and specific inhibitor of MEK/ERK, U0126, was sufficient to abolish the synergistic nature of the interaction between FASN blockade and E2-stimulated ERalpha transactivation.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	99-102
28240737-6	2017	Thus, treatment with the pure antiestrogen ICI 182 780 or the potent and specific inhibitor of MEK/ERK, U0126, was sufficient to abolish the synergistic nature of the interaction between FASN blockade and E2-stimulated ERalpha transactivation.	U 0126	104-109	fatty acid synthase	Homo sapiens	187-191
28240737-6	2017	Thus, treatment with the pure antiestrogen ICI 182 780 or the potent and specific inhibitor of MEK/ERK, U0126, was sufficient to abolish the synergistic nature of the interaction between FASN blockade and E2-stimulated ERalpha transactivation.	U 0126	104-109	estrogen receptor 1	Homo sapiens	219-226
28241017-5	2017	Inhibition of the signaling by either the EGFR inhibitors CI-1033 and BIBW2992 or the MEK/ERK inhibitor U0126 impairs germinative cell proliferation and larval growth.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	90-93
28218307-3	2017	Here we show that U0126 (a MEK inhibitor) and MK2206 (an AKT inhibitor) synergistically inhibit cell growth of deep endometriotic stromal cells (DES) grown on polyacrylamide gel substrates (PGS) of varying stiffness (2 or 30 kilopascal [kPa]) or plastic in vitro.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
27939449-5	2017	Meanwhile, cultivated tongues treated with MEK inhibitor U0126 or PD98059 showed significantly decreased cell proliferation in the tongue epithelium and the mesenchyme.	U 0126	57-62	midkine	Mus musculus	43-46
28144039-5	2017	KEGG pathway analysis and in vitro studies suggested that the ERK pathway is involved in KCNB1-mediated regulation of autophagy, which was confirmed by inhibition of KCNB1-induced autophagy by using a selective ERK1/2 inhibitor (U0126) or siERK1/2.	U 0126	229-234	mitogen-activated protein kinase 1	Homo sapiens	62-65
28144039-5	2017	KEGG pathway analysis and in vitro studies suggested that the ERK pathway is involved in KCNB1-mediated regulation of autophagy, which was confirmed by inhibition of KCNB1-induced autophagy by using a selective ERK1/2 inhibitor (U0126) or siERK1/2.	U 0126	229-234	potassium voltage-gated channel subfamily B member 1	Homo sapiens	89-94
28144039-5	2017	KEGG pathway analysis and in vitro studies suggested that the ERK pathway is involved in KCNB1-mediated regulation of autophagy, which was confirmed by inhibition of KCNB1-induced autophagy by using a selective ERK1/2 inhibitor (U0126) or siERK1/2.	U 0126	229-234	potassium voltage-gated channel subfamily B member 1	Homo sapiens	166-171
28144039-5	2017	KEGG pathway analysis and in vitro studies suggested that the ERK pathway is involved in KCNB1-mediated regulation of autophagy, which was confirmed by inhibition of KCNB1-induced autophagy by using a selective ERK1/2 inhibitor (U0126) or siERK1/2.	U 0126	229-234	mitogen-activated protein kinase 3	Homo sapiens	211-217
28165494-7	2017	Blocking MEK-ERK 1/2 signalling with a pharmacological inhibitor (U0126) greatly attenuated the detrimental effects observed in MD-1 knockout cardiomyocytes exposed to angiotensin II stimuli.	U 0126	66-71	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
28165494-7	2017	Blocking MEK-ERK 1/2 signalling with a pharmacological inhibitor (U0126) greatly attenuated the detrimental effects observed in MD-1 knockout cardiomyocytes exposed to angiotensin II stimuli.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	13-20
28165494-7	2017	Blocking MEK-ERK 1/2 signalling with a pharmacological inhibitor (U0126) greatly attenuated the detrimental effects observed in MD-1 knockout cardiomyocytes exposed to angiotensin II stimuli.	U 0126	66-71	angiotensinogen	Homo sapiens	168-182
27921117-10	2017	Blocking the ERK1/2 pathway in ASMSCs with U0126 corrected the abnormal osteogenic differentiation, inhibited MCP1 overexpression, and prevented subsequent monocyte dysfunction.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	13-19
27921117-10	2017	Blocking the ERK1/2 pathway in ASMSCs with U0126 corrected the abnormal osteogenic differentiation, inhibited MCP1 overexpression, and prevented subsequent monocyte dysfunction.	U 0126	43-48	C-C motif chemokine ligand 2	Homo sapiens	110-114
27852823-5	2017	In HPK1ARas cells, 1alpha,25(OH)2D3-induced nuclear localization and interaction of hRXRalpha are restored when cells are treated with the MEK1/2 inhibitor UO126 or following transfection of the non-phosphorylatable hRXRalpha Ala-260 mutant.	U 0126	156-161	retinoid X receptor alpha	Homo sapiens	84-93
27852823-5	2017	In HPK1ARas cells, 1alpha,25(OH)2D3-induced nuclear localization and interaction of hRXRalpha are restored when cells are treated with the MEK1/2 inhibitor UO126 or following transfection of the non-phosphorylatable hRXRalpha Ala-260 mutant.	U 0126	156-161	mitogen-activated protein kinase kinase 1	Homo sapiens	139-145
27852823-5	2017	In HPK1ARas cells, 1alpha,25(OH)2D3-induced nuclear localization and interaction of hRXRalpha are restored when cells are treated with the MEK1/2 inhibitor UO126 or following transfection of the non-phosphorylatable hRXRalpha Ala-260 mutant.	U 0126	156-161	retinoid X receptor alpha	Homo sapiens	216-225
27270426-5	2017	When ERK1/2 phosphorylation was reduced by an inhibitor (U0126) or siRNA inhibition, both pemetrexed-resistant sublines reduced their migration and invasion abilities.	U 0126	57-62	mitogen-activated protein kinase 3	Mus musculus	5-11
28100386-5	2017	Meanwhile, cervical cancer cell lines Siha (HPV16 positive) and C33A (HPV negative) were treated with ERK inhibitor U0126 in vitro.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	102-105
27865869-2	2017	U0126, a p-ERK1/2 inhibitor, was injected intracisternally before UAC implant.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	11-17
27865869-11	2017	Pretreatment with U0126 prevented the upregulation of both p-ERK1/2 and p-p38.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	61-67
27865869-11	2017	Pretreatment with U0126 prevented the upregulation of both p-ERK1/2 and p-p38.	U 0126	18-23	mitogen activated protein kinase 14	Rattus norvegicus	74-77
28101000-5	2016	Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2.	U 0126	76-81	mitogen activated protein kinase 3	Rattus norvegicus	96-102
28101000-5	2016	Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2.	U 0126	76-81	mitogen activated protein kinase 14	Rattus norvegicus	185-188
28101000-5	2016	Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2.	U 0126	76-81	mitogen activated protein kinase 3	Rattus norvegicus	192-198
27462868-8	2017	It also inactivated ERK1/2 and p38, and this effect was enhanced by treatment with the MEK inhibitor U0126.	U 0126	101-106	mitogen-activated protein kinase 3	Homo sapiens	20-26
27462868-8	2017	It also inactivated ERK1/2 and p38, and this effect was enhanced by treatment with the MEK inhibitor U0126.	U 0126	101-106	mitogen-activated protein kinase 1	Homo sapiens	31-34
27462868-8	2017	It also inactivated ERK1/2 and p38, and this effect was enhanced by treatment with the MEK inhibitor U0126.	U 0126	101-106	mitogen-activated protein kinase kinase 7	Homo sapiens	87-90
27436370-7	2017	PD153035 (EGFR inhibitor) and U0126 (ERK inhibitor) inhibited AQP3 expression and also the attachment and outgrowth of blastocysts.	U 0126	30-35	mitogen-activated protein kinase 1	Mus musculus	37-40
28036290-5	2017	YAP1 overexpression enhanced PTC cell proliferation by activating ERK1/2 and AKT, and these effects were impaired by treating the cells with the MEK inhibitor U0126 or the AKT inhibitor GSK690693.	U 0126	159-164	Yes1 associated transcriptional regulator	Homo sapiens	0-4
28036290-5	2017	YAP1 overexpression enhanced PTC cell proliferation by activating ERK1/2 and AKT, and these effects were impaired by treating the cells with the MEK inhibitor U0126 or the AKT inhibitor GSK690693.	U 0126	159-164	mitogen-activated protein kinase kinase 7	Homo sapiens	145-148
28186140-6	2017	Niacin showed a selected additive effect on chemoattractant-induced activation of ERK1/2, JNK and PI3K pathways, but only the MEK inhibitor UO126 reduced niacin-mediated inhibition of macrophage chemotaxis, while activation of ERK1/2 by EGF alone did not inhibit fMLF-mediated migration of HEK293T cells co-expressing HCA2 and fMLF receptor FPR1.	U 0126	140-145	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	0-6
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	mitogen-activated protein kinase kinase 1	Homo sapiens	34-40
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	interleukin 1 beta	Homo sapiens	95-103
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	PDZ domain containing 1	Homo sapiens	131-136
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	155-158
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	159-163
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	mitogen-activated protein kinase 8	Homo sapiens	169-172
28170408-7	2017	TNFalpha also caused transient stimulation of p38MAPK and ERK1/2 in hCMEC/D3 cells, and the occludin band-shift induced by TNFalpha was suppressed by SB202190, an inhibitor for p38MAPK, and partly by U0126, the MEK1/2-ERK1/2 inhibitor.	U 0126	200-205	tumor necrosis factor	Homo sapiens	0-8
28170408-7	2017	TNFalpha also caused transient stimulation of p38MAPK and ERK1/2 in hCMEC/D3 cells, and the occludin band-shift induced by TNFalpha was suppressed by SB202190, an inhibitor for p38MAPK, and partly by U0126, the MEK1/2-ERK1/2 inhibitor.	U 0126	200-205	occludin	Homo sapiens	92-100
28170408-7	2017	TNFalpha also caused transient stimulation of p38MAPK and ERK1/2 in hCMEC/D3 cells, and the occludin band-shift induced by TNFalpha was suppressed by SB202190, an inhibitor for p38MAPK, and partly by U0126, the MEK1/2-ERK1/2 inhibitor.	U 0126	200-205	tumor necrosis factor	Homo sapiens	123-131
27889473-4	2017	Using reporter gene assays and Western blotting, we found that endothelial cell-conditioned medium (ECCM) led to nuclear translocation of beta-catenin and an increase in beta-catenin-dependent transcription that could be blocked by U0126, an inhibitor of the mitogen-activated protein kinase pathway.	U 0126	232-237	catenin beta 1	Homo sapiens	138-150
27889473-4	2017	Using reporter gene assays and Western blotting, we found that endothelial cell-conditioned medium (ECCM) led to nuclear translocation of beta-catenin and an increase in beta-catenin-dependent transcription that could be blocked by U0126, an inhibitor of the mitogen-activated protein kinase pathway.	U 0126	232-237	catenin beta 1	Homo sapiens	170-182
28151469-6	2017	Treatment with an antioxidant reagent or a specific inhibitor of MAPK, U0126, and a JNK inhibitor significantly attenuated the expression of BNIP3 triggered by UVB, followed by the induction of cell death by apoptosis.	U 0126	71-76	BCL2 interacting protein 3	Homo sapiens	141-146
28152057-7	2017	The nobiletin-induced phase delay was blocked by co-treatment with U0126, an ERK inhibitor.	U 0126	67-72	mitogen-activated protein kinase 1	Mus musculus	77-80
27776993-7	2017	Lixisenatide also reduced the Abeta25-35 acute application induced intracellular calcium overload, which was abolished by U0126, a specific MEK1/2 inhibitor.	U 0126	122-127	mitogen activated protein kinase kinase 1	Rattus norvegicus	140-146
28012925-7	2017	Interestingly, treatment with ERK1/2 inhibitor U0126 effectively abrogated CSE-triggered EMT and ERK1/2/AP-1 activation.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	30-36
28012925-7	2017	Interestingly, treatment with ERK1/2 inhibitor U0126 effectively abrogated CSE-triggered EMT and ERK1/2/AP-1 activation.	U 0126	47-52	IL2 inducible T cell kinase	Homo sapiens	89-92
28012925-7	2017	Interestingly, treatment with ERK1/2 inhibitor U0126 effectively abrogated CSE-triggered EMT and ERK1/2/AP-1 activation.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	97-103
28012925-7	2017	Interestingly, treatment with ERK1/2 inhibitor U0126 effectively abrogated CSE-triggered EMT and ERK1/2/AP-1 activation.	U 0126	47-52	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	104-108
26916448-10	2017	SB203580 (p38 inhibitor) and U0126 (MEK1/2 inhibitor) significantly inhibited the PM2.5 -induced enhanced contraction and increased mRNA and protein expression of muscarinic receptors.	U 0126	29-34	mitogen-activated protein kinase kinase 1	Mus musculus	36-42
27171670-9	2017	In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126.	U 0126	82-87	AKT serine/threonine kinase 1	Homo sapiens	36-39
27171670-9	2017	In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126.	U 0126	82-87	mitogen-activated protein kinase 3	Homo sapiens	44-50
27171670-9	2017	In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126.	U 0126	82-87	AKT serine/threonine kinase 1	Homo sapiens	143-146
27171670-9	2017	In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126.	U 0126	206-211	AKT serine/threonine kinase 1	Homo sapiens	36-39
27171670-9	2017	In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126.	U 0126	206-211	mitogen-activated protein kinase 3	Homo sapiens	44-50
27171670-9	2017	In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126.	U 0126	206-211	AKT serine/threonine kinase 1	Homo sapiens	143-146
27838497-5	2017	Blockade of this fentanyl-induced ERK activation by microinjection of U0126, an ERK inhibitor, into the CeLC reversed the behavioral hypersensitivity in a dose-dependent manner.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	34-37
27838497-5	2017	Blockade of this fentanyl-induced ERK activation by microinjection of U0126, an ERK inhibitor, into the CeLC reversed the behavioral hypersensitivity in a dose-dependent manner.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	80-83
27769854-3	2017	The inibitory action of L-AP4 was abrogated by (i) the mGlu7 receptor antagonist, XAP044; (ii) the C-terminal portion of type-2 G protein coupled receptor kinase; and (iii) the MAP kinase inhibitors, UO126 and PD98059.	U 0126	200-205	transcription factor AP-4	Homo sapiens	26-29
27975125-8	2017	We found that intracerebroventricular injection of the selective MAPK/ERK inhibitor U0126 (5 mug/2 mul) and the selective PI3K inhibitor LY294002 (10 nmol/2 mul) significantly inhibited the anti-immobility effect of Lu AA33810 in the FST in rats, suggesting that MAPK/ERK and PI3K signaling pathways could be involved in the antidepressant-like effect of Lu AA33810.	U 0126	84-89	Eph receptor B1	Rattus norvegicus	268-271
27574032-7	2017	A BMP inhibitor (LDN-193189) and Erk1/2 signaling pathway inhibitor (U0126) reduced these findings in the Tcf12 silencing group.	U 0126	69-74	mitogen-activated protein kinase 3	Mus musculus	33-39
27574032-7	2017	A BMP inhibitor (LDN-193189) and Erk1/2 signaling pathway inhibitor (U0126) reduced these findings in the Tcf12 silencing group.	U 0126	69-74	transcription factor 12	Mus musculus	106-111
29762991-8	2017	Conversely,after U0126 treatment,the expression levels of p-ERK1 /2,c-Myc and vimentin decreased significantly,while E-cadherin expression level increased.	U 0126	17-22	mitogen-activated protein kinase 1	Homo sapiens	60-67
29762991-8	2017	Conversely,after U0126 treatment,the expression levels of p-ERK1 /2,c-Myc and vimentin decreased significantly,while E-cadherin expression level increased.	U 0126	17-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	68-73
29762991-8	2017	Conversely,after U0126 treatment,the expression levels of p-ERK1 /2,c-Myc and vimentin decreased significantly,while E-cadherin expression level increased.	U 0126	17-22	vimentin	Homo sapiens	78-86
29762991-8	2017	Conversely,after U0126 treatment,the expression levels of p-ERK1 /2,c-Myc and vimentin decreased significantly,while E-cadherin expression level increased.	U 0126	17-22	cadherin 1	Homo sapiens	117-127
28286738-5	2017	PMA-induced activation of mTORC1 signaling was partially prevented by treatment with U0126 (a selective inhibitor of MEK1/2) or BIX-02189 (a selective inhibitor of MEK5) and completely blocked with BIM-I (a selective inhibitor of upstream PKC).	U 0126	85-90	CREB regulated transcription coactivator 1	Mus musculus	26-32
28286738-5	2017	PMA-induced activation of mTORC1 signaling was partially prevented by treatment with U0126 (a selective inhibitor of MEK1/2) or BIX-02189 (a selective inhibitor of MEK5) and completely blocked with BIM-I (a selective inhibitor of upstream PKC).	U 0126	85-90	mitogen-activated protein kinase kinase 1	Homo sapiens	117-123
28286738-6	2017	TSC2 phosphorylation at Ser664 (an ERK-dependent phosphorylation site) was prevented with U0126, and BIM-I treatment blocked PMA-induced phosphorylation of TSC2 at multiple residues (Ser664, Ser939, and Thr1462).	U 0126	90-95	TSC complex subunit 2	Homo sapiens	0-4
28286738-6	2017	TSC2 phosphorylation at Ser664 (an ERK-dependent phosphorylation site) was prevented with U0126, and BIM-I treatment blocked PMA-induced phosphorylation of TSC2 at multiple residues (Ser664, Ser939, and Thr1462).	U 0126	90-95	mitogen-activated protein kinase 1	Homo sapiens	35-38
28034754-5	2017	Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists.	U 0126	177-182	mitogen-activated protein kinase kinase 1	Mus musculus	36-42
28034754-5	2017	Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists.	U 0126	177-182	mitogen-activated protein kinase 3	Mus musculus	47-53
28034754-5	2017	Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists.	U 0126	177-182	nuclear receptor subfamily 1, group H, member 3	Mus musculus	80-83
28034754-5	2017	Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists.	U 0126	177-182	midkine	Mus musculus	36-39
28034754-5	2017	Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists.	U 0126	177-182	mitogen-activated protein kinase 1	Mus musculus	47-50
27888104-5	2017	To elucidate the role of ERK1/2 activated by the two PPARgamma agonists, the effect of U0126, an inhibitor of ERK1/2, on PPARgamma-agonist-induced cell death was examined.	U 0126	87-92	peroxisome proliferator activated receptor gamma	Homo sapiens	121-130
27888104-6	2017	Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death.	U 0126	28-33	latexin	Homo sapiens	24-27
27888104-6	2017	Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	88-94
27888104-6	2017	Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death.	U 0126	28-33	BCL2 apoptosis regulator	Homo sapiens	122-127
27816766-8	2017	A mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway inhibitor, U0126, significantly reduced FGF9-induced CCND1 mRNA expression to basal levels.	U 0126	105-110	fibroblast growth factor 9	Bos taurus	134-138
27816766-8	2017	A mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway inhibitor, U0126, significantly reduced FGF9-induced CCND1 mRNA expression to basal levels.	U 0126	105-110	cyclin D1	Bos taurus	147-152
27702388-9	2017	EGFR inhibitor (AG1478), PI3K-AKT inhibitor (LY294002), ERK inhibitor (U0126), and STAT3 inhibitor (STA-21) significantly blocked EGF-induced HF-MSC proliferation.	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	56-59
27702388-10	2017	Moreover, AG1478, LY294002, and U0126 significantly decreased p-EGFR, p-AKT, and p-ERK1/2 expression.	U 0126	32-37	epidermal growth factor receptor	Homo sapiens	64-68
27702388-10	2017	Moreover, AG1478, LY294002, and U0126 significantly decreased p-EGFR, p-AKT, and p-ERK1/2 expression.	U 0126	32-37	AKT serine/threonine kinase 1	Homo sapiens	72-75
27702388-10	2017	Moreover, AG1478, LY294002, and U0126 significantly decreased p-EGFR, p-AKT, and p-ERK1/2 expression.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	83-89
29926606-7	2017	The ERK1/2 pathway activator Staurosporine aglycone reduces the mRNA and protein expression of CLCA2 in rats PASMCs and the ERK1/2 pathway inhibitor U0126 induces the upregulation of the mRNA and protein expressiosn of CLCA2 in rats PASMCs.	U 0126	149-154	mitogen activated protein kinase 3	Rattus norvegicus	4-10
29926606-7	2017	The ERK1/2 pathway activator Staurosporine aglycone reduces the mRNA and protein expression of CLCA2 in rats PASMCs and the ERK1/2 pathway inhibitor U0126 induces the upregulation of the mRNA and protein expressiosn of CLCA2 in rats PASMCs.	U 0126	149-154	chloride channel accessory 5	Rattus norvegicus	95-100
29926606-7	2017	The ERK1/2 pathway activator Staurosporine aglycone reduces the mRNA and protein expression of CLCA2 in rats PASMCs and the ERK1/2 pathway inhibitor U0126 induces the upregulation of the mRNA and protein expressiosn of CLCA2 in rats PASMCs.	U 0126	149-154	mitogen activated protein kinase 3	Rattus norvegicus	124-130
29926606-7	2017	The ERK1/2 pathway activator Staurosporine aglycone reduces the mRNA and protein expression of CLCA2 in rats PASMCs and the ERK1/2 pathway inhibitor U0126 induces the upregulation of the mRNA and protein expressiosn of CLCA2 in rats PASMCs.	U 0126	149-154	chloride channel accessory 5	Rattus norvegicus	219-224
28081631-6	2017	In addition, we found an increase in the phosphorylation of extracellular signal-regulated kinase (ERK, Thr202/Thr204) and AKT (Ser473) after BA treatment, and inhibition of ERK activation by the pharmacological inhibitor U0126 or ERK siRNA blocked BA-induced autophagy.	U 0126	222-227	mitogen-activated protein kinase 1	Homo sapiens	60-97
28081631-6	2017	In addition, we found an increase in the phosphorylation of extracellular signal-regulated kinase (ERK, Thr202/Thr204) and AKT (Ser473) after BA treatment, and inhibition of ERK activation by the pharmacological inhibitor U0126 or ERK siRNA blocked BA-induced autophagy.	U 0126	222-227	mitogen-activated protein kinase 1	Homo sapiens	99-102
28081631-6	2017	In addition, we found an increase in the phosphorylation of extracellular signal-regulated kinase (ERK, Thr202/Thr204) and AKT (Ser473) after BA treatment, and inhibition of ERK activation by the pharmacological inhibitor U0126 or ERK siRNA blocked BA-induced autophagy.	U 0126	222-227	mitogen-activated protein kinase 1	Homo sapiens	174-177
28081631-6	2017	In addition, we found an increase in the phosphorylation of extracellular signal-regulated kinase (ERK, Thr202/Thr204) and AKT (Ser473) after BA treatment, and inhibition of ERK activation by the pharmacological inhibitor U0126 or ERK siRNA blocked BA-induced autophagy.	U 0126	222-227	mitogen-activated protein kinase 1	Homo sapiens	174-177
28395336-10	2017	An ERK1/2 inhibitor (U0126) suppressed the PGC proliferation that would otherwise be stimulated by high FGF9 treatment, and increased Nanos2 expression in XY PGCs.	U 0126	21-26	mitogen-activated protein kinase 3	Mus musculus	3-9
28395342-7	2017	Also, the abundance of cytoplasmic p-AKT protein was decreased by Wortmannin and U0126, and p-ERK1/2 protein was reduced only by U0126.	U 0126	81-86	AKT serine/threonine kinase 1	Homo sapiens	37-40
28395342-7	2017	Also, the abundance of cytoplasmic p-AKT protein was decreased by Wortmannin and U0126, and p-ERK1/2 protein was reduced only by U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	94-100
28395336-10	2017	An ERK1/2 inhibitor (U0126) suppressed the PGC proliferation that would otherwise be stimulated by high FGF9 treatment, and increased Nanos2 expression in XY PGCs.	U 0126	21-26	progastricsin (pepsinogen C)	Mus musculus	43-46
28642873-8	2017	Finally, by applying the ERK1/2 and p38 inhibitors, U0126 and SB203580, we demonstrated that the SAA-induced VSMC phenotype switch was p38-dependent.	U 0126	52-57	serum amyloid A1 cluster	Homo sapiens	97-100
28395336-10	2017	An ERK1/2 inhibitor (U0126) suppressed the PGC proliferation that would otherwise be stimulated by high FGF9 treatment, and increased Nanos2 expression in XY PGCs.	U 0126	21-26	fibroblast growth factor 9	Mus musculus	104-108
28395336-10	2017	An ERK1/2 inhibitor (U0126) suppressed the PGC proliferation that would otherwise be stimulated by high FGF9 treatment, and increased Nanos2 expression in XY PGCs.	U 0126	21-26	nanos C2HC-type zinc finger 2	Mus musculus	134-140
28395342-6	2017	In addition, FGF2 increases phosphorylation of AKT, P70S6K, S6, ERK1/2, JNK, P38, and P90RSK in a time-dependent manner, and increases in their expression was suppressed by Wortmannin (a phosphatidylinositol 3-kinase [PI3K] inhibitor), U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and SB203580 (a P38 inhibitor) based on western blot analyses.	U 0126	236-241	fibroblast growth factor 2	Homo sapiens	13-17
27778412-8	2017	However, the increased IL-6 was blocked by pre-treatment of MLO-Y4 cells with the ERK1/2 inhibitor U0126 (10 microM), and the enhanced RANKL was blocked by the STAT3 inhibitor S3I-201 (100 microM).	U 0126	99-104	interleukin 6	Mus musculus	23-27
27778412-8	2017	However, the increased IL-6 was blocked by pre-treatment of MLO-Y4 cells with the ERK1/2 inhibitor U0126 (10 microM), and the enhanced RANKL was blocked by the STAT3 inhibitor S3I-201 (100 microM).	U 0126	99-104	mitogen-activated protein kinase 3	Mus musculus	82-88
29268268-6	2017	Three specific MAPK blockers, U0126, SB20358 and SP600125, were used to block ERK1/2, P38 and JNK during trans-differentiation.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	78-84
29268268-6	2017	Three specific MAPK blockers, U0126, SB20358 and SP600125, were used to block ERK1/2, P38 and JNK during trans-differentiation.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	86-89
29268268-6	2017	Three specific MAPK blockers, U0126, SB20358 and SP600125, were used to block ERK1/2, P38 and JNK during trans-differentiation.	U 0126	30-35	mitogen-activated protein kinase 8	Homo sapiens	94-97
28810249-9	2017	Furthermore, we observed that CXCL10 inhibition resulted in less activation of ERK phosphorylation, and ERK pathway inhibition by a specific inhibitor, U0126, prevented CXCL10 induced MRMC proliferation and the activation of phosphorylated ERK.	U 0126	152-157	mitogen-activated protein kinase 1	Mus musculus	104-107
28810249-9	2017	Furthermore, we observed that CXCL10 inhibition resulted in less activation of ERK phosphorylation, and ERK pathway inhibition by a specific inhibitor, U0126, prevented CXCL10 induced MRMC proliferation and the activation of phosphorylated ERK.	U 0126	152-157	chemokine (C-X-C motif) ligand 10	Mus musculus	169-175
28810249-9	2017	Furthermore, we observed that CXCL10 inhibition resulted in less activation of ERK phosphorylation, and ERK pathway inhibition by a specific inhibitor, U0126, prevented CXCL10 induced MRMC proliferation and the activation of phosphorylated ERK.	U 0126	152-157	mitogen-activated protein kinase 1	Mus musculus	104-107
29190630-9	2017	Treatment with a specific MEK inhibitor (U0126) enhanced the inhibitory effects of alpha-mangostin on cell migration and invasion, and the phosphorylation of ERK and MEK.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	26-29
28977794-15	2017	Inhibition of ERK1/2 phosphorylation with U0126 decreased C2C12 cell differentiation.	U 0126	42-47	mitogen-activated protein kinase 3	Mus musculus	14-20
29190630-9	2017	Treatment with a specific MEK inhibitor (U0126) enhanced the inhibitory effects of alpha-mangostin on cell migration and invasion, and the phosphorylation of ERK and MEK.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	158-161
29190630-9	2017	Treatment with a specific MEK inhibitor (U0126) enhanced the inhibitory effects of alpha-mangostin on cell migration and invasion, and the phosphorylation of ERK and MEK.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	166-169
29190630-10	2017	Moreover, alpha-mangostin inhibited the expression of the MMP-9 mRNA levels as well as the activity of MMP-9 promoter, and these suppressive effects were further enhanced by U0126.	U 0126	174-179	matrix metallopeptidase 9	Homo sapiens	58-63
28491103-7	2017	However, the phosphorylation enhancement was partially abolished in the presence of LY294002 (PI3K inhibitor) and U0126 (ERK inhibitor).	U 0126	114-119	Eph receptor B1	Rattus norvegicus	121-124
26825658-8	2017	Moreover, tensile force activated extracellular signal-related kinase 1/2 (ERK1/2) signaling in sagittal sutures, and the ERK1/2 inhibitor, U0126, partially inhibited tensile-force-induced Ctgf expression.	U 0126	140-145	mitogen-activated protein kinase 3	Homo sapiens	122-128
29234375-5	2017	Furthermore, the Kidney-replenishing herb treatment stimulated the phosphorylation of ERK1/2, and blocking the signaling pathway by mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited Kidney-replenishing herb-induced SOCS-3 transcription, depressed proliferation, and promoted apoptosis of human trophoblasts.	U 0126	180-185	mitogen-activated protein kinase 3	Homo sapiens	86-92
29234375-5	2017	Furthermore, the Kidney-replenishing herb treatment stimulated the phosphorylation of ERK1/2, and blocking the signaling pathway by mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited Kidney-replenishing herb-induced SOCS-3 transcription, depressed proliferation, and promoted apoptosis of human trophoblasts.	U 0126	180-185	mitogen-activated protein kinase 3	Homo sapiens	158-162
29234375-5	2017	Furthermore, the Kidney-replenishing herb treatment stimulated the phosphorylation of ERK1/2, and blocking the signaling pathway by mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited Kidney-replenishing herb-induced SOCS-3 transcription, depressed proliferation, and promoted apoptosis of human trophoblasts.	U 0126	180-185	mitogen-activated protein kinase kinase 7	Homo sapiens	164-167
29234375-5	2017	Furthermore, the Kidney-replenishing herb treatment stimulated the phosphorylation of ERK1/2, and blocking the signaling pathway by mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited Kidney-replenishing herb-induced SOCS-3 transcription, depressed proliferation, and promoted apoptosis of human trophoblasts.	U 0126	180-185	suppressor of cytokine signaling 3	Homo sapiens	230-236
28183201-7	2017	U0126 (an ERK1/2 MAPK inhibitor) and SB203580 (a p38 MAPK inhibitor) inhibited TiO2 NPs-induced MUC5B expression.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	10-16
28183201-7	2017	U0126 (an ERK1/2 MAPK inhibitor) and SB203580 (a p38 MAPK inhibitor) inhibited TiO2 NPs-induced MUC5B expression.	U 0126	0-5	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	96-101
26825658-8	2017	Moreover, tensile force activated extracellular signal-related kinase 1/2 (ERK1/2) signaling in sagittal sutures, and the ERK1/2 inhibitor, U0126, partially inhibited tensile-force-induced Ctgf expression.	U 0126	140-145	cellular communication network factor 2	Homo sapiens	189-193
27237101-12	2017	This effect is reversed by the beta (beta)-adrenoceptor antagonist propranolol, extracellular signal-regulated kinases (ERK) inhibitor U0126, and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	U 0126	135-140	mitogen-activated protein kinase 1	Homo sapiens	80-118
27237101-12	2017	This effect is reversed by the beta (beta)-adrenoceptor antagonist propranolol, extracellular signal-regulated kinases (ERK) inhibitor U0126, and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	U 0126	135-140	mitogen-activated protein kinase 1	Homo sapiens	120-123
27237101-14	2017	NE up-regulates LPS-induced c-Fos expression, which is counteracted by propranolol, U0126, and SP600125.	U 0126	84-89	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
27035885-5	2017	The role of the ERK1/2 pathway was investigated by using the pharmacological inhibitor U0126.	U 0126	87-92	mitogen-activated protein kinase 3	Homo sapiens	16-22
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	mitogen-activated protein kinase 3	Mus musculus	68-74
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	jun proto-oncogene	Mus musculus	129-134
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	matrix metallopeptidase 2	Mus musculus	155-160
28642873-8	2017	Finally, by applying the ERK1/2 and p38 inhibitors, U0126 and SB203580, we demonstrated that the SAA-induced VSMC phenotype switch was p38-dependent.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	135-138
27734226-7	2017	MEK1/2 inhibitor, U0126, blocks C1ql1/Ctrp14-, and C1ql4/Ctrp11-induced capillary tube formation and cell migration.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
27734226-7	2017	MEK1/2 inhibitor, U0126, blocks C1ql1/Ctrp14-, and C1ql4/Ctrp11-induced capillary tube formation and cell migration.	U 0126	18-23	complement C1q like 1	Homo sapiens	32-37
27734226-7	2017	MEK1/2 inhibitor, U0126, blocks C1ql1/Ctrp14-, and C1ql4/Ctrp11-induced capillary tube formation and cell migration.	U 0126	18-23	complement C1q like 4	Homo sapiens	51-56
27734226-7	2017	MEK1/2 inhibitor, U0126, blocks C1ql1/Ctrp14-, and C1ql4/Ctrp11-induced capillary tube formation and cell migration.	U 0126	18-23	complement C1q like 4	Homo sapiens	57-63
28337946-10	2017	Furthermore, trinitrobenzene sulfonic acid-induced extracellular signal-regulated kinase activation and Nav1.8 up-regulation in dorsal root ganglias were reversed by intrathecal application with AMD3100 as well as by blockade of extracellular signal-regulated kinase activation by intrathecal U0126.	U 0126	293-298	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	104-110
27840956-6	2017	HGF-stimulated cell motility of ARMS cell lines was inhibited by U0126 (ERK1/2 inhibitor) but was only partially inhibited by PD98059 (ERK1 inhibitor) or rapamycin (mTOR inhibitor) as observed in wound-healing and migration assays.	U 0126	65-70	hepatocyte growth factor	Homo sapiens	0-3
27840956-6	2017	HGF-stimulated cell motility of ARMS cell lines was inhibited by U0126 (ERK1/2 inhibitor) but was only partially inhibited by PD98059 (ERK1 inhibitor) or rapamycin (mTOR inhibitor) as observed in wound-healing and migration assays.	U 0126	65-70	mitogen-activated protein kinase 3	Homo sapiens	72-78
27840956-6	2017	HGF-stimulated cell motility of ARMS cell lines was inhibited by U0126 (ERK1/2 inhibitor) but was only partially inhibited by PD98059 (ERK1 inhibitor) or rapamycin (mTOR inhibitor) as observed in wound-healing and migration assays.	U 0126	65-70	mitogen-activated protein kinase 3	Homo sapiens	72-76
27840956-7	2017	Western blotting revealed that ERK1/2 was dephosphorylated by U0126 to a higher extent than by PD98059 in the ARMS cells.	U 0126	62-67	mitogen-activated protein kinase 3	Homo sapiens	31-37
28281844-9	2017	SDF-1 promoted the proliferation of SGC-7901 cells, the phosphorylation of ERK1/2, p38 and CXCR7 knockdown distinctly reversed these changes; the proliferation stimulated with SDF-1 was attenuated by U0126 (MEK1/2 inhibitor).	U 0126	200-205	C-X-C motif chemokine ligand 12	Homo sapiens	0-5
28281844-9	2017	SDF-1 promoted the proliferation of SGC-7901 cells, the phosphorylation of ERK1/2, p38 and CXCR7 knockdown distinctly reversed these changes; the proliferation stimulated with SDF-1 was attenuated by U0126 (MEK1/2 inhibitor).	U 0126	200-205	mitogen-activated protein kinase 3	Homo sapiens	75-81
28281844-9	2017	SDF-1 promoted the proliferation of SGC-7901 cells, the phosphorylation of ERK1/2, p38 and CXCR7 knockdown distinctly reversed these changes; the proliferation stimulated with SDF-1 was attenuated by U0126 (MEK1/2 inhibitor).	U 0126	200-205	mitogen-activated protein kinase 1	Homo sapiens	83-86
28281844-9	2017	SDF-1 promoted the proliferation of SGC-7901 cells, the phosphorylation of ERK1/2, p38 and CXCR7 knockdown distinctly reversed these changes; the proliferation stimulated with SDF-1 was attenuated by U0126 (MEK1/2 inhibitor).	U 0126	200-205	C-X-C motif chemokine ligand 12	Homo sapiens	176-181
28281844-9	2017	SDF-1 promoted the proliferation of SGC-7901 cells, the phosphorylation of ERK1/2, p38 and CXCR7 knockdown distinctly reversed these changes; the proliferation stimulated with SDF-1 was attenuated by U0126 (MEK1/2 inhibitor).	U 0126	200-205	mitogen-activated protein kinase kinase 1	Homo sapiens	207-213
28097093-5	2017	Treatment of human umbilical vein endothelial cells (HUVECs) with Akt inhibitor LY294002 results in diminished miR-20a and miR-31 production, while Erk inhibitor U0126 prevented VEGF-stimulated expression of miR-20a but not that of miR-31.	U 0126	162-167	mitogen-activated protein kinase 1	Homo sapiens	148-151
28097093-5	2017	Treatment of human umbilical vein endothelial cells (HUVECs) with Akt inhibitor LY294002 results in diminished miR-20a and miR-31 production, while Erk inhibitor U0126 prevented VEGF-stimulated expression of miR-20a but not that of miR-31.	U 0126	162-167	vascular endothelial growth factor A	Homo sapiens	178-182
28097093-5	2017	Treatment of human umbilical vein endothelial cells (HUVECs) with Akt inhibitor LY294002 results in diminished miR-20a and miR-31 production, while Erk inhibitor U0126 prevented VEGF-stimulated expression of miR-20a but not that of miR-31.	U 0126	162-167	microRNA 20a	Homo sapiens	208-215
28097093-5	2017	Treatment of human umbilical vein endothelial cells (HUVECs) with Akt inhibitor LY294002 results in diminished miR-20a and miR-31 production, while Erk inhibitor U0126 prevented VEGF-stimulated expression of miR-20a but not that of miR-31.	U 0126	162-167	microRNA 31	Homo sapiens	232-238
27852061-8	2016	Treating heterologously transfected thyroid cells with MEK inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO promoter activity.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
27852061-8	2016	Treating heterologously transfected thyroid cells with MEK inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO promoter activity.	U 0126	69-74	forkhead box E1	Homo sapiens	85-90
27852061-8	2016	Treating heterologously transfected thyroid cells with MEK inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO promoter activity.	U 0126	69-74	ETS transcription factor ELK1	Homo sapiens	91-95
27852061-8	2016	Treating heterologously transfected thyroid cells with MEK inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO promoter activity.	U 0126	69-74	telomerase reverse transcriptase	Homo sapiens	121-125
27852061-8	2016	Treating heterologously transfected thyroid cells with MEK inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO promoter activity.	U 0126	69-74	thyroid peroxidase	Homo sapiens	130-133
27720869-9	2016	In addition, the application of ERK1/2 inhibitors (PD98059 and U0126) abrogated the nuclear translocation of Egr1 induced by APAP in hepatocytes.	U 0126	63-68	mitogen-activated protein kinase 3	Mus musculus	32-38
27720869-9	2016	In addition, the application of ERK1/2 inhibitors (PD98059 and U0126) abrogated the nuclear translocation of Egr1 induced by APAP in hepatocytes.	U 0126	63-68	early growth response 1	Mus musculus	109-113
27836799-9	2016	Interestingly, only the ERK inhibitor U0126, but not the JNK inhibitor SP600125 and p38 MAPK inhibitor SB203580, weakened the induction of 0.3muM cucurbitacin-I in hypertrophy, autophagy and apoptosis.	U 0126	38-43	Eph receptor B1	Rattus norvegicus	24-27
27835878-13	2016	Intriguingly, pretreatment with U0126, an inhibitor of ERK1/2, had similar effects with apocynin.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	55-61
27868128-6	2016	By utilizing the ERK inhibitor U0126 and the NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC), we confirmed that STIM1 can be regulated by ERK and NF-kappaB.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	17-20
27868128-6	2016	By utilizing the ERK inhibitor U0126 and the NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC), we confirmed that STIM1 can be regulated by ERK and NF-kappaB.	U 0126	31-36	stromal interaction molecule 1	Homo sapiens	119-124
27868128-6	2016	By utilizing the ERK inhibitor U0126 and the NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC), we confirmed that STIM1 can be regulated by ERK and NF-kappaB.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	145-148
27522508-11	2016	Furthermore, expression of Runx2, ALP and OCN, the osteogenic regulators, was reversed by SB203580 and U0126.	U 0126	103-108	RUNX family transcription factor 2	Homo sapiens	27-32
27522508-11	2016	Furthermore, expression of Runx2, ALP and OCN, the osteogenic regulators, was reversed by SB203580 and U0126.	U 0126	103-108	ATHS	Homo sapiens	34-37
27522508-11	2016	Furthermore, expression of Runx2, ALP and OCN, the osteogenic regulators, was reversed by SB203580 and U0126.	U 0126	103-108	bone gamma-carboxyglutamate protein	Homo sapiens	42-45
27194217-9	2016	The role of extracellular signal-regulated kinase (ERK) 1/2 and/or ERK 5 signalling in PCB-induced ROS production was implicated through the reduction in ROS in the presence of the specific inhibitor U0126, whereas reduced ROS production after the use of SB203580 and SP600125 indicated the involvement of the p38 mitogen-activated protein kinase (MAPK) and c-Jun amino-terminal kinase (JNK) pathways, respectively.	U 0126	200-205	mitogen-activated protein kinase 3	Homo sapiens	12-59
27194217-9	2016	The role of extracellular signal-regulated kinase (ERK) 1/2 and/or ERK 5 signalling in PCB-induced ROS production was implicated through the reduction in ROS in the presence of the specific inhibitor U0126, whereas reduced ROS production after the use of SB203580 and SP600125 indicated the involvement of the p38 mitogen-activated protein kinase (MAPK) and c-Jun amino-terminal kinase (JNK) pathways, respectively.	U 0126	200-205	pyruvate carboxylase	Homo sapiens	87-90
27925454-5	2016	However, the pretreatment of Rap1A-overexpressing cells with the Notch inhibitor DAPT or ERK inhibitor (U0126) inhibited the up-regulated expression of those molecules.	U 0126	104-109	RAP1A, member of RAS oncogene family	Homo sapiens	29-34
27925454-5	2016	However, the pretreatment of Rap1A-overexpressing cells with the Notch inhibitor DAPT or ERK inhibitor (U0126) inhibited the up-regulated expression of those molecules.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	89-92
26303380-4	2016	The extracellular signal-regulated kinases (ERK) inhibitor U0126 suppressed cerulein-induced phosphorylation of serine 431 and reorganization of K8.	U 0126	59-64	mitogen-activated protein kinase 1	Homo sapiens	4-42
26303380-4	2016	The extracellular signal-regulated kinases (ERK) inhibitor U0126 suppressed cerulein-induced phosphorylation of serine 431 and reorganization of K8.	U 0126	59-64	mitogen-activated protein kinase 1	Homo sapiens	44-47
26303380-4	2016	The extracellular signal-regulated kinases (ERK) inhibitor U0126 suppressed cerulein-induced phosphorylation of serine 431 and reorganization of K8.	U 0126	59-64	keratin 8	Homo sapiens	145-147
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	matrix metallopeptidase 9	Mus musculus	162-167
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	mast cell protease 1	Mus musculus	169-207
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	chemokine (C-C motif) ligand 5	Mus musculus	213-275
29348704-5	2017	Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES).	U 0126	18-23	chemokine (C-C motif) ligand 5	Mus musculus	277-283
27151923-8	2016	To interfere with PDGF-B signaling, we injected nephritic rats with PDGF-B neutralizing aptamers or the MEK/ERK inhibitor U0126.	U 0126	122-127	Eph receptor B1	Rattus norvegicus	108-111
26970256-8	2016	Moreover, treatment of JAR and JEG3 cells with both apigenin and pharmacological inhibitors of PI3K/AKT (LY294002) and ERK1/2 (U0126) revealed synergistic anti-proliferative effects.	U 0126	127-132	mitogen-activated protein kinase 3	Homo sapiens	119-125
27748912-11	2016	Mechanistically, the AKT inhibitor (AKT inhibitor IV) and ERK inhibitor (U0126) significantly decreased the expression of Snail, as well as the levels of fibronectin and CTGF which were induced by high glucose.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	58-61
27748912-11	2016	Mechanistically, the AKT inhibitor (AKT inhibitor IV) and ERK inhibitor (U0126) significantly decreased the expression of Snail, as well as the levels of fibronectin and CTGF which were induced by high glucose.	U 0126	73-78	snail family transcriptional repressor 1	Homo sapiens	122-127
27748912-11	2016	Mechanistically, the AKT inhibitor (AKT inhibitor IV) and ERK inhibitor (U0126) significantly decreased the expression of Snail, as well as the levels of fibronectin and CTGF which were induced by high glucose.	U 0126	73-78	fibronectin 1	Homo sapiens	154-165
27748912-11	2016	Mechanistically, the AKT inhibitor (AKT inhibitor IV) and ERK inhibitor (U0126) significantly decreased the expression of Snail, as well as the levels of fibronectin and CTGF which were induced by high glucose.	U 0126	73-78	cellular communication network factor 2	Homo sapiens	170-174
27167250-11	2016	In the presence of the MEK1/2 inhibitor U0126, cell proliferation was further reduced by rapamycin treatment.	U 0126	40-45	mitogen-activated protein kinase kinase 1	Homo sapiens	23-29
27647309-8	2016	Furthermore, when ERK signaling was blocked by the inhibitor U0126, the neuronal marker expression of NG2 cells was substantially increased.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	18-21
26696494-7	2016	In addition, inhibition of extracellular protein kinase (ERK) with U0126 shared with the AST the same beneficial effects in reducing Abeta-induced apoptosis.	U 0126	67-72	Eph receptor B1	Rattus norvegicus	27-55
26696494-7	2016	In addition, inhibition of extracellular protein kinase (ERK) with U0126 shared with the AST the same beneficial effects in reducing Abeta-induced apoptosis.	U 0126	67-72	Eph receptor B1	Rattus norvegicus	57-60
26696494-7	2016	In addition, inhibition of extracellular protein kinase (ERK) with U0126 shared with the AST the same beneficial effects in reducing Abeta-induced apoptosis.	U 0126	67-72	amyloid beta precursor protein	Rattus norvegicus	133-138
26808296-5	2016	In addition, infection with H. pylori resulted in an increased intracellular level of Snail in gastric cancer cells, which was abrogated in the presence of U0126 and LY294002, inhibitors of MEK/Erk and PI3K/Akt pathways, respectively.	U 0126	156-161	snail family transcriptional repressor 1	Homo sapiens	86-91
26808296-5	2016	In addition, infection with H. pylori resulted in an increased intracellular level of Snail in gastric cancer cells, which was abrogated in the presence of U0126 and LY294002, inhibitors of MEK/Erk and PI3K/Akt pathways, respectively.	U 0126	156-161	mitogen-activated protein kinase 1	Homo sapiens	194-197
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	zinc fingers and homeoboxes 2	Homo sapiens	47-50
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	mitogen-activated protein kinase 1	Homo sapiens	55-58
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	Parkinsonism associated deglycase	Homo sapiens	145-149
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	mitogen-activated protein kinase 1	Homo sapiens	178-181
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	Parkinsonism associated deglycase	Homo sapiens	217-221
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	nuclear receptor subfamily 4 group A member 2	Homo sapiens	232-237
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	zinc fingers and homeoboxes 2	Homo sapiens	255-258
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	mitogen-activated protein kinase kinase 7	Homo sapiens	259-262
26873851-4	2016	Further investigation showed that signaling of Raf/MEK/ERK MAPKs is involved in this regulatory process and that activation induced by exogenous DJ-1 is antagonized by U0126, an ERK pathway inhibitor, indicating that DJ-1 modulates Nurr1 activity via the Raf/MEK/ERK pathway.	U 0126	168-173	mitogen-activated protein kinase 1	Homo sapiens	178-181
27678157-8	2016	Phosphorylation of ERK was abolished in presence of U0126, further confirming the role of ERK pathway in vorinostat-induced differentiation of NS-1 cells.	U 0126	52-57	Eph receptor B1	Rattus norvegicus	19-22
27678157-8	2016	Phosphorylation of ERK was abolished in presence of U0126, further confirming the role of ERK pathway in vorinostat-induced differentiation of NS-1 cells.	U 0126	52-57	Eph receptor B1	Rattus norvegicus	90-93
27770611-7	2016	Inactivation of mitogen-activated protein kinase (MAPK3/1) by U0126 inhibited LH-induced CREB phosphorylation and EGF-like factors gene expression, whereas the activation of LH receptor increased Akt/protein kinase B phosphorylation, which is involved in LH-induced CREB phosphorylation and the expression of EGF-like factors.	U 0126	62-67	mitogen-activated protein kinase 3	Homo sapiens	50-57
27770611-7	2016	Inactivation of mitogen-activated protein kinase (MAPK3/1) by U0126 inhibited LH-induced CREB phosphorylation and EGF-like factors gene expression, whereas the activation of LH receptor increased Akt/protein kinase B phosphorylation, which is involved in LH-induced CREB phosphorylation and the expression of EGF-like factors.	U 0126	62-67	cAMP responsive element binding protein 1	Homo sapiens	89-93
27770611-7	2016	Inactivation of mitogen-activated protein kinase (MAPK3/1) by U0126 inhibited LH-induced CREB phosphorylation and EGF-like factors gene expression, whereas the activation of LH receptor increased Akt/protein kinase B phosphorylation, which is involved in LH-induced CREB phosphorylation and the expression of EGF-like factors.	U 0126	62-67	protein tyrosine kinase 2 beta	Homo sapiens	200-216
27770611-7	2016	Inactivation of mitogen-activated protein kinase (MAPK3/1) by U0126 inhibited LH-induced CREB phosphorylation and EGF-like factors gene expression, whereas the activation of LH receptor increased Akt/protein kinase B phosphorylation, which is involved in LH-induced CREB phosphorylation and the expression of EGF-like factors.	U 0126	62-67	cAMP responsive element binding protein 1	Homo sapiens	266-270
27878252-6	2016	The ERK1/2 specific inhibitor, U0126, augmented the inhibitory effects of TMZ on the proliferation, migration and invasion of the glioma C6 cells, and the mitogen-activated protein kinase kinase/ERK pathway activator, curcumin, attenuated the inhibitory effects of TMZ on the proliferation and motility of the glioma C6 cells.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	4-10
26991852-7	2016	The results showed that coumestrol-induced phosphorylation of ERK1/2 MAPK and P90RSK was blocked by U0126.	U 0126	100-105	mitogen-activated protein kinase 3	Sus scrofa	62-68
27878252-6	2016	The ERK1/2 specific inhibitor, U0126, augmented the inhibitory effects of TMZ on the proliferation, migration and invasion of the glioma C6 cells, and the mitogen-activated protein kinase kinase/ERK pathway activator, curcumin, attenuated the inhibitory effects of TMZ on the proliferation and motility of the glioma C6 cells.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	4-7
27592408-9	2016	Moreover, the effect of Apelin-13 to up-regulate VEGF was suppressed by extracellular signal-regulated kinase (ERK) inhibitor U0126 and phosphatidylinositol 3"-kinase (PI3K) inhibitor LY294002.	U 0126	126-131	vascular endothelial growth factor A	Homo sapiens	49-53
27592408-9	2016	Moreover, the effect of Apelin-13 to up-regulate VEGF was suppressed by extracellular signal-regulated kinase (ERK) inhibitor U0126 and phosphatidylinositol 3"-kinase (PI3K) inhibitor LY294002.	U 0126	126-131	mitogen-activated protein kinase 1	Homo sapiens	111-114
27748943-5	2016	When ERK activity was inhibited by U0126, the expression of c-Fos also decreased.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	5-8
27748943-5	2016	When ERK activity was inhibited by U0126, the expression of c-Fos also decreased.	U 0126	35-40	FBJ osteosarcoma oncogene	Mus musculus	60-65
28101233-5	2016	MMP-1 induction was blocked by the mitogen-activated protein kinase (MAPK) kinase inhibitors PD98059 and U0126.	U 0126	105-110	matrix metallopeptidase 1	Homo sapiens	0-5
27878252-7	2016	Additionally, the western blotting in the present study demonstrated that TMZ and U0126 decreased the expression of vascular endothelial growth factor-C (VEGF-C), and the expression level was restored by curcumin, suggesting that VEGF-C may be the downstream effector of ERK1/2.	U 0126	82-87	vascular endothelial growth factor C	Homo sapiens	116-152
27878252-7	2016	Additionally, the western blotting in the present study demonstrated that TMZ and U0126 decreased the expression of vascular endothelial growth factor-C (VEGF-C), and the expression level was restored by curcumin, suggesting that VEGF-C may be the downstream effector of ERK1/2.	U 0126	82-87	vascular endothelial growth factor C	Homo sapiens	154-160
27878252-7	2016	Additionally, the western blotting in the present study demonstrated that TMZ and U0126 decreased the expression of vascular endothelial growth factor-C (VEGF-C), and the expression level was restored by curcumin, suggesting that VEGF-C may be the downstream effector of ERK1/2.	U 0126	82-87	vascular endothelial growth factor C	Homo sapiens	230-236
27878252-7	2016	Additionally, the western blotting in the present study demonstrated that TMZ and U0126 decreased the expression of vascular endothelial growth factor-C (VEGF-C), and the expression level was restored by curcumin, suggesting that VEGF-C may be the downstream effector of ERK1/2.	U 0126	82-87	mitogen-activated protein kinase 3	Homo sapiens	271-277
27669639-7	2016	In addition, dNPA increased phosphorylation of extracellular signal-regulated kinase (ERK) in Neuro 2A cells, which was completely antagonized by pretreatment with U0126.	U 0126	164-169	mitogen-activated protein kinase 1	Mus musculus	47-84
27669639-7	2016	In addition, dNPA increased phosphorylation of extracellular signal-regulated kinase (ERK) in Neuro 2A cells, which was completely antagonized by pretreatment with U0126.	U 0126	164-169	mitogen-activated protein kinase 1	Mus musculus	86-89
27668317-1	2016	BACKGROUND: To assess the effects of the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor PJ34 and ERK1/2 inhibitor U0126 on the proliferation and epithelial mesenchymal transitions (EMT) of cisplatin resistant ovarian cancer SKOV-3 cells.	U 0126	117-122	mitogen-activated protein kinase 3	Homo sapiens	100-106
27668317-3	2016	Expression changes of E-cadherin and vimentin with PJ34 and U0126 treatment was examined using Western blot and quantitative PCR.	U 0126	60-65	cadherin 1	Homo sapiens	22-32
27668317-3	2016	Expression changes of E-cadherin and vimentin with PJ34 and U0126 treatment was examined using Western blot and quantitative PCR.	U 0126	60-65	vimentin	Homo sapiens	37-45
27668317-6	2016	PJ34 and U0126 suppressed the expression of vimentin and enhanced the expression of E-cadherin.	U 0126	9-14	vimentin	Homo sapiens	44-52
27668317-6	2016	PJ34 and U0126 suppressed the expression of vimentin and enhanced the expression of E-cadherin.	U 0126	9-14	cadherin 1	Homo sapiens	84-94
27668317-9	2016	PJ34 inhibited the proliferation and invasion of SKOV-3 cells which can be enhanced by ERK1/2 inhibitor U0126.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	87-93
27638195-9	2016	Pharmacological inhibition of ERK1/2 by the MEK1/2 inhibitor U0126 and of Akt by MK-2206 virtually abolished NIS stimulation by TSH and the synergistic effect of IGF-1.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	30-36
27638195-9	2016	Pharmacological inhibition of ERK1/2 by the MEK1/2 inhibitor U0126 and of Akt by MK-2206 virtually abolished NIS stimulation by TSH and the synergistic effect of IGF-1.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Homo sapiens	44-50
27638195-9	2016	Pharmacological inhibition of ERK1/2 by the MEK1/2 inhibitor U0126 and of Akt by MK-2206 virtually abolished NIS stimulation by TSH and the synergistic effect of IGF-1.	U 0126	61-66	insulin like growth factor 1	Homo sapiens	162-167
27764816-7	2016	Finally, inhibition of MEK/ERK signalling by U0126 resulted in a reduction of DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this oncogenic pathway.Taken together, our data indicate that altered expression of DNMT3B plays a key role in ERMS development since its silencing is able to reverse cell cancer phenotype by rescuing myogenic program.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	23-26
27592458-11	2016	Blockage of the ERK1/2 signaling pathway and NF-kappaB using the MEK1/2 inhibitor (PD98059 and U0126) or IkappaB kinase inhibitor (wedelolactone) significantly abolished Hcy-induced up-regulation of ETB receptor.	U 0126	95-100	mitogen activated protein kinase 3	Rattus norvegicus	16-22
27764816-7	2016	Finally, inhibition of MEK/ERK signalling by U0126 resulted in a reduction of DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this oncogenic pathway.Taken together, our data indicate that altered expression of DNMT3B plays a key role in ERMS development since its silencing is able to reverse cell cancer phenotype by rescuing myogenic program.	U 0126	45-50	DNA methyltransferase 3 beta	Homo sapiens	115-121
27764816-7	2016	Finally, inhibition of MEK/ERK signalling by U0126 resulted in a reduction of DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this oncogenic pathway.Taken together, our data indicate that altered expression of DNMT3B plays a key role in ERMS development since its silencing is able to reverse cell cancer phenotype by rescuing myogenic program.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	27-30
27764816-7	2016	Finally, inhibition of MEK/ERK signalling by U0126 resulted in a reduction of DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this oncogenic pathway.Taken together, our data indicate that altered expression of DNMT3B plays a key role in ERMS development since its silencing is able to reverse cell cancer phenotype by rescuing myogenic program.	U 0126	45-50	DNA methyltransferase 3 beta	Homo sapiens	115-121
27764816-7	2016	Finally, inhibition of MEK/ERK signalling by U0126 resulted in a reduction of DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this oncogenic pathway.Taken together, our data indicate that altered expression of DNMT3B plays a key role in ERMS development since its silencing is able to reverse cell cancer phenotype by rescuing myogenic program.	U 0126	45-50	DNA methyltransferase 3 beta	Homo sapiens	78-84
29450133-13	2016	Confocal microscopy revealed that in U0126 treated cells ERalpha displayed an even distribution across the cytoplasm as seen in untreated Tam-R cells.	U 0126	37-42	estrogen receptor 1	Homo sapiens	57-64
27874084-5	2016	We also observed that inhibiting the activity of ERK with specific inhibitor U0126 led to reduced autophagic level, while knockdown of autophagic gene Beclin-1 and Atg5 decreased the levels of ERK and p38 phosphorylation.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	49-52
27773818-5	2016	Carbachol-stimulated eIF4B phosphorylation was significantly reduced by the MEK1/2 inhibitor U0126, indicating that the MEK1/2-ERK1/2 pathway plays an important role in mAChR-mediated eIF4B phosphorylation.	U 0126	93-98	eukaryotic translation initiation factor 4B	Homo sapiens	21-26
27773818-5	2016	Carbachol-stimulated eIF4B phosphorylation was significantly reduced by the MEK1/2 inhibitor U0126, indicating that the MEK1/2-ERK1/2 pathway plays an important role in mAChR-mediated eIF4B phosphorylation.	U 0126	93-98	mitogen-activated protein kinase kinase 1	Homo sapiens	76-82
27773818-5	2016	Carbachol-stimulated eIF4B phosphorylation was significantly reduced by the MEK1/2 inhibitor U0126, indicating that the MEK1/2-ERK1/2 pathway plays an important role in mAChR-mediated eIF4B phosphorylation.	U 0126	93-98	mitogen-activated protein kinase kinase 1	Homo sapiens	120-126
27773818-5	2016	Carbachol-stimulated eIF4B phosphorylation was significantly reduced by the MEK1/2 inhibitor U0126, indicating that the MEK1/2-ERK1/2 pathway plays an important role in mAChR-mediated eIF4B phosphorylation.	U 0126	93-98	mitogen-activated protein kinase 3	Homo sapiens	127-133
27773818-5	2016	Carbachol-stimulated eIF4B phosphorylation was significantly reduced by the MEK1/2 inhibitor U0126, indicating that the MEK1/2-ERK1/2 pathway plays an important role in mAChR-mediated eIF4B phosphorylation.	U 0126	93-98	eukaryotic translation initiation factor 4B	Homo sapiens	184-189
27846317-4	2016	The MEK inhibitor U0126 (20 muM) significantly decreased the surface PD-L1 levels by 50-60% compared with dimethyl sulfoxide (p &lt; 0.0001).	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
27846317-4	2016	The MEK inhibitor U0126 (20 muM) significantly decreased the surface PD-L1 levels by 50-60% compared with dimethyl sulfoxide (p &lt; 0.0001).	U 0126	18-23	latexin	Homo sapiens	28-31
27846317-4	2016	The MEK inhibitor U0126 (20 muM) significantly decreased the surface PD-L1 levels by 50-60% compared with dimethyl sulfoxide (p &lt; 0.0001).	U 0126	18-23	CD274 molecule	Homo sapiens	69-74
27484511-12	2016	Finally, the employment of NAC and MAPK inhibitors (U0126, SP600125 and SB203580) remarkably blocked the S phase arrest, apoptosis and down-regulation of P-gp induced by Z5.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	35-39
27662662-8	2016	Downregulation of TRPM7 promoted cell cycle arrest at G0/G1 phase and apoptosis in vitro, which could be recovered by pre-treatment with U0126 to deactivate ERK1/2, suggesting a close correlation between TRPM7 and the MAPK signaling pathway.	U 0126	137-142	transient receptor potential cation channel subfamily M member 7	Homo sapiens	18-23
27662662-8	2016	Downregulation of TRPM7 promoted cell cycle arrest at G0/G1 phase and apoptosis in vitro, which could be recovered by pre-treatment with U0126 to deactivate ERK1/2, suggesting a close correlation between TRPM7 and the MAPK signaling pathway.	U 0126	137-142	mitogen-activated protein kinase 3	Homo sapiens	157-163
27662662-8	2016	Downregulation of TRPM7 promoted cell cycle arrest at G0/G1 phase and apoptosis in vitro, which could be recovered by pre-treatment with U0126 to deactivate ERK1/2, suggesting a close correlation between TRPM7 and the MAPK signaling pathway.	U 0126	137-142	transient receptor potential cation channel subfamily M member 7	Homo sapiens	204-209
27662662-8	2016	Downregulation of TRPM7 promoted cell cycle arrest at G0/G1 phase and apoptosis in vitro, which could be recovered by pre-treatment with U0126 to deactivate ERK1/2, suggesting a close correlation between TRPM7 and the MAPK signaling pathway.	U 0126	137-142	mitogen-activated protein kinase 3	Homo sapiens	218-222
27484511-12	2016	Finally, the employment of NAC and MAPK inhibitors (U0126, SP600125 and SB203580) remarkably blocked the S phase arrest, apoptosis and down-regulation of P-gp induced by Z5.	U 0126	52-57	phosphoglycolate phosphatase	Homo sapiens	154-158
27619643-5	2016	After CD147 stealth siRNA transfection treatment, the production of VEGF was reduced depended on the inhibition efficiency of CD147 siRNAs.The special signaling pathway inhibitors LY294002, SP600125, SB203580 and U0126 were added to cultures respectively and the results showed LY294002 dose-dependently inhibited the expression of VEGF.	U 0126	213-218	basigin (Ok blood group)	Homo sapiens	6-11
27619643-5	2016	After CD147 stealth siRNA transfection treatment, the production of VEGF was reduced depended on the inhibition efficiency of CD147 siRNAs.The special signaling pathway inhibitors LY294002, SP600125, SB203580 and U0126 were added to cultures respectively and the results showed LY294002 dose-dependently inhibited the expression of VEGF.	U 0126	213-218	vascular endothelial growth factor A	Homo sapiens	68-72
27619643-5	2016	After CD147 stealth siRNA transfection treatment, the production of VEGF was reduced depended on the inhibition efficiency of CD147 siRNAs.The special signaling pathway inhibitors LY294002, SP600125, SB203580 and U0126 were added to cultures respectively and the results showed LY294002 dose-dependently inhibited the expression of VEGF.	U 0126	213-218	vascular endothelial growth factor A	Homo sapiens	332-336
26320741-5	2016	LPS and Pam3csk4 also induced IRAK1/4-, ERK- and ROS-dependent activation of activator protein-1 (AP-1), IL-1beta transcription, and IL-1beta processing because significant inhibition in AP-1 activity, IL-1beta transcription, Pro- and mature IL-beta expression, and caspase-1 activity was observed with PD98059, U0126, DPI, NAC, an IRAK1/4 inhibitor, tanshinone IIa, and IRAK1 siRNA treatment.	U 0126	312-317	interleukin 1 receptor associated kinase 1	Homo sapiens	30-35
26320741-5	2016	LPS and Pam3csk4 also induced IRAK1/4-, ERK- and ROS-dependent activation of activator protein-1 (AP-1), IL-1beta transcription, and IL-1beta processing because significant inhibition in AP-1 activity, IL-1beta transcription, Pro- and mature IL-beta expression, and caspase-1 activity was observed with PD98059, U0126, DPI, NAC, an IRAK1/4 inhibitor, tanshinone IIa, and IRAK1 siRNA treatment.	U 0126	312-317	mitogen-activated protein kinase 1	Homo sapiens	40-43
26320741-5	2016	LPS and Pam3csk4 also induced IRAK1/4-, ERK- and ROS-dependent activation of activator protein-1 (AP-1), IL-1beta transcription, and IL-1beta processing because significant inhibition in AP-1 activity, IL-1beta transcription, Pro- and mature IL-beta expression, and caspase-1 activity was observed with PD98059, U0126, DPI, NAC, an IRAK1/4 inhibitor, tanshinone IIa, and IRAK1 siRNA treatment.	U 0126	312-317	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	77-96
26320741-5	2016	LPS and Pam3csk4 also induced IRAK1/4-, ERK- and ROS-dependent activation of activator protein-1 (AP-1), IL-1beta transcription, and IL-1beta processing because significant inhibition in AP-1 activity, IL-1beta transcription, Pro- and mature IL-beta expression, and caspase-1 activity was observed with PD98059, U0126, DPI, NAC, an IRAK1/4 inhibitor, tanshinone IIa, and IRAK1 siRNA treatment.	U 0126	312-317	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-102
27461751-9	2016	In addition, the PM2.5-induced increases in ETB- and ETA-mediated vasoconstriction and receptor expressions could be notably decreased by MEK1/2 inhibitor, U0126 and Raf inhibitor, SB386023, suggesting that the upregulation of ETB and ETA receptors is related with MEK/ERK1/2 pathway.	U 0126	156-161	endothelin receptor type B	Rattus norvegicus	44-47
27461751-9	2016	In addition, the PM2.5-induced increases in ETB- and ETA-mediated vasoconstriction and receptor expressions could be notably decreased by MEK1/2 inhibitor, U0126 and Raf inhibitor, SB386023, suggesting that the upregulation of ETB and ETA receptors is related with MEK/ERK1/2 pathway.	U 0126	156-161	endothelin receptor type A	Rattus norvegicus	53-56
26656929-6	2016	Farrerol-stimulated p27 expression, p38 MAPK activation, and cell growth inhibition were attenuated by pretreatment with U0126, an MEK1/2 inhibitor.	U 0126	121-126	cyclin dependent kinase inhibitor 1B	Homo sapiens	20-23
26656929-6	2016	Farrerol-stimulated p27 expression, p38 MAPK activation, and cell growth inhibition were attenuated by pretreatment with U0126, an MEK1/2 inhibitor.	U 0126	121-126	mitogen-activated protein kinase 1	Homo sapiens	36-39
26656929-6	2016	Farrerol-stimulated p27 expression, p38 MAPK activation, and cell growth inhibition were attenuated by pretreatment with U0126, an MEK1/2 inhibitor.	U 0126	121-126	mitogen-activated protein kinase 3	Homo sapiens	40-44
26656929-6	2016	Farrerol-stimulated p27 expression, p38 MAPK activation, and cell growth inhibition were attenuated by pretreatment with U0126, an MEK1/2 inhibitor.	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	131-137
27756053-8	2016	U0126, an ERK inhibitor, and SB203580, a p38 inhibitor, decreased the expression of CD69 upon TCR stimulation and inhibited CD4+ T cell differentiation, indicating that both ERK and p38 are suggested to be critical molecular targets of costunolide.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
27756053-8	2016	U0126, an ERK inhibitor, and SB203580, a p38 inhibitor, decreased the expression of CD69 upon TCR stimulation and inhibited CD4+ T cell differentiation, indicating that both ERK and p38 are suggested to be critical molecular targets of costunolide.	U 0126	0-5	CD69 molecule	Homo sapiens	84-88
27756053-8	2016	U0126, an ERK inhibitor, and SB203580, a p38 inhibitor, decreased the expression of CD69 upon TCR stimulation and inhibited CD4+ T cell differentiation, indicating that both ERK and p38 are suggested to be critical molecular targets of costunolide.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	174-177
27756053-8	2016	U0126, an ERK inhibitor, and SB203580, a p38 inhibitor, decreased the expression of CD69 upon TCR stimulation and inhibited CD4+ T cell differentiation, indicating that both ERK and p38 are suggested to be critical molecular targets of costunolide.	U 0126	0-5	mitogen-activated protein kinase 14	Homo sapiens	182-185
27601158-7	2016	Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively.	U 0126	92-97	prohibitin 2	Homo sapiens	10-13
27601158-7	2016	Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively.	U 0126	92-97	matrix metallopeptidase 9	Homo sapiens	40-44
27601158-7	2016	Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively.	U 0126	92-97	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	49-54
27601158-7	2016	Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	78-81
27353438-7	2016	U0126 also inhibited IFN-gamma secretion and Fas expression close to control levels.	U 0126	0-5	interferon gamma	Homo sapiens	21-30
27748860-12	2016	The effect of BMP-9 on osteoclast differentiation was reduced by transfection with siRNA ALK1, however, the effect was enhanced by the ERK1/2 pathway inhibitor, U0126.	U 0126	161-166	growth differentiation factor 2	Mus musculus	14-19
27748860-12	2016	The effect of BMP-9 on osteoclast differentiation was reduced by transfection with siRNA ALK1, however, the effect was enhanced by the ERK1/2 pathway inhibitor, U0126.	U 0126	161-166	activin A receptor, type II-like 1	Mus musculus	89-93
27748860-12	2016	The effect of BMP-9 on osteoclast differentiation was reduced by transfection with siRNA ALK1, however, the effect was enhanced by the ERK1/2 pathway inhibitor, U0126.	U 0126	161-166	mitogen-activated protein kinase 3	Mus musculus	135-141
27629357-6	2016	Pretreating the cells with the ERK kinase1/2 (MEK1/2) inhibitor U0126 obviously inhibited the proliferation of C2C12 cells.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	31-34
27900017-8	2016	The ERK inhibitor, U0126, and AKT inhibitor treatments blocked the effect of SIX1 on proliferation.	U 0126	19-24	SIX homeobox 1	Homo sapiens	77-81
27693704-6	2016	Combined treatment with a MKK1/2 inhibitor (U0126 or PD98059) further decreased the TS expression in astaxanthin-exposed NSCLC cells.	U 0126	44-49	mitogen-activated protein kinase kinase 1	Homo sapiens	26-30
27693704-6	2016	Combined treatment with a MKK1/2 inhibitor (U0126 or PD98059) further decreased the TS expression in astaxanthin-exposed NSCLC cells.	U 0126	44-49	thymidylate synthetase	Homo sapiens	84-86
27774945-12	2016	Treatment by baicalein alone or in combination with U0126 for 24 hours significantly decreased ERK1/2 and Bcl-2 mRNA expressions, and upregulated Bax mRNA expression.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	95-101
27774945-12	2016	Treatment by baicalein alone or in combination with U0126 for 24 hours significantly decreased ERK1/2 and Bcl-2 mRNA expressions, and upregulated Bax mRNA expression.	U 0126	52-57	BCL2 apoptosis regulator	Homo sapiens	106-111
27774945-12	2016	Treatment by baicalein alone or in combination with U0126 for 24 hours significantly decreased ERK1/2 and Bcl-2 mRNA expressions, and upregulated Bax mRNA expression.	U 0126	52-57	BCL2 associated X, apoptosis regulator	Homo sapiens	146-149
27605672-8	2016	Furthermore, the replication of CSFV was markedly inhibited in PK-15 cells treated with U0126, a specific inhibitor for MEK1/2/ERK1/2, whereas MEK2 did not affect CSFV replication after blocking the interferon-induced Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway by ruxolitinib, a JAK-STAT-specific inhibitor.	U 0126	88-93	mitogen-activated protein kinase 3	Sus scrofa	127-133
27994507-7	2016	Blocking the ERK1/2 signaling pathway with the MEK inhibitor U0126 and catalpol significantly protected PreOLs from ROS-mediated apoptosis under OGD.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	13-19
27994507-7	2016	Blocking the ERK1/2 signaling pathway with the MEK inhibitor U0126 and catalpol significantly protected PreOLs from ROS-mediated apoptosis under OGD.	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
27768739-8	2016	Inhibition of either GSK-3beta (with SB216763) or ERK1/2 (with U0126) abolished RLIPC-induced antiarrhythmic activity and GSK-3beta Ser9 and ERK1/2 phosphorylation, leaving GSK-3beta Tyr216 phosphorylation unchanged.	U 0126	63-68	mitogen activated protein kinase 3	Rattus norvegicus	50-56
27768722-10	2016	Overexpression of GPC6 induced ERK1/2 phosphorylation, and co-treatment with the ERK inhibitor U0126 attenuated the GPC6-induced increase in NPPA, NPPB and protein synthesis.	U 0126	95-100	glypican 6	Homo sapiens	18-22
27768722-10	2016	Overexpression of GPC6 induced ERK1/2 phosphorylation, and co-treatment with the ERK inhibitor U0126 attenuated the GPC6-induced increase in NPPA, NPPB and protein synthesis.	U 0126	95-100	glypican 6	Homo sapiens	116-120
27768722-10	2016	Overexpression of GPC6 induced ERK1/2 phosphorylation, and co-treatment with the ERK inhibitor U0126 attenuated the GPC6-induced increase in NPPA, NPPB and protein synthesis.	U 0126	95-100	natriuretic peptide A	Homo sapiens	141-145
27768722-10	2016	Overexpression of GPC6 induced ERK1/2 phosphorylation, and co-treatment with the ERK inhibitor U0126 attenuated the GPC6-induced increase in NPPA, NPPB and protein synthesis.	U 0126	95-100	natriuretic peptide B	Homo sapiens	147-151
27629357-6	2016	Pretreating the cells with the ERK kinase1/2 (MEK1/2) inhibitor U0126 obviously inhibited the proliferation of C2C12 cells.	U 0126	64-69	mitogen-activated protein kinase kinase 1	Mus musculus	46-52
27316791-6	2016	Small interfering RNA of hBVR (si-hBVR) was used to knockdown the expression of hBVR, and U0126 was applied to inhibit the ERK1/2 signaling in MCF-7, T-47D cells.	U 0126	90-95	mitogen-activated protein kinase 3	Homo sapiens	123-129
27343376-0	2016	U0126 attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway.	U 0126	0-5	midkine	Mus musculus	92-95
27343376-0	2016	U0126 attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	96-99
27343376-0	2016	U0126 attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway.	U 0126	0-5	early growth response 1	Mus musculus	100-105
27343376-3	2016	The aim of this study was to determine the protective effect of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126), an ERK kinase inhibitor, on myocardial ischemia/reperfusion (I/R) injury and the mechanisms involved.	U 0126	64-124	mitogen-activated protein kinase 1	Mus musculus	137-140
27343376-3	2016	The aim of this study was to determine the protective effect of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126), an ERK kinase inhibitor, on myocardial ischemia/reperfusion (I/R) injury and the mechanisms involved.	U 0126	126-131	mitogen-activated protein kinase 1	Mus musculus	137-140
27343376-7	2016	Moreover, U0126 reduced the caspase-3 activity and the number of TUNEL-positive cardiomyocytes, which together indicate decreased apoptosis.	U 0126	10-15	caspase 3	Mus musculus	28-37
27343376-8	2016	Additionally, U0126 remarkable reduced the level of Beclin-1 and LC3 and increased p62 expression, which indicates that U0126 suppressed H/R-induced autophagy.	U 0126	14-19	beclin 1, autophagy related	Mus musculus	52-60
27343376-8	2016	Additionally, U0126 remarkable reduced the level of Beclin-1 and LC3 and increased p62 expression, which indicates that U0126 suppressed H/R-induced autophagy.	U 0126	14-19	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	65-68
27343376-8	2016	Additionally, U0126 remarkable reduced the level of Beclin-1 and LC3 and increased p62 expression, which indicates that U0126 suppressed H/R-induced autophagy.	U 0126	14-19	nucleoporin 62	Mus musculus	83-86
27343376-8	2016	Additionally, U0126 remarkable reduced the level of Beclin-1 and LC3 and increased p62 expression, which indicates that U0126 suppressed H/R-induced autophagy.	U 0126	120-125	beclin 1, autophagy related	Mus musculus	52-60
27343376-8	2016	Additionally, U0126 remarkable reduced the level of Beclin-1 and LC3 and increased p62 expression, which indicates that U0126 suppressed H/R-induced autophagy.	U 0126	120-125	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	65-68
27343376-8	2016	Additionally, U0126 remarkable reduced the level of Beclin-1 and LC3 and increased p62 expression, which indicates that U0126 suppressed H/R-induced autophagy.	U 0126	120-125	nucleoporin 62	Mus musculus	83-86
27343376-9	2016	Furthermore, the relationship between U0126 and MEK/ERK pathway activation in H/R-induced cardiomyocytes was also investigated.	U 0126	38-43	midkine	Mus musculus	48-51
27343376-9	2016	Furthermore, the relationship between U0126 and MEK/ERK pathway activation in H/R-induced cardiomyocytes was also investigated.	U 0126	38-43	mitogen-activated protein kinase 1	Mus musculus	52-55
27343376-10	2016	U0126 ameliorated H/R injury through inhibition of the MEK/ERK pathway and by suppressing in the downstream EGR-1 expression.	U 0126	0-5	midkine	Mus musculus	55-58
27343376-10	2016	U0126 ameliorated H/R injury through inhibition of the MEK/ERK pathway and by suppressing in the downstream EGR-1 expression.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	59-62
27343376-10	2016	U0126 ameliorated H/R injury through inhibition of the MEK/ERK pathway and by suppressing in the downstream EGR-1 expression.	U 0126	0-5	early growth response 1	Mus musculus	108-113
27343376-11	2016	Together, our research suggests that U0126 may protect against H/R injury by preventing H/R-induced myocardium apoptosis and autophagy via the MEK/ERK/EGR-1 pathway, and may be a potential therapeutic approach for attenuating myocardial I/R injury.	U 0126	37-42	midkine	Mus musculus	143-146
27343376-11	2016	Together, our research suggests that U0126 may protect against H/R injury by preventing H/R-induced myocardium apoptosis and autophagy via the MEK/ERK/EGR-1 pathway, and may be a potential therapeutic approach for attenuating myocardial I/R injury.	U 0126	37-42	mitogen-activated protein kinase 1	Mus musculus	147-150
27343376-11	2016	Together, our research suggests that U0126 may protect against H/R injury by preventing H/R-induced myocardium apoptosis and autophagy via the MEK/ERK/EGR-1 pathway, and may be a potential therapeutic approach for attenuating myocardial I/R injury.	U 0126	37-42	early growth response 1	Mus musculus	151-156
27539609-9	2016	Additionally, both the inhibitory effect on COX-2 and ICAM-1 expression and the induction of PPARgamma expression by ISL in TNF-alpha-stimulated HT-29 cells was abolished by the addition of U0126, a specific ERK1/2 inhibitor.	U 0126	190-195	prostaglandin-endoperoxide synthase 2	Homo sapiens	44-49
27539609-9	2016	Additionally, both the inhibitory effect on COX-2 and ICAM-1 expression and the induction of PPARgamma expression by ISL in TNF-alpha-stimulated HT-29 cells was abolished by the addition of U0126, a specific ERK1/2 inhibitor.	U 0126	190-195	intercellular adhesion molecule 1	Homo sapiens	54-60
27539609-9	2016	Additionally, both the inhibitory effect on COX-2 and ICAM-1 expression and the induction of PPARgamma expression by ISL in TNF-alpha-stimulated HT-29 cells was abolished by the addition of U0126, a specific ERK1/2 inhibitor.	U 0126	190-195	peroxisome proliferator activated receptor gamma	Homo sapiens	93-102
27539609-9	2016	Additionally, both the inhibitory effect on COX-2 and ICAM-1 expression and the induction of PPARgamma expression by ISL in TNF-alpha-stimulated HT-29 cells was abolished by the addition of U0126, a specific ERK1/2 inhibitor.	U 0126	190-195	tumor necrosis factor	Homo sapiens	124-133
27539609-9	2016	Additionally, both the inhibitory effect on COX-2 and ICAM-1 expression and the induction of PPARgamma expression by ISL in TNF-alpha-stimulated HT-29 cells was abolished by the addition of U0126, a specific ERK1/2 inhibitor.	U 0126	190-195	mitogen-activated protein kinase 3	Homo sapiens	208-214
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	40-46
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	90-96
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	U 0126	48-53	mitogen-activated protein kinase 9	Homo sapiens	101-105
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	U 0126	48-53	mitogen-activated protein kinase 8	Homo sapiens	106-109
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	151-154
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	155-159
27434868-7	2016	Pretreatment with 5mM N-acetyl-l-cysteine (an inhibitor of ROS formation) or 10muM U0126 (an inhibitor of ERK1/2) significantly prevented the induction of periostin in CSE-treated PASMCs.	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	106-112
27434868-7	2016	Pretreatment with 5mM N-acetyl-l-cysteine (an inhibitor of ROS formation) or 10muM U0126 (an inhibitor of ERK1/2) significantly prevented the induction of periostin in CSE-treated PASMCs.	U 0126	83-88	periostin	Homo sapiens	155-164
27302893-8	2016	Pretreatment with inhibitors of either ERK1/2 (U0126) or [Ca(2+)]i (BAPTA-AM) notably attenuated the GPR120-mediated adipogenesis.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	39-45
27302893-8	2016	Pretreatment with inhibitors of either ERK1/2 (U0126) or [Ca(2+)]i (BAPTA-AM) notably attenuated the GPR120-mediated adipogenesis.	U 0126	47-52	free fatty acid receptor 4	Homo sapiens	101-107
27571877-11	2016	At the meantime, p38 and JNK were not affected by AG and were only inhibited by U0126.	U 0126	80-85	mitogen activated protein kinase 14	Rattus norvegicus	17-20
27571877-11	2016	At the meantime, p38 and JNK were not affected by AG and were only inhibited by U0126.	U 0126	80-85	mitogen-activated protein kinase 8	Rattus norvegicus	25-28
27402431-4	2016	After injury, the mice were injected with U0126 (MAPK/ERK signaling pathway inhibitor) via the femoral vein.	U 0126	42-47	mitogen-activated protein kinase 1	Mus musculus	49-53
27402431-4	2016	After injury, the mice were injected with U0126 (MAPK/ERK signaling pathway inhibitor) via the femoral vein.	U 0126	42-47	mitogen-activated protein kinase 1	Mus musculus	54-57
26645822-7	2016	In addition, we found that the protective effects of GS-Rb1 are dose and time dependent and are partially mediated through phosphorylation of ERK1/2 signaling pathway, as evidenced by the abolishment of GS-Rb1-mediated elevation of p-ERK1/2 expression and inhibition of Cx40 expressions when ERK inhibitor U0126 was used.	U 0126	306-311	mitogen-activated protein kinase 3	Mus musculus	142-148
26645822-7	2016	In addition, we found that the protective effects of GS-Rb1 are dose and time dependent and are partially mediated through phosphorylation of ERK1/2 signaling pathway, as evidenced by the abolishment of GS-Rb1-mediated elevation of p-ERK1/2 expression and inhibition of Cx40 expressions when ERK inhibitor U0126 was used.	U 0126	306-311	mitogen-activated protein kinase 1	Mus musculus	142-145
26036653-7	2016	Furthermore, C-CPE 194 and C-CPE m19 significantly enhanced the permeability of human recombinant insulin across HNECs and the permeability was also inhibited by U0126.	U 0126	162-167	insulin	Homo sapiens	98-105
27473926-10	2016	The effects of visfatin on proliferation and apoptosis were abrogated by treatment with the PI3K inhibitor LY294002 and MEK inhibitor U0126.	U 0126	134-139	nicotinamide phosphoribosyltransferase	Homo sapiens	15-23
27473926-10	2016	The effects of visfatin on proliferation and apoptosis were abrogated by treatment with the PI3K inhibitor LY294002 and MEK inhibitor U0126.	U 0126	134-139	mitogen-activated protein kinase kinase 7	Homo sapiens	120-123
28011945-12	2016	Inhibition of ERK1/2 by 10 muM U0126 attenuated OXA-stimulated INS-1E cell proliferation.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	14-20
27296115-5	2016	Western Blot analysis detected both TrkB receptor isoforms in the synaptosomes but the BDNF effect seems to be mediated by TrkB-FL since: 1) the tyrosine kinase inhibitor, k252a, prevented the effect of BDNF, and 2) the effect of BDNF was lost in the presence of specific inhibitors of TrkB signalling pathways, namely U73122, LY294002 and U0126 (inhibitors of PLC, Akt and MAPK pathways, respectively).	U 0126	340-345	brain-derived neurotrophic factor	Rattus norvegicus	87-91
27296115-5	2016	Western Blot analysis detected both TrkB receptor isoforms in the synaptosomes but the BDNF effect seems to be mediated by TrkB-FL since: 1) the tyrosine kinase inhibitor, k252a, prevented the effect of BDNF, and 2) the effect of BDNF was lost in the presence of specific inhibitors of TrkB signalling pathways, namely U73122, LY294002 and U0126 (inhibitors of PLC, Akt and MAPK pathways, respectively).	U 0126	340-345	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	123-127
27296115-5	2016	Western Blot analysis detected both TrkB receptor isoforms in the synaptosomes but the BDNF effect seems to be mediated by TrkB-FL since: 1) the tyrosine kinase inhibitor, k252a, prevented the effect of BDNF, and 2) the effect of BDNF was lost in the presence of specific inhibitors of TrkB signalling pathways, namely U73122, LY294002 and U0126 (inhibitors of PLC, Akt and MAPK pathways, respectively).	U 0126	340-345	brain-derived neurotrophic factor	Rattus norvegicus	203-207
27296115-5	2016	Western Blot analysis detected both TrkB receptor isoforms in the synaptosomes but the BDNF effect seems to be mediated by TrkB-FL since: 1) the tyrosine kinase inhibitor, k252a, prevented the effect of BDNF, and 2) the effect of BDNF was lost in the presence of specific inhibitors of TrkB signalling pathways, namely U73122, LY294002 and U0126 (inhibitors of PLC, Akt and MAPK pathways, respectively).	U 0126	340-345	brain-derived neurotrophic factor	Rattus norvegicus	203-207
27296115-5	2016	Western Blot analysis detected both TrkB receptor isoforms in the synaptosomes but the BDNF effect seems to be mediated by TrkB-FL since: 1) the tyrosine kinase inhibitor, k252a, prevented the effect of BDNF, and 2) the effect of BDNF was lost in the presence of specific inhibitors of TrkB signalling pathways, namely U73122, LY294002 and U0126 (inhibitors of PLC, Akt and MAPK pathways, respectively).	U 0126	340-345	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	123-127
27388240-8	2016	Inhibition of ERK by a specific chemical inhibitor, U0126, promoted neuronal generation, especially of tyrosine hydroxylase-positive neurons.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	14-17
27591897-7	2016	Inhibition of ERK1/2 phosphorylation by UO126 entirely abrogated the response of p-Ser166-Mdm2 to VEGF-A treatment, while Akt phosphorylation inhibition by wortmannin led to further elevations in p-Ser166-Mdm2.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	14-20
27591897-7	2016	Inhibition of ERK1/2 phosphorylation by UO126 entirely abrogated the response of p-Ser166-Mdm2 to VEGF-A treatment, while Akt phosphorylation inhibition by wortmannin led to further elevations in p-Ser166-Mdm2.	U 0126	40-45	MDM2 proto-oncogene	Homo sapiens	90-94
27591897-7	2016	Inhibition of ERK1/2 phosphorylation by UO126 entirely abrogated the response of p-Ser166-Mdm2 to VEGF-A treatment, while Akt phosphorylation inhibition by wortmannin led to further elevations in p-Ser166-Mdm2.	U 0126	40-45	vascular endothelial growth factor A	Homo sapiens	98-104
27678303-5	2016	MEK1/2 inhibitor U0126 blocked HG-induced HIF-1alpha and ERK1/2 activation in both above two cells.	U 0126	17-22	hypoxia inducible factor 1 subunit alpha	Macaca mulatta	42-52
27564099-6	2016	NAC(ROS scavenger) and U0126(ERK inhibitor) inhibited apoptosis induced by curcumin and cisplatin.	U 0126	23-28	mitogen-activated protein kinase 1	Homo sapiens	29-32
27658230-7	2016	ERK inhibition by U0126 not only induced recovery of myotube formation in old myoblasts but also facilitated muscle regeneration after injury in aged muscle.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	0-3
27632174-7	2016	Pretreatment with PI3K (LY294002), p38 MAPK (SB203580) and MEK (U0126) inhibitors completely inhibited Ang1-mediated increase of MIP-1beta intracellular and extracellular protein levels.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	59-62
27632174-7	2016	Pretreatment with PI3K (LY294002), p38 MAPK (SB203580) and MEK (U0126) inhibitors completely inhibited Ang1-mediated increase of MIP-1beta intracellular and extracellular protein levels.	U 0126	64-69	angiopoietin 1	Homo sapiens	103-107
27632174-7	2016	Pretreatment with PI3K (LY294002), p38 MAPK (SB203580) and MEK (U0126) inhibitors completely inhibited Ang1-mediated increase of MIP-1beta intracellular and extracellular protein levels.	U 0126	64-69	C-C motif chemokine ligand 4	Homo sapiens	129-138
27624978-8	2016	In addition, overexpressing ITGA6 promoted radiation resistance in cells, and this effect was neutralized by the PI3K inhibitor LY294002 and MEK inhibitor U0126.	U 0126	155-160	integrin subunit alpha 6	Homo sapiens	28-33
27624978-8	2016	In addition, overexpressing ITGA6 promoted radiation resistance in cells, and this effect was neutralized by the PI3K inhibitor LY294002 and MEK inhibitor U0126.	U 0126	155-160	mitogen-activated protein kinase kinase 7	Homo sapiens	141-144
27616044-13	2016	hITF increased MMP2 and MMP9 mRNA levels and E-cadherin degradation and U0126 and AG490 abolished this effect of hITF.	U 0126	72-77	trefoil factor 3	Homo sapiens	113-117
27365310-6	2016	ApoE deficient (apoE(-/-)) mice receiving U0126 treatment had reduced sinus lesions in the aortic root which was associated with activated macrophage ABCG1 expression in the lesion areas.	U 0126	42-47	apolipoprotein E	Mus musculus	0-4
27365310-6	2016	ApoE deficient (apoE(-/-)) mice receiving U0126 treatment had reduced sinus lesions in the aortic root which was associated with activated macrophage ABCG1 expression in the lesion areas.	U 0126	42-47	apolipoprotein E	Mus musculus	16-20
27365310-6	2016	ApoE deficient (apoE(-/-)) mice receiving U0126 treatment had reduced sinus lesions in the aortic root which was associated with activated macrophage ABCG1 expression in the lesion areas.	U 0126	42-47	ATP binding cassette subfamily G member 1	Mus musculus	150-155
27582556-5	2016	In addition, KR-36676 decreased UII-induced phosphorylation of ERK, and UII-induced cell proliferation was also significantly inhibited by a known ERK inhibitor U0126.	U 0126	161-166	urotensin 2	Homo sapiens	32-35
27582556-5	2016	In addition, KR-36676 decreased UII-induced phosphorylation of ERK, and UII-induced cell proliferation was also significantly inhibited by a known ERK inhibitor U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	63-66
27582556-5	2016	In addition, KR-36676 decreased UII-induced phosphorylation of ERK, and UII-induced cell proliferation was also significantly inhibited by a known ERK inhibitor U0126.	U 0126	161-166	urotensin 2	Homo sapiens	72-75
27582556-5	2016	In addition, KR-36676 decreased UII-induced phosphorylation of ERK, and UII-induced cell proliferation was also significantly inhibited by a known ERK inhibitor U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	147-150
27335313-10	2016	In addition, BCAO-induced mechanical allodynia was significantly decreased by intrathecal administration of U0126, an inhibitor of ERK.	U 0126	108-113	mitogen-activated protein kinase 1	Mus musculus	131-134
27208502-6	2016	ALK5 inhibition with SB431542 or ALK1/2/3/6 with dorsomorphin-1, inhibition of Smad3 activation with SIS3, and inhibition of the MAPK/Erk1/2 with U0126, demonstrates the involvement of these pathways in BMP9-induced ECM synthesis in MEFs.	U 0126	146-151	mitogen-activated protein kinase 1	Mus musculus	129-133
27208502-6	2016	ALK5 inhibition with SB431542 or ALK1/2/3/6 with dorsomorphin-1, inhibition of Smad3 activation with SIS3, and inhibition of the MAPK/Erk1/2 with U0126, demonstrates the involvement of these pathways in BMP9-induced ECM synthesis in MEFs.	U 0126	146-151	mitogen-activated protein kinase 3	Mus musculus	134-140
27607135-7	2016	AG1478 and U0126 were used as the inhibitor of EGFR and ERK1/2, respectively.	U 0126	11-16	epidermal growth factor receptor	Homo sapiens	47-51
27607135-7	2016	AG1478 and U0126 were used as the inhibitor of EGFR and ERK1/2, respectively.	U 0126	11-16	mitogen-activated protein kinase 3	Homo sapiens	56-62
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	ubiquitin C-terminal hydrolase L1	Homo sapiens	10-16
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	62-68
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	basigin (Ok blood group)	Homo sapiens	137-142
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	matrix metallopeptidase 2	Homo sapiens	144-148
26293643-7	2016	Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9.	U 0126	52-57	matrix metallopeptidase 9	Homo sapiens	154-158
27460700-6	2016	Blocking the ERK1/2 pathway by U0126 inhibited CREB phosphorylation and also suppressed A549 cell proliferation.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	13-19
27460700-6	2016	Blocking the ERK1/2 pathway by U0126 inhibited CREB phosphorylation and also suppressed A549 cell proliferation.	U 0126	31-36	cAMP responsive element binding protein 1	Homo sapiens	47-51
27588145-10	2016	In addition, daphnetin induced the expression of HSP70 in a dose- and time-dependent manner, and daphnetin-induced HSP70 expression was reduced by extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 in PC12 cells.	U 0126	205-210	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	49-54
27588145-10	2016	In addition, daphnetin induced the expression of HSP70 in a dose- and time-dependent manner, and daphnetin-induced HSP70 expression was reduced by extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 in PC12 cells.	U 0126	205-210	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	115-120
27588145-10	2016	In addition, daphnetin induced the expression of HSP70 in a dose- and time-dependent manner, and daphnetin-induced HSP70 expression was reduced by extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 in PC12 cells.	U 0126	205-210	mitogen activated protein kinase 3	Rattus norvegicus	147-194
27487136-11	2016	CAV1-silenced cells showed reduced levels of p-RSK1 and treatment with U0126 provoked the same effect.	U 0126	71-76	caveolin 1	Homo sapiens	0-4
27412967-11	2016	Finally, we treated the co-cultured system with an Akt inhibitor (T3830) and an ERK1/2 inhibitor (U0126).	U 0126	98-103	mitogen-activated protein kinase 3	Homo sapiens	80-86
27412967-12	2016	Both T3830 and U0126 blocked the suppression of miR-222 by DDC in LX-2.	U 0126	15-20	microRNA 222	Homo sapiens	48-55
27582689-5	2016	The ethanol-induced suppression was reduced by the D1R antagonist SCH23390 or the PKA inhibitor H89, was prevented by the Akt inhibitor triciribine or the GSk3beta inhibitor SB415286, was enhanced by the NMDA receptor antagonist D-AP5, but was not affected by the MAPK inhibitor U0126 or PI3K inhibitor wortmanin.	U 0126	279-284	AKT serine/threonine kinase 1	Rattus norvegicus	122-125
27339895-6	2016	Three hours later, IkappaBalpha starts to degrade, and ERK returns to basal or non-phosphorylation, and this lasts for the next 12 h. Finally, expression of CD3 and CD8 occurs in MOLT-4 along with reappearance of the IkappaBalpha ERK WWOX complex near 24 h. Inhibition of ERK phosphorylation by U0126 or IkappaBalpha degradation by MG132 prevents MOLT-4 maturation.	U 0126	295-300	CD8a molecule	Homo sapiens	165-168
27138645-14	2016	These effects were suppressed by the phosphatidylinositol 3"-kinase (PI3K) inhibitor LY294002 and the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	102-143
27138645-14	2016	These effects were suppressed by the phosphatidylinositol 3"-kinase (PI3K) inhibitor LY294002 and the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	145-151
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	U 0126	163-168	Oncogene OVC (ovarian adenocarcinoma oncogene)	Homo sapiens	31-35
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	U 0126	163-168	mitogen-activated protein kinase 1	Homo sapiens	101-146
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	U 0126	163-168	mitogen-activated protein kinase 1	Homo sapiens	148-151
27698691-7	2016	In addition, LRIG1-mediated suppression of PTEN expression was inhibited by the U0126 inhibitor, which suggests that LRIG1 may inhibit the activation of PTEN signaling molecules by triggering the mitogen-activated protein kinase (MAPK)/MAPK kinase 1 (MEK) signaling pathway.	U 0126	80-85	leucine rich repeats and immunoglobulin like domains 1	Homo sapiens	13-18
27698691-7	2016	In addition, LRIG1-mediated suppression of PTEN expression was inhibited by the U0126 inhibitor, which suggests that LRIG1 may inhibit the activation of PTEN signaling molecules by triggering the mitogen-activated protein kinase (MAPK)/MAPK kinase 1 (MEK) signaling pathway.	U 0126	80-85	phosphatase and tensin homolog	Homo sapiens	43-47
27698691-7	2016	In addition, LRIG1-mediated suppression of PTEN expression was inhibited by the U0126 inhibitor, which suggests that LRIG1 may inhibit the activation of PTEN signaling molecules by triggering the mitogen-activated protein kinase (MAPK)/MAPK kinase 1 (MEK) signaling pathway.	U 0126	80-85	leucine rich repeats and immunoglobulin like domains 1	Homo sapiens	117-122
27698691-7	2016	In addition, LRIG1-mediated suppression of PTEN expression was inhibited by the U0126 inhibitor, which suggests that LRIG1 may inhibit the activation of PTEN signaling molecules by triggering the mitogen-activated protein kinase (MAPK)/MAPK kinase 1 (MEK) signaling pathway.	U 0126	80-85	phosphatase and tensin homolog	Homo sapiens	153-157
27698691-7	2016	In addition, LRIG1-mediated suppression of PTEN expression was inhibited by the U0126 inhibitor, which suggests that LRIG1 may inhibit the activation of PTEN signaling molecules by triggering the mitogen-activated protein kinase (MAPK)/MAPK kinase 1 (MEK) signaling pathway.	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	251-254
27258934-9	2016	Pretreatment with U0126 or MK-801 blocked pro-cognitive-like effect of CART suggesting involvement of NMDA-ERK pathway in CART"s action.	U 0126	18-23	CART prepropeptide	Rattus norvegicus	71-75
27258934-9	2016	Pretreatment with U0126 or MK-801 blocked pro-cognitive-like effect of CART suggesting involvement of NMDA-ERK pathway in CART"s action.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	107-110
27258934-9	2016	Pretreatment with U0126 or MK-801 blocked pro-cognitive-like effect of CART suggesting involvement of NMDA-ERK pathway in CART"s action.	U 0126	18-23	CART prepropeptide	Rattus norvegicus	122-126
27258934-12	2016	This effect was attenuated following pretreatment with U0126 or MK-801, suggesting the activation of ERK signaling cascade through NMDA receptors.	U 0126	55-60	Eph receptor B1	Rattus norvegicus	101-104
26873620-7	2016	The MEK inhibitor U0126 decreased cell proliferation independently of the presence of K-ras but reduced migration and ECM proteins expression only in wild-type fibroblasts, while the PI3K-AKT inhibitor LY294002 decreased cell proliferation, migration, and ECM synthesis in both types of fibroblasts.	U 0126	18-23	midkine	Mus musculus	4-7
27248356-9	2016	MEK/ERK inhibitor U0126 alone elevated autophagy in OGD conditions, but impaired TK-induced autophagy.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
27248356-9	2016	MEK/ERK inhibitor U0126 alone elevated autophagy in OGD conditions, but impaired TK-induced autophagy.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
27248356-9	2016	MEK/ERK inhibitor U0126 alone elevated autophagy in OGD conditions, but impaired TK-induced autophagy.	U 0126	18-23	kallikrein 1	Homo sapiens	81-83
27802587-7	2016	Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	140-143
27802587-7	2016	Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis.	U 0126	147-152	mitogen-activated protein kinase kinase 7	Homo sapiens	156-159
27802587-7	2016	Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	140-143
27641443-8	2016	Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events.	U 0126	174-179	estrogen receptor 1	Homo sapiens	15-22
27641443-8	2016	Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events.	U 0126	174-179	progesterone receptor	Homo sapiens	27-29
27641443-8	2016	Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events.	U 0126	174-179	progesterone receptor	Homo sapiens	58-60
27641443-8	2016	Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events.	U 0126	174-179	mitogen-activated protein kinase 1	Homo sapiens	116-120
27641443-8	2016	Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events.	U 0126	174-179	mitogen-activated protein kinase 1	Homo sapiens	121-124
27641443-8	2016	Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events.	U 0126	174-179	AKT serine/threonine kinase 1	Homo sapiens	129-132
27729863-7	2016	Neuroprotective effects of DISS and TFSA on Glu-induced decrease in cell viability were blocked by MAPK/ERK1/2 inhibitor (U0126) and PI3-K inhibitor (LY290042).	U 0126	122-127	mitogen-activated protein kinase 3	Homo sapiens	104-110
27564099-9	2016	Moreover, pretreatment with U0126 suppressed curcumin and cisplatin-induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells.	U 0126	28-33	tumor protein p53	Homo sapiens	92-95
27564099-9	2016	Moreover, pretreatment with U0126 suppressed curcumin and cisplatin-induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells.	U 0126	28-33	H3 histone pseudogene 16	Homo sapiens	97-100
27564099-9	2016	Moreover, pretreatment with U0126 suppressed curcumin and cisplatin-induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells.	U 0126	28-33	signal transducer and activator of transcription 3	Homo sapiens	108-113
27564111-10	2016	Inhibition of pERK1/2 expression by a specific ERK1/2 inhibitor U0126 and a special small interfering RNA attenuated levels of leptin-induced osteocalcin expression, indicating that ERK1/2 mediates, in part, the effects of leptin on osteocalcin.	U 0126	64-69	mitogen-activated protein kinase 3	Mus musculus	15-21
27564111-10	2016	Inhibition of pERK1/2 expression by a specific ERK1/2 inhibitor U0126 and a special small interfering RNA attenuated levels of leptin-induced osteocalcin expression, indicating that ERK1/2 mediates, in part, the effects of leptin on osteocalcin.	U 0126	64-69	mitogen-activated protein kinase 3	Mus musculus	47-53
27557506-9	2016	Additionally, in SEPT2/7-overexpressing cells, the MEK specific inhibitor U0126 was able to correct the high active status of MEK/ERK while normalizing the increased invasive behaviors of these cells.	U 0126	74-79	septin 2	Homo sapiens	17-22
27557506-9	2016	Additionally, in SEPT2/7-overexpressing cells, the MEK specific inhibitor U0126 was able to correct the high active status of MEK/ERK while normalizing the increased invasive behaviors of these cells.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
27557506-9	2016	Additionally, in SEPT2/7-overexpressing cells, the MEK specific inhibitor U0126 was able to correct the high active status of MEK/ERK while normalizing the increased invasive behaviors of these cells.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
27557506-9	2016	Additionally, in SEPT2/7-overexpressing cells, the MEK specific inhibitor U0126 was able to correct the high active status of MEK/ERK while normalizing the increased invasive behaviors of these cells.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	130-133
27503681-8	2016	Finally, on the basis of results obtained using U0126, an ERK1/2 inhibitor, the ERK1/2 signalling pathway was proposed for the multidrug resistance-reversing effect of Y8 in K562/ADR cells.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	58-64
27503681-8	2016	Finally, on the basis of results obtained using U0126, an ERK1/2 inhibitor, the ERK1/2 signalling pathway was proposed for the multidrug resistance-reversing effect of Y8 in K562/ADR cells.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	80-86
27612201-6	2016	By addition of U0126, the specific inhibitor of MEK1/2, the expression of kidney-type glutaminase (KGA, a critical glutaminase in glutaminolysis) was significantly decreased.	U 0126	15-20	mitogen-activated protein kinase kinase 1	Homo sapiens	48-54
27612201-6	2016	By addition of U0126, the specific inhibitor of MEK1/2, the expression of kidney-type glutaminase (KGA, a critical glutaminase in glutaminolysis) was significantly decreased.	U 0126	15-20	glutaminase	Homo sapiens	74-97
27612201-6	2016	By addition of U0126, the specific inhibitor of MEK1/2, the expression of kidney-type glutaminase (KGA, a critical glutaminase in glutaminolysis) was significantly decreased.	U 0126	15-20	glutaminase	Homo sapiens	99-102
27604655-8	2016	MAPK pathway inhibitor, U0126 and PI3KCA inhibitor LY294002 also decreased levels of ets-1, phosphor-ERK and phosphor-AKT on Western blot assay.	U 0126	24-29	ETS proto-oncogene 1, transcription factor	Homo sapiens	85-90
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	23-26
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	epidermal growth factor	Homo sapiens	65-68
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	cadherin 1	Homo sapiens	77-87
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	154-157
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	158-161
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	epidermal growth factor	Homo sapiens	185-188
27369075-6	2016	On the other hand, the MEK inhibitor U0126 was found to suppress EGF-induced E-cadherin down-regulation at the transcriptional level, suggesting that the MEK/ERK pathway is involved in EGF-induced E-cadherin down-regulation.	U 0126	37-42	cadherin 1	Homo sapiens	197-207
27498780-7	2016	ERK1/2 inhibitor U0126 (10 mumol/L) and NF-kappaB inhibitor JSH-23 (10 mumol/L) both markedly suppressed glucose- and angiotensin II-induced fibronectin and collagen expressions in cardiac fibroblasts.	U 0126	17-22	mitogen-activated protein kinase 3	Mus musculus	0-6
27498780-7	2016	ERK1/2 inhibitor U0126 (10 mumol/L) and NF-kappaB inhibitor JSH-23 (10 mumol/L) both markedly suppressed glucose- and angiotensin II-induced fibronectin and collagen expressions in cardiac fibroblasts.	U 0126	17-22	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	118-132
27498780-7	2016	ERK1/2 inhibitor U0126 (10 mumol/L) and NF-kappaB inhibitor JSH-23 (10 mumol/L) both markedly suppressed glucose- and angiotensin II-induced fibronectin and collagen expressions in cardiac fibroblasts.	U 0126	17-22	fibronectin 1	Mus musculus	141-152
27267062-6	2016	Fgf signaling in regenerating myocytes involves the MAPK/ERK pathway: inhibition of MEK activity with U0126 mimicked the phenotype of the Fgf receptor inhibition on both muscle regeneration and cell proliferation, and activated ERK (p-ERK) was detected in injured muscles by immunofluorescence and western blot.	U 0126	102-107	mitogen-activated protein kinase 1	Danio rerio	52-56
27698534-9	2016	Furthermore, a NF-kappaB inhibitor BAY 11-7082 and a MEK inhibitor U0126 blocked the changes caused by RKIP down-regulation after OGD.	U 0126	67-72	phosphatidylethanolamine binding protein 1	Rattus norvegicus	103-107
27112440-6	2016	When combining GAS with the MEK inhibitor U0126 or the JNK inhibitor SP600125, we observed a synergistic effect against Abeta (1-42)-induced reduction in cell viability of NPCs.	U 0126	42-47	midkine	Mus musculus	28-31
27588132-10	2016	In addiiton, expression of LC3II/LC3I decreased and the expression of BAX/Bcl-2 increased in the matrine + U0126 group compared with the matrine alone group.	U 0126	107-112	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
27588132-10	2016	In addiiton, expression of LC3II/LC3I decreased and the expression of BAX/Bcl-2 increased in the matrine + U0126 group compared with the matrine alone group.	U 0126	107-112	BCL2 apoptosis regulator	Homo sapiens	74-79
29786234-11	2016	When compared with HI+Rg1 group, the expressions of p-Erk1/2 and HIF-1alpha proteins in HI+Rg1+U0126 group were significantly decreased (P&lt;0.05), while expression of CC3 protein was significantly increased at 4 and 24 hours (P&lt;0.05).	U 0126	95-100	mitogen activated protein kinase 3	Rattus norvegicus	54-60
27486656-5	2016	Furthermore, hypoxia-induced CTGF expression was reduced by an MEK inhibitor (PD98059), MEK1 siRNA, ERK inhibitor (U0126), ERK1 siRNA, and MEKK1 siRNA.	U 0126	115-120	cellular communication network factor 2	Homo sapiens	29-33
27486656-6	2016	Both PD98059 and U0126 significantly attenuated hypoxia-induced CTGF-luciferase activity.	U 0126	17-22	cellular communication network factor 2	Homo sapiens	64-68
27486656-10	2016	Hypoxia-induced GLI-1 and GLI-2 translocation into the nucleus was significantly attenuated by U0126.	U 0126	95-100	GLI family zinc finger 1	Homo sapiens	16-21
27486656-10	2016	Hypoxia-induced GLI-1 and GLI-2 translocation into the nucleus was significantly attenuated by U0126.	U 0126	95-100	GLI family zinc finger 2	Homo sapiens	26-31
27648362-8	2016	After treatment with ERK1/2 chemical inhibitor (U0126), DEC2"s inhibitory effect on ERK/NF-kappaB/EMT was further decreased.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	21-27
27648362-8	2016	After treatment with ERK1/2 chemical inhibitor (U0126), DEC2"s inhibitory effect on ERK/NF-kappaB/EMT was further decreased.	U 0126	48-53	basic helix-loop-helix family member e41	Homo sapiens	56-60
27648362-8	2016	After treatment with ERK1/2 chemical inhibitor (U0126), DEC2"s inhibitory effect on ERK/NF-kappaB/EMT was further decreased.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	21-24
27648362-8	2016	After treatment with ERK1/2 chemical inhibitor (U0126), DEC2"s inhibitory effect on ERK/NF-kappaB/EMT was further decreased.	U 0126	48-53	nuclear factor kappa B subunit 1	Homo sapiens	88-97
27648362-8	2016	After treatment with ERK1/2 chemical inhibitor (U0126), DEC2"s inhibitory effect on ERK/NF-kappaB/EMT was further decreased.	U 0126	48-53	IL2 inducible T cell kinase	Homo sapiens	98-101
27042827-11	2016	Application of the MEK/ERK1/2 inhibitor U-0126 resulted in down-regulation of TNF-alpha-induced MMP9 secretion and abrogation of the enhanced concentration of proteases in the lipid rafts.	U 0126	40-46	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
27042827-11	2016	Application of the MEK/ERK1/2 inhibitor U-0126 resulted in down-regulation of TNF-alpha-induced MMP9 secretion and abrogation of the enhanced concentration of proteases in the lipid rafts.	U 0126	40-46	mitogen-activated protein kinase 3	Homo sapiens	23-29
27042827-11	2016	Application of the MEK/ERK1/2 inhibitor U-0126 resulted in down-regulation of TNF-alpha-induced MMP9 secretion and abrogation of the enhanced concentration of proteases in the lipid rafts.	U 0126	40-46	tumor necrosis factor	Homo sapiens	78-87
27042827-11	2016	Application of the MEK/ERK1/2 inhibitor U-0126 resulted in down-regulation of TNF-alpha-induced MMP9 secretion and abrogation of the enhanced concentration of proteases in the lipid rafts.	U 0126	40-46	matrix metallopeptidase 9	Homo sapiens	96-100
27363707-5	2016	We evaluated the levels of IkappaBalpha, a component of the classical activation pathway of the transcription factor NF-kappaB, and we observed IkappaBalpha reduction after stimulation with FFAR1/GPR40 agonists, an effect that was inhibited by GW1100 or the inhibitors UO126, SB203580 or LY294002.	U 0126	269-274	NFKB inhibitor alpha	Bos taurus	27-39
27363707-5	2016	We evaluated the levels of IkappaBalpha, a component of the classical activation pathway of the transcription factor NF-kappaB, and we observed IkappaBalpha reduction after stimulation with FFAR1/GPR40 agonists, an effect that was inhibited by GW1100 or the inhibitors UO126, SB203580 or LY294002.	U 0126	269-274	NFKB inhibitor alpha	Bos taurus	144-156
27363707-5	2016	We evaluated the levels of IkappaBalpha, a component of the classical activation pathway of the transcription factor NF-kappaB, and we observed IkappaBalpha reduction after stimulation with FFAR1/GPR40 agonists, an effect that was inhibited by GW1100 or the inhibitors UO126, SB203580 or LY294002.	U 0126	269-274	free fatty acid receptor 1	Bos taurus	190-195
27363707-7	2016	Finally, the FFAR1/GPR40 agonist-induced MMP-9 granule release was reduced by GW1100 and UO126.	U 0126	89-94	free fatty acid receptor 1	Bos taurus	13-18
27363707-7	2016	Finally, the FFAR1/GPR40 agonist-induced MMP-9 granule release was reduced by GW1100 and UO126.	U 0126	89-94	matrix metallopeptidase 9	Bos taurus	41-46
27097549-7	2016	Western blot results identified upregulated Erk phosphorylation in the spinal cord-injured neurons, and also showed that U0126 inhibited phosphorylation of Erk, which is a downstream kinase in the Ras/Raf signaling pathway.	U 0126	121-126	mitogen-activated protein kinase 1	Mus musculus	44-47
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	U 0126	100-105	mitogen activated protein kinase 14	Rattus norvegicus	20-23
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	U 0126	100-105	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
27097549-7	2016	Western blot results identified upregulated Erk phosphorylation in the spinal cord-injured neurons, and also showed that U0126 inhibited phosphorylation of Erk, which is a downstream kinase in the Ras/Raf signaling pathway.	U 0126	121-126	mitogen-activated protein kinase 1	Mus musculus	156-159
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	U 0126	100-105	Eph receptor B1	Rattus norvegicus	28-31
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	U 0126	100-105	nitric oxide synthase 2	Rattus norvegicus	139-143
27097549-7	2016	Western blot results identified upregulated Erk phosphorylation in the spinal cord-injured neurons, and also showed that U0126 inhibited phosphorylation of Erk, which is a downstream kinase in the Ras/Raf signaling pathway.	U 0126	121-126	zinc fingers and homeoboxes 2	Mus musculus	201-204
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	U 0126	100-105	interleukin 1 beta	Rattus norvegicus	159-167
27212444-9	2016	In addition, the MEK1/2 inhibitor, U0126 significantly reduced SHS exposure-increased ETA receptor mRNA and protein levels as well as contractile responses mediated by ETA receptors.	U 0126	35-40	mitogen activated protein kinase kinase 1	Rattus norvegicus	17-23
27212444-14	2016	By using U0126 could inhibit the phosphorylated ERK1/2 protein but not MEK1/2.	U 0126	9-14	mitogen activated protein kinase 3	Rattus norvegicus	48-54
27034231-8	2016	In vitro inhibition with the ERK protein inhibitor U0126 mitigated ERK protein activation levels with a concomitant reduction in alkaline phosphatase activity.	U 0126	51-56	mitogen-activated protein kinase 1	Mus musculus	29-32
27034231-8	2016	In vitro inhibition with the ERK protein inhibitor U0126 mitigated ERK protein activation levels with a concomitant reduction in alkaline phosphatase activity.	U 0126	51-56	mitogen-activated protein kinase 1	Mus musculus	67-70
27034344-8	2016	This effect was abolished by treating the mice with U0126, a specific ERK pathway inhibitor, showing that, in vivo, the deleterious role of FPR2 also occurs through an ERK-dependent pathway.	U 0126	52-57	mitogen-activated protein kinase 1	Mus musculus	70-73
27034344-8	2016	This effect was abolished by treating the mice with U0126, a specific ERK pathway inhibitor, showing that, in vivo, the deleterious role of FPR2 also occurs through an ERK-dependent pathway.	U 0126	52-57	formyl peptide receptor 2	Mus musculus	140-144
27034344-8	2016	This effect was abolished by treating the mice with U0126, a specific ERK pathway inhibitor, showing that, in vivo, the deleterious role of FPR2 also occurs through an ERK-dependent pathway.	U 0126	52-57	mitogen-activated protein kinase 1	Mus musculus	168-171
27305660-7	2016	RESULTS: YAMC cells treated with PHGG exhibited significantly enhanced wound healing compared to the control cells; however, this enhancement was inhibited by both Y-27632 (RhoA inhibitor) and U0126 (ERK1/2 inhibitor).	U 0126	193-198	mitogen-activated protein kinase 3	Mus musculus	200-206
27404388-6	2016	Reducing COUP-TFII by U0126 or siRNA against COUP-TFII prevented the anti-osteogenic effect of FGF2, indicating that COUP-TFII plays a key role in the FGF2-mediated determination of osteoblast differentiation capability.	U 0126	22-27	nuclear receptor subfamily 2, group F, member 2	Mus musculus	9-18
27404388-6	2016	Reducing COUP-TFII by U0126 or siRNA against COUP-TFII prevented the anti-osteogenic effect of FGF2, indicating that COUP-TFII plays a key role in the FGF2-mediated determination of osteoblast differentiation capability.	U 0126	22-27	fibroblast growth factor 2	Mus musculus	95-99
27404388-6	2016	Reducing COUP-TFII by U0126 or siRNA against COUP-TFII prevented the anti-osteogenic effect of FGF2, indicating that COUP-TFII plays a key role in the FGF2-mediated determination of osteoblast differentiation capability.	U 0126	22-27	fibroblast growth factor 2	Mus musculus	151-155
27259234-7	2016	And ERK1/2 phosphorylation inhibition using specific inhibitor U0126 effectively suppressed cyclin A2 expression, and reduced G1/S-phase arrest induced by Ary.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	4-10
27259234-7	2016	And ERK1/2 phosphorylation inhibition using specific inhibitor U0126 effectively suppressed cyclin A2 expression, and reduced G1/S-phase arrest induced by Ary.	U 0126	63-68	cyclin A2	Homo sapiens	92-101
27170343-10	2016	Additionally, either LY294002 or U0126 treatment could inhibit STAT3 phosphorylation, whereas AG490 administration also reduced both Akt and ERK1/2 phosphorylation, indicating an interplay exists between RISK and SAFE pathways in melatonin"s cardioprotective effect.	U 0126	33-38	signal transducer and activator of transcription 3	Rattus norvegicus	63-68
26781487-5	2016	The involvement of extracellular regulated kinase (ERK) 1/2 and focal adhesion kinase (FAK) was studied by their specific inhibitors U0126 and PF-228, respectively.	U 0126	133-138	protein tyrosine kinase 2	Rattus norvegicus	64-85
27347410-8	2016	ICI182780 and U0126 could significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2.	U 0126	14-19	tyrosinase	Homo sapiens	131-134
27347410-8	2016	ICI182780 and U0126 could significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2.	U 0126	14-19	tyrosinase related protein 1	Homo sapiens	136-141
27347410-8	2016	ICI182780 and U0126 could significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2.	U 0126	14-19	dopachrome tautomerase	Homo sapiens	143-148
27347410-8	2016	ICI182780 and U0126 could significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	150-154
27347410-8	2016	ICI182780 and U0126 could significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	156-160
27347410-8	2016	ICI182780 and U0126 could significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2.	U 0126	14-19	mitogen-activated protein kinase 9	Homo sapiens	165-169
27298141-8	2016	The results showed that constitutive activation of MEK1 nullified the cardiac protection in RGS14 transgenic mice, and inhibition of MEK-ERK1/2 by U0126 reversed RGS14 deletion-related hypertrophic aggravation.	U 0126	147-152	mitogen-activated protein kinase 3	Mus musculus	137-143
27298141-8	2016	The results showed that constitutive activation of MEK1 nullified the cardiac protection in RGS14 transgenic mice, and inhibition of MEK-ERK1/2 by U0126 reversed RGS14 deletion-related hypertrophic aggravation.	U 0126	147-152	regulator of G-protein signaling 14	Mus musculus	162-167
26781487-5	2016	The involvement of extracellular regulated kinase (ERK) 1/2 and focal adhesion kinase (FAK) was studied by their specific inhibitors U0126 and PF-228, respectively.	U 0126	133-138	protein tyrosine kinase 2	Rattus norvegicus	87-90
26781487-6	2016	Compared with their stretched counterparts, unstretched MCA segments showed a significantly increased ETB receptor-mediated contractile response after 12 hr of incubation, which was attenuated by either U0126 or PF-228.	U 0126	203-208	endothelin receptor type B	Rattus norvegicus	102-105
26757161-11	2016	Administration of MEK inhibitor, U0126, improved mortality and reduced both viral load and cytokine levels.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
27102414-5	2016	Inhibiting ERK pathway activation with U0126 (a MEK1/2 inhibitor) markedly blocked LukS-PV-induced differentiation and decreased the phosphorylation of c-JUN and c-FOS.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	11-14
27102414-5	2016	Inhibiting ERK pathway activation with U0126 (a MEK1/2 inhibitor) markedly blocked LukS-PV-induced differentiation and decreased the phosphorylation of c-JUN and c-FOS.	U 0126	39-44	mitogen-activated protein kinase kinase 1	Homo sapiens	48-54
27102414-5	2016	Inhibiting ERK pathway activation with U0126 (a MEK1/2 inhibitor) markedly blocked LukS-PV-induced differentiation and decreased the phosphorylation of c-JUN and c-FOS.	U 0126	39-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	152-157
27102414-5	2016	Inhibiting ERK pathway activation with U0126 (a MEK1/2 inhibitor) markedly blocked LukS-PV-induced differentiation and decreased the phosphorylation of c-JUN and c-FOS.	U 0126	39-44	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	162-167
26581032-6	2016	However, its proliferative effect was diminished by a MEK1/2 inhibitor (U0126) and TrkB siRNA transfection.	U 0126	72-77	mitogen-activated protein kinase kinase 1	Homo sapiens	54-60
26581032-10	2016	Moreover, OBA9 cells pretreated with SP600125 or p75 siRNA showed cell proliferation by BDNF stimulation, though it was reduced by U0126 and TrkB siRNA.	U 0126	131-136	PC4 and SFRS1 interacting protein 1	Homo sapiens	49-52
27168176-11	2016	The altered BCRP expression and function by ammonia and H2 O2 were restored by ROS scavenger N-acetylcysteine and ERK1/2 inhibitor U0126.	U 0126	131-136	mitogen activated protein kinase 3	Rattus norvegicus	114-120
27043257-10	2016	Western blot analysis revealed enhanced phosphorylated ERK1/2 signaling after addition of rh128 or C11 peptide and reduced phosphorylated ERK1/2 signaling after blocking with a specific MAPK inhibitor (U0126).	U 0126	202-207	mitogen-activated protein kinase 3	Homo sapiens	138-144
27043257-10	2016	Western blot analysis revealed enhanced phosphorylated ERK1/2 signaling after addition of rh128 or C11 peptide and reduced phosphorylated ERK1/2 signaling after blocking with a specific MAPK inhibitor (U0126).	U 0126	202-207	mitogen-activated protein kinase 3	Homo sapiens	186-190
27155559-7	2016	With the pretreatment of U0126 (MEK1/2 inhibitor), SB203580 (p38 inhibitor) or BAY 11-7082 (NF-kappaB inhibitor), the aggravated damage in the alpha-irradiated Beas-2B cells could be largely alleviated.	U 0126	25-30	mitogen-activated protein kinase kinase 1	Homo sapiens	32-38
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	U 0126	27-32	mitogen-activated protein kinase 14	Mus musculus	85-88
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	U 0126	27-32	mitogen-activated protein kinase 8	Mus musculus	93-96
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	U 0126	27-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	U 0126	27-32	colony stimulating factor 3 (granulocyte)	Mus musculus	178-183
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	U 0126	27-32	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	185-191
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	U 0126	27-32	colony stimulating factor 1 (macrophage)	Mus musculus	186-191
27143440-6	2016	The neuroprotective effects of Res were suppressed by pretreatment with MK801, an NMDA receptor blocker, or U0126, an extracellular signal regulated kinase 1/2 (ERK1/2) kinase inhibitor.	U 0126	108-113	mitogen activated protein kinase 3	Rattus norvegicus	118-159
27143440-6	2016	The neuroprotective effects of Res were suppressed by pretreatment with MK801, an NMDA receptor blocker, or U0126, an extracellular signal regulated kinase 1/2 (ERK1/2) kinase inhibitor.	U 0126	108-113	mitogen activated protein kinase 3	Rattus norvegicus	161-167
27169363-7	2016	Furthermore, we demonstrated inhibitor-specific profiling of MEK1 phosphospecies by using three MEK inhibitors: TAK-733, PD98059, and U0126.	U 0126	134-139	mitogen-activated protein kinase kinase 1	Homo sapiens	61-65
27169363-7	2016	Furthermore, we demonstrated inhibitor-specific profiling of MEK1 phosphospecies by using three MEK inhibitors: TAK-733, PD98059, and U0126.	U 0126	134-139	mitogen-activated protein kinase kinase 1	Homo sapiens	61-64
27175589-7	2016	Meanwhile, overexpression of Pinin attenuates GD initiated poly ADP-ribose polymerase (PARP) cleavage and ERK1/2 dephosphorylation, which can be completely blocked with MEK1/2 inhibitor U0126.	U 0126	186-191	pinin, desmosome associated protein	Homo sapiens	29-34
27175589-7	2016	Meanwhile, overexpression of Pinin attenuates GD initiated poly ADP-ribose polymerase (PARP) cleavage and ERK1/2 dephosphorylation, which can be completely blocked with MEK1/2 inhibitor U0126.	U 0126	186-191	poly(ADP-ribose) polymerase 1	Homo sapiens	59-85
27175589-7	2016	Meanwhile, overexpression of Pinin attenuates GD initiated poly ADP-ribose polymerase (PARP) cleavage and ERK1/2 dephosphorylation, which can be completely blocked with MEK1/2 inhibitor U0126.	U 0126	186-191	poly(ADP-ribose) polymerase 1	Homo sapiens	87-91
27175589-7	2016	Meanwhile, overexpression of Pinin attenuates GD initiated poly ADP-ribose polymerase (PARP) cleavage and ERK1/2 dephosphorylation, which can be completely blocked with MEK1/2 inhibitor U0126.	U 0126	186-191	mitogen-activated protein kinase 3	Homo sapiens	106-112
27175589-7	2016	Meanwhile, overexpression of Pinin attenuates GD initiated poly ADP-ribose polymerase (PARP) cleavage and ERK1/2 dephosphorylation, which can be completely blocked with MEK1/2 inhibitor U0126.	U 0126	186-191	mitogen-activated protein kinase kinase 1	Homo sapiens	169-175
27213581-4	2016	Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059.	U 0126	316-321	ADP-ribosylation factor 1	Mus musculus	64-68
27213581-4	2016	Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059.	U 0126	316-321	ADP-ribosylation factor 1	Mus musculus	214-218
27213581-4	2016	Furthermore, we have shown that overexpression and knockdown of ARF1 produce opposing effects on prostate cancer cell proliferation, anchorage-independent growth and tumor growth in mouse xenograft models and that ARF1-mediated cell proliferation can be abolished by the Raf1 inhibitor GW5074 and the MEK inhibitors U0126 and PD98059.	U 0126	316-321	v-raf-leukemia viral oncogene 1	Mus musculus	271-275
27223076-8	2016	Importantly, activin B-induced cell migration was inhibited by forced-expression of E-cadherin or pre-treatment with the activin/TGF-beta type I receptor inhibitor SB431542 or the MEK inhibitor U0126.	U 0126	194-199	inhibin subunit beta E	Homo sapiens	13-20
27223076-8	2016	Importantly, activin B-induced cell migration was inhibited by forced-expression of E-cadherin or pre-treatment with the activin/TGF-beta type I receptor inhibitor SB431542 or the MEK inhibitor U0126.	U 0126	194-199	mitogen-activated protein kinase kinase 7	Homo sapiens	180-183
27349568-6	2016	WISP1 enhanced TLR4 mediated ERK signaling and U0126 (an ERK inhibitor) blocked LPS induced beta3 integrin expression and WISP1 enhanced TNF-alpha release.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	57-60
27349568-6	2016	WISP1 enhanced TLR4 mediated ERK signaling and U0126 (an ERK inhibitor) blocked LPS induced beta3 integrin expression and WISP1 enhanced TNF-alpha release.	U 0126	47-52	cellular communication network factor 4	Mus musculus	122-127
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	U 0126	26-31	mitogen-activated protein kinase kinase 1	Homo sapiens	8-14
27301426-6	2016	Our results demonstrate that tRNA interacts with the wild-type and mutant MEK2 in pancreatic cancer cells; furthermore, the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction.	U 0126	139-144	mitochondrially encoded tRNA glycine	Homo sapiens	29-33
27301426-6	2016	Our results demonstrate that tRNA interacts with the wild-type and mutant MEK2 in pancreatic cancer cells; furthermore, the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction.	U 0126	139-144	mitogen-activated protein kinase kinase 2	Homo sapiens	74-78
27301426-6	2016	Our results demonstrate that tRNA interacts with the wild-type and mutant MEK2 in pancreatic cancer cells; furthermore, the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction.	U 0126	139-144	mitogen-activated protein kinase kinase 2	Homo sapiens	124-128
27301426-6	2016	Our results demonstrate that tRNA interacts with the wild-type and mutant MEK2 in pancreatic cancer cells; furthermore, the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction.	U 0126	139-144	mitochondrially encoded tRNA glycine	Homo sapiens	171-175
27301426-6	2016	Our results demonstrate that tRNA interacts with the wild-type and mutant MEK2 in pancreatic cancer cells; furthermore, the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction.	U 0126	139-144	mitogen-activated protein kinase kinase 2	Homo sapiens	124-128
27125977-5	2016	Interestingly, the effect of CTRP6 siRNA was attenuated by U0126 (a special p-Erk1/2 inhibitor) in myoblasts.	U 0126	59-64	C1q and TNF related 6	Homo sapiens	29-34
27125977-5	2016	Interestingly, the effect of CTRP6 siRNA was attenuated by U0126 (a special p-Erk1/2 inhibitor) in myoblasts.	U 0126	59-64	mitogen-activated protein kinase 3	Homo sapiens	78-84
27009876-9	2016	MEK/ERK inhibitor U0126 remarkably blocked the Cav-1-induced counteraction against apoptosis following hypoxia, indicating Ras/Raf/ERK pathway is required for the Cav-1"s prosurvival role.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
27009876-9	2016	MEK/ERK inhibitor U0126 remarkably blocked the Cav-1-induced counteraction against apoptosis following hypoxia, indicating Ras/Raf/ERK pathway is required for the Cav-1"s prosurvival role.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
27009876-9	2016	MEK/ERK inhibitor U0126 remarkably blocked the Cav-1-induced counteraction against apoptosis following hypoxia, indicating Ras/Raf/ERK pathway is required for the Cav-1"s prosurvival role.	U 0126	18-23	caveolin 1	Homo sapiens	47-52
27009876-9	2016	MEK/ERK inhibitor U0126 remarkably blocked the Cav-1-induced counteraction against apoptosis following hypoxia, indicating Ras/Raf/ERK pathway is required for the Cav-1"s prosurvival role.	U 0126	18-23	zinc fingers and homeoboxes 2	Homo sapiens	127-130
27009876-9	2016	MEK/ERK inhibitor U0126 remarkably blocked the Cav-1-induced counteraction against apoptosis following hypoxia, indicating Ras/Raf/ERK pathway is required for the Cav-1"s prosurvival role.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	131-134
27009876-9	2016	MEK/ERK inhibitor U0126 remarkably blocked the Cav-1-induced counteraction against apoptosis following hypoxia, indicating Ras/Raf/ERK pathway is required for the Cav-1"s prosurvival role.	U 0126	18-23	caveolin 1	Homo sapiens	163-168
26906511-11	2016	In addition, DPI (NOX4 inhibitor) and U0126 (ERK1/2 inhibitor) rather than NAC decreased the protein expression of NOX4.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	45-51
26906511-11	2016	In addition, DPI (NOX4 inhibitor) and U0126 (ERK1/2 inhibitor) rather than NAC decreased the protein expression of NOX4.	U 0126	38-43	NADPH oxidase 4	Homo sapiens	115-119
26906511-12	2016	NAC, DPI, and U0126 increased the protein expression of eNOS.	U 0126	14-19	nitric oxide synthase 3	Homo sapiens	56-60
26906511-13	2016	Furthermore, U0126 rather than DPI and NAC decreased the protein expression of p-ERK1/2.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	81-87
27091895-9	2016	In addition, the requirement of the MEK1/2-ERK1/2 signaling for RGS12-mediated cardiac hypertrophy was confirmed in rescue experiments using the MEK1/2-specific inhibitor U0126.	U 0126	171-176	mitogen activated protein kinase kinase 1	Rattus norvegicus	36-42
27091895-9	2016	In addition, the requirement of the MEK1/2-ERK1/2 signaling for RGS12-mediated cardiac hypertrophy was confirmed in rescue experiments using the MEK1/2-specific inhibitor U0126.	U 0126	171-176	mitogen activated protein kinase 3	Rattus norvegicus	43-49
27091895-9	2016	In addition, the requirement of the MEK1/2-ERK1/2 signaling for RGS12-mediated cardiac hypertrophy was confirmed in rescue experiments using the MEK1/2-specific inhibitor U0126.	U 0126	171-176	regulator of G-protein signaling 12	Rattus norvegicus	64-69
27091895-9	2016	In addition, the requirement of the MEK1/2-ERK1/2 signaling for RGS12-mediated cardiac hypertrophy was confirmed in rescue experiments using the MEK1/2-specific inhibitor U0126.	U 0126	171-176	mitogen activated protein kinase kinase 1	Rattus norvegicus	145-151
27122190-5	2016	In addition, the nuclear factor-kappaB (NF-kappaB) inhibitor, Bay 11-7082, and mitogen-activated protein kinase (MAPK) inhibitors (SB203580 and U0126) respectively reduced the adhesion of monocytes to TNF-alpha-stimulated HUVECs, and suppressed ICAM-1 and VCAM-1 expression in TNF-alpha stimulated HUVECs.	U 0126	144-149	nuclear factor kappa B subunit 1	Homo sapiens	17-38
27122190-5	2016	In addition, the nuclear factor-kappaB (NF-kappaB) inhibitor, Bay 11-7082, and mitogen-activated protein kinase (MAPK) inhibitors (SB203580 and U0126) respectively reduced the adhesion of monocytes to TNF-alpha-stimulated HUVECs, and suppressed ICAM-1 and VCAM-1 expression in TNF-alpha stimulated HUVECs.	U 0126	144-149	tumor necrosis factor	Homo sapiens	201-210
27122190-5	2016	In addition, the nuclear factor-kappaB (NF-kappaB) inhibitor, Bay 11-7082, and mitogen-activated protein kinase (MAPK) inhibitors (SB203580 and U0126) respectively reduced the adhesion of monocytes to TNF-alpha-stimulated HUVECs, and suppressed ICAM-1 and VCAM-1 expression in TNF-alpha stimulated HUVECs.	U 0126	144-149	intercellular adhesion molecule 1	Homo sapiens	245-251
27122190-5	2016	In addition, the nuclear factor-kappaB (NF-kappaB) inhibitor, Bay 11-7082, and mitogen-activated protein kinase (MAPK) inhibitors (SB203580 and U0126) respectively reduced the adhesion of monocytes to TNF-alpha-stimulated HUVECs, and suppressed ICAM-1 and VCAM-1 expression in TNF-alpha stimulated HUVECs.	U 0126	144-149	vascular cell adhesion molecule 1	Homo sapiens	256-262
27122190-5	2016	In addition, the nuclear factor-kappaB (NF-kappaB) inhibitor, Bay 11-7082, and mitogen-activated protein kinase (MAPK) inhibitors (SB203580 and U0126) respectively reduced the adhesion of monocytes to TNF-alpha-stimulated HUVECs, and suppressed ICAM-1 and VCAM-1 expression in TNF-alpha stimulated HUVECs.	U 0126	144-149	tumor necrosis factor	Homo sapiens	277-286
26576043-5	2016	The role of ERK1/2 and p38MAPK pathways were determined by their inhibitors U0126 and SB202190 respectively.	U 0126	76-81	mitogen-activated protein kinase 3	Homo sapiens	12-18
26915107-6	2016	Using immunocytochemistry analysis, we observed that the ERK specific inhibitor U0126 blocked the ERK activation induced by high glucose and reversed the inhibitory effect of high glucose on P0 expression.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	57-60
26915107-6	2016	Using immunocytochemistry analysis, we observed that the ERK specific inhibitor U0126 blocked the ERK activation induced by high glucose and reversed the inhibitory effect of high glucose on P0 expression.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	98-101
27035858-7	2016	Combined treatment with DTT and U0126, an inhibitor of ERK upstream activators mitogen-activated protein kinase (MAPK) kinase 1 and 2 (MEK1/2), blocked autophagy flux in HeLa cells.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	55-58
27035858-7	2016	Combined treatment with DTT and U0126, an inhibitor of ERK upstream activators mitogen-activated protein kinase (MAPK) kinase 1 and 2 (MEK1/2), blocked autophagy flux in HeLa cells.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	113-117
27035858-7	2016	Combined treatment with DTT and U0126, an inhibitor of ERK upstream activators mitogen-activated protein kinase (MAPK) kinase 1 and 2 (MEK1/2), blocked autophagy flux in HeLa cells.	U 0126	32-37	mitogen-activated protein kinase kinase 1	Homo sapiens	135-141
26715278-6	2016	Blocking ERK activation by U0126 or siRNAs was able to potentiate the pro-apoptotic activity of OA on cancer cells.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	9-12
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	95-101
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	U 0126	26-31	ribosomal protein S6 kinase B1	Homo sapiens	103-109
26994515-9	2016	Also, a MEK1/2 inhibitor (U0126) significantly decreased naringenin-induced phosphorylation of ERK1/2, P70S6K and S6K proteins in pTr cells.	U 0126	26-31	ribosomal protein S6 kinase B1	Homo sapiens	106-109
27240461-7	2016	Moreover, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and/or the ERK inhibitor U0126 counteracted the protective effect of liraglutide.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	81-84
27091075-9	2016	After treatment with MEK inhibitor U0126, ERK1-2 showed no activation, with a consequent decrease in Nrf2, no increase in HO-1 and a significant increase of iNOS.	U 0126	35-40	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
27091075-9	2016	After treatment with MEK inhibitor U0126, ERK1-2 showed no activation, with a consequent decrease in Nrf2, no increase in HO-1 and a significant increase of iNOS.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	42-48
27091075-9	2016	After treatment with MEK inhibitor U0126, ERK1-2 showed no activation, with a consequent decrease in Nrf2, no increase in HO-1 and a significant increase of iNOS.	U 0126	35-40	NFE2 like bZIP transcription factor 2	Homo sapiens	101-105
27091075-9	2016	After treatment with MEK inhibitor U0126, ERK1-2 showed no activation, with a consequent decrease in Nrf2, no increase in HO-1 and a significant increase of iNOS.	U 0126	35-40	nitric oxide synthase 2	Homo sapiens	157-161
27213360-9	2016	Similarly, Ang II-induced ERK phosphorylation was suppressed with MK0626 and Ang II-induced DPP4 activity was suppressed by U0126.	U 0126	124-129	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	11-17
27213360-9	2016	Similarly, Ang II-induced ERK phosphorylation was suppressed with MK0626 and Ang II-induced DPP4 activity was suppressed by U0126.	U 0126	124-129	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	77-83
27213360-9	2016	Similarly, Ang II-induced ERK phosphorylation was suppressed with MK0626 and Ang II-induced DPP4 activity was suppressed by U0126.	U 0126	124-129	dipeptidylpeptidase 4	Mus musculus	92-96
27129169-11	2016	Importantly, the effects of betacellulin on E-cadherin, Slug and cell migration were attenuated by pre-treatment with either U0126 or LY294002.	U 0126	125-130	betacellulin	Homo sapiens	28-40
27129169-11	2016	Importantly, the effects of betacellulin on E-cadherin, Slug and cell migration were attenuated by pre-treatment with either U0126 or LY294002.	U 0126	125-130	cadherin 1	Homo sapiens	44-54
27129169-11	2016	Importantly, the effects of betacellulin on E-cadherin, Slug and cell migration were attenuated by pre-treatment with either U0126 or LY294002.	U 0126	125-130	snail family transcriptional repressor 2	Homo sapiens	56-60
27045084-6	2016	In vitro, MEK1/2 inhibitors (PD98059 and U0126) substantially inhibited phosphorylation of MEK1/2 and ERK1/2.	U 0126	41-46	mitogen-activated protein kinase kinase 1	Mus musculus	10-16
27045084-6	2016	In vitro, MEK1/2 inhibitors (PD98059 and U0126) substantially inhibited phosphorylation of MEK1/2 and ERK1/2.	U 0126	41-46	mitogen-activated protein kinase kinase 1	Mus musculus	91-97
27045084-6	2016	In vitro, MEK1/2 inhibitors (PD98059 and U0126) substantially inhibited phosphorylation of MEK1/2 and ERK1/2.	U 0126	41-46	mitogen-activated protein kinase 3	Mus musculus	102-108
27178245-6	2016	We found that p42/p44 mitogen-activated protein kinase inhibitors, PD98059 and U0126, suppressed the induction of pre-long-term potentiation.	U 0126	79-84	cyclin dependent kinase 20	Homo sapiens	14-17
27178245-6	2016	We found that p42/p44 mitogen-activated protein kinase inhibitors, PD98059 and U0126, suppressed the induction of pre-long-term potentiation.	U 0126	79-84	interferon induced protein 44	Homo sapiens	18-21
26923440-5	2016	Using the inhibitors AH7614, K252c, U0126, wortmannin, and LY294002, we demonstrate that the effect of DHA is mediated through GPR120 to downstream PKC/MAPK and PI3K signaling.	U 0126	36-41	free fatty acid receptor 4	Homo sapiens	127-133
27168723-5	2015	c-myc activation was inhibited upon treatment with ERK, PI3 kinase, and c-src pathway inhibitors, U0126, LY294002, and PP2.	U 0126	98-103	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
27217781-7	2016	Furthermore, overexpressed HER2 induced the ERK phosphorylation, and this was abolished by the treatment with U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	110-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
27217781-7	2016	Furthermore, overexpressed HER2 induced the ERK phosphorylation, and this was abolished by the treatment with U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	44-47
27217781-7	2016	Furthermore, overexpressed HER2 induced the ERK phosphorylation, and this was abolished by the treatment with U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	148-151
27217781-7	2016	Furthermore, overexpressed HER2 induced the ERK phosphorylation, and this was abolished by the treatment with U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	175-178
27217781-8	2016	HER2-induced expression and promoter activity of COX-2 were also suppressed by U0126, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	79-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
27217781-8	2016	HER2-induced expression and promoter activity of COX-2 were also suppressed by U0126, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	79-84	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-54
27217781-8	2016	HER2-induced expression and promoter activity of COX-2 were also suppressed by U0126, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
27217781-8	2016	HER2-induced expression and promoter activity of COX-2 were also suppressed by U0126, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	110-113
27217781-8	2016	HER2-induced expression and promoter activity of COX-2 were also suppressed by U0126, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	79-84	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	142-147
27217781-9	2016	In addition, HER2 induced activation of AKT signaling pathway, which was reversed by pretreatment with U0126 and COX-2 siRNA.	U 0126	103-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
27217781-10	2016	MTT and invasion assays revealed that HER2 induced cell proliferation and invasion that were reversed by pretreatment with U0126 and COX-2 siRNA.	U 0126	123-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
27009860-3	2016	In accordance, ERK2 was found to phosphorylate EBNA1 serine 383 in a reaction suppressed by H20 (a structural congener of the ERK inhibitor), U0126 (an inhibitor of MEK kinase), and mutations at substrate (S383A) or putative ERK docking sites.	U 0126	142-147	mitogen-activated protein kinase 1	Homo sapiens	15-19
27009860-3	2016	In accordance, ERK2 was found to phosphorylate EBNA1 serine 383 in a reaction suppressed by H20 (a structural congener of the ERK inhibitor), U0126 (an inhibitor of MEK kinase), and mutations at substrate (S383A) or putative ERK docking sites.	U 0126	142-147	EBNA-1	Human gammaherpesvirus 4	47-52
27009860-3	2016	In accordance, ERK2 was found to phosphorylate EBNA1 serine 383 in a reaction suppressed by H20 (a structural congener of the ERK inhibitor), U0126 (an inhibitor of MEK kinase), and mutations at substrate (S383A) or putative ERK docking sites.	U 0126	142-147	mitogen-activated protein kinase 1	Homo sapiens	15-18
27009860-4	2016	Wild-type (S383) and phosphomimetic (S383D) EBNA1 demonstrated comparable transactivation function, which was suppressed by H20 or U0126.	U 0126	131-136	EBNA-1	Human gammaherpesvirus 4	44-49
27009860-6	2016	ERK2 knock-down by siRNA, or treatment with U0126 or H20 repressed EBNA1-dependent transactivation.Collectively, these data indicate that blocking ERK2-directed phosphorylation can suppress EBNA1-transactivation function in latent EBV-infected cells, validating ERK2 as a drug target for EBV-associated disorders.	U 0126	44-49	EBNA-1	Human gammaherpesvirus 4	67-72
27009860-6	2016	ERK2 knock-down by siRNA, or treatment with U0126 or H20 repressed EBNA1-dependent transactivation.Collectively, these data indicate that blocking ERK2-directed phosphorylation can suppress EBNA1-transactivation function in latent EBV-infected cells, validating ERK2 as a drug target for EBV-associated disorders.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	147-151
27009860-6	2016	ERK2 knock-down by siRNA, or treatment with U0126 or H20 repressed EBNA1-dependent transactivation.Collectively, these data indicate that blocking ERK2-directed phosphorylation can suppress EBNA1-transactivation function in latent EBV-infected cells, validating ERK2 as a drug target for EBV-associated disorders.	U 0126	44-49	EBNA-1	Human gammaherpesvirus 4	190-195
27016422-8	2016	Blocking PI-3K through wortmannin or ERK1/2 through U0126 attenuated argon-mediated neuroprotection.These data provide a new molecular mechanism for the potential application of Argon as a neuroprotectant in HIE.	U 0126	52-57	mitogen activated protein kinase 3	Rattus norvegicus	37-43
27009860-6	2016	ERK2 knock-down by siRNA, or treatment with U0126 or H20 repressed EBNA1-dependent transactivation.Collectively, these data indicate that blocking ERK2-directed phosphorylation can suppress EBNA1-transactivation function in latent EBV-infected cells, validating ERK2 as a drug target for EBV-associated disorders.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	147-151
27135658-2	2016	MATERIAL AND METHODS We observed the relationship between the activation of ERK1/2 in the rat spinal cord and intrathecal transplantation of MSCs, as well as the effect of U0126, a MEK1/2 (upstream protein of ERK1/2) inhibitor, on a spinal cord ischemia-reperfusion injury model in rats using Basso Beattie Bresnahan (BBB) scoring, somatosensory evoked potentials (SSEPs), immunohistochemistry, and Western blot analysis.	U 0126	172-177	mitogen activated protein kinase kinase 1	Rattus norvegicus	181-187
26919896-9	2016	Inhibition of the ERK pathway using U0126 enhanced cytomix-induced caspase-3 activity.	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	18-21
26919896-9	2016	Inhibition of the ERK pathway using U0126 enhanced cytomix-induced caspase-3 activity.	U 0126	36-41	caspase 3	Homo sapiens	67-76
26861188-11	2016	U0126, a MEK inhibitor, also decreased FRA1 phosphorylation and expression as well as MMP-1 expression.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
26861188-11	2016	U0126, a MEK inhibitor, also decreased FRA1 phosphorylation and expression as well as MMP-1 expression.	U 0126	0-5	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	39-43
26861188-11	2016	U0126, a MEK inhibitor, also decreased FRA1 phosphorylation and expression as well as MMP-1 expression.	U 0126	0-5	matrix metallopeptidase 1	Homo sapiens	86-91
27119567-9	2016	Growth stimulation by IL-27 was suppressed by the specific MEK inhibitor, U0126, indicating that IL-27-induced cell proliferation is mainly mediated through the activation of the MAPK/ERK signaling pathway.	U 0126	74-79	interleukin 27	Homo sapiens	22-27
27119567-9	2016	Growth stimulation by IL-27 was suppressed by the specific MEK inhibitor, U0126, indicating that IL-27-induced cell proliferation is mainly mediated through the activation of the MAPK/ERK signaling pathway.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	59-62
27119567-9	2016	Growth stimulation by IL-27 was suppressed by the specific MEK inhibitor, U0126, indicating that IL-27-induced cell proliferation is mainly mediated through the activation of the MAPK/ERK signaling pathway.	U 0126	74-79	interleukin 27	Homo sapiens	97-102
27119567-9	2016	Growth stimulation by IL-27 was suppressed by the specific MEK inhibitor, U0126, indicating that IL-27-induced cell proliferation is mainly mediated through the activation of the MAPK/ERK signaling pathway.	U 0126	74-79	mitogen-activated protein kinase 3	Homo sapiens	179-183
27119567-9	2016	Growth stimulation by IL-27 was suppressed by the specific MEK inhibitor, U0126, indicating that IL-27-induced cell proliferation is mainly mediated through the activation of the MAPK/ERK signaling pathway.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	184-187
27018068-6	2016	The CBF-induced upregulation of zonula occludens-1 and occludin was prevented by U0126 or SB203580, suggesting the involvement of the MEK and p38 MAPK pathways in the CBF-induced changes in tight junctions.	U 0126	81-86	CCAAT/enhancer binding protein zeta	Rattus norvegicus	167-170
27035254-11	2016	Anti-RAGE antibody and the ERK1/2 inhibitor, U0126, attenuated the HMGB1-mediated changes in barrier permeability, restored the expression levels of occludin and claudin-1 and pevented the redistribution of E-cadherin and beta-catenin.	U 0126	45-50	mitogen-activated protein kinase 3	Homo sapiens	27-33
27035254-11	2016	Anti-RAGE antibody and the ERK1/2 inhibitor, U0126, attenuated the HMGB1-mediated changes in barrier permeability, restored the expression levels of occludin and claudin-1 and pevented the redistribution of E-cadherin and beta-catenin.	U 0126	45-50	high mobility group box 1	Homo sapiens	67-72
27035254-11	2016	Anti-RAGE antibody and the ERK1/2 inhibitor, U0126, attenuated the HMGB1-mediated changes in barrier permeability, restored the expression levels of occludin and claudin-1 and pevented the redistribution of E-cadherin and beta-catenin.	U 0126	45-50	occludin	Homo sapiens	149-157
27035254-11	2016	Anti-RAGE antibody and the ERK1/2 inhibitor, U0126, attenuated the HMGB1-mediated changes in barrier permeability, restored the expression levels of occludin and claudin-1 and pevented the redistribution of E-cadherin and beta-catenin.	U 0126	45-50	claudin 1	Homo sapiens	162-171
27035254-11	2016	Anti-RAGE antibody and the ERK1/2 inhibitor, U0126, attenuated the HMGB1-mediated changes in barrier permeability, restored the expression levels of occludin and claudin-1 and pevented the redistribution of E-cadherin and beta-catenin.	U 0126	45-50	cadherin 1	Homo sapiens	207-217
27035254-11	2016	Anti-RAGE antibody and the ERK1/2 inhibitor, U0126, attenuated the HMGB1-mediated changes in barrier permeability, restored the expression levels of occludin and claudin-1 and pevented the redistribution of E-cadherin and beta-catenin.	U 0126	45-50	catenin beta 1	Homo sapiens	222-234
27018068-6	2016	The CBF-induced upregulation of zonula occludens-1 and occludin was prevented by U0126 or SB203580, suggesting the involvement of the MEK and p38 MAPK pathways in the CBF-induced changes in tight junctions.	U 0126	81-86	CCAAT/enhancer binding protein zeta	Rattus norvegicus	4-7
27018068-6	2016	The CBF-induced upregulation of zonula occludens-1 and occludin was prevented by U0126 or SB203580, suggesting the involvement of the MEK and p38 MAPK pathways in the CBF-induced changes in tight junctions.	U 0126	81-86	occludin	Rattus norvegicus	55-63
26986870-8	2016	Inhibition of MAPKs using specific inhibitors (ERK inhibitor U0126, JNK inhibitor SP600125 and P38 inhibitor SB202190) facilitated TRAIL-mediated apoptosis and cytotoxicity.	U 0126	61-66	TNF superfamily member 10	Homo sapiens	131-136
26993765-7	2016	Both BAY 11-7085-induced autophagy and GR activation were down regulated with PPAR-gamma agonist, 15d-PGJ2 and MEK/ERK inhibitor UO126.	U 0126	129-134	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
26987083-8	2016	Inactivation of the AKT pathway by GSK690693 significantly decreased NaHS-induced p-ERK1/2 expression, and inhibition of the ERK1/2 pathway by U0126 markedly increased NaHS-induced p-AKT expression.	U 0126	143-148	mitogen-activated protein kinase 3	Homo sapiens	125-131
26987083-8	2016	Inactivation of the AKT pathway by GSK690693 significantly decreased NaHS-induced p-ERK1/2 expression, and inhibition of the ERK1/2 pathway by U0126 markedly increased NaHS-induced p-AKT expression.	U 0126	143-148	AKT serine/threonine kinase 1	Homo sapiens	183-186
27008853-5	2016	Additionally, p53 knockout attenuated the apoptosis, and the apoptosis-related protein bax expression and cleaved caspase-3 activation induced by MPE in the p53 knockout C57BL/6 mice, whereas JNK inhibitor SP600125 but not ERK inhibitor U0126 inhibited MPE-induced apoptosis, supporting the conclusion that JNK/p53 might play a critical role in the tubular cell apoptosis induced by MPE and other 3-MCPD fatty acid esters.	U 0126	237-242	transformation related protein 53, pseudogene	Mus musculus	14-17
27008853-5	2016	Additionally, p53 knockout attenuated the apoptosis, and the apoptosis-related protein bax expression and cleaved caspase-3 activation induced by MPE in the p53 knockout C57BL/6 mice, whereas JNK inhibitor SP600125 but not ERK inhibitor U0126 inhibited MPE-induced apoptosis, supporting the conclusion that JNK/p53 might play a critical role in the tubular cell apoptosis induced by MPE and other 3-MCPD fatty acid esters.	U 0126	237-242	mitogen-activated protein kinase 8	Mus musculus	192-195
26996579-6	2016	RESULTS: OSM-induced MMP-2 and -9 protein expression was significantly suppressed by STAT3 inhibition with stattic and STAT3 siRNA silencing, whereas the ERK1/2 inhibitor (U0126) and ERK silencing significantly suppressed OSM-induced MMP-2 protein expression.	U 0126	172-177	mitogen-activated protein kinase 1	Homo sapiens	154-157
27126934-6	2016	In vitro, human lung fibroblasts (HLF-1) were pretreated with the ERK1/2 inhibitor U0126 or the MSK1 inhibitor H89 respectively, and then treated with the human recombinant IL-33 (rIL-33).	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	66-72
27126934-9	2016	RESULTS: The pre-treatment with the ERK1/2 inhibitor U0126 or anti-IL-33 antibody significantly abolished the OVA-induced airway remodeling, increased expressions of IL-33, alpha-SMA, Col1, and phosphorylation of ERK1/2 and MSK1 in the airway of mice.	U 0126	53-58	mitogen-activated protein kinase 3	Mus musculus	36-42
27126934-9	2016	RESULTS: The pre-treatment with the ERK1/2 inhibitor U0126 or anti-IL-33 antibody significantly abolished the OVA-induced airway remodeling, increased expressions of IL-33, alpha-SMA, Col1, and phosphorylation of ERK1/2 and MSK1 in the airway of mice.	U 0126	53-58	interleukin 33	Mus musculus	166-171
27126934-9	2016	RESULTS: The pre-treatment with the ERK1/2 inhibitor U0126 or anti-IL-33 antibody significantly abolished the OVA-induced airway remodeling, increased expressions of IL-33, alpha-SMA, Col1, and phosphorylation of ERK1/2 and MSK1 in the airway of mice.	U 0126	53-58	actin alpha 2, smooth muscle, aorta	Mus musculus	173-182
27126934-9	2016	RESULTS: The pre-treatment with the ERK1/2 inhibitor U0126 or anti-IL-33 antibody significantly abolished the OVA-induced airway remodeling, increased expressions of IL-33, alpha-SMA, Col1, and phosphorylation of ERK1/2 and MSK1 in the airway of mice.	U 0126	53-58	mitogen-activated protein kinase 3	Mus musculus	213-219
27126934-9	2016	RESULTS: The pre-treatment with the ERK1/2 inhibitor U0126 or anti-IL-33 antibody significantly abolished the OVA-induced airway remodeling, increased expressions of IL-33, alpha-SMA, Col1, and phosphorylation of ERK1/2 and MSK1 in the airway of mice.	U 0126	53-58	ribosomal protein S6 kinase, polypeptide 5	Mus musculus	224-228
27126934-10	2016	In vitro, the increased expressions of alpha-SMA and Col1 and the phosphorylation of ERK1/2 and MSK1 induced by rIL-33 in HLF-1 cells were markedly inhibited by the pre-treatment with U0126 or H89.	U 0126	184-189	actin alpha 2, smooth muscle, aorta	Mus musculus	39-48
27126934-10	2016	In vitro, the increased expressions of alpha-SMA and Col1 and the phosphorylation of ERK1/2 and MSK1 induced by rIL-33 in HLF-1 cells were markedly inhibited by the pre-treatment with U0126 or H89.	U 0126	184-189	mitogen-activated protein kinase 3	Mus musculus	85-91
27126934-10	2016	In vitro, the increased expressions of alpha-SMA and Col1 and the phosphorylation of ERK1/2 and MSK1 induced by rIL-33 in HLF-1 cells were markedly inhibited by the pre-treatment with U0126 or H89.	U 0126	184-189	ribosomal protein S6 kinase, polypeptide 5	Mus musculus	96-100
27126934-10	2016	In vitro, the increased expressions of alpha-SMA and Col1 and the phosphorylation of ERK1/2 and MSK1 induced by rIL-33 in HLF-1 cells were markedly inhibited by the pre-treatment with U0126 or H89.	U 0126	184-189	interleukin 33	Rattus norvegicus	112-118
26993765-7	2016	Both BAY 11-7085-induced autophagy and GR activation were down regulated with PPAR-gamma agonist, 15d-PGJ2 and MEK/ERK inhibitor UO126.	U 0126	129-134	mitogen-activated protein kinase 1	Homo sapiens	115-118
26919095-6	2016	CK2-inhibition by CX-5011 induces cell death by apoptosis and acts synergistically with imatinib or the MEK-inhibitor U0126 in reducing the viability of imatinib-resistant CML cells.	U 0126	118-123	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
26776764-7	2016	Treatment with ERK1/2 inhibitor U0126 or curcumin effectively abrogated benzidine-triggered cell proliferation and ERK1/2/AP-1 activation.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	15-21
26948085-9	2016	Insulin (200 nmol/L) markedly enhanced the phosphorylation of Akt and decreased LC3-II expression in A549 cells, which were reversed by pretreatment with hyperoside, whereas the MEK1/2 inhibitor U0126 (20 mumol/L) did not blocked hyperoside-induced LC3-II expression.	U 0126	195-200	insulin	Homo sapiens	0-7
26948085-9	2016	Insulin (200 nmol/L) markedly enhanced the phosphorylation of Akt and decreased LC3-II expression in A549 cells, which were reversed by pretreatment with hyperoside, whereas the MEK1/2 inhibitor U0126 (20 mumol/L) did not blocked hyperoside-induced LC3-II expression.	U 0126	195-200	AKT serine/threonine kinase 1	Homo sapiens	62-65
26948085-9	2016	Insulin (200 nmol/L) markedly enhanced the phosphorylation of Akt and decreased LC3-II expression in A549 cells, which were reversed by pretreatment with hyperoside, whereas the MEK1/2 inhibitor U0126 (20 mumol/L) did not blocked hyperoside-induced LC3-II expression.	U 0126	195-200	mitogen-activated protein kinase kinase 1	Homo sapiens	178-184
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	growth differentiation factor 2	Homo sapiens	18-23
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	alkaline phosphatase, placental	Homo sapiens	32-35
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	118-121
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	mitogen-activated protein kinase 8	Homo sapiens	123-146
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	mitogen-activated protein kinase 8	Homo sapiens	148-151
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	158-199
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	U 0126	87-92	mitogen-activated protein kinase 3	Homo sapiens	201-207
26769675-6	2016	ERK activation resulted in elevated IKBKAP transcription and IKAP protein levels, whereas pretreatment with the MAPK inhibitor U0126 blocked elevation of the IKAP protein level.	U 0126	127-132	elongator acetyltransferase complex subunit 1	Homo sapiens	158-162
27122993-7	2016	We found that NaF (1~5 mM) application induced a reduction in light transmittance (decreased volume) in CA1 hippocampus, which was completely reversed by MAP kinase inhibitor U0126 (10 microM).	U 0126	175-180	carbonic anhydrase 1	Rattus norvegicus	104-107
26776764-7	2016	Treatment with ERK1/2 inhibitor U0126 or curcumin effectively abrogated benzidine-triggered cell proliferation and ERK1/2/AP-1 activation.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	115-121
26776764-7	2016	Treatment with ERK1/2 inhibitor U0126 or curcumin effectively abrogated benzidine-triggered cell proliferation and ERK1/2/AP-1 activation.	U 0126	32-37	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	122-126
26935265-12	2016	Furthermore, by applying an ERK inhibitor, U0126, the effect of NC on the expression of MMP-2/9 and inhibition of cell migration and invasion was verified.	U 0126	43-48	matrix metallopeptidase 2	Homo sapiens	88-95
26826667-4	2016	In this study, using HEK293 cells stably expressing human H3R and mouse primary cortical neurons endogenously expressing mouse H3R, we found that the H3R-mediated activation of ERK1/2 was significantly blocked by both the pertussis toxin and the MEK1/2 inhibitor U0126.	U 0126	263-268	histamine receptor H3	Homo sapiens	58-61
26826667-4	2016	In this study, using HEK293 cells stably expressing human H3R and mouse primary cortical neurons endogenously expressing mouse H3R, we found that the H3R-mediated activation of ERK1/2 was significantly blocked by both the pertussis toxin and the MEK1/2 inhibitor U0126.	U 0126	263-268	histamine receptor H3	Mus musculus	127-130
26826667-4	2016	In this study, using HEK293 cells stably expressing human H3R and mouse primary cortical neurons endogenously expressing mouse H3R, we found that the H3R-mediated activation of ERK1/2 was significantly blocked by both the pertussis toxin and the MEK1/2 inhibitor U0126.	U 0126	263-268	histamine receptor H3	Mus musculus	127-130
26826667-4	2016	In this study, using HEK293 cells stably expressing human H3R and mouse primary cortical neurons endogenously expressing mouse H3R, we found that the H3R-mediated activation of ERK1/2 was significantly blocked by both the pertussis toxin and the MEK1/2 inhibitor U0126.	U 0126	263-268	mitogen-activated protein kinase 3	Mus musculus	177-183
26825317-8	2016	Erk1/2 activation as well as the phosphorylation of the linker region of Smad2 and MMT could be blocked by the MEK inhibitor, U0126, suggesting that such activation may be a potential pharmaceutical target to prevent MMT.	U 0126	126-131	mitogen activated protein kinase 3	Rattus norvegicus	0-6
26825317-8	2016	Erk1/2 activation as well as the phosphorylation of the linker region of Smad2 and MMT could be blocked by the MEK inhibitor, U0126, suggesting that such activation may be a potential pharmaceutical target to prevent MMT.	U 0126	126-131	SMAD family member 2	Rattus norvegicus	73-78
26780941-7	2016	On the contrary, we observed that elevated IL-8 mRNA expression was suppressed by a specific MEK1/2 inhibitor, UO126, but not by the specific PI-3K inhibitor LY294002, in TamR cells, whereas, we found that overexpression of constitutively active-MEK (CA-MEK) significantly increased the levels of IL-8 mRNA expression in TamS cells.	U 0126	111-116	C-X-C motif chemokine ligand 8	Homo sapiens	43-47
26780941-7	2016	On the contrary, we observed that elevated IL-8 mRNA expression was suppressed by a specific MEK1/2 inhibitor, UO126, but not by the specific PI-3K inhibitor LY294002, in TamR cells, whereas, we found that overexpression of constitutively active-MEK (CA-MEK) significantly increased the levels of IL-8 mRNA expression in TamS cells.	U 0126	111-116	mitogen-activated protein kinase kinase 1	Homo sapiens	93-99
26780941-7	2016	On the contrary, we observed that elevated IL-8 mRNA expression was suppressed by a specific MEK1/2 inhibitor, UO126, but not by the specific PI-3K inhibitor LY294002, in TamR cells, whereas, we found that overexpression of constitutively active-MEK (CA-MEK) significantly increased the levels of IL-8 mRNA expression in TamS cells.	U 0126	111-116	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
26796921-4	2016	Tunicamycin (TM), an ER stress inducer, constitutively activates the mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK), and (MEK)/ERK pathway which plays a role in upregulation of GRP78 by ER stress in that inhibition of MEK by U0126 reduces the levels of GRP78 and blocks its upregulation by TM.	U 0126	262-267	mitogen-activated protein kinase 1	Homo sapiens	103-107
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	18-21
26796921-4	2016	Tunicamycin (TM), an ER stress inducer, constitutively activates the mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK), and (MEK)/ERK pathway which plays a role in upregulation of GRP78 by ER stress in that inhibition of MEK by U0126 reduces the levels of GRP78 and blocks its upregulation by TM.	U 0126	262-267	mitogen-activated protein kinase 1	Homo sapiens	148-151
26796921-4	2016	Tunicamycin (TM), an ER stress inducer, constitutively activates the mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK), and (MEK)/ERK pathway which plays a role in upregulation of GRP78 by ER stress in that inhibition of MEK by U0126 reduces the levels of GRP78 and blocks its upregulation by TM.	U 0126	262-267	mitogen-activated protein kinase 1	Homo sapiens	164-167
26796921-5	2016	Inhibition of the MEK/ERK pathway by U0126 sensitizes breast cancer cells to TM-induced apoptosis.	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
26796921-5	2016	Inhibition of the MEK/ERK pathway by U0126 sensitizes breast cancer cells to TM-induced apoptosis.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	22-25
26796921-6	2016	Inhibition of GRP78 by siRNA knockdown enhances TM- and U0126-induced apoptosis in breast cancer cells.	U 0126	56-61	heat shock protein family A (Hsp70) member 5	Homo sapiens	14-19
26868262-6	2016	However, the specific MEK/ERK inhibitor U0126 effectively abrogated the differentiation induced by PsA in vitro.	U 0126	40-45	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
26868262-6	2016	However, the specific MEK/ERK inhibitor U0126 effectively abrogated the differentiation induced by PsA in vitro.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	26-29
26868262-6	2016	However, the specific MEK/ERK inhibitor U0126 effectively abrogated the differentiation induced by PsA in vitro.	U 0126	40-45	aminopeptidase puromycin sensitive	Homo sapiens	99-102
26537583-6	2016	We observed that elevated IL-8 mRNA expression and protein secretion were suppressed by a specific MEK1/2 inhibitor, UO126.	U 0126	117-122	C-X-C motif chemokine ligand 8	Homo sapiens	26-30
26537583-6	2016	We observed that elevated IL-8 mRNA expression and protein secretion were suppressed by a specific MEK1/2 inhibitor, UO126.	U 0126	117-122	mitogen-activated protein kinase kinase 1	Homo sapiens	99-105
26537583-11	2016	A diversity of MEK blockers, including UO126, may be promising for treating TNBC patients.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	15-18
27087370-10	2016	In the TD47 cells, the S100A14 mRNA levels in the control, 1 ng/ml EGF and 10 ng/ml EGF + U0126 treatment groups were 1.00+-0.04, 1.56+-0.04 and 1.00+-0.10, respectively (P&lt;0.05).	U 0126	90-95	S100 calcium binding protein A14	Homo sapiens	23-30
27081296-10	2016	Furthermore, K252a, U0126, and LY294002, the inhibitors for TrkA, extracellular signal-regulated kinases 1/2 (ERK1/2), and phosphatidylinositol 3-kinase (PI3K)/AKT, respectively, were used in combination with NGF in the assays analyzing VEGF expression and cell proliferation.	U 0126	20-25	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	60-64
26748241-0	2016	mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells.	U 0126	49-54	mitogen-activated protein kinase kinase 1	Homo sapiens	32-38
26748241-6	2016	Here, we characterized the genomic and phenotypic changes of U251 and T98G glioblastoma cell lines long-term treated with TEM or U0126, an inhibitor of MEK1/2.	U 0126	129-134	mitogen-activated protein kinase kinase 1	Homo sapiens	152-158
26811873-3	2016	Fifty-four compounds were detected, and the contents of metabolites from the citric acid cycle increased in response to the insulin treatment for 4 h, which was sensitive to U0126 and LY294002, inhibitors for mitogen-activated protein kinase kinase-1 and phosphoinositide 3-kinase, respectively.	U 0126	174-179	insulin	Homo sapiens	124-131
26811873-7	2016	The contents of free amino acids were slightly decreased by the insulin treatment, while the co-treatment with U0126 and LY294002 abrogated these insulin-mediated decreases.	U 0126	111-116	insulin	Homo sapiens	146-153
26849940-6	2016	Furthermore, U0126, an ERK1/2 inhibitor, markedly down-regulated Bcl-2 level, up-regulated the levels of Bax, cleaved caspase-3/9, and enhanced Cytochrome c release inducted by dioscin.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	23-29
26849940-6	2016	Furthermore, U0126, an ERK1/2 inhibitor, markedly down-regulated Bcl-2 level, up-regulated the levels of Bax, cleaved caspase-3/9, and enhanced Cytochrome c release inducted by dioscin.	U 0126	13-18	BCL2 apoptosis regulator	Homo sapiens	65-70
26849940-6	2016	Furthermore, U0126, an ERK1/2 inhibitor, markedly down-regulated Bcl-2 level, up-regulated the levels of Bax, cleaved caspase-3/9, and enhanced Cytochrome c release inducted by dioscin.	U 0126	13-18	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
26849940-6	2016	Furthermore, U0126, an ERK1/2 inhibitor, markedly down-regulated Bcl-2 level, up-regulated the levels of Bax, cleaved caspase-3/9, and enhanced Cytochrome c release inducted by dioscin.	U 0126	13-18	cytochrome c, somatic	Homo sapiens	144-156
26980390-9	2016	SYK-induced MUC5AC expression was significantly attenuated by pretreatment with U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor).	U 0126	80-85	spleen associated tyrosine kinase	Homo sapiens	0-3
26980390-9	2016	SYK-induced MUC5AC expression was significantly attenuated by pretreatment with U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor).	U 0126	80-85	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	12-18
26764533-8	2016	The amitriptyline-induced expression of both total and individual BDNF mRNA variants (exon I, IV and VI) were blocked by MEK inhibitor U0126, indicating MEK/ERK signaling is required in the expression of BDNF.	U 0126	135-140	brain-derived neurotrophic factor	Rattus norvegicus	66-70
26764533-8	2016	The amitriptyline-induced expression of both total and individual BDNF mRNA variants (exon I, IV and VI) were blocked by MEK inhibitor U0126, indicating MEK/ERK signaling is required in the expression of BDNF.	U 0126	135-140	Eph receptor B1	Rattus norvegicus	157-160
26764533-8	2016	The amitriptyline-induced expression of both total and individual BDNF mRNA variants (exon I, IV and VI) were blocked by MEK inhibitor U0126, indicating MEK/ERK signaling is required in the expression of BDNF.	U 0126	135-140	brain-derived neurotrophic factor	Rattus norvegicus	204-208
26514426-5	2016	MEK inhibitor U0126, NF-kappaB inhibitor BAY-11-7085, and siRNA targeting p65/RelA significantly inhibited IL-1alpha or IL-beta-induced ADAM17 expression.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
26514426-5	2016	MEK inhibitor U0126, NF-kappaB inhibitor BAY-11-7085, and siRNA targeting p65/RelA significantly inhibited IL-1alpha or IL-beta-induced ADAM17 expression.	U 0126	14-19	interleukin 1 alpha	Homo sapiens	107-116
26514426-5	2016	MEK inhibitor U0126, NF-kappaB inhibitor BAY-11-7085, and siRNA targeting p65/RelA significantly inhibited IL-1alpha or IL-beta-induced ADAM17 expression.	U 0126	14-19	ADAM metallopeptidase domain 17	Homo sapiens	136-142
26635037-7	2016	Furthermore, hepatocyte ERK1/2 phosphorylation is enhanced by neutralizing anti-BMP2/4 antibodies and suppressed in vitro in a dose-dependent manner by BMP2, resulting in converse effects on hepcidin expression, and hepatocytes treated with MEK/ERK1/2 inhibitor U0126 in combination with BMP2 exhibit an additive increase in hepcidin expression.	U 0126	262-267	mitogen-activated protein kinase 3	Mus musculus	24-30
26635037-7	2016	Furthermore, hepatocyte ERK1/2 phosphorylation is enhanced by neutralizing anti-BMP2/4 antibodies and suppressed in vitro in a dose-dependent manner by BMP2, resulting in converse effects on hepcidin expression, and hepatocytes treated with MEK/ERK1/2 inhibitor U0126 in combination with BMP2 exhibit an additive increase in hepcidin expression.	U 0126	262-267	bone morphogenetic protein 2	Mus musculus	152-156
26658215-8	2016	The increase in gamma-ENaC mRNA expression in response to aldosterone was MEK1/2-dependently reduced in LC, since it could be restored toward normal by MEK1/2 inhibition through U0126.	U 0126	178-183	sodium channel epithelial 1 subunit gamma	Homo sapiens	16-26
26658215-8	2016	The increase in gamma-ENaC mRNA expression in response to aldosterone was MEK1/2-dependently reduced in LC, since it could be restored toward normal by MEK1/2 inhibition through U0126.	U 0126	178-183	mitogen-activated protein kinase kinase 1	Homo sapiens	152-158
26778265-14	2016	The cells grown on RRM/MTA surfaces showed sustained up-regulation of ERK phosphorylation, and blocking ERK signaling with U0126 significantly reduced RRM- and MTA-dependent cell survival.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	104-107
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	interleukin 1 beta	Homo sapiens	62-66
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	interleukin 6	Homo sapiens	75-78
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	C-X-C motif chemokine ligand 8	Homo sapiens	80-85
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	C-C motif chemokine ligand 2	Homo sapiens	87-91
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	C-X-C motif chemokine ligand 8	Homo sapiens	123-128
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	C-C motif chemokine ligand 2	Homo sapiens	130-134
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	nuclear factor kappa B subunit 1	Homo sapiens	163-172
26786718-11	2016	ICI 182780, U0126 (an ERK1/2 inhibitor) and SP600125 (a JNK inhibitor) prevented the increases in arterial relaxation and eNOS levels.	U 0126	12-17	mitogen activated protein kinase 3	Rattus norvegicus	22-28
26743906-7	2016	U0126, a highly selective inhibitor of extracellular ERK1/2 MAPK signaling, significantly suppressed the antioxidative and osteogenic effects in HAMSCs.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	53-59
26743906-7	2016	U0126, a highly selective inhibitor of extracellular ERK1/2 MAPK signaling, significantly suppressed the antioxidative and osteogenic effects in HAMSCs.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	60-64
26847477-10	2016	Treatment with NC reduced the phosphorylation of ERK and by using an ERK inhibitor, U0126, the roles of NC in apoptotic induction and the inhibition of proliferation were further demonstrated.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	69-72
26980653-3	2016	Endothelial inducing cells was incubated with U0126, a specific p-ERK1/2 inhibitor.	U 0126	46-51	mitogen-activated protein kinase 3	Homo sapiens	66-72
26373299-8	2016	RESULTS: We demonstrated that the inhibition of the MAPK and NF-kB survival pathways with U0126 and caffeic acid phenethyl ester (CAPE), respectively, produced strong inhibition of pancreatic tumor cell growth without inducing apoptotic death.	U 0126	90-95	nuclear factor kappa B subunit 1	Homo sapiens	61-66
26980653-10	2016	The mRNA expressions of CD31 and VEGF in induced+U0126 group were decreased to 0.09+-0.18 and 0.49+-0.17, which were both significantly different with those in induced group (P&lt;0.05).	U 0126	49-54	platelet and endothelial cell adhesion molecule 1	Homo sapiens	24-28
26980653-10	2016	The mRNA expressions of CD31 and VEGF in induced+U0126 group were decreased to 0.09+-0.18 and 0.49+-0.17, which were both significantly different with those in induced group (P&lt;0.05).	U 0126	49-54	vascular endothelial growth factor A	Homo sapiens	33-37
26980653-11	2016	The proportion of CD31(+) to VE-cadherin(+) cells of induced+U0126 group were decreased to 5.22+-0.85 and 3.56+-0.87, which were both significantly different with those in induced group (P&lt;0.05).	U 0126	61-66	platelet and endothelial cell adhesion molecule 1	Homo sapiens	18-22
26980653-11	2016	The proportion of CD31(+) to VE-cadherin(+) cells of induced+U0126 group were decreased to 5.22+-0.85 and 3.56+-0.87, which were both significantly different with those in induced group (P&lt;0.05).	U 0126	61-66	cadherin 5	Homo sapiens	29-40
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	prominin 1	Mus musculus	116-121
26981206-14	2016	The inhibitory effect of Hcy on the apoE promoter activity was counteracted by MAPK/ERK kinase 1/2 (MEK1/2) inhibitor U0126, suggesting that MEK1/2 is involved in the downregulation of apoE promoter activity by Hcy.	U 0126	118-123	apolipoprotein E	Homo sapiens	36-40
26981206-14	2016	The inhibitory effect of Hcy on the apoE promoter activity was counteracted by MAPK/ERK kinase 1/2 (MEK1/2) inhibitor U0126, suggesting that MEK1/2 is involved in the downregulation of apoE promoter activity by Hcy.	U 0126	118-123	mitogen-activated protein kinase kinase 1	Homo sapiens	100-106
26981206-14	2016	The inhibitory effect of Hcy on the apoE promoter activity was counteracted by MAPK/ERK kinase 1/2 (MEK1/2) inhibitor U0126, suggesting that MEK1/2 is involved in the downregulation of apoE promoter activity by Hcy.	U 0126	118-123	mitogen-activated protein kinase kinase 1	Homo sapiens	141-147
26981206-14	2016	The inhibitory effect of Hcy on the apoE promoter activity was counteracted by MAPK/ERK kinase 1/2 (MEK1/2) inhibitor U0126, suggesting that MEK1/2 is involved in the downregulation of apoE promoter activity by Hcy.	U 0126	118-123	apolipoprotein E	Homo sapiens	185-189
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	midkine	Mus musculus	9-12
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	mitogen-activated protein kinase 1	Mus musculus	13-16
26861698-9	2016	GICs showed diverse drug sensitivity, but inhibitions of RTK and RAF/MEK or PI3K by combinations such as EGFR inhibitor and MEK inhibitor, sorafenib and U0126, erlotinib and BKM120, and EGFR inhibitor and sorafenib showed synergy in different subtypes of GICs.	U 0126	153-158	ret proto-oncogene	Homo sapiens	57-60
26861698-9	2016	GICs showed diverse drug sensitivity, but inhibitions of RTK and RAF/MEK or PI3K by combinations such as EGFR inhibitor and MEK inhibitor, sorafenib and U0126, erlotinib and BKM120, and EGFR inhibitor and sorafenib showed synergy in different subtypes of GICs.	U 0126	153-158	zinc fingers and homeoboxes 2	Homo sapiens	65-68
26390196-10	2016	Although the cAMP-dependent protein kinase A (PKA)-specific inhibitor H89 did not affect IP extract-induced lipolysis, the extracellular signal-regulated kinase (ERK1/2) inhibitor U0126 significantly abrogated IP extract-activated glycerol release.	U 0126	180-185	mitogen-activated protein kinase 3	Mus musculus	162-168
26892527-8	2016	Analyses of the underlying molecular mechanism revealed that ACE3-mediated protection against cardiac hypertrophy by suppressing the activation of mitogen-activated protein kinase kinase (MEK)-regulated extracellular signal-regulated protein kinase (ERK1/2) signaling, which was further evidenced by the observation that inhibition of the MEK-ERK1/2 signaling by U0126 rescued the exacerbated hypertrophic phenotype in ACE3-deficient mice.	U 0126	363-368	angiotensin I converting enzyme (peptidyl-dipeptidase A) 3	Mus musculus	61-65
26892527-8	2016	Analyses of the underlying molecular mechanism revealed that ACE3-mediated protection against cardiac hypertrophy by suppressing the activation of mitogen-activated protein kinase kinase (MEK)-regulated extracellular signal-regulated protein kinase (ERK1/2) signaling, which was further evidenced by the observation that inhibition of the MEK-ERK1/2 signaling by U0126 rescued the exacerbated hypertrophic phenotype in ACE3-deficient mice.	U 0126	363-368	midkine	Mus musculus	147-186
26892527-8	2016	Analyses of the underlying molecular mechanism revealed that ACE3-mediated protection against cardiac hypertrophy by suppressing the activation of mitogen-activated protein kinase kinase (MEK)-regulated extracellular signal-regulated protein kinase (ERK1/2) signaling, which was further evidenced by the observation that inhibition of the MEK-ERK1/2 signaling by U0126 rescued the exacerbated hypertrophic phenotype in ACE3-deficient mice.	U 0126	363-368	midkine	Mus musculus	188-191
26892527-8	2016	Analyses of the underlying molecular mechanism revealed that ACE3-mediated protection against cardiac hypertrophy by suppressing the activation of mitogen-activated protein kinase kinase (MEK)-regulated extracellular signal-regulated protein kinase (ERK1/2) signaling, which was further evidenced by the observation that inhibition of the MEK-ERK1/2 signaling by U0126 rescued the exacerbated hypertrophic phenotype in ACE3-deficient mice.	U 0126	363-368	mitogen-activated protein kinase 3	Mus musculus	250-256
26881424-9	2016	Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells.	U 0126	60-65	BEN domain containing 3	Mus musculus	16-21
26881424-9	2016	Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells.	U 0126	60-65	mitogen-activated protein kinase 1	Mus musculus	78-81
26881424-9	2016	Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells.	U 0126	60-65	caveolin 1, caveolae protein	Mus musculus	146-151
26881424-9	2016	Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells.	U 0126	60-65	caveolin 1, caveolae protein	Mus musculus	190-195
26881424-9	2016	Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells.	U 0126	60-65	matrix metallopeptidase 2	Mus musculus	200-210
26881424-9	2016	Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells.	U 0126	60-65	fibronectin 1	Mus musculus	256-267
26783339-7	2016	Furthermore, if we blocked LPS-induced ERK signaling by U0126, the expression of connexin 43 and UDP release was also inhibited dramatically.	U 0126	56-61	gap junction protein, alpha 1	Mus musculus	81-92
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	chemokine (C-X-C motif) receptor 4	Mus musculus	123-128
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	Nanog homeobox	Mus musculus	133-138
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	mitogen-activated protein kinase 1	Mus musculus	170-174
26897742-8	2016	RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers.	U 0126	27-32	mitogen-activated protein kinase 14	Mus musculus	190-193
26897742-14	2016	In U0126-treated rhabdospheres, the expression of the stem cell markers CD133 and CXCR4 decreased and dropped even more markedly following combined treatment.	U 0126	3-8	prominin 1	Mus musculus	72-77
26897742-14	2016	In U0126-treated rhabdospheres, the expression of the stem cell markers CD133 and CXCR4 decreased and dropped even more markedly following combined treatment.	U 0126	3-8	chemokine (C-X-C motif) receptor 4	Mus musculus	82-87
26102008-7	2016	Further, ERK inhibitors such as PD98059 and U0126 blocked phosphorylation of Nrf2 as well as the protective effect of oxyresveratrol in mitochondria.	U 0126	44-49	mitogen-activated protein kinase 1	Mus musculus	9-12
26847701-4	2016	Mechanistically, KCTD12 suppresses CRC cell stemness markers, such as CD44, CD133 and CD29, by inhibiting the ERK pathway, as the ERK1/2 inhibitor U0126 abolishes the increase in expression of CRC cell stemness markers induced by the down-regulation of KCTD12.	U 0126	147-152	mitogen-activated protein kinase 3	Homo sapiens	130-136
26102008-7	2016	Further, ERK inhibitors such as PD98059 and U0126 blocked phosphorylation of Nrf2 as well as the protective effect of oxyresveratrol in mitochondria.	U 0126	44-49	nuclear factor, erythroid derived 2, like 2	Mus musculus	77-81
26847701-4	2016	Mechanistically, KCTD12 suppresses CRC cell stemness markers, such as CD44, CD133 and CD29, by inhibiting the ERK pathway, as the ERK1/2 inhibitor U0126 abolishes the increase in expression of CRC cell stemness markers induced by the down-regulation of KCTD12.	U 0126	147-152	potassium channel tetramerization domain containing 12	Homo sapiens	17-23
26847701-4	2016	Mechanistically, KCTD12 suppresses CRC cell stemness markers, such as CD44, CD133 and CD29, by inhibiting the ERK pathway, as the ERK1/2 inhibitor U0126 abolishes the increase in expression of CRC cell stemness markers induced by the down-regulation of KCTD12.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	110-113
26847701-4	2016	Mechanistically, KCTD12 suppresses CRC cell stemness markers, such as CD44, CD133 and CD29, by inhibiting the ERK pathway, as the ERK1/2 inhibitor U0126 abolishes the increase in expression of CRC cell stemness markers induced by the down-regulation of KCTD12.	U 0126	147-152	potassium channel tetramerization domain containing 12	Homo sapiens	253-259
26839969-5	2016	PL-PP-induced LIF expression was decreased in the presence of a p38 kinase inhibitor SB203580 and an MEK/ERK inhibitor U0126.	U 0126	119-124	pyridoxal (pyridoxine, vitamin B6) phosphatase	Mus musculus	0-5
26839969-5	2016	PL-PP-induced LIF expression was decreased in the presence of a p38 kinase inhibitor SB203580 and an MEK/ERK inhibitor U0126.	U 0126	119-124	LIF interleukin 6 family cytokine	Homo sapiens	14-17
26839969-5	2016	PL-PP-induced LIF expression was decreased in the presence of a p38 kinase inhibitor SB203580 and an MEK/ERK inhibitor U0126.	U 0126	119-124	mitogen-activated protein kinase kinase 7	Homo sapiens	101-104
26839969-5	2016	PL-PP-induced LIF expression was decreased in the presence of a p38 kinase inhibitor SB203580 and an MEK/ERK inhibitor U0126.	U 0126	119-124	mitogen-activated protein kinase 1	Homo sapiens	105-108
26748289-8	2016	U-0126, the mitogen-activated protein kinase inhibitors, could reverse macrophage migration induced by Kv1.3 channel overexpression.	U 0126	0-6	potassium voltage-gated channel subfamily A member 3	Homo sapiens	103-108
26748289-9	2016	Downregulation of Kv1.3 channel by siRNA could not further inhibit cell migration when cells were treated with U-0126.	U 0126	111-117	potassium voltage-gated channel subfamily A member 3	Homo sapiens	18-23
26140667-9	2016	The MAPK inhibitor U0126 also blocked neutrophil elastase-induced inflammation and pain.	U 0126	19-24	elastase, neutrophil expressed	Mus musculus	38-57
26608500-11	2016	Furthermore, the expression of COX-2 was attenuated by both Akt inhibitor (LY294002) and ERK inhibitor (U0126), and IkappaBalpha degradation was suppressed by LY294002.	U 0126	104-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	31-36
26618262-9	2016	U0126 (a MEK1/2 inhibitor) and SB203580 (a p38 inhibitor) significantly suppressed PM2.5-induced increases in ETB receptor-mediated contractile responses, mRNA and protein levels.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	9-15
26618262-9	2016	U0126 (a MEK1/2 inhibitor) and SB203580 (a p38 inhibitor) significantly suppressed PM2.5-induced increases in ETB receptor-mediated contractile responses, mRNA and protein levels.	U 0126	0-5	endothelin receptor type B	Rattus norvegicus	110-113
26505315-13	2016	Likewise, diquafosol-treated cells showed acceleration of gap closure in cell migration assay, which was inhibited by suramin, BAPTA/AM, AG1478, and U0126 (MEK inhibitor).	U 0126	149-154	mitogen-activated protein kinase kinase 7	Homo sapiens	156-159
26573963-8	2016	Expression of all of these inflammatory mediators was blocked by pre-treatment with BAY11-7082, U0126, and SB203580, which are inhibitors of nuclear factor (NF)-kappaB, ERK1/2, and p38 MAPK, respectively.	U 0126	96-101	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	141-167
26573963-8	2016	Expression of all of these inflammatory mediators was blocked by pre-treatment with BAY11-7082, U0126, and SB203580, which are inhibitors of nuclear factor (NF)-kappaB, ERK1/2, and p38 MAPK, respectively.	U 0126	96-101	mitogen-activated protein kinase 3	Mus musculus	169-175
26573963-8	2016	Expression of all of these inflammatory mediators was blocked by pre-treatment with BAY11-7082, U0126, and SB203580, which are inhibitors of nuclear factor (NF)-kappaB, ERK1/2, and p38 MAPK, respectively.	U 0126	96-101	mitogen-activated protein kinase 14	Mus musculus	181-189
26771235-7	2016	These events were associated with the ERK1/2 pathway activation and an ERK1/2 inhibitor (U0126) inhibited cell proliferation, migration, and invasion induced by overexpression of TG2.	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	71-77
26608500-11	2016	Furthermore, the expression of COX-2 was attenuated by both Akt inhibitor (LY294002) and ERK inhibitor (U0126), and IkappaBalpha degradation was suppressed by LY294002.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	89-92
26707062-8	2016	The addition of U0126 resulted in a marked reduction of lipid deposition, upregulation of ABCA1/G1 expression and suppression of CD36 expression in Ox-LDL-stimulated macrophages.	U 0126	16-21	ATP binding cassette subfamily A member 1	Rattus norvegicus	90-95
26363191-4	2016	This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation.	U 0126	69-74	mitogen activated protein kinase 3	Rattus norvegicus	5-11
26336156-7	2016	Finally, we studied the connection between ERK and PKCd and showed that in the presence of the MEK inhibitor U0126, PKCd expression is decreased, and Fli-1 expression is increased in response to M-CSF.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	43-46
26336156-7	2016	Finally, we studied the connection between ERK and PKCd and showed that in the presence of the MEK inhibitor U0126, PKCd expression is decreased, and Fli-1 expression is increased in response to M-CSF.	U 0126	109-114	protein kinase C delta	Homo sapiens	51-55
26336156-7	2016	Finally, we studied the connection between ERK and PKCd and showed that in the presence of the MEK inhibitor U0126, PKCd expression is decreased, and Fli-1 expression is increased in response to M-CSF.	U 0126	109-114	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
26336156-7	2016	Finally, we studied the connection between ERK and PKCd and showed that in the presence of the MEK inhibitor U0126, PKCd expression is decreased, and Fli-1 expression is increased in response to M-CSF.	U 0126	109-114	protein kinase C delta	Homo sapiens	116-120
26336156-7	2016	Finally, we studied the connection between ERK and PKCd and showed that in the presence of the MEK inhibitor U0126, PKCd expression is decreased, and Fli-1 expression is increased in response to M-CSF.	U 0126	109-114	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	150-155
26336156-7	2016	Finally, we studied the connection between ERK and PKCd and showed that in the presence of the MEK inhibitor U0126, PKCd expression is decreased, and Fli-1 expression is increased in response to M-CSF.	U 0126	109-114	colony stimulating factor 1	Homo sapiens	195-200
26363191-4	2016	This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation.	U 0126	69-74	mitogen activated protein kinase 3	Rattus norvegicus	61-67
26363191-4	2016	This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation.	U 0126	69-74	mitogen activated protein kinase 3	Rattus norvegicus	61-67
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	U 0126	69-74	FBJ osteosarcoma oncogene	Mus musculus	26-31
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	U 0126	69-74	mitogen-activated protein kinase 1	Mus musculus	135-139
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	U 0126	69-74	mitogen-activated protein kinase kinase 1	Mus musculus	156-162
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	U 0126	69-74	mitogen-activated protein kinase kinase 5	Mus musculus	182-186
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	U 0126	69-74	mitogen-activated protein kinase 8	Mus musculus	231-234
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	U 0126	69-74	mitogen-activated protein kinase 14	Mus musculus	263-266
26545627-11	2016	U0126 inhibited the increases in the serum levels and vessel wall expression of IL-1beta and TNF-alpha and enhanced the NA shrinkage dose-response curve caused by mmLDL, as observed by a significantly decreased Emax value (P&lt;0.01).	U 0126	0-5	interleukin 1 beta	Mus musculus	80-88
26545627-11	2016	U0126 inhibited the increases in the serum levels and vessel wall expression of IL-1beta and TNF-alpha and enhanced the NA shrinkage dose-response curve caused by mmLDL, as observed by a significantly decreased Emax value (P&lt;0.01).	U 0126	0-5	tumor necrosis factor	Mus musculus	93-102
27078996-11	2016	Compared with the vehicle control group, the phosphorylation of ERK and CREB could be elevated in the 3 JBQHR groups (P &lt; 0.05), and could be inhibited by U0126 (P &lt; 0.01).	U 0126	158-163	mitogen-activated protein kinase 1	Homo sapiens	64-67
27078996-11	2016	Compared with the vehicle control group, the phosphorylation of ERK and CREB could be elevated in the 3 JBQHR groups (P &lt; 0.05), and could be inhibited by U0126 (P &lt; 0.01).	U 0126	158-163	cAMP responsive element binding protein 1	Homo sapiens	72-76
26858639-10	2016	Such stimulation could be attenuated by TP antagonist SQ29548 or MEK inhibitor U0126.	U 0126	79-84	midkine	Mus musculus	65-68
26621121-9	2016	We also found that the neuroprotective role of AMN082 was completely reversed by ERK1/2 inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126).	U 0126	98-157	mitogen activated protein kinase 3	Rattus norvegicus	81-87
26621121-9	2016	We also found that the neuroprotective role of AMN082 was completely reversed by ERK1/2 inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126).	U 0126	159-164	mitogen activated protein kinase 3	Rattus norvegicus	81-87
26818512-9	2016	The MEK inhibitor U0126 blocked rosi-restored AMPAR expression and LTP induction in seipin-nKO mice, but the Trk family inhibitor K252a did not.	U 0126	18-23	midkine	Mus musculus	4-7
26818512-9	2016	The MEK inhibitor U0126 blocked rosi-restored AMPAR expression and LTP induction in seipin-nKO mice, but the Trk family inhibitor K252a did not.	U 0126	18-23	Berardinelli-Seip congenital lipodystrophy 2 (seipin)	Mus musculus	84-90
26566727-8	2016	Inhibition of MEK1/2 using U0126 led to a sequential temporal reduction of phospho-p42/44 and subsequent Scleraxis expression.	U 0126	27-32	mitogen-activated protein kinase kinase 1	Homo sapiens	14-20
26566727-8	2016	Inhibition of MEK1/2 using U0126 led to a sequential temporal reduction of phospho-p42/44 and subsequent Scleraxis expression.	U 0126	27-32	erythrocyte membrane protein band 4.2	Homo sapiens	83-86
26863034-5	2016	This shows that FGF18 induces expression of MyoD and ERK phosphorylation and both endogenous and FGF18 induced MyoD expression is inhibited by U0126.	U 0126	143-148	fibroblast growth factor 18	Gallus gallus	16-21
26863034-5	2016	This shows that FGF18 induces expression of MyoD and ERK phosphorylation and both endogenous and FGF18 induced MyoD expression is inhibited by U0126.	U 0126	143-148	fibroblast growth factor 18	Gallus gallus	97-102
26620571-11	2016	Moreover, EGF stimulated migration of pLE cells, but this stimulatory effect was blocked by U0126, a pharmacological inhibitor or ERK1/2 MAPK.	U 0126	92-97	epidermal growth factor	Sus scrofa	10-13
26902401-12	2016	Treatment with curcumin or U0126, a specific MAPK inhibitor, or suppression of cellular uptake of copper by siRNA knockdown of copper transporter protein 1 (CTR1) blocked copper-induced cell proliferation.	U 0126	27-32	mitogen-activated protein kinase 1	Mus musculus	45-49
26754532-13	2016	U0126, an inhibitor of mitogen-activated protein kinase (MEK), can reverse the effects of Gab2 on EMT.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	23-55
26754532-13	2016	U0126, an inhibitor of mitogen-activated protein kinase (MEK), can reverse the effects of Gab2 on EMT.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
26754532-13	2016	U0126, an inhibitor of mitogen-activated protein kinase (MEK), can reverse the effects of Gab2 on EMT.	U 0126	0-5	GRB2 associated binding protein 2	Homo sapiens	90-94
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	U 0126	98-103	fibronectin 1	Homo sapiens	25-36
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	U 0126	98-103	cadherin 1	Homo sapiens	38-48
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	U 0126	98-103	transforming growth factor beta receptor 1	Homo sapiens	53-61
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	U 0126	98-103	mitogen-activated protein kinase 1	Homo sapiens	84-87
26637807-8	2016	TGF-beta1-induced MMP-9 expression was decreased by both a MEK inhibitor, UO126, and a smad3 inhibitor, SIS3.	U 0126	74-79	transforming growth factor beta 1	Homo sapiens	0-9
26637807-8	2016	TGF-beta1-induced MMP-9 expression was decreased by both a MEK inhibitor, UO126, and a smad3 inhibitor, SIS3.	U 0126	74-79	matrix metallopeptidase 9	Homo sapiens	18-23
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	mitogen-activated protein kinase 3	Homo sapiens	66-72
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	epidermal growth factor	Homo sapiens	133-136
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	149-159
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	AKT serine/threonine kinase 1	Homo sapiens	189-192
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	mitogen-activated protein kinase 3	Homo sapiens	194-200
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	mechanistic target of rapamycin kinase	Homo sapiens	205-209
26738434-7	2016	Inhibition of p38 MAPK by SB023580 or pERK by U0126 abolished the proliferation and up-regulatory effects of irisin on Runx2 expression and ALP activity.	U 0126	46-51	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	38-42
26738434-7	2016	Inhibition of p38 MAPK by SB023580 or pERK by U0126 abolished the proliferation and up-regulatory effects of irisin on Runx2 expression and ALP activity.	U 0126	46-51	fibronectin type III domain containing 5	Homo sapiens	109-115
26738434-7	2016	Inhibition of p38 MAPK by SB023580 or pERK by U0126 abolished the proliferation and up-regulatory effects of irisin on Runx2 expression and ALP activity.	U 0126	46-51	RUNX family transcription factor 2	Homo sapiens	119-124
26494252-5	2016	Addition of Erk inhibitor U0126 enhanced gstp1-2 mRNA expression during transition from blastula to the segmentation stage and from pharyngula until the hatching stage.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	12-15
26494252-5	2016	Addition of Erk inhibitor U0126 enhanced gstp1-2 mRNA expression during transition from blastula to the segmentation stage and from pharyngula until the hatching stage.	U 0126	26-31	glutathione S-transferase pi 1.2	Danio rerio	41-48
26494252-8	2016	Activation of cAMP/Creb pathway by forskolin prevented gstp1-2 expression, whereas U0126 suppressed Creb phosphorylation, thus setting up Creb as a proximal transmitter of Erk inhibitory effect.	U 0126	83-88	mitogen-activated protein kinase 1	Homo sapiens	172-175
26520031-6	2016	Ten ng/ml IL-1beta increased levels of phosphorylated (p)-ERK1/2 proteins in pLE cells within 15 min post-treatment, and this IL-1beta-induced phosphorylated status was inhibited by increasing doses of U0126 (ERK1/2 inhibitor).	U 0126	202-207	interleukin-1 beta	Sus scrofa	10-18
26520031-6	2016	Ten ng/ml IL-1beta increased levels of phosphorylated (p)-ERK1/2 proteins in pLE cells within 15 min post-treatment, and this IL-1beta-induced phosphorylated status was inhibited by increasing doses of U0126 (ERK1/2 inhibitor).	U 0126	202-207	mitogen-activated protein kinase 3	Sus scrofa	58-64
26520031-6	2016	Ten ng/ml IL-1beta increased levels of phosphorylated (p)-ERK1/2 proteins in pLE cells within 15 min post-treatment, and this IL-1beta-induced phosphorylated status was inhibited by increasing doses of U0126 (ERK1/2 inhibitor).	U 0126	202-207	interleukin-1 beta	Sus scrofa	126-134
26520031-7	2016	In addition IL-1beta increased p-P70S6K, p-P90S6K, p-S6, and p-P38 proteins in a time-dependent manner, but IL-1beta-induced activation of P70S6K and S6 proteins was significantly decreased in the presence of pharmacological inhibitors for ERK1/2 (U0126), MTOR (rapamycin), and P38 (SB203580).	U 0126	248-253	interleukin-1 beta	Sus scrofa	12-20
26520031-7	2016	In addition IL-1beta increased p-P70S6K, p-P90S6K, p-S6, and p-P38 proteins in a time-dependent manner, but IL-1beta-induced activation of P70S6K and S6 proteins was significantly decreased in the presence of pharmacological inhibitors for ERK1/2 (U0126), MTOR (rapamycin), and P38 (SB203580).	U 0126	248-253	interleukin-1 beta	Sus scrofa	108-116
26881015-6	2016	ICAM-1 expression was dose-dependently inhibited by U0126 (a specific inhibitor of MEK1/2, a signal upstream from ERK1/2), SB203580 (a specific inhibitor of p38(MAPK)), and SN50 (a specific inhibitor of NF-kappaB).	U 0126	52-57	intercellular adhesion molecule 1	Homo sapiens	0-6
26788032-9	2016	U0126 decreased the phosphorylation of ERK1/2, and LY294002 decreased the phosphorylation of AKT; each could significantly inhibit LDR-induced 2BS cell proliferation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	39-45
26492523-11	2016	Aspirin, U0126, LY294002 and 5z-7-oxozeaenol attenuated the IL-1beta-induced MCP-1 expression.	U 0126	9-14	interleukin 1 beta	Homo sapiens	60-68
26492523-11	2016	Aspirin, U0126, LY294002 and 5z-7-oxozeaenol attenuated the IL-1beta-induced MCP-1 expression.	U 0126	9-14	C-C motif chemokine ligand 2	Homo sapiens	77-82
26492523-12	2016	In addition, 5z-7-oxozeaenol, LY294002, U0126 and aspirin prevented the IL-1beta-induced MCP-1 secretion of pulp cells.	U 0126	40-45	interleukin 1 beta	Mus musculus	72-80
26492523-12	2016	In addition, 5z-7-oxozeaenol, LY294002, U0126 and aspirin prevented the IL-1beta-induced MCP-1 secretion of pulp cells.	U 0126	40-45	mast cell protease 1	Mus musculus	89-94
26989682-6	2016	Moreover, gene profiling of osteogenic markers, alkaline phosphatase (ALP) activity measurement, and alizarin red staining demonstrated that the application of U0126, a specific inhibitor for ERK activation, completely prohibited hUCMSC osteogenic differentiation.	U 0126	160-165	alkaline phosphatase, placental	Homo sapiens	48-68
26989682-6	2016	Moreover, gene profiling of osteogenic markers, alkaline phosphatase (ALP) activity measurement, and alizarin red staining demonstrated that the application of U0126, a specific inhibitor for ERK activation, completely prohibited hUCMSC osteogenic differentiation.	U 0126	160-165	alkaline phosphatase, placental	Homo sapiens	70-73
26989682-6	2016	Moreover, gene profiling of osteogenic markers, alkaline phosphatase (ALP) activity measurement, and alizarin red staining demonstrated that the application of U0126, a specific inhibitor for ERK activation, completely prohibited hUCMSC osteogenic differentiation.	U 0126	160-165	mitogen-activated protein kinase 1	Homo sapiens	192-195
26989682-7	2016	However, when U0126 was removed from the culture at day 9, ERK activation and osteogenic differentiation of hUCMSCs were partially recovered.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	59-62
26507774-10	2016	Both a ERK1/2 inhibitor (U0126) and ERK2 siRNA, but not ERK1 siRNA, abolished the protective effect of ATRA against doxorubicin-induced toxicity in H9c2 cells.	U 0126	25-30	mitogen activated protein kinase 3	Rattus norvegicus	7-13
26507774-10	2016	Both a ERK1/2 inhibitor (U0126) and ERK2 siRNA, but not ERK1 siRNA, abolished the protective effect of ATRA against doxorubicin-induced toxicity in H9c2 cells.	U 0126	25-30	mitogen activated protein kinase 3	Rattus norvegicus	7-11
27941335-9	2016	After U0126 was added, ECE-1 expression and ET-1 levels decreased significantly.	U 0126	6-11	endothelin-converting enzyme 1	Oryctolagus cuniculus	23-28
27941335-9	2016	After U0126 was added, ECE-1 expression and ET-1 levels decreased significantly.	U 0126	6-11	endothelin-1	Oryctolagus cuniculus	44-48
26295829-8	2016	Furthermore, TSG significantly induced the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and a specific ERK inhibitor-U0126 inhibited TSG-mediated secretion of BDNF, GDNF and NGF.	U 0126	139-144	brain-derived neurotrophic factor	Rattus norvegicus	181-185
26295829-8	2016	Furthermore, TSG significantly induced the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and a specific ERK inhibitor-U0126 inhibited TSG-mediated secretion of BDNF, GDNF and NGF.	U 0126	139-144	glial cell derived neurotrophic factor	Rattus norvegicus	187-191
26917259-3	2016	Primary hAECs cultures from 120 patients were incubated with Salvia miltiorrhiza or/and ERK1/2 inhibitor-- U0126.	U 0126	107-112	mitogen-activated protein kinase 3	Homo sapiens	88-94
26917259-5	2016	The results were: (1) In hAECs with normal amniotic fluid volume, treatment with 10 micromol/L of U0126 for 6 h resulted in the optimal inhibition of p-ERK1/2 (P&lt;0.05).	U 0126	98-103	mitogen-activated protein kinase 3	Homo sapiens	152-158
26917259-8	2016	(2) In hAECs with isolated oligohydramnios, treatment with 5 mumol/L of U0126 for 2 h resulted in the optimal inhibition of p-ERK1/2 and the lowest expression of aquaporin 3 (P&lt;0.05).	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	126-132
26409848-9	2016	Eotaxin-1 induced up to 5.8 and 7.2-fold increases in the expression of MMP-9 mRNA and protein, respectively following 12h incubation with FLS, which was inhibited by antagonist of CCR3 SB328437 and an inhibitor of ERK U0126, indicating that action of eotaxin-1 on FLS seemed via CCR3 and ERK signaling pathway.	U 0126	219-224	C-C motif chemokine ligand 11	Homo sapiens	0-9
26409848-9	2016	Eotaxin-1 induced up to 5.8 and 7.2-fold increases in the expression of MMP-9 mRNA and protein, respectively following 12h incubation with FLS, which was inhibited by antagonist of CCR3 SB328437 and an inhibitor of ERK U0126, indicating that action of eotaxin-1 on FLS seemed via CCR3 and ERK signaling pathway.	U 0126	219-224	matrix metallopeptidase 9	Homo sapiens	72-77
26409848-9	2016	Eotaxin-1 induced up to 5.8 and 7.2-fold increases in the expression of MMP-9 mRNA and protein, respectively following 12h incubation with FLS, which was inhibited by antagonist of CCR3 SB328437 and an inhibitor of ERK U0126, indicating that action of eotaxin-1 on FLS seemed via CCR3 and ERK signaling pathway.	U 0126	219-224	C-C motif chemokine receptor 3	Homo sapiens	181-185
27504140-4	2016	Intrathecal administration of MAPKs inhibitors, SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and U0126 (ERK inhibitor), resulted in a partial reduction in CCD-induced mechanical allodynia.	U 0126	104-109	Eph receptor B1	Rattus norvegicus	111-114
26573712-7	2016	Furthermore, we demonstrated that GAS6 activated the mitogen-activated protein kinase kinase 1/2-extracellular signal-regulated kinase 1/2 pathway during pressure overload-induced cardiac hypertrophy, and the pharmacological mitogen-activated protein kinase kinase 1/2 inhibitor U0126 almost completely reversed GAS6 overexpression-induced cardiac hypertrophy and fibrosis, resulting in improved cardiac function.	U 0126	279-284	growth arrest specific 6	Mus musculus	34-38
27190513-7	2016	Ghrelin-mediated protection of dexamethasone-induced apoptosis of INS-1 cells was attenuated using the ERK inhibitor U0126 (10 muM), and cell viability increased using the p38MAPK inhibitor SB203580 (10 muM).	U 0126	117-122	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
27190513-7	2016	Ghrelin-mediated protection of dexamethasone-induced apoptosis of INS-1 cells was attenuated using the ERK inhibitor U0126 (10 muM), and cell viability increased using the p38MAPK inhibitor SB203580 (10 muM).	U 0126	117-122	insulin 1	Rattus norvegicus	66-71
27190513-7	2016	Ghrelin-mediated protection of dexamethasone-induced apoptosis of INS-1 cells was attenuated using the ERK inhibitor U0126 (10 muM), and cell viability increased using the p38MAPK inhibitor SB203580 (10 muM).	U 0126	117-122	Eph receptor B1	Rattus norvegicus	103-106
26572581-11	2016	Moreover, orexin A upregulated ERK phosphorylation; however, U0126 or chloroquine abrogated ERK phosphorylation and decreased autophagy, compared to treatment with orexin A alone.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	92-95
26647805-6	2016	Furthermore, SW480-derived exosomes promoted the migration of recipient HepG2 cells in a wound-healing assay, which was suppressed by pretreatment with U0126, an upstream inhibitor of ERK1/2.	U 0126	152-157	mitogen-activated protein kinase 3	Homo sapiens	184-190
26433471-7	2016	Fl-hIL-33-induced increases in EOC cell migration, invasive potential and proliferation were specifically abrogated by treatment with the ERK inhibitor U0126 while JNK inhibitor SP600125 only disrupted IL-33-induced enhancement of cell viability.	U 0126	152-157	mitogen-activated protein kinase 1	Homo sapiens	138-141
26433471-7	2016	Fl-hIL-33-induced increases in EOC cell migration, invasive potential and proliferation were specifically abrogated by treatment with the ERK inhibitor U0126 while JNK inhibitor SP600125 only disrupted IL-33-induced enhancement of cell viability.	U 0126	152-157	interleukin 33	Homo sapiens	4-9
26463993-10	2016	Addition of U0126, an inhibitor of ERK1/2, prevented appearance of senescent features induced by excess NaCl.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	35-41
26724951-7	2016	Moreover, siRNA for IR-A and U0126, a specific inhibitor of MEK, were used to further investigate the relationship between the IR/MEK/ERK pathway and abnormal proliferation and differentiation of IECs in DM mice.	U 0126	29-34	midkine	Mus musculus	60-63
27990160-10	2016	LY294002 (10 muM), U0126 (10 muM), AZD8055 (1 muM), and sunitinib (1 muM) inhibited PPGL cell proliferation in ten primary cultures of tissues, including four from patients with gene mutations.	U 0126	19-24	latexin	Homo sapiens	29-32
27990160-10	2016	LY294002 (10 muM), U0126 (10 muM), AZD8055 (1 muM), and sunitinib (1 muM) inhibited PPGL cell proliferation in ten primary cultures of tissues, including four from patients with gene mutations.	U 0126	19-24	latexin	Homo sapiens	29-32
27990160-10	2016	LY294002 (10 muM), U0126 (10 muM), AZD8055 (1 muM), and sunitinib (1 muM) inhibited PPGL cell proliferation in ten primary cultures of tissues, including four from patients with gene mutations.	U 0126	19-24	latexin	Homo sapiens	29-32
26111538-7	2016	To further investigate the role of ROS/ERK1/2 in MWCNTs-induced SOD-2 overexpression, prior to MWCNTs exposure, cells were pretreated with the Mitogen-activated protein kinase kinase 1/2 (MEK 1/2) inhibitor (U0126) or with NAC.	U 0126	208-213	mitogen-activated protein kinase kinase 1	Homo sapiens	143-186
27008260-8	2016	Epicatechin activated the extracellular signal-regulated kinase (ERK) and the treatment with an ERK inhibitor (U0126) blocked the expression of DSPP.	U 0126	111-116	mitogen-activated protein kinase 1	Homo sapiens	26-63
27008260-8	2016	Epicatechin activated the extracellular signal-regulated kinase (ERK) and the treatment with an ERK inhibitor (U0126) blocked the expression of DSPP.	U 0126	111-116	mitogen-activated protein kinase 1	Homo sapiens	96-99
27008260-8	2016	Epicatechin activated the extracellular signal-regulated kinase (ERK) and the treatment with an ERK inhibitor (U0126) blocked the expression of DSPP.	U 0126	111-116	dentin sialophosphoprotein	Homo sapiens	144-148
27193734-3	2016	In this study, we identified that the mitogen-activated protein kinase (MAPK) inhibitor U0126 inhibits the cytotoxic effects of BEA on A549 cells.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	72-76
27193734-8	2016	Furthermore, treatment with MEK1/2 inhibitor U0126 was capable to attenuate the BEA induced typical apoptotic morphological change, apoptotic cells, and MEK1/2-ERK42/44-90RSK signaling pathway.	U 0126	45-50	mitogen-activated protein kinase kinase 1	Homo sapiens	28-34
27193734-8	2016	Furthermore, treatment with MEK1/2 inhibitor U0126 was capable to attenuate the BEA induced typical apoptotic morphological change, apoptotic cells, and MEK1/2-ERK42/44-90RSK signaling pathway.	U 0126	45-50	mitogen-activated protein kinase kinase 1	Homo sapiens	153-159
25421211-11	2016	And the neuroprotective role of synaptic NMDA activity was able to be reversed by MEK1/2 inhibitor U0126 in vitro.	U 0126	99-104	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
26772774-13	2016	Pretreating macrophages with an ERK inhibitor, U0126, dose-dependently antagonized WISP"s synergistic effect on Poly(I:C)-induced TNF-alpha release.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	32-35
27833763-2	2016	The animals were randomly divided into a control, a CCI, and a U0126 (MEK1/2 inhibitor) group.	U 0126	63-68	mitogen activated protein kinase kinase 1	Rattus norvegicus	70-76
26881015-6	2016	ICAM-1 expression was dose-dependently inhibited by U0126 (a specific inhibitor of MEK1/2, a signal upstream from ERK1/2), SB203580 (a specific inhibitor of p38(MAPK)), and SN50 (a specific inhibitor of NF-kappaB).	U 0126	52-57	mitogen-activated protein kinase kinase 1	Homo sapiens	83-89
26881015-6	2016	ICAM-1 expression was dose-dependently inhibited by U0126 (a specific inhibitor of MEK1/2, a signal upstream from ERK1/2), SB203580 (a specific inhibitor of p38(MAPK)), and SN50 (a specific inhibitor of NF-kappaB).	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	114-120
26881015-6	2016	ICAM-1 expression was dose-dependently inhibited by U0126 (a specific inhibitor of MEK1/2, a signal upstream from ERK1/2), SB203580 (a specific inhibitor of p38(MAPK)), and SN50 (a specific inhibitor of NF-kappaB).	U 0126	52-57	nuclear factor kappa B subunit 1	Homo sapiens	203-212
26881015-7	2016	U0126 and SB203580 both counteracted the activation of NF-kappaB, whereas the phosphorylation of ERK1/2 and p38(MAPK) was not blocked by SN50.	U 0126	0-5	nuclear factor kappa B subunit 1	Homo sapiens	55-64
26881015-8	2016	ERK1/2 phosphorylation was blocked by U0126 but not by SB203580, and p38(MAPK) activity was reduced by SB203580 but not by U0126.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	0-6
26697075-8	2016	Moreover, the effect of HAMSCs was significantly inhibited by U0126, a highly selective inhibitor of extracellular signaling-regulated kinase 1/2 (ERK1/2) signaling.	U 0126	62-67	mitogen-activated protein kinase 3	Homo sapiens	147-153
26528854-8	2015	Mechanistic analyses showed that overexpression of EGF decreased the miR-622 level in A549 cells, and this reduction could be rescued by administrating U0126, an inhibitor of ERK.	U 0126	152-157	microRNA 622	Homo sapiens	69-76
27123007-7	2016	Moreover, [Ca(2+)]o-induced promotion of pBMSCs proliferation, the changes of proliferative genes expression levels, and the activation of ERK1/2 signaling pathway were effectively blocked by U0126, a selective ERK kinase inhibitor.	U 0126	192-197	mitogen-activated protein kinase 3	Homo sapiens	139-145
27123007-7	2016	Moreover, [Ca(2+)]o-induced promotion of pBMSCs proliferation, the changes of proliferative genes expression levels, and the activation of ERK1/2 signaling pathway were effectively blocked by U0126, a selective ERK kinase inhibitor.	U 0126	192-197	mitogen-activated protein kinase 1	Homo sapiens	139-142
26242263-9	2016	These effects of CCL18 were prevented by ERK1/2 selective inhibitor U0126 as well as NF-kappaB selective inhibitor BAY117082.	U 0126	68-73	C-C motif chemokine ligand 18	Homo sapiens	17-22
26242263-9	2016	These effects of CCL18 were prevented by ERK1/2 selective inhibitor U0126 as well as NF-kappaB selective inhibitor BAY117082.	U 0126	68-73	mitogen-activated protein kinase 3	Homo sapiens	41-47
26528854-8	2015	Mechanistic analyses showed that overexpression of EGF decreased the miR-622 level in A549 cells, and this reduction could be rescued by administrating U0126, an inhibitor of ERK.	U 0126	152-157	mitogen-activated protein kinase 1	Homo sapiens	175-178
26694325-7	2015	VEGF-induced proliferation was reduced either by U-0126 or LY-294002.	U 0126	49-55	vascular endothelial growth factor A	Mus musculus	0-4
26616889-5	2015	IgG-mediated phosphorylation of ERK-1/2 was associated with an increased cytotoxicity of CGN, which could be blocked by ERK-1/2 pathway inhibitor U0126.	U 0126	146-151	mitogen-activated protein kinase 3	Homo sapiens	32-39
26733817-8	2015	Moreover, in IC slices from IoN-CCI rats, U0126, an inhibitor of ERK activation, decreased both the amplitude and the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) and reduced the paired-pulse ratio (PPR) of Vc-projecting neurons.	U 0126	42-47	Eph receptor B1	Rattus norvegicus	65-68
26733817-10	2015	Finally, intra-IC infusion of U0126 obviously decreased Fos expression in the Vc, accompanied by the alleviation of both nociceptive behavior and negative emotions.	U 0126	30-35	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	56-59
26616889-5	2015	IgG-mediated phosphorylation of ERK-1/2 was associated with an increased cytotoxicity of CGN, which could be blocked by ERK-1/2 pathway inhibitor U0126.	U 0126	146-151	mitogen-activated protein kinase 3	Homo sapiens	120-127
26694420-8	2015	Experiments using the specific MEK inhibitor U0126 showed that MytiLec-induced phosphorylation of the MEK-ERK pathway up-regulated expression of the cyclin-dependent kinase inhibitor p21, leading to cell cycle arrest and TNF-alpha production.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
26432159-9	2015	However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and p-p70S6K.	U 0126	31-36	phosphatase and tensin homolog	Homo sapiens	172-176
26432159-9	2015	However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and p-p70S6K.	U 0126	31-36	ribosomal protein S6 kinase B1	Homo sapiens	183-189
26549149-2	2015	The MEK inhibitor U0126 and the ERK inhibitor FR180204 clearly inhibited IL-1beta-induced prostaglandin E2 release and COX-2 mRNA expression.	U 0126	18-23	interleukin 1 beta	Canis lupus familiaris	73-81
26694420-8	2015	Experiments using the specific MEK inhibitor U0126 showed that MytiLec-induced phosphorylation of the MEK-ERK pathway up-regulated expression of the cyclin-dependent kinase inhibitor p21, leading to cell cycle arrest and TNF-alpha production.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
26694420-8	2015	Experiments using the specific MEK inhibitor U0126 showed that MytiLec-induced phosphorylation of the MEK-ERK pathway up-regulated expression of the cyclin-dependent kinase inhibitor p21, leading to cell cycle arrest and TNF-alpha production.	U 0126	45-50	H3 histone pseudogene 16	Homo sapiens	183-186
26694420-8	2015	Experiments using the specific MEK inhibitor U0126 showed that MytiLec-induced phosphorylation of the MEK-ERK pathway up-regulated expression of the cyclin-dependent kinase inhibitor p21, leading to cell cycle arrest and TNF-alpha production.	U 0126	45-50	tumor necrosis factor	Homo sapiens	221-230
26658076-12	2015	CQ stimulated ERK1/2 phosphorylation, and U0126 prevented the CQ-induced COX-2 expression and prostaglandin E2 (PGE2) production.	U 0126	42-47	prostaglandin-endoperoxide synthase 2	Homo sapiens	73-78
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	U 0126	54-59	mitogen-activated protein kinase 8	Homo sapiens	5-8
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	13-19
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	U 0126	54-59	tumor necrosis factor	Homo sapiens	104-107
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	U 0126	54-59	pentraxin 3	Homo sapiens	116-120
26636577-6	2015	A decrease in infarct size was observed in an in vivo model of myocardial I/R injury in HCQ treated animals and furthermore this protection was blocked in the presence of the ERK1/2 inhibitor U0126.	U 0126	192-197	mitogen activated protein kinase 3	Rattus norvegicus	175-181
26690179-8	2015	These effects were abolished by pretreatment with the MAPK inhibitor U0126, which inhibits enzymes MEK1 and MEK2.	U 0126	69-74	mitogen-activated protein kinase 3	Homo sapiens	54-58
26690179-8	2015	These effects were abolished by pretreatment with the MAPK inhibitor U0126, which inhibits enzymes MEK1 and MEK2.	U 0126	69-74	mitogen-activated protein kinase kinase 1	Homo sapiens	99-103
26690179-8	2015	These effects were abolished by pretreatment with the MAPK inhibitor U0126, which inhibits enzymes MEK1 and MEK2.	U 0126	69-74	mitogen-activated protein kinase kinase 2	Homo sapiens	108-112
26690179-9	2015	In addition, U0126 inhibited the phosphorylation of ERK 1/2 in response to the trisaccharide dose-dependently.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	52-59
26514924-9	2015	AG-1478 (a specific EGFR tyrosine kinase inhibitor) and U0126 (a specific MEK inhibitor) completely mitigated the growth promoting effect of CPF.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
26409001-4	2015	The inhibition of ERK1/2 phosphorylation using the specific MEK inhibitor U0126 partially abrogates the autophagy as well as the clearance of mutant huntingtin protein aggregates mediated by EHNs suggesting that nanorods stimulate the activation of MEK/ERK1/2 signaling pathway during autophagy process.	U 0126	74-79	mitogen-activated protein kinase 3	Homo sapiens	18-24
26409001-4	2015	The inhibition of ERK1/2 phosphorylation using the specific MEK inhibitor U0126 partially abrogates the autophagy as well as the clearance of mutant huntingtin protein aggregates mediated by EHNs suggesting that nanorods stimulate the activation of MEK/ERK1/2 signaling pathway during autophagy process.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
26409001-4	2015	The inhibition of ERK1/2 phosphorylation using the specific MEK inhibitor U0126 partially abrogates the autophagy as well as the clearance of mutant huntingtin protein aggregates mediated by EHNs suggesting that nanorods stimulate the activation of MEK/ERK1/2 signaling pathway during autophagy process.	U 0126	74-79	huntingtin	Homo sapiens	149-159
26409001-4	2015	The inhibition of ERK1/2 phosphorylation using the specific MEK inhibitor U0126 partially abrogates the autophagy as well as the clearance of mutant huntingtin protein aggregates mediated by EHNs suggesting that nanorods stimulate the activation of MEK/ERK1/2 signaling pathway during autophagy process.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	249-252
26409001-4	2015	The inhibition of ERK1/2 phosphorylation using the specific MEK inhibitor U0126 partially abrogates the autophagy as well as the clearance of mutant huntingtin protein aggregates mediated by EHNs suggesting that nanorods stimulate the activation of MEK/ERK1/2 signaling pathway during autophagy process.	U 0126	74-79	mitogen-activated protein kinase 3	Homo sapiens	253-259
26720469-12	2015	The effect of EPO was abolished by sEPOR and U0126.	U 0126	45-50	erythropoietin	Rattus norvegicus	14-17
26490843-6	2015	Treatment with an inhibitor of Egfr transactivation, AG1478, and an inhibitor of the mitogen-activated protein kinase (MAPK) 3/1 pathway, U0126, increased spontaneous OM and blocked the inhibitory effects of BPA, E2, and the selective GPER agonist, G-1.	U 0126	138-143	mitogen-activated protein kinase 3	Danio rerio	119-123
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	U 0126	155-160	mitogen-activated protein kinase 3	Mus musculus	138-144
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	U 0126	155-160	mitogen-activated protein kinase 8	Mus musculus	217-220
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	U 0126	155-160	mitogen-activated protein kinase 3	Mus musculus	222-228
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	U 0126	155-160	mitogen-activated protein kinase 14	Mus musculus	233-236
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	U 0126	155-160	mitogen-activated protein kinase 8	Mus musculus	217-220
26398946-7	2015	The MEK inhibitor U0126 abolished the rosi-rescued cell proliferation and cyclin A expression in seipin-nKO mice.	U 0126	18-23	midkine	Mus musculus	4-7
26398946-7	2015	The MEK inhibitor U0126 abolished the rosi-rescued cell proliferation and cyclin A expression in seipin-nKO mice.	U 0126	18-23	cyclin A2	Mus musculus	74-82
26398946-7	2015	The MEK inhibitor U0126 abolished the rosi-rescued cell proliferation and cyclin A expression in seipin-nKO mice.	U 0126	18-23	Berardinelli-Seip congenital lipodystrophy 2 (seipin)	Mus musculus	97-103
26398946-10	2015	Finally, rosi treatment for 10 days could alleviate the depression-like phenotype in seipin-nKO mice, and this alleviation was blocked by the MEK inhibitor U0126.	U 0126	156-161	Berardinelli-Seip congenital lipodystrophy 2 (seipin)	Mus musculus	85-91
26398946-10	2015	Finally, rosi treatment for 10 days could alleviate the depression-like phenotype in seipin-nKO mice, and this alleviation was blocked by the MEK inhibitor U0126.	U 0126	156-161	midkine	Mus musculus	142-145
26472194-10	2015	Down-regulation of ERK1/2 activity, by using selective ERK1/2 inhibitor (U0126) or siERK1/2, led to an inhibition of SNG-induced autophagic cell death.	U 0126	73-78	mitogen-activated protein kinase 3	Homo sapiens	19-25
26424114-6	2015	The inhibition of MEK/ERK1/2 or PI3K/AKT activity by U0126 or wortmannin, but not the inhibition of phospholipase Cgamma by U73122, prevented FGF9-induced gamma-GCS and HO-1 upregulation, changes in cellular redox status, and neuroprotection against MPP(+) toxicity in primary cortical and dopaminergic neurons.	U 0126	53-58	mitogen activated protein kinase 3	Rattus norvegicus	22-28
26424114-6	2015	The inhibition of MEK/ERK1/2 or PI3K/AKT activity by U0126 or wortmannin, but not the inhibition of phospholipase Cgamma by U73122, prevented FGF9-induced gamma-GCS and HO-1 upregulation, changes in cellular redox status, and neuroprotection against MPP(+) toxicity in primary cortical and dopaminergic neurons.	U 0126	53-58	AKT serine/threonine kinase 1	Rattus norvegicus	37-40
26424114-6	2015	The inhibition of MEK/ERK1/2 or PI3K/AKT activity by U0126 or wortmannin, but not the inhibition of phospholipase Cgamma by U73122, prevented FGF9-induced gamma-GCS and HO-1 upregulation, changes in cellular redox status, and neuroprotection against MPP(+) toxicity in primary cortical and dopaminergic neurons.	U 0126	53-58	fibroblast growth factor 9	Rattus norvegicus	142-146
26424114-7	2015	Furthermore, FGF9 treatment enhanced the promoter activity of the cAMP-response element binding protein (CREB) and nuclear factor erythroid-derived 2-like 2 (Nrf2), and this phenomenon was blocked by PD173014 or U0126 or wortmannin.	U 0126	212-217	fibroblast growth factor 9	Rattus norvegicus	13-17
26424114-7	2015	Furthermore, FGF9 treatment enhanced the promoter activity of the cAMP-response element binding protein (CREB) and nuclear factor erythroid-derived 2-like 2 (Nrf2), and this phenomenon was blocked by PD173014 or U0126 or wortmannin.	U 0126	212-217	cAMP responsive element binding protein 1	Rattus norvegicus	66-103
26424114-7	2015	Furthermore, FGF9 treatment enhanced the promoter activity of the cAMP-response element binding protein (CREB) and nuclear factor erythroid-derived 2-like 2 (Nrf2), and this phenomenon was blocked by PD173014 or U0126 or wortmannin.	U 0126	212-217	cAMP responsive element binding protein 1	Rattus norvegicus	105-109
26424114-7	2015	Furthermore, FGF9 treatment enhanced the promoter activity of the cAMP-response element binding protein (CREB) and nuclear factor erythroid-derived 2-like 2 (Nrf2), and this phenomenon was blocked by PD173014 or U0126 or wortmannin.	U 0126	212-217	NFE2 like bZIP transcription factor 2	Rattus norvegicus	115-156
26424114-7	2015	Furthermore, FGF9 treatment enhanced the promoter activity of the cAMP-response element binding protein (CREB) and nuclear factor erythroid-derived 2-like 2 (Nrf2), and this phenomenon was blocked by PD173014 or U0126 or wortmannin.	U 0126	212-217	NFE2 like bZIP transcription factor 2	Rattus norvegicus	158-162
26305625-6	2015	The ERK kinase inhibitor, U0126, was then used to inhibit the activity of ERK.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	4-7
26305625-6	2015	The ERK kinase inhibitor, U0126, was then used to inhibit the activity of ERK.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	74-77
26305625-7	2015	Treatment with U0126 led to a significant reduction in the number of autophagosomes indicating that the CVB3-induced autophagosome accumulation may have occurred via the ERK pathway.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	170-173
27551480-8	2015	Furthermore, levels of phosphor-TSC2 (Ser664) were increased after treatment with FVII and PAR2 agonist whereas these were significantly abolished in the presence of a potent and specific MEK/ERK inhibitor U0126.	U 0126	206-211	TSC complex subunit 2	Homo sapiens	32-36
27551480-8	2015	Furthermore, levels of phosphor-TSC2 (Ser664) were increased after treatment with FVII and PAR2 agonist whereas these were significantly abolished in the presence of a potent and specific MEK/ERK inhibitor U0126.	U 0126	206-211	F2R like trypsin receptor 1	Homo sapiens	91-95
27551480-8	2015	Furthermore, levels of phosphor-TSC2 (Ser664) were increased after treatment with FVII and PAR2 agonist whereas these were significantly abolished in the presence of a potent and specific MEK/ERK inhibitor U0126.	U 0126	206-211	mitogen-activated protein kinase kinase 7	Homo sapiens	188-191
27551480-8	2015	Furthermore, levels of phosphor-TSC2 (Ser664) were increased after treatment with FVII and PAR2 agonist whereas these were significantly abolished in the presence of a potent and specific MEK/ERK inhibitor U0126.	U 0126	206-211	mitogen-activated protein kinase 1	Homo sapiens	192-195
26772774-13	2016	Pretreating macrophages with an ERK inhibitor, U0126, dose-dependently antagonized WISP"s synergistic effect on Poly(I:C)-induced TNF-alpha release.	U 0126	47-52	tumor necrosis factor	Mus musculus	130-139
27028823-0	2016	[Alpha-1 Antitrypsin Affects U0126-Induced Cytotoxicity in Colon Cancer Cell Line (HCT116)].	U 0126	29-34	serpin family A member 1	Homo sapiens	1-20
27028823-6	2016	The dominantly recovered cell viability was observed in the co-treatment with MEK1/2 inhibitor U0126.	U 0126	95-100	mitogen-activated protein kinase kinase 1	Homo sapiens	78-84
27028823-7	2016	In addition, it was revealed that AAT almost completely abolished U0126-induced apoptosis through maintenance of the autophagy process.	U 0126	66-71	serpin family A member 1	Homo sapiens	34-37
26359088-8	2015	Widdrol-induced phosphorylation of PKC, MEK, and ERK, which are related to the PKC-MAPK pathway, and their phosphorylation was inhibited by their inhibitors (H-7, U0126, and PD-98059, respectively).	U 0126	163-168	proline rich transmembrane protein 2	Homo sapiens	35-38
26359088-8	2015	Widdrol-induced phosphorylation of PKC, MEK, and ERK, which are related to the PKC-MAPK pathway, and their phosphorylation was inhibited by their inhibitors (H-7, U0126, and PD-98059, respectively).	U 0126	163-168	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
26359088-8	2015	Widdrol-induced phosphorylation of PKC, MEK, and ERK, which are related to the PKC-MAPK pathway, and their phosphorylation was inhibited by their inhibitors (H-7, U0126, and PD-98059, respectively).	U 0126	163-168	mitogen-activated protein kinase 1	Homo sapiens	49-52
26359088-8	2015	Widdrol-induced phosphorylation of PKC, MEK, and ERK, which are related to the PKC-MAPK pathway, and their phosphorylation was inhibited by their inhibitors (H-7, U0126, and PD-98059, respectively).	U 0126	163-168	proline rich transmembrane protein 2	Homo sapiens	79-82
26359088-8	2015	Widdrol-induced phosphorylation of PKC, MEK, and ERK, which are related to the PKC-MAPK pathway, and their phosphorylation was inhibited by their inhibitors (H-7, U0126, and PD-98059, respectively).	U 0126	163-168	mitogen-activated protein kinase 1	Homo sapiens	83-87
26807180-8	2015	Furthermore, a specific inhibitor of the ERK1/2 pathway, U0126, decreased the FXa-induced pro-inflammatory cytokines expression significantly.	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	41-47
26807180-8	2015	Furthermore, a specific inhibitor of the ERK1/2 pathway, U0126, decreased the FXa-induced pro-inflammatory cytokines expression significantly.	U 0126	57-62	coagulation factor X	Homo sapiens	78-81
29124230-14	2015	In addition, SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor) significantly suppressed the expression of TNF-alpha and IL-8 in LPS-stimulated THP-1 cells.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	49-55
29124230-14	2015	In addition, SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor) significantly suppressed the expression of TNF-alpha and IL-8 in LPS-stimulated THP-1 cells.	U 0126	42-47	tumor necrosis factor	Homo sapiens	110-119
29124230-14	2015	In addition, SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor) significantly suppressed the expression of TNF-alpha and IL-8 in LPS-stimulated THP-1 cells.	U 0126	42-47	C-X-C motif chemokine ligand 8	Homo sapiens	124-128
25990228-9	2015	Furthermore, PKM2, cyclin D1, and active caspase-3 protein expression decreased by intravitreal injection of U0126, a highly selective inhibitor of MAPK/ERK kinase.	U 0126	109-114	pyruvate kinase M1/2	Rattus norvegicus	13-17
25990228-9	2015	Furthermore, PKM2, cyclin D1, and active caspase-3 protein expression decreased by intravitreal injection of U0126, a highly selective inhibitor of MAPK/ERK kinase.	U 0126	109-114	cyclin D1	Rattus norvegicus	19-28
25990228-9	2015	Furthermore, PKM2, cyclin D1, and active caspase-3 protein expression decreased by intravitreal injection of U0126, a highly selective inhibitor of MAPK/ERK kinase.	U 0126	109-114	caspase 3	Rattus norvegicus	41-50
26075533-9	2015	Treatment with ERK1/2 inhibitors (PD98059 and U0126) abolished the antagonistic effect of TGF-beta1 on TNF-alpha mediated catabolic responses.	U 0126	46-51	mitogen activated protein kinase 3	Rattus norvegicus	15-21
26075533-9	2015	Treatment with ERK1/2 inhibitors (PD98059 and U0126) abolished the antagonistic effect of TGF-beta1 on TNF-alpha mediated catabolic responses.	U 0126	46-51	transforming growth factor, beta 1	Rattus norvegicus	90-99
26075533-9	2015	Treatment with ERK1/2 inhibitors (PD98059 and U0126) abolished the antagonistic effect of TGF-beta1 on TNF-alpha mediated catabolic responses.	U 0126	46-51	tumor necrosis factor	Rattus norvegicus	103-112
26476886-8	2015	Further investigation showed that suppression of P38 activation by SB203580 increased the cell viability and also prevented cleavage of caspase-3 and PARP, inhibition of ERK1/2 with U0126 had the opposite action.	U 0126	182-187	mitogen-activated protein kinase 1	Homo sapiens	49-52
26476886-8	2015	Further investigation showed that suppression of P38 activation by SB203580 increased the cell viability and also prevented cleavage of caspase-3 and PARP, inhibition of ERK1/2 with U0126 had the opposite action.	U 0126	182-187	mitogen-activated protein kinase 3	Homo sapiens	170-176
26041383-11	2015	Both CYP1B1 siRNA and ERK-specific inhibitor U0126 suppressed NNK-mediated ERalpha up-regulation, suggesting that ERalpha was downstream of CYP1B1 and ERK.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	22-25
26041383-11	2015	Both CYP1B1 siRNA and ERK-specific inhibitor U0126 suppressed NNK-mediated ERalpha up-regulation, suggesting that ERalpha was downstream of CYP1B1 and ERK.	U 0126	45-50	estrogen receptor 1	Homo sapiens	75-82
26041383-11	2015	Both CYP1B1 siRNA and ERK-specific inhibitor U0126 suppressed NNK-mediated ERalpha up-regulation, suggesting that ERalpha was downstream of CYP1B1 and ERK.	U 0126	45-50	estrogen receptor 1	Homo sapiens	114-121
26041383-11	2015	Both CYP1B1 siRNA and ERK-specific inhibitor U0126 suppressed NNK-mediated ERalpha up-regulation, suggesting that ERalpha was downstream of CYP1B1 and ERK.	U 0126	45-50	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	140-146
26041383-11	2015	Both CYP1B1 siRNA and ERK-specific inhibitor U0126 suppressed NNK-mediated ERalpha up-regulation, suggesting that ERalpha was downstream of CYP1B1 and ERK.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	151-154
26240040-7	2015	In the picroside and U0126 groups, the neurological behavioral function was improved, and the number of apoptotic cells and the expression of pMEK1/2, pERK1/2, and COX2 decreased significantly when compared to the model group.	U 0126	21-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	164-168
26297384-3	2015	Here, we found that the downward phase of the U50488 dose-response curve was blocked by an inhibitor of extracellular signal-regulated kinase (ERK) activation U0126.	U 0126	159-164	mitogen-activated protein kinase 1	Homo sapiens	104-141
26297384-3	2015	Here, we found that the downward phase of the U50488 dose-response curve was blocked by an inhibitor of extracellular signal-regulated kinase (ERK) activation U0126.	U 0126	159-164	mitogen-activated protein kinase 1	Homo sapiens	143-146
26302186-10	2015	Finally, both AKT and ERK inhibitors (LY294002 and UO126) blocked effects of LPS on the depression of ENaC-gamma.	U 0126	51-56	AKT serine/threonine kinase 1	Homo sapiens	14-17
26302186-10	2015	Finally, both AKT and ERK inhibitors (LY294002 and UO126) blocked effects of LPS on the depression of ENaC-gamma.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	22-25
26302186-10	2015	Finally, both AKT and ERK inhibitors (LY294002 and UO126) blocked effects of LPS on the depression of ENaC-gamma.	U 0126	51-56	sodium channel epithelial 1 subunit gamma	Homo sapiens	102-112
26151099-6	2015	The increase in Per1 mRNA by simultaneous treatment with Glu, 5-HT and DA was dependent on extracellular signal-regulated kinase (ERK) activation, since pretreatment with ERK inhibitor U0126 (3 muM) blocked Per1 expression.	U 0126	185-190	Eph receptor B1	Rattus norvegicus	91-128
26151099-6	2015	The increase in Per1 mRNA by simultaneous treatment with Glu, 5-HT and DA was dependent on extracellular signal-regulated kinase (ERK) activation, since pretreatment with ERK inhibitor U0126 (3 muM) blocked Per1 expression.	U 0126	185-190	Eph receptor B1	Rattus norvegicus	130-133
26151099-6	2015	The increase in Per1 mRNA by simultaneous treatment with Glu, 5-HT and DA was dependent on extracellular signal-regulated kinase (ERK) activation, since pretreatment with ERK inhibitor U0126 (3 muM) blocked Per1 expression.	U 0126	185-190	Eph receptor B1	Rattus norvegicus	171-174
26722318-2	2015	A375 Human melanoma cells were treated with U0126 (ERK signaling pathway inhibitor) and BMS-345541 (NF-kappaB inhibitor), alone or in combination.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	51-54
26058873-7	2015	Furthermore, U0126 (MEK inhibitor) was used to treat these NPC cell lines.	U 0126	13-18	mitogen-activated protein kinase kinase 7	Homo sapiens	20-23
26058873-8	2015	CCL2 and CXCL16 expression levels and cell proliferation were significantly inhibited by U0126 in a dose- and time-dependent manner.	U 0126	89-94	C-C motif chemokine ligand 2	Homo sapiens	0-4
26058873-8	2015	CCL2 and CXCL16 expression levels and cell proliferation were significantly inhibited by U0126 in a dose- and time-dependent manner.	U 0126	89-94	C-X-C motif chemokine ligand 16	Homo sapiens	9-15
26392309-5	2015	U0126, a specific inhibitor of ERK1/2 pathway was employed to block the ERK1/2 signaling pathway.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	31-37
26392309-5	2015	U0126, a specific inhibitor of ERK1/2 pathway was employed to block the ERK1/2 signaling pathway.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	72-78
26392309-6	2015	Western blotting analysis showed that alcohol significantly enhanced the levels of phosphorylated ERK1/2 and induced hyperacetylation of histone3, which were both effectively prevented with U0126.	U 0126	190-195	mitogen activated protein kinase 3	Rattus norvegicus	98-104
26392309-7	2015	Real-time PCR showed that U0126 treatment significantly decreased alcohol-induced over-expression of GATA4 and MEF2c, and the basal expression level of GATA4, but did not affect MEF2c.	U 0126	26-31	GATA binding protein 4	Rattus norvegicus	101-106
26392309-7	2015	Real-time PCR showed that U0126 treatment significantly decreased alcohol-induced over-expression of GATA4 and MEF2c, and the basal expression level of GATA4, but did not affect MEF2c.	U 0126	26-31	myocyte enhancer factor 2C	Rattus norvegicus	111-116
26392309-7	2015	Real-time PCR showed that U0126 treatment significantly decreased alcohol-induced over-expression of GATA4 and MEF2c, and the basal expression level of GATA4, but did not affect MEF2c.	U 0126	26-31	GATA binding protein 4	Rattus norvegicus	152-157
26392309-8	2015	ChIP assay showed that U0126 treatment significantly decreased alcohol-induced hyperacetylation of histone3 near the promoter regions of GATA4 and MEF2c.	U 0126	23-28	GATA binding protein 4	Rattus norvegicus	137-142
26392309-8	2015	ChIP assay showed that U0126 treatment significantly decreased alcohol-induced hyperacetylation of histone3 near the promoter regions of GATA4 and MEF2c.	U 0126	23-28	myocyte enhancer factor 2C	Rattus norvegicus	147-152
26392309-9	2015	The basal acetylation level of histone3 near the promoter region of GATA4 was affected by U0126 as well, but not that near the promoter region of MEF2c.	U 0126	90-95	GATA binding protein 4	Rattus norvegicus	68-73
26503112-6	2015	It is suggested the ERK signaling pathway was involving in this process because an ERK antagonist U0126 could inhibit PO"s effects mentioned above, as well as an ERK pathway agonist Ceramide C6 could enhance them.	U 0126	98-103	Eph receptor B1	Rattus norvegicus	20-23
26503112-6	2015	It is suggested the ERK signaling pathway was involving in this process because an ERK antagonist U0126 could inhibit PO"s effects mentioned above, as well as an ERK pathway agonist Ceramide C6 could enhance them.	U 0126	98-103	Eph receptor B1	Rattus norvegicus	83-86
26503112-6	2015	It is suggested the ERK signaling pathway was involving in this process because an ERK antagonist U0126 could inhibit PO"s effects mentioned above, as well as an ERK pathway agonist Ceramide C6 could enhance them.	U 0126	98-103	Eph receptor B1	Rattus norvegicus	83-86
26486958-10	2015	Accordingly, IL-22 mRNA half-life as determined in TPA/A23187-stimulated Jurkat T cells decreased under the influence of the MEK1/2 inhibitor U0126.	U 0126	142-147	interleukin 22	Homo sapiens	13-18
26486958-10	2015	Accordingly, IL-22 mRNA half-life as determined in TPA/A23187-stimulated Jurkat T cells decreased under the influence of the MEK1/2 inhibitor U0126.	U 0126	142-147	mitogen-activated protein kinase kinase 1	Homo sapiens	125-131
26483408-9	2016	We show that the A subunit-dependent ERK1/2 activation is mediated through ZAK-dependent signaling, and inhibition of ERK1/2 activation via the MEK1/2 inhibitors U0126 and PD98059 results in decreased Stx1-mediated IL-8 mRNA.	U 0126	162-167	mitogen-activated protein kinase 3	Homo sapiens	118-124
26483408-9	2016	We show that the A subunit-dependent ERK1/2 activation is mediated through ZAK-dependent signaling, and inhibition of ERK1/2 activation via the MEK1/2 inhibitors U0126 and PD98059 results in decreased Stx1-mediated IL-8 mRNA.	U 0126	162-167	mitogen-activated protein kinase kinase 1	Homo sapiens	144-150
26483408-9	2016	We show that the A subunit-dependent ERK1/2 activation is mediated through ZAK-dependent signaling, and inhibition of ERK1/2 activation via the MEK1/2 inhibitors U0126 and PD98059 results in decreased Stx1-mediated IL-8 mRNA.	U 0126	162-167	syntaxin 1A	Homo sapiens	201-205
26483408-9	2016	We show that the A subunit-dependent ERK1/2 activation is mediated through ZAK-dependent signaling, and inhibition of ERK1/2 activation via the MEK1/2 inhibitors U0126 and PD98059 results in decreased Stx1-mediated IL-8 mRNA.	U 0126	162-167	C-X-C motif chemokine ligand 8	Homo sapiens	215-219
26477505-6	2015	U0126, an inhibitor of ERK, reduced VSMC migration.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	23-26
26527881-9	2015	This Eag1 upregulation was prevented by EGF and the ERK1/2 inhibitor U0126 in only lung cancer cells; vascular endothelial growth factor did not prevent Eag1 upregulation.	U 0126	69-74	potassium voltage-gated channel subfamily H member 1	Homo sapiens	5-9
26527881-9	2015	This Eag1 upregulation was prevented by EGF and the ERK1/2 inhibitor U0126 in only lung cancer cells; vascular endothelial growth factor did not prevent Eag1 upregulation.	U 0126	69-74	mitogen-activated protein kinase 3	Homo sapiens	52-58
26770645-8	2015	Since ManLAM is the major component of water phase, we found that ManLAM induced IL-37 mRNA and protein expression in a time and dose-dependent manner, while this activity was almost totally abolished by the ERK1/2 (U0126) and p38 (SB203580) inhibitor.	U 0126	216-221	interleukin 37	Homo sapiens	81-86
26770645-8	2015	Since ManLAM is the major component of water phase, we found that ManLAM induced IL-37 mRNA and protein expression in a time and dose-dependent manner, while this activity was almost totally abolished by the ERK1/2 (U0126) and p38 (SB203580) inhibitor.	U 0126	216-221	mitogen-activated protein kinase 3	Homo sapiens	208-214
26186064-3	2015	We have also shown that metformin activates the ERK pathway in Ph+ALL cells, SUP-B15, a side effect that can be overcome by U0126 (MEK1/2 inhibitor) or imatinib.	U 0126	124-129	mitogen-activated protein kinase 1	Homo sapiens	48-51
26303640-8	2015	An inhibitor of the MAPK/AP-1 pathway (U0126) and the silencing of c-jun significantly suppressed CCL22 induction and the recruitment of Tregs by activated STING.	U 0126	39-44	C-C motif chemokine ligand 22	Homo sapiens	98-103
26186064-3	2015	We have also shown that metformin activates the ERK pathway in Ph+ALL cells, SUP-B15, a side effect that can be overcome by U0126 (MEK1/2 inhibitor) or imatinib.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Homo sapiens	131-137
25862329-4	2015	Then, we investigated the potential mechanisms and found that liraglutide promoted neurite outgrowth in a dose-dependant manner, and this effect could be partially inhibited by MEK-ERK inhibitor U0126.	U 0126	195-200	mitogen-activated protein kinase kinase 7	Homo sapiens	177-180
26212550-8	2015	However, combined treatment with MKK1/2 inhibitor U0126 and minocycline further decreased the Rad51 expression and cell viability of NSCLC cells.	U 0126	50-55	mitogen-activated protein kinase kinase 1	Homo sapiens	33-37
26212550-8	2015	However, combined treatment with MKK1/2 inhibitor U0126 and minocycline further decreased the Rad51 expression and cell viability of NSCLC cells.	U 0126	50-55	RAD51 recombinase	Homo sapiens	94-99
26065826-9	2015	The MAPK inhibitors PD98059 (MEK1/2), U0126 (MEK1/2) and SB203580 (P38) prevented but did not reverse paclitaxel-induced behavioral hypersensitivity.	U 0126	38-43	mitogen activated protein kinase 3	Rattus norvegicus	4-8
26065826-9	2015	The MAPK inhibitors PD98059 (MEK1/2), U0126 (MEK1/2) and SB203580 (P38) prevented but did not reverse paclitaxel-induced behavioral hypersensitivity.	U 0126	38-43	mitogen activated protein kinase kinase 1	Rattus norvegicus	45-51
25862329-4	2015	Then, we investigated the potential mechanisms and found that liraglutide promoted neurite outgrowth in a dose-dependant manner, and this effect could be partially inhibited by MEK-ERK inhibitor U0126.	U 0126	195-200	mitogen-activated protein kinase 1	Homo sapiens	181-184
25862329-5	2015	Besides, liraglutide induced an increase of p-ERK/ERK expression, which could be blocked in the presence of U0126.	U 0126	108-113	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	44-49
25862329-5	2015	Besides, liraglutide induced an increase of p-ERK/ERK expression, which could be blocked in the presence of U0126.	U 0126	108-113	mitogen-activated protein kinase 1	Homo sapiens	46-49
25919495-9	2015	Furthermore, treatment with U0126, a mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor, suppressed spinal ERK activation and COX-2 mRNA and protein expression induced by intrathecal injection of ephrinB1-Fc.	U 0126	28-33	prostaglandin-endoperoxide synthase 2	Homo sapiens	162-167
25919495-9	2015	Furthermore, treatment with U0126, a mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor, suppressed spinal ERK activation and COX-2 mRNA and protein expression induced by intrathecal injection of ephrinB1-Fc.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	37-107
25919495-9	2015	Furthermore, treatment with U0126, a mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor, suppressed spinal ERK activation and COX-2 mRNA and protein expression induced by intrathecal injection of ephrinB1-Fc.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
25919495-9	2015	Furthermore, treatment with U0126, a mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor, suppressed spinal ERK activation and COX-2 mRNA and protein expression induced by intrathecal injection of ephrinB1-Fc.	U 0126	28-33	EPH receptor B2	Homo sapiens	143-146
26153524-4	2015	This potentiation also required the activation of PKA and ERK pathways to occur as it was inhibited by KT5720 and U0126, respectively.	U 0126	114-119	Eph receptor B1	Rattus norvegicus	58-61
26310353-9	2015	Of note, the inhibition of ERK or p38 MAPK by U0126 or SB203580, respectively, decreased the apoptosis induced by cisplatin; however, enhanced apoptotic effects were observed with the use of ERK/p38 MAPK inhibitor in combination with butein.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	27-30
26310353-9	2015	Of note, the inhibition of ERK or p38 MAPK by U0126 or SB203580, respectively, decreased the apoptosis induced by cisplatin; however, enhanced apoptotic effects were observed with the use of ERK/p38 MAPK inhibitor in combination with butein.	U 0126	46-51	mitogen-activated protein kinase 14	Homo sapiens	34-37
26310353-9	2015	Of note, the inhibition of ERK or p38 MAPK by U0126 or SB203580, respectively, decreased the apoptosis induced by cisplatin; however, enhanced apoptotic effects were observed with the use of ERK/p38 MAPK inhibitor in combination with butein.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	191-194
26310353-9	2015	Of note, the inhibition of ERK or p38 MAPK by U0126 or SB203580, respectively, decreased the apoptosis induced by cisplatin; however, enhanced apoptotic effects were observed with the use of ERK/p38 MAPK inhibitor in combination with butein.	U 0126	46-51	mitogen-activated protein kinase 14	Homo sapiens	195-198
26107116-8	2015	Stereotaxic injection of U0126, a potent inhibitor of the ERK pathway, within the BLA blocked stress-induced behavioral depression.	U 0126	25-30	mitogen-activated protein kinase 1	Mus musculus	58-61
26299281-7	2015	Notably, U0126, a selective inhibitor of ERK1/2, was observed to mimic the above-mentioned cytoprotective activity of H2S.	U 0126	9-14	mitogen-activated protein kinase 3	Homo sapiens	41-47
25023718-6	2015	The mitogen-activated ERK-kinase (MEK) inhibitor U0126 abolished ERK1/2 phosphorylation, in vitro fertilization rate and the acrosome reaction induced by ZP or EGF but not by the Ca2+-ionophore A23187.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	4-32
25023718-6	2015	The mitogen-activated ERK-kinase (MEK) inhibitor U0126 abolished ERK1/2 phosphorylation, in vitro fertilization rate and the acrosome reaction induced by ZP or EGF but not by the Ca2+-ionophore A23187.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
25023718-6	2015	The mitogen-activated ERK-kinase (MEK) inhibitor U0126 abolished ERK1/2 phosphorylation, in vitro fertilization rate and the acrosome reaction induced by ZP or EGF but not by the Ca2+-ionophore A23187.	U 0126	49-54	mitogen-activated protein kinase 3	Homo sapiens	65-71
25023718-6	2015	The mitogen-activated ERK-kinase (MEK) inhibitor U0126 abolished ERK1/2 phosphorylation, in vitro fertilization rate and the acrosome reaction induced by ZP or EGF but not by the Ca2+-ionophore A23187.	U 0126	49-54	epidermal growth factor	Homo sapiens	160-163
25023718-9	2015	Direct determination of intracellular [Ca2+] revealed that Ca2+ influx induced by EGF or ZP was completely blocked by U0126.	U 0126	118-123	epidermal growth factor	Homo sapiens	82-85
26116232-4	2015	Pretreatment with H89, a specific inhibitor of PKA, and U0126, a specific inhibitor of ERK1/2 significantly inhibited both hCG-induced eIF5A mRNA expression and hypusination of eIF5A protein.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	87-93
25919495-9	2015	Furthermore, treatment with U0126, a mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor, suppressed spinal ERK activation and COX-2 mRNA and protein expression induced by intrathecal injection of ephrinB1-Fc.	U 0126	28-33	ephrin B1	Homo sapiens	232-240
26116232-4	2015	Pretreatment with H89, a specific inhibitor of PKA, and U0126, a specific inhibitor of ERK1/2 significantly inhibited both hCG-induced eIF5A mRNA expression and hypusination of eIF5A protein.	U 0126	56-61	hypertrichosis 2 (generalised, congenital)	Homo sapiens	123-126
26033246-5	2015	Pharmacological Src and ERK kinase pathway inhibitors (PP2 and U0126) reverse these phosphorylations and rescue Ca2+ signaling.	U 0126	63-68	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	16-19
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Mus musculus	14-20
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	35-40	mitogen-activated protein kinase 3	Mus musculus	21-27
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Mus musculus	100-106
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	35-40	mitogen-activated protein kinase 3	Mus musculus	107-113
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	203-208	mitogen-activated protein kinase kinase 1	Mus musculus	14-20
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	203-208	mitogen-activated protein kinase 3	Mus musculus	21-27
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	203-208	mitogen-activated protein kinase kinase 1	Mus musculus	100-106
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	203-208	mitogen-activated protein kinase 3	Mus musculus	107-113
26356837-7	2015	Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction.	U 0126	203-208	glycogen synthase kinase 3 beta	Mus musculus	126-135
25957086-7	2015	When the AAR was blocked (U0126, or ERK/GCN2 siRNA), both IGFBP-1 secretion and hyperphosphorylation (pSer101/pSer119/pSer169) due to leucine deprivation were prevented.	U 0126	26-31	insulin like growth factor binding protein 1	Homo sapiens	58-65
26022979-8	2015	Inhibiting ERK and JNK with U0126 and SP600125 respectively, we found that the autophagy level of the cells treated with AgNPs and radiation were attenuated.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	11-14
25917210-10	2015	However, inhibitors of PI3K/AKT and ERK1/2 (LY294002 or U0126) not only suppressed geraniin-induced nuclear translocation of Nrf2 but also abolished the expression of HO-1, NQO1 and GSH.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	36-42
25917210-10	2015	However, inhibitors of PI3K/AKT and ERK1/2 (LY294002 or U0126) not only suppressed geraniin-induced nuclear translocation of Nrf2 but also abolished the expression of HO-1, NQO1 and GSH.	U 0126	56-61	NFE2 like bZIP transcription factor 2	Homo sapiens	125-129
25917210-10	2015	However, inhibitors of PI3K/AKT and ERK1/2 (LY294002 or U0126) not only suppressed geraniin-induced nuclear translocation of Nrf2 but also abolished the expression of HO-1, NQO1 and GSH.	U 0126	56-61	heme oxygenase 1	Homo sapiens	167-171
25917210-10	2015	However, inhibitors of PI3K/AKT and ERK1/2 (LY294002 or U0126) not only suppressed geraniin-induced nuclear translocation of Nrf2 but also abolished the expression of HO-1, NQO1 and GSH.	U 0126	56-61	NAD(P)H quinone dehydrogenase 1	Homo sapiens	173-177
26022979-8	2015	Inhibiting ERK and JNK with U0126 and SP600125 respectively, we found that the autophagy level of the cells treated with AgNPs and radiation were attenuated.	U 0126	28-33	mitogen-activated protein kinase 8	Homo sapiens	19-22
25858022-8	2015	Doxorubicin-induced caspase-3 cleavage was inhibited by U0126, a MEK inhibitor or SB203580, a p38 inhibitor.	U 0126	56-61	caspase 3	Rattus norvegicus	20-29
26118633-8	2015	Furthermore, we found that U0126 (a specific inhibitor of MAPKs) strongly inhibited the IKK/IkappaB/NF-kappaB-dependent release of pro-inflammatory cytokines and iNOS gene expression.	U 0126	27-32	nuclear factor kappa B subunit 1	Homo sapiens	100-109
26022182-5	2015	The MEK inhibitor U0126 at 0.5muM caused no major blockade of the basal r-ERG current, but impaired the TRH inhibitory effect on r-ERG.	U 0126	18-23	thyrotropin releasing hormone	Rattus norvegicus	104-107
26022182-5	2015	The MEK inhibitor U0126 at 0.5muM caused no major blockade of the basal r-ERG current, but impaired the TRH inhibitory effect on r-ERG.	U 0126	18-23	RAS-like, estrogen-regulated, growth-inhibitor	Rattus norvegicus	129-134
25882870-19	2015	However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells.	U 0126	57-62	EPH receptor B2	Homo sapiens	27-30
25882870-19	2015	However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells.	U 0126	57-62	AKT serine/threonine kinase 1	Homo sapiens	31-34
25882870-19	2015	However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	66-69
25882870-19	2015	However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells.	U 0126	57-62	EPH receptor B2	Homo sapiens	70-73
25882870-19	2015	However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells.	U 0126	57-62	transforming growth factor beta 1	Homo sapiens	135-144
26118633-8	2015	Furthermore, we found that U0126 (a specific inhibitor of MAPKs) strongly inhibited the IKK/IkappaB/NF-kappaB-dependent release of pro-inflammatory cytokines and iNOS gene expression.	U 0126	27-32	nitric oxide synthase 2	Homo sapiens	162-166
26133391-6	2015	The expression of the KLF8 protein was higher in 10/14 (71.43%) fresh cancer tissues compared with adjacent normal tissues, and the blockade of ERK signaling by U0126 decreased the expression of KLF8 in a time- and dose-dependent manner.	U 0126	161-166	Kruppel-like factor 8	Mus musculus	22-26
26018028-6	2015	Inhibition of Met and ERK by small hairpin RNA and U0126, respectively, significantly inhibited hypoxia-induced the invasive potential of RMCCA-1 cells (P&lt;0.05).	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	22-25
26133391-6	2015	The expression of the KLF8 protein was higher in 10/14 (71.43%) fresh cancer tissues compared with adjacent normal tissues, and the blockade of ERK signaling by U0126 decreased the expression of KLF8 in a time- and dose-dependent manner.	U 0126	161-166	mitogen-activated protein kinase 1	Mus musculus	144-147
26133391-6	2015	The expression of the KLF8 protein was higher in 10/14 (71.43%) fresh cancer tissues compared with adjacent normal tissues, and the blockade of ERK signaling by U0126 decreased the expression of KLF8 in a time- and dose-dependent manner.	U 0126	161-166	Kruppel-like factor 8	Mus musculus	195-199
26622667-8	2015	Combined treatment with ERK inhibitor U0126 and curcumin resulted in a synergistic reduction in MMP-2/-9 expression; the invasive capabilities of HEC-1B cells were also inhibited.	U 0126	38-43	mitogen-activated protein kinase 1	Homo sapiens	24-27
26622667-8	2015	Combined treatment with ERK inhibitor U0126 and curcumin resulted in a synergistic reduction in MMP-2/-9 expression; the invasive capabilities of HEC-1B cells were also inhibited.	U 0126	38-43	matrix metallopeptidase 2	Homo sapiens	96-104
26622667-8	2015	Combined treatment with ERK inhibitor U0126 and curcumin resulted in a synergistic reduction in MMP-2/-9 expression; the invasive capabilities of HEC-1B cells were also inhibited.	U 0126	38-43	NDC80 kinetochore complex component	Homo sapiens	146-151
26176197-4	2015	Additionally, QUE and rTMS promoted the proliferation and increased the expression of pERK1/2 and BDNF in hippocampal-derived neural stem cells (NSCs), and these effects were abolished by U0126.	U 0126	188-193	brain-derived neurotrophic factor	Rattus norvegicus	98-102
26116232-4	2015	Pretreatment with H89, a specific inhibitor of PKA, and U0126, a specific inhibitor of ERK1/2 significantly inhibited both hCG-induced eIF5A mRNA expression and hypusination of eIF5A protein.	U 0126	56-61	eukaryotic translation initiation factor 5A	Homo sapiens	135-140
26116232-4	2015	Pretreatment with H89, a specific inhibitor of PKA, and U0126, a specific inhibitor of ERK1/2 significantly inhibited both hCG-induced eIF5A mRNA expression and hypusination of eIF5A protein.	U 0126	56-61	eukaryotic translation initiation factor 5A	Homo sapiens	177-182
26012717-2	2015	Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity.	U 0126	102-107	mitogen-activated protein kinase 1	Mus musculus	76-80
26012717-2	2015	Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity.	U 0126	102-107	mitogen-activated protein kinase 1	Mus musculus	81-84
26012717-2	2015	Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity.	U 0126	102-107	microRNA 181a-2	Mus musculus	171-179
26012717-2	2015	Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity.	U 0126	102-107	prospero homeobox 1	Mus musculus	180-185
26012717-2	2015	Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity.	U 0126	102-107	notch 1	Mus musculus	186-192
25935536-8	2015	Additionally, LY294002 (Akt pathway inhibitor) or U0126 (ERK pathway inhibitor) significantly suppressed SOX-2-overexpression-induced migration and invasion in SiHa cells.	U 0126	50-55	SRY-box transcription factor 2	Homo sapiens	105-110
26211648-9	2015	Addition of the ERK1/2 inhibitor U0126 significantly reduced the ability of MgSO4 to protect neurons from CoCl2-induced mitochondrial apoptotic events.	U 0126	33-38	mitogen-activated protein kinase 3	Mus musculus	16-22
26315599-7	2015	The proliferative effect of leptin was significantly reduced by the pretreatment of U0126 (0.5 muM), a MEK inhibitor, in A10 cells.	U 0126	84-89	leptin	Homo sapiens	28-34
26315599-7	2015	The proliferative effect of leptin was significantly reduced by the pretreatment of U0126 (0.5 muM), a MEK inhibitor, in A10 cells.	U 0126	84-89	latexin	Homo sapiens	95-98
26315599-7	2015	The proliferative effect of leptin was significantly reduced by the pretreatment of U0126 (0.5 muM), a MEK inhibitor, in A10 cells.	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
26241478-6	2015	Inhibition of ERK signaling by using U0126 decreased the pro-migration and pro-angiogenic effect of irisin on HUVEC.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	14-17
26827533-8	2015	CONCLUSION: Low oxygen reduced Kv1.5 mRNA and protein expressions, U0126 could resistant the Kv1.5 channel lower expression caused by hypoxia.	U 0126	67-72	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	93-98
26193421-5	2015	In addition, we found that S100P induction of miR-21 expression involves ERK and is suppressed by the MEK inhibitor U0126.	U 0126	116-121	S100 calcium binding protein P	Homo sapiens	27-32
26193421-5	2015	In addition, we found that S100P induction of miR-21 expression involves ERK and is suppressed by the MEK inhibitor U0126.	U 0126	116-121	microRNA 21	Homo sapiens	46-52
26193421-5	2015	In addition, we found that S100P induction of miR-21 expression involves ERK and is suppressed by the MEK inhibitor U0126.	U 0126	116-121	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
26288183-8	2015	While inhibition of ERK1/2 by MEK1/2 inhibitor, U0126, could reduce the expression of LC3-II in nedaplatin-resistant NPC cells.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	20-26
26288183-8	2015	While inhibition of ERK1/2 by MEK1/2 inhibitor, U0126, could reduce the expression of LC3-II in nedaplatin-resistant NPC cells.	U 0126	48-53	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
26116534-4	2015	The Netrin-1-induced RSC96 cells migration was significantly attenuated by inhibition of p38 and PI3K through pretreatment with SB203580 and LY294002 respectively, but not inhibition of MEK1/2 and JNK by U0126-EtOH and SP600125 individually.	U 0126	204-209	netrin 1	Rattus norvegicus	4-12
26043684-5	2015	Addition of U0126 (an inhibitor of ERK1/2) or LY294002 (a PI3K inhibitor) blocked PDGF-induced effects on phosphorylation of signaling proteins.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	35-41
26043684-6	2015	Combinations of PDGF and U0126 decreased PDGF-induced p-ERK1/2 and p-AKT1, but combinations of PDGF and LY294002 blocked only PDGF-induced AKT phosphorylation.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	56-62
26043684-6	2015	Combinations of PDGF and U0126 decreased PDGF-induced p-ERK1/2 and p-AKT1, but combinations of PDGF and LY294002 blocked only PDGF-induced AKT phosphorylation.	U 0126	25-30	AKT serine/threonine kinase 1	Homo sapiens	69-73
26043684-6	2015	Combinations of PDGF and U0126 decreased PDGF-induced p-ERK1/2 and p-AKT1, but combinations of PDGF and LY294002 blocked only PDGF-induced AKT phosphorylation.	U 0126	25-30	AKT serine/threonine kinase 1	Homo sapiens	69-72
26043684-8	2015	Immunoreactive p-ERK1/2 and p-RPS6 proteins were abundant in pTr cells treated with PDGF, but U0126 reduced PDGF-induced p-ERK1/2 and p-RPS6 levels to basal amounts.	U 0126	94-99	mitogen-activated protein kinase 3	Homo sapiens	123-129
26043684-8	2015	Immunoreactive p-ERK1/2 and p-RPS6 proteins were abundant in pTr cells treated with PDGF, but U0126 reduced PDGF-induced p-ERK1/2 and p-RPS6 levels to basal amounts.	U 0126	94-99	ribosomal protein S6	Homo sapiens	136-140
26163453-7	2015	The increase in HO-1 expression was significantly inhibited by U0126, an ERK1/2 inhibitor.	U 0126	63-68	heme oxygenase 1	Homo sapiens	16-20
26163453-7	2015	The increase in HO-1 expression was significantly inhibited by U0126, an ERK1/2 inhibitor.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	73-79
26241478-6	2015	Inhibition of ERK signaling by using U0126 decreased the pro-migration and pro-angiogenic effect of irisin on HUVEC.	U 0126	37-42	fibronectin type III domain containing 5	Homo sapiens	100-106
26241478-7	2015	Also, U0126 inhibited the elevated expression of MMP-2 and MMP-9 when they were treated with irisin.	U 0126	6-11	matrix metallopeptidase 2	Homo sapiens	49-54
26241478-7	2015	Also, U0126 inhibited the elevated expression of MMP-2 and MMP-9 when they were treated with irisin.	U 0126	6-11	matrix metallopeptidase 9	Homo sapiens	59-64
26241478-7	2015	Also, U0126 inhibited the elevated expression of MMP-2 and MMP-9 when they were treated with irisin.	U 0126	6-11	fibronectin type III domain containing 5	Homo sapiens	93-99
25999259-9	2015	U0126 down-regulated both MAPK and Wnt/beta-catenin signaling pathways and up-regulated Olfm1 expression.	U 0126	0-5	catenin beta 1	Homo sapiens	39-51
25999259-9	2015	U0126 down-regulated both MAPK and Wnt/beta-catenin signaling pathways and up-regulated Olfm1 expression.	U 0126	0-5	olfactomedin 1	Homo sapiens	88-93
26301220-11	2015	Surprisingly, inhibition of MEK with U0126 only partially restored CD24 mRNA expression but not surface protein expression.	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	28-31
26301220-11	2015	Surprisingly, inhibition of MEK with U0126 only partially restored CD24 mRNA expression but not surface protein expression.	U 0126	37-42	CD24 molecule	Homo sapiens	67-71
26001858-3	2015	METHODS: SCAPs were exposed to TGF-beta1 with/without pretreatment and coincubation by SB431542 (an ALK5/Smad 2/3 inhibitor) or U0126 (a MEK/ERK inhibitor).	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	137-140
26001858-10	2015	Pretreatment by U0126 and SB431542 effectively prevented the TGF-beta1-induced cell growth and collagen content in SCAPs.	U 0126	16-21	transforming growth factor beta 1	Homo sapiens	61-70
26001858-12	2015	U0126 prevented 0.5 ng/mL TGF-beta1-induced ALP activity but showed little effect on 10 ng/mL TGF-beta1-induced decline of ALP in SCAPs.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	26-35
26035715-0	2015	U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model.	U 0126	0-5	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog	Danio rerio	53-57
26035715-5	2015	Subsequently, we tested the potential of this model for drug screening by evaluating a known small-molecule inhibitor, U0126, which targets the KRAS signaling pathway.	U 0126	119-124	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog	Danio rerio	144-148
26035715-7	2015	In contrast, the proliferation and migration of Mia PaCa-2 cells in zebrafish larvae were substantially repressed following U0126 treatment.	U 0126	124-129	MIA SH3 domain containing	Homo sapiens	48-51
26035796-6	2015	The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist).	U 0126	142-147	BCL2 apoptosis regulator	Homo sapiens	18-35
26035796-6	2015	The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist).	U 0126	142-147	BCL2 apoptosis regulator	Homo sapiens	37-42
26035796-6	2015	The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist).	U 0126	142-147	adrenomedullin	Homo sapiens	79-82
26035796-6	2015	The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist).	U 0126	142-147	mitogen-activated protein kinase kinase 7	Homo sapiens	174-177
26035796-6	2015	The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist).	U 0126	142-147	adrenomedullin	Homo sapiens	181-184
25656500-4	2015	Cortisol production and peNOS were measured in response to pretreatment with the MEK/ERK1/2 pathway inhibitor UO126 (UO) and adrenocorticotropic hormone (ACTH) stimulation.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84
25656500-4	2015	Cortisol production and peNOS were measured in response to pretreatment with the MEK/ERK1/2 pathway inhibitor UO126 (UO) and adrenocorticotropic hormone (ACTH) stimulation.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	85-91
25656500-5	2015	UO126 reduced ACTH-stimulated cortisol in both normoxic and LTH FACs.	U 0126	0-5	proopiomelanocortin	Homo sapiens	14-18
25656500-8	2015	UO126 had no effect on 22R-OHC-treated cells, but reduced cortisol in cells treated with WSC and/or ACTH.	U 0126	0-5	proopiomelanocortin	Homo sapiens	100-104
25881893-11	2015	A MEK inhibitor, U0126, suppressed not only the H2O2-induced ERK phosphorylation but also cytosolic protein release from rat astrocytes.	U 0126	17-22	Eph receptor B1	Rattus norvegicus	61-64
26201295-7	2015	By contrast, calcium chelator BAPTM/AM and MEK inhibitor (U0126) can reverse Rap2B-induced ERK1/2 phosphorylation.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
26201295-7	2015	By contrast, calcium chelator BAPTM/AM and MEK inhibitor (U0126) can reverse Rap2B-induced ERK1/2 phosphorylation.	U 0126	58-63	RAP2B, member of RAS oncogene family	Homo sapiens	77-82
26201295-7	2015	By contrast, calcium chelator BAPTM/AM and MEK inhibitor (U0126) can reverse Rap2B-induced ERK1/2 phosphorylation.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	91-97
25857968-2	2015	We demonstrated that CPS-F not only inhibits platelet-derived growth factor BB (PDGF-BB)-induced intracellular reactive oxygen species (ROS) generation, and up-regulation of tumor necrosis factor-alpha (TNF-alpha), TNF-alpha receptor 1 (TNFR1), and monocyte chemotactic protein-1 (MCP-1), but also acts synergistically in combination with MAPK/ERK inhibitor U0126 and PI3K/Akt inhibitor LY294002.	U 0126	358-363	tumor necrosis factor	Homo sapiens	203-212
26217181-4	2015	Ten nanomolar T, E2 or P4 induced nestin(+) cell proliferation within 20 min and enhanced neurosphere growth over 7 days irrespective of sex, which was abolished by Erk inhibition with 20 muM U0126.	U 0126	192-197	mitogen-activated protein kinase 1	Mus musculus	165-168
25843685-6	2015	Whereas Akt1 activation resulted in Mek1 activation as evidenced by increased ERK1/2 phosphorylation, Mek1 inhibition using U0126 or DN-Mek1 resulted in enhanced Akt1 phosphorylation.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Homo sapiens	102-106
25843685-6	2015	Whereas Akt1 activation resulted in Mek1 activation as evidenced by increased ERK1/2 phosphorylation, Mek1 inhibition using U0126 or DN-Mek1 resulted in enhanced Akt1 phosphorylation.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Homo sapiens	102-106
25843685-6	2015	Whereas Akt1 activation resulted in Mek1 activation as evidenced by increased ERK1/2 phosphorylation, Mek1 inhibition using U0126 or DN-Mek1 resulted in enhanced Akt1 phosphorylation.	U 0126	124-129	AKT serine/threonine kinase 1	Homo sapiens	162-166
26151310-11	2015	U0126, an inhibitor of ERK, reversed the effects of UC-MSC-CM on breast cancer cell proliferation and migration.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	23-26
25754021-5	2015	The PI3K/AKT inhibitor LY294002 or the MEK/ERK inhibitor U0126 attenuated the effect of morroniside on human OA chondrocytes, indicating that the activation of AKT and ERK contributed to the regulation of morroniside in human OA chondrocytes.	U 0126	57-62	mitogen-activated protein kinase 1	Homo sapiens	43-46
25754021-5	2015	The PI3K/AKT inhibitor LY294002 or the MEK/ERK inhibitor U0126 attenuated the effect of morroniside on human OA chondrocytes, indicating that the activation of AKT and ERK contributed to the regulation of morroniside in human OA chondrocytes.	U 0126	57-62	AKT serine/threonine kinase 1	Homo sapiens	160-163
25933688-10	2015	The effect of RAS mutants was reversed when MET inhibition was combined with MEK inhibitors AZD6244 and UO126.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
25963415-6	2015	Microglia proliferation (EDU + microglia) and inflammatory and oxidative stress responses were attenuated by UO126 (ERK pathway inhibitor) 24 h after thrombin stimulation, an activity that was prevented by AM630 (CB2R selective antagonist).	U 0126	109-114	Eph receptor B1	Rattus norvegicus	116-119
25963415-6	2015	Microglia proliferation (EDU + microglia) and inflammatory and oxidative stress responses were attenuated by UO126 (ERK pathway inhibitor) 24 h after thrombin stimulation, an activity that was prevented by AM630 (CB2R selective antagonist).	U 0126	109-114	coagulation factor II	Rattus norvegicus	150-158
26622636-8	2015	U0126, an ERK inhibitor, also suppressed the invasion and adhesion of MDA-MB-231 cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
26222055-8	2015	These changes were abrogated by U0126, a selective ERK1/2 inhibitor.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	51-57
26201295-9	2015	In addition, overexpression of Rap2B promotes cell proliferation, migration and invasion abilities, which could be neutralized by BAPTM/AM and U0126.	U 0126	143-148	RAP2B, member of RAS oncogene family	Homo sapiens	31-36
25661849-10	2015	Besides, it was also found that the enhanced phosphorylation of CREB was evidently reversed under excitotoxic conditions after treating with U0126 (the selective inhibitor of ERK).	U 0126	141-146	cAMP responsive element binding protein 1	Homo sapiens	64-68
25661849-10	2015	Besides, it was also found that the enhanced phosphorylation of CREB was evidently reversed under excitotoxic conditions after treating with U0126 (the selective inhibitor of ERK).	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	175-178
25811962-8	2015	Inhibition of the upstream kinase MEK-1/2 with U0126 attenuates the phosphorylation of both ERK-1/2 and HSF1, and significantly enhances drug cytotoxicity.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Homo sapiens	34-41
25811962-8	2015	Inhibition of the upstream kinase MEK-1/2 with U0126 attenuates the phosphorylation of both ERK-1/2 and HSF1, and significantly enhances drug cytotoxicity.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	92-99
25811962-8	2015	Inhibition of the upstream kinase MEK-1/2 with U0126 attenuates the phosphorylation of both ERK-1/2 and HSF1, and significantly enhances drug cytotoxicity.	U 0126	47-52	heat shock transcription factor 1	Homo sapiens	104-108
25817573-5	2015	We next show that this activation of the MAPK pathway is inhibited by the MEK inhibitor U0126, is not dependent on calcium signaling at the Y1 receptor (no effect upon inhibition of phospholipase C, protein kinase C or protein kinase D) but instead dependent on Gbeta/gamma and associated signaling pathways that activate PI3-kinase.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
25846811-10	2015	We also found that the inhibition of ERK activity by U0126 restored AMPK activation after metformin treatment.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	37-40
25846811-10	2015	We also found that the inhibition of ERK activity by U0126 restored AMPK activation after metformin treatment.	U 0126	53-58	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	68-72
26062551-7	2015	In addition, 1alpha,25(OH)2D3 induced activation of extracellular signal-regulated kinases (ERKs), whereas the ERK inhibitor U0126 ameliorated the upregulation of DSPP and DMP1 and reduced the mineralization enhanced by 1alpha,25(OH)2D3.	U 0126	125-130	dentin sialophosphoprotein	Homo sapiens	163-167
25976656-17	2015	In addition, U0126 treatment decreased levels of phosphorylated ERK; however, it resulted in increased levels of phosphorylated AKT in endometriotic stromal cells compared with vehicle-treated cells (both P &lt; 0.05).	U 0126	13-18	mitogen-activated protein kinase 1	Mus musculus	64-67
25976656-17	2015	In addition, U0126 treatment decreased levels of phosphorylated ERK; however, it resulted in increased levels of phosphorylated AKT in endometriotic stromal cells compared with vehicle-treated cells (both P &lt; 0.05).	U 0126	13-18	thymoma viral proto-oncogene 1	Mus musculus	128-131
26062551-7	2015	In addition, 1alpha,25(OH)2D3 induced activation of extracellular signal-regulated kinases (ERKs), whereas the ERK inhibitor U0126 ameliorated the upregulation of DSPP and DMP1 and reduced the mineralization enhanced by 1alpha,25(OH)2D3.	U 0126	125-130	dentin matrix acidic phosphoprotein 1	Homo sapiens	172-176
26109504-10	2015	Importantly, the ERK1/2 inhibitor U0126 reduced the upregulation of fibroblast growth factor-2 and fibrosis biomarkers in angiotensin II-treated fibroblasts.	U 0126	34-39	mitogen activated protein kinase 3	Rattus norvegicus	17-23
26109504-10	2015	Importantly, the ERK1/2 inhibitor U0126 reduced the upregulation of fibroblast growth factor-2 and fibrosis biomarkers in angiotensin II-treated fibroblasts.	U 0126	34-39	fibroblast growth factor 2	Rattus norvegicus	68-94
26109504-10	2015	Importantly, the ERK1/2 inhibitor U0126 reduced the upregulation of fibroblast growth factor-2 and fibrosis biomarkers in angiotensin II-treated fibroblasts.	U 0126	34-39	angiotensinogen	Rattus norvegicus	122-136
25862966-8	2015	Co-treatment with MAPKs inhibitors U0126, SB202190 and SP600125 indicated JNK and p38 pathways were involved in the course.	U 0126	35-40	mitogen-activated protein kinase 8	Homo sapiens	74-77
26114754-4	2015	In this study, we showed that U0126, a MEK1/2 inhibitor, decreases lipopolysaccharide (LPS)-stimulated G-CSF promoter activity, mRNA expression and protein secretion.	U 0126	30-35	mitogen-activated protein kinase kinase 1	Homo sapiens	39-45
26114754-4	2015	In this study, we showed that U0126, a MEK1/2 inhibitor, decreases lipopolysaccharide (LPS)-stimulated G-CSF promoter activity, mRNA expression and protein secretion.	U 0126	30-35	colony stimulating factor 3	Homo sapiens	103-108
25862966-8	2015	Co-treatment with MAPKs inhibitors U0126, SB202190 and SP600125 indicated JNK and p38 pathways were involved in the course.	U 0126	35-40	mitogen-activated protein kinase 14	Homo sapiens	82-85
26114754-7	2015	Further chromatin immunoprecipitation (ChIP) assays revealed that U0126 inhibits LPS-induced binding of NF-kappaB (p50/p65) and C/EBPbeta to the G-CSF promoter, but not their nuclear protein levels.	U 0126	66-71	nuclear factor kappa B subunit 1	Homo sapiens	115-118
26114754-7	2015	Further chromatin immunoprecipitation (ChIP) assays revealed that U0126 inhibits LPS-induced binding of NF-kappaB (p50/p65) and C/EBPbeta to the G-CSF promoter, but not their nuclear protein levels.	U 0126	66-71	RELA proto-oncogene, NF-kB subunit	Homo sapiens	119-122
26309511-5	2015	Cells were treated with U0126 to inhibit ERK MAPK pathway.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	41-44
26114754-7	2015	Further chromatin immunoprecipitation (ChIP) assays revealed that U0126 inhibits LPS-induced binding of NF-kappaB (p50/p65) and C/EBPbeta to the G-CSF promoter, but not their nuclear protein levels.	U 0126	66-71	CCAAT enhancer binding protein beta	Homo sapiens	128-137
26114754-7	2015	Further chromatin immunoprecipitation (ChIP) assays revealed that U0126 inhibits LPS-induced binding of NF-kappaB (p50/p65) and C/EBPbeta to the G-CSF promoter, but not their nuclear protein levels.	U 0126	66-71	colony stimulating factor 3	Homo sapiens	145-150
26309511-5	2015	Cells were treated with U0126 to inhibit ERK MAPK pathway.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	45-49
25728945-9	2015	Role of ERK signaling in LCN2-mediated up-regulation of SLUG was assayed by using ERK inhibitor U0126.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	8-11
25896660-11	2015	Extracellular regulated protein kinases (ERKs) are activated, while the inhibition of ERK by U0126 increases the expression of BMP4.	U 0126	93-98	bone morphogenetic protein 4	Homo sapiens	127-131
25728945-9	2015	Role of ERK signaling in LCN2-mediated up-regulation of SLUG was assayed by using ERK inhibitor U0126.	U 0126	96-101	lipocalin 2	Homo sapiens	25-29
25910076-4	2015	Treatment with 10 muM U0126 significantly inhibited the relative expression of SlMPK1, SlMPK2, and SlMPK3 (P &lt; 0.05).	U 0126	22-27	Mitogen-activated protein kinase	Solanum lycopersicum	79-85
25910076-4	2015	Treatment with 10 muM U0126 significantly inhibited the relative expression of SlMPK1, SlMPK2, and SlMPK3 (P &lt; 0.05).	U 0126	22-27	mitogen-activated protein kinase 2	Solanum lycopersicum	87-93
25910076-4	2015	Treatment with 10 muM U0126 significantly inhibited the relative expression of SlMPK1, SlMPK2, and SlMPK3 (P &lt; 0.05).	U 0126	22-27	mitogen-activated protein kinase 3	Solanum lycopersicum	99-105
25910076-6	2015	The activities of defense enzymes, including beta-1,3-glucanases (GLU), chitinase (CHI), phenylalanine ammonia lyase (PAL), and polyphenol oxidase (PPO), decreased after U0126 treatment.	U 0126	170-175	phenylalanine ammonia-lyase	Solanum lycopersicum	89-116
25910076-7	2015	Meanwhile, H2O2 content increased, and catalase (CAT), ascorbate peroxidase (APX), and peroxidase (POD) activities decreased after U0126 treatment.	U 0126	131-136	catalase isozyme 1	Solanum lycopersicum	39-47
25910076-7	2015	Meanwhile, H2O2 content increased, and catalase (CAT), ascorbate peroxidase (APX), and peroxidase (POD) activities decreased after U0126 treatment.	U 0126	131-136	catalase isozyme 1	Solanum lycopersicum	49-52
25910076-7	2015	Meanwhile, H2O2 content increased, and catalase (CAT), ascorbate peroxidase (APX), and peroxidase (POD) activities decreased after U0126 treatment.	U 0126	131-136	cytosolic ascorbate peroxidase 2	Solanum lycopersicum	55-75
25910076-7	2015	Meanwhile, H2O2 content increased, and catalase (CAT), ascorbate peroxidase (APX), and peroxidase (POD) activities decreased after U0126 treatment.	U 0126	131-136	cytosolic ascorbate peroxidase 2	Solanum lycopersicum	77-80
25910076-7	2015	Meanwhile, H2O2 content increased, and catalase (CAT), ascorbate peroxidase (APX), and peroxidase (POD) activities decreased after U0126 treatment.	U 0126	131-136	peroxidase	Solanum lycopersicum	65-75
25910076-7	2015	Meanwhile, H2O2 content increased, and catalase (CAT), ascorbate peroxidase (APX), and peroxidase (POD) activities decreased after U0126 treatment.	U 0126	131-136	peroxidase	Solanum lycopersicum	99-102
25463304-5	2015	TPA induced the phosphorylation of the MAP kinase, ERK, and U0126, an inhibitor of the MAP kinase kinase, MEK1, blocked the down-regulation of AKR1B10 by TPA, indicating that the MAP kinase ERK plays a role in regulating the expression of AKR1B10.	U 0126	60-65	aldo-keto reductase family 1 member B10	Homo sapiens	143-150
25463304-5	2015	TPA induced the phosphorylation of the MAP kinase, ERK, and U0126, an inhibitor of the MAP kinase kinase, MEK1, blocked the down-regulation of AKR1B10 by TPA, indicating that the MAP kinase ERK plays a role in regulating the expression of AKR1B10.	U 0126	60-65	aldo-keto reductase family 1 member B10	Homo sapiens	239-246
25817573-5	2015	We next show that this activation of the MAPK pathway is inhibited by the MEK inhibitor U0126, is not dependent on calcium signaling at the Y1 receptor (no effect upon inhibition of phospholipase C, protein kinase C or protein kinase D) but instead dependent on Gbeta/gamma and associated signaling pathways that activate PI3-kinase.	U 0126	88-93	mitogen-activated protein kinase 3	Homo sapiens	41-45
26070151-6	2015	Cd-induced cytotoxic injury could be attenuated by co-treatment with an extracellular signal-regulated kinase (ERK) inhibitor (U0126) and a p38 inhibitor (SB202190) but was not affected by co-treatment with a c-Jun N-terminal kinase (JNK) inhibitor (SP600125).	U 0126	127-132	Eph receptor B1	Rattus norvegicus	72-109
26070151-6	2015	Cd-induced cytotoxic injury could be attenuated by co-treatment with an extracellular signal-regulated kinase (ERK) inhibitor (U0126) and a p38 inhibitor (SB202190) but was not affected by co-treatment with a c-Jun N-terminal kinase (JNK) inhibitor (SP600125).	U 0126	127-132	Eph receptor B1	Rattus norvegicus	111-114
26061016-7	2015	Claudin-2 expression was decreased by LY-294002, a phosphatidylinositol 3-kinase (PI3-K) inhibitor, and U0126, a MEK inhibitor.	U 0126	104-109	claudin 2	Homo sapiens	0-9
26061016-7	2015	Claudin-2 expression was decreased by LY-294002, a phosphatidylinositol 3-kinase (PI3-K) inhibitor, and U0126, a MEK inhibitor.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	113-116
26061016-10	2015	Both LY-294002 and U0126 inhibited promoter activity of claudin-2, but quercetin did not.	U 0126	19-24	claudin 2	Homo sapiens	56-65
25728945-9	2015	Role of ERK signaling in LCN2-mediated up-regulation of SLUG was assayed by using ERK inhibitor U0126.	U 0126	96-101	snail family transcriptional repressor 2	Homo sapiens	56-60
25728945-9	2015	Role of ERK signaling in LCN2-mediated up-regulation of SLUG was assayed by using ERK inhibitor U0126.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	82-85
25908764-9	2015	Hematoxylin and eosin staining and immunohistochemistry of proliferating cell nuclear antigen and smooth muscle actin demonstrated that balloon injury-induced intimal thickening and neointimal vascular smooth muscle cell proliferation were significantly abrogated in the presence of IRAK1/4 inhibitor, IRAK1 siRNA, and U0126.	U 0126	319-324	interleukin-1 receptor-associated kinase 1	Rattus norvegicus	283-290
25908764-9	2015	Hematoxylin and eosin staining and immunohistochemistry of proliferating cell nuclear antigen and smooth muscle actin demonstrated that balloon injury-induced intimal thickening and neointimal vascular smooth muscle cell proliferation were significantly abrogated in the presence of IRAK1/4 inhibitor, IRAK1 siRNA, and U0126.	U 0126	319-324	interleukin-1 receptor-associated kinase 1	Rattus norvegicus	283-288
25904014-5	2015	Inhibition of the MEK1/2-MAPK pathway with U0126 leads to reduced levels of phosphorylated myosin-regulatory light chain (pMRLC) and causes a reduction in cortical tension, effects that are mimicked by treatment with the myosin light chain kinase (MLCK) inhibitor ML-7.	U 0126	43-48	mitogen-activated protein kinase kinase 1	Homo sapiens	18-24
25781541-6	2015	The MEK inhibitor U0126 and the S1P1/3 receptor antagonist VPC23019 blocked the increased migration of SK-2ko cells.	U 0126	18-23	midkine	Mus musculus	4-7
25904014-5	2015	Inhibition of the MEK1/2-MAPK pathway with U0126 leads to reduced levels of phosphorylated myosin-regulatory light chain (pMRLC) and causes a reduction in cortical tension, effects that are mimicked by treatment with the myosin light chain kinase (MLCK) inhibitor ML-7.	U 0126	43-48	myosin light chain kinase	Homo sapiens	221-246
25904014-5	2015	Inhibition of the MEK1/2-MAPK pathway with U0126 leads to reduced levels of phosphorylated myosin-regulatory light chain (pMRLC) and causes a reduction in cortical tension, effects that are mimicked by treatment with the myosin light chain kinase (MLCK) inhibitor ML-7.	U 0126	43-48	myosin light chain kinase	Homo sapiens	248-252
25840641-12	2015	Pretreatment with U0126 (ERK inhibitor) but not rapamycin (mTOR inhibitor) abrogated the IL-9-mediated IL-8 production.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	25-28
25976462-8	2015	Interestingly, U0126 (an ERK1/2 inhibitor) reduced IL-13 production in a concentration-dependent manner.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	25-31
25976462-8	2015	Interestingly, U0126 (an ERK1/2 inhibitor) reduced IL-13 production in a concentration-dependent manner.	U 0126	15-20	interleukin 13	Homo sapiens	51-56
25831202-7	2015	Inhibition of ERK by its inhibitor U0126 or by its specific small interfering RNA (siRNA) blocked the CaA-induced improvement in cell viability and the protective effects against H2O2-mediated DNA damage.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	14-17
25816245-12	2015	However, the HNP-1-induced production of IL-8 was suppressed by the ERK1/2 inhibitor, U0126, but not by the p38 MAPK inhibitor, SB203580.	U 0126	86-91	HNP1	Homo sapiens	13-18
25816245-12	2015	However, the HNP-1-induced production of IL-8 was suppressed by the ERK1/2 inhibitor, U0126, but not by the p38 MAPK inhibitor, SB203580.	U 0126	86-91	C-X-C motif chemokine ligand 8	Homo sapiens	41-45
25816245-12	2015	However, the HNP-1-induced production of IL-8 was suppressed by the ERK1/2 inhibitor, U0126, but not by the p38 MAPK inhibitor, SB203580.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	68-74
25951933-7	2015	LY294002 and U0126 inhibited activation of p-PI-3K/Akt and p-Erk expression by Western blot and attenuated the expression of inflammation factors in BV2 cells by fluorescence staining.	U 0126	13-18	thymoma viral proto-oncogene 1	Mus musculus	51-54
25951933-7	2015	LY294002 and U0126 inhibited activation of p-PI-3K/Akt and p-Erk expression by Western blot and attenuated the expression of inflammation factors in BV2 cells by fluorescence staining.	U 0126	13-18	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	59-64
25745068-9	2015	U0126, a specific ERK inhibitor, also increased DGAT2 expression and cellular lipid accumulation.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	18-21
25745068-9	2015	U0126, a specific ERK inhibitor, also increased DGAT2 expression and cellular lipid accumulation.	U 0126	0-5	diacylglycerol O-acyltransferase 2	Mus musculus	48-53
25948790-6	2015	ERK1/2 specific inhibitor U0126 suppressed the proliferation, migration and invasion of those cells.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	0-6
26034353-8	2015	Cells treated with MEK1 inhibitor (i.e., U0126) before siSGK1 transfection showed a reversal of the siSGK1-induced cellular apoptosis.	U 0126	41-46	mitogen-activated protein kinase kinase 1	Homo sapiens	19-23
26019344-10	2015	Infusion of RU486 or the Erk1/2 inhibitor U0126, but not propranolol or the PKA inhibitor Rp-cAMPS, into the CA1 before extinction disrupted the formation of extinction LTM, suggesting that hippocampal GR and Erk1/2 but not betaAR or PKA play critical roles in this process.	U 0126	42-47	mitogen activated protein kinase 3	Rattus norvegicus	25-31
26019344-10	2015	Infusion of RU486 or the Erk1/2 inhibitor U0126, but not propranolol or the PKA inhibitor Rp-cAMPS, into the CA1 before extinction disrupted the formation of extinction LTM, suggesting that hippocampal GR and Erk1/2 but not betaAR or PKA play critical roles in this process.	U 0126	42-47	carbonic anhydrase 1	Rattus norvegicus	109-112
26019344-10	2015	Infusion of RU486 or the Erk1/2 inhibitor U0126, but not propranolol or the PKA inhibitor Rp-cAMPS, into the CA1 before extinction disrupted the formation of extinction LTM, suggesting that hippocampal GR and Erk1/2 but not betaAR or PKA play critical roles in this process.	U 0126	42-47	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	202-204
25797400-5	2015	Inhibition of MAP kinase activation with 50muM U0126 or pre-treatment with the PKC inhibitor bisindolylmaleimide 1 (BIS-1; 10muM) prevented the NGF-mediated activation of the apoE promoter.	U 0126	47-52	apolipoprotein E	Rattus norvegicus	175-179
26221267-8	2015	Since ManLAM is the major component of water phase, we found that ManLAM induced IL-37 mRNA and protein expression in a time and dose-dependent manner, while this activity was almost totally abolished by the ERK1/2 (U0126) and p38 (SB203580) inhibitor.	U 0126	216-221	interleukin 37	Homo sapiens	81-86
26221267-8	2015	Since ManLAM is the major component of water phase, we found that ManLAM induced IL-37 mRNA and protein expression in a time and dose-dependent manner, while this activity was almost totally abolished by the ERK1/2 (U0126) and p38 (SB203580) inhibitor.	U 0126	216-221	mitogen-activated protein kinase 3	Homo sapiens	208-214
26037082-6	2015	NMC stimulation resulted in a significant 3- to 4-fold activation of Akt and Erk, whereas pretreatment with Akt (A6730) and Erk (U0126) inhibitors decreased NMC-induced fibroblast proliferation dose-dependently.	U 0126	129-134	mitogen-activated protein kinase 1	Mus musculus	124-127
25951933-4	2015	Furthermore, PI-3K/Akt inhibitor (LY294402) and Erk inhibitor (U0126) were used as antagonists to detect the secretion mechanisms of cytokines in BV2 cells stimulated by apelin.	U 0126	63-68	apelin	Mus musculus	170-176
25760375-6	2015	Activation of the extracellular signal-related kinases (ERK) 1/2 and RUNX-2 in CACB-cultured ADSCs was observed, and this activation was attenuated by the MeK inhibitor U0126.	U 0126	169-174	runt-related transcription factor 2	Oryctolagus cuniculus	69-75
26463615-4	2015	ERK inhibitor U0126 was used.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	0-3
25961946-6	2015	U0126 (a selective inhibitor of MEK that disrupts downstream activation of ERK1/2) downregulated the phosphorylation of ERK1/2, p90RSK and MSK1.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	32-35
25961946-6	2015	U0126 (a selective inhibitor of MEK that disrupts downstream activation of ERK1/2) downregulated the phosphorylation of ERK1/2, p90RSK and MSK1.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	75-81
25961946-6	2015	U0126 (a selective inhibitor of MEK that disrupts downstream activation of ERK1/2) downregulated the phosphorylation of ERK1/2, p90RSK and MSK1.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	120-126
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	mitogen-activated protein kinase 3	Mus musculus	33-39
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	nerve growth factor	Mus musculus	65-68
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	91-97
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	nerve growth factor	Mus musculus	157-160
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	172-178
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	198-202
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	mitogen-activated protein kinase 3	Mus musculus	203-209
25737208-5	2015	Blockade of trkA (K252alpha) and ERK1/2 (U0126) in GCs decreased NGF-induced expression of CDKN1A and did not alter the expression of TRP53, indicating that NGF stimulates CDKN1A expression via the trkA-ERK1/2 pathway in a TRP53-independent manner.	U 0126	41-46	transformation related protein 53	Mus musculus	223-228
25737208-6	2015	Meanwhile, ESR2, a tumor suppressor which is exclusively expressed in GCs, was suppressed in NGF-induced GC proliferation, and this effect was abrogated by U0126.	U 0126	156-161	estrogen receptor 2 (beta)	Mus musculus	11-15
25737208-6	2015	Meanwhile, ESR2, a tumor suppressor which is exclusively expressed in GCs, was suppressed in NGF-induced GC proliferation, and this effect was abrogated by U0126.	U 0126	156-161	nerve growth factor	Mus musculus	93-96
25975246-7	2015	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited ASD-induced MUC8 and MUC5B expressions.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	7-13
25975246-7	2015	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited ASD-induced MUC8 and MUC5B expressions.	U 0126	0-5	mucin 8	Homo sapiens	86-90
25975246-7	2015	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited ASD-induced MUC8 and MUC5B expressions.	U 0126	0-5	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	95-100
25840641-12	2015	Pretreatment with U0126 (ERK inhibitor) but not rapamycin (mTOR inhibitor) abrogated the IL-9-mediated IL-8 production.	U 0126	18-23	interleukin 9	Homo sapiens	89-93
25840641-12	2015	Pretreatment with U0126 (ERK inhibitor) but not rapamycin (mTOR inhibitor) abrogated the IL-9-mediated IL-8 production.	U 0126	18-23	C-X-C motif chemokine ligand 8	Homo sapiens	103-107
25707920-6	2015	Further studies demonstrated that the administration of OXT alleviated ASD-like symptoms and significantly inhibited phosphorylation of ERK; the inhibitory effect was similar to that of U0126, an ERK signalling inhibitor.	U 0126	186-191	oxytocin	Mus musculus	56-59
25572945-12	2015	The analgesic effects of GDNF were partly, but significantly, inhibited by prior injection of U0126 into the LC.	U 0126	94-99	glial cell derived neurotrophic factor	Rattus norvegicus	25-29
25655003-6	2015	ST2 receptor was silenced by siRNA, and ERK1/2 pathway was inhibited by U0126.	U 0126	72-77	ST2	Homo sapiens	0-3
25655003-6	2015	ST2 receptor was silenced by siRNA, and ERK1/2 pathway was inhibited by U0126.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	40-46
25801217-11	2015	The p44/42 inhibitor U0126 reversed the down-regulation of CTCs induced by AOPPs in the Caco-2 monolayer.	U 0126	21-26	interferon induced protein 44	Homo sapiens	4-7
25614461-12	2015	Moreover, pretreatment with MEK/ERK signal transduction inhibitors, PD98059 and U0126, significantly inhibited BSO-mediated induction of sEH and cellular hypertrophic marker gene expression.	U 0126	80-85	Eph receptor B1	Rattus norvegicus	32-35
25614461-12	2015	Moreover, pretreatment with MEK/ERK signal transduction inhibitors, PD98059 and U0126, significantly inhibited BSO-mediated induction of sEH and cellular hypertrophic marker gene expression.	U 0126	80-85	epoxide hydrolase 2	Rattus norvegicus	137-140
25707920-6	2015	Further studies demonstrated that the administration of OXT alleviated ASD-like symptoms and significantly inhibited phosphorylation of ERK; the inhibitory effect was similar to that of U0126, an ERK signalling inhibitor.	U 0126	186-191	mitogen-activated protein kinase 1	Mus musculus	136-139
25707920-6	2015	Further studies demonstrated that the administration of OXT alleviated ASD-like symptoms and significantly inhibited phosphorylation of ERK; the inhibitory effect was similar to that of U0126, an ERK signalling inhibitor.	U 0126	186-191	mitogen-activated protein kinase 1	Mus musculus	196-199
25483228-9	2015	Furthermore, dorsal hippocampal infusion of the ERK inhibitor U0126 blocked the memory-enhancing effects of BSA-P, but not R5020.	U 0126	62-67	mitogen-activated protein kinase 1	Mus musculus	48-51
25738334-6	2015	The pharmacological inhibition of ERK (using U0126) or Akt (using LY294002) suppressed the 20GPPD-induced expression of HAS2, whereas treatment with an epidermal growth factor receptor (EGFR) inhibitor (AG1478) or an intracellular Ca2+ chelator (BAPTA/AM) did not exert any observable effects.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	34-37
25738334-6	2015	The pharmacological inhibition of ERK (using U0126) or Akt (using LY294002) suppressed the 20GPPD-induced expression of HAS2, whereas treatment with an epidermal growth factor receptor (EGFR) inhibitor (AG1478) or an intracellular Ca2+ chelator (BAPTA/AM) did not exert any observable effects.	U 0126	45-50	hyaluronan synthase 2	Homo sapiens	120-124
25748730-4	2015	Concanavalin A (ConA) at 20 mug/mL produced a 5.2-fold increase in IL-8 mRNA by 8h, and a 14.2-fold rise in IL-8 levels by 16 h. Inhibition of MEK (ERK kinase) and extracellular signal-regulated kinase (ERK) by PD98059 and U0126, or inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002 blocked both ConA-induced IL-8 mRNA expression and IL-8 secretion.	U 0126	223-228	mitogen-activated protein kinase kinase 7	Homo sapiens	143-146
25748730-4	2015	Concanavalin A (ConA) at 20 mug/mL produced a 5.2-fold increase in IL-8 mRNA by 8h, and a 14.2-fold rise in IL-8 levels by 16 h. Inhibition of MEK (ERK kinase) and extracellular signal-regulated kinase (ERK) by PD98059 and U0126, or inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002 blocked both ConA-induced IL-8 mRNA expression and IL-8 secretion.	U 0126	223-228	mitogen-activated protein kinase 1	Homo sapiens	148-151
25748730-6	2015	Combining paeoniflorin with U0126 or LY294002 at low doses showed supra-additive inhibition of not only phospho-ERK1/2 and phospho-Akt by 46.4% and 35.0%, but also IL-8 release by 42.4% and 36.1% and IL-8 mRNA expression by 43.5% and 31.8%, respectively.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	112-118
25748730-6	2015	Combining paeoniflorin with U0126 or LY294002 at low doses showed supra-additive inhibition of not only phospho-ERK1/2 and phospho-Akt by 46.4% and 35.0%, but also IL-8 release by 42.4% and 36.1% and IL-8 mRNA expression by 43.5% and 31.8%, respectively.	U 0126	28-33	AKT serine/threonine kinase 1	Homo sapiens	131-134
25748730-6	2015	Combining paeoniflorin with U0126 or LY294002 at low doses showed supra-additive inhibition of not only phospho-ERK1/2 and phospho-Akt by 46.4% and 35.0%, but also IL-8 release by 42.4% and 36.1% and IL-8 mRNA expression by 43.5% and 31.8%, respectively.	U 0126	28-33	C-X-C motif chemokine ligand 8	Homo sapiens	164-168
25748730-6	2015	Combining paeoniflorin with U0126 or LY294002 at low doses showed supra-additive inhibition of not only phospho-ERK1/2 and phospho-Akt by 46.4% and 35.0%, but also IL-8 release by 42.4% and 36.1% and IL-8 mRNA expression by 43.5% and 31.8%, respectively.	U 0126	28-33	C-X-C motif chemokine ligand 8	Homo sapiens	200-204
25934479-4	2015	Extracellular signal-regulated kinase (ERK)1/2 inhibitor U0126 was pre-injected into I/R-induced mice to test the role of ERK1/2 in regulating autophagy.	U 0126	57-62	mitogen-activated protein kinase 3	Mus musculus	0-46
25527444-5	2015	In a hypoxia model of Schwann cells in vitro, we found that U0126, an ERK antagonist, inhibited not only morphological changes of cultures Schwann cells but also upregulation of both AQP1 and phosphorylated ERK.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	70-73
25527444-5	2015	In a hypoxia model of Schwann cells in vitro, we found that U0126, an ERK antagonist, inhibited not only morphological changes of cultures Schwann cells but also upregulation of both AQP1 and phosphorylated ERK.	U 0126	60-65	aquaporin 1 (Colton blood group)	Homo sapiens	183-187
25527444-5	2015	In a hypoxia model of Schwann cells in vitro, we found that U0126, an ERK antagonist, inhibited not only morphological changes of cultures Schwann cells but also upregulation of both AQP1 and phosphorylated ERK.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	207-210
25662951-8	2015	Treatment with U0126, a MAPK pathway inhibitor, reduces Pol IIser5p association with the JUNB proximal promoter and reduces JUNB expression.	U 0126	15-20	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	89-93
25662951-8	2015	Treatment with U0126, a MAPK pathway inhibitor, reduces Pol IIser5p association with the JUNB proximal promoter and reduces JUNB expression.	U 0126	15-20	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	124-128
25662951-10	2015	U0126 treatment reduces OSM-induced Pol IIser5p binding to the JUNB proximal promoter and JUNB expression, but does not reduce pSTAT3 levels or the association of pSTAT3 with the JUNB proximal promoter.	U 0126	0-5	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	63-67
25662951-10	2015	U0126 treatment reduces OSM-induced Pol IIser5p binding to the JUNB proximal promoter and JUNB expression, but does not reduce pSTAT3 levels or the association of pSTAT3 with the JUNB proximal promoter.	U 0126	0-5	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-94
25662951-10	2015	U0126 treatment reduces OSM-induced Pol IIser5p binding to the JUNB proximal promoter and JUNB expression, but does not reduce pSTAT3 levels or the association of pSTAT3 with the JUNB proximal promoter.	U 0126	0-5	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-94
25846007-6	2015	Furthermore, the injection of both the mTOR antagonist rapamycin and the ERK1/2 antagonist U0126 into the lateral ventricle of the brain attenuated CCI-induced neuropathic pain.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	73-79
25846007-8	2015	The coadministration of rapamycin and U0126 inhibited the rapamycin-induced upregulation of ERK, and had a greater effect on pain behaviors than did the single-drug administrations.	U 0126	38-43	mitogen-activated protein kinase 1	Homo sapiens	92-95
25749008-3	2015	Preincubation of U118 cells with the selective MEK1/2 inhibitor U0126, which inhibits MEK1/2-mediated activation of ERK1/2, led to a switch from necrosis to caspase-dependent apoptosis following edelfosine treatment.	U 0126	64-69	mitogen-activated protein kinase kinase 1	Homo sapiens	47-53
25749008-3	2015	Preincubation of U118 cells with the selective MEK1/2 inhibitor U0126, which inhibits MEK1/2-mediated activation of ERK1/2, led to a switch from necrosis to caspase-dependent apoptosis following edelfosine treatment.	U 0126	64-69	mitogen-activated protein kinase kinase 1	Homo sapiens	86-92
25749008-3	2015	Preincubation of U118 cells with the selective MEK1/2 inhibitor U0126, which inhibits MEK1/2-mediated activation of ERK1/2, led to a switch from necrosis to caspase-dependent apoptosis following edelfosine treatment.	U 0126	64-69	mitogen-activated protein kinase 3	Homo sapiens	116-122
25749008-4	2015	Combined treatment of U0126 and edelfosine totally inhibited ERK1/2 phosphorylation, and led to RIPK1 and RelA/NF-kappaB degradation, together with a strong activation of caspase-3 and -8.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	61-67
25749008-4	2015	Combined treatment of U0126 and edelfosine totally inhibited ERK1/2 phosphorylation, and led to RIPK1 and RelA/NF-kappaB degradation, together with a strong activation of caspase-3 and -8.	U 0126	22-27	receptor interacting serine/threonine kinase 1	Homo sapiens	96-101
25749008-4	2015	Combined treatment of U0126 and edelfosine totally inhibited ERK1/2 phosphorylation, and led to RIPK1 and RelA/NF-kappaB degradation, together with a strong activation of caspase-3 and -8.	U 0126	22-27	RELA proto-oncogene, NF-kB subunit	Homo sapiens	106-110
25749008-4	2015	Combined treatment of U0126 and edelfosine totally inhibited ERK1/2 phosphorylation, and led to RIPK1 and RelA/NF-kappaB degradation, together with a strong activation of caspase-3 and -8.	U 0126	22-27	nuclear factor kappa B subunit 1	Homo sapiens	111-120
25749008-4	2015	Combined treatment of U0126 and edelfosine totally inhibited ERK1/2 phosphorylation, and led to RIPK1 and RelA/NF-kappaB degradation, together with a strong activation of caspase-3 and -8.	U 0126	22-27	caspase 3	Homo sapiens	171-187
25796352-10	2015	Compared to AM251 treatment alone, inhibition of ERK1/2 by UO126 in the presence of AM251 decreased phosphorylation of S6K1, S6 and and 4E-BP1 at Thr(37/46).	U 0126	59-64	mitogen-activated protein kinase 3	Homo sapiens	49-55
25796352-10	2015	Compared to AM251 treatment alone, inhibition of ERK1/2 by UO126 in the presence of AM251 decreased phosphorylation of S6K1, S6 and and 4E-BP1 at Thr(37/46).	U 0126	59-64	BP1	Homo sapiens	139-142
25373870-7	2015	To determine the role of ERK in defeat stress-induced behavioral sensitization, we bilaterally microinjected the MAPK/ERK kinase inhibitor U0126 (1 mug/side) or vehicle (20 % DMSO) into the ventral tegmental area (VTA) prior to each of four defeats.	U 0126	139-144	Eph receptor B1	Rattus norvegicus	118-121
25527158-7	2015	Moreover, inhibition of ERK1/2 by U0126 or transfection with the siERK plasmid significantly abolished the fisetin-inhibited migration and invasion through activation of the ERK1/2 pathway.	U 0126	34-39	mitogen-activated protein kinase 3	Homo sapiens	24-30
25757908-7	2015	Afterward, treated with MAPK pathways inhibitors, only ERK inhibitor(U0126)could reduce the expression of EMT markers in SV-HUC-1 cells, but not p38 and JNK inhibitor(SB203580, SP600125), which indicated that benzidine induces the epithelial-mesenchymal transition in human uroepithelial cells through ERK1/2 pathway.	U 0126	69-74	mitogen-activated protein kinase 3	Homo sapiens	24-28
25757908-7	2015	Afterward, treated with MAPK pathways inhibitors, only ERK inhibitor(U0126)could reduce the expression of EMT markers in SV-HUC-1 cells, but not p38 and JNK inhibitor(SB203580, SP600125), which indicated that benzidine induces the epithelial-mesenchymal transition in human uroepithelial cells through ERK1/2 pathway.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	55-58
25757908-7	2015	Afterward, treated with MAPK pathways inhibitors, only ERK inhibitor(U0126)could reduce the expression of EMT markers in SV-HUC-1 cells, but not p38 and JNK inhibitor(SB203580, SP600125), which indicated that benzidine induces the epithelial-mesenchymal transition in human uroepithelial cells through ERK1/2 pathway.	U 0126	69-74	mitogen-activated protein kinase 3	Homo sapiens	302-308
25879875-12	2015	Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656) suppressed the AF-6/afadin knockdown-induced invasive capability.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	14-18
25879875-12	2015	Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656) suppressed the AF-6/afadin knockdown-induced invasive capability.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	19-22
25879875-12	2015	Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656) suppressed the AF-6/afadin knockdown-induced invasive capability.	U 0126	37-42	afadin, adherens junction formation factor	Homo sapiens	76-80
25879875-12	2015	Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656) suppressed the AF-6/afadin knockdown-induced invasive capability.	U 0126	37-42	afadin, adherens junction formation factor	Homo sapiens	81-87
25735975-5	2015	This effect was inhibited by U0126, an inhibitor of ERK kinase (MEK).	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	52-55
25735975-5	2015	This effect was inhibited by U0126, an inhibitor of ERK kinase (MEK).	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	64-67
25743092-10	2015	In addition, the induction of FN by HER2 was down-regulated by the MEK 1/2 specific inhibitor, U0126.	U 0126	95-100	fibronectin 1	Homo sapiens	30-32
25743092-10	2015	In addition, the induction of FN by HER2 was down-regulated by the MEK 1/2 specific inhibitor, U0126.	U 0126	95-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
25743092-10	2015	In addition, the induction of FN by HER2 was down-regulated by the MEK 1/2 specific inhibitor, U0126.	U 0126	95-100	mitogen-activated protein kinase kinase 1	Homo sapiens	67-74
25727021-4	2015	This reactivation largely depends on the NF-kappaB and MAPK signaling pathways because either overexpression of a super-repressor form of IkappaBalpha or pretreatment with a MEK inhibitor U0126 diminished provirus reactivation by C1.	U 0126	188-193	mitogen-activated protein kinase kinase 7	Homo sapiens	174-177
25999956-8	2015	Moreover, both MEK1/2 and ERK1/2 expression increased significantly, and cellular hypertrophy was markedly attenuated by U0126, an ERK1/2 inhibitor.	U 0126	121-126	mitogen activated protein kinase kinase 1	Rattus norvegicus	15-21
25999956-8	2015	Moreover, both MEK1/2 and ERK1/2 expression increased significantly, and cellular hypertrophy was markedly attenuated by U0126, an ERK1/2 inhibitor.	U 0126	121-126	mitogen activated protein kinase 3	Rattus norvegicus	26-32
25999956-8	2015	Moreover, both MEK1/2 and ERK1/2 expression increased significantly, and cellular hypertrophy was markedly attenuated by U0126, an ERK1/2 inhibitor.	U 0126	121-126	mitogen activated protein kinase 3	Rattus norvegicus	131-137
25999956-11	2015	In view of the potent and selective activity of the ERK inhibitor U0126, this agent warrants further investigation as a candidate for preventing hyperphosphate-induced cardiac hypertrophy in CKD and dialysis patients.	U 0126	66-71	mitogen-activated protein kinase 1	Homo sapiens	52-55
25576343-11	2015	Inhibition of ERK1/2 activation by U0126 (an ERK1/2 inhibitor) and pFLAG-CMV-ERK1(K71R) (negative mutant of ERK1) reversed the expression of liver-specific genes in hUCMSCs and affected hepatic function significantly.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	14-20
25576343-11	2015	Inhibition of ERK1/2 activation by U0126 (an ERK1/2 inhibitor) and pFLAG-CMV-ERK1(K71R) (negative mutant of ERK1) reversed the expression of liver-specific genes in hUCMSCs and affected hepatic function significantly.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	14-18
24777577-4	2015	The MEK/ERK inhibitor U0126 could inhibit ERK1/2 phosphorylation, further inhibiting the proliferation of NSCs in the SGZ and SVZ but had no effect on the phosphorylation of Akt.	U 0126	22-27	midkine	Mus musculus	4-7
24777577-4	2015	The MEK/ERK inhibitor U0126 could inhibit ERK1/2 phosphorylation, further inhibiting the proliferation of NSCs in the SGZ and SVZ but had no effect on the phosphorylation of Akt.	U 0126	22-27	mitogen-activated protein kinase 1	Mus musculus	8-11
24777577-4	2015	The MEK/ERK inhibitor U0126 could inhibit ERK1/2 phosphorylation, further inhibiting the proliferation of NSCs in the SGZ and SVZ but had no effect on the phosphorylation of Akt.	U 0126	22-27	mitogen-activated protein kinase 3	Mus musculus	42-48
25961946-6	2015	U0126 (a selective inhibitor of MEK that disrupts downstream activation of ERK1/2) downregulated the phosphorylation of ERK1/2, p90RSK and MSK1.	U 0126	0-5	ribosomal protein S6 kinase A1	Homo sapiens	128-134
25961946-6	2015	U0126 (a selective inhibitor of MEK that disrupts downstream activation of ERK1/2) downregulated the phosphorylation of ERK1/2, p90RSK and MSK1.	U 0126	0-5	ribosomal protein S6 kinase A5	Homo sapiens	139-143
23255524-4	2015	With pharmacological inhibition of the ERK pathway by the MEK1/ERK inhibitor U0126 during hydrostatic pressure application on days 10-14, the increase in Young"s modulus induced by hydrostatic pressure was blocked.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	39-42
23255524-4	2015	With pharmacological inhibition of the ERK pathway by the MEK1/ERK inhibitor U0126 during hydrostatic pressure application on days 10-14, the increase in Young"s modulus induced by hydrostatic pressure was blocked.	U 0126	77-82	mitogen-activated protein kinase kinase 1	Homo sapiens	58-62
23255524-4	2015	With pharmacological inhibition of the ERK pathway by the MEK1/ERK inhibitor U0126 during hydrostatic pressure application on days 10-14, the increase in Young"s modulus induced by hydrostatic pressure was blocked.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	63-66
25739982-6	2015	U0126 (5 muM), a specific inhibitor of (MEK1/2), and 10-DEBC (2 muM), a selective inhibitor of AKT, both significantly reduced 17beta-estradiol-induced phosphorylation of mTOR.	U 0126	0-5	mechanistic target of rapamycin kinase	Homo sapiens	171-175
25527444-8	2015	AQP1 might be a potential target, and the ERK antagonist U0126 could be a new drug for the treatment of HSV-1-induced Bell"s palsy in an early stage.	U 0126	57-62	mitogen-activated protein kinase 1	Mus musculus	42-45
25721671-6	2015	CDK4 levels remains high during S phase peak and G0/G1 arrest while CDK6 expression decreases at 12 h and increases again al 24 h. The up-regulation of CDKs 4 and 6 by 1,25D (6 h) was abolished in C2C12 cells pre-treated with the ERK1/2 inhibitor, UO126.	U 0126	248-253	cyclin-dependent kinase 6	Mus musculus	152-164
25676809-7	2015	In addition, our results showed that the up-regulation of M1 mRNA was blocked by an ERK inhibitor, U0126.	U 0126	99-104	mitogen-activated protein kinase 1	Homo sapiens	84-87
25799554-4	2015	U0126, a specific inhibitor of MEK (MAPK kinase), was added into the maturation culture medium to block the EGF-mediated MAPK3/1 pathway with different doses.	U 0126	0-5	mitogen-activated protein kinase 3	Ovis aries	121-126
25778692-6	2015	Pretreatment of cells with ERK inhibitor (U0126) and PI3K inhibitor (LY294002) significantly potentiated the inhibitory effect of RuPOP on cell growth, migration and invasion.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	27-30
25314926-7	2015	The ERK1/2 activity-specific inhibitor U0126 remarkably blocked the Rb2-induced antiapoptotic effect in response to Dex-induced apoptosis.	U 0126	39-44	mitogen-activated protein kinase 3	Mus musculus	4-10
25314926-7	2015	The ERK1/2 activity-specific inhibitor U0126 remarkably blocked the Rb2-induced antiapoptotic effect in response to Dex-induced apoptosis.	U 0126	39-44	RB transcriptional corepressor like 2	Mus musculus	68-71
25739982-6	2015	U0126 (5 muM), a specific inhibitor of (MEK1/2), and 10-DEBC (2 muM), a selective inhibitor of AKT, both significantly reduced 17beta-estradiol-induced phosphorylation of mTOR.	U 0126	0-5	latexin	Homo sapiens	9-12
25739982-6	2015	U0126 (5 muM), a specific inhibitor of (MEK1/2), and 10-DEBC (2 muM), a selective inhibitor of AKT, both significantly reduced 17beta-estradiol-induced phosphorylation of mTOR.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	40-46
25451977-7	2015	In both gestational tissues, MEK1/2 (U0126; 10 microM) or p38 inhibition (SB203580; 10 microM) suppressed OT-induced COX-2 expression, but OT-induced p65-phosphorylation was only inhibited in amnion, suggesting OT activation of NF-kappaB in amnion is MAPK-dependent.	U 0126	37-42	mitogen-activated protein kinase kinase 1	Homo sapiens	29-35
25746394-6	2015	Intra-NAc shell infusion U0126, an inhibitor of the Mitogen-activated protein kinase kinase (MEK), prevented the retrieval-induced up-regulation of pERK1/2, pCREB, Arc/Arg3.1, and membrane GluR1 immediately after retrieval of morphine CPP.	U 0126	25-30	activity-regulated cytoskeleton-associated protein	Rattus norvegicus	164-174
25746394-6	2015	Intra-NAc shell infusion U0126, an inhibitor of the Mitogen-activated protein kinase kinase (MEK), prevented the retrieval-induced up-regulation of pERK1/2, pCREB, Arc/Arg3.1, and membrane GluR1 immediately after retrieval of morphine CPP.	U 0126	25-30	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	189-194
25451977-7	2015	In both gestational tissues, MEK1/2 (U0126; 10 microM) or p38 inhibition (SB203580; 10 microM) suppressed OT-induced COX-2 expression, but OT-induced p65-phosphorylation was only inhibited in amnion, suggesting OT activation of NF-kappaB in amnion is MAPK-dependent.	U 0126	37-42	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	117-122
25562427-4	2015	It also induced phosphorylation of CREB (cAMP response element binding protein), but this effect appeared to be mediated indirectly by extracellular signal-regulated kinase (ERK) rather than directly by PKA, given that it was attenuated by the ERK signaling inhibitor U0126.	U 0126	268-273	cAMP responsive element binding protein 1	Mus musculus	35-39
25734900-12	2015	S1P-induced c-Jun activation was reduced by PP1, AG1478, AG1296, U0126, SP600125, SB202190, or LY294002.	U 0126	65-70	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-17
25800444-5	2015	To explore the effect of ERK1/2 pathway on AQP4 expression in scratch-injured astrocytes, 10 micromol/L U0126 (ERK1/2 inhibitor) was incubated in the medium at 30 min before the scratch-injury in some groups.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	25-31
25800444-5	2015	To explore the effect of ERK1/2 pathway on AQP4 expression in scratch-injured astrocytes, 10 micromol/L U0126 (ERK1/2 inhibitor) was incubated in the medium at 30 min before the scratch-injury in some groups.	U 0126	104-109	aquaporin 4	Rattus norvegicus	43-47
25800444-5	2015	To explore the effect of ERK1/2 pathway on AQP4 expression in scratch-injured astrocytes, 10 micromol/L U0126 (ERK1/2 inhibitor) was incubated in the medium at 30 min before the scratch-injury in some groups.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	111-117
25800444-8	2015	Furthermore, pretreatment with U0126 blocked both ERK1/2 activation and decrease in AQP4 expression induced by scratch-injury.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	50-56
25800444-8	2015	Furthermore, pretreatment with U0126 blocked both ERK1/2 activation and decrease in AQP4 expression induced by scratch-injury.	U 0126	31-36	aquaporin 4	Rattus norvegicus	84-88
25562430-5	2015	Consistently, OSM-induced stabilization of the SOCS3 transcript is impaired in the presence of inhibitors that specifically block activation of MEK1/2 (U0126) and ERK1/2 (FR180204) or upon knock-down of ERK1/2 expression using specific siRNA.	U 0126	152-157	suppressor of cytokine signaling 3	Mus musculus	47-52
25562430-5	2015	Consistently, OSM-induced stabilization of the SOCS3 transcript is impaired in the presence of inhibitors that specifically block activation of MEK1/2 (U0126) and ERK1/2 (FR180204) or upon knock-down of ERK1/2 expression using specific siRNA.	U 0126	152-157	mitogen-activated protein kinase kinase 1	Mus musculus	144-150
25562427-4	2015	It also induced phosphorylation of CREB (cAMP response element binding protein), but this effect appeared to be mediated indirectly by extracellular signal-regulated kinase (ERK) rather than directly by PKA, given that it was attenuated by the ERK signaling inhibitor U0126.	U 0126	268-273	cAMP responsive element binding protein 1	Mus musculus	41-78
25562427-4	2015	It also induced phosphorylation of CREB (cAMP response element binding protein), but this effect appeared to be mediated indirectly by extracellular signal-regulated kinase (ERK) rather than directly by PKA, given that it was attenuated by the ERK signaling inhibitor U0126.	U 0126	268-273	mitogen-activated protein kinase 1	Mus musculus	135-172
25562427-4	2015	It also induced phosphorylation of CREB (cAMP response element binding protein), but this effect appeared to be mediated indirectly by extracellular signal-regulated kinase (ERK) rather than directly by PKA, given that it was attenuated by the ERK signaling inhibitor U0126.	U 0126	268-273	mitogen-activated protein kinase 1	Mus musculus	244-247
26045756-8	2015	The ERK1/2 inhibitor U0126 and the Akt inhibitor LY294002 also inhibited hypoxia-induced HIF-1alpha and VEGF production.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	4-10
25544181-5	2015	IFN-alpha-dependent ERK1/2 phosphorylation was blocked by MEK inhibitor U0126.	U 0126	72-77	interferon alpha 1	Homo sapiens	0-9
25544181-5	2015	IFN-alpha-dependent ERK1/2 phosphorylation was blocked by MEK inhibitor U0126.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	20-26
25544181-5	2015	IFN-alpha-dependent ERK1/2 phosphorylation was blocked by MEK inhibitor U0126.	U 0126	72-77	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
25544181-6	2015	Pharmacological inhibition of ERK1/2 by U0126 or siRNA-mediated knockdown of ERK1/2 resulted in suppressive effects on HCV RNA levels and expression of HCV nonstructural protein 3 and envelope protein 2, establishing an important role for ERK pathway in HCV replication.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	30-36
25544181-6	2015	Pharmacological inhibition of ERK1/2 by U0126 or siRNA-mediated knockdown of ERK1/2 resulted in suppressive effects on HCV RNA levels and expression of HCV nonstructural protein 3 and envelope protein 2, establishing an important role for ERK pathway in HCV replication.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	30-33
25596807-11	2015	Specific inhibitors for phosphoinositide 3-kinase; PI3K (LY294002 and worhmannin) and ERK1/2 inhibitors (PD98059 and U0126) suppressed DCA- and acid-induced NF-kappaB activation.	U 0126	117-122	mitogen-activated protein kinase 3	Homo sapiens	86-92
25542137-10	2015	Knockdown of p38 and ERK1/2 by their respective specific siRNAs or inhibition of p38 and ERK1/2 phosphorylation by their respective inhibitors (SB203580 and U0126) eliminated the increase in PCV2 replication induced by OTA.	U 0126	157-162	mitogen-activated protein kinase 3	Sus scrofa	89-95
25471019-8	2015	Furthermore, BAG3 knockdown increased the HT-induced phosphorylation of ERK after HT treatment, and the ERK inhibitor U0126 significantly improved the viability of the cells treated with a combination of BAG3 knockdown and HT.	U 0126	118-123	mitogen-activated protein kinase 1	Homo sapiens	104-107
25471019-8	2015	Furthermore, BAG3 knockdown increased the HT-induced phosphorylation of ERK after HT treatment, and the ERK inhibitor U0126 significantly improved the viability of the cells treated with a combination of BAG3 knockdown and HT.	U 0126	118-123	BAG cochaperone 3	Homo sapiens	204-208
25578563-8	2015	Furthermore, the PI3K inhibitors LY294002, BKM120 and MEK inhibitors U0126, PD0325901 blocked the enhanced S6K1 activity induced by Kb.	U 0126	69-74	ribosomal protein S6 kinase B1	Homo sapiens	107-111
26045756-8	2015	The ERK1/2 inhibitor U0126 and the Akt inhibitor LY294002 also inhibited hypoxia-induced HIF-1alpha and VEGF production.	U 0126	21-26	vascular endothelial growth factor A	Homo sapiens	104-108
25492115-2	2015	In male rats, the MEK1/2 inhibitor U0126 reduces ischemia-induced endothelin type B (ETB) receptor upregulation, infarct size and improves acute neurologic function after experimental stroke.	U 0126	35-40	mitogen activated protein kinase kinase 1	Rattus norvegicus	18-24
25492115-2	2015	In male rats, the MEK1/2 inhibitor U0126 reduces ischemia-induced endothelin type B (ETB) receptor upregulation, infarct size and improves acute neurologic function after experimental stroke.	U 0126	35-40	endothelin receptor type B	Rattus norvegicus	85-88
25492115-8	2015	In vitro organ culture and tMCAO resulted in vascular ETB receptor upregulation and activation of ERK1/2 that was prevented by U0126.	U 0126	127-132	endothelin receptor type B	Rattus norvegicus	54-57
25492115-8	2015	In vitro organ culture and tMCAO resulted in vascular ETB receptor upregulation and activation of ERK1/2 that was prevented by U0126.	U 0126	127-132	mitogen activated protein kinase 3	Rattus norvegicus	98-104
25580562-12	2015	Moreover, inhibition of ERK1/2 with U0126 attenuated the BHBA-mediated reduction in Gsh-1 expression and GHRH synthesis and secretion.	U 0126	36-41	mitogen activated protein kinase 3	Rattus norvegicus	24-30
25604255-6	2015	Inhibition of the MAP kinase kinase (MEK)/ERK1/2 pathway using the specific MEK inhibitor U0126 significantly reduced ephrin-A2 messenger RNA upregulation upon compression.	U 0126	90-95	mitogen-activated protein kinase 3	Mus musculus	42-48
25604255-6	2015	Inhibition of the MAP kinase kinase (MEK)/ERK1/2 pathway using the specific MEK inhibitor U0126 significantly reduced ephrin-A2 messenger RNA upregulation upon compression.	U 0126	90-95	ephrin A2	Mus musculus	118-127
25580562-12	2015	Moreover, inhibition of ERK1/2 with U0126 attenuated the BHBA-mediated reduction in Gsh-1 expression and GHRH synthesis and secretion.	U 0126	36-41	GS homeobox 1	Rattus norvegicus	84-89
25580562-12	2015	Moreover, inhibition of ERK1/2 with U0126 attenuated the BHBA-mediated reduction in Gsh-1 expression and GHRH synthesis and secretion.	U 0126	36-41	growth hormone releasing hormone	Rattus norvegicus	105-109
25647783-3	2015	The aim of the present study was to evaluate the effects of ERK1/2 inhibitor U0126 on proliferation and apoptosis of cervical cancer cells and appraise the correlated mechanism of the effects.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	60-66
25647783-4	2015	In this study, the cell proliferation of Hela and C33A cervical cancer cells was tested by Cell Counting Kit-8 (CCK8) assay and cell counting after treated with ERK1/2 inhibitor U0126.	U 0126	178-183	mitogen-activated protein kinase 3	Homo sapiens	161-167
25647783-7	2015	The results indicated that after down-regulating ERK1/2 proteins with the inhibitor U0126, Hela and C33A cells proliferation was inhibited, cell apoptosis was promoted, the proportions of G0/G1 stage in cell cycle increased, and G2/M stages decreased.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	49-55
25726377-11	2015	Extracellular-signal-regulated kinase 1/2 (ERK1/2) inhibitor, U0126, prevented IGF1-induction of BOULE mRNA.	U 0126	62-67	mitogen-activated protein kinase 3	Mus musculus	0-41
25428269-7	2015	Further, inhibition of Smad2 signalling using an inhibitor of activin receptor-linked kinase 5 SB431542 reduced TGF-beta1-induced Nox4 expression, while inhibition of ERK1/2 with the inhibitor of mitogen-activated protein kinase kinase 1/2 U0126 decreased both basal and TGF-beta1-induced Nox4 expression.	U 0126	240-245	SMAD family member 2	Homo sapiens	23-28
25428269-7	2015	Further, inhibition of Smad2 signalling using an inhibitor of activin receptor-linked kinase 5 SB431542 reduced TGF-beta1-induced Nox4 expression, while inhibition of ERK1/2 with the inhibitor of mitogen-activated protein kinase kinase 1/2 U0126 decreased both basal and TGF-beta1-induced Nox4 expression.	U 0126	240-245	transforming growth factor beta 1	Homo sapiens	112-121
25428269-8	2015	Inhibition of ERK1/2 phosphorylation with U0126 did not affect Smad2 phosphorylation.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	14-20
25428269-9	2015	Finally, TGF-beta1 enhanced endothelial cell proliferation, which was reduced by U0126 but not by SB431542.	U 0126	81-86	transforming growth factor beta 1	Homo sapiens	9-18
25497010-4	2015	Treatment of the MEK inhibitor U0126 promoted IRF1 expression in 7 of 11 cancer cell lines we tested.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
25497010-4	2015	Treatment of the MEK inhibitor U0126 promoted IRF1 expression in 7 of 11 cancer cell lines we tested.	U 0126	31-36	interferon regulatory factor 1	Homo sapiens	46-50
25497010-7	2015	Moreover, apoptosis induction by U0126 was significantly reduced in IRF1 shRNA knockdown cells than vector control cells.	U 0126	33-38	interferon regulatory factor 1	Homo sapiens	68-72
25721209-7	2015	Further investigation into the underlying mechanisms responsible for the migratory effects revealed that MALAT2 induced the epithelial-mesenchymal transition (EMT) through an MEK/extracellular signal-regulated kinase-dependent mechanism as treatment with the MEK inhibitor, U0126, decreased migration and reversed the EMT in the MALAT2 over-expressed SGC-7901 cells.	U 0126	274-279	mitogen-activated protein kinase kinase 7	Homo sapiens	175-178
25726377-11	2015	Extracellular-signal-regulated kinase 1/2 (ERK1/2) inhibitor, U0126, prevented IGF1-induction of BOULE mRNA.	U 0126	62-67	mitogen-activated protein kinase 3	Mus musculus	43-49
25726377-11	2015	Extracellular-signal-regulated kinase 1/2 (ERK1/2) inhibitor, U0126, prevented IGF1-induction of BOULE mRNA.	U 0126	62-67	insulin-like growth factor 1	Mus musculus	79-83
25726377-12	2015	It was found that IGF1 increased CDC25A mRNA expression and that U0126 - but not flutamide - abolished the IGF1-induced CDC25A mRNA expression.	U 0126	65-70	insulin-like growth factor 1	Mus musculus	107-111
25726377-12	2015	It was found that IGF1 increased CDC25A mRNA expression and that U0126 - but not flutamide - abolished the IGF1-induced CDC25A mRNA expression.	U 0126	65-70	cell division cycle 25A	Mus musculus	120-126
25603052-10	2015	The inhibition of ERK by U0126 and PD0325901 enhanced the differentiation of BMSCs into adipocytes.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	18-21
25689862-7	2015	The Thr732 phosphorylation was U0126-sensitive and was observed in a kinase-dead mutant of ERK5 as well, suggesting that ERK1/2 can phosphorylate ERK5 at Thr732.	U 0126	31-36	mitogen-activated protein kinase 7	Homo sapiens	91-95
25689862-7	2015	The Thr732 phosphorylation was U0126-sensitive and was observed in a kinase-dead mutant of ERK5 as well, suggesting that ERK1/2 can phosphorylate ERK5 at Thr732.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	121-127
25689862-7	2015	The Thr732 phosphorylation was U0126-sensitive and was observed in a kinase-dead mutant of ERK5 as well, suggesting that ERK1/2 can phosphorylate ERK5 at Thr732.	U 0126	31-36	mitogen-activated protein kinase 7	Homo sapiens	146-150
25689862-11	2015	Finally, ER-32A and U0126 blocked ERK5-dependent MEF2C transcriptional activity.	U 0126	20-25	mitogen-activated protein kinase 7	Homo sapiens	34-38
25689862-11	2015	Finally, ER-32A and U0126 blocked ERK5-dependent MEF2C transcriptional activity.	U 0126	20-25	myocyte enhancer factor 2C	Homo sapiens	49-54
24947959-0	2015	Inhibition of tumor growth by U0126 is associated with induction of interferon-gamma production.	U 0126	30-35	interferon gamma	Mus musculus	68-84
24947959-5	2015	In this study, we determined that U0126, a MEK1/2 inhibitor, increased tumor-free and survival rates and decreased growth of inoculated Lewis lung carcinomas in wild type mice.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Mus musculus	43-49
24947959-11	2015	U0126 also inhibited chemicals-induced pulmonary carcinomas, which was associated with increased IFN-gamma expression in the lung.	U 0126	0-5	interferon gamma	Mus musculus	97-106
24947959-12	2015	Taken together, our study suggests that MEK1/2 inhibitors induce IFN-gamma production in an LXR-dependent manner and the induction of IFN-gamma expression can partially contribute to the anti-tumorigenic properties of U0126.	U 0126	218-223	mitogen-activated protein kinase kinase 1	Mus musculus	40-46
24947959-12	2015	Taken together, our study suggests that MEK1/2 inhibitors induce IFN-gamma production in an LXR-dependent manner and the induction of IFN-gamma expression can partially contribute to the anti-tumorigenic properties of U0126.	U 0126	218-223	interferon gamma	Mus musculus	65-74
25592318-6	2015	The decreased ERK phosphorylation caused by pretreatment with U0126, an inhibitor of MEK, suppressed the expression of LC3-II compared with PD treatment alone, suggesting that ERK pathway may have a critical function in PD-triggered autophagy.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	14-17
25592318-6	2015	The decreased ERK phosphorylation caused by pretreatment with U0126, an inhibitor of MEK, suppressed the expression of LC3-II compared with PD treatment alone, suggesting that ERK pathway may have a critical function in PD-triggered autophagy.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	85-88
25592318-6	2015	The decreased ERK phosphorylation caused by pretreatment with U0126, an inhibitor of MEK, suppressed the expression of LC3-II compared with PD treatment alone, suggesting that ERK pathway may have a critical function in PD-triggered autophagy.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	176-179
24947959-12	2015	Taken together, our study suggests that MEK1/2 inhibitors induce IFN-gamma production in an LXR-dependent manner and the induction of IFN-gamma expression can partially contribute to the anti-tumorigenic properties of U0126.	U 0126	218-223	nuclear receptor subfamily 1, group H, member 3	Mus musculus	92-95
24947959-12	2015	Taken together, our study suggests that MEK1/2 inhibitors induce IFN-gamma production in an LXR-dependent manner and the induction of IFN-gamma expression can partially contribute to the anti-tumorigenic properties of U0126.	U 0126	218-223	interferon gamma	Mus musculus	134-143
25679223-6	2015	The MEK inhibitor U0126 blocks the inhibitory effect of Src on FAT4 mRNA expression and Src-induced actin depolymerization.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
25675437-5	2015	TNF-alpha-mediated responses were attenuated by pretreatment with the inhibitor of PKCs (Ro318220), PKCdelta (Rottlerin), MEK1/2 (U0126), JNK1/2 (SP600125), or AP-1 (Tanshinone IIA) and transfection with siRNA of TNFR1, TRAF2, JNK2, p42, or c-Jun.	U 0126	130-135	tumor necrosis factor	Homo sapiens	0-9
25679223-6	2015	The MEK inhibitor U0126 blocks the inhibitory effect of Src on FAT4 mRNA expression and Src-induced actin depolymerization.	U 0126	18-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	56-59
25679223-6	2015	The MEK inhibitor U0126 blocks the inhibitory effect of Src on FAT4 mRNA expression and Src-induced actin depolymerization.	U 0126	18-23	FAT atypical cadherin 4	Homo sapiens	63-67
25679223-6	2015	The MEK inhibitor U0126 blocks the inhibitory effect of Src on FAT4 mRNA expression and Src-induced actin depolymerization.	U 0126	18-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	88-91
24928309-6	2015	Experiments with mice deficient in netrin-1 receptor DCC (deleted in colorectal cancer, DCC+/-), or reperfusion with netrin-1/UO126 or netrin-1/PTIO, attenuated the protective effects of netrin-1, implicating intermediate roles of DCC, ERK1/2 and NO.	U 0126	126-131	netrin 1	Mus musculus	117-125
24928309-6	2015	Experiments with mice deficient in netrin-1 receptor DCC (deleted in colorectal cancer, DCC+/-), or reperfusion with netrin-1/UO126 or netrin-1/PTIO, attenuated the protective effects of netrin-1, implicating intermediate roles of DCC, ERK1/2 and NO.	U 0126	126-131	netrin 1	Mus musculus	117-125
24928309-6	2015	Experiments with mice deficient in netrin-1 receptor DCC (deleted in colorectal cancer, DCC+/-), or reperfusion with netrin-1/UO126 or netrin-1/PTIO, attenuated the protective effects of netrin-1, implicating intermediate roles of DCC, ERK1/2 and NO.	U 0126	126-131	netrin 1	Mus musculus	117-125
24928309-8	2015	Electron spin resonance (ESR) determination of NO production from isolated left ventricles demonstrated that netrin-1 improves NO bioavailability, which was attenuated by UO126 or in DCC+/-mice, suggesting upstream roles of DCC and ERK1/2 in NO production.	U 0126	171-176	netrin 1	Mus musculus	109-117
24928309-9	2015	Netrin-1 further reduced mitochondrial swelling and mitochondrial superoxide production, which was absent when co-treated with PTIO or UO126, or in DCC+/-mice, indicating critical roles of DCC, ERK1/2 and NO in preserving mitochondrial integrity.	U 0126	135-140	netrin 1	Mus musculus	0-8
25529535-7	2015	MEK inhibitor, U0126, treatment sensitized PLX4032-resistant cells to death and re-established their danger-signalling capacity.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
25529535-10	2015	Interestingly, autophagy abrogation was particularly efficacious in boosting cell death and ecto-CRT/ecto-HSP90 in PLX4032-resistant cells upon blockage of MEK hyper-activation by U0126.	U 0126	180-185	mitogen-activated protein kinase kinase 7	Homo sapiens	156-159
25519184-11	2015	A specific inhibitor of the ERK signaling pathway, U0126, prevented DS1-induced LHbeta and FSHbeta promoter activity almost completely; however, H89, a PKA inhibitor, did not modulate the effect of DS1.	U 0126	51-56	luteinizing hormone beta	Mus musculus	80-86
25519184-11	2015	A specific inhibitor of the ERK signaling pathway, U0126, prevented DS1-induced LHbeta and FSHbeta promoter activity almost completely; however, H89, a PKA inhibitor, did not modulate the effect of DS1.	U 0126	51-56	follicle stimulating hormone beta	Mus musculus	91-98
24047601-4	2015	We investigated the role of ERK in sleep-dependent ODP consolidation by inhibiting the ERK-activating enzyme MEK in V1 (via U0126) during post-MD sleep.	U 0126	124-129	mitogen-activated protein kinase 1	Homo sapiens	28-31
24047601-4	2015	We investigated the role of ERK in sleep-dependent ODP consolidation by inhibiting the ERK-activating enzyme MEK in V1 (via U0126) during post-MD sleep.	U 0126	124-129	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
24047601-7	2015	U0126 abolished ODP consolidation and reduced both phosphorylation of eukaryotic initiation factor 4E (eIF4E) and levels of the synaptic marker PSD-95.	U 0126	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	70-101
24047601-7	2015	U0126 abolished ODP consolidation and reduced both phosphorylation of eukaryotic initiation factor 4E (eIF4E) and levels of the synaptic marker PSD-95.	U 0126	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	103-108
24047601-7	2015	U0126 abolished ODP consolidation and reduced both phosphorylation of eukaryotic initiation factor 4E (eIF4E) and levels of the synaptic marker PSD-95.	U 0126	0-5	discs large MAGUK scaffold protein 4	Homo sapiens	144-150
24047601-8	2015	Furthermore, interfering with ERK-mediated translation by inhibiting MAP kinase-interacting kinase 1 (Mnk1) with CGP57380 mimicked the effects of U0126.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	30-33
24047601-8	2015	Furthermore, interfering with ERK-mediated translation by inhibiting MAP kinase-interacting kinase 1 (Mnk1) with CGP57380 mimicked the effects of U0126.	U 0126	146-151	MAPK interacting serine/threonine kinase 1	Homo sapiens	69-100
24047601-8	2015	Furthermore, interfering with ERK-mediated translation by inhibiting MAP kinase-interacting kinase 1 (Mnk1) with CGP57380 mimicked the effects of U0126.	U 0126	146-151	MAPK interacting serine/threonine kinase 1	Homo sapiens	102-106
25363751-0	2015	U0126 promotes osteogenesis of rat bone-marrow-derived mesenchymal stem cells by activating BMP/Smad signaling pathway.	U 0126	0-5	SMAD family member 1	Rattus norvegicus	96-100
25363751-1	2015	U0126 has been reported as a specific inhibitor of the ERK1/2 signaling pathway, which plays a vital role during the osteogenic differentiation of mesenchymal stem cells (MSCs).	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	55-61
25363751-4	2015	Our data indicate that U0126 enhances the BMP/Smad signaling pathway in rat MSCs, while inhibiting the ERK1/2 signaling pathway.	U 0126	23-28	SMAD family member 1	Rattus norvegicus	46-50
25461399-11	2015	Both Bapta-AM and U0126, but not SB202190, restored the levels of intracellular free Ca(2+) concentration, phosphorylated Pyk2 and Src-pY527.	U 0126	18-23	PTK2 protein tyrosine kinase 2 beta	Mus musculus	122-126
25461399-11	2015	Both Bapta-AM and U0126, but not SB202190, restored the levels of intracellular free Ca(2+) concentration, phosphorylated Pyk2 and Src-pY527.	U 0126	18-23	Rous sarcoma oncogene	Mus musculus	131-134
23836369-6	2015	The inhibitory effects of ERK inhibitor, U0126, on 2-ABP-induced caspase-3 activity were not detected.	U 0126	41-46	amine oxidase copper containing 1	Homo sapiens	53-56
23836369-6	2015	The inhibitory effects of ERK inhibitor, U0126, on 2-ABP-induced caspase-3 activity were not detected.	U 0126	41-46	caspase 3	Homo sapiens	65-74
24853881-5	2015	Specific or selective inhibitors were used for the MEK1/2 and the c-Src pathways (UO126 and PP2, respectively).	U 0126	82-87	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	66-71
25239226-6	2015	Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580.	U 0126	111-116	interleukin 6	Homo sapiens	13-17
25239226-6	2015	Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580.	U 0126	111-116	interleukin 1 beta	Homo sapiens	32-40
25524297-11	2015	In addition, PTTH-stimulated histone H3 phosphorylation was partially reduced by U0126, a specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, indicating the involvement of ERK.	U 0126	81-86	prothoracicotropic hormone	Bombyx mori	13-17
25524297-11	2015	In addition, PTTH-stimulated histone H3 phosphorylation was partially reduced by U0126, a specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, indicating the involvement of ERK.	U 0126	81-86	extracellular regulated MAP kinase	Bombyx mori	139-142
25524297-11	2015	In addition, PTTH-stimulated histone H3 phosphorylation was partially reduced by U0126, a specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, indicating the involvement of ERK.	U 0126	81-86	extracellular regulated MAP kinase	Bombyx mori	197-200
25515760-9	2015	However, the OX1R antagonist SB334867 (10-6 M), ERK1/2 antagonist U0126 (30 microM) or the combination of antagonists blocked the effects of orexin A to a certain extent.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	48-54
25515760-9	2015	However, the OX1R antagonist SB334867 (10-6 M), ERK1/2 antagonist U0126 (30 microM) or the combination of antagonists blocked the effects of orexin A to a certain extent.	U 0126	66-71	hypocretin neuropeptide precursor	Homo sapiens	141-147
25211367-8	2015	Inhibition of MEK1/2 by U0126 resulted in decreased RANKL expression suggesting that stimulation through MEK1/2 was a prerequisite.	U 0126	24-29	mitogen-activated protein kinase kinase 1	Homo sapiens	14-20
25211367-8	2015	Inhibition of MEK1/2 by U0126 resulted in decreased RANKL expression suggesting that stimulation through MEK1/2 was a prerequisite.	U 0126	24-29	TNF superfamily member 11	Homo sapiens	52-57
25407271-0	2015	MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats.	U 0126	17-22	mitogen activated protein kinase kinase 1	Rattus norvegicus	0-6
25272052-8	2015	Calcium chelators, (1,2-bis(o-aminophenoxy) ethane-N,N,N",N"-tetraacetic acid) acetoxymethyl ester and EGTA, and ERK1/2 inhibitor U0126 abolished chemokine (C-C motif) ligand 2 release from astrocytes.	U 0126	130-135	mitogen-activated protein kinase 3	Homo sapiens	113-119
25348362-8	2015	Treatment with U0126, a specific inhibitor of MEK, significantly suppressed LPS-induced expression of LOX-1 at both the mRNA and protein levels.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
25348362-8	2015	Treatment with U0126, a specific inhibitor of MEK, significantly suppressed LPS-induced expression of LOX-1 at both the mRNA and protein levels.	U 0126	15-20	oxidized low density lipoprotein receptor 1	Homo sapiens	102-107
25348362-9	2015	Furthermore, LOX-1 promoter activity was significantly augmented by LPS stimulation; this augmentation was prevented by U0126 treatment.	U 0126	120-125	oxidized low density lipoprotein receptor 1	Homo sapiens	13-18
25373458-6	2015	The phosphorylation of HSP27 induced by HG was blocked by the specific phosphoinositide 3-kinase (PI3K) inhibitor LY294002 and the specific extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 in a concentration-dependent manner, with peak inhibition rates of 62.6 and 56.1%, respectively.	U 0126	198-203	heat shock protein family B (small) member 1	Homo sapiens	23-28
25373458-6	2015	The phosphorylation of HSP27 induced by HG was blocked by the specific phosphoinositide 3-kinase (PI3K) inhibitor LY294002 and the specific extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 in a concentration-dependent manner, with peak inhibition rates of 62.6 and 56.1%, respectively.	U 0126	198-203	mitogen-activated protein kinase 3	Homo sapiens	140-187
25421411-17	2015	Significant inhibition of p42 MAPK phosphorylation by U0126 was observed (p = 0.012).	U 0126	54-59	erythrocyte membrane protein band 4.2	Homo sapiens	26-29
25544156-1	2015	U0126 is a potent and selective inhibitor of MEK1 and MEK2 kinases.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	45-49
25544156-1	2015	U0126 is a potent and selective inhibitor of MEK1 and MEK2 kinases.	U 0126	0-5	mitogen activated protein kinase kinase 2	Rattus norvegicus	54-58
25544156-3	2015	In particular, U0126 has been used in a number of studies to show that inhibition of the Raf/MEK/ERK pathway protects neuronal cells against oxidative stress.	U 0126	15-20	Eph receptor B1	Rattus norvegicus	97-100
25482449-5	2015	Furthermore, TMEPAI gene activation by EGF and TGF-beta signaling was reduced by the MEK inhibitor U0126.	U 0126	99-104	prostate transmembrane protein, androgen induced 1	Homo sapiens	13-19
25482449-5	2015	Furthermore, TMEPAI gene activation by EGF and TGF-beta signaling was reduced by the MEK inhibitor U0126.	U 0126	99-104	epidermal growth factor	Homo sapiens	39-42
25482449-5	2015	Furthermore, TMEPAI gene activation by EGF and TGF-beta signaling was reduced by the MEK inhibitor U0126.	U 0126	99-104	transforming growth factor beta 1	Homo sapiens	47-55
25482449-5	2015	Furthermore, TMEPAI gene activation by EGF and TGF-beta signaling was reduced by the MEK inhibitor U0126.	U 0126	99-104	mitogen-activated protein kinase kinase 7	Homo sapiens	85-88
25563324-8	2015	Furthermore, western blot and the ERK1/2 inhibitor U0126 were used to identify the specific signaling pathway by which RIP140 induces differentiation of N2a cells.	U 0126	51-56	nuclear receptor interacting protein 1	Mus musculus	119-125
25310956-5	2015	The involvement of these signaling systems in the mechanism of the nucleoside action was strengthened by a reduction of the protective effect when glial cells were pretreated with U0126 or LY294002, the specific inhibitors of MEK1/2 and PI3K, respectively.	U 0126	180-185	mitogen activated protein kinase kinase 1	Rattus norvegicus	226-232
26521828-5	2015	The neuroprotective effect of everolimus was almost completely prevented by the mitogen-activated protein kinase/ERK kinase inhibitor U0126 (1 nmol).	U 0126	134-139	Eph receptor B1	Rattus norvegicus	113-116
26027837-4	2015	Moreover, the TNF receptor 1 shedding induced by irciniastatin A was blocked by the MAP kinase/ERK kinase inhibitor U0126, but not by the p38 MAP kinase inhibitor SB203580 or the JNK inhibitor SP600125.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	95-98
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	26-29
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	48-53	MUC3	Homo sapiens	80-87
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	48-53	MUC3	Homo sapiens	89-93
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	48-53	lipase E, hormone sensitive type	Homo sapiens	130-133
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	48-53	MUC3	Homo sapiens	159-163
25644510-6	2015	The effects of the MEK inhibitor U0126 on oncogenic KRAS were evaluated.	U 0126	33-38	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog	Danio rerio	52-56
25644510-12	2015	In a krt5-derived stable and inducible transgenic line, expression of oncogenic KRAS resulted in skin hyperplasia, and the MEK inhibitor U0126 effectively suppressed this pro-proliferative effects.	U 0126	137-142	keratin 5	Danio rerio	5-9
25363751-4	2015	Our data indicate that U0126 enhances the BMP/Smad signaling pathway in rat MSCs, while inhibiting the ERK1/2 signaling pathway.	U 0126	23-28	mitogen activated protein kinase 3	Rattus norvegicus	103-109
25363751-5	2015	Furthermore, Western blot results demonstrate that U0126 increases Smad1/5/8 phosphorylation synergistically with beta-glycerophosphate.	U 0126	51-56	SMAD family member 1	Rattus norvegicus	67-74
24597568-7	2015	Intra-DH injection of AP5 or intra-BLA injection of AP-5 or U0126 before extinction training significantly attenuated ERK and CREB phosphorylation in the BLA and impaired the extinction of CPA behaviour.	U 0126	60-65	Eph receptor B1	Rattus norvegicus	118-121
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	13-18	bone morphogenetic protein 2	Rattus norvegicus	61-65
24597568-7	2015	Intra-DH injection of AP5 or intra-BLA injection of AP-5 or U0126 before extinction training significantly attenuated ERK and CREB phosphorylation in the BLA and impaired the extinction of CPA behaviour.	U 0126	60-65	cAMP responsive element binding protein 1	Rattus norvegicus	126-130
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	13-18	SMAD family member 1	Rattus norvegicus	145-154
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	13-18	bone morphogenetic protein 2	Rattus norvegicus	183-187
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	13-18	bone morphogenetic protein 2	Rattus norvegicus	183-187
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	13-18	SMAD family member 1	Rattus norvegicus	145-149
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	214-219	bone morphogenetic protein 2	Rattus norvegicus	61-65
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	214-219	SMAD family member 1	Rattus norvegicus	145-154
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	214-219	bone morphogenetic protein 2	Rattus norvegicus	183-187
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	214-219	bone morphogenetic protein 2	Rattus norvegicus	183-187
25363751-6	2015	In addition, U0126 significantly increases the expression of BMP2 during the process of osteogenesis in rat MSCs and the level of phosphorylated Smad1/5/8 is significantly reduced by BMP2 antibody, suggesting that U0126 also promotes the expression of BMP2 to enhance Smad proteins phosphorylation.	U 0126	214-219	SMAD family member 1	Rattus norvegicus	145-149
25363751-7	2015	Thus, we demonstrate a novel function for U0126 in promoting osteogenic differentiation of rat MSCs by the activation of the BMP/Smad signaling pathway.	U 0126	42-47	SMAD family member 1	Rattus norvegicus	129-133
24984876-8	2015	Importantly, inhibition of the MAPK signaling pathway using SB203580 (p38 MAPK inhibitor), U0126 (extracellular signal-regulated kinase inhibitor), and SP600125 (c-Jun NH2-terminal kinase inhibitor) significantly potentiated the SUN-induced BNP and beta-MHC mRNA levels, but did alter the alpha-MHC level.	U 0126	91-96	natriuretic peptide B	Rattus norvegicus	241-244
24005261-6	2015	These changes were reversed by inhibition of extracellular signal-regulated kinase1/2 (ERK1/2) via the specific ERK1/2 inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Mus musculus	45-85
24005261-6	2015	These changes were reversed by inhibition of extracellular signal-regulated kinase1/2 (ERK1/2) via the specific ERK1/2 inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Mus musculus	87-93
24005261-6	2015	These changes were reversed by inhibition of extracellular signal-regulated kinase1/2 (ERK1/2) via the specific ERK1/2 inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Mus musculus	112-118
25756510-7	2015	Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2.	U 0126	104-109	EPH receptor B2	Homo sapiens	99-102
25756510-7	2015	Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2.	U 0126	104-109	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	121-125
25756510-7	2015	Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2.	U 0126	104-109	BCL2 like 11	Homo sapiens	158-161
25756510-7	2015	Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2.	U 0126	104-109	BCL2 like 11	Homo sapiens	173-176
25756510-7	2015	Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2.	U 0126	104-109	BCL2 apoptosis regulator	Homo sapiens	188-195
26184424-7	2015	Testosterone content was significantly decreased in the DHEA-treated group pre-incubated with U0126 (p-ERK1/2 inhibitor).	U 0126	94-99	mitogen activated protein kinase 3	Rattus norvegicus	103-109
26207671-8	2015	Treatment of Snail-overexpressing 22Rv1 cells with LY294002, PI3K/AKT inhibitor or U0126, MEK inhibitor, decreased cell migration significantly, but only LY294002 significantly reduced Rac1 activity, suggesting that Snail promotes Rac1 activation via the PI3K/AKT pathway.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
24820887-11	2015	The ERK1/2 antagonist U0126, p38 antagonist SB203580 and JNK antagonist SP600125 significantly reversed the facial mechanical allodynia in ION-CCI rats.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	4-10
24820887-12	2015	However, the ERK1/2 antagonist U0126, p38 antagonist SB203580 but not JNK antagonist SP600125 significantly increased BKCa currents in ION-CCI TG neurons.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	13-19
24820887-12	2015	However, the ERK1/2 antagonist U0126, p38 antagonist SB203580 but not JNK antagonist SP600125 significantly increased BKCa currents in ION-CCI TG neurons.	U 0126	31-36	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	118-122
26184424-8	2015	Additionally, the rise in p-ERK1/2, 3beta-HSD and 17beta-HSD protein levels induced by DHEA was reversed when cells were pre-incubated with U0126.	U 0126	140-145	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	36-45
26184424-8	2015	Additionally, the rise in p-ERK1/2, 3beta-HSD and 17beta-HSD protein levels induced by DHEA was reversed when cells were pre-incubated with U0126.	U 0126	140-145	hydroxysteroid (17-beta) dehydrogenase 3	Rattus norvegicus	50-60
26184424-8	2015	Additionally, the rise in p-ERK1/2, 3beta-HSD and 17beta-HSD protein levels induced by DHEA was reversed when cells were pre-incubated with U0126.	U 0126	140-145	mitogen activated protein kinase 3	Rattus norvegicus	28-34
25788387-6	2015	One hour prior to adenoviral injections, rats were intraperitoneally administrated with 10 mg/kg U0126 (a specific MEK/ERK1/2 inhibitor) or DMSO (vehicle control).	U 0126	97-102	mitogen activated protein kinase 3	Rattus norvegicus	119-125
24647791-15	2015	LY294002 and U0126 attenuated IL-1beta-induced ICAM-1 expression and sICAM-1 production.	U 0126	13-18	interleukin 1 beta	Homo sapiens	30-38
24647791-15	2015	LY294002 and U0126 attenuated IL-1beta-induced ICAM-1 expression and sICAM-1 production.	U 0126	13-18	intercellular adhesion molecule 1	Homo sapiens	47-53
25446723-7	2015	In addition, we show that neurocan, aggrecan, and brevican levels are significantly reduced when TGFbeta is administered in the presence of either the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin, but not the MEK1/2 inhibitor U0126.	U 0126	237-242	transforming growth factor beta 1	Homo sapiens	97-104
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	209-214	mitogen-activated protein kinase 1	Homo sapiens	26-29
25774422-4	2015	Incubating cells with the ERK pathway inhibitor U0126 for 30 min alleviated the mucin 3 (MUC3) expression suppressed by 3-oxo-C12-HSL, and the upregulation of MUC3 expression induced by a 48-h incubation with U0126-reduced cell death.	U 0126	209-214	MUC3	Homo sapiens	159-163
25492214-9	2015	U0126, an ERK inhibitor, blocked curcumin-induced apoptosis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
26245187-8	2015	Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25, while it decreased the IL-1beta immunoreactivity in neurons.	U 0126	19-24	synaptosome associated protein 25	Rattus norvegicus	72-79
26855970-0	2015	U0126, an Inhibitor of MEK1/2, Increases Tumor Necrosis Factor-alpha-Induced Apoptosis, but not Interleukin-6 Induced Apoptosis in C-28/I2 Human Chondrocytes.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	23-29
26855970-0	2015	U0126, an Inhibitor of MEK1/2, Increases Tumor Necrosis Factor-alpha-Induced Apoptosis, but not Interleukin-6 Induced Apoptosis in C-28/I2 Human Chondrocytes.	U 0126	0-5	tumor necrosis factor	Homo sapiens	41-68
26855970-5	2015	The number of apoptotic C28/I2 chondrocytes was significantly increased (p=1.3 x 10-5) by the combination of rhTNF-alpha and U0126 (10 muM) compared to rhTNF-alpha alone.	U 0126	125-130	latexin	Homo sapiens	135-138
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	44-49	latexin	Homo sapiens	54-57
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	92-131
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	135-139
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	44-49	latexin	Homo sapiens	219-222
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	246-250
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	209-214	latexin	Homo sapiens	54-57
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	209-214	mitogen-activated protein kinase 1	Homo sapiens	92-131
26855970-7	2015	The LI-COR  western blot system showed that U0126 (10 muM) inhibited the phosphorylation of extracellular signal-regulated kinase-2 (p-ERK2) by phorbol myristate acetate-treated immortalized myometrial cells, U0126 (10 muM) did not alter total U-ERK2.	U 0126	209-214	mitogen-activated protein kinase 1	Homo sapiens	135-139
26855970-11	2015	They also suggested that inhibiting ERK2 phosphorylation via U0126-mediated inhibition of MEK1/2 activity, increased rhTNF-alpha-induced C-28/I2 chondrocyte apoptosis.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	36-40
26855970-11	2015	They also suggested that inhibiting ERK2 phosphorylation via U0126-mediated inhibition of MEK1/2 activity, increased rhTNF-alpha-induced C-28/I2 chondrocyte apoptosis.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Homo sapiens	90-96
25746833-6	2015	In addition, a MEK inhibitor (U0126) was used in invasion assays to determine the effect of the MEK/ERK signaling pathway.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	15-18
26245187-8	2015	Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25, while it decreased the IL-1beta immunoreactivity in neurons.	U 0126	19-24	interleukin 1 beta	Rattus norvegicus	104-112
25203596-8	2015	And the expression of arginase-1 and TGF-beta1 was partially blocked by the pretreated ERK biochemical inhibitor (U0126) instead of the JNK inhibitor (SP600125) and p38MAPK inhibitor (SB203580).	U 0126	114-119	arginase, liver	Mus musculus	22-32
26670373-5	2015	Mechanism analysis revealed that dipyridamole induced the phosphorylation of mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinases (ERK) and its effect on cell growth was attenuated by the MEK inhibitor, U0126.	U 0126	239-244	mitogen-activated protein kinase kinase 7	Homo sapiens	77-116
26670373-5	2015	Mechanism analysis revealed that dipyridamole induced the phosphorylation of mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinases (ERK) and its effect on cell growth was attenuated by the MEK inhibitor, U0126.	U 0126	239-244	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
25203596-8	2015	And the expression of arginase-1 and TGF-beta1 was partially blocked by the pretreated ERK biochemical inhibitor (U0126) instead of the JNK inhibitor (SP600125) and p38MAPK inhibitor (SB203580).	U 0126	114-119	transforming growth factor, beta 1	Mus musculus	37-46
26670373-5	2015	Mechanism analysis revealed that dipyridamole induced the phosphorylation of mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinases (ERK) and its effect on cell growth was attenuated by the MEK inhibitor, U0126.	U 0126	239-244	mitogen-activated protein kinase kinase 7	Homo sapiens	224-227
25203596-8	2015	And the expression of arginase-1 and TGF-beta1 was partially blocked by the pretreated ERK biochemical inhibitor (U0126) instead of the JNK inhibitor (SP600125) and p38MAPK inhibitor (SB203580).	U 0126	114-119	mitogen-activated protein kinase 1	Mus musculus	87-90
25108669-8	2015	Furthermore, U0126 was found to antagonize the changes caused by RKIP downregulation after exposure to radiation.	U 0126	13-18	phosphatidylethanolamine binding protein 1	Rattus norvegicus	65-69
26273426-7	2015	But the ERK inhibitor U0126 or PI3K/Akt inhibitor LY294002 produced no obvious effect.	U 0126	22-27	mitogen-activated protein kinase 1	Homo sapiens	8-11
25527729-9	2015	The oxidative DNA damage observed was transient, likely due to DNA repair; furthermore, higher damage was achieved upon inhibition of ERK activation by pre-treatment with U0126, suggesting a role for ERK in DNA damage repair.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	134-137
25527729-9	2015	The oxidative DNA damage observed was transient, likely due to DNA repair; furthermore, higher damage was achieved upon inhibition of ERK activation by pre-treatment with U0126, suggesting a role for ERK in DNA damage repair.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	200-203
24934279-9	2015	A mitogen-activated protein kinase (MAPK) inhibitor, U0126, suppressed BDNF"s accelerating effect on cell death.	U 0126	53-58	brain-derived neurotrophic factor	Rattus norvegicus	71-75
26349244-2	2015	We have found that addition of U0126 or PD98059 to not-stimulated with EGF ells for 30 min has no effect on radially organized MT system.	U 0126	31-36	epidermal growth factor	Homo sapiens	71-74
26349244-12	2015	The inhibitors were also shown to affect differently phospho-ERK 1 and 2 forms: U0126 completely inhibited phospho-ERK1 and 2, white, in the presence of PD98059, the two ERK forms demonstrated sharp transient activation in 15 min after stimulation, but only phospho-ERK2 could be detected after 60 min of endocytosis.	U 0126	80-85	mitogen-activated protein kinase 3	Homo sapiens	61-72
25514788-7	2014	The treatment of adherent HeyA8 cells with an inhibitor of the MEK-ERK pathway, U0126, resulted in a significant increase in surface CXCR4 expression.	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
25514788-7	2014	The treatment of adherent HeyA8 cells with an inhibitor of the MEK-ERK pathway, U0126, resulted in a significant increase in surface CXCR4 expression.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	67-70
25514788-7	2014	The treatment of adherent HeyA8 cells with an inhibitor of the MEK-ERK pathway, U0126, resulted in a significant increase in surface CXCR4 expression.	U 0126	80-85	C-X-C motif chemokine receptor 4	Homo sapiens	133-138
25143346-9	2014	Furthermore, the increase in DRA mRNA expression by CS of B. breve and B. infantis was blocked in the presence of the transcription inhibitor actinomycin D (5 muM) and the ERK1/2 MAPK pathway inhibitor U0126 (10 muM).	U 0126	202-207	solute carrier family 26, member 3	Mus musculus	29-32
25497784-13	2014	Both U0126 and C compound almost completely prevented LPS-induced TNF-alpha production.	U 0126	5-10	tumor necrosis factor	Homo sapiens	66-75
25403108-5	2014	Extracellular regulated protein kinase (ERK) was activated after treatment with GA in HepG2 cells and pretreatment with U0126 or PD98059, the MEK inhibitors, reversed GA-triggered autophagy as evidenced by decreased expression of LC3-II and formation of autophagosomes, respectively.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	0-38
25403108-5	2014	Extracellular regulated protein kinase (ERK) was activated after treatment with GA in HepG2 cells and pretreatment with U0126 or PD98059, the MEK inhibitors, reversed GA-triggered autophagy as evidenced by decreased expression of LC3-II and formation of autophagosomes, respectively.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	40-43
25403108-5	2014	Extracellular regulated protein kinase (ERK) was activated after treatment with GA in HepG2 cells and pretreatment with U0126 or PD98059, the MEK inhibitors, reversed GA-triggered autophagy as evidenced by decreased expression of LC3-II and formation of autophagosomes, respectively.	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	142-145
25216733-8	2014	MK-801 and nifedipine, inhibitors of calcium entry, and H-89 and UO126, inhibitors of PKA and ERK signaling respectively, exacerbated neuronal death only in severely damaged neurons, while ROS-scavenger quercetin and calcium chelator BAPTA attenuated toxicity only at lower concentration.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	94-97
25501336-7	2014	This suppression was reversed by ERK1/2 inhibitor (U0126).	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	33-39
24819614-0	2014	U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	9-56
24819614-0	2014	U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	58-68
24819614-0	2014	U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.	U 0126	0-5	nuclear receptor subfamily 1 group I member 2	Homo sapiens	145-164
24819614-0	2014	U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.	U 0126	0-5	nuclear receptor subfamily 1 group I member 2	Homo sapiens	166-169
24819614-4	2014	We found that U0126, a prototype dual MEK1/2 inhibitor, is a potent inducer of CYP3A4, CYP3A5 and CYP3A7 mRNA expression (&gt;100-fold) in HepG2 cells and CYP3A4 mRNA expression in primary human hepatocytes.	U 0126	14-19	mitogen-activated protein kinase kinase 1	Homo sapiens	38-44
24819614-4	2014	We found that U0126, a prototype dual MEK1/2 inhibitor, is a potent inducer of CYP3A4, CYP3A5 and CYP3A7 mRNA expression (&gt;100-fold) in HepG2 cells and CYP3A4 mRNA expression in primary human hepatocytes.	U 0126	14-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
24819614-4	2014	We found that U0126, a prototype dual MEK1/2 inhibitor, is a potent inducer of CYP3A4, CYP3A5 and CYP3A7 mRNA expression (&gt;100-fold) in HepG2 cells and CYP3A4 mRNA expression in primary human hepatocytes.	U 0126	14-19	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	87-93
24819614-4	2014	We found that U0126, a prototype dual MEK1/2 inhibitor, is a potent inducer of CYP3A4, CYP3A5 and CYP3A7 mRNA expression (&gt;100-fold) in HepG2 cells and CYP3A4 mRNA expression in primary human hepatocytes.	U 0126	14-19	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	98-104
24819614-4	2014	We found that U0126, a prototype dual MEK1/2 inhibitor, is a potent inducer of CYP3A4, CYP3A5 and CYP3A7 mRNA expression (&gt;100-fold) in HepG2 cells and CYP3A4 mRNA expression in primary human hepatocytes.	U 0126	14-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
24819614-6	2014	In gene reporter assays, U0126 activates a CYP3A4 promoter luciferase reporter construct containing PXR response elements (PXREs), but not a construct containing mutated PXREs.	U 0126	25-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
24819614-6	2014	In gene reporter assays, U0126 activates a CYP3A4 promoter luciferase reporter construct containing PXR response elements (PXREs), but not a construct containing mutated PXREs.	U 0126	25-30	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103
24819614-7	2014	Based on a ligand binding assay and the examination of a PXR mutant expressing an obstructed ligand binding pocket, we found that U0126 is a ligand of PXR.	U 0126	130-135	nuclear receptor subfamily 1 group I member 2	Homo sapiens	57-60
24819614-7	2014	Based on a ligand binding assay and the examination of a PXR mutant expressing an obstructed ligand binding pocket, we found that U0126 is a ligand of PXR.	U 0126	130-135	nuclear receptor subfamily 1 group I member 2	Homo sapiens	151-154
24819614-8	2014	We also found that U0126 up-regulates the mRNA expression of the nuclear receptors HNF4alpha, CAR, VDR and PXR but abolishes small heterodimer partner (SHP) corepressor expression in HepG2 cells.	U 0126	19-24	hepatocyte nuclear factor 4 alpha	Homo sapiens	83-92
24819614-8	2014	We also found that U0126 up-regulates the mRNA expression of the nuclear receptors HNF4alpha, CAR, VDR and PXR but abolishes small heterodimer partner (SHP) corepressor expression in HepG2 cells.	U 0126	19-24	CXADR pseudogene 1	Homo sapiens	94-97
24819614-8	2014	We also found that U0126 up-regulates the mRNA expression of the nuclear receptors HNF4alpha, CAR, VDR and PXR but abolishes small heterodimer partner (SHP) corepressor expression in HepG2 cells.	U 0126	19-24	vitamin D receptor	Homo sapiens	99-102
24819614-8	2014	We also found that U0126 up-regulates the mRNA expression of the nuclear receptors HNF4alpha, CAR, VDR and PXR but abolishes small heterodimer partner (SHP) corepressor expression in HepG2 cells.	U 0126	19-24	nuclear receptor subfamily 1 group I member 2	Homo sapiens	107-110
24819614-8	2014	We also found that U0126 up-regulates the mRNA expression of the nuclear receptors HNF4alpha, CAR, VDR and PXR but abolishes small heterodimer partner (SHP) corepressor expression in HepG2 cells.	U 0126	19-24	nuclear receptor subfamily 0 group B member 2	Homo sapiens	152-155
24819614-11	2014	In conclusion, we found that U0126 is an atypical PXR ligand that via direct (binding and activation of PXR) and indirect (SHP dowregulation) mechanisms selectively restores CYP3A genes in HepG2 cells.	U 0126	29-34	nuclear receptor subfamily 1 group I member 2	Homo sapiens	50-53
24819614-11	2014	In conclusion, we found that U0126 is an atypical PXR ligand that via direct (binding and activation of PXR) and indirect (SHP dowregulation) mechanisms selectively restores CYP3A genes in HepG2 cells.	U 0126	29-34	nuclear receptor subfamily 1 group I member 2	Homo sapiens	104-107
24819614-11	2014	In conclusion, we found that U0126 is an atypical PXR ligand that via direct (binding and activation of PXR) and indirect (SHP dowregulation) mechanisms selectively restores CYP3A genes in HepG2 cells.	U 0126	29-34	nuclear receptor subfamily 0 group B member 2	Homo sapiens	123-126
25503106-7	2014	Additionally, AICAR increased ERK1/2 phosphorylation, and inhibition of ERK1/2 by U0126, an ERK1/2 kinase inhibitor, or by siRNA decreased AICAR-induced TER responses.	U 0126	82-87	mitogen activated protein kinase 3	Rattus norvegicus	72-78
25127907-8	2014	U0126 partly reversed this inhibitory effect of TGF-beta1.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	48-57
25466909-5	2014	The importance of ERK for MSC differentiation was demonstrated by using the inhibitor of ERK activation, U0126, which completely suppressed osteogenesis of GH-stimulated MSCs on NSQ50.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	18-21
25466909-5	2014	The importance of ERK for MSC differentiation was demonstrated by using the inhibitor of ERK activation, U0126, which completely suppressed osteogenesis of GH-stimulated MSCs on NSQ50.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	89-92
25269412-3	2014	In general, pharmacological perturbation of PI3/Akt (application of MK-2206) and MEK/ERK1/2 (application of PD0325901 or U0126) signaling led to a cell line and drug-specific decrease in the proliferation and migration potential of thyroid carcinoma cells, although to a varying extent.	U 0126	121-126	peptidase inhibitor 3	Homo sapiens	44-47
25269412-3	2014	In general, pharmacological perturbation of PI3/Akt (application of MK-2206) and MEK/ERK1/2 (application of PD0325901 or U0126) signaling led to a cell line and drug-specific decrease in the proliferation and migration potential of thyroid carcinoma cells, although to a varying extent.	U 0126	121-126	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84
25269412-3	2014	In general, pharmacological perturbation of PI3/Akt (application of MK-2206) and MEK/ERK1/2 (application of PD0325901 or U0126) signaling led to a cell line and drug-specific decrease in the proliferation and migration potential of thyroid carcinoma cells, although to a varying extent.	U 0126	121-126	mitogen-activated protein kinase 3	Homo sapiens	85-91
25598661-6	2014	Treatment with Akt inhibitor IV or U0126 resulted in significantly attenuated expression of TLR6 and IL-1alpha induced by 27OHChol and 27OHChol plus FSL-1, respectively.	U 0126	35-40	toll like receptor 6	Homo sapiens	92-96
25598661-6	2014	Treatment with Akt inhibitor IV or U0126 resulted in significantly attenuated expression of TLR6 and IL-1alpha induced by 27OHChol and 27OHChol plus FSL-1, respectively.	U 0126	35-40	interleukin 1 alpha	Homo sapiens	101-110
25598661-6	2014	Treatment with Akt inhibitor IV or U0126 resulted in significantly attenuated expression of TLR6 and IL-1alpha induced by 27OHChol and 27OHChol plus FSL-1, respectively.	U 0126	35-40	follistatin like 1	Homo sapiens	149-154
25304236-8	2014	Although argininosuccinate synthase induction could not be induced in vitro, a drug targeting pathway previously demonstrated to be associated with Ser62 cMyc phosphorylation - U0126 - in combination with CoArgIPEG demonstrated an in-vitro synergistic response (combination indices 0.13+-0.10 and 0.14+-0.10 with or without citrulline, respectively).	U 0126	177-182	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	154-158
24799176-7	2014	Furthermore, inhibiting ERK1/2 phosphorylation by microinjection of U0126, a MAPK kinase (MEK) inhibitor, into the mPFC attenuated SPS + CFA- and SPS- but not CFA-induced mechanical allodynia, anxiety-like behavior, and cognitive impairments.	U 0126	68-73	mitogen-activated protein kinase 3	Homo sapiens	24-30
24799176-7	2014	Furthermore, inhibiting ERK1/2 phosphorylation by microinjection of U0126, a MAPK kinase (MEK) inhibitor, into the mPFC attenuated SPS + CFA- and SPS- but not CFA-induced mechanical allodynia, anxiety-like behavior, and cognitive impairments.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
25242412-13	2014	Mechanistically, CXCR7 signaling inhibited HNF4alpha through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2.	U 0126	141-146	atypical chemokine receptor 3	Homo sapiens	17-22
25242412-13	2014	Mechanistically, CXCR7 signaling inhibited HNF4alpha through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2.	U 0126	141-146	hepatocyte nuclear factor 4 alpha	Homo sapiens	43-52
25242412-13	2014	Mechanistically, CXCR7 signaling inhibited HNF4alpha through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	61-99
25242412-13	2014	Mechanistically, CXCR7 signaling inhibited HNF4alpha through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	101-104
25242412-13	2014	Mechanistically, CXCR7 signaling inhibited HNF4alpha through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	164-168
25242412-13	2014	Mechanistically, CXCR7 signaling inhibited HNF4alpha through extracellular regulated protein kinase (ERK) activation, which was inhibited by U0126, an inhibitor of MAPK/ERK kinases 1 and 2.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	169-172
25269647-5	2014	In contrast, EGF-induced CD44 expression was decreased by a MEK1/2 inhibitor, UO126, or STAT3 inhibitor, STAT3 VI, respectively.	U 0126	78-83	CD44 molecule (Indian blood group)	Homo sapiens	25-29
25451564-5	2014	Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	23-64
25451564-5	2014	Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	66-72
25451564-5	2014	Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	138-144
25451564-5	2014	Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets.	U 0126	13-18	NSFL1 cofactor	Rattus norvegicus	149-152
25520861-6	2014	ABCG2-specific inhibitor, fumitremorgin C (FTC), and mitogen-activated protein kinase (MAPK) pathway inhibitor, U0126, inhibited cell proliferation and promoted cell apoptosis by degrading endogenous ABCG2 in Hep-2T cells.	U 0126	112-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	200-205
25241249-2	2014	Here we describe the antiviral activity of the MEK1/2 inhibitor U0126 against Yellow fever virus 17D vaccine strain (YFV-17D).	U 0126	64-69	mitogen-activated protein kinase kinase 1	Homo sapiens	47-53
25241249-4	2014	Pharmacological inhibition of MEK1/2 through U0126 treatment of VERO cells blockades not only the YFV-stimulated ERK1/2 phosphorylation, but also inhibits YFV replication by ~99%.	U 0126	45-50	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
25489417-4	2014	Paraquat treatment resulted in activation of ERK, and U0126, inhibitors of the MEK/ERK signaling pathway, prevented apoptosis.	U 0126	54-59	midkine	Mus musculus	79-82
25489417-4	2014	Paraquat treatment resulted in activation of ERK, and U0126, inhibitors of the MEK/ERK signaling pathway, prevented apoptosis.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	83-86
25149325-3	2014	In fact, inhibition of ERK phosphorylation by the MEK inhibitor U0126 reversibly delayed bud detachment and prevented formation of the dpERK-positive cell cluster indicating de novo-phosphorylation of ERK at the late bud base.	U 0126	64-69	mitogen-activated protein kinase 1	Homo sapiens	23-26
25149325-3	2014	In fact, inhibition of ERK phosphorylation by the MEK inhibitor U0126 reversibly delayed bud detachment and prevented formation of the dpERK-positive cell cluster indicating de novo-phosphorylation of ERK at the late bud base.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	50-53
25149325-3	2014	In fact, inhibition of ERK phosphorylation by the MEK inhibitor U0126 reversibly delayed bud detachment and prevented formation of the dpERK-positive cell cluster indicating de novo-phosphorylation of ERK at the late bud base.	U 0126	64-69	mitogen-activated protein kinase 1	Homo sapiens	137-140
25673531-8	2014	Treatment with UO126 or transfection with ERK specific siRNA (small interfering RNA) resulted in the abolishment of ERK activation as well as LHR mRNA downregulation.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	116-119
25673531-8	2014	Treatment with UO126 or transfection with ERK specific siRNA (small interfering RNA) resulted in the abolishment of ERK activation as well as LHR mRNA downregulation.	U 0126	15-20	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	142-145
25218161-12	2014	Interestingly, PKC pathway inhibitor AEB071 (Sotrastaurin) (0.1 muM) or ERK inhibitor U0126 (1 muM) or NF-kappaB inhibitor PDTC (1 muM) could affect suppression of AS-IV on cell invasion, at least partially.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	72-75
24787365-5	2014	By contrast, the ERK inhibitor U0126 attenuated only the ABG001-increased number of newborn cells, while the PI3K inhibitor LY294002 prevented mainly the ABG001-enhanced neurite growth.	U 0126	31-36	Eph receptor B2	Mus musculus	17-20
24610459-9	2014	Moreover, TGF-beta1/FGF2-mediated EMT of HERS cells was reversed by the MEK1/2 inhibitor U0126.	U 0126	89-94	transforming growth factor beta 1	Homo sapiens	10-19
24610459-9	2014	Moreover, TGF-beta1/FGF2-mediated EMT of HERS cells was reversed by the MEK1/2 inhibitor U0126.	U 0126	89-94	fibroblast growth factor 2	Homo sapiens	20-24
24610459-9	2014	Moreover, TGF-beta1/FGF2-mediated EMT of HERS cells was reversed by the MEK1/2 inhibitor U0126.	U 0126	89-94	mitogen-activated protein kinase kinase 1	Homo sapiens	72-78
25063220-3	2014	Treatment with Ang IIinduced RANKL expression in a dose- and time-dependent manner in osteoblasts, which was attenuated by pre-treatment with an AT1 receptor antagonist (olmesartan), ROS scavenger (N-acetylcysteine, NAC), or the ERK inhibitor (U0126), but not with AT2R antagonist (PD123319).	U 0126	244-249	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	15-18
25063220-3	2014	Treatment with Ang IIinduced RANKL expression in a dose- and time-dependent manner in osteoblasts, which was attenuated by pre-treatment with an AT1 receptor antagonist (olmesartan), ROS scavenger (N-acetylcysteine, NAC), or the ERK inhibitor (U0126), but not with AT2R antagonist (PD123319).	U 0126	244-249	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	29-34
25063220-6	2014	Moreover, Ang II enhanced the ERK1/2 phosphorylation, which was abrogated by pre-treatment with olmesartan, NAC, DPI, or U0126 in osteoblasts.	U 0126	121-126	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	10-16
25063220-6	2014	Moreover, Ang II enhanced the ERK1/2 phosphorylation, which was abrogated by pre-treatment with olmesartan, NAC, DPI, or U0126 in osteoblasts.	U 0126	121-126	mitogen-activated protein kinase 3	Mus musculus	30-36
25174327-8	2014	Erk1/2 inhibition with either U0126 treatment or specific siRNA silencing resulted in decreases in p-ser STAT3 and cyclin D1 levels and increases in p-tyr STAT3 in OSCC cells.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	0-6
25174327-8	2014	Erk1/2 inhibition with either U0126 treatment or specific siRNA silencing resulted in decreases in p-ser STAT3 and cyclin D1 levels and increases in p-tyr STAT3 in OSCC cells.	U 0126	30-35	signal transducer and activator of transcription 3	Homo sapiens	105-110
25174327-8	2014	Erk1/2 inhibition with either U0126 treatment or specific siRNA silencing resulted in decreases in p-ser STAT3 and cyclin D1 levels and increases in p-tyr STAT3 in OSCC cells.	U 0126	30-35	cyclin D1	Homo sapiens	115-124
25175278-7	2014	Treatment with ERK1/2 inhibitor U0126 significantly inhibited the increased proliferation, migration and invasion of EPO gene-transfected cells.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	15-21
25175278-7	2014	Treatment with ERK1/2 inhibitor U0126 significantly inhibited the increased proliferation, migration and invasion of EPO gene-transfected cells.	U 0126	32-37	erythropoietin	Homo sapiens	117-120
25175278-8	2014	U0126 treatment suppressed the induction of MMP-9 expression through NF-kappaB binding activity in EPO gene transfectants.	U 0126	0-5	matrix metallopeptidase 9	Homo sapiens	44-49
25175278-8	2014	U0126 treatment suppressed the induction of MMP-9 expression through NF-kappaB binding activity in EPO gene transfectants.	U 0126	0-5	nuclear factor kappa B subunit 1	Homo sapiens	69-78
25175278-8	2014	U0126 treatment suppressed the induction of MMP-9 expression through NF-kappaB binding activity in EPO gene transfectants.	U 0126	0-5	erythropoietin	Homo sapiens	99-102
25085839-9	2014	Marked dephosphorylation of ERK1/2 and down-regulation of uPA expression were detected when BCPAP was treated with a MEK inhibitor, U0126.	U 0126	132-137	mitogen-activated protein kinase 3	Homo sapiens	28-34
25085839-9	2014	Marked dephosphorylation of ERK1/2 and down-regulation of uPA expression were detected when BCPAP was treated with a MEK inhibitor, U0126.	U 0126	132-137	plasminogen activator, urokinase	Homo sapiens	58-61
25085839-9	2014	Marked dephosphorylation of ERK1/2 and down-regulation of uPA expression were detected when BCPAP was treated with a MEK inhibitor, U0126.	U 0126	132-137	mitogen-activated protein kinase kinase 7	Homo sapiens	117-120
25186781-8	2014	U0126 and SB203580 completely blocked the FSS-induced increases in ALP activity and osteogenic gene mRNA expression and osteoid nodules formation.	U 0126	0-5	alkaline phosphatase, placental	Homo sapiens	67-70
25503106-7	2014	Additionally, AICAR increased ERK1/2 phosphorylation, and inhibition of ERK1/2 by U0126, an ERK1/2 kinase inhibitor, or by siRNA decreased AICAR-induced TER responses.	U 0126	82-87	mitogen activated protein kinase 3	Rattus norvegicus	72-78
25503106-9	2014	Furthermore, pretreatment with U0126 significantly suppressed AMPK-modulated phosphorylation, redistribution, and interaction with occludin of claudin-4.	U 0126	31-36	occludin	Rattus norvegicus	131-139
25503106-9	2014	Furthermore, pretreatment with U0126 significantly suppressed AMPK-modulated phosphorylation, redistribution, and interaction with occludin of claudin-4.	U 0126	31-36	claudin 4	Rattus norvegicus	143-152
25338001-6	2014	Inhibition of ERK signaling with U0126 decreased the pro-proliferation effect of irisin on HUVECs.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	14-17
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	5-10
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	7-10
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	cyclin D1	Homo sapiens	118-126
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	51-56
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	198-203
25260414-5	2014	When p-ERK was inhibited using U0126 (inhibitor of p-ERK), cell viability decreased and the expression of p-c-Jun and cyclinD1 was reduced accordingly, suggesting that p-ERK functions upstream of p-c-Jun and cyclinD1.	U 0126	31-36	cyclin D1	Homo sapiens	208-216
25341042-9	2014	Targeting extracellular regulated kinase pathway by using U0126 inhibitor or using CCX771, a selective CXCR7 antagonist, drastically reduced CXCR7-mediated cell proliferation.	U 0126	58-63	atypical chemokine receptor 3	Homo sapiens	141-146
25338001-6	2014	Inhibition of ERK signaling with U0126 decreased the pro-proliferation effect of irisin on HUVECs.	U 0126	33-38	fibronectin type III domain containing 5	Homo sapiens	81-87
25550802-9	2014	Furthermore, the MEK [MAPK (mitogen-activated protein kinase)/Erk1/2]/Erk1/2 inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	87-92	epidermal growth factor	Homo sapiens	108-111
25550778-8	2014	Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression.	U 0126	84-89	basigin (Ok blood group)	Homo sapiens	36-41
25550802-9	2014	Furthermore, the MEK [MAPK (mitogen-activated protein kinase)/Erk1/2]/Erk1/2 inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	87-92	aquaporin 8	Homo sapiens	120-124
25550778-8	2014	Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	57-60
25550778-8	2014	Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	70-73
25550802-10	2014	AQP8 expression was decreased from 3.92-fold (EGF-treated) to 1.38-fold (U0126-treated) in Eca-109.	U 0126	73-78	aquaporin 8	Homo sapiens	0-4
25550778-8	2014	Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression.	U 0126	84-89	basigin (Ok blood group)	Homo sapiens	105-110
24746144-11	2014	The [Ca(2+)]i peak induced by ATP or BzATP in OGD group was decreased by ERK inhibitor U0126.	U 0126	87-92	Eph receptor B1	Rattus norvegicus	73-76
25550778-8	2014	Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression.	U 0126	84-89	matrix metallopeptidase 2	Homo sapiens	148-153
25550778-8	2014	Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression.	U 0126	84-89	matrix metallopeptidase 9	Homo sapiens	155-160
25550802-9	2014	Furthermore, the MEK [MAPK (mitogen-activated protein kinase)/Erk1/2]/Erk1/2 inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	87-92	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
25550802-9	2014	Furthermore, the MEK [MAPK (mitogen-activated protein kinase)/Erk1/2]/Erk1/2 inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	87-92	mitogen-activated protein kinase 3	Homo sapiens	62-68
25550802-9	2014	Furthermore, the MEK [MAPK (mitogen-activated protein kinase)/Erk1/2]/Erk1/2 inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	87-92	mitogen-activated protein kinase 3	Homo sapiens	70-76
25336953-10	2014	U0126 (an inhibitor of Erk), but not SB 239063 (an inhibitor of p38) or SP600125 (an inhibitor of JNK), enhanced CuONP-induced viability loss.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	23-26
25275324-10	2014	U0126, a selective MEK/ERK inhibitor, reduced the augmented LPS-induced inflammation in Spred-2(-/-) mice.	U 0126	0-5	midkine	Mus musculus	19-22
25275324-10	2014	U0126, a selective MEK/ERK inhibitor, reduced the augmented LPS-induced inflammation in Spred-2(-/-) mice.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	23-26
25275324-10	2014	U0126, a selective MEK/ERK inhibitor, reduced the augmented LPS-induced inflammation in Spred-2(-/-) mice.	U 0126	0-5	sprouty-related EVH1 domain containing 2	Mus musculus	88-95
23635511-10	2014	ERK phosphorylation inhibitor U0126 completely reversed the protective effects of melatonin, suggesting that melatonin improves MSC survival and function through activating the ERK1/2 signaling pathway.	U 0126	30-35	mitogen activated protein kinase 3	Rattus norvegicus	177-183
25145543-8	2014	After using mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway inhibitor, U0126, the effect of EMF was reduced.	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
25236495-9	2014	Moreover, ERK pathway inhibitor U0126 prevented Nrf2 phosphorylation at Ser40 to retard Nrf2 nuclear translocation, thus decreasing antioxidant gene transcription.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	10-13
25236495-9	2014	Moreover, ERK pathway inhibitor U0126 prevented Nrf2 phosphorylation at Ser40 to retard Nrf2 nuclear translocation, thus decreasing antioxidant gene transcription.	U 0126	32-37	NFE2 like bZIP transcription factor 2	Homo sapiens	48-52
25236495-9	2014	Moreover, ERK pathway inhibitor U0126 prevented Nrf2 phosphorylation at Ser40 to retard Nrf2 nuclear translocation, thus decreasing antioxidant gene transcription.	U 0126	32-37	NFE2 like bZIP transcription factor 2	Homo sapiens	88-92
25192050-7	2014	LY294002 and SB203580 decreased the expression of HIF-1alpha and VEGF after HPC, whereas U0126 increased HIF-1alpha and VEGF after tGCI.	U 0126	89-94	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	105-115
24797702-3	2014	To investigate the single-cell changes in PC12 neuronal differentiation that occur when inhibited by U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), we directly injected the chemical into individual target cells and analyzed the outcomes (neurite outgrowth) at the single-cell level.	U 0126	101-106	mitogen-activated protein kinase kinase 7	Homo sapiens	124-163
24797702-3	2014	To investigate the single-cell changes in PC12 neuronal differentiation that occur when inhibited by U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), we directly injected the chemical into individual target cells and analyzed the outcomes (neurite outgrowth) at the single-cell level.	U 0126	101-106	mitogen-activated protein kinase kinase 7	Homo sapiens	165-168
24797702-5	2014	It was possible to analyze the inhibitive effect of U0126 even when the injected quantity was lower than the lower limit for inhibition when added to culture medium (0.1 muM, identical to 1.2 x 10(8) molecules per cell on dish).	U 0126	52-57	latexin	Homo sapiens	170-173
25128810-6	2014	The effects of hispidin on Akt and ERK phosphorylation were abrogated by LY294002 (a PI3K/Akt inhibitor) and U0126 (an ERK1/2 inhibitor).	U 0126	109-114	AKT serine/threonine kinase 1	Rattus norvegicus	27-30
25128810-6	2014	The effects of hispidin on Akt and ERK phosphorylation were abrogated by LY294002 (a PI3K/Akt inhibitor) and U0126 (an ERK1/2 inhibitor).	U 0126	109-114	mitogen activated protein kinase 3	Rattus norvegicus	119-125
24865975-9	2014	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 during and after OGD significantly reduced the protective effects of hypothermia on apoptosis and myelination, respectively.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	30-36
25192050-7	2014	LY294002 and SB203580 decreased the expression of HIF-1alpha and VEGF after HPC, whereas U0126 increased HIF-1alpha and VEGF after tGCI.	U 0126	89-94	vascular endothelial growth factor A	Rattus norvegicus	120-124
25149989-3	2014	The aim of our study was to examine the influence of a chronic, intrathecal administration of parthenolide (PTL, inhibitor of NF-kappaB) and U0126 (inhibitor of MEK1/2) on nociception and morphine effectiveness in a rat model of neuropathy.	U 0126	141-146	mitogen activated protein kinase kinase 1	Rattus norvegicus	161-167
24514755-6	2014	In contrast, the inhibition of the ERK1/2 pathway by PD98059 or U0126 reduced the expression of all differentiation markers studied.	U 0126	64-69	mitogen-activated protein kinase 3	Homo sapiens	35-41
25122800-7	2014	Additionally, treatment with U0126 inhibits the Rta-induced autophagy and the expression of autophagy genes, indicating that the autophagic activation is caused by the activation of extracellular signal-regulated kinase (ERK) signaling by Rta.	U 0126	29-34	RNA binding fox-1 homolog 2	Homo sapiens	48-51
25122800-7	2014	Additionally, treatment with U0126 inhibits the Rta-induced autophagy and the expression of autophagy genes, indicating that the autophagic activation is caused by the activation of extracellular signal-regulated kinase (ERK) signaling by Rta.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	182-219
25122800-7	2014	Additionally, treatment with U0126 inhibits the Rta-induced autophagy and the expression of autophagy genes, indicating that the autophagic activation is caused by the activation of extracellular signal-regulated kinase (ERK) signaling by Rta.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	221-224
25122800-7	2014	Additionally, treatment with U0126 inhibits the Rta-induced autophagy and the expression of autophagy genes, indicating that the autophagic activation is caused by the activation of extracellular signal-regulated kinase (ERK) signaling by Rta.	U 0126	29-34	RNA binding fox-1 homolog 2	Homo sapiens	239-242
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	51-57
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	58-61
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	U 0126	13-18	ETS transcription factor ELK1	Homo sapiens	108-113
25773924-9	2014	Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2-treated MDA-MB-231 cells.	U 0126	13-18	carbonyl reductase 1	Homo sapiens	125-132
25027398-7	2014	Conversely, U0126, an ERK1/2 inhibitor, enhanced the VA-induced apoptotic signals.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	22-28
25100553-8	2014	In addition, the proliferation of SCs decreased in a dose-dependent manner in response to both U0126 and RRD-251, which indicates that both the MEK/ERK and the pRb/Raf-1 signaling pathway play important roles in pRb phosphorylation in damaged neonatal chicken utricle.	U 0126	95-100	RB transcriptional corepressor 1	Gallus gallus	160-163
25100553-8	2014	In addition, the proliferation of SCs decreased in a dose-dependent manner in response to both U0126 and RRD-251, which indicates that both the MEK/ERK and the pRb/Raf-1 signaling pathway play important roles in pRb phosphorylation in damaged neonatal chicken utricle.	U 0126	95-100	Raf-1 proto-oncogene, serine/threonine kinase	Gallus gallus	164-169
25100553-8	2014	In addition, the proliferation of SCs decreased in a dose-dependent manner in response to both U0126 and RRD-251, which indicates that both the MEK/ERK and the pRb/Raf-1 signaling pathway play important roles in pRb phosphorylation in damaged neonatal chicken utricle.	U 0126	95-100	RB transcriptional corepressor 1	Gallus gallus	212-215
25352744-5	2014	ERK1/2 activity was inhibited by intravitreal injection of U0126, a highly selective inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2).	U 0126	59-64	mitogen activated protein kinase 3	Rattus norvegicus	0-6
25268131-12	2014	The inhibitory effect of U-II on DOX-increased apoptosis was attenuated by inhibitors of ERK (U0126) and PI3K/Akt (LY294002).	U 0126	94-99	urotensin 2	Homo sapiens	25-29
25268131-12	2014	The inhibitory effect of U-II on DOX-increased apoptosis was attenuated by inhibitors of ERK (U0126) and PI3K/Akt (LY294002).	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	89-92
25352744-5	2014	ERK1/2 activity was inhibited by intravitreal injection of U0126, a highly selective inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2).	U 0126	59-64	mitogen-activated protein kinase 12	Rattus norvegicus	98-134
25352744-5	2014	ERK1/2 activity was inhibited by intravitreal injection of U0126, a highly selective inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2).	U 0126	59-64	mitogen-activated protein kinase 12	Rattus norvegicus	136-142
25226519-7	2014	In the rats administered with the selective ERK inhibitor U0126, decreased tissue destruction was observed.	U 0126	58-63	Eph receptor B1	Rattus norvegicus	44-47
25226519-8	2014	Phospho-ERK activation was visibly blocked and the MMP-1, MMP-3, and MMP-13 mRNA and protein levels were lower than the corresponding levels in the CSD without U0126 group.	U 0126	160-165	Eph receptor B1	Rattus norvegicus	8-11
25226519-8	2014	Phospho-ERK activation was visibly blocked and the MMP-1, MMP-3, and MMP-13 mRNA and protein levels were lower than the corresponding levels in the CSD without U0126 group.	U 0126	160-165	matrix metallopeptidase 13	Rattus norvegicus	69-75
25056346-6	2014	U-0126, a MEK inhibitor, abolished the stiff matrix-induced dedifferentiation and proliferation.	U 0126	0-6	midkine	Mus musculus	10-13
25202904-6	2014	Additionally, stimulation of UMUC3 cells with U46619 increased pFOXO3-S294 expression, which could be attenuated by treatment with a TP antagonist (PTXA2) or ERK inhibitor (U0126).	U 0126	173-178	mitogen-activated protein kinase 1	Homo sapiens	158-161
25212780-12	2014	Specificity of PEDF"s activity was confirmed using the pharmacological inhibitors LY294002, SH6, and U0126.	U 0126	101-106	serpin family F member 1	Homo sapiens	15-19
25197981-8	2014	The MAPK inhibitors SB203580 and U0126 lowered the impact of Emdogain on IL-11 expression.	U 0126	33-38	interleukin 11	Homo sapiens	73-78
25198581-8	2014	ERK1/2 inhibitor U0126 and JNK2 inhibitor SP600125 attenuated the increase of proliferation induced by NAAG.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	0-6
24953186-5	2014	Specific inhibition of STAT3 and ERK1/2 phosphorylation through AG490 and U0126, respectively, and STAT3 down-regulation using shRNA verified that the SHP-2/ERK/MAPK pathway regulates the expression of CDX2 in basal conditions, and the CDX2 up-regulation by IL-6 is through the JAK/STAT pathway in NUGC-4 cells whereas in MKN45 cells both pathways contribute to the CDX2 up-regulation.	U 0126	74-79	signal transducer and activator of transcription 3	Homo sapiens	23-28
24953186-5	2014	Specific inhibition of STAT3 and ERK1/2 phosphorylation through AG490 and U0126, respectively, and STAT3 down-regulation using shRNA verified that the SHP-2/ERK/MAPK pathway regulates the expression of CDX2 in basal conditions, and the CDX2 up-regulation by IL-6 is through the JAK/STAT pathway in NUGC-4 cells whereas in MKN45 cells both pathways contribute to the CDX2 up-regulation.	U 0126	74-79	mitogen-activated protein kinase 3	Homo sapiens	33-39
25042242-7	2014	This effect was abolished by both U0126 (inhibitor of ERK1/2) and also by L-NAME.	U 0126	34-39	mitogen activated protein kinase 3	Rattus norvegicus	54-60
24953186-5	2014	Specific inhibition of STAT3 and ERK1/2 phosphorylation through AG490 and U0126, respectively, and STAT3 down-regulation using shRNA verified that the SHP-2/ERK/MAPK pathway regulates the expression of CDX2 in basal conditions, and the CDX2 up-regulation by IL-6 is through the JAK/STAT pathway in NUGC-4 cells whereas in MKN45 cells both pathways contribute to the CDX2 up-regulation.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	33-36
24953855-6	2014	ERK inhibitor U0126 suppressed the migration, invasion, MMP-9 expression, and NF-kappaB binding activity in IL-15-treated 5637 cells.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	0-3
24953855-6	2014	ERK inhibitor U0126 suppressed the migration, invasion, MMP-9 expression, and NF-kappaB binding activity in IL-15-treated 5637 cells.	U 0126	14-19	matrix metallopeptidase 9	Homo sapiens	56-61
24953855-6	2014	ERK inhibitor U0126 suppressed the migration, invasion, MMP-9 expression, and NF-kappaB binding activity in IL-15-treated 5637 cells.	U 0126	14-19	nuclear factor kappa B subunit 1	Homo sapiens	78-87
24953855-6	2014	ERK inhibitor U0126 suppressed the migration, invasion, MMP-9 expression, and NF-kappaB binding activity in IL-15-treated 5637 cells.	U 0126	14-19	interleukin 15	Homo sapiens	108-113
24948367-6	2014	RESULTS: The ERK1/2 pathway inhibitor U0126 and the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside similarly inhibited FcepsilonRI-mediated mast cell signals in vitro and anaphylaxis in vivo.	U 0126	38-43	mitogen-activated protein kinase 3	Mus musculus	13-19
24948367-6	2014	RESULTS: The ERK1/2 pathway inhibitor U0126 and the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside similarly inhibited FcepsilonRI-mediated mast cell signals in vitro and anaphylaxis in vivo.	U 0126	38-43	Fc receptor, IgE, high affinity I, alpha polypeptide	Mus musculus	142-153
25017118-8	2014	Pretreatment with the ERK1/2-specific inhibitor U0126 and pertussis toxin prevented the suppression of cyclin D1 expression, however did not affect DNA ladder formation.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	22-28
25017118-8	2014	Pretreatment with the ERK1/2-specific inhibitor U0126 and pertussis toxin prevented the suppression of cyclin D1 expression, however did not affect DNA ladder formation.	U 0126	48-53	cyclin D1	Homo sapiens	103-112
25225522-8	2014	The result of Western blot analysis showed increase in B7-H1 expression caused by the extracellular signaling that was related to ERK activation and the ERK inhibitor U0126 was found to reverse this increase.	U 0126	167-172	CD274 molecule	Homo sapiens	55-60
25225522-8	2014	The result of Western blot analysis showed increase in B7-H1 expression caused by the extracellular signaling that was related to ERK activation and the ERK inhibitor U0126 was found to reverse this increase.	U 0126	167-172	mitogen-activated protein kinase 1	Homo sapiens	153-156
24967690-4	2014	This effect was blocked by eupafolin, TLR-4 antibody, antioxidants (APO and NAC), as well as inhibitors, including U0126 (ERK1/2), SB202190 (p38), SP600125 (JNK1/2), and Tanshinone IIA (AP-1).	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	122-128
25246059-5	2014	Further, ERK inhibitor U0126 and NFkappaB inhibitor MG132 also inhibited A549 cell proliferation similar to 50 kappaM scutellarein treatment from 24 h to 48 h. The experimental results showed that scutellarein could inhibit proliferation of the human lung cancer cell line A549 through ERK and NFkappaB mediated by the EGFR pathway.	U 0126	23-28	mitogen-activated protein kinase 1	Homo sapiens	9-12
24573389-6	2014	Inhibition of ERK1/2 signaling via U0126 markedly blocked UA-induced MC proliferation.	U 0126	35-40	mitogen activated protein kinase 3	Rattus norvegicus	14-20
24726885-2	2014	MEK inhibition by U0126 only partially antagonized EGF/serum-induced cell migration from the basal follicular surface into the matrix.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
24936068-5	2014	We show that chemical inhibition of RAF by sorafenib or shRNA-mediated knockdown of B-Raf reduces T cell resistance to shear stress to alpha4beta1 integrin ligands vascular cell adhesion molecule 1 (VCAM-1) and fibronectin, whereas inhibition of MEK/ERK by U0126 had no effect.	U 0126	257-262	zinc fingers and homeoboxes 2	Homo sapiens	36-39
24936068-5	2014	We show that chemical inhibition of RAF by sorafenib or shRNA-mediated knockdown of B-Raf reduces T cell resistance to shear stress to alpha4beta1 integrin ligands vascular cell adhesion molecule 1 (VCAM-1) and fibronectin, whereas inhibition of MEK/ERK by U0126 had no effect.	U 0126	257-262	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	84-89
24970684-5	2014	Finally, the blockade of ERK pathway by U0126 abolishes the genotype-mediated different effects on gene expression and progesterone production (Mann-Whitney"s U-test; p &gt;= 0.005; n = 3).	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	25-28
24998254-12	2014	In mechanically stretched cardiomyocytes, CGP53353 (a PKCbetaI inhibitor) prevented ERK phosphorylation and autophagic responses, while U0126 (an ERK inhibitor) blocked autophagic responses.	U 0126	136-141	mitogen-activated protein kinase 1	Mus musculus	146-149
24823860-5	2014	Exposure to blocking antibodies against human beta1 integrin or alpha2beta1 integrin or the pharmacological inhibition of Src and ERK activity by PP1 and U0126, respectively, effectively reduced cell motility and raised cell stiffness.	U 0126	154-159	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	122-125
24823860-5	2014	Exposure to blocking antibodies against human beta1 integrin or alpha2beta1 integrin or the pharmacological inhibition of Src and ERK activity by PP1 and U0126, respectively, effectively reduced cell motility and raised cell stiffness.	U 0126	154-159	mitogen-activated protein kinase 1	Homo sapiens	130-133
25031361-12	2014	Both FSH- and EGF-induced upregulation were inhibited by U0126, an MAPK kinase inhibitor, indicating that FSH and EGF regulate NT expression via a MAPK-dependent pathway.	U 0126	57-62	follicle stimulating hormone beta	Mus musculus	5-8
25031361-12	2014	Both FSH- and EGF-induced upregulation were inhibited by U0126, an MAPK kinase inhibitor, indicating that FSH and EGF regulate NT expression via a MAPK-dependent pathway.	U 0126	57-62	epidermal growth factor	Mus musculus	14-17
25031361-12	2014	Both FSH- and EGF-induced upregulation were inhibited by U0126, an MAPK kinase inhibitor, indicating that FSH and EGF regulate NT expression via a MAPK-dependent pathway.	U 0126	57-62	follicle stimulating hormone beta	Mus musculus	106-109
25031361-12	2014	Both FSH- and EGF-induced upregulation were inhibited by U0126, an MAPK kinase inhibitor, indicating that FSH and EGF regulate NT expression via a MAPK-dependent pathway.	U 0126	57-62	epidermal growth factor	Mus musculus	114-117
25031361-12	2014	Both FSH- and EGF-induced upregulation were inhibited by U0126, an MAPK kinase inhibitor, indicating that FSH and EGF regulate NT expression via a MAPK-dependent pathway.	U 0126	57-62	neurotensin	Mus musculus	127-129
25026397-7	2014	Also, P7 rats were pretreated with 75 mug/kg dexmedetomidine alone, or given the ERK inhibitor U0126 before dexmedetomidine pretreatment, or pretreated with the p38 MAPK inhibitor SB203580 or JNK inhibitor SP600125 alone, and then exposed to 0.75% isoflurane for 6h.	U 0126	95-100	Eph receptor B1	Rattus norvegicus	81-84
24679950-7	2014	The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT.	U 0126	50-55	mitogen activated protein kinase 3	Rattus norvegicus	96-137
24679950-7	2014	The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT.	U 0126	50-55	mitogen activated protein kinase 3	Rattus norvegicus	263-267
24867259-7	2014	In addition, nutlin-3 stimulated phosphorylation of ELK1, which was prevented by all compounds that inhibited nutlin-3-induced ERK1/2 such as U0126, PFT-mu and TEMPO.	U 0126	142-147	ETS transcription factor ELK1	Homo sapiens	52-56
24488601-6	2014	Pharmacological inhibition of mitogen-activated protein kinase 1 (ERK1/2), CaMKII, and Trk (with U0126, KN93, or K252a, respectively) partially attenuated the stimulatory effect of DISS on phospho-CREB and BDNF expression; however, it was not inhibited by pharmacological inhibition of PKA or PI3K (with H89 and LY294002, respectively).	U 0126	97-102	mitogen-activated protein kinase 1	Homo sapiens	30-64
24488601-6	2014	Pharmacological inhibition of mitogen-activated protein kinase 1 (ERK1/2), CaMKII, and Trk (with U0126, KN93, or K252a, respectively) partially attenuated the stimulatory effect of DISS on phospho-CREB and BDNF expression; however, it was not inhibited by pharmacological inhibition of PKA or PI3K (with H89 and LY294002, respectively).	U 0126	97-102	mitogen-activated protein kinase 3	Homo sapiens	66-72
24488601-6	2014	Pharmacological inhibition of mitogen-activated protein kinase 1 (ERK1/2), CaMKII, and Trk (with U0126, KN93, or K252a, respectively) partially attenuated the stimulatory effect of DISS on phospho-CREB and BDNF expression; however, it was not inhibited by pharmacological inhibition of PKA or PI3K (with H89 and LY294002, respectively).	U 0126	97-102	neurotrophic receptor tyrosine kinase 1	Homo sapiens	87-90
24792035-5	2014	Similar results were observed when VSMC were pretreated with either U0126 or SB203580, which are selective inhibitors of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase, respectively, thus suggesting that these kinases are important for the induction of MMP-2 expression by PDGF-BB.	U 0126	68-73	mitogen activated protein kinase 14	Rattus norvegicus	163-199
24792035-5	2014	Similar results were observed when VSMC were pretreated with either U0126 or SB203580, which are selective inhibitors of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase, respectively, thus suggesting that these kinases are important for the induction of MMP-2 expression by PDGF-BB.	U 0126	68-73	matrix metallopeptidase 2	Rattus norvegicus	285-290
25013510-7	2014	Further investigation into the underlying mechanisms responsible for the migratory effects revealed that BANCR induced the epithelial-mesenchymal transition (EMT) through an MEK/extracellular signal-regulated kinase-dependent mechanism as treatment with the MEK inhibitor, U0126 decreased migration and reversed the EMT in the BANCR-overexpressed HCT116 cells.	U 0126	273-278	BRAF-activated non-protein coding RNA	Homo sapiens	105-110
25013510-7	2014	Further investigation into the underlying mechanisms responsible for the migratory effects revealed that BANCR induced the epithelial-mesenchymal transition (EMT) through an MEK/extracellular signal-regulated kinase-dependent mechanism as treatment with the MEK inhibitor, U0126 decreased migration and reversed the EMT in the BANCR-overexpressed HCT116 cells.	U 0126	273-278	mitogen-activated protein kinase kinase 7	Homo sapiens	174-177
25013510-7	2014	Further investigation into the underlying mechanisms responsible for the migratory effects revealed that BANCR induced the epithelial-mesenchymal transition (EMT) through an MEK/extracellular signal-regulated kinase-dependent mechanism as treatment with the MEK inhibitor, U0126 decreased migration and reversed the EMT in the BANCR-overexpressed HCT116 cells.	U 0126	273-278	BRAF-activated non-protein coding RNA	Homo sapiens	327-332
25108437-8	2014	Pretreatment of PMNs with U0126 mostly inhibited the anti-apoptosis effect of IL-17 at 5 mug/L on PMNs of TB patients and normal subjects.	U 0126	26-31	interleukin 17A	Homo sapiens	78-83
25324681-13	2014	Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398.	U 0126	78-83	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	11-16
25324681-13	2014	Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398.	U 0126	78-83	vascular endothelial growth factor A	Rattus norvegicus	28-32
25324681-13	2014	Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398.	U 0126	78-83	mitogen activated protein kinase 3	Rattus norvegicus	61-67
24858691-7	2014	Similar results were obtained with Sorafenib, a multi-kinase inhibitor and U0126, a MEK1 inhibitor.	U 0126	75-80	mitogen-activated protein kinase kinase 1	Homo sapiens	84-88
23995792-5	2014	The Ras-ERK pathway was responsible for the disruption of stress fibers because inhibition of MEK with UO126 or small interfering RNA (siRNA) against K-Ras or ERK1/2 resulted in restoration of stress fibers and focal adhesions.	U 0126	103-108	mitogen-activated protein kinase 1	Mus musculus	8-11
23995792-5	2014	The Ras-ERK pathway was responsible for the disruption of stress fibers because inhibition of MEK with UO126 or small interfering RNA (siRNA) against K-Ras or ERK1/2 resulted in restoration of stress fibers and focal adhesions.	U 0126	103-108	midkine	Mus musculus	94-97
24677149-5	2014	Furthermore, taurine induced activation of extracellular signal regulated kinase (ERK) and pretreatment with the ERK inhibitor U0126 abolished the taurine-induced osteogenesis of hMSCs.	U 0126	127-132	mitogen-activated protein kinase 1	Homo sapiens	43-80
24677149-5	2014	Furthermore, taurine induced activation of extracellular signal regulated kinase (ERK) and pretreatment with the ERK inhibitor U0126 abolished the taurine-induced osteogenesis of hMSCs.	U 0126	127-132	mitogen-activated protein kinase 1	Homo sapiens	113-116
24452839-10	2014	The MEK-specific inhibitor U0126 could antagonize the positive effect of IL-11 on cell growth.	U 0126	27-32	midkine	Mus musculus	4-7
24452839-10	2014	The MEK-specific inhibitor U0126 could antagonize the positive effect of IL-11 on cell growth.	U 0126	27-32	interleukin 11	Mus musculus	73-78
24950815-3	2014	To determine the beneficial effect of SST on lipopolysaccharide (LPS)-induced damage of the tight junction (TJ) and its mechanisms, Caco2 cells pretreated with SST (1nM) or MEK inhibitor U0126 (10muM) were exposed to LPS.	U 0126	187-192	mitogen-activated protein kinase kinase 7	Homo sapiens	173-176
24668750-5	2014	SDF-1alpha/CXCR-4-mediated CXCR7 translocation was significantly reduced by inhibitors of ERK1/2-(U0126-10 muM) and cyclophilinA (CyPA)-(NIM811-10 muM) by 28 and 46%, respectively.	U 0126	98-103	chemokine (C-X-C motif) receptor 4	Mus musculus	11-17
24668750-5	2014	SDF-1alpha/CXCR-4-mediated CXCR7 translocation was significantly reduced by inhibitors of ERK1/2-(U0126-10 muM) and cyclophilinA (CyPA)-(NIM811-10 muM) by 28 and 46%, respectively.	U 0126	98-103	atypical chemokine receptor 3	Mus musculus	27-32
24668750-5	2014	SDF-1alpha/CXCR-4-mediated CXCR7 translocation was significantly reduced by inhibitors of ERK1/2-(U0126-10 muM) and cyclophilinA (CyPA)-(NIM811-10 muM) by 28 and 46%, respectively.	U 0126	98-103	mitogen-activated protein kinase 3	Mus musculus	90-96
24789460-5	2014	The mechanisms were involved in upregulating MMP-9 expression through increasing AP-1 transcriptional activity via ERK1/2 pathway; these effects were dose-dependently inhibited by silencing ERK1/2 or using U0126.	U 0126	206-211	matrix metallopeptidase 9	Homo sapiens	45-50
24789460-5	2014	The mechanisms were involved in upregulating MMP-9 expression through increasing AP-1 transcriptional activity via ERK1/2 pathway; these effects were dose-dependently inhibited by silencing ERK1/2 or using U0126.	U 0126	206-211	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	81-85
24789460-5	2014	The mechanisms were involved in upregulating MMP-9 expression through increasing AP-1 transcriptional activity via ERK1/2 pathway; these effects were dose-dependently inhibited by silencing ERK1/2 or using U0126.	U 0126	206-211	mitogen-activated protein kinase 3	Homo sapiens	115-121
24964901-6	2014	Additionally, CTX III similar to wortmannin (a PI3K inhibitor) and U0126 (an upstream kinase regulating ERK1/2 inhibitor) attenuated cell migration and invasion induced by HGF.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	104-110
24964901-6	2014	Additionally, CTX III similar to wortmannin (a PI3K inhibitor) and U0126 (an upstream kinase regulating ERK1/2 inhibitor) attenuated cell migration and invasion induced by HGF.	U 0126	67-72	hepatocyte growth factor	Homo sapiens	172-175
24532130-6	2014	We also found out that GLO1 is translocated into the nucleus to a higher extent in QRsP-11 compared to QR-32 cells, which can be reversed by using a MEK inhibitor (U0126).	U 0126	164-169	glyoxalase 1	Mus musculus	23-27
24532130-6	2014	We also found out that GLO1 is translocated into the nucleus to a higher extent in QRsP-11 compared to QR-32 cells, which can be reversed by using a MEK inhibitor (U0126).	U 0126	164-169	midkine	Mus musculus	149-152
24810969-9	2014	A MEK inhibitor (U0126) prevented the differentiation of OPCs into O4-positive cells, while a p38MAPK inhibitor (PD169316) blocked progression into O4-positive and into GC-positive stages of differentiation.	U 0126	17-22	mitogen-activated protein kinase kinase 7	Homo sapiens	2-5
24866134-8	2014	Pretreatment with U0126, an inhibitor of extracellular signal-regulated kinases 1/2 phosphorylation, abolished the inhibition of elastin gene transcription by A23187.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	41-83
24866134-8	2014	Pretreatment with U0126, an inhibitor of extracellular signal-regulated kinases 1/2 phosphorylation, abolished the inhibition of elastin gene transcription by A23187.	U 0126	18-23	elastin	Rattus norvegicus	129-136
24866134-9	2014	In vitro, U0126 increased elastin synthesis and in vivo, 24 hours after an intravenous administration, elastin gene transcription and elastin mRNA levels were increased in the rat aorta.	U 0126	10-15	elastin	Rattus norvegicus	26-33
24866134-9	2014	In vitro, U0126 increased elastin synthesis and in vivo, 24 hours after an intravenous administration, elastin gene transcription and elastin mRNA levels were increased in the rat aorta.	U 0126	10-15	elastin	Rattus norvegicus	103-110
24866134-9	2014	In vitro, U0126 increased elastin synthesis and in vivo, 24 hours after an intravenous administration, elastin gene transcription and elastin mRNA levels were increased in the rat aorta.	U 0126	10-15	elastin	Rattus norvegicus	103-110
24866134-10	2014	A chronic treatment, diffusing U0126 for 10 weeks, increased aortic elastin content without changing cell number and collagen content.	U 0126	31-36	elastin	Rattus norvegicus	68-75
24971930-7	2014	ERK phosphorylation in the testis was significantly inhibited by Go6983 and U0126, inhibitors of protein kinase C (PKC) and mitogen-associated protein kinase kinase 1/2 (MEK), respectively, but not by H-89, a protein kinase A (PKA) inhibitor, indicating that ERK was activated in the testis via PKC and MEK but not via PKA.	U 0126	76-81	extracellular regulated MAP kinase	Bombyx mori	0-3
24971930-7	2014	ERK phosphorylation in the testis was significantly inhibited by Go6983 and U0126, inhibitors of protein kinase C (PKC) and mitogen-associated protein kinase kinase 1/2 (MEK), respectively, but not by H-89, a protein kinase A (PKA) inhibitor, indicating that ERK was activated in the testis via PKC and MEK but not via PKA.	U 0126	76-81	MAP kinse-ERK kinase	Bombyx mori	124-168
24971930-7	2014	ERK phosphorylation in the testis was significantly inhibited by Go6983 and U0126, inhibitors of protein kinase C (PKC) and mitogen-associated protein kinase kinase 1/2 (MEK), respectively, but not by H-89, a protein kinase A (PKA) inhibitor, indicating that ERK was activated in the testis via PKC and MEK but not via PKA.	U 0126	76-81	extracellular regulated MAP kinase	Bombyx mori	259-262
24971930-7	2014	ERK phosphorylation in the testis was significantly inhibited by Go6983 and U0126, inhibitors of protein kinase C (PKC) and mitogen-associated protein kinase kinase 1/2 (MEK), respectively, but not by H-89, a protein kinase A (PKA) inhibitor, indicating that ERK was activated in the testis via PKC and MEK but not via PKA.	U 0126	76-81	MAP kinse-ERK kinase	Bombyx mori	303-306
24971930-8	2014	The inhibition of ERK phosphorylation by Go6983 or U0126 was reduced by 20-30% by d-serine.	U 0126	51-56	extracellular regulated MAP kinase	Bombyx mori	18-21
24933421-8	2014	The ERK1/2 activity-specific inhibitor U0126 remarkably blocked 17beta-E2-induced TFII-I phosphorylation and Grp78 expression in response to ER stress.	U 0126	39-44	mitogen-activated protein kinase 3	Mus musculus	4-10
24933421-8	2014	The ERK1/2 activity-specific inhibitor U0126 remarkably blocked 17beta-E2-induced TFII-I phosphorylation and Grp78 expression in response to ER stress.	U 0126	39-44	general transcription factor II I	Mus musculus	82-88
24933421-8	2014	The ERK1/2 activity-specific inhibitor U0126 remarkably blocked 17beta-E2-induced TFII-I phosphorylation and Grp78 expression in response to ER stress.	U 0126	39-44	heat shock protein 5	Mus musculus	109-114
24769160-10	2014	The addition of the PKA inhibitor KT5720, the MAP kinase inhibitor U0126, and the PI3 kinase inhibitor LY294002 abrogated the GPR3-mediated antiapoptotic effect in a potassium-deprivation model of apoptosis, whereas the PKC inhibitor Go6976 did not affect the antiapoptotic function of GPR3.	U 0126	67-72	G-protein coupled receptor 3	Mus musculus	126-130
24726849-7	2014	The use of U0126, a specific inhibitor of MEK1/2, proved that H2O2-induced decrease of occludin in EA.hy926 cells was likely associated with activation of ERK1/2, which indicated that the regulation of farrerol on occludin expression in H2O2-induced EA.hy926 cells was likely related to the modulation of ERK1/2 activation.	U 0126	11-16	mitogen-activated protein kinase kinase 1	Homo sapiens	42-48
24726849-7	2014	The use of U0126, a specific inhibitor of MEK1/2, proved that H2O2-induced decrease of occludin in EA.hy926 cells was likely associated with activation of ERK1/2, which indicated that the regulation of farrerol on occludin expression in H2O2-induced EA.hy926 cells was likely related to the modulation of ERK1/2 activation.	U 0126	11-16	occludin	Homo sapiens	87-95
24726849-7	2014	The use of U0126, a specific inhibitor of MEK1/2, proved that H2O2-induced decrease of occludin in EA.hy926 cells was likely associated with activation of ERK1/2, which indicated that the regulation of farrerol on occludin expression in H2O2-induced EA.hy926 cells was likely related to the modulation of ERK1/2 activation.	U 0126	11-16	mitogen-activated protein kinase 3	Homo sapiens	155-161
24859929-9	2014	Importantly, pharmacological inhibition of PI3K/AKT (Wortmannin) and ERK1/2 (U0126) pathways abrogated the melusin protective effect.	U 0126	77-82	mitogen-activated protein kinase 3	Mus musculus	69-75
24859929-9	2014	Importantly, pharmacological inhibition of PI3K/AKT (Wortmannin) and ERK1/2 (U0126) pathways abrogated the melusin protective effect.	U 0126	77-82	integrin beta 1 binding protein 2	Mus musculus	107-114
24925646-9	2014	The ERK1/2 inhibitor U0126 inhibited Egr-1 and IL-8 expression as well as IL-8 release, but the JNK and p38 inhibitors did not have the inhibitory effects.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	4-10
24925646-9	2014	The ERK1/2 inhibitor U0126 inhibited Egr-1 and IL-8 expression as well as IL-8 release, but the JNK and p38 inhibitors did not have the inhibitory effects.	U 0126	21-26	early growth response 1	Homo sapiens	37-42
24925646-9	2014	The ERK1/2 inhibitor U0126 inhibited Egr-1 and IL-8 expression as well as IL-8 release, but the JNK and p38 inhibitors did not have the inhibitory effects.	U 0126	21-26	C-X-C motif chemokine ligand 8	Homo sapiens	47-51
24925646-9	2014	The ERK1/2 inhibitor U0126 inhibited Egr-1 and IL-8 expression as well as IL-8 release, but the JNK and p38 inhibitors did not have the inhibitory effects.	U 0126	21-26	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	23-64
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	U 0126	66-71	bone gamma-carboxyglutamate protein	Homo sapiens	199-202
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	U 0126	66-71	dentin sialophosphoprotein	Homo sapiens	204-208
24687528-8	2014	Inhibition of MAPK3/1 activation with MEK inhibitor U0126 only partially blocked LIF-induced nuclear maturation, although it attenuated oocyte cytoplasmic maturation.	U 0126	52-57	mitogen-activated protein kinase 3	Bos taurus	14-19
24725889-7	2014	Further treatment with TLR9 ligand CpG-ODN, TLR9 inhibitor chloroquine (CQ) or ERK1/2 inhibitor U0126 demonstrated that TLR9-ERK1/2 pathway was involved in the NSCs-induced microglial activation.	U 0126	96-101	mitogen-activated protein kinase 3	Mus musculus	79-85
24725889-7	2014	Further treatment with TLR9 ligand CpG-ODN, TLR9 inhibitor chloroquine (CQ) or ERK1/2 inhibitor U0126 demonstrated that TLR9-ERK1/2 pathway was involved in the NSCs-induced microglial activation.	U 0126	96-101	mitogen-activated protein kinase 3	Mus musculus	125-131
24687528-8	2014	Inhibition of MAPK3/1 activation with MEK inhibitor U0126 only partially blocked LIF-induced nuclear maturation, although it attenuated oocyte cytoplasmic maturation.	U 0126	52-57	LIF interleukin 6 family cytokine	Bos taurus	81-84
24793006-8	2014	Inhibition of ERK activation by U0126 blocks the effect of MBG on C/EBPalpha expression and on rosiglitazone-induced adipogenesis.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	14-17
24736838-8	2014	Stimulation of the RAS/RAF/mitogen activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway using growth factors enhanced OA1 expression and melanoma cell migration, whereas inhibition of this pathway using U0126 was observed to markedly decrease OA1 expression and the number of migrated cells.	U 0126	240-245	zinc fingers and homeoboxes 2	Homo sapiens	23-26
24807674-7	2014	Furthermore, the downregulation of Gal-3 by siRNA resulted in significantly decreased activity of the MEK/ERK signaling pathway, and the treatment of HepG2 cells with MEK/ERK inhibitor U0126 significantly reduced the mRNA and protein levels of uPAR.	U 0126	185-190	galectin 3	Homo sapiens	35-40
24807674-7	2014	Furthermore, the downregulation of Gal-3 by siRNA resulted in significantly decreased activity of the MEK/ERK signaling pathway, and the treatment of HepG2 cells with MEK/ERK inhibitor U0126 significantly reduced the mRNA and protein levels of uPAR.	U 0126	185-190	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
24807674-7	2014	Furthermore, the downregulation of Gal-3 by siRNA resulted in significantly decreased activity of the MEK/ERK signaling pathway, and the treatment of HepG2 cells with MEK/ERK inhibitor U0126 significantly reduced the mRNA and protein levels of uPAR.	U 0126	185-190	mitogen-activated protein kinase 1	Homo sapiens	106-109
24807674-7	2014	Furthermore, the downregulation of Gal-3 by siRNA resulted in significantly decreased activity of the MEK/ERK signaling pathway, and the treatment of HepG2 cells with MEK/ERK inhibitor U0126 significantly reduced the mRNA and protein levels of uPAR.	U 0126	185-190	mitogen-activated protein kinase kinase 7	Homo sapiens	167-170
24807674-7	2014	Furthermore, the downregulation of Gal-3 by siRNA resulted in significantly decreased activity of the MEK/ERK signaling pathway, and the treatment of HepG2 cells with MEK/ERK inhibitor U0126 significantly reduced the mRNA and protein levels of uPAR.	U 0126	185-190	mitogen-activated protein kinase 1	Homo sapiens	171-174
24807674-7	2014	Furthermore, the downregulation of Gal-3 by siRNA resulted in significantly decreased activity of the MEK/ERK signaling pathway, and the treatment of HepG2 cells with MEK/ERK inhibitor U0126 significantly reduced the mRNA and protein levels of uPAR.	U 0126	185-190	plasminogen activator, urokinase receptor	Homo sapiens	244-248
25001936-10	2014	CONCLUSION: Wortmannin and U0126 can suppress the promoting effect of insulin on the differentiation of skeletal myoblasts into myocytes in rats and decrease the formation of myotubes and the expression of myogenin.	U 0126	27-32	myogenin	Rattus norvegicus	206-214
24657783-8	2014	This was corroborated by testing the effect produced on TNF-alpha promoter by the treatment with Raf/MEK/ERK (U0126), NF-kB (Bay-11-7082) and PI3K (Ly294-002) cell signaling inhibitors.	U 0126	110-115	tumor necrosis factor	Homo sapiens	56-65
24657783-8	2014	This was corroborated by testing the effect produced on TNF-alpha promoter by the treatment with Raf/MEK/ERK (U0126), NF-kB (Bay-11-7082) and PI3K (Ly294-002) cell signaling inhibitors.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	105-108
24657783-9	2014	Treatment with U0126 and Bay-117082 reduced the activity of TNF-alpha promoter mediated by NEP (41.5+-3.2, 70% inhibition; and 80.6+-7.4, 35% inhibition, respectively) compared to mock-treated control.	U 0126	15-20	tumor necrosis factor	Homo sapiens	60-69
24657783-9	2014	Treatment with U0126 and Bay-117082 reduced the activity of TNF-alpha promoter mediated by NEP (41.5+-3.2, 70% inhibition; and 80.6+-7.4, 35% inhibition, respectively) compared to mock-treated control.	U 0126	15-20	membrane metalloendopeptidase	Homo sapiens	91-94
24605772-6	2014	Pretreatment with U0126 or Bay11-7082, respectively, could decrease IL-1beta, IL-6, and TNF-alpha productions induced by OM85-BV.	U 0126	18-23	interleukin 1 beta	Mus musculus	68-76
24605772-6	2014	Pretreatment with U0126 or Bay11-7082, respectively, could decrease IL-1beta, IL-6, and TNF-alpha productions induced by OM85-BV.	U 0126	18-23	interleukin 6	Mus musculus	78-82
24605772-6	2014	Pretreatment with U0126 or Bay11-7082, respectively, could decrease IL-1beta, IL-6, and TNF-alpha productions induced by OM85-BV.	U 0126	18-23	tumor necrosis factor	Mus musculus	88-97
24967732-6	2014	Moreover, combination treatment of BANCR knockdown and suppression ERK1/2 or JNK (induced by specific inhibitors U0126 or SP600125 respectively) produced synergistic inhibitory effects in vitro.	U 0126	113-118	BRAF-activated non-protein coding RNA	Homo sapiens	35-40
24967732-6	2014	Moreover, combination treatment of BANCR knockdown and suppression ERK1/2 or JNK (induced by specific inhibitors U0126 or SP600125 respectively) produced synergistic inhibitory effects in vitro.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	67-73
24967732-6	2014	Moreover, combination treatment of BANCR knockdown and suppression ERK1/2 or JNK (induced by specific inhibitors U0126 or SP600125 respectively) produced synergistic inhibitory effects in vitro.	U 0126	113-118	mitogen-activated protein kinase 8	Homo sapiens	77-80
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	U 0126	210-215	mitogen-activated protein kinase 1	Homo sapiens	52-55
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	U 0126	210-215	mitogen-activated protein kinase 8	Homo sapiens	86-89
24793006-8	2014	Inhibition of ERK activation by U0126 blocks the effect of MBG on C/EBPalpha expression and on rosiglitazone-induced adipogenesis.	U 0126	32-37	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	66-76
24914776-6	2014	Activation of ERK1/2 by H2O2 was suppressed by cabergoline, and an ERK signaling pathway inhibitor, U0126, similarly protected cortical neurons from cell death.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	14-20
24914776-6	2014	Activation of ERK1/2 by H2O2 was suppressed by cabergoline, and an ERK signaling pathway inhibitor, U0126, similarly protected cortical neurons from cell death.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	14-17
24610348-5	2014	In addition, DHF induced the activation of extracellular signal-regulated kinase (ERK), while U0126 (a specific pharmacological inhibitor of ERK kinase) abrogated DHF-activated Nrf2 and HO-1 expression.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	141-144
24405580-6	2014	MEK/ERK inhibitor U0126 and SCL/TAL1 down-regulation showed similar inhibitory effects on erythroid, myeloid, and megakaryoid differentiation.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
24405580-6	2014	MEK/ERK inhibitor U0126 and SCL/TAL1 down-regulation showed similar inhibitory effects on erythroid, myeloid, and megakaryoid differentiation.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
24405580-8	2014	MEK/ERK inhibitor U0126 could not affect the expression of SCL/TAL1 mRNA or protein.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
24610348-5	2014	In addition, DHF induced the activation of extracellular signal-regulated kinase (ERK), while U0126 (a specific pharmacological inhibitor of ERK kinase) abrogated DHF-activated Nrf2 and HO-1 expression.	U 0126	94-99	NFE2 like bZIP transcription factor 2	Homo sapiens	177-181
24610348-5	2014	In addition, DHF induced the activation of extracellular signal-regulated kinase (ERK), while U0126 (a specific pharmacological inhibitor of ERK kinase) abrogated DHF-activated Nrf2 and HO-1 expression.	U 0126	94-99	heme oxygenase 1	Homo sapiens	186-190
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	U 0126	199-204	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	102-105
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	U 0126	199-204	mitogen-activated protein kinase kinase 7	Homo sapiens	184-187
24676456-12	2014	The combination of an mTOR inhibitor (e.g., rapamycin) and an MEK inhibitor (e.g., U0126) may offer effective treatment for MFH, as this combination effectively activates apoptotic pathways.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
24676782-6	2014	MEK/ERK inhibition by U0126 reverted the transformed phenotype and significantly enhanced the radiosensitivity of T98G, U87MG, U138MG cells but not of the U251MG cell line under hypoxic conditions.	U 0126	22-27	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
24676782-6	2014	MEK/ERK inhibition by U0126 reverted the transformed phenotype and significantly enhanced the radiosensitivity of T98G, U87MG, U138MG cells but not of the U251MG cell line under hypoxic conditions.	U 0126	22-27	mitogen-activated protein kinase 1	Homo sapiens	4-7
24676782-7	2014	U0126 and ERK silencing by siRNA reduced the levels of DNA protein kinase catalytic subunit (DNA-PKcs), Ku70 and K80 proteins and clearly reduced HIF-1alpha activity and protein expression.	U 0126	0-5	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	55-91
24676782-7	2014	U0126 and ERK silencing by siRNA reduced the levels of DNA protein kinase catalytic subunit (DNA-PKcs), Ku70 and K80 proteins and clearly reduced HIF-1alpha activity and protein expression.	U 0126	0-5	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	93-101
24714800-5	2014	In addition, inactivation of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor, U0126, completely prevented the TGFbeta2-induced upregulation of alpha-SMA, collagen type I, collagen type IV and fibronectin.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	29-35
23677851-11	2014	In particular, NP-induced cell death was significantly suppressed by U0126, a specific inhibitor of ERK.	U 0126	69-74	mitogen-activated protein kinase 1	Mus musculus	100-103
24714800-5	2014	In addition, inactivation of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor, U0126, completely prevented the TGFbeta2-induced upregulation of alpha-SMA, collagen type I, collagen type IV and fibronectin.	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
24714800-5	2014	In addition, inactivation of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor, U0126, completely prevented the TGFbeta2-induced upregulation of alpha-SMA, collagen type I, collagen type IV and fibronectin.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	66-72
24714800-5	2014	In addition, inactivation of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor, U0126, completely prevented the TGFbeta2-induced upregulation of alpha-SMA, collagen type I, collagen type IV and fibronectin.	U 0126	84-89	transforming growth factor beta 2	Homo sapiens	116-124
24714800-5	2014	In addition, inactivation of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor, U0126, completely prevented the TGFbeta2-induced upregulation of alpha-SMA, collagen type I, collagen type IV and fibronectin.	U 0126	84-89	fibronectin 1	Homo sapiens	149-209
24510654-6	2014	The ERK inhibitor U0126 (1 nmol/eye) almost completely abolished rapamycin"s inhibition of NMDA-induced apoptosis.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	4-7
24792379-8	2014	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) significantly attenuated TSLP-induced MUC5B mRNA expression.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	7-13
24760148-7	2014	The effect of A1AT on angptl4 expression was significantly diminished in cells pretreated with a specific inhibitor of ERK1/2 activation (UO126), irreversible and selective PPARgamma antagonist (GW9662), or genistein, a ligand for PPARgamma.	U 0126	138-143	angiopoietin like 4	Homo sapiens	22-29
24760148-7	2014	The effect of A1AT on angptl4 expression was significantly diminished in cells pretreated with a specific inhibitor of ERK1/2 activation (UO126), irreversible and selective PPARgamma antagonist (GW9662), or genistein, a ligand for PPARgamma.	U 0126	138-143	mitogen-activated protein kinase 3	Homo sapiens	119-125
24682241-6	2014	The effect of the extracellular signal-regulated kinase (ERK) inhibitor U0126 was studied by adding U0126 (5 microg/microl, 4 microl) into the culture medium during transient ischemia; as a control, we used treatment of cells with 50 microM of resveratrol.	U 0126	72-77	mitogen-activated protein kinase 1	Mus musculus	18-55
24682241-6	2014	The effect of the extracellular signal-regulated kinase (ERK) inhibitor U0126 was studied by adding U0126 (5 microg/microl, 4 microl) into the culture medium during transient ischemia; as a control, we used treatment of cells with 50 microM of resveratrol.	U 0126	72-77	mitogen-activated protein kinase 1	Mus musculus	57-60
24682241-6	2014	The effect of the extracellular signal-regulated kinase (ERK) inhibitor U0126 was studied by adding U0126 (5 microg/microl, 4 microl) into the culture medium during transient ischemia; as a control, we used treatment of cells with 50 microM of resveratrol.	U 0126	100-105	mitogen-activated protein kinase 1	Mus musculus	57-60
24522860-6	2014	M3 mAChR-mediated IL-8 expression was almost completely inhibited by the NF-kappaB inhibitor BAY11-7082 and, to a lesser extent, by U0126, SB203580, and SP600125, which are inhibitors for ERK1/2, p38, and JNK, respectively.	U 0126	132-137	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
24727856-12	2014	The ERK inhibitor U0126 resulted in lower BUN and serum creatinine, suggesting a mechanistic role of ERK in AKI.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	4-7
24727856-12	2014	The ERK inhibitor U0126 resulted in lower BUN and serum creatinine, suggesting a mechanistic role of ERK in AKI.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	101-104
24682241-13	2014	Treatment with U0126 inhibited MMP-9 and Bax expression and caspase-3 activation, while it further promoted the expression of the anti-apoptotic molecule Bcl-2, suggesting that resveratrol inhibits MMP-9 expression and cell apoptosis by attenuating the activation of ERK1/2.	U 0126	15-20	matrix metallopeptidase 9	Mus musculus	31-36
24682241-13	2014	Treatment with U0126 inhibited MMP-9 and Bax expression and caspase-3 activation, while it further promoted the expression of the anti-apoptotic molecule Bcl-2, suggesting that resveratrol inhibits MMP-9 expression and cell apoptosis by attenuating the activation of ERK1/2.	U 0126	15-20	BCL2-associated X protein	Mus musculus	41-44
24682241-13	2014	Treatment with U0126 inhibited MMP-9 and Bax expression and caspase-3 activation, while it further promoted the expression of the anti-apoptotic molecule Bcl-2, suggesting that resveratrol inhibits MMP-9 expression and cell apoptosis by attenuating the activation of ERK1/2.	U 0126	15-20	caspase 3	Mus musculus	60-69
24682241-13	2014	Treatment with U0126 inhibited MMP-9 and Bax expression and caspase-3 activation, while it further promoted the expression of the anti-apoptotic molecule Bcl-2, suggesting that resveratrol inhibits MMP-9 expression and cell apoptosis by attenuating the activation of ERK1/2.	U 0126	15-20	B cell leukemia/lymphoma 2	Mus musculus	154-159
24682241-13	2014	Treatment with U0126 inhibited MMP-9 and Bax expression and caspase-3 activation, while it further promoted the expression of the anti-apoptotic molecule Bcl-2, suggesting that resveratrol inhibits MMP-9 expression and cell apoptosis by attenuating the activation of ERK1/2.	U 0126	15-20	matrix metallopeptidase 9	Mus musculus	198-203
24682241-13	2014	Treatment with U0126 inhibited MMP-9 and Bax expression and caspase-3 activation, while it further promoted the expression of the anti-apoptotic molecule Bcl-2, suggesting that resveratrol inhibits MMP-9 expression and cell apoptosis by attenuating the activation of ERK1/2.	U 0126	15-20	mitogen-activated protein kinase 3	Mus musculus	267-273
24974583-11	2014	Treatment of B16F10 cells with U0126, an ERK inhibitor, or SB203580, a p38 inhibitor, suppressed the migration and invasion abilities of B16F10 cells.	U 0126	31-36	mitogen-activated protein kinase 1	Mus musculus	41-44
24792379-8	2014	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) significantly attenuated TSLP-induced MUC5B mRNA expression.	U 0126	0-5	thymic stromal lymphopoietin	Homo sapiens	89-93
24792379-8	2014	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) significantly attenuated TSLP-induced MUC5B mRNA expression.	U 0126	0-5	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	102-107
24792379-10	2014	In the primary cultures of normal nasal epithelial cells, TSLP significantly increased MUC5B mRNA expression, which was significantly attenuated after pretreatment with U0126 and SB203580.	U 0126	169-174	thymic stromal lymphopoietin	Homo sapiens	58-62
24792379-10	2014	In the primary cultures of normal nasal epithelial cells, TSLP significantly increased MUC5B mRNA expression, which was significantly attenuated after pretreatment with U0126 and SB203580.	U 0126	169-174	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	87-92
23770856-8	2014	Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAF(V600E) melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAF(V600E) or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis.	U 0126	266-271	MLX interacting protein	Homo sapiens	18-21
24613724-11	2014	In vivo inhibition of ERK with U0126 blocked the effect of STX and restored clonidine antinociception.	U 0126	31-36	Eph receptor B1	Rattus norvegicus	22-25
24613724-11	2014	In vivo inhibition of ERK with U0126 blocked the effect of STX and restored clonidine antinociception.	U 0126	31-36	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Rattus norvegicus	59-62
23770856-8	2014	Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAF(V600E) melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAF(V600E) or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis.	U 0126	266-271	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
24788939-5	2014	Meanwhile, blockade of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor U0126 strongly prevented TGFbeta2-induced the downregulation of P-cadherin, and the upregulation of alpha-SMA, collagen type IV, N-cadherin and fibronectin in RPE cells.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	23-29
24360976-5	2014	Moreover, NF-kappaB inhibitor (BAY 11-7028) and ERK inhibitor (U0126) also mimicked the inhibitory effects of honokiol in TNF-alpha-treated RASMCs.	U 0126	63-68	Eph receptor B1	Rattus norvegicus	48-51
24360976-5	2014	Moreover, NF-kappaB inhibitor (BAY 11-7028) and ERK inhibitor (U0126) also mimicked the inhibitory effects of honokiol in TNF-alpha-treated RASMCs.	U 0126	63-68	tumor necrosis factor	Rattus norvegicus	122-131
24631630-3	2014	When PDLSCs were induced to differentiate to SCs, the cells were treated with U0126, an Erk1/2 pathway specific inhibitor, and its potential effect on SC differentiation was appraised using Western-blotting, immunostaining, and reverse transcriptase PCR.	U 0126	78-83	mitogen-activated protein kinase 1	Canis lupus familiaris	88-94
25050009-6	2014	U0126, an MAPK kinase inhibitor, prevented the mRNA and protein expressions of ZO-1, occludin, claudin-1 increase induced by GLP-2 (p&lt;0.05).	U 0126	0-5	zonula occludens 1	Sus scrofa	79-83
25050009-6	2014	U0126, an MAPK kinase inhibitor, prevented the mRNA and protein expressions of ZO-1, occludin, claudin-1 increase induced by GLP-2 (p&lt;0.05).	U 0126	0-5	occludin	Sus scrofa	85-93
25050009-6	2014	U0126, an MAPK kinase inhibitor, prevented the mRNA and protein expressions of ZO-1, occludin, claudin-1 increase induced by GLP-2 (p&lt;0.05).	U 0126	0-5	claudin 1	Sus scrofa	95-104
24506284-3	2014	KEY RESULTS: AG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR1 /PAR2 agonists, EGF and angiotensin-II, but not by PGF2alpha , the COX-produced metabolites of arachidonate and KCl.	U 0126	93-98	coagulation factor II thrombin receptor	Homo sapiens	134-138
24506284-3	2014	KEY RESULTS: AG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR1 /PAR2 agonists, EGF and angiotensin-II, but not by PGF2alpha , the COX-produced metabolites of arachidonate and KCl.	U 0126	93-98	F2R like trypsin receptor 1	Homo sapiens	140-144
24506284-3	2014	KEY RESULTS: AG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR1 /PAR2 agonists, EGF and angiotensin-II, but not by PGF2alpha , the COX-produced metabolites of arachidonate and KCl.	U 0126	93-98	epidermal growth factor	Homo sapiens	155-158
24506284-3	2014	KEY RESULTS: AG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR1 /PAR2 agonists, EGF and angiotensin-II, but not by PGF2alpha , the COX-produced metabolites of arachidonate and KCl.	U 0126	93-98	angiotensinogen	Homo sapiens	163-177
24532149-6	2014	Moreover, U0126, a MEK inhibitor, rescued the lung phenotype and vascularization by regulation of ERK signaling.	U 0126	10-15	midkine	Mus musculus	19-22
24458360-7	2014	Treatment of obese mice with the ERK inhibitor U0126 rescued Baf60c and Deptor expression in skeletal muscle and lowered blood glucose.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	33-36
24578384-15	2014	Both N-acetyl-l-cysteine and U0126 significantly inhibited CTRP3-induced upregulation of Runx2 and calcified nodule formation.	U 0126	29-34	RUNX family transcription factor 2	Rattus norvegicus	89-94
24379355-7	2014	The effect of insulin on hepcidin disappeared when the signal transducer and activator of transcription 3 pathway was blocked and could be partially inhibited by U0126.	U 0126	162-167	insulin	Homo sapiens	14-21
24379355-7	2014	The effect of insulin on hepcidin disappeared when the signal transducer and activator of transcription 3 pathway was blocked and could be partially inhibited by U0126.	U 0126	162-167	hepcidin antimicrobial peptide	Rattus norvegicus	25-33
24599349-9	2014	Interestingly, the Erk pathway inhibitor U0126, but neither PI3K-Akt inhibitor LY294002 nor p38 inhibitor SB203580, mimicked the inhibitory action of RSV on glutamate-induced tPA up-regulation.	U 0126	41-46	Eph receptor B1	Rattus norvegicus	19-22
24811302-7	2014	AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition.	U 0126	117-122	mitogen activated protein kinase 3	Rattus norvegicus	15-21
24811302-7	2014	AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition.	U 0126	117-122	mitogen-activated protein kinase 8	Rattus norvegicus	23-26
24811302-7	2014	AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition.	U 0126	117-122	mitogen activated protein kinase 14	Rattus norvegicus	32-35
24331979-4	2014	Our results showed that the treatments of SB203580 (the inhibitor of p38) and U0126 (the inhibitor of ERK1/2) suppressed the adipogenesis induced by differentiation medium, and the treatments of PF573228 (a specific inhibitor of FAK), Y27632 (a specific inhibitor of RhoA/ROCK) and cytochalasin D (an inhibitor of cytoskeletal organization) promoted the adipogenesis.	U 0126	78-83	mitogen-activated protein kinase 3	Homo sapiens	102-108
24331979-4	2014	Our results showed that the treatments of SB203580 (the inhibitor of p38) and U0126 (the inhibitor of ERK1/2) suppressed the adipogenesis induced by differentiation medium, and the treatments of PF573228 (a specific inhibitor of FAK), Y27632 (a specific inhibitor of RhoA/ROCK) and cytochalasin D (an inhibitor of cytoskeletal organization) promoted the adipogenesis.	U 0126	78-83	protein tyrosine kinase 2	Homo sapiens	229-232
24331979-4	2014	Our results showed that the treatments of SB203580 (the inhibitor of p38) and U0126 (the inhibitor of ERK1/2) suppressed the adipogenesis induced by differentiation medium, and the treatments of PF573228 (a specific inhibitor of FAK), Y27632 (a specific inhibitor of RhoA/ROCK) and cytochalasin D (an inhibitor of cytoskeletal organization) promoted the adipogenesis.	U 0126	78-83	ras homolog family member A	Homo sapiens	267-271
24331979-6	2014	Moreover, the treatments of PF573228, Y27632 and cytochalasin D promoted p38 and ERK1/2 phosphorylations, and the treatments of U0126 and SB203580 decreased p38 and ERK1/2 phosphorylations, respectively.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	157-160
24331979-6	2014	Moreover, the treatments of PF573228, Y27632 and cytochalasin D promoted p38 and ERK1/2 phosphorylations, and the treatments of U0126 and SB203580 decreased p38 and ERK1/2 phosphorylations, respectively.	U 0126	128-133	mitogen-activated protein kinase 3	Homo sapiens	165-171
24280725-6	2014	The restoration of the downregulated expression levels of Krt1 and Krt10 induced by IL-4 with the MEK (mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase) inhibitor U0126 indicated the involvement of the p44/42 MAPK signaling pathway in the attenuated expression.	U 0126	199-204	keratin 1	Homo sapiens	58-62
24280725-6	2014	The restoration of the downregulated expression levels of Krt1 and Krt10 induced by IL-4 with the MEK (mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase) inhibitor U0126 indicated the involvement of the p44/42 MAPK signaling pathway in the attenuated expression.	U 0126	199-204	keratin 10	Homo sapiens	67-72
24280725-6	2014	The restoration of the downregulated expression levels of Krt1 and Krt10 induced by IL-4 with the MEK (mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase) inhibitor U0126 indicated the involvement of the p44/42 MAPK signaling pathway in the attenuated expression.	U 0126	199-204	interleukin 4	Homo sapiens	84-88
24280725-6	2014	The restoration of the downregulated expression levels of Krt1 and Krt10 induced by IL-4 with the MEK (mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase) inhibitor U0126 indicated the involvement of the p44/42 MAPK signaling pathway in the attenuated expression.	U 0126	199-204	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
24280725-6	2014	The restoration of the downregulated expression levels of Krt1 and Krt10 induced by IL-4 with the MEK (mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase) inhibitor U0126 indicated the involvement of the p44/42 MAPK signaling pathway in the attenuated expression.	U 0126	199-204	general transcription factor IIH subunit 2	Homo sapiens	238-241
24337667-2	2014	It has previously been shown that blocking activation of extracellular signal-regulated kinase (ERK) with the MEK inhibitor U0126 mitigates brain damage in rodent models of ischemic stroke.	U 0126	124-129	mitogen-activated protein kinase 1	Mus musculus	57-94
24337667-2	2014	It has previously been shown that blocking activation of extracellular signal-regulated kinase (ERK) with the MEK inhibitor U0126 mitigates brain damage in rodent models of ischemic stroke.	U 0126	124-129	mitogen-activated protein kinase 1	Mus musculus	96-99
24337667-2	2014	It has previously been shown that blocking activation of extracellular signal-regulated kinase (ERK) with the MEK inhibitor U0126 mitigates brain damage in rodent models of ischemic stroke.	U 0126	124-129	midkine	Mus musculus	110-113
24524846-5	2014	Second, in mouse pain models using formalin and complete Freund adjuvant, we found that acupuncture attenuated the nociceptive behavior and the mechanical allodynia; these effects were blocked when ERK cascade was interrupted by the mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) inhibitor U0126 (.8 mug/muL).	U 0126	329-334	mitogen-activated protein kinase 1	Mus musculus	198-201
24524846-5	2014	Second, in mouse pain models using formalin and complete Freund adjuvant, we found that acupuncture attenuated the nociceptive behavior and the mechanical allodynia; these effects were blocked when ERK cascade was interrupted by the mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) inhibitor U0126 (.8 mug/muL).	U 0126	329-334	midkine	Mus musculus	233-272
24088960-8	2014	FGF23-induced ERK1/2 phosphorylation was inhibited by SU5402 (FGFR1 inhibitor) and U0126 (MEK inhibitor).	U 0126	83-88	fibroblast growth factor 23	Rattus norvegicus	0-5
24088960-8	2014	FGF23-induced ERK1/2 phosphorylation was inhibited by SU5402 (FGFR1 inhibitor) and U0126 (MEK inhibitor).	U 0126	83-88	mitogen activated protein kinase 3	Rattus norvegicus	14-20
24088960-9	2014	FGF23 enhanced phosphate-induced calcification in Klotho-overexpressing vascular smooth muscle cells and increased osteoblastic marker expression, which was inhibited by U0126.	U 0126	170-175	fibroblast growth factor 23	Rattus norvegicus	0-5
24434636-8	2014	By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	83-86
24434636-8	2014	By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine.	U 0126	35-40	mitogen-activated protein kinase 14	Mus musculus	88-91
24434636-8	2014	By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine.	U 0126	35-40	mitogen-activated protein kinase 8	Mus musculus	96-99
24626525-8	2014	Furthermore, inhibition of Mek activity with UO126 mimicked the effects of cholera toxin.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
24604010-4	2014	The ERK pathway was inhibited by the specific MEK inhibitor U0126.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	4-7
24604010-4	2014	The ERK pathway was inhibited by the specific MEK inhibitor U0126.	U 0126	60-65	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
24855825-0	2014	The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
24855825-0	2014	The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.	U 0126	21-26	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	94-97
24855825-0	2014	The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.	U 0126	21-26	EPH receptor B2	Homo sapiens	98-101
24855825-7	2014	However, U0126, a MEK1/2 inhibitor, could counteract the up-regulation induced by imatinib, and the combination of imatinib and U0126 could overcome the resistance to imatinib in K562R cells.	U 0126	9-14	mitogen-activated protein kinase kinase 1	Homo sapiens	18-24
24788754-9	2014	U0126, a specific inhibitor of ERK1/2, completely abolished the effect of PTK6 overexpression on cellular migration and invasion.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	31-37
24788754-9	2014	U0126, a specific inhibitor of ERK1/2, completely abolished the effect of PTK6 overexpression on cellular migration and invasion.	U 0126	0-5	protein tyrosine kinase 6	Homo sapiens	74-78
24941796-3	2014	METHODS: A panel of human melanoma cell lines and fresh melanoma isolates was assessed for their sensitivity to the MEK inhibitor U0126 and/or AKT inhibitor LY294002.	U 0126	130-135	mitogen-activated protein kinase kinase 7	Homo sapiens	116-119
24768830-4	2014	Isoprenaline beta-AR mediated vasodilation of aortic rings was potentiated by the ERK1/2 inhibitor, U0126, in the presence or absence of endothelium or L-NAME, whereas inhibition of p38 had no impact.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	82-88
24782617-6	2014	A MEK inhibitor (U0126) was used to determine whether IGF-1-induced collagen I expression was mediated by extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent mechanism.	U 0126	17-22	insulin-like growth factor 1	Rattus norvegicus	54-59
24582811-11	2014	Specific inhibition of ERK1/2 by U0126 or PI3K by LY294002 reduced the IGF1-induced differentiation.	U 0126	33-38	mitogen-activated protein kinase 3	Mus musculus	23-29
24582811-11	2014	Specific inhibition of ERK1/2 by U0126 or PI3K by LY294002 reduced the IGF1-induced differentiation.	U 0126	33-38	insulin-like growth factor 1	Mus musculus	71-75
24561081-3	2014	Signaling inhibitors, PD98059/U0126 (extracellular signal-regulated kinase (ERK) inhibitors) and SB203580/SB202190 (p38 inhibitors), revealed that tensile force-mediated BMP-2 expression was dependent on activation of the ERK1/2 and p38 mitogen-activated protein (MAP) kinase pathways.	U 0126	30-35	bone morphogenetic protein 2	Homo sapiens	170-175
24727858-7	2014	Moreover, we utilized Src tyrosine kinase inhibitor PP2 and two MEK inhibitors PD98059 and U0126 to elucidate the rapid nongenomic activation of Src/MEK/ERK1/2 cascade on endogenous transcription.	U 0126	91-96	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	145-148
24727858-7	2014	Moreover, we utilized Src tyrosine kinase inhibitor PP2 and two MEK inhibitors PD98059 and U0126 to elucidate the rapid nongenomic activation of Src/MEK/ERK1/2 cascade on endogenous transcription.	U 0126	91-96	mitogen-activated protein kinase kinase 7	Homo sapiens	149-152
24727858-7	2014	Moreover, we utilized Src tyrosine kinase inhibitor PP2 and two MEK inhibitors PD98059 and U0126 to elucidate the rapid nongenomic activation of Src/MEK/ERK1/2 cascade on endogenous transcription.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	153-159
24727858-8	2014	Our data showed that BPAF-induced transcription could be significantly blocked by PP2, PD98059 and U0126, suggesting activation of ERK1/2 was also required to regulate endogenous transcription.	U 0126	99-104	mitogen-activated protein kinase 3	Homo sapiens	131-137
24719563-9	2014	ERK1/2 showed increased phosphorylation by genistein treatment after reperfusion, and an ERK1/2 inhibitor U0126 abolished this protective effect of genistein in terms of infarct volumes, neurological scores and cellular apoptosis.	U 0126	106-111	mitogen-activated protein kinase 3	Mus musculus	89-95
24512724-8	2014	Administration of the ERK1/2 inhibitor U0126 decreased the infarct ratio and improved protein clearance by autophagy in the HBO group.	U 0126	39-44	mitogen activated protein kinase 3	Rattus norvegicus	22-28
24708812-6	2014	Consistently, intrathecal administration of the ERK phosphorylation inhibitor U0126 dramatically reduces the scratching behaviors induced by histamine and DNFB, but not by chloroquine.	U 0126	78-83	mitogen-activated protein kinase 1	Mus musculus	48-51
24118820-7	2014	These injuries were significantly attenuated by the pre-treatment of cells with either naringin or SB203580 (a selective inhibitor of p38 MAPK) or U0126 (a selective inhibitor of extracellular signal regulated kinase 1/2, ERK1/2) or SP600125 (a selective inhibitor of c-jun N-termanal kinase, JNK) before exposure to HG, respectively.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	179-220
24118820-7	2014	These injuries were significantly attenuated by the pre-treatment of cells with either naringin or SB203580 (a selective inhibitor of p38 MAPK) or U0126 (a selective inhibitor of extracellular signal regulated kinase 1/2, ERK1/2) or SP600125 (a selective inhibitor of c-jun N-termanal kinase, JNK) before exposure to HG, respectively.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	222-228
24118820-7	2014	These injuries were significantly attenuated by the pre-treatment of cells with either naringin or SB203580 (a selective inhibitor of p38 MAPK) or U0126 (a selective inhibitor of extracellular signal regulated kinase 1/2, ERK1/2) or SP600125 (a selective inhibitor of c-jun N-termanal kinase, JNK) before exposure to HG, respectively.	U 0126	147-152	mitogen-activated protein kinase 8	Rattus norvegicus	293-296
24365239-8	2014	The CCh-induced enhancement of TER recovery was also blocked by either U0126 (ERK pathway inhibitor) or PF-228 (FAK inhibitor).	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	78-81
23995352-9	2014	Pretreatment with a PKA inhibitor (Rp-cAMPs) and an ERK1/2 inhibitor (U0126) significantly attenuated hydroxytyrosol-stimulated lipolysis.	U 0126	70-75	mitogen-activated protein kinase 3	Homo sapiens	52-58
24458360-7	2014	Treatment of obese mice with the ERK inhibitor U0126 rescued Baf60c and Deptor expression in skeletal muscle and lowered blood glucose.	U 0126	47-52	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3	Mus musculus	61-67
24458360-7	2014	Treatment of obese mice with the ERK inhibitor U0126 rescued Baf60c and Deptor expression in skeletal muscle and lowered blood glucose.	U 0126	47-52	DEP domain containing MTOR-interacting protein	Mus musculus	72-78
24788939-5	2014	Meanwhile, blockade of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor U0126 strongly prevented TGFbeta2-induced the downregulation of P-cadherin, and the upregulation of alpha-SMA, collagen type IV, N-cadherin and fibronectin in RPE cells.	U 0126	77-82	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
24788939-5	2014	Meanwhile, blockade of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor U0126 strongly prevented TGFbeta2-induced the downregulation of P-cadherin, and the upregulation of alpha-SMA, collagen type IV, N-cadherin and fibronectin in RPE cells.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	60-66
24788939-5	2014	Meanwhile, blockade of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor U0126 strongly prevented TGFbeta2-induced the downregulation of P-cadherin, and the upregulation of alpha-SMA, collagen type IV, N-cadherin and fibronectin in RPE cells.	U 0126	77-82	transforming growth factor beta 2	Homo sapiens	102-110
24788939-5	2014	Meanwhile, blockade of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor U0126 strongly prevented TGFbeta2-induced the downregulation of P-cadherin, and the upregulation of alpha-SMA, collagen type IV, N-cadherin and fibronectin in RPE cells.	U 0126	77-82	cadherin 2	Homo sapiens	206-216
24788939-5	2014	Meanwhile, blockade of ERK1/2 signaling with a specific MEK/ERK1/2 inhibitor U0126 strongly prevented TGFbeta2-induced the downregulation of P-cadherin, and the upregulation of alpha-SMA, collagen type IV, N-cadherin and fibronectin in RPE cells.	U 0126	77-82	fibronectin 1	Homo sapiens	221-232
24357338-6	2014	Furthermore, SB203580 (an inhibitor of p38) decreased the percentage of apoptotic cells whereas arsenite-stimulated toxicity was enhanced by U0126 (an inhibitor of ERK1/2).	U 0126	141-146	mitogen activated protein kinase 3	Rattus norvegicus	164-170
24530412-9	2014	It is noteworthy that a tyrosine kinase receptor inhibitor, K252a, an MEK-ERK inhibitor (U0126), and a PI3Kinase-Akt inhibitor (LY294002) remarkably attenuated TrkB, ERK, and Akt phosphorylation as well as increase of OPN mRNA expression in the HCEM cells, respectively.	U 0126	89-94	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
24530412-9	2014	It is noteworthy that a tyrosine kinase receptor inhibitor, K252a, an MEK-ERK inhibitor (U0126), and a PI3Kinase-Akt inhibitor (LY294002) remarkably attenuated TrkB, ERK, and Akt phosphorylation as well as increase of OPN mRNA expression in the HCEM cells, respectively.	U 0126	89-94	EPH receptor B2	Homo sapiens	74-77
24530412-9	2014	It is noteworthy that a tyrosine kinase receptor inhibitor, K252a, an MEK-ERK inhibitor (U0126), and a PI3Kinase-Akt inhibitor (LY294002) remarkably attenuated TrkB, ERK, and Akt phosphorylation as well as increase of OPN mRNA expression in the HCEM cells, respectively.	U 0126	89-94	neurotrophic receptor tyrosine kinase 2	Homo sapiens	160-164
24504262-5	2014	U0126, an ERK1/2-specific inhibitor, blocked IL-7-induced cell migration and invasion, and also suppressed the expression of MMP-9 in the presence of IL-7.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	10-16
24504262-5	2014	U0126, an ERK1/2-specific inhibitor, blocked IL-7-induced cell migration and invasion, and also suppressed the expression of MMP-9 in the presence of IL-7.	U 0126	0-5	interleukin 7	Homo sapiens	45-49
24504262-5	2014	U0126, an ERK1/2-specific inhibitor, blocked IL-7-induced cell migration and invasion, and also suppressed the expression of MMP-9 in the presence of IL-7.	U 0126	0-5	matrix metallopeptidase 9	Homo sapiens	125-130
24504262-5	2014	U0126, an ERK1/2-specific inhibitor, blocked IL-7-induced cell migration and invasion, and also suppressed the expression of MMP-9 in the presence of IL-7.	U 0126	0-5	interleukin 7	Homo sapiens	150-154
24321199-6	2014	These ameliorating effects of orexin-A on spatial learning and memory were attenuated by the intracerebroventricular injection of the OX1R antagonist SB334867 or the ERK1/2 inhibitor U0126.	U 0126	183-188	hypocretin neuropeptide precursor	Rattus norvegicus	30-38
24421112-2	2014	We established that JUNV induces a biphasic activation of ERK and we proved that a specific inhibitor of the ERK pathway, U0126, impairs viral replication.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	58-61
24421112-2	2014	We established that JUNV induces a biphasic activation of ERK and we proved that a specific inhibitor of the ERK pathway, U0126, impairs viral replication.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	109-112
24492838-10	2014	Intracerebroventricular administration of the ERK phosphorylation inhibitor U 0126 before a hyperosmotic challenge reduced the number of both phosphoERK-immunopositive neurones and Fos expressing neurones in osmosensitive forebrain regions.	U 0126	76-82	Eph receptor B1	Rattus norvegicus	46-49
24492838-10	2014	Intracerebroventricular administration of the ERK phosphorylation inhibitor U 0126 before a hyperosmotic challenge reduced the number of both phosphoERK-immunopositive neurones and Fos expressing neurones in osmosensitive forebrain regions.	U 0126	76-82	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	181-184
24344240-10	2014	And the IL-33-induced CCL2/CCR2 expression was abrogated by treatment with the NF-kappaB inhibitor BAY 11-7082 or ERK1/2 inhibitor U0126.	U 0126	131-136	interleukin 33	Homo sapiens	8-13
24344240-10	2014	And the IL-33-induced CCL2/CCR2 expression was abrogated by treatment with the NF-kappaB inhibitor BAY 11-7082 or ERK1/2 inhibitor U0126.	U 0126	131-136	C-C motif chemokine ligand 2	Homo sapiens	22-26
24344240-10	2014	And the IL-33-induced CCL2/CCR2 expression was abrogated by treatment with the NF-kappaB inhibitor BAY 11-7082 or ERK1/2 inhibitor U0126.	U 0126	131-136	C-C motif chemokine receptor 2	Homo sapiens	27-31
24344240-10	2014	And the IL-33-induced CCL2/CCR2 expression was abrogated by treatment with the NF-kappaB inhibitor BAY 11-7082 or ERK1/2 inhibitor U0126.	U 0126	131-136	mitogen-activated protein kinase 3	Homo sapiens	114-120
25206883-3	2014	In this study, transient whole-brain ischemia was induced by four-vessel occlusion in normal and diabetic rats, and extracellular signal-regulated kinase 1/2 inhibitor (U0126) was administered into diabetic rats 30 minutes before ischemia as a pretreatment.	U 0126	169-174	mitogen activated protein kinase 3	Rattus norvegicus	116-157
25206883-4	2014	Results showed that the number of surviving neurons in the hippocampal CA1 region was reduced, extracellular signal-regulated kinase 1/2 phosphorylation and Ku70 activity were decreased, and pro-apoptotic Bax expression was upregulated after intervention using U0126.	U 0126	261-266	mitogen activated protein kinase 3	Rattus norvegicus	95-134
25206883-4	2014	Results showed that the number of surviving neurons in the hippocampal CA1 region was reduced, extracellular signal-regulated kinase 1/2 phosphorylation and Ku70 activity were decreased, and pro-apoptotic Bax expression was upregulated after intervention using U0126.	U 0126	261-266	BCL2 associated X, apoptosis regulator	Rattus norvegicus	205-208
24480726-9	2014	The MAP kinase-ERK inhibitor, U0126 dose-dependently attenuated the nociceptive behavior and spinal ERK activation to i.t.	U 0126	30-35	mitogen-activated protein kinase 1	Mus musculus	15-18
24480726-9	2014	The MAP kinase-ERK inhibitor, U0126 dose-dependently attenuated the nociceptive behavior and spinal ERK activation to i.t.	U 0126	30-35	mitogen-activated protein kinase 1	Mus musculus	100-103
24321199-6	2014	These ameliorating effects of orexin-A on spatial learning and memory were attenuated by the intracerebroventricular injection of the OX1R antagonist SB334867 or the ERK1/2 inhibitor U0126.	U 0126	183-188	mitogen activated protein kinase 3	Rattus norvegicus	166-172
24508636-10	2014	Furthermore, IGF-I significantly stimulated both proliferation and migration of pTr cells, but these effects were blocked by P38 inhibitor (SB203580), U0126, MTOR inhibitor (rapamycin) and LY294002.	U 0126	151-156	insulin like growth factor 1	Sus scrofa	13-18
24642693-3	2014	The aim was to characterize the time-course of receptor upregulation and associated neuronal damage after global ischemia and investigate whether treatment with the MEK1/2 inhibitor U0126 can prevent cerebrovascular receptor upregulation and thereby improve functional outcome after global cerebral ischemia.	U 0126	182-187	mitogen activated protein kinase kinase 1	Rattus norvegicus	165-171
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	mitogen-activated protein kinase 3	Sus scrofa	23-29
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	insulin like growth factor 1	Sus scrofa	54-59
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	AKT serine/threonine kinase 1	Sus scrofa	68-72
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	insulin like growth factor 1	Sus scrofa	155-160
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	mitogen-activated protein kinase 3	Sus scrofa	188-194
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	AKT serine/threonine kinase 1	Sus scrofa	199-203
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	AKT serine/threonine kinase 1	Sus scrofa	199-203
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	mitogen-activated protein kinase 3	Sus scrofa	188-194
24642246-5	2014	2) UTP significantly inhibited IA and the expression of Kv1.4, Kv3.4 and Kv4.2 subunits in TG neurons, which could be reversed by the P2 receptor antagonist suramin and the ERK antagonist U0126.	U 0126	188-193	potassium voltage-gated channel subfamily A member 4	Rattus norvegicus	56-61
24642246-5	2014	2) UTP significantly inhibited IA and the expression of Kv1.4, Kv3.4 and Kv4.2 subunits in TG neurons, which could be reversed by the P2 receptor antagonist suramin and the ERK antagonist U0126.	U 0126	188-193	potassium voltage-gated channel subfamily D member 2	Rattus norvegicus	73-78
24642693-8	2014	Treatment with U0126 normalised cerebrovascular ETB and 5-HT1B receptor expression and contractile function, reduced hippocampal cell death and improved survival rate compared to vehicle treated animals.	U 0126	15-20	endothelin receptor type B	Rattus norvegicus	48-62
24642246-5	2014	2) UTP significantly inhibited IA and the expression of Kv1.4, Kv3.4 and Kv4.2 subunits in TG neurons, which could be reversed by the P2 receptor antagonist suramin and the ERK antagonist U0126.	U 0126	188-193	Eph receptor B1	Rattus norvegicus	173-176
24642693-10	2014	The enhanced cerebrovascular contractility can be prevented by treatment with the MEK1/2 inhibitor U0126, diminishes neuronal damage and improves survival rate, suggesting MEK1/2 inhibition as a novel strategy for early treatment of neurological consequences following global cerebral ischemia.	U 0126	99-104	mitogen activated protein kinase kinase 1	Rattus norvegicus	82-88
24642693-10	2014	The enhanced cerebrovascular contractility can be prevented by treatment with the MEK1/2 inhibitor U0126, diminishes neuronal damage and improves survival rate, suggesting MEK1/2 inhibition as a novel strategy for early treatment of neurological consequences following global cerebral ischemia.	U 0126	99-104	mitogen activated protein kinase kinase 1	Rattus norvegicus	172-178
24486524-6	2014	These cells also exhibited higher proliferation in the presence of MEK-inhibitor UO126, reciprocally correlating with preferential susceptibility to the pyruvate analog 3-bromopyruvate (3-BrPA) without a comparable response to 2-deoxyglucose.	U 0126	81-86	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	tumor necrosis factor	Homo sapiens	13-22
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	mitogen-activated protein kinase 8	Homo sapiens	34-40
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	erythrocyte membrane protein band 4.2	Homo sapiens	45-48
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	interferon induced protein 44	Homo sapiens	49-52
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	mitogen-activated protein kinase 3	Homo sapiens	53-57
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	mitogen-activated protein kinase 8	Homo sapiens	34-38
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	U 0126	146-151	erythrocyte membrane protein band 4.2	Homo sapiens	203-206
24481325-7	2014	Furthermore, TAM, E2, and G1 promoted CAF proliferation and cell-cycle progression, both of which were blocked by GPER interference, the selective GPER antagonist G15, the epidermal growth factor receptor (EGFR) inhibitor AG1478, and the ERK1/2 inhibitor U0126.	U 0126	255-260	cystatin 12, pseudogene	Homo sapiens	18-28
24811485-6	2014	Combined treatment of cells with BafA1 and the ERK1/2 inhibitor U0126 further augmented cell death.	U 0126	64-69	mitogen-activated protein kinase 3	Mus musculus	47-53
24440771-3	2014	The combination of gefitinib with ERK inhibition (by U0126) restored gefitinib susceptibility in PC9-GR, but PI3K-Akt inhibition with LY294002 did not.	U 0126	53-58	EPH receptor B2	Homo sapiens	34-37
24481325-7	2014	Furthermore, TAM, E2, and G1 promoted CAF proliferation and cell-cycle progression, both of which were blocked by GPER interference, the selective GPER antagonist G15, the epidermal growth factor receptor (EGFR) inhibitor AG1478, and the ERK1/2 inhibitor U0126.	U 0126	255-260	lysine acetyltransferase 2B	Homo sapiens	38-41
24481325-7	2014	Furthermore, TAM, E2, and G1 promoted CAF proliferation and cell-cycle progression, both of which were blocked by GPER interference, the selective GPER antagonist G15, the epidermal growth factor receptor (EGFR) inhibitor AG1478, and the ERK1/2 inhibitor U0126.	U 0126	255-260	G protein-coupled estrogen receptor 1	Homo sapiens	114-118
24481325-9	2014	GPER-induced aromatase upregulation was probably responsible for this phenomenon, as TAM- and G1-induced CYP19A1 gene expression was reduced by GPER knockdown and G15, AG1478, and U0126 administration.	U 0126	180-185	G protein-coupled estrogen receptor 1	Homo sapiens	0-4
24606810-6	2014	Pretreatment with the MEK1/2 inhibitor U0126 abrogated the effects of EA at acupoints on cerebral infarct size, neurological deficits, active caspase-3 protein, and apoptosis in the ischemic cortex after 3 d of reperfusion.	U 0126	39-44	mitogen activated protein kinase kinase 1	Rattus norvegicus	22-28
24481325-9	2014	GPER-induced aromatase upregulation was probably responsible for this phenomenon, as TAM- and G1-induced CYP19A1 gene expression was reduced by GPER knockdown and G15, AG1478, and U0126 administration.	U 0126	180-185	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	105-112
24451985-7	2014	The addition of U0126, an inhibitor of ERK1/2, inhibited VEGF-induced ERK1/2 phosphorylation, but AKT1 phosphorylation was not affected.	U 0126	16-21	mitogen-activated protein kinase 3	Homo sapiens	39-45
24606810-6	2014	Pretreatment with the MEK1/2 inhibitor U0126 abrogated the effects of EA at acupoints on cerebral infarct size, neurological deficits, active caspase-3 protein, and apoptosis in the ischemic cortex after 3 d of reperfusion.	U 0126	39-44	caspase 3	Rattus norvegicus	142-151
24606810-7	2014	Pretreatment with U0126 also abrogated the effects of EA at acupoints on pMEK1/2, pERK1/2, pp90RSK, pBad, and NeuN expression, but did not influence BDNF and pRaf-1 expression.	U 0126	18-23	RNA binding fox-1 homolog 3	Rattus norvegicus	110-114
24451985-7	2014	The addition of U0126, an inhibitor of ERK1/2, inhibited VEGF-induced ERK1/2 phosphorylation, but AKT1 phosphorylation was not affected.	U 0126	16-21	vascular endothelial growth factor A	Homo sapiens	57-61
24451985-7	2014	The addition of U0126, an inhibitor of ERK1/2, inhibited VEGF-induced ERK1/2 phosphorylation, but AKT1 phosphorylation was not affected.	U 0126	16-21	mitogen-activated protein kinase 3	Homo sapiens	70-76
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	U 0126	129-134	vascular endothelial growth factor A	Homo sapiens	13-17
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	185-191
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	U 0126	129-134	mechanistic target of rapamycin kinase	Homo sapiens	193-197
24440742-13	2014	Inhibition of phosphoinositide-3-kinase (PI3K) by wortmannin and ERK1/2 by U0126 reduced Ft1-evoked relaxations and eNOS phosphorylation.	U 0126	75-80	mitogen activated protein kinase 3	Rattus norvegicus	65-71
23917632-7	2014	Moreover, rhArg could induce ERK1/2 activation in a dose- and time-dependent manner and rhArg-induced autophagy was attenuated when p-ERK1/2 was inhibited by MEK 1/2 inhibitor, U0126.	U 0126	177-182	mitogen-activated protein kinase 3	Homo sapiens	134-140
24709100-3	2014	RESULTS: The U0126 and siRNAs specific for SphK2 blocked the export of SphK2 from nuclei to cytoplasm and increased the apoptosis of HCT116 cells following NaBT exposure.	U 0126	13-18	sphingosine kinase 2	Homo sapiens	43-48
24709100-3	2014	RESULTS: The U0126 and siRNAs specific for SphK2 blocked the export of SphK2 from nuclei to cytoplasm and increased the apoptosis of HCT116 cells following NaBT exposure.	U 0126	13-18	sphingosine kinase 2	Homo sapiens	71-76
24709100-5	2014	Furthermore, transfection of HCT116 cells with constitutively activated PKD plasmids recovered the U0126-blocked export of SphK2.	U 0126	99-104	sphingosine kinase 2	Homo sapiens	123-128
24378341-6	2014	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, suppressed the osteogenic differentiation induced by TGF-beta alone.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	51-55
24237253-4	2014	Other erythroid markers such as gamma-globin and CD71 (transferrin receptor) were also increased by NH2Cl and U0126.	U 0126	110-115	transferrin receptor	Homo sapiens	49-53
24237253-4	2014	Other erythroid markers such as gamma-globin and CD71 (transferrin receptor) were also increased by NH2Cl and U0126.	U 0126	110-115	transferrin receptor	Homo sapiens	55-75
24237253-5	2014	In contrast, CD61 (integrin beta3) and CD42b (GP1balpha) expression, markers of megakaryocytic differentiation, was increased by staurosporine, but did not change significantly by NH2Cl and U0126.	U 0126	190-195	integrin subunit beta 3	Homo sapiens	13-17
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	fibroblast growth factor 2	Homo sapiens	33-37
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	anosmin 1	Homo sapiens	42-51
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	113-117
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	174-180
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	181-185
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	fibroblast growth factor receptor 1	Homo sapiens	235-240
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	fibroblast growth factor 2	Homo sapiens	258-262
24375670-8	2014	The chemoattraction exhibited by FGF2 and anosmin-1 on OPCs was blocked by the mitogen-activated protein kinase (MAPK) inhibitor U0126, suggesting that the activation of the ERK1/2 MAPK signaling pathway following interaction with the FGFR1 is necessary for FGF2 and anosmin-1 to exert their chemotactic effect.	U 0126	129-134	anosmin 1	Homo sapiens	267-276
24406428-7	2014	This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways.	U 0126	163-168	interleukin 6	Mus musculus	56-60
24406428-7	2014	This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways.	U 0126	163-168	mitogen-activated protein kinase 1	Mus musculus	108-145
24406428-7	2014	This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways.	U 0126	163-168	mitogen-activated protein kinase 1	Mus musculus	147-150
24406428-7	2014	This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways.	U 0126	163-168	mitogen-activated protein kinase 1	Mus musculus	200-203
24378341-6	2014	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, suppressed the osteogenic differentiation induced by TGF-beta alone.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	57-60
24378341-6	2014	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, suppressed the osteogenic differentiation induced by TGF-beta alone.	U 0126	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	69-72
24378341-6	2014	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, suppressed the osteogenic differentiation induced by TGF-beta alone.	U 0126	85-90	transforming growth factor beta 1	Homo sapiens	145-153
24378341-7	2014	Moreover, U0126 completely suppressed the osteogenic differentiation synergistically induced by TGF-beta and PDGF, whereas the phosphoinositide-3-kinase (PI3K) inhibitor, LY294002, only partially suppressed this effect.	U 0126	10-15	transforming growth factor beta 1	Homo sapiens	96-104
24515297-6	2014	Phosphorylation of ERK1/2 and p38 MAPKs by ORA was blocked with U0126 and SB203580 inhibitors, respectively.	U 0126	64-69	mitogen activated protein kinase 3	Rattus norvegicus	19-25
23959527-8	2014	Moreover, addition of the Erk1/2 inhibitor U0126 partially blocked Smad7-siRNA-induced CS closure.	U 0126	43-48	mitogen activated protein kinase 3	Rattus norvegicus	26-32
23959527-8	2014	Moreover, addition of the Erk1/2 inhibitor U0126 partially blocked Smad7-siRNA-induced CS closure.	U 0126	43-48	SMAD family member 7	Rattus norvegicus	67-72
25337569-6	2014	The pharmacological inhibitors of these kinases both U0126 (MEK1/2 inhibitor) and LY294002 (PI3K inhibitor) abrogated the NF-kappaB DNA binding activity in MDA-MB-231 cells.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	60-66
24190281-5	2014	In addition, this protective response is specifically reversed by U0126, an ERK inhibitor, which promotes cell death only when it is administered together with Glu.	U 0126	66-71	Eph receptor B1	Rattus norvegicus	76-79
24203573-6	2014	Pre-treatment with the selective ERK inhibitor U0126 attenuated haloperidol-induced increase in D2R upregulation.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	33-36
24161965-7	2014	When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells.	U 0126	81-86	mitogen-activated protein kinase 1	Mus musculus	55-59
24161965-7	2014	When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells.	U 0126	81-86	mitogen-activated protein kinase 1	Mus musculus	60-63
24161965-7	2014	When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells.	U 0126	81-86	ATP binding cassette subfamily G member 2	Canis lupus familiaris	88-93
24366394-7	2014	Finally, overexpression of Sirt6 inhibited phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), and blocking the ERK1/2 pathway with chemical-specific inhibitor U0126, attenuated the tumor suppressive effect of overexpression of Sirt6.	U 0126	180-185	sirtuin 6	Homo sapiens	27-32
24366394-7	2014	Finally, overexpression of Sirt6 inhibited phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), and blocking the ERK1/2 pathway with chemical-specific inhibitor U0126, attenuated the tumor suppressive effect of overexpression of Sirt6.	U 0126	180-185	mitogen-activated protein kinase 1	Homo sapiens	62-104
24366394-7	2014	Finally, overexpression of Sirt6 inhibited phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), and blocking the ERK1/2 pathway with chemical-specific inhibitor U0126, attenuated the tumor suppressive effect of overexpression of Sirt6.	U 0126	180-185	mitogen-activated protein kinase 3	Homo sapiens	132-138
24366394-7	2014	Finally, overexpression of Sirt6 inhibited phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), and blocking the ERK1/2 pathway with chemical-specific inhibitor U0126, attenuated the tumor suppressive effect of overexpression of Sirt6.	U 0126	180-185	sirtuin 6	Homo sapiens	248-253
24515297-6	2014	Phosphorylation of ERK1/2 and p38 MAPKs by ORA was blocked with U0126 and SB203580 inhibitors, respectively.	U 0126	64-69	mitogen activated protein kinase 14	Rattus norvegicus	30-33
24176808-7	2014	METHODS: Human intervertebral disc cells were cultured in alginate beads, and treated with TNF-alpha, or TNF- alpha plus BMP-7, pharmacological inhibitor of ERK1/2 (U0126), p38 (SB203580), or NFkappaB (BAY 11-7082).	U 0126	165-170	bone morphogenetic protein 7	Homo sapiens	121-126
24604861-6	2014	In vagina of laying hens, mucin expression was upregulated by LPS, whereas it was suppressed by inhibitors of transcriptional factors, namely, ALLN (an inhibitor of IkappaB proteolysis), BAY-117085 (an NFkappaB inhibitor), U0126 [a mitogen-activated protein kinase (MAPK) inhibitor], and transhinone IIA [an activated protein 1 (AP-1) inhibitor].	U 0126	223-228	mucin 2, oligomeric mucus/gel-forming	Gallus gallus	26-31
24440569-6	2014	E2 and ICI also induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 phosphorylation by U0126 profoundly impeded calpain activation triggered by estrogenic and antiestrogenic stimulations indicating implication of ERK1/2 in the GPR30-mediated action.	U 0126	146-151	cystatin 12, pseudogene	Homo sapiens	0-10
24440569-6	2014	E2 and ICI also induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 phosphorylation by U0126 profoundly impeded calpain activation triggered by estrogenic and antiestrogenic stimulations indicating implication of ERK1/2 in the GPR30-mediated action.	U 0126	146-151	mitogen-activated protein kinase 3	Homo sapiens	120-126
24440569-6	2014	E2 and ICI also induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 phosphorylation by U0126 profoundly impeded calpain activation triggered by estrogenic and antiestrogenic stimulations indicating implication of ERK1/2 in the GPR30-mediated action.	U 0126	146-151	calpain 1	Homo sapiens	171-178
24440569-6	2014	E2 and ICI also induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 phosphorylation by U0126 profoundly impeded calpain activation triggered by estrogenic and antiestrogenic stimulations indicating implication of ERK1/2 in the GPR30-mediated action.	U 0126	146-151	mitogen-activated protein kinase 3	Homo sapiens	120-126
24440569-6	2014	E2 and ICI also induced phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 phosphorylation by U0126 profoundly impeded calpain activation triggered by estrogenic and antiestrogenic stimulations indicating implication of ERK1/2 in the GPR30-mediated action.	U 0126	146-151	G protein-coupled estrogen receptor 1	Homo sapiens	286-291
24309234-5	2014	Furthermore, PDGF-BB-stimulated ERK activation was significantly inhibited by CPS-2, and this inhibitory effect was synergistically potentiated by U0126.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	32-35
24695490-9	2014	However, preventing ERK1/2 activation further increased H2O2-induced cell death with U0126, an inhibitor of ERK upstream kinase MEK1/2.	U 0126	85-90	mitogen-activated protein kinase 3	Homo sapiens	20-26
24695490-9	2014	However, preventing ERK1/2 activation further increased H2O2-induced cell death with U0126, an inhibitor of ERK upstream kinase MEK1/2.	U 0126	85-90	mitogen-activated protein kinase kinase 1	Homo sapiens	128-134
24520418-10	2014	CSF2 significantly stimulated pTr cell proliferation and, U0126, rapamycin and LY294002 blocked this CSF2-induced proliferation of pTr cells.	U 0126	58-63	colony stimulating factor 2	Homo sapiens	101-105
24356971-10	2014	The MEK1/2 inhibitor, U0126, and mutation of the ERK-dependent phosphorylation site (T678A) prevented complement-induced GEF-H1 activation, indicating a role for the ERK pathway.	U 0126	22-27	Rho/Rac guanine nucleotide exchange factor 2	Rattus norvegicus	121-127
24316274-7	2014	Pre-treatment of A549 cells with the MEK1/2 inhibitor U0126 (10muM) decreased PCN-induced ERK1/2 phosphorylation and protected cells against apoptosis and cell injury suggesting a role for ERK signalling.	U 0126	54-59	mitogen-activated protein kinase kinase 1	Homo sapiens	37-43
24316274-7	2014	Pre-treatment of A549 cells with the MEK1/2 inhibitor U0126 (10muM) decreased PCN-induced ERK1/2 phosphorylation and protected cells against apoptosis and cell injury suggesting a role for ERK signalling.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	90-96
24316274-7	2014	Pre-treatment of A549 cells with the MEK1/2 inhibitor U0126 (10muM) decreased PCN-induced ERK1/2 phosphorylation and protected cells against apoptosis and cell injury suggesting a role for ERK signalling.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	90-93
23134192-5	2014	Inhibition of activation of ERK by the ERK inhibitor U0126 nearly blocked the Icariin-induced proliferation of Sertoli cells.	U 0126	53-58	Eph receptor B1	Rattus norvegicus	28-31
23134192-5	2014	Inhibition of activation of ERK by the ERK inhibitor U0126 nearly blocked the Icariin-induced proliferation of Sertoli cells.	U 0126	53-58	Eph receptor B1	Rattus norvegicus	39-42
24502696-4	2014	Here we demonstrated that TNF-alpha-induced MMP-9 expression was attenuated by Act.D, CHI, PP1, U0126, SB202190, SP600125, and Bay11-7082, and by the transfection with siRNAs for ERK2, p38 MAPK, and JNK2.	U 0126	96-101	tumor necrosis factor	Mus musculus	26-35
24502696-4	2014	Here we demonstrated that TNF-alpha-induced MMP-9 expression was attenuated by Act.D, CHI, PP1, U0126, SB202190, SP600125, and Bay11-7082, and by the transfection with siRNAs for ERK2, p38 MAPK, and JNK2.	U 0126	96-101	matrix metallopeptidase 9	Mus musculus	44-49
24502696-7	2014	TNF-alpha time-dependently induced MMP-9 promoter activity which was also inhibited by PP1, U0126, SB202190, SP600125, or Bay11-7082.	U 0126	92-97	tumor necrosis factor	Mus musculus	0-9
24502696-7	2014	TNF-alpha time-dependently induced MMP-9 promoter activity which was also inhibited by PP1, U0126, SB202190, SP600125, or Bay11-7082.	U 0126	92-97	matrix metallopeptidase 9	Mus musculus	35-40
24302760-7	2014	Tan treatment induced the phosphorylation and nuclear translocation of Nrf2 and subsequently increased the expression of HO-1, and these effects were abolished by the specific ERK inhibitors, PD98059 and U0126.	U 0126	204-209	NFE2 like bZIP transcription factor 2	Homo sapiens	71-75
24302760-7	2014	Tan treatment induced the phosphorylation and nuclear translocation of Nrf2 and subsequently increased the expression of HO-1, and these effects were abolished by the specific ERK inhibitors, PD98059 and U0126.	U 0126	204-209	heme oxygenase 1	Homo sapiens	121-125
24197118-6	2014	Ccr5 signaling was dependent on the mitogen-activated protein kinase kinase (Map2k) but not the phosphoinositide 3-kinase (Pi3k) pathway because treatment with U0126 inhibited upregulation of Erdr1, but treatment with LY294002 increased the expression by 3.44 +- 0.92-fold (P &lt; 0.05).	U 0126	160-165	chemokine (C-C motif) receptor 5	Mus musculus	0-4
24197118-6	2014	Ccr5 signaling was dependent on the mitogen-activated protein kinase kinase (Map2k) but not the phosphoinositide 3-kinase (Pi3k) pathway because treatment with U0126 inhibited upregulation of Erdr1, but treatment with LY294002 increased the expression by 3.44 +- 0.92-fold (P &lt; 0.05).	U 0126	160-165	erythroid differentiation regulator 1	Mus musculus	192-197
24375019-3	2014	The SIN-1 action on mEPSC amplitude was completely blocked by U0126, a selective MEK inhibitor, suggesting that MEK contributed to the action of ONOO(-) on mEPSCs.	U 0126	62-67	MAPK associated protein 1	Homo sapiens	4-9
24375019-3	2014	The SIN-1 action on mEPSC amplitude was completely blocked by U0126, a selective MEK inhibitor, suggesting that MEK contributed to the action of ONOO(-) on mEPSCs.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84
24375019-3	2014	The SIN-1 action on mEPSC amplitude was completely blocked by U0126, a selective MEK inhibitor, suggesting that MEK contributed to the action of ONOO(-) on mEPSCs.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
24498195-8	2014	MAP kinase kinase inhibitor U0126 intrathecal delivery significantly suppressed the elevation of p-Cdk5(S159), Cdk5 activity and pain response behavior (Heat hyperalgesia, Spontaneous flinches) induced by CFA or formalin injection.	U 0126	28-33	cyclin dependent kinase 5	Homo sapiens	99-103
24498195-8	2014	MAP kinase kinase inhibitor U0126 intrathecal delivery significantly suppressed the elevation of p-Cdk5(S159), Cdk5 activity and pain response behavior (Heat hyperalgesia, Spontaneous flinches) induced by CFA or formalin injection.	U 0126	28-33	cyclin dependent kinase 5	Homo sapiens	111-115
24036423-4	2014	Investigation of the role of p44/42 and mTOR on metabolic activity and protein content per cell, demonstrated that in the presence of MAPK inhibitor U0126 and mTOR inhibitor Ku-63794, that the mTOR pathway is responsible for the reduction in PTC metabolic activity in response to leptin.	U 0126	149-154	interferon induced protein 44	Homo sapiens	29-32
24036423-4	2014	Investigation of the role of p44/42 and mTOR on metabolic activity and protein content per cell, demonstrated that in the presence of MAPK inhibitor U0126 and mTOR inhibitor Ku-63794, that the mTOR pathway is responsible for the reduction in PTC metabolic activity in response to leptin.	U 0126	149-154	mechanistic target of rapamycin kinase	Homo sapiens	40-44
24036423-4	2014	Investigation of the role of p44/42 and mTOR on metabolic activity and protein content per cell, demonstrated that in the presence of MAPK inhibitor U0126 and mTOR inhibitor Ku-63794, that the mTOR pathway is responsible for the reduction in PTC metabolic activity in response to leptin.	U 0126	149-154	leptin	Homo sapiens	280-286
24269630-4	2014	This is supported by the findings that pretreatment with U0126 or PD98059, expression of dominant negative MKK1, or overexpression of PP2A prevented hsBAFF-induced activation of Erk1/2 and cell proliferation/viability in the cells.	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	178-184
25004876-7	2014	Furthermore, an ERK inhibitor, U0126, was applied to the rings.	U 0126	31-36	Eph receptor B1	Rattus norvegicus	16-19
25124631-7	2014	Furthermore, the MEK (MAPK (mitogen-activated protein kinase)/Erk (extracellular signal regulated kinase)/Erk inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
25124631-7	2014	Furthermore, the MEK (MAPK (mitogen-activated protein kinase)/Erk (extracellular signal regulated kinase)/Erk inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	120-125	mitogen-activated protein kinase 3	Homo sapiens	22-26
25124631-7	2014	Furthermore, the MEK (MAPK (mitogen-activated protein kinase)/Erk (extracellular signal regulated kinase)/Erk inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	62-65
25124631-7	2014	Furthermore, the MEK (MAPK (mitogen-activated protein kinase)/Erk (extracellular signal regulated kinase)/Erk inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	106-109
25124631-7	2014	Furthermore, the MEK (MAPK (mitogen-activated protein kinase)/Erk (extracellular signal regulated kinase)/Erk inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	120-125	epidermal growth factor	Homo sapiens	141-144
25124631-7	2014	Furthermore, the MEK (MAPK (mitogen-activated protein kinase)/Erk (extracellular signal regulated kinase)/Erk inhibitor U0126 also inhibited EGF-induced AQP8 expression and cell migration.	U 0126	120-125	aquaporin 8	Homo sapiens	153-157
25124631-8	2014	AQP8 expression was decreased from 1.21-fold (EGF-treated) to 0.43-fold (U0126-treated).	U 0126	73-78	aquaporin 8	Homo sapiens	0-4
24989012-7	2014	Finally, the memory ameliorating effects of alpha- or beta-amyrin on the scopolamine-induced cognitive impairments were significantly blocked by ERK inhibitor U0126.	U 0126	159-164	mitogen-activated protein kinase 1	Mus musculus	145-148
24877090-6	2014	The MAPK inhibitor U0126 blocked ERK1/2 activation and reduced Schwann cell proliferation as well as induction of c-Jun transcription.	U 0126	19-24	mitogen activated protein kinase 3	Rattus norvegicus	4-8
24877090-6	2014	The MAPK inhibitor U0126 blocked ERK1/2 activation and reduced Schwann cell proliferation as well as induction of c-Jun transcription.	U 0126	19-24	mitogen activated protein kinase 3	Rattus norvegicus	33-39
24071787-5	2014	Inactivation of the epidermal growth factor receptor (EGFR) kinase activity with AG1478 and the mitogen-regulated kinase activity with U0126 completely prevented ERK1/2 activation in the FSH-stimulated and HBCDD-exposed granulosa cells.	U 0126	135-140	mitogen activated protein kinase 3	Rattus norvegicus	162-168
24071787-10	2014	Addition of U0126 and AG1478 restored Lhr level in the FSH-stimulated and HBCDD-exposed granulosa cells.	U 0126	12-17	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	38-41
24220799-8	2014	Administration of 2-CL-IB-MECA at reperfusion significantly upregulated the status of p-ERK1/2 and p-AKT compared to time matched controls in a UO126 and Wortmannin sensitive manner respectively.	U 0126	144-149	mitogen activated protein kinase 3	Rattus norvegicus	88-94
24220799-8	2014	Administration of 2-CL-IB-MECA at reperfusion significantly upregulated the status of p-ERK1/2 and p-AKT compared to time matched controls in a UO126 and Wortmannin sensitive manner respectively.	U 0126	144-149	AKT serine/threonine kinase 1	Rattus norvegicus	101-104
24073690-8	2014	Western blot analysis of cells treated with an EGF receptor inhibitor (AG1478) or MEK1/2 inhibitor (U0126) was performed to reveal the relationship between EGF receptor activation and rebamipide-induced MAM expression.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
24113427-7	2014	Of these kinases, only the inhibition of ERK1/2 by U0126, which was a specific inhibitor of mitogen-activated protein kinase/ERK1/2, effectively blocked the TGF-beta1-induced expression of TIMP-1.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	41-47
24113427-7	2014	Of these kinases, only the inhibition of ERK1/2 by U0126, which was a specific inhibitor of mitogen-activated protein kinase/ERK1/2, effectively blocked the TGF-beta1-induced expression of TIMP-1.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	125-131
24113427-7	2014	Of these kinases, only the inhibition of ERK1/2 by U0126, which was a specific inhibitor of mitogen-activated protein kinase/ERK1/2, effectively blocked the TGF-beta1-induced expression of TIMP-1.	U 0126	51-56	transforming growth factor beta 1	Homo sapiens	157-166
24113427-7	2014	Of these kinases, only the inhibition of ERK1/2 by U0126, which was a specific inhibitor of mitogen-activated protein kinase/ERK1/2, effectively blocked the TGF-beta1-induced expression of TIMP-1.	U 0126	51-56	TIMP metallopeptidase inhibitor 1	Homo sapiens	189-195
24150604-7	2014	Inhibition of the p38 MAPK by SB203580 and ERK by U0126 abolished the upregulatory effect of irisin on UCP-1.	U 0126	50-55	mitogen-activated protein kinase 1	Mus musculus	43-46
24150604-7	2014	Inhibition of the p38 MAPK by SB203580 and ERK by U0126 abolished the upregulatory effect of irisin on UCP-1.	U 0126	50-55	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	103-108
24182621-8	2014	Pretreatment with intra-BLA infusion of U0126 (MEK inhibitor), but not into the adjacent central nucleus of the amygdala, attenuated the stress-induced promoting influence on fear memory formation.	U 0126	40-45	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
24294901-12	2014	The effect was blocked by the specific p38 MAPK inhibitor SB203580 and ERK inhibitor U0126.	U 0126	85-90	mitogen-activated protein kinase 1	Mus musculus	71-74
23881718-6	2014	PAP/HIP-dependent adipocytes growth is sensitive to the MEK inhibitor U0126.	U 0126	70-75	phospholipid phosphatase 1	Mus musculus	0-3
23881718-6	2014	PAP/HIP-dependent adipocytes growth is sensitive to the MEK inhibitor U0126.	U 0126	70-75	midkine	Mus musculus	56-59
24268047-9	2014	EGF prompted the cell movement in both HepG2 and HCCLM3 and regulated the production of CXCL5 and CXCL8 from HCC, which were inhibited by EGFR inhibitor, Erk inhibitor (U0126), or PI3K inhibitors (BEZ-235 and SHBM1009).	U 0126	169-174	C-X-C motif chemokine ligand 5	Homo sapiens	88-93
24268047-9	2014	EGF prompted the cell movement in both HepG2 and HCCLM3 and regulated the production of CXCL5 and CXCL8 from HCC, which were inhibited by EGFR inhibitor, Erk inhibitor (U0126), or PI3K inhibitors (BEZ-235 and SHBM1009).	U 0126	169-174	C-X-C motif chemokine ligand 8	Homo sapiens	98-103
24268047-9	2014	EGF prompted the cell movement in both HepG2 and HCCLM3 and regulated the production of CXCL5 and CXCL8 from HCC, which were inhibited by EGFR inhibitor, Erk inhibitor (U0126), or PI3K inhibitors (BEZ-235 and SHBM1009).	U 0126	169-174	mitogen-activated protein kinase 1	Homo sapiens	154-157
24304472-8	2014	Treatment with U0126 reversed the effects of NE on c-Fos expression, p38 mitogen-activated protein kinase (MAPK) phosphorylation and TNF-alpha production, but not NF-kappaB activation in LPS-challenged cardiomyocytes.	U 0126	15-20	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-56
24304472-8	2014	Treatment with U0126 reversed the effects of NE on c-Fos expression, p38 mitogen-activated protein kinase (MAPK) phosphorylation and TNF-alpha production, but not NF-kappaB activation in LPS-challenged cardiomyocytes.	U 0126	15-20	mitogen activated protein kinase 14	Rattus norvegicus	69-105
24304472-8	2014	Treatment with U0126 reversed the effects of NE on c-Fos expression, p38 mitogen-activated protein kinase (MAPK) phosphorylation and TNF-alpha production, but not NF-kappaB activation in LPS-challenged cardiomyocytes.	U 0126	15-20	mitogen-activated protein kinase 1	Mus musculus	107-111
24304472-8	2014	Treatment with U0126 reversed the effects of NE on c-Fos expression, p38 mitogen-activated protein kinase (MAPK) phosphorylation and TNF-alpha production, but not NF-kappaB activation in LPS-challenged cardiomyocytes.	U 0126	15-20	tumor necrosis factor	Rattus norvegicus	133-142
24019108-7	2014	Addition of the chemical ERK inhibitors, PD98059 and U0126, significantly inhibited ERK protein phosphorylation, accompanied by induced DNA ladder formation, cleavage of caspase 3 and PARP protein in COLO205 cells.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	25-28
24019108-7	2014	Addition of the chemical ERK inhibitors, PD98059 and U0126, significantly inhibited ERK protein phosphorylation, accompanied by induced DNA ladder formation, cleavage of caspase 3 and PARP protein in COLO205 cells.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	84-87
24019108-7	2014	Addition of the chemical ERK inhibitors, PD98059 and U0126, significantly inhibited ERK protein phosphorylation, accompanied by induced DNA ladder formation, cleavage of caspase 3 and PARP protein in COLO205 cells.	U 0126	53-58	caspase 3	Homo sapiens	170-179
24019108-7	2014	Addition of the chemical ERK inhibitors, PD98059 and U0126, significantly inhibited ERK protein phosphorylation, accompanied by induced DNA ladder formation, cleavage of caspase 3 and PARP protein in COLO205 cells.	U 0126	53-58	collagen type XI alpha 2 chain	Homo sapiens	184-188
24510559-2	2014	METHODS: K562/A02 cells were treated with GCSsiRNA, pyrrolidine dithiocarbamate (PDTC, a NF-kappa B specific inhibitor) and U0126 (a MEK1/2 inhibitor), respectively.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Homo sapiens	133-139
24510559-8	2014	P-ERK1/2 was inhibited significantly when the cells were treated with 20 mu mol/L U0126 for 48 h. The expression of NF-kappa B p65 in nuclear and P-gp were also down-regulated.	U 0126	82-87	nuclear factor kappa B subunit 1	Homo sapiens	116-126
24510559-8	2014	P-ERK1/2 was inhibited significantly when the cells were treated with 20 mu mol/L U0126 for 48 h. The expression of NF-kappa B p65 in nuclear and P-gp were also down-regulated.	U 0126	82-87	RELA proto-oncogene, NF-kB subunit	Homo sapiens	127-130
24510559-8	2014	P-ERK1/2 was inhibited significantly when the cells were treated with 20 mu mol/L U0126 for 48 h. The expression of NF-kappa B p65 in nuclear and P-gp were also down-regulated.	U 0126	82-87	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
24489888-9	2014	Screening of a panel of small molecule compounds identified the MEK inhibitor U0126 as a potent inhibitor of surface PDGFRA expression.	U 0126	78-83	mitogen-activated protein kinase kinase 7	Homo sapiens	64-67
24489888-9	2014	Screening of a panel of small molecule compounds identified the MEK inhibitor U0126 as a potent inhibitor of surface PDGFRA expression.	U 0126	78-83	platelet derived growth factor receptor alpha	Homo sapiens	117-123
24489888-11	2014	Treatment with U0126 resulted in reduced co-localization between PDGFRA and intracellular trafficking molecules e.g. clathrin, RAB11 and early endosomal antigen-1, in parallel with enhanced co-localization between PDGFRA and the Golgi cisternae maker, Giantin, suggesting a deviation of PDGFRA from the endosomal trafficking and recycling compartment, to the Golgi network.	U 0126	15-20	platelet derived growth factor receptor alpha	Homo sapiens	65-71
24489888-11	2014	Treatment with U0126 resulted in reduced co-localization between PDGFRA and intracellular trafficking molecules e.g. clathrin, RAB11 and early endosomal antigen-1, in parallel with enhanced co-localization between PDGFRA and the Golgi cisternae maker, Giantin, suggesting a deviation of PDGFRA from the endosomal trafficking and recycling compartment, to the Golgi network.	U 0126	15-20	RAB11A, member RAS oncogene family	Homo sapiens	127-132
24489888-11	2014	Treatment with U0126 resulted in reduced co-localization between PDGFRA and intracellular trafficking molecules e.g. clathrin, RAB11 and early endosomal antigen-1, in parallel with enhanced co-localization between PDGFRA and the Golgi cisternae maker, Giantin, suggesting a deviation of PDGFRA from the endosomal trafficking and recycling compartment, to the Golgi network.	U 0126	15-20	platelet derived growth factor receptor alpha	Homo sapiens	214-220
24489888-11	2014	Treatment with U0126 resulted in reduced co-localization between PDGFRA and intracellular trafficking molecules e.g. clathrin, RAB11 and early endosomal antigen-1, in parallel with enhanced co-localization between PDGFRA and the Golgi cisternae maker, Giantin, suggesting a deviation of PDGFRA from the endosomal trafficking and recycling compartment, to the Golgi network.	U 0126	15-20	golgin B1	Homo sapiens	252-259
24489888-11	2014	Treatment with U0126 resulted in reduced co-localization between PDGFRA and intracellular trafficking molecules e.g. clathrin, RAB11 and early endosomal antigen-1, in parallel with enhanced co-localization between PDGFRA and the Golgi cisternae maker, Giantin, suggesting a deviation of PDGFRA from the endosomal trafficking and recycling compartment, to the Golgi network.	U 0126	15-20	platelet derived growth factor receptor alpha	Homo sapiens	214-220
24489888-12	2014	Furthermore, U0126 treatment in glioma cells induced an initial inhibition of ERK1/2 phosphorylation, followed by up-regulated ERK1/2 phosphorylation concomitant with diminished surface expression of PDGFRA.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	78-84
24489888-12	2014	Furthermore, U0126 treatment in glioma cells induced an initial inhibition of ERK1/2 phosphorylation, followed by up-regulated ERK1/2 phosphorylation concomitant with diminished surface expression of PDGFRA.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	127-133
24489888-12	2014	Furthermore, U0126 treatment in glioma cells induced an initial inhibition of ERK1/2 phosphorylation, followed by up-regulated ERK1/2 phosphorylation concomitant with diminished surface expression of PDGFRA.	U 0126	13-18	platelet derived growth factor receptor alpha	Homo sapiens	200-206
24489888-13	2014	Finally, down-regulation of surface PDGFRA expression by U0126 is concordant with reduced glioma cell proliferation.	U 0126	57-62	platelet derived growth factor receptor alpha	Homo sapiens	36-42
24213617-9	2014	Intriguingly, H2O2-induced expression of miR-145 was decreased by U0126 (10 mumol/l), a MEK1/2 inhibitor, and myocardin was decreased by anti-miR-145 (50 nmol/l) and U0126 (10 mumol/l).	U 0126	66-71	microRNA 145	Rattus norvegicus	41-48
24213617-9	2014	Intriguingly, H2O2-induced expression of miR-145 was decreased by U0126 (10 mumol/l), a MEK1/2 inhibitor, and myocardin was decreased by anti-miR-145 (50 nmol/l) and U0126 (10 mumol/l).	U 0126	66-71	mitogen activated protein kinase kinase 1	Rattus norvegicus	88-94
24213617-9	2014	Intriguingly, H2O2-induced expression of miR-145 was decreased by U0126 (10 mumol/l), a MEK1/2 inhibitor, and myocardin was decreased by anti-miR-145 (50 nmol/l) and U0126 (10 mumol/l).	U 0126	166-171	microRNA 145	Rattus norvegicus	41-48
24213617-9	2014	Intriguingly, H2O2-induced expression of miR-145 was decreased by U0126 (10 mumol/l), a MEK1/2 inhibitor, and myocardin was decreased by anti-miR-145 (50 nmol/l) and U0126 (10 mumol/l).	U 0126	166-171	microRNA 145	Rattus norvegicus	142-149
24416349-6	2014	Intriguingly, MEK/ERK inhibitors PD98059 and U0126 suppressed RAD001 plus MK-2206-induced beclin-1 expression, autophagy induction and cytotoxicity in HGC-27 cells.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
24416349-6	2014	Intriguingly, MEK/ERK inhibitors PD98059 and U0126 suppressed RAD001 plus MK-2206-induced beclin-1 expression, autophagy induction and cytotoxicity in HGC-27 cells.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	18-21
24416349-6	2014	Intriguingly, MEK/ERK inhibitors PD98059 and U0126 suppressed RAD001 plus MK-2206-induced beclin-1 expression, autophagy induction and cytotoxicity in HGC-27 cells.	U 0126	45-50	beclin 1	Homo sapiens	90-98
25482676-12	2014	MEK (U0126) inhibitor completely blocked dilong inhibited caspase 3 activation in High-KCS treated H9c2 cells.	U 0126	5-10	caspase 3	Rattus norvegicus	58-67
24717875-9	2014	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) significantly inhibited SEA-induced MUC5B mRNA expression.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	7-13
24717875-9	2014	U0126 (ERK1/2 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor) significantly inhibited SEA-induced MUC5B mRNA expression.	U 0126	0-5	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	100-105
24277030-7	2014	The combination of GCV and foscarnet was slightly synergistic; strong synergism was found when GCV was used with artemisinin-derived monomers or dimers or the MEK inhibitor U0126.	U 0126	173-178	mitogen-activated protein kinase kinase 7	Homo sapiens	159-162
24982891-2	2014	Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone.	U 0126	166-171	caspase 3	Homo sapiens	97-106
24982891-2	2014	Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone.	U 0126	166-171	mitogen-activated protein kinase 3	Homo sapiens	157-164
24982891-2	2014	Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone.	U 0126	166-171	interleukin 1 beta	Homo sapiens	201-210
24982891-2	2014	Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone.	U 0126	166-171	interleukin 1 beta	Homo sapiens	277-286
24854431-11	2014	Notably, application of ERK1/2 inhibitor U0126 (5muM) significantly repressed hypoxia-induced expression of LC-3 and Atg5, as well as conversion of LC3B-I to LC3B-II (p&lt;0.05).	U 0126	41-46	mitogen-activated protein kinase 3	Mus musculus	24-30
22454224-9	2014	Combined treatments of olaparib with a mitogen-activated protein kinase kinase (MEK) inhibitor U0126 completely suppressed expression of p-ERK.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	39-78
22454224-9	2014	Combined treatments of olaparib with a mitogen-activated protein kinase kinase (MEK) inhibitor U0126 completely suppressed expression of p-ERK.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
22454224-9	2014	Combined treatments of olaparib with a mitogen-activated protein kinase kinase (MEK) inhibitor U0126 completely suppressed expression of p-ERK.	U 0126	95-100	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	137-142
24854431-11	2014	Notably, application of ERK1/2 inhibitor U0126 (5muM) significantly repressed hypoxia-induced expression of LC-3 and Atg5, as well as conversion of LC3B-I to LC3B-II (p&lt;0.05).	U 0126	41-46	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	108-112
24854431-11	2014	Notably, application of ERK1/2 inhibitor U0126 (5muM) significantly repressed hypoxia-induced expression of LC-3 and Atg5, as well as conversion of LC3B-I to LC3B-II (p&lt;0.05).	U 0126	41-46	autophagy related 5	Mus musculus	117-121
25033895-6	2014	Furthermore, MCP-1-induced secretion of MMP-9 was inhibited by U0126 (inhibitor of the ERK 1/2 pathway) and SB203580 (inhibitor of the p38 MAPK pathway), but not SP600125 (inhibitor of the JNK1/2 pathway).	U 0126	63-68	C-C motif chemokine ligand 2	Homo sapiens	13-18
25033895-6	2014	Furthermore, MCP-1-induced secretion of MMP-9 was inhibited by U0126 (inhibitor of the ERK 1/2 pathway) and SB203580 (inhibitor of the p38 MAPK pathway), but not SP600125 (inhibitor of the JNK1/2 pathway).	U 0126	63-68	matrix metallopeptidase 9	Homo sapiens	40-45
25033895-6	2014	Furthermore, MCP-1-induced secretion of MMP-9 was inhibited by U0126 (inhibitor of the ERK 1/2 pathway) and SB203580 (inhibitor of the p38 MAPK pathway), but not SP600125 (inhibitor of the JNK1/2 pathway).	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	87-94
24622432-7	2014	For inhibitor studies, the cells were pre-incubated with the MEK1/2 inhibitor U0126.	U 0126	78-83	mitogen-activated protein kinase kinase 1	Homo sapiens	61-67
24622432-11	2014	And treatment with U0126 downregulated the phosphorylation of ERK1/2 and attenuated ATV-induced autophagy.	U 0126	19-24	mitogen-activated protein kinase 3	Homo sapiens	62-68
24080365-7	2014	The MAPK/ERK kinase inhibitor U0126, but not its inactive analog U0124, as well as the c-Raf-specific inhibitor GW5074, blocked the IGF-1-induced IA response.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	4-8
24080365-7	2014	The MAPK/ERK kinase inhibitor U0126, but not its inactive analog U0124, as well as the c-Raf-specific inhibitor GW5074, blocked the IGF-1-induced IA response.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	9-12
24080365-7	2014	The MAPK/ERK kinase inhibitor U0126, but not its inactive analog U0124, as well as the c-Raf-specific inhibitor GW5074, blocked the IGF-1-induced IA response.	U 0126	30-35	insulin like growth factor 1	Homo sapiens	132-137
24206109-8	2014	Furthermore, blocking ERK, PI3K and NFkappaB signaling pathways with U0126, LY294002 and pyrrolidine dithiocarbamate, respectively, significantly inhibited the mGluR2/3-mediated restorative effects.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	22-25
24206109-8	2014	Furthermore, blocking ERK, PI3K and NFkappaB signaling pathways with U0126, LY294002 and pyrrolidine dithiocarbamate, respectively, significantly inhibited the mGluR2/3-mediated restorative effects.	U 0126	69-74	nuclear factor kappa B subunit 1	Homo sapiens	36-44
24206109-8	2014	Furthermore, blocking ERK, PI3K and NFkappaB signaling pathways with U0126, LY294002 and pyrrolidine dithiocarbamate, respectively, significantly inhibited the mGluR2/3-mediated restorative effects.	U 0126	69-74	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	160-166
24883066-7	2014	U0126 treatment also exhibited the same effect as EA on Egr-1 level and subsequent cardioprotective effects.	U 0126	0-5	early growth response 1	Mus musculus	56-61
24348766-6	2014	At 14 and 28 days subsequent to the injury, the number of cells that were positive for GFAP expression in the U0126-treated group was significantly reduced and the GFAP-positive cells were observed to be smaller, with a reduced prominence and pale staining.	U 0126	110-115	glial fibrillary acidic protein	Rattus norvegicus	87-91
24389204-4	2014	U0126 or PTIO alone had no effect on infarct size but abolished the effects of netrin-1.	U 0126	0-5	netrin 1	Mus musculus	79-87
24448375-0	2014	ERK inhibitor U0126 enhanced SDT-induced cytotoxicity of human leukemia U937 cells.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	0-3
24448375-9	2014	Especially, pre-treatment with ERK inhibitor U0126 could additionally enhance SDT-induced cell viability loss, early- and late-apoptotic rate, chromatin condensation, DNA fragmentation and caspase-3 activation.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	31-34
24448375-9	2014	Especially, pre-treatment with ERK inhibitor U0126 could additionally enhance SDT-induced cell viability loss, early- and late-apoptotic rate, chromatin condensation, DNA fragmentation and caspase-3 activation.	U 0126	45-50	caspase 3	Homo sapiens	189-198
24189697-7	2014	The specific MEK/ERK inhibitor U0126 decreased the tumorigenic potential and improved the radiation response in all cellular models.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
24189697-7	2014	The specific MEK/ERK inhibitor U0126 decreased the tumorigenic potential and improved the radiation response in all cellular models.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	17-20
24189697-8	2014	The modulation of radioresponse upon U0126 treatment positively correlated with the inhibition of phospho-ERKs and the reduction of Aurora-B kinase expression.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	106-110
24189697-8	2014	The modulation of radioresponse upon U0126 treatment positively correlated with the inhibition of phospho-ERKs and the reduction of Aurora-B kinase expression.	U 0126	37-42	aurora kinase B	Homo sapiens	132-140
24189697-9	2014	In addition, upon U0126 treatment DNA-PKcs protein expression was found to be downregulated, indicating that the improved radiation response may be caused by decreased DNA double-strand damage repair mechanisms.	U 0126	18-23	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	34-42
24096320-7	2014	In addition, the Ras-mediated increase in HAdV replication was impaired by the mitogen-activated protein kinase/ERK kinase (MEK1) inhibitor U0126, suggesting direct involvement of the MEK1/ERK pathway in enhanced HAdV replication.	U 0126	140-145	mitogen-activated protein kinase 1	Homo sapiens	112-115
24096320-7	2014	In addition, the Ras-mediated increase in HAdV replication was impaired by the mitogen-activated protein kinase/ERK kinase (MEK1) inhibitor U0126, suggesting direct involvement of the MEK1/ERK pathway in enhanced HAdV replication.	U 0126	140-145	mitogen-activated protein kinase kinase 1	Homo sapiens	124-128
24096320-7	2014	In addition, the Ras-mediated increase in HAdV replication was impaired by the mitogen-activated protein kinase/ERK kinase (MEK1) inhibitor U0126, suggesting direct involvement of the MEK1/ERK pathway in enhanced HAdV replication.	U 0126	140-145	mitogen-activated protein kinase kinase 1	Homo sapiens	184-188
24096320-7	2014	In addition, the Ras-mediated increase in HAdV replication was impaired by the mitogen-activated protein kinase/ERK kinase (MEK1) inhibitor U0126, suggesting direct involvement of the MEK1/ERK pathway in enhanced HAdV replication.	U 0126	140-145	mitogen-activated protein kinase 1	Homo sapiens	189-192
23782309-9	2014	It was also observed that the ability of BPA to enhance histamine and CysLT release was inhibited by blocking the extracellular signal-regulated kinase (ERK) pathway with U0126 or by chelating extracellular calcium (Ca(2+)) using EGTA.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	114-151
23782309-9	2014	It was also observed that the ability of BPA to enhance histamine and CysLT release was inhibited by blocking the extracellular signal-regulated kinase (ERK) pathway with U0126 or by chelating extracellular calcium (Ca(2+)) using EGTA.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	153-156
24277696-6	2014	The thrombin-induced increases in IL-8/CXCL8 release and IL-8/CXCL8-luciferase were also inhibited by MEKK1 siRNA, PD98059 (an MEK inhibitor), U0126 (an ERK inhibitor), and RSK1 siRNA.	U 0126	143-148	coagulation factor II, thrombin	Homo sapiens	4-12
24277696-6	2014	The thrombin-induced increases in IL-8/CXCL8 release and IL-8/CXCL8-luciferase were also inhibited by MEKK1 siRNA, PD98059 (an MEK inhibitor), U0126 (an ERK inhibitor), and RSK1 siRNA.	U 0126	143-148	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
24277696-6	2014	The thrombin-induced increases in IL-8/CXCL8 release and IL-8/CXCL8-luciferase were also inhibited by MEKK1 siRNA, PD98059 (an MEK inhibitor), U0126 (an ERK inhibitor), and RSK1 siRNA.	U 0126	143-148	C-X-C motif chemokine ligand 8	Homo sapiens	57-61
24277696-6	2014	The thrombin-induced increases in IL-8/CXCL8 release and IL-8/CXCL8-luciferase were also inhibited by MEKK1 siRNA, PD98059 (an MEK inhibitor), U0126 (an ERK inhibitor), and RSK1 siRNA.	U 0126	143-148	C-X-C motif chemokine ligand 8	Homo sapiens	62-67
24881958-5	2014	The roles of ERK1/2 and p38 were further confirmed using the ERK1/2 inhibitor (U0126) and p38 inhibitor (SB203580).	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	13-19
24881958-5	2014	The roles of ERK1/2 and p38 were further confirmed using the ERK1/2 inhibitor (U0126) and p38 inhibitor (SB203580).	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	24-27
24881958-5	2014	The roles of ERK1/2 and p38 were further confirmed using the ERK1/2 inhibitor (U0126) and p38 inhibitor (SB203580).	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	61-67
24881958-6	2014	U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis.	U 0126	0-5	BCL2 associated X, apoptosis regulator	Homo sapiens	40-43
24881958-6	2014	U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis.	U 0126	0-5	BCL2 apoptosis regulator	Homo sapiens	44-49
24881958-6	2014	U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis.	U 0126	0-5	cytochrome c, somatic	Homo sapiens	81-93
24881958-6	2014	U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	204-210
24114663-5	2014	The activation of mitogen-activated protein kinases (MAPKs) was blocked by ISO, and NF-kappaB nuclear translocation was decreased by ISO both alone and together with NF-kappaB inhibitor (PDTC) and MAPKs inhibitors (U0126, SP 600125, and SB 203580).	U 0126	215-220	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
24203464-6	2014	Treatment with the MEK inhibitor U0126 followed by co-stimulation with EGF and TGF-beta1 prevented the upregulation of Snail protein, EMT and motility, without impairing Snail mRNA.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
24203464-6	2014	Treatment with the MEK inhibitor U0126 followed by co-stimulation with EGF and TGF-beta1 prevented the upregulation of Snail protein, EMT and motility, without impairing Snail mRNA.	U 0126	33-38	transforming growth factor beta 1	Homo sapiens	79-88
24203464-6	2014	Treatment with the MEK inhibitor U0126 followed by co-stimulation with EGF and TGF-beta1 prevented the upregulation of Snail protein, EMT and motility, without impairing Snail mRNA.	U 0126	33-38	snail family transcriptional repressor 1	Homo sapiens	119-124
24203464-6	2014	Treatment with the MEK inhibitor U0126 followed by co-stimulation with EGF and TGF-beta1 prevented the upregulation of Snail protein, EMT and motility, without impairing Snail mRNA.	U 0126	33-38	snail family transcriptional repressor 1	Homo sapiens	170-175
24145738-5	2014	In vitro experiments demonstrated that the overexpression of ETBR significantly enhanced the proliferation of oligodendroglioma cells and the activation of ERK compared with the controls, which was eliminated by the selective ETBR inhibitor BQ788 and ERK-specific inhibitor U0126, but not selective endothelin A receptor inhibitor BQ123.	U 0126	274-279	endothelin receptor type B	Mus musculus	61-65
24145738-5	2014	In vitro experiments demonstrated that the overexpression of ETBR significantly enhanced the proliferation of oligodendroglioma cells and the activation of ERK compared with the controls, which was eliminated by the selective ETBR inhibitor BQ788 and ERK-specific inhibitor U0126, but not selective endothelin A receptor inhibitor BQ123.	U 0126	274-279	mitogen-activated protein kinase 1	Mus musculus	156-159
24145738-5	2014	In vitro experiments demonstrated that the overexpression of ETBR significantly enhanced the proliferation of oligodendroglioma cells and the activation of ERK compared with the controls, which was eliminated by the selective ETBR inhibitor BQ788 and ERK-specific inhibitor U0126, but not selective endothelin A receptor inhibitor BQ123.	U 0126	274-279	mitogen-activated protein kinase 1	Mus musculus	251-254
24173825-6	2014	This effect was inhibited by pretreatment of Colo205 cells with the MEK-ERK chemical inhibitor, U0126.	U 0126	96-101	mitogen-activated protein kinase kinase 7	Homo sapiens	68-71
24173825-6	2014	This effect was inhibited by pretreatment of Colo205 cells with the MEK-ERK chemical inhibitor, U0126.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	72-75
24299309-4	2014	Inhibition of ERK1/2 signaling by MEK inhibitor U0126 promoted cell death via increased activation of caspases, drop in mitochondrial membrane potential and downregulation of XIAP, cIAP2 and Mcl-1.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	14-20
24299309-4	2014	Inhibition of ERK1/2 signaling by MEK inhibitor U0126 promoted cell death via increased activation of caspases, drop in mitochondrial membrane potential and downregulation of XIAP, cIAP2 and Mcl-1.	U 0126	48-53	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
24299309-4	2014	Inhibition of ERK1/2 signaling by MEK inhibitor U0126 promoted cell death via increased activation of caspases, drop in mitochondrial membrane potential and downregulation of XIAP, cIAP2 and Mcl-1.	U 0126	48-53	X-linked inhibitor of apoptosis	Homo sapiens	175-179
24299309-4	2014	Inhibition of ERK1/2 signaling by MEK inhibitor U0126 promoted cell death via increased activation of caspases, drop in mitochondrial membrane potential and downregulation of XIAP, cIAP2 and Mcl-1.	U 0126	48-53	baculoviral IAP repeat containing 3	Homo sapiens	181-186
24299309-4	2014	Inhibition of ERK1/2 signaling by MEK inhibitor U0126 promoted cell death via increased activation of caspases, drop in mitochondrial membrane potential and downregulation of XIAP, cIAP2 and Mcl-1.	U 0126	48-53	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	191-196
25700356-8	2014	Additionally, U0126, an ERK signaling inhibitor, exerted a reversible effect on TGF-beta1-induced EMT and inhibited FOXM1 expression.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	24-27
25700356-8	2014	Additionally, U0126, an ERK signaling inhibitor, exerted a reversible effect on TGF-beta1-induced EMT and inhibited FOXM1 expression.	U 0126	14-19	transforming growth factor beta 1	Homo sapiens	80-89
25700356-8	2014	Additionally, U0126, an ERK signaling inhibitor, exerted a reversible effect on TGF-beta1-induced EMT and inhibited FOXM1 expression.	U 0126	14-19	IL2 inducible T cell kinase	Homo sapiens	98-101
25700356-8	2014	Additionally, U0126, an ERK signaling inhibitor, exerted a reversible effect on TGF-beta1-induced EMT and inhibited FOXM1 expression.	U 0126	14-19	forkhead box M1	Homo sapiens	116-121
24790701-13	2014	Both myosin Va mRNA and protein expression significantly increased after BMP-2 administration and were inhibited by Erk1/2 inhibitor U0126.	U 0126	133-138	myosin VA	Homo sapiens	5-14
24790701-13	2014	Both myosin Va mRNA and protein expression significantly increased after BMP-2 administration and were inhibited by Erk1/2 inhibitor U0126.	U 0126	133-138	mitogen-activated protein kinase 3	Homo sapiens	116-122
24376709-7	2013	PI3K/AKT inhibitor LY294002 and MAPK/ERK kinase (MEK) inhibitor U0126 treatments study clearly indicated that Pls-mediated cell survival was dependent on the activation of these kinases.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	32-36
24315856-6	2014	Blockage of ERK1/2 and p38 MAPK signal pathways using MEK1/2 inhibitors (PD98059 and U0126) or p38 inhibitors (SB203580 and SB239063) significantly abolished the LDL-induced upregulation of vasoconstrictive ET(B) receptor expression.	U 0126	85-90	mitogen activated protein kinase 3	Rattus norvegicus	12-18
24315856-6	2014	Blockage of ERK1/2 and p38 MAPK signal pathways using MEK1/2 inhibitors (PD98059 and U0126) or p38 inhibitors (SB203580 and SB239063) significantly abolished the LDL-induced upregulation of vasoconstrictive ET(B) receptor expression.	U 0126	85-90	mitogen activated protein kinase 14	Rattus norvegicus	23-26
24315856-6	2014	Blockage of ERK1/2 and p38 MAPK signal pathways using MEK1/2 inhibitors (PD98059 and U0126) or p38 inhibitors (SB203580 and SB239063) significantly abolished the LDL-induced upregulation of vasoconstrictive ET(B) receptor expression.	U 0126	85-90	mitogen activated protein kinase kinase 1	Rattus norvegicus	54-60
24308485-10	2013	Pretreatment with SP600125, U0126, or SB600125 abrogated HymnPro-induced activation of caspases-3 and caspase-7 and the cleavage of PARP, suggesting that MAPK signalings are involved in HymnPro-induced apoptosis.	U 0126	28-33	caspase 7	Homo sapiens	102-111
24308485-10	2013	Pretreatment with SP600125, U0126, or SB600125 abrogated HymnPro-induced activation of caspases-3 and caspase-7 and the cleavage of PARP, suggesting that MAPK signalings are involved in HymnPro-induced apoptosis.	U 0126	28-33	poly(ADP-ribose) polymerase 1	Homo sapiens	132-136
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	U 0126	27-32	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	105-110
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	U 0126	27-32	mitogen-activated protein kinase 3	Mus musculus	112-118
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	U 0126	27-32	mitogen-activated protein kinase 14	Mus musculus	120-123
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	U 0126	27-32	mitogen-activated protein kinase 8	Mus musculus	129-132
24376609-10	2013	BisGMA-induced cytotoxicity, cPLA2 phosphorylation, PGE2 generation, and caspases activation were reduced by AACOCF3, U0126, SB203580, and SP600125, respectively (p&lt;0.05).	U 0126	118-123	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	29-34
24376827-8	2013	In the presence of the MEK inhibitors (PD98059 or UO126), or in cells transfected with the Protein Enriched in Astrocytes (PEA-15), a cytoplasmic anchor of ERK1/2 MAP kinases, TRX-1 nuclear migration and TXNIP down-regulation are no longer observed in cells exposed to oxidants.	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	156-162
24376709-7	2013	PI3K/AKT inhibitor LY294002 and MAPK/ERK kinase (MEK) inhibitor U0126 treatments study clearly indicated that Pls-mediated cell survival was dependent on the activation of these kinases.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	37-40
24358301-6	2013	DP treatment also caused a time-dependent increase in protein levels of extracellular signal-regulated kinase 1 and 2 (ERK1/2), and inhibition of ERK1/2 phosphorylation with U0126 resulted in a decreased DP-induced autophagy that was accompanied by an increased apoptosis and a decreased cell viability.	U 0126	174-179	mitogen-activated protein kinase 3	Homo sapiens	146-152
24211253-5	2013	Mechanistically, inhibition of MEK1 by both PD98059 and U0126 as well as RNAi reduces beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC), which acts as a potential endogenous YAP protector.	U 0126	56-61	mitogen-activated protein kinase kinase 1	Homo sapiens	31-35
24358311-8	2013	Pharmacological blockade of MAPK/ERK pathway using U0126, abolished PIMT/Med1-dependent gluconeogenic program leading to reduced hepatic glucose output.	U 0126	51-56	mitogen activated protein kinase 3	Rattus norvegicus	28-32
24358311-8	2013	Pharmacological blockade of MAPK/ERK pathway using U0126, abolished PIMT/Med1-dependent gluconeogenic program leading to reduced hepatic glucose output.	U 0126	51-56	mitogen activated protein kinase 3	Rattus norvegicus	33-36
24358311-8	2013	Pharmacological blockade of MAPK/ERK pathway using U0126, abolished PIMT/Med1-dependent gluconeogenic program leading to reduced hepatic glucose output.	U 0126	51-56	mediator complex subunit 1	Rattus norvegicus	73-77
24351811-9	2013	The mitogen-activated kinase/ERK kinase (MEK) inhibitor U0126 and the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 significantly decreased neurite outgrowth.	U 0126	56-61	Eph receptor B1	Rattus norvegicus	29-32
24211253-5	2013	Mechanistically, inhibition of MEK1 by both PD98059 and U0126 as well as RNAi reduces beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC), which acts as a potential endogenous YAP protector.	U 0126	56-61	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	149-153
24060240-6	2013	The 1alpha,25-dihydroxy-22-oxavitamin D3 (Oxa-D3) induced-sCD14 release was inhibited by U0126 (a specific inhibitor of extracellular signal-regulated kinase; ERK1/2) but not by SB203580 (a specific inhibitor of p38 MAPK), and ERK1/2 phosphorylation was accelerated by Oxa-D3.	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	159-165
24305604-11	2013	Inhibition of phosphorylated ERK with ERK inhibitor U0126 showed a significant decrease in autophagy.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	29-32
24305604-11	2013	Inhibition of phosphorylated ERK with ERK inhibitor U0126 showed a significant decrease in autophagy.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	38-41
24091596-9	2013	HMGB1 stimulation of HSC increased the phosphorylation of Src and Erk and HMGB1-induced HSC migration was blocked by the Src inhibitor PP2 and the Erk inhibitor U0126.	U 0126	161-166	high mobility group box 1	Homo sapiens	0-5
24091596-9	2013	HMGB1 stimulation of HSC increased the phosphorylation of Src and Erk and HMGB1-induced HSC migration was blocked by the Src inhibitor PP2 and the Erk inhibitor U0126.	U 0126	161-166	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	58-61
24091596-9	2013	HMGB1 stimulation of HSC increased the phosphorylation of Src and Erk and HMGB1-induced HSC migration was blocked by the Src inhibitor PP2 and the Erk inhibitor U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	66-69
24091596-9	2013	HMGB1 stimulation of HSC increased the phosphorylation of Src and Erk and HMGB1-induced HSC migration was blocked by the Src inhibitor PP2 and the Erk inhibitor U0126.	U 0126	161-166	high mobility group box 1	Homo sapiens	74-79
24091596-9	2013	HMGB1 stimulation of HSC increased the phosphorylation of Src and Erk and HMGB1-induced HSC migration was blocked by the Src inhibitor PP2 and the Erk inhibitor U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	147-150
23816505-4	2013	Both hyperosmolarity and H2O2 increased p-ERK1/2 and p-JNK, which were inhibited by U0126, a MEK inhibitor, and SP600125, a JNK inhibitor, respectively.	U 0126	84-89	mitogen-activated protein kinase 1	Canis lupus familiaris	42-48
23816505-5	2013	Immunoprecipitation assay showed that hyperosmolarity increased the association of nuclear Sp1 with c-Jun, which was inhibited by U0126 and SP600125.	U 0126	130-135	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	100-105
23816505-6	2013	In mouse inner medullary collecting duct cells and rat kidney slices, hyperosmolarity increased the expression level of claudin-4, which was inhibited by DPI, MnTBAP, U0126, and SP600125.	U 0126	167-172	claudin 4	Rattus norvegicus	120-129
23816505-7	2013	Hyperosmolarity increased luciferase reporter activity of claudin-4, which was inhibited by U0126, SP600125, Sp1 siRNA, and c-Jun siRNA.	U 0126	92-97	claudin 4	Canis lupus familiaris	58-67
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	mitogen-activated protein kinase 3	Homo sapiens	149-155
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	AKT serine/threonine kinase 1	Homo sapiens	157-160
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	mechanistic target of rapamycin kinase	Homo sapiens	165-169
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	mitogen-activated protein kinase 3	Homo sapiens	213-219
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	AKT serine/threonine kinase 1	Homo sapiens	221-224
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	mechanistic target of rapamycin kinase	Homo sapiens	229-233
24183830-6	2013	Moreover, UO126, a MEK inhibitor, reduces CD200 expression.	U 0126	10-15	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
24183830-6	2013	Moreover, UO126, a MEK inhibitor, reduces CD200 expression.	U 0126	10-15	CD200 molecule	Homo sapiens	42-47
24183830-7	2013	Furthermore, we observe that CD200-positive cells show reduced immunogenicity compared to normal lymphocytes and that such immunogenicity increases when UO126 is used.	U 0126	153-158	CD200 molecule	Homo sapiens	29-34
24075781-12	2013	Phosphorylation of ERK1/2 and subsequent secretion of MMP-9 were inhibited by the ERK inhibitor U0126 and not regulated by overexpressed IKKalpha.	U 0126	96-101	mitogen-activated protein kinase 3	Mus musculus	19-25
24075781-12	2013	Phosphorylation of ERK1/2 and subsequent secretion of MMP-9 were inhibited by the ERK inhibitor U0126 and not regulated by overexpressed IKKalpha.	U 0126	96-101	matrix metallopeptidase 9	Mus musculus	54-59
24075781-12	2013	Phosphorylation of ERK1/2 and subsequent secretion of MMP-9 were inhibited by the ERK inhibitor U0126 and not regulated by overexpressed IKKalpha.	U 0126	96-101	mitogen-activated protein kinase 1	Mus musculus	19-22
24055892-6	2013	BadSer155 phosphorylation by 6-OHDA was inhibited by PKA (H89) and MEK (U0126) inhibitors, indicating that it was mediated via the cAMP-PKA-sustained ERK1/2 system.	U 0126	72-77	mitogen activated protein kinase 3	Rattus norvegicus	150-156
24319338-13	2013	However, unlike the SB216763-treated cells, the UO126-treated cells showed a marked absence of Bcl-2, as well as phosphorylated Bcl-2 relative to the controls.	U 0126	48-53	BCL2 apoptosis regulator	Homo sapiens	95-100
24319338-13	2013	However, unlike the SB216763-treated cells, the UO126-treated cells showed a marked absence of Bcl-2, as well as phosphorylated Bcl-2 relative to the controls.	U 0126	48-53	BCL2 apoptosis regulator	Homo sapiens	128-133
24319338-14	2013	UO126 treatment of bovine lens epithelial cells showed similar results with pBcl-2 levels, while the Bcl-2 content appeared unchanged relative to the control cells.	U 0126	0-5	BCL2 apoptosis regulator	Bos taurus	77-82
24319338-19	2013	UO126, likewise, inhibits GSK-3beta activity, but unlike SB216763, inhibition of ERK phosphorylation induces the loss of intracellular pBcl-2 levels under conditions where intracellular BAX levels remain constant.	U 0126	0-5	glycogen synthase kinase 3 beta	Homo sapiens	26-35
24179688-9	2013	IL-8 production was decreased by pretreatment with the extracellular signal-regulated kinase (ERK) inhibitor U0126 but not with JNK inhibitor II or the p38 MAPK inhibitor SB202190.	U 0126	109-114	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
24179688-9	2013	IL-8 production was decreased by pretreatment with the extracellular signal-regulated kinase (ERK) inhibitor U0126 but not with JNK inhibitor II or the p38 MAPK inhibitor SB202190.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	55-92
24179688-9	2013	IL-8 production was decreased by pretreatment with the extracellular signal-regulated kinase (ERK) inhibitor U0126 but not with JNK inhibitor II or the p38 MAPK inhibitor SB202190.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	94-97
23743762-15	2013	However, the estradiol-enhanced LC3 protein expression was significantly suppressed by U0126 through inhibition of phosphorylation of extracellular signal-regulated kinase (ERK).	U 0126	87-92	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	32-35
23743762-15	2013	However, the estradiol-enhanced LC3 protein expression was significantly suppressed by U0126 through inhibition of phosphorylation of extracellular signal-regulated kinase (ERK).	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	134-171
23743762-15	2013	However, the estradiol-enhanced LC3 protein expression was significantly suppressed by U0126 through inhibition of phosphorylation of extracellular signal-regulated kinase (ERK).	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	173-176
24025354-6	2013	MEK inhibitor U0126 and GSK1120212 inhibited the motility, migration, and invasion of Smad4 knockdown cells, inhibited metastasis, and prolonged the survival of metastatic tumor-bearing mice.	U 0126	14-19	midkine	Mus musculus	0-3
24025354-6	2013	MEK inhibitor U0126 and GSK1120212 inhibited the motility, migration, and invasion of Smad4 knockdown cells, inhibited metastasis, and prolonged the survival of metastatic tumor-bearing mice.	U 0126	14-19	SMAD family member 4	Mus musculus	86-91
23891589-3	2013	The results showed that (1) UVB caused PDCD4 inhibition in JB6 cells; (2) exposure of cells to UVB caused a significant increase of miR-21, the upstream regulator of PDCD4, expression; (3) both inhibition of ERKs with U0126 and inhibition of p38 with SB203580 significantly reversed UVB-induced PDCD4 inhibition; (4) ROS scavenger, N-acetyl-l-cysteine reversed the inhibitory effect of UVB on PDCD4 expression.	U 0126	218-223	microRNA 21	Homo sapiens	132-138
24008433-6	2013	Inhibition of ERK using the specific inhibitor U0126 blocked the Phx-3-induced apoptosis only in part.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	14-17
23876632-6	2013	Our results showed that acetic acid-induced visceral nociception produced a persistent activation of ERK in the RVM area and a microinjection of a mitogen-activated ERK kinase (MEK) inhibitor, U0126, into the RVM area significantly inhibited the visceral noxious stimulation-induced behaviors in rats.	U 0126	193-198	Eph receptor B1	Rattus norvegicus	101-104
23876632-6	2013	Our results showed that acetic acid-induced visceral nociception produced a persistent activation of ERK in the RVM area and a microinjection of a mitogen-activated ERK kinase (MEK) inhibitor, U0126, into the RVM area significantly inhibited the visceral noxious stimulation-induced behaviors in rats.	U 0126	193-198	Eph receptor B1	Rattus norvegicus	165-168
24055799-8	2013	Additionally, PDGF-induced up-regulation of KCa3.1 and down-regulation of BSM contractile marker proteins were regulated by the ERK inhibitor U0126 and the AKT inhibitor LY294002.	U 0126	142-147	potassium calcium-activated channel subfamily N member 4	Homo sapiens	44-50
24055799-8	2013	Additionally, PDGF-induced up-regulation of KCa3.1 and down-regulation of BSM contractile marker proteins were regulated by the ERK inhibitor U0126 and the AKT inhibitor LY294002.	U 0126	142-147	mitogen-activated protein kinase 1	Homo sapiens	128-131
24094550-5	2013	SA-beta-gal activity and cytoplasm size in senescent hCPC(c-kit+) were significantly reduced, with reduced TP53 and cMdm2 expression after treatment with a specific ERK inhibitor (U0126).	U 0126	180-185	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	58-63
24094550-5	2013	SA-beta-gal activity and cytoplasm size in senescent hCPC(c-kit+) were significantly reduced, with reduced TP53 and cMdm2 expression after treatment with a specific ERK inhibitor (U0126).	U 0126	180-185	tumor protein p53	Homo sapiens	107-111
24094550-5	2013	SA-beta-gal activity and cytoplasm size in senescent hCPC(c-kit+) were significantly reduced, with reduced TP53 and cMdm2 expression after treatment with a specific ERK inhibitor (U0126).	U 0126	180-185	mitogen-activated protein kinase 1	Homo sapiens	165-168
24194944-9	2013	MEK inhibitor UO126 partly restores differentiation of 3T3-L1 cells that overexpress Brd2.	U 0126	14-19	midkine	Mus musculus	0-3
24194944-9	2013	MEK inhibitor UO126 partly restores differentiation of 3T3-L1 cells that overexpress Brd2.	U 0126	14-19	bromodomain containing 2	Mus musculus	85-89
23969277-4	2013	NIS mRNA levels remained repressed in TSH-stimulated primary thyroid cells co-treated with epidermal growth factor (EGF) and pan-MEK inhibitor U0126 in the presence of 5% fetal bovine serum or, independently of serum, in 3D cultured thyroid follicles.	U 0126	143-148	mitogen-activated protein kinase kinase 7	Homo sapiens	129-132
23851027-5	2013	Some mice were administered with U0126, a specific upstream inhibitor of ERK, daily during the recovery phase, beginning at 1day after ischemia until sacrifice.	U 0126	33-38	mitogen-activated protein kinase 1	Mus musculus	73-76
23851027-10	2013	Furthermore, U0126 elevated the expression of cell cycle arrest-related proteins, p21 and phospholylated-chk2 in the post-ischemic kidney.	U 0126	13-18	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	82-85
23851027-10	2013	Furthermore, U0126 elevated the expression of cell cycle arrest-related proteins, p21 and phospholylated-chk2 in the post-ischemic kidney.	U 0126	13-18	checkpoint kinase 2	Mus musculus	105-109
23851027-11	2013	U0126 mitigated the post-I/R increase of Sec10 which is a crucial component of exocyst complex and an important factor in ciliogenesis and tubulogenesis.	U 0126	0-5	exocyst complex component 5	Mus musculus	41-46
23851027-12	2013	U0126 also enhanced the expression of fibrosis-related proteins, TGF-beta1 and phosphorylated NF-kappaB after ischemia.	U 0126	0-5	transforming growth factor, beta 1	Mus musculus	65-74
23939423-10	2013	Heparin partially blocked the growth inhibitory effect, while the MEK inhibitor U0126 enhanced it.	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	66-69
24012919-8	2013	Treatment with U-0126, a MEK inhibitor, demonstrates that this radiation-induced inflammation in astrocytes is mediated through the MAP kinase pathway.	U 0126	15-21	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
24064688-5	2013	RESULTS: Inhibiting AKT with MK-2206 or MEK1/2 with U0126 for 24 hours in the absence of R5020 increased total and nuclear PRA and PRB protein levels in OSIS but not in eutopic endometrial stromal cells from disease-free patients from disease-free patients.	U 0126	52-57	AKT serine/threonine kinase 1	Homo sapiens	20-23
24064688-5	2013	RESULTS: Inhibiting AKT with MK-2206 or MEK1/2 with U0126 for 24 hours in the absence of R5020 increased total and nuclear PRA and PRB protein levels in OSIS but not in eutopic endometrial stromal cells from disease-free patients from disease-free patients.	U 0126	52-57	mitogen-activated protein kinase kinase 1	Homo sapiens	40-46
24064688-5	2013	RESULTS: Inhibiting AKT with MK-2206 or MEK1/2 with U0126 for 24 hours in the absence of R5020 increased total and nuclear PRA and PRB protein levels in OSIS but not in eutopic endometrial stromal cells from disease-free patients from disease-free patients.	U 0126	52-57	RB transcriptional corepressor 1	Homo sapiens	131-134
24096891-9	2013	Further studies revealed that PGRN can specifically facilitate ERK1,2 activation, and this activation can be abolished by U0126.	U 0126	122-127	granulin precursor	Homo sapiens	30-34
24096891-9	2013	Further studies revealed that PGRN can specifically facilitate ERK1,2 activation, and this activation can be abolished by U0126.	U 0126	122-127	mitogen-activated protein kinase 3	Homo sapiens	63-69
24002703-5	2013	Doxycycline (10 mug/mL), an inhibitor of MMP, markedly attenuated the hypoxia-induced downregulation of Cx43 protein expression at 6 h. The hypoxia-induced decrease in Cx43 protein expression was significantly reversed by U0126 (10 muM), a MEK/ERK1/2 inhibitor, at 6 and 12 h; LY294002 (30 muM), a PI3K inhibitor, downregulated Cx43 expression.	U 0126	222-227	matrix metallopeptidase 9	Homo sapiens	41-44
24002703-5	2013	Doxycycline (10 mug/mL), an inhibitor of MMP, markedly attenuated the hypoxia-induced downregulation of Cx43 protein expression at 6 h. The hypoxia-induced decrease in Cx43 protein expression was significantly reversed by U0126 (10 muM), a MEK/ERK1/2 inhibitor, at 6 and 12 h; LY294002 (30 muM), a PI3K inhibitor, downregulated Cx43 expression.	U 0126	222-227	gap junction protein alpha 1	Homo sapiens	104-108
24002703-5	2013	Doxycycline (10 mug/mL), an inhibitor of MMP, markedly attenuated the hypoxia-induced downregulation of Cx43 protein expression at 6 h. The hypoxia-induced decrease in Cx43 protein expression was significantly reversed by U0126 (10 muM), a MEK/ERK1/2 inhibitor, at 6 and 12 h; LY294002 (30 muM), a PI3K inhibitor, downregulated Cx43 expression.	U 0126	222-227	gap junction protein alpha 1	Homo sapiens	168-172
24002703-5	2013	Doxycycline (10 mug/mL), an inhibitor of MMP, markedly attenuated the hypoxia-induced downregulation of Cx43 protein expression at 6 h. The hypoxia-induced decrease in Cx43 protein expression was significantly reversed by U0126 (10 muM), a MEK/ERK1/2 inhibitor, at 6 and 12 h; LY294002 (30 muM), a PI3K inhibitor, downregulated Cx43 expression.	U 0126	222-227	gap junction protein alpha 1	Homo sapiens	168-172
24002703-6	2013	Hypoxia-induced MMP-9 activation was inhibited by treatment with LY294002, U0126, and, most especially, U0126.	U 0126	75-80	matrix metallopeptidase 9	Homo sapiens	16-21
24002703-6	2013	Hypoxia-induced MMP-9 activation was inhibited by treatment with LY294002, U0126, and, most especially, U0126.	U 0126	104-109	matrix metallopeptidase 9	Homo sapiens	16-21
24161621-5	2013	Moreover, expressions of c-Myc, Bad, Bax and ATM in SK-N-BE(2) cell line were significantly increased by U0126+ATO treatment as compared to treatment with ATO alone.	U 0126	105-110	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	25-30
24161621-5	2013	Moreover, expressions of c-Myc, Bad, Bax and ATM in SK-N-BE(2) cell line were significantly increased by U0126+ATO treatment as compared to treatment with ATO alone.	U 0126	105-110	BCL2 associated X, apoptosis regulator	Homo sapiens	37-40
24161621-5	2013	Moreover, expressions of c-Myc, Bad, Bax and ATM in SK-N-BE(2) cell line were significantly increased by U0126+ATO treatment as compared to treatment with ATO alone.	U 0126	105-110	ATM serine/threonine kinase	Homo sapiens	45-48
26889270-10	2013	Snail overexpression was associated with increased extracellular-signal-regulated kinase activity, and antagonism of this activity with mitogen-activated protein (MAPK) inhibitor, UO126, inhibited cell invasion and decreased uPA activity.	U 0126	180-185	snail family transcriptional repressor 1	Homo sapiens	0-5
26889270-10	2013	Snail overexpression was associated with increased extracellular-signal-regulated kinase activity, and antagonism of this activity with mitogen-activated protein (MAPK) inhibitor, UO126, inhibited cell invasion and decreased uPA activity.	U 0126	180-185	plasminogen activator, urokinase	Homo sapiens	225-228
24370050-3	2013	Flow cytometry was used to detect expression of VCAM-1 on BMMSC exposed to TNF-alpha at different concentrations, and the effect of ERK inhibitor U0126 on VCAM-1 of BMMSC.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	132-135
24370050-3	2013	Flow cytometry was used to detect expression of VCAM-1 on BMMSC exposed to TNF-alpha at different concentrations, and the effect of ERK inhibitor U0126 on VCAM-1 of BMMSC.	U 0126	146-151	vascular cell adhesion molecule 1	Homo sapiens	155-161
24370050-9	2013	TNF-alpha caused activation of ERK signal pathway, and U0126 suppressed this effect induced by TNF-alpha.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	31-34
24370050-9	2013	TNF-alpha caused activation of ERK signal pathway, and U0126 suppressed this effect induced by TNF-alpha.	U 0126	55-60	tumor necrosis factor	Homo sapiens	95-104
24211212-5	2013	Pre-treatment of EC with U0126 completed abrogated basal and SS-induced ERK activation, inhibited p-eNOS(Thr495) and increased NO production by SS.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	72-75
24211581-8	2013	The up-regulation of BNIP3 by KRas in this setting is mediated by the MAPK pathway, and is attenuated by the respective inhibitors (PD98059, U0126).	U 0126	141-146	BCL2 interacting protein 3	Homo sapiens	21-26
24211581-8	2013	The up-regulation of BNIP3 by KRas in this setting is mediated by the MAPK pathway, and is attenuated by the respective inhibitors (PD98059, U0126).	U 0126	141-146	KRAS proto-oncogene, GTPase	Homo sapiens	30-34
24045180-3	2013	EXPERIMENTAL DESIGN: The antiproliferative effects of OSI-906 and the MEK 1/2 inhibitor U0126 were analyzed both as single agents and in combination in 13 colorectal cancer cell lines in vitro.	U 0126	88-93	mitogen-activated protein kinase kinase 1	Homo sapiens	70-77
23872072-10	2013	Furthermore, inhibitors of NF-kappaB (PDTC), ERK (U0126 and PD98059) and JNK (SP600125) partially blocked the suppression by ox-LDL on the CSE mRNA levels.	U 0126	50-55	cystathionine gamma-lyase	Homo sapiens	139-142
23941747-6	2013	A MEK inhibitor, U0126, antagonized the up-regulation of nestin but not the down-regulation of GFAP.	U 0126	17-22	midkine	Mus musculus	2-5
24223965-5	2013	The protective effect of silencing TRPM7 against HG induced endothelial injury was abolished by U0126, an inhibitor of the extracellular signal-regulated kinase signaling pathway.	U 0126	96-101	transient receptor potential cation channel subfamily M member 7	Homo sapiens	35-40
24288470-3	2013	JEG-3 choriocarcinoma cells were cultured in presence/absence of LIF and the specific ERK1/2 inhibitor (U0126).	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	86-92
24120080-7	2013	Pre-treatment with losartan (10(-10)M) or MAPK pathway inhibitors (U0126 or SP600125) abolished aldosterone-induced MR upregulation and significantly inhibited the expression of the above fibrotic marker proteins, indicating the critical role of MR and the requirement for active AT1 in the development of aldosterone-induced atrial fibrosis.	U 0126	67-72	angiotensin II receptor type 1	Homo sapiens	280-283
23876460-6	2013	Interestingly, Cd could activate both ERK and JNK signaling pathways in C6 cells; however, gamma-secretase-mediated N-cad/CTF2 production by Cd was completely blocked by MEK1/2 inhibitors PD184352 and U0126, but not by a JNK inhibitor SP600125, demonstrating that the ERK signaling pathway plays a major role in the cleavage.	U 0126	201-206	cadherin 2	Homo sapiens	116-121
23876460-6	2013	Interestingly, Cd could activate both ERK and JNK signaling pathways in C6 cells; however, gamma-secretase-mediated N-cad/CTF2 production by Cd was completely blocked by MEK1/2 inhibitors PD184352 and U0126, but not by a JNK inhibitor SP600125, demonstrating that the ERK signaling pathway plays a major role in the cleavage.	U 0126	201-206	mitogen-activated protein kinase kinase 1	Homo sapiens	170-176
23876460-6	2013	Interestingly, Cd could activate both ERK and JNK signaling pathways in C6 cells; however, gamma-secretase-mediated N-cad/CTF2 production by Cd was completely blocked by MEK1/2 inhibitors PD184352 and U0126, but not by a JNK inhibitor SP600125, demonstrating that the ERK signaling pathway plays a major role in the cleavage.	U 0126	201-206	mitogen-activated protein kinase 1	Homo sapiens	268-271
24060240-6	2013	The 1alpha,25-dihydroxy-22-oxavitamin D3 (Oxa-D3) induced-sCD14 release was inhibited by U0126 (a specific inhibitor of extracellular signal-regulated kinase; ERK1/2) but not by SB203580 (a specific inhibitor of p38 MAPK), and ERK1/2 phosphorylation was accelerated by Oxa-D3.	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	227-233
23966319-5	2013	We showed that inhibition of ERK1/2 with the pharmacological inhibitor U0126 led to a 3-fold increase in 11beta-HSD2 activity, protein, and mRNA in primary human placental trophoblast cells.	U 0126	71-76	mitogen-activated protein kinase 3	Homo sapiens	29-35
23969332-7	2013	The treatment of the cells with the MEK1/2 inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis (o-aminophenylmercapto butadiene) abolished the expression of iNOS and STAT-1ser727 phosphorylation generated by rhIL-17A.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	36-42
23969332-7	2013	The treatment of the cells with the MEK1/2 inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis (o-aminophenylmercapto butadiene) abolished the expression of iNOS and STAT-1ser727 phosphorylation generated by rhIL-17A.	U 0126	53-58	nitric oxide synthase 2	Homo sapiens	154-158
23969332-7	2013	The treatment of the cells with the MEK1/2 inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis (o-aminophenylmercapto butadiene) abolished the expression of iNOS and STAT-1ser727 phosphorylation generated by rhIL-17A.	U 0126	53-58	signal transducer and activator of transcription 1	Homo sapiens	163-169
23966319-5	2013	We showed that inhibition of ERK1/2 with the pharmacological inhibitor U0126 led to a 3-fold increase in 11beta-HSD2 activity, protein, and mRNA in primary human placental trophoblast cells.	U 0126	71-76	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	105-116
24043889-5	2013	Accordingly, the Galphai inhibitor pertussis toxin and MEK inhibitor U0126 blocked C5a inhibition of LPS-induced IL-6 and TNF production from macrophages.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
24043889-5	2013	Accordingly, the Galphai inhibitor pertussis toxin and MEK inhibitor U0126 blocked C5a inhibition of LPS-induced IL-6 and TNF production from macrophages.	U 0126	69-74	complement C5a receptor 1	Homo sapiens	83-86
24043889-5	2013	Accordingly, the Galphai inhibitor pertussis toxin and MEK inhibitor U0126 blocked C5a inhibition of LPS-induced IL-6 and TNF production from macrophages.	U 0126	69-74	interleukin 6	Homo sapiens	113-117
24043889-5	2013	Accordingly, the Galphai inhibitor pertussis toxin and MEK inhibitor U0126 blocked C5a inhibition of LPS-induced IL-6 and TNF production from macrophages.	U 0126	69-74	tumor necrosis factor	Homo sapiens	122-125
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	U 0126	154-159	tumor necrosis factor	Rattus norvegicus	0-9
23966319-7	2013	Furthermore, U0126 increased the HSD11B2 promoter activity by 300%, indicating that ERK1/2 regulates placental 11beta-HSD2 expression through a transcriptional mechanism.	U 0126	13-18	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	33-40
23966319-7	2013	Furthermore, U0126 increased the HSD11B2 promoter activity by 300%, indicating that ERK1/2 regulates placental 11beta-HSD2 expression through a transcriptional mechanism.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	84-90
23966319-7	2013	Furthermore, U0126 increased the HSD11B2 promoter activity by 300%, indicating that ERK1/2 regulates placental 11beta-HSD2 expression through a transcriptional mechanism.	U 0126	13-18	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	111-122
23966319-10	2013	Importantly, U0126 completely abrogated the inhibitory effects of cadmium on placental 11beta-HSD2.	U 0126	13-18	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	87-98
24119616-11	2013	In addition, overexpression of Irf-1 promoted the activation of Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high glucose or normal glucose/H2O2 conditions.	U 0126	125-130	interferon regulatory factor 1	Homo sapiens	31-36
24119616-11	2013	In addition, overexpression of Irf-1 promoted the activation of Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high glucose or normal glucose/H2O2 conditions.	U 0126	125-130	mitogen-activated protein kinase 3	Homo sapiens	64-70
24119616-11	2013	In addition, overexpression of Irf-1 promoted the activation of Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high glucose or normal glucose/H2O2 conditions.	U 0126	125-130	interferon regulatory factor 1	Homo sapiens	101-106
24119616-11	2013	In addition, overexpression of Irf-1 promoted the activation of Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high glucose or normal glucose/H2O2 conditions.	U 0126	125-130	mitogen-activated protein kinase 3	Homo sapiens	145-151
24119616-11	2013	In addition, overexpression of Irf-1 promoted the activation of Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high glucose or normal glucose/H2O2 conditions.	U 0126	125-130	proliferating cell nuclear antigen	Homo sapiens	221-227
24119616-11	2013	In addition, overexpression of Irf-1 promoted the activation of Erk1/2 and when VSMCs overexpressing Irf-1 were treated with U0126, the specific Erk1/2 inhibitor abolished the proliferation of VSMCs, the up-regulation of cyclin E/CDK2 and the acceleration of cell cycle progression under high glucose or normal glucose/H2O2 conditions.	U 0126	125-130	cyclin dependent kinase 2	Homo sapiens	230-234
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	U 0126	154-159	synaptotagmin 1	Rattus norvegicus	110-113
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	U 0126	154-159	matrix metallopeptidase 9	Rattus norvegicus	121-126
24146543-9	2013	RESULTS: Baseline activation of ERK1/2 in the untreated RPE cells and LECs was decreased by treatment with U-0126.	U 0126	107-113	mitogen-activated protein kinase 1	Canis lupus familiaris	32-38
24124570-0	2013	MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
24146543-10	2013	Bolus hydrogen peroxide greatly increased ERK1/2 activation that had been blocked by U-0126, whereas GO had no significant effect on ERK1/2 phosphorylation.	U 0126	85-91	mitogen-activated protein kinase 1	Canis lupus familiaris	42-48
24124570-4	2013	The pan-MEK inhibitor U0126 has previously been shown to reverse the axon-protective effects of proteasome inhibition, suggesting that MEK-ERK signaling plays a role in delayed Wallerian degeneration, in addition to its established role in promoting neuronal survival.	U 0126	22-27	mitogen-activated protein kinase kinase 7	Homo sapiens	8-11
24146543-15	2013	CONCLUSIONS: Although U-0126 inhibited the hydrogen peroxide-induced increase in ERK1/2 phosphorylation, U-0126"s lack of inhibition of the peroxide-induced increase in intracellular ferritin levels indicates that this pathway is not involved in ferritin induction by hydrogen peroxide.	U 0126	22-28	mitogen-activated protein kinase 1	Canis lupus familiaris	81-87
24124570-4	2013	The pan-MEK inhibitor U0126 has previously been shown to reverse the axon-protective effects of proteasome inhibition, suggesting that MEK-ERK signaling plays a role in delayed Wallerian degeneration, in addition to its established role in promoting neuronal survival.	U 0126	22-27	mitogen-activated protein kinase kinase 7	Homo sapiens	135-138
24124570-4	2013	The pan-MEK inhibitor U0126 has previously been shown to reverse the axon-protective effects of proteasome inhibition, suggesting that MEK-ERK signaling plays a role in delayed Wallerian degeneration, in addition to its established role in promoting neuronal survival.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	139-142
24124570-6	2013	This suggests that an off-target effect of U0126 is responsible for reversion of the axon protective effects of Wld(S) expression or proteasome inhibition, rather than inhibition of MEK1/2-ERK1/2 or MEK5-ERK5 signaling.	U 0126	43-48	mitogen-activated protein kinase 7	Homo sapiens	204-208
24146543-17	2013	Since ferritin can shield cells from iron-catalyzed damage, this downstream effect likely plays a protective role, which, in the case of the ERK1/2 inhibitor, U-0126, demonstrates a potential therapeutic target.	U 0126	159-165	mitogen-activated protein kinase 1	Canis lupus familiaris	141-147
24098385-7	2013	Furthermore, inhibition of ERK1,2 activation with U0126 prevented the reduction of p-Akt/Akt by angiotensin II.	U 0126	50-55	angiotensinogen	Homo sapiens	96-110
24098385-5	2013	In the absence of angiotensin II, inhibition of ERK1,2 activation with U0126 or PD98059 resulted in a 2.1+-0.5 (p&lt;0.001) and 1.4+-0.2-fold (p&lt;0.05) increase in the p-Akt/Akt ratio, respectively.	U 0126	71-76	mitogen-activated protein kinase 3	Homo sapiens	48-54
23822636-5	2013	Inhibition of the ERK pathway by U0126 blocked ligand-induced Thr-669 phosphorylation as well as Tyr-1068 dephosphorylation.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	18-21
24098385-5	2013	In the absence of angiotensin II, inhibition of ERK1,2 activation with U0126 or PD98059 resulted in a 2.1+-0.5 (p&lt;0.001) and 1.4+-0.2-fold (p&lt;0.05) increase in the p-Akt/Akt ratio, respectively.	U 0126	71-76	AKT serine/threonine kinase 1	Homo sapiens	172-175
24098385-5	2013	In the absence of angiotensin II, inhibition of ERK1,2 activation with U0126 or PD98059 resulted in a 2.1+-0.5 (p&lt;0.001) and 1.4+-0.2-fold (p&lt;0.05) increase in the p-Akt/Akt ratio, respectively.	U 0126	71-76	AKT serine/threonine kinase 1	Homo sapiens	176-179
24098385-7	2013	Furthermore, inhibition of ERK1,2 activation with U0126 prevented the reduction of p-Akt/Akt by angiotensin II.	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	27-33
24098385-7	2013	Furthermore, inhibition of ERK1,2 activation with U0126 prevented the reduction of p-Akt/Akt by angiotensin II.	U 0126	50-55	AKT serine/threonine kinase 1	Homo sapiens	85-88
24098385-7	2013	Furthermore, inhibition of ERK1,2 activation with U0126 prevented the reduction of p-Akt/Akt by angiotensin II.	U 0126	50-55	AKT serine/threonine kinase 1	Homo sapiens	89-92
23870474-10	2013	ERK1/2 specific blocker U0126 blocked ERK phosphorylation, and it could down-regulate the expression of MMP-2/9.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	0-6
23870474-10	2013	ERK1/2 specific blocker U0126 blocked ERK phosphorylation, and it could down-regulate the expression of MMP-2/9.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	0-3
23870474-10	2013	ERK1/2 specific blocker U0126 blocked ERK phosphorylation, and it could down-regulate the expression of MMP-2/9.	U 0126	24-29	matrix metallopeptidase 2	Homo sapiens	104-111
23727409-10	2013	Inhibition of ERK by U0126 preserved cilia during cisplatin treatment and protected against apoptosis in HK-2 cells.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	14-17
23975242-10	2013	Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation.	U 0126	186-191	thymidine phosphorylase	Mus musculus	66-68
23975242-10	2013	Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation.	U 0126	186-191	mitogen-activated protein kinase 1	Mus musculus	114-117
23975242-10	2013	Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation.	U 0126	186-191	mitogen-activated protein kinase 1	Mus musculus	156-159
23975242-10	2013	Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation.	U 0126	186-191	mitogen-activated protein kinase 1	Mus musculus	156-159
23975242-10	2013	Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation.	U 0126	186-191	thymidine phosphorylase	Mus musculus	214-216
23770289-5	2013	Treatment with ERK1/2 inhibitor U0126 significantly inhibited induction of migration, MMP-9 expression, and activation of NF-kappaB and AP-1 in IL-5-treated cells.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	15-21
23770289-5	2013	Treatment with ERK1/2 inhibitor U0126 significantly inhibited induction of migration, MMP-9 expression, and activation of NF-kappaB and AP-1 in IL-5-treated cells.	U 0126	32-37	matrix metallopeptidase 9	Homo sapiens	86-91
23770289-5	2013	Treatment with ERK1/2 inhibitor U0126 significantly inhibited induction of migration, MMP-9 expression, and activation of NF-kappaB and AP-1 in IL-5-treated cells.	U 0126	32-37	nuclear factor kappa B subunit 1	Homo sapiens	122-131
23770289-5	2013	Treatment with ERK1/2 inhibitor U0126 significantly inhibited induction of migration, MMP-9 expression, and activation of NF-kappaB and AP-1 in IL-5-treated cells.	U 0126	32-37	interleukin 5	Homo sapiens	144-148
23912965-6	2013	Importantly, pre-treatment of the cells with 400 microM NaHS or 3 microM SB203580 (a selective inhibitor of p38 MAPK) or 15 microM U0126 (a selective inhibitor of ERK1/2) attenuated the HG-induced cardiomyocyte injury, leading to an increase in cell viability and a decrease in the number of apoptotic cells, preventing ROS generation, as well as the loss of MMP.	U 0126	131-136	mitogen activated protein kinase 3	Rattus norvegicus	163-169
23997215-9	2013	Inhibitors against PI3K (LY294002) and MEK1/2 (UO126) efficiently blocked IL-33-induced proliferation in all model systems used.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Homo sapiens	39-45
23997215-9	2013	Inhibitors against PI3K (LY294002) and MEK1/2 (UO126) efficiently blocked IL-33-induced proliferation in all model systems used.	U 0126	47-52	interleukin 33	Homo sapiens	74-79
23859404-3	2013	The mitogen-activated protein kinase kinase (MEK) inhibitor U0126 also reduced glutamate-induced H2O2 generation and inhibited phosphorylation of extracellular signal-regulated kinase (ERK) 1/2.	U 0126	60-65	midkine	Mus musculus	4-43
23859404-3	2013	The mitogen-activated protein kinase kinase (MEK) inhibitor U0126 also reduced glutamate-induced H2O2 generation and inhibited phosphorylation of extracellular signal-regulated kinase (ERK) 1/2.	U 0126	60-65	midkine	Mus musculus	45-48
23952963-7	2013	This effect could be suppressed by co-treatment with the ERK1/2 inhibitor U0126.	U 0126	74-79	mitogen activated protein kinase 3	Rattus norvegicus	57-63
23859404-3	2013	The mitogen-activated protein kinase kinase (MEK) inhibitor U0126 also reduced glutamate-induced H2O2 generation and inhibited phosphorylation of extracellular signal-regulated kinase (ERK) 1/2.	U 0126	60-65	mitogen-activated protein kinase 3	Mus musculus	146-193
23928058-12	2013	Inhibition of the PI3K/Akt/mTOR pathway by LY294002 induced nSR100 expression, whereas the specific MEK/ERK inhibitor U0126 inhibited nSR100 expression.	U 0126	118-123	mitogen-activated protein kinase kinase 7	Homo sapiens	100-103
23928058-12	2013	Inhibition of the PI3K/Akt/mTOR pathway by LY294002 induced nSR100 expression, whereas the specific MEK/ERK inhibitor U0126 inhibited nSR100 expression.	U 0126	118-123	mitogen-activated protein kinase 1	Homo sapiens	104-107
23928058-12	2013	Inhibition of the PI3K/Akt/mTOR pathway by LY294002 induced nSR100 expression, whereas the specific MEK/ERK inhibitor U0126 inhibited nSR100 expression.	U 0126	118-123	serine/arginine repetitive matrix 4	Homo sapiens	134-140
24098421-11	2013	Addition of ERK inhibitors (U0126 and PD98059) nullified the stimulatory effect of HLA-G5 on trophoblastic cell invasion.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	12-15
24183042-5	2013	RESULTS: Both BEZ235 and U0126 suppressed PTEN knockout cell proliferation, and their half inhibitory concentrations were 6.257 nmol/L and 22.85 mumol/L, respectively.	U 0126	25-30	phosphatase and tensin homolog	Homo sapiens	42-46
23616010-5	2013	Protein kinase Calpha (PKCalpha) inhibitor safingol and extracellular signal-regulated kinase 1 and 2 (ERK1/2) inhibitor U0126 abrogated the activation of c-Jun.	U 0126	121-126	mitogen-activated protein kinase 1	Homo sapiens	56-101
23616010-5	2013	Protein kinase Calpha (PKCalpha) inhibitor safingol and extracellular signal-regulated kinase 1 and 2 (ERK1/2) inhibitor U0126 abrogated the activation of c-Jun.	U 0126	121-126	mitogen-activated protein kinase 3	Homo sapiens	103-109
23616010-5	2013	Protein kinase Calpha (PKCalpha) inhibitor safingol and extracellular signal-regulated kinase 1 and 2 (ERK1/2) inhibitor U0126 abrogated the activation of c-Jun.	U 0126	121-126	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	155-160
23681803-6	2013	We further demonstrated that the roles of ATDC on cell invasion, MMP-9 upregulation, and AP-1 activation were dependent on extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) pathway activation, and ERK inhibitor U0126 or JNK inhibitor SP600125 blocked these effects of ATDC.	U 0126	247-252	ATM serine/threonine kinase	Homo sapiens	42-46
23954826-4	2013	In this study, we found that NGF, ERK agonist, prevented neurons against TPEN-induced apoptosis, whereas TPEN-induced apoptosis was potentiated by U0126, inhibitors of ERK.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	168-171
23902762-11	2013	Meanwhile, an MEK inhibitor (U0126) recovered sox2 and ngn1 transcript levels in cdk10 morphants.	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
23902762-11	2013	Meanwhile, an MEK inhibitor (U0126) recovered sox2 and ngn1 transcript levels in cdk10 morphants.	U 0126	29-34	SRY-box transcription factor 2	Homo sapiens	46-50
23902762-11	2013	Meanwhile, an MEK inhibitor (U0126) recovered sox2 and ngn1 transcript levels in cdk10 morphants.	U 0126	29-34	neurogenin 1	Homo sapiens	55-59
23902762-11	2013	Meanwhile, an MEK inhibitor (U0126) recovered sox2 and ngn1 transcript levels in cdk10 morphants.	U 0126	29-34	cyclin dependent kinase 10	Homo sapiens	81-86
23954826-5	2013	Moreover, TPEN-induced caspase-3 activity was further increased by the pretreatment with U0126, but it was further decreased by the pretreatment with NGF.	U 0126	89-94	caspase 3	Homo sapiens	23-32
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	19-25
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	insulin like growth factor binding protein 1	Homo sapiens	126-132
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	prolactin	Homo sapiens	137-140
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	185-191
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	206-209
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	ribosomal protein S6 kinase A5	Homo sapiens	211-215
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	signal transducer and activator of transcription 1	Homo sapiens	217-222
24086495-11	2013	Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3.	U 0126	37-42	signal transducer and activator of transcription 3	Homo sapiens	228-233
23805846-8	2013	Treatment with Fyn pathway inhibitors, Fyn kinase inhibitor PP2 and MEK inhibitor U0126, reversed the PrP(C)-induced tau reduction and Abeta oligomer treatment modulated Fyn kinase activity.	U 0126	82-87	prion protein	Homo sapiens	102-108
24073294-3	2013	METHODS: ERK1/2 activity was inhibited using the specific inhibitor, U0126, in intestinal epithelial cells under hypoxia/reoxygenation conditions and in mice subjected to 1 hour of intestinal ischemia followed by 6 hours reperfusion.	U 0126	69-74	mitogen-activated protein kinase 3	Mus musculus	9-15
23805846-8	2013	Treatment with Fyn pathway inhibitors, Fyn kinase inhibitor PP2 and MEK inhibitor U0126, reversed the PrP(C)-induced tau reduction and Abeta oligomer treatment modulated Fyn kinase activity.	U 0126	82-87	microtubule associated protein tau	Homo sapiens	117-120
24073294-9	2013	RESULTS: In vitro, inhibition of ERK1/2 by U0126 significantly decreased cell proliferation and migration but enhanced cell apoptosis.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	33-39
24073294-11	2013	In vivo, U0126 significantly increased cell apoptosis and decreased cell proliferation in the intestine, increased intestinal permeability, intestinal and lung neutrophil infiltration, and injury, as well as systemic pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta.	U 0126	9-14	tumor necrosis factor	Homo sapiens	245-254
24073294-11	2013	In vivo, U0126 significantly increased cell apoptosis and decreased cell proliferation in the intestine, increased intestinal permeability, intestinal and lung neutrophil infiltration, and injury, as well as systemic pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta.	U 0126	9-14	interleukin 6	Homo sapiens	256-260
24073294-11	2013	In vivo, U0126 significantly increased cell apoptosis and decreased cell proliferation in the intestine, increased intestinal permeability, intestinal and lung neutrophil infiltration, and injury, as well as systemic pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta.	U 0126	9-14	interleukin 1 beta	Homo sapiens	265-273
24073294-13	2013	Inhibition of ERK1/2 by U0126 also abolished activity of p70S6K both in vitro and in vivo models.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	14-20
24073294-13	2013	Inhibition of ERK1/2 by U0126 also abolished activity of p70S6K both in vitro and in vivo models.	U 0126	24-29	ribosomal protein S6 kinase B1	Homo sapiens	57-63
24073294-14	2013	CONCLUSION: Pharmacologic inhibition of ERK1/2 by U0126 worsens intestinal IR injury.	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	40-46
24133577-9	2013	Pretreatment with MAPK3/1 inhibitor U0126 abrogated the phosphorylation of NF-kappaB p65 and I-kappaB.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	18-23
23973710-7	2013	Treatment with 10 muM of MEK inhibitor U0126 or PD98059 increased miR-143, respectively, by 187 +- 18 and 152 +- 26-fold in BxPC-3 and 182 +- 7 and 136 +- 9-fold in HPAF-II.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
24049436-9	2013	Interestingly, pretreatment of RGCs with AG1024 (an IGF-1 inhibitor), U0126 (an Erk-1/2 inhibitor), and LY294002 (an Akt inhibitor) markedly attenuated the effects of IGF-1 treatment.	U 0126	70-75	mitogen activated protein kinase 3	Rattus norvegicus	80-87
24049436-9	2013	Interestingly, pretreatment of RGCs with AG1024 (an IGF-1 inhibitor), U0126 (an Erk-1/2 inhibitor), and LY294002 (an Akt inhibitor) markedly attenuated the effects of IGF-1 treatment.	U 0126	70-75	insulin-like growth factor 1	Rattus norvegicus	167-172
24133577-9	2013	Pretreatment with MAPK3/1 inhibitor U0126 abrogated the phosphorylation of NF-kappaB p65 and I-kappaB.	U 0126	36-41	nuclear factor kappa B subunit 1	Homo sapiens	75-84
24133577-9	2013	Pretreatment with MAPK3/1 inhibitor U0126 abrogated the phosphorylation of NF-kappaB p65 and I-kappaB.	U 0126	36-41	RELA proto-oncogene, NF-kB subunit	Homo sapiens	85-88
24044038-3	2013	This response was significantly attenuated by over 60% when ERK1/2 was inhibited by U0126 (7 mug) (P &lt; 0.05).	U 0126	84-89	mitogen activated protein kinase 3	Rattus norvegicus	60-66
23831393-6	2013	Correspondingly, MSK1 inhibition, via H89, or combined p38 and ERK MAPK inhibition, via SB203580 and U0126, diminished maximally stimulated GRE-regulated promoter activity using high concentrations of glucocorticoids.	U 0126	101-106	ribosomal protein S6 kinase, polypeptide 5	Mus musculus	17-21
23831393-6	2013	Correspondingly, MSK1 inhibition, via H89, or combined p38 and ERK MAPK inhibition, via SB203580 and U0126, diminished maximally stimulated GRE-regulated promoter activity using high concentrations of glucocorticoids.	U 0126	101-106	mitogen-activated protein kinase 14	Mus musculus	55-58
23831393-6	2013	Correspondingly, MSK1 inhibition, via H89, or combined p38 and ERK MAPK inhibition, via SB203580 and U0126, diminished maximally stimulated GRE-regulated promoter activity using high concentrations of glucocorticoids.	U 0126	101-106	mitogen-activated protein kinase 1	Mus musculus	63-66
24039775-9	2013	We also found that MBL-dependent inhibition of monocyte proliferation could be reversed by the TGF-beta receptor antagonist SB-431542, or by anti-TGF-beta1 antibody, or by the mitogen-activated protein kinase (MAPK) inhibitors specific for p38 (SB203580), but not ERK (U0126) or JNK (SP600125).	U 0126	269-274	mannose binding lectin 2	Homo sapiens	19-22
24039823-9	2013	Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	27-30
24039823-9	2013	Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited.	U 0126	42-47	matrix metallopeptidase 2	Homo sapiens	102-107
24039823-9	2013	Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited.	U 0126	42-47	matrix metallopeptidase 9	Homo sapiens	109-114
24039823-9	2013	Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited.	U 0126	42-47	plasminogen activator, urokinase	Homo sapiens	119-123
24039823-9	2013	Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited.	U 0126	42-47	TIMP metallopeptidase inhibitor 1	Homo sapiens	154-160
24039823-9	2013	Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited.	U 0126	42-47	TIMP metallopeptidase inhibitor 2	Homo sapiens	165-171
23045284-11	2013	However, it resulted from the activation of a phosphatidylinositol 3-kinases-like mitogen-activated protein kinase pathway, as assessed by the fact that LY294002 and U0126 restored high Cdx2 expression in hypoxia.	U 0126	166-171	caudal type homeobox 2	Homo sapiens	186-190
23045284-12	2013	Corroborating these results, U0126 recapitulated the increase of Cdx2 triggered by ITPP in subcutaneous colon tumor xenografts.	U 0126	29-34	caudal type homeobox 2	Homo sapiens	65-69
23707980-12	2013	Finally, intrathecal tPA elicits persistent mechanical allodynia, which is inhibited by the astroglial toxin alpha-amino adipate and the MEK (ERK kinase) inhibitor U0126.	U 0126	164-169	plasminogen activator, tissue	Mus musculus	21-24
23707980-12	2013	Finally, intrathecal tPA elicits persistent mechanical allodynia, which is inhibited by the astroglial toxin alpha-amino adipate and the MEK (ERK kinase) inhibitor U0126.	U 0126	164-169	midkine	Mus musculus	137-140
24023725-10	2013	Blockade of ERK signalling with U0126 did not reduce M1 mAChR-mediated cell-death significantly but inhibited the acute induction of EGR-1.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	12-15
24023725-10	2013	Blockade of ERK signalling with U0126 did not reduce M1 mAChR-mediated cell-death significantly but inhibited the acute induction of EGR-1.	U 0126	32-37	early growth response 1	Homo sapiens	133-138
23677800-9	2013	PP2 and the ERK inhibitor U0126 prevented robust ERK1/2 activation in cells exposed to DIDS or subjected to pHi reduction, but U0126 did not prevent SFK activation or the Na-K-ATPase activity response.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	12-15
23677800-9	2013	PP2 and the ERK inhibitor U0126 prevented robust ERK1/2 activation in cells exposed to DIDS or subjected to pHi reduction, but U0126 did not prevent SFK activation or the Na-K-ATPase activity response.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	49-55
23708800-7	2013	U0126 and GW5074 suppress the induction of Bag-1 by Chlamydia, implying that Chlamydia may up-regulate Bag-1 via the MAPK/ERK survival pathway.	U 0126	0-5	BAG cochaperone 1	Homo sapiens	43-48
23708800-7	2013	U0126 and GW5074 suppress the induction of Bag-1 by Chlamydia, implying that Chlamydia may up-regulate Bag-1 via the MAPK/ERK survival pathway.	U 0126	0-5	BAG cochaperone 1	Homo sapiens	103-108
23708800-7	2013	U0126 and GW5074 suppress the induction of Bag-1 by Chlamydia, implying that Chlamydia may up-regulate Bag-1 via the MAPK/ERK survival pathway.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	122-125
23684925-4	2013	The dual PI3K/mTOR inhibitor PI103 and the MEK inhibitor UO126 synergize to trigger apoptosis in several RMS cell lines in a highly synergistic manner (combination index &lt;0.1), whereas either agent alone induces minimal cell death.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
23684925-7	2013	Accordingly, PI103 alone increases ERK phosphorylation, while UO126 enhances Akt phosphorylation, consistent with negative crosstalks between these two signaling pathways.	U 0126	62-67	AKT serine/threonine kinase 1	Homo sapiens	77-80
23786209-7	2013	Moreover, the expression of both genes was downregulated by U0126, a MEK 1/2 inhibitor.	U 0126	60-65	mitogen-activated protein kinase kinase 1	Mus musculus	69-76
23852369-4	2013	Here we show that in p21- and p16-induced senescence, inhibitors of mitogen-activated/extracellular signal-regulated kinase (MEK) (U0126, PD184352 and siRNA) completely prevented cyclin D1 accumulation, making it undetectable.	U 0126	131-136	cyclin dependent kinase inhibitor 1A	Homo sapiens	21-24
23852369-4	2013	Here we show that in p21- and p16-induced senescence, inhibitors of mitogen-activated/extracellular signal-regulated kinase (MEK) (U0126, PD184352 and siRNA) completely prevented cyclin D1 accumulation, making it undetectable.	U 0126	131-136	cyclin dependent kinase inhibitor 2A	Homo sapiens	30-33
23852369-4	2013	Here we show that in p21- and p16-induced senescence, inhibitors of mitogen-activated/extracellular signal-regulated kinase (MEK) (U0126, PD184352 and siRNA) completely prevented cyclin D1 accumulation, making it undetectable.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	68-123
23852369-4	2013	Here we show that in p21- and p16-induced senescence, inhibitors of mitogen-activated/extracellular signal-regulated kinase (MEK) (U0126, PD184352 and siRNA) completely prevented cyclin D1 accumulation, making it undetectable.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
23852369-4	2013	Here we show that in p21- and p16-induced senescence, inhibitors of mitogen-activated/extracellular signal-regulated kinase (MEK) (U0126, PD184352 and siRNA) completely prevented cyclin D1 accumulation, making it undetectable.	U 0126	131-136	cyclin D1	Homo sapiens	179-188
23852369-6	2013	In such cells, U0126 by itself induced senescence that was remarkably cyclin D1 negative.	U 0126	15-20	cyclin D1	Homo sapiens	70-79
23852369-9	2013	We confirmed that the inhibitor of CDK4/6 caused cyclin D1 positive senescence in normal RPE cells, whereas U0126 prevented cyclin D1 expression.	U 0126	108-113	cyclin D1	Homo sapiens	124-133
23838318-7	2013	RESULTS: EGF upregulated p-YB-1, whereas MEK inhibitor (U0126, PD98059) decreased p-YB-1.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
23838318-7	2013	RESULTS: EGF upregulated p-YB-1, whereas MEK inhibitor (U0126, PD98059) decreased p-YB-1.	U 0126	56-61	Y-box binding protein 1	Homo sapiens	84-88
23772748-6	2013	U0126, which blocked the ERK1/2 pathway, exerted an additive effect on the icariin suppression of type IV collagen and fibronectin expression, enhancing the beneficial effects of icariin.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	25-31
23772748-6	2013	U0126, which blocked the ERK1/2 pathway, exerted an additive effect on the icariin suppression of type IV collagen and fibronectin expression, enhancing the beneficial effects of icariin.	U 0126	0-5	fibronectin 1	Rattus norvegicus	119-130
23781879-9	2013	However, these up-regulated expressions were prevented by ERK1/2 inhibitor U0126 in the physiological occlusal force-applied hPDLCs.	U 0126	75-80	mitogen-activated protein kinase 3	Homo sapiens	58-64
23682582-9	2013	Interestingly, pretreatment of mitogen-activated protein kinase kinases/extracellular signal-regulated kinase (MEK/ERK) signaling inhibitor U0126 had a similar effect as that of sorafenib pretreatment in hepatocellular carcinoma cells, whereas pretreatment of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling inhibitor LY294002 in the same cells had no effect on radiosensitization.	U 0126	140-145	mitogen-activated protein kinase 1	Homo sapiens	72-109
23682582-9	2013	Interestingly, pretreatment of mitogen-activated protein kinase kinases/extracellular signal-regulated kinase (MEK/ERK) signaling inhibitor U0126 had a similar effect as that of sorafenib pretreatment in hepatocellular carcinoma cells, whereas pretreatment of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling inhibitor LY294002 in the same cells had no effect on radiosensitization.	U 0126	140-145	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
23682582-9	2013	Interestingly, pretreatment of mitogen-activated protein kinase kinases/extracellular signal-regulated kinase (MEK/ERK) signaling inhibitor U0126 had a similar effect as that of sorafenib pretreatment in hepatocellular carcinoma cells, whereas pretreatment of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling inhibitor LY294002 in the same cells had no effect on radiosensitization.	U 0126	140-145	mitogen-activated protein kinase 1	Homo sapiens	115-118
23682582-9	2013	Interestingly, pretreatment of mitogen-activated protein kinase kinases/extracellular signal-regulated kinase (MEK/ERK) signaling inhibitor U0126 had a similar effect as that of sorafenib pretreatment in hepatocellular carcinoma cells, whereas pretreatment of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling inhibitor LY294002 in the same cells had no effect on radiosensitization.	U 0126	140-145	protein tyrosine kinase 2 beta	Homo sapiens	286-302
23682582-9	2013	Interestingly, pretreatment of mitogen-activated protein kinase kinases/extracellular signal-regulated kinase (MEK/ERK) signaling inhibitor U0126 had a similar effect as that of sorafenib pretreatment in hepatocellular carcinoma cells, whereas pretreatment of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling inhibitor LY294002 in the same cells had no effect on radiosensitization.	U 0126	140-145	AKT serine/threonine kinase 1	Homo sapiens	309-312
23554085-4	2013	The inhibition of stress kinases p38, JNK1,2, and MEK1,2 by SP600125, SB203580, and UO126, respectively, established the involvement of JNK1,2 and p38 as upstream, and ERK1,2 as downstream targets of Hsp70 induction.	U 0126	84-89	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	50-56
23554085-5	2013	Moreover, the effect of the MEK1,2 inhibitor UO126 revealed a new pathway of c-Jun activation by ERK1,2 in myogenic heat-stressed stem cells.	U 0126	45-50	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	28-34
23554085-5	2013	Moreover, the effect of the MEK1,2 inhibitor UO126 revealed a new pathway of c-Jun activation by ERK1,2 in myogenic heat-stressed stem cells.	U 0126	45-50	transcription factor Jun	Oryctolagus cuniculus	77-82
24383372-8	2013	ROS generation in response to TGF-beta1, measured as 2,7-dichlorofluorescein-diacetate fluorescence, was inhibited significantly by SB203580 and U0126, implicating both the p38 MAPK and Mekl/2/Erk1/2 signaling pathways.	U 0126	145-150	transforming growth factor beta 1	Homo sapiens	30-39
24383372-8	2013	ROS generation in response to TGF-beta1, measured as 2,7-dichlorofluorescein-diacetate fluorescence, was inhibited significantly by SB203580 and U0126, implicating both the p38 MAPK and Mekl/2/Erk1/2 signaling pathways.	U 0126	145-150	mitogen-activated protein kinase 1	Homo sapiens	173-176
24383372-8	2013	ROS generation in response to TGF-beta1, measured as 2,7-dichlorofluorescein-diacetate fluorescence, was inhibited significantly by SB203580 and U0126, implicating both the p38 MAPK and Mekl/2/Erk1/2 signaling pathways.	U 0126	145-150	mitogen-activated protein kinase 3	Homo sapiens	193-199
23697559-4	2013	The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively.	U 0126	252-257	mitogen-activated protein kinase 1	Homo sapiens	28-74
23697559-4	2013	The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively.	U 0126	252-257	mitogen-activated protein kinase 14	Homo sapiens	79-115
23697559-4	2013	The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively.	U 0126	252-257	high mobility group box 1	Homo sapiens	180-185
23697559-4	2013	The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively.	U 0126	252-257	mitogen-activated protein kinase 3	Homo sapiens	211-217
23697559-4	2013	The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively.	U 0126	252-257	mitogen-activated protein kinase 1	Homo sapiens	79-82
23697559-4	2013	The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively.	U 0126	252-257	high mobility group box 1	Homo sapiens	394-399
23697559-5	2013	HMGB1-induced activity of ERK1/2 and p38 was not fully inhibited in the presence of U0126 or SB203580.	U 0126	84-89	high mobility group box 1	Homo sapiens	0-5
23480207-6	2013	RESULTS: We found elevated pERK levels after treatment with IR and H2 O2 , which could be distinctly suppressed by U0126.	U 0126	115-120	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	27-31
23625939-9	2013	Addition of an anti-CD44 antibody or an MAPK inhibitor (U0126) abrogated the positive effects of HYAL2 on blastocyst rates.	U 0126	56-61	hyaluronidase 2	Bos taurus	97-102
23709326-7	2013	As further confirmation, Eca109 cells were treated with gradient concentration of U0126, a kind of MEK inhibitor, and expression of miR-21 was subsequently examined.	U 0126	82-87	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
23709326-7	2013	As further confirmation, Eca109 cells were treated with gradient concentration of U0126, a kind of MEK inhibitor, and expression of miR-21 was subsequently examined.	U 0126	82-87	microRNA 21	Homo sapiens	132-138
23709326-8	2013	It was found that U0126 can significantly decreased endogenous expression of miR-21.	U 0126	18-23	microRNA 21	Homo sapiens	77-83
23709326-9	2013	In parallel, U0126 decreased cell proliferation, migration and increased the apoptosis in Eca109 cells, with the expression of miR-21 being reduced significantly in U0126 group as compared with control groups.	U 0126	165-170	microRNA 21	Homo sapiens	127-133
23756732-3	2013	Rats were further treated with U0126 (an ERK1/2 phosphorylation inhibitor) 30 min before RA treatment to assess the effects of RA and ERK1/2 signaling in depressive-like behavior and hippocampal BDNF levels.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	41-47
23838122-7	2013	The inhibition of ERK 1/2 phosphorylation by U0126 significantly reduced the proliferation and oligodendrogenesis of NSCs, indicating that ERK 1/2 inhibition by proNGF partially explains its effects on NSC proliferation and oligodendrogenesis.	U 0126	45-50	mitogen-activated protein kinase 3	Mus musculus	18-25
23838122-7	2013	The inhibition of ERK 1/2 phosphorylation by U0126 significantly reduced the proliferation and oligodendrogenesis of NSCs, indicating that ERK 1/2 inhibition by proNGF partially explains its effects on NSC proliferation and oligodendrogenesis.	U 0126	45-50	mitogen-activated protein kinase 3	Mus musculus	139-146
23603476-6	2013	To investigate whether ERK signaling was involved in PPLGM-mediated cell death, we treated HT-29 cells with the MEK inhibitor U0126, prior to treating with PPLGM.	U 0126	126-131	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
23603476-7	2013	We found that U0126 attenuated PPLGM-induced activation of ERK and partially protected against PPLGM-induced cell death.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	59-62
23677800-9	2013	PP2 and the ERK inhibitor U0126 prevented robust ERK1/2 activation in cells exposed to DIDS or subjected to pHi reduction, but U0126 did not prevent SFK activation or the Na-K-ATPase activity response.	U 0126	26-31	glucose-6-phosphate isomerase	Homo sapiens	108-111
23852539-7	2013	Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126.	U 0126	119-124	midkine	Mus musculus	14-17
23852539-7	2013	Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126.	U 0126	119-124	mitogen-activated protein kinase 1	Mus musculus	18-21
23852539-7	2013	Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126.	U 0126	119-124	mitogen-activated protein kinase 1	Mus musculus	99-103
23852539-7	2013	Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126.	U 0126	119-124	mitogen-activated protein kinase 1	Mus musculus	105-108
23764463-7	2013	Furthermore, Icariin-mediated effects on osteoblasts were dramatically attenuated by treatment with specific inhibitors of MAPKs, U0126 (ERK inhibitor) and SP600125 (JNK inhibitor).	U 0126	130-135	mitogen-activated protein kinase 1	Mus musculus	137-140
23951036-10	2013	Inhibition of Akt activation by treating with phosphoinositide 3-kinase (PI3K) inhibitor LY294002 decreased IR cell invasion, whereas inhibition of Erk1/2 activation by mitogen-activated protein kinase kinase (MEK) inhibitor U0126 did not.	U 0126	225-230	AKT serine/threonine kinase 1	Homo sapiens	14-17
24015303-5	2013	ET-1 was inhibited by Bosentan, ERK1/2 mitogen activated protein kinase (MAPK) was inhibited by U0126 and p38 MAPK was inhibited by SB203580.	U 0126	96-101	endothelin 1	Homo sapiens	0-4
24015303-5	2013	ET-1 was inhibited by Bosentan, ERK1/2 mitogen activated protein kinase (MAPK) was inhibited by U0126 and p38 MAPK was inhibited by SB203580.	U 0126	96-101	mitogen-activated protein kinase 3	Homo sapiens	32-38
23848362-2	2013	The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2.	U 0126	89-94	microtubule associated protein 2	Homo sapiens	33-37
23848362-2	2013	The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2.	U 0126	89-94	mitogen-activated protein kinase kinase 1	Homo sapiens	40-46
23848362-2	2013	The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2.	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	51-57
23848362-2	2013	The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2.	U 0126	89-94	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
23848362-2	2013	The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2.	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	168-174
23951091-9	2013	Addition of the PI3K-inhibitor LY294002 and the MEK-inhibitor U0126 to the HMEC-1 inhibited this effect, suggesting that both Akt and ERK pathways are involved in hDPSC-mediated HMEC-1 migration.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
23951091-9	2013	Addition of the PI3K-inhibitor LY294002 and the MEK-inhibitor U0126 to the HMEC-1 inhibited this effect, suggesting that both Akt and ERK pathways are involved in hDPSC-mediated HMEC-1 migration.	U 0126	62-67	AKT serine/threonine kinase 1	Homo sapiens	126-129
23951091-9	2013	Addition of the PI3K-inhibitor LY294002 and the MEK-inhibitor U0126 to the HMEC-1 inhibited this effect, suggesting that both Akt and ERK pathways are involved in hDPSC-mediated HMEC-1 migration.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	134-137
24069351-6	2013	Blocking these pathways by specific inhibitor LY294002 or U0126 abrogated HMW-HA-regulated DSc proliferation and apoptosis.	U 0126	58-63	desmocollin 3	Homo sapiens	91-94
23678047-11	2013	Treatment with U0126 also blocked activation of NHE1 by SIA.	U 0126	15-20	solute carrier family 9 member A1	Canis lupus familiaris	48-52
23831464-7	2013	Treatment with cholesterol, LY294002, Akt inhibitor IV, U0126, and SP6001250 resulted in abrogation or significant attenuation of nystatin-induced CCL2 expression.	U 0126	56-61	C-C motif chemokine ligand 2	Homo sapiens	147-151
23747719-7	2013	Furthermore, blocking ERK signaling with U0126, a specific inhibitor for MEK, markedly inhibited EGF-induced uPAR expression and consequently cell invasion.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	22-25
23242737-7	2013	The functions of trigeminal ganglionic Nav 1.7 and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation were blocked with the microinjection of the Nav 1.7 antibody or U0126 into the trigeminal ganglion.	U 0126	182-187	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	39-46
23242737-7	2013	The functions of trigeminal ganglionic Nav 1.7 and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation were blocked with the microinjection of the Nav 1.7 antibody or U0126 into the trigeminal ganglion.	U 0126	182-187	mitogen activated protein kinase 3	Rattus norvegicus	51-92
23242737-7	2013	The functions of trigeminal ganglionic Nav 1.7 and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation were blocked with the microinjection of the Nav 1.7 antibody or U0126 into the trigeminal ganglion.	U 0126	182-187	mitogen activated protein kinase 3	Rattus norvegicus	94-100
23747719-7	2013	Furthermore, blocking ERK signaling with U0126, a specific inhibitor for MEK, markedly inhibited EGF-induced uPAR expression and consequently cell invasion.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	73-76
23747719-7	2013	Furthermore, blocking ERK signaling with U0126, a specific inhibitor for MEK, markedly inhibited EGF-induced uPAR expression and consequently cell invasion.	U 0126	41-46	epidermal growth factor	Homo sapiens	97-100
23747719-7	2013	Furthermore, blocking ERK signaling with U0126, a specific inhibitor for MEK, markedly inhibited EGF-induced uPAR expression and consequently cell invasion.	U 0126	41-46	plasminogen activator, urokinase receptor	Homo sapiens	109-113
23779254-5	2013	The pharmacologic inhibitors of ERK, U0126 and PD98059, effectively reduced IL-8 expression and the active forms of ERK signaling molecules, as detected by anti-phosphorylated p44/42 antibody.	U 0126	37-42	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
23828593-5	2013	Additionally, the ERK1/2 inhibitor U0126 were used to confirm the signalling pathway involved in CD147-mediated SGC7901 progression.	U 0126	35-40	basigin (Ok blood group)	Homo sapiens	97-102
23828593-8	2013	ERK1/2 inhibitor U0126 decreased the proliferation, and invasion of SGC7901 cells, and down-regulated the MMP-2 and MMP-9 activities.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	0-6
23828593-8	2013	ERK1/2 inhibitor U0126 decreased the proliferation, and invasion of SGC7901 cells, and down-regulated the MMP-2 and MMP-9 activities.	U 0126	17-22	matrix metallopeptidase 2	Homo sapiens	106-111
23828593-8	2013	ERK1/2 inhibitor U0126 decreased the proliferation, and invasion of SGC7901 cells, and down-regulated the MMP-2 and MMP-9 activities.	U 0126	17-22	matrix metallopeptidase 9	Homo sapiens	116-121
22354777-6	2013	U0126 treatment significantly reduced constitutive mRNA expression of FOS and EGR1, and dramatically suppressed the induction of FOS, EGR1 and IL8 mRNA in iAs(III)-treated cells.	U 0126	0-5	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-73
22354777-6	2013	U0126 treatment significantly reduced constitutive mRNA expression of FOS and EGR1, and dramatically suppressed the induction of FOS, EGR1 and IL8 mRNA in iAs(III)-treated cells.	U 0126	0-5	early growth response 1	Homo sapiens	78-82
22354777-6	2013	U0126 treatment significantly reduced constitutive mRNA expression of FOS and EGR1, and dramatically suppressed the induction of FOS, EGR1 and IL8 mRNA in iAs(III)-treated cells.	U 0126	0-5	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	129-132
22354777-6	2013	U0126 treatment significantly reduced constitutive mRNA expression of FOS and EGR1, and dramatically suppressed the induction of FOS, EGR1 and IL8 mRNA in iAs(III)-treated cells.	U 0126	0-5	early growth response 1	Homo sapiens	134-138
22354777-6	2013	U0126 treatment significantly reduced constitutive mRNA expression of FOS and EGR1, and dramatically suppressed the induction of FOS, EGR1 and IL8 mRNA in iAs(III)-treated cells.	U 0126	0-5	C-X-C motif chemokine ligand 8	Homo sapiens	143-146
23880270-6	2013	The ERK1/2 inhibitor U0126 was used to assess the role of this pathway on stage of the cell cycle and mineralization-dependent gene expressions of hDPCs by using flow cytometry and real-time polymerase chain reaction, respectively.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	4-10
23946690-6	2013	In addition, pretreatment with the MEK1/2 specific inhibitors, PD98059 or U0126 potently inhibited the CTGF production and ECM components accumulation in high glucose-stimulated VSMCs.	U 0126	74-79	mitogen activated protein kinase kinase 1	Rattus norvegicus	35-41
23946690-6	2013	In addition, pretreatment with the MEK1/2 specific inhibitors, PD98059 or U0126 potently inhibited the CTGF production and ECM components accumulation in high glucose-stimulated VSMCs.	U 0126	74-79	cellular communication network factor 2	Rattus norvegicus	103-107
23519519-7	2013	However, the administration of U0126, a MEK kinase inhibitor, partly blocked MEK1/2 and ERK1/2 phosphorylation induced by tGCI.	U 0126	31-36	mitogen activated protein kinase kinase 1	Rattus norvegicus	77-83
23606057-4	2013	Moreover, the up-regulation of transcripts for Nkx2.5 and GATA4 by NRG-1beta was blocked by the extracellular signal-related kinases (ERK) 1/2 inhibitor, U0126.	U 0126	154-159	NK2 homeobox 5	Mus musculus	47-53
23606057-4	2013	Moreover, the up-regulation of transcripts for Nkx2.5 and GATA4 by NRG-1beta was blocked by the extracellular signal-related kinases (ERK) 1/2 inhibitor, U0126.	U 0126	154-159	GATA binding protein 4	Mus musculus	58-63
23606057-4	2013	Moreover, the up-regulation of transcripts for Nkx2.5 and GATA4 by NRG-1beta was blocked by the extracellular signal-related kinases (ERK) 1/2 inhibitor, U0126.	U 0126	154-159	mitogen-activated protein kinase 3	Mus musculus	96-142
23519519-7	2013	However, the administration of U0126, a MEK kinase inhibitor, partly blocked MEK1/2 and ERK1/2 phosphorylation induced by tGCI.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	88-94
23756562-13	2013	Notably, the increased expression of phosphorylated p53 in HBE/TOB1 cells after IR was sufficiently blocked by U0126, a specific inhibitor of MEK1/2.	U 0126	111-116	tumor protein p53	Homo sapiens	52-55
23784034-10	2013	Following pre-treatment with the JNK inhibitor II (10 micromol/l), the p38 inhibitor SB202190 (10 micromol/l) or the ERK inhibitor U0126 (10 micromol/l) for 30 min, BEAS-2B cells were exposed to HCl for 30 min.	U 0126	131-136	mitogen-activated protein kinase 1	Homo sapiens	117-120
23756562-13	2013	Notably, the increased expression of phosphorylated p53 in HBE/TOB1 cells after IR was sufficiently blocked by U0126, a specific inhibitor of MEK1/2.	U 0126	111-116	transducer of ERBB2, 1	Homo sapiens	63-67
23756562-13	2013	Notably, the increased expression of phosphorylated p53 in HBE/TOB1 cells after IR was sufficiently blocked by U0126, a specific inhibitor of MEK1/2.	U 0126	111-116	mitogen-activated protein kinase kinase 1	Homo sapiens	142-148
23680829-8	2013	RESULTS: ERK specific inhibitor U0126 significantly inhibited IL-1-induced ERK activation.	U 0126	32-37	Eph receptor B1	Rattus norvegicus	9-12
23680829-8	2013	RESULTS: ERK specific inhibitor U0126 significantly inhibited IL-1-induced ERK activation.	U 0126	32-37	Eph receptor B1	Rattus norvegicus	75-78
23680829-10	2013	The decreased gene expression of collagen I, collagen II, collagen IX, and IGF-1 induced by IL-1 was also reversed by U0126.	U 0126	118-123	insulin-like growth factor 1	Rattus norvegicus	75-80
23922669-8	2013	Treatment with specific inhibitors LY294002 and U0126 reversed the CAFs-mediated cell proliferation (P&lt;0.0001), suggesting for a role of these pathways in modulating endometrial cancer cell proliferation.	U 0126	48-53	T-box transcription factor 1	Homo sapiens	67-71
23908690-3	2013	Ectopic expression of PIB5PA enhanced apoptosis induced by the RAF inhibitor PLX4720 in BRAF(V600E) and by the MEK inhibitor U0126 in both BRAF(V600E) and wild-type BRAF melanoma cells.	U 0126	125-130	inositol polyphosphate-5-phosphatase E	Homo sapiens	22-28
23908690-3	2013	Ectopic expression of PIB5PA enhanced apoptosis induced by the RAF inhibitor PLX4720 in BRAF(V600E) and by the MEK inhibitor U0126 in both BRAF(V600E) and wild-type BRAF melanoma cells.	U 0126	125-130	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
23908690-4	2013	This was due to inhibition of PI3K/Akt, as co-introduction of an active form of Akt (myr-Akt) abolished the effect of overexpression of PIB5PA on apoptosis induced by PLX4720 or U0126.	U 0126	178-183	AKT serine/threonine kinase 1	Homo sapiens	80-83
23908690-4	2013	This was due to inhibition of PI3K/Akt, as co-introduction of an active form of Akt (myr-Akt) abolished the effect of overexpression of PIB5PA on apoptosis induced by PLX4720 or U0126.	U 0126	178-183	AKT serine/threonine kinase 1	Homo sapiens	80-83
23908690-4	2013	This was due to inhibition of PI3K/Akt, as co-introduction of an active form of Akt (myr-Akt) abolished the effect of overexpression of PIB5PA on apoptosis induced by PLX4720 or U0126.	U 0126	178-183	inositol polyphosphate-5-phosphatase E	Homo sapiens	136-142
23806683-6	2013	In contrast, U0126, an inhibitor of mitogen-activated kinase kinase, suppressed SIRT2 protein level.	U 0126	13-18	sirtuin 2	Homo sapiens	80-85
23904987-5	2013	We treated melanoma cell lines displaying different BRAF and GNAQ mutational status with the mTOR inhibitor RAD001 and with the MEK1/2 inhibitor U0126 and evaluated the effects in the growth of the cell lines and in mTOR and MAPK pathway effectors expression.	U 0126	145-150	mitogen-activated protein kinase kinase 1	Homo sapiens	128-134
23904987-10	2013	U0126 leads to the reduction of MAPK and mTOR pathways activation in all cell lines tested.	U 0126	0-5	mechanistic target of rapamycin kinase	Homo sapiens	41-45
23874979-4	2013	Relative to controls, U0126-treated cells showed constitutive decreases in phosphorylation through a T cell receptor stimulation time course on tyrosine residues found on upstream signaling proteins (CD3 chains, Lck, ZAP-70), as well as downstream signaling proteins (VAV1, PLCgamma1, Itk, NCK1).	U 0126	22-27	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	212-215
23874979-4	2013	Relative to controls, U0126-treated cells showed constitutive decreases in phosphorylation through a T cell receptor stimulation time course on tyrosine residues found on upstream signaling proteins (CD3 chains, Lck, ZAP-70), as well as downstream signaling proteins (VAV1, PLCgamma1, Itk, NCK1).	U 0126	22-27	zeta chain of T cell receptor associated protein kinase 70	Homo sapiens	217-223
23874979-4	2013	Relative to controls, U0126-treated cells showed constitutive decreases in phosphorylation through a T cell receptor stimulation time course on tyrosine residues found on upstream signaling proteins (CD3 chains, Lck, ZAP-70), as well as downstream signaling proteins (VAV1, PLCgamma1, Itk, NCK1).	U 0126	22-27	vav guanine nucleotide exchange factor 1	Homo sapiens	268-272
23874979-4	2013	Relative to controls, U0126-treated cells showed constitutive decreases in phosphorylation through a T cell receptor stimulation time course on tyrosine residues found on upstream signaling proteins (CD3 chains, Lck, ZAP-70), as well as downstream signaling proteins (VAV1, PLCgamma1, Itk, NCK1).	U 0126	22-27	phospholipase C gamma 1	Homo sapiens	274-283
23874979-4	2013	Relative to controls, U0126-treated cells showed constitutive decreases in phosphorylation through a T cell receptor stimulation time course on tyrosine residues found on upstream signaling proteins (CD3 chains, Lck, ZAP-70), as well as downstream signaling proteins (VAV1, PLCgamma1, Itk, NCK1).	U 0126	22-27	IL2 inducible T cell kinase	Homo sapiens	285-288
23874979-4	2013	Relative to controls, U0126-treated cells showed constitutive decreases in phosphorylation through a T cell receptor stimulation time course on tyrosine residues found on upstream signaling proteins (CD3 chains, Lck, ZAP-70), as well as downstream signaling proteins (VAV1, PLCgamma1, Itk, NCK1).	U 0126	22-27	NCK adaptor protein 1	Homo sapiens	290-294
23435375-2	2013	Here, we show that BRAF depletion by siRNA or inhibition of its activity by treatment with BRAF inhibitor PLX4720 decreases migration and invasion in thyroid cancer cells expressing oncogenic (V600E)BRAF through a MEK/ERK-dependent mechanism, since treatment with the MEK inhibitor U0126 exerts the same effect.	U 0126	282-287	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	19-23
23435375-2	2013	Here, we show that BRAF depletion by siRNA or inhibition of its activity by treatment with BRAF inhibitor PLX4720 decreases migration and invasion in thyroid cancer cells expressing oncogenic (V600E)BRAF through a MEK/ERK-dependent mechanism, since treatment with the MEK inhibitor U0126 exerts the same effect.	U 0126	282-287	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	91-95
23435375-2	2013	Here, we show that BRAF depletion by siRNA or inhibition of its activity by treatment with BRAF inhibitor PLX4720 decreases migration and invasion in thyroid cancer cells expressing oncogenic (V600E)BRAF through a MEK/ERK-dependent mechanism, since treatment with the MEK inhibitor U0126 exerts the same effect.	U 0126	282-287	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	91-95
23435375-2	2013	Here, we show that BRAF depletion by siRNA or inhibition of its activity by treatment with BRAF inhibitor PLX4720 decreases migration and invasion in thyroid cancer cells expressing oncogenic (V600E)BRAF through a MEK/ERK-dependent mechanism, since treatment with the MEK inhibitor U0126 exerts the same effect.	U 0126	282-287	mitogen-activated protein kinase kinase 7	Homo sapiens	214-217
23435375-2	2013	Here, we show that BRAF depletion by siRNA or inhibition of its activity by treatment with BRAF inhibitor PLX4720 decreases migration and invasion in thyroid cancer cells expressing oncogenic (V600E)BRAF through a MEK/ERK-dependent mechanism, since treatment with the MEK inhibitor U0126 exerts the same effect.	U 0126	282-287	mitogen-activated protein kinase 1	Homo sapiens	218-221
23874979-6	2013	Although the majority of identified sites on T cell receptor signaling proteins showed decreases in phosphorylation, Tyr(598) of ZAP-70 showed elevated phosphorylation in response to U0126 treatment, suggesting differential regulation of this site via ERK feedback.	U 0126	183-188	zeta chain of T cell receptor associated protein kinase 70	Homo sapiens	129-135
23874979-6	2013	Although the majority of identified sites on T cell receptor signaling proteins showed decreases in phosphorylation, Tyr(598) of ZAP-70 showed elevated phosphorylation in response to U0126 treatment, suggesting differential regulation of this site via ERK feedback.	U 0126	183-188	mitogen-activated protein kinase 1	Homo sapiens	252-255
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	U 0126	13-18	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	65-71
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	U 0126	13-18	mitogen-activated protein kinase 8	Homo sapiens	83-86
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	91-94
23423712-12	2013	The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP.	U 0126	17-22	nuclear factor kappa B subunit 1	Homo sapiens	58-67
23423712-12	2013	The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP.	U 0126	17-22	BCL2 apoptosis regulator	Homo sapiens	105-110
23423712-12	2013	The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP.	U 0126	17-22	X-linked inhibitor of apoptosis	Homo sapiens	115-119
23360766-3	2013	Upon treatment with U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK) acting upstream of Erk1/2, Western-blotting and NMR congruently reported specific modulations of cellular phospho-Erk levels that translated into reduced kinase activities.	U 0126	20-25	mitogen-activated protein kinase kinase 7	Homo sapiens	43-82
23360766-3	2013	Upon treatment with U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK) acting upstream of Erk1/2, Western-blotting and NMR congruently reported specific modulations of cellular phospho-Erk levels that translated into reduced kinase activities.	U 0126	20-25	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
23360766-3	2013	Upon treatment with U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK) acting upstream of Erk1/2, Western-blotting and NMR congruently reported specific modulations of cellular phospho-Erk levels that translated into reduced kinase activities.	U 0126	20-25	mitogen-activated protein kinase 3	Homo sapiens	108-114
23360766-3	2013	Upon treatment with U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK) acting upstream of Erk1/2, Western-blotting and NMR congruently reported specific modulations of cellular phospho-Erk levels that translated into reduced kinase activities.	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	108-111
24648994-3	2013	ERCC1 is considered to be a closely related downstream target gene of extracellular signal-regulated kinase (ERK)1/2, since ERCC1 mRNA and protein levels may be inhibited by the ERK inhibitor U0126.	U 0126	192-197	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24648994-3	2013	ERCC1 is considered to be a closely related downstream target gene of extracellular signal-regulated kinase (ERK)1/2, since ERCC1 mRNA and protein levels may be inhibited by the ERK inhibitor U0126.	U 0126	192-197	mitogen-activated protein kinase 1	Homo sapiens	70-116
23526210-9	2013	Cyclic stretch increased the activation of the NF-kappaB signaling pathway, which was significantly decreased with the ERK inhibitor U0126.	U 0126	133-138	Eph receptor B1	Rattus norvegicus	119-122
23939027-9	2013	This effect was significantly reduced by the addition of inhibitors to MEK (PD98059, U0126), NF-kB (PDTC) and IkB protease inhibitor (TPCK).	U 0126	85-90	midkine	Mus musculus	71-74
23331101-10	2013	The inhibitor of ERK1/2, U0126, but not inhibitors of p38 MAPK and JNK, SB203580 and SP600125, decreased CpG ODN-mediated MMP-13 expression.	U 0126	25-30	mitogen-activated protein kinase 3	Mus musculus	17-23
23331101-10	2013	The inhibitor of ERK1/2, U0126, but not inhibitors of p38 MAPK and JNK, SB203580 and SP600125, decreased CpG ODN-mediated MMP-13 expression.	U 0126	25-30	matrix metallopeptidase 13	Mus musculus	122-128
23674093-10	2013	Treatment with U0126 (a mitogen-activated protein kinase inhibitor) drastically reduced basal levels of G-CSF and TNF-alpha-induced G-CSF in aggressive cancer cells.	U 0126	15-20	colony stimulating factor 3	Homo sapiens	104-109
23674093-10	2013	Treatment with U0126 (a mitogen-activated protein kinase inhibitor) drastically reduced basal levels of G-CSF and TNF-alpha-induced G-CSF in aggressive cancer cells.	U 0126	15-20	tumor necrosis factor	Homo sapiens	114-123
23674093-10	2013	Treatment with U0126 (a mitogen-activated protein kinase inhibitor) drastically reduced basal levels of G-CSF and TNF-alpha-induced G-CSF in aggressive cancer cells.	U 0126	15-20	colony stimulating factor 3	Homo sapiens	132-137
23380172-6	2013	The selective 5-HT2A receptor antagonist MDL 11,939, the general protein tyrosine kinase inhibitor genistein, and the extracellular signal-regulated kinase (ERK) pathway MEK inhibitor U0126, all attenuated DOI"s protective effect.	U 0126	184-189	mitogen-activated protein kinase 1	Homo sapiens	118-155
23380172-6	2013	The selective 5-HT2A receptor antagonist MDL 11,939, the general protein tyrosine kinase inhibitor genistein, and the extracellular signal-regulated kinase (ERK) pathway MEK inhibitor U0126, all attenuated DOI"s protective effect.	U 0126	184-189	mitogen-activated protein kinase 1	Homo sapiens	157-160
23380172-6	2013	The selective 5-HT2A receptor antagonist MDL 11,939, the general protein tyrosine kinase inhibitor genistein, and the extracellular signal-regulated kinase (ERK) pathway MEK inhibitor U0126, all attenuated DOI"s protective effect.	U 0126	184-189	mitogen-activated protein kinase kinase 7	Homo sapiens	170-173
23744338-5	2013	Further experiments with inhibitors revealed the co-treatment of U0126, PD98059, or ICI182780 (a general ER antagonist) with chrysin effectively abrogated the chrysin-induced osteogenesis and ERK1/2 activation.	U 0126	65-70	mitogen-activated protein kinase 3	Mus musculus	192-198
23588115-9	2013	In HBAFb AG1478, GM6001, the ERK1/2-inhibitor U0126 and the p38 inhibitor SB203580 suppressed bradykinin-induced cell proliferation, but only SB203580 reduced myofibroblast differentiation.	U 0126	46-51	mitogen-activated protein kinase 3	Homo sapiens	29-35
23588115-9	2013	In HBAFb AG1478, GM6001, the ERK1/2-inhibitor U0126 and the p38 inhibitor SB203580 suppressed bradykinin-induced cell proliferation, but only SB203580 reduced myofibroblast differentiation.	U 0126	46-51	kininogen 1	Homo sapiens	94-104
23577625-8	2013	The ERK1/2 inhibitor (U0126) and Akt inhibitor (T3830) abrogated the DDC-induced MMP-1 up-regulation.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	4-10
23577625-8	2013	The ERK1/2 inhibitor (U0126) and Akt inhibitor (T3830) abrogated the DDC-induced MMP-1 up-regulation.	U 0126	22-27	matrix metallopeptidase 1	Homo sapiens	81-86
23749901-1	2013	BACKGROUND/AIM: To investigate mechanisms of discrepancy in response to a MEK/ERK inhibitor, U0126, in KRAS- and BRAF-mutant colorectal cancer cells.	U 0126	93-98	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
23749901-1	2013	BACKGROUND/AIM: To investigate mechanisms of discrepancy in response to a MEK/ERK inhibitor, U0126, in KRAS- and BRAF-mutant colorectal cancer cells.	U 0126	93-98	mitogen-activated protein kinase 1	Homo sapiens	78-81
23749901-1	2013	BACKGROUND/AIM: To investigate mechanisms of discrepancy in response to a MEK/ERK inhibitor, U0126, in KRAS- and BRAF-mutant colorectal cancer cells.	U 0126	93-98	KRAS proto-oncogene, GTPase	Homo sapiens	103-108
23749901-1	2013	BACKGROUND/AIM: To investigate mechanisms of discrepancy in response to a MEK/ERK inhibitor, U0126, in KRAS- and BRAF-mutant colorectal cancer cells.	U 0126	93-98	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	113-117
23749901-5	2013	The western blot analysis revealed that by increasing the amount of U0126 resulted in inhibition of phospho-ERK, in HCT116 and to a lesser degree in HT29 cells.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	108-111
23749901-6	2013	Microarray profiling identified CYP1A1 and 1A2 overexpression in HT29 cells and that inhibition of CYP1A1 with alpha-naphthoflavone and furanfylline restored sensitivity to U0126 in HT29 cells.	U 0126	173-178	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	32-46
23749901-6	2013	Microarray profiling identified CYP1A1 and 1A2 overexpression in HT29 cells and that inhibition of CYP1A1 with alpha-naphthoflavone and furanfylline restored sensitivity to U0126 in HT29 cells.	U 0126	173-178	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	32-38
23683282-9	2013	In addition, MTA-induced mineralization was blocked by inhibition of extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) by using U0126, SB203580, and SP600125, respectively.	U 0126	160-165	mitogen-activated protein kinase 1	Homo sapiens	69-106
23683282-9	2013	In addition, MTA-induced mineralization was blocked by inhibition of extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) by using U0126, SB203580, and SP600125, respectively.	U 0126	160-165	mitogen-activated protein kinase 1	Homo sapiens	108-111
23683282-9	2013	In addition, MTA-induced mineralization was blocked by inhibition of extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) by using U0126, SB203580, and SP600125, respectively.	U 0126	160-165	mitogen-activated protein kinase 8	Homo sapiens	146-149
23329343-6	2013	Autophagy induced by IFN-beta was suppressed when p-ERK1/2 was impaired by treatment with U0126.	U 0126	90-95	interferon beta 1	Homo sapiens	21-29
23329343-6	2013	Autophagy induced by IFN-beta was suppressed when p-ERK1/2 was impaired by treatment with U0126.	U 0126	90-95	mitogen-activated protein kinase 3	Homo sapiens	52-58
23589028-10	2013	By contrast, the MEK inhibitor (U0126) almost completely eliminated PMA-induced basal adhesion and TNF production.	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
23589028-10	2013	By contrast, the MEK inhibitor (U0126) almost completely eliminated PMA-induced basal adhesion and TNF production.	U 0126	32-37	tumor necrosis factor	Homo sapiens	99-102
23535516-9	2013	Blockade of JAK and ERK pathways with AG490 and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-alpha-MSH.	U 0126	48-53	norrin cystine knot growth factor NDP	Rattus norvegicus	120-123
23535516-9	2013	Blockade of JAK and ERK pathways with AG490 and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-alpha-MSH.	U 0126	48-53	proopiomelanocortin	Rattus norvegicus	124-133
23538210-6	2013	Furthermore, CRH stimulated p53 mRNA via the ERK 1/2 pathway in the BRL-3A cell line and this was blocked by the ERK 1/2 antagonist U0126.	U 0126	132-137	corticotropin releasing hormone	Rattus norvegicus	13-16
23538210-6	2013	Furthermore, CRH stimulated p53 mRNA via the ERK 1/2 pathway in the BRL-3A cell line and this was blocked by the ERK 1/2 antagonist U0126.	U 0126	132-137	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	28-31
23538210-6	2013	Furthermore, CRH stimulated p53 mRNA via the ERK 1/2 pathway in the BRL-3A cell line and this was blocked by the ERK 1/2 antagonist U0126.	U 0126	132-137	mitogen activated protein kinase 3	Rattus norvegicus	45-52
23538210-6	2013	Furthermore, CRH stimulated p53 mRNA via the ERK 1/2 pathway in the BRL-3A cell line and this was blocked by the ERK 1/2 antagonist U0126.	U 0126	132-137	mitogen activated protein kinase 3	Rattus norvegicus	113-120
23610132-9	2013	Furthermore, the ERK1/2 inhibitor U0126 reversed the inhibitory effect of E2 on alpha,beta-me-ATP-induced pain and of PPT or G-1 on P2X3 receptor-mediated currents.	U 0126	34-39	mitogen activated protein kinase 3	Rattus norvegicus	17-23
23610132-9	2013	Furthermore, the ERK1/2 inhibitor U0126 reversed the inhibitory effect of E2 on alpha,beta-me-ATP-induced pain and of PPT or G-1 on P2X3 receptor-mediated currents.	U 0126	34-39	purinergic receptor P2X 3	Rattus norvegicus	125-136
23567618-7	2013	Mitogen-activated protein/extracellular signal-regulated kinase inhibitor U0126 abrogated TNF-alpha-, IFN-gamma-, and IL-1beta-induced and Janus-activated kinase inhibitor I reduced IFN-gamma-induced IL-33 production.	U 0126	74-79	tumor necrosis factor	Homo sapiens	90-99
23567618-7	2013	Mitogen-activated protein/extracellular signal-regulated kinase inhibitor U0126 abrogated TNF-alpha-, IFN-gamma-, and IL-1beta-induced and Janus-activated kinase inhibitor I reduced IFN-gamma-induced IL-33 production.	U 0126	74-79	interferon gamma	Homo sapiens	102-111
23567618-7	2013	Mitogen-activated protein/extracellular signal-regulated kinase inhibitor U0126 abrogated TNF-alpha-, IFN-gamma-, and IL-1beta-induced and Janus-activated kinase inhibitor I reduced IFN-gamma-induced IL-33 production.	U 0126	74-79	interleukin 1 beta	Homo sapiens	118-126
23266915-5	2013	The protective role of 17beta-estradiol against Abeta(1-42)-induced down-regulation of CREB pS133 was abolished by the mitogen-activated protein kinase (MAPK) pathway inhibitor U0126.	U 0126	177-182	cAMP responsive element binding protein 1	Rattus norvegicus	87-91
23266915-6	2013	Furthermore, 17beta-estradiol also prolonged the up-regulation of GSK-3beta pS9 for at least 8 h. However, this action of 17beta-estradiol was abrogated by PKA inhibitor H-89, AKT inhibitor LY294002, and MAPK inhibitor U0126.	U 0126	219-224	glycogen synthase kinase 3 beta	Rattus norvegicus	66-75
23266915-6	2013	Furthermore, 17beta-estradiol also prolonged the up-regulation of GSK-3beta pS9 for at least 8 h. However, this action of 17beta-estradiol was abrogated by PKA inhibitor H-89, AKT inhibitor LY294002, and MAPK inhibitor U0126.	U 0126	219-224	AKT serine/threonine kinase 1	Rattus norvegicus	176-179
23307752-3	2013	In this study, our data demonstrated that ERK inhibitors U0126 and PD98059 blocked glutamate-induced necroptosis in HT-22 cells, indicating the critical role of ERK activation in necroptosis.	U 0126	57-62	mitogen-activated protein kinase 1	Mus musculus	42-45
23307752-3	2013	In this study, our data demonstrated that ERK inhibitors U0126 and PD98059 blocked glutamate-induced necroptosis in HT-22 cells, indicating the critical role of ERK activation in necroptosis.	U 0126	57-62	mitogen-activated protein kinase 1	Mus musculus	161-164
23583632-6	2013	To dissect the signaling cascade involved in atrazine action in granulosa cells, we used U0126, a pharmacological inhibitor of ERK1/2.	U 0126	89-94	mitogen activated protein kinase 3	Rattus norvegicus	127-133
23583632-7	2013	U0126 prevents atrazine-induced decrease in LHR and CYP19A1 mRNA levels and estradiol production in the FSH-stimulated granulosa cells.	U 0126	0-5	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	44-47
23583632-7	2013	U0126 prevents atrazine-induced decrease in LHR and CYP19A1 mRNA levels and estradiol production in the FSH-stimulated granulosa cells.	U 0126	0-5	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	52-59
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	U 0126	126-131	gonadotropin releasing hormone 2	Homo sapiens	4-11
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	U 0126	126-131	mitogen-activated protein kinase 3	Homo sapiens	51-57
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	U 0126	126-131	mitogen-activated protein kinase 8	Homo sapiens	62-65
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	U 0126	126-131	mitogen-activated protein kinase 3	Homo sapiens	108-114
23786715-12	2013	Cell motility promoted by GnRH-II agonist was suppressed in cells that were pretreated with U0126 and SP600125.	U 0126	92-97	gonadotropin releasing hormone 2	Homo sapiens	26-33
23786715-13	2013	Moreover, U0126 and SP600125 abolished the GnRH-II agonist-induced activation of MMP-2.	U 0126	10-15	gonadotropin releasing hormone 2	Homo sapiens	43-50
23786715-13	2013	Moreover, U0126 and SP600125 abolished the GnRH-II agonist-induced activation of MMP-2.	U 0126	10-15	matrix metallopeptidase 2	Homo sapiens	81-86
23535237-7	2013	This effect was abolished by pretreatment of the cells with the p38 MAPK inhibitor SB-203580 (10 muM) 30 min before administration of ANG II or the ERK1/2 inhibitor U-0126 (10 muM).	U 0126	165-171	mitogen-activated protein kinase 3	Mus musculus	148-154
24648994-3	2013	ERCC1 is considered to be a closely related downstream target gene of extracellular signal-regulated kinase (ERK)1/2, since ERCC1 mRNA and protein levels may be inhibited by the ERK inhibitor U0126.	U 0126	192-197	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	124-129
24648994-3	2013	ERCC1 is considered to be a closely related downstream target gene of extracellular signal-regulated kinase (ERK)1/2, since ERCC1 mRNA and protein levels may be inhibited by the ERK inhibitor U0126.	U 0126	192-197	mitogen-activated protein kinase 1	Homo sapiens	109-112
23369528-5	2013	Inhibition of the extracellular signal-regulated kinase (ERK) pathway by U0126 treatment for 24 and 48h in CMT93-II cells markedly decreased claudin-2 from the apical junctional region and increased TER.	U 0126	73-78	mitogen-activated protein kinase 1	Mus musculus	18-55
23369528-5	2013	Inhibition of the extracellular signal-regulated kinase (ERK) pathway by U0126 treatment for 24 and 48h in CMT93-II cells markedly decreased claudin-2 from the apical junctional region and increased TER.	U 0126	73-78	mitogen-activated protein kinase 1	Mus musculus	57-60
23369528-5	2013	Inhibition of the extracellular signal-regulated kinase (ERK) pathway by U0126 treatment for 24 and 48h in CMT93-II cells markedly decreased claudin-2 from the apical junctional region and increased TER.	U 0126	73-78	claudin 2	Mus musculus	141-150
23369528-6	2013	However, claudin-4, -6, and -7 were still continuously localized at the apical junctional region by U0126 treatment.	U 0126	100-105	claudin 4	Mus musculus	9-30
23369528-7	2013	Moreover, the claudin-2 expression recovered at the apical junctional region after the removal of U0126 and TER decreased almost to the baseline level.	U 0126	98-103	claudin 2	Mus musculus	14-23
23980358-5	2013	RESULTS: (1) When compared with the control group, the expression level of p-ERK1/2 in hAECs in those with normal AFV and oligohydramnios obviously decreased in the U0126 group (P &lt; 0.05).	U 0126	165-170	mitogen-activated protein kinase 3	Homo sapiens	77-83
23980358-7	2013	The expression level of p-ERK1/2 in hAECs was higher in the CDI +U0126 group than in the U0126 group, but lower in the CDI + U0126 group than in the CDI group (P &lt; 0.05).	U 0126	65-70	mitogen-activated protein kinase 3	Homo sapiens	26-32
23980358-7	2013	The expression level of p-ERK1/2 in hAECs was higher in the CDI +U0126 group than in the U0126 group, but lower in the CDI + U0126 group than in the CDI group (P &lt; 0.05).	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	26-32
23980358-7	2013	The expression level of p-ERK1/2 in hAECs was higher in the CDI +U0126 group than in the U0126 group, but lower in the CDI + U0126 group than in the CDI group (P &lt; 0.05).	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	26-32
23980358-10	2013	(3) Compared with the vehicle control group, the expression level of AQP3 in hAECs with oligohydramnios significantly decreased in the U0126 group and increased in the CDI group (P &lt; 0.05).	U 0126	135-140	aquaporin 3 (Gill blood group)	Homo sapiens	69-73
23980358-11	2013	The expression level of AQP3 was lower in the U0126 + CDI group than in the CDI group, but higher in the U0126 +CDI group than in the U0126 group (P &lt; 0.05).	U 0126	46-51	aquaporin 3 (Gill blood group)	Homo sapiens	24-28
23980358-11	2013	The expression level of AQP3 was lower in the U0126 + CDI group than in the CDI group, but higher in the U0126 +CDI group than in the U0126 group (P &lt; 0.05).	U 0126	105-110	aquaporin 3 (Gill blood group)	Homo sapiens	24-28
23980358-11	2013	The expression level of AQP3 was lower in the U0126 + CDI group than in the CDI group, but higher in the U0126 +CDI group than in the U0126 group (P &lt; 0.05).	U 0126	105-110	aquaporin 3 (Gill blood group)	Homo sapiens	24-28
24265864-5	2013	Interestingly, pre-treatment with an ERK inhibitor, U0126, significantly enhanced cellular proliferation and tubular formation capacities of CPCs.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	37-40
23562504-6	2013	Furthermore, the addition of MEK (mitogen-activated protein kinase/ERK kinase) antagonists PD98059 and U0126 nearly abolished the beneficial effects of edaravone.	U 0126	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	29-32
23562504-6	2013	Furthermore, the addition of MEK (mitogen-activated protein kinase/ERK kinase) antagonists PD98059 and U0126 nearly abolished the beneficial effects of edaravone.	U 0126	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	34-77
23538162-5	2013	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor alpha antagonist ICI 82,780.	U 0126	108-113	mitogen-activated protein kinase 1	Homo sapiens	94-97
22751110-9	2013	Inhibition of MEK 1/2 with UO126 completely restored ERbeta growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ERbeta-induced proliferation.	U 0126	27-32	mitogen-activated protein kinase kinase 1	Mus musculus	14-21
22751110-9	2013	Inhibition of MEK 1/2 with UO126 completely restored ERbeta growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ERbeta-induced proliferation.	U 0126	27-32	estrogen receptor 2 (beta)	Mus musculus	53-59
23667643-7	2013	Pre-treatment of DCs with the extracellular signal-regulated kinase (ERK) inhibitor U0126 abolished cooperative induction of IL-10 by DEX and NDV.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	69-72
23667643-7	2013	Pre-treatment of DCs with the extracellular signal-regulated kinase (ERK) inhibitor U0126 abolished cooperative induction of IL-10 by DEX and NDV.	U 0126	84-89	interleukin 10	Homo sapiens	125-130
23667687-9	2013	Up-regulation of SLP-2 was effectively abrogated by the ERK1/2 inhibitors either PD98059 or U0126, but no effect was showed by the treatment of AKT inhibitors either LY294002 or MK-2206.	U 0126	92-97	stomatin like 2	Homo sapiens	17-22
23667687-9	2013	Up-regulation of SLP-2 was effectively abrogated by the ERK1/2 inhibitors either PD98059 or U0126, but no effect was showed by the treatment of AKT inhibitors either LY294002 or MK-2206.	U 0126	92-97	mitogen-activated protein kinase 3	Homo sapiens	56-62
23467745-9	2013	All of these effects were abolished by the H2R blocker famotidine or the ERK inhibitor U0126.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	73-76
23373714-6	2013	KEY RESULTS: ER stress dampened insulin-stimulated signals and glucose uptake, whereas treatment with the specific ERK inhibitor U0126 (25 muM) rescued impaired insulin signalling via AMPK activation.	U 0126	129-134	mitogen-activated protein kinase 1	Mus musculus	115-118
23609470-5	2013	The EGFR inhibitor gefitinib and the ERK pathway inhibitor U0126 resulted in partial and preferential growth inhibition of tamoxifen-resistant cells.	U 0126	59-64	mitogen-activated protein kinase 1	Homo sapiens	37-40
23114726-7	2013	The treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2/MMP-9 and phospho-ERK along with an inhibition on cell invasion and migration.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	40-43
23114726-7	2013	The treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2/MMP-9 and phospho-ERK along with an inhibition on cell invasion and migration.	U 0126	45-50	matrix metallopeptidase 2	Homo sapiens	93-98
23114726-7	2013	The treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2/MMP-9 and phospho-ERK along with an inhibition on cell invasion and migration.	U 0126	45-50	matrix metallopeptidase 9	Homo sapiens	99-104
23114726-7	2013	The treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2/MMP-9 and phospho-ERK along with an inhibition on cell invasion and migration.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	117-120
23415771-9	2013	In addition, MEK inhibitors U0126 or PD98059, but not mTOR specific inhibitors, rapamycin and Torin 1, inhibited rPMT-induced upregulation of CTGF.	U 0126	28-33	midkine	Mus musculus	13-16
23415771-9	2013	In addition, MEK inhibitors U0126 or PD98059, but not mTOR specific inhibitors, rapamycin and Torin 1, inhibited rPMT-induced upregulation of CTGF.	U 0126	28-33	cellular communication network factor 2	Mus musculus	142-146
23453973-6	2013	We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively.	U 0126	67-72	mitogen-activated protein kinase kinase 1	Homo sapiens	111-117
23453973-6	2013	We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively.	U 0126	67-72	mechanistic target of rapamycin kinase	Homo sapiens	128-132
23380370-6	2013	We found that inhibition of the p42/p44 MAPK signaling pathway with a MEK inhibitor (U0126) impairs PR-mediated gene induction, but not gene repression.	U 0126	85-90	cyclin dependent kinase 20	Homo sapiens	32-35
23380370-6	2013	We found that inhibition of the p42/p44 MAPK signaling pathway with a MEK inhibitor (U0126) impairs PR-mediated gene induction, but not gene repression.	U 0126	85-90	interferon induced protein 44	Homo sapiens	36-39
23380370-6	2013	We found that inhibition of the p42/p44 MAPK signaling pathway with a MEK inhibitor (U0126) impairs PR-mediated gene induction, but not gene repression.	U 0126	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
23380370-6	2013	We found that inhibition of the p42/p44 MAPK signaling pathway with a MEK inhibitor (U0126) impairs PR-mediated gene induction, but not gene repression.	U 0126	85-90	progesterone receptor	Homo sapiens	100-102
23380370-7	2013	In addition, the effects of U0126 on PR-mediated gene transcription are much greater with long-term versus short-term inhibition and are gene-specific.	U 0126	28-33	progesterone receptor	Homo sapiens	37-39
23373714-7	2013	In db/db mice, U0126 administration decreased markers of insulin resistance and increased the phosphorylations of Akt and AMPK in muscle tissues.	U 0126	15-20	thymoma viral proto-oncogene 1	Mus musculus	114-117
23401562-4	2013	Association of p67(phox) and phosphoPrdx6 in intact MPMVECs after angiotensin II stimulation was demonstrated by proximity ligation assay and was abolished by U0126, a MAP kinase inhibitor.	U 0126	159-164	methionine aminopeptidase 2	Mus musculus	15-18
23438680-4	2013	Interestingly, we found that zymosan-induced production of MIP-2 was blocked by pre-treatment with U0126, an inhibitor of mitogen-activated protein kinase/extracellular-signal-regulated kinase (ERK), and with BAY11-7082, an inhibitor of nuclear factor (NF)-kappaB.	U 0126	99-104	chemokine (C-X-C motif) ligand 2	Mus musculus	59-64
23438680-4	2013	Interestingly, we found that zymosan-induced production of MIP-2 was blocked by pre-treatment with U0126, an inhibitor of mitogen-activated protein kinase/extracellular-signal-regulated kinase (ERK), and with BAY11-7082, an inhibitor of nuclear factor (NF)-kappaB.	U 0126	99-104	mitogen-activated protein kinase 1	Mus musculus	194-197
23438680-4	2013	Interestingly, we found that zymosan-induced production of MIP-2 was blocked by pre-treatment with U0126, an inhibitor of mitogen-activated protein kinase/extracellular-signal-regulated kinase (ERK), and with BAY11-7082, an inhibitor of nuclear factor (NF)-kappaB.	U 0126	99-104	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	237-263
23438680-5	2013	Western blot analysis indicated that U0126 also inhibited the phosphorylation of p65 subunit of NF-kappaB (p65), indicating that MIP-2 was produced via the ERK/NF-kappaB pathway.	U 0126	37-42	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	81-84
23438680-5	2013	Western blot analysis indicated that U0126 also inhibited the phosphorylation of p65 subunit of NF-kappaB (p65), indicating that MIP-2 was produced via the ERK/NF-kappaB pathway.	U 0126	37-42	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	107-110
23438680-5	2013	Western blot analysis indicated that U0126 also inhibited the phosphorylation of p65 subunit of NF-kappaB (p65), indicating that MIP-2 was produced via the ERK/NF-kappaB pathway.	U 0126	37-42	chemokine (C-X-C motif) ligand 2	Mus musculus	129-134
23438680-5	2013	Western blot analysis indicated that U0126 also inhibited the phosphorylation of p65 subunit of NF-kappaB (p65), indicating that MIP-2 was produced via the ERK/NF-kappaB pathway.	U 0126	37-42	mitogen-activated protein kinase 1	Mus musculus	156-159
23585528-5	2013	We provide evidence of overexpression of STAT1 in FANCA-deficient cells which has both transcriptional and post-translational components, and is related to the constitutive activation of ERK in Fanconi anemia group A cells, since it can be reverted by treatment with U0126.	U 0126	267-272	signal transducer and activator of transcription 1	Homo sapiens	41-46
23585528-5	2013	We provide evidence of overexpression of STAT1 in FANCA-deficient cells which has both transcriptional and post-translational components, and is related to the constitutive activation of ERK in Fanconi anemia group A cells, since it can be reverted by treatment with U0126.	U 0126	267-272	FA complementation group A	Homo sapiens	50-55
23585528-5	2013	We provide evidence of overexpression of STAT1 in FANCA-deficient cells which has both transcriptional and post-translational components, and is related to the constitutive activation of ERK in Fanconi anemia group A cells, since it can be reverted by treatment with U0126.	U 0126	267-272	mitogen-activated protein kinase 1	Homo sapiens	187-190
23467622-9	2013	Signals acted upstream of ERK activation included generation of reactive oxygen species (ROS) and endoplasmic reticulum stress predominantly via the PERK-eIF2alpha pathway, as the MEK inhibitor U0126 did not inhibit the phosphorylation of PERK and eIF2alpha or the generation of ROS.	U 0126	194-199	mitogen-activated protein kinase 1	Homo sapiens	26-29
22932066-5	2013	MEK inhibitors--PD98059 and U0126--blocked the effect of bFGF on phosphorylated CREB while a p38-MAPK inhibitor--SB203580--blocked the effect of IL1beta on phosphorylated CREB.	U 0126	28-33	fibroblast growth factor 2	Rattus norvegicus	57-61
22932066-5	2013	MEK inhibitors--PD98059 and U0126--blocked the effect of bFGF on phosphorylated CREB while a p38-MAPK inhibitor--SB203580--blocked the effect of IL1beta on phosphorylated CREB.	U 0126	28-33	cAMP responsive element binding protein 1	Rattus norvegicus	80-84
22932066-8	2013	Concerning transferrin, PD98059 and U0126 were able to inhibit the ability of bFGF to stimulate its secre tion.	U 0126	36-41	fibroblast growth factor 2	Rattus norvegicus	78-82
23359590-11	2013	Inhibition of phosphoinositide 3-kinase (PI3K) by Ly294002 or inhibition of ERK by U0126 in vivo abolished CpG-ODN attenuation of CLP-induced cardiac dysfunction.	U 0126	83-88	mitogen-activated protein kinase 1	Mus musculus	76-79
23473787-5	2013	Downregulation of extracellular signal-regulated kinase (ERK) signaling using the ERK inhibitor U0126 and the calcium-channel blocker ketamine inhibited the upregulation of miR-21 expression and MMP9 protein level after cerebral ischemia.	U 0126	96-101	Eph receptor B1	Rattus norvegicus	18-55
23473787-5	2013	Downregulation of extracellular signal-regulated kinase (ERK) signaling using the ERK inhibitor U0126 and the calcium-channel blocker ketamine inhibited the upregulation of miR-21 expression and MMP9 protein level after cerebral ischemia.	U 0126	96-101	Eph receptor B1	Rattus norvegicus	57-60
23473787-5	2013	Downregulation of extracellular signal-regulated kinase (ERK) signaling using the ERK inhibitor U0126 and the calcium-channel blocker ketamine inhibited the upregulation of miR-21 expression and MMP9 protein level after cerebral ischemia.	U 0126	96-101	Eph receptor B1	Rattus norvegicus	82-85
23473787-5	2013	Downregulation of extracellular signal-regulated kinase (ERK) signaling using the ERK inhibitor U0126 and the calcium-channel blocker ketamine inhibited the upregulation of miR-21 expression and MMP9 protein level after cerebral ischemia.	U 0126	96-101	microRNA 21	Rattus norvegicus	173-179
23473787-5	2013	Downregulation of extracellular signal-regulated kinase (ERK) signaling using the ERK inhibitor U0126 and the calcium-channel blocker ketamine inhibited the upregulation of miR-21 expression and MMP9 protein level after cerebral ischemia.	U 0126	96-101	matrix metallopeptidase 9	Rattus norvegicus	195-199
23553034-7	2013	Improved migration of myoblasts treated with 1 muM BpV(Hopic) was associated with activation of PI3K/AKT and MAPK/ERK pathways, while their inhibition with either LY294002 or UO126, respectively, resulted in a reduction of C2C12 migration back to control levels.	U 0126	175-180	latexin	Homo sapiens	47-50
23262364-6	2013	Both cascades mediate GDNF stimulation of neuritogenesis, since application of the Akt inhibitor Wortmannin or the Erk inhibitor U0126 abolished GDNF/GFRalpha1-Fc stimulated neuritogenesis in P5 rats.	U 0126	129-134	glial cell derived neurotrophic factor	Rattus norvegicus	22-26
23262364-6	2013	Both cascades mediate GDNF stimulation of neuritogenesis, since application of the Akt inhibitor Wortmannin or the Erk inhibitor U0126 abolished GDNF/GFRalpha1-Fc stimulated neuritogenesis in P5 rats.	U 0126	129-134	Eph receptor B1	Rattus norvegicus	115-118
23262364-6	2013	Both cascades mediate GDNF stimulation of neuritogenesis, since application of the Akt inhibitor Wortmannin or the Erk inhibitor U0126 abolished GDNF/GFRalpha1-Fc stimulated neuritogenesis in P5 rats.	U 0126	129-134	glial cell derived neurotrophic factor	Rattus norvegicus	145-149
23262364-6	2013	Both cascades mediate GDNF stimulation of neuritogenesis, since application of the Akt inhibitor Wortmannin or the Erk inhibitor U0126 abolished GDNF/GFRalpha1-Fc stimulated neuritogenesis in P5 rats.	U 0126	129-134	GDNF family receptor alpha 1	Rattus norvegicus	150-159
23467984-4	2013	ERK1/2 activity was blocked by either the mitogen-induced extracellular kinase (MEK) inhibitor U0126 or a multi-kinase inhibitor sorafenib.	U 0126	95-100	mitogen-activated protein kinase 3	Homo sapiens	0-6
23467984-4	2013	ERK1/2 activity was blocked by either the mitogen-induced extracellular kinase (MEK) inhibitor U0126 or a multi-kinase inhibitor sorafenib.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	42-78
23467984-4	2013	ERK1/2 activity was blocked by either the mitogen-induced extracellular kinase (MEK) inhibitor U0126 or a multi-kinase inhibitor sorafenib.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
23467984-7	2013	Combination of DNR with MEK inhibitor U0126 synergistically inhibited K562 cell growth.	U 0126	38-43	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
23545258-5	2013	Similarly, MEK1/2 Inhibitor U0126 potentiated SKI II-induced apoptosis in hepatoma HepG2 cells, consistently with the further attenuation of Akt/ERK/NF-kappaB signaling pathway.	U 0126	28-33	mitogen-activated protein kinase kinase 1	Homo sapiens	11-17
23545258-5	2013	Similarly, MEK1/2 Inhibitor U0126 potentiated SKI II-induced apoptosis in hepatoma HepG2 cells, consistently with the further attenuation of Akt/ERK/NF-kappaB signaling pathway.	U 0126	28-33	AKT serine/threonine kinase 1	Homo sapiens	141-144
23545258-5	2013	Similarly, MEK1/2 Inhibitor U0126 potentiated SKI II-induced apoptosis in hepatoma HepG2 cells, consistently with the further attenuation of Akt/ERK/NF-kappaB signaling pathway.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	145-148
23545258-5	2013	Similarly, MEK1/2 Inhibitor U0126 potentiated SKI II-induced apoptosis in hepatoma HepG2 cells, consistently with the further attenuation of Akt/ERK/NF-kappaB signaling pathway.	U 0126	28-33	nuclear factor kappa B subunit 1	Homo sapiens	149-158
23545258-6	2013	It was also shown that the combination of SKI II and U0126 further attenuated the migration of hepatoma HepG2 cells via FAK/MLC-2 signaling pathway.	U 0126	53-58	protein tyrosine kinase 2	Homo sapiens	120-123
23545258-6	2013	It was also shown that the combination of SKI II and U0126 further attenuated the migration of hepatoma HepG2 cells via FAK/MLC-2 signaling pathway.	U 0126	53-58	myosin light chain 2	Homo sapiens	124-129
23617883-10	2013	U0126, an ERK signal inhibitor dramatically suppressed Angptl4 expression.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
23617883-10	2013	U0126, an ERK signal inhibitor dramatically suppressed Angptl4 expression.	U 0126	0-5	angiopoietin like 4	Homo sapiens	55-62
23620784-8	2013	Inhibition of ERK activation through multiple approaches, including treatment with the MEK inhibitor U0126, ectopic expression of dominant-negative MEK1(K97M), and knockdown of either ERK1 or ERK2 resulted in a robust reduction in PCSC propagation.	U 0126	101-106	mitogen-activated protein kinase 1	Homo sapiens	14-17
23620784-8	2013	Inhibition of ERK activation through multiple approaches, including treatment with the MEK inhibitor U0126, ectopic expression of dominant-negative MEK1(K97M), and knockdown of either ERK1 or ERK2 resulted in a robust reduction in PCSC propagation.	U 0126	101-106	mitogen-activated protein kinase kinase 7	Homo sapiens	87-90
23518641-8	2013	Further, EPO activates the PI3K and ERK1/2 pathways in cultured hippocampal neurons, and the PI3K/Akt inhibitor LY294002 and ERK1/2 inhibitor U0126 both blocked, at least in part, the suppressive effect of exogenous EPO on KA-induced calcium currents.	U 0126	142-147	erythropoietin	Rattus norvegicus	9-12
23518641-8	2013	Further, EPO activates the PI3K and ERK1/2 pathways in cultured hippocampal neurons, and the PI3K/Akt inhibitor LY294002 and ERK1/2 inhibitor U0126 both blocked, at least in part, the suppressive effect of exogenous EPO on KA-induced calcium currents.	U 0126	142-147	mitogen activated protein kinase 3	Rattus norvegicus	125-131
23518641-8	2013	Further, EPO activates the PI3K and ERK1/2 pathways in cultured hippocampal neurons, and the PI3K/Akt inhibitor LY294002 and ERK1/2 inhibitor U0126 both blocked, at least in part, the suppressive effect of exogenous EPO on KA-induced calcium currents.	U 0126	142-147	erythropoietin	Rattus norvegicus	216-219
23428580-8	2013	Pretreatment with the MAPK/ERK kinase inhibitor U0126 attenuated NMB-induced cell proliferation and DNA synthesis.	U 0126	48-53	mitogen activated protein kinase 3	Rattus norvegicus	22-26
23428580-8	2013	Pretreatment with the MAPK/ERK kinase inhibitor U0126 attenuated NMB-induced cell proliferation and DNA synthesis.	U 0126	48-53	mitogen activated protein kinase 3	Rattus norvegicus	27-30
23428580-8	2013	Pretreatment with the MAPK/ERK kinase inhibitor U0126 attenuated NMB-induced cell proliferation and DNA synthesis.	U 0126	48-53	neuromedin B	Rattus norvegicus	65-68
23430108-5	2013	MEK-ERK-regulated genes exhibited an overrepresentation of cognate sequences for the aryl hydrocarbon receptor (AhR) transcription factor, whose transcriptional and DNA-binding activities increased in MDDCs upon exposure to the MEK1/2 inhibitor U0126.	U 0126	245-250	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
23430108-5	2013	MEK-ERK-regulated genes exhibited an overrepresentation of cognate sequences for the aryl hydrocarbon receptor (AhR) transcription factor, whose transcriptional and DNA-binding activities increased in MDDCs upon exposure to the MEK1/2 inhibitor U0126.	U 0126	245-250	mitogen-activated protein kinase 1	Homo sapiens	4-7
23430108-5	2013	MEK-ERK-regulated genes exhibited an overrepresentation of cognate sequences for the aryl hydrocarbon receptor (AhR) transcription factor, whose transcriptional and DNA-binding activities increased in MDDCs upon exposure to the MEK1/2 inhibitor U0126.	U 0126	245-250	aryl hydrocarbon receptor	Homo sapiens	85-110
23430108-5	2013	MEK-ERK-regulated genes exhibited an overrepresentation of cognate sequences for the aryl hydrocarbon receptor (AhR) transcription factor, whose transcriptional and DNA-binding activities increased in MDDCs upon exposure to the MEK1/2 inhibitor U0126.	U 0126	245-250	aryl hydrocarbon receptor	Homo sapiens	112-115
23430108-5	2013	MEK-ERK-regulated genes exhibited an overrepresentation of cognate sequences for the aryl hydrocarbon receptor (AhR) transcription factor, whose transcriptional and DNA-binding activities increased in MDDCs upon exposure to the MEK1/2 inhibitor U0126.	U 0126	245-250	mitogen-activated protein kinase kinase 1	Homo sapiens	228-234
23585898-9	2013	The ERK1/2 inhibitor U0126 also blocked the function of the stress hormone, suggesting the involvement of ERK1/2 in the tumor-promoting effect of CRS.	U 0126	21-26	mitogen-activated protein kinase 3	Mus musculus	4-10
23585898-9	2013	The ERK1/2 inhibitor U0126 also blocked the function of the stress hormone, suggesting the involvement of ERK1/2 in the tumor-promoting effect of CRS.	U 0126	21-26	mitogen-activated protein kinase 3	Mus musculus	106-112
23473758-7	2013	Moreover, UO126 (the MEK-ERK inhibitor), not LY294002 (the PI3K-Akt inhibitor), inhibited the IGF1 induced increase in TAZ expression.	U 0126	10-15	Eph receptor B1	Rattus norvegicus	25-28
23473758-7	2013	Moreover, UO126 (the MEK-ERK inhibitor), not LY294002 (the PI3K-Akt inhibitor), inhibited the IGF1 induced increase in TAZ expression.	U 0126	10-15	insulin-like growth factor 1	Rattus norvegicus	94-98
23403511-5	2013	Under normoxia, we found that rapamycin (100 nM) induced an increase of pCREB that was prevented by mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or cAMP-dependent protein kinase (PKA) inhibitor H89.	U 0126	193-198	mitogen-activated protein kinase kinase 7	Homo sapiens	134-137
23403511-5	2013	Under normoxia, we found that rapamycin (100 nM) induced an increase of pCREB that was prevented by mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or cAMP-dependent protein kinase (PKA) inhibitor H89.	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	178-181
23403511-8	2013	Moreover, U0126 prevented the rapamycin-induced increase of Bcl-2 and VEGF-A levels.	U 0126	10-15	BCL2 apoptosis regulator	Homo sapiens	60-65
23403511-8	2013	Moreover, U0126 prevented the rapamycin-induced increase of Bcl-2 and VEGF-A levels.	U 0126	10-15	vascular endothelial growth factor A	Homo sapiens	70-76
23380724-10	2013	F. nucleatum Sup-induced MUC5AC production was blocked by the ERK pathway inhibitor U0126.	U 0126	84-89	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	25-31
23021350-7	2013	Furthermore, the expression of HO-1 was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	163-168	heme oxygenase 1	Mus musculus	31-35
23481295-10	2013	U0126, a specific inhibitor of mitogen activated protein kinases kinase, blocked ghrelin- and des-acyl ghrelin-induced ERK1/2 phosphorylation and cell proliferation in IEC-6 cells.	U 0126	0-5	ghrelin and obestatin prepropeptide	Rattus norvegicus	81-88
23481295-10	2013	U0126, a specific inhibitor of mitogen activated protein kinases kinase, blocked ghrelin- and des-acyl ghrelin-induced ERK1/2 phosphorylation and cell proliferation in IEC-6 cells.	U 0126	0-5	ghrelin and obestatin prepropeptide	Rattus norvegicus	103-110
23481295-10	2013	U0126, a specific inhibitor of mitogen activated protein kinases kinase, blocked ghrelin- and des-acyl ghrelin-induced ERK1/2 phosphorylation and cell proliferation in IEC-6 cells.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	119-125
23306863-4	2013	METHODS: We co-cultured monocyte-derived human DCs with melanoma cell lines pretreated with the MEK inhibitor U0126 or the BRAF inhibitor vemurafenib.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	96-99
23306863-8	2013	This suppression was reversed by MAPK blockade with U0126 and/or vemurafenib only in melanoma cell lines carrying a BRAF(V600E) mutation.	U 0126	52-57	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	116-121
23399805-9	2013	Circumventing this dilemma, we present evidence that concurrent inhibition of ERK phosphorylation (U0126) and CMV replication (acyclovir) obviates progressive pathogenesis and results in complete SG rescue (tumor regression).	U 0126	99-104	mitogen-activated protein kinase 1	Homo sapiens	78-81
23247634-5	2013	MEKs/ERKs inhibitor U0126 reverted the vitamin D anti-oxidant effects.	U 0126	20-25	mitogen-activated protein kinase 3	Homo sapiens	5-9
23345412-8	2013	In the early stage of sulfatide stimulation, phosphorylation of Erk as well as c-Src was noted, and inhibition of Erk activation with either U0126 or PD98059 significantly suppressed Sp1 phosphorylation and integrin alphaV expression.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	114-117
23626478-9	2013	Concurrent treatment with the MEK1/2 inhibitors, PD98059 or U0126 completely inhibited recombinant IGFBP-5-induced VSMC proliferation in WKY, while concurrent treatment with the phosphatidylinositol-3 kinase inhibitor, LY294002, had no effect.	U 0126	60-65	insulin-like growth factor binding protein 5	Rattus norvegicus	99-106
23827636-12	2013	In osteogenic medium, 50 muM PS extended phospho-ERK activation by osteogenic induction medium from 30 min to 8 h. U0126, an ERK inhibitor, suppressed the ALP expression induced by PS.	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	49-52
23827636-12	2013	In osteogenic medium, 50 muM PS extended phospho-ERK activation by osteogenic induction medium from 30 min to 8 h. U0126, an ERK inhibitor, suppressed the ALP expression induced by PS.	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	125-128
23827636-12	2013	In osteogenic medium, 50 muM PS extended phospho-ERK activation by osteogenic induction medium from 30 min to 8 h. U0126, an ERK inhibitor, suppressed the ALP expression induced by PS.	U 0126	115-120	alkaline phosphatase, placental	Homo sapiens	155-158
22875335-0	2013	Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.	U 0126	38-43	midkine	Mus musculus	24-27
22875335-10	2013	In addition, six Wt1-Igf2 mice were treated with a mitogen-activated protein kinase (MEK) inhibitor U0126 (50 mumol/kg i.p.)	U 0126	100-105	midkine	Mus musculus	51-83
22875335-10	2013	In addition, six Wt1-Igf2 mice were treated with a mitogen-activated protein kinase (MEK) inhibitor U0126 (50 mumol/kg i.p.)	U 0126	100-105	midkine	Mus musculus	85-88
22875335-21	2013	Treatment with a MEK 1/2 inhibitor U0126 did not cause the inhibition of tumor growth as compared to untreated animals.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Mus musculus	17-24
22875335-27	2013	Therapy with MEK inhibitor U0126 produces only a transient inhibition of tumor glycolytic activity but does not inhibit tumor growth, which is due to continuing IGF2-induced signaling from IGF1R through the PI3K-AKT-mTOR pathway.	U 0126	27-32	midkine	Mus musculus	13-16
22875335-27	2013	Therapy with MEK inhibitor U0126 produces only a transient inhibition of tumor glycolytic activity but does not inhibit tumor growth, which is due to continuing IGF2-induced signaling from IGF1R through the PI3K-AKT-mTOR pathway.	U 0126	27-32	insulin-like growth factor 2	Mus musculus	161-165
22875335-27	2013	Therapy with MEK inhibitor U0126 produces only a transient inhibition of tumor glycolytic activity but does not inhibit tumor growth, which is due to continuing IGF2-induced signaling from IGF1R through the PI3K-AKT-mTOR pathway.	U 0126	27-32	insulin-like growth factor I receptor	Mus musculus	189-194
23232926-7	2013	In addition, pretreatment with a Src inhibitor PP2 or an ERK inhibitor U0126 also attenuated vascular relaxation induced by the cumulative addition of 3",4"-dimethoxythioflavone.	U 0126	71-76	Eph receptor B1	Rattus norvegicus	57-60
23164613-4	2013	This effect is abolished by the selective 5-HTR7 antagonist SB-269970, by the ERK inhibitor U0126, by the cyclin-dependent kinase 5 (Cdk5) inhibitor roscovitine, as well as by cycloheximide, an inhibitor of protein synthesis.	U 0126	92-97	5-hydroxytryptamine (serotonin) receptor 7	Mus musculus	44-48
23164613-4	2013	This effect is abolished by the selective 5-HTR7 antagonist SB-269970, by the ERK inhibitor U0126, by the cyclin-dependent kinase 5 (Cdk5) inhibitor roscovitine, as well as by cycloheximide, an inhibitor of protein synthesis.	U 0126	92-97	Eph receptor B2	Mus musculus	78-81
23232446-4	2013	We show that the mitogen-activated protein kinase (MEK)/ERK1/2 inhibitor, U0126 (1.0 mug/0.5 mul/hemisphere), microinfused bilaterally into the BLA--but not the NACc--immediately after brief re-exposure to a previously cocaine-paired context (that is, cocaine-memory reactivation), significantly attenuated subsequent drug context-induced cocaine seeking relative to vehicle (VEH).	U 0126	74-79	mitogen activated protein kinase 3	Rattus norvegicus	56-62
23353996-4	2013	To verify the regulatory mechanism of TPA-induced             MMP-9 expression, we treated TPC-1 and MCF7 cells with the MEK1/2 inhibitor, UO126,             and TPA-induced MMP-9 expression was significantly decreased.	U 0126	139-144	matrix metallopeptidase 9	Homo sapiens	62-67
23353996-4	2013	To verify the regulatory mechanism of TPA-induced             MMP-9 expression, we treated TPC-1 and MCF7 cells with the MEK1/2 inhibitor, UO126,             and TPA-induced MMP-9 expression was significantly decreased.	U 0126	139-144	two pore segment channel 1	Homo sapiens	91-96
23353996-4	2013	To verify the regulatory mechanism of TPA-induced             MMP-9 expression, we treated TPC-1 and MCF7 cells with the MEK1/2 inhibitor, UO126,             and TPA-induced MMP-9 expression was significantly decreased.	U 0126	139-144	matrix metallopeptidase 9	Homo sapiens	174-179
23404329-6	2013	Furthermore, the cells pretreated with U0126 (ERK1/2 inhibitor) partially             abolished the effect of ACS on cell viability.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	46-52
23404329-6	2013	Furthermore, the cells pretreated with U0126 (ERK1/2 inhibitor) partially             abolished the effect of ACS on cell viability.	U 0126	39-44	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	110-113
23410723-8	2013	Pharmacologically inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 1/2 signaling with U0126 attenuated the CsA-induced cell migration and NF-kappaB activity in trophoblasts.	U 0126	132-137	mitogen-activated protein kinase 3	Homo sapiens	63-67
23410723-8	2013	Pharmacologically inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 1/2 signaling with U0126 attenuated the CsA-induced cell migration and NF-kappaB activity in trophoblasts.	U 0126	132-137	mitogen-activated protein kinase 3	Homo sapiens	69-116
23410723-8	2013	Pharmacologically inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 1/2 signaling with U0126 attenuated the CsA-induced cell migration and NF-kappaB activity in trophoblasts.	U 0126	132-137	nuclear factor kappa B subunit 1	Homo sapiens	184-193
23467542-6	2013	Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB.	U 0126	53-58	nuclear factor kappa B subunit 1	Homo sapiens	128-137
23467542-6	2013	Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB.	U 0126	83-88	nuclear factor kappa B subunit 1	Homo sapiens	128-137
23467542-7	2013	SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1.	U 0126	21-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
23467542-7	2013	SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1.	U 0126	21-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
23395731-8	2013	Activation of extracellular signal-related kinase (ERK) by OGD was dependent on alpha-dystroglycan binding, and inhibition of ERK activity with U0126 abrogated the loss of water uptake following OGD.	U 0126	144-149	mitogen-activated protein kinase 1	Homo sapiens	14-49
23395731-8	2013	Activation of extracellular signal-related kinase (ERK) by OGD was dependent on alpha-dystroglycan binding, and inhibition of ERK activity with U0126 abrogated the loss of water uptake following OGD.	U 0126	144-149	mitogen-activated protein kinase 1	Homo sapiens	126-129
23485457-5	2013	The MAPK pathway inhibitor U0126, inhibitor of MEK1/2 had the same effect, however inhibition of c-Jun and JNK1,2,3 with SP600125 did not lead to down-regulation.	U 0126	27-32	mitogen-activated protein kinase kinase 1	Homo sapiens	47-53
23402758-8	2013	The ERK inhibitor U0126 reduced the proliferation and expression of PCNA and cyclinD1, and ROCK1 and ROCK2 siRNA decreased the level of ERK in the nucleus.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	4-7
23402758-8	2013	The ERK inhibitor U0126 reduced the proliferation and expression of PCNA and cyclinD1, and ROCK1 and ROCK2 siRNA decreased the level of ERK in the nucleus.	U 0126	18-23	proliferating cell nuclear antigen	Rattus norvegicus	68-72
23402758-8	2013	The ERK inhibitor U0126 reduced the proliferation and expression of PCNA and cyclinD1, and ROCK1 and ROCK2 siRNA decreased the level of ERK in the nucleus.	U 0126	18-23	cyclin D1	Rattus norvegicus	77-85
23402758-8	2013	The ERK inhibitor U0126 reduced the proliferation and expression of PCNA and cyclinD1, and ROCK1 and ROCK2 siRNA decreased the level of ERK in the nucleus.	U 0126	18-23	Rho-associated coiled-coil containing protein kinase 2	Rattus norvegicus	101-106
23402758-8	2013	The ERK inhibitor U0126 reduced the proliferation and expression of PCNA and cyclinD1, and ROCK1 and ROCK2 siRNA decreased the level of ERK in the nucleus.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	136-139
23349233-4	2013	FSH-induced granulosa cell CCND2 protein content and proliferation were mimicked by forskolin and attenuated by inhibitors of protein kinase A (PKA; H89) and phosphatidylinositol 3-kinase (PI3K; LY294002) as well as PKA catalytic subunit (PRKACA) small interfering RNA (siRNA) and dominant-negative Akt (dn-Akt) but were not affected by mitogen-activated protein kinase kinase 1/2 (MEK1/2; U0126).	U 0126	390-395	cyclin D2	Rattus norvegicus	27-32
23349233-4	2013	FSH-induced granulosa cell CCND2 protein content and proliferation were mimicked by forskolin and attenuated by inhibitors of protein kinase A (PKA; H89) and phosphatidylinositol 3-kinase (PI3K; LY294002) as well as PKA catalytic subunit (PRKACA) small interfering RNA (siRNA) and dominant-negative Akt (dn-Akt) but were not affected by mitogen-activated protein kinase kinase 1/2 (MEK1/2; U0126).	U 0126	390-395	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	126-142
23620841-7	2013	A similar increase in the expression of both TNF-alpha protein and mRNA was also observed at 36 h and 48 h, which was significantly decreased in the presence of U0126 or lactacytin, but not SB203580.	U 0126	161-166	tumor necrosis factor	Homo sapiens	45-54
22913737-3	2013	We found that caspase-3 and Bax/Bcl-2 ratio, two hallmarks of apoptosis, were significantly decreased in the rats pre-treated with U0126 and PD169316, 7 days after Abeta injection.	U 0126	131-136	caspase 3	Rattus norvegicus	14-23
22913737-3	2013	We found that caspase-3 and Bax/Bcl-2 ratio, two hallmarks of apoptosis, were significantly decreased in the rats pre-treated with U0126 and PD169316, 7 days after Abeta injection.	U 0126	131-136	BCL2 associated X, apoptosis regulator	Rattus norvegicus	28-31
22913737-3	2013	We found that caspase-3 and Bax/Bcl-2 ratio, two hallmarks of apoptosis, were significantly decreased in the rats pre-treated with U0126 and PD169316, 7 days after Abeta injection.	U 0126	131-136	BCL2, apoptosis regulator	Rattus norvegicus	32-37
22913737-3	2013	We found that caspase-3 and Bax/Bcl-2 ratio, two hallmarks of apoptosis, were significantly decreased in the rats pre-treated with U0126 and PD169316, 7 days after Abeta injection.	U 0126	131-136	amyloid beta precursor protein	Rattus norvegicus	164-169
22913737-4	2013	This observation was in agreement with the results of immunostaining analysis of the hippocampus that showed decreased levels of terminal transferase dUTP nick end labelling positive cells in the hippocampus of U0126 and PD169316 pre-treated rats, compared with the Abeta-injected group.	U 0126	211-216	amyloid beta precursor protein	Rattus norvegicus	266-271
22913737-6	2013	Decreased levels of calpain-2 and caspase-12 in U0126 and PD169316 pre-treated rats confirmed the protective effects of these inhibitors.	U 0126	48-53	calpain 2	Rattus norvegicus	20-29
22913737-6	2013	Decreased levels of calpain-2 and caspase-12 in U0126 and PD169316 pre-treated rats confirmed the protective effects of these inhibitors.	U 0126	48-53	caspase 12	Rattus norvegicus	34-44
22913737-8	2013	U0126 and PD169316 activated Nrf2 and suppressed NF-kB pathways, 7 days after Abeta injection.	U 0126	0-5	NFE2 like bZIP transcription factor 2	Rattus norvegicus	29-33
22913737-8	2013	U0126 and PD169316 activated Nrf2 and suppressed NF-kB pathways, 7 days after Abeta injection.	U 0126	0-5	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	49-54
22913737-8	2013	U0126 and PD169316 activated Nrf2 and suppressed NF-kB pathways, 7 days after Abeta injection.	U 0126	0-5	amyloid beta precursor protein	Rattus norvegicus	78-83
23021350-7	2013	Furthermore, the expression of HO-1 was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	163-168	mitogen-activated protein kinase 1	Mus musculus	136-140
23021350-7	2013	Furthermore, the expression of HO-1 was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	163-168	mitogen-activated protein kinase 1	Mus musculus	141-144
23307144-9	2013	Furthermore, inactivation of ERK1/2 by U0126 offset the IRF3-deficient-mediated hypertrophic response induced by aortic banding.	U 0126	39-44	mitogen-activated protein kinase 3	Mus musculus	29-35
23307144-9	2013	Furthermore, inactivation of ERK1/2 by U0126 offset the IRF3-deficient-mediated hypertrophic response induced by aortic banding.	U 0126	39-44	interferon regulatory factor 3	Mus musculus	56-60
23386286-10	2013	Furthermore, these effects were abolished by PI3K inhibitor LY294002 and MEK1/2 inhibitor U0126.	U 0126	90-95	mitogen-activated protein kinase kinase 1	Mus musculus	73-79
23270470-5	2013	We adopted a combination of PI3K inhibitor (LY294002) and MEK inhibitor (U0126) against Gefitinib resistance in cell lines.	U 0126	73-78	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
23220614-6	2013	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	23-29
23220614-6	2013	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	U 0126	13-18	BCL2 associated X, apoptosis regulator	Homo sapiens	84-87
23220614-6	2013	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	U 0126	13-18	BCL2 apoptosis regulator	Homo sapiens	88-93
23220614-6	2013	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	U 0126	13-18	cytochrome c, somatic	Homo sapiens	116-128
23281060-5	2013	Blocking the ERK1/2 pathway with the MEK inhibitor UO126 largely protected oligodendrocytes against ischemic insults.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	13-19
23197404-5	2013	Here we show that while consolidation and reconsolidation are commonly dependent upon NMDA receptor activation in the dorsal hippocampus there is a double dissociation between the effects of the MEK inhibitor U0126 and the IKK inhibitor sulfasalazine.	U 0126	209-214	mitogen-activated protein kinase kinase 7	Homo sapiens	195-198
23314357-12	2013	The knockdown of MEK1/2 and ERK1/2 activity using U0126, a MEK inhibitor, or siRNAs, resulted in the enhancement of nutlin-3-induced apoptosis.	U 0126	50-55	mitogen-activated protein kinase kinase 1	Homo sapiens	17-23
23314357-12	2013	The knockdown of MEK1/2 and ERK1/2 activity using U0126, a MEK inhibitor, or siRNAs, resulted in the enhancement of nutlin-3-induced apoptosis.	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	28-34
23314357-12	2013	The knockdown of MEK1/2 and ERK1/2 activity using U0126, a MEK inhibitor, or siRNAs, resulted in the enhancement of nutlin-3-induced apoptosis.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
23281060-5	2013	Blocking the ERK1/2 pathway with the MEK inhibitor UO126 largely protected oligodendrocytes against ischemic insults.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	37-40
23281060-9	2013	Moreover, UO126 blocked the ischemia-induced increase in poly-[ADP]-ribosylation of proteins, and the poly[ADP]-ribose polymerase 1 (PARP-1) inhibitor DPQ significantly inhibited ischemia-induced oligodendroglial cell death-demonstrating that PARP-1 was required downstream in the Zn(2+)-ERK oligodendrocyte cell death pathway.	U 0126	10-15	poly(ADP-ribose) polymerase 1	Homo sapiens	243-249
23281060-9	2013	Moreover, UO126 blocked the ischemia-induced increase in poly-[ADP]-ribosylation of proteins, and the poly[ADP]-ribose polymerase 1 (PARP-1) inhibitor DPQ significantly inhibited ischemia-induced oligodendroglial cell death-demonstrating that PARP-1 was required downstream in the Zn(2+)-ERK oligodendrocyte cell death pathway.	U 0126	10-15	mitogen-activated protein kinase 1	Homo sapiens	288-291
22965193-6	2013	It was noted that HA + U0126 significantly reduced the levels of pERK, chondrocyte hypertrophic markers (COL10 and RUNX2) and degenerative markers (ADAMTs5 and MMP-13), however, increased the levels of chondrogenic markers (COL2) compared to untreated or the application of HA or U0126 alone.	U 0126	23-28	RUNX family transcription factor 2	Rattus norvegicus	115-120
22965193-6	2013	It was noted that HA + U0126 significantly reduced the levels of pERK, chondrocyte hypertrophic markers (COL10 and RUNX2) and degenerative markers (ADAMTs5 and MMP-13), however, increased the levels of chondrogenic markers (COL2) compared to untreated or the application of HA or U0126 alone.	U 0126	23-28	ADAM metallopeptidase with thrombospondin type 1 motif, 5	Rattus norvegicus	148-155
22965193-6	2013	It was noted that HA + U0126 significantly reduced the levels of pERK, chondrocyte hypertrophic markers (COL10 and RUNX2) and degenerative markers (ADAMTs5 and MMP-13), however, increased the levels of chondrogenic markers (COL2) compared to untreated or the application of HA or U0126 alone.	U 0126	23-28	matrix metallopeptidase 13	Rattus norvegicus	160-166
23076500-8	2013	The extracellular signal-regulated kinase (ERK) inhibitor, U0126, blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln suppression of CD.	U 0126	59-64	mitogen-activated protein kinase 1	Mus musculus	4-41
23076500-8	2013	The extracellular signal-regulated kinase (ERK) inhibitor, U0126, blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln suppression of CD.	U 0126	59-64	mitogen-activated protein kinase 1	Mus musculus	43-46
23076500-8	2013	The extracellular signal-regulated kinase (ERK) inhibitor, U0126, blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln suppression of CD.	U 0126	59-64	dual specificity phosphatase 1	Mus musculus	86-91
23291919-7	2013	Furthermore, the proliferative effect and promotion of NSCs differentiating predominantly into neurons of paroxetine was inhibited by U0126, an ERK1/2 phosphorylation inhibitor.	U 0126	134-139	mitogen activated protein kinase 3	Rattus norvegicus	144-150
23338747-10	2013	Consistent with these results, palmitate-induced             apoptosis was attenuated by the ERK1/2 inhibitor, U0126, through partial reduction             of intracellular ROS generation.	U 0126	111-116	mitogen activated protein kinase 3	Rattus norvegicus	93-99
23357480-7	2013	The above effects of rapamycin were prevented by pretreatment with the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126.	U 0126	164-169	mitogen-activated protein kinase kinase 7	Homo sapiens	71-103
22945392-0	2013	Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
22945392-4	2013	In this study, we monitored the effect of treatment with the mitogen-activated protein kinase (MEK) inhibitor U0126 in prostate and breast cancer cells.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	61-93
22945392-4	2013	In this study, we monitored the effect of treatment with the mitogen-activated protein kinase (MEK) inhibitor U0126 in prostate and breast cancer cells.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
23833969-4	2013	In inhibition test, U0126, the special inhibitor of ERK of different concentrations (0.1, 1, 10 rmol/L) were added into ECV304 cells culture media for 1 hour, then the cells were treated with AOPP-BSA for 24 hours, at last the protein levels in supernatant were detected by enzyme-linked immunosorbent assay (ELISA).	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	52-55
23833969-6	2013	When the ERK pathway was blocked by U0126, the promoting effects of AOPP-BSA on expressions of SDF-la protein in ECV304 cells were significantly inhibited in dose-dependent manner (P &lt; 0.05).	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	9-12
23879998-5	2013	In addition, ERK1/2 inhibitor U0126 was used to inhibit ERK1/2 activation and then the expression of miRNA-145 was detected.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	13-19
23879998-5	2013	In addition, ERK1/2 inhibitor U0126 was used to inhibit ERK1/2 activation and then the expression of miRNA-145 was detected.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	56-62
23879998-5	2013	In addition, ERK1/2 inhibitor U0126 was used to inhibit ERK1/2 activation and then the expression of miRNA-145 was detected.	U 0126	30-35	microRNA 145	Homo sapiens	101-110
23879998-9	2013	U0126 restored the miRNA-145 down-regulation induced by EGFR-activation in lung cancer cells.	U 0126	0-5	microRNA 145	Homo sapiens	19-28
23879998-9	2013	U0126 restored the miRNA-145 down-regulation induced by EGFR-activation in lung cancer cells.	U 0126	0-5	epidermal growth factor receptor	Homo sapiens	56-60
23197743-7	2013	In osteoblasts from males, ERK inhibitor U0126 (U), not p38 inhibitor (S), prevented the inhibitory effects of PTH on mineralization in early or mature osteoblasts.	U 0126	41-46	mitogen-activated protein kinase 1	Mus musculus	27-30
23271730-5	2013	Among the pathways examined, only ERK1/2 inhibitor U0126 significantly inhibited IL-20-induced migration and invasion.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	34-40
23271730-5	2013	Among the pathways examined, only ERK1/2 inhibitor U0126 significantly inhibited IL-20-induced migration and invasion.	U 0126	51-56	interleukin 20	Homo sapiens	81-86
23426509-7	2013	The promotion of skeletal myoblast cells proliferation by insulin was inhibited by PI3K inhibitor wortmannin or MEK inhibitor U0126, and the same phenomenon was shown in L6 and C2C12 cells.	U 0126	126-131	midkine	Mus musculus	112-115
23363008-7	2013	The employment of protein kinase inhibitors LY294002, SB203580, SP600125, and U0126 revealed that PI3K/Akt signaling pathway interplayed with MAPK signaling pathways.	U 0126	78-83	AKT serine/threonine kinase 1	Homo sapiens	103-106
23363008-7	2013	The employment of protein kinase inhibitors LY294002, SB203580, SP600125, and U0126 revealed that PI3K/Akt signaling pathway interplayed with MAPK signaling pathways.	U 0126	78-83	mitogen-activated protein kinase 3	Homo sapiens	142-146
23429283-8	2013	Furthermore, PI3K inhibitor LY294002 and Erk1/2 inhibitor U0126 suppressed the induction of HO-1 and translocation of Nrf-2 by xyloketal B, whereas P38 inhibitor SB203580 did not.	U 0126	58-63	mitogen-activated protein kinase 3	Danio rerio	41-47
23429283-8	2013	Furthermore, PI3K inhibitor LY294002 and Erk1/2 inhibitor U0126 suppressed the induction of HO-1 and translocation of Nrf-2 by xyloketal B, whereas P38 inhibitor SB203580 did not.	U 0126	58-63	heme oxygenase 1a	Danio rerio	92-96
23429283-8	2013	Furthermore, PI3K inhibitor LY294002 and Erk1/2 inhibitor U0126 suppressed the induction of HO-1 and translocation of Nrf-2 by xyloketal B, whereas P38 inhibitor SB203580 did not.	U 0126	58-63	nfe2 like bZIP transcription factor 2a	Danio rerio	118-123
23357557-6	2013	In addition to the TACE inhibitor TAPI-2, the MAP kinase or extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the c-Jun N-terminal kinase (JNK) inhibitor SP600125, suppressed the ectodomain shedding of TNF receptor 1 induced by deoxynivalenol and reversed its selective inhibition of TNF-alpha-induced ICAM-1 expression.	U 0126	127-132	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	U 0126	157-162	mitogen-activated protein kinase kinase 1	Homo sapiens	56-60
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	U 0126	157-162	mitogen-activated protein kinase 8	Homo sapiens	65-68
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	U 0126	157-162	mitogen-activated protein kinase kinase 1	Homo sapiens	141-145
23237828-7	2013	U0126 and PD98059, respectively, reduced cycloheximide-stimulated SOCS-3 mRNA expression, but SP600125 did not antagonize cycloheximide effect.	U 0126	0-5	suppressor of cytokine signaling 3	Homo sapiens	66-72
23296204-9	2013	Interestingly, a specific mitogen-activated protein kinase ERK inhibitor U0126, but not JNK kinase inhibitor SP600125, abrogated LF activation of BMP7 gene expression.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	59-62
23296204-9	2013	Interestingly, a specific mitogen-activated protein kinase ERK inhibitor U0126, but not JNK kinase inhibitor SP600125, abrogated LF activation of BMP7 gene expression.	U 0126	73-78	bone morphogenetic protein 7	Homo sapiens	146-150
23200779-7	2013	Hsf4b can promote FGF2-induced morphology transition from lens epithelial cell to the fiber cell, and this morphology transition can be inhibited by ERK1/2 inhibitor U0126.	U 0126	166-171	fibroblast growth factor 2	Mus musculus	18-22
23219579-9	2013	The Dex-induced increment of neuron survival in the ischemic CA1 and cortex was diminished by the PI3K inhibitor LY294002 and the MEK inhibitor U0126.	U 0126	144-149	carbonic anhydrase 1	Rattus norvegicus	61-64
23219579-10	2013	The increasing expressions of p-Akt and p-ERK1/2 induced by Dex in the ischemic hemisphere were markedly inhibited by LY294002 (or wortmannin) and U0126 (or PD98059), respectively.	U 0126	147-152	AKT serine/threonine kinase 1	Rattus norvegicus	32-35
23219579-10	2013	The increasing expressions of p-Akt and p-ERK1/2 induced by Dex in the ischemic hemisphere were markedly inhibited by LY294002 (or wortmannin) and U0126 (or PD98059), respectively.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	42-48
23219579-11	2013	The up-regulation of p-GSK-3beta by Dex in the ischemic hemisphere was significantly decreased by both LY294002 (or wortmannin) and U0126 (or PD98059).	U 0126	132-137	glycogen synthase kinase 3 beta	Rattus norvegicus	23-32
23200779-7	2013	Hsf4b can promote FGF2-induced morphology transition from lens epithelial cell to the fiber cell, and this morphology transition can be inhibited by ERK1/2 inhibitor U0126.	U 0126	166-171	mitogen-activated protein kinase 3	Mus musculus	149-155
23229794-12	2013	However, Akt inhibitor and U-0126 completely inhibited HGF-induced Slug activation.	U 0126	27-33	hepatocyte growth factor	Mus musculus	55-58
23229794-12	2013	However, Akt inhibitor and U-0126 completely inhibited HGF-induced Slug activation.	U 0126	27-33	snail family zinc finger 2	Mus musculus	67-71
22926956-6	2013	Notably, the activation of CB peptide-induced osteogenic differentiation was completely blocked to the basal level by the specific inhibitors for ERK1/2 (U0126) and Akt (LY294002).	U 0126	154-159	mitogen-activated protein kinase 3	Homo sapiens	146-152
23441133-10	2013	Analysis on signaling events demonstrated the activation of MAP kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) in radiation-treated cells, while U0126 (MEK/ERK inhibitor) blocked hypomethylation, recruitment of SP1, and uPA expression.	U 0126	162-167	mitogen-activated protein kinase kinase 7	Homo sapiens	169-172
23441133-10	2013	Analysis on signaling events demonstrated the activation of MAP kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) in radiation-treated cells, while U0126 (MEK/ERK inhibitor) blocked hypomethylation, recruitment of SP1, and uPA expression.	U 0126	162-167	mitogen-activated protein kinase 1	Homo sapiens	173-176
22788664-12	2013	Moreover, both the promoter activity and the LPS-induced release of IL-8 were diminished upon the administration of U0126 and SB203580, but not SP600125.	U 0126	116-121	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
23165320-6	2013	Overexpression of AQP3 induced by hEGF was inhibited by a PI3K/AKT inhibitor, LY294002, but the ERK inhibitor U0126 had a minor effect on the hEGF-induced AQP3 upregulation.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	96-99
23165320-6	2013	Overexpression of AQP3 induced by hEGF was inhibited by a PI3K/AKT inhibitor, LY294002, but the ERK inhibitor U0126 had a minor effect on the hEGF-induced AQP3 upregulation.	U 0126	110-115	epidermal growth factor	Homo sapiens	142-146
23165320-6	2013	Overexpression of AQP3 induced by hEGF was inhibited by a PI3K/AKT inhibitor, LY294002, but the ERK inhibitor U0126 had a minor effect on the hEGF-induced AQP3 upregulation.	U 0126	110-115	aquaporin 3 (Gill blood group)	Homo sapiens	155-159
23232767-8	2013	In addition, pretreatment with the MEK1/2 inhibitor U0126 but             not the PI3-K inhibitor LY294002 significantly enhanced doxorubicin-induced apoptosis             and decreased Bcl-xL expression in YAP-overexpressing HCC cells.	U 0126	52-57	mitogen-activated protein kinase kinase 1	Homo sapiens	35-41
23232767-8	2013	In addition, pretreatment with the MEK1/2 inhibitor U0126 but             not the PI3-K inhibitor LY294002 significantly enhanced doxorubicin-induced apoptosis             and decreased Bcl-xL expression in YAP-overexpressing HCC cells.	U 0126	52-57	BCL2 like 1	Homo sapiens	186-192
23232767-8	2013	In addition, pretreatment with the MEK1/2 inhibitor U0126 but             not the PI3-K inhibitor LY294002 significantly enhanced doxorubicin-induced apoptosis             and decreased Bcl-xL expression in YAP-overexpressing HCC cells.	U 0126	52-57	Yes1 associated transcriptional regulator	Homo sapiens	207-210
23232940-4	2013	Irradiated cells treated with             mitogen-activated protein kinase (MAPK) inhibitor U0126 were screened for pERK             levels.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	76-80
23469688-6	2013	Indeed, the specific inhibitors (LY294002 and U0126) of PI3K/PDK1/Akt and ERK showed similar anti-cancer properties to 8-TQ.	U 0126	46-51	pyruvate dehydrogenase kinase 1	Homo sapiens	61-65
23469688-6	2013	Indeed, the specific inhibitors (LY294002 and U0126) of PI3K/PDK1/Akt and ERK showed similar anti-cancer properties to 8-TQ.	U 0126	46-51	AKT serine/threonine kinase 1	Homo sapiens	66-69
23469688-6	2013	Indeed, the specific inhibitors (LY294002 and U0126) of PI3K/PDK1/Akt and ERK showed similar anti-cancer properties to 8-TQ.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	74-77
22878015-5	2013	However, pretreatment with the p38 MAP kinase inhibitor SB203580 and ERK inhibitor U0126 attenuated NO-induced cell toxicity, ROS production, and caspase-3 activation.	U 0126	83-88	mitogen-activated protein kinase 1	Mus musculus	69-72
22878015-5	2013	However, pretreatment with the p38 MAP kinase inhibitor SB203580 and ERK inhibitor U0126 attenuated NO-induced cell toxicity, ROS production, and caspase-3 activation.	U 0126	83-88	caspase 3	Mus musculus	146-155
23168047-5	2013	EGF receptor (EGFR) overexpression masked the effect of saliva on MB-231 cells, but its ability to inhibit MB-231 migration was enhanced by the EGFR inhibitor PD 168393 and MEK inhibitor U0126.	U 0126	187-192	epidermal growth factor receptor	Homo sapiens	0-12
23168047-5	2013	EGF receptor (EGFR) overexpression masked the effect of saliva on MB-231 cells, but its ability to inhibit MB-231 migration was enhanced by the EGFR inhibitor PD 168393 and MEK inhibitor U0126.	U 0126	187-192	mitogen-activated protein kinase kinase 7	Homo sapiens	173-176
23418614-7	2013	Cytotoxicity of LeTx was mimicked by the specific mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) inhibitor U0126, indicating that LeTx-induced cell death is mediated through the MEK1/2-extracellular signal-regulated kinase (ERK1/2) branch of the MAPK pathway.	U 0126	144-149	mitogen-activated protein kinase kinase 1	Homo sapiens	126-132
23418614-7	2013	Cytotoxicity of LeTx was mimicked by the specific mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) inhibitor U0126, indicating that LeTx-induced cell death is mediated through the MEK1/2-extracellular signal-regulated kinase (ERK1/2) branch of the MAPK pathway.	U 0126	144-149	mitogen-activated protein kinase kinase 1	Homo sapiens	215-221
23418614-7	2013	Cytotoxicity of LeTx was mimicked by the specific mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) inhibitor U0126, indicating that LeTx-induced cell death is mediated through the MEK1/2-extracellular signal-regulated kinase (ERK1/2) branch of the MAPK pathway.	U 0126	144-149	mitogen-activated protein kinase 3	Homo sapiens	261-267
23418614-7	2013	Cytotoxicity of LeTx was mimicked by the specific mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) inhibitor U0126, indicating that LeTx-induced cell death is mediated through the MEK1/2-extracellular signal-regulated kinase (ERK1/2) branch of the MAPK pathway.	U 0126	144-149	mitogen-activated protein kinase 3	Homo sapiens	283-287
23374450-11	2013	ERK1/2 inhibitor U0126 attenuated the increase of proliferation and cyclin D1 induced by VU0155041.	U 0126	17-22	mitogen activated protein kinase 3	Rattus norvegicus	0-6
23374450-11	2013	ERK1/2 inhibitor U0126 attenuated the increase of proliferation and cyclin D1 induced by VU0155041.	U 0126	17-22	cyclin D1	Rattus norvegicus	68-77
23343134-6	2013	The vessels were divided into ring segments and incubated for 48 h in the presence or absence of the specific MEK1/2 inhibitor U0126.	U 0126	127-132	mitogen-activated protein kinase kinase 1	Homo sapiens	110-116
23343134-10	2013	Incubation with U0126 diminished the maximum contraction elicited by application of ET-1, Ang II and U46619 in human cerebral arteries.	U 0126	16-21	endothelin 1	Homo sapiens	84-88
23200898-7	2013	Western blot analysis also showed that Danshensu increased phosphorylation of Akt and extracellular signal-related kinase 1/2 (ERK1/2) in H9c2 cells, and the protective effects of Danshensu were partially inhibited by phosphatidylinositol 3"-kinase (PI3K) specific inhibitor wortmannin or ERK specific inhibitor U0126.	U 0126	312-317	AKT serine/threonine kinase 1	Rattus norvegicus	78-81
23200898-7	2013	Western blot analysis also showed that Danshensu increased phosphorylation of Akt and extracellular signal-related kinase 1/2 (ERK1/2) in H9c2 cells, and the protective effects of Danshensu were partially inhibited by phosphatidylinositol 3"-kinase (PI3K) specific inhibitor wortmannin or ERK specific inhibitor U0126.	U 0126	312-317	mitogen activated protein kinase 3	Rattus norvegicus	127-133
23200898-7	2013	Western blot analysis also showed that Danshensu increased phosphorylation of Akt and extracellular signal-related kinase 1/2 (ERK1/2) in H9c2 cells, and the protective effects of Danshensu were partially inhibited by phosphatidylinositol 3"-kinase (PI3K) specific inhibitor wortmannin or ERK specific inhibitor U0126.	U 0126	312-317	Eph receptor B1	Rattus norvegicus	127-130
23320839-8	2013	RESULTS: Both Raf1 inhibitor (GW5074) and MEK inhibitors (U0126 and AZD6244) suppressed HCC cell growth in a dose dependent manner.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
23320839-9	2013	Pre-treatment of MEK inhibitor U0126 or AZD6244 sensitized HCC cells to gemcitabine or doxorubicin based chemotherapy.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
23320839-12	2013	MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
23320839-12	2013	MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	60-63
23320839-12	2013	MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation.	U 0126	15-20	ATP binding cassette subfamily C member 1	Homo sapiens	86-90
23320839-12	2013	MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation.	U 0126	15-20	ATP binding cassette subfamily C member 1	Homo sapiens	147-151
23320839-12	2013	MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation.	U 0126	15-20	ATP binding cassette subfamily C member 3	Homo sapiens	156-160
23320839-14	2013	MEK inhibirors U0126 and AZD6244 reduced MRP1 as well as MRP3 expression, and may contribute partially to the sensitization.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
23320839-14	2013	MEK inhibirors U0126 and AZD6244 reduced MRP1 as well as MRP3 expression, and may contribute partially to the sensitization.	U 0126	15-20	ATP binding cassette subfamily C member 3	Homo sapiens	57-61
23065701-8	2013	Treatment of fetal tibiae explants with mitogen activated protein kinase 1 and 2 inhibitors U0126 and PD325901 rescues the Npr2(pwe/pwe) growth defect, providing a promising foundation for skeletal dysplasia therapeutics.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	40-80
23065701-8	2013	Treatment of fetal tibiae explants with mitogen activated protein kinase 1 and 2 inhibitors U0126 and PD325901 rescues the Npr2(pwe/pwe) growth defect, providing a promising foundation for skeletal dysplasia therapeutics.	U 0126	92-97	natriuretic peptide receptor 2	Homo sapiens	123-127
23211593-7	2013	U0126 (ERK1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited IGF-1 induced MUC8 and MUC5B mRNA expression.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	7-13
23211593-7	2013	U0126 (ERK1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited IGF-1 induced MUC8 and MUC5B mRNA expression.	U 0126	0-5	insulin like growth factor 1	Homo sapiens	69-74
23211593-7	2013	U0126 (ERK1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited IGF-1 induced MUC8 and MUC5B mRNA expression.	U 0126	0-5	mucin 8	Homo sapiens	83-87
23211593-7	2013	U0126 (ERK1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) inhibited IGF-1 induced MUC8 and MUC5B mRNA expression.	U 0126	0-5	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	92-97
23211822-7	2013	U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	51-54
23211822-7	2013	U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively.	U 0126	0-5	mitogen-activated protein kinase 14	Homo sapiens	57-60
23211822-7	2013	U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively.	U 0126	0-5	mitogen-activated protein kinase 8	Homo sapiens	67-70
23311607-5	2013	The human cancer cells were treated with small interfering RNAs (siRNAs) and/or U0126, an inhibitor of MEK for indicated duration, followed by investigating the alterations of cell cycle and apoptosis as well as related proteins examined by flow cytometry and Western blot, respectively.	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
23311607-8	2013	Conversely, knockdown of Mirk/Dyrk1B by siRNA led to up-regulated activation of c-Raf-MEK-ERK1/2 pathway and subsequent changes in cell cycle proteins (cyclin D1, p27kip1), accompanied by increased growth rate and cells from G0/G1 into S of cell cycle which could be blocked by U0126 in a dose-dependent manner, indicating Mirk/Dyrk1B may sequester MAPK/ERK pathway, and vice versa.	U 0126	278-283	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	25-29
23311607-8	2013	Conversely, knockdown of Mirk/Dyrk1B by siRNA led to up-regulated activation of c-Raf-MEK-ERK1/2 pathway and subsequent changes in cell cycle proteins (cyclin D1, p27kip1), accompanied by increased growth rate and cells from G0/G1 into S of cell cycle which could be blocked by U0126 in a dose-dependent manner, indicating Mirk/Dyrk1B may sequester MAPK/ERK pathway, and vice versa.	U 0126	278-283	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	30-36
23311607-8	2013	Conversely, knockdown of Mirk/Dyrk1B by siRNA led to up-regulated activation of c-Raf-MEK-ERK1/2 pathway and subsequent changes in cell cycle proteins (cyclin D1, p27kip1), accompanied by increased growth rate and cells from G0/G1 into S of cell cycle which could be blocked by U0126 in a dose-dependent manner, indicating Mirk/Dyrk1B may sequester MAPK/ERK pathway, and vice versa.	U 0126	278-283	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	80-85
23286773-4	2013	RESULTS: To further characterize global ERK1/2-induced changes in membrane protein phosphorylation within human RBCs, a label-free quantitative phosphoproteomic analysis was applied to sickle and normal RBC membrane ghosts pre-treated with U0126, a specific inhibitor of MEK1/2, the upstream kinase of ERK1/2, in the presence or absence of recombinant active ERK2.	U 0126	240-245	mitogen-activated protein kinase 3	Homo sapiens	40-46
23363842-8	2013	U0126, an inhibitor of ERK pathway, prevented indoxyl sulfate-induced upregulation of Smad3 expression.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	23-26
23363842-8	2013	U0126, an inhibitor of ERK pathway, prevented indoxyl sulfate-induced upregulation of Smad3 expression.	U 0126	0-5	SMAD family member 3	Rattus norvegicus	86-91
23223107-15	2013	Either EA at acupoints or intrathecal injection of U0126 relieved allodynia and hyperalgesia and reduced the expression of P2X3 receptors and ERK1/2 phosphorylation in the spinal cord.	U 0126	51-56	purinergic receptor P2X 3	Rattus norvegicus	123-127
23223107-15	2013	Either EA at acupoints or intrathecal injection of U0126 relieved allodynia and hyperalgesia and reduced the expression of P2X3 receptors and ERK1/2 phosphorylation in the spinal cord.	U 0126	51-56	mitogen activated protein kinase 3	Rattus norvegicus	142-148
23441133-10	2013	Analysis on signaling events demonstrated the activation of MAP kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) in radiation-treated cells, while U0126 (MEK/ERK inhibitor) blocked hypomethylation, recruitment of SP1, and uPA expression.	U 0126	162-167	plasminogen activator, urokinase	Homo sapiens	237-240
23085266-10	2013	SB203580 and UO126, inhibitors of p38MAPK and ERK1/2-pathway, respectively, inhibited phosphorylation of p47phox on Ser345.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	46-52
23085266-10	2013	SB203580 and UO126, inhibitors of p38MAPK and ERK1/2-pathway, respectively, inhibited phosphorylation of p47phox on Ser345.	U 0126	13-18	neutrophil cytosolic factor 1	Homo sapiens	105-112
23098854-5	2013	In comparison to the vehicle control (DMSO), etoposide (ETOP)-induced DSBs in MCF7 cells were more rapidly repaired in the presence of U0126, a specific MEK inhibitor, based on the reduction of gammaH2AX and tail moments.	U 0126	135-140	mitogen-activated protein kinase kinase 7	Homo sapiens	153-156
23098854-9	2013	Consistent with the activation of DNA-PKcs being required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knockdown of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs.	U 0126	124-129	mitogen-activated protein kinase 1	Homo sapiens	103-106
23010081-8	2013	As a confirm to these observations, the erk inhibitor U0126 and the EGFR inhibitors Tyrphostin and Cetuximab were able to contrast AREG induction.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	40-43
23010081-8	2013	As a confirm to these observations, the erk inhibitor U0126 and the EGFR inhibitors Tyrphostin and Cetuximab were able to contrast AREG induction.	U 0126	54-59	amphiregulin	Homo sapiens	131-135
22773119-6	2013	The use of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a highly selective inhibitor of MEK1/2, reduced the enhanced autophagy and sensibility observed in G2019S LRRK2 mutation cells.	U 0126	11-70	mitogen-activated protein kinase kinase 1	Homo sapiens	112-118
22773119-6	2013	The use of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a highly selective inhibitor of MEK1/2, reduced the enhanced autophagy and sensibility observed in G2019S LRRK2 mutation cells.	U 0126	11-70	leucine rich repeat kinase 2	Homo sapiens	186-191
22773119-6	2013	The use of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a highly selective inhibitor of MEK1/2, reduced the enhanced autophagy and sensibility observed in G2019S LRRK2 mutation cells.	U 0126	72-77	mitogen-activated protein kinase kinase 1	Homo sapiens	112-118
22773119-6	2013	The use of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a highly selective inhibitor of MEK1/2, reduced the enhanced autophagy and sensibility observed in G2019S LRRK2 mutation cells.	U 0126	72-77	leucine rich repeat kinase 2	Homo sapiens	186-191
23032069-5	2013	To evaluate the role of ERK 1/2 on the expression and function of ABCG2, the expression of mitogen-activated protein kinase (MAPK)/ERK kinase (MEK), which preferentially activates ERK, was upregulated by transfection with the recombinant sense expression vector pcDNA3.1-MEK and downregulated by pretreatment with U0126, a specific MEK inhibitor.	U 0126	314-319	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-71
23032069-5	2013	To evaluate the role of ERK 1/2 on the expression and function of ABCG2, the expression of mitogen-activated protein kinase (MAPK)/ERK kinase (MEK), which preferentially activates ERK, was upregulated by transfection with the recombinant sense expression vector pcDNA3.1-MEK and downregulated by pretreatment with U0126, a specific MEK inhibitor.	U 0126	314-319	mitogen-activated protein kinase kinase 7	Homo sapiens	143-146
23032069-5	2013	To evaluate the role of ERK 1/2 on the expression and function of ABCG2, the expression of mitogen-activated protein kinase (MAPK)/ERK kinase (MEK), which preferentially activates ERK, was upregulated by transfection with the recombinant sense expression vector pcDNA3.1-MEK and downregulated by pretreatment with U0126, a specific MEK inhibitor.	U 0126	314-319	mitogen-activated protein kinase 1	Homo sapiens	131-134
23032069-8	2013	Contrarily, U0126 inhibited hypoxia- and MEK-upregulated ABCG2 expression.	U 0126	12-17	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
23032069-8	2013	Contrarily, U0126 inhibited hypoxia- and MEK-upregulated ABCG2 expression.	U 0126	12-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	57-62
23318214-6	2013	Furthermore, U0126 strongly inhibited PEMF-dependent ERK1/2 activation and neuritogenesis.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	53-59
23942151-7	2013	LPA induced phosphorylation of ERK and p38 MAP kinase in R182 cells and pretreatment of cells with the MEK-ERK pathway inhibitor U0126, but not the p38 MAPK inhibitor SB202190, resulted in abrogation of LPA-induced cell migration.	U 0126	129-134	mitogen-activated protein kinase 1	Homo sapiens	31-34
23942151-7	2013	LPA induced phosphorylation of ERK and p38 MAP kinase in R182 cells and pretreatment of cells with the MEK-ERK pathway inhibitor U0126, but not the p38 MAPK inhibitor SB202190, resulted in abrogation of LPA-induced cell migration.	U 0126	129-134	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
23942151-7	2013	LPA induced phosphorylation of ERK and p38 MAP kinase in R182 cells and pretreatment of cells with the MEK-ERK pathway inhibitor U0126, but not the p38 MAPK inhibitor SB202190, resulted in abrogation of LPA-induced cell migration.	U 0126	129-134	mitogen-activated protein kinase 1	Homo sapiens	107-110
23942151-8	2013	Pretreatment of R182 cells with U0126 attenuated LPA-induced mRNA levels of TAZ and its transcriptional target genes, such as CTGF and CYR61, without affecting phosphorylation level of YAP.	U 0126	32-37	cellular communication network factor 2	Homo sapiens	126-130
23942151-8	2013	Pretreatment of R182 cells with U0126 attenuated LPA-induced mRNA levels of TAZ and its transcriptional target genes, such as CTGF and CYR61, without affecting phosphorylation level of YAP.	U 0126	32-37	cellular communication network factor 1	Homo sapiens	135-140
24107539-6	2013	Using the pharmacological inhibitor of ERK activation U0126 we show that E2, through ERK activation, is able to enhance COXIV activity.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	39-42
24107539-6	2013	Using the pharmacological inhibitor of ERK activation U0126 we show that E2, through ERK activation, is able to enhance COXIV activity.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	85-88
24107539-6	2013	Using the pharmacological inhibitor of ERK activation U0126 we show that E2, through ERK activation, is able to enhance COXIV activity.	U 0126	54-59	cytochrome c oxidase subunit 4I1	Mus musculus	120-125
24335178-13	2013	Furthermore, ERK1/2 inhibitor U0126 or TAB1 siRNA mitigated these changes induced by cisplatin.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	13-19
23324267-3	2013	U0126 which is a highly selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway in mammalian cells has been demonstrated to have an anti-proliferative role in cancer cells.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	47-51
23324267-3	2013	U0126 which is a highly selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway in mammalian cells has been demonstrated to have an anti-proliferative role in cancer cells.	U 0126	0-5	mitogen-activated protein kinase kinase 2	Homo sapiens	56-60
23324267-3	2013	U0126 which is a highly selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway in mammalian cells has been demonstrated to have an anti-proliferative role in cancer cells.	U 0126	0-5	zinc fingers and homeoboxes 2	Homo sapiens	68-71
23324267-3	2013	U0126 which is a highly selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway in mammalian cells has been demonstrated to have an anti-proliferative role in cancer cells.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
23324267-3	2013	U0126 which is a highly selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway in mammalian cells has been demonstrated to have an anti-proliferative role in cancer cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	76-79
23162011-6	2013	This expression is inhibited by the addition of U0126, a specific MEK1/2 inhibitor.	U 0126	48-53	mitogen-activated protein kinase kinase 1	Homo sapiens	66-72
22933106-3	2013	We demonstrate that progesterone increases GLP-1 secretion and extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation in enteroendocrine GLUTag cells via mechanisms sensitive to the mitogen-activated protein kinase inhibitor U0126.	U 0126	235-240	glucagon	Mus musculus	43-48
22933106-3	2013	We demonstrate that progesterone increases GLP-1 secretion and extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation in enteroendocrine GLUTag cells via mechanisms sensitive to the mitogen-activated protein kinase inhibitor U0126.	U 0126	235-240	mitogen-activated protein kinase 3	Mus musculus	104-110
23183167-10	2013	A MAPK kinase inhibitor (U0126) abrogated the TFF2 peptide-mediated proliferation of MIN6 cells.	U 0126	25-30	trefoil factor 2 (spasmolytic protein 1)	Mus musculus	46-50
23762139-9	2013	Addition of U0126, a selective inhibitor of ERK, blocked D-induced Nrf2 activation and HO-1 induction and meanwhile reversed the protection of D against A beta 25 - 35-induced cell death.	U 0126	12-17	Eph receptor B1	Rattus norvegicus	44-47
23762139-9	2013	Addition of U0126, a selective inhibitor of ERK, blocked D-induced Nrf2 activation and HO-1 induction and meanwhile reversed the protection of D against A beta 25 - 35-induced cell death.	U 0126	12-17	NFE2 like bZIP transcription factor 2	Rattus norvegicus	67-71
23762139-9	2013	Addition of U0126, a selective inhibitor of ERK, blocked D-induced Nrf2 activation and HO-1 induction and meanwhile reversed the protection of D against A beta 25 - 35-induced cell death.	U 0126	12-17	heme oxygenase 1	Rattus norvegicus	87-91
24204396-6	2013	Moreover, treatment with U0126, an ERK inhibitor, completely blocked NF- kappa B activity.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	35-38
24204396-6	2013	Moreover, treatment with U0126, an ERK inhibitor, completely blocked NF- kappa B activity.	U 0126	25-30	nuclear factor kappa B subunit 1	Homo sapiens	69-80
23278900-5	2013	The treatment with LY294002, SP600125 or U0126 hindered the tension-induced TGFbeta2 upregulation, although the increase in NGF was regulated only by SP600125 or U0126, indicating the involvement of three signalling kinase pathways in the upregulation of TGFbeta2.	U 0126	41-46	transforming growth factor beta 2	Homo sapiens	76-84
23278900-5	2013	The treatment with LY294002, SP600125 or U0126 hindered the tension-induced TGFbeta2 upregulation, although the increase in NGF was regulated only by SP600125 or U0126, indicating the involvement of three signalling kinase pathways in the upregulation of TGFbeta2.	U 0126	41-46	transforming growth factor beta 2	Homo sapiens	255-263
23278900-5	2013	The treatment with LY294002, SP600125 or U0126 hindered the tension-induced TGFbeta2 upregulation, although the increase in NGF was regulated only by SP600125 or U0126, indicating the involvement of three signalling kinase pathways in the upregulation of TGFbeta2.	U 0126	162-167	nerve growth factor	Homo sapiens	124-127
23135610-5	2013	To validate RKIP induction through the extracellular signal regulated kinase (ERK) pathway, the cells were treated with U0126, an ERK inhibitor.	U 0126	120-125	phosphatidylethanolamine binding protein 1	Homo sapiens	12-16
23135610-5	2013	To validate RKIP induction through the extracellular signal regulated kinase (ERK) pathway, the cells were treated with U0126, an ERK inhibitor.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	39-76
23135610-5	2013	To validate RKIP induction through the extracellular signal regulated kinase (ERK) pathway, the cells were treated with U0126, an ERK inhibitor.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	78-81
23135610-5	2013	To validate RKIP induction through the extracellular signal regulated kinase (ERK) pathway, the cells were treated with U0126, an ERK inhibitor.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	130-133
23135610-9	2013	Furthermore, our results confirmed that U0126 treatment repressed ERK phosphorylation and induced RKIP expression.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	66-69
23135610-9	2013	Furthermore, our results confirmed that U0126 treatment repressed ERK phosphorylation and induced RKIP expression.	U 0126	40-45	phosphatidylethanolamine binding protein 1	Homo sapiens	98-102
22674427-7	2013	Inhibition of ERK activity by U0126, suppressed EPO-induced expression of GATA-4 protein in rat cardiac myocytes.	U 0126	30-35	Eph receptor B1	Rattus norvegicus	14-17
22674427-7	2013	Inhibition of ERK activity by U0126, suppressed EPO-induced expression of GATA-4 protein in rat cardiac myocytes.	U 0126	30-35	erythropoietin	Rattus norvegicus	48-51
22674427-7	2013	Inhibition of ERK activity by U0126, suppressed EPO-induced expression of GATA-4 protein in rat cardiac myocytes.	U 0126	30-35	GATA binding protein 4	Rattus norvegicus	74-80
23114032-6	2013	Notably, genetic (MEK1 silencing) or chemical (U0126) inhibition of ERK signaling restored constitutive STAT3 phosphorylation and inhibited the differentiation of SHED into endothelial cells.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	68-71
23114032-6	2013	Notably, genetic (MEK1 silencing) or chemical (U0126) inhibition of ERK signaling restored constitutive STAT3 phosphorylation and inhibited the differentiation of SHED into endothelial cells.	U 0126	47-52	signal transducer and activator of transcription 3	Homo sapiens	104-109
23671886-0	2013	The ERK1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina.	U 0126	21-26	mitogen activated protein kinase 3	Rattus norvegicus	4-10
23671886-0	2013	The ERK1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina.	U 0126	21-26	matrix metallopeptidase 9	Rattus norvegicus	71-76
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	mitogen activated protein kinase 3	Rattus norvegicus	35-41
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	mitogen activated protein kinase 3	Rattus norvegicus	99-105
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	matrix metallopeptidase 9	Rattus norvegicus	162-167
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	nitric oxide synthase 2	Rattus norvegicus	169-173
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	interleukin 6	Rattus norvegicus	175-179
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	tumor necrosis factor	Rattus norvegicus	185-195
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	212-218
23089915-6	2013	In parallel, Fas activation increased phosphorylation of ERK1/2, and FasL-induced lipolysis was blunted in the presence of the ERK-inhibitor U0126 or in ERK1/2-depleted adipocytes.	U 0126	141-146	mitogen-activated protein kinase 3	Mus musculus	57-63
23089915-6	2013	In parallel, Fas activation increased phosphorylation of ERK1/2, and FasL-induced lipolysis was blunted in the presence of the ERK-inhibitor U0126 or in ERK1/2-depleted adipocytes.	U 0126	141-146	Fas ligand (TNF superfamily, member 6)	Mus musculus	69-73
23089915-6	2013	In parallel, Fas activation increased phosphorylation of ERK1/2, and FasL-induced lipolysis was blunted in the presence of the ERK-inhibitor U0126 or in ERK1/2-depleted adipocytes.	U 0126	141-146	mitogen-activated protein kinase 1	Mus musculus	57-60
23115222-6	2013	Our results with selective mitogen-activated protein kinase kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene monoethanolate (U0126) argues for an important role of extracellular signal-regulated kinase-1/2 pathways activation in PNU-120596"s antinociceptive effects.	U 0126	157-162	mitogen-activated protein kinase 3	Mus musculus	196-237
24008236-6	2013	In addition, we investigated ROCK and ERK pathways by MEKK1/2 inhibitor U0126 and ROCK inhibitor Y27632.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	38-41
22947217-6	2013	Pretreatment with the ERK1/2 inhibitor U0126 for 3h, partially prevented this effect.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	22-28
23224239-9	2013	Inhibition of ERK1/2 by U0126 significantly decreased the apigenin/TRAIL-induced DR5 expression and apoptosis.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	14-20
23224239-9	2013	Inhibition of ERK1/2 by U0126 significantly decreased the apigenin/TRAIL-induced DR5 expression and apoptosis.	U 0126	24-29	TNF superfamily member 10	Homo sapiens	67-72
23224239-9	2013	Inhibition of ERK1/2 by U0126 significantly decreased the apigenin/TRAIL-induced DR5 expression and apoptosis.	U 0126	24-29	TNF receptor superfamily member 10b	Homo sapiens	81-84
23063465-9	2013	Treatment of both U0126 (an inhibitor of MEK) and LY294002 (an inhibitor of PI3 K), hampered the neuronal differentiation induced by Rg1.	U 0126	18-23	midkine	Mus musculus	41-44
23063465-9	2013	Treatment of both U0126 (an inhibitor of MEK) and LY294002 (an inhibitor of PI3 K), hampered the neuronal differentiation induced by Rg1.	U 0126	18-23	protein phosphatase 1, regulatory subunit 3A	Mus musculus	133-136
23063465-10	2013	Meantime, U0126 further decreased Rg1-induced p-Akt expression.	U 0126	10-15	protein phosphatase 1, regulatory subunit 3A	Mus musculus	34-37
23063465-10	2013	Meantime, U0126 further decreased Rg1-induced p-Akt expression.	U 0126	10-15	thymoma viral proto-oncogene 1	Mus musculus	48-51
24452062-8	2013	E2BSA produced a parallel and significant increase in the phosphorylation of ERK 2 only in OVX females, and pre-treatment with MEK/ERK 1/2 inhibitor, U0126 (10 mug), blocked the mER-mediated abolition of ORL1-mediated antinociception in OVX females.	U 0126	150-155	opioid related nociceptin receptor 1	Rattus norvegicus	204-208
23527077-8	2013	The underlying mechanisms of topography-enhanced neuronal differentiation are further revealed by directing suppression of mitogen-activated protein kinase/extracellular signaling-regulated kinase (MAPK/Erk) signaling pathway in ANSC using U0126, known to inhibit the activation of Erk.	U 0126	240-245	mitogen-activated protein kinase 1	Homo sapiens	198-202
23527077-8	2013	The underlying mechanisms of topography-enhanced neuronal differentiation are further revealed by directing suppression of mitogen-activated protein kinase/extracellular signaling-regulated kinase (MAPK/Erk) signaling pathway in ANSC using U0126, known to inhibit the activation of Erk.	U 0126	240-245	mitogen-activated protein kinase 1	Homo sapiens	203-206
23527077-8	2013	The underlying mechanisms of topography-enhanced neuronal differentiation are further revealed by directing suppression of mitogen-activated protein kinase/extracellular signaling-regulated kinase (MAPK/Erk) signaling pathway in ANSC using U0126, known to inhibit the activation of Erk.	U 0126	240-245	mitogen-activated protein kinase 1	Homo sapiens	282-285
23544048-8	2013	Further, the effect of curcumin on alpha-SMA, PAI-1, E-cadherin, TbetaR I and TbetaR II were reversed by ERK inhibitor U0126 or PPARgamma inhibitor BADGE, or PPARgamma shRNA.	U 0126	119-124	serpin family E member 1	Homo sapiens	46-51
23544048-8	2013	Further, the effect of curcumin on alpha-SMA, PAI-1, E-cadherin, TbetaR I and TbetaR II were reversed by ERK inhibitor U0126 or PPARgamma inhibitor BADGE, or PPARgamma shRNA.	U 0126	119-124	cadherin 1	Homo sapiens	53-63
23544048-8	2013	Further, the effect of curcumin on alpha-SMA, PAI-1, E-cadherin, TbetaR I and TbetaR II were reversed by ERK inhibitor U0126 or PPARgamma inhibitor BADGE, or PPARgamma shRNA.	U 0126	119-124	transforming growth factor beta receptor 1	Homo sapiens	65-73
23544048-8	2013	Further, the effect of curcumin on alpha-SMA, PAI-1, E-cadherin, TbetaR I and TbetaR II were reversed by ERK inhibitor U0126 or PPARgamma inhibitor BADGE, or PPARgamma shRNA.	U 0126	119-124	transforming growth factor beta receptor 2	Homo sapiens	78-87
23544048-8	2013	Further, the effect of curcumin on alpha-SMA, PAI-1, E-cadherin, TbetaR I and TbetaR II were reversed by ERK inhibitor U0126 or PPARgamma inhibitor BADGE, or PPARgamma shRNA.	U 0126	119-124	mitogen-activated protein kinase 1	Homo sapiens	105-108
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	U 0126	122-127	interleukin-1 beta	Oryctolagus cuniculus	0-8
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	U 0126	122-127	matrix metalloproteinase-9	Oryctolagus cuniculus	21-26
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	U 0126	122-127	matrix metalloproteinase-9	Oryctolagus cuniculus	42-47
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	U 0126	122-127	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	114-120
23505448-10	2013	Pretreatment with U0126 or SP600125 inhibited IL-1beta-induced AP-1 and NF-kappaB promoter activity, but not NF-kappaB translocation from the cytosol into the nucleus.	U 0126	18-23	interleukin-1 beta	Oryctolagus cuniculus	46-54
23409030-3	2013	UO126, a highly selective inhibitor of MEK1/MEK2, inhibited telomerase activity and hTERT mRNA expression induced by E2.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	39-43
23409030-3	2013	UO126, a highly selective inhibitor of MEK1/MEK2, inhibited telomerase activity and hTERT mRNA expression induced by E2.	U 0126	0-5	mitogen-activated protein kinase kinase 2	Homo sapiens	44-48
23409030-3	2013	UO126, a highly selective inhibitor of MEK1/MEK2, inhibited telomerase activity and hTERT mRNA expression induced by E2.	U 0126	0-5	telomerase reverse transcriptase	Homo sapiens	84-89
23409030-5	2013	Treatment with E2 resulted in rapid phosphorylation of p44/42 MAPK and increased MAPK activity which was abolished by UO126.	U 0126	118-123	interferon induced protein 44	Homo sapiens	55-58
23349801-11	2013	Addition of GFX with a MEK inhibitor, U0126, in the presence of FGF-2 and activin A provided a long-term stable undifferentiated state of hPS cells even though hPS cells were dissociated into single cells for passage.	U 0126	38-43	mitogen-activated protein kinase kinase 7	Homo sapiens	23-26
23349801-11	2013	Addition of GFX with a MEK inhibitor, U0126, in the presence of FGF-2 and activin A provided a long-term stable undifferentiated state of hPS cells even though hPS cells were dissociated into single cells for passage.	U 0126	38-43	fibroblast growth factor 2	Homo sapiens	64-69
23247123-11	2013	Finally, we showed incubation of macrophages with E. coli, and the ERK inhibitor U0126 increased CFU numbers and decreased intracellular levels of NO.	U 0126	81-86	mitogen-activated protein kinase 1	Mus musculus	67-70
22452662-8	2013	In vitro, heat stress caused damage and apoptosis in IEC-6 cells; inhibition of ERK1/2 activation (by U0126) exacerbated these effects, which were attenuated by inhibition of JNK (by SP600125) and p38 (by SB203580) activation.	U 0126	102-107	mitogen activated protein kinase 3	Rattus norvegicus	80-86
22452662-8	2013	In vitro, heat stress caused damage and apoptosis in IEC-6 cells; inhibition of ERK1/2 activation (by U0126) exacerbated these effects, which were attenuated by inhibition of JNK (by SP600125) and p38 (by SB203580) activation.	U 0126	102-107	mitogen-activated protein kinase 8	Rattus norvegicus	175-178
22452662-8	2013	In vitro, heat stress caused damage and apoptosis in IEC-6 cells; inhibition of ERK1/2 activation (by U0126) exacerbated these effects, which were attenuated by inhibition of JNK (by SP600125) and p38 (by SB203580) activation.	U 0126	102-107	mitogen activated protein kinase 14	Rattus norvegicus	197-200
23718075-0	2013	[TSPO ligand PK11195 and MAPK inhibitor UO126 modulate tspo expression level].	U 0126	40-45	translocator protein	Homo sapiens	55-59
23718075-4	2013	These results were confirmed by real time PCR: the increase in mRNA TSPO expression level was detected after incubation with PK11195 in concentration 100 nmol/L, and with UO126 in concentration 10 micromol/L.	U 0126	171-176	translocator protein	Homo sapiens	68-72
23718075-6	2013	So, we conclus de that TSPO ligand PK11195 and MAPK signaling partway inhibitor UO126 modulate TSPO expression.	U 0126	80-85	translocator protein	Homo sapiens	23-27
23718075-6	2013	So, we conclus de that TSPO ligand PK11195 and MAPK signaling partway inhibitor UO126 modulate TSPO expression.	U 0126	80-85	translocator protein	Homo sapiens	95-99
23259581-4	2012	Secondly, we investigated whether administration of a specific mitogen-activated protein kinase kinase (MEK)1/2 inhibitor, U0126, given at 6 h after SAH prevents activation of the MEK/extracellular signal-regulated kinase 1/2 pathway and the upregulation of cerebrovascular inflammatory mediators and improves neurological function.	U 0126	123-128	mitogen activated protein kinase kinase 1	Rattus norvegicus	104-111
23259581-4	2012	Secondly, we investigated whether administration of a specific mitogen-activated protein kinase kinase (MEK)1/2 inhibitor, U0126, given at 6 h after SAH prevents activation of the MEK/extracellular signal-regulated kinase 1/2 pathway and the upregulation of cerebrovascular inflammatory mediators and improves neurological function.	U 0126	123-128	mitogen activated protein kinase 3	Rattus norvegicus	184-223
23259581-12	2012	Treatment with U0126 starting at 6 h after SAH prevented activation of MEK-ERK1/2 signaling.	U 0126	15-20	mitogen activated protein kinase 3	Rattus norvegicus	75-81
23259581-16	2012	Inhibition of the MEK-ERK1/2 pathway by U0126 starting at 6 h post-SAH prevented upregulation of cytokines and MMP-9 in cerebral vessels, and improved neurological outcome.	U 0126	40-45	mitogen activated protein kinase 3	Rattus norvegicus	22-28
23259581-16	2012	Inhibition of the MEK-ERK1/2 pathway by U0126 starting at 6 h post-SAH prevented upregulation of cytokines and MMP-9 in cerebral vessels, and improved neurological outcome.	U 0126	40-45	matrix metallopeptidase 9	Rattus norvegicus	111-116
23123449-10	2012	Inhibition of ERK, one of the MAPKs, by U0126 improved the apoptosis inducing ability of PCBL.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	14-17
23335975-9	2013	FaDu cells treated with a p-ERK inhibitor (U0126) phenocopied the reduced cell proliferation, migration and invasion observed with miR-193b knockdown.	U 0126	43-48	mitogen-activated protein kinase 1	Homo sapiens	28-31
23335975-9	2013	FaDu cells treated with a p-ERK inhibitor (U0126) phenocopied the reduced cell proliferation, migration and invasion observed with miR-193b knockdown.	U 0126	43-48	microRNA 193b	Homo sapiens	131-139
23034941-5	2012	These signaling responses to ECFP/ANG II were inhibited by losartan (AT(1) blocker), PD123319 (AT(2) blocker), U0126 (MEK1/MEK2 inhibitor), and RO 106-9920 (NF-kappaB inhibitor).	U 0126	111-116	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	34-40
23129756-8	2012	The PI3K/AKT inhibitor Ly294002 inhibited S1P-directed migration by Th1 cells, whereas the ERK inhibitor U0126 inhibited Th2 cell S1P-directed migration.	U 0126	105-110	Eph receptor B2	Mus musculus	91-94
23129756-8	2012	The PI3K/AKT inhibitor Ly294002 inhibited S1P-directed migration by Th1 cells, whereas the ERK inhibitor U0126 inhibited Th2 cell S1P-directed migration.	U 0126	105-110	heart and neural crest derivatives expressed 2	Mus musculus	121-124
23188799-9	2012	Confirming this, the ERK1/2 inhibitor U0126 increased sensitivity to CP.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	21-27
23208416-8	2012	Inhibition of GIP expression by the PI3/AKT inhibitor, LY294002, was abrogated in STC-1 cells with reduced menin levels, whereas the MAPK inhibitor, UO126, inhibited the expression of GIP independent of menin.	U 0126	149-154	gastric inhibitory polypeptide	Mus musculus	184-187
23058367-7	2012	The pro-proliferative effect of BDNF was attenuated by TrkB kinase inhibitor (K252a) or ERK1/2 inhibitor (U0126) pretreatment, and by knocking down Egr-1.	U 0126	106-111	brain derived neurotrophic factor	Mus musculus	32-36
23058367-7	2012	The pro-proliferative effect of BDNF was attenuated by TrkB kinase inhibitor (K252a) or ERK1/2 inhibitor (U0126) pretreatment, and by knocking down Egr-1.	U 0126	106-111	mitogen-activated protein kinase 3	Mus musculus	88-94
23304816-1	2012	OBJECTIVE: To evaluate the activity of U0126, a MEK1/2 inhibitor, in downregulating the phosphorylation of ERK in colon cancer cell lines and to explore the correlation of phospho-flow cytometry with standardized methods to validate its use in clinical settings.	U 0126	39-44	mitogen-activated protein kinase kinase 1	Homo sapiens	48-54
23304816-1	2012	OBJECTIVE: To evaluate the activity of U0126, a MEK1/2 inhibitor, in downregulating the phosphorylation of ERK in colon cancer cell lines and to explore the correlation of phospho-flow cytometry with standardized methods to validate its use in clinical settings.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	107-110
23304816-8	2012	The western blot analysis revealed that increasing the amount of U0126 resulted in inhibition of phospho-ERK (p-ERK).	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	105-108
23304816-8	2012	The western blot analysis revealed that increasing the amount of U0126 resulted in inhibition of phospho-ERK (p-ERK).	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	112-115
23304816-9	2012	Fluorescence-activated cell sorting plots of phosphorylation of ERK demonstrated that the levels of p-ERK decreased with increasing concentrations of U0126.	U 0126	150-155	mitogen-activated protein kinase 1	Homo sapiens	64-67
23304816-9	2012	Fluorescence-activated cell sorting plots of phosphorylation of ERK demonstrated that the levels of p-ERK decreased with increasing concentrations of U0126.	U 0126	150-155	mitogen-activated protein kinase 1	Homo sapiens	102-105
22951300-4	2012	Treatment with rDDT increased levels of phosphorylated ERK1/2, but not p38, in SGBS cells, and rDDT-induced IL-6 mRNA expression was attenuated by pretreatment with an ERK inhibitor, U0126.	U 0126	183-188	D-dopachrome tautomerase	Rattus norvegicus	15-19
22951300-4	2012	Treatment with rDDT increased levels of phosphorylated ERK1/2, but not p38, in SGBS cells, and rDDT-induced IL-6 mRNA expression was attenuated by pretreatment with an ERK inhibitor, U0126.	U 0126	183-188	mitogen-activated protein kinase 3	Homo sapiens	55-61
22951300-4	2012	Treatment with rDDT increased levels of phosphorylated ERK1/2, but not p38, in SGBS cells, and rDDT-induced IL-6 mRNA expression was attenuated by pretreatment with an ERK inhibitor, U0126.	U 0126	183-188	D-dopachrome tautomerase	Rattus norvegicus	95-99
22951300-4	2012	Treatment with rDDT increased levels of phosphorylated ERK1/2, but not p38, in SGBS cells, and rDDT-induced IL-6 mRNA expression was attenuated by pretreatment with an ERK inhibitor, U0126.	U 0126	183-188	interleukin 6	Homo sapiens	108-112
23078124-9	2012	Branching morphogenesis of cultured E13 SMG rudiments was strongly suppressed by administration of U0126, an inhibitor for ERK1/2 activation, whereas the phosphorylation of ERK5 was not inhibited by U0126.	U 0126	99-104	mitogen-activated protein kinase 3	Mus musculus	123-129
22933112-8	2012	The improved response was prevented by U0126, an Erk inhibitor.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	49-52
23077075-10	2012	Accordingly, the inhibition of ERK signaling by U0126 (1 mum) counteracted the effect of calpain inhibition on 17betaE2-induced exacerbation of NMDA toxicity.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	31-34
23167467-8	2012	Enamel matrix derivative-induced VEGF production was significantly attenuated by SB203580, U0126, and LY294002.	U 0126	91-96	vascular endothelial growth factor A	Homo sapiens	33-37
22581747-7	2012	In addition, we found that pretreatment with the MAP kinase inhibitor U0126 completely blocked the desensitizing effect of repeated Ang II injections on water intake.	U 0126	70-75	angiotensinogen	Rattus norvegicus	132-138
22921460-8	2012	Application of exogenous NGF exclusively to the compartment containing DRG nerve terminals in an ex vivo ganglia-nerve preparation markedly increases the BDNF expression level in the DRG neuronal cell body that is placed in a different compartment; this BDNF elevation is attenuated by U0126, PD98059 and a specific ERK5 inhibitor BIX02188.	U 0126	286-291	nerve growth factor	Rattus norvegicus	25-28
22921460-8	2012	Application of exogenous NGF exclusively to the compartment containing DRG nerve terminals in an ex vivo ganglia-nerve preparation markedly increases the BDNF expression level in the DRG neuronal cell body that is placed in a different compartment; this BDNF elevation is attenuated by U0126, PD98059 and a specific ERK5 inhibitor BIX02188.	U 0126	286-291	brain-derived neurotrophic factor	Rattus norvegicus	254-258
22940540-8	2012	Be similar to the effects of GL, SP600125, U0126 and LY29400225, however not SB203580, also inhibited ConA-induced CD4(+)T cell proliferation, indicating the involvement of JNK, ERK and PI3K/AKT in this process.	U 0126	43-48	CD4 antigen	Mus musculus	115-118
22684547-11	2012	Moreover, SphK1 was required for the production of MMP-2/9 and uPA in tumor cells, which was suppressed by ERK1/2 inhibitor U0126, but enhanced by the p38 MAPK inhibitor SB203580.	U 0126	124-129	sphingosine kinase 1	Homo sapiens	10-15
22684547-11	2012	Moreover, SphK1 was required for the production of MMP-2/9 and uPA in tumor cells, which was suppressed by ERK1/2 inhibitor U0126, but enhanced by the p38 MAPK inhibitor SB203580.	U 0126	124-129	matrix metallopeptidase 2	Homo sapiens	51-58
22684547-11	2012	Moreover, SphK1 was required for the production of MMP-2/9 and uPA in tumor cells, which was suppressed by ERK1/2 inhibitor U0126, but enhanced by the p38 MAPK inhibitor SB203580.	U 0126	124-129	plasminogen activator, urokinase	Homo sapiens	63-66
22684547-11	2012	Moreover, SphK1 was required for the production of MMP-2/9 and uPA in tumor cells, which was suppressed by ERK1/2 inhibitor U0126, but enhanced by the p38 MAPK inhibitor SB203580.	U 0126	124-129	mitogen-activated protein kinase 3	Homo sapiens	107-113
23008020-9	2012	Importantly, NAC (a ROS scavenger) and U0126 (an ERK inhibitor) abolished AITC-reduced viability in MDA-MB-468 cells.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	49-52
23041765-5	2012	The pharmacologic inhibitor UO126 was used to block Erk1/2 signaling.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	52-58
22396328-9	2012	Wortmannin or U0126 abolished enhanced phosphorylation of GSK-3beta induced by curcumin.	U 0126	14-19	glycogen synthase kinase 3 beta	Rattus norvegicus	58-67
23000062-7	2012	In addition, ERK1/2 inhibitor U0126 abolished the proliferation and G1 to S phase transition of microglia stimulated by PTN, and inhibited the production of BDNF, CNTF and NGF induced by PTN.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	13-19
23000062-7	2012	In addition, ERK1/2 inhibitor U0126 abolished the proliferation and G1 to S phase transition of microglia stimulated by PTN, and inhibited the production of BDNF, CNTF and NGF induced by PTN.	U 0126	30-35	pleiotrophin	Homo sapiens	120-123
23000062-7	2012	In addition, ERK1/2 inhibitor U0126 abolished the proliferation and G1 to S phase transition of microglia stimulated by PTN, and inhibited the production of BDNF, CNTF and NGF induced by PTN.	U 0126	30-35	brain derived neurotrophic factor	Homo sapiens	157-161
23000062-7	2012	In addition, ERK1/2 inhibitor U0126 abolished the proliferation and G1 to S phase transition of microglia stimulated by PTN, and inhibited the production of BDNF, CNTF and NGF induced by PTN.	U 0126	30-35	ciliary neurotrophic factor	Homo sapiens	163-167
23000062-7	2012	In addition, ERK1/2 inhibitor U0126 abolished the proliferation and G1 to S phase transition of microglia stimulated by PTN, and inhibited the production of BDNF, CNTF and NGF induced by PTN.	U 0126	30-35	pleiotrophin	Homo sapiens	187-190
23028124-4	2012	Also, ouabain upregulated the expression of cyclin D1 and incorporation of [methyl-(3)H]thymidine, both of which were dependent on MAPK3/1 but not AKT intracellular cascade, as shown by pretreatment with MEK (MAP2K1/2) inhibitor U0126 and PI3K inhibitor wortmannin respectively.	U 0126	229-234	cyclin D1	Rattus norvegicus	44-53
23028124-4	2012	Also, ouabain upregulated the expression of cyclin D1 and incorporation of [methyl-(3)H]thymidine, both of which were dependent on MAPK3/1 but not AKT intracellular cascade, as shown by pretreatment with MEK (MAP2K1/2) inhibitor U0126 and PI3K inhibitor wortmannin respectively.	U 0126	229-234	mitogen activated protein kinase 3	Rattus norvegicus	131-138
23051850-9	2012	Luteolin also activated Akt and ERK, whereas the addition of LY294002 and U0126, the pharmacologic inhibitors of PI3K and ERK, attenuated luteolin-induced HO-1 expression and cytoprotective effect.	U 0126	74-79	Eph receptor B1	Rattus norvegicus	122-125
23237773-3	2012	It was shown that JTP-74057 directly bound to MEK1 and MEK2 and allosterically inhibited their kinase activities, and that its inhibitory characteristics were similar to those of the known and different chemotype of MEK inhibitors PD0325901 and U0126.	U 0126	245-250	mitogen-activated protein kinase kinase 1	Homo sapiens	46-50
23237773-3	2012	It was shown that JTP-74057 directly bound to MEK1 and MEK2 and allosterically inhibited their kinase activities, and that its inhibitory characteristics were similar to those of the known and different chemotype of MEK inhibitors PD0325901 and U0126.	U 0126	245-250	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
23051850-9	2012	Luteolin also activated Akt and ERK, whereas the addition of LY294002 and U0126, the pharmacologic inhibitors of PI3K and ERK, attenuated luteolin-induced HO-1 expression and cytoprotective effect.	U 0126	74-79	heme oxygenase 1	Rattus norvegicus	155-159
23362510-6	2012	Pharmacological blockade of ERK1/2 pathway with MEK1/2 inhibitors, U0126 and selumetinib (AZD6244) significantly attenuated the pro-apoptotic effects of field electric stimulation on the mutated LMNA iPSC-CMs.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	28-34
23257425-3	2012	NB4 cells were pretreated with U0126, a specific inhibitor for extracellular signal-regulated kinase (ERK) phosphorylation, ERK phosphorylation was assessed by Western blot analysis, apoptosis and cell adhesion ability were evaluated by flow cytometry and cell adhesion test respectively.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	63-100
23257425-3	2012	NB4 cells were pretreated with U0126, a specific inhibitor for extracellular signal-regulated kinase (ERK) phosphorylation, ERK phosphorylation was assessed by Western blot analysis, apoptosis and cell adhesion ability were evaluated by flow cytometry and cell adhesion test respectively.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	102-105
23257425-5	2012	The pretreatment of NB4 cells with 5 micromol/L U0126 could effectively inhibit the phosphorylation of ERK, and reduce cell apoptosis and adhesion induced by 5 mmol/L Met.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	103-106
23180942-7	2012	In both cell lines, MEK inhibitor U0126 and erlotinib attenuated DNA synthesis in a cumulative manner, whereas the AKT pathway-specific inhibitor did not enhance the effects of erlotinib.	U 0126	34-39	mitogen-activated protein kinase kinase 7	Homo sapiens	20-23
23362510-6	2012	Pharmacological blockade of ERK1/2 pathway with MEK1/2 inhibitors, U0126 and selumetinib (AZD6244) significantly attenuated the pro-apoptotic effects of field electric stimulation on the mutated LMNA iPSC-CMs.	U 0126	67-72	lamin A/C	Homo sapiens	195-199
22961803-6	2012	Strains UCC118 and CCUG38008 induced phosphorylation of extracellular signal-regulated kinase (ERK) in Caco-2 cells, and the ERK inhibitor U0126 attenuated the barrier-protecting effect of these strains.	U 0126	139-144	mitogen-activated protein kinase 1	Homo sapiens	95-98
22811489-14	2012	In addition, ERK1/2 inhibition by U0126 prevented acid-induced ERK1/2 phosphorylation and H(+)-ATPase-mediated pH(i) recovery but not phosphorylation of p38.	U 0126	34-39	mitogen-activated protein kinase 3	Mus musculus	13-19
22811489-14	2012	In addition, ERK1/2 inhibition by U0126 prevented acid-induced ERK1/2 phosphorylation and H(+)-ATPase-mediated pH(i) recovery but not phosphorylation of p38.	U 0126	34-39	mitogen-activated protein kinase 3	Mus musculus	63-69
22961803-6	2012	Strains UCC118 and CCUG38008 induced phosphorylation of extracellular signal-regulated kinase (ERK) in Caco-2 cells, and the ERK inhibitor U0126 attenuated the barrier-protecting effect of these strains.	U 0126	139-144	mitogen-activated protein kinase 1	Homo sapiens	125-128
23047827-6	2012	Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation.	U 0126	42-47	mitogen-activated protein kinase kinase 1	Homo sapiens	34-40
22706282-7	2012	Furthermore, mGlu5-mediated extracellular signal-regulated kinase (ERK) phosphorylation has been found to be partially involved in cell growth and migration, as detected by stimulation of (S)-3,5-Dihydroxyphenylglycine (DHPG), an agonist of the receptor, and blockage of MPEP and U0126, an inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK).	U 0126	280-285	mitogen-activated protein kinase 1	Homo sapiens	28-65
22706282-7	2012	Furthermore, mGlu5-mediated extracellular signal-regulated kinase (ERK) phosphorylation has been found to be partially involved in cell growth and migration, as detected by stimulation of (S)-3,5-Dihydroxyphenylglycine (DHPG), an agonist of the receptor, and blockage of MPEP and U0126, an inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK).	U 0126	280-285	mitogen-activated protein kinase 1	Homo sapiens	67-70
22974512-5	2012	These actions were abolished by the antiandrogen bicalutamide and by the inhibitor of MAPK kinase (MEK1/2) U0126, suggesting that testosterone exerts its stimulatory effect on COX2/PGs through a non-classical mechanism that involves the presence of androgen receptors and MAPK1/2 activation.	U 0126	107-112	prostaglandin G/H synthase 2	Mesocricetus auratus	176-180
22791363-9	2012	U0126, a MAP kinase/ERK kinase inhibitor, did not affect mRNA expression.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	20-23
22328534-12	2012	PD98059, MEK inhibitor, or U0126, ERK inhibitor, reduced SNU668 cell migration accompanying an increase in p-GSK-3alpha, beta-catenin and E-cadherin.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	34-37
22328534-12	2012	PD98059, MEK inhibitor, or U0126, ERK inhibitor, reduced SNU668 cell migration accompanying an increase in p-GSK-3alpha, beta-catenin and E-cadherin.	U 0126	27-32	glycogen synthase kinase 3 alpha	Homo sapiens	109-119
22328534-12	2012	PD98059, MEK inhibitor, or U0126, ERK inhibitor, reduced SNU668 cell migration accompanying an increase in p-GSK-3alpha, beta-catenin and E-cadherin.	U 0126	27-32	catenin beta 1	Homo sapiens	121-133
22328534-12	2012	PD98059, MEK inhibitor, or U0126, ERK inhibitor, reduced SNU668 cell migration accompanying an increase in p-GSK-3alpha, beta-catenin and E-cadherin.	U 0126	27-32	cadherin 1	Homo sapiens	138-148
22964022-8	2012	However, only the p38MAPK activity was critical for the Ang-II-induced fibrotic effects, as indicated by the decrease in the Ang-II-induced TGF-beta1 and CTGF expression and fibronectin levels by SB-203580, an inhibitor of the p38MAPK, but not by U0126, an inhibitor of ERK1/2 phosphorylation.	U 0126	247-252	angiotensinogen	Homo sapiens	56-62
22964022-8	2012	However, only the p38MAPK activity was critical for the Ang-II-induced fibrotic effects, as indicated by the decrease in the Ang-II-induced TGF-beta1 and CTGF expression and fibronectin levels by SB-203580, an inhibitor of the p38MAPK, but not by U0126, an inhibitor of ERK1/2 phosphorylation.	U 0126	247-252	angiotensinogen	Homo sapiens	125-131
22895544-8	2012	In addition, we found that similar to the effect of NaHS, pretreatment with NAC (a ROS scavenger) or U0126 (a MEK1/2 inhibitor) blocked the downregulation of GLT-1 expression induced by CoCl2.	U 0126	101-106	mitogen activated protein kinase kinase 1	Rattus norvegicus	110-116
22895544-8	2012	In addition, we found that similar to the effect of NaHS, pretreatment with NAC (a ROS scavenger) or U0126 (a MEK1/2 inhibitor) blocked the downregulation of GLT-1 expression induced by CoCl2.	U 0126	101-106	solute carrier family 1 member 2	Rattus norvegicus	158-163
22418790-2	2012	PACAP caused a concentration-dependent increase in the number of neurite-bearing cells and the expression of the substance P precursor (PPT) mRNA in 24 h. The effects of PACAP were mimicked by vasoactive intestinal polypeptide with lower potency and dibutyryl-cyclic AMP, and inhibited by inhibitors of protein kinase A, ERK kinase or p38 kinase, KT5720, U0126, or SB203580, respectively.	U 0126	355-360	adenylate cyclase activating polypeptide 1	Rattus norvegicus	0-5
22418790-2	2012	PACAP caused a concentration-dependent increase in the number of neurite-bearing cells and the expression of the substance P precursor (PPT) mRNA in 24 h. The effects of PACAP were mimicked by vasoactive intestinal polypeptide with lower potency and dibutyryl-cyclic AMP, and inhibited by inhibitors of protein kinase A, ERK kinase or p38 kinase, KT5720, U0126, or SB203580, respectively.	U 0126	355-360	tachykinin, precursor 1	Rattus norvegicus	136-139
22418790-2	2012	PACAP caused a concentration-dependent increase in the number of neurite-bearing cells and the expression of the substance P precursor (PPT) mRNA in 24 h. The effects of PACAP were mimicked by vasoactive intestinal polypeptide with lower potency and dibutyryl-cyclic AMP, and inhibited by inhibitors of protein kinase A, ERK kinase or p38 kinase, KT5720, U0126, or SB203580, respectively.	U 0126	355-360	adenylate cyclase activating polypeptide 1	Rattus norvegicus	170-175
22811014-9	2012	The intracisternal administration of U0126 (an MEK inhibitor), previous to the excitotoxic lesion, decreased the activation of ERK1/2 and the expression of cyclin D1 and cyclin B in the hippocampus.	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
22811014-9	2012	The intracisternal administration of U0126 (an MEK inhibitor), previous to the excitotoxic lesion, decreased the activation of ERK1/2 and the expression of cyclin D1 and cyclin B in the hippocampus.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	127-133
22811014-9	2012	The intracisternal administration of U0126 (an MEK inhibitor), previous to the excitotoxic lesion, decreased the activation of ERK1/2 and the expression of cyclin D1 and cyclin B in the hippocampus.	U 0126	37-42	cyclin D1	Homo sapiens	156-165
23271927-6	2012	Treatment with FSL-1 resulted in enhanced phosphorylation of Akt and mitogen-activated protein kinases and activation of protein kinase C. Treatment with pharmacological inhibitors, including SB202190, SP6001250, U0126, Akt inhibitor IV, LY294002, GF109203X, and RO318220 resulted in significantly attenuated FSL-1-mediated upregulation of CCL2 and IL-1beta.	U 0126	213-218	follistatin like 1	Homo sapiens	15-20
22878563-9	2012	However, when ERK1/2 phosphorylation was specifically inhibited by U0126, the increase in DJ-1 expression occurring during HP was almost completely abolished and, as a result, the delayed cardioprotection induced by HP was abolished, and the inhibitory effect of HP on H/R-induced oxidant stress was also reversed.	U 0126	67-72	mitogen activated protein kinase 3	Rattus norvegicus	14-20
22878563-9	2012	However, when ERK1/2 phosphorylation was specifically inhibited by U0126, the increase in DJ-1 expression occurring during HP was almost completely abolished and, as a result, the delayed cardioprotection induced by HP was abolished, and the inhibitory effect of HP on H/R-induced oxidant stress was also reversed.	U 0126	67-72	Parkinsonism associated deglycase	Rattus norvegicus	90-94
22940905-5	2012	Autophagy             that promoted by knockdown of RAB25 was not observed in cells where the ERK1/2             signaling pathway had been inhibited by U0126.	U 0126	153-158	RAB25, member RAS oncogene family	Homo sapiens	52-57
22940905-5	2012	Autophagy             that promoted by knockdown of RAB25 was not observed in cells where the ERK1/2             signaling pathway had been inhibited by U0126.	U 0126	153-158	mitogen-activated protein kinase 3	Homo sapiens	94-100
22936401-8	2012	Treatment with SB203580 and U0126 reduced PLpro-induced expression of TGF-beta1, vimentin, and type I collagen.	U 0126	28-33	transforming growth factor beta 1	Homo sapiens	70-79
22936401-8	2012	Treatment with SB203580 and U0126 reduced PLpro-induced expression of TGF-beta1, vimentin, and type I collagen.	U 0126	28-33	vimentin	Homo sapiens	81-89
22898350-7	2012	The neuroprotective effects of DJ-1 were blocked by phosphoinositol 3-kinase and the autophagy inhibitor, 3-methyladenine, and by the ERK pathway inhibitor, U0126.	U 0126	157-162	Parkinsonism associated deglycase	Rattus norvegicus	31-35
22949725-3	2012	Amphiregulin (AREG)-induced maturation of oocytes was efficiently blocked in GV by U0126, AG1478, and low concentrations of LY294002; H89, SB203580, and high concentrations of LY294002 allowed the oocytes to undergo breakdown of GV and blocked maturation in MI.	U 0126	83-88	amphiregulin	Sus scrofa	0-12
22949725-3	2012	Amphiregulin (AREG)-induced maturation of oocytes was efficiently blocked in GV by U0126, AG1478, and low concentrations of LY294002; H89, SB203580, and high concentrations of LY294002 allowed the oocytes to undergo breakdown of GV and blocked maturation in MI.	U 0126	83-88	amphiregulin	Sus scrofa	14-18
23083134-11	2012	Inhibition of ERK1/2 using U0126 or siRNA abolished EGF and/or IL-1beta-induced cell migration and invasion in a dose-dependent manner.	U 0126	27-32	mitogen-activated protein kinase 3	Homo sapiens	14-20
23083134-11	2012	Inhibition of ERK1/2 using U0126 or siRNA abolished EGF and/or IL-1beta-induced cell migration and invasion in a dose-dependent manner.	U 0126	27-32	epidermal growth factor	Homo sapiens	52-55
23083134-11	2012	Inhibition of ERK1/2 using U0126 or siRNA abolished EGF and/or IL-1beta-induced cell migration and invasion in a dose-dependent manner.	U 0126	27-32	interleukin 1 beta	Homo sapiens	63-71
22898350-7	2012	The neuroprotective effects of DJ-1 were blocked by phosphoinositol 3-kinase and the autophagy inhibitor, 3-methyladenine, and by the ERK pathway inhibitor, U0126.	U 0126	157-162	Eph receptor B1	Rattus norvegicus	134-137
22391414-12	2012	Moreover, incubation with either the transcriptional inhibitor actinomycin D or the mitogen-activated-protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 attenuated contractile ET(B) receptor upregulation.	U 0126	147-152	mitogen activated protein kinase kinase 1	Rattus norvegicus	84-127
22391414-12	2012	Moreover, incubation with either the transcriptional inhibitor actinomycin D or the mitogen-activated-protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 attenuated contractile ET(B) receptor upregulation.	U 0126	147-152	mitogen activated protein kinase kinase 1	Rattus norvegicus	129-135
22391414-12	2012	Moreover, incubation with either the transcriptional inhibitor actinomycin D or the mitogen-activated-protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 attenuated contractile ET(B) receptor upregulation.	U 0126	147-152	endothelin receptor type B	Rattus norvegicus	176-181
22391414-13	2012	U0126 attenuated ET(B) receptor protein levels after 24 h of incubation.	U 0126	0-5	endothelin receptor type B	Rattus norvegicus	17-22
22961271-10	2012	When U0126 was injected post-AIH, pLTF development was halted but not reversed, suggesting that ERK is critical for the development but not maintenance of pLTF.	U 0126	5-10	Eph receptor B1	Rattus norvegicus	96-99
23293787-4	2012	Finally, increasing doses of the MEK inhibitors, PD98,059 or U0126,were incubated with mIMCD-3 cells and the ET-1 dependent nitrite production determined.	U 0126	61-66	midkine	Mus musculus	33-36
23293787-4	2012	Finally, increasing doses of the MEK inhibitors, PD98,059 or U0126,were incubated with mIMCD-3 cells and the ET-1 dependent nitrite production determined.	U 0126	61-66	endothelin 1	Mus musculus	109-113
23050488-10	2012	In line with these results, the protective effect of adiponectin can be blocked by PI3K/Akt inhibitor LY294002, and palmitate-induced apoptosis can be attenuated by ERK1/2 inhibitor U0126.	U 0126	182-187	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	53-64
23050488-10	2012	In line with these results, the protective effect of adiponectin can be blocked by PI3K/Akt inhibitor LY294002, and palmitate-induced apoptosis can be attenuated by ERK1/2 inhibitor U0126.	U 0126	182-187	mitogen activated protein kinase 3	Rattus norvegicus	165-171
22949725-4	2012	Both FSH- and AREG-induced cumulus expansion was incompletely inhibited by H89 and completely inhibited by SB203580, U0126, AG1478, and LY294002.	U 0126	117-122	amphiregulin	Sus scrofa	14-18
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	U 0126	58-63	mitogen-activated protein kinase kinase 1	Mus musculus	41-47
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	U 0126	58-63	amphiregulin	Mus musculus	110-114
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	U 0126	58-63	epiregulin	Mus musculus	116-120
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	U 0126	58-63	betacellulin, epidermal growth factor family member	Mus musculus	122-125
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	U 0126	58-63	interleukin 6	Mus musculus	131-134
22533504-7	2012	EBs exposed to fl-hKITL also expressed higher levels of GRalpha than those exposed to mKITL (and tr-hKITL) which were reduced upon exposure to the ERK inhibitor U0126.	U 0126	161-166	KIT ligand	Homo sapiens	18-23
22533504-7	2012	EBs exposed to fl-hKITL also expressed higher levels of GRalpha than those exposed to mKITL (and tr-hKITL) which were reduced upon exposure to the ERK inhibitor U0126.	U 0126	161-166	KIT ligand	Homo sapiens	100-105
22533504-7	2012	EBs exposed to fl-hKITL also expressed higher levels of GRalpha than those exposed to mKITL (and tr-hKITL) which were reduced upon exposure to the ERK inhibitor U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	147-150
23035088-5	2012	Correspondingly, disruption of the epigenetic regulation of BDNF gene transcription with U0126 or suppression of BDNF signaling with Trk receptor antagonist K252a or BDNF scavenger tyrosine kinase receptor B (TrkB)-Fc blocked extinction of CPA behavior.	U 0126	89-94	brain-derived neurotrophic factor	Rattus norvegicus	60-64
22859407-7	2012	Furthermore, the effect of medetomidine (100 nM) was abolished by a preincubation with U-0126 (10 muM), a MEK1/2 inhibitor.	U 0126	87-93	mitogen-activated protein kinase kinase 1	Mus musculus	106-112
22674286-11	2012	Thrombin-mediated CCL2 production was attenuated by the thrombin inhibitor PPACK, the protein kinase Cdelta (PKCdelta) inhibitor rottlerin, the c-Src inhibitor PP2, epidermal growth factor receptor (EGFR) inhibitor AG-1478, MEK inhibitors PD98059 and U0126, or AP-1 inhibitors curcumin and tanshinone IIA.	U 0126	251-256	coagulation factor II, thrombin	Homo sapiens	0-8
22674286-11	2012	Thrombin-mediated CCL2 production was attenuated by the thrombin inhibitor PPACK, the protein kinase Cdelta (PKCdelta) inhibitor rottlerin, the c-Src inhibitor PP2, epidermal growth factor receptor (EGFR) inhibitor AG-1478, MEK inhibitors PD98059 and U0126, or AP-1 inhibitors curcumin and tanshinone IIA.	U 0126	251-256	C-C motif chemokine ligand 2	Homo sapiens	18-22
22705154-6	2012	Best-3 mRNA was augmented by ER stress and signaled through increased Ca(2+), oxidative stress and ERK1/2 phosphorylation, because it was attenuated by alpha-tocopherol, CAT expression, BAPTA-AM, calmodulin kinase inhibitor calmidazolium (40muM), ERK1/2 inhibitor U0126 (10muM), and ERK1/2 RNAi.	U 0126	264-269	bestrophin 3	Rattus norvegicus	0-6
26069646-8	2012	Monolayer experiments confirmed a link between increased ePPi accumulation and MMP-13 activity, which appeared to require calcium and was inhibited by the MEK1/2 inhibitor U0126.	U 0126	172-177	matrix metallopeptidase 13	Bos taurus	79-85
22581061-8	2012	Stretch-mediated I-Smad mRNAs of cells pre-treated with MAPK-ERK kinase inhibitor, U0126, were also determined.	U 0126	83-88	mitogen activated protein kinase 3	Rattus norvegicus	61-64
22581061-11	2012	U0126 significantly attenuated stretch-mediated decreases in Smad6 mRNA, but had no effect on stretch-mediated increases in Smad7 mRNA.	U 0126	0-5	SMAD family member 6	Rattus norvegicus	61-66
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	U 0126	87-92	toll like receptor 2	Homo sapiens	39-43
23013130-4	2012	Thus, the aim of the present study was to investigate the effects of an ERK inhibitor (U0126) on amyloidogenesis and cognitive function in Tg2576 mice.	U 0126	87-92	mitogen-activated protein kinase 1	Mus musculus	72-75
23013130-10	2012	Our results showed that U0126 attenuated memory impairment and inhibited Abeta deposition in the brains of Tg2576 mice.	U 0126	24-29	amyloid beta (A4) precursor protein	Mus musculus	73-78
23013130-11	2012	Further experiments revealed that the inhibition of Abeta deposition by U0126 was due to a reduction in beta-secretase and amyloid precursor protein expression in the brains of U0126-treated Tg2576 mice.	U 0126	72-77	amyloid beta (A4) precursor protein	Mus musculus	52-57
23013130-11	2012	Further experiments revealed that the inhibition of Abeta deposition by U0126 was due to a reduction in beta-secretase and amyloid precursor protein expression in the brains of U0126-treated Tg2576 mice.	U 0126	72-77	amyloid beta (A4) precursor protein	Mus musculus	123-148
23013130-11	2012	Further experiments revealed that the inhibition of Abeta deposition by U0126 was due to a reduction in beta-secretase and amyloid precursor protein expression in the brains of U0126-treated Tg2576 mice.	U 0126	177-182	amyloid beta (A4) precursor protein	Mus musculus	52-57
23013130-11	2012	Further experiments revealed that the inhibition of Abeta deposition by U0126 was due to a reduction in beta-secretase and amyloid precursor protein expression in the brains of U0126-treated Tg2576 mice.	U 0126	177-182	amyloid beta (A4) precursor protein	Mus musculus	123-148
22828134-7	2012	Inhibition of ERK1/2 activation with PD98059 or U0126 (two mitogen activated protein kinase kinase inhibitors) in vitro and in vivo significantly attenuates the SIRT1 and cleaved Caspase-3 expression to protect neuron against TBI-induced apoptosis.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	14-20
22828134-7	2012	Inhibition of ERK1/2 activation with PD98059 or U0126 (two mitogen activated protein kinase kinase inhibitors) in vitro and in vivo significantly attenuates the SIRT1 and cleaved Caspase-3 expression to protect neuron against TBI-induced apoptosis.	U 0126	48-53	sirtuin 1	Homo sapiens	161-166
22828134-7	2012	Inhibition of ERK1/2 activation with PD98059 or U0126 (two mitogen activated protein kinase kinase inhibitors) in vitro and in vivo significantly attenuates the SIRT1 and cleaved Caspase-3 expression to protect neuron against TBI-induced apoptosis.	U 0126	48-53	caspase 3	Homo sapiens	179-188
22359405-6	2012	Moreover, treatments with the EGF receptor kinase inhibitor AG1478 and the MEK inhibitor U0126 resulted in the diminishment of the effect of the three herbal extracts/natural compounds on keratinocyte proliferation, indicating that EGF receptor might have a significant role in this action.	U 0126	89-94	mitogen-activated protein kinase kinase 7	Homo sapiens	75-78
22359405-6	2012	Moreover, treatments with the EGF receptor kinase inhibitor AG1478 and the MEK inhibitor U0126 resulted in the diminishment of the effect of the three herbal extracts/natural compounds on keratinocyte proliferation, indicating that EGF receptor might have a significant role in this action.	U 0126	89-94	epidermal growth factor	Homo sapiens	232-235
22940059-4	2012	When the activity of MAPKs was blocked by their corresponding inhibitors (SB203580: p38; U0126: ERK; SP600125: JNK), the expression of TF was reduced significantly.	U 0126	89-94	mitogen-activated protein kinase 1	Homo sapiens	96-99
22940059-4	2012	When the activity of MAPKs was blocked by their corresponding inhibitors (SB203580: p38; U0126: ERK; SP600125: JNK), the expression of TF was reduced significantly.	U 0126	89-94	coagulation factor III, tissue factor	Homo sapiens	135-137
22925659-6	2012	LY294002 and U0126, inhibitors of PI3K and ERK1/2, respectively, reduced H2O2 generation in concentration-dependent manners.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	43-49
22943143-11	2012	Furthermore, U0126 could block the protective effect of bFGF by inhibiting the phosphorylation of ERK1/2.	U 0126	13-18	fibroblast growth factor 2	Mus musculus	56-60
22943143-11	2012	Furthermore, U0126 could block the protective effect of bFGF by inhibiting the phosphorylation of ERK1/2.	U 0126	13-18	mitogen-activated protein kinase 3	Mus musculus	98-104
22683691-5	2012	We demonstrated dependence of these effects on the ERK5 pathway by using the inhibitor UO126.	U 0126	87-92	mitogen-activated protein kinase 7	Homo sapiens	51-55
22927430-8	2012	Ablation of MAPK phosphorylation in Smad3-deficient cells with the MEK inhibitor U0126 further reduced cell survival but not migration.	U 0126	81-86	SMAD family member 3	Homo sapiens	36-41
22927430-8	2012	Ablation of MAPK phosphorylation in Smad3-deficient cells with the MEK inhibitor U0126 further reduced cell survival but not migration.	U 0126	81-86	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
22824956-6	2012	The prevention             of MEK by the pharmacologic inhibitors PD98059 and U0126, resulted in decreased             UDCA-induced apoptosis as shown by the reduction of apoptotic body formation,             caspase-8 activity, and caspase-3, -6 and PARP cleavage, indicating that ERK exerts             pro-apoptotic activity upon exposure to UDCA.	U 0126	78-83	mitogen-activated protein kinase kinase 7	Homo sapiens	30-33
22824956-6	2012	The prevention             of MEK by the pharmacologic inhibitors PD98059 and U0126, resulted in decreased             UDCA-induced apoptosis as shown by the reduction of apoptotic body formation,             caspase-8 activity, and caspase-3, -6 and PARP cleavage, indicating that ERK exerts             pro-apoptotic activity upon exposure to UDCA.	U 0126	78-83	caspase 8	Homo sapiens	209-218
22824956-6	2012	The prevention             of MEK by the pharmacologic inhibitors PD98059 and U0126, resulted in decreased             UDCA-induced apoptosis as shown by the reduction of apoptotic body formation,             caspase-8 activity, and caspase-3, -6 and PARP cleavage, indicating that ERK exerts             pro-apoptotic activity upon exposure to UDCA.	U 0126	78-83	caspase 3	Homo sapiens	233-246
22824956-6	2012	The prevention             of MEK by the pharmacologic inhibitors PD98059 and U0126, resulted in decreased             UDCA-induced apoptosis as shown by the reduction of apoptotic body formation,             caspase-8 activity, and caspase-3, -6 and PARP cleavage, indicating that ERK exerts             pro-apoptotic activity upon exposure to UDCA.	U 0126	78-83	collagen type XI alpha 2 chain	Homo sapiens	251-255
22824956-6	2012	The prevention             of MEK by the pharmacologic inhibitors PD98059 and U0126, resulted in decreased             UDCA-induced apoptosis as shown by the reduction of apoptotic body formation,             caspase-8 activity, and caspase-3, -6 and PARP cleavage, indicating that ERK exerts             pro-apoptotic activity upon exposure to UDCA.	U 0126	78-83	mitogen-activated protein kinase 1	Homo sapiens	282-285
22824956-7	2012	In addition, U0126 reduced UDCA-triggered             TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2/DR5) expression.	U 0126	13-18	TNF receptor superfamily member 10b	Homo sapiens	54-102
22824956-7	2012	In addition, U0126 reduced UDCA-triggered             TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2/DR5) expression.	U 0126	13-18	TNF receptor superfamily member 10b	Homo sapiens	104-112
22824956-7	2012	In addition, U0126 reduced UDCA-triggered             TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2/DR5) expression.	U 0126	13-18	TNF receptor superfamily member 10b	Homo sapiens	113-116
22683533-6	2012	In addition, CTX III similar to wortmannin (a PI3K inhibitor) and U0126 (an up-stream kinase regulating ERK1/2 inhibitor) attenuated cell migration and invasion induced by EGF.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	104-110
22683533-6	2012	In addition, CTX III similar to wortmannin (a PI3K inhibitor) and U0126 (an up-stream kinase regulating ERK1/2 inhibitor) attenuated cell migration and invasion induced by EGF.	U 0126	66-71	epidermal growth factor	Homo sapiens	172-175
22824620-6	2012	Additionally, MEK inhibitor (U0126) significantly attenuated arsenite-induced expression of Caveolin-1, IKKbeta and COX-2 while reducing eNOS expression.	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
22824620-6	2012	Additionally, MEK inhibitor (U0126) significantly attenuated arsenite-induced expression of Caveolin-1, IKKbeta and COX-2 while reducing eNOS expression.	U 0126	29-34	caveolin 1	Homo sapiens	92-102
22824620-6	2012	Additionally, MEK inhibitor (U0126) significantly attenuated arsenite-induced expression of Caveolin-1, IKKbeta and COX-2 while reducing eNOS expression.	U 0126	29-34	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	104-111
22824620-6	2012	Additionally, MEK inhibitor (U0126) significantly attenuated arsenite-induced expression of Caveolin-1, IKKbeta and COX-2 while reducing eNOS expression.	U 0126	29-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	116-121
22824620-6	2012	Additionally, MEK inhibitor (U0126) significantly attenuated arsenite-induced expression of Caveolin-1, IKKbeta and COX-2 while reducing eNOS expression.	U 0126	29-34	nitric oxide synthase 3	Homo sapiens	137-141
23001481-3	2012	Epithelial growth factor (EGF) was able to stimulate ERK activation and decreased HCV RNA load while a MAPK-ERK pathway inhibitor U0126 led to an elevated HCV RNA load and higher NS5A protein amounts in Con1 cells.	U 0126	130-135	mitogen-activated protein kinase 1	Homo sapiens	103-107
23001481-3	2012	Epithelial growth factor (EGF) was able to stimulate ERK activation and decreased HCV RNA load while a MAPK-ERK pathway inhibitor U0126 led to an elevated HCV RNA load and higher NS5A protein amounts in Con1 cells.	U 0126	130-135	mitogen-activated protein kinase 1	Homo sapiens	108-111
23001481-7	2012	In addition, cyclin-dependent kinases (CDKs) downstream of ERK may also be involved in the modulation of HCV replication since roscovitine, an inhibitor of CDKs had a similar effect to that of U0126.	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	59-62
22956616-9	2012	Using the specific inhibitor of ERK1/2, UO126, the resultant outcomes of this signaling pathway were determined to contribute significantly to cell survival.	U 0126	40-45	mitogen-activated protein kinase 3	Mus musculus	32-38
22922104-6	2012	Treatment with U0126, a specific inhibitor of the ERK1/2 cascade, prevented the HGF and the oxidative stress induced ABCG2 upregulation.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	50-56
22922104-6	2012	Treatment with U0126, a specific inhibitor of the ERK1/2 cascade, prevented the HGF and the oxidative stress induced ABCG2 upregulation.	U 0126	15-20	hepatocyte growth factor	Homo sapiens	80-83
22922104-6	2012	Treatment with U0126, a specific inhibitor of the ERK1/2 cascade, prevented the HGF and the oxidative stress induced ABCG2 upregulation.	U 0126	15-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	117-122
22659134-4	2012	High glucose-induced AP-1 DNA binding activity was decreased by Syk inhibitors and U0126 (an ERK inhibitor).	U 0126	83-88	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	21-25
22659134-4	2012	High glucose-induced AP-1 DNA binding activity was decreased by Syk inhibitors and U0126 (an ERK inhibitor).	U 0126	83-88	mitogen-activated protein kinase 1	Homo sapiens	93-96
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	126-130
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	131-134
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	U 0126	87-92	AKT serine/threonine kinase 1	Homo sapiens	144-147
22847216-5	2012	LPA-induced phosphorylation of CREB was efficiently blocked by U0126 and H89, inhibitors of the MAP kinases ERK1/2 and mitogen- and stress-activated protein kinase 1, respectively.	U 0126	63-68	cAMP responsive element binding protein 1	Homo sapiens	31-35
22847216-5	2012	LPA-induced phosphorylation of CREB was efficiently blocked by U0126 and H89, inhibitors of the MAP kinases ERK1/2 and mitogen- and stress-activated protein kinase 1, respectively.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	108-114
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	U 0126	132-137	epidermal growth factor receptor	Homo sapiens	0-4
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	U 0126	132-137	mitogen-activated protein kinase 1	Homo sapiens	9-12
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	U 0126	132-137	epidermal growth factor	Homo sapiens	0-3
22735833-5	2012	EGFR and ERK phosphorylation             induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and             U0126 (ERK inhibitor), respectively.	U 0126	132-137	mitogen-activated protein kinase 1	Homo sapiens	139-142
22735833-7	2012	The activity of AQP3 and cell migration were inhibited by PD153035,             U0126 and CuSO4 (AQP3 water transport inhibitor).	U 0126	80-85	aquaporin 3 (Gill blood group)	Homo sapiens	16-20
22534050-7	2012	ERK1/2 phosphorylation inhibitor U0126 can block downstream iNOS expression and NO generation.	U 0126	33-38	mitogen activated protein kinase 3	Rattus norvegicus	0-6
22534050-7	2012	ERK1/2 phosphorylation inhibitor U0126 can block downstream iNOS expression and NO generation.	U 0126	33-38	nitric oxide synthase 2	Rattus norvegicus	60-64
22580375-10	2012	Finally, pharmacological experiments showed that administration of inhibitors of either MAPK/ERK (U0126) or PI3K (LY294002) blocked VEGF-stimulation of hippocampal cell proliferation in vivo and in vitro.	U 0126	98-103	mitogen activated protein kinase 3	Rattus norvegicus	88-92
22580375-10	2012	Finally, pharmacological experiments showed that administration of inhibitors of either MAPK/ERK (U0126) or PI3K (LY294002) blocked VEGF-stimulation of hippocampal cell proliferation in vivo and in vitro.	U 0126	98-103	Eph receptor B1	Rattus norvegicus	93-96
22580375-10	2012	Finally, pharmacological experiments showed that administration of inhibitors of either MAPK/ERK (U0126) or PI3K (LY294002) blocked VEGF-stimulation of hippocampal cell proliferation in vivo and in vitro.	U 0126	98-103	vascular endothelial growth factor A	Rattus norvegicus	132-136
22710862-7	2012	To examine the involvement             of the ERK1/2 signaling pathway on IL-5-induced cell responses, we pretreated             HT1376 cells with the ERK1/2 inhibitor U0126 followed by IL-5 treatment.	U 0126	168-173	interleukin 5	Homo sapiens	74-78
22710862-7	2012	To examine the involvement             of the ERK1/2 signaling pathway on IL-5-induced cell responses, we pretreated             HT1376 cells with the ERK1/2 inhibitor U0126 followed by IL-5 treatment.	U 0126	168-173	mitogen-activated protein kinase 3	Homo sapiens	151-157
22710862-8	2012	The results             showed that U0126 treatment inhibited migration of IL-5-treated HT1376 cells.	U 0126	36-41	interleukin 5	Homo sapiens	75-79
22710862-9	2012	Moreover, IL-5-stimulated MMP-9 expression was suppressed by the addition of U0126.	U 0126	77-82	interleukin 5	Homo sapiens	10-14
22710862-9	2012	Moreover, IL-5-stimulated MMP-9 expression was suppressed by the addition of U0126.	U 0126	77-82	matrix metallopeptidase 9	Homo sapiens	26-31
22823995-13	2012	Interestingly, preincubation with mitogen-activated protein kinase (MAPK) cascade inhibitors U0126 (ERK pathway) and SB203580 (p38 pathway) decreased DIO3 mRNA levels and blocked the TGFbeta1-induced increase in DIO3 transcripts, suggesting that D3 induction might be mediated through the MAPK signaling pathway.	U 0126	93-98	iodothyronine deiodinase 3	Homo sapiens	150-154
22823995-13	2012	Interestingly, preincubation with mitogen-activated protein kinase (MAPK) cascade inhibitors U0126 (ERK pathway) and SB203580 (p38 pathway) decreased DIO3 mRNA levels and blocked the TGFbeta1-induced increase in DIO3 transcripts, suggesting that D3 induction might be mediated through the MAPK signaling pathway.	U 0126	93-98	transforming growth factor beta 1	Homo sapiens	183-191
22823995-13	2012	Interestingly, preincubation with mitogen-activated protein kinase (MAPK) cascade inhibitors U0126 (ERK pathway) and SB203580 (p38 pathway) decreased DIO3 mRNA levels and blocked the TGFbeta1-induced increase in DIO3 transcripts, suggesting that D3 induction might be mediated through the MAPK signaling pathway.	U 0126	93-98	iodothyronine deiodinase 3	Homo sapiens	212-216
22627808-5	2012	In addition, HRG-induced MMP-1 and -9 expression was significantly decreased by MEK1/2 inhibitor, U0126 but not by phosphatidylinositol 3-kinase (PI-3K) inhibitor, LY294002.	U 0126	98-103	matrix metallopeptidase 1	Homo sapiens	25-37
22828512-12	2012	Accordingly, inhibition of MEK/ERK-signaling by UO126 or inhibition of PI3K/Akt-signaling by LY294002 abolished the anti-apoptotic effects of ATP.	U 0126	48-53	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
22937527-12	2012	Addition of the ERK inhibitor U0126 was associated with dose-dependent IL-10 inhibition and reciprocal enhancement in IL-12, both correlating with ERK inhibition.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	16-19
22937527-12	2012	Addition of the ERK inhibitor U0126 was associated with dose-dependent IL-10 inhibition and reciprocal enhancement in IL-12, both correlating with ERK inhibition.	U 0126	30-35	interleukin 10	Homo sapiens	71-76
22937527-12	2012	Addition of the ERK inhibitor U0126 was associated with dose-dependent IL-10 inhibition and reciprocal enhancement in IL-12, both correlating with ERK inhibition.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	147-150
22912494-7	2012	The production of inflammatory molecules induced by the knockdown of Omi was blocked by the MEK1-specific inhibitor U0126.	U 0126	116-121	mitogen-activated protein kinase kinase 1	Mus musculus	92-96
22843885-9	2012	Cell proliferation was increased by 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of medulloblastoma cells, while it was suppressed following treatment with rapamycin or U0126 (MEK1/2 inhibitor).	U 0126	177-182	mitogen-activated protein kinase kinase 1	Homo sapiens	184-190
22463716-5	2012	Pharmacological inhibition of MEK/ERK1/2 signalling with U0126 significantly inhibited IFNgamma-induced increases in the transcytosis of non-invasive Escherichia coli (strain HB101).	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	34-40
22463716-5	2012	Pharmacological inhibition of MEK/ERK1/2 signalling with U0126 significantly inhibited IFNgamma-induced increases in the transcytosis of non-invasive Escherichia coli (strain HB101).	U 0126	57-62	interferon gamma	Homo sapiens	87-95
22537548-6	2012	Finally, the MEK inhibitor U0126 was utilized to block the ERK pathway and determine the role of Shp-2 in this pathway.	U 0126	27-32	Eph receptor B1	Rattus norvegicus	59-62
22537548-9	2012	The MEK inhibitor U0126 abolished Shp-2"s effect on apoptosis in cardiomyocytes.	U 0126	18-23	protein tyrosine phosphatase, non-receptor type 11	Rattus norvegicus	34-39
22875343-7	2012	Moreover, inhibition of ERK1/2 with U0126 enhanced the ability of DQA to potentiate imatinib-induced apoptosis, suggesting a role of the Raf/MEK/ERK pathway and the Bcr-Abl tyrosine kinase in the K562 cell survival.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	24-30
22875343-7	2012	Moreover, inhibition of ERK1/2 with U0126 enhanced the ability of DQA to potentiate imatinib-induced apoptosis, suggesting a role of the Raf/MEK/ERK pathway and the Bcr-Abl tyrosine kinase in the K562 cell survival.	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	24-27
22532442-5	2012	Both ERK phosphorylation and neuritogenesis were MEK dependent (blocked by 10 muM U0126) and PKA independent (insensitive to 30 muM H-89 or 100 nM myristoylated protein kinase A inhibitor).	U 0126	82-87	mitogen-activated protein kinase 1	Homo sapiens	5-8
22411631-5	2012	The specific mitogen-activated protein kinase kinase/ERK inhibitor, U0126, blocks N. fowleri-mediated AP-1 activation and subsequent IL-8 induction.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	53-56
22641097-10	2012	In thyroid carcinoma cell lines, the MEK inhibitor U0126 suppressed Runx2, suggesting an association of the MAPK/ERK pathway with Runx2 regulation.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	37-40
22641097-10	2012	In thyroid carcinoma cell lines, the MEK inhibitor U0126 suppressed Runx2, suggesting an association of the MAPK/ERK pathway with Runx2 regulation.	U 0126	51-56	RUNX family transcription factor 2	Homo sapiens	68-73
22641097-10	2012	In thyroid carcinoma cell lines, the MEK inhibitor U0126 suppressed Runx2, suggesting an association of the MAPK/ERK pathway with Runx2 regulation.	U 0126	51-56	RUNX family transcription factor 2	Homo sapiens	130-135
22678567-9	2012	Furthermore, the MEK1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580 markedly blocked the effect of CsA on cell apoptosis, apoptotic-related protein expression, and caspase-3 activation.	U 0126	34-39	mitogen activated protein kinase kinase 1	Rattus norvegicus	17-23
22678567-9	2012	Furthermore, the MEK1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580 markedly blocked the effect of CsA on cell apoptosis, apoptotic-related protein expression, and caspase-3 activation.	U 0126	34-39	caspase 3	Rattus norvegicus	172-181
22411631-5	2012	The specific mitogen-activated protein kinase kinase/ERK inhibitor, U0126, blocks N. fowleri-mediated AP-1 activation and subsequent IL-8 induction.	U 0126	68-73	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-106
22411631-5	2012	The specific mitogen-activated protein kinase kinase/ERK inhibitor, U0126, blocks N. fowleri-mediated AP-1 activation and subsequent IL-8 induction.	U 0126	68-73	C-X-C motif chemokine ligand 8	Homo sapiens	133-137
22957439-0	2012	The Raf-1 inhibitor GW5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine.	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	35-41
21554769-6	2012	While MAPK inactivation by regulator U0126 prevented NPB fusion in oocytes activated by ethanol or 5 min Sr2+ treatments, it had no effect on oocytes fertilized or activated by 6 h Sr2+ treatment.	U 0126	37-42	neuropeptide B	Mus musculus	53-56
22957439-5	2012	Phosphorylation of ERK1/2 at Thr-202/Tyr-204 and Raf-1 at Ser-338 were inhibited by the Raf-1 inhibitor GW5074, while the ERK1/2 pathway inhibitor U0126 decreased phosphorylation of ERK1/2.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	19-25
22957439-5	2012	Phosphorylation of ERK1/2 at Thr-202/Tyr-204 and Raf-1 at Ser-338 were inhibited by the Raf-1 inhibitor GW5074, while the ERK1/2 pathway inhibitor U0126 decreased phosphorylation of ERK1/2.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	122-128
22957439-5	2012	Phosphorylation of ERK1/2 at Thr-202/Tyr-204 and Raf-1 at Ser-338 were inhibited by the Raf-1 inhibitor GW5074, while the ERK1/2 pathway inhibitor U0126 decreased phosphorylation of ERK1/2.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	122-128
22957439-7	2012	Our results suggest that GW5074 and U0126 act as neuroprotants against 6-OHDA toxicity in PC12 cells by modulating Raf-1/ERK1/2 signaling systems.	U 0126	36-41	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	115-120
22957439-7	2012	Our results suggest that GW5074 and U0126 act as neuroprotants against 6-OHDA toxicity in PC12 cells by modulating Raf-1/ERK1/2 signaling systems.	U 0126	36-41	mitogen activated protein kinase 3	Rattus norvegicus	121-127
22654119-7	2012	Interestingly, the adhesion and migration of osteoblasts were decreased when these siRNA reagents as well as the ERK1/2 signaling pathway inhibitors, U0126 and PD98059, were present.	U 0126	150-155	mitogen activated protein kinase 3	Rattus norvegicus	113-119
22654119-8	2012	Further studies demonstrated that U0126 could inhibit the downstream integrin-dependent signaling pathways, such as the FAK signaling pathway, whereas it had no influence on the synthesis of integrin beta1 molecule.	U 0126	34-39	protein tyrosine kinase 2	Rattus norvegicus	120-123
22593575-11	2012	In vivo, administration of pioglitazone or U0126 alone increased PCSK9 expression in mouse liver but had little effect on PCSK9 secretion.	U 0126	43-48	proprotein convertase subtilisin/kexin type 9	Mus musculus	65-70
22609091-6	2012	Inhibition of the PI3K/Akt and ERK1/2 pathways by specific inhibitors, LY294002 and U0126, respectively, partially reduce the protective effect of bFGF.	U 0126	84-89	AKT serine/threonine kinase 1	Rattus norvegicus	23-26
22609091-6	2012	Inhibition of the PI3K/Akt and ERK1/2 pathways by specific inhibitors, LY294002 and U0126, respectively, partially reduce the protective effect of bFGF.	U 0126	84-89	mitogen activated protein kinase 3	Rattus norvegicus	31-37
22609091-6	2012	Inhibition of the PI3K/Akt and ERK1/2 pathways by specific inhibitors, LY294002 and U0126, respectively, partially reduce the protective effect of bFGF.	U 0126	84-89	fibroblast growth factor 2	Rattus norvegicus	147-151
22525723-9	2012	Simultaneously targeting the two pathways by using U0126 and LY294002 inhibitors or using CCX733, a selective CXCR7 antagonist drastically reduced CXCR7-induced EMT process.	U 0126	51-56	atypical chemokine receptor 3	Homo sapiens	147-152
22593575-12	2012	However, the co-treatment of pioglitazone and U0126 enhanced both PCSK9 expression and secretion.	U 0126	46-51	proprotein convertase subtilisin/kexin type 9	Homo sapiens	66-71
22765220-11	2012	Inhibition of ERK signaling in MCF7-Six1 cells with MEK1/2 inhibitors, U0126 and AZD6244, restores the TIC population of luminal breast cancer cells back to that observed in control cells.	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	14-17
22765220-11	2012	Inhibition of ERK signaling in MCF7-Six1 cells with MEK1/2 inhibitors, U0126 and AZD6244, restores the TIC population of luminal breast cancer cells back to that observed in control cells.	U 0126	71-76	SIX homeobox 1	Homo sapiens	36-40
22765220-11	2012	Inhibition of ERK signaling in MCF7-Six1 cells with MEK1/2 inhibitors, U0126 and AZD6244, restores the TIC population of luminal breast cancer cells back to that observed in control cells.	U 0126	71-76	mitogen-activated protein kinase kinase 1	Homo sapiens	52-58
22561298-6	2012	Furthermore, the VCAM-1 induction was significantly prevented by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002, whereas it was accelerated by the ERK inhibitor, U-0126.	U 0126	176-182	vascular cell adhesion molecule 1	Mus musculus	17-23
22561298-6	2012	Furthermore, the VCAM-1 induction was significantly prevented by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002, whereas it was accelerated by the ERK inhibitor, U-0126.	U 0126	176-182	mitogen-activated protein kinase 1	Mus musculus	161-164
22716212-6	2012	The Raf-1 inhibitor GW5074 and the ERK inhibitor U0126 had inhibitory effects that were similar to those of PTX on HSC proliferation.	U 0126	49-54	Eph receptor B1	Rattus norvegicus	35-38
22231145-9	2012	RESULTS: IL-1beta-induced cPLA2 expression was mediated through NOX activation/ROS production, which was attenuated by N-acetylcysteine (NAC; a scavenger of ROS), the inhibitors of NOX (diphenyleneiodonium chloride and apocynin), MEK-1/2 (U0126), and JNK-1/2 (SP600125), transfection with the respective siRNAs, and the overexpression of HO-1 in RASFs.	U 0126	239-244	interleukin 1 beta	Mus musculus	9-17
22231145-9	2012	RESULTS: IL-1beta-induced cPLA2 expression was mediated through NOX activation/ROS production, which was attenuated by N-acetylcysteine (NAC; a scavenger of ROS), the inhibitors of NOX (diphenyleneiodonium chloride and apocynin), MEK-1/2 (U0126), and JNK-1/2 (SP600125), transfection with the respective siRNAs, and the overexpression of HO-1 in RASFs.	U 0126	239-244	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	26-31
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	mitogen-activated protein kinase 1	Mus musculus	0-3
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	mitogen-activated protein kinase 8	Mus musculus	5-8
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	mitogen-activated protein kinase 14	Mus musculus	14-17
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	patchy fur	Mus musculus	50-53
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	patchy fur	Mus musculus	76-79
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	mitogen-activated protein kinase 1	Mus musculus	185-188
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	mitogen-activated protein kinase 8	Mus musculus	211-214
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	U 0126	178-183	mitogen-activated protein kinase 14	Mus musculus	240-243
22829704-5	2012	U0126 was used to inhibit ERK activation.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	26-29
22829704-10	2012	Preincubation with U0126 decreased apoptosis induced by ROS, anti-beta1-integrin mAb or RGDS, respectively.	U 0126	19-24	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	88-92
22350699-11	2012	Pretreatment with either the EGFR inhibitor AG1478 or the MEK-specific inhibitor U0126 abolished the effects of CA on cellular lipid accumulation and decreased both the protein expression and activity of PPARgamma.	U 0126	81-86	midkine	Mus musculus	58-61
22350699-11	2012	Pretreatment with either the EGFR inhibitor AG1478 or the MEK-specific inhibitor U0126 abolished the effects of CA on cellular lipid accumulation and decreased both the protein expression and activity of PPARgamma.	U 0126	81-86	peroxisome proliferator activated receptor gamma	Mus musculus	204-213
22242821-6	2012	U0126, a MEK1/2 inhibitor, prevented GO-inducible MDR-1 expression and abrogated GO resistance in HL-60/GOR cells.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	9-15
22242821-6	2012	U0126, a MEK1/2 inhibitor, prevented GO-inducible MDR-1 expression and abrogated GO resistance in HL-60/GOR cells.	U 0126	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	50-55
22242821-6	2012	U0126, a MEK1/2 inhibitor, prevented GO-inducible MDR-1 expression and abrogated GO resistance in HL-60/GOR cells.	U 0126	0-5	REXO1 like 1, pseudogene	Homo sapiens	104-107
22576740-5	2012	In MCF-7 cells, the ErbB2 inhibitor, AG825, the MAPK inhibitor, PD98059, and the MEK1/2 inhibitor, U0126, blocked the HRG-beta1-induced GPR30 expression.	U 0126	99-104	mitogen-activated protein kinase kinase 1	Homo sapiens	81-87
22576740-5	2012	In MCF-7 cells, the ErbB2 inhibitor, AG825, the MAPK inhibitor, PD98059, and the MEK1/2 inhibitor, U0126, blocked the HRG-beta1-induced GPR30 expression.	U 0126	99-104	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	122-127
22576740-5	2012	In MCF-7 cells, the ErbB2 inhibitor, AG825, the MAPK inhibitor, PD98059, and the MEK1/2 inhibitor, U0126, blocked the HRG-beta1-induced GPR30 expression.	U 0126	99-104	G protein-coupled estrogen receptor 1	Homo sapiens	136-141
22459175-4	2012	Treatment with the inhibitors of PI3-K (LY294002), Akt (SH-5), MEK1/2 (U0126), and JNK1/2 (SP600125) attenuated the outgrowth area, indicating that PI3-K/Akt, p42/p44 MAPK, and JNK1/2 are involved in the outgrowth of intact AM-expanded limbal epithelial cells.	U 0126	71-76	mitogen-activated protein kinase kinase 1	Homo sapiens	63-69
22561873-7	2012	These changes, which occur only after CSE stimulation, were prevented and reversed by anisodamine, and CSE-induced cyclin D1 expression was significantly inhibited by anisodamine and the specific inhibitor U0126, BAY11-7082 and LY294002.	U 0126	206-211	cyclin D1	Rattus norvegicus	115-124
22742729-8	2012	NGF-evoked CGRP up-regulation is also blocked by inhibition of the MEK/ERK pathway with specific MEK inhibitors U0126 and PD98059, but not by inhibition of the PI3K/Akt pathway with inhibitor LY294002.	U 0126	112-117	calcitonin-related polypeptide alpha	Rattus norvegicus	11-15
22742729-8	2012	NGF-evoked CGRP up-regulation is also blocked by inhibition of the MEK/ERK pathway with specific MEK inhibitors U0126 and PD98059, but not by inhibition of the PI3K/Akt pathway with inhibitor LY294002.	U 0126	112-117	Eph receptor B1	Rattus norvegicus	71-74
22510382-1	2012	In this study, we investigated the effect of intracerebroventricular administration of ERK and p38 specific inhibitors, U0126 and PD169316, respectively, on learning and memory deficits induced by amyloid beta (Abeta) in rats.	U 0126	120-125	amyloid beta precursor protein	Rattus norvegicus	211-216
22510382-3	2012	U0126 and/or PD169316 improved spatial learning in MWM in Abeta-injected rats, 20 days after Abeta-injection.	U 0126	0-5	amyloid beta precursor protein	Rattus norvegicus	58-63
22510382-3	2012	U0126 and/or PD169316 improved spatial learning in MWM in Abeta-injected rats, 20 days after Abeta-injection.	U 0126	0-5	amyloid beta precursor protein	Rattus norvegicus	93-98
22510382-6	2012	Moreover, U0126 and PD169316 activated peroxisome proliferator-activated receptor gamma coactivator-1a, nuclear respiratory factor 1, and mitochondrial transcription factor A, 7 days after Abeta-injection.	U 0126	10-15	PPARG coactivator 1 alpha	Rattus norvegicus	39-102
22510382-6	2012	Moreover, U0126 and PD169316 activated peroxisome proliferator-activated receptor gamma coactivator-1a, nuclear respiratory factor 1, and mitochondrial transcription factor A, 7 days after Abeta-injection.	U 0126	10-15	nuclear respiratory factor 1	Rattus norvegicus	104-132
22510382-6	2012	Moreover, U0126 and PD169316 activated peroxisome proliferator-activated receptor gamma coactivator-1a, nuclear respiratory factor 1, and mitochondrial transcription factor A, 7 days after Abeta-injection.	U 0126	10-15	amyloid beta precursor protein	Rattus norvegicus	189-194
22575507-5	2012	U0126, a specific MEK/ERK activation inhibitor, abrogated metformin-induced differentiation.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
22575507-5	2012	U0126, a specific MEK/ERK activation inhibitor, abrogated metformin-induced differentiation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	22-25
22790215-8	2012	We confirmed an increase in MEK1/2 phosphorylation in GCDCA-treated IEC-6 cells, and inhibition of MEK1/2 by U0126 clearly suppressed GCDCA-induced IEC-6 cell proliferation.	U 0126	109-114	mitogen activated protein kinase kinase 1	Rattus norvegicus	99-105
22249904-6	2012	The IGF-1-induced osteoblast proliferation was mediated via both MAPK and Akt pathways because the IGF-1-mediated cell proliferation was blocked by U0126, an MEK/MAPK inhibitor, or LY294002, a PI3-kinase inhibitor.	U 0126	148-153	insulin-like growth factor 1	Mus musculus	4-9
22249904-6	2012	The IGF-1-induced osteoblast proliferation was mediated via both MAPK and Akt pathways because the IGF-1-mediated cell proliferation was blocked by U0126, an MEK/MAPK inhibitor, or LY294002, a PI3-kinase inhibitor.	U 0126	148-153	thymoma viral proto-oncogene 1	Mus musculus	74-77
22249904-6	2012	The IGF-1-induced osteoblast proliferation was mediated via both MAPK and Akt pathways because the IGF-1-mediated cell proliferation was blocked by U0126, an MEK/MAPK inhibitor, or LY294002, a PI3-kinase inhibitor.	U 0126	148-153	insulin-like growth factor 1	Mus musculus	99-104
22556124-3	2012	When the level of ER beta was high, DHEA (10 - 7  mol/l) could effectively amplify the proliferation and inhibit the etoposide-induced apoptosis of hMG63 cells (p&lt;0.01 and p&lt;0.05, respectively), which was blocked by U0126.	U 0126	222-227	estrogen receptor 2	Homo sapiens	18-25
22356213-9	2012	Moreover, medium collected in the presence of U0126, an inhibitor of MAPK kinase (MEK), contained undetectable amounts of sphingosine and had no ability to down-regulate TSP-1 expression.	U 0126	46-51	mitogen-activated protein kinase kinase 7	Homo sapiens	82-85
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	71-110
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	0-5	interleukin 1 beta	Homo sapiens	139-147
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	7-66	mitogen-activated protein kinase kinase 7	Homo sapiens	71-110
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	7-66	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	7-66	interleukin 1 beta	Homo sapiens	139-147
22487933-8	2012	The synergistic action of osteostatin and Si-HA/FGF-2 on the VEGF system was abrogated by a mitogen-activated protein kinase inhibitor (U0126) and by the calcium antagonist verapamil.	U 0126	136-141	fibroblast growth factor 2	Mus musculus	48-53
22487933-8	2012	The synergistic action of osteostatin and Si-HA/FGF-2 on the VEGF system was abrogated by a mitogen-activated protein kinase inhibitor (U0126) and by the calcium antagonist verapamil.	U 0126	136-141	vascular endothelial growth factor A	Mus musculus	61-65
22584352-8	2012	UO126, a Raf/MEK/ERK signaling pathway inhibitor, impaired viral multiplication, while anisomycin, an activator of this pathway, enhanced it.	U 0126	0-5	zinc fingers and homeoboxes 2	Homo sapiens	9-12
22584352-8	2012	UO126, a Raf/MEK/ERK signaling pathway inhibitor, impaired viral multiplication, while anisomycin, an activator of this pathway, enhanced it.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
22584352-8	2012	UO126, a Raf/MEK/ERK signaling pathway inhibitor, impaired viral multiplication, while anisomycin, an activator of this pathway, enhanced it.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	17-20
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	84-88
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	89-95
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	C-X-C motif chemokine ligand 12	Homo sapiens	154-160
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	C-X-C motif chemokine receptor 4	Homo sapiens	165-170
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	C-X-C motif chemokine ligand 12	Homo sapiens	213-219
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	C-X-C motif chemokine receptor 4	Homo sapiens	223-228
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	matrix metallopeptidase 9	Homo sapiens	304-309
22495096-9	2012	Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast.	U 0126	110-115	matrix metallopeptidase 2	Homo sapiens	314-319
22314915-7	2012	Calcium exposure significantly enhanced rat BMSCs proliferation, as well as the proportion of the population in S phase, in a dose-dependent manner, effects which were abolished by NPS2390 (a CaSR antagonist) and U0126 (a MEK1/2 inhibitor).	U 0126	213-218	calcium-sensing receptor	Rattus norvegicus	192-196
22314915-7	2012	Calcium exposure significantly enhanced rat BMSCs proliferation, as well as the proportion of the population in S phase, in a dose-dependent manner, effects which were abolished by NPS2390 (a CaSR antagonist) and U0126 (a MEK1/2 inhibitor).	U 0126	213-218	mitogen activated protein kinase kinase 1	Rattus norvegicus	222-228
22441145-3	2012	The effect of Ras/MEK/ERK pathway on TGF-beta-mediated Lefty up-regulation was tested by adding K-ras small interfering RNA, MEK inhibitor U0126, or extracellular signal-regulated kinase (ERK) inhibitor LY294002.	U 0126	139-144	transforming growth factor beta 1	Homo sapiens	37-45
21933022-7	2012	Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
21933022-7	2012	Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	58-61
21933022-7	2012	Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels.	U 0126	45-50	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	80-84
21933022-7	2012	Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels.	U 0126	45-50	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	89-94
22511624-10	2012	Inhibition of ERK1/2 phosphorylation with U0126 was observed for changes in VEGF secretion.	U 0126	42-47	mitogen activated protein kinase 3	Rattus norvegicus	14-20
22511624-10	2012	Inhibition of ERK1/2 phosphorylation with U0126 was observed for changes in VEGF secretion.	U 0126	42-47	vascular endothelial growth factor A	Rattus norvegicus	76-80
22511624-13	2012	An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions.	U 0126	30-35	mitogen activated protein kinase 3	Rattus norvegicus	3-9
22511624-13	2012	An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions.	U 0126	30-35	mitogen activated protein kinase 3	Rattus norvegicus	68-74
22511624-13	2012	An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions.	U 0126	30-35	vascular endothelial growth factor A	Rattus norvegicus	149-153
22546605-6	2012	Both claudin-2 and p-ERK1/2 levels were decreased by EGF neutralizing antibody, EGF receptor (EGFR) siRNA, AG1478, an inhibitor of EGFR, U0126, an inhibitor of MEK, and the exogenous expression of dominant negative-MEK.	U 0126	137-142	claudin 2	Homo sapiens	5-14
22546605-6	2012	Both claudin-2 and p-ERK1/2 levels were decreased by EGF neutralizing antibody, EGF receptor (EGFR) siRNA, AG1478, an inhibitor of EGFR, U0126, an inhibitor of MEK, and the exogenous expression of dominant negative-MEK.	U 0126	137-142	mitogen-activated protein kinase 3	Homo sapiens	21-27
22546605-6	2012	Both claudin-2 and p-ERK1/2 levels were decreased by EGF neutralizing antibody, EGF receptor (EGFR) siRNA, AG1478, an inhibitor of EGFR, U0126, an inhibitor of MEK, and the exogenous expression of dominant negative-MEK.	U 0126	137-142	epidermal growth factor	Homo sapiens	53-56
22546605-10	2012	The promoter activity of human claudin-2 was decreased by AG1478 and U0126.	U 0126	69-74	claudin 2	Homo sapiens	31-40
22261330-7	2012	Furthermore, Immunoblotting studies revealed that HGF induced phosphorylation of ERK, and pre-treatment with U0126, a MAPK/ERK inhibitor, partially inhibited hHGF-induced increase in AQP3 expression.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	81-84
22261330-7	2012	Furthermore, Immunoblotting studies revealed that HGF induced phosphorylation of ERK, and pre-treatment with U0126, a MAPK/ERK inhibitor, partially inhibited hHGF-induced increase in AQP3 expression.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	118-122
22261330-7	2012	Furthermore, Immunoblotting studies revealed that HGF induced phosphorylation of ERK, and pre-treatment with U0126, a MAPK/ERK inhibitor, partially inhibited hHGF-induced increase in AQP3 expression.	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	123-126
22261330-7	2012	Furthermore, Immunoblotting studies revealed that HGF induced phosphorylation of ERK, and pre-treatment with U0126, a MAPK/ERK inhibitor, partially inhibited hHGF-induced increase in AQP3 expression.	U 0126	109-114	aquaporin 3 (Gill blood group)	Homo sapiens	183-187
22407386-8	2012	However, the presence of U0126, a selective inhibitor of ERK1/2, blocked the induction of Runx2 and subsequent osteogenic events.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	57-63
22407386-8	2012	However, the presence of U0126, a selective inhibitor of ERK1/2, blocked the induction of Runx2 and subsequent osteogenic events.	U 0126	25-30	RUNX family transcription factor 2	Homo sapiens	90-95
22593575-14	2012	In contrast, pioglitazone and/or U0126 increased LDLR protein expression and membrane translocation, SREBP2 processing, and CYP7A1 expression in the liver, which led to decreased total and LDL cholesterol levels in serum.	U 0126	33-38	low density lipoprotein receptor	Homo sapiens	49-53
22593575-14	2012	In contrast, pioglitazone and/or U0126 increased LDLR protein expression and membrane translocation, SREBP2 processing, and CYP7A1 expression in the liver, which led to decreased total and LDL cholesterol levels in serum.	U 0126	33-38	sterol regulatory element binding transcription factor 2	Homo sapiens	101-107
22593575-14	2012	In contrast, pioglitazone and/or U0126 increased LDLR protein expression and membrane translocation, SREBP2 processing, and CYP7A1 expression in the liver, which led to decreased total and LDL cholesterol levels in serum.	U 0126	33-38	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	124-130
22919733-12	2012	U0126, a specific MAP kinase (MEK1/2) inhibitor, blocked the ERK1/2 activation by MBS.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
22919733-12	2012	U0126, a specific MAP kinase (MEK1/2) inhibitor, blocked the ERK1/2 activation by MBS.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	61-67
22919733-12	2012	U0126, a specific MAP kinase (MEK1/2) inhibitor, blocked the ERK1/2 activation by MBS.	U 0126	0-5	MBS1	Homo sapiens	82-85
22678786-5	2012	RESULTS: After treated with U0126, P-ERK1/2 was decreased along with the increased U0126 concentration.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	37-43
22678786-6	2012	P-ERK1/2 and P-gp were apparently down-regulated by U0126 at the concentrations of 20 mumol/L, 40 mumol/L and 60 mumol/L.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	2-8
22678786-6	2012	P-ERK1/2 and P-gp were apparently down-regulated by U0126 at the concentrations of 20 mumol/L, 40 mumol/L and 60 mumol/L.	U 0126	52-57	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
22560902-4	2012	In this paper, we show that the MEK inhibitor U0126 induces flattened morphology, remodels the actin-based cytoskeleton, and potently inhibits chemotaxis and Matrigel invasion in the human lung cancer A549 cell line.	U 0126	46-51	mitogen-activated protein kinase kinase 7	Homo sapiens	32-35
22613074-12	2012	Particularly, IL-32alpha -induced TNFalpha, but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific inhibitors of nuclear factor kappa B (NFkappaB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively.	U 0126	127-132	tumor necrosis factor	Mus musculus	34-42
22613074-12	2012	Particularly, IL-32alpha -induced TNFalpha, but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific inhibitors of nuclear factor kappa B (NFkappaB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively.	U 0126	127-132	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	167-189
22613074-12	2012	Particularly, IL-32alpha -induced TNFalpha, but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific inhibitors of nuclear factor kappa B (NFkappaB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively.	U 0126	127-132	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	191-199
22613074-12	2012	Particularly, IL-32alpha -induced TNFalpha, but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific inhibitors of nuclear factor kappa B (NFkappaB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively.	U 0126	127-132	mitogen-activated protein kinase 3	Mus musculus	205-245
22613074-12	2012	Particularly, IL-32alpha -induced TNFalpha, but not IL-6 or MIP-2, was inhibited by dehydroxymethylepoxyquinomicin (DHMEQ) and U0126, which are specific inhibitors of nuclear factor kappa B (NFkappaB) and extracellular signal regulated kinase1/2 (ERK1/2), respectively.	U 0126	127-132	mitogen-activated protein kinase 3	Mus musculus	247-253
22538822-6	2012	However, the enhanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation.	U 0126	176-181	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	89-94
22538822-6	2012	However, the enhanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation.	U 0126	176-181	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	96-101
22538822-6	2012	However, the enhanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation.	U 0126	176-181	mitogen-activated protein kinase kinase 2	Homo sapiens	113-117
22538822-6	2012	However, the enhanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation.	U 0126	176-181	mitogen-activated protein kinase kinase 2	Homo sapiens	119-124
22571318-10	2012	MWCNTs caused ERK1,2 activation and inhibition of ERK1,2 (U0126) blocked MWCNT induction of COX-2 and PGE2 production, but did not reduce the induction of iNOS.	U 0126	58-63	mitogen-activated protein kinase 3	Mus musculus	50-56
22571318-10	2012	MWCNTs caused ERK1,2 activation and inhibition of ERK1,2 (U0126) blocked MWCNT induction of COX-2 and PGE2 production, but did not reduce the induction of iNOS.	U 0126	58-63	prostaglandin-endoperoxide synthase 2	Mus musculus	92-97
22543708-9	2012	The MAPK pathway inhibitors U0126 and PD98059 at the concentrations of 5 and 10 mumol/L inhibited invasion and metastasis of Bel-7402 cells induced by Shh, and decreased the expression of p-ERK1/2 and MMP-9.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	4-8
22543708-9	2012	The MAPK pathway inhibitors U0126 and PD98059 at the concentrations of 5 and 10 mumol/L inhibited invasion and metastasis of Bel-7402 cells induced by Shh, and decreased the expression of p-ERK1/2 and MMP-9.	U 0126	28-33	sonic hedgehog signaling molecule	Homo sapiens	151-154
22543708-9	2012	The MAPK pathway inhibitors U0126 and PD98059 at the concentrations of 5 and 10 mumol/L inhibited invasion and metastasis of Bel-7402 cells induced by Shh, and decreased the expression of p-ERK1/2 and MMP-9.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	190-196
22543708-9	2012	The MAPK pathway inhibitors U0126 and PD98059 at the concentrations of 5 and 10 mumol/L inhibited invasion and metastasis of Bel-7402 cells induced by Shh, and decreased the expression of p-ERK1/2 and MMP-9.	U 0126	28-33	matrix metallopeptidase 9	Homo sapiens	201-206
22103431-7	2012	Inhibition of ERK activation using either PD98059 [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] or U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) had no impact on Abeta production, and knockdown of endogenous GCS using small interfering RNA reduced cellular GSL levels without suppressing Abeta production or pERK formation.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	14-17
22103431-7	2012	Inhibition of ERK activation using either PD98059 [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] or U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) had no impact on Abeta production, and knockdown of endogenous GCS using small interfering RNA reduced cellular GSL levels without suppressing Abeta production or pERK formation.	U 0126	112-172	mitogen-activated protein kinase 1	Homo sapiens	14-17
22595112-12	2012	In addition, CpG ODN-induced IL-8 expression was markedly suppressed by U0126, but not by SB203580 and SP600125.	U 0126	72-77	chemokine (C-X-C motif) ligand 15	Mus musculus	29-33
22269118-10	2012	The ERK inhibitor U0126 almost completely abrogates TCR-induced cell death and, importantly, reverses the sensitizing effect of the NTAL protein on methylprednisolone-induced cell death.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
22269118-10	2012	The ERK inhibitor U0126 almost completely abrogates TCR-induced cell death and, importantly, reverses the sensitizing effect of the NTAL protein on methylprednisolone-induced cell death.	U 0126	18-23	linker for activation of T cells family member 2	Homo sapiens	132-136
22678010-7	2012	The MEK inhibitor, U0126, was used to inhibit ERK activation.	U 0126	19-24	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
22678010-7	2012	The MEK inhibitor, U0126, was used to inhibit ERK activation.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	46-49
22678010-11	2012	Cyclin D1 mRNA and protein concentrations in serum-stimulated podocytes were reduced after blocking ERK activation by U0126.	U 0126	118-123	cyclin D1	Homo sapiens	0-9
22678010-11	2012	Cyclin D1 mRNA and protein concentrations in serum-stimulated podocytes were reduced after blocking ERK activation by U0126.	U 0126	118-123	mitogen-activated protein kinase 1	Homo sapiens	100-103
22313459-5	2012	We confirmed the significant induction of EC-SOD in a TPA time-dependent manner, and that induction was completely blocked by pre-treatment with GF109203X, an inhibitor of protein kinase C, U0126 and PD98059, inhibitors of mitogen-activated protein kinase kinase/extracellular-signal regulated kinase.	U 0126	190-195	superoxide dismutase 3	Homo sapiens	42-48
22387281-7	2012	Blockage of ERK by the inhibitor U0126 or inhibition of NF-kappaB p65 by siRNA or Bay 11-7082 prevented the increases in miR-21 and the decreases in Spry1, Pten, and Pdcd4, the target proteins of miR-21, induced by arsenite.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	12-15
22387281-7	2012	Blockage of ERK by the inhibitor U0126 or inhibition of NF-kappaB p65 by siRNA or Bay 11-7082 prevented the increases in miR-21 and the decreases in Spry1, Pten, and Pdcd4, the target proteins of miR-21, induced by arsenite.	U 0126	33-38	microRNA 21	Homo sapiens	121-127
22294087-7	2012	Pretreatment of JEG-3 cells with a specific MAPK inhibitor (UO126) inhibited progesterone"s inhibitory effect on cell death.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	44-48
22461694-8	2012	Inhibition of MEK1/2 activity using PD98059 and U0126 reduced Fra-1 expression, DNA binding, MMP-9 promoter drive, and MMP-9 protein production.	U 0126	48-53	matrix metallopeptidase 9	Homo sapiens	93-98
21940036-10	2012	Furthermore, MEK1/2 inhibitor UO126 reversed the mesenchymal phenotype.	U 0126	30-35	mitogen-activated protein kinase kinase 1	Homo sapiens	13-19
21751216-7	2012	The effect of these factors on the differentiation of hFHPCs may be blocked by U0126, an inhibitor of the ERK1/2 signaling pathway.	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	106-112
22461694-8	2012	Inhibition of MEK1/2 activity using PD98059 and U0126 reduced Fra-1 expression, DNA binding, MMP-9 promoter drive, and MMP-9 protein production.	U 0126	48-53	matrix metallopeptidase 9	Homo sapiens	119-124
22116522-8	2012	In the mean time, reducing Erbin expression enhanced ERK phosphorylation, promoted the E-cadherin suppression, and induced alpha-SMA expression and fibronection secretion in response to TGF-beta1, which could be rescued if cells were treated with the inhibitor of MEK1/2 U0126.	U 0126	271-276	erbb2 interacting protein	Rattus norvegicus	27-32
22116522-8	2012	In the mean time, reducing Erbin expression enhanced ERK phosphorylation, promoted the E-cadherin suppression, and induced alpha-SMA expression and fibronection secretion in response to TGF-beta1, which could be rescued if cells were treated with the inhibitor of MEK1/2 U0126.	U 0126	271-276	transforming growth factor, beta 1	Rattus norvegicus	186-195
22285838-9	2012	Treatment of cells with the specific MEK1 inhibitor PD98059 or U0126 suppressed ERK1/2 phosphorylation and TGF-beta1 expression, and completely restored the level of STAT3 (Tyr705) phosphorylation in MAPCs cultured in HG media.	U 0126	63-68	mitogen activated protein kinase kinase 1	Rattus norvegicus	37-41
22396455-9	2012	Finally, pretreatment of the cells with either U0126 (ERK1/2 inhibitor) or ICI 182 780 (ER antagonist) blocked the upregulation of OBR by E(2) and prevented the E(2)-induced phosphorylation of ERK.	U 0126	47-52	mitogen-activated protein kinase 3	Mus musculus	54-60
22396455-9	2012	Finally, pretreatment of the cells with either U0126 (ERK1/2 inhibitor) or ICI 182 780 (ER antagonist) blocked the upregulation of OBR by E(2) and prevented the E(2)-induced phosphorylation of ERK.	U 0126	47-52	leptin receptor	Mus musculus	131-134
22396455-9	2012	Finally, pretreatment of the cells with either U0126 (ERK1/2 inhibitor) or ICI 182 780 (ER antagonist) blocked the upregulation of OBR by E(2) and prevented the E(2)-induced phosphorylation of ERK.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	54-57
22294037-9	2012	The inhibition by nocodazole of TNF-alpha-induced p38 activation was abolished by ERK-specific inhibitor U0126.	U 0126	105-110	tumor necrosis factor	Homo sapiens	32-41
22294037-9	2012	The inhibition by nocodazole of TNF-alpha-induced p38 activation was abolished by ERK-specific inhibitor U0126.	U 0126	105-110	mitogen-activated protein kinase 14	Homo sapiens	50-53
22294037-9	2012	The inhibition by nocodazole of TNF-alpha-induced p38 activation was abolished by ERK-specific inhibitor U0126.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	82-85
22387236-9	2012	The MEK1 inhibitor U0126 or siRNA-mediated knockdown of TrkC abolished the NT-3-induced upregulation of NGF in astrocytes.	U 0126	19-24	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-8
22387236-9	2012	The MEK1 inhibitor U0126 or siRNA-mediated knockdown of TrkC abolished the NT-3-induced upregulation of NGF in astrocytes.	U 0126	19-24	neurotrophin 3	Rattus norvegicus	75-79
22387236-9	2012	The MEK1 inhibitor U0126 or siRNA-mediated knockdown of TrkC abolished the NT-3-induced upregulation of NGF in astrocytes.	U 0126	19-24	nerve growth factor	Rattus norvegicus	104-107
22228200-5	2012	CHPG and CDPPB enhanced the activation of ERK after traumatic neuronal injury, and PD98059 and U0126, two selective MEK/ERK inhibitors, partly revised the protective effects.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	116-119
22228200-5	2012	CHPG and CDPPB enhanced the activation of ERK after traumatic neuronal injury, and PD98059 and U0126, two selective MEK/ERK inhibitors, partly revised the protective effects.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	120-123
22327383-5	2012	The MEK inhibitor U0126 downregulated             p-ERK, p-IkappaBalpha and p65 levels in SW620 cells.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
22327383-5	2012	The MEK inhibitor U0126 downregulated             p-ERK, p-IkappaBalpha and p65 levels in SW620 cells.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	52-55
22327383-5	2012	The MEK inhibitor U0126 downregulated             p-ERK, p-IkappaBalpha and p65 levels in SW620 cells.	U 0126	18-23	RELA proto-oncogene, NF-kB subunit	Homo sapiens	76-79
22329895-12	2012	These protective effects of urotensin II were abolished by prior inhibition of phosphatidylinositol 3-kinase/Akt by LY294002 (2-[4-morpholinyl]-8-phenyl-4H-1-benzopyran-4-one), and ERK by U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene).	U 0126	188-193	urotensin 2	Rattus norvegicus	28-40
22329895-12	2012	These protective effects of urotensin II were abolished by prior inhibition of phosphatidylinositol 3-kinase/Akt by LY294002 (2-[4-morpholinyl]-8-phenyl-4H-1-benzopyran-4-one), and ERK by U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene).	U 0126	195-255	urotensin 2	Rattus norvegicus	28-40
22425775-7	2012	The ErbB2 inhibitor AG825 and the MEK1/2 inhibitor U0126 also partly inhibit the enhanced migration and invasion.	U 0126	51-56	mitogen-activated protein kinase kinase 1	Homo sapiens	34-40
22337876-5	2012	These phenotypic changes are mediated in large part by the ERK-MAPK pathway, as the MEK inhibitor U0126 and shRNA-mediated knockdown of ERK2 significantly reversed these phenotypes.	U 0126	98-103	mitogen-activated protein kinase 1	Homo sapiens	59-62
22337876-5	2012	These phenotypic changes are mediated in large part by the ERK-MAPK pathway, as the MEK inhibitor U0126 and shRNA-mediated knockdown of ERK2 significantly reversed these phenotypes.	U 0126	98-103	mitogen-activated protein kinase 1	Homo sapiens	63-67
22337876-5	2012	These phenotypic changes are mediated in large part by the ERK-MAPK pathway, as the MEK inhibitor U0126 and shRNA-mediated knockdown of ERK2 significantly reversed these phenotypes.	U 0126	98-103	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
22198514-8	2012	Specific ERK1/2 inhibitors (SB386023 and U0126) and an NF-kappaB inhibitor (wedelolactone) attenuated the mmLDL-increased ET(B) receptor-mediated contraction and ET(B) receptor mRNA and protein levels.	U 0126	41-46	mitogen activated protein kinase 3	Rattus norvegicus	9-15
22198514-8	2012	Specific ERK1/2 inhibitors (SB386023 and U0126) and an NF-kappaB inhibitor (wedelolactone) attenuated the mmLDL-increased ET(B) receptor-mediated contraction and ET(B) receptor mRNA and protein levels.	U 0126	41-46	endothelin receptor type B	Rattus norvegicus	122-127
22198514-8	2012	Specific ERK1/2 inhibitors (SB386023 and U0126) and an NF-kappaB inhibitor (wedelolactone) attenuated the mmLDL-increased ET(B) receptor-mediated contraction and ET(B) receptor mRNA and protein levels.	U 0126	41-46	endothelin receptor type B	Rattus norvegicus	162-167
22298641-5	2012	Inhibition of JNK (with SP600125) or Erk1/2 (with U0126) partially prevented curcumin-induced cell death in the cells.	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	37-43
22182511-10	2012	In conclusion, data obtained by solely using the MEK inhibitor U0126 have to be carefully corroborated by using more selective inhibitors, such as PD0325901 or PD184352.	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
22613593-3	2012	METHODS: Primary human OBs and osteoclast-like cells were cultured and, we pretreated OBs with or without U0126 (a highly selective inhibitor of both MEK1 and MEK2).	U 0126	106-111	mitogen-activated protein kinase kinase 1	Homo sapiens	150-154
22613593-8	2012	Within the effective concentration range, the expression of phosphor-ERK1/2 and osteoprotegerin was increased by DHEA and blocked by U0126.	U 0126	133-138	mitogen-activated protein kinase 3	Homo sapiens	69-75
22613593-8	2012	Within the effective concentration range, the expression of phosphor-ERK1/2 and osteoprotegerin was increased by DHEA and blocked by U0126.	U 0126	133-138	TNF receptor superfamily member 11b	Homo sapiens	80-95
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	23-30
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	interleukin 12b	Mus musculus	59-67
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	interleukin 6	Mus musculus	69-73
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	mast cell protease 1	Mus musculus	75-80
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	intercellular adhesion molecule 1	Mus musculus	82-88
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	vascular cell adhesion molecule 1	Mus musculus	94-100
22135239-12	2012	Finally, a specific ERK1/2 inhibitor, UO126, blocked leptin-induced ERs regulation in ATDC5 cells, indicating that ERK1/2 mediates, partly, the effects of leptin on ERs.	U 0126	38-43	mitogen-activated protein kinase 3	Mus musculus	20-26
22285838-9	2012	Treatment of cells with the specific MEK1 inhibitor PD98059 or U0126 suppressed ERK1/2 phosphorylation and TGF-beta1 expression, and completely restored the level of STAT3 (Tyr705) phosphorylation in MAPCs cultured in HG media.	U 0126	63-68	mitogen activated protein kinase 3	Rattus norvegicus	80-86
22285838-9	2012	Treatment of cells with the specific MEK1 inhibitor PD98059 or U0126 suppressed ERK1/2 phosphorylation and TGF-beta1 expression, and completely restored the level of STAT3 (Tyr705) phosphorylation in MAPCs cultured in HG media.	U 0126	63-68	transforming growth factor, beta 1	Rattus norvegicus	107-116
22285838-9	2012	Treatment of cells with the specific MEK1 inhibitor PD98059 or U0126 suppressed ERK1/2 phosphorylation and TGF-beta1 expression, and completely restored the level of STAT3 (Tyr705) phosphorylation in MAPCs cultured in HG media.	U 0126	63-68	signal transducer and activator of transcription 3	Rattus norvegicus	166-171
21713404-6	2012	In addition, EMT was reversed by PI3K inhibitor LY294002 and MEK1/2 inhibitor U0126, which suggested that A549 cells under stimulation of TGF-beta1 undergo a switch into mesenchymal cells and PI3K/Akt and MAPK/Erk1/2 signaling pathways serve to regulate TGF-beta1-induced EMT of A549 cells.	U 0126	78-83	mitogen-activated protein kinase kinase 1	Homo sapiens	61-67
22286127-6	2012	NBP enhanced phosphorylation of ERK1/2 and fibroblast growth factor receptor 2 expression, which were inhibited by U0126.	U 0126	115-120	NUBP iron-sulfur cluster assembly factor 1, cytosolic	Homo sapiens	0-3
22286127-6	2012	NBP enhanced phosphorylation of ERK1/2 and fibroblast growth factor receptor 2 expression, which were inhibited by U0126.	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	32-38
22286127-6	2012	NBP enhanced phosphorylation of ERK1/2 and fibroblast growth factor receptor 2 expression, which were inhibited by U0126.	U 0126	115-120	fibroblast growth factor receptor 2	Homo sapiens	43-78
21713404-6	2012	In addition, EMT was reversed by PI3K inhibitor LY294002 and MEK1/2 inhibitor U0126, which suggested that A549 cells under stimulation of TGF-beta1 undergo a switch into mesenchymal cells and PI3K/Akt and MAPK/Erk1/2 signaling pathways serve to regulate TGF-beta1-induced EMT of A549 cells.	U 0126	78-83	transforming growth factor beta 1	Homo sapiens	138-147
22169949-8	2012	Furthermore, co-treatment with sub-effective dose of U0126, a mitogen-activated protein kinase inhibitor, blocked the upregulation of ERK phosphorylation and impaired memory retrieval, and bicuculline methiodide (BMI), a GABA(A) receptor antagonist, increased ERK phosphorylation induced by the retention trial and facilitated memory retrieval.	U 0126	53-58	mitogen-activated protein kinase 1	Mus musculus	134-137
21896500-7	2012	Levels of phosphorylated extracellular signal-regulated kinase 1 and 2 (p-ERK1/2) were restored by retroviral infection of mitogen-activated protein kinase (MEK) 1/2 and reduced by U0126 in PECs exposed to high albumin levels in culture and apoptosis measured by Hoechst staining.	U 0126	181-186	mitogen activated protein kinase 3	Rattus norvegicus	25-70
21896500-7	2012	Levels of phosphorylated extracellular signal-regulated kinase 1 and 2 (p-ERK1/2) were restored by retroviral infection of mitogen-activated protein kinase (MEK) 1/2 and reduced by U0126 in PECs exposed to high albumin levels in culture and apoptosis measured by Hoechst staining.	U 0126	181-186	mitogen activated protein kinase 3	Rattus norvegicus	74-80
21896500-7	2012	Levels of phosphorylated extracellular signal-regulated kinase 1 and 2 (p-ERK1/2) were restored by retroviral infection of mitogen-activated protein kinase (MEK) 1/2 and reduced by U0126 in PECs exposed to high albumin levels in culture and apoptosis measured by Hoechst staining.	U 0126	181-186	albumin	Rattus norvegicus	211-218
22449977-4	2012	Finally, the E2-induced effects could also be significantly suppressed by BAPTA or U0126, indicating involvement of calcium/ERK signaling.	U 0126	83-88	mitogen-activated protein kinase 1	Homo sapiens	124-127
22189943-4	2012	Treatment of HUVEC with UA and a calcium mobilization inhibitor (TMB-8) or a MEK/Erk pathway inhibitor (U0126) prevented translocation of HMGB1 from the nucleus, resulting in reduced cytoplasmic and circulating levels of HMGB1.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
22189943-4	2012	Treatment of HUVEC with UA and a calcium mobilization inhibitor (TMB-8) or a MEK/Erk pathway inhibitor (U0126) prevented translocation of HMGB1 from the nucleus, resulting in reduced cytoplasmic and circulating levels of HMGB1.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	81-84
22189943-4	2012	Treatment of HUVEC with UA and a calcium mobilization inhibitor (TMB-8) or a MEK/Erk pathway inhibitor (U0126) prevented translocation of HMGB1 from the nucleus, resulting in reduced cytoplasmic and circulating levels of HMGB1.	U 0126	104-109	high mobility group box 1	Homo sapiens	138-143
22189943-4	2012	Treatment of HUVEC with UA and a calcium mobilization inhibitor (TMB-8) or a MEK/Erk pathway inhibitor (U0126) prevented translocation of HMGB1 from the nucleus, resulting in reduced cytoplasmic and circulating levels of HMGB1.	U 0126	104-109	high mobility group box 1	Homo sapiens	221-226
22326785-10	2012	Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP.	U 0126	10-15	mitogen-activated protein kinase kinase 1	Mus musculus	19-68
22326785-10	2012	Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP.	U 0126	10-15	matrix metallopeptidase 13	Mus musculus	272-277
22326785-10	2012	Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP.	U 0126	10-15	matrix metallopeptidase 2	Mus musculus	279-284
22326785-10	2012	Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP.	U 0126	10-15	matrix metallopeptidase 9	Mus musculus	286-291
22326785-10	2012	Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP.	U 0126	10-15	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	297-304
21973306-9	2012	In contrast, U0126, a MKK1/2 inhibitor, augmented the cytotoxic effect and the down-regulation of TP by curcumin and MMC.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	22-28
22198505-8	2012	CONCLUSION: By performing a focused screen of chemical agents, we were able to show a distinct response of a genetic model of hypertrophic cardiomyopathy to the histone deacetylase inhibitor, Trichostatin A, and the mitogen-activated protein kinase kinase 1/2 inhibitor, U0126.	U 0126	271-276	mitogen-activated protein kinase kinase 1	Danio rerio	216-259
22313325-7	2012	U0126 (MAPK/extracellular-signal-regulated kinase (ERK) inhibitor) abrogated MAPK phosphorylation, caused by estradiol via c-ERbeta, more effectively than ICI 182780 (ER blocker) in either cell line.	U 0126	0-5	estrogen receptor 2	Homo sapiens	125-131
22147656-8	2012	Western blot analysis of extracellular signal-regulated kinase (ERK 1/2) phosphorylation and experiments with the MEK inhibitor U0126 indicated a specific mechanistic role of the ERK cascade in lipoprotein-mediated steroid hormone release.	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	114-117
22252084-13	2012	Cells pre-treated with U0126 and SP600125 were rescued from the GnRH antagonist-mediated inhibition of cell growth and did not exhibit GnRH antagonist-induced apoptosis and downstream GADD45alpha signaling.	U 0126	23-28	gonadotropin releasing hormone 1	Homo sapiens	64-68
22238304-6	2012	This effect of ORF12 protein was markedly inhibited by a MAPK/ERK kinase 1 and 2 (MEK1/2) inhibitor (U0126), partially blocked by a p38 inhibitor (SB202190), but not inhibited by a JNK inhibitor (SP600125).	U 0126	101-106	tegument protein VP11/12	Human alphaherpesvirus 3	15-20
22238304-6	2012	This effect of ORF12 protein was markedly inhibited by a MAPK/ERK kinase 1 and 2 (MEK1/2) inhibitor (U0126), partially blocked by a p38 inhibitor (SB202190), but not inhibited by a JNK inhibitor (SP600125).	U 0126	101-106	mitogen-activated protein kinase 3	Homo sapiens	57-61
22238304-6	2012	This effect of ORF12 protein was markedly inhibited by a MAPK/ERK kinase 1 and 2 (MEK1/2) inhibitor (U0126), partially blocked by a p38 inhibitor (SB202190), but not inhibited by a JNK inhibitor (SP600125).	U 0126	101-106	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
22005047-11	2012	MIF-induced potentiation of phenylephrine-evoked constriction was partially inhibited by PKC inhibitor chelerythrine, p38 inhibitor SB 203580, ERK1/2 inhibitor U0126, respectively.	U 0126	160-165	macrophage migration inhibitory factor	Rattus norvegicus	0-3
22252323-4	2012	Inhibition of VPS4B function by short hairpin VPS4B (sh-VPS4B) or expression of dominant negative VPS4B(E235Q) promotes anchorage-independent breast cancer cell growth and resistance to gefitinib, U0126, and genotoxicity.	U 0126	197-202	vacuolar protein sorting 4 homolog B	Homo sapiens	14-19
21161531-6	2012	Furthermore, IL-6 and IL-8 expression was quantified by real-time polymerase chain reaction (RT-PCR) and ELISAs from cells which were exposed to SB203580, U0126 and NaHS and stimulated by IL-1beta.	U 0126	155-160	interleukin 6	Homo sapiens	13-17
22135239-12	2012	Finally, a specific ERK1/2 inhibitor, UO126, blocked leptin-induced ERs regulation in ATDC5 cells, indicating that ERK1/2 mediates, partly, the effects of leptin on ERs.	U 0126	38-43	mitogen-activated protein kinase 3	Mus musculus	115-121
22198183-8	2012	Silencing ERK1/2 using siRNAs and the MEK/ERK inhibitor U0126 attenuated the radiation-induced phosphorylation of GSK3beta and altered the protein levels of Snail, alpha-SMA, and E-cadherin in RLE-6TN cells.	U 0126	56-61	mitogen activated protein kinase 3	Rattus norvegicus	10-16
22198183-8	2012	Silencing ERK1/2 using siRNAs and the MEK/ERK inhibitor U0126 attenuated the radiation-induced phosphorylation of GSK3beta and altered the protein levels of Snail, alpha-SMA, and E-cadherin in RLE-6TN cells.	U 0126	56-61	Eph receptor B1	Rattus norvegicus	10-13
22198183-8	2012	Silencing ERK1/2 using siRNAs and the MEK/ERK inhibitor U0126 attenuated the radiation-induced phosphorylation of GSK3beta and altered the protein levels of Snail, alpha-SMA, and E-cadherin in RLE-6TN cells.	U 0126	56-61	glycogen synthase kinase 3 beta	Rattus norvegicus	114-122
22198183-8	2012	Silencing ERK1/2 using siRNAs and the MEK/ERK inhibitor U0126 attenuated the radiation-induced phosphorylation of GSK3beta and altered the protein levels of Snail, alpha-SMA, and E-cadherin in RLE-6TN cells.	U 0126	56-61	actin gamma 2, smooth muscle	Rattus norvegicus	164-173
22198183-8	2012	Silencing ERK1/2 using siRNAs and the MEK/ERK inhibitor U0126 attenuated the radiation-induced phosphorylation of GSK3beta and altered the protein levels of Snail, alpha-SMA, and E-cadherin in RLE-6TN cells.	U 0126	56-61	cadherin 1	Rattus norvegicus	179-189
22401294-11	2012	Finally, we also observed that the efficacy of ATP-competitive inhibitors of mTOR was enhanced by U0126, a MEK inhibitor.	U 0126	98-103	mechanistic target of rapamycin kinase	Homo sapiens	77-81
22401294-11	2012	Finally, we also observed that the efficacy of ATP-competitive inhibitors of mTOR was enhanced by U0126, a MEK inhibitor.	U 0126	98-103	mitogen-activated protein kinase kinase 7	Homo sapiens	107-110
22329800-10	2012	Furthermore, c-Fos shRNA (short hairpin RNA) and AP-1 inhibitors/antagonists (U0126 and Tanshinone IIA) inhibited endogenous AKR1B10 expression and promoter activity in HepG2 cells cultured in vitro or inoculated subcutaneously in nude mice.	U 0126	78-83	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	13-18
22329800-10	2012	Furthermore, c-Fos shRNA (short hairpin RNA) and AP-1 inhibitors/antagonists (U0126 and Tanshinone IIA) inhibited endogenous AKR1B10 expression and promoter activity in HepG2 cells cultured in vitro or inoculated subcutaneously in nude mice.	U 0126	78-83	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	49-53
22329800-10	2012	Furthermore, c-Fos shRNA (short hairpin RNA) and AP-1 inhibitors/antagonists (U0126 and Tanshinone IIA) inhibited endogenous AKR1B10 expression and promoter activity in HepG2 cells cultured in vitro or inoculated subcutaneously in nude mice.	U 0126	78-83	aldo-keto reductase family 1 member B10	Homo sapiens	125-132
22329800-11	2012	U0126 also inhibited AKR1B10 expression induced by EGF.	U 0126	0-5	aldo-keto reductase family 1 member B10	Homo sapiens	21-28
22329800-11	2012	U0126 also inhibited AKR1B10 expression induced by EGF.	U 0126	0-5	epidermal growth factor	Homo sapiens	51-54
21913902-8	2012	They both increased phosphorylation of ERK1/2, and U0126 fully abolished these effects on ERK1/2 in H295 cells.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	90-96
21913902-9	2012	Furthermore, U0126 reversed the inhibitory effects of bufalin and cinobufagin on StAR protein expression and the binding of SF-1 to StAR gene promoter.	U 0126	13-18	steroidogenic acute regulatory protein	Homo sapiens	81-85
21913902-9	2012	Furthermore, U0126 reversed the inhibitory effects of bufalin and cinobufagin on StAR protein expression and the binding of SF-1 to StAR gene promoter.	U 0126	13-18	splicing factor 1	Homo sapiens	124-128
21913902-9	2012	Furthermore, U0126 reversed the inhibitory effects of bufalin and cinobufagin on StAR protein expression and the binding of SF-1 to StAR gene promoter.	U 0126	13-18	steroidogenic acute regulatory protein	Homo sapiens	132-136
22142512-7	2012	Our results showed that CRP markedly activated c-Raf/MEK/ERK and JAK1/ERK signaling pathways but not JAK1/STAT3 signaling pathway by using the phosphor-specific antibodies against these pathways, and blockages of c-Raf/MEK/ERK and JAK1/ERK signaling pathways by the specific ERK1/2 inhibitor U0126 and JAK1 inhibitor piceatannol could significantly decrease CRP-induced MMP-10 expression.	U 0126	292-297	C-reactive protein	Homo sapiens	24-27
22142512-7	2012	Our results showed that CRP markedly activated c-Raf/MEK/ERK and JAK1/ERK signaling pathways but not JAK1/STAT3 signaling pathway by using the phosphor-specific antibodies against these pathways, and blockages of c-Raf/MEK/ERK and JAK1/ERK signaling pathways by the specific ERK1/2 inhibitor U0126 and JAK1 inhibitor piceatannol could significantly decrease CRP-induced MMP-10 expression.	U 0126	292-297	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	47-52
22613537-7	2012	Specific inhibitor U0126 was used to block ERK/MAPK signal pathway, the alteration of HIF-1alpha and the related MDR proteins were investigated.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	43-46
22613537-7	2012	Specific inhibitor U0126 was used to block ERK/MAPK signal pathway, the alteration of HIF-1alpha and the related MDR proteins were investigated.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	47-51
22025280-4	2012	We determined             the effects of S-nitrosoglutathione (GSNO, NO-donor) and U0126 (MEK inhibitor)             on insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) signaling,             proliferation and invasion in cancer cell lines.	U 0126	83-88	insulin like growth factor 1	Homo sapiens	120-148
22025280-4	2012	We determined             the effects of S-nitrosoglutathione (GSNO, NO-donor) and U0126 (MEK inhibitor)             on insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) signaling,             proliferation and invasion in cancer cell lines.	U 0126	83-88	insulin like growth factor 1	Homo sapiens	150-155
22025280-6	2012	On the other hand, U0126 inhibits phosphorylation of ERK1/2, but upregulates             phosphorylation of IGF-IR and EGFR in MIAPaCa-2 and HCT-116 cells.	U 0126	19-24	mitogen-activated protein kinase 3	Homo sapiens	53-59
22025280-6	2012	On the other hand, U0126 inhibits phosphorylation of ERK1/2, but upregulates             phosphorylation of IGF-IR and EGFR in MIAPaCa-2 and HCT-116 cells.	U 0126	19-24	insulin like growth factor 1 receptor	Homo sapiens	108-114
22025280-6	2012	On the other hand, U0126 inhibits phosphorylation of ERK1/2, but upregulates             phosphorylation of IGF-IR and EGFR in MIAPaCa-2 and HCT-116 cells.	U 0126	19-24	epidermal growth factor receptor	Homo sapiens	119-123
22025280-7	2012	The combination             of GSNO and U0126 downregulates phosphorylation of IGF-IR, EGFR, Akt and ERK1/2             after stimulation by IGF-I and EGF.	U 0126	40-45	insulin like growth factor 1 receptor	Homo sapiens	79-85
22025280-7	2012	The combination             of GSNO and U0126 downregulates phosphorylation of IGF-IR, EGFR, Akt and ERK1/2             after stimulation by IGF-I and EGF.	U 0126	40-45	epidermal growth factor receptor	Homo sapiens	87-91
22025280-7	2012	The combination             of GSNO and U0126 downregulates phosphorylation of IGF-IR, EGFR, Akt and ERK1/2             after stimulation by IGF-I and EGF.	U 0126	40-45	AKT serine/threonine kinase 1	Homo sapiens	93-96
22025280-7	2012	The combination             of GSNO and U0126 downregulates phosphorylation of IGF-IR, EGFR, Akt and ERK1/2             after stimulation by IGF-I and EGF.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	101-107
22025280-7	2012	The combination             of GSNO and U0126 downregulates phosphorylation of IGF-IR, EGFR, Akt and ERK1/2             after stimulation by IGF-I and EGF.	U 0126	40-45	insulin like growth factor 1	Homo sapiens	79-84
22025280-7	2012	The combination             of GSNO and U0126 downregulates phosphorylation of IGF-IR, EGFR, Akt and ERK1/2             after stimulation by IGF-I and EGF.	U 0126	40-45	epidermal growth factor	Homo sapiens	87-90
22086152-7	2012	FRT liposomes loaded with carboplatin             exhibited the highest level of ERK phosphorylation, and the cytotoxic effect of             FRT carboplatin liposomes could be reversed by the MEK/ERK inhibitors, U0126 and             PD98059.	U 0126	213-218	mitogen-activated protein kinase 1	Homo sapiens	81-84
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	fibroblast growth factor 1	Homo sapiens	57-83
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	fibroblast growth factor 1	Homo sapiens	85-90
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	mitogen-activated protein kinase 1	Homo sapiens	100-153
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	mitogen-activated protein kinase 3	Homo sapiens	155-161
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	mitogen-activated protein kinase 3	Homo sapiens	182-186
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	mitogen-activated protein kinase 1	Homo sapiens	155-158
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	fibroblast growth factor 1	Homo sapiens	257-262
22108586-6	2012	In this study, we showed that suppression             of fibroblast growth factor 1 (FGF-1)-induced extracellular signal-regulated kinase             1/2 (ERK1/2) signaling with the MAPK/ERK kinase (MEK) inhibitor U0126 completely             abolished the FGF-1-induced proliferation of the ligament-derived EPC-like fibroblasts.	U 0126	214-219	enhancer of polycomb homolog 2	Homo sapiens	309-317
22108586-7	2012	In addition, U0126 treatment of FGF-1-stimulated ligament-derived EPC-like fibroblasts             significantly induced the SMC differentiation of the cells.	U 0126	13-18	fibroblast growth factor 1	Homo sapiens	32-37
22108586-7	2012	In addition, U0126 treatment of FGF-1-stimulated ligament-derived EPC-like fibroblasts             significantly induced the SMC differentiation of the cells.	U 0126	13-18	enhancer of polycomb homolog 2	Homo sapiens	66-74
22213462-8	2012	The antioxidant, MnTMPyP, and an ERK pathway inhibitor, U0126, both significantly prevented IS-induced disruption of intercellular contacts.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	33-36
22213462-11	2012	U0126 prevented the IS-induced MLCK and MLC phosphorylation.	U 0126	0-5	myosin light chain kinase	Homo sapiens	31-35
22213462-11	2012	U0126 prevented the IS-induced MLCK and MLC phosphorylation.	U 0126	0-5	modulator of VRAC current 1	Homo sapiens	31-34
22226905-6	2012	We further identified the signaling pathway of LOX-1/Ca(2+)/ROS/ERK/c-Fos was involved in oxLDL-mediated microRNA-29b overexpression after treating with the MAPTAM (Ca(2+) chelator), NAC (ROS scavenger), U0126 (ERK inhibitor) and c-Fos (one of the AP-1 proteins) shRNA, respectively.	U 0126	204-209	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	47-52
22226905-6	2012	We further identified the signaling pathway of LOX-1/Ca(2+)/ROS/ERK/c-Fos was involved in oxLDL-mediated microRNA-29b overexpression after treating with the MAPTAM (Ca(2+) chelator), NAC (ROS scavenger), U0126 (ERK inhibitor) and c-Fos (one of the AP-1 proteins) shRNA, respectively.	U 0126	204-209	mitogen-activated protein kinase 1	Mus musculus	64-67
22226905-6	2012	We further identified the signaling pathway of LOX-1/Ca(2+)/ROS/ERK/c-Fos was involved in oxLDL-mediated microRNA-29b overexpression after treating with the MAPTAM (Ca(2+) chelator), NAC (ROS scavenger), U0126 (ERK inhibitor) and c-Fos (one of the AP-1 proteins) shRNA, respectively.	U 0126	204-209	FBJ osteosarcoma oncogene	Mus musculus	68-73
22134701-6	2012	More importantly, U0126, a selective inhibitor of ERK1/2, mimicked the above cytoprotection of H(2)S against CoCl(2)-induced injury in H9c2 cells.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	50-56
22198573-8	2012	Moreover, the mGluR-LTD impairment displayed by the DeltaRG transgenic mice was rescued with the MEK-ERK inhibitor U0126.	U 0126	115-120	midkine	Mus musculus	97-100
22198573-8	2012	Moreover, the mGluR-LTD impairment displayed by the DeltaRG transgenic mice was rescued with the MEK-ERK inhibitor U0126.	U 0126	115-120	mitogen-activated protein kinase 1	Mus musculus	101-104
21161531-6	2012	Furthermore, IL-6 and IL-8 expression was quantified by real-time polymerase chain reaction (RT-PCR) and ELISAs from cells which were exposed to SB203580, U0126 and NaHS and stimulated by IL-1beta.	U 0126	155-160	C-X-C motif chemokine ligand 8	Homo sapiens	22-26
22169949-8	2012	Furthermore, co-treatment with sub-effective dose of U0126, a mitogen-activated protein kinase inhibitor, blocked the upregulation of ERK phosphorylation and impaired memory retrieval, and bicuculline methiodide (BMI), a GABA(A) receptor antagonist, increased ERK phosphorylation induced by the retention trial and facilitated memory retrieval.	U 0126	53-58	mitogen-activated protein kinase 1	Mus musculus	260-263
22138297-5	2012	FA was also found to trigger an early phosphorylation of p38 and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinases (MAPKs) in BEAS-2B cells, whose inhibition by ERK and p38 MAPK chemical inhibitors (U0126 and SB203580, respectively) counteracted FA-mediated induction of IL-11.	U 0126	230-235	mitogen-activated protein kinase 1	Homo sapiens	57-60
22157104-10	2012	Pretreatment with U0126 (ERK inhibitor) significantly suppressed the exacerbating effect of progesterone and the expression of inflammatory mediators.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	25-28
22138297-5	2012	FA was also found to trigger an early phosphorylation of p38 and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinases (MAPKs) in BEAS-2B cells, whose inhibition by ERK and p38 MAPK chemical inhibitors (U0126 and SB203580, respectively) counteracted FA-mediated induction of IL-11.	U 0126	230-235	mitogen-activated protein kinase 3	Homo sapiens	104-107
22138297-5	2012	FA was also found to trigger an early phosphorylation of p38 and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinases (MAPKs) in BEAS-2B cells, whose inhibition by ERK and p38 MAPK chemical inhibitors (U0126 and SB203580, respectively) counteracted FA-mediated induction of IL-11.	U 0126	230-235	mitogen-activated protein kinase 3	Homo sapiens	147-151
22052014-10	2012	Consistent with these data, PMA-induced Egr-1 interaction with the NHE2 promoter region was prevented in nuclear extracts from U0126-pretreated cells.	U 0126	127-132	early growth response 1	Homo sapiens	40-45
22052014-8	2012	In addition, blockade of PKCdelta by rottlerin, a PKCdelta-specific inhibitor, and ERK1/2 by U0126, a MEK-ERK inhibitor, abrogated PMA-induced Egr-1 expression.	U 0126	93-98	mitogen-activated protein kinase 3	Homo sapiens	83-89
22052014-8	2012	In addition, blockade of PKCdelta by rottlerin, a PKCdelta-specific inhibitor, and ERK1/2 by U0126, a MEK-ERK inhibitor, abrogated PMA-induced Egr-1 expression.	U 0126	93-98	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
22052014-8	2012	In addition, blockade of PKCdelta by rottlerin, a PKCdelta-specific inhibitor, and ERK1/2 by U0126, a MEK-ERK inhibitor, abrogated PMA-induced Egr-1 expression.	U 0126	93-98	mitogen-activated protein kinase 1	Homo sapiens	83-86
22052014-8	2012	In addition, blockade of PKCdelta by rottlerin, a PKCdelta-specific inhibitor, and ERK1/2 by U0126, a MEK-ERK inhibitor, abrogated PMA-induced Egr-1 expression.	U 0126	93-98	early growth response 1	Homo sapiens	143-148
22129618-6	2012	The effect of fourth ventricular administration of the ERK cascade blocker U0126 on amylin"s eating inhibitory action was tested in feeding trials.	U 0126	75-80	islet amyloid polypeptide	Rattus norvegicus	84-90
22129618-9	2012	Pretreatment of rats with U0126 decreased the number of pERK-positive neurons in the AP after amylin injection.	U 0126	26-31	islet amyloid polypeptide	Rattus norvegicus	94-100
22129618-10	2012	U0126 also attenuated the ability of amylin to reduce eating, at least when the animals had been fasted 24 h prior to the feeding trial.	U 0126	0-5	islet amyloid polypeptide	Rattus norvegicus	37-43
21839191-9	2012	The inhibition of the ERK pathway by U0126 blunted the Sr-induced PPARgamma2 repression while restoring the lipid accumulation.	U 0126	37-42	mitogen-activated protein kinase 1	Mus musculus	22-25
21839191-9	2012	The inhibition of the ERK pathway by U0126 blunted the Sr-induced PPARgamma2 repression while restoring the lipid accumulation.	U 0126	37-42	peroxisome proliferator activated receptor gamma	Mus musculus	66-76
22265865-6	2012	Amongst MAPK inhibitors, U0126, an inhibitor of MEK1/2, abrogated the EP4A-dependent effects.	U 0126	25-30	mitogen activated protein kinase kinase 1	Rattus norvegicus	48-54
21387162-12	2012	The importance of the EGFR signaling pathway in the estrogen-independent growth of ADAM12-L expressing cells was highlighted by the effect of EGFR inhibitors AG1478 and PD15035 or MAPK inhibitor U0126, each of which abolished the antiestrogen resistance in these cells.	U 0126	195-200	epidermal growth factor receptor	Homo sapiens	22-26
21387162-12	2012	The importance of the EGFR signaling pathway in the estrogen-independent growth of ADAM12-L expressing cells was highlighted by the effect of EGFR inhibitors AG1478 and PD15035 or MAPK inhibitor U0126, each of which abolished the antiestrogen resistance in these cells.	U 0126	195-200	ADAM metallopeptidase domain 12	Homo sapiens	83-89
22052014-10	2012	Consistent with these data, PMA-induced Egr-1 interaction with the NHE2 promoter region was prevented in nuclear extracts from U0126-pretreated cells.	U 0126	127-132	solute carrier family 9 member A2	Homo sapiens	67-71
22186413-9	2012	Pretreatment of mGLUTag cells with protein kinase A (H89 and protein kinase inhibitor) or MAPK kinase-ERK1/2 (PD98059 and U0126) inhibitors prevented sitagliptin-induced GLP-1 secretion (P &lt; 0.05-0.01).	U 0126	122-127	mitogen-activated protein kinase 3	Homo sapiens	90-94
22186413-9	2012	Pretreatment of mGLUTag cells with protein kinase A (H89 and protein kinase inhibitor) or MAPK kinase-ERK1/2 (PD98059 and U0126) inhibitors prevented sitagliptin-induced GLP-1 secretion (P &lt; 0.05-0.01).	U 0126	122-127	mitogen-activated protein kinase 3	Homo sapiens	102-108
22324945-11	2012	Mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) kinase (MEK)1/2 inhibitor U0126 inhibited the effect of IL-6/sIL-6R on ADAMTS-4 mRNA expression in FLS.	U 0126	108-113	mitogen-activated protein kinase kinase 1	Homo sapiens	40-97
22229442-6	2012	The stimulatory effect of AGE-BSA on MMP-9 was attenuated by inhibitors of extracellular-signal-regulated kinase (ERK1/2, U0126), p38 mitogen-activated protein kinase (MAPK, SB203580) and NF-kappaB, but not c-Jun N-terminal kinase.	U 0126	122-127	matrix metallopeptidase 9	Homo sapiens	37-42
22229442-9	2012	We also observed the involvement of NF-kappaB in AGE-BSA-induced MMP-9 activation, which was not blocked by U0126 and SB203580.	U 0126	108-113	matrix metallopeptidase 9	Homo sapiens	65-70
22085529-4	2012	Mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, UO126 and ERK inhibitor II, FR180204 blocked the Elk-1 phosphorylation and activation.	U 0126	61-66	ETS transcription factor ELK1	Homo sapiens	110-115
22324945-11	2012	Mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) kinase (MEK)1/2 inhibitor U0126 inhibited the effect of IL-6/sIL-6R on ADAMTS-4 mRNA expression in FLS.	U 0126	108-113	interleukin 6	Homo sapiens	138-142
22324945-11	2012	Mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) kinase (MEK)1/2 inhibitor U0126 inhibited the effect of IL-6/sIL-6R on ADAMTS-4 mRNA expression in FLS.	U 0126	108-113	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	153-161
22249458-7	2012	An ERK inhibitor U0126 and an antioxidant N-acetylcysteine prevented the expression and activity of beta-secretase, ERK activation, and reactive oxygen species generation in both neurons and PC12 cells expressing mutant PS2 in a dose-dependent manner.	U 0126	17-22	Eph receptor B1	Rattus norvegicus	3-6
22101421-0	2012	The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK             inhibitor U0126 in non-small cell lung cancer cells.	U 0126	90-95	mechanistic target of rapamycin kinase	Homo sapiens	20-24
22101421-0	2012	The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK             inhibitor U0126 in non-small cell lung cancer cells.	U 0126	90-95	mitogen-activated protein kinase kinase 7	Homo sapiens	64-67
22376253-4	2012	NRG-1 antibody added in conditional medium of BMSCs, si-ErbB3, and four Ras/Raf/MEK/ERK pathway inhibitors (FTS, Sulindac, U0126, and PD98059) were using to investigate the effect of AChRd levels.	U 0126	123-128	neuregulin 1	Mus musculus	0-5
22249458-7	2012	An ERK inhibitor U0126 and an antioxidant N-acetylcysteine prevented the expression and activity of beta-secretase, ERK activation, and reactive oxygen species generation in both neurons and PC12 cells expressing mutant PS2 in a dose-dependent manner.	U 0126	17-22	Eph receptor B1	Rattus norvegicus	116-119
22249458-7	2012	An ERK inhibitor U0126 and an antioxidant N-acetylcysteine prevented the expression and activity of beta-secretase, ERK activation, and reactive oxygen species generation in both neurons and PC12 cells expressing mutant PS2 in a dose-dependent manner.	U 0126	17-22	presenilin 2	Rattus norvegicus	220-223
21967732-10	2012	Treatment with a PI3-kinase inhibitor (LY-294002) or a MEK/ERK inhibitor (U0126) for 1 h prior to and during the FGF-2 treatment, each partially blocked the increased cystine uptake.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
21967732-10	2012	Treatment with a PI3-kinase inhibitor (LY-294002) or a MEK/ERK inhibitor (U0126) for 1 h prior to and during the FGF-2 treatment, each partially blocked the increased cystine uptake.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	59-62
21967732-10	2012	Treatment with a PI3-kinase inhibitor (LY-294002) or a MEK/ERK inhibitor (U0126) for 1 h prior to and during the FGF-2 treatment, each partially blocked the increased cystine uptake.	U 0126	74-79	fibroblast growth factor 2	Homo sapiens	113-118
22020547-7	2012	Our results showed that the TPA-induced up-regulation             of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor),             but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although             TPA increased the phosphorylation of ERK and JNK in MCF-7 cells.	U 0126	116-121	H3 histone pseudogene 16	Homo sapiens	69-72
22020547-7	2012	Our results showed that the TPA-induced up-regulation             of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor),             but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although             TPA increased the phosphorylation of ERK and JNK in MCF-7 cells.	U 0126	116-121	tumor protein p53	Homo sapiens	96-99
22020547-7	2012	Our results showed that the TPA-induced up-regulation             of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor),             but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although             TPA increased the phosphorylation of ERK and JNK in MCF-7 cells.	U 0126	116-121	mitogen-activated protein kinase kinase 1	Homo sapiens	125-131
22020547-7	2012	Our results showed that the TPA-induced up-regulation             of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor),             but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although             TPA increased the phosphorylation of ERK and JNK in MCF-7 cells.	U 0126	116-121	mitogen-activated protein kinase 14	Homo sapiens	209-212
22740901-10	2012	U0126, a specific inhibitor of ERK activation, decreased the rhKGF-induced phosphorylation of ERK and the growth rates of MIA PaCa-2 cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	31-34
22020547-7	2012	Our results showed that the TPA-induced up-regulation             of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor),             but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although             TPA increased the phosphorylation of ERK and JNK in MCF-7 cells.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	283-286
22740901-10	2012	U0126, a specific inhibitor of ERK activation, decreased the rhKGF-induced phosphorylation of ERK and the growth rates of MIA PaCa-2 cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	94-97
22020547-7	2012	Our results showed that the TPA-induced up-regulation             of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor),             but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although             TPA increased the phosphorylation of ERK and JNK in MCF-7 cells.	U 0126	116-121	mitogen-activated protein kinase 8	Homo sapiens	291-294
22740901-10	2012	U0126, a specific inhibitor of ERK activation, decreased the rhKGF-induced phosphorylation of ERK and the growth rates of MIA PaCa-2 cells.	U 0126	0-5	MIA SH3 domain containing	Homo sapiens	122-125
22033246-5	2012	In addition, EGF-induced MMP-9 expression was inhibited by UO126 (a MEK1/2 inhibitor) or SIS3 (a smad3 inhibitor), but not by SP600125 (a JNK inhibitor).	U 0126	59-64	epidermal growth factor	Homo sapiens	13-16
21618303-7	2012	In addition, U0126 inhibited DADS-induced MUC5B expression and DADS-activated phosphorylation of ERK1/2 MAPK.	U 0126	13-18	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	42-47
21618303-7	2012	In addition, U0126 inhibited DADS-induced MUC5B expression and DADS-activated phosphorylation of ERK1/2 MAPK.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	97-103
22512090-8	2012	Meanwhile, suppression of ERK1/2 phosphorylation by U0126 was associated with modest suppression of calcineurin activity.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	26-32
22048642-7	2012	Consistently, CSM-induced IL-8 release was blocked by SB203580, U0126, or MEK1 small interfering RNA (siRNA) but not SP600125.	U 0126	64-69	C-X-C motif chemokine ligand 8	Homo sapiens	26-30
22289259-7	2012	In addition, chondrocytes were pretreated with mitogen-activated protein kinase kinase inhibitor (U0126) prior to stimulation with eNAMPT and IGF-1.	U 0126	98-103	insulin like growth factor 1	Homo sapiens	142-147
22033246-5	2012	In addition, EGF-induced MMP-9 expression was inhibited by UO126 (a MEK1/2 inhibitor) or SIS3 (a smad3 inhibitor), but not by SP600125 (a JNK inhibitor).	U 0126	59-64	matrix metallopeptidase 9	Homo sapiens	25-30
22033246-5	2012	In addition, EGF-induced MMP-9 expression was inhibited by UO126 (a MEK1/2 inhibitor) or SIS3 (a smad3 inhibitor), but not by SP600125 (a JNK inhibitor).	U 0126	59-64	mitogen-activated protein kinase kinase 1	Homo sapiens	68-74
22056813-3	2012	This effect is mediated through a MEK/ERK-independent mechanism, since treatment with the MEK inhibitor U0126 does not exert any effect.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
22056813-3	2012	This effect is mediated through a MEK/ERK-independent mechanism, since treatment with the MEK inhibitor U0126 does not exert any effect.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	38-41
22056813-3	2012	This effect is mediated through a MEK/ERK-independent mechanism, since treatment with the MEK inhibitor U0126 does not exert any effect.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
22031604-10	2012	The specific ERK1/2 inhibitor U0126 inhibited both the ouabain-induced activation of the enzyme and the increase in cell viability.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	13-19
22273495-8	2012	The MEK inhibitor U0126 blocked IL-6-induced allodynia indicating that IL-6 produced this behavioral effect through the MAP kinase pathway.	U 0126	18-23	interleukin 6	Rattus norvegicus	32-36
22273495-8	2012	The MEK inhibitor U0126 blocked IL-6-induced allodynia indicating that IL-6 produced this behavioral effect through the MAP kinase pathway.	U 0126	18-23	interleukin 6	Rattus norvegicus	71-75
22273495-11	2012	Pretreatment with U0126 reversed hyperexcitability following IL-6 treatment.	U 0126	18-23	interleukin 6	Rattus norvegicus	61-65
21993883-9	2012	Additionally, IL-17A induced MAPK (ERK1/2 but not p38 MAPK or JNK) activation, and pharmacological inhibitors of MEK1/2 (U0126) but not of p38 MAPK (SB203580) or JNK (SP600125), significantly blocked the IL-17A-mediated G-CSF release.	U 0126	121-126	interleukin 17A	Homo sapiens	14-20
21993883-9	2012	Additionally, IL-17A induced MAPK (ERK1/2 but not p38 MAPK or JNK) activation, and pharmacological inhibitors of MEK1/2 (U0126) but not of p38 MAPK (SB203580) or JNK (SP600125), significantly blocked the IL-17A-mediated G-CSF release.	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	113-119
22119381-7	2012	Administration of U0126, an ERK1/2 inhibitor, inhibited cell growth but displayed no synergistic effect with APO866.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	28-34
23189948-6	2012	or a selective inhibitor of ERK1/2 phosphorylation by MEK1, U0126 (5 mg/kg, i.p.)	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	28-34
21849924-9	2012	Inhibition of GST by sulfasalazine, cGMP inhibition by ODQ, and MEK1/2 inhibition by UO126 attenuated the antiproliferative effect of JS-K, suggesting the involvement of various intracellular death signaling pathways.	U 0126	85-90	mitogen-activated protein kinase kinase 1	Homo sapiens	64-70
22094065-10	2012	Addition of the MEK-Inhibitor U0126 abolished the induced ERK 1/2 phosphorylation.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19
22094065-10	2012	Addition of the MEK-Inhibitor U0126 abolished the induced ERK 1/2 phosphorylation.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	58-65
22025495-11	2012	Significantly more phospho-ERK1/2-immunoreactive neurons in the superficial spinal dorsal horn were observed in the remifentanil 120-minute groups with hyperalgesia than in the 30-minute remifentanil groups without hyperalgesia, although U0126 did not suppress hyperalgesia.	U 0126	238-243	mitogen activated protein kinase 3	Rattus norvegicus	27-33
22075021-12	2012	The ratio of pERK/ERK in cerebrospinal fluid increased significantly in salvinorin-treated animals, which was inhibited by U0126.	U 0126	123-128	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	13-17
22075021-12	2012	The ratio of pERK/ERK in cerebrospinal fluid increased significantly in salvinorin-treated animals, which was inhibited by U0126.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	14-17
21993232-7	2012	Moreover, the AM-induced effect was significantly inhibited by U0126, an inhibitor of extracellular signaling-regulated kinase 1/2 (ERK1/2) signaling.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	132-138
22508063-9	2012	When PD98059, U0126 and LY294002 were pre-incubated with the cells for 30 min they diminished rPer a 7 induced reduction of TLR9 expression and IL-12 release, indicating these events are via activation of ERK and PI3K/Akt signaling pathways.	U 0126	14-19	toll-like receptor 9	Mus musculus	124-128
22739240-9	2012	The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression.	U 0126	161-166	mitogen-activated protein kinase 3	Homo sapiens	184-190
22739240-9	2012	The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression.	U 0126	161-166	mitogen-activated protein kinase kinase 1	Homo sapiens	207-213
22739240-9	2012	The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression.	U 0126	161-166	surfactant protein A1	Homo sapiens	259-263
22739240-9	2012	The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression.	U 0126	161-166	surfactant protein B	Homo sapiens	268-272
22739240-9	2012	The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression.	U 0126	161-166	surfactant protein A1	Homo sapiens	384-388
22739240-9	2012	The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression.	U 0126	161-166	surfactant protein B	Homo sapiens	413-417
22759955-5	2012	U0126, an ERK inhibitor, decreased hBMSCs proliferation and significantly blocked TNF-alpha -induced hBMSCs proliferation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
22759955-5	2012	U0126, an ERK inhibitor, decreased hBMSCs proliferation and significantly blocked TNF-alpha -induced hBMSCs proliferation.	U 0126	0-5	tumor necrosis factor	Homo sapiens	82-91
22759955-6	2012	In cells with IRAK1 or TRADD downregulation, the U0126 treatment inhibited hBMSCs proliferation and significantly suppressed TNF-alpha-induced hBMSCs proliferation.	U 0126	49-54	interleukin 1 receptor associated kinase 1	Homo sapiens	14-19
22759955-6	2012	In cells with IRAK1 or TRADD downregulation, the U0126 treatment inhibited hBMSCs proliferation and significantly suppressed TNF-alpha-induced hBMSCs proliferation.	U 0126	49-54	TNFRSF1A associated via death domain	Homo sapiens	23-28
22759955-6	2012	In cells with IRAK1 or TRADD downregulation, the U0126 treatment inhibited hBMSCs proliferation and significantly suppressed TNF-alpha-induced hBMSCs proliferation.	U 0126	49-54	tumor necrosis factor	Homo sapiens	125-134
22832115-3	2012	RESULTS: MAP kinase kinase-specific inhibitor, U0126 inhibited IL-1-induced phosphorylation of ERK1/2 and down-regulated ADAMTS-4 expression and activity.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	95-101
22832115-3	2012	RESULTS: MAP kinase kinase-specific inhibitor, U0126 inhibited IL-1-induced phosphorylation of ERK1/2 and down-regulated ADAMTS-4 expression and activity.	U 0126	47-52	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	121-129
22675954-7	2012	The increase of IL-8 stimulated by IL-1alpha or TNF-alpha was also suppressed by treatment with U0126 or SB203580.	U 0126	96-101	C-X-C motif chemokine ligand 8	Homo sapiens	16-20
22675954-7	2012	The increase of IL-8 stimulated by IL-1alpha or TNF-alpha was also suppressed by treatment with U0126 or SB203580.	U 0126	96-101	interleukin 1 alpha	Homo sapiens	35-44
22675954-7	2012	The increase of IL-8 stimulated by IL-1alpha or TNF-alpha was also suppressed by treatment with U0126 or SB203580.	U 0126	96-101	tumor necrosis factor	Homo sapiens	48-57
22827283-7	2012	Furthermore, the stress-induced increase in the expression of Cbfa1 mRNA and osteoblastic genes was inhibited by U0126, an ERK1/2 inhibitor.	U 0126	113-118	runt related transcription factor 2	Mus musculus	62-67
22827283-7	2012	Furthermore, the stress-induced increase in the expression of Cbfa1 mRNA and osteoblastic genes was inhibited by U0126, an ERK1/2 inhibitor.	U 0126	113-118	mitogen-activated protein kinase 3	Mus musculus	123-129
22064360-8	2012	Addition of pharmacological kinase inhibitors, U0126, SP600125, and LY294002, caused cytotoxicity and the last significantly attenuated NOB- and DTF-mediated antiapoptotic actions, indicating the involvement of PI3K/Akt signaling in their cytoprotective effects.	U 0126	47-52	AKT serine/threonine kinase 1	Rattus norvegicus	216-219
21945831-10	2012	The MEK1/2 inhibitors U0126 and PD98059 reversed the protective effects of COL1 and the decrease in proapoptotic proteins.	U 0126	22-27	mitogen-activated protein kinase kinase 1	Mus musculus	4-10
22009034-6	2012	Both function-blocking antibody against LfR and MEK inhibitor (U0126) resulted in inhibitory effects on apo-Lf-induced cell proliferation, whereas PI3K inhibitor (LY294002) significantly decreased both apo- and holo-Lf-induced proliferation.	U 0126	63-68	midkine	Mus musculus	48-51
22024154-7	2012	Moreover, suppression of ERK1/2 phosphorylation by the pharmacological inhibitor U0126 partially abolished the regulating effect of DJ-1 on tyrosine hydroxylase.	U 0126	81-86	mitogen-activated protein kinase 3	Homo sapiens	25-31
22024154-7	2012	Moreover, suppression of ERK1/2 phosphorylation by the pharmacological inhibitor U0126 partially abolished the regulating effect of DJ-1 on tyrosine hydroxylase.	U 0126	81-86	Parkinsonism associated deglycase	Homo sapiens	132-136
22834633-5	2012	Treatment with inhibitors of ERK (U0126) or p38 (SB203580) each reduced TNF-alpha-induced permeability in 39.5 C monolayers to levels in 37 C cells, but did not alter TNF-alpha-induced permeability in the 37 C cells.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	29-32
22834633-5	2012	Treatment with inhibitors of ERK (U0126) or p38 (SB203580) each reduced TNF-alpha-induced permeability in 39.5 C monolayers to levels in 37 C cells, but did not alter TNF-alpha-induced permeability in the 37 C cells.	U 0126	34-39	tumor necrosis factor	Homo sapiens	72-81
22312287-8	2012	In addition, the procyanidin-mediated Nrf2 expression was partly attenuated by PI3K inhibitor LY294002, and almost completely by p38 inhibitor SB202190, but neither by JNK inhibitor SP600125 nor by MEK1/2 inhibitor U0126.	U 0126	215-220	NFE2 like bZIP transcription factor 2	Homo sapiens	38-42
22942680-5	2012	Consistently, ODN MT01 induced up-regulation of osteocalcin, alkaline phosphatase (ALP) and type I collagen, which was inhibited by pre-treatment with the ERK1/2 inhibitor U0126 and the p38 inhibitor SB203580.	U 0126	172-177	bone gamma-carboxyglutamate protein	Homo sapiens	48-59
22942680-5	2012	Consistently, ODN MT01 induced up-regulation of osteocalcin, alkaline phosphatase (ALP) and type I collagen, which was inhibited by pre-treatment with the ERK1/2 inhibitor U0126 and the p38 inhibitor SB203580.	U 0126	172-177	alkaline phosphatase, placental	Homo sapiens	61-81
22942680-5	2012	Consistently, ODN MT01 induced up-regulation of osteocalcin, alkaline phosphatase (ALP) and type I collagen, which was inhibited by pre-treatment with the ERK1/2 inhibitor U0126 and the p38 inhibitor SB203580.	U 0126	172-177	alkaline phosphatase, placental	Homo sapiens	83-86
22942680-5	2012	Consistently, ODN MT01 induced up-regulation of osteocalcin, alkaline phosphatase (ALP) and type I collagen, which was inhibited by pre-treatment with the ERK1/2 inhibitor U0126 and the p38 inhibitor SB203580.	U 0126	172-177	mitogen-activated protein kinase 3	Homo sapiens	155-161
22685674-4	2012	Interestingly, TLR1 and TLR4 protein expression on ML-1 cells could be blocked by pretreatment with U0126, suggesting the role of an Erk1/2-induced differentiation signal in this process.	U 0126	100-105	toll like receptor 1	Homo sapiens	15-19
22685674-4	2012	Interestingly, TLR1 and TLR4 protein expression on ML-1 cells could be blocked by pretreatment with U0126, suggesting the role of an Erk1/2-induced differentiation signal in this process.	U 0126	100-105	toll like receptor 4	Homo sapiens	24-28
22685674-4	2012	Interestingly, TLR1 and TLR4 protein expression on ML-1 cells could be blocked by pretreatment with U0126, suggesting the role of an Erk1/2-induced differentiation signal in this process.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	133-139
22082983-6	2012	S100B-induced MCP-1 promoter activity via NF-kappaB binding sites and nuclear translocation of NF-kappaB p65 subunit were blocked by SP600125, U0126, and SB203580 in RAGE-A10.	U 0126	143-148	S100 calcium binding protein B	Rattus norvegicus	0-5
22082983-6	2012	S100B-induced MCP-1 promoter activity via NF-kappaB binding sites and nuclear translocation of NF-kappaB p65 subunit were blocked by SP600125, U0126, and SB203580 in RAGE-A10.	U 0126	143-148	C-C motif chemokine ligand 2	Rattus norvegicus	14-19
22082983-6	2012	S100B-induced MCP-1 promoter activity via NF-kappaB binding sites and nuclear translocation of NF-kappaB p65 subunit were blocked by SP600125, U0126, and SB203580 in RAGE-A10.	U 0126	143-148	advanced glycosylation end product-specific receptor	Rattus norvegicus	166-174
21678127-8	2012	In MLO-Y4 osteocytes and in MC3T3E1 and primary calvaria osteoblasts, U0126 strongly inhibited both basal expression of Dmp1 mRNA and FGF2-induced upregulation.	U 0126	70-75	dentin matrix protein 1	Mus musculus	120-124
21678127-8	2012	In MLO-Y4 osteocytes and in MC3T3E1 and primary calvaria osteoblasts, U0126 strongly inhibited both basal expression of Dmp1 mRNA and FGF2-induced upregulation.	U 0126	70-75	fibroblast growth factor 2	Mus musculus	134-138
21947243-6	2012	(2)HMGB1 incubation induced ERK1/2 activation in a time- and dose-dependent manner, which could be completely blocked by U0126 (MEK1/2 inhibitor) and partially reversed by RAGE knockdown.	U 0126	121-126	high mobility group box 1	Homo sapiens	3-8
21947243-6	2012	(2)HMGB1 incubation induced ERK1/2 activation in a time- and dose-dependent manner, which could be completely blocked by U0126 (MEK1/2 inhibitor) and partially reversed by RAGE knockdown.	U 0126	121-126	mitogen-activated protein kinase 3	Homo sapiens	28-34
21947243-6	2012	(2)HMGB1 incubation induced ERK1/2 activation in a time- and dose-dependent manner, which could be completely blocked by U0126 (MEK1/2 inhibitor) and partially reversed by RAGE knockdown.	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	128-134
21391218-6	2012	alphavbeta3 and alphavbeta5 integrin monoclonal antibody and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) inhibited the CCN6-induced increase of the migration and ICAM-1 up-regulation of chondrosarcoma cells.	U 0126	124-129	mitogen-activated protein kinase kinase 7	Homo sapiens	61-93
21391218-6	2012	alphavbeta3 and alphavbeta5 integrin monoclonal antibody and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) inhibited the CCN6-induced increase of the migration and ICAM-1 up-regulation of chondrosarcoma cells.	U 0126	124-129	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
21391218-6	2012	alphavbeta3 and alphavbeta5 integrin monoclonal antibody and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) inhibited the CCN6-induced increase of the migration and ICAM-1 up-regulation of chondrosarcoma cells.	U 0126	124-129	cellular communication network factor 6	Homo sapiens	145-149
21391218-6	2012	alphavbeta3 and alphavbeta5 integrin monoclonal antibody and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) inhibited the CCN6-induced increase of the migration and ICAM-1 up-regulation of chondrosarcoma cells.	U 0126	124-129	intercellular adhesion molecule 1	Homo sapiens	188-194
22007720-8	2012	Inhibiting activation of extracellular signal regulated kinases 1&amp;2 (ERK1/2) with U0126 prevented the CNTF-induced ubiquitination of TH and the associated decrease in protein half-life.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	73-79
22007720-8	2012	Inhibiting activation of extracellular signal regulated kinases 1&amp;2 (ERK1/2) with U0126 prevented the CNTF-induced ubiquitination of TH and the associated decrease in protein half-life.	U 0126	86-91	ciliary neurotrophic factor	Homo sapiens	106-110
22007720-8	2012	Inhibiting activation of extracellular signal regulated kinases 1&amp;2 (ERK1/2) with U0126 prevented the CNTF-induced ubiquitination of TH and the associated decrease in protein half-life.	U 0126	86-91	tyrosine hydroxylase	Homo sapiens	137-139
23209347-3	2012	We also demonstrated that OA-induced pulmonary injury is dependent on ERK1/2 activation, since U0126, an inhibitor of ERK1/2 phosphorylation, blocked neutrophil migration, oedema, and lipid body formation as well as IL-6, but not IL-1beta production.	U 0126	95-100	mitogen-activated protein kinase 3	Mus musculus	70-76
23209347-3	2012	We also demonstrated that OA-induced pulmonary injury is dependent on ERK1/2 activation, since U0126, an inhibitor of ERK1/2 phosphorylation, blocked neutrophil migration, oedema, and lipid body formation as well as IL-6, but not IL-1beta production.	U 0126	95-100	mitogen-activated protein kinase 3	Mus musculus	118-124
23209347-3	2012	We also demonstrated that OA-induced pulmonary injury is dependent on ERK1/2 activation, since U0126, an inhibitor of ERK1/2 phosphorylation, blocked neutrophil migration, oedema, and lipid body formation as well as IL-6, but not IL-1beta production.	U 0126	95-100	interleukin 6	Mus musculus	216-220
23209347-3	2012	We also demonstrated that OA-induced pulmonary injury is dependent on ERK1/2 activation, since U0126, an inhibitor of ERK1/2 phosphorylation, blocked neutrophil migration, oedema, and lipid body formation as well as IL-6, but not IL-1beta production.	U 0126	95-100	interleukin 1 beta	Mus musculus	230-238
23112573-16	2012	Insulin also increased the ratio of phospho-ERK/total-ERK in animals with normal visual exposure and in animals wearing positive lenses, compared to U0126- and Ly294002-injected eyes.	U 0126	149-154	insulin	Gallus gallus	0-7
23233790-8	2012	ERK and p38 were activated by SKF83959, and pretreatment with their inhibitors U0126 and SB203580, respectively, significantly blunted the SKF83959-induced cytoprotection.	U 0126	79-84	mitogen-activated protein kinase 1	Mus musculus	0-3
23285101-7	2012	But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	18-21
23285101-7	2012	But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly.	U 0126	35-40	forkhead box M1	Homo sapiens	78-83
23285101-7	2012	But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly.	U 0126	35-40	growth factor receptor bound protein 7	Homo sapiens	87-91
23285101-7	2012	But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly.	U 0126	35-40	growth factor receptor bound protein 7	Homo sapiens	145-149
23285101-7	2012	But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	151-154
23285101-7	2012	But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly.	U 0126	35-40	forkhead box M1	Homo sapiens	159-164
23285101-8	2012	Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	24-27
23029347-12	2012	MHC inhibitor BDM and ERK inhibitor U0126 both abolished above effect of AZA.	U 0126	36-41	mitogen-activated protein kinase 1	Mus musculus	22-25
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	signal transducer and activator of transcription 3	Homo sapiens	34-39
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	AKT serine/threonine kinase 1	Homo sapiens	46-49
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	53-56
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	57-60
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	leptin	Homo sapiens	124-130
23300886-7	2012	Pharmacological inhibition of JAK/STAT3, PI3K/Akt or MEK/ERK signaling by AG490, Wortmannin or U0126, respectively, reduced leptin-induced cyclin D1 expression and NP cell proliferation.	U 0126	95-100	cyclin D1	Homo sapiens	139-148
23185517-8	2012	Using MK-2206 in combination with rapamycin (mTORC1 inhibitor), LY294002 (PI3K inhibitor), or U0126 (MEK1/2 inhibitor), we show that Erk- mediated downstream activation of PI3K/Akt pathway results in resistance to Akt inhibition.	U 0126	94-99	mitogen-activated protein kinase kinase 1	Homo sapiens	101-107
23185517-8	2012	Using MK-2206 in combination with rapamycin (mTORC1 inhibitor), LY294002 (PI3K inhibitor), or U0126 (MEK1/2 inhibitor), we show that Erk- mediated downstream activation of PI3K/Akt pathway results in resistance to Akt inhibition.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	133-136
23082158-6	2012	We found that aggregation of TxA2 production and granule secretion by beta3Delta724 human platelets initiated by alphaIIb mediated outside-in signaling was inhibited by the Src family kinase inhibitor PP2 and the PI3K inhibitor wortmannin, respectively, but not by the MAPK inhibitor U0126.	U 0126	284-289	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	201-204
23028886-7	2012	Inhibition of ERK activity by U0126 suppressed DV-induced expression and secretion of VEGR in BECs.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	14-17
22957020-8	2012	As a pilot screen, 8,960 small chemicals were tested for Muv suppression, and AG1478 (an EGFR-TK inhibitor) and U0126 (a MEK inhibitor) were identified as potential inhibitors of EGFR-mediated biological function.	U 0126	112-117	epidermal growth factor receptor	Homo sapiens	179-183
22848597-7	2012	U0126, a specific MEK inhibitor, blocked the ERK activation by beta,beta-dimethylacrylshikonin and abrogated beta,beta-dimethylacrylshikonin -induced apoptosis.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
22970192-3	2012	Here, we identified 10 human cancer cell lines (out of 16) with increased sensitivity to the anti-viral effects of IFN-alpha after treatment with the MEK inhibitor U0126, suggesting that the Ras/MEK pathway underlies their reduced sensitivity to IFN.	U 0126	164-169	interferon alpha 1	Homo sapiens	115-124
22970192-3	2012	Here, we identified 10 human cancer cell lines (out of 16) with increased sensitivity to the anti-viral effects of IFN-alpha after treatment with the MEK inhibitor U0126, suggesting that the Ras/MEK pathway underlies their reduced sensitivity to IFN.	U 0126	164-169	mitogen-activated protein kinase kinase 7	Homo sapiens	150-153
22970192-3	2012	Here, we identified 10 human cancer cell lines (out of 16) with increased sensitivity to the anti-viral effects of IFN-alpha after treatment with the MEK inhibitor U0126, suggesting that the Ras/MEK pathway underlies their reduced sensitivity to IFN.	U 0126	164-169	mitogen-activated protein kinase kinase 7	Homo sapiens	195-198
22970192-3	2012	Here, we identified 10 human cancer cell lines (out of 16) with increased sensitivity to the anti-viral effects of IFN-alpha after treatment with the MEK inhibitor U0126, suggesting that the Ras/MEK pathway underlies their reduced sensitivity to IFN.	U 0126	164-169	interferon alpha 1	Homo sapiens	115-118
22970192-6	2012	Furthermore, the expression of a distinct subset of IFN inducible genes, that included RIGI, GBP2, IFIT2, BTN3A3, MAP2, MMP7 and STAT2, was restored or increased in HT1080 cells when the cells were co-treated with U0126 and IFN.	U 0126	214-219	interferon alpha 1	Homo sapiens	52-55
22970192-6	2012	Furthermore, the expression of a distinct subset of IFN inducible genes, that included RIGI, GBP2, IFIT2, BTN3A3, MAP2, MMP7 and STAT2, was restored or increased in HT1080 cells when the cells were co-treated with U0126 and IFN.	U 0126	214-219	DExD/H-box helicase 58	Homo sapiens	87-91
22848341-8	2012	The CsA-induced proliferation of human trophoblast cells was effectively abrogated by the EGFR inhibitor AG1478 as well as the ERK inhibitor U0126, but not by the PI3K/PKB inhibitor LY294002.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	127-130
22848597-7	2012	U0126, a specific MEK inhibitor, blocked the ERK activation by beta,beta-dimethylacrylshikonin and abrogated beta,beta-dimethylacrylshikonin -induced apoptosis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	45-48
22761812-7	2012	The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype.	U 0126	61-66	AKT serine/threonine kinase 1	Homo sapiens	23-26
22761812-7	2012	The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	31-37
22761812-7	2012	The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype.	U 0126	61-66	AKT serine/threonine kinase 1	Homo sapiens	137-140
22761812-7	2012	The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	145-151
22761812-7	2012	The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype.	U 0126	61-66	microRNA 21	Homo sapiens	178-184
22701712-8	2012	Furthermore, blocking ERK signaling with its inhibitor U0126 remarkably inhibited both EGF-induced Rac1 activation as well as cell migration, and ectopic expression of inactive mutant form of Rac1 (Rac1-T17N) also largely abolished EGF-induced cell migration.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	22-25
22701712-8	2012	Furthermore, blocking ERK signaling with its inhibitor U0126 remarkably inhibited both EGF-induced Rac1 activation as well as cell migration, and ectopic expression of inactive mutant form of Rac1 (Rac1-T17N) also largely abolished EGF-induced cell migration.	U 0126	55-60	epidermal growth factor	Homo sapiens	87-90
22701712-8	2012	Furthermore, blocking ERK signaling with its inhibitor U0126 remarkably inhibited both EGF-induced Rac1 activation as well as cell migration, and ectopic expression of inactive mutant form of Rac1 (Rac1-T17N) also largely abolished EGF-induced cell migration.	U 0126	55-60	Rac family small GTPase 1	Homo sapiens	99-103
22701712-8	2012	Furthermore, blocking ERK signaling with its inhibitor U0126 remarkably inhibited both EGF-induced Rac1 activation as well as cell migration, and ectopic expression of inactive mutant form of Rac1 (Rac1-T17N) also largely abolished EGF-induced cell migration.	U 0126	55-60	Rac family small GTPase 1	Homo sapiens	192-196
22701712-8	2012	Furthermore, blocking ERK signaling with its inhibitor U0126 remarkably inhibited both EGF-induced Rac1 activation as well as cell migration, and ectopic expression of inactive mutant form of Rac1 (Rac1-T17N) also largely abolished EGF-induced cell migration.	U 0126	55-60	Rac family small GTPase 1	Homo sapiens	192-196
22427990-12	2012	Inhibition of Mek1/2 kinases with U0126, and the resulting inhibition of Erk1/2 phosphorylation, induced the increase of both the level of Bim-EL and apoptosis of cells seeded on the N-cadherin substrate, suggesting that Erk phosphorylation is necessary for cell survival.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Mus musculus	14-20
22723831-8	2012	Inhibition of MEK1, using U0126, blunted this effect.	U 0126	26-31	mitogen-activated protein kinase kinase 1	Mus musculus	14-18
22662154-3	2012	We also combined these compounds with a MAPK pathway inhibitor (PD98059 or UO126) in cell lines with K-Ras alterations (mutations or amplification).	U 0126	75-80	KRAS proto-oncogene, GTPase	Homo sapiens	101-106
22662154-8	2012	The presence of a MEK inhibitor, PD98059 or UO126, sensitized the K-Ras mutant cells to NVP-BEZ235.	U 0126	44-49	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
22662154-8	2012	The presence of a MEK inhibitor, PD98059 or UO126, sensitized the K-Ras mutant cells to NVP-BEZ235.	U 0126	44-49	KRAS proto-oncogene, GTPase	Homo sapiens	66-71
22427990-12	2012	Inhibition of Mek1/2 kinases with U0126, and the resulting inhibition of Erk1/2 phosphorylation, induced the increase of both the level of Bim-EL and apoptosis of cells seeded on the N-cadherin substrate, suggesting that Erk phosphorylation is necessary for cell survival.	U 0126	34-39	BCL2-like 11 (apoptosis facilitator)	Mus musculus	139-142
22427990-12	2012	Inhibition of Mek1/2 kinases with U0126, and the resulting inhibition of Erk1/2 phosphorylation, induced the increase of both the level of Bim-EL and apoptosis of cells seeded on the N-cadherin substrate, suggesting that Erk phosphorylation is necessary for cell survival.	U 0126	34-39	cadherin 2	Mus musculus	183-193
22363546-6	2012	Inhibition of ERK1/2 using UO126 or PD98059 reduced but did not abolish OA-NO(2)-induced HIF-1alpha upregulation, suggesting that OA-NO(2)/HO-1-initiated HIF-1alpha induction is partially dependent on ERK1/2 activity.	U 0126	27-32	mitogen-activated protein kinase 3	Bos taurus	14-20
22276178-9	2012	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 resulted in a decreased AAI-induced autophagy that was accompanied by an increased apoptosis.	U 0126	58-63	mitogen activated protein kinase 3	Rattus norvegicus	30-36
22314491-7	2012	U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, caused significantly altered morphologies of early embryos together with a decrease in protein expression and kinase activity of AURKB.	U 0126	0-5	midkine	Mus musculus	18-57
22295107-7	2012	Both basal and ligand-induced migration and invasiveness of SUM149 cells were drastically reduced in the presence of MEK inhibitor U0126, implicating that the phosphorylation of ERK1/2 by MEK is involved in the observed motility and invasiveness of IBC cells.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	117-120
22295107-7	2012	Both basal and ligand-induced migration and invasiveness of SUM149 cells were drastically reduced in the presence of MEK inhibitor U0126, implicating that the phosphorylation of ERK1/2 by MEK is involved in the observed motility and invasiveness of IBC cells.	U 0126	131-136	mitogen-activated protein kinase 3	Homo sapiens	178-184
22295107-7	2012	Both basal and ligand-induced migration and invasiveness of SUM149 cells were drastically reduced in the presence of MEK inhibitor U0126, implicating that the phosphorylation of ERK1/2 by MEK is involved in the observed motility and invasiveness of IBC cells.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	188-191
22519916-6	2012	Furthermore, the treatment of inhibitors specific for Akt (LY294002) and ERK1/2 (U0126) to A549 cells resulted in reduced activity of proMMP-2.	U 0126	81-86	mitogen-activated protein kinase 3	Homo sapiens	73-79
21476855-10	2012	U0126, a specific inhibitor of ERK, could inhibit 5-Aza-induced expression of cardiac-specific genes and proteins in hucMSCs.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	31-34
22314491-7	2012	U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, caused significantly altered morphologies of early embryos together with a decrease in protein expression and kinase activity of AURKB.	U 0126	0-5	midkine	Mus musculus	59-62
22314491-7	2012	U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, caused significantly altered morphologies of early embryos together with a decrease in protein expression and kinase activity of AURKB.	U 0126	0-5	aurora kinase B	Mus musculus	204-209
21964438-4	2011	The PI3K inhibitor LY294002 did not influence the activation of AKT by the Grp75 overexpression under GD; however, the MEK inhibitor U0126 dramatically inhibited AKT phosphorylation in the same assay.	U 0126	133-138	AKT serine/threonine kinase 1	Rattus norvegicus	162-165
22188922-9	2011	Treatment of cells with UO126, an inhibitor of MEK, also inhibited the invasion potential of SCC13 cells.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
22152059-5	2011	We also find that U0126, an antagonist of the ERK1/2 pathway, could abolish (1) the activation activity of BER on the ERK1/2 pathway and (2) the inhibition activity of BER on the production of beta-amyloid40/42 and the expression of BACE.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	46-52
21989075-9	2011	A transforming-growth-factor-beta receptor 1 kinase inhibitor or Mitogen-activated-Protein-Kinase/Extracellular-Signal-regulated-Kinase kinase (ERK) inhibitor (U-0126) suppressed the proliferation of mesangial cells induced by advanced-glycation-end-product-cholesterol-aggregated-BSA dose-dependently.	U 0126	160-166	mitogen-activated protein kinase 1	Mus musculus	144-147
21989075-10	2011	U-0126 inhibited the phosphorylation of ERK1/2 in advanced-glycation-end-product-cholesterol-aggregated-BSA treated mesangial cells.	U 0126	0-6	mitogen-activated protein kinase 3	Mus musculus	40-46
22152059-5	2011	We also find that U0126, an antagonist of the ERK1/2 pathway, could abolish (1) the activation activity of BER on the ERK1/2 pathway and (2) the inhibition activity of BER on the production of beta-amyloid40/42 and the expression of BACE.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	118-124
22152059-5	2011	We also find that U0126, an antagonist of the ERK1/2 pathway, could abolish (1) the activation activity of BER on the ERK1/2 pathway and (2) the inhibition activity of BER on the production of beta-amyloid40/42 and the expression of BACE.	U 0126	18-23	beta-secretase 1	Homo sapiens	233-237
21881005-5	2011	The inhibition of HCO(3)(-) absorption was eliminated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)/ERK inhibitors U0126 and PD98059.	U 0126	153-158	midkine	Mus musculus	133-136
21881005-5	2011	The inhibition of HCO(3)(-) absorption was eliminated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)/ERK inhibitors U0126 and PD98059.	U 0126	153-158	mitogen-activated protein kinase 1	Mus musculus	138-141
21816853-6	2011	In addition, interference with the activity of RAF and MAPK3/1 by their inhibitors, manumycin and U0126, respectively, reduces ADM2-induced HTR-8SV/neo cell invasion and migration.	U 0126	98-103	zinc fingers and homeoboxes 2	Homo sapiens	47-50
21816853-6	2011	In addition, interference with the activity of RAF and MAPK3/1 by their inhibitors, manumycin and U0126, respectively, reduces ADM2-induced HTR-8SV/neo cell invasion and migration.	U 0126	98-103	mitogen-activated protein kinase 3	Homo sapiens	55-60
21816853-6	2011	In addition, interference with the activity of RAF and MAPK3/1 by their inhibitors, manumycin and U0126, respectively, reduces ADM2-induced HTR-8SV/neo cell invasion and migration.	U 0126	98-103	adrenomedullin 2	Homo sapiens	127-131
21889928-8	2011	Importantly, co-treatment with MEK/ERK inhibitor (U0126) and PI3K/Akt (LY294002) or mTOR (rapamycin) inhibitors, instead of ATO, also potentiates lonidamine-provoked apoptosis.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
21889928-8	2011	Importantly, co-treatment with MEK/ERK inhibitor (U0126) and PI3K/Akt (LY294002) or mTOR (rapamycin) inhibitors, instead of ATO, also potentiates lonidamine-provoked apoptosis.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	35-38
22829094-4	2011	Inhibition of the ERK activity by mitogen-activated extracellular signal regulated kinase (MEK) inhibitors (UO126 and PD98059) enhanced the cytotoxic activity of AZD1480.	U 0126	108-113	mitogen-activated protein kinase 3	Homo sapiens	18-21
22829094-4	2011	Inhibition of the ERK activity by mitogen-activated extracellular signal regulated kinase (MEK) inhibitors (UO126 and PD98059) enhanced the cytotoxic activity of AZD1480.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	91-94
22108021-6	2011	The MEK inhibitor U0126 antagonized resveratrol-induced apoptosis in C4-2 cells, but this effect was not seen with other MEK inhibitors.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
22466441-6	2011	In addition, lymphocytes treated with FA exhibited activation of extracellular regulated kinase (ERK) and treatments with U0126 (an ERK kinase inhibitor) attenuated the FA induced activation of Nrf2, resulting in a decrease in HO-1 expression.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	132-135
22466441-6	2011	In addition, lymphocytes treated with FA exhibited activation of extracellular regulated kinase (ERK) and treatments with U0126 (an ERK kinase inhibitor) attenuated the FA induced activation of Nrf2, resulting in a decrease in HO-1 expression.	U 0126	122-127	NFE2 like bZIP transcription factor 2	Homo sapiens	194-198
22466441-6	2011	In addition, lymphocytes treated with FA exhibited activation of extracellular regulated kinase (ERK) and treatments with U0126 (an ERK kinase inhibitor) attenuated the FA induced activation of Nrf2, resulting in a decrease in HO-1 expression.	U 0126	122-127	heme oxygenase 1	Homo sapiens	227-231
21930764-7	2011	Activation of the IL-8 promoter in transfected HEK293 cells was inhibited by manumycin A, BAY43-9006, U0126, and transfection with a dominant-negative Ras mutant.	U 0126	102-107	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
21850371-3	2011	Pharmacological targeting of the activated MEK/ERK1/2 module with the MEK inhibitor U0126 attenuates cell cycle progression (11 out of 11 cell lines), impairs single (7 out of 10) and collective cell migration (9 out of 11) and abolishes single cell emigration from monolayers (4 out of 9).	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
21850371-3	2011	Pharmacological targeting of the activated MEK/ERK1/2 module with the MEK inhibitor U0126 attenuates cell cycle progression (11 out of 11 cell lines), impairs single (7 out of 10) and collective cell migration (9 out of 11) and abolishes single cell emigration from monolayers (4 out of 9).	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	47-53
21850371-3	2011	Pharmacological targeting of the activated MEK/ERK1/2 module with the MEK inhibitor U0126 attenuates cell cycle progression (11 out of 11 cell lines), impairs single (7 out of 10) and collective cell migration (9 out of 11) and abolishes single cell emigration from monolayers (4 out of 9).	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	U 0126	32-37	interleukin 1 beta	Homo sapiens	82-87
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	U 0126	32-37	matrix metallopeptidase 1	Homo sapiens	98-103
21925842-8	2011	The specific pharmacological inhibitors UO126 and SP600125 were used to block Erk1/2 and JNK activity.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	78-84
21925842-8	2011	The specific pharmacological inhibitors UO126 and SP600125 were used to block Erk1/2 and JNK activity.	U 0126	40-45	mitogen-activated protein kinase 8	Homo sapiens	89-92
21925842-12	2011	Furthermore, in cav-1 depleted cells treated with the Erk inhibitor UO126, there was no increase in the levels of phospho-Erk1/2, phospho-Ets1, and MMP-1, suggesting that cav-1 mediated effects on MMP-1 and phospho-Ets1 are Erk1/2 dependent.	U 0126	68-73	caveolin 1	Homo sapiens	16-21
21925842-12	2011	Furthermore, in cav-1 depleted cells treated with the Erk inhibitor UO126, there was no increase in the levels of phospho-Erk1/2, phospho-Ets1, and MMP-1, suggesting that cav-1 mediated effects on MMP-1 and phospho-Ets1 are Erk1/2 dependent.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	54-57
21925842-12	2011	Furthermore, in cav-1 depleted cells treated with the Erk inhibitor UO126, there was no increase in the levels of phospho-Erk1/2, phospho-Ets1, and MMP-1, suggesting that cav-1 mediated effects on MMP-1 and phospho-Ets1 are Erk1/2 dependent.	U 0126	68-73	caveolin 1	Homo sapiens	171-176
21933187-7	2011	Furthermore, inhibitors of mTOR (rapamycin), c-Jun N-terminal kinase (SP600125) and extracellular signal-regulated kinase 1/2 (U0126), but not of p38 (PD169316), prevented Cd-induced neuronal cell death in part through inhibition of [Ca(2+) ](i) elevation and CaMKII phosphorylation.	U 0126	127-132	mitogen-activated protein kinase 3	Homo sapiens	84-125
22033920-5	2011	Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	60-64
22033920-5	2011	Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells.	U 0126	33-38	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
22033920-5	2011	Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells.	U 0126	33-38	PML nuclear body scaffold	Homo sapiens	114-117
22033920-5	2011	Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells.	U 0126	33-38	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	184-188
22033920-5	2011	Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells.	U 0126	33-38	PML nuclear body scaffold	Homo sapiens	193-196
22033920-7	2011	Although U0126 up-regulated exogenous wild-type PML levels, it did not have an effect on the steady-state level of a mutant form of PML that is defective in binding Pin1.	U 0126	9-14	PML nuclear body scaffold	Homo sapiens	48-51
20638679-13	2011	Inhibition of ERK (UO126) or p38 (SB203580), but not PI3K (LY294002 or wortmannin), blocked AGE-induced MMP-9 expression.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	14-17
20638679-13	2011	Inhibition of ERK (UO126) or p38 (SB203580), but not PI3K (LY294002 or wortmannin), blocked AGE-induced MMP-9 expression.	U 0126	19-24	matrix metallopeptidase 9	Homo sapiens	104-109
20809186-4	2011	Moreover, the impact of ERK1/2 inhibitor U0126 on the expressions of MMP-7 and MMP-14 was examined in human U87 glioma cells by western blot analysis.	U 0126	41-46	mitogen-activated protein kinase 3	Homo sapiens	24-30
20809186-4	2011	Moreover, the impact of ERK1/2 inhibitor U0126 on the expressions of MMP-7 and MMP-14 was examined in human U87 glioma cells by western blot analysis.	U 0126	41-46	matrix metallopeptidase 7	Homo sapiens	69-74
20809186-4	2011	Moreover, the impact of ERK1/2 inhibitor U0126 on the expressions of MMP-7 and MMP-14 was examined in human U87 glioma cells by western blot analysis.	U 0126	41-46	matrix metallopeptidase 14	Homo sapiens	79-85
20809186-5	2011	The expressions of MMP-7 and MMP-14 were significantly decreased in human U87 glioma cells after treatment with ERK1/2 inhibitor U0126.	U 0126	129-134	matrix metallopeptidase 7	Homo sapiens	19-24
20809186-5	2011	The expressions of MMP-7 and MMP-14 were significantly decreased in human U87 glioma cells after treatment with ERK1/2 inhibitor U0126.	U 0126	129-134	matrix metallopeptidase 14	Homo sapiens	29-35
20809186-5	2011	The expressions of MMP-7 and MMP-14 were significantly decreased in human U87 glioma cells after treatment with ERK1/2 inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Homo sapiens	112-118
21831883-9	2011	Additional results obtained with MAPK inhibitor U0126 close the gap between syncytium formation induced by gal-1 and MAPK activation in trophoblast cells.	U 0126	48-53	galectin 1	Homo sapiens	107-112
21933187-7	2011	Furthermore, inhibitors of mTOR (rapamycin), c-Jun N-terminal kinase (SP600125) and extracellular signal-regulated kinase 1/2 (U0126), but not of p38 (PD169316), prevented Cd-induced neuronal cell death in part through inhibition of [Ca(2+) ](i) elevation and CaMKII phosphorylation.	U 0126	127-132	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	260-266
22241959-6	2011	Treatment with the MEK inhibitor UO126 but not with PLX4032 inhibited cell growth and ERK activation.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
21993263-3	2011	Selective 5-HT(2A) receptor agonist, DOI, induced JEG-3 cell growth was inhibited by the inhibitor of JAK2 (AG490), MEK1/2 (U0126), phospholipase C-beta (PLC-beta; U73122) and protein kinase C-beta (PKC-beta; Go6976)), whereas the selective phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) had no effect.	U 0126	124-129	5-hydroxytryptamine receptor 2A	Homo sapiens	10-27
21741467-7	2011	In contrast, the MEK inhibitor (U0126) was suppressed autophagy and the effect of p-PD on ERK1/2, Beclin-1 and LC3B proteins expression, except for mutant p53.	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
21741467-7	2011	In contrast, the MEK inhibitor (U0126) was suppressed autophagy and the effect of p-PD on ERK1/2, Beclin-1 and LC3B proteins expression, except for mutant p53.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	90-96
21741467-7	2011	In contrast, the MEK inhibitor (U0126) was suppressed autophagy and the effect of p-PD on ERK1/2, Beclin-1 and LC3B proteins expression, except for mutant p53.	U 0126	32-37	beclin 1	Homo sapiens	98-106
21741467-7	2011	In contrast, the MEK inhibitor (U0126) was suppressed autophagy and the effect of p-PD on ERK1/2, Beclin-1 and LC3B proteins expression, except for mutant p53.	U 0126	32-37	microtubule associated protein 1 light chain 3 beta	Homo sapiens	111-115
22375417-7	2011	pERK1/2 level was examined by Western blotting after co-cultured with optimal concentration of gastrodin and effective specific ERK1/2 pathway inhibitors PD98059, U0126.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	1-7
22509540-6	2011	RESULTS: Cells in EGF group had significantly stronger migration ability than in control group (P = 0.0361), inhibitor AG1478 + EGF group (P = 0.0113), inhibitor LY294002 + EGF group (P = 0.0169), and inhibitor U0126 + EGF group (P = 0.0293).	U 0126	211-216	epidermal growth factor	Homo sapiens	18-21
22129063-6	2011	U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	7-27
22129063-6	2011	U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF.	U 0126	0-5	interleukin 6	Homo sapiens	111-115
22129063-6	2011	U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF.	U 0126	0-5	colony stimulating factor 2	Homo sapiens	120-126
21801813-7	2011	VEGF up-regulates the activity of ERK (extracellular signal-regulated kinase) in cultured cortical neurons and U0126 (a mitogen activated protein kinase kinase (MEK) inhibitor) suppressed VEGF induced activity of ERK.	U 0126	111-116	vascular endothelial growth factor A	Rattus norvegicus	188-192
21801813-7	2011	VEGF up-regulates the activity of ERK (extracellular signal-regulated kinase) in cultured cortical neurons and U0126 (a mitogen activated protein kinase kinase (MEK) inhibitor) suppressed VEGF induced activity of ERK.	U 0126	111-116	Eph receptor B1	Rattus norvegicus	213-216
21801813-8	2011	Furthermore, incubation of cells with U0126 attenuated the ability of VEGF to protect neurons against mechanical trauma-induced apoptosis.	U 0126	38-43	vascular endothelial growth factor A	Rattus norvegicus	70-74
22056560-6	2011	We found that Erk activation by overexpression of constitutively active MEK increased the mRNA and protein levels of Osterix and enhanced the transcriptional activity of Osterix, whereas U0126, an inhibitor of MEK, suppressed the protein levels of Osterix and the transcriptional activity.	U 0126	187-192	mitogen-activated protein kinase 1	Homo sapiens	14-17
22056560-6	2011	We found that Erk activation by overexpression of constitutively active MEK increased the mRNA and protein levels of Osterix and enhanced the transcriptional activity of Osterix, whereas U0126, an inhibitor of MEK, suppressed the protein levels of Osterix and the transcriptional activity.	U 0126	187-192	mitogen-activated protein kinase kinase 7	Homo sapiens	210-213
22037456-7	2011	TGF-beta-induced aberrant expression of class III beta-tubulin was significantly reduced by pretreatment with U0126, an inhibitor of ERK phosphorylation.	U 0126	110-115	transforming growth factor beta 1	Homo sapiens	0-8
22037456-7	2011	TGF-beta-induced aberrant expression of class III beta-tubulin was significantly reduced by pretreatment with U0126, an inhibitor of ERK phosphorylation.	U 0126	110-115	tubulin beta 3 class III	Homo sapiens	40-62
22156391-9	2011	Also, NAC, LY294002, U0126, GSK733, which all indirectly inhibit mTOR and have been shown to suppress the senescent phenotype in traditional models of mammalian cell senescence, also decreased lactate production and decelerated CS.	U 0126	21-26	mechanistic target of rapamycin kinase	Homo sapiens	65-69
21880834-8	2011	Addition of the ERK1/2 signaling inhibitor U0126 was able to prevent the TGF-beta(1)-mediated increase in TER and claudin expression.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	16-22
21880834-8	2011	Addition of the ERK1/2 signaling inhibitor U0126 was able to prevent the TGF-beta(1)-mediated increase in TER and claudin expression.	U 0126	43-48	transforming growth factor beta 1	Homo sapiens	73-83
21832242-4	2011	LPA(5)-dependent activation of NHE3 was blocked by mitogen-activated protein kinase kinase (MEK) inhibitor PD98059 and U0126, but not by phosphatidylinositol 3-kinase inhibitor LY294002 or phospholipase C-beta inhibitor U73122.	U 0126	119-124	lysophosphatidic acid receptor 5	Homo sapiens	0-5
21832242-4	2011	LPA(5)-dependent activation of NHE3 was blocked by mitogen-activated protein kinase kinase (MEK) inhibitor PD98059 and U0126, but not by phosphatidylinositol 3-kinase inhibitor LY294002 or phospholipase C-beta inhibitor U73122.	U 0126	119-124	solute carrier family 9 member A3	Homo sapiens	31-35
21854809-0	2011	Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo.	U 0126	40-45	midkine	Mus musculus	26-29
21840963-7	2011	Inhibitors of Src kinase (PP1), PI3K (wortmannin), and ERK1/2 (U0126) all blocked the T3-induced Na-K-ATPase activity.	U 0126	63-68	mitogen activated protein kinase 3	Rattus norvegicus	55-61
21854809-4	2011	In the present work we investigated whether the MEK inhibitor U0126, targeting the intracellular Raf/MEK/ERK signaling pathway, is able to suppress propagation of the 2009 pandemic IV H1N1v (v=variant) as well as highly pathogenic avian influenza viruses (HPAIV) in cell culture and also in vivo in the mouse lung.	U 0126	62-67	midkine	Mus musculus	48-51
21854809-4	2011	In the present work we investigated whether the MEK inhibitor U0126, targeting the intracellular Raf/MEK/ERK signaling pathway, is able to suppress propagation of the 2009 pandemic IV H1N1v (v=variant) as well as highly pathogenic avian influenza viruses (HPAIV) in cell culture and also in vivo in the mouse lung.	U 0126	62-67	midkine	Mus musculus	101-104
21854809-6	2011	Furthermore, we were able to demonstrate that treatment of mice with U0126 via the aerosol route led to (i) inhibition of MEK activation in the lung (ii) reduction of progeny IAV titers compared to untreated controls (iii) protection of IAV infected mice against a 100x lethal viral challenge.	U 0126	69-74	midkine	Mus musculus	122-125
22110196-11	2011	The mitogen-activated kinase (MEK) specific inhibitor U0126 was used on PANC-1 cells to restore gemcitabine sensitivity.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	4-28
21854809-8	2011	Thus, we conclude that U0126, by inhibiting the cellular target MEK, has an antiviral potential not only in vitro in cell culture, but also in vivo in the mouse model.	U 0126	23-28	midkine	Mus musculus	64-67
22110196-11	2011	The mitogen-activated kinase (MEK) specific inhibitor U0126 was used on PANC-1 cells to restore gemcitabine sensitivity.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	30-33
21711332-8	2011	Pretreatment of T lymphocytes with the MAPK p38 inhibitor SB203580 or the MEK1 inhibitor U0126 reduced the stimulatory effect of H2O2.	U 0126	89-94	mitogen-activated protein kinase kinase 1	Mus musculus	74-78
21819443-14	2011	Cytokine-induced ERK1/2 phosphorylation and cyclin D1 expression were attenuated by U0126, suggesting that the ERK1/2 and NF-kappaB signalling pathways were involved in cardiac fibroblast proliferation.	U 0126	84-89	mitogen activated protein kinase 3	Rattus norvegicus	17-23
21819443-14	2011	Cytokine-induced ERK1/2 phosphorylation and cyclin D1 expression were attenuated by U0126, suggesting that the ERK1/2 and NF-kappaB signalling pathways were involved in cardiac fibroblast proliferation.	U 0126	84-89	mitogen activated protein kinase 3	Rattus norvegicus	111-117
21935933-8	2011	Interestingly, apo-Lf stimulated extracellular signal-regulated mitogen-activated protein kinase (ERK) cascade to a significantly greater extent than holo-Lf and the apo-Lf induced proliferation was significantly inhibited by an ERK cascade inhibitor (U0126) and clathrin siRNA.	U 0126	252-257	mitogen-activated protein kinase 1	Homo sapiens	98-101
21935933-8	2011	Interestingly, apo-Lf stimulated extracellular signal-regulated mitogen-activated protein kinase (ERK) cascade to a significantly greater extent than holo-Lf and the apo-Lf induced proliferation was significantly inhibited by an ERK cascade inhibitor (U0126) and clathrin siRNA.	U 0126	252-257	mitogen-activated protein kinase 1	Homo sapiens	229-232
21878657-8	2011	IGF1R-induced gefitinib resistance was unaffected by MAP/Erk kinase inhibition with U0126 but was partially impaired by inhibition of phosphoinositide-3-kinase with LY294002.	U 0126	84-89	insulin like growth factor 1 receptor	Homo sapiens	0-5
21849984-9	2011	The enhancing effect of LB1 siRNA on spatial learning and on the phosphorylation of ERK/MAPK and SGK1 was blocked by co-treatment with the MEK inhibitor U0126 at a concentration that did not apparently affect spatial learning and ERK/MAPK phosphorylation alone.	U 0126	153-158	laminin subunit beta 1	Rattus norvegicus	24-27
21849984-9	2011	The enhancing effect of LB1 siRNA on spatial learning and on the phosphorylation of ERK/MAPK and SGK1 was blocked by co-treatment with the MEK inhibitor U0126 at a concentration that did not apparently affect spatial learning and ERK/MAPK phosphorylation alone.	U 0126	153-158	Eph receptor B1	Rattus norvegicus	84-87
21849984-9	2011	The enhancing effect of LB1 siRNA on spatial learning and on the phosphorylation of ERK/MAPK and SGK1 was blocked by co-treatment with the MEK inhibitor U0126 at a concentration that did not apparently affect spatial learning and ERK/MAPK phosphorylation alone.	U 0126	153-158	serum/glucocorticoid regulated kinase 1	Rattus norvegicus	97-101
21849984-9	2011	The enhancing effect of LB1 siRNA on spatial learning and on the phosphorylation of ERK/MAPK and SGK1 was blocked by co-treatment with the MEK inhibitor U0126 at a concentration that did not apparently affect spatial learning and ERK/MAPK phosphorylation alone.	U 0126	153-158	Eph receptor B1	Rattus norvegicus	230-233
22141136-7	2011	Accordingly, GF109203X a PKC inhibitor, U0126 a MEK1 inhibitor and PKCalpha/beta knockdown restore sensitivity to IM while PKCalpha or PKCbeta overexpression in CML cells promotes protection against IM-induced cell death.	U 0126	40-45	mitogen-activated protein kinase kinase 1	Homo sapiens	48-52
21982772-6	2011	We further showed that treatment with PAK18, a PAK1 peptide inhibitor, resulted in marked suppression of both ERK 1/2 phosphorylation and infectious virus production, which was comparable to that by U0126, a specific MEK/ERK inhibitor.	U 0126	199-204	p21 (RAC1) activated kinase 1	Homo sapiens	38-42
21768780-7	2011	Further, we found that both the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125, inhibited the atorvastatin-induced elevation of LC3-II, suggesting that the effect of atorvastatin on autophagy is mediated by the Erk and JNK pathways.	U 0126	49-54	mitogen-activated protein kinase kinase 1	Homo sapiens	32-38
21768780-7	2011	Further, we found that both the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125, inhibited the atorvastatin-induced elevation of LC3-II, suggesting that the effect of atorvastatin on autophagy is mediated by the Erk and JNK pathways.	U 0126	49-54	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	135-138
21948550-6	2011	RESULTS: FGF-2 stimulated cell proliferation in hCECs; the FGF-2 action was completely blocked by pathway-specific inhibitors for PI 3-kinase (LY294002) and MEK1/2 (U0126), respectively.	U 0126	165-170	fibroblast growth factor 2	Homo sapiens	9-14
21948550-6	2011	RESULTS: FGF-2 stimulated cell proliferation in hCECs; the FGF-2 action was completely blocked by pathway-specific inhibitors for PI 3-kinase (LY294002) and MEK1/2 (U0126), respectively.	U 0126	165-170	fibroblast growth factor 2	Homo sapiens	59-64
21948550-6	2011	RESULTS: FGF-2 stimulated cell proliferation in hCECs; the FGF-2 action was completely blocked by pathway-specific inhibitors for PI 3-kinase (LY294002) and MEK1/2 (U0126), respectively.	U 0126	165-170	mitogen-activated protein kinase kinase 1	Homo sapiens	157-163
21873423-5	2011	This interaction increased after EGF treatment and decreased after treatment with the MEK inhibitor U0126 as well as after knockdown of MEK1/2 by shRNA in Huh-7 cells.	U 0126	100-105	mitogen-activated protein kinase kinase 7	Homo sapiens	86-89
21873423-6	2011	The phosphorylation levels of Thr-38 of CAR decreased in U0126-treated Huh-7 cells.	U 0126	57-62	nuclear receptor subfamily 1 group I member 3	Homo sapiens	40-43
21777709-6	2011	Additionally, amino acid limitation (-AA) in HepG2 cells increased p-ERK and AAR pathway-related genes, while U0126 decreased p-ERK but did not completely reverse the activation of AAR pathway-related genes.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	128-131
21404021-8	2011	The bLF-mediated increases in VEGF and FGF2 mRNA and protein were inhibited by U0126, a specific inhibitor of the upstream kinase that activates p44/p42 MAP kinase (MEK).	U 0126	79-84	vascular endothelial growth factor A	Mus musculus	30-34
21404021-8	2011	The bLF-mediated increases in VEGF and FGF2 mRNA and protein were inhibited by U0126, a specific inhibitor of the upstream kinase that activates p44/p42 MAP kinase (MEK).	U 0126	79-84	fibroblast growth factor 2	Mus musculus	39-43
21404021-8	2011	The bLF-mediated increases in VEGF and FGF2 mRNA and protein were inhibited by U0126, a specific inhibitor of the upstream kinase that activates p44/p42 MAP kinase (MEK).	U 0126	79-84	mitogen-activated protein kinase 3	Mus musculus	145-148
21404021-8	2011	The bLF-mediated increases in VEGF and FGF2 mRNA and protein were inhibited by U0126, a specific inhibitor of the upstream kinase that activates p44/p42 MAP kinase (MEK).	U 0126	79-84	cyclin-dependent kinase 20	Mus musculus	149-152
21404021-8	2011	The bLF-mediated increases in VEGF and FGF2 mRNA and protein were inhibited by U0126, a specific inhibitor of the upstream kinase that activates p44/p42 MAP kinase (MEK).	U 0126	79-84	midkine	Mus musculus	165-168
21660051-6	2011	Moreover, the ERK-dependent Noxa-myeloid cell leukemia-1 (Mcl-1) pathway is also involved, as silencing of Noxa expression was cardioprotective and U0126 abolished both the increase in Noxa expression and in Mcl-1 degradation.	U 0126	148-153	mitogen-activated protein kinase 1	Homo sapiens	14-17
21660051-6	2011	Moreover, the ERK-dependent Noxa-myeloid cell leukemia-1 (Mcl-1) pathway is also involved, as silencing of Noxa expression was cardioprotective and U0126 abolished both the increase in Noxa expression and in Mcl-1 degradation.	U 0126	148-153	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	28-56
21660051-6	2011	Moreover, the ERK-dependent Noxa-myeloid cell leukemia-1 (Mcl-1) pathway is also involved, as silencing of Noxa expression was cardioprotective and U0126 abolished both the increase in Noxa expression and in Mcl-1 degradation.	U 0126	148-153	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	58-63
21660051-6	2011	Moreover, the ERK-dependent Noxa-myeloid cell leukemia-1 (Mcl-1) pathway is also involved, as silencing of Noxa expression was cardioprotective and U0126 abolished both the increase in Noxa expression and in Mcl-1 degradation.	U 0126	148-153	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	28-32
21660051-6	2011	Moreover, the ERK-dependent Noxa-myeloid cell leukemia-1 (Mcl-1) pathway is also involved, as silencing of Noxa expression was cardioprotective and U0126 abolished both the increase in Noxa expression and in Mcl-1 degradation.	U 0126	148-153	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	208-213
22088530-7	2011	U0126 significantly attentuated the expression of MUC5AC mRNA and protein induced by cigarette smoke (P &lt; 0.05).	U 0126	0-5	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	50-56
22088530-9	2011	CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein.	U 0126	38-43	mitogen activated protein kinase 3	Rattus norvegicus	27-34
22088530-9	2011	CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein.	U 0126	38-43	mitogen activated protein kinase 3	Rattus norvegicus	69-76
22088530-9	2011	CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein.	U 0126	38-43	mitogen activated protein kinase 3	Rattus norvegicus	69-76
22088530-9	2011	CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein.	U 0126	38-43	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	106-112
21828177-3	2011	IL-1beta increased activin betaA (INHBA) and follistatin (FST) mRNA expression within 6 h. A p38 MAPK inhibitor, SB202190, a MAPK/ERK kinase inhibitor, U0126, and an nuclear factor kappaB pathway inhibitor, SC-514, significantly suppressed the IL-1beta-stimulated INHBA and FST mRNA expression.	U 0126	152-157	interleukin 1 beta	Homo sapiens	0-8
21828177-3	2011	IL-1beta increased activin betaA (INHBA) and follistatin (FST) mRNA expression within 6 h. A p38 MAPK inhibitor, SB202190, a MAPK/ERK kinase inhibitor, U0126, and an nuclear factor kappaB pathway inhibitor, SC-514, significantly suppressed the IL-1beta-stimulated INHBA and FST mRNA expression.	U 0126	152-157	mitogen-activated protein kinase 14	Homo sapiens	93-96
21828177-6	2011	The PGE(2)-induced INHBA mRNA expression was significantly suppressed by U0126 and a protein kinase C inhibitor, Go 6983.	U 0126	73-78	inhibin subunit beta A	Homo sapiens	19-24
21928417-5	2011	Extracellular signal-regulated kinase (ERK) inhibitor U0126 application enabled us to specify postradiogenic cellular responses.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	0-37
21928417-5	2011	Extracellular signal-regulated kinase (ERK) inhibitor U0126 application enabled us to specify postradiogenic cellular responses.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	39-42
21617849-5	2011	Blocking the activation of Akt by the PI3-K-selective inhibitor wortmannin abrogated the anti-apoptotic effect of aspirin while the MEK inhibitor U0126 did not.	U 0126	146-151	AKT serine/threonine kinase 1	Homo sapiens	27-30
21617849-5	2011	Blocking the activation of Akt by the PI3-K-selective inhibitor wortmannin abrogated the anti-apoptotic effect of aspirin while the MEK inhibitor U0126 did not.	U 0126	146-151	mitogen-activated protein kinase kinase 7	Homo sapiens	132-135
21618587-8	2011	The selective MEK inhibitor U0126 inhibited ERK2 activation and partially suppressed cisplatin-induced EMT and CSC markers.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
21618587-8	2011	The selective MEK inhibitor U0126 inhibited ERK2 activation and partially suppressed cisplatin-induced EMT and CSC markers.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	44-48
21618587-10	2011	U0126 inhibited cisplatin-induced migration of cells in vivo, suggesting that ERK2 signaling is critical to cisplatin-induced EMT and CSC phenotypes, and that targeting ERK2 in the presence of cisplatin may reduce the burden of residual tumor, the ultimate cause of recurrence in ovarian cancer patients.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	78-82
21618587-10	2011	U0126 inhibited cisplatin-induced migration of cells in vivo, suggesting that ERK2 signaling is critical to cisplatin-induced EMT and CSC phenotypes, and that targeting ERK2 in the presence of cisplatin may reduce the burden of residual tumor, the ultimate cause of recurrence in ovarian cancer patients.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	169-173
21595016-6	2011	Caspase-3 activity assay demonstrated that the synergistic induction of apoptosis was significantly attenuated by MEK1/2 inhibitor U0126, but not by JNK or p38 inhibitor, suggesting that ERK activation is responsible for the synergistic effect.	U 0126	131-136	caspase 3	Homo sapiens	0-9
21595016-6	2011	Caspase-3 activity assay demonstrated that the synergistic induction of apoptosis was significantly attenuated by MEK1/2 inhibitor U0126, but not by JNK or p38 inhibitor, suggesting that ERK activation is responsible for the synergistic effect.	U 0126	131-136	mitogen-activated protein kinase kinase 1	Homo sapiens	114-120
21595016-6	2011	Caspase-3 activity assay demonstrated that the synergistic induction of apoptosis was significantly attenuated by MEK1/2 inhibitor U0126, but not by JNK or p38 inhibitor, suggesting that ERK activation is responsible for the synergistic effect.	U 0126	131-136	mitogen-activated protein kinase 1	Homo sapiens	187-190
21663740-5	2011	The MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, prevented the ectodomain shedding of TNF receptor 1 induced by cytotrienin A and reversed the inhibitory effects of cytotrienin A on the TNF-alpha-induced IkappaBalpha degradation.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
21663740-5	2011	The MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, prevented the ectodomain shedding of TNF receptor 1 induced by cytotrienin A and reversed the inhibitory effects of cytotrienin A on the TNF-alpha-induced IkappaBalpha degradation.	U 0126	18-23	tumor necrosis factor	Homo sapiens	240-249
21663740-5	2011	The MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, prevented the ectodomain shedding of TNF receptor 1 induced by cytotrienin A and reversed the inhibitory effects of cytotrienin A on the TNF-alpha-induced IkappaBalpha degradation.	U 0126	18-23	NFKB inhibitor alpha	Homo sapiens	258-270
21663740-6	2011	In the presence of both U0126 and SB203580, cytotrienin A inhibited TNF-alpha- and IL-1alpha-induced ICAM-1 expression at almost equivalent concentrations.	U 0126	24-29	tumor necrosis factor	Homo sapiens	68-77
21663740-6	2011	In the presence of both U0126 and SB203580, cytotrienin A inhibited TNF-alpha- and IL-1alpha-induced ICAM-1 expression at almost equivalent concentrations.	U 0126	24-29	interleukin 1 alpha	Homo sapiens	83-92
21663740-6	2011	In the presence of both U0126 and SB203580, cytotrienin A inhibited TNF-alpha- and IL-1alpha-induced ICAM-1 expression at almost equivalent concentrations.	U 0126	24-29	intercellular adhesion molecule 1	Homo sapiens	101-107
21793567-0	2011	Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.	U 0126	88-93	mitogen-activated protein kinase kinase 1	Homo sapiens	16-20
21867693-3	2011	Exposure of the human colonic myofibroblast cell line 18Co to TNF-alpha and bradykinin induced synergistic MMP-3 mRNA and protein expression, which were blocked by the preferential PKC inhibitors GF109203X and Go6983 and by the MEK inhibitor U0126.	U 0126	242-247	tumor necrosis factor	Homo sapiens	62-71
21867693-3	2011	Exposure of the human colonic myofibroblast cell line 18Co to TNF-alpha and bradykinin induced synergistic MMP-3 mRNA and protein expression, which were blocked by the preferential PKC inhibitors GF109203X and Go6983 and by the MEK inhibitor U0126.	U 0126	242-247	kininogen 1	Homo sapiens	76-86
21810436-8	2011	In contrast, MKK1/2 inhibitor, U0126 was shown to augment the cytotoxicity of curcumin and MMC through downregulation of ERK1/2 activation and Rad51 expression.	U 0126	31-36	mitogen-activated protein kinase kinase 1	Homo sapiens	13-19
21810436-8	2011	In contrast, MKK1/2 inhibitor, U0126 was shown to augment the cytotoxicity of curcumin and MMC through downregulation of ERK1/2 activation and Rad51 expression.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	121-127
21810436-8	2011	In contrast, MKK1/2 inhibitor, U0126 was shown to augment the cytotoxicity of curcumin and MMC through downregulation of ERK1/2 activation and Rad51 expression.	U 0126	31-36	RAD51 recombinase	Homo sapiens	143-148
21658425-9	2011	Notably, the MEK/ERK inhibitor U0126 reversed AAI-induced apoptosis and reduced both FLAP, mGST3 and mitochondrial/caspase protein expression.	U 0126	31-36	arachidonate 5-lipoxygenase activating protein	Sus scrofa	85-89
21658425-9	2011	Notably, the MEK/ERK inhibitor U0126 reversed AAI-induced apoptosis and reduced both FLAP, mGST3 and mitochondrial/caspase protein expression.	U 0126	31-36	glutathione S-transferase, pi 2	Mus musculus	91-96
21730054-12	2011	U0126, an MEK inhibitor, and DPQ, a poly(ADP-ribose) polymerase-1 inhibitor, suppressed PMA-induced up-regulation of H1R gene expression.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	10-13
21757746-8	2011	Using a luciferase reporter, we demonstrated that LPS treatment induced IL6 promoter-driven luciferase which was suppressed using MEK/ERK pharmacologic inhibitors (PD98059 or U0126) and RNAi-induced depletion of N-Ras.	U 0126	175-180	interleukin 6	Homo sapiens	72-75
21757746-8	2011	Using a luciferase reporter, we demonstrated that LPS treatment induced IL6 promoter-driven luciferase which was suppressed using MEK/ERK pharmacologic inhibitors (PD98059 or U0126) and RNAi-induced depletion of N-Ras.	U 0126	175-180	NRAS proto-oncogene, GTPase	Homo sapiens	212-217
21963187-9	2011	The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
21963187-9	2011	The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells.	U 0126	18-23	matrix metallopeptidase 9	Homo sapiens	124-129
21963187-9	2011	The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells.	U 0126	18-23	matrix metallopeptidase 9	Homo sapiens	154-159
21819443-13	2011	Furthermore, inflammation-induced cardiac fibroblast proliferation was also blocked by the mitogen-activated protein kinase kinase 1/2 inhibitor U0126 (100 nmol/L) and the NF-kappaB inhibitor pyrrolidine dithiocarbamate (1 mumol/L).	U 0126	145-150	mitogen activated protein kinase kinase 1	Rattus norvegicus	91-132
21988724-7	2011	Dorsomorphin induced rapid and sustained ERK1/2 activation; however, dorsomorphin-mediated ERK1/2 activation and neuritogenesis were robustly inhibited in the presence of U0126 or H89, but not GW441756.	U 0126	171-176	mitogen activated protein kinase 3	Rattus norvegicus	91-97
21791217-11	2011	Isoflurane stimulated an increase in HIF1alpha in EC but not in CM under normal oxygen tension (3.5 +- 0.1 vs. 0.79 +- 0.15 fold change density) and this action was blocked by pretreatment with the Mitogen-activated Protein/Extracellular Signal-regulated Kinase inhibitor U0126.	U 0126	272-277	hypoxia inducible factor 1 subunit alpha	Homo sapiens	37-46
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	U 0126	220-225	insulin	Homo sapiens	4-11
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	U 0126	220-225	mechanistic target of rapamycin kinase	Homo sapiens	158-187
21871514-7	2011	We also found that ICV pretreatment with U0126, a specific MEK1/2 inhibitor, attenuated the 1000muM ouabain-induced increase in TH phosphorylation at Ser19, Ser31, and Ser40, as well as the hyperactivity of rats.	U 0126	41-46	mitogen activated protein kinase kinase 1	Rattus norvegicus	59-65
21871514-7	2011	We also found that ICV pretreatment with U0126, a specific MEK1/2 inhibitor, attenuated the 1000muM ouabain-induced increase in TH phosphorylation at Ser19, Ser31, and Ser40, as well as the hyperactivity of rats.	U 0126	41-46	tyrosine hydroxylase	Rattus norvegicus	128-130
21681580-6	2011	The infusion of either MEK inhibitor U0126 or NMDA receptor antagonist MK-801 in the CeA not only suppresses the activation of ERK1/2 in the CeA but also abolishes the expression of CPP.	U 0126	37-42	mitogen activated protein kinase 3	Rattus norvegicus	127-133
22169722-6	2011	The phosphorylation of ERK increased at 30 min and decreased after 1 h. U0126 significantly inhibited SiO2 -induced expression changes in E-cadherin and alpha-SMA.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	23-26
22169722-6	2011	The phosphorylation of ERK increased at 30 min and decreased after 1 h. U0126 significantly inhibited SiO2 -induced expression changes in E-cadherin and alpha-SMA.	U 0126	72-77	cadherin 1	Homo sapiens	138-148
21211106-8	2011	Extinction induced the phosphorylation of ERK1 in dorsal CA1 while intra-CA1 infusion of the MEK inhibitor U0126 blocked extinction of the avoidance response.	U 0126	107-112	carbonic anhydrase 1	Rattus norvegicus	73-76
22005063-4	2011	PTX-increased B7-H1 mRNA expression was significantly blocked by MEK inhibitor U0126.	U 0126	79-84	CD274 molecule	Homo sapiens	14-19
22005063-4	2011	PTX-increased B7-H1 mRNA expression was significantly blocked by MEK inhibitor U0126.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	65-68
21647938-5	2011	Our data revealed that U0126, an inhibitor of both ERK5 and ERK1/2, increased the levels of BDNF mRNA, whereas the MEK1/2-specific inhibitor PD184352 did not, suggesting that ERK5 exerts negative control over BDNF expression.	U 0126	23-28	mitogen-activated protein kinase 7	Homo sapiens	51-55
21647938-5	2011	Our data revealed that U0126, an inhibitor of both ERK5 and ERK1/2, increased the levels of BDNF mRNA, whereas the MEK1/2-specific inhibitor PD184352 did not, suggesting that ERK5 exerts negative control over BDNF expression.	U 0126	23-28	mitogen-activated protein kinase 3	Homo sapiens	60-66
21647938-5	2011	Our data revealed that U0126, an inhibitor of both ERK5 and ERK1/2, increased the levels of BDNF mRNA, whereas the MEK1/2-specific inhibitor PD184352 did not, suggesting that ERK5 exerts negative control over BDNF expression.	U 0126	23-28	brain derived neurotrophic factor	Homo sapiens	92-96
21647938-5	2011	Our data revealed that U0126, an inhibitor of both ERK5 and ERK1/2, increased the levels of BDNF mRNA, whereas the MEK1/2-specific inhibitor PD184352 did not, suggesting that ERK5 exerts negative control over BDNF expression.	U 0126	23-28	mitogen-activated protein kinase 7	Homo sapiens	175-179
21647938-5	2011	Our data revealed that U0126, an inhibitor of both ERK5 and ERK1/2, increased the levels of BDNF mRNA, whereas the MEK1/2-specific inhibitor PD184352 did not, suggesting that ERK5 exerts negative control over BDNF expression.	U 0126	23-28	brain derived neurotrophic factor	Homo sapiens	209-213
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	6-12
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	F2R like trypsin receptor 1	Homo sapiens	73-77
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	NFKB inhibitor alpha	Homo sapiens	94-107
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	nuclear factor kappa B subunit 1	Homo sapiens	108-117
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	RELA proto-oncogene, NF-kB subunit	Homo sapiens	119-122
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	nuclear factor kappa B subunit 1	Homo sapiens	153-162
21625939-7	2011	While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IkappaB-alpha/NF-kappaB (p65/Rel) expression in the cells, NF-kappaB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells.	U 0126	24-29	F2R like trypsin receptor 1	Homo sapiens	223-227
21478912-10	2011	Use of MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors reduced afadin-dependent migration and invasion.	U 0126	15-20	mitogen-activated protein kinase kinase 1	Homo sapiens	7-13
21478912-10	2011	Use of MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors reduced afadin-dependent migration and invasion.	U 0126	15-20	afadin, adherens junction formation factor	Homo sapiens	66-72
21841811-9	2011	The treatment of the cells with a specific ERK inhibitor U0126 (10 mumol/L) mimicked the effect of ATF6 over-expression and restored the insulin-stimulated IR phosphorylation.	U 0126	57-62	mitogen-activated protein kinase 1	Homo sapiens	43-46
21841811-9	2011	The treatment of the cells with a specific ERK inhibitor U0126 (10 mumol/L) mimicked the effect of ATF6 over-expression and restored the insulin-stimulated IR phosphorylation.	U 0126	57-62	activating transcription factor 6	Homo sapiens	99-103
21841811-9	2011	The treatment of the cells with a specific ERK inhibitor U0126 (10 mumol/L) mimicked the effect of ATF6 over-expression and restored the insulin-stimulated IR phosphorylation.	U 0126	57-62	insulin	Homo sapiens	137-144
21841811-9	2011	The treatment of the cells with a specific ERK inhibitor U0126 (10 mumol/L) mimicked the effect of ATF6 over-expression and restored the insulin-stimulated IR phosphorylation.	U 0126	57-62	insulin receptor	Homo sapiens	156-158
22040433-10	2011	Furthermore, 30-minute pretreatment with 10 micromol/L U0126, specific antagonist for ERK kinase (MEK) prevented the increase in phosphorylation of ERK1/ERK2 and abolished cell cycle progression and the proliferation of PASMCs induced by sildenafil.	U 0126	55-60	mitogen-activated protein kinase 3	Sus scrofa	148-152
21621583-11	2011	The addition of cAMP and PKA inhibitors, SQ22536 and H-89, respectively, reduced proliferation only in oxLDL-treated cells, whereas the addition of ERK1/2 inhibitor U0126 blocked proliferation in both control and oxLDL-treated cells.	U 0126	165-170	mitogen-activated protein kinase 3	Mus musculus	148-154
21621583-12	2011	C/EBPbeta nuclear expression and DNA-binding activity were reduced by U0126, under all tested conditions.	U 0126	70-75	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	0-9
22040433-10	2011	Furthermore, 30-minute pretreatment with 10 micromol/L U0126, specific antagonist for ERK kinase (MEK) prevented the increase in phosphorylation of ERK1/ERK2 and abolished cell cycle progression and the proliferation of PASMCs induced by sildenafil.	U 0126	55-60	mitogen-activated protein kinase 1	Sus scrofa	153-157
21790999-9	2011	Similarly, ERK targeting with the selective inhibitor U0126 impaired DOX-induced toxicity.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	11-14
21710492-2	2011	Here, we show, using a synthetic small-molecule MEK1/2 inhibitor (U0126) and RNA silencing of ERK1 and 2, comparatively, that ERK2 is critical to transformation and homeostasis of human epithelioid malignant mesotheliomas (MMs), asbestos-induced tumors with a poor prognosis.	U 0126	66-71	mitogen-activated protein kinase 1	Homo sapiens	126-130
21439396-6	2011	Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process.	U 0126	167-172	interleukin 6	Mus musculus	38-42
21439396-6	2011	Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process.	U 0126	167-172	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	47-53
21439396-6	2011	Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process.	U 0126	167-172	mitogen-activated protein kinase kinase 1	Mus musculus	150-156
21660968-3	2011	EGF decreased surface and total levels of CLDN2, which was inhibited by U0126, a MEK inhibitor.	U 0126	72-77	epidermal growth factor	Canis lupus familiaris	0-3
23675235-8	2011	Additionally, IL-2 enhanced lymphoma cell survival by overcoming kinase inhibitor U0126-induced growth arrest and apoptosis.	U 0126	82-87	interleukin 2	Homo sapiens	14-18
21660968-3	2011	EGF decreased surface and total levels of CLDN2, which was inhibited by U0126, a MEK inhibitor.	U 0126	72-77	claudin 2	Canis lupus familiaris	42-47
21660968-5	2011	The fluorescence signal for CLDN2 disappeared on treatment with EGF, which was inhibited by U0126.	U 0126	92-97	claudin 2	Canis lupus familiaris	28-33
21660968-5	2011	The fluorescence signal for CLDN2 disappeared on treatment with EGF, which was inhibited by U0126.	U 0126	92-97	epidermal growth factor	Canis lupus familiaris	64-67
21660968-9	2011	EGF increased the association of CLDN2 with clathrin and adaptin alpha which was inhibited by U0126.	U 0126	94-99	epidermal growth factor	Canis lupus familiaris	0-3
21660968-9	2011	EGF increased the association of CLDN2 with clathrin and adaptin alpha which was inhibited by U0126.	U 0126	94-99	claudin 2	Canis lupus familiaris	33-38
20680516-7	2011	ERK 1/2 phosphorylation was observed after xenon or LPS treatment which was inhibited by the use of the MEK inhibitor U0126.	U 0126	118-123	midkine	Mus musculus	104-107
21593766-6	2011	CCL21 expression by HMVEC-dLy was blocked by a JAK inhibitor 1, JAK3 inhibitor, and U0126 (a MAPK kinase inhibitor) in vitro, all of which blocked phosphorylation of MAPK 44/42.	U 0126	84-89	C-C motif chemokine ligand 21	Homo sapiens	0-5
21593766-7	2011	In addition, injection of U0126 into murine skin significantly decreased CCL21 mRNA and protein expression.	U 0126	26-31	C-C motif chemokine ligand 21	Homo sapiens	73-78
20680516-7	2011	ERK 1/2 phosphorylation was observed after xenon or LPS treatment which was inhibited by the use of the MEK inhibitor U0126.	U 0126	118-123	mitogen-activated protein kinase 3	Mus musculus	0-7
21104457-6	2011	We find that activation of ERK1/2 occurs in homocysteine-treated PC12 cells and blockade of ERK1/2 with U0126 abolished the homocysteine-induced cytotoxicity and inhibitory effect on endogenous H(2)S generation.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	27-33
21104457-6	2011	We find that activation of ERK1/2 occurs in homocysteine-treated PC12 cells and blockade of ERK1/2 with U0126 abolished the homocysteine-induced cytotoxicity and inhibitory effect on endogenous H(2)S generation.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	92-98
21277645-7	2011	Effect on cytotoxicity after ERK inhibition by U0126 was also assessed.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	29-32
22866134-6	2011	Moreover, treatment with a MEK1/2 inhibitor (U0126) attenuated the effect of bFGF-induced cholangiocarcinoma cell migration.	U 0126	45-50	mitogen-activated protein kinase kinase 1	Homo sapiens	27-33
21277645-11	2011	ERK"s effect in antagonism was further confirmed by using U0126.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	0-3
21547453-8	2011	And the differentiation induced by AMG was abrogated when the MDPC-23 cells were treated with U0126 and SB203580, the inhibitors of ERK1/2 and p38, respectively.	U 0126	94-99	amelogenin, X-linked	Mus musculus	35-38
21547453-8	2011	And the differentiation induced by AMG was abrogated when the MDPC-23 cells were treated with U0126 and SB203580, the inhibitors of ERK1/2 and p38, respectively.	U 0126	94-99	mitogen-activated protein kinase 3	Mus musculus	132-138
21547453-8	2011	And the differentiation induced by AMG was abrogated when the MDPC-23 cells were treated with U0126 and SB203580, the inhibitors of ERK1/2 and p38, respectively.	U 0126	94-99	mitogen-activated protein kinase 14	Mus musculus	143-146
21601581-10	2011	Both nociceptive behavioral response and spinal ERK activation induced by intraplantar capsaicin were reduced by U0126, an upstream inhibitor of ERK phosphorylation.	U 0126	113-118	mitogen-activated protein kinase 1	Mus musculus	48-51
21601581-10	2011	Both nociceptive behavioral response and spinal ERK activation induced by intraplantar capsaicin were reduced by U0126, an upstream inhibitor of ERK phosphorylation.	U 0126	113-118	mitogen-activated protein kinase 1	Mus musculus	145-148
22866134-6	2011	Moreover, treatment with a MEK1/2 inhibitor (U0126) attenuated the effect of bFGF-induced cholangiocarcinoma cell migration.	U 0126	45-50	fibroblast growth factor 2	Homo sapiens	77-81
21705143-7	2011	Functional blockade of spinal ERK1/2 activity via intrathecal administration of the upstream MEK inhibitor U0126 attenuated distention-evoked bladder nociception and caused a significant downward shift of the VMR stimulus-response curve.	U 0126	107-112	mitogen-activated protein kinase 3	Mus musculus	30-36
21158569-8	2011	The treatment of U0126 blocked TRX-induced increase in cell proliferation.	U 0126	17-22	thioredoxin	Homo sapiens	31-34
21705143-7	2011	Functional blockade of spinal ERK1/2 activity via intrathecal administration of the upstream MEK inhibitor U0126 attenuated distention-evoked bladder nociception and caused a significant downward shift of the VMR stimulus-response curve.	U 0126	107-112	midkine	Mus musculus	93-96
21763338-5	2011	Furthermore, pre-treatment with an estrogen receptors (ERs) antagonist, ICI182,780, or an ERK-activating kinase inhibitor, U0126, significantly attenuated EB- or BPA-induced phosphorylations of NR1, NR2B, and ERK within 1 h. These data suggest that BPA rapidly enhanced short-term passive avoidance memory in the developing rats.	U 0126	123-128	Eph receptor B1	Rattus norvegicus	90-93
21470077-6	2011	COX-2 expression was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	144-149	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
21470077-6	2011	COX-2 expression was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	144-149	mitogen-activated protein kinase 1	Homo sapiens	122-125
21763338-5	2011	Furthermore, pre-treatment with an estrogen receptors (ERs) antagonist, ICI182,780, or an ERK-activating kinase inhibitor, U0126, significantly attenuated EB- or BPA-induced phosphorylations of NR1, NR2B, and ERK within 1 h. These data suggest that BPA rapidly enhanced short-term passive avoidance memory in the developing rats.	U 0126	123-128	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	194-197
21763338-5	2011	Furthermore, pre-treatment with an estrogen receptors (ERs) antagonist, ICI182,780, or an ERK-activating kinase inhibitor, U0126, significantly attenuated EB- or BPA-induced phosphorylations of NR1, NR2B, and ERK within 1 h. These data suggest that BPA rapidly enhanced short-term passive avoidance memory in the developing rats.	U 0126	123-128	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	199-203
21763338-5	2011	Furthermore, pre-treatment with an estrogen receptors (ERs) antagonist, ICI182,780, or an ERK-activating kinase inhibitor, U0126, significantly attenuated EB- or BPA-induced phosphorylations of NR1, NR2B, and ERK within 1 h. These data suggest that BPA rapidly enhanced short-term passive avoidance memory in the developing rats.	U 0126	123-128	Eph receptor B1	Rattus norvegicus	209-212
21871121-12	2011	Treatment with U0126 significantly reduced the enhanced SMC expression of TNF-alpha, TNF-R1 and TNF-R2 immunoreactivities after 24 and 48 h of organ culture.	U 0126	15-20	tumor necrosis factor	Rattus norvegicus	74-83
21871121-12	2011	Treatment with U0126 significantly reduced the enhanced SMC expression of TNF-alpha, TNF-R1 and TNF-R2 immunoreactivities after 24 and 48 h of organ culture.	U 0126	15-20	TNF receptor superfamily member 1A	Rattus norvegicus	85-91
21871121-12	2011	Treatment with U0126 significantly reduced the enhanced SMC expression of TNF-alpha, TNF-R1 and TNF-R2 immunoreactivities after 24 and 48 h of organ culture.	U 0126	15-20	TNF receptor superfamily member 1B	Rattus norvegicus	96-102
21667293-6	2011	CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells.	U 0126	109-114	cellular communication network factor 2	Mus musculus	0-4
21624361-6	2011	C8-C1P markedly activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) within 5min, and the activation could be prevented by U0126, a MEK inhibitor.	U 0126	135-140	mitogen activated protein kinase 3	Rattus norvegicus	26-71
21624361-6	2011	C8-C1P markedly activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) within 5min, and the activation could be prevented by U0126, a MEK inhibitor.	U 0126	135-140	mitogen activated protein kinase 3	Rattus norvegicus	73-79
21631569-12	2011	Pretreatment with AG490, AG1478, U0126 or EGF Ab completely or partially inhibited the proliferation of chondrocytes and activation of Erk1/2 and EGFR.	U 0126	33-38	mitogen activated protein kinase 3	Rattus norvegicus	135-141
21631569-12	2011	Pretreatment with AG490, AG1478, U0126 or EGF Ab completely or partially inhibited the proliferation of chondrocytes and activation of Erk1/2 and EGFR.	U 0126	33-38	epidermal growth factor receptor	Rattus norvegicus	146-150
21575631-5	2011	Knockdown of ERK1/2 using specific siRNA, as well as known inhibitors (PD98059 and U0126), effectively suppressed the expression of cyclin-A and Cdk2, and reduced S-phase arrest and apoptosis induced by pemetrexed.	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	13-19
21575631-5	2011	Knockdown of ERK1/2 using specific siRNA, as well as known inhibitors (PD98059 and U0126), effectively suppressed the expression of cyclin-A and Cdk2, and reduced S-phase arrest and apoptosis induced by pemetrexed.	U 0126	83-88	cyclin A2	Homo sapiens	132-140
21575631-5	2011	Knockdown of ERK1/2 using specific siRNA, as well as known inhibitors (PD98059 and U0126), effectively suppressed the expression of cyclin-A and Cdk2, and reduced S-phase arrest and apoptosis induced by pemetrexed.	U 0126	83-88	cyclin dependent kinase 2	Homo sapiens	145-149
21520062-8	2011	Association of p300 and histone H4 to cPLA(2) promoter was inhibited by U0126, SB202190, and SP600125.	U 0126	72-77	E1A binding protein p300	Homo sapiens	15-19
21667293-6	2011	CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells.	U 0126	109-114	midkine	Mus musculus	91-94
21667293-6	2011	CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells.	U 0126	109-114	mitogen-activated protein kinase 1	Mus musculus	95-98
21667293-6	2011	CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells.	U 0126	109-114	cellular communication network factor 2	Mus musculus	131-135
21667293-7	2011	Expression of CCN1, CCN3 and CCN4 was not reduced by PP2 or U0126; in fact, expression of CCN4 mRNA was elevated by PP2 or U0126 treatment.	U 0126	123-128	cellular communication network factor 1	Mus musculus	14-18
21667293-7	2011	Expression of CCN1, CCN3 and CCN4 was not reduced by PP2 or U0126; in fact, expression of CCN4 mRNA was elevated by PP2 or U0126 treatment.	U 0126	123-128	cellular communication network factor 4	Mus musculus	90-94
21718706-13	2011	Selective p44/42 kinase inhibitor UO126 successfully inhibited TGF-beta(1) production.	U 0126	34-39	interferon induced protein 44	Homo sapiens	10-13
21718706-13	2011	Selective p44/42 kinase inhibitor UO126 successfully inhibited TGF-beta(1) production.	U 0126	34-39	transforming growth factor beta 1	Homo sapiens	63-74
21388428-5	2011	Addition of the MAPK kinase (MAPKK) MEK inhibitor U0126 inhibited IL-6/TNF-alpha secretion in a dose-dependent manner.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
21672583-4	2011	The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012.	U 0126	209-214	mitogen-activated protein kinase 14	Homo sapiens	223-237
21672583-4	2011	The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012.	U 0126	209-214	mitogen-activated protein kinase 8	Homo sapiens	280-303
21672583-4	2011	The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012.	U 0126	209-214	mitogen-activated protein kinase 8	Homo sapiens	305-308
21860067-5	2011	We have demonstrated in human colon carcinoma cells that inhibition of the RAS/RAF pathway by U0126 decreases p-ERK protein expression and also inhibits GLI-luciferase activity and GLI1 mRNA and protein levels.	U 0126	94-99	zinc fingers and homeoboxes 2	Homo sapiens	79-82
21860067-5	2011	We have demonstrated in human colon carcinoma cells that inhibition of the RAS/RAF pathway by U0126 decreases p-ERK protein expression and also inhibits GLI-luciferase activity and GLI1 mRNA and protein levels.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	112-115
21860067-5	2011	We have demonstrated in human colon carcinoma cells that inhibition of the RAS/RAF pathway by U0126 decreases p-ERK protein expression and also inhibits GLI-luciferase activity and GLI1 mRNA and protein levels.	U 0126	94-99	GLI family zinc finger 1	Homo sapiens	153-156
21860067-5	2011	We have demonstrated in human colon carcinoma cells that inhibition of the RAS/RAF pathway by U0126 decreases p-ERK protein expression and also inhibits GLI-luciferase activity and GLI1 mRNA and protein levels.	U 0126	94-99	GLI family zinc finger 1	Homo sapiens	181-185
21388428-5	2011	Addition of the MAPK kinase (MAPKK) MEK inhibitor U0126 inhibited IL-6/TNF-alpha secretion in a dose-dependent manner.	U 0126	50-55	interleukin 6	Homo sapiens	66-70
21388428-5	2011	Addition of the MAPK kinase (MAPKK) MEK inhibitor U0126 inhibited IL-6/TNF-alpha secretion in a dose-dependent manner.	U 0126	50-55	tumor necrosis factor	Homo sapiens	71-80
21616090-9	2011	Blockage of autophagy with the MEK inhibitor U0126 potentiated 5-MF-induced gamma-H2AX formation and caspase-2 activation.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
21616090-9	2011	Blockage of autophagy with the MEK inhibitor U0126 potentiated 5-MF-induced gamma-H2AX formation and caspase-2 activation.	U 0126	45-50	caspase 2	Homo sapiens	101-110
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	tumor necrosis factor	Mus musculus	43-46
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	interleukin 6	Mus musculus	55-59
22097732-6	2011	Fos-like positive neurons in dorsal horn of withdrawal group were 380 +/- 71, which were higher than those of U0126 group(287 +/- 54, P &lt; 0.05).	U 0126	110-115	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-3
22097732-7	2011	Also nNOS and iNOS positive neurons in dorsal horn of U0126 group were 180 +/- 32, 10.8 +/- 2.8 respectively, which were significantly lower than that of withdrawal group (239 +/- 45, 16.8 +/- 5.1, P &lt; 0.05).	U 0126	54-59	nitric oxide synthase 1	Rattus norvegicus	5-9
22097732-7	2011	Also nNOS and iNOS positive neurons in dorsal horn of U0126 group were 180 +/- 32, 10.8 +/- 2.8 respectively, which were significantly lower than that of withdrawal group (239 +/- 45, 16.8 +/- 5.1, P &lt; 0.05).	U 0126	54-59	nitric oxide synthase 2	Rattus norvegicus	14-18
22097732-8	2011	Compared with withdrawal group, levels of nNOS and iNOS protein in spinal cord of U0126 group were significantly lower.	U 0126	82-87	nitric oxide synthase 1	Rattus norvegicus	42-46
22097732-8	2011	Compared with withdrawal group, levels of nNOS and iNOS protein in spinal cord of U0126 group were significantly lower.	U 0126	82-87	nitric oxide synthase 2	Rattus norvegicus	51-55
21474650-5	2011	U-0126, but not SB-202190 and SP-600125, also attenuated EGF-mediated prevention of acetaldehyde effect on the midregion F-actin ring.	U 0126	0-6	epidermal growth factor	Homo sapiens	57-60
21474650-10	2011	U-0126, but not SB-202190 and SP-600125, prevented EGF effect on tyrosine-phosphorylation of occludin and ZO-1, but not claudin-3, E-cadherin, or beta-catenin.	U 0126	0-6	epidermal growth factor	Homo sapiens	51-54
21474650-10	2011	U-0126, but not SB-202190 and SP-600125, prevented EGF effect on tyrosine-phosphorylation of occludin and ZO-1, but not claudin-3, E-cadherin, or beta-catenin.	U 0126	0-6	occludin	Homo sapiens	93-101
21474650-10	2011	U-0126, but not SB-202190 and SP-600125, prevented EGF effect on tyrosine-phosphorylation of occludin and ZO-1, but not claudin-3, E-cadherin, or beta-catenin.	U 0126	0-6	tight junction protein 1	Homo sapiens	106-110
21474650-10	2011	U-0126, but not SB-202190 and SP-600125, prevented EGF effect on tyrosine-phosphorylation of occludin and ZO-1, but not claudin-3, E-cadherin, or beta-catenin.	U 0126	0-6	cadherin 1	Homo sapiens	131-141
21474650-10	2011	U-0126, but not SB-202190 and SP-600125, prevented EGF effect on tyrosine-phosphorylation of occludin and ZO-1, but not claudin-3, E-cadherin, or beta-catenin.	U 0126	0-6	catenin beta 1	Homo sapiens	146-158
21536288-7	2011	The mitogenic effect of MCP-3 appeared to be dependent on ERK1/2 MAPK and PI3K signaling pathway activation, as demonstrated by the reduction of MCP-3-induced CASMC proliferation observed after the treatment of cells with U0126 (1 muM) and LY-294002 (5muM), selective inhibitors of ERK 1/2 and PI3K activation, respectively.	U 0126	222-227	C-C motif chemokine ligand 7	Homo sapiens	24-29
21536288-7	2011	The mitogenic effect of MCP-3 appeared to be dependent on ERK1/2 MAPK and PI3K signaling pathway activation, as demonstrated by the reduction of MCP-3-induced CASMC proliferation observed after the treatment of cells with U0126 (1 muM) and LY-294002 (5muM), selective inhibitors of ERK 1/2 and PI3K activation, respectively.	U 0126	222-227	mitogen-activated protein kinase 3	Homo sapiens	58-64
21536288-7	2011	The mitogenic effect of MCP-3 appeared to be dependent on ERK1/2 MAPK and PI3K signaling pathway activation, as demonstrated by the reduction of MCP-3-induced CASMC proliferation observed after the treatment of cells with U0126 (1 muM) and LY-294002 (5muM), selective inhibitors of ERK 1/2 and PI3K activation, respectively.	U 0126	222-227	mitogen-activated protein kinase 3	Homo sapiens	65-69
21536288-7	2011	The mitogenic effect of MCP-3 appeared to be dependent on ERK1/2 MAPK and PI3K signaling pathway activation, as demonstrated by the reduction of MCP-3-induced CASMC proliferation observed after the treatment of cells with U0126 (1 muM) and LY-294002 (5muM), selective inhibitors of ERK 1/2 and PI3K activation, respectively.	U 0126	222-227	C-C motif chemokine ligand 7	Homo sapiens	145-150
21536288-7	2011	The mitogenic effect of MCP-3 appeared to be dependent on ERK1/2 MAPK and PI3K signaling pathway activation, as demonstrated by the reduction of MCP-3-induced CASMC proliferation observed after the treatment of cells with U0126 (1 muM) and LY-294002 (5muM), selective inhibitors of ERK 1/2 and PI3K activation, respectively.	U 0126	222-227	latexin	Homo sapiens	231-234
21536288-7	2011	The mitogenic effect of MCP-3 appeared to be dependent on ERK1/2 MAPK and PI3K signaling pathway activation, as demonstrated by the reduction of MCP-3-induced CASMC proliferation observed after the treatment of cells with U0126 (1 muM) and LY-294002 (5muM), selective inhibitors of ERK 1/2 and PI3K activation, respectively.	U 0126	222-227	mitogen-activated protein kinase 3	Homo sapiens	282-289
21069809-6	2011	Inhibitors of AMPK (araA), p38MAPK (SB202190), and ERK1/2 (PD98059 and U0126) but not JNK (SP600125) suppressed gAd-induced IL-6 production.	U 0126	71-76	mitogen activated protein kinase 3	Rattus norvegicus	51-57
21722369-10	2011	Phosphorylation of ERK (p-ERK) and the transcription factor cAMP response element-binding protein (p-CREB) increased in the spinal cord of CIBP rats, which was attenuated by intrathecal injection of fluorocitrate or U0126.	U 0126	216-221	Eph receptor B1	Rattus norvegicus	19-22
21722369-10	2011	Phosphorylation of ERK (p-ERK) and the transcription factor cAMP response element-binding protein (p-CREB) increased in the spinal cord of CIBP rats, which was attenuated by intrathecal injection of fluorocitrate or U0126.	U 0126	216-221	cAMP responsive element binding protein 1	Rattus norvegicus	101-105
21474604-5	2011	However, these assays indicated that T172 dephosphorylation during maturation-associated AMPK deactivation did not require MAPK and that an observed inhibition of GVBD elicited by the MAPK kinase blocker U0126 was actually due to ectopic AMPK activation rather than MAPK inactivation.	U 0126	204-209	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	89-93
21474604-5	2011	However, these assays indicated that T172 dephosphorylation during maturation-associated AMPK deactivation did not require MAPK and that an observed inhibition of GVBD elicited by the MAPK kinase blocker U0126 was actually due to ectopic AMPK activation rather than MAPK inactivation.	U 0126	204-209	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	238-242
22041445-17	2011	Similarly, the expression of p-ERK was significantly higher with EGF treatment (812.2+-3.5) vs. without EGF group (453.4+-5.8) (P&lt;0.05), while the ERK inhibitor U0126 significantly inhibited the increased p-ERK content in response to EGF treatment (71.0+-1.2 vs. 812.2+-3.5, P&lt;0.05).	U 0126	164-169	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	29-34
22041445-17	2011	Similarly, the expression of p-ERK was significantly higher with EGF treatment (812.2+-3.5) vs. without EGF group (453.4+-5.8) (P&lt;0.05), while the ERK inhibitor U0126 significantly inhibited the increased p-ERK content in response to EGF treatment (71.0+-1.2 vs. 812.2+-3.5, P&lt;0.05).	U 0126	164-169	mitogen-activated protein kinase 1	Homo sapiens	31-34
22041445-19	2011	(5) The ERK inhibitor U0126 also significantly reduced the expression of EGF-induced MMP-9 (0.623+-0.030 vs. 2.112+-0.056, P&lt;0.05) and NF-kappaB (0.325+-0.082 vs. 0.939+-0.153, P&lt;0.05).	U 0126	22-27	mitogen-activated protein kinase 1	Homo sapiens	8-11
22041445-19	2011	(5) The ERK inhibitor U0126 also significantly reduced the expression of EGF-induced MMP-9 (0.623+-0.030 vs. 2.112+-0.056, P&lt;0.05) and NF-kappaB (0.325+-0.082 vs. 0.939+-0.153, P&lt;0.05).	U 0126	22-27	matrix metallopeptidase 9	Homo sapiens	85-90
22041445-19	2011	(5) The ERK inhibitor U0126 also significantly reduced the expression of EGF-induced MMP-9 (0.623+-0.030 vs. 2.112+-0.056, P&lt;0.05) and NF-kappaB (0.325+-0.082 vs. 0.939+-0.153, P&lt;0.05).	U 0126	22-27	nuclear factor kappa B subunit 1	Homo sapiens	138-147
21621512-8	2011	Inhibition of ERK 1/2 with a pharmacological inhibitor (U0126) decreased HUVEC migration and tube formation; these effects too were prevented by SNAP.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	14-21
21463260-6	2011	Serum-induced phosphorylation and degradation of JDP2 are specific to JNK activation since a JNK inhibitor (SP600125) abolishes these effects, whereas p38 and MEK inhibitors (SB203580 and UO126) have no effect.	U 0126	188-193	Jun dimerization protein 2	Homo sapiens	49-53
20924558-9	2011	Pre-treatment with ERK1/2 inhibitor, U0126, increased cell susceptibility to (PhSe)(2).	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	19-25
21073857-6	2011	U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK, and TRPM6 levels.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
21073857-6	2011	U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK, and TRPM6 levels.	U 0126	0-5	epidermal growth factor	Homo sapiens	34-37
21073857-6	2011	U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK, and TRPM6 levels.	U 0126	0-5	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	59-64
21073857-6	2011	U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK, and TRPM6 levels.	U 0126	0-5	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	66-71
21073857-6	2011	U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK, and TRPM6 levels.	U 0126	0-5	transient receptor potential cation channel subfamily M member 6	Homo sapiens	77-82
21730054-12	2011	U0126, an MEK inhibitor, and DPQ, a poly(ADP-ribose) polymerase-1 inhibitor, suppressed PMA-induced up-regulation of H1R gene expression.	U 0126	0-5	histamine receptor H1	Homo sapiens	117-120
21726525-6	2011	It was demonstrated that both U0126, an Erk1/2 inhibitor, and U73122, a PLCgamma inhibitor, increased the proportion of cells in the G(0)/G(1) phase of the cell cycle.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	40-46
21762482-5	2011	RESULTS: We report that U0126, an inhibitor of the prosurvival MEK-ERK pathway, increases bim mRNA levels in sympathetic neurons in the presence of NGF.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
21762482-5	2011	RESULTS: We report that U0126, an inhibitor of the prosurvival MEK-ERK pathway, increases bim mRNA levels in sympathetic neurons in the presence of NGF.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	67-70
21762482-5	2011	RESULTS: We report that U0126, an inhibitor of the prosurvival MEK-ERK pathway, increases bim mRNA levels in sympathetic neurons in the presence of NGF.	U 0126	24-29	BCL2 like 11	Homo sapiens	90-93
21474650-4	2011	Pretreatment of cell monolayers with U-0126 (inhibitor of ERK activation), but not SB-202190 and SP-600125 (p38 MAPK and JNK inhibitors), significantly attenuated EGF-mediated prevention of acetaldehyde-induced changes in resistance, inulin permeability, and redistribution of occludin and ZO-1.	U 0126	37-43	mitogen-activated protein kinase 1	Homo sapiens	58-61
21474650-4	2011	Pretreatment of cell monolayers with U-0126 (inhibitor of ERK activation), but not SB-202190 and SP-600125 (p38 MAPK and JNK inhibitors), significantly attenuated EGF-mediated prevention of acetaldehyde-induced changes in resistance, inulin permeability, and redistribution of occludin and ZO-1.	U 0126	37-43	epidermal growth factor	Homo sapiens	163-166
21474650-4	2011	Pretreatment of cell monolayers with U-0126 (inhibitor of ERK activation), but not SB-202190 and SP-600125 (p38 MAPK and JNK inhibitors), significantly attenuated EGF-mediated prevention of acetaldehyde-induced changes in resistance, inulin permeability, and redistribution of occludin and ZO-1.	U 0126	37-43	occludin	Homo sapiens	277-285
21474650-4	2011	Pretreatment of cell monolayers with U-0126 (inhibitor of ERK activation), but not SB-202190 and SP-600125 (p38 MAPK and JNK inhibitors), significantly attenuated EGF-mediated prevention of acetaldehyde-induced changes in resistance, inulin permeability, and redistribution of occludin and ZO-1.	U 0126	37-43	tight junction protein 1	Homo sapiens	290-294
21490369-7	2011	GH stimulated hepatic expression of IGF-1 mRNA as well as the secretion of IGF-1, effects that were partially or completely blocked by U0126, LY294002, and Hex.	U 0126	135-140	insulin-like growth factor I	Oncorhynchus mykiss	36-41
21490369-7	2011	GH stimulated hepatic expression of IGF-1 mRNA as well as the secretion of IGF-1, effects that were partially or completely blocked by U0126, LY294002, and Hex.	U 0126	135-140	insulin-like growth factor I	Oncorhynchus mykiss	75-80
21558393-10	2011	Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Mus musculus	17-23
21558393-10	2011	Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling.	U 0126	35-40	mucin 1, transmembrane	Mus musculus	150-154
21606674-6	2011	Activation of ERK1/2 was crucial for IFNgamma-induced cell death because MEK1/2 inhibitors, PD0325901 and U0126 efficiently protected cells from apoptosis by suppressing caspase-3 activation.	U 0126	106-111	mitogen-activated protein kinase 3	Homo sapiens	14-20
21606674-6	2011	Activation of ERK1/2 was crucial for IFNgamma-induced cell death because MEK1/2 inhibitors, PD0325901 and U0126 efficiently protected cells from apoptosis by suppressing caspase-3 activation.	U 0126	106-111	interferon gamma	Homo sapiens	37-45
21606674-6	2011	Activation of ERK1/2 was crucial for IFNgamma-induced cell death because MEK1/2 inhibitors, PD0325901 and U0126 efficiently protected cells from apoptosis by suppressing caspase-3 activation.	U 0126	106-111	caspase 3	Homo sapiens	170-179
21666489-10	2011	Furthermore, after treatment with U0126, the cell invasion ability no longer advanced even under the effect of IGF-I either.	U 0126	34-39	insulin like growth factor 1	Homo sapiens	111-116
21444628-6	2011	Blocking ERK1/2 activation by MKK1/2 inhibitor [U0126; 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene)] decreased TS and TP protein levels in both cell lines treated with cisplatin.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	9-15
21444628-6	2011	Blocking ERK1/2 activation by MKK1/2 inhibitor [U0126; 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene)] decreased TS and TP protein levels in both cell lines treated with cisplatin.	U 0126	48-53	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
21444628-6	2011	Blocking ERK1/2 activation by MKK1/2 inhibitor [U0126; 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene)] decreased TS and TP protein levels in both cell lines treated with cisplatin.	U 0126	48-53	thymidine phosphorylase	Homo sapiens	134-136
21444628-6	2011	Blocking ERK1/2 activation by MKK1/2 inhibitor [U0126; 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene)] decreased TS and TP protein levels in both cell lines treated with cisplatin.	U 0126	55-115	mitogen-activated protein kinase 3	Homo sapiens	9-15
21444628-6	2011	Blocking ERK1/2 activation by MKK1/2 inhibitor [U0126; 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene)] decreased TS and TP protein levels in both cell lines treated with cisplatin.	U 0126	55-115	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
21444628-6	2011	Blocking ERK1/2 activation by MKK1/2 inhibitor [U0126; 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene)] decreased TS and TP protein levels in both cell lines treated with cisplatin.	U 0126	55-115	thymidine phosphorylase	Homo sapiens	134-136
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	U 0126	73-78	erythrocyte membrane protein band 4.2	Mus musculus	9-12
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	U 0126	73-78	mitogen-activated protein kinase 3	Mus musculus	13-16
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	U 0126	73-78	mitogen-activated protein kinase 3	Mus musculus	17-21
21453685-7	2011	alpha5beta1 monoclonal antibody and MAPK kinase (MEK) inhibitors (PD98059 and U0126) inhibited the WISP-1-induced increase of the migration and MMP-2 up-regulation of chondrosarcoma cells.	U 0126	78-83	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
21453685-7	2011	alpha5beta1 monoclonal antibody and MAPK kinase (MEK) inhibitors (PD98059 and U0126) inhibited the WISP-1-induced increase of the migration and MMP-2 up-regulation of chondrosarcoma cells.	U 0126	78-83	cellular communication network factor 4	Homo sapiens	99-105
21453685-7	2011	alpha5beta1 monoclonal antibody and MAPK kinase (MEK) inhibitors (PD98059 and U0126) inhibited the WISP-1-induced increase of the migration and MMP-2 up-regulation of chondrosarcoma cells.	U 0126	78-83	matrix metallopeptidase 2	Homo sapiens	144-149
21458501-5	2011	Using mitogen-activated protein kinase kinases inhibitor U0126, we found that the mRNA expression levels of ATP synthase, cytochrome-C, mitochondrial transcription factor A, and mitofusin 2 were reduced.	U 0126	57-62	cytochrome c, somatic	Homo sapiens	122-134
21458501-5	2011	Using mitogen-activated protein kinase kinases inhibitor U0126, we found that the mRNA expression levels of ATP synthase, cytochrome-C, mitochondrial transcription factor A, and mitofusin 2 were reduced.	U 0126	57-62	transcription factor A, mitochondrial	Homo sapiens	136-172
21458501-5	2011	Using mitogen-activated protein kinase kinases inhibitor U0126, we found that the mRNA expression levels of ATP synthase, cytochrome-C, mitochondrial transcription factor A, and mitofusin 2 were reduced.	U 0126	57-62	mitofusin 2	Homo sapiens	178-189
21458501-7	2011	Importantly, over-expression of PGC-1beta partially reversed the reduction of mitochondrial mass upon U0126 treatment.	U 0126	102-107	PPARG coactivator 1 beta	Homo sapiens	32-41
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	interleukin 6	Mus musculus	175-179
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	mitogen-activated protein kinase 14	Mus musculus	230-233
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	signal transducer and activator of transcription 3	Mus musculus	238-243
21244852-6	2011	The mechanism conducted demonstrated that 17beta-estradial activated ERK1/2 but not JNK and p38, and U0126, an ERK1/2 pathway inhibitor, significantly downregulated vitamin D receptor expression induced by 17beta-estradial in MC3T3-E1 cells.	U 0126	101-106	mitogen-activated protein kinase 3	Mus musculus	111-117
21447633-6	2011	Upon cell activation phosphorylated Ser-30-DCLK-short was translocated from the cytoplasm into the nucleus, and the ERK blocker U0126 inhibited this process.	U 0126	128-133	mitogen-activated protein kinase 1 L homeolog	Xenopus laevis	116-119
21244852-6	2011	The mechanism conducted demonstrated that 17beta-estradial activated ERK1/2 but not JNK and p38, and U0126, an ERK1/2 pathway inhibitor, significantly downregulated vitamin D receptor expression induced by 17beta-estradial in MC3T3-E1 cells.	U 0126	101-106	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	165-183
21426904-8	2011	Inhibition of MAP kinase kinase (MEK) with U0126 also blocked bradykinin-induced ERK1/2 phosphorylation.	U 0126	43-48	mitogen-activated protein kinase kinase 7	Homo sapiens	14-31
21426904-8	2011	Inhibition of MAP kinase kinase (MEK) with U0126 also blocked bradykinin-induced ERK1/2 phosphorylation.	U 0126	43-48	mitogen-activated protein kinase kinase 7	Homo sapiens	33-36
21426904-8	2011	Inhibition of MAP kinase kinase (MEK) with U0126 also blocked bradykinin-induced ERK1/2 phosphorylation.	U 0126	43-48	kininogen 1	Homo sapiens	62-72
21426904-8	2011	Inhibition of MAP kinase kinase (MEK) with U0126 also blocked bradykinin-induced ERK1/2 phosphorylation.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	81-87
21385599-6	2011	AA induced the ERK phosphorylation, and this was abolished by the treatment of U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	79-84	mitogen-activated protein kinase 1	Mus musculus	15-18
21385599-6	2011	AA induced the ERK phosphorylation, and this was abolished by the treatment of U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	79-84	midkine	Mus musculus	117-120
21385599-6	2011	AA induced the ERK phosphorylation, and this was abolished by the treatment of U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK.	U 0126	79-84	mitogen-activated protein kinase 1	Mus musculus	144-147
21385599-7	2011	AA-induced expression and promoter activity of COX-2 were suppressed by U0126.	U 0126	72-77	cytochrome c oxidase II, mitochondrial	Mus musculus	47-52
21385599-8	2011	U0126 treatment attenuated AA-induced transactivation of AP-1 and NF-kappaB, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	66-75
21385599-8	2011	U0126 treatment attenuated AA-induced transactivation of AP-1 and NF-kappaB, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	0-5	midkine	Mus musculus	97-100
21385599-8	2011	U0126 treatment attenuated AA-induced transactivation of AP-1 and NF-kappaB, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	101-104
21385599-8	2011	U0126 treatment attenuated AA-induced transactivation of AP-1 and NF-kappaB, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression.	U 0126	0-5	cytochrome c oxidase II, mitochondrial	Mus musculus	133-138
21455571-10	2011	Correspondingly, U0126 quenched ERK phosphorylation and reduced the expression of molecules involved in migration.	U 0126	17-22	mitogen-activated protein kinase 1	Homo sapiens	32-35
21573703-6	2011	Furthermore, inhibition of the MEK pathway with U0126 reduced DNMT1 expression, but not that of DNMT3a and 3b, and restored the hypoxia-inducibility of BNIP3, suggesting that the DNA methylation of the BNIP3 promoter was mediated by DNMT1 via the MEK pathway.	U 0126	48-53	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
21421992-7	2011	U0126 treatment increased secretion of both apoB100 and TG and decreased the ubiquitination and cellular accumu-lation of apoB-100.	U 0126	0-5	apolipoprotein B	Homo sapiens	44-51
21421992-7	2011	U0126 treatment increased secretion of both apoB100 and TG and decreased the ubiquitination and cellular accumu-lation of apoB-100.	U 0126	0-5	apolipoprotein B	Homo sapiens	122-130
21421992-8	2011	Furthermore, p97 knockdown caused apoB-100 to accumulate in the cell, but if gp78 was concomitantly reduced or assembly was enhanced by U0126 treatment, cellular apoB-100 returned toward baseline.	U 0126	136-141	apolipoprotein B	Homo sapiens	162-170
21338358-8	2011	IL-8 up-regulation by LL-37 was completely abrogated by 20 mum U0126, consistent with transient phosphorylation of p44/42 MAP kinases.	U 0126	63-68	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
21338358-8	2011	IL-8 up-regulation by LL-37 was completely abrogated by 20 mum U0126, consistent with transient phosphorylation of p44/42 MAP kinases.	U 0126	63-68	cathelicidin antimicrobial peptide	Homo sapiens	22-27
21338358-8	2011	IL-8 up-regulation by LL-37 was completely abrogated by 20 mum U0126, consistent with transient phosphorylation of p44/42 MAP kinases.	U 0126	63-68	interferon induced protein 44	Homo sapiens	115-118
21573703-6	2011	Furthermore, inhibition of the MEK pathway with U0126 reduced DNMT1 expression, but not that of DNMT3a and 3b, and restored the hypoxia-inducibility of BNIP3, suggesting that the DNA methylation of the BNIP3 promoter was mediated by DNMT1 via the MEK pathway.	U 0126	48-53	DNA methyltransferase 1	Homo sapiens	62-67
21573703-6	2011	Furthermore, inhibition of the MEK pathway with U0126 reduced DNMT1 expression, but not that of DNMT3a and 3b, and restored the hypoxia-inducibility of BNIP3, suggesting that the DNA methylation of the BNIP3 promoter was mediated by DNMT1 via the MEK pathway.	U 0126	48-53	BCL2 interacting protein 3	Homo sapiens	152-157
21573703-6	2011	Furthermore, inhibition of the MEK pathway with U0126 reduced DNMT1 expression, but not that of DNMT3a and 3b, and restored the hypoxia-inducibility of BNIP3, suggesting that the DNA methylation of the BNIP3 promoter was mediated by DNMT1 via the MEK pathway.	U 0126	48-53	BCL2 interacting protein 3	Homo sapiens	202-207
21573703-6	2011	Furthermore, inhibition of the MEK pathway with U0126 reduced DNMT1 expression, but not that of DNMT3a and 3b, and restored the hypoxia-inducibility of BNIP3, suggesting that the DNA methylation of the BNIP3 promoter was mediated by DNMT1 via the MEK pathway.	U 0126	48-53	DNA methyltransferase 1	Homo sapiens	233-238
21573703-6	2011	Furthermore, inhibition of the MEK pathway with U0126 reduced DNMT1 expression, but not that of DNMT3a and 3b, and restored the hypoxia-inducibility of BNIP3, suggesting that the DNA methylation of the BNIP3 promoter was mediated by DNMT1 via the MEK pathway.	U 0126	48-53	mitogen-activated protein kinase kinase 7	Homo sapiens	247-250
21276846-7	2011	In addition, ERK inhibitor (U0126) treated cells exhibited decreased MMP-9 activity in the zymographic assay.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	13-16
21477078-4	2011	Treatment of melanoma cells with the MEK1/2 inhibitor, U0126, or the two pan-CDK and GSK3 inhibitors, Flavopiridol and R547, resulted in decreased linker phosphorylation of Smad2 and Smad3.	U 0126	55-60	SMAD family member 2	Homo sapiens	173-178
21477078-4	2011	Treatment of melanoma cells with the MEK1/2 inhibitor, U0126, or the two pan-CDK and GSK3 inhibitors, Flavopiridol and R547, resulted in decreased linker phosphorylation of Smad2 and Smad3.	U 0126	55-60	SMAD family member 3	Homo sapiens	183-188
21354245-7	2011	Pretreatment of rat primary astrocytes with the MAPK kinase inhibitor U0126 or the JNK inhibitor SP600125 strongly inhibited imipramine-stimulated EGR-1 expression.	U 0126	70-75	mitogen-activated protein kinase 1	Mus musculus	48-52
21354245-7	2011	Pretreatment of rat primary astrocytes with the MAPK kinase inhibitor U0126 or the JNK inhibitor SP600125 strongly inhibited imipramine-stimulated EGR-1 expression.	U 0126	70-75	early growth response 1	Rattus norvegicus	147-152
21276846-7	2011	In addition, ERK inhibitor (U0126) treated cells exhibited decreased MMP-9 activity in the zymographic assay.	U 0126	28-33	matrix metallopeptidase 9	Homo sapiens	69-74
21300145-7	2011	Exposure of HL-60 cells with AAI activated both ERK1/2 and p38 kinase phosphorylation, while only MEK1/2 inhibitor, U0126, significantly decreased AAI-mediated ROS.	U 0126	116-121	mitogen-activated protein kinase kinase 1	Homo sapiens	98-104
21875481-2	2011	METHODS: The expression level of p-ERK1/2 after serum starvation and treatment with U0126 inhibitor was detected in esophageal cancer cell line EC9706 by Western blot assay.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	35-41
21875481-6	2011	The expression level of p-ERK1/2 in Ec9706 cells reached a peak at 10 min after transient serum stimulation, and p-ERK1/2 expression was totally restrained after the treatment with 50 micromol/L U0126.	U 0126	195-200	mitogen-activated protein kinase 3	Homo sapiens	26-32
21875481-6	2011	The expression level of p-ERK1/2 in Ec9706 cells reached a peak at 10 min after transient serum stimulation, and p-ERK1/2 expression was totally restrained after the treatment with 50 micromol/L U0126.	U 0126	195-200	mitogen-activated protein kinase 3	Homo sapiens	115-121
21621740-8	2011	The ERK kinase inhibitor, U0126, partially prevented the induction of PAI-1 by AGEs.	U 0126	26-31	mitogen activated protein kinase 3	Rattus norvegicus	4-7
21621740-8	2011	The ERK kinase inhibitor, U0126, partially prevented the induction of PAI-1 by AGEs.	U 0126	26-31	serpin family E member 1	Rattus norvegicus	70-75
21438539-5	2011	Nrf2 expression was attenuated by LY294002 and U0126, inhibitors of phosphatidylinositol-3-kinase and MEK1/2, respectively.	U 0126	47-52	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
21376032-7	2011	U0126, a specific ERK activation inhibitor, abrogated icaritin-induced G2/M cell cycle arrest and cell apoptosis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	18-21
21438539-5	2011	Nrf2 expression was attenuated by LY294002 and U0126, inhibitors of phosphatidylinositol-3-kinase and MEK1/2, respectively.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Homo sapiens	102-108
21384922-11	2011	Preincubation of submandibular glands with ERK1/2 inhibitors PD98059 or U0126 inhibited carbachol-induced F-actin redistribution.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	43-49
21282571-6	2011	The contribution of non-Smad signaling pathways to TGF-beta-induced alpha-SMA and PAI-1 expression was assessed using the small molecule inhibitors U0126 and LY294002.	U 0126	148-153	transforming growth factor beta 1	Homo sapiens	51-59
21282571-9	2011	The MEK-inhibitor U0126 blocked TGF-beta-induced PAI-1 expression, whereas alpha-SMA expression was enhanced.	U 0126	18-23	transforming growth factor beta 1	Homo sapiens	32-40
21282571-9	2011	The MEK-inhibitor U0126 blocked TGF-beta-induced PAI-1 expression, whereas alpha-SMA expression was enhanced.	U 0126	18-23	serpin family E member 1	Homo sapiens	49-54
21478672-7	2011	We also observed an increase in ERK phosphorylation in ARCaP Snail-transfected cells as compared to control ARCaP-Neo cells, and inhibition of the MAPK pathway with UO126 inhibitor in ARCaP Snail-transfected cells abrogated Snail-mediated decrease in cell adhesion and reinduced a5, a2 and b1 integrin expression.	U 0126	165-170	mitogen-activated protein kinase 1	Homo sapiens	32-35
21447487-9	2011	Subsequent activation of MMPs resulted in increased cell migration, invasion, and wound-healing activity under hypoxia-reoxygenation, which was decreased by LY294002 (AKT inhibitor) and U0126 (ERK inhibitor) in rat cardiac fibroblasts.	U 0126	186-191	matrix metallopeptidase 2	Rattus norvegicus	25-29
21447487-9	2011	Subsequent activation of MMPs resulted in increased cell migration, invasion, and wound-healing activity under hypoxia-reoxygenation, which was decreased by LY294002 (AKT inhibitor) and U0126 (ERK inhibitor) in rat cardiac fibroblasts.	U 0126	186-191	Eph receptor B1	Rattus norvegicus	193-196
21478672-7	2011	We also observed an increase in ERK phosphorylation in ARCaP Snail-transfected cells as compared to control ARCaP-Neo cells, and inhibition of the MAPK pathway with UO126 inhibitor in ARCaP Snail-transfected cells abrogated Snail-mediated decrease in cell adhesion and reinduced a5, a2 and b1 integrin expression.	U 0126	165-170	snail family transcriptional repressor 1	Homo sapiens	61-66
21478672-7	2011	We also observed an increase in ERK phosphorylation in ARCaP Snail-transfected cells as compared to control ARCaP-Neo cells, and inhibition of the MAPK pathway with UO126 inhibitor in ARCaP Snail-transfected cells abrogated Snail-mediated decrease in cell adhesion and reinduced a5, a2 and b1 integrin expression.	U 0126	165-170	snail family transcriptional repressor 1	Homo sapiens	190-195
21478672-7	2011	We also observed an increase in ERK phosphorylation in ARCaP Snail-transfected cells as compared to control ARCaP-Neo cells, and inhibition of the MAPK pathway with UO126 inhibitor in ARCaP Snail-transfected cells abrogated Snail-mediated decrease in cell adhesion and reinduced a5, a2 and b1 integrin expression.	U 0126	165-170	snail family transcriptional repressor 1	Homo sapiens	190-195
20868664-10	2011	U0126 inhibited only phosphorylation of ERK1/2, while SP600125 at higher concentrations not only inhibited phosphorylation of c-Jun but also ERK1/2 phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	40-46
21484156-7	2011	Interestingly, U0126 induced apoptosis and blocked the above-mentioned proteins in a similar way to IL-1beta.	U 0126	15-20	interleukin 1 beta	Homo sapiens	100-108
21492167-6	2011	Polymyxin (TLR4 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor) and U0126 (MEK1/2 inhibitor) antagonized the effects of the LPS on ACh-induced contractions in duodenal smooth muscle.	U 0126	91-96	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	98-104
21901168-3	2011	Chemical inhibitors U0126 and PD98059 block mitogen-activated protein kinase kinase 1 (MEK1)-mediated phosphorylation of extracellular signal-regulated kinase (ERK) and prevent apoptosis.	U 0126	20-25	mitogen-activated protein kinase kinase 1	Homo sapiens	44-85
21901168-3	2011	Chemical inhibitors U0126 and PD98059 block mitogen-activated protein kinase kinase 1 (MEK1)-mediated phosphorylation of extracellular signal-regulated kinase (ERK) and prevent apoptosis.	U 0126	20-25	mitogen-activated protein kinase kinase 1	Homo sapiens	87-91
21901168-3	2011	Chemical inhibitors U0126 and PD98059 block mitogen-activated protein kinase kinase 1 (MEK1)-mediated phosphorylation of extracellular signal-regulated kinase (ERK) and prevent apoptosis.	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	121-158
21901168-3	2011	Chemical inhibitors U0126 and PD98059 block mitogen-activated protein kinase kinase 1 (MEK1)-mediated phosphorylation of extracellular signal-regulated kinase (ERK) and prevent apoptosis.	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	160-163
21901168-6	2011	U0126 inhibits PMA-induced dissociation of WOX1/MEK1 complex and supports survival of Jurkat cells.	U 0126	0-5	WW domain containing oxidoreductase	Homo sapiens	43-47
21901168-6	2011	U0126 inhibits PMA-induced dissociation of WOX1/MEK1 complex and supports survival of Jurkat cells.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	48-52
21244427-7	2011	The protective action of PACAP was blocked by the protein kinase A inhibitor H89, the protein kinase C inhibitor chelerythrine and the mitogen-activated protein (MAP)-kinase kinase (MEK) inhibitor U0126.	U 0126	197-202	adenylate cyclase activating polypeptide 1	Rattus norvegicus	25-30
21354320-8	2011	U0126 prevented the endotoxin-induced increase in phosphorylated ERK1/2 and iNOS expressions.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	65-71
21354320-8	2011	U0126 prevented the endotoxin-induced increase in phosphorylated ERK1/2 and iNOS expressions.	U 0126	0-5	nitric oxide synthase 2	Rattus norvegicus	76-80
21544242-8	2011	The AKT and ERK inhibitors, LY294002 and U0126, suppressed HIF-1alpha and VEGF expression and angiogenesis.	U 0126	41-46	AKT serine/threonine kinase 1	Homo sapiens	4-7
21440529-9	2011	The specific MEK inhibitor, U0126, significantly blocks EGF and TGF-alpha-mediated ERK1/2 activation and subsequent MMP1 induction in SK-BR3 cells.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
21440529-9	2011	The specific MEK inhibitor, U0126, significantly blocks EGF and TGF-alpha-mediated ERK1/2 activation and subsequent MMP1 induction in SK-BR3 cells.	U 0126	28-33	epidermal growth factor	Homo sapiens	56-59
21440529-9	2011	The specific MEK inhibitor, U0126, significantly blocks EGF and TGF-alpha-mediated ERK1/2 activation and subsequent MMP1 induction in SK-BR3 cells.	U 0126	28-33	transforming growth factor alpha	Homo sapiens	64-73
21440529-9	2011	The specific MEK inhibitor, U0126, significantly blocks EGF and TGF-alpha-mediated ERK1/2 activation and subsequent MMP1 induction in SK-BR3 cells.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	83-89
21440529-9	2011	The specific MEK inhibitor, U0126, significantly blocks EGF and TGF-alpha-mediated ERK1/2 activation and subsequent MMP1 induction in SK-BR3 cells.	U 0126	28-33	matrix metallopeptidase 1	Homo sapiens	116-120
21544242-8	2011	The AKT and ERK inhibitors, LY294002 and U0126, suppressed HIF-1alpha and VEGF expression and angiogenesis.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	12-15
21544242-8	2011	The AKT and ERK inhibitors, LY294002 and U0126, suppressed HIF-1alpha and VEGF expression and angiogenesis.	U 0126	41-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
21544242-8	2011	The AKT and ERK inhibitors, LY294002 and U0126, suppressed HIF-1alpha and VEGF expression and angiogenesis.	U 0126	41-46	vascular endothelial growth factor A	Homo sapiens	74-78
21295555-5	2011	The riluzole-induced CREB phosphorylation was completely blocked by a mitogen-activated protein kinase kinase (MEK) inhibitor (U0126).	U 0126	127-132	cAMP responsive element binding protein 1	Rattus norvegicus	21-25
21492439-5	2011	Biphasic activation of both pathways was suppressed by the selective inhibitor, Ly294002 for PI3K and U0126 for MAPK kinase (MEK1/2), respectively.	U 0126	102-107	mitogen-activated protein kinase kinase 1	Homo sapiens	125-131
21228323-9	2011	Inhibitors of ERK (PD98059 and U0126) abolish the antiinflammatory signal mediated by APC.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	14-17
21228323-9	2011	Inhibitors of ERK (PD98059 and U0126) abolish the antiinflammatory signal mediated by APC.	U 0126	31-36	APC regulator of WNT signaling pathway	Homo sapiens	86-89
21508358-7	2011	The 143B cells treated with U0126, a MEK/ERK inhibitor, had significantly lower in vitro invasion ability compared with controls.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	37-40
21297032-7	2011	The inhibition of MEK1 using PD-98059 and U-0126 significantly reduced the phosphorylation and activity of Nox5 in response to PMA but not to the calcium-mobilizing stimulus ionomycin.	U 0126	42-48	NADPH oxidase 5	Homo sapiens	107-111
21250784-6	2011	ERK inhibition by U0126 or Nrf2 suppression by Nrf2 RNAi transfection almost completely abrogated the cytoprotection against menadione-induced apoptosis in (-)Sch B-pre-treated cells.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	0-3
21214543-6	2011	Our evaluation of possible cellular mechanisms suggested that G-proteins, phospholipase C and the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) are involved in catestatin-induced mast cell activation as evidenced by the inhibitory effects of pertussis toxin (G-protein inhibitor), U-73122 (phospholipase C inhibitor) and U0126 (ERK inhibitor), respectively.	U 0126	352-357	mitogen-activated protein kinase 1	Homo sapiens	170-173
21214543-6	2011	Our evaluation of possible cellular mechanisms suggested that G-proteins, phospholipase C and the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) are involved in catestatin-induced mast cell activation as evidenced by the inhibitory effects of pertussis toxin (G-protein inhibitor), U-73122 (phospholipase C inhibitor) and U0126 (ERK inhibitor), respectively.	U 0126	352-357	chromogranin A	Homo sapiens	191-201
21300799-7	2011	In contrast, MAPK/ERK pathway inhibition with UO126 significantly potentiates excitotoxic oligodendrocyte death and increases cytochrome c release, mitochondrial depolarization, and mitochondrial calcium overload produced by AMPA receptor stimulation.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	18-21
21300799-7	2011	In contrast, MAPK/ERK pathway inhibition with UO126 significantly potentiates excitotoxic oligodendrocyte death and increases cytochrome c release, mitochondrial depolarization, and mitochondrial calcium overload produced by AMPA receptor stimulation.	U 0126	46-51	cytochrome c, somatic	Homo sapiens	126-138
21552007-10	2011	And, it was shown that GM130 detached from the spindle poles in oocytes treated with MEK specific inhibitor U0126.	U 0126	108-113	golgi autoantigen, golgin subfamily a, 2	Mus musculus	23-28
21552007-10	2011	And, it was shown that GM130 detached from the spindle poles in oocytes treated with MEK specific inhibitor U0126.	U 0126	108-113	midkine	Mus musculus	85-88
21233129-6	2011	Only after intraperitoneal treatment of U0126, an inhibitor of ERK phosphorylation, was lens development restored in Nf1 mutants.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	63-66
21233129-6	2011	Only after intraperitoneal treatment of U0126, an inhibitor of ERK phosphorylation, was lens development restored in Nf1 mutants.	U 0126	40-45	neurofibromin 1	Homo sapiens	117-120
20446028-5	2011	At high LPS concentration some compounds even potentiated TNF-alpha production in the rat assay, which could be reverted in the presence of the ERK pathway inhibitor U0126.	U 0126	166-171	tumor necrosis factor	Rattus norvegicus	58-67
20446028-5	2011	At high LPS concentration some compounds even potentiated TNF-alpha production in the rat assay, which could be reverted in the presence of the ERK pathway inhibitor U0126.	U 0126	166-171	Eph receptor B1	Rattus norvegicus	144-147
21262967-8	2011	Phosphorylation as well as PLA(2) activity and ROS generation were markedly reduced by the MAPK inhibitor, U0126.	U 0126	107-112	phospholipase A2, group IB, pancreas	Mus musculus	27-33
21508358-7	2011	The 143B cells treated with U0126, a MEK/ERK inhibitor, had significantly lower in vitro invasion ability compared with controls.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	41-44
20857409-7	2011	Also, inhibitors of KIT downstream effectors, U0126 that blocks MEK1/2 as well as wortmannin and LY294002 that inhibit phosphatidylinositol 3-kinase-dependent AKT phosphorylation, inhibited the proliferation of MCC-1 cells.	U 0126	46-51	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	20-23
20857409-7	2011	Also, inhibitors of KIT downstream effectors, U0126 that blocks MEK1/2 as well as wortmannin and LY294002 that inhibit phosphatidylinositol 3-kinase-dependent AKT phosphorylation, inhibited the proliferation of MCC-1 cells.	U 0126	46-51	AKT serine/threonine kinase 1	Homo sapiens	159-162
21193948-7	2011	Both ERK inhibition by U0126 and Nrf2 suppression by Nrf2 RNAi transfection largely abolished the cytoprotection against hypoxia/reoxygenation-induced apoptosis in (-)Sch B-pretreated cells.	U 0126	23-28	Eph receptor B1	Rattus norvegicus	5-8
21278199-6	2011	Treatment with the specific ERK1/2 inhibitor U0126 during the whole differentiation period hampered hMSCs" adipogenic differentiation, as lipid droplets appeared in very few cells and were reduced in number and size.	U 0126	45-50	mitogen-activated protein kinase 3	Homo sapiens	28-34
20597604-4	2011	The aim in the present study was to determine whether treatment with the MEK1/2 inhibitor U0126 can prevent cerebrovascular receptor upregulation and improve functional outcome after experimental SAH in rats.	U 0126	90-95	mitogen activated protein kinase kinase 1	Rattus norvegicus	73-79
20597604-12	2011	Endothelin-B and 5-HT(1B) expression levels in U0126-treated SAH-induced rats were at the levels in sham-operated rats (101.9 +- 13.38% and 91.44 +- 16.75%, respectively).	U 0126	47-52	endothelin receptor type B	Rattus norvegicus	0-12
20597604-12	2011	Endothelin-B and 5-HT(1B) expression levels in U0126-treated SAH-induced rats were at the levels in sham-operated rats (101.9 +- 13.38% and 91.44 +- 16.75%, respectively).	U 0126	47-52	5-hydroxytryptamine receptor 1B	Rattus norvegicus	17-24
20597604-14	2011	CONCLUSIONS: The authors demonstrated that experimental SAH induces upregulation of ET(B) and 5-HT(1B) receptors in cerebrovascular smooth muscles and that treatment with the MEK1/2 inhibitor U0126 abolishes this receptor upregulation.	U 0126	192-197	endothelin receptor type B	Rattus norvegicus	84-102
20597604-14	2011	CONCLUSIONS: The authors demonstrated that experimental SAH induces upregulation of ET(B) and 5-HT(1B) receptors in cerebrovascular smooth muscles and that treatment with the MEK1/2 inhibitor U0126 abolishes this receptor upregulation.	U 0126	192-197	mitogen activated protein kinase kinase 1	Rattus norvegicus	175-181
21219922-6	2011	Phosphorylated forms of mitogen-activated protein kinases (MAPKs)-including extracellular signal-regulated protein kinase (ERK), c-Jun NH2-terminal kinase, and p38-increased after CdCl2 exposure, whereas treatment with the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 suppressed the accumulation and phosphorylation of c-Fos.	U 0126	249-254	mitogen-activated protein kinase 1	Homo sapiens	59-63
21292824-7	2011	Consistent with a role for ERKs in GH-induced expression of these genes, treatment with U0126 to block ERK phosphorylation inhibited their GH-induced expression.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	27-31
21292824-7	2011	Consistent with a role for ERKs in GH-induced expression of these genes, treatment with U0126 to block ERK phosphorylation inhibited their GH-induced expression.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	27-30
21241747-6	2011	In contrast, the MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase) inhibitor U0126 suppressed the synergism without inhibiting CA-induced NGF expression.	U 0126	111-116	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
21241747-6	2011	In contrast, the MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase) inhibitor U0126 suppressed the synergism without inhibiting CA-induced NGF expression.	U 0126	111-116	mitogen-activated protein kinase kinase 7	Homo sapiens	22-99
21241747-6	2011	In contrast, the MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase) inhibitor U0126 suppressed the synergism without inhibiting CA-induced NGF expression.	U 0126	111-116	nerve growth factor	Homo sapiens	172-175
21178106-10	2011	Pretreatment of HEK-293 cells with the JAK inhibitor P6 or the ERK inhibitor U0126 blocked ERK phosphorylation.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	63-66
21178106-10	2011	Pretreatment of HEK-293 cells with the JAK inhibitor P6 or the ERK inhibitor U0126 blocked ERK phosphorylation.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	91-94
21178106-11	2011	Both P6 and U0126 also inhibited the stimulatory effect of LIF on T-type Ca(2+) channel expression.	U 0126	12-17	LIF interleukin 6 family cytokine	Homo sapiens	59-62
20848085-6	2011	Pretreatment with the MAP kinase/ERK kinase 1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by MBZ, ABZ, FBZ, or OBZ treatment in THP-1 cells, but the p38 mitogen-activated protein kinase inhibitor SB203580 or JNK1/2 inhibitor SP600125 did not.	U 0126	58-63	C-X-C motif chemokine ligand 8	Homo sapiens	105-109
20848085-6	2011	Pretreatment with the MAP kinase/ERK kinase 1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by MBZ, ABZ, FBZ, or OBZ treatment in THP-1 cells, but the p38 mitogen-activated protein kinase inhibitor SB203580 or JNK1/2 inhibitor SP600125 did not.	U 0126	58-63	tumor necrosis factor	Homo sapiens	114-122
20848085-6	2011	Pretreatment with the MAP kinase/ERK kinase 1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by MBZ, ABZ, FBZ, or OBZ treatment in THP-1 cells, but the p38 mitogen-activated protein kinase inhibitor SB203580 or JNK1/2 inhibitor SP600125 did not.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	189-192
20848085-6	2011	Pretreatment with the MAP kinase/ERK kinase 1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by MBZ, ABZ, FBZ, or OBZ treatment in THP-1 cells, but the p38 mitogen-activated protein kinase inhibitor SB203580 or JNK1/2 inhibitor SP600125 did not.	U 0126	58-63	mitogen-activated protein kinase 8	Homo sapiens	248-254
21084714-5	2011	The inhibition of MAPK3/1 by U0126 did not affect the activation of MAPK14 by ET-1.	U 0126	29-34	mitogen activated protein kinase 3	Rattus norvegicus	18-23
21167264-10	2011	However, when the cells were pretreated with inhibitors (5-aza-CdR or U0126) for 24h, the effects of arsenite on RECK, MMP-9, -2, uPA and VEGF expression were suppressed.	U 0126	70-75	reversion inducing cysteine rich protein with kazal motifs	Homo sapiens	113-117
21167264-10	2011	However, when the cells were pretreated with inhibitors (5-aza-CdR or U0126) for 24h, the effects of arsenite on RECK, MMP-9, -2, uPA and VEGF expression were suppressed.	U 0126	70-75	matrix metallopeptidase 9	Homo sapiens	119-124
21167264-10	2011	However, when the cells were pretreated with inhibitors (5-aza-CdR or U0126) for 24h, the effects of arsenite on RECK, MMP-9, -2, uPA and VEGF expression were suppressed.	U 0126	70-75	proline rich acidic protein 1	Homo sapiens	130-133
21167264-10	2011	However, when the cells were pretreated with inhibitors (5-aza-CdR or U0126) for 24h, the effects of arsenite on RECK, MMP-9, -2, uPA and VEGF expression were suppressed.	U 0126	70-75	vascular endothelial growth factor A	Homo sapiens	138-142
21130731-6	2011	Inhibition of AKT activation by phosphoinocitide 3-kinase (PI3K) inhibitor LY294002 resulted in reduced Bcl-2 expression and enhanced Bax expression and thus induced apoptosis in the resistant cells, whereas inhibition of ERK1/2 activation by mitogen-activated protein kinase (MEK) inhibitor U0126 did not induce apoptosis without affecting the expression of Bcl-2 and Bax but decreased cell growth.	U 0126	292-297	AKT serine/threonine kinase 1	Homo sapiens	14-17
20857415-6	2011	In support of this speculation, OFSS inhibition of TNF-alpha-induced apoptosis was unaffected by inhibitors of several pro-survival signaling pathways including pI3-kinase (LY294002), MAPK/ERK kinase (PD98059 or U0126), intracellular Ca2+ release (U73122), NO production (L-NAME), or protein synthesis (cycloheximide) that were applied to cells during exposure to OFSS and during TNF-alpha treatment.	U 0126	212-217	tumor necrosis factor	Mus musculus	51-60
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	U 0126	137-142	mitogen-activated protein kinase 3	Mus musculus	119-125
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	U 0126	137-142	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	154-160
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	U 0126	137-142	interleukin 6	Mus musculus	170-174
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	U 0126	137-142	mitogen-activated protein kinase 3	Mus musculus	213-219
21496421-9	2011	U0126 blocked the preconditioning induced by dual exposure to 3vol% isoflurane (6.13% +- 1.56%, P &lt; 0.01) and ERK1/2 activities.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	113-119
25961241-5	2011	Increased phosphorylation of p44/42MAPK and c-Raf reflected removal of insulin from the medium and proliferation of all three cell lines was inhibited to a lesser extent by PD98059 and U0126 following long-term oestrogen/insulin withdrawal, demonstrating a reduced dependence on the MAPK pathway.	U 0126	185-190	interferon induced protein 44	Homo sapiens	29-32
25961241-5	2011	Increased phosphorylation of p44/42MAPK and c-Raf reflected removal of insulin from the medium and proliferation of all three cell lines was inhibited to a lesser extent by PD98059 and U0126 following long-term oestrogen/insulin withdrawal, demonstrating a reduced dependence on the MAPK pathway.	U 0126	185-190	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	44-49
25961241-5	2011	Increased phosphorylation of p44/42MAPK and c-Raf reflected removal of insulin from the medium and proliferation of all three cell lines was inhibited to a lesser extent by PD98059 and U0126 following long-term oestrogen/insulin withdrawal, demonstrating a reduced dependence on the MAPK pathway.	U 0126	185-190	insulin	Homo sapiens	71-78
21328467-6	2011	Pretreatment of A549 cells with the MAPK kinase (MEK) inhibitor PD98059 or U0126 inhibited RANKL-mediated migration and ICAM-1 expression.	U 0126	75-80	TNF superfamily member 11	Homo sapiens	91-96
21328467-6	2011	Pretreatment of A549 cells with the MAPK kinase (MEK) inhibitor PD98059 or U0126 inhibited RANKL-mediated migration and ICAM-1 expression.	U 0126	75-80	intercellular adhesion molecule 1	Homo sapiens	120-126
21129045-5	2011	Treatment of melanotrophs in vitro with the mitogen-activated protein kinase kinase inhibitor U0126 markedly reduced ERK phosphorylation and lowered the transcription as well as the translation of POMC.	U 0126	94-99	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	117-120
21129045-5	2011	Treatment of melanotrophs in vitro with the mitogen-activated protein kinase kinase inhibitor U0126 markedly reduced ERK phosphorylation and lowered the transcription as well as the translation of POMC.	U 0126	94-99	proopiomelanocortin L homeolog	Xenopus laevis	197-201
21209378-8	2011	The NRAS(Q61K) mutation sensitized Hut78 cells toward growth inhibition by the MEK inhibitors U0126, AZD6244, and PD0325901.	U 0126	94-99	NRAS proto-oncogene, GTPase	Homo sapiens	4-8
21209378-8	2011	The NRAS(Q61K) mutation sensitized Hut78 cells toward growth inhibition by the MEK inhibitors U0126, AZD6244, and PD0325901.	U 0126	94-99	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
21340437-8	2011	The results showed U0126 prevented the activation of Erk1/2 maintained by GRP75, but the total Erk1/2 expression was not affected.	U 0126	19-24	mitogen activated protein kinase 3	Rattus norvegicus	53-59
21340437-8	2011	The results showed U0126 prevented the activation of Erk1/2 maintained by GRP75, but the total Erk1/2 expression was not affected.	U 0126	19-24	heat shock protein family A (Hsp70) member 9	Rattus norvegicus	74-79
21340437-11	2011	These results suggest U0126 prevents protective effect of GRP75 on PC12 cells by inhibiting Erk1/2 phosphorylation, which certifies that GRP75 can inhibit the mitochondria-dependent apoptotic pathway through Raf/Mek/Erk1/2 signaling cascade.	U 0126	22-27	heat shock protein family A (Hsp70) member 9	Rattus norvegicus	58-63
21340437-11	2011	These results suggest U0126 prevents protective effect of GRP75 on PC12 cells by inhibiting Erk1/2 phosphorylation, which certifies that GRP75 can inhibit the mitochondria-dependent apoptotic pathway through Raf/Mek/Erk1/2 signaling cascade.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	92-98
21340437-11	2011	These results suggest U0126 prevents protective effect of GRP75 on PC12 cells by inhibiting Erk1/2 phosphorylation, which certifies that GRP75 can inhibit the mitochondria-dependent apoptotic pathway through Raf/Mek/Erk1/2 signaling cascade.	U 0126	22-27	heat shock protein family A (Hsp70) member 9	Rattus norvegicus	137-142
21340437-11	2011	These results suggest U0126 prevents protective effect of GRP75 on PC12 cells by inhibiting Erk1/2 phosphorylation, which certifies that GRP75 can inhibit the mitochondria-dependent apoptotic pathway through Raf/Mek/Erk1/2 signaling cascade.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	216-222
21108934-4	2011	Real-time quantitative RT-PCR and Western blot showed that Ang II upregulates FGF2 expression and that these effects were attenuated by U0126 or SB203580, but not by SP600125.	U 0126	136-141	angiotensinogen	Rattus norvegicus	59-65
21108934-4	2011	Real-time quantitative RT-PCR and Western blot showed that Ang II upregulates FGF2 expression and that these effects were attenuated by U0126 or SB203580, but not by SP600125.	U 0126	136-141	fibroblast growth factor 2	Rattus norvegicus	78-82
21108934-7	2011	Using both EMSA and chromatin immunoprecipitation (ChIP) analyses, we also showed that Ang II increases binding of GATA4 to DNA, and that this effect is attenuated in the presence of U0126 or SB203580, but not in the presence of SP600125.	U 0126	183-188	angiotensinogen	Rattus norvegicus	87-93
21108934-7	2011	Using both EMSA and chromatin immunoprecipitation (ChIP) analyses, we also showed that Ang II increases binding of GATA4 to DNA, and that this effect is attenuated in the presence of U0126 or SB203580, but not in the presence of SP600125.	U 0126	183-188	GATA binding protein 4	Rattus norvegicus	115-120
21378337-3	2011	MEK inhibitor, U0126 [1,4-diamino-2,3-dicyano-1,4-bis (2-aminophynyltio) butadiene], was used for cell proliferation assays.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
21290546-7	2011	Inhibition of Erk1/2 activation by the MEK inhibitor U0126 attenuated the neuronal differentiation-inducing effect of baicalin.	U 0126	53-58	mitogen-activated protein kinase 3	Mus musculus	14-20
21290546-7	2011	Inhibition of Erk1/2 activation by the MEK inhibitor U0126 attenuated the neuronal differentiation-inducing effect of baicalin.	U 0126	53-58	midkine	Mus musculus	39-42
21293469-10	2011	In particular, pharmacological inhibition of ERK hyper-phosphorylation by U0126 prevented LTD induction in the DLS and attenuated ethanol withdrawal syndrome as well.	U 0126	74-79	Eph receptor B1	Rattus norvegicus	45-48
21378337-6	2011	Treatment with U0126 resulted in dose- and time-dependent inhibition of cell proliferation and suppression of p-ERK expression, opposite to promotion of p-MEK.	U 0126	15-20	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	110-115
21378337-6	2011	Treatment with U0126 resulted in dose- and time-dependent inhibition of cell proliferation and suppression of p-ERK expression, opposite to promotion of p-MEK.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	155-158
21270272-5	2011	Although U0126, an ERK inhibitor, enhanced insulin sensitivity and attenuated oxidative stress-induced insulin resistance, LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), worsened the insulin resistance.	U 0126	9-14	mitogen-activated protein kinase 1	Mus musculus	19-22
21270272-6	2011	Moreover, insulin increased Nrf2 transcriptional activity, which was blocked by LY294002 but enhanced by U0126.	U 0126	105-110	nuclear factor, erythroid derived 2, like 2	Mus musculus	28-32
20594879-8	2011	Chronic intrathecal treatment (5mug/rat/day for 7days) by U0126 and MK801, which blocked MEK (an upstream kinase of extracellular signal-regulated protein kinase: ERK) and the NMDAR respectively, simultaneously suppressed somatic mechanical hyperalgesia developed by diabetic rats and decreased pNR1.	U 0126	58-63	Eph receptor B1	Rattus norvegicus	163-166
21156725-6	2011	PPACK, U0126, U-73122, 2-APB or GF-109203X suppressed the increases in production of IL-8, GROalpha and MCP-1 induced by thrombin (P &lt; 0.001, P &lt;0.001 and P &lt;0.001, respectively).	U 0126	7-12	C-X-C motif chemokine ligand 8	Homo sapiens	85-89
21156725-6	2011	PPACK, U0126, U-73122, 2-APB or GF-109203X suppressed the increases in production of IL-8, GROalpha and MCP-1 induced by thrombin (P &lt; 0.001, P &lt;0.001 and P &lt;0.001, respectively).	U 0126	7-12	C-X-C motif chemokine ligand 1	Homo sapiens	91-99
21156725-6	2011	PPACK, U0126, U-73122, 2-APB or GF-109203X suppressed the increases in production of IL-8, GROalpha and MCP-1 induced by thrombin (P &lt; 0.001, P &lt;0.001 and P &lt;0.001, respectively).	U 0126	7-12	C-C motif chemokine ligand 2	Homo sapiens	104-109
21156725-6	2011	PPACK, U0126, U-73122, 2-APB or GF-109203X suppressed the increases in production of IL-8, GROalpha and MCP-1 induced by thrombin (P &lt; 0.001, P &lt;0.001 and P &lt;0.001, respectively).	U 0126	7-12	coagulation factor II, thrombin	Homo sapiens	121-129
20803555-8	2011	The CB2-induced stimulation of CREB and cyclin D1 is inhibitable by pertussis toxin, the MEK-Erk1/2 inhibitors PD098059 and U0126, and Mapkapk2 siRNA.	U 0126	124-129	cannabinoid receptor 2 (macrophage)	Mus musculus	4-7
20803555-8	2011	The CB2-induced stimulation of CREB and cyclin D1 is inhibitable by pertussis toxin, the MEK-Erk1/2 inhibitors PD098059 and U0126, and Mapkapk2 siRNA.	U 0126	124-129	cAMP responsive element binding protein 1	Mus musculus	31-35
20803555-8	2011	The CB2-induced stimulation of CREB and cyclin D1 is inhibitable by pertussis toxin, the MEK-Erk1/2 inhibitors PD098059 and U0126, and Mapkapk2 siRNA.	U 0126	124-129	cyclin D1	Mus musculus	40-49
20803555-8	2011	The CB2-induced stimulation of CREB and cyclin D1 is inhibitable by pertussis toxin, the MEK-Erk1/2 inhibitors PD098059 and U0126, and Mapkapk2 siRNA.	U 0126	124-129	midkine	Mus musculus	89-92
21268080-5	2011	CSE-induced c-Fos expression was inhibited by pretreatment with the inhibitors of MEK1 (U0126) and p38 MAPK (SB202190) or transfection with siRNAs of p42 and p38.	U 0126	88-93	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-17
21268080-5	2011	CSE-induced c-Fos expression was inhibited by pretreatment with the inhibitors of MEK1 (U0126) and p38 MAPK (SB202190) or transfection with siRNAs of p42 and p38.	U 0126	88-93	mitogen-activated protein kinase kinase 1	Homo sapiens	82-86
21297102-6	2011	U0126, PKC412, PF2341066, dasatinib, and axitinib downregulated vimentin expression by 70% to 90% as compared to untreated spheroids.	U 0126	0-5	vimentin	Homo sapiens	64-72
20834195-8	2011	U0126 treatment resulted in aberrant expression of Cdc2 and GDF9, while roscovitine significantly maintained all five maternal transcripts at very high levels in treated COCs compared with the control group.	U 0126	0-5	cyclin dependent kinase 1	Sus scrofa	51-55
20834195-8	2011	U0126 treatment resulted in aberrant expression of Cdc2 and GDF9, while roscovitine significantly maintained all five maternal transcripts at very high levels in treated COCs compared with the control group.	U 0126	0-5	growth differentiation factor 9	Sus scrofa	60-64
21147848-5	2011	Inhibition of protein kinase A using H-89 or ERK1/2 by U0126 abolished the LH-induced LHR mRNA down-regulation.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	45-51
21147848-5	2011	Inhibition of protein kinase A using H-89 or ERK1/2 by U0126 abolished the LH-induced LHR mRNA down-regulation.	U 0126	55-60	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	86-89
21087357-13	2011	U0126 blocked the effect of LPS on acetylcholine, prostaglandin E(2), KCl, and EFS-induced contractions, the levels of carbonyls and MDA+4-HDA and p-ERK and COX-2 expression.	U 0126	0-5	prostaglandin G/H synthase 2	Oryctolagus cuniculus	157-162
21094261-8	2011	CTS induced activation of p38 MAPK, and CTS induction of RUNX-2, MMP-13 and ADAMTS-5 mRNA was down-regulated by the selective p38 MAPK inhibitor SB203580 but not by the p44/42 MAPK inhibitor U0126, or the JNK MAPK inhibitor JNK inhibitor II.	U 0126	191-196	RUNX family transcription factor 2	Homo sapiens	57-63
21094261-8	2011	CTS induced activation of p38 MAPK, and CTS induction of RUNX-2, MMP-13 and ADAMTS-5 mRNA was down-regulated by the selective p38 MAPK inhibitor SB203580 but not by the p44/42 MAPK inhibitor U0126, or the JNK MAPK inhibitor JNK inhibitor II.	U 0126	191-196	mitogen-activated protein kinase 14	Homo sapiens	126-129
20724126-8	2011	Furthermore, specific pharmacological inhibitors of ERK kinase (U0126) and p38 MAPK (SB203580) also suppressed the production of IL-12 induced by garlic lectin.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	52-55
21461238-6	2011	NAD(+)- and NADP(+)-mediated CCL2 release was significantly attenuated by SP6001250, U0126, LY294002, Akt inhibitor IV, RO318220, GF109203X, and diphenyleneiodium chloride.	U 0126	85-90	C-C motif chemokine ligand 2	Homo sapiens	29-33
20464500-5	2011	To further study the ERK/MAPK signaling pathway in EC9706 and Heepic cell line, U0126 a kind of specific inhibitor of MEK was used.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	21-24
20464500-5	2011	To further study the ERK/MAPK signaling pathway in EC9706 and Heepic cell line, U0126 a kind of specific inhibitor of MEK was used.	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
20464500-6	2011	This study showed that U0126 can block the phosphorylation of ERK1/2 in a short time, the complete inhibition concentration for EC9706 and Heepic cell line is 50 and 20 muM, respectively.	U 0126	23-28	mitogen-activated protein kinase 3	Homo sapiens	62-68
20464500-6	2011	This study showed that U0126 can block the phosphorylation of ERK1/2 in a short time, the complete inhibition concentration for EC9706 and Heepic cell line is 50 and 20 muM, respectively.	U 0126	23-28	latexin	Homo sapiens	169-172
21056681-9	2011	SIS3, a selective Smad3 inhibitor, and UO126 both inhibited p44/42 MAP kinase phosphorylation and attenuated subsequent VEGF production by fibroblasts.	U 0126	39-44	interferon induced protein 44	Homo sapiens	60-63
21056681-9	2011	SIS3, a selective Smad3 inhibitor, and UO126 both inhibited p44/42 MAP kinase phosphorylation and attenuated subsequent VEGF production by fibroblasts.	U 0126	39-44	vascular endothelial growth factor A	Homo sapiens	120-124
21315000-10	2011	The release of Leptin in AACOCF3 1.0 mumol/L, 10.0 mumol/L and U0126 1.0 mumol/L, 5.0 mumol/L groups was significantly higher than LPS 20 mug/ml stimulation group (all P&lt;0.05).	U 0126	63-68	leptin	Homo sapiens	15-21
21248106-5	2011	The tyrosine kinase inhibitor, K252a, and the mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), prevented BDNF"s suppressive effects on cocaine-seeking.	U 0126	135-194	Eph receptor B1	Rattus norvegicus	72-109
21152870-11	2011	Furthermore, ERK1/2 inhibitor (U0126, at 10 muM) could intervene in all regulating effects of PAR2 or/and TLR4.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	13-19
21152870-11	2011	Furthermore, ERK1/2 inhibitor (U0126, at 10 muM) could intervene in all regulating effects of PAR2 or/and TLR4.	U 0126	31-36	F2R like trypsin receptor 1	Homo sapiens	94-98
21152870-11	2011	Furthermore, ERK1/2 inhibitor (U0126, at 10 muM) could intervene in all regulating effects of PAR2 or/and TLR4.	U 0126	31-36	toll like receptor 4	Homo sapiens	106-110
21040761-11	2011	However, when cells were pretreated with inhibitors (5-aza-CdR or U0126), the effects of arsenite on Cyclin-D1 and p16 expression were suppressed.	U 0126	66-71	cyclin D1	Homo sapiens	101-110
21040761-11	2011	However, when cells were pretreated with inhibitors (5-aza-CdR or U0126), the effects of arsenite on Cyclin-D1 and p16 expression were suppressed.	U 0126	66-71	cyclin dependent kinase inhibitor 2A	Homo sapiens	115-118
21056972-5	2011	When we examined a role for ERK in regulating cardiac MTs, we showed that the MEK/ERK-inhibitor U0126 increased glu-MT density in either control cardiac myocytes or following exposure to hypertrophic agents.	U 0126	96-101	mitogen-activated protein kinase 1	Mus musculus	28-31
21056972-5	2011	When we examined a role for ERK in regulating cardiac MTs, we showed that the MEK/ERK-inhibitor U0126 increased glu-MT density in either control cardiac myocytes or following exposure to hypertrophic agents.	U 0126	96-101	midkine	Mus musculus	78-81
21056972-5	2011	When we examined a role for ERK in regulating cardiac MTs, we showed that the MEK/ERK-inhibitor U0126 increased glu-MT density in either control cardiac myocytes or following exposure to hypertrophic agents.	U 0126	96-101	mitogen-activated protein kinase 1	Mus musculus	82-85
21093414-6	2011	The ROS scavenger, N-acetyl cysteine partially reversed Snail-mediated EMT after 7 days characterized by increased E-cadherin levels and decreased ERK activity, while treatment with the MEK inhibitor, UO126, resulted in a more marked effect by 3 days, characterized by cells returning back to the epithelial morphology and increased E-cadherin.	U 0126	201-206	snail family transcriptional repressor 1	Homo sapiens	56-61
21093414-6	2011	The ROS scavenger, N-acetyl cysteine partially reversed Snail-mediated EMT after 7 days characterized by increased E-cadherin levels and decreased ERK activity, while treatment with the MEK inhibitor, UO126, resulted in a more marked effect by 3 days, characterized by cells returning back to the epithelial morphology and increased E-cadherin.	U 0126	201-206	cadherin 1	Homo sapiens	115-125
21093414-6	2011	The ROS scavenger, N-acetyl cysteine partially reversed Snail-mediated EMT after 7 days characterized by increased E-cadherin levels and decreased ERK activity, while treatment with the MEK inhibitor, UO126, resulted in a more marked effect by 3 days, characterized by cells returning back to the epithelial morphology and increased E-cadherin.	U 0126	201-206	mitogen-activated protein kinase kinase 7	Homo sapiens	186-189
21093414-6	2011	The ROS scavenger, N-acetyl cysteine partially reversed Snail-mediated EMT after 7 days characterized by increased E-cadherin levels and decreased ERK activity, while treatment with the MEK inhibitor, UO126, resulted in a more marked effect by 3 days, characterized by cells returning back to the epithelial morphology and increased E-cadherin.	U 0126	201-206	cadherin 1	Homo sapiens	333-343
20961289-4	2011	EGF (epidermal growth factor) potentiated H2O2-induced tight junction disruption in under-differentiated cell monolayers, which was attenuated by the MEK [MAPK (mitogen-activated protein kinase)/ERK kinase] inhibitor U0126.	U 0126	217-222	epidermal growth factor	Homo sapiens	0-3
20961289-4	2011	EGF (epidermal growth factor) potentiated H2O2-induced tight junction disruption in under-differentiated cell monolayers, which was attenuated by the MEK [MAPK (mitogen-activated protein kinase)/ERK kinase] inhibitor U0126.	U 0126	217-222	epidermal growth factor	Homo sapiens	5-28
20961289-4	2011	EGF (epidermal growth factor) potentiated H2O2-induced tight junction disruption in under-differentiated cell monolayers, which was attenuated by the MEK [MAPK (mitogen-activated protein kinase)/ERK kinase] inhibitor U0126.	U 0126	217-222	mitogen-activated protein kinase kinase 7	Homo sapiens	150-153
20961289-4	2011	EGF (epidermal growth factor) potentiated H2O2-induced tight junction disruption in under-differentiated cell monolayers, which was attenuated by the MEK [MAPK (mitogen-activated protein kinase)/ERK kinase] inhibitor U0126.	U 0126	217-222	mitogen-activated protein kinase 3	Homo sapiens	155-159
20961289-5	2011	In contrast, EGF prevented H2O2-induced disruption of tight junctions in differentiated cell monolayers, which was also attenuated by U0126.	U 0126	134-139	epidermal growth factor	Homo sapiens	13-16
20848307-8	2011	Short-term sequential exposure of cells to U0126, C278, and NGF enhanced phosphorylation of extracellular signal-regulated kinase (ERK) in comparison with cells treated with only the MEK inhibitor and NGF.	U 0126	43-48	Eph receptor B1	Rattus norvegicus	92-129
20848307-8	2011	Short-term sequential exposure of cells to U0126, C278, and NGF enhanced phosphorylation of extracellular signal-regulated kinase (ERK) in comparison with cells treated with only the MEK inhibitor and NGF.	U 0126	43-48	Eph receptor B1	Rattus norvegicus	131-134
20851839-13	2011	U0126 reduced the enhanced pERK1/2-ir, while U0124 had no such effect; the CGRP-ir in neurons and glial cells was reduced at 48 hours and in parallel the CGRP mRNA expression was lower at 24 hours.	U 0126	0-5	calcitonin-related polypeptide alpha	Rattus norvegicus	75-79
20851839-13	2011	U0126 reduced the enhanced pERK1/2-ir, while U0124 had no such effect; the CGRP-ir in neurons and glial cells was reduced at 48 hours and in parallel the CGRP mRNA expression was lower at 24 hours.	U 0126	0-5	calcitonin-related polypeptide alpha	Rattus norvegicus	154-158
21799677-7	2011	In addition, Dilong stimulated ERK1/2 and p38 phosphorylation was attenuated by pretreatment with chemical inhibitors (U0126 and SB203580), and small interfering ERK1/2 and p38 RNA, resulting in migration and uPA-related signal pathway inhibition.	U 0126	119-124	mitogen activated protein kinase 3	Rattus norvegicus	31-37
21799677-7	2011	In addition, Dilong stimulated ERK1/2 and p38 phosphorylation was attenuated by pretreatment with chemical inhibitors (U0126 and SB203580), and small interfering ERK1/2 and p38 RNA, resulting in migration and uPA-related signal pathway inhibition.	U 0126	119-124	mitogen activated protein kinase 14	Rattus norvegicus	42-45
19351710-5	2011	Pharmacological inhibition by U0126 demonstrated that ERK1/2 inactivation alone was enough to inhibit tube formation and induce apoptosis.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	54-60
19351710-6	2011	It was also shown that EEBP and U0126 similarly induced activation of caspase-3 and cleavage of poly ADP-ribose polymerase (PARP) and lamin A/C, all of which are molecular markers of apoptosis.	U 0126	32-37	caspase 3	Homo sapiens	70-79
19351710-6	2011	It was also shown that EEBP and U0126 similarly induced activation of caspase-3 and cleavage of poly ADP-ribose polymerase (PARP) and lamin A/C, all of which are molecular markers of apoptosis.	U 0126	32-37	poly(ADP-ribose) polymerase 1	Homo sapiens	96-122
19351710-6	2011	It was also shown that EEBP and U0126 similarly induced activation of caspase-3 and cleavage of poly ADP-ribose polymerase (PARP) and lamin A/C, all of which are molecular markers of apoptosis.	U 0126	32-37	poly(ADP-ribose) polymerase 1	Homo sapiens	124-128
19351710-6	2011	It was also shown that EEBP and U0126 similarly induced activation of caspase-3 and cleavage of poly ADP-ribose polymerase (PARP) and lamin A/C, all of which are molecular markers of apoptosis.	U 0126	32-37	lamin A/C	Homo sapiens	134-143
20967757-9	2011	Finally, we observed in primary cultured rat hepatocytes that U0126 (a selective inhibitor of MAPK/ERK kinase1/2) corrected hCRP-induced impairment of insulin signaling.	U 0126	62-67	mitogen activated protein kinase 3	Rattus norvegicus	94-98
20967757-9	2011	Finally, we observed in primary cultured rat hepatocytes that U0126 (a selective inhibitor of MAPK/ERK kinase1/2) corrected hCRP-induced impairment of insulin signaling.	U 0126	62-67	C-reactive protein	Homo sapiens	124-128
21109933-9	2011	Finally, we found that CYLD expression was triggered by the multikinase inhibitor, sorafenib, by the inhibition of Raf-1, as well as by the blockage of the pro-survival kinases, MEK (U0126) and the epidermal growth factor receptor (AG1478).	U 0126	183-188	CYLD lysine 63 deubiquitinase	Homo sapiens	23-27
21131601-6	2011	The MEK inhibitor, U0126, blocked both PMA- and anti-IgM-induced upregulation of TbetaRII.	U 0126	19-24	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
21131601-6	2011	The MEK inhibitor, U0126, blocked both PMA- and anti-IgM-induced upregulation of TbetaRII.	U 0126	19-24	transforming growth factor beta receptor 2	Homo sapiens	81-89
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	transforming growth factor beta 1	Homo sapiens	23-31
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	transforming growth factor beta receptor 2	Homo sapiens	103-111
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	transforming growth factor beta receptor 2	Homo sapiens	162-170
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	transforming growth factor beta 1	Homo sapiens	194-202
20953701-5	2011	The MEK inhibitor U0126 suppressed ERK activity and phosphorylation of Raf-1 at Ser289/296/301 but not Raf-1 activation elicited by its dephosphorylation at S259 following ischemia.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	35-38
20953701-5	2011	The MEK inhibitor U0126 suppressed ERK activity and phosphorylation of Raf-1 at Ser289/296/301 but not Raf-1 activation elicited by its dephosphorylation at S259 following ischemia.	U 0126	18-23	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	71-76
21155840-9	2011	PDTC inhibited the production of IL-8 and TNF-alpha, while U0126 inhibited the synthesis of IFN-beta.	U 0126	59-64	interferon beta 1	Rattus norvegicus	92-100
22140508-8	2011	Blocking ERK and p38 MAP kinase signaling by U0126 and SB203580, respectively, diminished MSK1 phosphorylation in UVB-irradiated mouse skin.	U 0126	45-50	mitogen-activated protein kinase 1	Mus musculus	9-12
22140508-8	2011	Blocking ERK and p38 MAP kinase signaling by U0126 and SB203580, respectively, diminished MSK1 phosphorylation in UVB-irradiated mouse skin.	U 0126	45-50	mitogen-activated protein kinase 14	Mus musculus	17-20
22140508-8	2011	Blocking ERK and p38 MAP kinase signaling by U0126 and SB203580, respectively, diminished MSK1 phosphorylation in UVB-irradiated mouse skin.	U 0126	45-50	ribosomal protein S6 kinase, polypeptide 5	Mus musculus	90-94
21738696-6	2011	Treatment of cells with UO126, an inhibitor of MEK, also inhibited the migration of melanoma cells.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
21293101-7	2011	The effect of ERK1/2 inhibition by U0126 on phenylephrine-induced contraction was studied in organ-bath experiments.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	14-20
21293101-11	2011	Incubation of prostate tissue with U0126 (30 muM) resulted in ERK1/2 inhibition.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	62-68
21155050-4	2011	RESULTS: ERK1/2 inhibition by U0126 suppressed proliferator-activated receptor (PPAR)gamma expression and lipid accumulation, while it decreased the mRNA expression of adipogenic genes (lipoprotein lipase, PPARgamma, and adipocyte protein) and osteogenic genes (type I collagen and osteopontin).	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	9-15
21155050-4	2011	RESULTS: ERK1/2 inhibition by U0126 suppressed proliferator-activated receptor (PPAR)gamma expression and lipid accumulation, while it decreased the mRNA expression of adipogenic genes (lipoprotein lipase, PPARgamma, and adipocyte protein) and osteogenic genes (type I collagen and osteopontin).	U 0126	30-35	peroxisome proliferator activated receptor gamma	Homo sapiens	80-90
21155050-4	2011	RESULTS: ERK1/2 inhibition by U0126 suppressed proliferator-activated receptor (PPAR)gamma expression and lipid accumulation, while it decreased the mRNA expression of adipogenic genes (lipoprotein lipase, PPARgamma, and adipocyte protein) and osteogenic genes (type I collagen and osteopontin).	U 0126	30-35	peroxisome proliferator activated receptor gamma	Homo sapiens	206-293
21205894-12	2011	VEGF blockade, the PI3K-specific inhibitor LY294002, and the MAPK/ERK1/2 (MEK1/2)-specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, and the inhibitors also reduced IL-25-induced proliferation and VEGF expression.	U 0126	101-106	mitogen-activated protein kinase 3	Homo sapiens	61-65
21205894-12	2011	VEGF blockade, the PI3K-specific inhibitor LY294002, and the MAPK/ERK1/2 (MEK1/2)-specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, and the inhibitors also reduced IL-25-induced proliferation and VEGF expression.	U 0126	101-106	mitogen-activated protein kinase 3	Homo sapiens	66-72
21205894-12	2011	VEGF blockade, the PI3K-specific inhibitor LY294002, and the MAPK/ERK1/2 (MEK1/2)-specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, and the inhibitors also reduced IL-25-induced proliferation and VEGF expression.	U 0126	101-106	mitogen-activated protein kinase kinase 1	Homo sapiens	74-80
21205894-12	2011	VEGF blockade, the PI3K-specific inhibitor LY294002, and the MAPK/ERK1/2 (MEK1/2)-specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, and the inhibitors also reduced IL-25-induced proliferation and VEGF expression.	U 0126	101-106	interleukin 25	Homo sapiens	131-136
21248106-7	2011	Additionally, BDNF"s ability to normalize cocaine-mediated decreases in ERK and CREB phosphorylation was blocked by U0126, demonstrating that ERK/MAPK activation mediated the behavioral effects.	U 0126	116-121	cAMP responsive element binding protein 1	Rattus norvegicus	80-84
21248106-7	2011	Additionally, BDNF"s ability to normalize cocaine-mediated decreases in ERK and CREB phosphorylation was blocked by U0126, demonstrating that ERK/MAPK activation mediated the behavioral effects.	U 0126	116-121	Eph receptor B1	Rattus norvegicus	142-145
21248136-10	2011	Combined application of inhibitors of ERK (U0126) and PKA (KT5720) was necessary to block completely the excitatory effects of a ROS donor (tBOOH).	U 0126	43-48	EPH receptor B2	Homo sapiens	38-41
20971161-9	2011	Intrathecal injections of the ERK 1/2 inhibitor U0126 successfully rescued the mice from the abdominal hyperalgesia for up to 24 h after the injection and also reversed the enhanced expression of ERK 1/2.	U 0126	48-53	mitogen-activated protein kinase 3	Mus musculus	30-37
20971161-9	2011	Intrathecal injections of the ERK 1/2 inhibitor U0126 successfully rescued the mice from the abdominal hyperalgesia for up to 24 h after the injection and also reversed the enhanced expression of ERK 1/2.	U 0126	48-53	mitogen-activated protein kinase 3	Mus musculus	196-203
21151160-6	2011	Blockage of the Erk1/2 pathway by U0126 (10 mumol/L) inhibited cardiac differentiation while ouabain (20 mumol/L) rescued the effect.	U 0126	34-39	mitogen-activated protein kinase 3	Mus musculus	16-22
22037177-1	2011	PURPOSE: To investigate the effects of gefitinib (EGFR-TKI), LY294002 (PI3K inhibitor) and U0126 (MEK inhibitor) on proliferation and apoptosis in five non-small cell lung cancer (NSCLC) cell lines (PC9, PC9/AB2, H1975, H1299 and A549).	U 0126	91-96	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
21483099-8	2011	As regards to S910, cell-treatment with the MEK inhibitor UO126 and ERK5-silencing indicated its targeting by ERK5.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	44-47
21483099-8	2011	As regards to S910, cell-treatment with the MEK inhibitor UO126 and ERK5-silencing indicated its targeting by ERK5.	U 0126	58-63	mitogen-activated protein kinase 7	Homo sapiens	110-114
21804216-12	2011	However, inhibition of the ERK1/2 pathway using the mitogen-activated protein kinase (MEK)/ERK inhibitor U0126 partially suppressed autophagy.	U 0126	105-110	mitogen-activated protein kinase 3	Homo sapiens	27-33
21804216-12	2011	However, inhibition of the ERK1/2 pathway using the mitogen-activated protein kinase (MEK)/ERK inhibitor U0126 partially suppressed autophagy.	U 0126	105-110	mitogen-activated protein kinase kinase 7	Homo sapiens	52-84
21804216-12	2011	However, inhibition of the ERK1/2 pathway using the mitogen-activated protein kinase (MEK)/ERK inhibitor U0126 partially suppressed autophagy.	U 0126	105-110	mitogen-activated protein kinase kinase 7	Homo sapiens	86-89
21804216-12	2011	However, inhibition of the ERK1/2 pathway using the mitogen-activated protein kinase (MEK)/ERK inhibitor U0126 partially suppressed autophagy.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	27-30
21191179-5	2011	Treatment of the BRAFV600E-positive PTC cell line, BCPAP, with the MEK/ERK inhibitor U0126 reduced uPAR RNA levels by 90%.	U 0126	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
21191179-5	2011	Treatment of the BRAFV600E-positive PTC cell line, BCPAP, with the MEK/ERK inhibitor U0126 reduced uPAR RNA levels by 90%.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	71-74
21191179-5	2011	Treatment of the BRAFV600E-positive PTC cell line, BCPAP, with the MEK/ERK inhibitor U0126 reduced uPAR RNA levels by 90%.	U 0126	85-90	plasminogen activator, urokinase receptor	Homo sapiens	99-103
21799677-7	2011	In addition, Dilong stimulated ERK1/2 and p38 phosphorylation was attenuated by pretreatment with chemical inhibitors (U0126 and SB203580), and small interfering ERK1/2 and p38 RNA, resulting in migration and uPA-related signal pathway inhibition.	U 0126	119-124	proline-rich acidic protein 1	Rattus norvegicus	209-212
21631964-2	2011	The aim of our study was to investigate the effect of mitoxantrone and two protein kinase inhibitors - caffeine (inhibitor of ATM kinase) and U0126 (inhibitor of MEK1/2 kinase) - on MOLT-4 and Jurkat leukaemic cell lines.	U 0126	142-147	mitogen-activated protein kinase kinase 1	Homo sapiens	162-168
20809699-8	2011	The levels of G-CSF mRNA in PGM-treated PBMC could be reduced by ERK inhibitor U0126 and NF-kappaB inhibitor pyrrolidine dithiocarbamate, respectively.	U 0126	79-84	phosphoglycerate mutase-like protein	Glycine max	28-31
21293096-6	2011	The inhibitors of EGFR (AG1478) or ERK (U0126) significantly mitigated the bile acid-mediated promotion of HCV replication.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	35-38
21293096-7	2011	When AG1478 or U0126 were added to the treatment of bile acids and IFN-alpha, they were able to restore the anti-HCV effects of IFN-alpha.	U 0126	15-20	interferon alpha 1	Homo sapiens	67-76
21293096-7	2011	When AG1478 or U0126 were added to the treatment of bile acids and IFN-alpha, they were able to restore the anti-HCV effects of IFN-alpha.	U 0126	15-20	interferon alpha 1	Homo sapiens	128-137
20524210-7	2011	TSP-1 mRNA levels were increased in CoCl(2)-exposed astrocytes in the presence of the inhibitors (U0126 and PD98059) of mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK), when compared to that detected in the culture only exposed to CoCl(2).	U 0126	98-103	thrombospondin 1	Rattus norvegicus	0-5
20524210-7	2011	TSP-1 mRNA levels were increased in CoCl(2)-exposed astrocytes in the presence of the inhibitors (U0126 and PD98059) of mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK), when compared to that detected in the culture only exposed to CoCl(2).	U 0126	98-103	Eph receptor B1	Rattus norvegicus	198-201
21077177-7	2011	The reduction of EC-SOD and Cu/Zn-SOD was attenuated by pretreatments with GF109203X (an inhibitor of protein kinase C, PKC), diphenyleneiodonium (an inhibitor of NOX), and U0126 (an inhibitor of mitogen-activated protein kinase kinase, MEK/extracellular-signal regulated kinase, ERK).	U 0126	173-178	superoxide dismutase 3	Homo sapiens	17-23
20964536-8	2011	Co-administration of U 0126, an ERK antagonist, and Phe fully restored dilation to cromakalim, calcitonin gene-related peptide (CGRP), and NS 1619, in males after FPI.	U 0126	21-27	mitogen-activated protein kinase 1	Homo sapiens	32-35
20964536-8	2011	Co-administration of U 0126, an ERK antagonist, and Phe fully restored dilation to cromakalim, calcitonin gene-related peptide (CGRP), and NS 1619, in males after FPI.	U 0126	21-27	calcitonin related polypeptide alpha	Homo sapiens	95-126
20964536-8	2011	Co-administration of U 0126, an ERK antagonist, and Phe fully restored dilation to cromakalim, calcitonin gene-related peptide (CGRP), and NS 1619, in males after FPI.	U 0126	21-27	calcitonin related polypeptide alpha	Homo sapiens	128-132
20383584-7	2011	Furthermore, the effect of SDF-1alpha on mitochondrial pathway was neutralized by using PI3K inhibitor (Wortmannin) and ERK1/2 inhibitor (U0126).	U 0126	138-143	mitogen-activated protein kinase 3	Homo sapiens	120-126
21220498-0	2011	MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
21220498-0	2011	MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
21220498-7	2011	The specific MEK/ERK inhibitor, U0126, reduced the clonogenic potential of the three cell lines, and was affected by radiation.	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
21220498-7	2011	The specific MEK/ERK inhibitor, U0126, reduced the clonogenic potential of the three cell lines, and was affected by radiation.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	17-20
21220498-8	2011	U0126 inhibited phospho-active ERK1/2 and reduced DNA protein kinase catalytic subunit (DNA-PKcs) suggesting that ERKs and DNA-PKcs cooperate in radioprotection of rhabdomyosarcoma cells.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	31-37
21220498-8	2011	U0126 inhibited phospho-active ERK1/2 and reduced DNA protein kinase catalytic subunit (DNA-PKcs) suggesting that ERKs and DNA-PKcs cooperate in radioprotection of rhabdomyosarcoma cells.	U 0126	0-5	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	50-96
21220498-8	2011	U0126 inhibited phospho-active ERK1/2 and reduced DNA protein kinase catalytic subunit (DNA-PKcs) suggesting that ERKs and DNA-PKcs cooperate in radioprotection of rhabdomyosarcoma cells.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	114-118
21220498-8	2011	U0126 inhibited phospho-active ERK1/2 and reduced DNA protein kinase catalytic subunit (DNA-PKcs) suggesting that ERKs and DNA-PKcs cooperate in radioprotection of rhabdomyosarcoma cells.	U 0126	0-5	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	88-96
21220498-9	2011	The TE671 cell line xenotransplanted in mice showed a reduction in tumor mass and increase in the time of tumor progression with U0126 treatment associated with reduced DNA-PKcs, an effect enhanced by radiotherapy.	U 0126	129-134	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	169-177
21220499-7	2011	Interestingly, sorafenib and the MEK inhibitor U0126 markedly inhibited the HGF-induced morphologic changes, SNAI1 upregulation, and cadherin switching, whereas the PI3 kinase inhibitor wortmannin did not.	U 0126	47-52	mitogen-activated protein kinase kinase 7	Homo sapiens	33-36
21220499-7	2011	Interestingly, sorafenib and the MEK inhibitor U0126 markedly inhibited the HGF-induced morphologic changes, SNAI1 upregulation, and cadherin switching, whereas the PI3 kinase inhibitor wortmannin did not.	U 0126	47-52	hepatocyte growth factor	Homo sapiens	76-79
21220499-7	2011	Interestingly, sorafenib and the MEK inhibitor U0126 markedly inhibited the HGF-induced morphologic changes, SNAI1 upregulation, and cadherin switching, whereas the PI3 kinase inhibitor wortmannin did not.	U 0126	47-52	snail family transcriptional repressor 1	Homo sapiens	109-114
21106247-6	2011	PRRSV-induced RANTES transcription was dramatically inhibited by administration of a dominant-negative mutant of IkappaB kinase alpha (mIkappaBalpha), NF-kappaB inhibitor BAY11-7082 or ERK1/2 inhibitor U0126.	U 0126	202-207	C-C motif chemokine ligand 5	Homo sapiens	14-20
22076135-4	2011	Pretreatment of brain slices with the mitogen-activated protein kinase kinase -1 and -2 (MEK1/2) inhibitor U0126 blocked the leptin-mediated decrease in firing frequency of VTA dopamine neurons.	U 0126	107-112	mitogen activated protein kinase kinase 1	Rattus norvegicus	38-87
22076135-4	2011	Pretreatment of brain slices with the mitogen-activated protein kinase kinase -1 and -2 (MEK1/2) inhibitor U0126 blocked the leptin-mediated decrease in firing frequency of VTA dopamine neurons.	U 0126	107-112	mitogen activated protein kinase kinase 1	Rattus norvegicus	89-95
22076135-5	2011	The anorexigenic effects of VTA-administered leptin were also blocked by pretreatment with U0126, which effectively blocked phosphorylation of ERK1/2 but not STAT3.	U 0126	91-96	mitogen activated protein kinase 3	Rattus norvegicus	143-149
22076135-5	2011	The anorexigenic effects of VTA-administered leptin were also blocked by pretreatment with U0126, which effectively blocked phosphorylation of ERK1/2 but not STAT3.	U 0126	91-96	signal transducer and activator of transcription 3	Rattus norvegicus	158-163
22031842-7	2011	Furthermore, VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm(2) was blocked by pretreatment of endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration.	U 0126	220-225	vascular cell adhesion molecule 1	Homo sapiens	13-19
22031842-7	2011	Furthermore, VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm(2) was blocked by pretreatment of endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration.	U 0126	220-225	mitogen-activated protein kinase 1	Homo sapiens	171-175
22031842-7	2011	Furthermore, VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm(2) was blocked by pretreatment of endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration.	U 0126	220-225	mitogen-activated protein kinase kinase 7	Homo sapiens	188-191
22031842-7	2011	Furthermore, VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm(2) was blocked by pretreatment of endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration.	U 0126	220-225	mitogen-activated protein kinase 1	Homo sapiens	171-174
22031842-7	2011	Furthermore, VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm(2) was blocked by pretreatment of endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration.	U 0126	220-225	mitogen-activated protein kinase 1	Homo sapiens	192-195
21980400-6	2011	Both PI3K inhibitor LY294002 and ERK inhibitor U0126 suppressed hypoxia-induced Rac1 activation as well as HIF-1alpha expression.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	33-36
21980400-6	2011	Both PI3K inhibitor LY294002 and ERK inhibitor U0126 suppressed hypoxia-induced Rac1 activation as well as HIF-1alpha expression.	U 0126	47-52	Rac family small GTPase 1	Homo sapiens	80-84
21980400-6	2011	Both PI3K inhibitor LY294002 and ERK inhibitor U0126 suppressed hypoxia-induced Rac1 activation as well as HIF-1alpha expression.	U 0126	47-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	107-117
21858223-8	2011	Conversely, inhibition of FOXM1 expression by either thiostrepton or U0126 could significantly impair FOXM1 mediated oncogenic capacities.	U 0126	69-74	forkhead box M1	Homo sapiens	26-31
21858223-8	2011	Conversely, inhibition of FOXM1 expression by either thiostrepton or U0126 could significantly impair FOXM1 mediated oncogenic capacities.	U 0126	69-74	forkhead box M1	Homo sapiens	102-107
21858223-9	2011	However, the down-regulation of FOXM1 by either thiostrepton or U0126 required the presence of p53 in ovarian cancer cells.	U 0126	64-69	forkhead box M1	Homo sapiens	32-37
21858223-9	2011	However, the down-regulation of FOXM1 by either thiostrepton or U0126 required the presence of p53 in ovarian cancer cells.	U 0126	64-69	tumor protein p53	Homo sapiens	95-98
21635820-4	2011	Stimulation with LIF resulted in the activation of both signal transducer and activator of transcription (STAT) 3 Tyr(705) and ERK1/2, but inhibition of ERK1/2 signalling by pretreatment of cells with U0126 (10 microM) for 2h resulted in abrogation of LIF-mediated increases in G(2)/M transition, with a significant decrease (P &lt; 0.05) in absolute cell numbers compared with control.	U 0126	201-206	LIF interleukin 6 family cytokine	Homo sapiens	17-20
20926971-4	2010	Bromodeoxyuridine (BrdU) incorporation into the neurosphere cells induced by leptin was suppressed by LY294002, a PI3 K inhibitor, but not by U0126, a MEK1/2 inhibitor, which activates ERK1/2, although U0126 decreased phosphorylated extracellular signal regulated kinase levels.	U 0126	202-207	leptin	Homo sapiens	77-83
21209852-5	2010	LPA also increased ERK activity and the MEK inhibitor U0126 could block LPA-induced ERK activity and cell migration.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
21209852-5	2010	LPA also increased ERK activity and the MEK inhibitor U0126 could block LPA-induced ERK activity and cell migration.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	84-87
21053276-5	2010	Further investigation indicated that the percentage of beating EBs and the TnT positive area were decreased by the extracellular signal-related kinases (ERK)-1/2 inhibitor U0126 and the p38 inhibitor SB203580, but not by the Jun amino-terminal kinases (JNK) inhibitor SP600125.	U 0126	172-177	troponin T2, cardiac	Mus musculus	75-78
21053276-5	2010	Further investigation indicated that the percentage of beating EBs and the TnT positive area were decreased by the extracellular signal-related kinases (ERK)-1/2 inhibitor U0126 and the p38 inhibitor SB203580, but not by the Jun amino-terminal kinases (JNK) inhibitor SP600125.	U 0126	172-177	mitogen-activated protein kinase 3	Mus musculus	115-161
21053276-7	2010	ET-1 induced an increase in the percentage of spindle cells was also inhibited by U0126.	U 0126	82-87	endothelin 1	Mus musculus	0-4
21159167-3	2010	Using the MEK1/2 inhibitor, U0126 and stably transfected shERK1 and shERK2 MM cell lines, we show that inhibition of both ERK1 and 2 sensitizes MM cells to Dox.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	122-132
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	BCL2 apoptosis regulator	Homo sapiens	99-103
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	ATP binding cassette subfamily B member 1	Homo sapiens	105-110
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	ATP binding cassette subfamily C member 3	Homo sapiens	112-117
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	BCL2 apoptosis regulator	Homo sapiens	133-137
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	BRCA1 DNA repair associated	Homo sapiens	152-157
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	BRCA2 DNA repair associated	Homo sapiens	159-164
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	nuclear receptor subfamily 4 group A member 1	Homo sapiens	167-183
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	estrogen receptor 2	Homo sapiens	189-193
21159167-4	2010	RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells.	U 0126	9-14	peroxisome proliferator activated receptor gamma	Homo sapiens	195-204
21098662-8	2010	The remaining LTD was reduced by anisomycin, an inhibitor of protein synthesis, by U0126, an inhibitor of MEK1/2 kinases, and by rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suggesting mediation by the same mechanisms as in WT.	U 0126	83-88	mitogen-activated protein kinase kinase 1	Homo sapiens	106-112
21248106-5	2011	The tyrosine kinase inhibitor, K252a, and the mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), prevented BDNF"s suppressive effects on cocaine-seeking.	U 0126	135-194	brain-derived neurotrophic factor	Rattus norvegicus	207-211
21248106-7	2011	Additionally, BDNF"s ability to normalize cocaine-mediated decreases in ERK and CREB phosphorylation was blocked by U0126, demonstrating that ERK/MAPK activation mediated the behavioral effects.	U 0126	116-121	brain-derived neurotrophic factor	Rattus norvegicus	14-18
20843811-12	2010	Activation of ERK and the downstream target Elk-1 could be inhibited by the MEK inhibitor U0126.	U 0126	90-95	Eph receptor B1	Rattus norvegicus	14-17
20843811-12	2010	Activation of ERK and the downstream target Elk-1 could be inhibited by the MEK inhibitor U0126.	U 0126	90-95	ETS transcription factor ELK1	Rattus norvegicus	44-49
20889506-8	2010	In addition, we found that inhibition of ERK1/2 phosphorylation by U0126 resulted in a decreased phosphorylation of PLCgamma1, suggesting a feedback loop between ERK1/2 and PLCgamma1.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	41-47
20889506-8	2010	In addition, we found that inhibition of ERK1/2 phosphorylation by U0126 resulted in a decreased phosphorylation of PLCgamma1, suggesting a feedback loop between ERK1/2 and PLCgamma1.	U 0126	67-72	phospholipase C gamma 1	Homo sapiens	116-125
20828639-7	2010	The PI3K and MEK/ERK pathway inhibitors Ly294002 and U0126 reduced RANKL expression levels in vitro.	U 0126	53-58	midkine	Mus musculus	13-16
20889506-8	2010	In addition, we found that inhibition of ERK1/2 phosphorylation by U0126 resulted in a decreased phosphorylation of PLCgamma1, suggesting a feedback loop between ERK1/2 and PLCgamma1.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	162-168
20889506-8	2010	In addition, we found that inhibition of ERK1/2 phosphorylation by U0126 resulted in a decreased phosphorylation of PLCgamma1, suggesting a feedback loop between ERK1/2 and PLCgamma1.	U 0126	67-72	phospholipase C gamma 1	Homo sapiens	173-182
20828639-7	2010	The PI3K and MEK/ERK pathway inhibitors Ly294002 and U0126 reduced RANKL expression levels in vitro.	U 0126	53-58	mitogen-activated protein kinase 1	Mus musculus	17-20
20828639-7	2010	The PI3K and MEK/ERK pathway inhibitors Ly294002 and U0126 reduced RANKL expression levels in vitro.	U 0126	53-58	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	67-72
20814991-6	2010	We report that the ERK MAPK pathway inhibitor U0126 can almost completely block induction of desiccation early response genes in a human cell line, suggesting a role for the ERK signal transduction pathway in the stress response.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	19-22
20814675-12	2010	MEK inhibitors, including UO126 and AZD6244, reduced B7-H1 expression and restored CTL-mediated lysis of blast cells.	U 0126	26-31	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
20814675-12	2010	MEK inhibitors, including UO126 and AZD6244, reduced B7-H1 expression and restored CTL-mediated lysis of blast cells.	U 0126	26-31	CD274 antigen	Mus musculus	53-58
21355419-9	2010	Pretreatment with U0126 reduced GFAP and ERK1/2 expression and increased lesion volumes in response to stimulation at 10 Hz.	U 0126	18-23	glial fibrillary acidic protein	Rattus norvegicus	32-36
21355419-9	2010	Pretreatment with U0126 reduced GFAP and ERK1/2 expression and increased lesion volumes in response to stimulation at 10 Hz.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	41-47
20814991-6	2010	We report that the ERK MAPK pathway inhibitor U0126 can almost completely block induction of desiccation early response genes in a human cell line, suggesting a role for the ERK signal transduction pathway in the stress response.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	174-177
20931347-6	2010	We report that (1) organ culture of the TG is possible with preserved morphology, (2) organ culture is associated with enhanced expression of cytokines and mitogen-activated protein kinases (MAPKs) primarily in neurons, (3) CGRP can induce expression of some cytokines and (4) cytokine expression is still upregulated following MAPK pathway inhibition by MEK inhibitor U0126 and pp38 inhibitor SB202192, but the cytokine expression is abolished when co-incubating with the JNK inhibitor SP600125.	U 0126	369-374	calcitonin-related polypeptide alpha	Rattus norvegicus	224-228
21071512-10	2010	Treatment with U0126 could abrogate the activation of p-MAPK and p-MEK, whereas LY294002 treatment had no effect on the PI3K/AKT pathway.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
20855443-6	2010	Blockage of ERK1/2 or AKT activation by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126; MKK1/2 inhibitor) or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; phosphatidyl inositol 3-kinase inhibitor), respectively, decreased the gemcitabine-induced Rad51 expression.	U 0126	94-99	mitogen-activated protein kinase 3	Homo sapiens	12-18
20855443-6	2010	Blockage of ERK1/2 or AKT activation by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126; MKK1/2 inhibitor) or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; phosphatidyl inositol 3-kinase inhibitor), respectively, decreased the gemcitabine-induced Rad51 expression.	U 0126	94-99	AKT serine/threonine kinase 1	Homo sapiens	22-25
20881039-4	2010	Extracellular signal-regulated receptor kinase (ERK) and p38 mitogen-activated protein kinase inhibitors (U0126 and SB203580) were sufficient to block Nup hyperphosphorylation in EMCV-infected or L-expressing cells.	U 0126	106-111	mitogen-activated protein kinase 14	Homo sapiens	57-60
20869113-5	2010	The neuroprotective effects of TRH (10 muM) and RGH-2202 (10 muM) on St-induced cell death was attenuated by inhibitors of PI3-K pathway (wortmannin and LY294002), but not MAPK/ERK1/2 (PD98059 and U0126).	U 0126	197-202	thyrotropin releasing hormone	Homo sapiens	31-34
21205476-2	2010	METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	37-40
20886187-7	2010	Results showed that U0126, an inhibitor of extracellular signal-regulated kinase (ERK) kinase (MEK), almost completely suppressed EIII-induced PAI-1 expression.	U 0126	20-25	serpin family E member 1	Homo sapiens	143-148
21205476-2	2010	METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway.	U 0126	51-56	AKT serine/threonine kinase 1	Homo sapiens	85-88
21205476-2	2010	METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
21205476-2	2010	METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	97-100
21205476-2	2010	METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway.	U 0126	51-56	AKT serine/threonine kinase 1	Homo sapiens	153-156
21205476-2	2010	METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway.	U 0126	51-56	AKT serine/threonine kinase 1	Homo sapiens	153-156
21205476-8	2010	It is notable that both myr-Akt overexpression and MEK inhibitor U0126 inhibited endoplasmic reticulum stress-induced G0/G1 phase arrest in SMMC-7721 cells.	U 0126	65-70	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
21057728-7	2010	Blocking phosphorylation of ERK1/2 by MAPK inhibitors U0126 and PD98059, and inhibiting activation of NF-kappaB by IkappaB (IkappaB) kinase inhibitors wedelolactone or IMD-0354, abolished the DSP effects.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	28-34
21118521-8	2010	The mitogen-activated protein kinase (MAPK) or ERK Kinase (MEK) inhibitor, U0126, only partially inhibited the ccp1-dependent BrdU incorporation, indicating that other signaling pathway may be involved in ccp1-induced cell proliferation.	U 0126	75-80	coiled-coil domain containing 115	Homo sapiens	111-115
21118521-8	2010	The mitogen-activated protein kinase (MAPK) or ERK Kinase (MEK) inhibitor, U0126, only partially inhibited the ccp1-dependent BrdU incorporation, indicating that other signaling pathway may be involved in ccp1-induced cell proliferation.	U 0126	75-80	coiled-coil domain containing 115	Homo sapiens	205-209
20399244-11	2010	Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2.	U 0126	10-15	mitogen activated protein kinase kinase 1	Rattus norvegicus	60-66
20399244-11	2010	Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2.	U 0126	10-15	mitogen activated protein kinase 3	Rattus norvegicus	123-129
20399244-11	2010	Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2.	U 0126	10-15	AKT serine/threonine kinase 1	Rattus norvegicus	134-137
20399244-11	2010	Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2.	U 0126	10-15	heme oxygenase 1	Rattus norvegicus	180-184
20399244-11	2010	Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2.	U 0126	10-15	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	189-193
20399244-11	2010	Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2.	U 0126	10-15	NFE2 like bZIP transcription factor 2	Rattus norvegicus	261-265
20851880-5	2010	Erk activation by overexpression of constitutively active MEK1 increased Runx2 transcriptional activity, whereas U0126, an inhibitor of MEK1/2, suppressed basal Runx2 transcriptional activity and BMP-induced Runx2 acetylation and stabilization.	U 0126	113-118	mitogen-activated protein kinase kinase 1	Homo sapiens	136-142
20851880-5	2010	Erk activation by overexpression of constitutively active MEK1 increased Runx2 transcriptional activity, whereas U0126, an inhibitor of MEK1/2, suppressed basal Runx2 transcriptional activity and BMP-induced Runx2 acetylation and stabilization.	U 0126	113-118	RUNX family transcription factor 2	Homo sapiens	161-166
20851880-5	2010	Erk activation by overexpression of constitutively active MEK1 increased Runx2 transcriptional activity, whereas U0126, an inhibitor of MEK1/2, suppressed basal Runx2 transcriptional activity and BMP-induced Runx2 acetylation and stabilization.	U 0126	113-118	bone morphogenetic protein 1	Homo sapiens	196-199
20851880-5	2010	Erk activation by overexpression of constitutively active MEK1 increased Runx2 transcriptional activity, whereas U0126, an inhibitor of MEK1/2, suppressed basal Runx2 transcriptional activity and BMP-induced Runx2 acetylation and stabilization.	U 0126	113-118	RUNX family transcription factor 2	Homo sapiens	161-166
20738258-3	2010	We found that treatment of HMBA (hexamethylene bisacetamide)-induced MEL cells with the ERK pathway inhibitor UO126 results in an increase in intracellular haem and haemoglobin levels.	U 0126	110-115	mitogen-activated protein kinase 1	Mus musculus	88-91
21062976-5	2010	GADD45beta induction was not found after treatment with either the mitogen-activated protein kinase-extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126 or the Raf inhibitor ZM336372, suggesting that GADD45beta induction by sorafenib was independent of Raf/MEK/ERK signaling activity.	U 0126	167-172	growth arrest and DNA damage inducible beta	Homo sapiens	0-10
20716444-10	2010	The increased upregulation of contractile ET(B) receptors by DSP was abrogated by U0126, SP600125, actinomycin D, and cycloheximide, suggesting that the underlying molecular mechanisms involved in this process include activation of MEK and JNK MAPK-mediated transcription and translation of new contractile ET(B) receptors.	U 0126	82-87	endothelin receptor type B	Rattus norvegicus	42-47
20691769-6	2010	Translation inhibitor anisomycin and ERK inhibitor U0126 blocked E2 effects.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	37-40
20816674-7	2010	Furthermore, H2O2 accumulation was also suppressed by U0126, a MEK/ERK inhibitor, in a concentration-dependent manner.	U 0126	54-59	midkine	Mus musculus	63-66
20816674-7	2010	Furthermore, H2O2 accumulation was also suppressed by U0126, a MEK/ERK inhibitor, in a concentration-dependent manner.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	67-70
21057728-7	2010	Blocking phosphorylation of ERK1/2 by MAPK inhibitors U0126 and PD98059, and inhibiting activation of NF-kappaB by IkappaB (IkappaB) kinase inhibitors wedelolactone or IMD-0354, abolished the DSP effects.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	38-42
20868229-10	2010	Furthermore, U0126, which inhibits ERK1/2 phosphorylation by upstream MAPK/ERK kinases (MEK)1/2, reduced VD3-mediated differentiation and abrogated the effects of cadmium.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	35-41
20868229-10	2010	Furthermore, U0126, which inhibits ERK1/2 phosphorylation by upstream MAPK/ERK kinases (MEK)1/2, reduced VD3-mediated differentiation and abrogated the effects of cadmium.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	70-74
20868229-10	2010	Furthermore, U0126, which inhibits ERK1/2 phosphorylation by upstream MAPK/ERK kinases (MEK)1/2, reduced VD3-mediated differentiation and abrogated the effects of cadmium.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	75-95
20967466-10	2010	A specific MAPK inhibitor, U0126, was used to block ERK activity.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	11-15
20978199-6	2010	Treatment with the MEK inhibitor U0126 did not attenuate the emergence of aneuploidy but prevented the growth of aneuploid cells.	U 0126	33-38	midkine	Mus musculus	19-22
20967466-10	2010	A specific MAPK inhibitor, U0126, was used to block ERK activity.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	52-55
20578981-8	2010	We transduced the ErbB2 over-expressing BC line, BT474, with the HRAS (V12) mutant, then treated it with ErbB-family and phosphorylated MEK (MEKPP) inhibitors, Lapatinib and U0126, respectively.	U 0126	174-179	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
20578981-8	2010	We transduced the ErbB2 over-expressing BC line, BT474, with the HRAS (V12) mutant, then treated it with ErbB-family and phosphorylated MEK (MEKPP) inhibitors, Lapatinib and U0126, respectively.	U 0126	174-179	epidermal growth factor receptor	Homo sapiens	18-22
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	transforming growth factor beta 1	Homo sapiens	36-45
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	mitogen-activated protein kinase 3	Homo sapiens	75-81
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	mitogen-activated protein kinase kinase 7	Homo sapiens	130-133
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	mitogen-activated protein kinase 3	Homo sapiens	134-140
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	transforming growth factor beta 1	Homo sapiens	155-164
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	mitogen-activated protein kinase 1	Homo sapiens	14-51
20815659-2	2010	Pretreatment of these cells with the selective MEK1/2 (mitogen-activated protein kinase/extracellular signal-regulated kinase [ERK] kinase 1/2) inhibitor U0126 blocked ERK1/2 activation and inhibited cytokine-induced production of these inflammatory mediators.	U 0126	154-159	mitogen-activated protein kinase kinase 1	Homo sapiens	47-53
20815659-2	2010	Pretreatment of these cells with the selective MEK1/2 (mitogen-activated protein kinase/extracellular signal-regulated kinase [ERK] kinase 1/2) inhibitor U0126 blocked ERK1/2 activation and inhibited cytokine-induced production of these inflammatory mediators.	U 0126	154-159	mitogen-activated protein kinase 3	Homo sapiens	168-174
20815659-4	2010	U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes.	U 0126	0-5	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	30-52
20815659-4	2010	U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes.	U 0126	0-5	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	54-59
20815659-4	2010	U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes.	U 0126	0-5	nitric oxide synthase 2	Homo sapiens	65-86
20815659-4	2010	U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes.	U 0126	0-5	nitric oxide synthase 2	Homo sapiens	88-92
20815659-4	2010	U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	145-151
20815659-8	2010	Since tumor-derived cells were more sensitive than nontumorigenic cells to the antiproliferative effects of U0126, MEK1/2 inhibition may serve as an attractive chemotherapeutic target.	U 0126	108-113	mitogen-activated protein kinase kinase 1	Homo sapiens	115-121
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	mitogen-activated protein kinase 1	Homo sapiens	53-56
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	mitogen-activated protein kinase 8	Homo sapiens	62-85
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	mitogen-activated protein kinase 8	Homo sapiens	87-90
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	matrix metallopeptidase 9	Homo sapiens	145-150
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	mitogen-activated protein kinase 1	Homo sapiens	189-192
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	U 0126	215-220	mitogen-activated protein kinase 8	Homo sapiens	230-233
21040551-11	2010	E2-increased HBO1 protein expression was significantly suppressed by treatment with inhibitor of MEK1/2 (U0126) in T47 D and MCF-7 cells.	U 0126	105-110	lysine acetyltransferase 7	Homo sapiens	13-17
21040551-11	2010	E2-increased HBO1 protein expression was significantly suppressed by treatment with inhibitor of MEK1/2 (U0126) in T47 D and MCF-7 cells.	U 0126	105-110	mitogen-activated protein kinase kinase 1	Homo sapiens	97-103
20654633-14	2010	Behavioral experiments showed that U0126, a MAPK/ERK kinase (MEK) inhibitor, dose-dependently attenuated the behavioral response to i.t.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	44-48
20861219-7	2010	Inhibition of p44/42 extracellular signal-regulated kinase (ERK) phosphorylation, with 0.5 mumol/L of the specific MAPK pharmacological inhibitor U0126 for 2 h, restored the barrier function of the differentiated intestinal epithelial cell monolayers.	U 0126	146-151	interferon induced protein 44	Homo sapiens	14-17
20861219-7	2010	Inhibition of p44/42 extracellular signal-regulated kinase (ERK) phosphorylation, with 0.5 mumol/L of the specific MAPK pharmacological inhibitor U0126 for 2 h, restored the barrier function of the differentiated intestinal epithelial cell monolayers.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	21-58
20861219-7	2010	Inhibition of p44/42 extracellular signal-regulated kinase (ERK) phosphorylation, with 0.5 mumol/L of the specific MAPK pharmacological inhibitor U0126 for 2 h, restored the barrier function of the differentiated intestinal epithelial cell monolayers.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	60-63
20861219-7	2010	Inhibition of p44/42 extracellular signal-regulated kinase (ERK) phosphorylation, with 0.5 mumol/L of the specific MAPK pharmacological inhibitor U0126 for 2 h, restored the barrier function of the differentiated intestinal epithelial cell monolayers.	U 0126	146-151	mitogen-activated protein kinase 1	Homo sapiens	115-119
20861219-9	2010	The U0126 also restored the intestinal expression of claudin-4 protein, thereby demonstrating that MAPK activation is involved in claudin-4 protein expression and claudin-4 is involved in the maintenance of the intestinal epithelial cell barrier function.	U 0126	4-9	claudin 4	Homo sapiens	53-62
20861219-9	2010	The U0126 also restored the intestinal expression of claudin-4 protein, thereby demonstrating that MAPK activation is involved in claudin-4 protein expression and claudin-4 is involved in the maintenance of the intestinal epithelial cell barrier function.	U 0126	4-9	mitogen-activated protein kinase 1	Homo sapiens	99-103
20861219-9	2010	The U0126 also restored the intestinal expression of claudin-4 protein, thereby demonstrating that MAPK activation is involved in claudin-4 protein expression and claudin-4 is involved in the maintenance of the intestinal epithelial cell barrier function.	U 0126	4-9	claudin 4	Homo sapiens	130-139
20861219-9	2010	The U0126 also restored the intestinal expression of claudin-4 protein, thereby demonstrating that MAPK activation is involved in claudin-4 protein expression and claudin-4 is involved in the maintenance of the intestinal epithelial cell barrier function.	U 0126	4-9	claudin 4	Homo sapiens	130-139
20870738-6	2010	In contrast, the mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) kinase (MEK) inhibitor U0126 (but not the phosphoinositide 3-kinase inhibitor LY294002) prevented the drug-induced suppression as determined by reverse transcription-PCR and promoter assays.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	94-97
20870738-6	2010	In contrast, the mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) kinase (MEK) inhibitor U0126 (but not the phosphoinositide 3-kinase inhibitor LY294002) prevented the drug-induced suppression as determined by reverse transcription-PCR and promoter assays.	U 0126	122-127	mitogen-activated protein kinase kinase 7	Homo sapiens	107-110
20637248-11	2010	Changes in occludin expression and localization could be inhibited by the ERK1/2 inhibitor U0126.	U 0126	91-96	occludin	Homo sapiens	11-19
20637248-11	2010	Changes in occludin expression and localization could be inhibited by the ERK1/2 inhibitor U0126.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	74-80
20878136-6	2010	Treatment with specific inhibitors of the MAPK or STST3 pathway (UO126 or AG490, respectively), in contrast to treatment with the Akt pathway inhibitor LY294002, significantly inhibited the dihydrotestosterone-induced activation of both wild-type and mutant ARs; however, activation of W741L mutant AR by bicalutamide was significantly inhibited by treatment with UO126, in contrast to treatment with AG490 or LY294002.	U 0126	65-70	androgen receptor	Homo sapiens	258-260
20709750-10	2010	24-h stimulation with adiponectin significantly increased cell viability by decreasing cellular apoptosis, and this was prevented by dominant negative Akt, wortmannin (PI3K inhibitor), and U0126 (MEK inhibitor).	U 0126	189-194	adiponectin, C1Q and collagen domain containing	Mus musculus	22-33
20709750-10	2010	24-h stimulation with adiponectin significantly increased cell viability by decreasing cellular apoptosis, and this was prevented by dominant negative Akt, wortmannin (PI3K inhibitor), and U0126 (MEK inhibitor).	U 0126	189-194	midkine	Mus musculus	196-199
20709750-11	2010	Moreover, adiponectin regulated insulin gene expression and glucose-stimulated insulin secretion, which was also prevented by wortmannin and U0126 treatment.	U 0126	141-146	adiponectin, C1Q and collagen domain containing	Mus musculus	10-21
21042538-9	2010	Treatment of U0126 (MEK1/2 inhibitor) restored osteogenic differentiation enhanced by Pam(3)CSK(4).	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	20-26
20669973-2	2010	The purpose of this study is to evaluate the antitumor activity of MEK inhibitor U0126 in combination with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in pancreatic cancer cells.	U 0126	81-86	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
20669973-5	2010	The selective MEK inhibitor U0126 completely abolished 17-AAG induced ERK1/2 activation and resulted in more than 80% of phospho-ERK degradation after only 15 min treatment.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
20669973-5	2010	The selective MEK inhibitor U0126 completely abolished 17-AAG induced ERK1/2 activation and resulted in more than 80% of phospho-ERK degradation after only 15 min treatment.	U 0126	28-33	N-methylpurine DNA glycosylase	Homo sapiens	58-61
20669973-5	2010	The selective MEK inhibitor U0126 completely abolished 17-AAG induced ERK1/2 activation and resulted in more than 80% of phospho-ERK degradation after only 15 min treatment.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	70-76
20669973-5	2010	The selective MEK inhibitor U0126 completely abolished 17-AAG induced ERK1/2 activation and resulted in more than 80% of phospho-ERK degradation after only 15 min treatment.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	70-73
20669973-6	2010	Moreover, U0126 had complementary effect on 17-AAG regulated oncogenic and cell cycle related proteins.	U 0126	10-15	N-methylpurine DNA glycosylase	Homo sapiens	47-50
20669973-7	2010	Although 17-AAG downregulated cyclin D1, cyclin E, CDK4 and CDK6, it led to cyclin A and CDK2 accumulation, which was reversed by the addition of U0126.	U 0126	146-151	N-methylpurine DNA glycosylase	Homo sapiens	12-15
20669973-7	2010	Although 17-AAG downregulated cyclin D1, cyclin E, CDK4 and CDK6, it led to cyclin A and CDK2 accumulation, which was reversed by the addition of U0126.	U 0126	146-151	cyclin dependent kinase 4	Homo sapiens	51-55
20669973-7	2010	Although 17-AAG downregulated cyclin D1, cyclin E, CDK4 and CDK6, it led to cyclin A and CDK2 accumulation, which was reversed by the addition of U0126.	U 0126	146-151	cyclin dependent kinase 6	Homo sapiens	60-64
20669973-7	2010	Although 17-AAG downregulated cyclin D1, cyclin E, CDK4 and CDK6, it led to cyclin A and CDK2 accumulation, which was reversed by the addition of U0126.	U 0126	146-151	cyclin A2	Homo sapiens	76-84
20669973-7	2010	Although 17-AAG downregulated cyclin D1, cyclin E, CDK4 and CDK6, it led to cyclin A and CDK2 accumulation, which was reversed by the addition of U0126.	U 0126	146-151	cyclin dependent kinase 2	Homo sapiens	89-93
20669973-10	2010	Taken together, these data demonstrate that MEK inhibitor U0126 potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	44-47
20669973-10	2010	Taken together, these data demonstrate that MEK inhibitor U0126 potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.	U 0126	58-63	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
20669973-10	2010	Taken together, these data demonstrate that MEK inhibitor U0126 potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.	U 0126	58-63	N-methylpurine DNA glycosylase	Homo sapiens	111-114
20526801-5	2010	Furthermore, we also demonstrate that either chemical inhibition of MEK/ERK (U0126) or stable downregulation of PDGFRbeta by shRNA similarly results in the loss of PDGF-induced ERK phosphorylation and abolishes Rac1/Pak1 activation and cell migration in response to PDGF.	U 0126	77-82	mitogen-activated protein kinase kinase 7	Homo sapiens	68-71
20526801-5	2010	Furthermore, we also demonstrate that either chemical inhibition of MEK/ERK (U0126) or stable downregulation of PDGFRbeta by shRNA similarly results in the loss of PDGF-induced ERK phosphorylation and abolishes Rac1/Pak1 activation and cell migration in response to PDGF.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	72-75
20526801-5	2010	Furthermore, we also demonstrate that either chemical inhibition of MEK/ERK (U0126) or stable downregulation of PDGFRbeta by shRNA similarly results in the loss of PDGF-induced ERK phosphorylation and abolishes Rac1/Pak1 activation and cell migration in response to PDGF.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	177-180
20685868-10	2010	Moreover, inhibiting the ERK1/2 and p38 pathways with U0126 and SB239063, respectively, prevented kisspeptin induction of NPY mRNA expression and secretion.	U 0126	54-59	mitogen-activated protein kinase 3	Mus musculus	25-31
20685868-10	2010	Moreover, inhibiting the ERK1/2 and p38 pathways with U0126 and SB239063, respectively, prevented kisspeptin induction of NPY mRNA expression and secretion.	U 0126	54-59	mitogen-activated protein kinase 14	Mus musculus	36-39
20685868-10	2010	Moreover, inhibiting the ERK1/2 and p38 pathways with U0126 and SB239063, respectively, prevented kisspeptin induction of NPY mRNA expression and secretion.	U 0126	54-59	KiSS-1 metastasis-suppressor	Mus musculus	98-108
20685868-10	2010	Moreover, inhibiting the ERK1/2 and p38 pathways with U0126 and SB239063, respectively, prevented kisspeptin induction of NPY mRNA expression and secretion.	U 0126	54-59	neuropeptide Y	Mus musculus	122-125
20542106-9	2010	An increase in cyclin D1 expression, that could be inhibited by 10 microM LY 294002 or 20 microM U0126, was observed when cells were incubated with 500 microM ADP.	U 0126	97-102	cyclin D1	Gallus gallus	15-24
20818498-4	2010	We found that U0126, a specific inhibitor of ERK1/2, and SB203580, a specific inhibitor of p38, down-regulated the TGF-beta1-induced phosphorylation of Smad2 at both linker and C-terminal sites in rat mesangial cells.	U 0126	14-19	mitogen activated protein kinase 3	Rattus norvegicus	45-51
20818498-4	2010	We found that U0126, a specific inhibitor of ERK1/2, and SB203580, a specific inhibitor of p38, down-regulated the TGF-beta1-induced phosphorylation of Smad2 at both linker and C-terminal sites in rat mesangial cells.	U 0126	14-19	transforming growth factor, beta 1	Rattus norvegicus	115-124
20818498-4	2010	We found that U0126, a specific inhibitor of ERK1/2, and SB203580, a specific inhibitor of p38, down-regulated the TGF-beta1-induced phosphorylation of Smad2 at both linker and C-terminal sites in rat mesangial cells.	U 0126	14-19	SMAD family member 2	Rattus norvegicus	152-157
20445124-9	2010	U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity.	U 0126	0-5	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	93-97
20821752-12	2010	Treating endometriotic cells with A771726, PD98059 or U0126 abrogated the phosphorylation of ERK and significantly decreased the cellular proliferation in vitro.	U 0126	54-59	mitogen-activated protein kinase 1	Homo sapiens	93-96
20524145-4	2010	Unexpectedly, the p38 MAPK inhibitor SB203580 produced an increase of cathepsin L content, while the p44/42 MAPK signaling cascade inhibitor U0126 produced a remarkable shift of cathepsin L processing in favor of procathepsin L. In both cases, cathepsin B level and processing were not affected.	U 0126	141-146	interferon induced protein 44	Homo sapiens	101-104
20524145-4	2010	Unexpectedly, the p38 MAPK inhibitor SB203580 produced an increase of cathepsin L content, while the p44/42 MAPK signaling cascade inhibitor U0126 produced a remarkable shift of cathepsin L processing in favor of procathepsin L. In both cases, cathepsin B level and processing were not affected.	U 0126	141-146	cathepsin L	Homo sapiens	178-189
20524145-4	2010	Unexpectedly, the p38 MAPK inhibitor SB203580 produced an increase of cathepsin L content, while the p44/42 MAPK signaling cascade inhibitor U0126 produced a remarkable shift of cathepsin L processing in favor of procathepsin L. In both cases, cathepsin B level and processing were not affected.	U 0126	141-146	cathepsin B	Homo sapiens	244-255
20691686-4	2010	Inhibition of ERK by U0126 or siRNA prevented both the hypercapnia-induced Na,K-ATPase endocytosis and impairment of AFR.	U 0126	21-26	Eph receptor B1	Rattus norvegicus	14-17
20553909-5	2010	However, TSA inhibited the TGF-beta1-induced phosphorylation of extracellular signal regulated kinase (ERK), and the MAPK/ERK kinase inhibitor U0126, which specifically inhibits ERK, also prevented TGF-beta1-induced apoptosis.	U 0126	143-148	mitogen-activated protein kinase 1	Homo sapiens	117-121
20553909-5	2010	However, TSA inhibited the TGF-beta1-induced phosphorylation of extracellular signal regulated kinase (ERK), and the MAPK/ERK kinase inhibitor U0126, which specifically inhibits ERK, also prevented TGF-beta1-induced apoptosis.	U 0126	143-148	mitogen-activated protein kinase 1	Homo sapiens	122-125
20553909-5	2010	However, TSA inhibited the TGF-beta1-induced phosphorylation of extracellular signal regulated kinase (ERK), and the MAPK/ERK kinase inhibitor U0126, which specifically inhibits ERK, also prevented TGF-beta1-induced apoptosis.	U 0126	143-148	mitogen-activated protein kinase 1	Homo sapiens	122-125
20553909-5	2010	However, TSA inhibited the TGF-beta1-induced phosphorylation of extracellular signal regulated kinase (ERK), and the MAPK/ERK kinase inhibitor U0126, which specifically inhibits ERK, also prevented TGF-beta1-induced apoptosis.	U 0126	143-148	transforming growth factor beta 1	Homo sapiens	198-207
20554644-9	2010	The MEK/ERK inhibitor U0126 eliminated inhibition of HCO(3)(-) absorption by bath LPS but had no effect on inhibition by Pam(3)CSK(4).	U 0126	22-27	midkine	Mus musculus	4-7
20554644-9	2010	The MEK/ERK inhibitor U0126 eliminated inhibition of HCO(3)(-) absorption by bath LPS but had no effect on inhibition by Pam(3)CSK(4).	U 0126	22-27	Eph receptor B2	Mus musculus	8-11
20450880-6	2010	Since certain flavonoids are known to inhibit mitogen-activated protein kinases (MAPKs), we confirmed the contribution of MAPK/ERK kinase (MEK) to the AhR-mediated signal transduction by using U0126, an inhibitor of MEK1/2.	U 0126	193-198	aryl-hydrocarbon receptor	Mus musculus	151-154
20450880-6	2010	Since certain flavonoids are known to inhibit mitogen-activated protein kinases (MAPKs), we confirmed the contribution of MAPK/ERK kinase (MEK) to the AhR-mediated signal transduction by using U0126, an inhibitor of MEK1/2.	U 0126	193-198	mitogen-activated protein kinase kinase 1	Mus musculus	216-222
20450880-7	2010	U0126 suppressed TCDD-induced phosphorylation of the AhR and Arnt followed by the DNA-binding activity of the AhR.	U 0126	0-5	aryl-hydrocarbon receptor	Mus musculus	53-56
20450880-7	2010	U0126 suppressed TCDD-induced phosphorylation of the AhR and Arnt followed by the DNA-binding activity of the AhR.	U 0126	0-5	aryl hydrocarbon receptor nuclear translocator	Mus musculus	61-65
20450880-7	2010	U0126 suppressed TCDD-induced phosphorylation of the AhR and Arnt followed by the DNA-binding activity of the AhR.	U 0126	0-5	aryl-hydrocarbon receptor	Mus musculus	110-113
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	23-68
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	70-73
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	91-94
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	snail family transcriptional repressor 2	Homo sapiens	129-134
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	snail family transcriptional repressor 2	Homo sapiens	148-152
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	cadherin 1	Homo sapiens	178-188
20427760-4	2010	U0126, an inhibitor of extracellular signal-regulated protein kinase (ERK), attenuated the CsA-induced transcriptional repressor SNAI2 (also called Slug) expression and restored E-cadherin expression inhibited by CsA in JEG-3 cells.	U 0126	0-5	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	213-216
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	U 0126	161-166	mitogen-activated protein kinase 3	Homo sapiens	75-79
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	U 0126	161-166	mitogen-activated protein kinase 3	Homo sapiens	218-224
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	226-229
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	U 0126	161-166	mitogen-activated protein kinase 8	Homo sapiens	239-245
20182834-9	2010	The extracellular signal-regulated kinase (ERK) signalling pathway appears to regulate HSP70 protein expression in these cells, as the mitogen-activated protein-ERK kinase 1/2 (MEK1/2) inhibitor, U0126, significantly reduced HSP70 protein levels.	U 0126	196-201	heat shock protein 70 B2-like	Biomphalaria glabrata	87-92
20182834-9	2010	The extracellular signal-regulated kinase (ERK) signalling pathway appears to regulate HSP70 protein expression in these cells, as the mitogen-activated protein-ERK kinase 1/2 (MEK1/2) inhibitor, U0126, significantly reduced HSP70 protein levels.	U 0126	196-201	heat shock protein 70 B2-like	Biomphalaria glabrata	225-230
20471474-6	2010	siRNA-mediated silencing of class I PI3K or Akt1/2 genes also significantly decreased U0126-resistant ERK phosphorylation.	U 0126	86-91	AKT serine/threonine kinase 1	Homo sapiens	44-50
20471474-6	2010	siRNA-mediated silencing of class I PI3K or Akt1/2 genes also significantly decreased U0126-resistant ERK phosphorylation.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	102-105
20408896-9	2010	In addition, treatment of cont-DCs with U0126, a specific inhibitor of the ERK pathway, reduced the TLR-mediated production by the DCs of IL-23 but not IL-12.	U 0126	40-45	mitogen-activated protein kinase 1	Mus musculus	75-78
20408896-9	2010	In addition, treatment of cont-DCs with U0126, a specific inhibitor of the ERK pathway, reduced the TLR-mediated production by the DCs of IL-23 but not IL-12.	U 0126	40-45	interleukin 23, alpha subunit p19	Mus musculus	138-143
20506406-5	2010	p38 MAPK activation suppression by SB202190 (p38 MAPK inhibitor) abolished posttranscriptional up-regulation of ADAM17 in PLA(2)-treated cells, while treatment with U0126 (MEK1 and MEK2 inhibitor) increased ADAM17 maturation in SK-N-SH cells.	U 0126	165-170	mitogen-activated protein kinase 14	Homo sapiens	0-3
20506406-5	2010	p38 MAPK activation suppression by SB202190 (p38 MAPK inhibitor) abolished posttranscriptional up-regulation of ADAM17 in PLA(2)-treated cells, while treatment with U0126 (MEK1 and MEK2 inhibitor) increased ADAM17 maturation in SK-N-SH cells.	U 0126	165-170	mitogen-activated protein kinase 1	Homo sapiens	4-8
20506406-5	2010	p38 MAPK activation suppression by SB202190 (p38 MAPK inhibitor) abolished posttranscriptional up-regulation of ADAM17 in PLA(2)-treated cells, while treatment with U0126 (MEK1 and MEK2 inhibitor) increased ADAM17 maturation in SK-N-SH cells.	U 0126	165-170	mitogen-activated protein kinase 14	Homo sapiens	45-48
20506406-5	2010	p38 MAPK activation suppression by SB202190 (p38 MAPK inhibitor) abolished posttranscriptional up-regulation of ADAM17 in PLA(2)-treated cells, while treatment with U0126 (MEK1 and MEK2 inhibitor) increased ADAM17 maturation in SK-N-SH cells.	U 0126	165-170	ADAM metallopeptidase domain 17	Homo sapiens	112-118
20506406-5	2010	p38 MAPK activation suppression by SB202190 (p38 MAPK inhibitor) abolished posttranscriptional up-regulation of ADAM17 in PLA(2)-treated cells, while treatment with U0126 (MEK1 and MEK2 inhibitor) increased ADAM17 maturation in SK-N-SH cells.	U 0126	165-170	phospholipase A2 group IB	Homo sapiens	122-128
20506523-5	2010	Pretreatment of JJ012 cells with MAPK kinase (MEK) inhibitors, PD98059 or U0126, inhibited the RANKL-induced migration and integrin expression.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
20506523-5	2010	Pretreatment of JJ012 cells with MAPK kinase (MEK) inhibitors, PD98059 or U0126, inhibited the RANKL-induced migration and integrin expression.	U 0126	74-79	TNF superfamily member 11	Homo sapiens	95-100
20471392-5	2010	PAI-1 protein expression induced by UTP was dependent on protein kinase C (PKC) and extracellular signal-regulated kinase (ERK), based on blockade by the PKC inhibitor Ro-31-8220 and the ERK inhibitor U0126, respectively.	U 0126	201-206	serpin family E member 1	Rattus norvegicus	0-5
20471392-5	2010	PAI-1 protein expression induced by UTP was dependent on protein kinase C (PKC) and extracellular signal-regulated kinase (ERK), based on blockade by the PKC inhibitor Ro-31-8220 and the ERK inhibitor U0126, respectively.	U 0126	201-206	Eph receptor B1	Rattus norvegicus	84-121
20471392-5	2010	PAI-1 protein expression induced by UTP was dependent on protein kinase C (PKC) and extracellular signal-regulated kinase (ERK), based on blockade by the PKC inhibitor Ro-31-8220 and the ERK inhibitor U0126, respectively.	U 0126	201-206	Eph receptor B1	Rattus norvegicus	123-126
20471392-5	2010	PAI-1 protein expression induced by UTP was dependent on protein kinase C (PKC) and extracellular signal-regulated kinase (ERK), based on blockade by the PKC inhibitor Ro-31-8220 and the ERK inhibitor U0126, respectively.	U 0126	201-206	Eph receptor B1	Rattus norvegicus	187-190
20663526-11	2010	Interferon-alpha treatment altered the ability of cells to activate extracellular signal-regulated kinase while inhibiting extracellular signal-regulated kinase with UO126 abrogated TRAIL and interferon-alpha apoptotic synergy.	U 0126	166-171	TNF superfamily member 10	Homo sapiens	182-187
20470842-5	2010	CPW-399 induction of delta subunit mRNA was reduced by prior treatment with either the MEK1/2 inhibitor U0126 or protein kinase A (PKA) inhibitors KT 5720 and H89.	U 0126	104-109	mitogen-activated protein kinase kinase 1	Mus musculus	87-93
20664988-4	2010	When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a &gt;60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells.	U 0126	83-88	phosphatase and tensin homolog	Homo sapiens	153-157
20664988-4	2010	When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a &gt;60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells.	U 0126	83-88	phosphatase and tensin homolog	Homo sapiens	238-242
20664988-4	2010	When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a &gt;60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells.	U 0126	191-196	AKT serine/threonine kinase 1	Homo sapiens	14-17
20664988-4	2010	When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a &gt;60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells.	U 0126	191-196	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
20664988-5	2010	FACS analysis demonstrated that the subG0/G1 apoptotic fraction was significantly increased in MDA-MB-468 PTEN cells after U0126 treatment, while LY294002 treatment in both cell lines and U0126 treatment in MDA-MB-468 vec cells led to a modest increase in the apoptotic fraction.	U 0126	123-128	phosphatase and tensin homolog	Homo sapiens	106-110
20664988-7	2010	p-Erk levels were significantly lower after U0126 treatment in MDA-MB-468 PTEN cells.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	2-5
20664988-7	2010	p-Erk levels were significantly lower after U0126 treatment in MDA-MB-468 PTEN cells.	U 0126	44-49	phosphatase and tensin homolog	Homo sapiens	74-78
21053363-8	2010	We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Mus musculus	18-24
21053363-8	2010	We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway.	U 0126	35-40	midkine	Mus musculus	18-21
21053363-8	2010	We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	87-90
21053363-8	2010	We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway.	U 0126	35-40	FBJ osteosarcoma oncogene	Mus musculus	91-96
20816994-8	2010	Pretreatment with a MAP kinase/ERK kinase (MEK)1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by terbinafine treatment in THP-1 cells, but p38 MAPK inhibitor SB203580 did not.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Homo sapiens	31-50
20816994-8	2010	Pretreatment with a MAP kinase/ERK kinase (MEK)1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by terbinafine treatment in THP-1 cells, but p38 MAPK inhibitor SB203580 did not.	U 0126	61-66	C-X-C motif chemokine ligand 8	Homo sapiens	108-112
20816994-8	2010	Pretreatment with a MAP kinase/ERK kinase (MEK)1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by terbinafine treatment in THP-1 cells, but p38 MAPK inhibitor SB203580 did not.	U 0126	61-66	tumor necrosis factor	Homo sapiens	117-125
20816994-8	2010	Pretreatment with a MAP kinase/ERK kinase (MEK)1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFalpha levels by terbinafine treatment in THP-1 cells, but p38 MAPK inhibitor SB203580 did not.	U 0126	61-66	GLI family zinc finger 2	Homo sapiens	161-166
20942929-7	2010	4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity.	U 0126	36-41	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	59-67
20942929-7	2010	4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity.	U 0126	36-41	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	111-119
20942929-7	2010	4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity.	U 0126	36-41	mitogen-activated protein kinase 1	Mus musculus	143-146
20615400-8	2010	Organ culture was associated with elevated pERK1/2 in the vascular smooth muscle cells: the MEK1/2 inhibitor U0126 attenuated the endothelin ET(B) receptor mediated contraction at post-translational level or by changing the receptor affinities.	U 0126	109-114	mitogen activated protein kinase kinase 1	Rattus norvegicus	92-98
20615400-9	2010	The serotonin 5-HT(1B) receptor and prostanoid TP receptor mediated contractions were abolished by U0126.	U 0126	99-104	thromboxane A2 receptor	Rattus norvegicus	36-58
20600713-8	2010	Furthermore, Cd(2+)-induced release of TNF-alpha from primary human monocytes was blocked by inhibitors for ERK 1/2 (U0126) and p38 MAPK (SB202190), demonstrating that MAPKs are involved in the induction of TNF-alpha by Cd(2+).	U 0126	117-122	tumor necrosis factor	Homo sapiens	39-48
20600713-8	2010	Furthermore, Cd(2+)-induced release of TNF-alpha from primary human monocytes was blocked by inhibitors for ERK 1/2 (U0126) and p38 MAPK (SB202190), demonstrating that MAPKs are involved in the induction of TNF-alpha by Cd(2+).	U 0126	117-122	mitogen-activated protein kinase 3	Homo sapiens	108-115
19880820-6	2010	Interestingly, MEK1 pathway inhibition with PD98059 or U0126 significantly enhanced HRV-16-induced IRF-1 mRNA levels in BEAS-2B cells and HBEs, although IRF-1 protein expression was only enhanced in HBEs.	U 0126	55-60	interferon regulatory factor 1	Homo sapiens	99-104
20811713-5	2010	Inhibition of this pathway by U0126 treatment in E1 cells resulted in the re-expression of palladin, relocalization of E-cadherin to the adherens junctions and a reversal of EMT features.	U 0126	30-35	palladin, cytoskeletal associated protein	Homo sapiens	91-99
20811713-5	2010	Inhibition of this pathway by U0126 treatment in E1 cells resulted in the re-expression of palladin, relocalization of E-cadherin to the adherens junctions and a reversal of EMT features.	U 0126	30-35	cadherin 1	Homo sapiens	119-129
20445124-9	2010	U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	23-29
20445124-9	2010	U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity.	U 0126	0-5	vascular endothelial growth factor A	Rattus norvegicus	50-54
20445124-9	2010	U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	82-88
20875145-8	2010	Similar inhibition was observed using inhibitors of IkappaB-kinase-2 (SC514) and MEK1/2 (U0126), both downstream effectors of PKC.	U 0126	89-94	mitogen-activated protein kinase kinase 1	Homo sapiens	81-87
20633629-7	2010	U0126, inhibitor of ERK1/2, significantly reduced CA and RA effects on cell differentiation and AChE activity.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	20-26
20633629-7	2010	U0126, inhibitor of ERK1/2, significantly reduced CA and RA effects on cell differentiation and AChE activity.	U 0126	0-5	acetylcholinesterase	Rattus norvegicus	96-100
20534867-9	2010	Moreover, we found that their upregulation was dependent on ERK, using the ERK pathway inhibitor U-0126.	U 0126	97-103	mitogen-activated protein kinase 1	Homo sapiens	60-63
20534867-9	2010	Moreover, we found that their upregulation was dependent on ERK, using the ERK pathway inhibitor U-0126.	U 0126	97-103	mitogen-activated protein kinase 1	Homo sapiens	75-78
20800791-11	2010	Furthermore, ERK1/2 (U0126) and JNK (SP600125) inhibitors inhibited CraA-induced IL-8 secretion by 100% and 45%, respectively.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	13-19
20800791-11	2010	Furthermore, ERK1/2 (U0126) and JNK (SP600125) inhibitors inhibited CraA-induced IL-8 secretion by 100% and 45%, respectively.	U 0126	21-26	C-X-C motif chemokine ligand 8	Homo sapiens	81-85
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	U 0126	199-204	tumor necrosis factor	Homo sapiens	0-3
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	U 0126	199-204	tumor necrosis factor	Homo sapiens	98-101
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	U 0126	199-204	TNF receptor superfamily member 1A	Homo sapiens	114-122
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	U 0126	199-204	mitogen-activated protein kinase 13	Homo sapiens	174-181
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	U 0126	199-204	tumor necrosis factor	Homo sapiens	98-101
20448669-4	2010	Interestingly, a combination of ALK gene silencing with U0126, a kinase inhibitor specific for the extracellular signal-regulated kinases 1/2 pathway, resulted in an augmented reduction in cellular JunB expression.	U 0126	56-61	ALK receptor tyrosine kinase	Homo sapiens	32-35
20448669-4	2010	Interestingly, a combination of ALK gene silencing with U0126, a kinase inhibitor specific for the extracellular signal-regulated kinases 1/2 pathway, resulted in an augmented reduction in cellular JunB expression.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	99-141
20448669-4	2010	Interestingly, a combination of ALK gene silencing with U0126, a kinase inhibitor specific for the extracellular signal-regulated kinases 1/2 pathway, resulted in an augmented reduction in cellular JunB expression.	U 0126	56-61	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	198-202
20471474-2	2010	In contrast to MCF7 cells, ERK phosphorylation in T47D cells displayed resistance to MEK inhibition by several structurally different compounds, such as U0126, PD 098059 and PD 198306, MEK suppression by small interfering RNA (siRNA) and was also less sensitive to PI3K inhibition by wortmannin.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	27-30
20471474-2	2010	In contrast to MCF7 cells, ERK phosphorylation in T47D cells displayed resistance to MEK inhibition by several structurally different compounds, such as U0126, PD 098059 and PD 198306, MEK suppression by small interfering RNA (siRNA) and was also less sensitive to PI3K inhibition by wortmannin.	U 0126	153-158	mitogen-activated protein kinase kinase 7	Homo sapiens	85-88
20583135-5	2010	IGFBP5 down-regulation, similar to neuronal differentiation, is mediated by the MAPK pathway since U0126, an inhibitor of MEK1/2, effectively blocked it.	U 0126	99-104	insulin like growth factor binding protein 5	Homo sapiens	0-6
20583135-5	2010	IGFBP5 down-regulation, similar to neuronal differentiation, is mediated by the MAPK pathway since U0126, an inhibitor of MEK1/2, effectively blocked it.	U 0126	99-104	mitogen-activated protein kinase kinase 1	Homo sapiens	122-128
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	transferrin receptor	Mus musculus	15-18
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	ribosomal protein S6 kinase polypeptide 1	Mus musculus	19-22
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	mitogen-activated protein kinase 1	Mus musculus	62-65
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	mitogen-activated protein kinase kinase 1	Mus musculus	99-103
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	mitogen-activated protein kinase kinase 2	Mus musculus	105-126
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	transferrin receptor	Mus musculus	180-183
20557427-6	2010	Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK).	U 0126	147-152	ribosomal protein S6 kinase polypeptide 1	Mus musculus	184-187
20654633-14	2010	Behavioral experiments showed that U0126, a MAPK/ERK kinase (MEK) inhibitor, dose-dependently attenuated the behavioral response to i.t.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	49-52
20540975-9	2010	Treatment of cells with U0126, a selective ERK1/2 inhibitor, markedly diminished PRRSV infection and its inhibitory effect on PRRSV replication was exerted at the early stage in virus infection.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	43-49
20595932-4	2010	RESULTS: Screening with inhibitors revealed specific inhibition only with the map kinase (MEK)/extracellular signal regulated kinase (ERK) inhibitor, U0126.	U 0126	150-155	mitogen-activated protein kinase 1	Mus musculus	134-137
20595932-4	2010	RESULTS: Screening with inhibitors revealed specific inhibition only with the map kinase (MEK)/extracellular signal regulated kinase (ERK) inhibitor, U0126.	U 0126	150-155	midkine	Mus musculus	90-93
19998339-11	2010	Hypoxia significantly enhanced adhesion of SGC7901 cells to laminin in a time-dependent manner, which might be inhibited by the MEK inhibitor U0126 and MGr1-Ag/37LRP siRNA.	U 0126	142-147	mitogen-activated protein kinase kinase 7	Homo sapiens	128-131
20649568-6	2010	In mechanistic terms, the NO-triggered effect occurred independently of cGMP, but involved the classical mitogen-activated protein kinase cascade because the MEK inhibitor U0126 abolished the NO-induced SK-1 expression.	U 0126	172-177	mitogen-activated protein kinase kinase 7	Homo sapiens	158-161
19998339-5	2010	Furthermore, U0126, the MEK inhibitor, inhibited hypoxia- and MEK-induced MGr1-Ag/37LRP promoter activity in a dose-dependent manner.	U 0126	13-18	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
19998339-5	2010	Furthermore, U0126, the MEK inhibitor, inhibited hypoxia- and MEK-induced MGr1-Ag/37LRP promoter activity in a dose-dependent manner.	U 0126	13-18	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
19998339-5	2010	Furthermore, U0126, the MEK inhibitor, inhibited hypoxia- and MEK-induced MGr1-Ag/37LRP promoter activity in a dose-dependent manner.	U 0126	13-18	MGR1	Homo sapiens	74-78
19998339-5	2010	Furthermore, U0126, the MEK inhibitor, inhibited hypoxia- and MEK-induced MGr1-Ag/37LRP promoter activity in a dose-dependent manner.	U 0126	13-18	ribosomal protein SA	Homo sapiens	82-87
20600008-2	2010	Cell-based screening experiments disclosed that the MEK (MAP kinase kinase) inhibitors, U0126 and PD184352, suppress Abeta secretion from human neuronal SH-SY5Y cells expressing Swedish mutant APP.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
20600008-2	2010	Cell-based screening experiments disclosed that the MEK (MAP kinase kinase) inhibitors, U0126 and PD184352, suppress Abeta secretion from human neuronal SH-SY5Y cells expressing Swedish mutant APP.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	57-74
20600008-2	2010	Cell-based screening experiments disclosed that the MEK (MAP kinase kinase) inhibitors, U0126 and PD184352, suppress Abeta secretion from human neuronal SH-SY5Y cells expressing Swedish mutant APP.	U 0126	88-93	amyloid beta precursor protein	Homo sapiens	117-122
20553273-7	2010	By using MEK1/2 inhibitor U0126, PI3K inhibitor LY294002, and STAT3 or STAT5 siRNAs, JAK2 V617F was found to specifically use the STAT3 pathway to enhance LAP expression, while STAT5, Ras/MEK/ERK and PI3K/Akt, but not STAT3 pathways, were able to stimulate cell proliferation.	U 0126	26-31	Janus kinase 2	Homo sapiens	85-89
20553273-7	2010	By using MEK1/2 inhibitor U0126, PI3K inhibitor LY294002, and STAT3 or STAT5 siRNAs, JAK2 V617F was found to specifically use the STAT3 pathway to enhance LAP expression, while STAT5, Ras/MEK/ERK and PI3K/Akt, but not STAT3 pathways, were able to stimulate cell proliferation.	U 0126	26-31	signal transducer and activator of transcription 3	Homo sapiens	130-135
20553273-7	2010	By using MEK1/2 inhibitor U0126, PI3K inhibitor LY294002, and STAT3 or STAT5 siRNAs, JAK2 V617F was found to specifically use the STAT3 pathway to enhance LAP expression, while STAT5, Ras/MEK/ERK and PI3K/Akt, but not STAT3 pathways, were able to stimulate cell proliferation.	U 0126	26-31	signal transducer and activator of transcription 3	Homo sapiens	130-135
20649568-6	2010	In mechanistic terms, the NO-triggered effect occurred independently of cGMP, but involved the classical mitogen-activated protein kinase cascade because the MEK inhibitor U0126 abolished the NO-induced SK-1 expression.	U 0126	172-177	sphingosine kinase 1	Homo sapiens	203-207
20725141-9	2010	ET-1-induced pulmonary SMC migration was blocked by the structurally distinct MEK inhibitors PD98059 and U0126, consistent with a role for ERK1/2 MAP kinase.	U 0126	105-110	endothelin 1	Homo sapiens	0-4
20592496-8	2010	Additionally, treatment with As(2)O(3) in combination with inhibitors specific for MEK (U0126) in HOS and MNNG cells resulted in a marked inhibition of cell invasion and As(2)O(3) could significantly reduce PMA-induced invasion.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	83-86
20535114-12	2010	ERK1/2 inhibition in vivo (U0126) prevented LF-induced diameter reduction.	U 0126	27-32	mitogen activated protein kinase 3	Rattus norvegicus	0-6
20707645-12	2010	U0126, a potent and selective MEK1/2 inhibitor, inhibited up-regulation of pERK1/2 which was stimulated by magnetic stimulation.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	30-36
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	22-65
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	67-73
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	103-109
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	heme oxygenase 1	Homo sapiens	133-137
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	173-179
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	208-214
20430097-6	2010	Pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, U0126, inhibited CaMKII-induced stimulation of HO-1 promoter activity, suggesting that ERK1/2 is a downstream mediator of CaMKII in BDMC signaling to HO-1 expression.	U 0126	86-91	heme oxygenase 1	Homo sapiens	236-240
20370578-4	2010	Inhibition of FGF receptors or of MEK1/2 and PI3K with specific inhibitors (PD173074, U0126 or LY294002, respectively) restored TSP-1 mRNA expression in the presence of FGF-8 in S115 cells.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	34-40
20370578-4	2010	Inhibition of FGF receptors or of MEK1/2 and PI3K with specific inhibitors (PD173074, U0126 or LY294002, respectively) restored TSP-1 mRNA expression in the presence of FGF-8 in S115 cells.	U 0126	86-91	thrombospondin 1	Homo sapiens	128-133
20370578-5	2010	Furthermore, U0126 and LY294002 increased TSP-1 mRNA expression in S115 cells over-expressing FGF-8.	U 0126	13-18	thrombospondin 1	Homo sapiens	42-47
20370578-5	2010	Furthermore, U0126 and LY294002 increased TSP-1 mRNA expression in S115 cells over-expressing FGF-8.	U 0126	13-18	fibroblast growth factor 8	Homo sapiens	94-99
20589721-7	2010	MEK1/2 inhibitor (U0126) increased NOS2 expression, whereas GD1a treatment decreased it.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Mus musculus	0-6
20596606-5	2010	PD98059 and U0126, MEK/ERK inhibitors, inhibit UV-induced AQP3 loss.	U 0126	12-17	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
20596606-5	2010	PD98059 and U0126, MEK/ERK inhibitors, inhibit UV-induced AQP3 loss.	U 0126	12-17	mitogen-activated protein kinase 1	Homo sapiens	23-26
20596606-5	2010	PD98059 and U0126, MEK/ERK inhibitors, inhibit UV-induced AQP3 loss.	U 0126	12-17	aquaporin 3 (Gill blood group)	Homo sapiens	58-62
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	U 0126	51-56	interleukin 1 beta	Homo sapiens	0-8
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	U 0126	51-56	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-24
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	85-88
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	U 0126	51-56	mitogen-activated protein kinase 8	Homo sapiens	93-96
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	U 0126	51-56	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-111
20432452-7	2010	IL-1beta-stimulated ICAM-1 gene expression was attenuated by pretreatment with U0126, SP600125, tanshinone IIA, or helenalin, revealed by ICAM-1 promoter assay and real-time RT-PCR analysis.	U 0126	79-84	interleukin 1 beta	Homo sapiens	0-8
20432452-7	2010	IL-1beta-stimulated ICAM-1 gene expression was attenuated by pretreatment with U0126, SP600125, tanshinone IIA, or helenalin, revealed by ICAM-1 promoter assay and real-time RT-PCR analysis.	U 0126	79-84	intercellular adhesion molecule 1	Homo sapiens	20-26
20432452-7	2010	IL-1beta-stimulated ICAM-1 gene expression was attenuated by pretreatment with U0126, SP600125, tanshinone IIA, or helenalin, revealed by ICAM-1 promoter assay and real-time RT-PCR analysis.	U 0126	79-84	intercellular adhesion molecule 1	Homo sapiens	138-144
20589721-7	2010	MEK1/2 inhibitor (U0126) increased NOS2 expression, whereas GD1a treatment decreased it.	U 0126	18-23	nitric oxide synthase 2, inducible	Mus musculus	35-39
20589721-8	2010	Co-treating the cells with GD1a and U0126 blocked the inhibition of NOS2 expression, suggesting that the GD1a signal is mediated by ERK1/2.	U 0126	36-41	nitric oxide synthase 2, inducible	Mus musculus	68-72
20589721-8	2010	Co-treating the cells with GD1a and U0126 blocked the inhibition of NOS2 expression, suggesting that the GD1a signal is mediated by ERK1/2.	U 0126	36-41	mitogen-activated protein kinase 3	Mus musculus	132-138
20477948-7	2010	ATP-induced mRNA expression of CXCL2 was inhibited by INCA-6 (an NFAT inhibitor), SB203580 (a p38 inhibitor), U0126 (a MEK-ERK inhibitor) and JNK inhibitor II (a JNK inhibitor).	U 0126	110-115	C-X-C motif chemokine ligand 2	Homo sapiens	31-36
20596631-8	2010	The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-alpha protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035.	U 0126	104-109	gastrin releasing peptide	Homo sapiens	14-17
19765730-11	2010	Treatment with extracellular signal-regulated kinase (ERK) inhibitor (U0126), but not P38 MAPK inhibitor (SB203580) or phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin), markedly suppressed the expression of c-met protein in MHCC97-H cells.	U 0126	70-75	mitogen-activated protein kinase 1	Homo sapiens	54-57
19962780-9	2010	In contrast, blocking ERK1/2 activation by U0126 (an MKK1/2 inhibitor) decreased cisplatin-elicited ERCC1 expression and enhanced cisplatin-induced cytotoxicity.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	22-28
19962780-9	2010	In contrast, blocking ERK1/2 activation by U0126 (an MKK1/2 inhibitor) decreased cisplatin-elicited ERCC1 expression and enhanced cisplatin-induced cytotoxicity.	U 0126	43-48	mitogen-activated protein kinase kinase 1	Homo sapiens	53-59
19962780-9	2010	In contrast, blocking ERK1/2 activation by U0126 (an MKK1/2 inhibitor) decreased cisplatin-elicited ERCC1 expression and enhanced cisplatin-induced cytotoxicity.	U 0126	43-48	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	100-105
20596631-8	2010	The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-alpha protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	21-27
20827342-6	2010	Additionally, in order to assess the signal pathway of neuroblastoma differentiation induced by RA and DLK1 knockdown, treatment with the specific MEK/ERK inhibitors, U0126 and PD 98059, was applied to differentiated neuroblastoma cells.	U 0126	167-172	mitogen-activated protein kinase kinase 7	Homo sapiens	147-150
20827342-6	2010	Additionally, in order to assess the signal pathway of neuroblastoma differentiation induced by RA and DLK1 knockdown, treatment with the specific MEK/ERK inhibitors, U0126 and PD 98059, was applied to differentiated neuroblastoma cells.	U 0126	167-172	mitogen-activated protein kinase 1	Homo sapiens	151-154
20827342-8	2010	The MEK/ERK inhibitor U0126 completely inhibited neuronal differentiation induced by both RA and DLK1 knockdown, whereas PD98059 partially blocked neuronal differentiation.	U 0126	22-27	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
20827342-8	2010	The MEK/ERK inhibitor U0126 completely inhibited neuronal differentiation induced by both RA and DLK1 knockdown, whereas PD98059 partially blocked neuronal differentiation.	U 0126	22-27	mitogen-activated protein kinase 1	Homo sapiens	8-11
20827342-8	2010	The MEK/ERK inhibitor U0126 completely inhibited neuronal differentiation induced by both RA and DLK1 knockdown, whereas PD98059 partially blocked neuronal differentiation.	U 0126	22-27	delta like non-canonical Notch ligand 1	Homo sapiens	97-101
20827342-10	2010	This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK pathway, U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown.	U 0126	123-128	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
20827342-10	2010	This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK pathway, U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	110-113
20827342-10	2010	This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK pathway, U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	176-179
20827342-10	2010	This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK pathway, U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown.	U 0126	123-128	delta like non-canonical Notch ligand 1	Homo sapiens	213-217
20596631-8	2010	The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-alpha protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
20596631-9	2010	The effect of GRP on the growth of HepG2 cells was significantly attenuated by PD176252 or U0126.	U 0126	91-96	gastrin releasing peptide	Homo sapiens	14-17
20495822-7	2010	Furthermore, the Ang II-induced BSM hyperresponsiveness to CCh was attenuated by pretreatment with U-0126, a p42/44 ERK kinase (MEK-1/2) inhibitor.	U 0126	99-105	Eph receptor B1	Rattus norvegicus	116-119
20495822-7	2010	Furthermore, the Ang II-induced BSM hyperresponsiveness to CCh was attenuated by pretreatment with U-0126, a p42/44 ERK kinase (MEK-1/2) inhibitor.	U 0126	99-105	mitogen activated protein kinase kinase 1	Rattus norvegicus	128-135
20495822-7	2010	Furthermore, the Ang II-induced BSM hyperresponsiveness to CCh was attenuated by pretreatment with U-0126, a p42/44 ERK kinase (MEK-1/2) inhibitor.	U 0126	99-105	angiotensinogen	Rattus norvegicus	17-23
20819641-11	2010	The effects of MAPK/ERK kinase (MEK)-inhibitor U0126 on CGRP-induced MCP-1 expression in primary rat osteoblasts were examined.	U 0126	47-52	calcitonin-related polypeptide alpha	Rattus norvegicus	56-60
20599756-11	2010	The cell migration-promoting activity was abolished by MEK1 inhibitors, U0126 and PD98059, suggesting that ERK1/2 activation is crucial for Bm-TFF2 to stimulate cell migration.	U 0126	72-77	trefoil factor 2	Homo sapiens	143-147
20427083-4	2010	By direct suppression of mitogen-activated protein kinase/extracellular signaling-regulated kinase1/2 (MAPK/Erk1/2) signaling pathway in NSCs using U0126, known to inhibit the activation of Erk1/2, we demonstrated that the enhancement of Erk1/2 pathway is one of the effects of H-UNCD-induced NSCs differentiation.	U 0126	148-153	mitogen-activated protein kinase 3	Homo sapiens	108-114
20427083-4	2010	By direct suppression of mitogen-activated protein kinase/extracellular signaling-regulated kinase1/2 (MAPK/Erk1/2) signaling pathway in NSCs using U0126, known to inhibit the activation of Erk1/2, we demonstrated that the enhancement of Erk1/2 pathway is one of the effects of H-UNCD-induced NSCs differentiation.	U 0126	148-153	mitogen-activated protein kinase 3	Homo sapiens	190-196
20427083-4	2010	By direct suppression of mitogen-activated protein kinase/extracellular signaling-regulated kinase1/2 (MAPK/Erk1/2) signaling pathway in NSCs using U0126, known to inhibit the activation of Erk1/2, we demonstrated that the enhancement of Erk1/2 pathway is one of the effects of H-UNCD-induced NSCs differentiation.	U 0126	148-153	mitogen-activated protein kinase 3	Homo sapiens	190-196
20819641-11	2010	The effects of MAPK/ERK kinase (MEK)-inhibitor U0126 on CGRP-induced MCP-1 expression in primary rat osteoblasts were examined.	U 0126	47-52	C-C motif chemokine ligand 2	Rattus norvegicus	69-74
20819641-14	2010	Pretreatment of cultured rat osteoblasts with MEK inhibitor U0126 resulted in dose-dependent inhibitions of CGRP-induced MCP-1 mRNA and protein levels.	U 0126	60-65	calcitonin-related polypeptide alpha	Rattus norvegicus	108-112
20819641-14	2010	Pretreatment of cultured rat osteoblasts with MEK inhibitor U0126 resulted in dose-dependent inhibitions of CGRP-induced MCP-1 mRNA and protein levels.	U 0126	60-65	C-C motif chemokine ligand 2	Rattus norvegicus	121-126
20444941-8	2010	GW5074 and U0126 inhibited the phosphorylation of ERK1/2 and NF-kappaB p65 (S536).	U 0126	11-16	mitogen activated protein kinase 3	Rattus norvegicus	50-56
20444941-8	2010	GW5074 and U0126 inhibited the phosphorylation of ERK1/2 and NF-kappaB p65 (S536).	U 0126	11-16	synaptotagmin 1	Rattus norvegicus	71-74
20047993-5	2010	Both p38 (RWJ-67657) and MEK1/2 (U0126) inhibitors suppressed all these effects by IS.	U 0126	33-38	mitogen-activated protein kinase kinase 1	Homo sapiens	25-31
20463056-2	2010	VEGF-induced cell migration was blocked by specific kinase inhibitors of JNK1/2 (SP600125), c-Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and phosphatidylinositol 3-kinase/Akt (wortmannin) but not ERK2/1 (U0126) and p38MAPK (SB203580).	U 0126	233-238	vascular endothelial growth factor A	Homo sapiens	0-4
20463056-2	2010	VEGF-induced cell migration was blocked by specific kinase inhibitors of JNK1/2 (SP600125), c-Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and phosphatidylinositol 3-kinase/Akt (wortmannin) but not ERK2/1 (U0126) and p38MAPK (SB203580).	U 0126	233-238	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	92-97
20125114-8	2010	PDTC inhibited the production of IL-8 and TNF-alpha whereas U0126 inhibited the synthesis of IFN-beta.	U 0126	60-65	interferon beta 1	Homo sapiens	93-101
20412391-3	2010	The activation of ERK1/2, but not p38, is responsible for zinc neurotoxicity as only U0126, a MEK inhibitor that blocks ERK1/2 phosphorylation, significantly protects cortical neurons from zinc exposure.	U 0126	85-90	mitogen activated protein kinase 3	Rattus norvegicus	18-24
20403072-4	2010	Pre-treatment with U0126, a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2), inhibited ERK1/2 phosphorylation, and significantly attenuated apoptosis and increased neuronal survival.	U 0126	19-24	mitogen activated protein kinase 3	Rattus norvegicus	50-54
20403072-4	2010	Pre-treatment with U0126, a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2), inhibited ERK1/2 phosphorylation, and significantly attenuated apoptosis and increased neuronal survival.	U 0126	19-24	Eph receptor B1	Rattus norvegicus	55-58
20403072-4	2010	Pre-treatment with U0126, a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2), inhibited ERK1/2 phosphorylation, and significantly attenuated apoptosis and increased neuronal survival.	U 0126	19-24	mitogen activated protein kinase kinase 1	Rattus norvegicus	72-78
20403072-4	2010	Pre-treatment with U0126, a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2), inhibited ERK1/2 phosphorylation, and significantly attenuated apoptosis and increased neuronal survival.	U 0126	19-24	mitogen activated protein kinase 3	Rattus norvegicus	91-97
20412391-3	2010	The activation of ERK1/2, but not p38, is responsible for zinc neurotoxicity as only U0126, a MEK inhibitor that blocks ERK1/2 phosphorylation, significantly protects cortical neurons from zinc exposure.	U 0126	85-90	mitogen activated protein kinase 3	Rattus norvegicus	120-126
20652496-6	2010	Treatment with U0126, a selective inhibitor, abolished CTRP6-stimulated IL-10 induction.	U 0126	15-20	C1q and tumor necrosis factor related protein 6	Mus musculus	55-60
20186556-9	2010	Although MAPK/ERK 1/2 inhibitor U0126 significantly inhibited laser-enhanced cell proliferation, activation of stress-activated protein kinases/Jun N-terminal kinase (SAPK/JNK) and p38 MAPK was not clearly detected.	U 0126	32-37	mitogen-activated protein kinase 3	Mus musculus	14-21
20571072-8	2010	Experiments with the mitogen-activated protein kinase/ERK kinase inhibitor U0126 suggest a unique role for ERK downregulation in the observed effects.	U 0126	75-80	mitogen-activated protein kinase 1	Homo sapiens	54-57
20571072-8	2010	Experiments with the mitogen-activated protein kinase/ERK kinase inhibitor U0126 suggest a unique role for ERK downregulation in the observed effects.	U 0126	75-80	mitogen-activated protein kinase 1	Homo sapiens	107-110
20652496-6	2010	Treatment with U0126, a selective inhibitor, abolished CTRP6-stimulated IL-10 induction.	U 0126	15-20	interleukin 10	Mus musculus	72-77
22966358-14	2010	siRNA-mediated silencing and deactivation induced by U0126 in MAPK p42 led to growth inhibition in the HeLa cells.	U 0126	53-58	nucleoporin 43	Homo sapiens	67-70
20591071-12	2010	Through ERK inhibitor (U0126) and NF-kB inhibitor (caffeine acid phenethyl ester) treatment, it was proven that ERK and NF-kB regulated chitinase-induced IL-8 expression.	U 0126	23-28	mitogen-activated protein kinase 1	Homo sapiens	112-115
20591071-12	2010	Through ERK inhibitor (U0126) and NF-kB inhibitor (caffeine acid phenethyl ester) treatment, it was proven that ERK and NF-kB regulated chitinase-induced IL-8 expression.	U 0126	23-28	C-X-C motif chemokine ligand 8	Homo sapiens	154-158
20483735-6	2010	MAPK activation-loop phosphorylation was elevated in wounds of IL-6Ralpha-deficient mice, and treatment of wounds in these mice with the MEK inhibitor U0126 resulted in a delay in wound healing suggesting that aberrant ERK activation may contribute to improved healing.	U 0126	151-156	interleukin 6 receptor, alpha	Mus musculus	63-73
21029692-9	2010	But after adding the inhibitor AG490 and U0126, respectively, the activities of luciferase were significantly decreased by 95.7% (U0126) and 33.0% (AG490) in co-transfected AGS cells and 94.8% (U0126) and 86.2% (AG490) in co-transfected SGC-7901 cells with pcDNA3.1ZEO(-)/CagA and PGL/GP (P &lt; 0.05).	U 0126	41-46	S100 calcium binding protein A8	Homo sapiens	272-276
20469933-5	2010	The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts).	U 0126	30-35	mitogen-activated protein kinase kinase 1	Mus musculus	4-10
20469933-5	2010	The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts).	U 0126	30-35	translocator protein	Mus musculus	80-84
20469933-5	2010	The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts).	U 0126	30-35	translocator protein	Mus musculus	106-110
20469933-5	2010	The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts).	U 0126	30-35	translocator protein	Mus musculus	185-189
20469933-5	2010	The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts).	U 0126	30-35	translocator protein	Mus musculus	209-213
20364107-7	2010	Furthermore, a mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 inhibited hEGF-induced AQP3 expression and cell migration or proliferation.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	15-47
20364107-7	2010	Furthermore, a mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 inhibited hEGF-induced AQP3 expression and cell migration or proliferation.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
20364107-7	2010	Furthermore, a mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 inhibited hEGF-induced AQP3 expression and cell migration or proliferation.	U 0126	108-113	epidermal growth factor	Homo sapiens	124-128
20364107-7	2010	Furthermore, a mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 inhibited hEGF-induced AQP3 expression and cell migration or proliferation.	U 0126	108-113	aquaporin 3 (Gill blood group)	Homo sapiens	137-141
20483735-6	2010	MAPK activation-loop phosphorylation was elevated in wounds of IL-6Ralpha-deficient mice, and treatment of wounds in these mice with the MEK inhibitor U0126 resulted in a delay in wound healing suggesting that aberrant ERK activation may contribute to improved healing.	U 0126	151-156	midkine	Mus musculus	137-140
20483735-6	2010	MAPK activation-loop phosphorylation was elevated in wounds of IL-6Ralpha-deficient mice, and treatment of wounds in these mice with the MEK inhibitor U0126 resulted in a delay in wound healing suggesting that aberrant ERK activation may contribute to improved healing.	U 0126	151-156	mitogen-activated protein kinase 1	Mus musculus	219-222
20371608-7	2010	bFGF- and EGF-induced beta1-integrin up-regulation and proliferation were inhibited after treatment with a mitogen-activated protein kinase kinase inhibitor, U0126, which indicates the dependence on the mitogen-activated protein kinase pathway.	U 0126	158-163	fibroblast growth factor 2	Mus musculus	0-4
20361963-5	2010	Induction of cell migration by scratching the confluent monolayer culture of these cells activated both EGFR and ERK, and their inhibitors AG1478 and U0126 substantially suppressed scratch-induced keratinocyte migration.	U 0126	150-155	mitogen-activated protein kinase 1	Mus musculus	113-116
20451499-5	2010	SB202129 and U0126 also significantly attenuated thrombin-mediated release of IL-6 and CXCL8 proteins from HAoSMC.	U 0126	13-18	coagulation factor II, thrombin	Homo sapiens	49-57
20451499-5	2010	SB202129 and U0126 also significantly attenuated thrombin-mediated release of IL-6 and CXCL8 proteins from HAoSMC.	U 0126	13-18	interleukin 6	Homo sapiens	78-82
20451499-5	2010	SB202129 and U0126 also significantly attenuated thrombin-mediated release of IL-6 and CXCL8 proteins from HAoSMC.	U 0126	13-18	C-X-C motif chemokine ligand 8	Homo sapiens	87-92
20501858-7	2010	Accordingly, the number of CD151-positive colonies with internal lumen was increased by approximately 5-fold when cells were cultured in the presence of MAP/ERK kinase (U0126) and phosphoinositide 3-kinase (LY29004) inhibitors.	U 0126	169-174	CD151 molecule (Raph blood group)	Homo sapiens	27-32
20664988-4	2010	When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a &gt;60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
20664988-4	2010	When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a &gt;60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells.	U 0126	83-88	mitogen-activated protein kinase 1	Homo sapiens	59-62
20399245-6	2010	A specific ERK inhibitor, U0126, reduced the synapsin I-area without affecting the MAP2-area.	U 0126	26-31	Eph receptor B1	Rattus norvegicus	11-14
20399245-6	2010	A specific ERK inhibitor, U0126, reduced the synapsin I-area without affecting the MAP2-area.	U 0126	26-31	synapsin I	Rattus norvegicus	45-55
20338920-5	2010	EphrinB2 agonist-induced increase in VEGF mRNA levels in hHSC was associated with increased phosphorylation of Erk and was significantly blocked by U0126 (20 microM), an inhibitor of MEK, which is a kinase upstream from Erk (P &lt; 0.05, n = 3).	U 0126	148-153	ephrin B2	Homo sapiens	0-8
20338920-5	2010	EphrinB2 agonist-induced increase in VEGF mRNA levels in hHSC was associated with increased phosphorylation of Erk and was significantly blocked by U0126 (20 microM), an inhibitor of MEK, which is a kinase upstream from Erk (P &lt; 0.05, n = 3).	U 0126	148-153	vascular endothelial growth factor A	Homo sapiens	37-41
20338920-5	2010	EphrinB2 agonist-induced increase in VEGF mRNA levels in hHSC was associated with increased phosphorylation of Erk and was significantly blocked by U0126 (20 microM), an inhibitor of MEK, which is a kinase upstream from Erk (P &lt; 0.05, n = 3).	U 0126	148-153	EPH receptor B2	Homo sapiens	111-114
20338920-5	2010	EphrinB2 agonist-induced increase in VEGF mRNA levels in hHSC was associated with increased phosphorylation of Erk and was significantly blocked by U0126 (20 microM), an inhibitor of MEK, which is a kinase upstream from Erk (P &lt; 0.05, n = 3).	U 0126	148-153	mitogen-activated protein kinase kinase 7	Homo sapiens	183-186
20338920-5	2010	EphrinB2 agonist-induced increase in VEGF mRNA levels in hHSC was associated with increased phosphorylation of Erk and was significantly blocked by U0126 (20 microM), an inhibitor of MEK, which is a kinase upstream from Erk (P &lt; 0.05, n = 3).	U 0126	148-153	EPH receptor B2	Homo sapiens	220-223
20380623-4	2010	To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively.	U 0126	126-131	mitogen-activated protein kinase 1	Homo sapiens	88-91
20380623-4	2010	To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively.	U 0126	126-131	mitogen-activated protein kinase 8	Homo sapiens	93-96
20380623-4	2010	To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively.	U 0126	126-131	mitogen-activated protein kinase 14	Homo sapiens	102-105
20371701-5	2010	Inhibition of ERK phosphorylation with U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene] blocked IGF-I induction of IGF response element reporter gene activity.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	14-17
20371701-5	2010	Inhibition of ERK phosphorylation with U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene] blocked IGF-I induction of IGF response element reporter gene activity.	U 0126	39-44	insulin like growth factor 1	Homo sapiens	119-124
20371701-5	2010	Inhibition of ERK phosphorylation with U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene] blocked IGF-I induction of IGF response element reporter gene activity.	U 0126	46-109	mitogen-activated protein kinase 1	Homo sapiens	14-17
20371701-5	2010	Inhibition of ERK phosphorylation with U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene] blocked IGF-I induction of IGF response element reporter gene activity.	U 0126	46-109	insulin like growth factor 1	Homo sapiens	119-124
20371701-6	2010	Western blotting revealed that IGF-I treatment resulted in phosphorylation of ERK that was specifically inhibited by U0126.	U 0126	117-122	insulin like growth factor 1	Homo sapiens	31-36
20371701-6	2010	Western blotting revealed that IGF-I treatment resulted in phosphorylation of ERK that was specifically inhibited by U0126.	U 0126	117-122	mitogen-activated protein kinase 1	Homo sapiens	78-81
20371701-7	2010	ERK activation led to phosphorylation of T739 (an ERK site) on Sp1 that was diminished by U0126 or overexpression of PSF.	U 0126	90-95	mitogen-activated protein kinase 1	Homo sapiens	0-3
20371701-7	2010	ERK activation led to phosphorylation of T739 (an ERK site) on Sp1 that was diminished by U0126 or overexpression of PSF.	U 0126	90-95	mitogen-activated protein kinase 1	Homo sapiens	50-53
20362031-9	2010	This activation was abolished in the presence of dominant negative Ras or MEK inhibitor U0126, indicating the requirements of Ras and MEK.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
20362031-9	2010	This activation was abolished in the presence of dominant negative Ras or MEK inhibitor U0126, indicating the requirements of Ras and MEK.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	134-137
20371608-7	2010	bFGF- and EGF-induced beta1-integrin up-regulation and proliferation were inhibited after treatment with a mitogen-activated protein kinase kinase inhibitor, U0126, which indicates the dependence on the mitogen-activated protein kinase pathway.	U 0126	158-163	epidermal growth factor	Mus musculus	10-13
20222144-8	2010	Levels of phospho-ERK were increased by IL-1beta, and the MEK/ERK inhibitor U0126 decreased HMGB1 upregulation in the stimulated astrocytes.	U 0126	76-81	Eph receptor B1	Rattus norvegicus	62-65
20222144-8	2010	Levels of phospho-ERK were increased by IL-1beta, and the MEK/ERK inhibitor U0126 decreased HMGB1 upregulation in the stimulated astrocytes.	U 0126	76-81	high mobility group box 1	Rattus norvegicus	92-97
20222144-11	2010	Blockade of IL-1beta-stimulated HMGB1 release with the ERK inhibitor U0126 was accompanied by a downregulation of CRM1.	U 0126	69-74	interleukin 1 beta	Rattus norvegicus	12-20
20222144-11	2010	Blockade of IL-1beta-stimulated HMGB1 release with the ERK inhibitor U0126 was accompanied by a downregulation of CRM1.	U 0126	69-74	high mobility group box 1	Rattus norvegicus	32-37
20222144-11	2010	Blockade of IL-1beta-stimulated HMGB1 release with the ERK inhibitor U0126 was accompanied by a downregulation of CRM1.	U 0126	69-74	Eph receptor B1	Rattus norvegicus	55-58
20512084-5	2010	The Hep2 cells transfected with siRNA-SH3GL2 were treated by U0126 (selective MEK1/2 Inhibitor), and the phosphorylated ERK1/2 proteins were detected by Western blotting; cell proliferation and apoptosis were detected subsequently.	U 0126	61-66	SH3 domain containing GRB2 like 2, endophilin A1	Homo sapiens	38-44
20004665-6	2010	Pre-perfusion with DCC-antibody, U0126 (MEK1/2 inhibitor), L-NAME or PTIO (NO(*) scavenger) attenuated protective effects of netrin-1 on infarct size and NO(*) production, indicating upstream roles of DCC and ERK1/2 in NO(*) production, as well as an essential role of NO(*) in cardioprotection.	U 0126	33-38	netrin 1	Mus musculus	125-133
20004665-12	2010	Of note, cardiac apoptosis was significantly attenuated by netrin-1, which was reversed by DCC-antibody, U0126, L-NAME or PTIO.	U 0126	105-110	netrin 1	Mus musculus	59-67
20402964-7	2010	Accordingly, the co-application of the p38 MAPK and ERK inhibitors SB203580 and UO126 reduced KA-induced cell death, mimicking PAR-2-mediated neuroprotection.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	52-55
20402964-7	2010	Accordingly, the co-application of the p38 MAPK and ERK inhibitors SB203580 and UO126 reduced KA-induced cell death, mimicking PAR-2-mediated neuroprotection.	U 0126	80-85	F2R like trypsin receptor 1	Homo sapiens	127-132
19909402-12	2010	The MEK inhibitor U0126 was found to inhibit cyclosporine A-induced Hsp47 expression (p &lt; 0.05).	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
19909402-12	2010	The MEK inhibitor U0126 was found to inhibit cyclosporine A-induced Hsp47 expression (p &lt; 0.05).	U 0126	18-23	serpin family H member 1	Homo sapiens	68-73
19728154-10	2010	Pretreatment with U0126 to podocyte completely inhibited ERK activation, with complete suppression podocyte apoptosis and ameliorated nephrin protein expression along with the phosphorylation of nephrin in podocyte injury.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	57-60
20512084-8	2010	However, if ERK1/2 was inhibited by U0126, the apoptosis rate increased and proliferation decreased inversely.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	12-18
19728154-10	2010	Pretreatment with U0126 to podocyte completely inhibited ERK activation, with complete suppression podocyte apoptosis and ameliorated nephrin protein expression along with the phosphorylation of nephrin in podocyte injury.	U 0126	18-23	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	134-141
20406620-6	2010	Blockade of MAPK signaling cascade with MEK inhibitor U0126 promotes the interaction and subsequently inhibits ERalpha activity via enhanced recruitment of SMRT, leading to reduced expression of ERalpha target genes.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
19728154-10	2010	Pretreatment with U0126 to podocyte completely inhibited ERK activation, with complete suppression podocyte apoptosis and ameliorated nephrin protein expression along with the phosphorylation of nephrin in podocyte injury.	U 0126	18-23	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	195-202
20515943-7	2010	In addition, both wortmannin and U0126, but not dasatinib, attenuated cell scattering and migration induced by HGF, suggesting the involvement of the phosphoinositide 3-kinase and mitogen-activated protein kinase pathways, but not of Src or focal adhesion kinase, in HGF-mediated motogenic effects.	U 0126	33-38	hepatocyte growth factor	Homo sapiens	111-114
20515943-7	2010	In addition, both wortmannin and U0126, but not dasatinib, attenuated cell scattering and migration induced by HGF, suggesting the involvement of the phosphoinositide 3-kinase and mitogen-activated protein kinase pathways, but not of Src or focal adhesion kinase, in HGF-mediated motogenic effects.	U 0126	33-38	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	234-237
20515943-7	2010	In addition, both wortmannin and U0126, but not dasatinib, attenuated cell scattering and migration induced by HGF, suggesting the involvement of the phosphoinositide 3-kinase and mitogen-activated protein kinase pathways, but not of Src or focal adhesion kinase, in HGF-mediated motogenic effects.	U 0126	33-38	hepatocyte growth factor	Homo sapiens	267-270
20215560-11	2010	PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126.	U 0126	215-220	coagulation factor II (thrombin) receptor	Rattus norvegicus	0-4
20215560-11	2010	PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126.	U 0126	215-220	mitogen activated protein kinase 3	Rattus norvegicus	16-22
20215560-11	2010	PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126.	U 0126	215-220	Eph receptor B1	Rattus norvegicus	16-19
20215560-11	2010	PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126.	U 0126	266-271	coagulation factor II (thrombin) receptor	Rattus norvegicus	0-4
20215560-11	2010	PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126.	U 0126	266-271	mitogen activated protein kinase 3	Rattus norvegicus	16-22
20215560-11	2010	PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126.	U 0126	266-271	Eph receptor B1	Rattus norvegicus	16-19
20172001-6	2010	Inhibition of this ERK activation by U0126, a specific inhibitor of MEK1/2, severely impaired virus production.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	19-22
20172001-6	2010	Inhibition of this ERK activation by U0126, a specific inhibitor of MEK1/2, severely impaired virus production.	U 0126	37-42	mitogen-activated protein kinase kinase 1	Homo sapiens	68-74
20399747-5	2010	Moreover, both DOI-induced cell proliferation and phosphorylation of ERK1 and 2 proteins were inhibited by PD98059 and U0126, selective inhibitors of MEK in a concentration-dependent manner.	U 0126	119-124	mitogen-activated protein kinase 3	Mus musculus	69-79
20399747-5	2010	Moreover, both DOI-induced cell proliferation and phosphorylation of ERK1 and 2 proteins were inhibited by PD98059 and U0126, selective inhibitors of MEK in a concentration-dependent manner.	U 0126	119-124	midkine	Mus musculus	150-153
20406620-6	2010	Blockade of MAPK signaling cascade with MEK inhibitor U0126 promotes the interaction and subsequently inhibits ERalpha activity via enhanced recruitment of SMRT, leading to reduced expression of ERalpha target genes.	U 0126	54-59	estrogen receptor 1	Homo sapiens	111-118
20091775-8	2010	Moreover, inhibition of MEK-ERK pathway by infusion the MEK inhibitor U0126 in VTA blocked the establishment of morphine-induced CPP.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	28-31
20075392-6	2010	Moreover, U0126, or anti-integrinbeta1 neutralizing antibody, reverses the decreased TIMP1 expression and the increased invasiveness of trophoblast cells, and the antibody also inhibits the MAPK3/1 phosphorylation induced by CD82 silence.	U 0126	10-15	TIMP metallopeptidase inhibitor 1	Homo sapiens	85-90
20075392-6	2010	Moreover, U0126, or anti-integrinbeta1 neutralizing antibody, reverses the decreased TIMP1 expression and the increased invasiveness of trophoblast cells, and the antibody also inhibits the MAPK3/1 phosphorylation induced by CD82 silence.	U 0126	10-15	mitogen-activated protein kinase 3	Homo sapiens	190-195
20075392-6	2010	Moreover, U0126, or anti-integrinbeta1 neutralizing antibody, reverses the decreased TIMP1 expression and the increased invasiveness of trophoblast cells, and the antibody also inhibits the MAPK3/1 phosphorylation induced by CD82 silence.	U 0126	10-15	CD82 molecule	Homo sapiens	225-229
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	interleukin 6	Mus musculus	38-42
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	interleukin 13	Mus musculus	51-56
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	121-124
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	thymoma viral proto-oncogene 1	Mus musculus	129-132
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	162-167	midkine	Mus musculus	46-49
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	162-167	mitogen-activated protein kinase 1	Mus musculus	50-53
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	162-167	E26 avian leukemia oncogene 1, 5' domain	Mus musculus	81-85
20404718-5	2010	Bax and BID were inhibited with lentiviral shRNA, and ERK activation was blocked with the MEK1,2 inhibitor, U0126.	U 0126	108-113	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
20404718-5	2010	Bax and BID were inhibited with lentiviral shRNA, and ERK activation was blocked with the MEK1,2 inhibitor, U0126.	U 0126	108-113	mitogen-activated protein kinase 1	Homo sapiens	54-57
20404718-5	2010	Bax and BID were inhibited with lentiviral shRNA, and ERK activation was blocked with the MEK1,2 inhibitor, U0126.	U 0126	108-113	mitogen-activated protein kinase kinase 1	Homo sapiens	90-96
20404718-11	2010	Vpr induced sustained ERK activation in HK2 cells and incubation with U0126 reduced Vpr-induced caspase-8 activation, BID cleavage and apoptosis.	U 0126	70-75	mitogen-activated protein kinase 1	Homo sapiens	22-25
20404718-11	2010	Vpr induced sustained ERK activation in HK2 cells and incubation with U0126 reduced Vpr-induced caspase-8 activation, BID cleavage and apoptosis.	U 0126	70-75	caspase 8	Homo sapiens	96-105
20404718-11	2010	Vpr induced sustained ERK activation in HK2 cells and incubation with U0126 reduced Vpr-induced caspase-8 activation, BID cleavage and apoptosis.	U 0126	70-75	BH3 interacting domain death agonist	Homo sapiens	118-121
20338184-10	2010	Re-addition of Mg(2+) increased p-ERK1/2 levels, which were inhibited by U0126, a specific inhibitor of a MEK-ERK cascade.	U 0126	73-78	mitogen-activated protein kinase 1	Canis lupus familiaris	34-40
20130271-7	2010	Accumulation of HBEGF at reduced oxygen was blocked only by a combination of U0126, SB203580, and SP600125.	U 0126	77-82	heparin binding EGF like growth factor	Homo sapiens	16-21
20074637-8	2010	Furthermore, induction of the ERK module by LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126.	U 0126	190-195	mitogen-activated protein kinase 1	Homo sapiens	30-33
20074637-8	2010	Furthermore, induction of the ERK module by LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126.	U 0126	190-195	leucine rich repeat kinase 2	Homo sapiens	44-49
20074637-8	2010	Furthermore, induction of the ERK module by LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126.	U 0126	190-195	synuclein alpha	Homo sapiens	105-109
20074637-8	2010	Furthermore, induction of the ERK module by LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126.	U 0126	190-195	mitogen-activated protein kinase 1	Homo sapiens	164-168
20074637-8	2010	Furthermore, induction of the ERK module by LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126.	U 0126	190-195	mitogen-activated protein kinase 1	Homo sapiens	169-172
20097509-10	2010	Finally, U0126, a MAPK ERK1/2 inhibitor, decreased OA- and LA-induced progesterone secretion (P&lt;0.05), suggesting that these UFAs could stimulate progesterone secretion partly through MAPK ERK1/2 in the absence of IGF-1 and FSH in goat granulosa cells.	U 0126	9-14	mitogen-activated protein kinase 1	Capra hircus	23-29
20097509-10	2010	Finally, U0126, a MAPK ERK1/2 inhibitor, decreased OA- and LA-induced progesterone secretion (P&lt;0.05), suggesting that these UFAs could stimulate progesterone secretion partly through MAPK ERK1/2 in the absence of IGF-1 and FSH in goat granulosa cells.	U 0126	9-14	mitogen-activated protein kinase 1	Capra hircus	192-198
20097509-10	2010	Finally, U0126, a MAPK ERK1/2 inhibitor, decreased OA- and LA-induced progesterone secretion (P&lt;0.05), suggesting that these UFAs could stimulate progesterone secretion partly through MAPK ERK1/2 in the absence of IGF-1 and FSH in goat granulosa cells.	U 0126	9-14	insulin-like growth factor I	Capra hircus	217-222
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	162-167	midkine	Mus musculus	148-151
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	162-167	midkine	Mus musculus	148-151
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	midkine	Mus musculus	46-49
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	mitogen-activated protein kinase 1	Mus musculus	50-53
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	E26 avian leukemia oncogene 1, 5' domain	Mus musculus	81-85
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	midkine	Mus musculus	148-151
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	midkine	Mus musculus	148-151
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	mitogen-activated protein kinase 1	Mus musculus	268-271
20406620-6	2010	Blockade of MAPK signaling cascade with MEK inhibitor U0126 promotes the interaction and subsequently inhibits ERalpha activity via enhanced recruitment of SMRT, leading to reduced expression of ERalpha target genes.	U 0126	54-59	nuclear receptor corepressor 2	Homo sapiens	156-160
20406620-6	2010	Blockade of MAPK signaling cascade with MEK inhibitor U0126 promotes the interaction and subsequently inhibits ERalpha activity via enhanced recruitment of SMRT, leading to reduced expression of ERalpha target genes.	U 0126	54-59	estrogen receptor 1	Homo sapiens	195-202
20406620-8	2010	Moreover, the growth of MCF-7 cells stably expressing SMRT showed a robust repression in the presence of TAM and U0126.	U 0126	113-118	nuclear receptor corepressor 2	Homo sapiens	54-58
20112284-5	2010	Subsequently, the LPS-stimulated cPLA(2)alpha phosphorylation was attenuated by pretreatment with a MEK1/2 inhibitor (U0126), suggesting that LPS-stimulated cPLA(2)alpha phosphorylation and activity are mediated through an ERK-dependent mechanism.	U 0126	118-123	phospholipase A2 group IVA	Homo sapiens	33-45
20112284-5	2010	Subsequently, the LPS-stimulated cPLA(2)alpha phosphorylation was attenuated by pretreatment with a MEK1/2 inhibitor (U0126), suggesting that LPS-stimulated cPLA(2)alpha phosphorylation and activity are mediated through an ERK-dependent mechanism.	U 0126	118-123	mitogen-activated protein kinase kinase 1	Homo sapiens	100-106
20112284-5	2010	Subsequently, the LPS-stimulated cPLA(2)alpha phosphorylation was attenuated by pretreatment with a MEK1/2 inhibitor (U0126), suggesting that LPS-stimulated cPLA(2)alpha phosphorylation and activity are mediated through an ERK-dependent mechanism.	U 0126	118-123	phospholipase A2 group IVA	Homo sapiens	157-169
20112284-5	2010	Subsequently, the LPS-stimulated cPLA(2)alpha phosphorylation was attenuated by pretreatment with a MEK1/2 inhibitor (U0126), suggesting that LPS-stimulated cPLA(2)alpha phosphorylation and activity are mediated through an ERK-dependent mechanism.	U 0126	118-123	mitogen-activated protein kinase 1	Homo sapiens	223-226
20202085-5	2010	Treatment with UO126, inhibitor of MEK1, threo-beta-benzyloxyaspartic acid, glutamate transporter inhibitor, and FK506, a cytoprotective drug prevented ERK activation and glutamate-induced apoptosis.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	152-155
20368270-4	2010	Treatment with a p38MAPK inhibitor (SB203580), an ERK inhibitor (PD98059), or an MEK inhibitor (U0126), suppressed the increase in MCP1 expression caused by hypertonic NaCl, whereas a JNK inhibitor (SP600125) and an AP1 inhibitor (curcumin) failed to attenuate MCP1 mRNA expression by NaCl.	U 0126	96-101	C-C motif chemokine ligand 2	Rattus norvegicus	131-135
19427779-3	2010	Genistein- and equol-induced cell proliferation and S-phase entry were blocked by the ERalpha antagonists 4-hydroxytamoxifen and ICI 182,780 and by the mitogen-activated protein kinase 1/2 inhibitor U0126.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	152-186
19427779-6	2010	Inhibition of ERK1/2 phosphorylation by U0126 led to complete suppression of genistein- and equol-induced estrogen response element reporter activity and to suppression of the estrogen-responsive gene pS2.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	14-20
19427779-6	2010	Inhibition of ERK1/2 phosphorylation by U0126 led to complete suppression of genistein- and equol-induced estrogen response element reporter activity and to suppression of the estrogen-responsive gene pS2.	U 0126	40-45	trefoil factor 1	Homo sapiens	201-204
20074623-10	2010	Increased of fEPSPs induced by PAF treatment completely and/or partly inhibited by KN93 and/or U0126 treatment.	U 0126	95-100	PCNA clamp associated factor	Rattus norvegicus	31-34
20232365-7	2010	AS-induced cell death was potentiated by inhibition of extracellular signal-regulated kinases (ERK) 1/2 signaling with U0126 and PD98059.	U 0126	119-124	mitogen-activated protein kinase 1	Homo sapiens	55-103
20233320-8	2010	Pharmacological agents NAC, U0126, and PD98059 were found to decrease the CsA-induced PAI-1 mRNA and protein expression (P &lt; 0.05).	U 0126	28-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	74-77
20233320-8	2010	Pharmacological agents NAC, U0126, and PD98059 were found to decrease the CsA-induced PAI-1 mRNA and protein expression (P &lt; 0.05).	U 0126	28-33	serpin family E member 1	Homo sapiens	86-91
19788349-7	2010	The increase in VEGF by EMFs was inhibited by the ERK1/2 inhibitor U0126 but not by SB203580 and SP600125, which are p38 and JNK inhibitors, respectively, suggesting VEGF regulation by ERK1/2.	U 0126	67-72	vascular endothelial growth factor A	Mus musculus	16-20
19788349-7	2010	The increase in VEGF by EMFs was inhibited by the ERK1/2 inhibitor U0126 but not by SB203580 and SP600125, which are p38 and JNK inhibitors, respectively, suggesting VEGF regulation by ERK1/2.	U 0126	67-72	mitogen-activated protein kinase 3	Mus musculus	50-56
19788349-7	2010	The increase in VEGF by EMFs was inhibited by the ERK1/2 inhibitor U0126 but not by SB203580 and SP600125, which are p38 and JNK inhibitors, respectively, suggesting VEGF regulation by ERK1/2.	U 0126	67-72	vascular endothelial growth factor A	Mus musculus	166-170
19788349-7	2010	The increase in VEGF by EMFs was inhibited by the ERK1/2 inhibitor U0126 but not by SB203580 and SP600125, which are p38 and JNK inhibitors, respectively, suggesting VEGF regulation by ERK1/2.	U 0126	67-72	mitogen-activated protein kinase 3	Mus musculus	185-191
20177148-9	2010	Moreover, LPA-induced alpha-SMA expression was abrogated by treatment with the ERK inhibitor U0126 or the phosphoinositide-3-kinase inhibitor LY294002, but not the PLC inhibitor U73122.	U 0126	93-98	mitogen-activated protein kinase 1	Homo sapiens	79-82
20177148-10	2010	LPA-induced VEGF secretion was inhibited by LY294002, whereas LPA-induced SDF-1 secretion was markedly attenuated by U0126, U73122, and LY294002.	U 0126	117-122	C-X-C motif chemokine ligand 12	Homo sapiens	74-79
20442784-9	2010	Inhibition with U0126 and SP600125 prevented stretch-induced phosphorylation increases of ERK and JNK, respectively, however neither prevented increases in permeability following 10 minutes.	U 0126	16-21	Eph receptor B1	Rattus norvegicus	90-93
20442784-9	2010	Inhibition with U0126 and SP600125 prevented stretch-induced phosphorylation increases of ERK and JNK, respectively, however neither prevented increases in permeability following 10 minutes.	U 0126	16-21	mitogen-activated protein kinase 8	Rattus norvegicus	98-101
20206231-4	2010	ERK inhibitor (U0126) in part blocked the differentiation of the NSCs into neurons induced by TMP.	U 0126	15-20	Eph receptor B1	Rattus norvegicus	0-3
20331962-6	2010	We found that N/OFQ, PDBu, and IDB increased the amount of phosphorylated ERK-1/2 and Elk-1; U0126, a specific inhibitor for ERK-1/2, attenuated the inhibitory effect of N/OFQ on the I(K).	U 0126	93-98	mitogen activated protein kinase 3	Rattus norvegicus	74-81
20331962-6	2010	We found that N/OFQ, PDBu, and IDB increased the amount of phosphorylated ERK-1/2 and Elk-1; U0126, a specific inhibitor for ERK-1/2, attenuated the inhibitory effect of N/OFQ on the I(K).	U 0126	93-98	ETS transcription factor ELK1	Rattus norvegicus	86-91
20331962-6	2010	We found that N/OFQ, PDBu, and IDB increased the amount of phosphorylated ERK-1/2 and Elk-1; U0126, a specific inhibitor for ERK-1/2, attenuated the inhibitory effect of N/OFQ on the I(K).	U 0126	93-98	mitogen activated protein kinase 3	Rattus norvegicus	125-132
20302373-6	2010	Luteolin also persistently activated extracellular signal-regulated protein kinase 1/2 (ERK1/2); while the addition of U0126, a pharmacological MEK/ERK inhibitor, attenuated luteolin-induced Nrf2 binding activity, HO-1 expression, cytoprotective effect, and neurite outgrowth.	U 0126	119-124	Eph receptor B1	Rattus norvegicus	88-91
20302373-6	2010	Luteolin also persistently activated extracellular signal-regulated protein kinase 1/2 (ERK1/2); while the addition of U0126, a pharmacological MEK/ERK inhibitor, attenuated luteolin-induced Nrf2 binding activity, HO-1 expression, cytoprotective effect, and neurite outgrowth.	U 0126	119-124	NFE2 like bZIP transcription factor 2	Rattus norvegicus	191-195
20302373-6	2010	Luteolin also persistently activated extracellular signal-regulated protein kinase 1/2 (ERK1/2); while the addition of U0126, a pharmacological MEK/ERK inhibitor, attenuated luteolin-induced Nrf2 binding activity, HO-1 expression, cytoprotective effect, and neurite outgrowth.	U 0126	119-124	heme oxygenase 1	Rattus norvegicus	214-218
19962423-10	2010	The ERK inhibitor U0126 could reverse the extended stability of the transcripts.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
20167866-6	2010	LTA-stimulated NF-kappaB translocation or cPLA(2) phosphorylation was attenuated by pretreatment with LY294002, SB202190, U0126, or SP600125.	U 0126	122-127	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	15-24
20167866-6	2010	LTA-stimulated NF-kappaB translocation or cPLA(2) phosphorylation was attenuated by pretreatment with LY294002, SB202190, U0126, or SP600125.	U 0126	122-127	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	42-49
19995368-9	2010	The bFGF-induced proliferation was suppressed by the MEK inhibitors PD98059 and U0126, and the JNK inhibitor SP600125.	U 0126	80-85	fibroblast growth factor 2	Homo sapiens	4-8
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	40-46
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	ETS proto-oncogene 1, transcription factor	Homo sapiens	47-51
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	matrix metallopeptidase 1	Homo sapiens	73-77
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	83-89
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	83-89
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	ETS proto-oncogene 1, transcription factor	Homo sapiens	150-154
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	matrix metallopeptidase 1	Homo sapiens	197-201
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	cellular communication network factor 2	Homo sapiens	208-212
20201953-8	2010	Consistent with the stimulatory role of ERK1/2/Ets1 in the expression of MMP1, the ERK1/2 inhibitor UO126 prevented the phosphorylation of ERK1/2 and Ets1 and completely abrogated the induction of MMP1 after CCN2 overexpression, while having no effect on c-Jun activation.	U 0126	100-105	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	255-260
20049896-7	2010	Inhibition of MEK1/2 by PD98059 or U0126 increased acute effects and disrupted chronic effects of EGF on Na(+) reabsorption.	U 0126	35-40	epidermal growth factor	Mus musculus	98-101
20132484-5	2010	GDNF-mediated increases in GAD and the synaptic markers were blocked by the MEK inhibitor UO126, but not by the phosphoinositide 3-kinase inhibitor LY294002.	U 0126	90-95	glial cell derived neurotrophic factor	Homo sapiens	0-4
20132484-5	2010	GDNF-mediated increases in GAD and the synaptic markers were blocked by the MEK inhibitor UO126, but not by the phosphoinositide 3-kinase inhibitor LY294002.	U 0126	90-95	glutamate decarboxylase 1	Homo sapiens	27-30
20132484-5	2010	GDNF-mediated increases in GAD and the synaptic markers were blocked by the MEK inhibitor UO126, but not by the phosphoinositide 3-kinase inhibitor LY294002.	U 0126	90-95	mitogen-activated protein kinase kinase 7	Homo sapiens	76-79
20171009-11	2010	Intrathecal pre-treatment with either MK-801 or U0126 similarly prevented the Shank1 accumulation and alleviated both the behavioral signs of pain.	U 0126	48-53	SH3 and multiple ankyrin repeat domains 1	Rattus norvegicus	78-84
20100175-6	2010	At 2 h, IL-1beta-induced expression of GM-CSF protein, but not mRNA, was sensitive to the MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitors PD098059 and U0126.	U 0126	211-216	interleukin 1 beta	Homo sapiens	8-16
20100175-6	2010	At 2 h, IL-1beta-induced expression of GM-CSF protein, but not mRNA, was sensitive to the MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitors PD098059 and U0126.	U 0126	211-216	colony stimulating factor 2	Homo sapiens	39-45
20100175-6	2010	At 2 h, IL-1beta-induced expression of GM-CSF protein, but not mRNA, was sensitive to the MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitors PD098059 and U0126.	U 0126	211-216	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
20100175-6	2010	At 2 h, IL-1beta-induced expression of GM-CSF protein, but not mRNA, was sensitive to the MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitors PD098059 and U0126.	U 0126	211-216	mitogen-activated protein kinase 1	Homo sapiens	95-99
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	U 0126	172-177	interleukin 17A	Mus musculus	31-37
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	U 0126	172-177	interleukin 17F	Mus musculus	42-48
19914201-5	2010	Re-addition of Mg(2+) induced the tight junctional localization of claudin-16, which was inhibited by U0126, a MEK inhibitor.	U 0126	102-107	claudin 16	Canis lupus familiaris	67-77
19937979-4	2010	TRPM6 mRNA expression was increased by EGF, which was inhibited by U0126, an MEK inhibitor.	U 0126	67-72	transient receptor potential cation channel subfamily M member 6	Homo sapiens	0-5
19937979-4	2010	TRPM6 mRNA expression was increased by EGF, which was inhibited by U0126, an MEK inhibitor.	U 0126	67-72	epidermal growth factor	Homo sapiens	39-42
19937979-4	2010	TRPM6 mRNA expression was increased by EGF, which was inhibited by U0126, an MEK inhibitor.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
19937979-9	2010	EGF increased p-ERK1/2, c-Fos, c-Jun, and p-c-Jun levels, which were inhibited by U0126.	U 0126	82-87	epidermal growth factor	Homo sapiens	0-3
19937979-9	2010	EGF increased p-ERK1/2, c-Fos, c-Jun, and p-c-Jun levels, which were inhibited by U0126.	U 0126	82-87	mitogen-activated protein kinase 3	Homo sapiens	16-22
19937979-9	2010	EGF increased p-ERK1/2, c-Fos, c-Jun, and p-c-Jun levels, which were inhibited by U0126.	U 0126	82-87	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
19780202-9	2010	The presence of the ERK inhibitor U0126 did not alter the stretch-induced decrease of beta-catenin levels.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	20-23
19952304-5	2010	Inhibition of mitogen-activated protein kinase kinase (MEK) by either 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) or 2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide (CI-1040, PD184352) produced a similar inhibition of the growth of all the MCF10 cell lines in 2D.	U 0126	124-129	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
20356956-6	2010	Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest.	U 0126	183-188	E26 avian leukemia oncogene 1, 5' domain	Mus musculus	272-276
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	U 0126	120-125	defensin beta 103B	Homo sapiens	27-32
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	U 0126	120-125	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	45-49
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	U 0126	120-125	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-69
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	177-216
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	218-221
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	U 0126	120-125	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	224-227
20384770-5	2010	NMDA-induced MCP-1 production was significantly inhibited by U0126, an inhibitor of extracellular signal-regulated kinase (ERK).	U 0126	61-66	C-C motif chemokine ligand 2	Rattus norvegicus	13-18
20384770-5	2010	NMDA-induced MCP-1 production was significantly inhibited by U0126, an inhibitor of extracellular signal-regulated kinase (ERK).	U 0126	61-66	Eph receptor B1	Rattus norvegicus	84-121
20384770-5	2010	NMDA-induced MCP-1 production was significantly inhibited by U0126, an inhibitor of extracellular signal-regulated kinase (ERK).	U 0126	61-66	Eph receptor B1	Rattus norvegicus	123-126
20384770-7	2010	Treatment with U0126 during only the early phase (U0126 was washed out at 15 or 30 min after NMDA administration) suppressed early activation of ERK in neuronal cells, but not later activation of ERK in astrocytes.	U 0126	15-20	Eph receptor B1	Rattus norvegicus	145-148
20384770-7	2010	Treatment with U0126 during only the early phase (U0126 was washed out at 15 or 30 min after NMDA administration) suppressed early activation of ERK in neuronal cells, but not later activation of ERK in astrocytes.	U 0126	15-20	Eph receptor B1	Rattus norvegicus	196-199
20384770-7	2010	Treatment with U0126 during only the early phase (U0126 was washed out at 15 or 30 min after NMDA administration) suppressed early activation of ERK in neuronal cells, but not later activation of ERK in astrocytes.	U 0126	50-55	Eph receptor B1	Rattus norvegicus	145-148
20384770-9	2010	In contrast, delayed application of U0126 at 3 h after the beginning of NMDA treatment inhibited MCP-1 production to the same degree as that observed when U0126 was applied from 3 h before NMDA administration.	U 0126	36-41	C-C motif chemokine ligand 2	Rattus norvegicus	97-102
20085809-11	2010	The promotion of chondrogenesis by FGF-2 was significantly suppressed by U0126, an inhibitor of the extracellular signal-regulated protein kinase (Erk) pathway, and by Erk-1 siRNA.	U 0126	73-78	fibroblast growth factor 2	Mus musculus	35-40
20085809-11	2010	The promotion of chondrogenesis by FGF-2 was significantly suppressed by U0126, an inhibitor of the extracellular signal-regulated protein kinase (Erk) pathway, and by Erk-1 siRNA.	U 0126	73-78	mitogen-activated protein kinase 1	Mus musculus	100-145
20085809-11	2010	The promotion of chondrogenesis by FGF-2 was significantly suppressed by U0126, an inhibitor of the extracellular signal-regulated protein kinase (Erk) pathway, and by Erk-1 siRNA.	U 0126	73-78	mitogen-activated protein kinase 1	Mus musculus	147-150
20085809-14	2010	The promotion of gliogenesis by FGF-2 was not only inhibited by U0126 but also by LY294002 and rapamycin, inhibitors of the Akt pathway, and by Akt-1 siRNA.	U 0126	64-69	fibroblast growth factor 2	Mus musculus	32-37
19820419-7	2010	The COX-2-positive BxPC-3 but not the COX-2-negative MiaPaCa-2 treated with 100-nmol/L PGE2 induced phosphorylated extracellular signal-related kinase that was blocked by the mitogen-activated protein kinase kinase inhibitor U0126, demonstrating the ability of PGE2 to activate ERK.	U 0126	225-230	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9
19032432-8	2010	Pre-treatment of sperm with U0126, a MEK inhibitor, significantly suppressed both the AR and phosphorylation of MEK/ERK1 in a dose-dependent manner.	U 0126	28-33	mitogen-activated protein kinase 3	Sus scrofa	116-120
19958762-8	2010	Both IL-1beta-induced iNOS expression and NO production in ASMCs of G-K and control rats were markedly reduced in the presence of an ERK inhibitor, U0126 or PD98059.	U 0126	148-153	interleukin 1 beta	Rattus norvegicus	5-13
19958762-8	2010	Both IL-1beta-induced iNOS expression and NO production in ASMCs of G-K and control rats were markedly reduced in the presence of an ERK inhibitor, U0126 or PD98059.	U 0126	148-153	nitric oxide synthase 2	Rattus norvegicus	22-26
19955189-9	2010	The MEK-ERK1/2 pathway inhibitor, U0126, reduced the SRL, CsA, and CsA/SRL-induced increase in TER.	U 0126	34-39	mitogen-activated protein kinase 1	Canis lupus familiaris	8-14
19955189-10	2010	U0126 also reduced the CsA and CsA/SRL-induced increase in the membrane localization of claudin-1.	U 0126	0-5	claudin 1	Canis lupus familiaris	88-97
19733855-5	2010	In addition, IL-8 up-regulation in response to GSA was inhibited by resveratrol, curcumin, diphenyleneiodium, U0126, and SB202190.	U 0126	110-115	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
20088787-6	2010	Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance.	U 0126	126-131	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
20088787-6	2010	Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance.	U 0126	126-131	mitogen-activated protein kinase kinase 7	Homo sapiens	163-166
20088787-6	2010	Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance.	U 0126	126-131	EPH receptor B2	Homo sapiens	167-170
20056821-7	2010	CRH-activated ERK1/ERK2, p38-MAPK, stress-activated protein kinase/c-Jun NH(2)-terminal kinase, protein kinase C, and Akt pathways and CRH-induced ACTH synthesis was significantly decreased in the presence of U0126 or SB203580.	U 0126	209-214	corticotropin releasing hormone	Mus musculus	0-3
20126974-7	2010	A MEK1/2 inhibitor U0126 blocked both androgen- and rFGF-8-induced DNA synthesis.	U 0126	19-24	mitogen-activated protein kinase kinase 1	Homo sapiens	2-8
20126974-7	2010	A MEK1/2 inhibitor U0126 blocked both androgen- and rFGF-8-induced DNA synthesis.	U 0126	19-24	fibroblast growth factor 8	Rattus norvegicus	52-58
19927299-5	2010	Increases in Fas/FasL protein expression, caspase-8 activation, the production of tBid and the loss of mitochondrial membrane potential were noted with K562 cells that were treated with a combination of U0126 and AA.	U 0126	203-208	Fas ligand	Homo sapiens	17-21
19927299-5	2010	Increases in Fas/FasL protein expression, caspase-8 activation, the production of tBid and the loss of mitochondrial membrane potential were noted with K562 cells that were treated with a combination of U0126 and AA.	U 0126	203-208	caspase 8	Homo sapiens	42-51
19927299-6	2010	Down-regulation of FADD attenuated U0126-evoked degradation of procaspase-8 and Bid.	U 0126	35-40	Fas associated via death domain	Homo sapiens	19-23
19927299-7	2010	Abolition of p38 MAPK activation abrogated U0126-elicited Fas/FasL up-regulation in AA-treated cells.	U 0126	43-48	mitogen-activated protein kinase 14	Homo sapiens	13-16
19927299-7	2010	Abolition of p38 MAPK activation abrogated U0126-elicited Fas/FasL up-regulation in AA-treated cells.	U 0126	43-48	Fas ligand	Homo sapiens	62-66
19927299-8	2010	U0126 pretreatment suppressed c-Fos phosphorylation but increased p38 MAPK-mediated c-Jun phosphorylation.	U 0126	0-5	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
19927299-8	2010	U0126 pretreatment suppressed c-Fos phosphorylation but increased p38 MAPK-mediated c-Jun phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 14	Homo sapiens	66-69
19927299-8	2010	U0126 pretreatment suppressed c-Fos phosphorylation but increased p38 MAPK-mediated c-Jun phosphorylation.	U 0126	0-5	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	84-89
20020442-5	2010	Interestingly, in thapsigargin and tunicamycin-stressed chondrocytes induction of the proapoptotic transcription factor CHOP preceded that of the anti-apoptotic BiP by 12 h. Although both of these agents caused sustained Akt and ERK phosphorylation; inhibition of Akt phosphorylation sensitized chondrocytes to ER stress, while blocking ERK signaling by U0126 had no effect.	U 0126	354-359	DNA damage inducible transcript 3	Homo sapiens	120-124
20401565-7	2010	In cells pretreated with both AG490 and U0126, phosphorylation of Tyr-705 STAT3, JAK2, and ERK1/2 was suppressed.	U 0126	40-45	signal transducer and activator of transcription 3	Homo sapiens	74-79
20401565-7	2010	In cells pretreated with both AG490 and U0126, phosphorylation of Tyr-705 STAT3, JAK2, and ERK1/2 was suppressed.	U 0126	40-45	Janus kinase 2	Homo sapiens	81-85
20401565-7	2010	In cells pretreated with both AG490 and U0126, phosphorylation of Tyr-705 STAT3, JAK2, and ERK1/2 was suppressed.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	91-97
20187933-2	2010	In this study, we hypothesised that inhibition of the cerebrovascular inflammatory reaction with a specific MEK1/2 inhibitor (U0126) to block transcription or a combined receptor blockade would reduce infarct size and improve neurological score.	U 0126	126-131	mitogen activated protein kinase kinase 1	Rattus norvegicus	108-114
20187933-4	2010	Two groups of treated animals were studied; (i) one group received intraperitoneal administration of a specific MEK1/2 inhibitor (U0126) starting at 0, 6, or 12 hours after the occlusion, and (ii) a second group received two specific receptor antagonists (a combination of the angiotensin AT1 receptor inhibitor Candesartan and the endothelin ETA receptor antagonist ZD1611), given immediately after occlusion.	U 0126	130-135	mitogen activated protein kinase kinase 1	Rattus norvegicus	112-118
20187933-8	2010	U0126, given intraperitoneal at zero or 6 hours after the ischemic event, but not at 12 hours, reduced the infarct volume (11.7 +/- 2% and 15 +/- 3%, respectively), normalized pERK1/2, and prevented elevation of the expressions of TNF-alpha IL-1ss, IL-6 and iNOS.	U 0126	0-5	tumor necrosis factor	Rattus norvegicus	231-240
20187933-8	2010	U0126, given intraperitoneal at zero or 6 hours after the ischemic event, but not at 12 hours, reduced the infarct volume (11.7 +/- 2% and 15 +/- 3%, respectively), normalized pERK1/2, and prevented elevation of the expressions of TNF-alpha IL-1ss, IL-6 and iNOS.	U 0126	0-5	interleukin 6	Rattus norvegicus	249-253
20187933-8	2010	U0126, given intraperitoneal at zero or 6 hours after the ischemic event, but not at 12 hours, reduced the infarct volume (11.7 +/- 2% and 15 +/- 3%, respectively), normalized pERK1/2, and prevented elevation of the expressions of TNF-alpha IL-1ss, IL-6 and iNOS.	U 0126	0-5	nitric oxide synthase 2	Rattus norvegicus	258-262
20167130-9	2010	Furthermore, treatment of Fuji cells with a specific MEK/ERK inhibitor, U0126, also markedly decreased CD133 expression, but there was no significant effect in Caco-2 cells, suggesting cell type-specific regulation of CD133 expression.	U 0126	72-77	prominin 1	Homo sapiens	103-108
20167130-9	2010	Furthermore, treatment of Fuji cells with a specific MEK/ERK inhibitor, U0126, also markedly decreased CD133 expression, but there was no significant effect in Caco-2 cells, suggesting cell type-specific regulation of CD133 expression.	U 0126	72-77	prominin 1	Homo sapiens	218-223
20167130-9	2010	Furthermore, treatment of Fuji cells with a specific MEK/ERK inhibitor, U0126, also markedly decreased CD133 expression, but there was no significant effect in Caco-2 cells, suggesting cell type-specific regulation of CD133 expression.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	57-60
19799875-8	2010	Moreover, cellular ERCC1 and Rad51 protein and mRNA levels were specifically inhibited by U0126, a MKK1/2 inhibitor.	U 0126	90-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
19799875-8	2010	Moreover, cellular ERCC1 and Rad51 protein and mRNA levels were specifically inhibited by U0126, a MKK1/2 inhibitor.	U 0126	90-95	RAD51 recombinase	Homo sapiens	29-34
19799875-8	2010	Moreover, cellular ERCC1 and Rad51 protein and mRNA levels were specifically inhibited by U0126, a MKK1/2 inhibitor.	U 0126	90-95	mitogen-activated protein kinase kinase 1	Homo sapiens	99-105
20025870-8	2010	The Ras inhibitor manumycin A, the MEK1/2 inhibitor U0126, and the JNK inhibitor SP600125, greatly reduce the increase in ANGPTL4 expression by PMA.	U 0126	52-57	mitogen-activated protein kinase kinase 1	Homo sapiens	35-41
20025870-8	2010	The Ras inhibitor manumycin A, the MEK1/2 inhibitor U0126, and the JNK inhibitor SP600125, greatly reduce the increase in ANGPTL4 expression by PMA.	U 0126	52-57	angiopoietin like 4	Homo sapiens	122-129
19931294-9	2010	Upregulation of Egr-1 in hepatocytes by DCA and CDCA was prevented by the MEK inhibitors U0126 and SL-327.	U 0126	89-94	early growth response 1	Mus musculus	16-21
19765858-6	2010	Application of the specific MAPK phosphorylation inhibitor U0126 revealed that while U0126 treatment decreases the phosphorylation of MAPK and the progression from telophase to early cytokinesis is significantly inhibited.	U 0126	59-64	probable serine/threonine-protein kinase WNK4	Nicotiana tabacum	28-32
19765858-6	2010	Application of the specific MAPK phosphorylation inhibitor U0126 revealed that while U0126 treatment decreases the phosphorylation of MAPK and the progression from telophase to early cytokinesis is significantly inhibited.	U 0126	59-64	probable serine/threonine-protein kinase WNK4	Nicotiana tabacum	134-138
19765858-6	2010	Application of the specific MAPK phosphorylation inhibitor U0126 revealed that while U0126 treatment decreases the phosphorylation of MAPK and the progression from telophase to early cytokinesis is significantly inhibited.	U 0126	85-90	probable serine/threonine-protein kinase WNK4	Nicotiana tabacum	28-32
19765858-6	2010	Application of the specific MAPK phosphorylation inhibitor U0126 revealed that while U0126 treatment decreases the phosphorylation of MAPK and the progression from telophase to early cytokinesis is significantly inhibited.	U 0126	85-90	probable serine/threonine-protein kinase WNK4	Nicotiana tabacum	134-138
19931294-10	2010	Furthermore, pretreatment of mice with U0126 prevented upregulation of Egr-1 in the liver after BDL.	U 0126	39-44	early growth response 1	Mus musculus	71-76
20135719-9	2010	Inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway by the PI3K inhibitor, LY294002, markedly suppressed HGF-stimulated invasion of both CCA cell lines, and inhibition of the ERK pathway by U0126 suppressed HGF-induced invasion of the KKU-M213 cell line but had a moderate effect on HuCCA-1 cells.	U 0126	201-206	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	18-43
20135719-9	2010	Inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway by the PI3K inhibitor, LY294002, markedly suppressed HGF-stimulated invasion of both CCA cell lines, and inhibition of the ERK pathway by U0126 suppressed HGF-induced invasion of the KKU-M213 cell line but had a moderate effect on HuCCA-1 cells.	U 0126	201-206	AKT serine/threonine kinase 1	Homo sapiens	51-54
19996316-5	2010	Specifically, we identified the extracellular signal-regulated kinase (ERK) signaling pathway as a mediator of signals from FcgammaR activation to cyclin D1 expression, because cyclin D1 expression associated with FcgammaR cross-linking was attenuated by specific inhibitors of the ERK1/2 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.	U 0126	320-325	mitogen-activated protein kinase 1	Homo sapiens	32-69
20154358-8	2010	Local delivery of U0126 during the induction of perforant path LTP blocked transcriptional activation of Arc/Arg3.1 in a small region near the injection site and blocked Arc/Arg3.1 protein expression over a wider region.	U 0126	18-23	activity regulated cytoskeleton associated protein	Homo sapiens	105-115
20154358-8	2010	Local delivery of U0126 during the induction of perforant path LTP blocked transcriptional activation of Arc/Arg3.1 in a small region near the injection site and blocked Arc/Arg3.1 protein expression over a wider region.	U 0126	18-23	activity regulated cytoskeleton associated protein	Homo sapiens	170-180
19996316-5	2010	Specifically, we identified the extracellular signal-regulated kinase (ERK) signaling pathway as a mediator of signals from FcgammaR activation to cyclin D1 expression, because cyclin D1 expression associated with FcgammaR cross-linking was attenuated by specific inhibitors of the ERK1/2 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.	U 0126	320-325	mitogen-activated protein kinase 1	Homo sapiens	71-74
19996316-5	2010	Specifically, we identified the extracellular signal-regulated kinase (ERK) signaling pathway as a mediator of signals from FcgammaR activation to cyclin D1 expression, because cyclin D1 expression associated with FcgammaR cross-linking was attenuated by specific inhibitors of the ERK1/2 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.	U 0126	320-325	cyclin D1	Homo sapiens	177-186
19996316-5	2010	Specifically, we identified the extracellular signal-regulated kinase (ERK) signaling pathway as a mediator of signals from FcgammaR activation to cyclin D1 expression, because cyclin D1 expression associated with FcgammaR cross-linking was attenuated by specific inhibitors of the ERK1/2 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.	U 0126	320-325	cyclin D1	Homo sapiens	147-156
19846601-6	2010	U0126 prevented GnRH-stimulated gonadotropin subunit promoter activation dose dependently, and 10 muM of U0126 reduced the effects of GnRH on the Lhb and Fshb promoters to 79.15% and 55.66%, respectively.	U 0126	0-5	follicle stimulating hormone beta	Mus musculus	154-158
19846601-6	2010	U0126 prevented GnRH-stimulated gonadotropin subunit promoter activation dose dependently, and 10 muM of U0126 reduced the effects of GnRH on the Lhb and Fshb promoters to 79.15% and 55.66%, respectively.	U 0126	105-110	gonadotropin releasing hormone 1	Mus musculus	16-20
19846601-3	2010	GnRH-induced MAPK3/1 activation was completely inhibited by U0126, a MEK inhibitor, whereas GnRH-induced DUSP1 expression was partially inhibited by U0126.	U 0126	60-65	gonadotropin releasing hormone 1	Mus musculus	0-4
19846601-6	2010	U0126 prevented GnRH-stimulated gonadotropin subunit promoter activation dose dependently, and 10 muM of U0126 reduced the effects of GnRH on the Lhb and Fshb promoters to 79.15% and 55.66%, respectively.	U 0126	105-110	gonadotropin releasing hormone 1	Mus musculus	134-138
19846601-3	2010	GnRH-induced MAPK3/1 activation was completely inhibited by U0126, a MEK inhibitor, whereas GnRH-induced DUSP1 expression was partially inhibited by U0126.	U 0126	60-65	mitogen-activated protein kinase 3	Mus musculus	13-18
19846601-6	2010	U0126 prevented GnRH-stimulated gonadotropin subunit promoter activation dose dependently, and 10 muM of U0126 reduced the effects of GnRH on the Lhb and Fshb promoters to 79.15% and 55.66%, respectively.	U 0126	105-110	luteinizing hormone beta	Mus musculus	146-149
19846601-6	2010	U0126 prevented GnRH-stimulated gonadotropin subunit promoter activation dose dependently, and 10 muM of U0126 reduced the effects of GnRH on the Lhb and Fshb promoters to 79.15% and 55.66%, respectively.	U 0126	105-110	follicle stimulating hormone beta	Mus musculus	154-158
19846601-3	2010	GnRH-induced MAPK3/1 activation was completely inhibited by U0126, a MEK inhibitor, whereas GnRH-induced DUSP1 expression was partially inhibited by U0126.	U 0126	60-65	midkine	Mus musculus	69-72
19800403-5	2010	Consistently, EV71-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaBalpha in the cytosol was blocked by pretreatment with the selective inhibitors of MEK1/2 (U0126) and NF-kappaB (Bay11-7085), respectively, suggesting that MEK1/2-p42/p44 MAPK cascade linking to NF-kappaB was involved in COX-2 expression.	U 0126	190-195	nuclear factor kappa B subunit 1	Homo sapiens	47-56
19846601-3	2010	GnRH-induced MAPK3/1 activation was completely inhibited by U0126, a MEK inhibitor, whereas GnRH-induced DUSP1 expression was partially inhibited by U0126.	U 0126	149-154	gonadotropin releasing hormone 1	Mus musculus	92-96
19846601-3	2010	GnRH-induced MAPK3/1 activation was completely inhibited by U0126, a MEK inhibitor, whereas GnRH-induced DUSP1 expression was partially inhibited by U0126.	U 0126	149-154	dual specificity phosphatase 1	Mus musculus	105-110
19846601-6	2010	U0126 prevented GnRH-stimulated gonadotropin subunit promoter activation dose dependently, and 10 muM of U0126 reduced the effects of GnRH on the Lhb and Fshb promoters to 79.15% and 55.66%, respectively.	U 0126	0-5	gonadotropin releasing hormone 1	Mus musculus	16-20
19913294-7	2010	Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2.	U 0126	49-54	hepatocyte growth factor	Mus musculus	30-33
19913294-7	2010	Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2.	U 0126	49-54	mitogen-activated protein kinase kinase 1	Mus musculus	58-64
19913294-7	2010	Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2.	U 0126	49-54	hepatocyte growth factor	Mus musculus	92-95
19913294-7	2010	Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2.	U 0126	49-54	bone morphogenetic protein 2	Mus musculus	111-116
19913294-7	2010	Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2.	U 0126	49-54	mitogen-activated protein kinase 3	Mus musculus	145-151
19800403-5	2010	Consistently, EV71-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaBalpha in the cytosol was blocked by pretreatment with the selective inhibitors of MEK1/2 (U0126) and NF-kappaB (Bay11-7085), respectively, suggesting that MEK1/2-p42/p44 MAPK cascade linking to NF-kappaB was involved in COX-2 expression.	U 0126	190-195	nuclear factor kappa B subunit 1	Homo sapiens	201-210
19800403-5	2010	Consistently, EV71-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaBalpha in the cytosol was blocked by pretreatment with the selective inhibitors of MEK1/2 (U0126) and NF-kappaB (Bay11-7085), respectively, suggesting that MEK1/2-p42/p44 MAPK cascade linking to NF-kappaB was involved in COX-2 expression.	U 0126	190-195	erythrocyte membrane protein band 4.2	Homo sapiens	262-265
19800403-5	2010	Consistently, EV71-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaBalpha in the cytosol was blocked by pretreatment with the selective inhibitors of MEK1/2 (U0126) and NF-kappaB (Bay11-7085), respectively, suggesting that MEK1/2-p42/p44 MAPK cascade linking to NF-kappaB was involved in COX-2 expression.	U 0126	190-195	mitogen-activated protein kinase 3	Homo sapiens	266-274
19800403-5	2010	Consistently, EV71-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaBalpha in the cytosol was blocked by pretreatment with the selective inhibitors of MEK1/2 (U0126) and NF-kappaB (Bay11-7085), respectively, suggesting that MEK1/2-p42/p44 MAPK cascade linking to NF-kappaB was involved in COX-2 expression.	U 0126	190-195	nuclear factor kappa B subunit 1	Homo sapiens	201-210
19768635-6	2010	Further, the treatment of specific inhibitor for ERK (U0126) to A549 cells could inhibit TPA-induced MMP-2 and u-PA expressions along with an inhibition on cell invasion and migration.	U 0126	54-59	matrix metallopeptidase 2	Homo sapiens	101-106
19936794-8	2010	Inhibition of mitogen-activated protein kinase-Erk1/2 signaling using an Erk1/2-specific inhibitor (UO126) abolished SCCM-induced Erk1/2 phosphorylation and neuritogenesis completely.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	47-53
19936794-8	2010	Inhibition of mitogen-activated protein kinase-Erk1/2 signaling using an Erk1/2-specific inhibitor (UO126) abolished SCCM-induced Erk1/2 phosphorylation and neuritogenesis completely.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	73-79
19936794-8	2010	Inhibition of mitogen-activated protein kinase-Erk1/2 signaling using an Erk1/2-specific inhibitor (UO126) abolished SCCM-induced Erk1/2 phosphorylation and neuritogenesis completely.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	73-79
20043073-7	2010	Prevention of PI3K by LY294002 blocked heat shock/GD-induced apoptosis without reversing the cell death mode to necrosis, while inhibition of MEK1/2 by U0126 reversed heat shock/GD-induced apoptosis to necrosis, indicating a different role(s) of PI3K and ERK1/2 in heat shock/GD-induced cell death mode determination.	U 0126	152-157	mitogen-activated protein kinase kinase 1	Homo sapiens	142-148
19763792-8	2010	In addition, Elk-1 phosphorylation and luciferase activity in response to carbachol treatment was also dependent upon CaM kinases and was inhibited by U0126, STO-609, and siRNA knockdown of CaM kinases and ERK2.	U 0126	151-156	ETS transcription factor ELK1	Homo sapiens	13-18
19763792-8	2010	In addition, Elk-1 phosphorylation and luciferase activity in response to carbachol treatment was also dependent upon CaM kinases and was inhibited by U0126, STO-609, and siRNA knockdown of CaM kinases and ERK2.	U 0126	151-156	mitogen-activated protein kinase 1	Homo sapiens	206-210
19763792-9	2010	Finally, blockade of either CaM KK (with STO-609) or ERK (with U0126) activities resulted in the inhibition of carbachol- and estrogen-mediated cyclin D1 expression and MCF-7 cell growth.	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	53-56
19763792-9	2010	Finally, blockade of either CaM KK (with STO-609) or ERK (with U0126) activities resulted in the inhibition of carbachol- and estrogen-mediated cyclin D1 expression and MCF-7 cell growth.	U 0126	63-68	cyclin D1	Homo sapiens	144-153
19882665-5	2010	Moreover, the effect of Sox2 on NPC self-renewal is completely inhibited by AG1478, a specific inhibitor for Egfr; it is also inhibited by LY294002 and U0126, selective antagonists for phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (Erk1/2), respectively.	U 0126	152-157	SRY-box transcription factor 2	Homo sapiens	24-28
19882665-5	2010	Moreover, the effect of Sox2 on NPC self-renewal is completely inhibited by AG1478, a specific inhibitor for Egfr; it is also inhibited by LY294002 and U0126, selective antagonists for phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (Erk1/2), respectively.	U 0126	152-157	mitogen-activated protein kinase 3	Homo sapiens	265-271
20102637-8	2010	The hypoxia mediated increase in MMP1 expression and chondrosarcoma invasion could be inhibited by siRNA directed at HIF-1a or CXCR4, the CXCR4 inhibitor AMD3100, as well as with ERK inhibitor U0126 and ERK siRNA.	U 0126	193-198	matrix metallopeptidase 1	Homo sapiens	33-37
20102637-8	2010	The hypoxia mediated increase in MMP1 expression and chondrosarcoma invasion could be inhibited by siRNA directed at HIF-1a or CXCR4, the CXCR4 inhibitor AMD3100, as well as with ERK inhibitor U0126 and ERK siRNA.	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	179-182
20068179-5	2010	These mitotic abnormalities were suppressed by expression of a B-Raf(V600E) mutant-specific shRNA or by the addition of the mitogen-activated protein/ERK kinase-specific inhibitor U0126.	U 0126	180-185	mitogen-activated protein kinase 1	Homo sapiens	150-153
19850060-9	2010	Pharmacological inhibition of system X(c)(-) prevented the effect of micromolar homocysteine concentrations, and U0126-mediated inhibition of ERK(1/2) phosphorylation enhanced homocysteine-induced death.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	142-149
19895795-10	2010	Pharmacological inhibitors of MEK (U0126) and ERK (PD98059) also blocked neurite outgrowth in cells plated on laminin-1.	U 0126	35-40	mitogen-activated protein kinase kinase 7	Homo sapiens	30-33
19860845-4	2010	Furthermore, suppression of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase activity by their specific inhibitors, U0126 and SB203580, abrogated CD24-induced proliferation in vitro.	U 0126	147-152	mitogen-activated protein kinase 14	Homo sapiens	71-74
19860845-4	2010	Furthermore, suppression of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase activity by their specific inhibitors, U0126 and SB203580, abrogated CD24-induced proliferation in vitro.	U 0126	147-152	CD24 molecule	Homo sapiens	177-181
19959938-3	2010	In this study, we demonstrated that the MAPK specific inhibitor U0126 prevented the HGF-induced invasion of SKOV-3 cells.	U 0126	64-69	hepatocyte growth factor	Homo sapiens	84-87
23119142-8	2010	Addition of the MEK inhibitor U0126 into the transfected L02 cells described above inhibited ERK phosphorylation and hTERT expression.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19
23119142-8	2010	Addition of the MEK inhibitor U0126 into the transfected L02 cells described above inhibited ERK phosphorylation and hTERT expression.	U 0126	30-35	telomerase reverse transcriptase	Homo sapiens	117-122
20413844-6	2010	MEK was inhibited by U0126.	U 0126	21-26	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
21063091-5	2010	Although preventing ERK1/2- p90RSK signaling pathway (10 mumol/L U0126) mimicked SIL effect, SIL did not blunt the acidosis-mediated increase in kinases activation.	U 0126	65-70	mitogen activated protein kinase 3	Rattus norvegicus	20-26
21063106-7	2010	In addition, PAF-induced migration of hBMSCs was abrogated by pretreating cells with mitogen-activated protein kinase (MAPK) inhibitors, including the MEK inhibitor U0126, the p38 MAPK inhibitor SB202190, and the JNK inhibitor SP600125.	U 0126	165-170	PCNA clamp associated factor	Homo sapiens	13-16
19948989-14	2010	Extracellular signal-regulated kinase 1/2 inhibition in vivo (U0126) prevented hypertrophy in high-flow arteries.	U 0126	62-67	mitogen activated protein kinase 3	Rattus norvegicus	0-41
19956840-4	2010	We further found that inhibition of ERK1/2 by U0126 abolished the effects of hypoxia to switch the cell death mode and to suppress mitochondrial ROS production, indicating an important role(s) of the ERK pathway in cell death mode determination.	U 0126	46-51	mitogen-activated protein kinase 3	Homo sapiens	36-42
19956840-4	2010	We further found that inhibition of ERK1/2 by U0126 abolished the effects of hypoxia to switch the cell death mode and to suppress mitochondrial ROS production, indicating an important role(s) of the ERK pathway in cell death mode determination.	U 0126	46-51	mitogen-activated protein kinase 3	Homo sapiens	36-39
20957068-8	2010	Adenosine preconditioning induced neuroprotection and Bim degradation was blocked by the MEK inhibitor UO126 (10microM).	U 0126	103-108	Bcl2-like 11	Rattus norvegicus	54-57
20508392-7	2010	Olmesartan, U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and PP2 potently inhibited AII-induced RASMC migration.	U 0126	12-17	angiotensinogen	Homo sapiens	96-99
20410673-7	2010	Furthermore, the activation of Nrf2 was suppressed by U0126, which is an inhibitor of the extracellular signal regulated protein kinase 1/2 (ERK1/2) pathway, suggesting involvement of ERK1/2-dependent pathway in the irradiation-induced activation of Nrf2.	U 0126	54-59	nuclear factor, erythroid derived 2, like 2	Mus musculus	31-35
20410673-7	2010	Furthermore, the activation of Nrf2 was suppressed by U0126, which is an inhibitor of the extracellular signal regulated protein kinase 1/2 (ERK1/2) pathway, suggesting involvement of ERK1/2-dependent pathway in the irradiation-induced activation of Nrf2.	U 0126	54-59	mitogen-activated protein kinase 3	Mus musculus	141-147
20410673-7	2010	Furthermore, the activation of Nrf2 was suppressed by U0126, which is an inhibitor of the extracellular signal regulated protein kinase 1/2 (ERK1/2) pathway, suggesting involvement of ERK1/2-dependent pathway in the irradiation-induced activation of Nrf2.	U 0126	54-59	mitogen-activated protein kinase 3	Mus musculus	184-190
20410673-7	2010	Furthermore, the activation of Nrf2 was suppressed by U0126, which is an inhibitor of the extracellular signal regulated protein kinase 1/2 (ERK1/2) pathway, suggesting involvement of ERK1/2-dependent pathway in the irradiation-induced activation of Nrf2.	U 0126	54-59	nuclear factor, erythroid derived 2, like 2	Mus musculus	250-254
19893321-8	2010	MEK inhibition with PD98059 or U0126 as well as store-operated calcium entry inhibition antagonized the effect of 7betaOHC.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
19854889-6	2010	This down-regulation was attenuated by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), which blocks the phosphorylation of ERK.	U 0126	93-98	mitogen-activated protein kinase 1	Mus musculus	137-140
20017911-8	2009	Consistently, blocking the ERK1/2 pathway with U0126, the selective inhibitor of the ERK upstream mitogen-activated protein (MAP)-ERK kinase (MEK), results in a dramatic reduction (by almost 100%) of the capability of Hp to induce monocyte migration.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	27-33
20017911-8	2009	Consistently, blocking the ERK1/2 pathway with U0126, the selective inhibitor of the ERK upstream mitogen-activated protein (MAP)-ERK kinase (MEK), results in a dramatic reduction (by almost 100%) of the capability of Hp to induce monocyte migration.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	27-30
20017911-8	2009	Consistently, blocking the ERK1/2 pathway with U0126, the selective inhibitor of the ERK upstream mitogen-activated protein (MAP)-ERK kinase (MEK), results in a dramatic reduction (by almost 100%) of the capability of Hp to induce monocyte migration.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	85-88
19920183-5	2009	Interestingly, we noticed that a 48-hour treatment with U0126 [specific mitogen-activated protein/ERK kinase (MEK)-1/2 inhibitor] was needed to significantly inhibit breast cancer cell migration, whereas this inhibitor blocked ERK activity within 1 hour.	U 0126	56-61	mitogen-activated protein kinase kinase 1	Homo sapiens	72-118
19920183-5	2009	Interestingly, we noticed that a 48-hour treatment with U0126 [specific mitogen-activated protein/ERK kinase (MEK)-1/2 inhibitor] was needed to significantly inhibit breast cancer cell migration, whereas this inhibitor blocked ERK activity within 1 hour.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	98-101
19735699-3	2009	In the present study, we further tested this interpretation by administering unilateral infusions of U0126 (in 50% dimethyl sulfoxide (DMSO) vehicle) to block phosphorylation of extracellular signal-responsive kinase (ERK) in the amygdala prior to CS-US pairings.	U 0126	101-106	Eph receptor B1	Rattus norvegicus	178-216
19735699-3	2009	In the present study, we further tested this interpretation by administering unilateral infusions of U0126 (in 50% dimethyl sulfoxide (DMSO) vehicle) to block phosphorylation of extracellular signal-responsive kinase (ERK) in the amygdala prior to CS-US pairings.	U 0126	101-106	Eph receptor B1	Rattus norvegicus	218-221
19716834-6	2009	Phosphorylation of histone H3 by DMA(III) was effectively reduced by ZM447439 (Aurora kinase inhibitor) and slightly reduced by U0126 (MEK inhibitor).	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	135-138
19737531-8	2009	U0126, a MEK pathway inhibitor, suppressed activation of Egr-1 expression by CpG ODN.	U 0126	0-5	midkine	Mus musculus	9-12
19737531-8	2009	U0126, a MEK pathway inhibitor, suppressed activation of Egr-1 expression by CpG ODN.	U 0126	0-5	early growth response 1	Mus musculus	57-62
19808909-9	2009	Further studies revealed that PEDF, or U-0126, a specific MAPK/ERK inhibitor, sequentially inhibited the early activation of ERK and MCE.	U 0126	39-45	mitogen-activated protein kinase 1	Homo sapiens	58-62
19808909-9	2009	Further studies revealed that PEDF, or U-0126, a specific MAPK/ERK inhibitor, sequentially inhibited the early activation of ERK and MCE.	U 0126	39-45	mitogen-activated protein kinase 1	Homo sapiens	63-66
19808909-9	2009	Further studies revealed that PEDF, or U-0126, a specific MAPK/ERK inhibitor, sequentially inhibited the early activation of ERK and MCE.	U 0126	39-45	mitogen-activated protein kinase 1	Homo sapiens	125-128
19749163-4	2009	Phorbol 12,13-dibutyrate (PDBu)-mediated PKC activation produced a robust contractile response, which was increased a further 20 to 30% by U-0126 (MEK inhibitor) in cerebral arteries of both age groups.	U 0126	139-145	mitogen-activated protein kinase kinase 7	Homo sapiens	147-150
19833152-9	2009	Inhibition of ERK by UO126 decreased the phosphorylation of Ser31 and this lead to a 50% decrease in the basal level of phosphorylation of Ser40 in hTH1.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	14-17
19833152-9	2009	Inhibition of ERK by UO126 decreased the phosphorylation of Ser31 and this lead to a 50% decrease in the basal level of phosphorylation of Ser40 in hTH1.	U 0126	21-26	negative elongation factor complex member C/D	Homo sapiens	148-152
19935875-8	2009	The ERK1/2 inhibitor U0126 did not affect contraction, but treatment led to depressed MMP-1, MMP-3, and alpha2 mRNA levels.	U 0126	21-26	matrix metallopeptidase 3	Homo sapiens	93-98
19798745-6	2010	Furthermore, inhibitors of the MAPK and PI3K-Akt signaling pathways, U0126 and LY294002, attenuated the effects of PA6CM, significantly increasing the number of apoptotic cells and decreasing the number of viable cells among the ES cell-derived NS/PCs.	U 0126	69-74	mitogen-activated protein kinase 1	Mus musculus	31-35
19830833-8	2010	Blockade of ERK or Akt signaling with U0126 or LY294002 cancelled the OPC-protective effects of astrocyte-conditioned media.	U 0126	38-43	Eph receptor B1	Rattus norvegicus	12-15
19830833-8	2010	Blockade of ERK or Akt signaling with U0126 or LY294002 cancelled the OPC-protective effects of astrocyte-conditioned media.	U 0126	38-43	AKT serine/threonine kinase 1	Rattus norvegicus	19-22
19887895-7	2010	Moreover, cholesterol depletion-induced TIMP-2 expression and MMP-2 activation was significantly decreased by MEK inhibitor U0126, and JNK inhibitor SP600125, respectively.	U 0126	124-129	TIMP metallopeptidase inhibitor 2	Homo sapiens	40-46
19887895-7	2010	Moreover, cholesterol depletion-induced TIMP-2 expression and MMP-2 activation was significantly decreased by MEK inhibitor U0126, and JNK inhibitor SP600125, respectively.	U 0126	124-129	matrix metallopeptidase 2	Homo sapiens	62-67
19887895-7	2010	Moreover, cholesterol depletion-induced TIMP-2 expression and MMP-2 activation was significantly decreased by MEK inhibitor U0126, and JNK inhibitor SP600125, respectively.	U 0126	124-129	mitogen-activated protein kinase kinase 7	Homo sapiens	110-113
19881545-6	2010	Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1"s effects in this model.	U 0126	106-111	BAG cochaperone 1	Homo sapiens	16-21
19881545-6	2010	Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1"s effects in this model.	U 0126	106-111	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	128-133
19881545-6	2010	Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1"s effects in this model.	U 0126	106-111	BAG cochaperone 1	Homo sapiens	213-218
19610096-6	2010	This induction could be blocked by inhibition of MEK1/2 using U0126, and suggests that AQP1 is specifically induced in reactive astrocytes via the mitogen-activated protein kinases signaling pathway.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Homo sapiens	49-55
19610096-6	2010	This induction could be blocked by inhibition of MEK1/2 using U0126, and suggests that AQP1 is specifically induced in reactive astrocytes via the mitogen-activated protein kinases signaling pathway.	U 0126	62-67	aquaporin 1 (Colton blood group)	Homo sapiens	87-91
20026063-4	2010	All specific NFkappaB and MAPKs pathway inhibitors (pyrrolidine dithiocarbamate, AG490, U0126, SB203580 and SP600125) remarkably attenuated NO production induced by the beta-glucan.	U 0126	88-93	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	13-21
20068074-5	2010	SLPI-mediated survival was reduced by the MAP/extracellular signal-regulated kinase (ERK) kinase inhibitor, U0126, and a humanized neutralizing monoclonal anti-SLPI antibody, CR012.	U 0126	108-113	secretory leukocyte peptidase inhibitor	Homo sapiens	0-4
20068074-11	2010	Inhibition of MAP/ERK kinase with U0126 increased paclitaxel injury and overcame SLPI-mediated cell protection.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	18-21
20068074-11	2010	Inhibition of MAP/ERK kinase with U0126 increased paclitaxel injury and overcame SLPI-mediated cell protection.	U 0126	34-39	secretory leukocyte peptidase inhibitor	Homo sapiens	81-85
19910580-7	2010	Inhibition of ERK1/2 by U0126/PD-98059 or overexpression of a dominant negative p53 comparably inhibited S100B-induced myocyte apoptosis.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	14-20
19910580-7	2010	Inhibition of ERK1/2 by U0126/PD-98059 or overexpression of a dominant negative p53 comparably inhibited S100B-induced myocyte apoptosis.	U 0126	24-29	S100 calcium binding protein B	Rattus norvegicus	105-110
20039412-9	2010	Moreover, up-regulation of VCAM-1 increased the adhesion of lymphocytes to the RASF monolayer, and this adhesion was attenuated by pretreatment with helenalin, U0126, SP600125, or SB202190 prior to exposure to TNFalpha or by anti-VCAM-1 antibody before the addition of lymphocytes.	U 0126	160-165	vascular cell adhesion molecule 1	Homo sapiens	27-33
20039412-9	2010	Moreover, up-regulation of VCAM-1 increased the adhesion of lymphocytes to the RASF monolayer, and this adhesion was attenuated by pretreatment with helenalin, U0126, SP600125, or SB202190 prior to exposure to TNFalpha or by anti-VCAM-1 antibody before the addition of lymphocytes.	U 0126	160-165	tumor necrosis factor	Homo sapiens	210-218
20039412-9	2010	Moreover, up-regulation of VCAM-1 increased the adhesion of lymphocytes to the RASF monolayer, and this adhesion was attenuated by pretreatment with helenalin, U0126, SP600125, or SB202190 prior to exposure to TNFalpha or by anti-VCAM-1 antibody before the addition of lymphocytes.	U 0126	160-165	vascular cell adhesion molecule 1	Homo sapiens	230-236
19843070-9	2010	However, using an ERK1/2 inhibitor, U0126, we found that we could reduce phospho-ERK1/2 levels in K562/R cells and restore their sensitivity to imatinib.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	18-24
19843070-9	2010	However, using an ERK1/2 inhibitor, U0126, we found that we could reduce phospho-ERK1/2 levels in K562/R cells and restore their sensitivity to imatinib.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	81-87
19914607-5	2010	Importantly, pharmacological treatment of thymocytes with the MEK inhibitor UO126 revealed that PMA-induced ERK1/2 activation was proapoptotic, whereas serum starvation-induced ERK1/2 activation inhibited apoptosis and promoted cell survival.	U 0126	76-81	midkine	Mus musculus	62-65
19914607-5	2010	Importantly, pharmacological treatment of thymocytes with the MEK inhibitor UO126 revealed that PMA-induced ERK1/2 activation was proapoptotic, whereas serum starvation-induced ERK1/2 activation inhibited apoptosis and promoted cell survival.	U 0126	76-81	mitogen-activated protein kinase 3	Mus musculus	108-114
19914607-5	2010	Importantly, pharmacological treatment of thymocytes with the MEK inhibitor UO126 revealed that PMA-induced ERK1/2 activation was proapoptotic, whereas serum starvation-induced ERK1/2 activation inhibited apoptosis and promoted cell survival.	U 0126	76-81	mitogen-activated protein kinase 3	Mus musculus	177-183
20798501-11	2010	Inhibiting this activation pharmacologically, using U0126, a ERK1/2 inhibitor, or SB203580, a p38 inhibitor, resulted in significantly lower ALP activity and osteocalcin protein expression.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	61-67
20798501-11	2010	Inhibiting this activation pharmacologically, using U0126, a ERK1/2 inhibitor, or SB203580, a p38 inhibitor, resulted in significantly lower ALP activity and osteocalcin protein expression.	U 0126	52-57	alkaline phosphatase, placental	Homo sapiens	141-144
20798501-11	2010	Inhibiting this activation pharmacologically, using U0126, a ERK1/2 inhibitor, or SB203580, a p38 inhibitor, resulted in significantly lower ALP activity and osteocalcin protein expression.	U 0126	52-57	bone gamma-carboxyglutamate protein	Homo sapiens	158-169
21220918-10	2010	Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126.	U 0126	144-149	mitogen-activated protein kinase 1	Mus musculus	38-41
21220918-10	2010	Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126.	U 0126	144-149	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	46-50
21220918-10	2010	Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126.	U 0126	144-149	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	51-54
21220918-10	2010	Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126.	U 0126	144-149	transforming growth factor, beta 1	Mus musculus	81-90
21220918-10	2010	Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126.	U 0126	144-149	mitogen-activated protein kinase 1	Mus musculus	130-133
21220918-11	2010	Both U0126 and NF-kappaB inhibitor PDTC obviously inhibited the increment of TRPC6 protein and the flux of cytosolic free Ca(2+) induced by TGF-beta1.	U 0126	5-10	transient receptor potential cation channel, subfamily C, member 6	Mus musculus	77-82
21220918-11	2010	Both U0126 and NF-kappaB inhibitor PDTC obviously inhibited the increment of TRPC6 protein and the flux of cytosolic free Ca(2+) induced by TGF-beta1.	U 0126	5-10	transforming growth factor, beta 1	Mus musculus	140-149
19797611-2	2010	Treatment with 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) (an extracellular signal-regulated kinase inhibitor) suppressed the HGF-induced expression of UGT1A1 and CYP2B6, as well as p16, p21, and p27 in HepG2 cells.	U 0126	69-74	hepatocyte growth factor	Homo sapiens	144-147
19797611-2	2010	Treatment with 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) (an extracellular signal-regulated kinase inhibitor) suppressed the HGF-induced expression of UGT1A1 and CYP2B6, as well as p16, p21, and p27 in HepG2 cells.	U 0126	69-74	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	170-176
19797611-2	2010	Treatment with 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) (an extracellular signal-regulated kinase inhibitor) suppressed the HGF-induced expression of UGT1A1 and CYP2B6, as well as p16, p21, and p27 in HepG2 cells.	U 0126	69-74	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	181-187
19797611-2	2010	Treatment with 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) (an extracellular signal-regulated kinase inhibitor) suppressed the HGF-induced expression of UGT1A1 and CYP2B6, as well as p16, p21, and p27 in HepG2 cells.	U 0126	69-74	cyclin dependent kinase inhibitor 2A	Homo sapiens	200-203
19797611-2	2010	Treatment with 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) (an extracellular signal-regulated kinase inhibitor) suppressed the HGF-induced expression of UGT1A1 and CYP2B6, as well as p16, p21, and p27 in HepG2 cells.	U 0126	69-74	H3 histone pseudogene 16	Homo sapiens	205-208
19797611-2	2010	Treatment with 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) (an extracellular signal-regulated kinase inhibitor) suppressed the HGF-induced expression of UGT1A1 and CYP2B6, as well as p16, p21, and p27 in HepG2 cells.	U 0126	69-74	dynactin subunit 6	Homo sapiens	214-217
20136620-4	2010	Lympho-activation and proliferation induced by AcF1 was partially inhibited by U0126, a selective mitogen activated protein kinase kinase (MKK) inhibitor.	U 0126	79-84	albumin conformation factor 1	Mus musculus	47-51
20707649-9	2010	With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed.	U 0126	21-26	epidermal growth factor receptor	Rattus norvegicus	62-66
20707649-9	2010	With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed.	U 0126	21-26	cellular communication network factor 2	Rattus norvegicus	68-72
20707649-9	2010	With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed.	U 0126	21-26	TGFB-induced factor homeobox 1	Rattus norvegicus	74-78
20707649-9	2010	With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed.	U 0126	21-26	vascular endothelial growth factor A	Rattus norvegicus	80-85
20707649-9	2010	With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed.	U 0126	21-26	oxidative stress induced growth inhibitor 1	Rattus norvegicus	87-92
20707649-9	2010	With the addition of U0126, further up- or down-regulation of Egfr, Ctgf, Tgif, Vegfa, Okl38 and Gdf15 in response to heat stress was observed.	U 0126	21-26	growth differentiation factor 15	Rattus norvegicus	97-102
21318151-5	2010	Finally, the MEK1/2 inhibitor U0126 enhances growth-suppressive effect of EGCG.	U 0126	30-35	mitogen-activated protein kinase kinase 1	Homo sapiens	13-19
20492173-6	2010	Further, the treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2 and MMP-9 expressions along with an inhibition on cell invasion and migration.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	49-52
20492173-6	2010	Further, the treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2 and MMP-9 expressions along with an inhibition on cell invasion and migration.	U 0126	54-59	matrix metallopeptidase 2	Homo sapiens	102-107
20492173-6	2010	Further, the treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2 and MMP-9 expressions along with an inhibition on cell invasion and migration.	U 0126	54-59	matrix metallopeptidase 9	Homo sapiens	112-117
19801501-4	2010	Following SSH between cDNA libraries from FD-Fms cells stimulated by M-CSF for 8 h in the presence or the absence of the MEK inhibitor U0126, we isolated DUSP5.	U 0126	135-140	mitogen-activated protein kinase kinase 7	Homo sapiens	121-124
19797620-11	2010	The ERK1/2 inhibitor U0126 (10 microM) attenuated EGF-induced cell migration and ERK1/2 but not EGFR phosphorylation.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	4-10
19797620-11	2010	The ERK1/2 inhibitor U0126 (10 microM) attenuated EGF-induced cell migration and ERK1/2 but not EGFR phosphorylation.	U 0126	21-26	epidermal growth factor	Homo sapiens	50-53
19797620-11	2010	The ERK1/2 inhibitor U0126 (10 microM) attenuated EGF-induced cell migration and ERK1/2 but not EGFR phosphorylation.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	81-87
20424388-4	2010	IL-1beta-induced COX-2 expression in all of the above cells was abolished in the presence of U0126, an inhibitor of extracellular signal-regulated kinases (ERK).	U 0126	93-98	interleukin 1 beta	Rattus norvegicus	0-8
20424388-4	2010	IL-1beta-induced COX-2 expression in all of the above cells was abolished in the presence of U0126, an inhibitor of extracellular signal-regulated kinases (ERK).	U 0126	93-98	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	17-22
21472214-6	2010	Furthermore, the addition of dissociation factor (DF) or U0126 (a MEK inhibitor) significantly induced changes in the mRNA expression and protein intracellular localisation of Tjp-2, and in the simultaneous cell dissociation of PC-1.0 and PC-1 cells.	U 0126	57-62	tight junction protein ZO-2	Mesocricetus auratus	176-181
19956875-7	2010	ISO transiently activated MAPK/ERK1/2 in tumor cells which could be blocked either by ICI 118551 or U0126, but not by H-89, LY294002, or PD153035.	U 0126	100-105	mitogen-activated protein kinase 3	Homo sapiens	31-37
19820417-7	2010	Administration of LY294002 resulted in complete abrogation of CXCL12-induced proliferation in PanIN, 5143LM, and PANC-1 cells but not 5143PDA cells, whereas UO126 resulted in complete abrogation of CXCR4-enhanced proliferation in all cell lines.	U 0126	157-162	C-X-C motif chemokine receptor 4	Homo sapiens	198-203
21071999-6	2010	PFT-alpha-induced COX-2 expression was significantly decreased by UO126 and LY294002 in MDA-MB231 cells.	U 0126	66-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-23
20398495-5	2010	However, compared with H/R group, these changes were significantly attenuated in GLP-1 + H/R group [the activity of LDH (128.47 +/- 7.96) U/L vs. (223.96 +/- 22.10) U/L, P &lt; 0.01, and cardiomyocyte apoptosis rate (2.84 +/- 2.56)% vs. (12.58 +/- 6.69)%, P &lt; 0.01, and Caspase-3 activity (36,809 +/- 4750) RLU vs. (57,602 +/- 9161) RLU, P &lt; 0.01], while LY294002 (PI3K inhibitor) and UO126 (MAPK inhibitor) could block the effects of GLP-1 in cardiomyocytes underwent H/R injury.	U 0126	391-396	glucagon	Rattus norvegicus	81-86
19788916-5	2009	The phospholipid inhibits induction of MAPK and NF-kappaB in similar fashion to the MEK1/2-inhibitor, U0126 (10 microM).	U 0126	102-107	mitogen-activated protein kinase kinase 1	Homo sapiens	84-90
20034375-8	2009	Areg, Ereg and Tace/Adam17 gene expressions were not suppressed by PI3K inhibitor (LY294002), whereas PKA inhibitor (H89), p38 MAPK inhibitor (SB203580) and MEK inhibitor (U0126) significantly suppressed these gene expressions.	U 0126	172-177	mitogen-activated protein kinase kinase 7	Homo sapiens	157-160
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	120-125	mitogen-activated protein kinase 3	Homo sapiens	19-25
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	120-125	hyaluronan synthase 2	Homo sapiens	54-58
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	120-125	TNF alpha induced protein 6	Homo sapiens	60-67
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	120-125	prostaglandin-endoperoxide synthase 2	Homo sapiens	72-77
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	226-231	mitogen-activated protein kinase 3	Homo sapiens	19-25
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	226-231	hyaluronan synthase 2	Homo sapiens	54-58
20034375-9	2009	Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group.	U 0126	226-231	TNF alpha induced protein 6	Homo sapiens	60-67
19551815-12	2009	Moreover, the activation level of pERK1 was dramatically increased by exogenous FGF10 alone and by combined treatment with FGF10 and U0126.	U 0126	133-138	fibroblast growth factor 10	Mus musculus	80-85
19769948-4	2009	PRL induced Egr-1 mRNA expression in 4B cells, an effect which was prevented by the MEK inhibitor, U0126.	U 0126	99-104	prolactin	Rattus norvegicus	0-3
19769948-4	2009	PRL induced Egr-1 mRNA expression in 4B cells, an effect which was prevented by the MEK inhibitor, U0126.	U 0126	99-104	early growth response 1	Rattus norvegicus	12-17
19923532-13	2009	Intrathecal injections of MK-801 or U0126 15 min before the ligation similarly prevented the injury-associated changes in Homer1 protein levels and the behavioral signs of pain.	U 0126	36-41	homer scaffold protein 1	Rattus norvegicus	122-128
19768635-6	2010	Further, the treatment of specific inhibitor for ERK (U0126) to A549 cells could inhibit TPA-induced MMP-2 and u-PA expressions along with an inhibition on cell invasion and migration.	U 0126	54-59	plasminogen activator, urokinase	Homo sapiens	111-115
19651524-7	2009	U0126, PD98059 and LY204002 almost completely abolished GM-CSF induced IL-4 release when they were preincubated with P815 cells for 30 min, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	56-62
19733237-4	2009	Cells treated at early stage with the MEK-specific inhibitors, PD184352 and U0126, reduced both the MHC protein level and MCK promoter activity, demonstrating that high MEK1 activity at the mid-stage is required for myogenic differentiation.	U 0126	76-81	creatine kinase, muscle	Mus musculus	122-125
19733237-4	2009	Cells treated at early stage with the MEK-specific inhibitors, PD184352 and U0126, reduced both the MHC protein level and MCK promoter activity, demonstrating that high MEK1 activity at the mid-stage is required for myogenic differentiation.	U 0126	76-81	mitogen-activated protein kinase kinase 1	Mus musculus	169-173
19651524-7	2009	U0126, PD98059 and LY204002 almost completely abolished GM-CSF induced IL-4 release when they were preincubated with P815 cells for 30 min, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	interleukin 4	Mus musculus	71-75
19651524-7	2009	U0126, PD98059 and LY204002 almost completely abolished GM-CSF induced IL-4 release when they were preincubated with P815 cells for 30 min, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	151-154
19651524-7	2009	U0126, PD98059 and LY204002 almost completely abolished GM-CSF induced IL-4 release when they were preincubated with P815 cells for 30 min, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	thymoma viral proto-oncogene 1	Mus musculus	159-162
19961386-11	2009	The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580).	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	18-24
19961386-11	2009	The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580).	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	29-32
19961386-11	2009	The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580).	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	91-95
19961386-11	2009	The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580).	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	18-21
19961386-11	2009	The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580).	U 0126	115-120	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
19646499-5	2009	In functional studies with an A2B5- and nestin-positive, O4-negative murine glial precursor cell line, VEGF-C and -D stimulated phosphorylation of the kinases Erk1/2; this signal transduction was inhibited by UO126.	U 0126	209-214	vascular endothelial growth factor C	Mus musculus	103-109
19426585-5	2009	METHODS: Unilateral sciatic nerve crush was performed, and inhibition of ERK was achieved by intraperitoneal injection of 300 microg kg(-1) day(-1) of u0126 for 2 weeks in the inhibitor group.	U 0126	151-156	mitogen-activated protein kinase 1	Homo sapiens	73-76
19666073-9	2009	U0126, an inhibitor of MEK, the upstream activator of ERK1/2, completely blocked induction of ERK1/2 phosphorylation.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	23-26
19646499-5	2009	In functional studies with an A2B5- and nestin-positive, O4-negative murine glial precursor cell line, VEGF-C and -D stimulated phosphorylation of the kinases Erk1/2; this signal transduction was inhibited by UO126.	U 0126	209-214	mitogen-activated protein kinase 3	Mus musculus	159-165
19666073-9	2009	U0126, an inhibitor of MEK, the upstream activator of ERK1/2, completely blocked induction of ERK1/2 phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	54-60
19833733-5	2009	Inhibition of MEK1/2 by either PD98059 or U0126 suppressed the induction of apoptosis of PKCdelta-depleted MDA-MB-231 cells but did not support survival of MCF-7 or MDA-MB-468 cells.	U 0126	42-47	mitogen-activated protein kinase kinase 1	Homo sapiens	14-20
19666073-9	2009	U0126, an inhibitor of MEK, the upstream activator of ERK1/2, completely blocked induction of ERK1/2 phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	94-100
19819736-4	2009	Two study groups, neurons displaying epileptiform activity and the same neurons treated with ERK1/2 inhibitor U0126, were studied at six time points, 0 min, 30 min, 2h, 6h, 12h, and 24h following discharge.	U 0126	110-115	mitogen activated protein kinase 3	Rattus norvegicus	93-99
19770485-7	2009	Pretreatment of BV2 cells with an inhibitor specific for ERK (U0126) markedly abated the expression of ERK and MMP-2.	U 0126	62-67	mitogen-activated protein kinase 1	Mus musculus	57-60
19770485-7	2009	Pretreatment of BV2 cells with an inhibitor specific for ERK (U0126) markedly abated the expression of ERK and MMP-2.	U 0126	62-67	mitogen-activated protein kinase 1	Mus musculus	103-106
19770485-7	2009	Pretreatment of BV2 cells with an inhibitor specific for ERK (U0126) markedly abated the expression of ERK and MMP-2.	U 0126	62-67	matrix metallopeptidase 2	Mus musculus	111-116
19943942-5	2009	This hypothesis is supported by further findings that U0126, the ERK inhibitor, induced a reduction of adult hippocampal progenitor cells in DG after cerebral ischemia and down-regulated phospho-ERK and phospho-CREB expression, but no effect was detected on the activities of Src and Raf.	U 0126	54-59	EPH receptor B2	Homo sapiens	65-68
19943942-5	2009	This hypothesis is supported by further findings that U0126, the ERK inhibitor, induced a reduction of adult hippocampal progenitor cells in DG after cerebral ischemia and down-regulated phospho-ERK and phospho-CREB expression, but no effect was detected on the activities of Src and Raf.	U 0126	54-59	EPH receptor B2	Homo sapiens	195-198
19943942-5	2009	This hypothesis is supported by further findings that U0126, the ERK inhibitor, induced a reduction of adult hippocampal progenitor cells in DG after cerebral ischemia and down-regulated phospho-ERK and phospho-CREB expression, but no effect was detected on the activities of Src and Raf.	U 0126	54-59	cAMP responsive element binding protein 1	Homo sapiens	211-215
19943942-5	2009	This hypothesis is supported by further findings that U0126, the ERK inhibitor, induced a reduction of adult hippocampal progenitor cells in DG after cerebral ischemia and down-regulated phospho-ERK and phospho-CREB expression, but no effect was detected on the activities of Src and Raf.	U 0126	54-59	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	276-279
19943942-5	2009	This hypothesis is supported by further findings that U0126, the ERK inhibitor, induced a reduction of adult hippocampal progenitor cells in DG after cerebral ischemia and down-regulated phospho-ERK and phospho-CREB expression, but no effect was detected on the activities of Src and Raf.	U 0126	54-59	zinc fingers and homeoboxes 2	Homo sapiens	284-287
19833733-5	2009	Inhibition of MEK1/2 by either PD98059 or U0126 suppressed the induction of apoptosis of PKCdelta-depleted MDA-MB-231 cells but did not support survival of MCF-7 or MDA-MB-468 cells.	U 0126	42-47	protein kinase C delta	Homo sapiens	89-97
20003811-0	2009	STAT1/2 is involved in the inhibition of cell growth induced by U0126 in HeLa cells.	U 0126	64-69	signal transducer and activator of transcription 1	Homo sapiens	0-7
19930715-9	2009	Similarly, inhibition of ERK1/2 phosphorylation with U0126 or MMP activity with GM6001 also impaired PRL-3-induced invasion.	U 0126	53-58	mitogen-activated protein kinase 3	Homo sapiens	25-31
19930715-9	2009	Similarly, inhibition of ERK1/2 phosphorylation with U0126 or MMP activity with GM6001 also impaired PRL-3-induced invasion.	U 0126	53-58	protein tyrosine phosphatase 4A3	Homo sapiens	101-106
19919690-9	2009	Treatment of WM9 cells with 30 microM U0126 MEK inhibitor, decreased ERK1/2 phosphorylation and resulted in a decrease in HIF-1alpha expression.	U 0126	38-43	mitogen-activated protein kinase kinase 7	Homo sapiens	44-47
19919690-9	2009	Treatment of WM9 cells with 30 microM U0126 MEK inhibitor, decreased ERK1/2 phosphorylation and resulted in a decrease in HIF-1alpha expression.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	69-75
19919690-9	2009	Treatment of WM9 cells with 30 microM U0126 MEK inhibitor, decreased ERK1/2 phosphorylation and resulted in a decrease in HIF-1alpha expression.	U 0126	38-43	hypoxia inducible factor 1 subunit alpha	Homo sapiens	122-132
19919690-10	2009	However, a 24 h treatment with 10 microM U0126 totally eliminated Erk1/2 phosphorylation, but did not change HIF-1alpha levels.	U 0126	41-46	mitogen-activated protein kinase 3	Homo sapiens	66-72
19919690-12	2009	CONCLUSION: We speculate that metabolic products of U0126 decrease HIF-1alpha expression through "off target" effects.	U 0126	52-57	hypoxia inducible factor 1 subunit alpha	Homo sapiens	67-77
19917087-14	2009	Although H89 (a selective inhibitor of PKA) does not affect LH-mediated changes in Akt, U0126 (a potent MEK inhibitor) suppressed LH-induced Akt phosphorylation, CYP17A1 expression, and androgen production in theca cells.	U 0126	88-93	AKT serine/threonine kinase 1	Bos taurus	141-144
19917087-14	2009	Although H89 (a selective inhibitor of PKA) does not affect LH-mediated changes in Akt, U0126 (a potent MEK inhibitor) suppressed LH-induced Akt phosphorylation, CYP17A1 expression, and androgen production in theca cells.	U 0126	88-93	steroid 17-alpha-hydroxylase/17,20 lyase	Bos taurus	162-169
20003811-6	2009	U0126 induced up-regulation of ERK1/2 and down-regulation of phosphorylated ERK1/2, increased STAT1 and STAT2 expression in a dose-dependent manner, and activated STAT1/2 via their phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	31-37
20003811-6	2009	U0126 induced up-regulation of ERK1/2 and down-regulation of phosphorylated ERK1/2, increased STAT1 and STAT2 expression in a dose-dependent manner, and activated STAT1/2 via their phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	76-82
20003811-6	2009	U0126 induced up-regulation of ERK1/2 and down-regulation of phosphorylated ERK1/2, increased STAT1 and STAT2 expression in a dose-dependent manner, and activated STAT1/2 via their phosphorylation.	U 0126	0-5	signal transducer and activator of transcription 1	Homo sapiens	94-99
20003811-6	2009	U0126 induced up-regulation of ERK1/2 and down-regulation of phosphorylated ERK1/2, increased STAT1 and STAT2 expression in a dose-dependent manner, and activated STAT1/2 via their phosphorylation.	U 0126	0-5	signal transducer and activator of transcription 2	Homo sapiens	104-109
20003811-6	2009	U0126 induced up-regulation of ERK1/2 and down-regulation of phosphorylated ERK1/2, increased STAT1 and STAT2 expression in a dose-dependent manner, and activated STAT1/2 via their phosphorylation.	U 0126	0-5	signal transducer and activator of transcription 1	Homo sapiens	163-170
20003811-7	2009	AG490 markedly inhibited the phosphorylation of STAT1 and STAT2 and slightly increased that of ERK1/2 inhibited by U0126.	U 0126	115-120	mitogen-activated protein kinase 3	Homo sapiens	95-101
20003811-8	2009	We suggest that STAT1/2 is involved in the inhibition of cell growth induced by U0126 in HeLa cells.	U 0126	80-85	signal transducer and activator of transcription 1	Homo sapiens	16-23
19734941-6	2009	Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13.	U 0126	60-65	zinc fingers and homeoboxes 2	Homo sapiens	18-21
19755425-4	2009	Local infusion of the ERK inhibitor U0126 inhibited LTP maintenance and Arc protein expression, blocked changes in eIF4E and eIF2alpha phosphorylation state, and prevented initiation complex (eIF4F) formation.	U 0126	36-41	Eph receptor B1	Rattus norvegicus	22-25
19755425-4	2009	Local infusion of the ERK inhibitor U0126 inhibited LTP maintenance and Arc protein expression, blocked changes in eIF4E and eIF2alpha phosphorylation state, and prevented initiation complex (eIF4F) formation.	U 0126	36-41	eukaryotic translation initiation factor 4E	Rattus norvegicus	115-120
19755425-4	2009	Local infusion of the ERK inhibitor U0126 inhibited LTP maintenance and Arc protein expression, blocked changes in eIF4E and eIF2alpha phosphorylation state, and prevented initiation complex (eIF4F) formation.	U 0126	36-41	eukaryotic translation initiation factor 2A	Rattus norvegicus	125-134
19715751-10	2009	In contrast, TPA-induced MMP-9 and COX-2 expression was decreased by UO126 (MEK 1/2 inhibitor).	U 0126	69-74	matrix metallopeptidase 9	Homo sapiens	25-30
19715751-10	2009	In contrast, TPA-induced MMP-9 and COX-2 expression was decreased by UO126 (MEK 1/2 inhibitor).	U 0126	69-74	prostaglandin-endoperoxide synthase 2	Homo sapiens	35-40
19715751-10	2009	In contrast, TPA-induced MMP-9 and COX-2 expression was decreased by UO126 (MEK 1/2 inhibitor).	U 0126	69-74	mitogen-activated protein kinase kinase 1	Homo sapiens	76-83
19734941-6	2009	Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13.	U 0126	60-65	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
19734941-6	2009	Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13.	U 0126	60-65	EPH receptor B2	Homo sapiens	26-29
19734941-6	2009	Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13.	U 0126	60-65	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
19734941-6	2009	Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13.	U 0126	60-65	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	120-126
19729613-8	2009	Furthermore, simvastatin and the ERK inhibitor U0126 reversed AngII-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	33-36
19729613-8	2009	Furthermore, simvastatin and the ERK inhibitor U0126 reversed AngII-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells.	U 0126	47-52	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	62-67
18941890-11	2009	Inhibition of Erk1/2 by U0126 (10 microM) decreased p-ser118-ERalpha by 51.7 +/- 8.5% and decreased p-ser167-ERalpha by 41.9 +/- 16.9% whereas inhibition of Akt by LY294002 (20 microM) and wortmannin (500 nM) or by siRNA knock-down, had no effect on p-ser167-ERalpha expression.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	14-20
18941890-11	2009	Inhibition of Erk1/2 by U0126 (10 microM) decreased p-ser118-ERalpha by 51.7 +/- 8.5% and decreased p-ser167-ERalpha by 41.9 +/- 16.9% whereas inhibition of Akt by LY294002 (20 microM) and wortmannin (500 nM) or by siRNA knock-down, had no effect on p-ser167-ERalpha expression.	U 0126	24-29	estrogen receptor 1	Homo sapiens	61-68
18941890-11	2009	Inhibition of Erk1/2 by U0126 (10 microM) decreased p-ser118-ERalpha by 51.7 +/- 8.5% and decreased p-ser167-ERalpha by 41.9 +/- 16.9% whereas inhibition of Akt by LY294002 (20 microM) and wortmannin (500 nM) or by siRNA knock-down, had no effect on p-ser167-ERalpha expression.	U 0126	24-29	estrogen receptor 1	Homo sapiens	109-116
18941890-11	2009	Inhibition of Erk1/2 by U0126 (10 microM) decreased p-ser118-ERalpha by 51.7 +/- 8.5% and decreased p-ser167-ERalpha by 41.9 +/- 16.9% whereas inhibition of Akt by LY294002 (20 microM) and wortmannin (500 nM) or by siRNA knock-down, had no effect on p-ser167-ERalpha expression.	U 0126	24-29	AKT serine/threonine kinase 1	Homo sapiens	157-160
18941890-11	2009	Inhibition of Erk1/2 by U0126 (10 microM) decreased p-ser118-ERalpha by 51.7 +/- 8.5% and decreased p-ser167-ERalpha by 41.9 +/- 16.9% whereas inhibition of Akt by LY294002 (20 microM) and wortmannin (500 nM) or by siRNA knock-down, had no effect on p-ser167-ERalpha expression.	U 0126	24-29	estrogen receptor 1	Homo sapiens	109-116
19616091-6	2009	In addition, the IL-1 beta-induced c-Jun phosphorylation was reduced by pretreatment with U0126 or SP600125.	U 0126	90-95	interleukin 1 beta	Homo sapiens	17-26
19616091-6	2009	In addition, the IL-1 beta-induced c-Jun phosphorylation was reduced by pretreatment with U0126 or SP600125.	U 0126	90-95	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	35-40
19616091-7	2009	IL-1 beta stimulated the transcriptional activity of wild-type MMP-9 promoter in A549 cells, which was inhibited by U0126, SB203580, SP600125, and helenalin.	U 0126	116-121	interleukin 1 beta	Homo sapiens	0-9
19616091-7	2009	IL-1 beta stimulated the transcriptional activity of wild-type MMP-9 promoter in A549 cells, which was inhibited by U0126, SB203580, SP600125, and helenalin.	U 0126	116-121	matrix metallopeptidase 9	Homo sapiens	63-68
19616091-9	2009	Finally, the IL-1 beta-induced MMP-9 expression led to cell migration which was attenuated by pretreatment with U0126, SB203580, SP600125, helenalin, or MMP-2/9 inhibitor.	U 0126	112-117	interleukin 1 beta	Homo sapiens	13-22
19616091-9	2009	Finally, the IL-1 beta-induced MMP-9 expression led to cell migration which was attenuated by pretreatment with U0126, SB203580, SP600125, helenalin, or MMP-2/9 inhibitor.	U 0126	112-117	matrix metallopeptidase 9	Homo sapiens	31-36
19560459-6	2009	In addition, the expression of phosphorylated ERK1/2-pathway-proteins after incubation with GM-CSF and after inhibiting MEK1/2 with U0126 was analyzed.	U 0126	132-137	mitogen-activated protein kinase 3	Mus musculus	46-52
19560459-6	2009	In addition, the expression of phosphorylated ERK1/2-pathway-proteins after incubation with GM-CSF and after inhibiting MEK1/2 with U0126 was analyzed.	U 0126	132-137	mitogen-activated protein kinase kinase 1	Mus musculus	120-126
19560459-13	2009	Concerning signaling pathways, incubation with GM-CSF activates the ERK1/2 pathway, whereas inhibition of MEK1/2 with U0126 strongly decreased the phosphorylation downstream in the ERK1/2 pathway, and the antiapoptotic activity of GM-CSF in vitro.	U 0126	118-123	mitogen-activated protein kinase kinase 1	Mus musculus	106-112
19560459-13	2009	Concerning signaling pathways, incubation with GM-CSF activates the ERK1/2 pathway, whereas inhibition of MEK1/2 with U0126 strongly decreased the phosphorylation downstream in the ERK1/2 pathway, and the antiapoptotic activity of GM-CSF in vitro.	U 0126	118-123	mitogen-activated protein kinase 3	Mus musculus	181-187
19560459-13	2009	Concerning signaling pathways, incubation with GM-CSF activates the ERK1/2 pathway, whereas inhibition of MEK1/2 with U0126 strongly decreased the phosphorylation downstream in the ERK1/2 pathway, and the antiapoptotic activity of GM-CSF in vitro.	U 0126	118-123	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	231-237
20009893-3	2009	After exposure to 17beta-estradiol and/or to the mitogen-activated protein kinase (MAPK) inhibitor U0126 and to the PI3K inhibitor LY294002, the expression of KLK4 in the endometrial cancer cell lines KLE and RL95-2 was detected with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot.	U 0126	99-104	kallikrein related peptidase 4	Homo sapiens	159-163
20009893-7	2009	Quantitative reverse transcriptase PCR and Western blot analysis showed that estrogen can up-regulate the expression of KLK4 in endometrial cancer cell lines KLE and RL95-2, and the up-regulation effect of 17beta-estradiol on KLK4 can be inhibited by U0126 in the 2 endometrial cancer cell lines but not by LY294002.	U 0126	251-256	kallikrein related peptidase 4	Homo sapiens	120-124
19548254-3	2009	The increase in lipolysis with Oligonol was prevented completely by pretreatment with either PD98059 or U0126, selective ERK1/2 inhibitors, which also prevented the reduction in the expression of perilipin protein.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	121-127
19419315-7	2009	U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	7-13
19419315-7	2009	U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1.	U 0126	0-5	matrix Gla protein	Mus musculus	50-53
19419315-7	2009	U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1.	U 0126	0-5	fos-like antigen 1	Mus musculus	58-63
19419315-7	2009	U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	92-98
19419315-7	2009	U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1.	U 0126	0-5	matrix Gla protein	Mus musculus	142-145
19419315-7	2009	U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1.	U 0126	0-5	fos-like antigen 1	Mus musculus	150-155
19812189-10	2009	Addition of the ERK1/2 inhibitor U0126 was associated with dose-dependent inhibition of IL-10 and reciprocal enhancement of IL-12.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	16-22
19812189-10	2009	Addition of the ERK1/2 inhibitor U0126 was associated with dose-dependent inhibition of IL-10 and reciprocal enhancement of IL-12.	U 0126	33-38	interleukin 10	Homo sapiens	88-93
19469685-6	2009	The data further showed that TMT increased phosphorylation of Erk1/2 in the motor cortex as well as the spinal cord injury area, and inhibition of Erk1/2 activity by administration of the MEK1 inhibitors PD98059 and U0126 reduced collateral outgrowth of descending CST axons in TMT animals.	U 0126	216-221	mitogen activated protein kinase 3	Rattus norvegicus	147-153
19469685-6	2009	The data further showed that TMT increased phosphorylation of Erk1/2 in the motor cortex as well as the spinal cord injury area, and inhibition of Erk1/2 activity by administration of the MEK1 inhibitors PD98059 and U0126 reduced collateral outgrowth of descending CST axons in TMT animals.	U 0126	216-221	mitogen activated protein kinase kinase 1	Rattus norvegicus	188-192
19684256-7	2009	However, repeated coadministration of U0126 and morphine into the PAG blocked ERK1/2 phosphorylation and enhanced the development of morphine tolerance.	U 0126	38-43	mitogen activated protein kinase 3	Rattus norvegicus	78-84
19526460-8	2009	Amongst all compounds tested, only the MEK inhibitors U0126 and PD0325901, showed the expected specificity pattern.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
19924065-6	2009	TNF-alpha-induced MMP-9 expression was inhibited by the MEK1/2 specific inhibitor, UO126.	U 0126	83-88	tumor necrosis factor	Homo sapiens	0-9
19723624-3	2009	Here we show that in chronic constriction injury-treated rat spinal cords, up-regulation of SIP30 (SNAP25-interacting protein 30), which is involved in the development and maintenance of chronic constriction injury-induced neuropathic pain, correlates with ERK activation and that the up-regulation of SIP30 is suppressed by intrathecal delivery of the MEK inhibitor U0126.	U 0126	367-372	ZW10 interacting kinetochore protein	Rattus norvegicus	92-97
19723624-3	2009	Here we show that in chronic constriction injury-treated rat spinal cords, up-regulation of SIP30 (SNAP25-interacting protein 30), which is involved in the development and maintenance of chronic constriction injury-induced neuropathic pain, correlates with ERK activation and that the up-regulation of SIP30 is suppressed by intrathecal delivery of the MEK inhibitor U0126.	U 0126	367-372	ZW10 interacting kinetochore protein	Rattus norvegicus	99-128
19723624-3	2009	Here we show that in chronic constriction injury-treated rat spinal cords, up-regulation of SIP30 (SNAP25-interacting protein 30), which is involved in the development and maintenance of chronic constriction injury-induced neuropathic pain, correlates with ERK activation and that the up-regulation of SIP30 is suppressed by intrathecal delivery of the MEK inhibitor U0126.	U 0126	367-372	Eph receptor B1	Rattus norvegicus	257-260
19723624-3	2009	Here we show that in chronic constriction injury-treated rat spinal cords, up-regulation of SIP30 (SNAP25-interacting protein 30), which is involved in the development and maintenance of chronic constriction injury-induced neuropathic pain, correlates with ERK activation and that the up-regulation of SIP30 is suppressed by intrathecal delivery of the MEK inhibitor U0126.	U 0126	367-372	ZW10 interacting kinetochore protein	Rattus norvegicus	302-307
19924065-6	2009	TNF-alpha-induced MMP-9 expression was inhibited by the MEK1/2 specific inhibitor, UO126.	U 0126	83-88	matrix metallopeptidase 9	Homo sapiens	18-23
19924065-6	2009	TNF-alpha-induced MMP-9 expression was inhibited by the MEK1/2 specific inhibitor, UO126.	U 0126	83-88	mitogen-activated protein kinase kinase 1	Homo sapiens	56-62
19589334-11	2009	injection of M3G evoked a definite activation of ERK in the lumbar dorsal spinal cord, which was prevented dose-dependently by U0126, a MAP kinase-ERK inhibitor.	U 0126	127-132	mitogen-activated protein kinase 1	Mus musculus	49-52
19762685-5	2009	Oxidative stress induced by microinjection of angiotensin II into RVLM augmented UCP2 mRNA or protein expression in RVLM, which was antagonized by comicroinjection of NADPH oxidase inhibitor (diphenyleneiodonium chloride), superoxide dismutase mimetic (tempol), or p38 mitogen-activated protein kinase inhibitor (SB203580) but not by extracellular signal-regulated kinase 1/2 inhibitor (U0126).	U 0126	387-392	angiotensinogen	Rattus norvegicus	46-60
19762685-5	2009	Oxidative stress induced by microinjection of angiotensin II into RVLM augmented UCP2 mRNA or protein expression in RVLM, which was antagonized by comicroinjection of NADPH oxidase inhibitor (diphenyleneiodonium chloride), superoxide dismutase mimetic (tempol), or p38 mitogen-activated protein kinase inhibitor (SB203580) but not by extracellular signal-regulated kinase 1/2 inhibitor (U0126).	U 0126	387-392	uncoupling protein 2	Rattus norvegicus	81-85
19615362-6	2009	We confirmed that the p38 MAPK inhibitor SB203580 and ERK inhibitor U0126 suppressed NGF-induced neurite outgrowth of PC12 cells, and found that the inhibitory effects of HA on phosphorylation of ERKs, but not of p38 MAPK, were restored by the anti-RHAMM antibody.	U 0126	68-73	Eph receptor B1	Rattus norvegicus	54-57
19615362-6	2009	We confirmed that the p38 MAPK inhibitor SB203580 and ERK inhibitor U0126 suppressed NGF-induced neurite outgrowth of PC12 cells, and found that the inhibitory effects of HA on phosphorylation of ERKs, but not of p38 MAPK, were restored by the anti-RHAMM antibody.	U 0126	68-73	nerve growth factor	Rattus norvegicus	85-88
19589334-11	2009	injection of M3G evoked a definite activation of ERK in the lumbar dorsal spinal cord, which was prevented dose-dependently by U0126, a MAP kinase-ERK inhibitor.	U 0126	127-132	mitogen-activated protein kinase 1	Mus musculus	147-150
19667405-3	2009	Addition of the specific MEK1/2 inhibitor U0126 resulted in decreased proliferation of neutrophil progenitors.	U 0126	42-47	mitogen-activated protein kinase kinase 1	Homo sapiens	25-31
19631230-8	2009	Inhibition of ERK1/2 kinase with U0126 reduced both cell death and ROS formation, suggesting that ERK1/2 activation is involved in OH-PCB toxicity.	U 0126	33-38	mitogen activated protein kinase 3	Rattus norvegicus	98-104
19631230-8	2009	Inhibition of ERK1/2 kinase with U0126 reduced both cell death and ROS formation, suggesting that ERK1/2 activation is involved in OH-PCB toxicity.	U 0126	33-38	mitogen activated protein kinase 3	Rattus norvegicus	14-20
19577553-9	2009	When the cells were pretreated with inhibitors 5-aza-CdR or U0126 for 24h, the effect of arsenite on ERK1/2, LC3B, Beclin-1 and DAPK proteins expression is suppressed.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	101-107
19703961-10	2009	Inhibition of ERK1/2 by 1 microm U0126 inhibited zint-beta(2)-AR stimulation of I(Ca,L) in +LMN myocytes and LMN myocytes in which cAMP/PKA was inhibited by KT5720.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	14-20
19703961-10	2009	Inhibition of ERK1/2 by 1 microm U0126 inhibited zint-beta(2)-AR stimulation of I(Ca,L) in +LMN myocytes and LMN myocytes in which cAMP/PKA was inhibited by KT5720.	U 0126	33-38	adrenoceptor beta 2	Homo sapiens	54-64
19577553-9	2009	When the cells were pretreated with inhibitors 5-aza-CdR or U0126 for 24h, the effect of arsenite on ERK1/2, LC3B, Beclin-1 and DAPK proteins expression is suppressed.	U 0126	60-65	microtubule associated protein 1 light chain 3 beta	Homo sapiens	109-113
19577553-9	2009	When the cells were pretreated with inhibitors 5-aza-CdR or U0126 for 24h, the effect of arsenite on ERK1/2, LC3B, Beclin-1 and DAPK proteins expression is suppressed.	U 0126	60-65	beclin 1	Homo sapiens	115-123
19577553-9	2009	When the cells were pretreated with inhibitors 5-aza-CdR or U0126 for 24h, the effect of arsenite on ERK1/2, LC3B, Beclin-1 and DAPK proteins expression is suppressed.	U 0126	60-65	death associated protein kinase 1	Homo sapiens	128-132
19625374-5	2009	The MEK/ERK inhibitor U0126 eliminated inhibition by bath LPS but had no effect on inhibition by lumen LPS.	U 0126	22-27	midkine	Mus musculus	4-7
19625374-5	2009	The MEK/ERK inhibitor U0126 eliminated inhibition by bath LPS but had no effect on inhibition by lumen LPS.	U 0126	22-27	mitogen-activated protein kinase 1	Mus musculus	8-11
19669889-8	2009	Furthermore, both wortamannin (PI3K inhibitor) and U0126 (MEK1/2 inhibitor) markedly enhanced EGCG-induced apoptosis during I/R, whereas SP600125 (JNK inhibitor) attenuated the action of EGCG.	U 0126	51-56	mitogen-activated protein kinase kinase 1	Homo sapiens	58-64
19762761-5	2009	U0126 (an ERK kinase inhibitor) was injected twice, an intraneural injection (20 nmol/2 microL) 30 min before PSL, and a perineural injection (20 nmol/10 microL) on Day 1 after PSL.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	10-13
19652666-4	2009	Here, we report that FGF-induced PY of FRS2 can be attenuated by EGF co-stimulation in PC12 cells; this inhibitory effect could be completely reversed by U0126, an inhibitor of MEK.	U 0126	154-159	fibroblast growth factor receptor substrate 2	Rattus norvegicus	39-43
19775283-8	2009	These increases in pCREB and pERK were blocked by U0126 (inhibitor of ERK1/2), which also prevented the increase in passive avoidance task latency time after tanshinone I.	U 0126	50-55	mitogen-activated protein kinase 3	Mus musculus	70-76
19214505-7	2009	The responses were completely inhibited by blocking the ERK1/2 pathway with U0126.	U 0126	76-81	mitogen-activated protein kinase 3	Homo sapiens	56-62
19589865-6	2009	The MAPK kinase-1/2 inhibitor, U0126, fully restored cAMP down-regulation of CCND1, but not cAMP up-regulation of IGFBP1, in hESF of women with vs. without endometriosis.	U 0126	31-36	cyclin D1	Homo sapiens	77-82
19778406-4	2009	However, such decreases were blocked by the pretreatment with two MAPK kinase inhibitors PD98059 and U0126.	U 0126	101-106	MPK14 - putative MAPK	Zea mays	66-70
19443725-8	2009	SB415286 or U0126 (10 microM) suppression of Erk1/2 phosphorylation blocked EGF-induced MKP-1 phosphorylation.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	45-51
19443725-8	2009	SB415286 or U0126 (10 microM) suppression of Erk1/2 phosphorylation blocked EGF-induced MKP-1 phosphorylation.	U 0126	12-17	epidermal growth factor	Homo sapiens	76-79
19443725-8	2009	SB415286 or U0126 (10 microM) suppression of Erk1/2 phosphorylation blocked EGF-induced MKP-1 phosphorylation.	U 0126	12-17	dual specificity phosphatase 1	Homo sapiens	88-93
19475568-5	2009	RGD peptide, alphavbeta3 monoclonal antibody and MAPK kinase (MEK) inhibitors (PD98059 and U0126) but not RAD peptide inhibited the OPN-induced increase of the migration and MMP-9 up-regulation of chondrosarcoma cells.	U 0126	91-96	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
19475568-5	2009	RGD peptide, alphavbeta3 monoclonal antibody and MAPK kinase (MEK) inhibitors (PD98059 and U0126) but not RAD peptide inhibited the OPN-induced increase of the migration and MMP-9 up-regulation of chondrosarcoma cells.	U 0126	91-96	secreted phosphoprotein 1	Homo sapiens	132-135
19893732-9	2009	The antiproliferative effects of TP, MKP-1 siRNA, and vanadate were significantly abolished by U0126, but not by SB203580 or SP600125.	U 0126	95-100	dual specificity phosphatase 1	Mus musculus	37-42
19628634-7	2009	Lansoprazole promoted the phosphorylation of extracellular signal-regulated kinase (ERK), and lansoprazole-induced HO-1 up-regulation was suppressed by U0126, an ERK-specific inhibitor.	U 0126	152-157	Eph receptor B1	Rattus norvegicus	45-82
19540241-10	2009	Finally, we demonstrated that hic-5 upregulation occurs downstream of MEK1/2-ERK1/2 signaling as inhibition of MEK1/2 using U0126 inhibitor completely inhibited hic-5 upregulation by PE.	U 0126	124-129	transforming growth factor beta 1 induced transcript 1	Homo sapiens	30-35
19540241-10	2009	Finally, we demonstrated that hic-5 upregulation occurs downstream of MEK1/2-ERK1/2 signaling as inhibition of MEK1/2 using U0126 inhibitor completely inhibited hic-5 upregulation by PE.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Homo sapiens	70-76
19540241-10	2009	Finally, we demonstrated that hic-5 upregulation occurs downstream of MEK1/2-ERK1/2 signaling as inhibition of MEK1/2 using U0126 inhibitor completely inhibited hic-5 upregulation by PE.	U 0126	124-129	mitogen-activated protein kinase 3	Homo sapiens	77-83
19540241-10	2009	Finally, we demonstrated that hic-5 upregulation occurs downstream of MEK1/2-ERK1/2 signaling as inhibition of MEK1/2 using U0126 inhibitor completely inhibited hic-5 upregulation by PE.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Homo sapiens	111-117
19540241-10	2009	Finally, we demonstrated that hic-5 upregulation occurs downstream of MEK1/2-ERK1/2 signaling as inhibition of MEK1/2 using U0126 inhibitor completely inhibited hic-5 upregulation by PE.	U 0126	124-129	transforming growth factor beta 1 induced transcript 1	Homo sapiens	161-166
19563893-6	2009	Experiments with the MEK inhibitor UO126 suggest involvement of the MAP kinase signal transduction pathway.	U 0126	35-40	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
19628634-7	2009	Lansoprazole promoted the phosphorylation of extracellular signal-regulated kinase (ERK), and lansoprazole-induced HO-1 up-regulation was suppressed by U0126, an ERK-specific inhibitor.	U 0126	152-157	Eph receptor B1	Rattus norvegicus	84-87
19628634-7	2009	Lansoprazole promoted the phosphorylation of extracellular signal-regulated kinase (ERK), and lansoprazole-induced HO-1 up-regulation was suppressed by U0126, an ERK-specific inhibitor.	U 0126	152-157	heme oxygenase 1	Rattus norvegicus	115-119
19628634-7	2009	Lansoprazole promoted the phosphorylation of extracellular signal-regulated kinase (ERK), and lansoprazole-induced HO-1 up-regulation was suppressed by U0126, an ERK-specific inhibitor.	U 0126	152-157	Eph receptor B1	Rattus norvegicus	162-165
19609283-7	2009	The enhancement in growth was associated with the activation of extracellular signal-regulated kinase (ERK) and both these responses were attenuated by the MEK inhibitor U0126.	U 0126	170-175	mitogen-activated protein kinase 1	Homo sapiens	64-101
19609283-7	2009	The enhancement in growth was associated with the activation of extracellular signal-regulated kinase (ERK) and both these responses were attenuated by the MEK inhibitor U0126.	U 0126	170-175	mitogen-activated protein kinase 1	Homo sapiens	103-106
19609283-7	2009	The enhancement in growth was associated with the activation of extracellular signal-regulated kinase (ERK) and both these responses were attenuated by the MEK inhibitor U0126.	U 0126	170-175	mitogen-activated protein kinase kinase 7	Homo sapiens	156-159
19608641-3	2009	EGF increases the phosphorylation of cAMP-responsive element-binding protein (p-CREB) and its association with the coregulator, CCAAT/enhancer binding protein beta, whereas blocking the EGF-induced ERK1/2 phosphorylation with MAPK inhibitors (PD98059/U0126) markedly reduced these effects.	U 0126	251-256	epidermal growth factor	Homo sapiens	0-3
19608641-3	2009	EGF increases the phosphorylation of cAMP-responsive element-binding protein (p-CREB) and its association with the coregulator, CCAAT/enhancer binding protein beta, whereas blocking the EGF-induced ERK1/2 phosphorylation with MAPK inhibitors (PD98059/U0126) markedly reduced these effects.	U 0126	251-256	cAMP responsive element binding protein 1	Homo sapiens	80-84
19608641-3	2009	EGF increases the phosphorylation of cAMP-responsive element-binding protein (p-CREB) and its association with the coregulator, CCAAT/enhancer binding protein beta, whereas blocking the EGF-induced ERK1/2 phosphorylation with MAPK inhibitors (PD98059/U0126) markedly reduced these effects.	U 0126	251-256	CCAAT enhancer binding protein beta	Homo sapiens	128-163
19608641-3	2009	EGF increases the phosphorylation of cAMP-responsive element-binding protein (p-CREB) and its association with the coregulator, CCAAT/enhancer binding protein beta, whereas blocking the EGF-induced ERK1/2 phosphorylation with MAPK inhibitors (PD98059/U0126) markedly reduced these effects.	U 0126	251-256	epidermal growth factor	Homo sapiens	186-189
19788733-16	2009	Treatment of the cells with toxin B-1470 and U0126 significantly reduced bradykinin-induced IL-8 release alone or in combination with the activators of PKA and Epac.	U 0126	45-50	kininogen 1	Homo sapiens	73-83
19712974-4	2009	A pivotal role of PKA was implicated in addition to partial involvement of PKC and ERK1/2 in PACAP-induced VIP gene expression as H-89, Bisindolylmaleimide I (BIS), Go6976 and U0126 attenuated the VIP mRNA expression by 93%, 58%, 58% and 40%, respectively.	U 0126	176-181	adenylate cyclase activating polypeptide 1	Homo sapiens	93-98
19712974-4	2009	A pivotal role of PKA was implicated in addition to partial involvement of PKC and ERK1/2 in PACAP-induced VIP gene expression as H-89, Bisindolylmaleimide I (BIS), Go6976 and U0126 attenuated the VIP mRNA expression by 93%, 58%, 58% and 40%, respectively.	U 0126	176-181	vasoactive intestinal peptide	Homo sapiens	107-110
19712974-8	2009	PACAP also enhanced the FOS gene expression and individual presence of H-89, BIS, Go6976 and U0126 partially attenuated the PACAP induced FOS mRNA expression.	U 0126	93-98	adenylate cyclase activating polypeptide 1	Homo sapiens	0-5
19712974-8	2009	PACAP also enhanced the FOS gene expression and individual presence of H-89, BIS, Go6976 and U0126 partially attenuated the PACAP induced FOS mRNA expression.	U 0126	93-98	adenylate cyclase activating polypeptide 1	Homo sapiens	124-129
19712974-8	2009	PACAP also enhanced the FOS gene expression and individual presence of H-89, BIS, Go6976 and U0126 partially attenuated the PACAP induced FOS mRNA expression.	U 0126	93-98	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	138-141
19615971-4	2009	In contrast, treatment with the selective MEK inhibitor U0126 (but not with the inactive analog U0124) inhibited carbachol-induced p70S6K1 activation, indicating that the MEK/ERK/RSK pathway plays a critical role in p70S6K1 activation in GPCR-stimulated T84 cells.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
19615971-4	2009	In contrast, treatment with the selective MEK inhibitor U0126 (but not with the inactive analog U0124) inhibited carbachol-induced p70S6K1 activation, indicating that the MEK/ERK/RSK pathway plays a critical role in p70S6K1 activation in GPCR-stimulated T84 cells.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	171-174
19615971-4	2009	In contrast, treatment with the selective MEK inhibitor U0126 (but not with the inactive analog U0124) inhibited carbachol-induced p70S6K1 activation, indicating that the MEK/ERK/RSK pathway plays a critical role in p70S6K1 activation in GPCR-stimulated T84 cells.	U 0126	56-61	EPH receptor B2	Homo sapiens	175-178
19615971-4	2009	In contrast, treatment with the selective MEK inhibitor U0126 (but not with the inactive analog U0124) inhibited carbachol-induced p70S6K1 activation, indicating that the MEK/ERK/RSK pathway plays a critical role in p70S6K1 activation in GPCR-stimulated T84 cells.	U 0126	56-61	ribosomal protein S6 kinase A2	Homo sapiens	179-182
19539699-2	2009	In this study, we found that inactivation of Erk1/2 with U0126 in NSCs significantly promoted neuronal differentiation and inhibited proliferation.	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	45-51
19706403-6	2009	Inhibition of ERK1/2 hyperactivity as a result of Q79R expression was achieved by injection of the MAPK/ERK kinase inhibitor U0126 during pregnancy.	U 0126	125-130	mitogen-activated protein kinase 3	Mus musculus	14-20
19706403-6	2009	Inhibition of ERK1/2 hyperactivity as a result of Q79R expression was achieved by injection of the MAPK/ERK kinase inhibitor U0126 during pregnancy.	U 0126	125-130	mitogen-activated protein kinase 1	Mus musculus	99-103
19706403-6	2009	Inhibition of ERK1/2 hyperactivity as a result of Q79R expression was achieved by injection of the MAPK/ERK kinase inhibitor U0126 during pregnancy.	U 0126	125-130	mitogen-activated protein kinase 1	Mus musculus	14-17
19631649-1	2009	It was found that C-reactive protein (CRP) could significantly increase the expression and activity of tissue factor (TF), but decrease that of tissue factor pathway inhibitor (TFPI) in human umbilical vein endothelial cells (HUVECs) in dose- and time-dependent manners, which could be antagonized by PDTC and U0126.	U 0126	310-315	tissue factor pathway inhibitor	Homo sapiens	177-181
19935875-8	2009	The ERK1/2 inhibitor U0126 did not affect contraction, but treatment led to depressed MMP-1, MMP-3, and alpha2 mRNA levels.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	4-10
19775474-9	2009	Testosterone induced ERK and Akt phosphorylation, which could be abrogated by ER-alpha 36 shRNA knockdown or the kinase inhibitors, U0126 and LY294002, and the aromatase inhibitor letrozole.	U 0126	132-137	mitogen-activated protein kinase 1	Homo sapiens	21-24
19775474-9	2009	Testosterone induced ERK and Akt phosphorylation, which could be abrogated by ER-alpha 36 shRNA knockdown or the kinase inhibitors, U0126 and LY294002, and the aromatase inhibitor letrozole.	U 0126	132-137	AKT serine/threonine kinase 1	Homo sapiens	29-32
19505457-9	2009	Blocking of ERK1/2 activation by U0126 (an MKK1/2 inhibitor) lowered Rad51 protein levels and cell viability in emodin-treated H1650 and A549 cells.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	12-18
19505457-9	2009	Blocking of ERK1/2 activation by U0126 (an MKK1/2 inhibitor) lowered Rad51 protein levels and cell viability in emodin-treated H1650 and A549 cells.	U 0126	33-38	mitogen-activated protein kinase kinase 1	Homo sapiens	43-49
19505457-9	2009	Blocking of ERK1/2 activation by U0126 (an MKK1/2 inhibitor) lowered Rad51 protein levels and cell viability in emodin-treated H1650 and A549 cells.	U 0126	33-38	RAD51 recombinase	Homo sapiens	69-74
19788733-16	2009	Treatment of the cells with toxin B-1470 and U0126 significantly reduced bradykinin-induced IL-8 release alone or in combination with the activators of PKA and Epac.	U 0126	45-50	C-X-C motif chemokine ligand 8	Homo sapiens	92-96
19788733-16	2009	Treatment of the cells with toxin B-1470 and U0126 significantly reduced bradykinin-induced IL-8 release alone or in combination with the activators of PKA and Epac.	U 0126	45-50	Rap guanine nucleotide exchange factor 3	Homo sapiens	160-164
19996130-5	2009	Inhibition of upstream kinase MEK1/2 by U0126 partially suppressed RAPA-induced ERK1/2 activation.	U 0126	40-45	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
19467701-5	2009	Catalase (500 and 1000 U/ml) and U0126 (10 and 20 microm, a MEK inhibitor) effectively prevented the BisGMA-induced ERK activation, PGE(2) production and COX-2 expression.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
19467701-5	2009	Catalase (500 and 1000 U/ml) and U0126 (10 and 20 microm, a MEK inhibitor) effectively prevented the BisGMA-induced ERK activation, PGE(2) production and COX-2 expression.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	116-119
19467701-5	2009	Catalase (500 and 1000 U/ml) and U0126 (10 and 20 microm, a MEK inhibitor) effectively prevented the BisGMA-induced ERK activation, PGE(2) production and COX-2 expression.	U 0126	33-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	154-159
19996130-5	2009	Inhibition of upstream kinase MEK1/2 by U0126 partially suppressed RAPA-induced ERK1/2 activation.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	80-86
19522858-11	2009	U0126, an extracellular signal-regulated kinase (ERK) pathway inhibitor, inhibited the up-regulation of MMP-1 by PDGF.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-47
19522858-11	2009	U0126, an extracellular signal-regulated kinase (ERK) pathway inhibitor, inhibited the up-regulation of MMP-1 by PDGF.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	49-52
19522858-11	2009	U0126, an extracellular signal-regulated kinase (ERK) pathway inhibitor, inhibited the up-regulation of MMP-1 by PDGF.	U 0126	0-5	matrix metallopeptidase 1	Homo sapiens	104-109
19522858-12	2009	The synergistic/additive up-regulation of MMP-3 and TIMP-1 was inhibited by U0126 and SB431542, a Smad pathway inhibitor.	U 0126	76-81	matrix metallopeptidase 3	Homo sapiens	42-47
19522858-12	2009	The synergistic/additive up-regulation of MMP-3 and TIMP-1 was inhibited by U0126 and SB431542, a Smad pathway inhibitor.	U 0126	76-81	TIMP metallopeptidase inhibitor 1	Homo sapiens	52-58
19546355-9	2009	Moreover, the translocation of NF-kappaB in nucleus resulted from Ang II was reduced by treatment with U0126.	U 0126	103-108	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	31-40
19427855-4	2009	This dual function of MeCP2 was abolished by the MEK inhibitor U0126.	U 0126	63-68	methyl-CpG binding protein 2	Homo sapiens	22-27
19546355-9	2009	Moreover, the translocation of NF-kappaB in nucleus resulted from Ang II was reduced by treatment with U0126.	U 0126	103-108	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	66-72
19427855-4	2009	This dual function of MeCP2 was abolished by the MEK inhibitor U0126.	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
19559571-10	2009	The HB-EGF-induced eNOS activation was significantly blocked by the p42/p44 MAPK inhibitor U0126 and the phosphatidylinositol 3-kinase (P13K) inhibitor LY294002.	U 0126	91-96	heparin binding EGF like growth factor	Homo sapiens	4-10
19530228-10	2009	In addition, beta-1,4-GalT I production was drastically suppressed by U0126 (ERK inhibitor), SB203580 (p38 inhibitor), or SP600125 (SAPK/JNK inhibitor), which indicated that Schwann cells which regulated beta-1,4-GalT I expression after LPS stimulation were via ERK, SAPK/JNK, and P38 MAP kinase signal pathways.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	77-80
19559571-10	2009	The HB-EGF-induced eNOS activation was significantly blocked by the p42/p44 MAPK inhibitor U0126 and the phosphatidylinositol 3-kinase (P13K) inhibitor LY294002.	U 0126	91-96	cyclin dependent kinase 20	Homo sapiens	68-71
19559571-10	2009	The HB-EGF-induced eNOS activation was significantly blocked by the p42/p44 MAPK inhibitor U0126 and the phosphatidylinositol 3-kinase (P13K) inhibitor LY294002.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	72-80
19559571-12	2009	The HB-EGF-induced VEGF production was blocked by U0126 and LY294002.	U 0126	50-55	heparin binding EGF like growth factor	Homo sapiens	4-10
19559571-12	2009	The HB-EGF-induced VEGF production was blocked by U0126 and LY294002.	U 0126	50-55	vascular endothelial growth factor A	Homo sapiens	19-23
19157634-8	2009	Furthermore, blocking ERK1/2 activation by U0126 (MKK1/2 inhibitor) and knocking down Rad51 expression by transfection with small interfering RNA of Rad51 can enhance the cytotoxicity of celecoxib.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	22-28
19641137-7	2009	However, retrovirus-mediated expression of NFATc1 in pOCs rescued the defect in pOC fusion, despite the presence of U0126 and cyclosporin A.	U 0126	116-121	nuclear factor of activated T cells 1	Homo sapiens	43-49
19549072-4	2009	Western blotting experiments showed that H(3)R-mediated activation of Akt in cultured rat cortical neurons was inhibited by LY 294004 and U0126, suggesting that it depends on phosphoinositide-3-kinase and mitogen-activated protein kinase kinase.	U 0126	138-143	AKT serine/threonine kinase 1	Rattus norvegicus	70-73
19723873-10	2009	The MEK inhibitor U0126 inhibited this phosphorylation and reduced MMP-1 gene induction.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
19653226-7	2009	We also found that U0126, an ERK kinase inhibitor, suppressed the sulforaphane-induced HO-1 expression and nuclear translocation of Nrf2.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	29-32
19653226-7	2009	We also found that U0126, an ERK kinase inhibitor, suppressed the sulforaphane-induced HO-1 expression and nuclear translocation of Nrf2.	U 0126	19-24	heme oxygenase 1	Homo sapiens	87-91
19653226-7	2009	We also found that U0126, an ERK kinase inhibitor, suppressed the sulforaphane-induced HO-1 expression and nuclear translocation of Nrf2.	U 0126	19-24	NFE2 like bZIP transcription factor 2	Homo sapiens	132-136
19723873-10	2009	The MEK inhibitor U0126 inhibited this phosphorylation and reduced MMP-1 gene induction.	U 0126	18-23	matrix metallopeptidase 1	Homo sapiens	67-72
19454529-11	2009	Further, use of the MEK 1/2 inhibitor U0126, which inhibits ER stress-induced autophagy induction and ERK activation, showed that ERK, a MAPK family member, was necessary to the induction of autophagy.	U 0126	38-43	mitogen activated protein kinase kinase 1	Rattus norvegicus	20-27
19454529-11	2009	Further, use of the MEK 1/2 inhibitor U0126, which inhibits ER stress-induced autophagy induction and ERK activation, showed that ERK, a MAPK family member, was necessary to the induction of autophagy.	U 0126	38-43	Eph receptor B1	Rattus norvegicus	102-105
19454529-11	2009	Further, use of the MEK 1/2 inhibitor U0126, which inhibits ER stress-induced autophagy induction and ERK activation, showed that ERK, a MAPK family member, was necessary to the induction of autophagy.	U 0126	38-43	Eph receptor B1	Rattus norvegicus	130-133
19806178-7	2009	Furthermore, inhibition of MAPK/ERK pathway with U0126 prevented viral protein expression in infected cells.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	27-31
19806178-7	2009	Furthermore, inhibition of MAPK/ERK pathway with U0126 prevented viral protein expression in infected cells.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	32-35
19376214-6	2009	Phosphorylated forms of mitogen-activated protein kinases (MAPKs)-including extracellular signal-regulated protein kinase (ERK), c-Jun NH(2)-terminal kinase, and p38-increased after NaF exposure, while treatment with the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 markedly suppressed COX-2 expression.	U 0126	247-252	mitogen-activated protein kinase 1	Homo sapiens	76-121
19581298-5	2009	U0126, at 30 mum, that blocks ERK1/2 signaling selectively attenuated neurite outgrowth induced by NGF and Bt(2)cAMP, but BIX02188 and BIX02189, at 30 mum, that block ERK5 signaling and an ERK5 dominant-negative mutant suppressed only NGF-induced neurite outgrowth.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	30-36
19581298-5	2009	U0126, at 30 mum, that blocks ERK1/2 signaling selectively attenuated neurite outgrowth induced by NGF and Bt(2)cAMP, but BIX02188 and BIX02189, at 30 mum, that block ERK5 signaling and an ERK5 dominant-negative mutant suppressed only NGF-induced neurite outgrowth.	U 0126	0-5	nerve growth factor	Rattus norvegicus	99-102
19581298-5	2009	U0126, at 30 mum, that blocks ERK1/2 signaling selectively attenuated neurite outgrowth induced by NGF and Bt(2)cAMP, but BIX02188 and BIX02189, at 30 mum, that block ERK5 signaling and an ERK5 dominant-negative mutant suppressed only NGF-induced neurite outgrowth.	U 0126	0-5	mitogen-activated protein kinase 7	Rattus norvegicus	167-171
19581298-5	2009	U0126, at 30 mum, that blocks ERK1/2 signaling selectively attenuated neurite outgrowth induced by NGF and Bt(2)cAMP, but BIX02188 and BIX02189, at 30 mum, that block ERK5 signaling and an ERK5 dominant-negative mutant suppressed only NGF-induced neurite outgrowth.	U 0126	0-5	mitogen-activated protein kinase 7	Rattus norvegicus	189-193
19581298-5	2009	U0126, at 30 mum, that blocks ERK1/2 signaling selectively attenuated neurite outgrowth induced by NGF and Bt(2)cAMP, but BIX02188 and BIX02189, at 30 mum, that block ERK5 signaling and an ERK5 dominant-negative mutant suppressed only NGF-induced neurite outgrowth.	U 0126	0-5	nerve growth factor	Rattus norvegicus	235-238
19698189-7	2009	After basal ERK phosphorylation was down-regulated with U0126 in MHCC97-H cells, cellular responsiveness to sorafenib was assessed by cell viability assay.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	12-15
19698189-13	2009	After the basal ERK phosphorylation level in MHCC97-H cells was reduced with U0126, they were significantly less sensitive to sorafenib-mediated growth inhibition, with an IC50 of 17.31 +/- 1.62 microM versus 10.81 +/- 1.24 microM (P = 0.0281).	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	16-19
19533841-8	2009	The induction of follistatin gene expression by GnRH was completely inhibited by H89, a protein kinase A inhibitor, and U0126, a MEK inhibitor.	U 0126	120-125	gonadotropin releasing hormone 1	Mus musculus	48-52
19533841-8	2009	The induction of follistatin gene expression by GnRH was completely inhibited by H89, a protein kinase A inhibitor, and U0126, a MEK inhibitor.	U 0126	120-125	midkine	Mus musculus	129-132
19446581-4	2009	TRH-induced follistatin expression was significantly abrogated in the presence of MEK inhibitor, U0126.	U 0126	97-102	thyrotropin releasing hormone	Rattus norvegicus	0-3
19446581-4	2009	TRH-induced follistatin expression was significantly abrogated in the presence of MEK inhibitor, U0126.	U 0126	97-102	follistatin	Rattus norvegicus	12-23
19501068-9	2009	Also, U0126, a specific MEK inhibitor, was able to protect PC-12 cells from H(2)O(2) exposure, showing that inhibiting ERK phosphorylation is sufficient to provide protection.	U 0126	6-11	Eph receptor B1	Rattus norvegicus	119-122
19501068-10	2009	Cumulatively, these results indicate that Clozapine, N-desmethylclozapine, DETC, and U0126 protect PC-12 cells by blocking the cell-type specific H(2)O(2) induced increase in ERK phosphorylation.	U 0126	85-90	Eph receptor B1	Rattus norvegicus	175-178
19470835-6	2009	Pretreatment with UO126 abolished the combined effects, demonstrating Erk1/2 requirement.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	70-76
19502554-6	2009	Incubation with the MEK1/ERK1/2 inhibitor U-0126 (10 microM) completely abolished the increases in VEGF and thus HIF-1alpha, suggesting the involvement of ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase kinase 1	Homo sapiens	20-24
19502554-6	2009	Incubation with the MEK1/ERK1/2 inhibitor U-0126 (10 microM) completely abolished the increases in VEGF and thus HIF-1alpha, suggesting the involvement of ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase 3	Homo sapiens	25-31
19502554-6	2009	Incubation with the MEK1/ERK1/2 inhibitor U-0126 (10 microM) completely abolished the increases in VEGF and thus HIF-1alpha, suggesting the involvement of ERK1/2 activation.	U 0126	42-48	vascular endothelial growth factor A	Homo sapiens	99-103
19502554-6	2009	Incubation with the MEK1/ERK1/2 inhibitor U-0126 (10 microM) completely abolished the increases in VEGF and thus HIF-1alpha, suggesting the involvement of ERK1/2 activation.	U 0126	42-48	hypoxia inducible factor 1 subunit alpha	Homo sapiens	113-123
19502554-6	2009	Incubation with the MEK1/ERK1/2 inhibitor U-0126 (10 microM) completely abolished the increases in VEGF and thus HIF-1alpha, suggesting the involvement of ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase 3	Homo sapiens	155-161
19125248-6	2009	Treatment of tumor cells with U-0126, an inhibitor of mitogen-activated protein kinase/Erk, also down-regulated the expression of MMP11.	U 0126	30-36	mitogen-activated protein kinase 1	Mus musculus	87-90
19125248-6	2009	Treatment of tumor cells with U-0126, an inhibitor of mitogen-activated protein kinase/Erk, also down-regulated the expression of MMP11.	U 0126	30-36	matrix metallopeptidase 11	Mus musculus	130-135
19481073-5	2009	Induction of Jag1 was efficiently blocked by U0126, a specific inhibitor of MAPK/ERK signaling, indicating a requirement for signaling through this pathway downstream of the FGF receptor.	U 0126	45-50	jagged canonical Notch ligand 1	Rattus norvegicus	13-17
19406941-5	2009	Using selective inhibitors of ERK1/2 (UO126) or Akt phosphorylation (LY294002), we show that the ERK1/2 and Akt cascades are both involved in the hCG- and EGF-dependent proliferation of Leydig cells, but only the ERK1/2 cascade is involved in their antiapoptotic actions.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	30-36
19406941-5	2009	Using selective inhibitors of ERK1/2 (UO126) or Akt phosphorylation (LY294002), we show that the ERK1/2 and Akt cascades are both involved in the hCG- and EGF-dependent proliferation of Leydig cells, but only the ERK1/2 cascade is involved in their antiapoptotic actions.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	97-103
19406941-5	2009	Using selective inhibitors of ERK1/2 (UO126) or Akt phosphorylation (LY294002), we show that the ERK1/2 and Akt cascades are both involved in the hCG- and EGF-dependent proliferation of Leydig cells, but only the ERK1/2 cascade is involved in their antiapoptotic actions.	U 0126	38-43	AKT serine/threonine kinase 1	Homo sapiens	108-111
19406941-5	2009	Using selective inhibitors of ERK1/2 (UO126) or Akt phosphorylation (LY294002), we show that the ERK1/2 and Akt cascades are both involved in the hCG- and EGF-dependent proliferation of Leydig cells, but only the ERK1/2 cascade is involved in their antiapoptotic actions.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	97-103
19478813-6	2009	This CYP11B2 induction was almost completely suppressed by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, whereas olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), only partially suppressed CS-induced CYP11B2 expression and ERK phosphorylation.	U 0126	132-137	cytochrome P450, family 11, subfamily b, polypeptide 2	Rattus norvegicus	5-12
19478813-6	2009	This CYP11B2 induction was almost completely suppressed by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, whereas olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), only partially suppressed CS-induced CYP11B2 expression and ERK phosphorylation.	U 0126	132-137	Eph receptor B1	Rattus norvegicus	77-114
19478813-6	2009	This CYP11B2 induction was almost completely suppressed by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, whereas olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), only partially suppressed CS-induced CYP11B2 expression and ERK phosphorylation.	U 0126	132-137	Eph receptor B1	Rattus norvegicus	116-119
19478813-6	2009	This CYP11B2 induction was almost completely suppressed by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, whereas olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), only partially suppressed CS-induced CYP11B2 expression and ERK phosphorylation.	U 0126	132-137	angiotensinogen	Rattus norvegicus	178-184
19478813-6	2009	This CYP11B2 induction was almost completely suppressed by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, whereas olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), only partially suppressed CS-induced CYP11B2 expression and ERK phosphorylation.	U 0126	132-137	cytochrome P450, family 11, subfamily b, polypeptide 2	Rattus norvegicus	247-254
19478813-6	2009	This CYP11B2 induction was almost completely suppressed by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, whereas olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), only partially suppressed CS-induced CYP11B2 expression and ERK phosphorylation.	U 0126	132-137	Eph receptor B1	Rattus norvegicus	270-273
19205734-10	2009	Combined administration of U0126 (MEK inhibitor) and LY294002 (PI3K inhibitor) significantly enhanced ActD-induced apoptosis in vitro and suppressed xenograft tumor growth in vivo.	U 0126	27-32	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
19415692-6	2009	In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002.	U 0126	114-119	prolactin	Homo sapiens	13-16
19415692-6	2009	In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002.	U 0126	114-119	AKT serine/threonine kinase 1	Homo sapiens	46-49
19436314-9	2009	U0126, an ERK MAPK antagonist, also maintained cerebrovasodilation post H/I.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
19436314-10	2009	Neuronal degeneration in CA1 hippocampus after H/I was not improved by tPA, but was ameliorated by RBC-tPA and U0126.	U 0126	111-116	carbonic anhydrase 1	Homo sapiens	25-28
19454577-10	2009	The contribution of an ERK1/ERK2-mediated signaling pathway was identified by detecting NGF-dependent phosphorylation of these proteins and by blocking their activity with the inhibitor U0126.	U 0126	186-191	mitogen-activated protein kinase 3	Homo sapiens	23-27
19454577-10	2009	The contribution of an ERK1/ERK2-mediated signaling pathway was identified by detecting NGF-dependent phosphorylation of these proteins and by blocking their activity with the inhibitor U0126.	U 0126	186-191	mitogen-activated protein kinase 1	Homo sapiens	28-32
19778377-3	2009	Insulin increased the interaction between pY19-caveolin-2 and phospho-ERK, and that interaction was inhibited by a MEK inhibitor U0126.	U 0126	129-134	insulin	Homo sapiens	0-7
19778377-3	2009	Insulin increased the interaction between pY19-caveolin-2 and phospho-ERK, and that interaction was inhibited by a MEK inhibitor U0126.	U 0126	129-134	caveolin 2	Homo sapiens	47-57
19778377-3	2009	Insulin increased the interaction between pY19-caveolin-2 and phospho-ERK, and that interaction was inhibited by a MEK inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase 1	Homo sapiens	70-73
19778377-3	2009	Insulin increased the interaction between pY19-caveolin-2 and phospho-ERK, and that interaction was inhibited by a MEK inhibitor U0126.	U 0126	129-134	mitogen-activated protein kinase kinase 7	Homo sapiens	115-118
19778377-5	2009	Insulin relocalized phospho-ERK and pY19-caveolin-2 to the nucleus and their nuclear co-localization was impaired by U0126.	U 0126	117-122	insulin	Homo sapiens	0-7
19778377-5	2009	Insulin relocalized phospho-ERK and pY19-caveolin-2 to the nucleus and their nuclear co-localization was impaired by U0126.	U 0126	117-122	mitogen-activated protein kinase 1	Homo sapiens	28-31
19778377-5	2009	Insulin relocalized phospho-ERK and pY19-caveolin-2 to the nucleus and their nuclear co-localization was impaired by U0126.	U 0126	117-122	caveolin 2	Homo sapiens	41-51
19423651-6	2009	Furthermore, EGF treatments enhanced miR-206 levels in MCF-7 cells and ERalpha-negative, EGFR-positive MDA-MB-231 cells, whereas EGFR small interfering RNA, or PD153035, an EGFR inhibitor, or U0126, a MAPK kinase inhibitor, significantly reduced miR-206 levels in MDA-MB-231 cells.	U 0126	192-197	epidermal growth factor	Homo sapiens	13-16
19671683-8	2009	Blocking the activations of ERK1/2 and AKT by MKK1/2 inhibitor (U0126) and phosphoinositide 3-kinase inhibitor (wortmannin) suppressed the expression of Rad51 and enhanced the erlotinib-induced cell death in erlotinib-resistant cells.	U 0126	64-69	mitogen-activated protein kinase 3	Homo sapiens	28-34
19671683-8	2009	Blocking the activations of ERK1/2 and AKT by MKK1/2 inhibitor (U0126) and phosphoinositide 3-kinase inhibitor (wortmannin) suppressed the expression of Rad51 and enhanced the erlotinib-induced cell death in erlotinib-resistant cells.	U 0126	64-69	AKT serine/threonine kinase 1	Homo sapiens	39-42
19671683-8	2009	Blocking the activations of ERK1/2 and AKT by MKK1/2 inhibitor (U0126) and phosphoinositide 3-kinase inhibitor (wortmannin) suppressed the expression of Rad51 and enhanced the erlotinib-induced cell death in erlotinib-resistant cells.	U 0126	64-69	mitogen-activated protein kinase kinase 1	Homo sapiens	46-52
19671683-8	2009	Blocking the activations of ERK1/2 and AKT by MKK1/2 inhibitor (U0126) and phosphoinositide 3-kinase inhibitor (wortmannin) suppressed the expression of Rad51 and enhanced the erlotinib-induced cell death in erlotinib-resistant cells.	U 0126	64-69	RAD51 recombinase	Homo sapiens	153-158
19726282-0	2009	[Effect of MAPK signal transduction pathway inhibitor U0126 on aquaporin 4 expression in alveolar type II cells in rats with oleic acid-induced acute lung injury].	U 0126	54-59	aquaporin 4	Rattus norvegicus	63-74
19726282-8	2009	RT-PCR demonstrated significantly increased AQP-4 mRNA expression in ALI group as compared with that in the normal control group, and U0126 treatment resulted in obvious reduction in AQP-4 mRNA expression in the U0126 treatment group.	U 0126	134-139	aquaporin 4	Rattus norvegicus	183-188
19726282-8	2009	RT-PCR demonstrated significantly increased AQP-4 mRNA expression in ALI group as compared with that in the normal control group, and U0126 treatment resulted in obvious reduction in AQP-4 mRNA expression in the U0126 treatment group.	U 0126	212-217	aquaporin 4	Rattus norvegicus	183-188
19379716-4	2009	The ERK kinase (MEK)1/2 inhibitor U-0126 and p38MAPK inhibitor SB203580 blocked HMGB1 release in response to OGD.	U 0126	34-40	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-23
19501039-8	2009	MEK inhibitors, PD98059 and U-0126, which inhibited ERK phosphorylation were shown to elevate 15-PGDH levels very significantly.	U 0126	28-34	carbonyl reductase 1	Homo sapiens	94-101
19409881-4	2009	EGF increased p-ERK1/2 levels, which were inhibited by U0126, a MEK inhibitor.	U 0126	55-60	epidermal growth factor	Canis lupus familiaris	0-3
19409881-4	2009	EGF increased p-ERK1/2 levels, which were inhibited by U0126, a MEK inhibitor.	U 0126	55-60	mitogen-activated protein kinase 1	Canis lupus familiaris	16-22
19409881-7	2009	EGF increased Sp1 expression within 1h, which was inhibited by U0126.	U 0126	63-68	epidermal growth factor	Canis lupus familiaris	0-3
19359388-5	2009	Progesterone-induced proliferation was not dependent on conversion to metabolites and was antagonized by the ERK(1/2) inhibitor UO126.	U 0126	128-133	mitogen activated protein kinase 3	Rattus norvegicus	109-116
19447102-5	2009	In addition, we found that treatment of the cells with extracellular signal-regulated kinase (ERK) inhibitor (U0126) reduced lindenenyl acetate-induced HO-1 expression.	U 0126	110-115	mitogen-activated protein kinase 1	Mus musculus	55-92
19447102-5	2009	In addition, we found that treatment of the cells with extracellular signal-regulated kinase (ERK) inhibitor (U0126) reduced lindenenyl acetate-induced HO-1 expression.	U 0126	110-115	mitogen-activated protein kinase 1	Mus musculus	94-97
19288493-6	2009	Moreover, U0126-induced MEK inhibition did not induce apoptosis in any cell line, reinforcing the hypothesis of a MEK/ERK-independent mechanism of sorafenib activity.	U 0126	10-15	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
19533291-4	2009	SC-1 alone induced neuronal differentiation through extracellular signal-regulated kinase (ERK) 1/2 activation that is essential for nerve growth factor (NGF)-induced neuronal differentiation, as shown by the suppression with MEK1/2 inhibitors, PD98059 and U0126.	U 0126	257-262	mitogen activated protein kinase 3	Rattus norvegicus	52-99
19357132-7	2009	Because Bi and U0126, an inhibitor of the MAP kinase kinases 1 and 2 (MAP2K1/2), abolished testosterone actions on MAPK3/1 and PTGS2, our studies suggest that testosterone directly induces PTGS2/PGF(2alpha) in hamster Leydig cells via androgen receptors and a non-classical mechanism that involves MAPK3/1 activation.	U 0126	15-20	prostaglandin G/H synthase 2	Mesocricetus auratus	127-132
19357132-7	2009	Because Bi and U0126, an inhibitor of the MAP kinase kinases 1 and 2 (MAP2K1/2), abolished testosterone actions on MAPK3/1 and PTGS2, our studies suggest that testosterone directly induces PTGS2/PGF(2alpha) in hamster Leydig cells via androgen receptors and a non-classical mechanism that involves MAPK3/1 activation.	U 0126	15-20	prostaglandin G/H synthase 2	Mesocricetus auratus	189-194
19614922-10	2009	Inhibitors of the mitogen-activated protein kinases MEK/ERK1/2 (PD98059 and U0126), and p38 (SB203580) attenuated HGF-induced keratinocyte in vitro scratch-wound healing.	U 0126	76-81	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
19614922-10	2009	Inhibitors of the mitogen-activated protein kinases MEK/ERK1/2 (PD98059 and U0126), and p38 (SB203580) attenuated HGF-induced keratinocyte in vitro scratch-wound healing.	U 0126	76-81	hepatocyte growth factor	Homo sapiens	114-117
19406746-7	2009	Suppressing cellular MAPK by silencing ERK1/2 or by treatment with U0126, a MAPK inhibitor, partially blocked the escalation of HIF-1 activity resulting from SMG-1 deficiency in hypoxic cells.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	21-25
19406746-7	2009	Suppressing cellular MAPK by silencing ERK1/2 or by treatment with U0126, a MAPK inhibitor, partially blocked the escalation of HIF-1 activity resulting from SMG-1 deficiency in hypoxic cells.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	76-80
19406746-7	2009	Suppressing cellular MAPK by silencing ERK1/2 or by treatment with U0126, a MAPK inhibitor, partially blocked the escalation of HIF-1 activity resulting from SMG-1 deficiency in hypoxic cells.	U 0126	67-72	hypoxia inducible factor 1 subunit alpha	Homo sapiens	128-133
19478560-7	2009	Taken together this suggests that (a) simultaneous activation of PI-3K and MEK is required to ensure cellular senescence and (b) U0126 and LY294002 suppress senescence via the rapamycin-sensitive pathway.	U 0126	129-134	mitogen-activated protein kinase kinase 7	Homo sapiens	75-78
19491261-4	2009	The rapid decrease in AR was not due to increased AR protein degradation and was not blocked by phosphatidylinositol 3-kinase (LY294002) or MEK (UO126) inhibitors.	U 0126	145-150	androgen receptor	Homo sapiens	22-24
19274665-9	2009	We observed ERK kinase inhibitor, U0126, but not phosphatidylinositol 3-kinase (PI-3K), LY294002, or protein kinase A (PKA) inhibitor, H-89, inhibited stromal CM or androgen-induced PSA promoter luciferase activities, and anchorage-independent growth of LNCaP cells.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	12-15
19494320-8	2009	The ERK inhibitor U0126 blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln"s protective activity against endotoxic shock.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	4-7
19494320-8	2009	The ERK inhibitor U0126 blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln"s protective activity against endotoxic shock.	U 0126	18-23	dual specificity phosphatase 1	Mus musculus	44-49
19497125-5	2009	The specific MEK1/2 inhibitor U0126, given intraperitoneal zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 +/- 2% and 14.6 +/- 3%, respectively; P &lt; 0.05), improved neurological function, normalized expression of phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls.	U 0126	30-35	mitogen activated protein kinase kinase 1	Rattus norvegicus	13-19
19497125-5	2009	The specific MEK1/2 inhibitor U0126, given intraperitoneal zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 +/- 2% and 14.6 +/- 3%, respectively; P &lt; 0.05), improved neurological function, normalized expression of phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls.	U 0126	30-35	mitogen activated protein kinase 3	Rattus norvegicus	272-278
19497125-5	2009	The specific MEK1/2 inhibitor U0126, given intraperitoneal zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 +/- 2% and 14.6 +/- 3%, respectively; P &lt; 0.05), improved neurological function, normalized expression of phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls.	U 0126	30-35	matrix metallopeptidase 9	Rattus norvegicus	306-311
19497125-5	2009	The specific MEK1/2 inhibitor U0126, given intraperitoneal zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 +/- 2% and 14.6 +/- 3%, respectively; P &lt; 0.05), improved neurological function, normalized expression of phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls.	U 0126	30-35	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	316-322
19297452-9	2009	The MAPK 1/2 inhibitor U0126 also blocks the effect of TGF-alpha or EGF on ENaC, indicating that the MAPK1/2 pathway is involved in the TGF-alpha- or EGF-induced inhibition of ENaC.	U 0126	23-28	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	4-10
19297452-9	2009	The MAPK 1/2 inhibitor U0126 also blocks the effect of TGF-alpha or EGF on ENaC, indicating that the MAPK1/2 pathway is involved in the TGF-alpha- or EGF-induced inhibition of ENaC.	U 0126	23-28	transforming growth factor alpha L homeolog	Xenopus laevis	55-64
19297452-9	2009	The MAPK 1/2 inhibitor U0126 also blocks the effect of TGF-alpha or EGF on ENaC, indicating that the MAPK1/2 pathway is involved in the TGF-alpha- or EGF-induced inhibition of ENaC.	U 0126	23-28	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	101-106
19297452-9	2009	The MAPK 1/2 inhibitor U0126 also blocks the effect of TGF-alpha or EGF on ENaC, indicating that the MAPK1/2 pathway is involved in the TGF-alpha- or EGF-induced inhibition of ENaC.	U 0126	23-28	transforming growth factor alpha L homeolog	Xenopus laevis	136-145
19297452-11	2009	Pretreatment of the cells with U0126 potentiates the acute TGF-alpha- or EGF-induced stimulation of ENaC.	U 0126	31-36	transforming growth factor alpha L homeolog	Xenopus laevis	59-68
19233864-6	2009	In addition, the ATPgammaS-stimulated cPLA2 expression was inhibited by U0126, SB202190, helenalin, celecoxib (a selective COX-2 inhibitor), and PGE2 receptor antagonists (AH6809, GW627368X, and SC-19220).	U 0126	72-77	phospholipase A2 group IVA	Rattus norvegicus	38-43
19385051-12	2009	On the other hand, EGF-induced MMP-9 expression was decreased by the MEK1/2 inhibitor,UO126.	U 0126	86-91	epidermal growth factor	Homo sapiens	19-22
19385051-12	2009	On the other hand, EGF-induced MMP-9 expression was decreased by the MEK1/2 inhibitor,UO126.	U 0126	86-91	matrix metallopeptidase 9	Homo sapiens	31-36
19385051-12	2009	On the other hand, EGF-induced MMP-9 expression was decreased by the MEK1/2 inhibitor,UO126.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	69-75
19395858-6	2009	However, pretreatment with UO126 protected from SNP-mediated cell death including counteracting apoptosis-associated Bax expression and PARP cleavage, plus reversing loss of Cu,Zn-SOD.	U 0126	27-32	BCL2 associated X, apoptosis regulator	Homo sapiens	117-120
19395858-6	2009	However, pretreatment with UO126 protected from SNP-mediated cell death including counteracting apoptosis-associated Bax expression and PARP cleavage, plus reversing loss of Cu,Zn-SOD.	U 0126	27-32	poly(ADP-ribose) polymerase 1	Homo sapiens	136-140
19631649-1	2009	It was found that C-reactive protein (CRP) could significantly increase the expression and activity of tissue factor (TF), but decrease that of tissue factor pathway inhibitor (TFPI) in human umbilical vein endothelial cells (HUVECs) in dose- and time-dependent manners, which could be antagonized by PDTC and U0126.	U 0126	310-315	C-reactive protein	Homo sapiens	18-36
19631649-1	2009	It was found that C-reactive protein (CRP) could significantly increase the expression and activity of tissue factor (TF), but decrease that of tissue factor pathway inhibitor (TFPI) in human umbilical vein endothelial cells (HUVECs) in dose- and time-dependent manners, which could be antagonized by PDTC and U0126.	U 0126	310-315	C-reactive protein	Homo sapiens	38-41
19502238-7	2009	Inhibition of Erk1/2 phosphorylation by the chemical inhibitor U0126 suppressed the cytolytic activity of NK92 cells, but had no effect on NK-target conjugate formation.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	14-20
19131643-10	2009	IGFBP-5-induced migration was blocked by the MEK1/2 inhibitor U0126, suggesting that IGFBP-5-induced migration occurs via MAPK activation.	U 0126	62-67	insulin like growth factor binding protein 5	Homo sapiens	0-7
19131643-10	2009	IGFBP-5-induced migration was blocked by the MEK1/2 inhibitor U0126, suggesting that IGFBP-5-induced migration occurs via MAPK activation.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Homo sapiens	45-51
19131643-10	2009	IGFBP-5-induced migration was blocked by the MEK1/2 inhibitor U0126, suggesting that IGFBP-5-induced migration occurs via MAPK activation.	U 0126	62-67	insulin like growth factor binding protein 5	Homo sapiens	85-92
19531642-7	2009	In association with the facilitated RS-induced SRP, an intrathecal beta-estradiol injection elicited ERK1/2 and NR2B subunit phosphorylation that were both reversed by intrathecal roscovitine and U-0126.	U 0126	196-202	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	112-116
19820359-5	2009	Membrane type 1 matrix metalloproteinase induction was blocked by mitogen-activated protein kinase or extracellular signal-regulated kinase inhibitors PD98059 and U0126 but not by phosphatidylinositol-3 kinase (PI3-K) inhibitors LY294002 and wortmannin.	U 0126	163-168	matrix metallopeptidase 14	Homo sapiens	0-40
19820359-6	2009	Interestingly, the mitogen-activated protein kinase or extracellular signal-regulated kinase inhibitors PD98059 and U0126 actually increased MMP-2 mRNA and protein synthesis, whereas the PI3-K inhibitors LY294002 and wortmannin further suppressed the expression of MMP-2.	U 0126	116-121	matrix metallopeptidase 2	Homo sapiens	141-146
19820359-6	2009	Interestingly, the mitogen-activated protein kinase or extracellular signal-regulated kinase inhibitors PD98059 and U0126 actually increased MMP-2 mRNA and protein synthesis, whereas the PI3-K inhibitors LY294002 and wortmannin further suppressed the expression of MMP-2.	U 0126	116-121	matrix metallopeptidase 2	Homo sapiens	265-270
19672022-8	2009	MAPK/ERK kinase inhibitors (PD98059, U0126), but not the JNK inhibitor (SP600125) or p38 inhibitor (SB203580), significantly inhibited promoter activation by HG.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	0-4
19399830-5	2009	Pretreated of JJ012 cells with MAPK kinase (MEK) inhibitors PD98059 or U0126 inhibited the GDNF-mediated migration and integrin expression.	U 0126	71-76	mitogen-activated protein kinase kinase 7	Homo sapiens	44-47
19399830-5	2009	Pretreated of JJ012 cells with MAPK kinase (MEK) inhibitors PD98059 or U0126 inhibited the GDNF-mediated migration and integrin expression.	U 0126	71-76	glial cell derived neurotrophic factor	Homo sapiens	91-95
19399830-9	2009	Furthermore, the GDNF-mediated increasing of kappaB-luciferase activity was inhibited by PD98059, U0126, PDTC and TPCK or MEK, ERK, IKKalpha, and IKKbeta mutants.	U 0126	98-103	glial cell derived neurotrophic factor	Homo sapiens	17-21
19415692-4	2009	Pre-treatment of macrophages with SB203580, a specific inhibitor of the mitogen-activated kinases (MAPK) p38, or with U0126, an inhibitor of MAPK p44/42, prevented both basal and exogenous PRL-mediated CHIT-1 expression.	U 0126	118-123	interferon induced protein 44	Homo sapiens	146-149
19415692-4	2009	Pre-treatment of macrophages with SB203580, a specific inhibitor of the mitogen-activated kinases (MAPK) p38, or with U0126, an inhibitor of MAPK p44/42, prevented both basal and exogenous PRL-mediated CHIT-1 expression.	U 0126	118-123	prolactin	Homo sapiens	189-192
19415692-4	2009	Pre-treatment of macrophages with SB203580, a specific inhibitor of the mitogen-activated kinases (MAPK) p38, or with U0126, an inhibitor of MAPK p44/42, prevented both basal and exogenous PRL-mediated CHIT-1 expression.	U 0126	118-123	chitinase 1	Homo sapiens	202-208
19712552-6	2009	The leptin-promoted GVBD and first polar body extrusion were blocked by a mitogen-activated protein kinase extracellular signal regulated kinase kinases (MEK)1/2 inhibitor, U0126, but not its inactive analogue U0124.	U 0126	173-178	mitogen-activated protein kinase kinase 1	Mus musculus	107-161
19641115-6	2009	Smad2/3 phosphorylation increased following treatment with TGFbeta1, ethanol, and PD98059 (or U0126) plus ethanol.	U 0126	94-99	SMAD family member 2	Rattus norvegicus	0-5
19575782-8	2009	The ET-1-induced activation of ERK1/2 was completely abolished by MEK1/2 inhibitors U0126 and SL327, and partially inhibited by the MEK1 inhibitor PD98059.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	31-37
19575782-8	2009	The ET-1-induced activation of ERK1/2 was completely abolished by MEK1/2 inhibitors U0126 and SL327, and partially inhibited by the MEK1 inhibitor PD98059.	U 0126	84-89	mitogen-activated protein kinase kinase 1	Homo sapiens	66-72
19575782-8	2009	The ET-1-induced activation of ERK1/2 was completely abolished by MEK1/2 inhibitors U0126 and SL327, and partially inhibited by the MEK1 inhibitor PD98059.	U 0126	84-89	mitogen-activated protein kinase kinase 1	Homo sapiens	66-70
19419999-3	2009	The MEK/ERK inhibitor U0126 abolished phosphorylation of NHE1 and p90(RSK) as well as ERK1/2.	U 0126	22-27	Eph receptor B1	Rattus norvegicus	8-11
19419999-3	2009	The MEK/ERK inhibitor U0126 abolished phosphorylation of NHE1 and p90(RSK) as well as ERK1/2.	U 0126	22-27	solute carrier family 9 member A1	Rattus norvegicus	57-61
19419999-3	2009	The MEK/ERK inhibitor U0126 abolished phosphorylation of NHE1 and p90(RSK) as well as ERK1/2.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	86-92
19443747-7	2009	U-0126, which blocks enzymes immediately upstream of ERK, affected sensitivity to both agonists equally between control and HLU.	U 0126	0-6	Eph receptor B1	Rattus norvegicus	53-56
19377096-2	2009	In this report, we demonstrate that 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), a selective inhibitor of mitogen-activated protein kinase kinase (MEK), significantly enhances the cytotoxicity of CA4 in BEL-7402 cells, independently of MEK inhibition.	U 0126	90-95	mitogen-activated protein kinase kinase 7	Homo sapiens	123-162
19377096-2	2009	In this report, we demonstrate that 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), a selective inhibitor of mitogen-activated protein kinase kinase (MEK), significantly enhances the cytotoxicity of CA4 in BEL-7402 cells, independently of MEK inhibition.	U 0126	90-95	mitogen-activated protein kinase kinase 7	Homo sapiens	164-167
19377096-2	2009	In this report, we demonstrate that 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), a selective inhibitor of mitogen-activated protein kinase kinase (MEK), significantly enhances the cytotoxicity of CA4 in BEL-7402 cells, independently of MEK inhibition.	U 0126	90-95	carbonic anhydrase 4	Homo sapiens	213-216
19377096-2	2009	In this report, we demonstrate that 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), a selective inhibitor of mitogen-activated protein kinase kinase (MEK), significantly enhances the cytotoxicity of CA4 in BEL-7402 cells, independently of MEK inhibition.	U 0126	90-95	mitogen-activated protein kinase kinase 7	Homo sapiens	253-256
19377096-3	2009	This independence is evidenced by the fact that another, more specific MEK inhibitor, PD0325901 [N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-[2-fluoro-4-iodo-phenylamino]-benzamide], does not have the same effect as U0126.	U 0126	217-222	mitogen-activated protein kinase kinase 7	Homo sapiens	71-74
19377096-5	2009	U0126, but not PD0325901, inhibits CA4 glucuronidation, thereby blocking microtubule reassembly and enhancing CA4-induced G(2)/M cell-cycle arrest.	U 0126	0-5	carbonic anhydrase 4	Homo sapiens	35-38
19377096-5	2009	U0126, but not PD0325901, inhibits CA4 glucuronidation, thereby blocking microtubule reassembly and enhancing CA4-induced G(2)/M cell-cycle arrest.	U 0126	0-5	carbonic anhydrase 4	Homo sapiens	110-113
19377096-6	2009	Consistent with this, U0126 significantly enhances CA4-induced cytotoxicity for cells in which CA4 glucuronidation occurs, but not for cells in which such glucuronidation does not occur.	U 0126	22-27	carbonic anhydrase 4	Homo sapiens	51-54
19377096-6	2009	Consistent with this, U0126 significantly enhances CA4-induced cytotoxicity for cells in which CA4 glucuronidation occurs, but not for cells in which such glucuronidation does not occur.	U 0126	22-27	carbonic anhydrase 4	Homo sapiens	95-98
21475874-9	2009	U0126 is an inhibitor of MEK, which is an upstream activator for ERK.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
21475874-9	2009	U0126 is an inhibitor of MEK, which is an upstream activator for ERK.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	65-68
19425605-7	2009	Inclusion of the PPARalpha inhibitor, MK-886, or MAPK inhibitor, U0126, completely blocks the LAPL-induced apoA-I and HL accumulation in the media.	U 0126	65-70	apolipoprotein A1	Homo sapiens	107-113
19425605-7	2009	Inclusion of the PPARalpha inhibitor, MK-886, or MAPK inhibitor, U0126, completely blocks the LAPL-induced apoA-I and HL accumulation in the media.	U 0126	65-70	lipase C, hepatic type	Homo sapiens	118-120
19912689-3	2009	RESULTS: ERK inhibitor U0126 inhibited the expression of the c-Met in HBx-transfected HepG2 cells.	U 0126	23-28	mitogen-activated protein kinase 1	Homo sapiens	9-12
19912689-3	2009	RESULTS: ERK inhibitor U0126 inhibited the expression of the c-Met in HBx-transfected HepG2 cells.	U 0126	23-28	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	61-66
19912689-3	2009	RESULTS: ERK inhibitor U0126 inhibited the expression of the c-Met in HBx-transfected HepG2 cells.	U 0126	23-28	X protein	Hepatitis B virus	70-73
19912689-5	2009	Furthermore, the ERK inhibitor U0126 also inhibited the invasiveness of HBX-transfected HepG2 cells.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	17-20
19912689-5	2009	Furthermore, the ERK inhibitor U0126 also inhibited the invasiveness of HBX-transfected HepG2 cells.	U 0126	31-36	X protein	Hepatitis B virus	72-75
19411256-10	2009	Inhibition of pERK by the pharmacological inhibitor U0126 specifically blocks KLF5-induced MKP-1 phosphorylation and stabilization.	U 0126	52-57	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	14-18
19411256-10	2009	Inhibition of pERK by the pharmacological inhibitor U0126 specifically blocks KLF5-induced MKP-1 phosphorylation and stabilization.	U 0126	52-57	Kruppel like factor 5	Homo sapiens	78-82
19411256-10	2009	Inhibition of pERK by the pharmacological inhibitor U0126 specifically blocks KLF5-induced MKP-1 phosphorylation and stabilization.	U 0126	52-57	dual specificity phosphatase 1	Homo sapiens	91-96
19428337-3	2009	In the present study we could elucidate the role of extracellular signal-related MAPK in the murine model of LPS-induced acute lung injury by using U0126, a specific inhibitor of MEK1/2, upstream kinases of ERK.	U 0126	148-153	mitogen-activated protein kinase 1	Mus musculus	81-85
19428337-3	2009	In the present study we could elucidate the role of extracellular signal-related MAPK in the murine model of LPS-induced acute lung injury by using U0126, a specific inhibitor of MEK1/2, upstream kinases of ERK.	U 0126	148-153	mitogen-activated protein kinase kinase 1	Mus musculus	179-185
19428337-3	2009	In the present study we could elucidate the role of extracellular signal-related MAPK in the murine model of LPS-induced acute lung injury by using U0126, a specific inhibitor of MEK1/2, upstream kinases of ERK.	U 0126	148-153	mitogen-activated protein kinase 1	Mus musculus	207-210
19428337-4	2009	Phosphorylation of ERK was inhibited by U0126 in vivo as well as in vitro.	U 0126	40-45	mitogen-activated protein kinase 1	Mus musculus	19-22
19428337-5	2009	In freshly isolated human peripheral blood mononuclear cells U0126 dose-dependently blocked the release of IL-2 and TNF-alpha.	U 0126	61-66	interleukin 2	Homo sapiens	107-111
19428337-5	2009	In freshly isolated human peripheral blood mononuclear cells U0126 dose-dependently blocked the release of IL-2 and TNF-alpha.	U 0126	61-66	tumor necrosis factor	Homo sapiens	116-125
19428337-8	2009	Pretreatment of mice with U0126 significantly reduced lung neutrophilia and diminished levels of TNF-alpha and chemotactic MIP-2 and KC in bronchoalveolar fluid.	U 0126	26-31	tumor necrosis factor	Mus musculus	97-106
19428337-8	2009	Pretreatment of mice with U0126 significantly reduced lung neutrophilia and diminished levels of TNF-alpha and chemotactic MIP-2 and KC in bronchoalveolar fluid.	U 0126	26-31	chemokine (C-X-C motif) ligand 2	Mus musculus	123-128
19428337-10	2009	Histological examination of lung tissues revealed that ERK MAPK inhibition using U0126 efficiently attenuated LPS-induced pulmonary inflammatory responses.	U 0126	81-86	mitogen-activated protein kinase 1	Mus musculus	55-58
19428337-10	2009	Histological examination of lung tissues revealed that ERK MAPK inhibition using U0126 efficiently attenuated LPS-induced pulmonary inflammatory responses.	U 0126	81-86	mitogen-activated protein kinase 1	Mus musculus	59-63
19560630-10	2009	MEK 1/2 inhibitor, U-0126 inhibited Ang II response and its potentiation by ethanol.	U 0126	19-25	mitogen activated protein kinase kinase 1	Rattus norvegicus	0-7
19560630-10	2009	MEK 1/2 inhibitor, U-0126 inhibited Ang II response and its potentiation by ethanol.	U 0126	19-25	angiotensinogen	Rattus norvegicus	36-42
19376214-6	2009	Phosphorylated forms of mitogen-activated protein kinases (MAPKs)-including extracellular signal-regulated protein kinase (ERK), c-Jun NH(2)-terminal kinase, and p38-increased after NaF exposure, while treatment with the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 markedly suppressed COX-2 expression.	U 0126	247-252	C-X-C motif chemokine ligand 8	Homo sapiens	182-185
19376214-6	2009	Phosphorylated forms of mitogen-activated protein kinases (MAPKs)-including extracellular signal-regulated protein kinase (ERK), c-Jun NH(2)-terminal kinase, and p38-increased after NaF exposure, while treatment with the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 markedly suppressed COX-2 expression.	U 0126	247-252	mitogen-activated protein kinase 1	Homo sapiens	59-63
19258520-3	2009	In the present study, we employed small-molecule MAPK kinase (MEK) inhibitors, including U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene] and PD184161 (Neoplasia 8:1-8, 2006), in HepG2 and Hep3B human HCC cell lines to identify potential mechanism(s) of resistance.	U 0126	89-94	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
19424591-7	2009	Finally, the Mek 1/2 inhibitor U0126 significantly potentiated growth inhibition of B16 cells triggered by 5,7-dimethoxycoumarin, suggesting that down-regulation of Raf/Mek/Erk pathway sensitizes melanoma cells to 5,7-dimethoxycoumarin treatment.	U 0126	31-36	mitogen-activated protein kinase kinase 1	Homo sapiens	13-20
19424591-7	2009	Finally, the Mek 1/2 inhibitor U0126 significantly potentiated growth inhibition of B16 cells triggered by 5,7-dimethoxycoumarin, suggesting that down-regulation of Raf/Mek/Erk pathway sensitizes melanoma cells to 5,7-dimethoxycoumarin treatment.	U 0126	31-36	zinc fingers and homeoboxes 2	Homo sapiens	165-168
19424591-7	2009	Finally, the Mek 1/2 inhibitor U0126 significantly potentiated growth inhibition of B16 cells triggered by 5,7-dimethoxycoumarin, suggesting that down-regulation of Raf/Mek/Erk pathway sensitizes melanoma cells to 5,7-dimethoxycoumarin treatment.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
19424591-7	2009	Finally, the Mek 1/2 inhibitor U0126 significantly potentiated growth inhibition of B16 cells triggered by 5,7-dimethoxycoumarin, suggesting that down-regulation of Raf/Mek/Erk pathway sensitizes melanoma cells to 5,7-dimethoxycoumarin treatment.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	173-176
19418600-8	2009	The addition of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor, U0126, did not inhibit GSK-3beta phosphorylation in dechorionated eggs, although U0126 dose-dependently inhibited ERK phosphorylation.	U 0126	128-133	extracellular regulated MAP kinase	Bombyx mori	99-102
19418600-8	2009	The addition of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor, U0126, did not inhibit GSK-3beta phosphorylation in dechorionated eggs, although U0126 dose-dependently inhibited ERK phosphorylation.	U 0126	128-133	MAP kinse-ERK kinase	Bombyx mori	112-115
19286921-10	2009	The latter effect was abolished by the mitogen-activated protein kinase kinase 1/2 inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene ethanolate], although the prevention of anisomycin-induced macrophage death by SB202190 remained unchanged.	U 0126	93-98	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	39-80
19258520-4	2009	U0126 dose-dependently suppressed ERK phosphorylation at both 1- and 24-h time points in HepG2 cells, previously shown to be sensitive to growth inhibition by U0126.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	34-37
19258520-4	2009	U0126 dose-dependently suppressed ERK phosphorylation at both 1- and 24-h time points in HepG2 cells, previously shown to be sensitive to growth inhibition by U0126.	U 0126	159-164	mitogen-activated protein kinase 1	Homo sapiens	34-37
19258520-7	2009	Several MEK/ERK pathway intermediates were up-regulated in Hep3B cells; furthermore, transfection of Raf-1 small interfering RNA to suppress MEK/ERK pathway activation sensitized Hep3B cells to U0126.	U 0126	194-199	mitogen-activated protein kinase kinase 7	Homo sapiens	8-11
19258520-7	2009	Several MEK/ERK pathway intermediates were up-regulated in Hep3B cells; furthermore, transfection of Raf-1 small interfering RNA to suppress MEK/ERK pathway activation sensitized Hep3B cells to U0126.	U 0126	194-199	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	101-106
19542681-4	2009	An ERK-MAPK pathway inhibitor (U0126), but not a p38 kinase inhibitor (SB203580) or a JNK inhibitor (SP600125), also selectively inhibited IL-1beta-induced MMP-13 production in HAC.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	3-6
19542681-4	2009	An ERK-MAPK pathway inhibitor (U0126), but not a p38 kinase inhibitor (SB203580) or a JNK inhibitor (SP600125), also selectively inhibited IL-1beta-induced MMP-13 production in HAC.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	7-11
19542681-4	2009	An ERK-MAPK pathway inhibitor (U0126), but not a p38 kinase inhibitor (SB203580) or a JNK inhibitor (SP600125), also selectively inhibited IL-1beta-induced MMP-13 production in HAC.	U 0126	31-36	interleukin 1 beta	Homo sapiens	139-147
19542681-4	2009	An ERK-MAPK pathway inhibitor (U0126), but not a p38 kinase inhibitor (SB203580) or a JNK inhibitor (SP600125), also selectively inhibited IL-1beta-induced MMP-13 production in HAC.	U 0126	31-36	matrix metallopeptidase 13	Homo sapiens	156-162
19181503-5	2009	Interestingly, TPA-induced MMP-9 expression was significantly inhibited by UO126, but not by SP600125 and SB203580.	U 0126	75-80	matrix metallopeptidase 9	Homo sapiens	27-32
19509115-5	2009	MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH(2)-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production.	U 0126	19-24	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
19509115-5	2009	MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH(2)-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production.	U 0126	19-24	vascular endothelial growth factor A	Homo sapiens	103-107
19424626-9	2009	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, blocked CTRP3/cartducin-induced cell proliferation.	U 0126	40-45	mitogen-activated protein kinase kinase 1	Mus musculus	21-27
19424626-9	2009	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, blocked CTRP3/cartducin-induced cell proliferation.	U 0126	40-45	C1q and tumor necrosis factor related protein 3	Mus musculus	55-60
19424626-9	2009	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, blocked CTRP3/cartducin-induced cell proliferation.	U 0126	40-45	C1q and tumor necrosis factor related protein 3	Mus musculus	61-70
19181503-8	2009	TPA-induced VEGF expression was also suppressed by UO126.	U 0126	51-56	vascular endothelial growth factor A	Homo sapiens	12-16
19376927-5	2009	U0126, a MAP kinase inhibitor, prevents Vg1RBP cortical release and Vg1 mRNA solubilization in meiotically maturing eggs, while injection of MKK6-DD, a constitutively activated MAP kinase kinase, promotes the release of both Vg1RBP and Vg1 mRNA from insoluble cortical structures.	U 0126	0-5	insulin like growth factor 2 mRNA binding protein 3 L homeolog	Xenopus laevis	40-46
19376927-5	2009	U0126, a MAP kinase inhibitor, prevents Vg1RBP cortical release and Vg1 mRNA solubilization in meiotically maturing eggs, while injection of MKK6-DD, a constitutively activated MAP kinase kinase, promotes the release of both Vg1RBP and Vg1 mRNA from insoluble cortical structures.	U 0126	0-5	growth differentiation factor 1 S homeolog	Xenopus laevis	40-43
19376927-5	2009	U0126, a MAP kinase inhibitor, prevents Vg1RBP cortical release and Vg1 mRNA solubilization in meiotically maturing eggs, while injection of MKK6-DD, a constitutively activated MAP kinase kinase, promotes the release of both Vg1RBP and Vg1 mRNA from insoluble cortical structures.	U 0126	0-5	insulin like growth factor 2 mRNA binding protein 3 L homeolog	Xenopus laevis	225-231
19376927-5	2009	U0126, a MAP kinase inhibitor, prevents Vg1RBP cortical release and Vg1 mRNA solubilization in meiotically maturing eggs, while injection of MKK6-DD, a constitutively activated MAP kinase kinase, promotes the release of both Vg1RBP and Vg1 mRNA from insoluble cortical structures.	U 0126	0-5	growth differentiation factor 1 S homeolog	Xenopus laevis	68-71
19332537-6	2009	RSK-dependent Ser-260 phosphorylation was sensitive to the MEK inhibitor UO126 and the RSK inhibitor BID-1870.	U 0126	73-78	ribosomal protein S6 kinase A2	Homo sapiens	0-3
18584900-3	2009	RESULTS: E(2)-promoted VSMC proliferation was accompanied with an increased phosphorylation of ERK1/2, which could be blocked by MEK inhibitor U0126; the E(2)-induced VSMC apoptosis, which appeared mainly in the G2/M phase, was related with the activation of p38 and could be blocked by p38 inhibitor SB203580.	U 0126	143-148	mitogen activated protein kinase 3	Rattus norvegicus	95-101
18584900-3	2009	RESULTS: E(2)-promoted VSMC proliferation was accompanied with an increased phosphorylation of ERK1/2, which could be blocked by MEK inhibitor U0126; the E(2)-induced VSMC apoptosis, which appeared mainly in the G2/M phase, was related with the activation of p38 and could be blocked by p38 inhibitor SB203580.	U 0126	143-148	mitogen activated protein kinase 14	Rattus norvegicus	259-262
18584900-3	2009	RESULTS: E(2)-promoted VSMC proliferation was accompanied with an increased phosphorylation of ERK1/2, which could be blocked by MEK inhibitor U0126; the E(2)-induced VSMC apoptosis, which appeared mainly in the G2/M phase, was related with the activation of p38 and could be blocked by p38 inhibitor SB203580.	U 0126	143-148	mitogen activated protein kinase 14	Rattus norvegicus	287-290
19332537-6	2009	RSK-dependent Ser-260 phosphorylation was sensitive to the MEK inhibitor UO126 and the RSK inhibitor BID-1870.	U 0126	73-78	mitogen-activated protein kinase kinase 7	Homo sapiens	59-62
19289102-5	2009	The effect of TRH on MKP-1 expression was completely prevented in the presence of the MEK inhibitor, U0126.	U 0126	101-106	thyrotropin releasing hormone	Rattus norvegicus	14-17
19159647-4	2009	Rats were bilaterally implanted with cannulas in the dHP or mPFC and were microinjected with U0126, a specific inhibitor of ERK upstream activator, or vehicle for 7 consecutive days.	U 0126	93-98	Eph receptor B1	Rattus norvegicus	124-127
19289102-5	2009	The effect of TRH on MKP-1 expression was completely prevented in the presence of the MEK inhibitor, U0126.	U 0126	101-106	dual specificity phosphatase 1	Rattus norvegicus	21-26
19125410-5	2009	The inhibition of an extracellular signal-regulated kinase (ERK) pathway by PD98059 and U0126 significantly suppressed ATPgammaS-induced MCP-1 mRNA expression and protein production, while inhibition of c-Jun N-terminal kinase by SP600125 resulted in the partial suppression.	U 0126	88-93	Eph receptor B1	Rattus norvegicus	21-58
19301259-5	2009	RGD peptide, alphavbeta3 monoclonal antibody (mAb) and MAPK kinase (MEK) inhibitors (PD98059 and U0126) but not RAD peptide inhibited the CTGF-induced increase of the migration and MMP-13 up-regulation of chondrosarcoma cells.	U 0126	97-102	cellular communication network factor 2	Homo sapiens	138-142
19301259-9	2009	The CTGF-mediated increases in kappaB-luciferase activities were inhibited by RGD, PD98059, U0126 or FAK, and ERK2 mutant.	U 0126	92-97	cellular communication network factor 2	Homo sapiens	4-8
19125410-5	2009	The inhibition of an extracellular signal-regulated kinase (ERK) pathway by PD98059 and U0126 significantly suppressed ATPgammaS-induced MCP-1 mRNA expression and protein production, while inhibition of c-Jun N-terminal kinase by SP600125 resulted in the partial suppression.	U 0126	88-93	Eph receptor B1	Rattus norvegicus	60-63
19125410-5	2009	The inhibition of an extracellular signal-regulated kinase (ERK) pathway by PD98059 and U0126 significantly suppressed ATPgammaS-induced MCP-1 mRNA expression and protein production, while inhibition of c-Jun N-terminal kinase by SP600125 resulted in the partial suppression.	U 0126	88-93	C-C motif chemokine ligand 2	Rattus norvegicus	137-142
19326946-8	2009	Furthermore, the ERK inhibitor (U0126) could result in reduced activities of MMP-2 and u-PA concomitantly with a marked inhibition on cell invasion and migration.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	17-20
19326946-8	2009	Furthermore, the ERK inhibitor (U0126) could result in reduced activities of MMP-2 and u-PA concomitantly with a marked inhibition on cell invasion and migration.	U 0126	32-37	matrix metallopeptidase 2	Homo sapiens	77-82
19326946-8	2009	Furthermore, the ERK inhibitor (U0126) could result in reduced activities of MMP-2 and u-PA concomitantly with a marked inhibition on cell invasion and migration.	U 0126	32-37	plasminogen activator, urokinase	Homo sapiens	87-91
19347030-6	2009	Furthermore, pharmacological inhibition by PD98059 or UO126 of MEK and therefore of ERK1/2 activation restored sensitivity of STC1-/- cells to oxidative stress.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
19347030-6	2009	Furthermore, pharmacological inhibition by PD98059 or UO126 of MEK and therefore of ERK1/2 activation restored sensitivity of STC1-/- cells to oxidative stress.	U 0126	54-59	mitogen-activated protein kinase 3	Homo sapiens	84-90
19347030-6	2009	Furthermore, pharmacological inhibition by PD98059 or UO126 of MEK and therefore of ERK1/2 activation restored sensitivity of STC1-/- cells to oxidative stress.	U 0126	54-59	stanniocalcin 1	Homo sapiens	126-130
19286964-11	2009	4) The enhanced ET-1-induced contraction was reduced by MEK/ERK pathway inhibitors (PD-98059 or U0126).	U 0126	96-101	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
19251839-8	2009	MEK inhibitors PD-98059, U0126, and Raf1 kinase inhibitor I, significantly inhibited IL-11 production, whereas overexpression of a Raf1 dominant-negative mutant inhibited its expression.	U 0126	25-30	interleukin 11	Homo sapiens	85-90
19286964-11	2009	4) The enhanced ET-1-induced contraction was reduced by MEK/ERK pathway inhibitors (PD-98059 or U0126).	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	60-63
19151362-7	2009	U0126, a specific inhibitor of MEK1/2, the upstream activator of ERK1/2, abolishes HDL- and S1P-induced Stat3 activation, whereas the p38 MAPK blocker SB203580 has no significant effect.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	31-37
19151362-7	2009	U0126, a specific inhibitor of MEK1/2, the upstream activator of ERK1/2, abolishes HDL- and S1P-induced Stat3 activation, whereas the p38 MAPK blocker SB203580 has no significant effect.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	65-71
19151362-7	2009	U0126, a specific inhibitor of MEK1/2, the upstream activator of ERK1/2, abolishes HDL- and S1P-induced Stat3 activation, whereas the p38 MAPK blocker SB203580 has no significant effect.	U 0126	0-5	signal transducer and activator of transcription 3	Rattus norvegicus	104-109
19176641-12	2009	U-0126, the mitogen-activated protein kinase kinase (MAPK kinase) inhibitors blocked ERK activation and cell proliferation induced by diazoxide.	U 0126	0-6	mitogen-activated protein kinase 1	Mus musculus	85-88
18710710-11	2009	Progesterone stimulated phosphorylation of eNOS within 30 minutes, and this effect was completely blocked by an inhibitor of PI3/Akt pathway, wortmannin, and by the extracellular signal-regulated kinase 1,2 pathway blocker UO126.	U 0126	223-228	mitogen-activated protein kinase 3	Homo sapiens	165-204
19210515-8	2009	We stereotactically administered ERK antagonist U0126, or inactive control U0124, to the trigeminal ganglion of CFA+E2-treated rats.	U 0126	48-53	Eph receptor B1	Rattus norvegicus	33-36
19546256-7	2009	The participation of the MEK/ERK1/2 pathway was confirmed by exposure of the cells to the MEK inhibitor U0126.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
19546256-7	2009	The participation of the MEK/ERK1/2 pathway was confirmed by exposure of the cells to the MEK inhibitor U0126.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	29-35
19546256-7	2009	The participation of the MEK/ERK1/2 pathway was confirmed by exposure of the cells to the MEK inhibitor U0126.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
19493891-6	2009	NaF-induced apoptosis was markedly suppressed by treatment with the JNK inhibitor, SP600125, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	149-154	mitogen-activated protein kinase 1	Mus musculus	122-126
19291788-11	2009	Coadministration of the thrombin inhibitor hirudin or the MEK (mitogen-activated protein kinase) inhibitor U0126 significantly attenuated the enhanced liver damage caused by ethanol preexposure; this protection correlated with a significant blunting of the induction of PAI-1 caused by ethanol/LPS.	U 0126	107-112	midkine	Mus musculus	58-61
19291788-11	2009	Coadministration of the thrombin inhibitor hirudin or the MEK (mitogen-activated protein kinase) inhibitor U0126 significantly attenuated the enhanced liver damage caused by ethanol preexposure; this protection correlated with a significant blunting of the induction of PAI-1 caused by ethanol/LPS.	U 0126	107-112	midkine	Mus musculus	63-95
19291788-11	2009	Coadministration of the thrombin inhibitor hirudin or the MEK (mitogen-activated protein kinase) inhibitor U0126 significantly attenuated the enhanced liver damage caused by ethanol preexposure; this protection correlated with a significant blunting of the induction of PAI-1 caused by ethanol/LPS.	U 0126	107-112	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	270-275
19291788-11	2009	Coadministration of the thrombin inhibitor hirudin or the MEK (mitogen-activated protein kinase) inhibitor U0126 significantly attenuated the enhanced liver damage caused by ethanol preexposure; this protection correlated with a significant blunting of the induction of PAI-1 caused by ethanol/LPS.	U 0126	107-112	toll-like receptor 4	Mus musculus	294-297
19493891-6	2009	NaF-induced apoptosis was markedly suppressed by treatment with the JNK inhibitor, SP600125, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	U 0126	149-154	mitogen-activated protein kinase 1	Mus musculus	127-130
19223455-7	2009	Chemical blockade of MEK kinase using a specific inhibitor U0126 increases the interaction and hence repression of AR by the corepressor SMRT in LNCaP PCa cells.	U 0126	59-64	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
19162037-10	2009	Preinjection of PI3K inhibitor LY294002, MEK 1/2 inhibitor U0126 and JAK-2 inhibitor AG-490 partially abrogated the JWH-133 mediated infarct size reduction.	U 0126	59-64	mitogen-activated protein kinase kinase 1	Mus musculus	41-48
19223455-7	2009	Chemical blockade of MEK kinase using a specific inhibitor U0126 increases the interaction and hence repression of AR by the corepressor SMRT in LNCaP PCa cells.	U 0126	59-64	androgen receptor	Homo sapiens	115-117
19223455-7	2009	Chemical blockade of MEK kinase using a specific inhibitor U0126 increases the interaction and hence repression of AR by the corepressor SMRT in LNCaP PCa cells.	U 0126	59-64	nuclear receptor corepressor 2	Homo sapiens	137-141
18843268-6	2009	Moreover, inhibition of the hippocampal MEK/ERK pathway with the specific MEK inhibitor U0126, decreased depression-like behaviors in the forced swim test and tail suspension test of CRF2-/- mice.	U 0126	88-93	midkine	Mus musculus	40-43
19187440-3	2009	iNOS expression was attenuated by the MAPK/extracellular signal-regulated kinase pathway inhibitor U0126 and the phosphorylated forms of extracellular signal-regulated kinase 1 and 2 were detectable in microglia treated with albumin or fraction V. Glutamate release was prevented by l-alpha-aminoadipate and glutathione levels in microglia rose on exposure to albumin.	U 0126	99-104	nitric oxide synthase 2	Rattus norvegicus	0-4
19187440-3	2009	iNOS expression was attenuated by the MAPK/extracellular signal-regulated kinase pathway inhibitor U0126 and the phosphorylated forms of extracellular signal-regulated kinase 1 and 2 were detectable in microglia treated with albumin or fraction V. Glutamate release was prevented by l-alpha-aminoadipate and glutathione levels in microglia rose on exposure to albumin.	U 0126	99-104	mitogen activated protein kinase 3	Rattus norvegicus	38-42
18995898-4	2009	In the presence of SB202190, the ED(50) values for the farnesyltransferase inhibitor FPT inhibitor II and MEK inhibitor U0126 were significantly decreased.	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
18949556-6	2009	The ERK inhibitor U0126 and the Akt inhibitor LY984002 increased the kaempferol-induced cell death and overexpression of MEK, the upstream kinase of ERK, and Akt prevented the cell death.	U 0126	18-23	AKT serine/threonine kinase 1	Homo sapiens	158-161
19232318-7	2009	Using calcium-free culture conditions or the specific inhibitor of ERK phosphorylation (UO126), we demonstrated that Pi effects on Glvr-1 and -2 up-regulation require the presence of calcium and involve ERK signalling pathways.	U 0126	88-93	solute carrier family 20, member 1	Mus musculus	131-144
19176891-5	2009	Using Western blot analysis, we show that the robust increase in tyrosine hydroxylase phosphorylation obtained with intraperitoneal CCK is significantly attenuated in rats pretreated with the ERK-pathway blocker U0126 injected into the 4th ventricle.	U 0126	212-217	cholecystokinin	Rattus norvegicus	132-135
19176891-5	2009	Using Western blot analysis, we show that the robust increase in tyrosine hydroxylase phosphorylation obtained with intraperitoneal CCK is significantly attenuated in rats pretreated with the ERK-pathway blocker U0126 injected into the 4th ventricle.	U 0126	212-217	mitogen activated protein kinase 3	Rattus norvegicus	192-195
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-3
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	4-8
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	9-13
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase 1	Homo sapiens	29-33
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	118-121
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	122-126
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	127-131
19414386-5	2009	p21(WAF1/Cip1) induction and cdc2 reduction were observed and this reduction was abolished through the suppression of p21(WAF1/Cip1) induction by the MEK1/2 inhibitor U0126.	U 0126	167-172	mitogen-activated protein kinase kinase 1	Homo sapiens	150-156
19233864-5	2009	Furthermore, the ATPgammaS-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaBalpha was blocked by U0126 and helenalin.	U 0126	129-134	NFKB inhibitor alpha	Rattus norvegicus	101-113
19368807-7	2009	The treatment of a MAP kinase inhibitor (U0126) significantly blocked the expression of PRiMA transcript and promoter-driven luciferase activity as induced by the differentiation of cortical neurons.	U 0126	41-46	proline rich membrane anchor 1	Homo sapiens	88-93
18843268-6	2009	Moreover, inhibition of the hippocampal MEK/ERK pathway with the specific MEK inhibitor U0126, decreased depression-like behaviors in the forced swim test and tail suspension test of CRF2-/- mice.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	44-47
18843268-6	2009	Moreover, inhibition of the hippocampal MEK/ERK pathway with the specific MEK inhibitor U0126, decreased depression-like behaviors in the forced swim test and tail suspension test of CRF2-/- mice.	U 0126	88-93	midkine	Mus musculus	74-77
18949556-6	2009	The ERK inhibitor U0126 and the Akt inhibitor LY984002 increased the kaempferol-induced cell death and overexpression of MEK, the upstream kinase of ERK, and Akt prevented the cell death.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
18949556-6	2009	The ERK inhibitor U0126 and the Akt inhibitor LY984002 increased the kaempferol-induced cell death and overexpression of MEK, the upstream kinase of ERK, and Akt prevented the cell death.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	121-124
18949556-6	2009	The ERK inhibitor U0126 and the Akt inhibitor LY984002 increased the kaempferol-induced cell death and overexpression of MEK, the upstream kinase of ERK, and Akt prevented the cell death.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	149-152
19336886-4	2009	Pretreatment with U0126, an inhibitor of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) 1/2, abrogated CXCL12-induced PAI-1 expression.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	81-141
19336886-4	2009	Pretreatment with U0126, an inhibitor of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) 1/2, abrogated CXCL12-induced PAI-1 expression.	U 0126	18-23	C-X-C motif chemokine ligand 12	Homo sapiens	153-159
19336886-4	2009	Pretreatment with U0126, an inhibitor of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) 1/2, abrogated CXCL12-induced PAI-1 expression.	U 0126	18-23	serpin family E member 1	Homo sapiens	168-173
19207476-9	2009	Combination treatment with DY-9760e and U0126, a MEK inhibitor, totally blocked the ET-1-induced ANP and BNP expression.	U 0126	40-45	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
19207476-9	2009	Combination treatment with DY-9760e and U0126, a MEK inhibitor, totally blocked the ET-1-induced ANP and BNP expression.	U 0126	40-45	endothelin 1	Homo sapiens	84-88
19207476-9	2009	Combination treatment with DY-9760e and U0126, a MEK inhibitor, totally blocked the ET-1-induced ANP and BNP expression.	U 0126	40-45	natriuretic peptide B	Homo sapiens	105-108
19207476-10	2009	DY-9760e treatment (3 microM) significantly inhibited the ET-1-induced hypertrophy and combination treatment with DY-9760e and U0126 totally blocked the ET-1-induced hypertrophy in cultured cardiomyocytes.	U 0126	127-132	endothelin 1	Homo sapiens	153-157
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	mitogen-activated protein kinase kinase 1	Homo sapiens	13-19
19414352-7	2009	In addition, the MEK inhibitor U0126 inhibited EGR1 expression, while the phosphatidylinositol 3-kinase inhibitor LY294002 did not.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
19414352-7	2009	In addition, the MEK inhibitor U0126 inhibited EGR1 expression, while the phosphatidylinositol 3-kinase inhibitor LY294002 did not.	U 0126	31-36	early growth response 1	Homo sapiens	47-51
19232341-6	2009	The phosphorylation of ERKs and cytosolic phospholipase A(2) was attenuated by U0126, a mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor.	U 0126	79-84	phospholipase A2 group IVA	Rattus norvegicus	32-60
19232341-6	2009	The phosphorylation of ERKs and cytosolic phospholipase A(2) was attenuated by U0126, a mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor.	U 0126	79-84	Eph receptor B1	Rattus norvegicus	23-26
19280714-4	2009	Furthermore, CSE-induced cPLA2 expression was attenuated by pretreatment with the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), which were further confirmed by transfection with siRNAs of JNK1, p42, and p38 to down-regulate the expression of respective proteins and reduce cPLA2 expression.	U 0126	104-109	phospholipase A2 group IVA	Homo sapiens	25-30
19280714-4	2009	Furthermore, CSE-induced cPLA2 expression was attenuated by pretreatment with the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), which were further confirmed by transfection with siRNAs of JNK1, p42, and p38 to down-regulate the expression of respective proteins and reduce cPLA2 expression.	U 0126	104-109	mitogen-activated protein kinase kinase 1	Homo sapiens	96-102
19074803-10	2009	U0126 inhibited Ad-myr-PKCalpha-stimulated proliferation a maximum of 70%.	U 0126	0-5	protein kinase C, alpha	Rattus norvegicus	23-31
19074803-13	2009	Ad-myr-PKCalpha caused ERK 1/2 to translocate to the nucleus in rat and human cells, but the translocation was blocked by U0126.	U 0126	122-127	protein kinase C, alpha	Rattus norvegicus	7-15
19345795-6	2009	PGF(2alpha)-induced IL-8 production and mRNA expression were inhibited by U0126 (an inhibitor of mitogen-activated protein kinase kinase [MEK1/2]) inhibitor), whereas SQ22536 (an adenylate cyclase inhibitor) enhanced this event.	U 0126	74-79	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
19345795-6	2009	PGF(2alpha)-induced IL-8 production and mRNA expression were inhibited by U0126 (an inhibitor of mitogen-activated protein kinase kinase [MEK1/2]) inhibitor), whereas SQ22536 (an adenylate cyclase inhibitor) enhanced this event.	U 0126	74-79	mitogen-activated protein kinase kinase 1	Homo sapiens	138-144
19371583-3	2009	While testing the effect of kinase inhibitors in cortical cell cultures, we observed that HO activity was consistently decreased by the MEK inhibitor U0126.	U 0126	150-155	mitogen-activated protein kinase kinase 7	Homo sapiens	136-139
19371583-5	2009	The MEK inhibitors U0126 and SL327 and the ERK inhibitor FR180204 reduced baseline culture HO activity by 35-50%, without altering the activity of recombinant HO-1 or HO-2; negative control compounds U0124 and FR180289 had no effect.	U 0126	19-24	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
19201463-5	2009	TNF-mediated stimulation of CCL2 secretion was completely inhibited by incubating the trophoblast cells with the p38-MAPK inhibitor SB203580, whereas CCL5 secretion was inhibited by treating the trophoblast cells with inhibitors specific for JNK (SP600125) and ERK kinase (U0126).	U 0126	273-278	tumor necrosis factor	Homo sapiens	0-3
19228841-10	2009	Inhibition of phosphorylated ERK (pERK) expression by U0126 reduced endothelial cell death by OGD.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	29-32
19161339-7	2009	Ternary complexes have also been solved between npMEK1, a nucleotide, and an allosteric non-ATP competitive inhibitor: ATP-gammaS with compound 1 and ADP with either U0126 or the MEK1 clinical candidate PD325089 at 1.8, 2.0, and 2.5 A, respectively.	U 0126	166-171	mitogen-activated protein kinase kinase 1	Homo sapiens	50-54
19330912-8	2009	While being pretreated with the selective inhibitor of ERK1/2 U0126, the anti-apoptosis effect of the pharmacological serum on the OBs was almost completely blocked.	U 0126	62-67	mitogen-activated protein kinase 3	Mus musculus	55-61
19285017-8	2009	Furthermore, LPA-induced Rat-2 cell proliferation was decreased markedly by ERK inhibitor (U0126) and partially by MSK inhibitor (H89).	U 0126	91-96	Eph receptor B1	Rattus norvegicus	76-79
19162127-7	2009	ET-1 was able to enhance the IL-6 promoter activity and its stimulatory effect was inhibited by GF109203X, U0126, salicylate, dominant negative CREB and mithramycin A.	U 0126	107-112	endothelin 1	Mus musculus	0-4
19162127-7	2009	ET-1 was able to enhance the IL-6 promoter activity and its stimulatory effect was inhibited by GF109203X, U0126, salicylate, dominant negative CREB and mithramycin A.	U 0126	107-112	interleukin 6	Mus musculus	29-33
18852162-2	2009	The E(2)-induced proliferation was associated with the activation of extracellular signal-regulated kinase (MAPK)3/1 and up-regulation of cyclin D1 and E, which were suppressed by the addition of an MAP2K inhibitor (U0126) or an ER antagonist (ICI 182 780).	U 0126	216-221	mitogen-activated protein kinase 3	Homo sapiens	108-112
18852162-2	2009	The E(2)-induced proliferation was associated with the activation of extracellular signal-regulated kinase (MAPK)3/1 and up-regulation of cyclin D1 and E, which were suppressed by the addition of an MAP2K inhibitor (U0126) or an ER antagonist (ICI 182 780).	U 0126	216-221	cyclin D1	Homo sapiens	138-153
18852162-2	2009	The E(2)-induced proliferation was associated with the activation of extracellular signal-regulated kinase (MAPK)3/1 and up-regulation of cyclin D1 and E, which were suppressed by the addition of an MAP2K inhibitor (U0126) or an ER antagonist (ICI 182 780).	U 0126	216-221	estrogen receptor 1	Homo sapiens	229-231
19148588-5	2009	The presence of MEK inhibitors PD 98059 and U0126 caused a delay in G(2)/M phase.	U 0126	44-49	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19
18989867-5	2009	PD98059, U0126 or a combination of both inhibitors were able to completely block TBT-induced activation of p44/42.	U 0126	9-14	interferon induced protein 44	Homo sapiens	107-110
18989867-6	2009	However, when p44/42 activation was blocked by the presence of PD98059, U0126 or the combination, subsequent exposure to TBT was still able to decrease the lytic function of NK cells.	U 0126	72-77	interferon induced protein 44	Homo sapiens	14-17
18680102-9	2009	Additionally, UO126 and ODQ inhibited the migration restoring effects of L-arginine in L-NAME-treated cells, suggesting the involvement of cGMP and MAPK pathways in NO-mediated migration.	U 0126	14-19	mitogen-activated protein kinase 3	Homo sapiens	148-152
19258428-0	2009	MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
19258428-0	2009	MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
19258428-2	2009	In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.	U 0126	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
19258428-2	2009	In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	44-47
19258428-2	2009	In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.	U 0126	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
19258428-2	2009	In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	71-74
19258428-2	2009	In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.	U 0126	85-90	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	100-105
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	77-80
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	163-166
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	171-176
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	215-218
19258428-4	2009	Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression.	U 0126	104-109	platelet and endothelial cell adhesion molecule 1	Homo sapiens	275-279
19258428-6	2009	The RD-M1 cultured xenograft tumor-derived cell line and the ERMS cell line TE671 responded to U0126 by arresting growth, down-regulating c-Myc, and initiating myogenesis.	U 0126	95-100	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	138-143
19028507-5	2009	Inhibition of ERKs by prior treatment of cells with 10muM U0126 relieves cadmium-mediated inhibition of apoptosis/bax induction/caspase-9 activation.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	14-18
19028507-5	2009	Inhibition of ERKs by prior treatment of cells with 10muM U0126 relieves cadmium-mediated inhibition of apoptosis/bax induction/caspase-9 activation.	U 0126	58-63	BCL2 associated X, apoptosis regulator	Homo sapiens	114-117
19028507-5	2009	Inhibition of ERKs by prior treatment of cells with 10muM U0126 relieves cadmium-mediated inhibition of apoptosis/bax induction/caspase-9 activation.	U 0126	58-63	caspase 9	Homo sapiens	128-137
19192276-10	2009	U0126 (inhibitor of ERK pathway) decreased CGRP induced proliferation of DNA synthesis.In vivo study, histological examination of the lung indicated proliferation of alveolar epithelial cells in the rhCGRP-treated group and the nuclei of alveolar epithelial cells were positive for PCNA immunostaining.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	20-23
19192276-10	2009	U0126 (inhibitor of ERK pathway) decreased CGRP induced proliferation of DNA synthesis.In vivo study, histological examination of the lung indicated proliferation of alveolar epithelial cells in the rhCGRP-treated group and the nuclei of alveolar epithelial cells were positive for PCNA immunostaining.	U 0126	0-5	calcitonin related polypeptide alpha	Homo sapiens	43-47
19192276-10	2009	U0126 (inhibitor of ERK pathway) decreased CGRP induced proliferation of DNA synthesis.In vivo study, histological examination of the lung indicated proliferation of alveolar epithelial cells in the rhCGRP-treated group and the nuclei of alveolar epithelial cells were positive for PCNA immunostaining.	U 0126	0-5	proliferating cell nuclear antigen	Homo sapiens	282-286
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	U 0126	64-69	tumor necrosis factor	Homo sapiens	0-9
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	U 0126	64-69	vascular endothelial growth factor A	Homo sapiens	18-22
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	U 0126	64-69	mitogen-activated protein kinase 8	Homo sapiens	95-98
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
19126648-4	2009	RGD peptide, alphavbeta3 monoclonal antibody and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) but not RAD peptide inhibited the Cyr61-induced increase of the migration and MMP-13 upregulation of chondrosarcoma cells.	U 0126	112-117	cellular communication network factor 1	Homo sapiens	153-158
18314110-8	2009	RESULT(S): Following stimulation by thrombin and TRP-6, the production of VEGF, MMP-1, and active MMP-2 statistically significantly increased; U0126 and PPACK statistically significantly suppressed the increases in the production of VEGF, MMP-1, and active MMP-2 induced by thrombin and TRAP-6.	U 0126	143-148	coagulation factor II, thrombin	Homo sapiens	36-44
18314110-8	2009	RESULT(S): Following stimulation by thrombin and TRP-6, the production of VEGF, MMP-1, and active MMP-2 statistically significantly increased; U0126 and PPACK statistically significantly suppressed the increases in the production of VEGF, MMP-1, and active MMP-2 induced by thrombin and TRAP-6.	U 0126	143-148	transient receptor potential cation channel subfamily C member 6	Homo sapiens	49-54
18314110-8	2009	RESULT(S): Following stimulation by thrombin and TRP-6, the production of VEGF, MMP-1, and active MMP-2 statistically significantly increased; U0126 and PPACK statistically significantly suppressed the increases in the production of VEGF, MMP-1, and active MMP-2 induced by thrombin and TRAP-6.	U 0126	143-148	vascular endothelial growth factor A	Homo sapiens	233-237
18314110-8	2009	RESULT(S): Following stimulation by thrombin and TRP-6, the production of VEGF, MMP-1, and active MMP-2 statistically significantly increased; U0126 and PPACK statistically significantly suppressed the increases in the production of VEGF, MMP-1, and active MMP-2 induced by thrombin and TRAP-6.	U 0126	143-148	matrix metallopeptidase 1	Homo sapiens	239-244
18314110-8	2009	RESULT(S): Following stimulation by thrombin and TRP-6, the production of VEGF, MMP-1, and active MMP-2 statistically significantly increased; U0126 and PPACK statistically significantly suppressed the increases in the production of VEGF, MMP-1, and active MMP-2 induced by thrombin and TRAP-6.	U 0126	143-148	matrix metallopeptidase 2	Homo sapiens	257-262
18314110-8	2009	RESULT(S): Following stimulation by thrombin and TRP-6, the production of VEGF, MMP-1, and active MMP-2 statistically significantly increased; U0126 and PPACK statistically significantly suppressed the increases in the production of VEGF, MMP-1, and active MMP-2 induced by thrombin and TRAP-6.	U 0126	143-148	coagulation factor II, thrombin	Homo sapiens	274-282
19201463-5	2009	TNF-mediated stimulation of CCL2 secretion was completely inhibited by incubating the trophoblast cells with the p38-MAPK inhibitor SB203580, whereas CCL5 secretion was inhibited by treating the trophoblast cells with inhibitors specific for JNK (SP600125) and ERK kinase (U0126).	U 0126	273-278	mitogen-activated protein kinase 14	Homo sapiens	113-116
19326083-7	2009	The tectoridin-induced estrogenic effect was severely abrogated by treatment with U0126, a specific MEK1/2 inhibitor.	U 0126	82-87	mitogen-activated protein kinase kinase 1	Homo sapiens	100-106
19215954-6	2009	Inhibition of ERK activation with U0126, a specific MEK1/2 inhibitor, significantly reduced viral progeny release.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	14-17
19215954-6	2009	Inhibition of ERK activation with U0126, a specific MEK1/2 inhibitor, significantly reduced viral progeny release.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Homo sapiens	52-58
19285010-5	2009	A MEK inhibitor, U0126, increased E-cadherin or claudin 4 mRNA and protein expression, and potently inhibited cell invasion.	U 0126	17-22	mitogen-activated protein kinase kinase 7	Homo sapiens	2-5
19285010-5	2009	A MEK inhibitor, U0126, increased E-cadherin or claudin 4 mRNA and protein expression, and potently inhibited cell invasion.	U 0126	17-22	cadherin 1	Homo sapiens	34-44
19285010-5	2009	A MEK inhibitor, U0126, increased E-cadherin or claudin 4 mRNA and protein expression, and potently inhibited cell invasion.	U 0126	17-22	claudin 4	Homo sapiens	48-57
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	U 0126	23-28	nuclear receptor subfamily 1 group I member 3	Homo sapiens	54-57
18409071-8	2009	In concert, inhibition of Erk with U0126 preferentially reduced growth of resistant cell lines.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	26-29
19084521-7	2009	U0126, a mitogen-activated protein/extracellular signal-regulated kinase 1 and 2 inhibitor, partially blocked the rescue effect of latnanoprost acid (p=0.013).	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	35-80
19038233-4	2009	A specific inhibitor of ERK1/2 phosphorylation by MEK1/2 (U0126) abrogates these phenomena.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	24-30
19038233-4	2009	A specific inhibitor of ERK1/2 phosphorylation by MEK1/2 (U0126) abrogates these phenomena.	U 0126	58-63	mitogen-activated protein kinase kinase 1	Homo sapiens	50-56
19000637-6	2009	By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization.	U 0126	115-120	mitogen activated protein kinase 3	Rattus norvegicus	82-88
19000637-6	2009	By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization.	U 0126	115-120	mitogen activated protein kinase 3	Rattus norvegicus	158-164
19000637-6	2009	By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization.	U 0126	115-120	mitogen activated protein kinase 3	Rattus norvegicus	158-164
19000637-6	2009	By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization.	U 0126	218-223	mitogen activated protein kinase 3	Rattus norvegicus	82-88
19144724-6	2009	We show that two parallel pathways are involved in the neuralising activity of Syn4: FGF/ERK, which is sensitive to dominant-negative FGF receptor and to the inhibitors SU5402 and U0126, and a PKC pathway, which is dependent on the intracellular domain of Syn4.	U 0126	180-185	syndecan 4 S homeolog	Xenopus laevis	79-83
19144724-6	2009	We show that two parallel pathways are involved in the neuralising activity of Syn4: FGF/ERK, which is sensitive to dominant-negative FGF receptor and to the inhibitors SU5402 and U0126, and a PKC pathway, which is dependent on the intracellular domain of Syn4.	U 0126	180-185	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	89-92
18927218-8	2009	Inhibition of Akt phosphorylation using Akt inhibitor VIII reversed the inhibitory effect of FSH on thr 172 phosphorylation of AMPK, whereas ERK inhibitor U0126 had no effect.	U 0126	155-160	AKT serine/threonine kinase 1	Rattus norvegicus	14-17
19100675-8	2009	Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis.	U 0126	82-87	mitogen-activated protein kinase 1	Mus musculus	14-51
19100675-8	2009	Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis.	U 0126	82-87	mitogen-activated protein kinase 1	Mus musculus	53-56
19100675-8	2009	Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis.	U 0126	82-87	midkine	Mus musculus	63-66
19100675-8	2009	Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis.	U 0126	82-87	mitogen-activated protein kinase 1	Mus musculus	67-70
19100675-8	2009	Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis.	U 0126	82-87	BCL2-like 11 (apoptosis facilitator)	Mus musculus	137-140
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	ribosomal protein S6 kinase A1	Homo sapiens	80-85
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	glycogen synthase kinase 3 beta	Homo sapiens	110-119
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	ribosomal protein S6 kinase A1	Homo sapiens	167-172
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	catenin beta 1	Homo sapiens	174-186
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	protein-L-isoaspartate (D-aspartate) O-methyltransferase	Homo sapiens	191-195
18936144-9	2009	TGFbeta1-induced alpha-SMA expression was reduced by MEK inhibition (U0126); however, the levels of pERK, pSmad3, or the extent of the interaction between pSmad3 and CBP induced by TGFbeta1 were not affected by FSK.	U 0126	69-74	actin, aortic smooth muscle	Oryctolagus cuniculus	17-26
19015047-6	2009	The important role of ERK1/2 in DHEA effect was further confirmed by using ERK1/2 inhibitor U0126.	U 0126	92-97	mitogen-activated protein kinase 3	Homo sapiens	22-28
19015047-6	2009	The important role of ERK1/2 in DHEA effect was further confirmed by using ERK1/2 inhibitor U0126.	U 0126	92-97	mitogen-activated protein kinase 3	Homo sapiens	75-81
19054278-8	2009	Interestingly, inhibition of mitogen-activated protein kinase pathway with PD98096 or U0126 caused a decrease in reactive oxygen species production suggesting that activation of ERK1/2 could further exacerbate the oxidative stress caused by glutamate-induced toxicity; however, these inhibitors had no effect on OA-induced toxicity.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	178-184
18950865-8	2009	The inhibitor of mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway (U0126, 10microM) prevented LTA stimulation of MMP 9 secretion; however, the inhibitors of p38 (SB203580, 10microM) and Jun N-terminal kinase (JNK; SP600125, 10microM) presented any effect.	U 0126	109-114	matrix metallopeptidase 9	Rattus norvegicus	155-160
18854639-3	2009	Polarized light microscopy revealed that the MII spindle rapidly (within approximately 15 min) lost birefringence upon treatment of the egg with U0126, indicating decreased organization at the molecular level upon MEK inhibition.	U 0126	145-150	midkine	Mus musculus	214-217
19041697-7	2009	The MEK1/2 specific inhibitor U0126 blocked DNA synthesis stimulated by estradiol (E2) and the E2-Cd mixtures.	U 0126	30-35	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
18620900-7	2009	In addition, all these effects could be partially blocked by U0126, a specific inhibitor of mitogen-activated protein kinase kinase (MEK or MAPKK), or LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K).	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	133-136
19059445-6	2009	These signaling responses were blocked by an antibody to the enterostatin receptor (beta subunit of F1-ATPase), by the pERK inhibitor U0126 and by the P2Y receptor antagonist Suramin.	U 0126	134-139	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	119-123
19059445-12	2009	U0126 blocked the effect of enterostatin on KLF4 expression.	U 0126	0-5	Kruppel-like factor 4 (gut)	Mus musculus	44-48
18988709-4	2009	HGF exhibited a mitogenic activity on SVZ cell cultures in a mitogen-activated protein kinase (MAPK) (ERK1/2)-dependent manner as U0126, a specific MAPK inhibitor, blocked it.	U 0126	130-135	hepatocyte growth factor	Canis lupus familiaris	0-3
18988709-4	2009	HGF exhibited a mitogenic activity on SVZ cell cultures in a mitogen-activated protein kinase (MAPK) (ERK1/2)-dependent manner as U0126, a specific MAPK inhibitor, blocked it.	U 0126	130-135	mitogen-activated protein kinase 1	Canis lupus familiaris	95-99
18988709-4	2009	HGF exhibited a mitogenic activity on SVZ cell cultures in a mitogen-activated protein kinase (MAPK) (ERK1/2)-dependent manner as U0126, a specific MAPK inhibitor, blocked it.	U 0126	130-135	mitogen-activated protein kinase 1	Canis lupus familiaris	102-108
18988709-4	2009	HGF exhibited a mitogenic activity on SVZ cell cultures in a mitogen-activated protein kinase (MAPK) (ERK1/2)-dependent manner as U0126, a specific MAPK inhibitor, blocked it.	U 0126	130-135	mitogen-activated protein kinase 1	Canis lupus familiaris	148-152
19287196-5	2009	U46619 activated ERK and p38 MAPK, and pretreatment of the cells with the MEK inhibitor U0126 or the p38 MAPK inhibitor SB202190 abrogated the U46619-induced migration, proliferation, and alpha-SMA expression.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
19063870-3	2009	The ERK1/2 inhibitor, U0126, injected at ischemia onset, attenuated the increase in phosphorylated ERK1/2 (P-ERK1/2) after reperfusion.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	4-10
19063870-3	2009	The ERK1/2 inhibitor, U0126, injected at ischemia onset, attenuated the increase in phosphorylated ERK1/2 (P-ERK1/2) after reperfusion.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	99-105
19063870-3	2009	The ERK1/2 inhibitor, U0126, injected at ischemia onset, attenuated the increase in phosphorylated ERK1/2 (P-ERK1/2) after reperfusion.	U 0126	22-27	mitogen activated protein kinase 3	Rattus norvegicus	99-105
19087874-6	2009	Treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) abolished the ERK1/2 protein phosphorylation and blunted LTC(4)S expression.	U 0126	42-102	mitogen-activated protein kinase 3	Homo sapiens	15-22
19087874-6	2009	Treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) abolished the ERK1/2 protein phosphorylation and blunted LTC(4)S expression.	U 0126	42-102	mitogen-activated protein kinase 3	Homo sapiens	125-131
19087874-6	2009	Treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) abolished the ERK1/2 protein phosphorylation and blunted LTC(4)S expression.	U 0126	42-102	leukotriene C4 synthase	Homo sapiens	168-175
19087874-6	2009	Treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) abolished the ERK1/2 protein phosphorylation and blunted LTC(4)S expression.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	15-22
19063862-8	2009	Under amino acid limitation, phosphorylation of ERK1/2 was increased and the blockage of ERK1/2 by the inhibitor U0126 partially restored WNT5a mRNA level.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	89-95
19087874-6	2009	Treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) abolished the ERK1/2 protein phosphorylation and blunted LTC(4)S expression.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	125-131
19087874-6	2009	Treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) abolished the ERK1/2 protein phosphorylation and blunted LTC(4)S expression.	U 0126	104-109	leukotriene C4 synthase	Homo sapiens	168-175
19063862-8	2009	Under amino acid limitation, phosphorylation of ERK1/2 was increased and the blockage of ERK1/2 by the inhibitor U0126 partially restored WNT5a mRNA level.	U 0126	113-118	Wnt family member 5A	Homo sapiens	138-143
19028451-5	2009	IL-8 up-regulation in response to HSP90 was also attenuated by IkappaB, rasveratrol, curcumin, diphenyleneiodium, N-acetylcystein, U0126, and SB202190.	U 0126	131-136	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
19028451-5	2009	IL-8 up-regulation in response to HSP90 was also attenuated by IkappaB, rasveratrol, curcumin, diphenyleneiodium, N-acetylcystein, U0126, and SB202190.	U 0126	131-136	heat shock protein 90 alpha family class A member 1	Homo sapiens	34-39
19026667-9	2009	The inhibition of GJIC by AAP was restored in the presence of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126, but not in the presence of other signal inhibitors and antioxidant (PKC inhibitors, EGFR inhibitor, NADPH oxidase inhibitor, catalase, vitamin E, or AA), indicating the critical involvement of MEK signaling in the GJIC inhibitory activity of AAP.	U 0126	162-167	Eph receptor B1	Rattus norvegicus	134-137
19026667-9	2009	The inhibition of GJIC by AAP was restored in the presence of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126, but not in the presence of other signal inhibitors and antioxidant (PKC inhibitors, EGFR inhibitor, NADPH oxidase inhibitor, catalase, vitamin E, or AA), indicating the critical involvement of MEK signaling in the GJIC inhibitory activity of AAP.	U 0126	162-167	epidermal growth factor receptor	Rattus norvegicus	253-257
19026667-10	2009	Phosphorylation of ERK and connexin 43 (Cx43) was observed following AAP treatment, and this was reversed by U0126.	U 0126	109-114	Eph receptor B1	Rattus norvegicus	19-22
19026667-10	2009	Phosphorylation of ERK and connexin 43 (Cx43) was observed following AAP treatment, and this was reversed by U0126.	U 0126	109-114	gap junction protein, alpha 1	Rattus norvegicus	27-38
19026667-10	2009	Phosphorylation of ERK and connexin 43 (Cx43) was observed following AAP treatment, and this was reversed by U0126.	U 0126	109-114	gap junction protein, alpha 1	Rattus norvegicus	40-44
18806276-8	2009	The stimulation of vasculogenesis of ES cells upon treatment with PDGF-BB was significantly inhibited by the ERK1,2 inhibitor U0126, the NADPH oxidase inhibitors DPI, apocynin, 4-(2-aminoethyl)benzenesulfonylfluoride and VAS2870, the free radical scavengers vitamin E, and N-(2-mercaptopropionyl)glycin as well as by BAPTA.	U 0126	126-131	mitogen-activated protein kinase 3	Mus musculus	109-115
18836482-6	2009	Pretreatment of cells with rapamycin, inhibiting mTOR or U0126 to inhibit MEK, had little effect on eIF4B ser422 phosphorylation.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
18945217-9	2009	RESULTS: U0126, the inhibitor of ERK, eliminated or significantly attenuated the LTP induced by HFS of the PS in the DMS.	U 0126	9-14	Eph receptor B1	Rattus norvegicus	33-36
19331140-9	2009	RESULTS: Y-27632 reduced phosphorylation of ERK1/2 at 0.5 and 2 h. U0126 in combination with Y-27632 led to a more pronounced repression of platelet-derived growth factor (PDGF)- or fibronectin (FN)-induced ERK1/2 activation than U0126 treatment alone.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	44-50
19331140-9	2009	RESULTS: Y-27632 reduced phosphorylation of ERK1/2 at 0.5 and 2 h. U0126 in combination with Y-27632 led to a more pronounced repression of platelet-derived growth factor (PDGF)- or fibronectin (FN)-induced ERK1/2 activation than U0126 treatment alone.	U 0126	67-72	fibronectin 1	Homo sapiens	182-193
19331140-9	2009	RESULTS: Y-27632 reduced phosphorylation of ERK1/2 at 0.5 and 2 h. U0126 in combination with Y-27632 led to a more pronounced repression of platelet-derived growth factor (PDGF)- or fibronectin (FN)-induced ERK1/2 activation than U0126 treatment alone.	U 0126	67-72	fibronectin 1	Homo sapiens	195-197
19331140-9	2009	RESULTS: Y-27632 reduced phosphorylation of ERK1/2 at 0.5 and 2 h. U0126 in combination with Y-27632 led to a more pronounced repression of platelet-derived growth factor (PDGF)- or fibronectin (FN)-induced ERK1/2 activation than U0126 treatment alone.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	207-213
19331140-9	2009	RESULTS: Y-27632 reduced phosphorylation of ERK1/2 at 0.5 and 2 h. U0126 in combination with Y-27632 led to a more pronounced repression of platelet-derived growth factor (PDGF)- or fibronectin (FN)-induced ERK1/2 activation than U0126 treatment alone.	U 0126	230-235	mitogen-activated protein kinase 3	Homo sapiens	44-50
19331140-11	2009	Furthermore, PDGF and FN-induced cell proliferation was suppressed by pre-treatment with Y-27632 or U0126, with the greatest reduction achieved by a combination of the two inhibitors.	U 0126	100-105	fibronectin 1	Homo sapiens	22-24
19144181-3	2009	METHODS: Chondrocytes were treated with TNFalpha with or without the MEK1/2 inhibitor U0126 for 24 hours.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	69-75
19144181-7	2009	RESULTS: Approximately 20% of the genes regulated by TNFalpha in chondrocytes were sensitive to U0126.	U 0126	96-101	tumor necrosis factor	Homo sapiens	53-61
19144181-8	2009	Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive.	U 0126	152-157	collagen type II alpha 1 chain	Homo sapiens	62-68
19144181-8	2009	Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive.	U 0126	152-157	aggrecan	Homo sapiens	70-74
19144181-8	2009	Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive.	U 0126	152-157	hyaluronan and proteoglycan link protein 1	Homo sapiens	79-85
19144181-8	2009	Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive.	U 0126	152-157	matrix metallopeptidase 12	Homo sapiens	129-135
19144181-8	2009	Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive.	U 0126	152-157	matrix metallopeptidase 9	Homo sapiens	140-145
19144181-8	2009	Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive.	U 0126	152-157	colony stimulating factor 1	Homo sapiens	224-229
19144181-9	2009	TNFalpha-induced regulation of Sox9 and NFkappaB activity was also U0126 insensitive.	U 0126	67-72	tumor necrosis factor	Homo sapiens	0-8
19144181-10	2009	Conversely, TNFalpha-increased early growth response 1 (Egr-1) DNA binding was U0126 sensitive.	U 0126	79-84	tumor necrosis factor	Homo sapiens	12-20
19144181-10	2009	Conversely, TNFalpha-increased early growth response 1 (Egr-1) DNA binding was U0126 sensitive.	U 0126	79-84	early growth response 1	Homo sapiens	56-61
19130938-6	2009	RESULTS: Pretreatment of effector CD8(+) T cells with U0126 suppressed anti-CD3/anti-CD28-induced ERK1/2 phosphorylation and cytokine production, but did not affect LTB(4)-induced Ca(2+) mobilization or chemotaxis.	U 0126	54-59	CD3 antigen, epsilon polypeptide	Mus musculus	76-79
19471096-7	2009	On the contrary, ERK1/2 affects cytoskeleton organization and focal complexes assembly during H/R, since U0126 improved actin and tubulin cytoskeleton structure, reduced cell contraction and prevented paxillin redistribution.	U 0126	105-110	mitogen activated protein kinase 3	Rattus norvegicus	17-23
18787018-4	2009	Interestingly, the high expression of Ago2 in ERalpha(-) cells was severely blunted by inhibition of the epidermal growth factor (EGF) receptor/MAPK signaling pathway, using either a pharmacological MAPK kinase inhibitor, U0126, or a small interfering RNA directed against EGF receptor.	U 0126	222-227	argonaute RISC catalytic component 2	Homo sapiens	38-42
18787018-4	2009	Interestingly, the high expression of Ago2 in ERalpha(-) cells was severely blunted by inhibition of the epidermal growth factor (EGF) receptor/MAPK signaling pathway, using either a pharmacological MAPK kinase inhibitor, U0126, or a small interfering RNA directed against EGF receptor.	U 0126	222-227	estrogen receptor 1	Homo sapiens	46-53
18973754-7	2009	The addition of either the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 or Akt inhibitor LY294002 also led to a marked inhibition of the AngII-induced VEGF mRNA and protein production.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	27-68
18973754-7	2009	The addition of either the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 or Akt inhibitor LY294002 also led to a marked inhibition of the AngII-induced VEGF mRNA and protein production.	U 0126	88-93	mitogen-activated protein kinase 3	Homo sapiens	70-76
18973754-7	2009	The addition of either the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 or Akt inhibitor LY294002 also led to a marked inhibition of the AngII-induced VEGF mRNA and protein production.	U 0126	88-93	angiotensinogen	Homo sapiens	159-164
18973754-7	2009	The addition of either the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 or Akt inhibitor LY294002 also led to a marked inhibition of the AngII-induced VEGF mRNA and protein production.	U 0126	88-93	vascular endothelial growth factor A	Homo sapiens	173-177
18835871-8	2009	The blockade of MEK (by U0126) reduced the expression of LH-induced Ar and Ep biosynthesis.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19
19082492-8	2009	Treatment with U0126 and transfection with dominant negative ERK plasmid resulted in the decreased phosphorylation of ERK and Akt.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	61-64
19082492-8	2009	Treatment with U0126 and transfection with dominant negative ERK plasmid resulted in the decreased phosphorylation of ERK and Akt.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	118-121
19082492-8	2009	Treatment with U0126 and transfection with dominant negative ERK plasmid resulted in the decreased phosphorylation of ERK and Akt.	U 0126	15-20	AKT serine/threonine kinase 1	Homo sapiens	126-129
18658095-9	2009	Wounding-, LPA-, and ATP-induced HB-EGF shedding and EGFR activation were attenuated by the MAPK/ERK kinase (MEK) inhibitors PD98059 and U0126, as well as by ADAM10 and -17 inhibitors.	U 0126	137-142	heparin binding EGF like growth factor	Homo sapiens	33-39
18658095-9	2009	Wounding-, LPA-, and ATP-induced HB-EGF shedding and EGFR activation were attenuated by the MAPK/ERK kinase (MEK) inhibitors PD98059 and U0126, as well as by ADAM10 and -17 inhibitors.	U 0126	137-142	epidermal growth factor receptor	Homo sapiens	53-57
18658095-9	2009	Wounding-, LPA-, and ATP-induced HB-EGF shedding and EGFR activation were attenuated by the MAPK/ERK kinase (MEK) inhibitors PD98059 and U0126, as well as by ADAM10 and -17 inhibitors.	U 0126	137-142	mitogen-activated protein kinase 3	Homo sapiens	92-96
18658095-9	2009	Wounding-, LPA-, and ATP-induced HB-EGF shedding and EGFR activation were attenuated by the MAPK/ERK kinase (MEK) inhibitors PD98059 and U0126, as well as by ADAM10 and -17 inhibitors.	U 0126	137-142	mitogen-activated protein kinase 1	Homo sapiens	97-100
19046323-7	2009	Both P6 and U0126 inhibited the stimulatory effect of CNTF on T-type channel expression.	U 0126	12-17	ciliary neurotrophic factor	Gallus gallus	54-58
19122365-7	2009	NMDA-induced CINC-1 mRNA expression was significantly inhibited by U0126, a mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	148-151
19122365-7	2009	NMDA-induced CINC-1 mRNA expression was significantly inhibited by U0126, a mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	161-164
18824136-7	2009	Moreover, both promoter activity and release of IL-8 were inhibited by U0126 and curcumin, but not by SB202190, epigallocatechin 3-gallate and resveratrol.	U 0126	71-76	C-X-C motif chemokine ligand 8	Homo sapiens	48-52
19253433-0	2009	[Protective effect of MEK inhibitor (U0126) on donor testes from ischemia-reperfusion injury after orthotopic testicular transplantation in rats].	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
19253433-1	2009	OBJECTIVE: To determine the effect of MEK inhibitor (U0126) on donor testes from ischemia-reperfusion injury after orthotopic testicular transplantation in rats.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
18824601-8	2008	Reflecting the interaction of STAT3 with other cellular pathways, nifuroxazide shows enhanced cytotoxicity when combined with either the histone deacetylase inhibitor depsipeptide or the MEK inhibitor UO126.	U 0126	201-206	mitogen-activated protein kinase kinase 7	Homo sapiens	187-190
18854173-4	2008	The PAR2-triggered IL-8 release was suppressed by inhibitors of MEK (U0126) or PI3-kinase (LY294002), and PAR2 stimulation indeed activated the downstream kinases, ERK and Akt.	U 0126	69-74	F2R like trypsin receptor 1	Homo sapiens	4-8
18854173-4	2008	The PAR2-triggered IL-8 release was suppressed by inhibitors of MEK (U0126) or PI3-kinase (LY294002), and PAR2 stimulation indeed activated the downstream kinases, ERK and Akt.	U 0126	69-74	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
18854173-4	2008	The PAR2-triggered IL-8 release was suppressed by inhibitors of MEK (U0126) or PI3-kinase (LY294002), and PAR2 stimulation indeed activated the downstream kinases, ERK and Akt.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	64-67
18854173-5	2008	U0126 blocked the phosphorylation of ERK, but not Akt, and LY294002 blocked the phosphorylation of Akt, but not ERK.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	37-40
18834856-6	2008	The specific MEK inhibitor, U0126, significantly blocks TRAIL-mediated NF-kappaB activation and subsequent MMP-9 induction.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
18834856-6	2008	The specific MEK inhibitor, U0126, significantly blocks TRAIL-mediated NF-kappaB activation and subsequent MMP-9 induction.	U 0126	28-33	TNF superfamily member 10	Homo sapiens	56-61
18834856-6	2008	The specific MEK inhibitor, U0126, significantly blocks TRAIL-mediated NF-kappaB activation and subsequent MMP-9 induction.	U 0126	28-33	nuclear factor kappa B subunit 1	Homo sapiens	71-80
18834856-6	2008	The specific MEK inhibitor, U0126, significantly blocks TRAIL-mediated NF-kappaB activation and subsequent MMP-9 induction.	U 0126	28-33	matrix metallopeptidase 9	Homo sapiens	107-112
18806830-4	2008	However, treatment with the MEK1/2 inhibitors U0126, PD184352 or the novel clinical candidate AZD6244 (ARRY-142886) overcomes growth factor independence, causing CRC cell death.	U 0126	46-51	mitogen-activated protein kinase kinase 1	Homo sapiens	28-34
19052522-5	2008	Interestingly, TNF-alpha-induced MMP-9 activity and expression was decreased by UO126 and SB203580, but not by SP600125.	U 0126	80-85	tumor necrosis factor	Homo sapiens	15-24
19052522-5	2008	Interestingly, TNF-alpha-induced MMP-9 activity and expression was decreased by UO126 and SB203580, but not by SP600125.	U 0126	80-85	matrix metallopeptidase 9	Homo sapiens	33-38
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	140-143
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	144-147
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	U 0126	52-57	mechanistic target of rapamycin kinase	Homo sapiens	174-178
18955661-9	2008	The effect of Ang II was abolished by the AT1R antagonist candesartan and the mitogen-activated protein kinase inhibitor UO126, whereas the Ang type 2 receptor antagonist PD-123319 and NO synthase inhibitor N(G)-nitro-L-arginine methyl ester had no effect.	U 0126	121-126	angiotensinogen	Rattus norvegicus	14-20
18552392-11	2008	Pretreatment of cells with SB203580, an inhibitor for p38MAP kinase, reduced the H(2)O(2)- and TGF-beta2-stimulated Hsp27 expression, whereas pretreatment with PD98059 and U0126, specific inhibitors of ERK1/2, and SP600125, a specific c-Jun N-terminal kinase inhibitor, had no effects.	U 0126	172-177	mitogen-activated protein kinase 14	Homo sapiens	54-67
18552392-11	2008	Pretreatment of cells with SB203580, an inhibitor for p38MAP kinase, reduced the H(2)O(2)- and TGF-beta2-stimulated Hsp27 expression, whereas pretreatment with PD98059 and U0126, specific inhibitors of ERK1/2, and SP600125, a specific c-Jun N-terminal kinase inhibitor, had no effects.	U 0126	172-177	transforming growth factor beta 2	Homo sapiens	95-104
18672053-6	2008	Moreover, LY294002, or PD98059, or U0126 partially inhibit 5-HT-stimulated increases in GAD67 or GAD65 expression.	U 0126	35-40	glutamate decarboxylase 1	Rattus norvegicus	88-93
18672053-6	2008	Moreover, LY294002, or PD98059, or U0126 partially inhibit 5-HT-stimulated increases in GAD67 or GAD65 expression.	U 0126	35-40	glutamate decarboxylase 2	Rattus norvegicus	97-102
18468633-9	2008	The MEK inhibitor U0126 decreased phospho-ERK in both HCC lines.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
18468633-9	2008	The MEK inhibitor U0126 decreased phospho-ERK in both HCC lines.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	42-45
19074839-10	2008	In HNSCC cells, the bradykinin-induced expression of COX-2 was inhibited by the EGFR kinase inhibitor gefitinib or mitogen-activated protein kinase kinase inhibitors (PD98059 or U0126).	U 0126	178-183	kininogen 1	Homo sapiens	20-30
19074839-10	2008	In HNSCC cells, the bradykinin-induced expression of COX-2 was inhibited by the EGFR kinase inhibitor gefitinib or mitogen-activated protein kinase kinase inhibitors (PD98059 or U0126).	U 0126	178-183	prostaglandin-endoperoxide synthase 2	Homo sapiens	53-58
19154323-7	2008	Although aldosterone had no effect on collagen I and II expression, it increased expression of alpha-SMA and collagen III and IV and decreased that of E-cadherin in HKC cells after 48 h. These effects could be prevented by a ERK pathway inhibitor, U0126, or by a selective MR antagonist, spironolactone.	U 0126	248-253	cadherin 1	Homo sapiens	151-161
19154323-7	2008	Although aldosterone had no effect on collagen I and II expression, it increased expression of alpha-SMA and collagen III and IV and decreased that of E-cadherin in HKC cells after 48 h. These effects could be prevented by a ERK pathway inhibitor, U0126, or by a selective MR antagonist, spironolactone.	U 0126	248-253	mitogen-activated protein kinase 3	Homo sapiens	225-228
18758753-10	2008	Up-regulated mRNA and protein expression of c-fos and fosB was abolished by SB204741, AG1478, and by U0126, an inhibitor of ERK phosphorylation by MAP kinase/ERK kinase.	U 0126	101-106	FBJ osteosarcoma oncogene	Mus musculus	44-49
18758753-10	2008	Up-regulated mRNA and protein expression of c-fos and fosB was abolished by SB204741, AG1478, and by U0126, an inhibitor of ERK phosphorylation by MAP kinase/ERK kinase.	U 0126	101-106	FBJ osteosarcoma oncogene B	Mus musculus	54-58
18758753-10	2008	Up-regulated mRNA and protein expression of c-fos and fosB was abolished by SB204741, AG1478, and by U0126, an inhibitor of ERK phosphorylation by MAP kinase/ERK kinase.	U 0126	101-106	mitogen-activated protein kinase 1	Mus musculus	124-127
18758753-10	2008	Up-regulated mRNA and protein expression of c-fos and fosB was abolished by SB204741, AG1478, and by U0126, an inhibitor of ERK phosphorylation by MAP kinase/ERK kinase.	U 0126	101-106	mitogen-activated protein kinase 1	Mus musculus	158-161
18588920-5	2008	Furthermore, the OFQ-induced nociception could be attenuated by pretreatment with the mitogen-activated protein kinase/ERK kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminopheylthio)butadiene (U0126).	U 0126	206-211	Eph receptor B1	Rattus norvegicus	119-122
18588920-7	2008	The effect was blocked by the antagonist (Nphe(1))nociceptin(1-13)NH(2) and attenuated by U0126, suggesting that the activation of ERK pathways is involved in the OFQ-induced nociceptive effect in the NAc of rats.	U 0126	90-95	Eph receptor B1	Rattus norvegicus	131-134
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P &gt; 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P &lt; 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P &lt; 0.05], as compared with those of the PMA treated group.	U 0126	11-16	gap junction protein alpha 1	Homo sapiens	45-55
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P &gt; 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P &lt; 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P &lt; 0.05], as compared with those of the PMA treated group.	U 0126	11-16	mitogen-activated protein kinase 3	Homo sapiens	151-157
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P &gt; 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P &lt; 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P &lt; 0.05], as compared with those of the PMA treated group.	U 0126	11-16	mitogen-activated protein kinase 3	Homo sapiens	161-167
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P &gt; 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P &lt; 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P &lt; 0.05], as compared with those of the PMA treated group.	U 0126	11-16	cyclin D1	Homo sapiens	197-205
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P &gt; 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P &lt; 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P &lt; 0.05], as compared with those of the PMA treated group.	U 0126	11-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	207-210
19134409-7	2008	In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P &gt; 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P &lt; 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P &lt; 0.05], as compared with those of the PMA treated group.	U 0126	11-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	211-215
18725270-5	2008	Localized peripheral administration of a single dose of the MEK inhibitor U0126 (1 mug/10 mul) significantly suppressed neuronal hyper-responsiveness to thermal stimulus and chemical (melittin)-induced tonic firing of WDR neurons after full establishment of a spinally sensitized state.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
19080332-3	2008	The aim of this study was to investigate interactions and cross-talks between MEK1/2-extracellular signal-related kinase (ERK1/2) signaling and G protein-couple signaling in synoviocytes of collagen-induced arthritis (CIA) rats by the stimulation of interleukin-1 (IL-1), U0126, isoprenaline hydrochloride and aminophylline respectively.	U 0126	272-277	mitogen activated protein kinase kinase 1	Rattus norvegicus	78-84
19080332-3	2008	The aim of this study was to investigate interactions and cross-talks between MEK1/2-extracellular signal-related kinase (ERK1/2) signaling and G protein-couple signaling in synoviocytes of collagen-induced arthritis (CIA) rats by the stimulation of interleukin-1 (IL-1), U0126, isoprenaline hydrochloride and aminophylline respectively.	U 0126	272-277	mitogen activated protein kinase 3	Rattus norvegicus	122-128
19080332-13	2008	U0126 inhibited Gi, cAMP and PKA of synoviocytes stimulated by rIL-1alpha.	U 0126	0-5	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	29-32
19080332-13	2008	U0126 inhibited Gi, cAMP and PKA of synoviocytes stimulated by rIL-1alpha.	U 0126	0-5	interleukin 1 alpha	Rattus norvegicus	63-73
19020031-8	2008	Relative to vehicle controls, infusion of U0126 impaired training-induced increases in Arc/Arg3.1 expression.	U 0126	42-47	activity-regulated cytoskeleton-associated protein	Rattus norvegicus	87-97
18715715-11	2008	U0126, a specific inhibitor of the MEK1/2, greatly down-regulated the enhanced current.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	35-41
18828601-6	2008	The inhibition of GJIC and phosphorylation of Cx43 and ERK1/2 by EGCG were completely blocked by U0126, a pharmacological inhibitor of mitogen-activated protein kinase/ERK kinase.	U 0126	97-102	gap junction protein, alpha 1	Rattus norvegicus	46-50
18685068-9	2008	KT5720 and U0126 significantly inhibited the AM-induced lipolysis, whereas KT5720, but not U0126, significantly inhibited the isoproterenol-induced lipolysis.	U 0126	11-16	adrenomedullin	Rattus norvegicus	45-47
18701654-6	2008	Azide"s effect on p-ERK1/2 abundance and glucose transport in Clone 9 cells was partially abolished by the MEK1/2 inhibitor U0126.	U 0126	124-129	mitogen activated protein kinase 3	Rattus norvegicus	20-26
18701654-6	2008	Azide"s effect on p-ERK1/2 abundance and glucose transport in Clone 9 cells was partially abolished by the MEK1/2 inhibitor U0126.	U 0126	124-129	mitogen activated protein kinase kinase 1	Rattus norvegicus	107-113
18775851-7	2008	U-0126 blocked the phosphorylation and nuclear translocation of both ERK1/2 and p53, whereas PFT-alpha blocked only the changes in p53.	U 0126	0-6	mitogen activated protein kinase 3	Rattus norvegicus	69-75
18775851-7	2008	U-0126 blocked the phosphorylation and nuclear translocation of both ERK1/2 and p53, whereas PFT-alpha blocked only the changes in p53.	U 0126	0-6	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	80-83
19093035-7	2008	Pre-treatment with the MAP kinase kinase (MEK)-1/2 inhibitor U0126 showed that cytokine-triggered NF-kappaB nuclear translocation and transcriptional activity are mediated by activation of extracellular regulated kinase (ERK).	U 0126	61-66	mitogen-activated protein kinase kinase 2	Homo sapiens	23-50
19093035-7	2008	Pre-treatment with the MAP kinase kinase (MEK)-1/2 inhibitor U0126 showed that cytokine-triggered NF-kappaB nuclear translocation and transcriptional activity are mediated by activation of extracellular regulated kinase (ERK).	U 0126	61-66	nuclear factor kappa B subunit 1	Homo sapiens	98-107
19093035-7	2008	Pre-treatment with the MAP kinase kinase (MEK)-1/2 inhibitor U0126 showed that cytokine-triggered NF-kappaB nuclear translocation and transcriptional activity are mediated by activation of extracellular regulated kinase (ERK).	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	189-219
19093035-7	2008	Pre-treatment with the MAP kinase kinase (MEK)-1/2 inhibitor U0126 showed that cytokine-triggered NF-kappaB nuclear translocation and transcriptional activity are mediated by activation of extracellular regulated kinase (ERK).	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	221-224
18949356-6	2008	Studies with signaling molecule inhibitors AG1478, U0126 and SB203580 (specific inhibitors of EGFR, MEK1/2 and p38 respectively) showed inhibition of uPA levels in both basal and irradiated-IOMM-Lee cells.	U 0126	51-56	mitogen-activated protein kinase kinase 1	Homo sapiens	100-106
18949356-6	2008	Studies with signaling molecule inhibitors AG1478, U0126 and SB203580 (specific inhibitors of EGFR, MEK1/2 and p38 respectively) showed inhibition of uPA levels in both basal and irradiated-IOMM-Lee cells.	U 0126	51-56	mitogen-activated protein kinase 14	Homo sapiens	111-114
18949356-6	2008	Studies with signaling molecule inhibitors AG1478, U0126 and SB203580 (specific inhibitors of EGFR, MEK1/2 and p38 respectively) showed inhibition of uPA levels in both basal and irradiated-IOMM-Lee cells.	U 0126	51-56	plasminogen activator, urokinase	Homo sapiens	150-153
18641171-9	2008	The mitogen-activated protein kinase kinase inhibitor, U0126, effectively decreased mitogen-activated protein kinase phosphorylation and stimulated differentiation in ASB15- and ASB15Con cells.	U 0126	55-60	ankyrin repeat and SOCS box-containing 15	Mus musculus	167-172
18641171-9	2008	The mitogen-activated protein kinase kinase inhibitor, U0126, effectively decreased mitogen-activated protein kinase phosphorylation and stimulated differentiation in ASB15- and ASB15Con cells.	U 0126	55-60	ankyrin repeat and SOCS box-containing 15	Mus musculus	178-183
18824519-5	2009	This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126.	U 0126	100-105	mitogen-activated protein kinase 1	Mus musculus	30-33
18824519-5	2009	This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126.	U 0126	100-105	mitogen-activated protein kinase 1	Mus musculus	68-72
18824519-5	2009	This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126.	U 0126	100-105	mitogen-activated protein kinase 1	Mus musculus	73-76
19109160-9	2009	A MEK1/2 inhibitor (U0126) significantly inhibited MUC5AC production.	U 0126	20-25	mitogen-activated protein kinase kinase 1	Homo sapiens	2-8
19109160-9	2009	A MEK1/2 inhibitor (U0126) significantly inhibited MUC5AC production.	U 0126	20-25	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	51-57
18668140-8	2009	Treatment of melanoma cells with the MEK inhibitor U0126 decreased NF-kappaB binding to its DNA recognition sequence, implicating the MAPK pathway in NF-kappaB activation.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	37-40
18668140-8	2009	Treatment of melanoma cells with the MEK inhibitor U0126 decreased NF-kappaB binding to its DNA recognition sequence, implicating the MAPK pathway in NF-kappaB activation.	U 0126	51-56	nuclear factor kappa B subunit 1	Homo sapiens	67-76
18668140-8	2009	Treatment of melanoma cells with the MEK inhibitor U0126 decreased NF-kappaB binding to its DNA recognition sequence, implicating the MAPK pathway in NF-kappaB activation.	U 0126	51-56	nuclear factor kappa B subunit 1	Homo sapiens	150-159
19590238-9	2009	YB-1-stimulated cell proliferation was blocked by U0126, a specific inhibitor of ERK1/2.	U 0126	50-55	Y box binding protein 1	Rattus norvegicus	0-4
19590238-9	2009	YB-1-stimulated cell proliferation was blocked by U0126, a specific inhibitor of ERK1/2.	U 0126	50-55	mitogen activated protein kinase 3	Rattus norvegicus	81-87
19590238-10	2009	ERK1/2 regulated YB-1 expression in MCs stimulated with TGF-beta, an effect that was inhibited by U0126.	U 0126	98-103	mitogen activated protein kinase 3	Rattus norvegicus	0-6
19590238-10	2009	ERK1/2 regulated YB-1 expression in MCs stimulated with TGF-beta, an effect that was inhibited by U0126.	U 0126	98-103	Y box binding protein 1	Rattus norvegicus	17-21
19082454-6	2009	Furthermore, we examined the effects of U0126, a specific inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK), on migration and invasion in SACC-LM cells, showing U0126 not only inactivated ERK1/2, but also inhibited migration and invasion of SACC-LM.	U 0126	40-45	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
19082454-6	2009	Furthermore, we examined the effects of U0126, a specific inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK), on migration and invasion in SACC-LM cells, showing U0126 not only inactivated ERK1/2, but also inhibited migration and invasion of SACC-LM.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	206-212
19082454-6	2009	Furthermore, we examined the effects of U0126, a specific inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK), on migration and invasion in SACC-LM cells, showing U0126 not only inactivated ERK1/2, but also inhibited migration and invasion of SACC-LM.	U 0126	179-184	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
19082454-6	2009	Furthermore, we examined the effects of U0126, a specific inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK), on migration and invasion in SACC-LM cells, showing U0126 not only inactivated ERK1/2, but also inhibited migration and invasion of SACC-LM.	U 0126	179-184	mitogen-activated protein kinase 3	Homo sapiens	206-212
19672126-15	2009	In HCEC, a p38 (SB203580) and a JNK pathway inhibitor (JNK inhibitor I) inhibited migration rates more than U0126-induced ERK, whereas the JNK inhibitor I inactive analogue had no effect.	U 0126	108-113	mitogen-activated protein kinase 14	Mus musculus	11-14
19672126-15	2009	In HCEC, a p38 (SB203580) and a JNK pathway inhibitor (JNK inhibitor I) inhibited migration rates more than U0126-induced ERK, whereas the JNK inhibitor I inactive analogue had no effect.	U 0126	108-113	mitogen-activated protein kinase 1	Mus musculus	122-125
18637712-8	2009	hsBAFF-stimulated B cell proliferation was obviously reduced by mitogen extracellular kinase 1/2 (MEK1/2, upstream of ERK1/2) inhibitor U0126.	U 0126	136-141	mitogen-activated protein kinase kinase 1	Mus musculus	98-104
18637712-8	2009	hsBAFF-stimulated B cell proliferation was obviously reduced by mitogen extracellular kinase 1/2 (MEK1/2, upstream of ERK1/2) inhibitor U0126.	U 0126	136-141	mitogen-activated protein kinase 3	Mus musculus	118-124
19877417-7	2009	MLA increased the effect of the MEK1/2 kinase inhibitor (U0126), while suppressive effect of MLA itself was decreased.	U 0126	57-62	mitogen-activated protein kinase kinase 2	Gallus gallus	32-38
18798257-7	2008	When Erk1/2 was inhibited by U0126 before addition of OSU03012, growth inhibition and apoptosis induced by OSU03012 were attenuated.	U 0126	29-34	mitogen-activated protein kinase 3	Homo sapiens	5-11
18798257-9	2008	When cells were allowed to accumulate in S-phase before addition of U0126, apoptosis also was attenuated suggesting that Erk1/2 is required for both progression of cells into the S-phase and apoptosis.	U 0126	68-73	mitogen-activated protein kinase 3	Homo sapiens	121-127
19052216-7	2008	Finally, stimulation of central amygdala ERK and CREB phosphorylation by NMDA enhanced drug CPP after 1 d of withdrawal from morphine, an effect reversed by U0126.	U 0126	157-162	Eph receptor B1	Rattus norvegicus	41-44
19052216-7	2008	Finally, stimulation of central amygdala ERK and CREB phosphorylation by NMDA enhanced drug CPP after 1 d of withdrawal from morphine, an effect reversed by U0126.	U 0126	157-162	cAMP responsive element binding protein 1	Rattus norvegicus	49-53
19093255-6	2008	Treatment of tumor cells with U-0126, an inhibitor of MAPK/Erk, also down-regulated MMP11 and MDR1 expression.	U 0126	30-36	mitogen-activated protein kinase 1	Homo sapiens	59-62
19093255-6	2008	Treatment of tumor cells with U-0126, an inhibitor of MAPK/Erk, also down-regulated MMP11 and MDR1 expression.	U 0126	30-36	matrix metallopeptidase 11	Homo sapiens	84-89
19093255-6	2008	Treatment of tumor cells with U-0126, an inhibitor of MAPK/Erk, also down-regulated MMP11 and MDR1 expression.	U 0126	30-36	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
18810761-6	2008	Inhibition of ERK activation by U0126 suppressed the effects of La3+ on osteoblast activity.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	14-17
19088370-3	2008	Treatment with As(2)O(3) resulted in rapid phosphorylation of the p42/p44 MAPK which could be abolished by addition of the MAPK inhibitor, U0126.	U 0126	139-144	cyclin dependent kinase 20	Homo sapiens	66-69
19088370-3	2008	Treatment with As(2)O(3) resulted in rapid phosphorylation of the p42/p44 MAPK which could be abolished by addition of the MAPK inhibitor, U0126.	U 0126	139-144	mitogen-activated protein kinase 3	Homo sapiens	70-78
19040998-10	2008	Furthermore, treatment of Raf-1-activated cells with U0126, a specific inhibitor of MEK, abrogated these Raf-1-induced effects indicating that the suppression of the metastatic phenotype in MTC cells is a MEK-dependent pathway.	U 0126	53-58	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	26-31
19040998-10	2008	Furthermore, treatment of Raf-1-activated cells with U0126, a specific inhibitor of MEK, abrogated these Raf-1-induced effects indicating that the suppression of the metastatic phenotype in MTC cells is a MEK-dependent pathway.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
19040998-10	2008	Furthermore, treatment of Raf-1-activated cells with U0126, a specific inhibitor of MEK, abrogated these Raf-1-induced effects indicating that the suppression of the metastatic phenotype in MTC cells is a MEK-dependent pathway.	U 0126	53-58	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	105-110
19040998-10	2008	Furthermore, treatment of Raf-1-activated cells with U0126, a specific inhibitor of MEK, abrogated these Raf-1-induced effects indicating that the suppression of the metastatic phenotype in MTC cells is a MEK-dependent pathway.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	205-208
18695355-8	2008	Cytochrome c release during osteoclast apoptosis was inhibited by AG490 treatment, but this effect was inhibited in the presence of LY294002 or U0126.	U 0126	144-149	cytochrome c, somatic	Homo sapiens	0-12
18959417-6	2008	Inhibitors of ERK (U0126) and Akt (LY294002), but not JNK (SP600125) and p38 MAPK (SB203580), suppressed SeC-induced S-phase arrest and apoptosis in MCF-7 cells.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	14-17
18703234-6	2008	Thus, exposure of BV-2 cells to IFN-gamma in the presence of the selective MEK inhibitor U0126 or a neutralizing anti-TNF-alpha antibody significantly reduced IFN-gamma dependent NF-kappa B activation and iNOs expression.	U 0126	89-94	interferon gamma	Mus musculus	32-41
18703234-6	2008	Thus, exposure of BV-2 cells to IFN-gamma in the presence of the selective MEK inhibitor U0126 or a neutralizing anti-TNF-alpha antibody significantly reduced IFN-gamma dependent NF-kappa B activation and iNOs expression.	U 0126	89-94	midkine	Mus musculus	75-78
18703234-6	2008	Thus, exposure of BV-2 cells to IFN-gamma in the presence of the selective MEK inhibitor U0126 or a neutralizing anti-TNF-alpha antibody significantly reduced IFN-gamma dependent NF-kappa B activation and iNOs expression.	U 0126	89-94	interferon gamma	Mus musculus	159-168
18703234-6	2008	Thus, exposure of BV-2 cells to IFN-gamma in the presence of the selective MEK inhibitor U0126 or a neutralizing anti-TNF-alpha antibody significantly reduced IFN-gamma dependent NF-kappa B activation and iNOs expression.	U 0126	89-94	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	179-189
18703234-6	2008	Thus, exposure of BV-2 cells to IFN-gamma in the presence of the selective MEK inhibitor U0126 or a neutralizing anti-TNF-alpha antibody significantly reduced IFN-gamma dependent NF-kappa B activation and iNOs expression.	U 0126	89-94	nitric oxide synthase 2, inducible	Mus musculus	205-209
18828601-6	2008	The inhibition of GJIC and phosphorylation of Cx43 and ERK1/2 by EGCG were completely blocked by U0126, a pharmacological inhibitor of mitogen-activated protein kinase/ERK kinase.	U 0126	97-102	mitogen activated protein kinase 3	Rattus norvegicus	55-61
18828601-6	2008	The inhibition of GJIC and phosphorylation of Cx43 and ERK1/2 by EGCG were completely blocked by U0126, a pharmacological inhibitor of mitogen-activated protein kinase/ERK kinase.	U 0126	97-102	mitogen activated protein kinase 3	Rattus norvegicus	55-58
19080172-7	2008	However, the changes of LDH activity, apoptosis rate, and caspase-3 activity were inhibited by LY294002 and UO126 respectively.	U 0126	108-113	caspase 3	Rattus norvegicus	58-67
18954524-9	2008	Inhibition of ERK by U0126 (1,4-diamino-2,3-dicyano- 1,4-bis[2-aminophenylthio]butadiene) significantly suppressed uric acid-induced ET-1 expression, implicating this pathway in the response to uric acid.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	14-17
18954524-9	2008	Inhibition of ERK by U0126 (1,4-diamino-2,3-dicyano- 1,4-bis[2-aminophenylthio]butadiene) significantly suppressed uric acid-induced ET-1 expression, implicating this pathway in the response to uric acid.	U 0126	21-26	endothelin 1	Homo sapiens	133-137
18954524-9	2008	Inhibition of ERK by U0126 (1,4-diamino-2,3-dicyano- 1,4-bis[2-aminophenylthio]butadiene) significantly suppressed uric acid-induced ET-1 expression, implicating this pathway in the response to uric acid.	U 0126	28-88	mitogen-activated protein kinase 1	Homo sapiens	14-17
18954524-9	2008	Inhibition of ERK by U0126 (1,4-diamino-2,3-dicyano- 1,4-bis[2-aminophenylthio]butadiene) significantly suppressed uric acid-induced ET-1 expression, implicating this pathway in the response to uric acid.	U 0126	28-88	endothelin 1	Homo sapiens	133-137
18775851-6	2008	The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-alpha, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin.	U 0126	131-137	mitogen activated protein kinase 3	Rattus norvegicus	29-35
18775851-6	2008	The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-alpha, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin.	U 0126	131-137	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	40-43
18775851-6	2008	The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-alpha, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin.	U 0126	131-137	Eph receptor B1	Rattus norvegicus	29-32
18775851-6	2008	The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-alpha, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin.	U 0126	131-137	BCL2, apoptosis regulator	Rattus norvegicus	210-215
18764868-5	2008	Phosphorylation of ERK1/2 mitogen-activated protein kinase (MAPK) induced by G-CSF inhibited by the antioxidant N-acetyl-L-cysteine (NAC), ERK1/2 inhibitor PD98059, or U0126.	U 0126	168-173	mitogen-activated protein kinase 3	Homo sapiens	19-25
18764868-5	2008	Phosphorylation of ERK1/2 mitogen-activated protein kinase (MAPK) induced by G-CSF inhibited by the antioxidant N-acetyl-L-cysteine (NAC), ERK1/2 inhibitor PD98059, or U0126.	U 0126	168-173	mitogen-activated protein kinase 3	Homo sapiens	60-64
18764868-5	2008	Phosphorylation of ERK1/2 mitogen-activated protein kinase (MAPK) induced by G-CSF inhibited by the antioxidant N-acetyl-L-cysteine (NAC), ERK1/2 inhibitor PD98059, or U0126.	U 0126	168-173	colony stimulating factor 3	Homo sapiens	77-82
18764868-5	2008	Phosphorylation of ERK1/2 mitogen-activated protein kinase (MAPK) induced by G-CSF inhibited by the antioxidant N-acetyl-L-cysteine (NAC), ERK1/2 inhibitor PD98059, or U0126.	U 0126	168-173	mitogen-activated protein kinase 3	Homo sapiens	139-145
18767967-6	2008	U0126, a selective inhibitor of upstream MEK, had a similar effect as PD98059 on butyrate-induced GADD153 mRNA upregulation.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
18767967-6	2008	U0126, a selective inhibitor of upstream MEK, had a similar effect as PD98059 on butyrate-induced GADD153 mRNA upregulation.	U 0126	0-5	DNA damage inducible transcript 3	Homo sapiens	98-105
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	mitogen-activated protein kinase 14	Homo sapiens	4-7
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	12-15
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	interleukin 17A	Homo sapiens	88-93
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	C-X-C motif chemokine ligand 10	Homo sapiens	97-103
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	interleukin 17A	Homo sapiens	183-188
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	C-X-C motif chemokine ligand 8	Homo sapiens	192-197
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	220-224
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	C-X-C motif chemokine ligand 10	Homo sapiens	283-289
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	C-X-C motif chemokine ligand 8	Homo sapiens	315-320
18941244-8	2008	The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17.	U 0126	48-53	interleukin 17A	Homo sapiens	183-188
19130938-6	2009	RESULTS: Pretreatment of effector CD8(+) T cells with U0126 suppressed anti-CD3/anti-CD28-induced ERK1/2 phosphorylation and cytokine production, but did not affect LTB(4)-induced Ca(2+) mobilization or chemotaxis.	U 0126	54-59	CD28 antigen	Mus musculus	85-89
19130938-6	2009	RESULTS: Pretreatment of effector CD8(+) T cells with U0126 suppressed anti-CD3/anti-CD28-induced ERK1/2 phosphorylation and cytokine production, but did not affect LTB(4)-induced Ca(2+) mobilization or chemotaxis.	U 0126	54-59	mitogen-activated protein kinase 3	Mus musculus	98-104
19130938-7	2009	Adoptive transfer of U0126-treated CD8(+) T cells into sensitized mice before secondary allergen challenge resulted in significant decreases in AHR, eosinophilic inflammation, goblet cell metaplasia, and IL-5 and IL-13 levels in bronchoalveolar lavage fluid of recipient mice.	U 0126	21-26	interleukin 5	Mus musculus	204-208
19130938-7	2009	Adoptive transfer of U0126-treated CD8(+) T cells into sensitized mice before secondary allergen challenge resulted in significant decreases in AHR, eosinophilic inflammation, goblet cell metaplasia, and IL-5 and IL-13 levels in bronchoalveolar lavage fluid of recipient mice.	U 0126	21-26	interleukin 13	Mus musculus	213-218
18989526-10	2008	MEK/ERK inhibitor U0126 blocked PMA effect on promoter activity of the -1042/-1 construct.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
18496814-7	2008	Among various signal inhibitors, the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 also inhibited PMA-induced COX-2 expression and COX-2 promoter activation.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	37-80
18496814-7	2008	Among various signal inhibitors, the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 also inhibited PMA-induced COX-2 expression and COX-2 promoter activation.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
18496814-7	2008	Among various signal inhibitors, the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 also inhibited PMA-induced COX-2 expression and COX-2 promoter activation.	U 0126	100-105	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-138
18496814-7	2008	Among various signal inhibitors, the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 also inhibited PMA-induced COX-2 expression and COX-2 promoter activation.	U 0126	100-105	prostaglandin-endoperoxide synthase 2	Homo sapiens	154-159
18496814-8	2008	The activity of AP-1-driven promoter, but not nuclear factor-kappa B (NF-kappaB), was inhibited by U0126.	U 0126	99-104	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-20
18787043-4	2008	We found that short-term inhibition of p42/p44 MAPK activity either by a MAPK kinase inhibitor, U0126, or by depletion of kinase with small interfering RNA caused target gene-specific reductions in AR activity.	U 0126	96-101	cyclin dependent kinase 20	Homo sapiens	39-42
18787043-4	2008	We found that short-term inhibition of p42/p44 MAPK activity either by a MAPK kinase inhibitor, U0126, or by depletion of kinase with small interfering RNA caused target gene-specific reductions in AR activity.	U 0126	96-101	general transcription factor IIH subunit 2	Homo sapiens	43-46
18787043-4	2008	We found that short-term inhibition of p42/p44 MAPK activity either by a MAPK kinase inhibitor, U0126, or by depletion of kinase with small interfering RNA caused target gene-specific reductions in AR activity.	U 0126	96-101	androgen receptor	Homo sapiens	198-200
18787043-5	2008	AR enhances histone H3 acetylation of target genes that are sensitive to U0126 including prostate-specific antigen and TMPRSS2, but does not increase histone H3 acetylation of the U0126-resistant PMEPA1 gene.	U 0126	73-78	androgen receptor	Homo sapiens	0-2
18787043-7	2008	Long-term treatment (24-48 h) with U0126 causes a G1 cell cycle arrest and reduces AR expression both through a decrease in AR mRNA and a reduction in AR protein stability.	U 0126	35-40	androgen receptor	Homo sapiens	83-85
18787043-7	2008	Long-term treatment (24-48 h) with U0126 causes a G1 cell cycle arrest and reduces AR expression both through a decrease in AR mRNA and a reduction in AR protein stability.	U 0126	35-40	androgen receptor	Homo sapiens	124-126
18787043-7	2008	Long-term treatment (24-48 h) with U0126 causes a G1 cell cycle arrest and reduces AR expression both through a decrease in AR mRNA and a reduction in AR protein stability.	U 0126	35-40	androgen receptor	Homo sapiens	124-126
18989526-10	2008	MEK/ERK inhibitor U0126 blocked PMA effect on promoter activity of the -1042/-1 construct.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
18726893-10	2008	Inhibition of ERK activation with the MEK inhibitor U0126 had minor effects on adherent cell growth, but greatly decreased growth in soft agar.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
18726893-10	2008	Inhibition of ERK activation with the MEK inhibitor U0126 had minor effects on adherent cell growth, but greatly decreased growth in soft agar.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	14-17
18847491-11	2008	Pretreatment of cells with pifithrin-alpha or U0126, specific inhibitors of p53 or MEK-1/2, significantly attenuated Triphala-induced apoptosis.	U 0126	46-51	tumor protein p53	Homo sapiens	76-79
18847491-11	2008	Pretreatment of cells with pifithrin-alpha or U0126, specific inhibitors of p53 or MEK-1/2, significantly attenuated Triphala-induced apoptosis.	U 0126	46-51	mitogen-activated protein kinase kinase 1	Homo sapiens	83-90
18847491-12	2008	Moreover, NAC or U0126 pretreatment significantly attenuated Triphala-induced p53 transcriptional activity.	U 0126	17-22	tumor protein p53	Homo sapiens	78-81
18832566-5	2008	Interestingly, YC-1-induced enhancement of LTP in the LA was reversed by concurrent application of the MEK inhibitor U0126, suggesting that the NO-cGMP-PKG signaling pathway may promote synaptic plasticity and fear memory formation in the LA, in part by activating the ERK/MAPK signaling cascade.	U 0126	117-122	glutathione S-transferase alpha 1	Rattus norvegicus	15-19
18832566-5	2008	Interestingly, YC-1-induced enhancement of LTP in the LA was reversed by concurrent application of the MEK inhibitor U0126, suggesting that the NO-cGMP-PKG signaling pathway may promote synaptic plasticity and fear memory formation in the LA, in part by activating the ERK/MAPK signaling cascade.	U 0126	117-122	Eph receptor B1	Rattus norvegicus	269-272
18676875-9	2008	MAPK inhibitor U0126 decreased CTGF-induced cell migration and did not interfere with CTGF-induced IQGAP1 expression, suggesting that MAPK pathway is downstream of IQGAP1.	U 0126	15-20	cellular communication network factor 2	Homo sapiens	31-35
18567640-7	2008	Incubation of ventricular cardiomyocytes with PGE(2) led to a time-dependent decrease in the DOX-induced caspase3 activation, reaching a maximal inhibition of 70 +/- 5% after 4 h. Similarly, PGE(2) inhibited DOX-induced DNA fragmentation by 58 +/- 5% after 24 h. This antiapoptotic action of PGE(2) was strongly reduced by the ERK1/2 inhibitor, U0126, whereas the p38 MAP kinase inhibitor, SB203580, had no effect.	U 0126	345-350	caspase 3	Rattus norvegicus	105-113
18655827-8	2008	Furthermore, a MEK-specific inhibitor (U0126) abrogated BK-induced TGF-beta1 secretion, Smad2 phosphorylation, and alpha-SMA expression.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	15-18
18667445-8	2008	Moreover, suppression of MAP kinase by small-interfering RNA or its upstream MEK1/2-selective inhibitor U0126 abrogated cell invasion enhanced by Aur-A overexpression.	U 0126	104-109	mitogen-activated protein kinase kinase 1	Homo sapiens	77-83
18667445-8	2008	Moreover, suppression of MAP kinase by small-interfering RNA or its upstream MEK1/2-selective inhibitor U0126 abrogated cell invasion enhanced by Aur-A overexpression.	U 0126	104-109	aurora kinase A	Homo sapiens	146-151
18655827-8	2008	Furthermore, a MEK-specific inhibitor (U0126) abrogated BK-induced TGF-beta1 secretion, Smad2 phosphorylation, and alpha-SMA expression.	U 0126	39-44	transforming growth factor beta 1	Homo sapiens	67-76
18655827-8	2008	Furthermore, a MEK-specific inhibitor (U0126) abrogated BK-induced TGF-beta1 secretion, Smad2 phosphorylation, and alpha-SMA expression.	U 0126	39-44	SMAD family member 2	Homo sapiens	88-93
18707899-8	2008	Inhibition of ERK1/2 activity by the ERK-selective inhibitor U0126 reverses the ability of IL-21 to upregulate cytokine production, suggesting that IL-21-induced cytokine production is dependent on ERK1/2 activation.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	14-20
18707899-8	2008	Inhibition of ERK1/2 activity by the ERK-selective inhibitor U0126 reverses the ability of IL-21 to upregulate cytokine production, suggesting that IL-21-induced cytokine production is dependent on ERK1/2 activation.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	14-17
18707899-8	2008	Inhibition of ERK1/2 activity by the ERK-selective inhibitor U0126 reverses the ability of IL-21 to upregulate cytokine production, suggesting that IL-21-induced cytokine production is dependent on ERK1/2 activation.	U 0126	61-66	interleukin 21	Homo sapiens	91-96
18707899-8	2008	Inhibition of ERK1/2 activity by the ERK-selective inhibitor U0126 reverses the ability of IL-21 to upregulate cytokine production, suggesting that IL-21-induced cytokine production is dependent on ERK1/2 activation.	U 0126	61-66	interleukin 21	Homo sapiens	148-153
18599551-9	2008	Blockade of ERK1/2 with PD98059 and U0126 prevented the effect of androgen on HERG protein abundance.	U 0126	36-41	potassium voltage-gated channel subfamily H member 2	Homo sapiens	78-82
18583546-9	2008	In addition, PGE(2) and butaprost increased c-Fos expression and activator protein 1 (AP-1) transcriptional activity, which were abolished by the mitogen-activated protein kinase/Erk kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-butadiene ethanolate (U0126).	U 0126	277-282	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
18703135-9	2008	Pretreatment with inhibitors of JNK (SP600125) and Erk1/2 (U0126) partially blocked Cd-induced cleavage of caspase-3 and prevented cell death.	U 0126	59-64	mitogen-activated protein kinase 3	Homo sapiens	51-57
18703135-9	2008	Pretreatment with inhibitors of JNK (SP600125) and Erk1/2 (U0126) partially blocked Cd-induced cleavage of caspase-3 and prevented cell death.	U 0126	59-64	caspase 3	Homo sapiens	107-116
19125865-6	2008	Cannula-directed infusion of a pharmacological inhibitor of ERK activation (U0126) immediately before training blocked the development of habituation of the zenk gene response.	U 0126	76-81	mitogen-activated protein kinase 1	Homo sapiens	60-63
18583546-9	2008	In addition, PGE(2) and butaprost increased c-Fos expression and activator protein 1 (AP-1) transcriptional activity, which were abolished by the mitogen-activated protein kinase/Erk kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-butadiene ethanolate (U0126).	U 0126	277-282	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
18583546-9	2008	In addition, PGE(2) and butaprost increased c-Fos expression and activator protein 1 (AP-1) transcriptional activity, which were abolished by the mitogen-activated protein kinase/Erk kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-butadiene ethanolate (U0126).	U 0126	277-282	mitogen-activated protein kinase 1	Homo sapiens	179-182
18270979-10	2008	Forth, treatment with U0126, a non-competitive MEK1/2 inhibitor, did not affect germinal vesicle breakdown, but caused chromosome mis-alignment in all MI oocytes examined and abnormal spindle organization as well as small cytoplasmic spindle-like structure formation in MII oocytes.	U 0126	22-27	mitogen activated protein kinase kinase 1	Rattus norvegicus	47-53
18710947-7	2008	SPC recruitment and protein changes were inhibited by siRNA specific to lactate dehydrogenase, TrxR, or HIF-1 and by oxamate, apocynin, U0126, N-acetylcysteine, dithioerythritol, and antibodies to VEGF or SDF-1.	U 0126	136-141	sparse coat	Mus musculus	0-3
18694962-4	2008	The key site, serine 454, resembles a mitogen-activated protein kinase phosphorylation site, and its modification was blocked by the MEK1 inhibitor U0126, implying that extracellular signal-regulated kinase 1/2 (ERK1/2) is the serum-inducible kinase that phosphorylates MKL1.	U 0126	148-153	mitogen-activated protein kinase kinase 1	Homo sapiens	133-137
18694962-4	2008	The key site, serine 454, resembles a mitogen-activated protein kinase phosphorylation site, and its modification was blocked by the MEK1 inhibitor U0126, implying that extracellular signal-regulated kinase 1/2 (ERK1/2) is the serum-inducible kinase that phosphorylates MKL1.	U 0126	148-153	mitogen-activated protein kinase 1	Homo sapiens	169-210
18644622-6	2008	Furthermore, neuroprotection of CART is abolished by CART knockdown and by pretreatment with ERK antagonist PD98059 and U0126, but not with p38 or JNK antagonists SB203580 or SP600125.	U 0126	120-125	CART prepropeptide	Mus musculus	32-36
18694962-4	2008	The key site, serine 454, resembles a mitogen-activated protein kinase phosphorylation site, and its modification was blocked by the MEK1 inhibitor U0126, implying that extracellular signal-regulated kinase 1/2 (ERK1/2) is the serum-inducible kinase that phosphorylates MKL1.	U 0126	148-153	mitogen-activated protein kinase 3	Homo sapiens	212-218
18694962-4	2008	The key site, serine 454, resembles a mitogen-activated protein kinase phosphorylation site, and its modification was blocked by the MEK1 inhibitor U0126, implying that extracellular signal-regulated kinase 1/2 (ERK1/2) is the serum-inducible kinase that phosphorylates MKL1.	U 0126	148-153	myocardin related transcription factor A	Homo sapiens	270-274
18813828-6	2008	After the cells were pretreated with a MEK inhibitor U0126, activations of these checkpoint kinases were abrogated and the cell death was enhanced.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
18671962-8	2008	Pretreatment of cells with U0126, an inhibitor of the upstream activator of mitogen-activated protein kinase kinase, or with AG1478, a selective epidermal growth factor receptor kinase inhibitor, reduced the urotensin II-increased extracellular signal-regulated kinase phosphorylation.	U 0126	27-32	urotensin 2	Rattus norvegicus	208-220
18660503-6	2008	In contrast, the combination of a PI3K inhibitor plus the MEK/ERK inhibitor U0126 completely eliminated inhibition by NGF.	U 0126	76-81	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
18660503-6	2008	In contrast, the combination of a PI3K inhibitor plus the MEK/ERK inhibitor U0126 completely eliminated inhibition by NGF.	U 0126	76-81	mitogen-activated protein kinase 1	Homo sapiens	62-65
18660503-6	2008	In contrast, the combination of a PI3K inhibitor plus the MEK/ERK inhibitor U0126 completely eliminated inhibition by NGF.	U 0126	76-81	nerve growth factor	Homo sapiens	118-121
18671962-9	2008	Antioxidants, U0126, and AG1478, all significantly inhibited urotensin II-increased cell proliferation in cardiac fibroblasts.	U 0126	14-19	urotensin 2	Rattus norvegicus	61-73
18602369-5	2008	Indeed, HDAC6-knockdown cells were more sensitive than control cells to the MEK inhibitor U0126.	U 0126	90-95	histone deacetylase 6	Homo sapiens	8-13
18555587-5	2008	U0126 (MEK1/2 inhibitor) and PD98059 (MEK1 inhibitor) reduced the gAd-induced G-CSF mRNA expression and G-CSF protein production.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	7-13
18555587-5	2008	U0126 (MEK1/2 inhibitor) and PD98059 (MEK1 inhibitor) reduced the gAd-induced G-CSF mRNA expression and G-CSF protein production.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	7-11
18555587-5	2008	U0126 (MEK1/2 inhibitor) and PD98059 (MEK1 inhibitor) reduced the gAd-induced G-CSF mRNA expression and G-CSF protein production.	U 0126	0-5	colony stimulating factor 3 (granulocyte)	Mus musculus	78-83
18555587-5	2008	U0126 (MEK1/2 inhibitor) and PD98059 (MEK1 inhibitor) reduced the gAd-induced G-CSF mRNA expression and G-CSF protein production.	U 0126	0-5	colony stimulating factor 3 (granulocyte)	Mus musculus	104-109
18555587-7	2008	In addition, the gAd-induced phosphorylation of MEK1/2 and ERK1/2 was dramatically reduced by PD98059 and U0126, respectively.	U 0126	106-111	mitogen-activated protein kinase kinase 1	Mus musculus	48-54
18555587-7	2008	In addition, the gAd-induced phosphorylation of MEK1/2 and ERK1/2 was dramatically reduced by PD98059 and U0126, respectively.	U 0126	106-111	mitogen-activated protein kinase 3	Mus musculus	59-65
18793415-3	2008	Here we explored the role of the MEK/ERK pathway in receptor expression following ischemic brain injury using the specific MEK1 inhibitor U0126.	U 0126	138-143	Eph receptor B1	Rattus norvegicus	37-40
18793415-3	2008	Here we explored the role of the MEK/ERK pathway in receptor expression following ischemic brain injury using the specific MEK1 inhibitor U0126.	U 0126	138-143	mitogen activated protein kinase kinase 1	Rattus norvegicus	123-127
18793415-10	2008	Blockade of transcription with the MEK1 inhibitor U0126, given at the onset of reperfusion or as late as 6 hours after the insult, reduced transcription (pERK1/2 and pElk-1), the enhanced vascular receptor expression, and attenuated the cerebral infarct and improved neurology score.	U 0126	50-55	mitogen activated protein kinase kinase 1	Rattus norvegicus	35-39
18521085-4	2008	DNA synthesis and cells in S phase analysed by flow cytometry, correlated with strong inhibition of Cdk1 and cyclin E levels, are strongly reduced after exposure to the MEK inhibitor, U0126.	U 0126	184-189	cyclin-dependent kinase 1	Mus musculus	100-104
18602369-5	2008	Indeed, HDAC6-knockdown cells were more sensitive than control cells to the MEK inhibitor U0126.	U 0126	90-95	mitogen-activated protein kinase kinase 7	Homo sapiens	76-79
18521085-4	2008	DNA synthesis and cells in S phase analysed by flow cytometry, correlated with strong inhibition of Cdk1 and cyclin E levels, are strongly reduced after exposure to the MEK inhibitor, U0126.	U 0126	184-189	midkine	Mus musculus	169-172
18573356-10	2008	U0126, an inhibitor of ERK1/2, blocked the increase in osteogenesis markers.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	23-29
18543351-5	2008	Pharmacological agents, U0126 and PD98059 (mitogen-activated protein kinases (MAPK) kinases (MEK) inhibitors), and AG1478 (an EGF receptor kinase inhibitor) blocked the cell rounding and FAK dephosphorylation.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
18543351-5	2008	Pharmacological agents, U0126 and PD98059 (mitogen-activated protein kinases (MAPK) kinases (MEK) inhibitors), and AG1478 (an EGF receptor kinase inhibitor) blocked the cell rounding and FAK dephosphorylation.	U 0126	24-29	protein tyrosine kinase 2	Homo sapiens	187-190
19238727-6	2008	In mesenchyme-free SMG epithelium cultured with EGF, FGF7 and FGF10, U0126 (MEK inhibitor) completely blocked cleft formation, whereas U73122 (PLCgamma1 inhibitor) suppressed stalk elongation.	U 0126	69-74	small nuclear ribonucleoprotein polypeptide G	Mus musculus	19-22
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	epidermal growth factor	Homo sapiens	5-8
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	epidermal growth factor receptor	Homo sapiens	31-35
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	AKT serine/threonine kinase 1	Homo sapiens	77-80
19238727-6	2008	In mesenchyme-free SMG epithelium cultured with EGF, FGF7 and FGF10, U0126 (MEK inhibitor) completely blocked cleft formation, whereas U73122 (PLCgamma1 inhibitor) suppressed stalk elongation.	U 0126	69-74	epidermal growth factor	Mus musculus	48-51
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	mitogen-activated protein kinase kinase 7	Homo sapiens	82-85
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	mitogen-activated protein kinase 1	Homo sapiens	86-89
19238727-6	2008	In mesenchyme-free SMG epithelium cultured with EGF, FGF7 and FGF10, U0126 (MEK inhibitor) completely blocked cleft formation, whereas U73122 (PLCgamma1 inhibitor) suppressed stalk elongation.	U 0126	69-74	fibroblast growth factor 10	Mus musculus	62-67
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	mitogen-activated protein kinase 14	Homo sapiens	95-98
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	mitogen-activated protein kinase 1	Homo sapiens	99-103
18729215-6	2008	With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown.	U 0126	149-154	epidermal growth factor	Homo sapiens	31-34
19238727-6	2008	In mesenchyme-free SMG epithelium cultured with EGF, FGF7 and FGF10, U0126 (MEK inhibitor) completely blocked cleft formation, whereas U73122 (PLCgamma1 inhibitor) suppressed stalk elongation.	U 0126	69-74	midkine	Mus musculus	76-79
18837745-2	2008	In this study, the activation of MAPK/ERK was inhibited using the upstream inhibitor of MAPK-ERK-kinase (MEK) U0126, and the effects on focal brain ischaemia were evaluated during normo- and hyperglycaemia.	U 0126	110-115	Eph receptor B1	Rattus norvegicus	38-41
18338254-7	2008	Interestingly, inhibition of ERK by U0126 completely prevented artepillin C-induced p38 MAPK phosphorylation of PC12m3 cells.	U 0126	36-41	Eph receptor B1	Rattus norvegicus	29-32
18691227-3	2008	Here, we demonstrate that inhibition of the ERK pathway by the MEK inhibitor U0126 or PD98059 significantly potentiates EGF- and FGF-induced Akt phosphorylation at both Thr308 and Ser473.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	44-47
18691227-3	2008	Here, we demonstrate that inhibition of the ERK pathway by the MEK inhibitor U0126 or PD98059 significantly potentiates EGF- and FGF-induced Akt phosphorylation at both Thr308 and Ser473.	U 0126	77-82	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
18691227-3	2008	Here, we demonstrate that inhibition of the ERK pathway by the MEK inhibitor U0126 or PD98059 significantly potentiates EGF- and FGF-induced Akt phosphorylation at both Thr308 and Ser473.	U 0126	77-82	AKT serine/threonine kinase 1	Homo sapiens	141-144
18691227-5	2008	Furthermore, the enhanced Akt phosphorylation induced by U0126 is inhibited by the PI3-kinase inhibitor LY294002, and is accompanied by the up-regulation of Ras activity.	U 0126	57-62	AKT serine/threonine kinase 1	Homo sapiens	26-29
18513372-4	2008	PC12 cells exposed to nerve growth factor (NGFDPC12) exhibit high E-FABP expression that is blocked by mitogen-activated protein kinase kinase (MEK) inhibitor U0126.	U 0126	159-164	nerve growth factor	Rattus norvegicus	22-41
18513372-4	2008	PC12 cells exposed to nerve growth factor (NGFDPC12) exhibit high E-FABP expression that is blocked by mitogen-activated protein kinase kinase (MEK) inhibitor U0126.	U 0126	159-164	fatty acid binding protein 5	Rattus norvegicus	66-72
18338254-3	2008	Artepillin C induced-neurite outgrowth of PC12m3 cells was inhibited by the ERK inhibitor U0126 and by the p38 MAPK inhibitor SB203580.	U 0126	90-95	Eph receptor B1	Rattus norvegicus	76-79
18657070-7	2008	The accumulation of MEK2-GFP in endosomes was also blocked by siRNA depletion of RAF kinases and by the MEK1/2 inhibitor, UO126.	U 0126	122-127	mitogen-activated protein kinase kinase 2	Homo sapiens	20-24
18657070-7	2008	The accumulation of MEK2-GFP in endosomes was also blocked by siRNA depletion of RAF kinases and by the MEK1/2 inhibitor, UO126.	U 0126	122-127	mitogen-activated protein kinase kinase 1	Homo sapiens	104-110
18566004-5	2008	Chemokine-induced myoblast proliferation was abolished by pertussis toxin and the MEK1/2 inhibitor U0126, implicating both Galphai-coupled receptors and ERK1/2-dependent signalling.	U 0126	99-104	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
18566004-5	2008	Chemokine-induced myoblast proliferation was abolished by pertussis toxin and the MEK1/2 inhibitor U0126, implicating both Galphai-coupled receptors and ERK1/2-dependent signalling.	U 0126	99-104	mitogen-activated protein kinase 3	Homo sapiens	153-159
18411006-3	2008	In the presence of U-0126 (10microM), a p42/44 mitogen-activated protein kinase (MAPK) kinase inhibitor, Ang II further increased Tyr705 phosphorylation of STAT3 but completely abrogated Ser727 phosphorylation of STAT3.	U 0126	19-25	angiotensinogen	Rattus norvegicus	105-111
18411006-3	2008	In the presence of U-0126 (10microM), a p42/44 mitogen-activated protein kinase (MAPK) kinase inhibitor, Ang II further increased Tyr705 phosphorylation of STAT3 but completely abrogated Ser727 phosphorylation of STAT3.	U 0126	19-25	signal transducer and activator of transcription 3	Rattus norvegicus	156-161
18411006-3	2008	In the presence of U-0126 (10microM), a p42/44 mitogen-activated protein kinase (MAPK) kinase inhibitor, Ang II further increased Tyr705 phosphorylation of STAT3 but completely abrogated Ser727 phosphorylation of STAT3.	U 0126	19-25	signal transducer and activator of transcription 3	Rattus norvegicus	213-218
18487224-6	2008	CXCL12 treatment enhanced extracellular signal-regulated kinase (ERK) pathway activation and the motility/invasiveness of LHSCC cell lines, which were blocked by treatment with a CXCR4 antagonist (AMD3100) and a specific MEK inhibitor (U0126).	U 0126	236-241	C-X-C motif chemokine ligand 12	Homo sapiens	0-6
18487224-6	2008	CXCL12 treatment enhanced extracellular signal-regulated kinase (ERK) pathway activation and the motility/invasiveness of LHSCC cell lines, which were blocked by treatment with a CXCR4 antagonist (AMD3100) and a specific MEK inhibitor (U0126).	U 0126	236-241	mitogen-activated protein kinase 1	Homo sapiens	26-63
18487224-8	2008	Again, U0126 almost inhibited the induction of MMP-13 in HEp-2 cells by stimulating CXCL12.	U 0126	7-12	matrix metallopeptidase 13	Homo sapiens	47-53
18487224-8	2008	Again, U0126 almost inhibited the induction of MMP-13 in HEp-2 cells by stimulating CXCL12.	U 0126	7-12	C-X-C motif chemokine ligand 12	Homo sapiens	84-90
18508236-7	2008	NGF-induced p38 MAPK phosphorylation was abolished by inhibitors of Src (PP1, PP2, and SU6656) and MEK1/2 (U0126).	U 0126	107-112	mitogen activated protein kinase 14	Rattus norvegicus	12-15
18508236-7	2008	NGF-induced p38 MAPK phosphorylation was abolished by inhibitors of Src (PP1, PP2, and SU6656) and MEK1/2 (U0126).	U 0126	107-112	mitogen activated protein kinase kinase 1	Rattus norvegicus	99-105
18607173-9	2008	Increased PAI-1 mRNA was attenuated significantly by U0126 and PD98059, specific inhibitors of mitogen-activated protein kinase.	U 0126	53-58	serpin family E member 1	Homo sapiens	10-15
18982462-1	2008	We have analyzed a possible role of mitogen-activated protein kinase (MAPK) and activator protein-1 (AP-1) in the regulation of FSH-induced tissue type plasminogen activator (tPA) production in granulosa cells (GCs) prepared from DES-treated immature rats; Treatment of the cells in the presence of FSH with MAPK inhibitors, such as UO126 or SB203580, significantly decreased the FSH-induced tPA production, suggesting that multiple signaling pathways may be involved in FSH-regulated tPA expression.	U 0126	333-338	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	101-105
18982462-1	2008	We have analyzed a possible role of mitogen-activated protein kinase (MAPK) and activator protein-1 (AP-1) in the regulation of FSH-induced tissue type plasminogen activator (tPA) production in granulosa cells (GCs) prepared from DES-treated immature rats; Treatment of the cells in the presence of FSH with MAPK inhibitors, such as UO126 or SB203580, significantly decreased the FSH-induced tPA production, suggesting that multiple signaling pathways may be involved in FSH-regulated tPA expression.	U 0126	333-338	plasminogen activator, tissue type	Rattus norvegicus	175-178
18478568-11	2008	Blockade of MEK1/2, the upstream kinase for p44/42, with U0126 prevented p44/42 activation, restored IL-12p70, and permitted effective generation of Th1-responses.	U 0126	57-62	mitogen-activated protein kinase kinase 1	Homo sapiens	12-18
18478568-11	2008	Blockade of MEK1/2, the upstream kinase for p44/42, with U0126 prevented p44/42 activation, restored IL-12p70, and permitted effective generation of Th1-responses.	U 0126	57-62	interferon induced protein 44	Homo sapiens	44-47
18478568-11	2008	Blockade of MEK1/2, the upstream kinase for p44/42, with U0126 prevented p44/42 activation, restored IL-12p70, and permitted effective generation of Th1-responses.	U 0126	57-62	interferon induced protein 44	Homo sapiens	73-76
18478568-11	2008	Blockade of MEK1/2, the upstream kinase for p44/42, with U0126 prevented p44/42 activation, restored IL-12p70, and permitted effective generation of Th1-responses.	U 0126	57-62	negative elongation factor complex member C/D	Homo sapiens	149-152
18650553-6	2008	Concomitantly, blocking of MEK1/2 activation by U0126 significantly inhibited the generation of the active form of MMP-1 without affecting the total production of this collagenase.	U 0126	48-53	mitogen-activated protein kinase kinase 1	Homo sapiens	27-33
18650553-6	2008	Concomitantly, blocking of MEK1/2 activation by U0126 significantly inhibited the generation of the active form of MMP-1 without affecting the total production of this collagenase.	U 0126	48-53	matrix metallopeptidase 1	Homo sapiens	115-120
18508903-5	2008	Inhibition of ERK activation with U0126, a specific ERK inhibitor, significantly reduced viral production.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	14-17
18508903-5	2008	Inhibition of ERK activation with U0126, a specific ERK inhibitor, significantly reduced viral production.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	52-55
18508903-6	2008	Investigations into the mechanism of ERK1/2 regulation revealed that all steps of the viral life cycle, including early and late protein expression as well as subgenomic and genomic RNA transcription, were diminished during U0126 treatment of monolayers.	U 0126	224-229	mitogen-activated protein kinase 3	Homo sapiens	37-43
19967052-5	2008	HSP22-induced IL-8 release was inhibited by U0126, but not by SB202190.	U 0126	44-49	heat shock protein family B (small) member 8	Homo sapiens	0-5
19967052-5	2008	HSP22-induced IL-8 release was inhibited by U0126, but not by SB202190.	U 0126	44-49	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
18499891-9	2008	Indeed, many of the effects of OSM (increased cell division, maintenance of CFC, and maintenance of high CD34 expression) could be mimicked by using the mitogen-activated protein kinase kinase inhibitor U0126.	U 0126	203-208	CD34 molecule	Homo sapiens	105-109
18499891-10	2008	More importantly, NOD/SCID-repopulating activity was preserved in the KL/U0126-stimulated cells, but not in cells stimulated with a combination of KL and the p38 MAPK inhibitor SB203580.	U 0126	73-78	atrophin 1	Homo sapiens	18-21
18499891-10	2008	More importantly, NOD/SCID-repopulating activity was preserved in the KL/U0126-stimulated cells, but not in cells stimulated with a combination of KL and the p38 MAPK inhibitor SB203580.	U 0126	73-78	KIT ligand	Homo sapiens	70-72
18788932-8	2008	Moreover, the pERK1/2 and pAkt upregulation induced by FGF-2 and -4 were completely abolished by treatment with the MEK1/2 inhibitor, U0126 and the PI3K inhibitor, LY294002.	U 0126	134-139	mitogen-activated protein kinase kinase 1	Homo sapiens	116-122
18788932-10	2008	As a consequence of PI3K-Akt and ERK1/2, the upregulation of c-Jun in the Sca-1(+) BMMSCs, after stimulation with FGF-2 or FGF-4, was observed after 12 and 24 h. Moreover, the activation of c-Jun in FGF-2- and FGF-4-treated Sca-1(+) BMMSCs was significantly reduced by U0126.	U 0126	269-274	AKT serine/threonine kinase 1	Homo sapiens	25-28
18788932-10	2008	As a consequence of PI3K-Akt and ERK1/2, the upregulation of c-Jun in the Sca-1(+) BMMSCs, after stimulation with FGF-2 or FGF-4, was observed after 12 and 24 h. Moreover, the activation of c-Jun in FGF-2- and FGF-4-treated Sca-1(+) BMMSCs was significantly reduced by U0126.	U 0126	269-274	mitogen-activated protein kinase 3	Homo sapiens	33-39
18788932-10	2008	As a consequence of PI3K-Akt and ERK1/2, the upregulation of c-Jun in the Sca-1(+) BMMSCs, after stimulation with FGF-2 or FGF-4, was observed after 12 and 24 h. Moreover, the activation of c-Jun in FGF-2- and FGF-4-treated Sca-1(+) BMMSCs was significantly reduced by U0126.	U 0126	269-274	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-66
18788932-10	2008	As a consequence of PI3K-Akt and ERK1/2, the upregulation of c-Jun in the Sca-1(+) BMMSCs, after stimulation with FGF-2 or FGF-4, was observed after 12 and 24 h. Moreover, the activation of c-Jun in FGF-2- and FGF-4-treated Sca-1(+) BMMSCs was significantly reduced by U0126.	U 0126	269-274	fibroblast growth factor 2	Homo sapiens	114-119
18788932-10	2008	As a consequence of PI3K-Akt and ERK1/2, the upregulation of c-Jun in the Sca-1(+) BMMSCs, after stimulation with FGF-2 or FGF-4, was observed after 12 and 24 h. Moreover, the activation of c-Jun in FGF-2- and FGF-4-treated Sca-1(+) BMMSCs was significantly reduced by U0126.	U 0126	269-274	fibroblast growth factor 4	Homo sapiens	123-128
19100107-6	2008	These effects could be significantly blocked by both PI3K inhibitor, LY294002 and ERK1/2 inhibitor, U0126.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	82-88
18538762-9	2008	Tyrosine kinase inhibitor (tyrphostin A25) and mitogen-activated protein kinase (MAPK)/ERK inhibitors (1,4-diamino-2,3-dicyano-1,4-bis [2-aminophenylthio]butadiene (U 0126)) inhibited angiotensin II- and pyrogallol-induced potentiation of EFS-induced contraction, while inactive forms of these inhibitors did not show any inhibitory effects.	U 0126	103-163	Eph receptor B1	Rattus norvegicus	87-90
18538762-9	2008	Tyrosine kinase inhibitor (tyrphostin A25) and mitogen-activated protein kinase (MAPK)/ERK inhibitors (1,4-diamino-2,3-dicyano-1,4-bis [2-aminophenylthio]butadiene (U 0126)) inhibited angiotensin II- and pyrogallol-induced potentiation of EFS-induced contraction, while inactive forms of these inhibitors did not show any inhibitory effects.	U 0126	103-163	angiotensinogen	Rattus norvegicus	184-198
18561899-12	2008	Instead, inhibition of MEK1/2 with U0126 partially reduced the heat shock-enhancement of NGF-stimulated neurite elongation.	U 0126	35-40	mitogen activated protein kinase kinase 1	Rattus norvegicus	23-29
18561899-12	2008	Instead, inhibition of MEK1/2 with U0126 partially reduced the heat shock-enhancement of NGF-stimulated neurite elongation.	U 0126	35-40	nerve growth factor	Rattus norvegicus	89-92
18345028-3	2008	We found that the highly selective MEK1/2 inhibitors U0126 and PD98059, and the expressed dominant-negative form of extracellular signal-regulated kinase (ERK), completely block Axl-mediated MMP-9 activation.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	35-41
18345028-3	2008	We found that the highly selective MEK1/2 inhibitors U0126 and PD98059, and the expressed dominant-negative form of extracellular signal-regulated kinase (ERK), completely block Axl-mediated MMP-9 activation.	U 0126	53-58	AXL receptor tyrosine kinase	Homo sapiens	178-181
18345028-3	2008	We found that the highly selective MEK1/2 inhibitors U0126 and PD98059, and the expressed dominant-negative form of extracellular signal-regulated kinase (ERK), completely block Axl-mediated MMP-9 activation.	U 0126	53-58	matrix metallopeptidase 9	Homo sapiens	191-196
18751377-4	2008	A differentiating effect on Caco-2 cells was not seen with cyanidin or cyanidin-3-glucoside but the action of the fruit extracts was additive with the action of butyrate and with the MEK1/2 inhibitor U0126.	U 0126	200-205	mitogen-activated protein kinase kinase 1	Homo sapiens	183-189
18467140-10	2008	ERK inhibitors PD98059 and U0126 blocked both heat stress-induced and plated-derived growth factor (PDGF)-induced ERK1/2 phosphorylation, and also diminished heat-induced Hsp70 expression.	U 0126	27-32	mitogen-activated protein kinase 1	Danio rerio	114-120
18467140-10	2008	ERK inhibitors PD98059 and U0126 blocked both heat stress-induced and plated-derived growth factor (PDGF)-induced ERK1/2 phosphorylation, and also diminished heat-induced Hsp70 expression.	U 0126	27-32	heat shock protein 8-like	Danio rerio	171-176
18752316-7	2008	In contrast, inhibition of ERK by U0126 further potentiated heavy metal-mediated effects on Nqo1 mRNA, while only potentiated Hg(2+)-mediated induction of Nqo1 activity.	U 0126	34-39	NAD(P)H dehydrogenase, quinone 1	Mus musculus	92-96
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase kinase 1	Homo sapiens	32-38
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	118-124
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase 9	Homo sapiens	129-133
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase 9	Homo sapiens	134-137
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	118-121
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase 9	Homo sapiens	245-249
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	U 0126	63-68	mitogen-activated protein kinase 9	Homo sapiens	250-253
18410500-6	2008	Both U0126 and the suppression of ERK1/2 expression with small interfering RNA effectively blocked the 4HPR-induced neuronal differentiation of RPE cells and the expression of calretinin.	U 0126	5-10	calbindin 2	Homo sapiens	176-186
18557893-11	2008	The Elk-1 phosphorylation inhibitor U-0126 inhibited the increase in c-fos expression.	U 0126	36-42	ELK1, member of ETS oncogene family	Mus musculus	4-9
18557893-11	2008	The Elk-1 phosphorylation inhibitor U-0126 inhibited the increase in c-fos expression.	U 0126	36-42	FBJ osteosarcoma oncogene	Mus musculus	69-74
18424783-5	2008	Inhibition of ERK1/2 signaling using U0126 enhanced HIF-1alpha stabilization, implicating ERK1/2 dephosphorylation as a contributing mechanism in NO-mediated HIF-1alpha activation.	U 0126	37-42	mitogen-activated protein kinase 3	Homo sapiens	14-20
18424783-5	2008	Inhibition of ERK1/2 signaling using U0126 enhanced HIF-1alpha stabilization, implicating ERK1/2 dephosphorylation as a contributing mechanism in NO-mediated HIF-1alpha activation.	U 0126	37-42	hypoxia inducible factor 1 subunit alpha	Homo sapiens	52-62
18332870-6	2008	Treatment with U0126, a specific inhibitor of MAPK/ERK1,2 completely downregulates CDDP-induced VEGF and Flt1 expression and induction/expansion of SP fraction in all three cell lines, indicating that these effects are mediated through MAPK/ERK1,2 signaling.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	51-57
18332870-6	2008	Treatment with U0126, a specific inhibitor of MAPK/ERK1,2 completely downregulates CDDP-induced VEGF and Flt1 expression and induction/expansion of SP fraction in all three cell lines, indicating that these effects are mediated through MAPK/ERK1,2 signaling.	U 0126	15-20	vascular endothelial growth factor A	Homo sapiens	96-100
18332870-6	2008	Treatment with U0126, a specific inhibitor of MAPK/ERK1,2 completely downregulates CDDP-induced VEGF and Flt1 expression and induction/expansion of SP fraction in all three cell lines, indicating that these effects are mediated through MAPK/ERK1,2 signaling.	U 0126	15-20	fms related receptor tyrosine kinase 1	Homo sapiens	105-109
18332870-6	2008	Treatment with U0126, a specific inhibitor of MAPK/ERK1,2 completely downregulates CDDP-induced VEGF and Flt1 expression and induction/expansion of SP fraction in all three cell lines, indicating that these effects are mediated through MAPK/ERK1,2 signaling.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	241-247
18573207-7	2008	We acutely blocked ERK activation in the CeA by infusing the MEK inhibitor U0126 into the right or the left hemisphere and then measured the behavioral effects on inflammation-induced mechanical hypersensitivity in mice.	U 0126	75-80	mitogen-activated protein kinase 1	Mus musculus	19-22
18573207-7	2008	We acutely blocked ERK activation in the CeA by infusing the MEK inhibitor U0126 into the right or the left hemisphere and then measured the behavioral effects on inflammation-induced mechanical hypersensitivity in mice.	U 0126	75-80	carcinoembryonic antigen gene family	Mus musculus	41-44
18573207-7	2008	We acutely blocked ERK activation in the CeA by infusing the MEK inhibitor U0126 into the right or the left hemisphere and then measured the behavioral effects on inflammation-induced mechanical hypersensitivity in mice.	U 0126	75-80	midkine	Mus musculus	61-64
18457920-9	2008	The induction of c-fos, c-jun, nur77, and zif268 by hypoxia was inhibited by naloxone (0.1 microM) and MAPK inhibitors (10 microM of U0126, D98059, SB203580).	U 0126	133-138	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	17-22
18457920-9	2008	The induction of c-fos, c-jun, nur77, and zif268 by hypoxia was inhibited by naloxone (0.1 microM) and MAPK inhibitors (10 microM of U0126, D98059, SB203580).	U 0126	133-138	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	31-36
18457920-9	2008	The induction of c-fos, c-jun, nur77, and zif268 by hypoxia was inhibited by naloxone (0.1 microM) and MAPK inhibitors (10 microM of U0126, D98059, SB203580).	U 0126	133-138	early growth response 1	Rattus norvegicus	42-48
18457920-9	2008	The induction of c-fos, c-jun, nur77, and zif268 by hypoxia was inhibited by naloxone (0.1 microM) and MAPK inhibitors (10 microM of U0126, D98059, SB203580).	U 0126	133-138	mitogen activated protein kinase 3	Rattus norvegicus	103-107
18583944-6	2008	More importantly, when p-MEK1/2 activity was blocked by U0126, Plk1 lost its normal localization at the spindle poles, which might be one of the most vital factors causing the abnormal spindles in MEK1/2-inhibited oocytes.	U 0126	56-61	mitogen-activated protein kinase kinase 1	Mus musculus	25-31
18583944-6	2008	More importantly, when p-MEK1/2 activity was blocked by U0126, Plk1 lost its normal localization at the spindle poles, which might be one of the most vital factors causing the abnormal spindles in MEK1/2-inhibited oocytes.	U 0126	56-61	polo like kinase 1	Mus musculus	63-67
18583944-6	2008	More importantly, when p-MEK1/2 activity was blocked by U0126, Plk1 lost its normal localization at the spindle poles, which might be one of the most vital factors causing the abnormal spindles in MEK1/2-inhibited oocytes.	U 0126	56-61	mitogen-activated protein kinase kinase 1	Mus musculus	197-203
18424438-6	2008	The MEK1/2 inhibitor U0126 and knockdown of MEK1/2 expression with small interfering RNAs effectively blocked the phosphorylation of p65/RelA(Ser(276)) but not that of Ser(536), suggesting that this phosphorylation is dependent on the activation of the MEK1/2-ERK1/2 pathway.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
18424438-6	2008	The MEK1/2 inhibitor U0126 and knockdown of MEK1/2 expression with small interfering RNAs effectively blocked the phosphorylation of p65/RelA(Ser(276)) but not that of Ser(536), suggesting that this phosphorylation is dependent on the activation of the MEK1/2-ERK1/2 pathway.	U 0126	21-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	133-136
18424438-6	2008	The MEK1/2 inhibitor U0126 and knockdown of MEK1/2 expression with small interfering RNAs effectively blocked the phosphorylation of p65/RelA(Ser(276)) but not that of Ser(536), suggesting that this phosphorylation is dependent on the activation of the MEK1/2-ERK1/2 pathway.	U 0126	21-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	137-141
18417718-9	2008	While octylphenol was shown to increase activities of the estrogen receptor (ER) and MEK1, signaling was demonstrated to be blocked by pretreatment with either ICI-182780 (an ERalpha antagonist) or U-0126 (a MEK1 inhibitor), in which both inhibitors prevented octylphenol-stimulated phosphorylation of ERK.	U 0126	198-204	estrogen receptor 1	Homo sapiens	77-79
18417718-9	2008	While octylphenol was shown to increase activities of the estrogen receptor (ER) and MEK1, signaling was demonstrated to be blocked by pretreatment with either ICI-182780 (an ERalpha antagonist) or U-0126 (a MEK1 inhibitor), in which both inhibitors prevented octylphenol-stimulated phosphorylation of ERK.	U 0126	198-204	mitogen-activated protein kinase kinase 1	Homo sapiens	208-212
18417718-9	2008	While octylphenol was shown to increase activities of the estrogen receptor (ER) and MEK1, signaling was demonstrated to be blocked by pretreatment with either ICI-182780 (an ERalpha antagonist) or U-0126 (a MEK1 inhibitor), in which both inhibitors prevented octylphenol-stimulated phosphorylation of ERK.	U 0126	198-204	mitogen-activated protein kinase 1	Homo sapiens	302-305
18322274-4	2008	We showed that blocking mitogen-activated protein kinase 3 (MAPK3)/MAPK1 signaling by U0126 attenuated CsA-increased cell viability and invasiveness of trophoblasts.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	24-58
18322274-4	2008	We showed that blocking mitogen-activated protein kinase 3 (MAPK3)/MAPK1 signaling by U0126 attenuated CsA-increased cell viability and invasiveness of trophoblasts.	U 0126	86-91	mitogen-activated protein kinase 3	Homo sapiens	60-65
18322274-4	2008	We showed that blocking mitogen-activated protein kinase 3 (MAPK3)/MAPK1 signaling by U0126 attenuated CsA-increased cell viability and invasiveness of trophoblasts.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	67-72
18520049-10	2008	Consistent with the increased phosphorylation of MAPKs, the ERK kinase MEK inhibitor, U0126 (3 nmol), attenuated the induction phase (co-administration with ATP) and early maintenance phase (1-d post-ATP administration) of the i.t.	U 0126	86-91	Eph receptor B1	Rattus norvegicus	60-63
18641289-4	2008	The intracellular distribution of pERK and ROCK-I was examined in the presence of Ap(4)A or Ap(3)A (100 microM) with U0126 and Y27632 (100 nM).	U 0126	117-122	rho-associated protein kinase 1	Oryctolagus cuniculus	43-49
18567920-9	2008	CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580).	U 0126	196-201	peptidylprolyl isomerase A	Homo sapiens	0-4
18567920-9	2008	CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580).	U 0126	196-201	matrix metallopeptidase 9	Homo sapiens	60-65
18567920-9	2008	CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580).	U 0126	196-201	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	150-155
18670215-11	2008	The inhibition of ERK1/2 activation by U0126 and PD98059 blocked both R5 and X4 HIV-1 replication.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	18-24
18495839-6	2008	SS-14-inhibited expression of GH receptor (GHR) mRNA was blocked by U0126 but not by LY294002.	U 0126	68-73	growth hormone receptor	Oncorhynchus mykiss	30-41
18495839-6	2008	SS-14-inhibited expression of GH receptor (GHR) mRNA was blocked by U0126 but not by LY294002.	U 0126	68-73	growth hormone receptor	Oncorhynchus mykiss	43-46
18573488-8	2008	Furthermore, fluoxetine-induced activation of both the cAMP-response element-binding (CREB) protein and extracellular signal-regulated protein kinases (ERK1/2), which was abolished by the selective inhibitor of MAP kinase kinase (MEK) 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), and increased cyclin D1 expression.	U 0126	235-294	mitogen-activated protein kinase 3	Homo sapiens	152-158
18573488-8	2008	Furthermore, fluoxetine-induced activation of both the cAMP-response element-binding (CREB) protein and extracellular signal-regulated protein kinases (ERK1/2), which was abolished by the selective inhibitor of MAP kinase kinase (MEK) 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), and increased cyclin D1 expression.	U 0126	235-294	cyclin D1	Homo sapiens	318-327
18573488-8	2008	Furthermore, fluoxetine-induced activation of both the cAMP-response element-binding (CREB) protein and extracellular signal-regulated protein kinases (ERK1/2), which was abolished by the selective inhibitor of MAP kinase kinase (MEK) 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), and increased cyclin D1 expression.	U 0126	296-301	mitogen-activated protein kinase 3	Homo sapiens	152-158
18502099-5	2008	Interestingly, we found that Sp1 was eliminated from the IL-6 promoter after treatment with the ERK inhibitor U0126.	U 0126	110-115	interleukin 6	Homo sapiens	57-61
18502099-5	2008	Interestingly, we found that Sp1 was eliminated from the IL-6 promoter after treatment with the ERK inhibitor U0126.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	96-99
18502099-6	2008	The importance of ERK and Sp1 in regulating IL-6 transcription was, furthermore, supported by the observation that treatment of U266 cells with U0126 or mithramycin, an antibiotic that prevents Sp1-DNA binding, abrogated constitutive IL-6 transcription.	U 0126	144-149	mitogen-activated protein kinase 1	Homo sapiens	18-21
18502099-6	2008	The importance of ERK and Sp1 in regulating IL-6 transcription was, furthermore, supported by the observation that treatment of U266 cells with U0126 or mithramycin, an antibiotic that prevents Sp1-DNA binding, abrogated constitutive IL-6 transcription.	U 0126	144-149	interleukin 6	Homo sapiens	44-48
18502099-6	2008	The importance of ERK and Sp1 in regulating IL-6 transcription was, furthermore, supported by the observation that treatment of U266 cells with U0126 or mithramycin, an antibiotic that prevents Sp1-DNA binding, abrogated constitutive IL-6 transcription.	U 0126	144-149	interleukin 6	Homo sapiens	234-238
18579559-6	2008	Conversely, block of NF-kB signaling by sulfasalazine or short interfering RNA (siRNA) or ERK signaling by UO126 caused iNOS downregulation in HCC cell lines.	U 0126	107-112	mitogen-activated protein kinase 1	Homo sapiens	90-93
18579559-6	2008	Conversely, block of NF-kB signaling by sulfasalazine or short interfering RNA (siRNA) or ERK signaling by UO126 caused iNOS downregulation in HCC cell lines.	U 0126	107-112	nitric oxide synthase 2	Homo sapiens	120-124
18574076-4	2008	Intracerebroventricular administration of PD98059 and UO126, 2 selective p44/42 MAPK inhibitors, induced significant decreases in mean arterial pressure, heart rate, and renal sympathetic nerve activity in HF rats, but had no effect on these variables in sham-operated rats.	U 0126	54-59	mitogen activated protein kinase 3	Rattus norvegicus	73-76
18636178-8	2008	PD153035, an EGFR inhibitor, and U0126, an ERK inhibitor, inhibit atRA-induced upregulation of AQP3.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	43-46
18636178-8	2008	PD153035, an EGFR inhibitor, and U0126, an ERK inhibitor, inhibit atRA-induced upregulation of AQP3.	U 0126	33-38	aquaporin 3 (Gill blood group)	Homo sapiens	95-99
18483753-7	2008	After 1-h pretreatment with a lower concentration of MEK inhibitor U0126, the level of phosphorylated pRb was restored, indicating a release of cell cycle arrest.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	53-56
18483753-7	2008	After 1-h pretreatment with a lower concentration of MEK inhibitor U0126, the level of phosphorylated pRb was restored, indicating a release of cell cycle arrest.	U 0126	67-72	RB transcriptional corepressor 1	Homo sapiens	102-105
18266953-6	2008	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 or PD98059 resulted in a decrease in TNF-induced autophagy that was accompanied by an increase in cleavage of caspase-7, -8, -9 and PARP Furthermore, inhibition of ERK1/2 signalling resulted in decreased clonogenic capacity of MCF-7 cells.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	30-36
18266953-6	2008	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 or PD98059 resulted in a decrease in TNF-induced autophagy that was accompanied by an increase in cleavage of caspase-7, -8, -9 and PARP Furthermore, inhibition of ERK1/2 signalling resulted in decreased clonogenic capacity of MCF-7 cells.	U 0126	58-63	tumor necrosis factor	Homo sapiens	101-104
18266953-6	2008	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 or PD98059 resulted in a decrease in TNF-induced autophagy that was accompanied by an increase in cleavage of caspase-7, -8, -9 and PARP Furthermore, inhibition of ERK1/2 signalling resulted in decreased clonogenic capacity of MCF-7 cells.	U 0126	58-63	caspase 7	Homo sapiens	174-191
18266953-6	2008	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 or PD98059 resulted in a decrease in TNF-induced autophagy that was accompanied by an increase in cleavage of caspase-7, -8, -9 and PARP Furthermore, inhibition of ERK1/2 signalling resulted in decreased clonogenic capacity of MCF-7 cells.	U 0126	58-63	collagen type XI alpha 2 chain	Homo sapiens	196-200
18266953-6	2008	Pharmacological inhibition of ERK1/2 phosphorylation with U0126 or PD98059 resulted in a decrease in TNF-induced autophagy that was accompanied by an increase in cleavage of caspase-7, -8, -9 and PARP Furthermore, inhibition of ERK1/2 signalling resulted in decreased clonogenic capacity of MCF-7 cells.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	228-234
18323781-5	2008	Similar results were obtained with combinations of the MEK inhibitors U0126 (30 microM) or PD98059 (50 microM) with rapamycin (10 nM).	U 0126	70-75	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
18604197-5	2008	When exogenously expressed in quiescent cells, IQGAP3 was capable of inducing cell-cycle re-entry, which was completely inhibited by the MEK inhibitor U0126.	U 0126	151-156	IQ motif containing GTPase activating protein 3	Homo sapiens	47-53
18604197-5	2008	When exogenously expressed in quiescent cells, IQGAP3 was capable of inducing cell-cycle re-entry, which was completely inhibited by the MEK inhibitor U0126.	U 0126	151-156	mitogen-activated protein kinase kinase 7	Homo sapiens	137-140
18788932-8	2008	Moreover, the pERK1/2 and pAkt upregulation induced by FGF-2 and -4 were completely abolished by treatment with the MEK1/2 inhibitor, U0126 and the PI3K inhibitor, LY294002.	U 0126	134-139	fibroblast growth factor 2	Homo sapiens	55-67
18474417-6	2008	Pharmacological inhibition of MEK1/2-ERK1/2 pathway with UO126 blocked caspase-3 activation, decreased AP-1 binding to DNA and inhibited apoptosis.	U 0126	57-62	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
18474417-6	2008	Pharmacological inhibition of MEK1/2-ERK1/2 pathway with UO126 blocked caspase-3 activation, decreased AP-1 binding to DNA and inhibited apoptosis.	U 0126	57-62	mitogen-activated protein kinase 3	Homo sapiens	37-43
18474417-6	2008	Pharmacological inhibition of MEK1/2-ERK1/2 pathway with UO126 blocked caspase-3 activation, decreased AP-1 binding to DNA and inhibited apoptosis.	U 0126	57-62	caspase 3	Homo sapiens	71-80
18474417-6	2008	Pharmacological inhibition of MEK1/2-ERK1/2 pathway with UO126 blocked caspase-3 activation, decreased AP-1 binding to DNA and inhibited apoptosis.	U 0126	57-62	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
18477477-6	2008	When we treated HCE-T cells with the ERK-specific inhibitor U0126, cell migration and the expression of integrin beta1 were completely blocked.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	37-40
18477477-6	2008	When we treated HCE-T cells with the ERK-specific inhibitor U0126, cell migration and the expression of integrin beta1 were completely blocked.	U 0126	60-65	integrin subunit beta 1	Homo sapiens	104-118
18631385-6	2008	Membrane-permeable inhibitors of PKA (KT5720, 1 microM; cAMPS-Rp, 10 microM) and ERK (U0126, 1 microM) activation inhibited synaptic plasticity in slices from arthritic rats but had no effect on normal transmission in control slices.	U 0126	86-91	Eph receptor B1	Rattus norvegicus	81-84
18456735-8	2008	Pretreatment of VSMC with ERK1/2-MAP kinase inhibitor (U-0126, 1 microM) reduced alphavbeta(3)-integrin, TGF-beta1, and collagen type 1 content.	U 0126	55-61	mitogen-activated protein kinase 3	Mus musculus	26-32
18456735-8	2008	Pretreatment of VSMC with ERK1/2-MAP kinase inhibitor (U-0126, 1 microM) reduced alphavbeta(3)-integrin, TGF-beta1, and collagen type 1 content.	U 0126	55-61	transforming growth factor, beta 1	Mus musculus	105-114
18493739-7	2008	This activation of translational factors and the associated elevation of insulin synthesis were completely blocked by the calcium channel blocker verapamil and partially blocked by the mammalian target of rapamycin (mTOR) inhibitor rapamycin, the protein kinase A (PKA) inhibitor Rp-8-Br-cAMPs and the mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase (MEK) inhibitor U0126; a combination of inhibitors exhibited additive effects.	U 0126	397-402	mechanistic target of rapamycin kinase	Rattus norvegicus	216-220
18346844-7	2008	Administration of 5 microM imatinib and 1 microM U0126 (MEK inhibitor) significantly suppressed pancreatic cell growth.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	U 0126	113-118	tumor necrosis factor	Homo sapiens	0-9
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	U 0126	113-118	erythrocyte membrane protein band 4.2	Homo sapiens	40-43
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	U 0126	113-118	interferon induced protein 44	Homo sapiens	44-47
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	U 0126	113-118	mitogen-activated protein kinase 1	Homo sapiens	48-52
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	U 0126	113-118	mitogen-activated protein kinase 8	Homo sapiens	57-60
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	U 0126	247-252	nuclear factor kappa B subunit 1	Homo sapiens	32-41
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	U 0126	247-252	tumor necrosis factor	Homo sapiens	45-54
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	U 0126	247-252	matrix metallopeptidase 9	Homo sapiens	63-68
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	U 0126	247-252	tumor necrosis factor	Homo sapiens	105-114
18336852-7	2008	MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125.	U 0126	136-141	matrix metallopeptidase 9	Homo sapiens	0-5
18336852-7	2008	MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125.	U 0126	136-141	tumor necrosis factor	Homo sapiens	40-49
18336852-7	2008	MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125.	U 0126	136-141	matrix metallopeptidase 9	Homo sapiens	91-96
18486126-8	2008	The effect of vasopressin was abolished in the presence of AG1478, indicating its dependence upon transactivation, and by U0126 an inhibitor of the MAP kinase/ERK kinase (MEK), and thus of ERK 1/2 phosphorylation.	U 0126	122-127	arginine vasopressin	Homo sapiens	14-25
18486126-8	2008	The effect of vasopressin was abolished in the presence of AG1478, indicating its dependence upon transactivation, and by U0126 an inhibitor of the MAP kinase/ERK kinase (MEK), and thus of ERK 1/2 phosphorylation.	U 0126	122-127	mitogen-activated protein kinase kinase 7	Homo sapiens	148-169
18486126-8	2008	The effect of vasopressin was abolished in the presence of AG1478, indicating its dependence upon transactivation, and by U0126 an inhibitor of the MAP kinase/ERK kinase (MEK), and thus of ERK 1/2 phosphorylation.	U 0126	122-127	mitogen-activated protein kinase kinase 7	Homo sapiens	171-174
18390828-7	2008	Selective MEK inhibitors (U0126 and PD-98059) blocked both IL-8/CXCL8 release and ERK1/2 phosphorylation.	U 0126	26-31	C-X-C motif chemokine ligand 8	Homo sapiens	59-63
18390828-7	2008	Selective MEK inhibitors (U0126 and PD-98059) blocked both IL-8/CXCL8 release and ERK1/2 phosphorylation.	U 0126	26-31	C-X-C motif chemokine ligand 8	Homo sapiens	64-69
18390828-7	2008	Selective MEK inhibitors (U0126 and PD-98059) blocked both IL-8/CXCL8 release and ERK1/2 phosphorylation.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	82-88
18218921-6	2008	This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta1 signaling.	U 0126	195-200	fibroblast growth factor 2	Homo sapiens	253-258
18218921-6	2008	This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta1 signaling.	U 0126	195-200	transforming growth factor beta 1	Homo sapiens	270-279
18338254-7	2008	Interestingly, inhibition of ERK by U0126 completely prevented artepillin C-induced p38 MAPK phosphorylation of PC12m3 cells.	U 0126	36-41	mitogen activated protein kinase 14	Rattus norvegicus	84-87
18645229-0	2008	Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor.	U 0126	63-68	mitogen-activated protein kinase 8	Homo sapiens	30-33
18645229-0	2008	Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor.	U 0126	63-68	aryl hydrocarbon receptor	Homo sapiens	148-173
18645229-3	2008	Unfortunately, the inhibitors of JNK and ERK MAPKs, i.e. SP600125 and U0126, respectively, affect AhR-CYP1A signaling pathway because they are partial agonists of AhR and induce CYP1A genes.	U 0126	70-75	mitogen-activated protein kinase 8	Homo sapiens	33-36
18383343-9	2008	Inhibitors of Ras (FTA), Raf (Bay 54-9085) and MEK (UO126), but not of phosphatidylinositol 3-kinase (PI3K) (LY294002) and of protein kinase C (BIM) pathways, inhibited uPA activity and cell invasion.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
18645229-3	2008	Unfortunately, the inhibitors of JNK and ERK MAPKs, i.e. SP600125 and U0126, respectively, affect AhR-CYP1A signaling pathway because they are partial agonists of AhR and induce CYP1A genes.	U 0126	70-75	aryl hydrocarbon receptor	Homo sapiens	98-101
18645229-3	2008	Unfortunately, the inhibitors of JNK and ERK MAPKs, i.e. SP600125 and U0126, respectively, affect AhR-CYP1A signaling pathway because they are partial agonists of AhR and induce CYP1A genes.	U 0126	70-75	aryl hydrocarbon receptor	Homo sapiens	163-166
18442799-5	2008	Treatment with the MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, reversed the diminished expression of cell surface TNF-R1 as well as the blockade of TNF-alpha-induced IkappaBalpha degradation in Ac-CHX-treated cells.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
18263604-8	2008	The possibility of a causal relationship between ERK1/2 activation and cyst cell proliferation was assessed in vivo in the acute perinatal Pkd1 model of ADPKD using MEK1/2 inhibitor U0126.	U 0126	182-187	mitogen-activated protein kinase 3	Mus musculus	49-55
18442799-5	2008	Treatment with the MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, reversed the diminished expression of cell surface TNF-R1 as well as the blockade of TNF-alpha-induced IkappaBalpha degradation in Ac-CHX-treated cells.	U 0126	33-38	TNF receptor superfamily member 1A	Homo sapiens	169-175
18442799-5	2008	Treatment with the MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, reversed the diminished expression of cell surface TNF-R1 as well as the blockade of TNF-alpha-induced IkappaBalpha degradation in Ac-CHX-treated cells.	U 0126	33-38	tumor necrosis factor	Homo sapiens	203-212
18442799-5	2008	Treatment with the MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, reversed the diminished expression of cell surface TNF-R1 as well as the blockade of TNF-alpha-induced IkappaBalpha degradation in Ac-CHX-treated cells.	U 0126	33-38	NFKB inhibitor alpha	Homo sapiens	221-233
18309089-8	2008	Two transactivation inhibitors partially inhibited ERK1/2 phosphorylation, and U0126 partially inhibited EGFR transactivation, indicating that MEK may be involved both upstream and downstream of EGFR activation.	U 0126	79-84	epidermal growth factor receptor	Homo sapiens	105-109
18331583-9	2008	The stimulatory effect of NPY on cell proliferation was reduced by L-nitroarginine-methyl-esther (L-NAME; 500 microM), a nitric oxide synthase inhibitor, 1H-[1,2,4]oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ; 20 microM), a soluble guanylyl cyclase inhibitor or U0126 (1 microM), an inhibitor of the extracellular signal-regulated kinase 1/2 (ERK 1/2).	U 0126	258-263	neuropeptide Y	Rattus norvegicus	26-29
18309089-4	2008	However, the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-butadiene ethanolate] decreased extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, completely inhibited the rapid decrease in binding, and partially inhibited the sustained decrease.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	13-52
18339969-9	2008	The increase in PAI-1 expression, fibrin deposition, and liver damage caused by LPS + resistin was almost completely prevented either by inhibiting the coagulation cascade, hirudin, or by blocking MAP kinase signaling, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene], indicating that these pathways play a causal role in observed enhanced liver damage caused by resistin.	U 0126	219-224	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	16-21
18309089-4	2008	However, the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-butadiene ethanolate] decreased extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, completely inhibited the rapid decrease in binding, and partially inhibited the sustained decrease.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
18309089-4	2008	However, the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)-butadiene ethanolate] decreased extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, completely inhibited the rapid decrease in binding, and partially inhibited the sustained decrease.	U 0126	69-74	mitogen-activated protein kinase 3	Homo sapiens	163-210
18309089-8	2008	Two transactivation inhibitors partially inhibited ERK1/2 phosphorylation, and U0126 partially inhibited EGFR transactivation, indicating that MEK may be involved both upstream and downstream of EGFR activation.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	143-146
18339969-9	2008	The increase in PAI-1 expression, fibrin deposition, and liver damage caused by LPS + resistin was almost completely prevented either by inhibiting the coagulation cascade, hirudin, or by blocking MAP kinase signaling, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene], indicating that these pathways play a causal role in observed enhanced liver damage caused by resistin.	U 0126	219-224	toll-like receptor 4	Mus musculus	80-83
18339969-9	2008	The increase in PAI-1 expression, fibrin deposition, and liver damage caused by LPS + resistin was almost completely prevented either by inhibiting the coagulation cascade, hirudin, or by blocking MAP kinase signaling, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene], indicating that these pathways play a causal role in observed enhanced liver damage caused by resistin.	U 0126	219-224	resistin	Mus musculus	86-94
18339969-9	2008	The increase in PAI-1 expression, fibrin deposition, and liver damage caused by LPS + resistin was almost completely prevented either by inhibiting the coagulation cascade, hirudin, or by blocking MAP kinase signaling, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene], indicating that these pathways play a causal role in observed enhanced liver damage caused by resistin.	U 0126	226-286	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	16-21
18339969-9	2008	The increase in PAI-1 expression, fibrin deposition, and liver damage caused by LPS + resistin was almost completely prevented either by inhibiting the coagulation cascade, hirudin, or by blocking MAP kinase signaling, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene], indicating that these pathways play a causal role in observed enhanced liver damage caused by resistin.	U 0126	226-286	toll-like receptor 4	Mus musculus	80-83
18339969-9	2008	The increase in PAI-1 expression, fibrin deposition, and liver damage caused by LPS + resistin was almost completely prevented either by inhibiting the coagulation cascade, hirudin, or by blocking MAP kinase signaling, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene], indicating that these pathways play a causal role in observed enhanced liver damage caused by resistin.	U 0126	226-286	resistin	Mus musculus	86-94
18353995-4	2008	Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells.	U 0126	132-137	mitogen-activated protein kinase kinase 7	Homo sapiens	21-60
18385518-9	2008	beta(1)Pix-induced p27(kip1) down-regulation was blocked by U0126 but not by wortmannin.	U 0126	60-65	interferon alpha inducible protein 27	Homo sapiens	19-22
18353995-4	2008	Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells.	U 0126	132-137	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
18353995-4	2008	Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells.	U 0126	132-137	mitogen-activated protein kinase 3	Homo sapiens	166-172
18353995-4	2008	Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells.	U 0126	132-137	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	212-217
18362162-5	2008	Treatment with the MEK inhibitor U0126 inhibits ERK activation and decreases Notch and beta-catenin/T-cell factor (TCF) reporter activity resulting from Msi1 expression.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
18362162-5	2008	Treatment with the MEK inhibitor U0126 inhibits ERK activation and decreases Notch and beta-catenin/T-cell factor (TCF) reporter activity resulting from Msi1 expression.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	48-51
18362162-5	2008	Treatment with the MEK inhibitor U0126 inhibits ERK activation and decreases Notch and beta-catenin/T-cell factor (TCF) reporter activity resulting from Msi1 expression.	U 0126	33-38	hepatocyte nuclear factor 4 alpha	Homo sapiens	87-113
18362162-5	2008	Treatment with the MEK inhibitor U0126 inhibits ERK activation and decreases Notch and beta-catenin/T-cell factor (TCF) reporter activity resulting from Msi1 expression.	U 0126	33-38	hepatocyte nuclear factor 4 alpha	Homo sapiens	115-118
18362162-5	2008	Treatment with the MEK inhibitor U0126 inhibits ERK activation and decreases Notch and beta-catenin/T-cell factor (TCF) reporter activity resulting from Msi1 expression.	U 0126	33-38	musashi RNA binding protein 1	Homo sapiens	153-157
18385518-9	2008	beta(1)Pix-induced p27(kip1) down-regulation was blocked by U0126 but not by wortmannin.	U 0126	60-65	cyclin dependent kinase inhibitor 1B	Homo sapiens	23-27
18771612-5	2008	RESULTS: U0126, but not SB203580 could inhibit the activation of ERK1/2 induced by electromagnetic exposure.	U 0126	9-14	mitogen activated protein kinase 3	Rattus norvegicus	65-71
18583239-3	2008	In another experiment, the cells were preincubated for 1 h in the presence of U0126 (an inhibitor of the MAPK/ERK kinase), irbesartan (an AT-1 receptor blocker), or antioxidant-N-acetylcysteine (NAC) prior to AngII exposure, and the protein expression of phospho-P42/44 and PDGF-B were measured with Western blotting.	U 0126	78-83	mitogen activated protein kinase 3	Rattus norvegicus	105-109
18583239-5	2008	RESULTS: AngII induced phospho-P42/44 expression in HSC-T6, which was abrogated by U0126 or irbesartan.	U 0126	83-88	angiotensinogen	Rattus norvegicus	9-14
18583239-7	2008	EMSA showed that AngII exposure of the HSC cells markedly increased EGR-1 DNA binding activity, reaching the maximum after 60 min of exposure followed by progressive declination; irbesartan and U0126 significantly suppressed AngII-induced EGR-1 activity enhancement.	U 0126	194-199	angiotensinogen	Rattus norvegicus	17-22
18583239-7	2008	EMSA showed that AngII exposure of the HSC cells markedly increased EGR-1 DNA binding activity, reaching the maximum after 60 min of exposure followed by progressive declination; irbesartan and U0126 significantly suppressed AngII-induced EGR-1 activity enhancement.	U 0126	194-199	early growth response 1	Rattus norvegicus	68-73
18583239-7	2008	EMSA showed that AngII exposure of the HSC cells markedly increased EGR-1 DNA binding activity, reaching the maximum after 60 min of exposure followed by progressive declination; irbesartan and U0126 significantly suppressed AngII-induced EGR-1 activity enhancement.	U 0126	194-199	angiotensinogen	Rattus norvegicus	225-230
18583239-7	2008	EMSA showed that AngII exposure of the HSC cells markedly increased EGR-1 DNA binding activity, reaching the maximum after 60 min of exposure followed by progressive declination; irbesartan and U0126 significantly suppressed AngII-induced EGR-1 activity enhancement.	U 0126	194-199	early growth response 1	Rattus norvegicus	239-244
18423597-6	2008	Either SB203580 or U0126 displayed inhibitory effect on icariin induced NF-kappaB and AP-1 activation.	U 0126	19-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	72-81
18423597-6	2008	Either SB203580 or U0126 displayed inhibitory effect on icariin induced NF-kappaB and AP-1 activation.	U 0126	19-24	jun proto-oncogene	Mus musculus	86-90
18403372-7	2008	An ERK cascade inhibitor, U0126, inversely augmented SUMO modification of SREBP-2.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	3-6
18071315-6	2008	In contrast, reduction of B-Raf by RNAi or inactivation of ERK by the MEK inhibitor U0126 resulted in a precipitous decline in Mps1 levels.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	59-62
18403372-7	2008	An ERK cascade inhibitor, U0126, inversely augmented SUMO modification of SREBP-2.	U 0126	26-31	sterol regulatory element binding transcription factor 2	Homo sapiens	74-81
18339311-3	2008	EGF increased the phosphorylation of ERK1/2 and TRPM6 expression that were inhibited by U0126 in renal epithelial NRK-52E cells.	U 0126	88-93	epidermal growth factor	Rattus norvegicus	0-3
18339311-3	2008	EGF increased the phosphorylation of ERK1/2 and TRPM6 expression that were inhibited by U0126 in renal epithelial NRK-52E cells.	U 0126	88-93	mitogen activated protein kinase 3	Rattus norvegicus	37-43
18339311-3	2008	EGF increased the phosphorylation of ERK1/2 and TRPM6 expression that were inhibited by U0126 in renal epithelial NRK-52E cells.	U 0126	88-93	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	48-53
18027882-5	2008	LPA induced activation of ERK through pertussis toxin-sensitive manner, and pretreatment of MSCs with U0126, a MEK inhibitor, or pertussis toxin attenuated the LPA-induced migration.	U 0126	102-107	mitogen-activated protein kinase 1	Homo sapiens	26-29
18027882-5	2008	LPA induced activation of ERK through pertussis toxin-sensitive manner, and pretreatment of MSCs with U0126, a MEK inhibitor, or pertussis toxin attenuated the LPA-induced migration.	U 0126	102-107	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
18071315-6	2008	In contrast, reduction of B-Raf by RNAi or inactivation of ERK by the MEK inhibitor U0126 resulted in a precipitous decline in Mps1 levels.	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
18071315-6	2008	In contrast, reduction of B-Raf by RNAi or inactivation of ERK by the MEK inhibitor U0126 resulted in a precipitous decline in Mps1 levels.	U 0126	84-89	TTK protein kinase	Homo sapiens	127-131
18418254-5	2008	Exogenous HGF-induced proliferation was inhibited by U0126, whereas migration was completely blocked by LY294002.	U 0126	53-58	hepatocyte growth factor	Homo sapiens	10-13
18224693-7	2008	Pretreatment of these cells with the selective MEK inhibitor U0126 effectively reduced the level of cisplatin-induced apoptosis.	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
18367304-5	2008	The AA release, induced by PCB 153, was partially inhibited by extracellular signal-regulated kinases 1/2 (ERK1/2) signalling inhibitor, U0126, and by cytosolic phospholipase A(2) (cPLA(2)) inhibitor, AACOCF(3).	U 0126	137-142	pyruvate carboxylase	Rattus norvegicus	27-30
18385910-10	2008	Extracellular regulated kinase (ERK) 1/2 inhibitor (U0126) or phosphoinositide kinase-3 (PI3K) inhibitor (LY294002) could partially block the response of Hsp105 and Hsp70 induced by heat treatment.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	0-40
18392682-5	2008	TA-induced cell death was attenuated by inhibition of extracellular signal-regulated kinases (ERK) 1/2 with U0126 and inhibition of p38(MAPK) with SB203580.	U 0126	108-113	mitogen-activated protein kinase 1	Homo sapiens	94-97
18385910-10	2008	Extracellular regulated kinase (ERK) 1/2 inhibitor (U0126) or phosphoinositide kinase-3 (PI3K) inhibitor (LY294002) could partially block the response of Hsp105 and Hsp70 induced by heat treatment.	U 0126	52-57	heat shock protein family H (Hsp110) member 1	Homo sapiens	154-160
18385910-10	2008	Extracellular regulated kinase (ERK) 1/2 inhibitor (U0126) or phosphoinositide kinase-3 (PI3K) inhibitor (LY294002) could partially block the response of Hsp105 and Hsp70 induced by heat treatment.	U 0126	52-57	heat shock protein family A (Hsp70) member 4	Homo sapiens	165-170
18547242-2	2008	We now show that a presynaptic ERK1/2 signalling pathway mediates the nongenomic effect, as it was blocked by the MEK inhibitors U0126 (10 microm) and PD098059 (40 microm) and occluded in H-Ras(G12V)-mutant mice with constitutive activation of the ERK1/2 presynaptic pathway.	U 0126	129-134	mitogen-activated protein kinase 3	Mus musculus	31-37
18311185-7	2008	Dexmedetomidine-induced EGF receptor phosphorylation was prevented by AG 1478, GM 6001, PP1 and GF 109203X and its induction of cfos and fosB by AG 1478 and by U0126 (10 microM), an inhibitor of ERK phosphorylation, indicating downstream effects of ERK(1/2) phosphorylation.	U 0126	160-165	epidermal growth factor	Homo sapiens	24-27
18311185-7	2008	Dexmedetomidine-induced EGF receptor phosphorylation was prevented by AG 1478, GM 6001, PP1 and GF 109203X and its induction of cfos and fosB by AG 1478 and by U0126 (10 microM), an inhibitor of ERK phosphorylation, indicating downstream effects of ERK(1/2) phosphorylation.	U 0126	160-165	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	137-141
18311185-7	2008	Dexmedetomidine-induced EGF receptor phosphorylation was prevented by AG 1478, GM 6001, PP1 and GF 109203X and its induction of cfos and fosB by AG 1478 and by U0126 (10 microM), an inhibitor of ERK phosphorylation, indicating downstream effects of ERK(1/2) phosphorylation.	U 0126	160-165	mitogen-activated protein kinase 3	Homo sapiens	249-256
18023131-8	2008	Both AG1478 and U0126 could lead to the failure of EGF-induced GVBD singly.	U 0126	16-21	epidermal growth factor	Homo sapiens	51-54
18547242-2	2008	We now show that a presynaptic ERK1/2 signalling pathway mediates the nongenomic effect, as it was blocked by the MEK inhibitors U0126 (10 microm) and PD098059 (40 microm) and occluded in H-Ras(G12V)-mutant mice with constitutive activation of the ERK1/2 presynaptic pathway.	U 0126	129-134	mitogen-activated protein kinase 3	Mus musculus	248-254
18425342-8	2008	In contrast, inhibition of extracellular signal-regulated kinase (ERK) by U0126 attenuated cisplatin-induced PARP cleavage.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	27-64
18293410-5	2008	Cultured schwannoma cells responded to CXCL16-stimulation by phosphorylation of kinases p42/44 (Erk 2/1) that could be inhibited by the MEK1/2-inhibitor U0126 indicating an involvement of the mitogen-activated protein kinase signal transduction pathway.	U 0126	153-158	C-X-C motif chemokine ligand 16	Homo sapiens	39-45
18293410-5	2008	Cultured schwannoma cells responded to CXCL16-stimulation by phosphorylation of kinases p42/44 (Erk 2/1) that could be inhibited by the MEK1/2-inhibitor U0126 indicating an involvement of the mitogen-activated protein kinase signal transduction pathway.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	96-103
18293410-5	2008	Cultured schwannoma cells responded to CXCL16-stimulation by phosphorylation of kinases p42/44 (Erk 2/1) that could be inhibited by the MEK1/2-inhibitor U0126 indicating an involvement of the mitogen-activated protein kinase signal transduction pathway.	U 0126	153-158	mitogen-activated protein kinase kinase 1	Homo sapiens	136-142
18425342-8	2008	In contrast, inhibition of extracellular signal-regulated kinase (ERK) by U0126 attenuated cisplatin-induced PARP cleavage.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	66-69
18425342-8	2008	In contrast, inhibition of extracellular signal-regulated kinase (ERK) by U0126 attenuated cisplatin-induced PARP cleavage.	U 0126	74-79	poly(ADP-ribose) polymerase 1	Homo sapiens	109-113
18064629-4	2008	MEK/ERK inhibitors PD98059 and U0126 inhibit UV-induced down-regulation of AQP3.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
18059019-9	2008	A specific inhibitor of the MAP kinase pathway, U0126, completely blocked the increase of MUC1 and MUC2 expression as well as mucus synthesis by LL-37.	U 0126	48-53	mucin 1, cell surface associated	Homo sapiens	90-94
18059019-9	2008	A specific inhibitor of the MAP kinase pathway, U0126, completely blocked the increase of MUC1 and MUC2 expression as well as mucus synthesis by LL-37.	U 0126	48-53	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	99-103
18064629-4	2008	MEK/ERK inhibitors PD98059 and U0126 inhibit UV-induced down-regulation of AQP3.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	4-7
18059019-9	2008	A specific inhibitor of the MAP kinase pathway, U0126, completely blocked the increase of MUC1 and MUC2 expression as well as mucus synthesis by LL-37.	U 0126	48-53	cathelicidin antimicrobial peptide	Homo sapiens	145-150
18064629-4	2008	MEK/ERK inhibitors PD98059 and U0126 inhibit UV-induced down-regulation of AQP3.	U 0126	31-36	aquaporin 3 (Gill blood group)	Homo sapiens	75-79
18194435-4	2008	Although mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated protein kinase (ERK) are activated by GW5074, pharmacological inhibition of MEK-ERK signaling by U0126 or PD98059 does not reduce neuroprotection suggesting that B-Raf signals through a non-canonical signaling pathway.	U 0126	187-192	mitogen-activated protein kinase kinase 7	Homo sapiens	166-169
18251703-12	2008	Pathway inhibitors, U0126 or LY294002, strongly increased both Bim mRNA and protein, confirming that both kinases regulate Bim.	U 0126	20-25	BCL2-like 11 (apoptosis facilitator)	Mus musculus	63-66
18251703-12	2008	Pathway inhibitors, U0126 or LY294002, strongly increased both Bim mRNA and protein, confirming that both kinases regulate Bim.	U 0126	20-25	BCL2-like 11 (apoptosis facilitator)	Mus musculus	123-126
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	117-176	mitogen-activated protein kinase 1	Homo sapiens	89-92
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	117-176	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
18569454-4	2008	Synergistic induction of CXCL10 by both Tat and IFN-gamma was susceptible to inhibition by the MEK1/2 inhibitor U0126 and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580.	U 0126	112-117	C-X-C motif chemokine ligand 10	Homo sapiens	25-31
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	117-176	leucine rich repeat kinase 2	Homo sapiens	193-198
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	117-176	mitogen-activated protein kinase 1	Homo sapiens	84-88
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	117-176	mitogen-activated protein kinase 1	Homo sapiens	267-270
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	178-183	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
18182054-7	2008	The mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK) kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) reduced LRRK2-induced neuritic autophagy and neurite shortening, implicating MAPK/ERK-related signaling.	U 0126	178-183	mitogen-activated protein kinase 1	Homo sapiens	84-88
18569454-4	2008	Synergistic induction of CXCL10 by both Tat and IFN-gamma was susceptible to inhibition by the MEK1/2 inhibitor U0126 and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580.	U 0126	112-117	tyrosine aminotransferase	Homo sapiens	40-43
18569454-4	2008	Synergistic induction of CXCL10 by both Tat and IFN-gamma was susceptible to inhibition by the MEK1/2 inhibitor U0126 and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580.	U 0126	112-117	interferon gamma	Homo sapiens	48-57
18569454-4	2008	Synergistic induction of CXCL10 by both Tat and IFN-gamma was susceptible to inhibition by the MEK1/2 inhibitor U0126 and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580.	U 0126	112-117	mitogen-activated protein kinase kinase 1	Homo sapiens	95-101
18702304-6	2008	PI3K and MAPK inhibitor, LY294002 and U0126 could inhibit hypoxia-induced HIF-1 and VEGF expression.	U 0126	38-43	vascular endothelial growth factor A	Homo sapiens	84-88
18287093-3	2008	The present studies demonstrate that inhibition of MEK activation in HepG2 human hepatoma cells by PD98059 or U0126 blocked the increased phosphorylation of eIF2alpha and ATF4 synthesis triggered by amino acid limitation, showing that the AAR requires activation of the MEK-ERK pathway.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
18445299-9	2008	Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly in lamina II of the dorsal horn.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
18445299-9	2008	Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly in lamina II of the dorsal horn.	U 0126	49-54	mitogen-activated protein kinase 3	Homo sapiens	131-137
18445299-9	2008	Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly in lamina II of the dorsal horn.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	144-147
18445299-9	2008	Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly in lamina II of the dorsal horn.	U 0126	49-54	mitogen-activated protein kinase 3	Homo sapiens	222-228
18445299-9	2008	Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly in lamina II of the dorsal horn.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	261-264
18287093-3	2008	The present studies demonstrate that inhibition of MEK activation in HepG2 human hepatoma cells by PD98059 or U0126 blocked the increased phosphorylation of eIF2alpha and ATF4 synthesis triggered by amino acid limitation, showing that the AAR requires activation of the MEK-ERK pathway.	U 0126	110-115	eukaryotic translation initiation factor 2A	Homo sapiens	157-166
18287093-3	2008	The present studies demonstrate that inhibition of MEK activation in HepG2 human hepatoma cells by PD98059 or U0126 blocked the increased phosphorylation of eIF2alpha and ATF4 synthesis triggered by amino acid limitation, showing that the AAR requires activation of the MEK-ERK pathway.	U 0126	110-115	activating transcription factor 4	Homo sapiens	171-175
18287093-3	2008	The present studies demonstrate that inhibition of MEK activation in HepG2 human hepatoma cells by PD98059 or U0126 blocked the increased phosphorylation of eIF2alpha and ATF4 synthesis triggered by amino acid limitation, showing that the AAR requires activation of the MEK-ERK pathway.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	270-273
18419805-0	2008	The small molecule Mek1/2 inhibitor U0126 disrupts the chordamesoderm to notochord transition in zebrafish.	U 0126	36-41	mitogen-activated protein kinase kinase 1	Mus musculus	19-23
18287093-3	2008	The present studies demonstrate that inhibition of MEK activation in HepG2 human hepatoma cells by PD98059 or U0126 blocked the increased phosphorylation of eIF2alpha and ATF4 synthesis triggered by amino acid limitation, showing that the AAR requires activation of the MEK-ERK pathway.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	274-277
18419805-2	2008	RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo.	U 0126	127-132	mitogen-activated protein kinase kinase 1	Mus musculus	46-50
17891781-9	2008	Furthermore, ERK inhibitors (U0126 and PD98059) suppressed LPA-stimulated activation of NF-kappaB and p65 phosphorylation whereas wortmannin showed no effect on NF-kappaB activation.	U 0126	29-34	Eph receptor B1	Rattus norvegicus	13-16
18419805-2	2008	RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo.	U 0126	127-132	mitogen-activated protein kinase kinase 1	Mus musculus	110-114
18419805-2	2008	RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo.	U 0126	127-132	mitogen-activated protein kinase kinase 1	Mus musculus	110-114
18419805-2	2008	RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo.	U 0126	127-132	mitogen-activated protein kinase 3	Danio rerio	188-194
18419805-6	2008	CONCLUSION: Using the small chemical U0126, we have established a novel link between MAPK-signaling and notochord differentiation.	U 0126	37-42	mitogen-activated protein kinase 1	Danio rerio	85-89
17902169-3	2008	Western blotting and RT-PCR analyses showed that S1P induced EGFR mRNA and protein expression in a time- and concentration-dependent manner, which was attenuated by inhibitors of MEK1/2 (U0126) and phosphatidylinositide 3-kinase (PI3K; wortmannin), and transfection with dominant negative mutants of ERK and Akt, respectively.	U 0126	187-192	epidermal growth factor receptor	Rattus norvegicus	61-65
17902169-5	2008	In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt which was attenuated by U0126 and wortmannin, respectively.	U 0126	114-119	mitogen activated protein kinase 3	Rattus norvegicus	73-81
17902169-5	2008	In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt which was attenuated by U0126 and wortmannin, respectively.	U 0126	114-119	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
17902169-9	2008	S1P-stimulated AP-1 subunits (c-Jun and c-Fos mRNA) expression was attenuated by U0126 and wortmannin, suggesting that MEK and PI3K/ERK cascade linking to AP-1 was involved in EGFR expression.	U 0126	81-86	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	15-19
17902169-9	2008	S1P-stimulated AP-1 subunits (c-Jun and c-Fos mRNA) expression was attenuated by U0126 and wortmannin, suggesting that MEK and PI3K/ERK cascade linking to AP-1 was involved in EGFR expression.	U 0126	81-86	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-45
17902169-9	2008	S1P-stimulated AP-1 subunits (c-Jun and c-Fos mRNA) expression was attenuated by U0126 and wortmannin, suggesting that MEK and PI3K/ERK cascade linking to AP-1 was involved in EGFR expression.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	132-135
17902169-9	2008	S1P-stimulated AP-1 subunits (c-Jun and c-Fos mRNA) expression was attenuated by U0126 and wortmannin, suggesting that MEK and PI3K/ERK cascade linking to AP-1 was involved in EGFR expression.	U 0126	81-86	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	155-159
17902169-9	2008	S1P-stimulated AP-1 subunits (c-Jun and c-Fos mRNA) expression was attenuated by U0126 and wortmannin, suggesting that MEK and PI3K/ERK cascade linking to AP-1 was involved in EGFR expression.	U 0126	81-86	epidermal growth factor receptor	Rattus norvegicus	176-180
18223161-6	2008	Two MEK1/2 inhibitors, U0126 and PD-98059, each abolished the T3-induced increase in the quantity of Na-K-ATPase alpha(1)-subunit plasma membrane protein and Na-K-ATPase activity.	U 0126	23-28	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-10
18292183-8	2008	U0126 (a MAP kinase inhibitor) attenuated the p40- and p75-mediated reduction of hydrogen peroxide-induced tight junction disruption and inulin permeability.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	46-49
18292183-8	2008	U0126 (a MAP kinase inhibitor) attenuated the p40- and p75-mediated reduction of hydrogen peroxide-induced tight junction disruption and inulin permeability.	U 0126	0-5	interleukin 2 receptor subunit beta	Homo sapiens	55-58
17979972-4	2008	The inhibition of the ERK pathway by U0126 (a specific ERK inhibitor) also had a dose-dependent antiproliferative effect on human keratinocytes.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	22-25
17979972-4	2008	The inhibition of the ERK pathway by U0126 (a specific ERK inhibitor) also had a dose-dependent antiproliferative effect on human keratinocytes.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	55-58
18295205-10	2008	Inhibition of MAPK with U0126 also blocked secretion stimulated by OPC-12759.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	14-18
17971154-7	2008	The amount of SC was also up-regulated by addition of TNF-alpha with U0126, an inhibitor of MEK1 and MEK2.	U 0126	69-74	tumor necrosis factor	Homo sapiens	54-63
17971154-7	2008	The amount of SC was also up-regulated by addition of TNF-alpha with U0126, an inhibitor of MEK1 and MEK2.	U 0126	69-74	mitogen-activated protein kinase kinase 1	Homo sapiens	92-96
17971154-7	2008	The amount of SC was also up-regulated by addition of TNF-alpha with U0126, an inhibitor of MEK1 and MEK2.	U 0126	69-74	mitogen-activated protein kinase kinase 2	Homo sapiens	101-105
18605443-8	2008	The above effects of bFGF could be attenuated by MEK inhibitor U0126.	U 0126	63-68	fibroblast growth factor 2	Homo sapiens	21-25
18605443-8	2008	The above effects of bFGF could be attenuated by MEK inhibitor U0126.	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
17943186-4	2008	The hyperplasia and hyaluronan production induced by all-trans RA were blocked with (1) AG1478, an inhibitor of the EGFR; (2) UO126, an inhibitor of the MAPK/ERK kinase, and (3) GM6001, an inhibitor of the matrix metalloproteinases.	U 0126	126-131	mitogen activated protein kinase 3	Rattus norvegicus	153-157
17943186-4	2008	The hyperplasia and hyaluronan production induced by all-trans RA were blocked with (1) AG1478, an inhibitor of the EGFR; (2) UO126, an inhibitor of the MAPK/ERK kinase, and (3) GM6001, an inhibitor of the matrix metalloproteinases.	U 0126	126-131	mitogen activated protein kinase 3	Rattus norvegicus	158-161
18182057-7	2008	In addition, N-cadherin expression was partially blocked when signaling from purinergic receptors to extracellular signal regulated protein kinase or Akt was inhibited by 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene or wortmannin, respectively.	U 0126	171-230	cadherin 2	Rattus norvegicus	13-23
18182057-7	2008	In addition, N-cadherin expression was partially blocked when signaling from purinergic receptors to extracellular signal regulated protein kinase or Akt was inhibited by 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene or wortmannin, respectively.	U 0126	171-230	AKT serine/threonine kinase 1	Rattus norvegicus	150-153
18357389-8	2008	The ERK1/2 inhibitor, U0126 and the p38 MAP kinase inhibitor, SB203580, significantly down-regulated TNF-alpha-induced MMP-9 expression and promoter activity.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	4-10
18357389-8	2008	The ERK1/2 inhibitor, U0126 and the p38 MAP kinase inhibitor, SB203580, significantly down-regulated TNF-alpha-induced MMP-9 expression and promoter activity.	U 0126	22-27	tumor necrosis factor	Homo sapiens	101-110
18357389-8	2008	The ERK1/2 inhibitor, U0126 and the p38 MAP kinase inhibitor, SB203580, significantly down-regulated TNF-alpha-induced MMP-9 expression and promoter activity.	U 0126	22-27	matrix metallopeptidase 9	Homo sapiens	119-124
18276593-8	2008	The EGFR inhibitor AG1478, completely blocked IL-8 and ICAM-1 expression to basal levels, as did the specific Erk1/2 inhibitor U0126.	U 0126	127-132	mitogen-activated protein kinase 3	Homo sapiens	110-116
18162528-10	2008	In addition, inhibition of MAPK signaling pathways with the MAPK kinase inhibitor U0126 or the p38 inhibitor SB203580 inhibited EtOH induction of CYP24A1.	U 0126	82-87	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	146-153
18412612-7	2008	The suppressed ethanol response in the OFC and AcbSh, key regions involved in ethanol preference and seeking, was restored by pre-treatment with UO126, demonstrating a recruitment of an ERK/MEK-mediated inhibitory regulation in the post-dependent state.	U 0126	145-150	Eph receptor B1	Rattus norvegicus	186-189
18412615-7	2008	Importantly, the anxiolytic effect of OT within the PVN was prevented by local inhibition of the MAP kinase cascade with a MEK1/2 inhibitor (U0126, 0.5 nmol/0.5 microL) locally infused prior to OT, indicating the causal involvement of this intracellular signalling cascade in the behavioural effect of OT.	U 0126	141-146	mitogen activated protein kinase kinase 1	Rattus norvegicus	123-129
18367630-8	2008	Inhibition of the pathway mitogen-activated extracellular signal-regulated protein kinase (MEK) 1/2 with UO126 diminished the proliferation of the Sertoli and Leydig cells in vitro.	U 0126	105-110	mitogen-activated protein kinase kinase 1	Mus musculus	26-99
18395090-10	2008	Furthermore, intrathecal administration of the mitogen-activated protein kinase kinase 1/2 inhibitor, U0126, altered the response to noxious GD.	U 0126	102-107	mitogen activated protein kinase kinase 1	Rattus norvegicus	47-90
18481005-5	2008	U0126 suppressed the effect of bFGF.	U 0126	0-5	fibroblast growth factor 2	Homo sapiens	31-35
18372406-5	2008	Phosphorylation of S104 and S106 can be inhibited by the MAP-erk kinase (MEK)1/2 inhibitor U0126 and by expression of kinase-dead Raf1.	U 0126	91-96	mitogen-activated protein kinase kinase 1	Homo sapiens	57-80
18339080-14	2008	By blocking the extracellular signal-regulated protein kinase (ERK1/2) activation by adding U0126, we could prevent the apoptosis induced by atorvastatin.	U 0126	92-97	mitogen activated protein kinase 3	Rattus norvegicus	63-69
17891781-9	2008	Furthermore, ERK inhibitors (U0126 and PD98059) suppressed LPA-stimulated activation of NF-kappaB and p65 phosphorylation whereas wortmannin showed no effect on NF-kappaB activation.	U 0126	29-34	synaptotagmin 1	Rattus norvegicus	102-105
17873909-5	2008	Consistently, combined suppression of RhoA and Mek/Erk or Bcl-2 pathways by sub-optimal dose of rhoA morpholino and pharmacological inhibitors for either Mek (U0126) or Bcl-2 (HA 14-1) can induce developmental abnormalities and enhanced apoptosis, similar to those caused by effective RhoA knockdown.	U 0126	159-164	ras homolog gene family, member Ab	Danio rerio	38-42
18093576-10	2008	Cadmium up-regulates BPDE-activated ERKs and ERK inhibition by U0126 relieves cadmium-mediated inhibition of BPDE-induced apoptosis.	U 0126	63-68	mitogen-activated protein kinase 1	Mus musculus	36-40
18178156-5	2008	C3a induced extracellular signal-regulated kinase (ERK) phosphorylation, and C3a-increased KLF5 promoter activity was completely inhibited by the MEK inhibitor U0126.	U 0126	160-165	Eph receptor B1	Rattus norvegicus	12-49
18178156-5	2008	C3a induced extracellular signal-regulated kinase (ERK) phosphorylation, and C3a-increased KLF5 promoter activity was completely inhibited by the MEK inhibitor U0126.	U 0126	160-165	Eph receptor B1	Rattus norvegicus	51-54
18178156-5	2008	C3a induced extracellular signal-regulated kinase (ERK) phosphorylation, and C3a-increased KLF5 promoter activity was completely inhibited by the MEK inhibitor U0126.	U 0126	160-165	Kruppel-like factor 5	Rattus norvegicus	91-95
17873909-5	2008	Consistently, combined suppression of RhoA and Mek/Erk or Bcl-2 pathways by sub-optimal dose of rhoA morpholino and pharmacological inhibitors for either Mek (U0126) or Bcl-2 (HA 14-1) can induce developmental abnormalities and enhanced apoptosis, similar to those caused by effective RhoA knockdown.	U 0126	159-164	BCL2 apoptosis regulator a	Danio rerio	58-63
17873909-5	2008	Consistently, combined suppression of RhoA and Mek/Erk or Bcl-2 pathways by sub-optimal dose of rhoA morpholino and pharmacological inhibitors for either Mek (U0126) or Bcl-2 (HA 14-1) can induce developmental abnormalities and enhanced apoptosis, similar to those caused by effective RhoA knockdown.	U 0126	159-164	ras homolog gene family, member Ab	Danio rerio	96-100
17873909-6	2008	Furthermore, U0126 abrogates the rescue by RhoA and MEK but not BCL-2.	U 0126	13-18	ras homolog gene family, member Ab	Danio rerio	43-47
18210138-11	2008	Furthermore, the induction of HIF-1 alpha protein, but not its mRNA, could be significantly inhibited by Erk1/2 pathway specific inhibitor, U0126.	U 0126	140-145	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	30-41
18210138-11	2008	Furthermore, the induction of HIF-1 alpha protein, but not its mRNA, could be significantly inhibited by Erk1/2 pathway specific inhibitor, U0126.	U 0126	140-145	Eph receptor B1	Rattus norvegicus	105-111
18202115-13	2008	The MEK1 and MEK2 inhibitors U-0126 and PD-98059 significantly attenuated the protection of IL-11 against caspase-3 and caspase-9 cleavage and cytoplasmic oligonucleosomal DNA accumulation.	U 0126	29-35	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-8
17453334-4	2008	Rosiglitazone-induced ERE activation is also dependent on activation of the Extracellular Signal-Regulated Kinase-Mitogen Activated Protein Kinase (ERK-MAPK) pathway, since it is inhibited by co-treatment with U0126, a specific inhibitor of this pathway.	U 0126	210-215	mitogen-activated protein kinase 1	Homo sapiens	148-151
18202115-13	2008	The MEK1 and MEK2 inhibitors U-0126 and PD-98059 significantly attenuated the protection of IL-11 against caspase-3 and caspase-9 cleavage and cytoplasmic oligonucleosomal DNA accumulation.	U 0126	29-35	mitogen activated protein kinase kinase 2	Rattus norvegicus	13-17
18202115-13	2008	The MEK1 and MEK2 inhibitors U-0126 and PD-98059 significantly attenuated the protection of IL-11 against caspase-3 and caspase-9 cleavage and cytoplasmic oligonucleosomal DNA accumulation.	U 0126	29-35	interleukin 11	Rattus norvegicus	92-97
18202115-13	2008	The MEK1 and MEK2 inhibitors U-0126 and PD-98059 significantly attenuated the protection of IL-11 against caspase-3 and caspase-9 cleavage and cytoplasmic oligonucleosomal DNA accumulation.	U 0126	29-35	caspase 3	Rattus norvegicus	106-115
18202115-13	2008	The MEK1 and MEK2 inhibitors U-0126 and PD-98059 significantly attenuated the protection of IL-11 against caspase-3 and caspase-9 cleavage and cytoplasmic oligonucleosomal DNA accumulation.	U 0126	29-35	caspase 9	Rattus norvegicus	120-129
17453334-4	2008	Rosiglitazone-induced ERE activation is also dependent on activation of the Extracellular Signal-Regulated Kinase-Mitogen Activated Protein Kinase (ERK-MAPK) pathway, since it is inhibited by co-treatment with U0126, a specific inhibitor of this pathway.	U 0126	210-215	mitogen-activated protein kinase 1	Homo sapiens	152-156
18234180-5	2008	The yield of the two meiotic divisions and the percentage of highly MPM-2-labeled pachytene and secondary spermatocytes (SII) were decreased in co-cultures treated with U0126, an inhibitor of the ERK-activating kinases, MEK1/2.	U 0126	169-174	mitogen activated protein kinase kinase 1	Rattus norvegicus	220-226
18078826-7	2008	In contrast, the ERK inhibitor U0126 further potentiated heavy metal-mediated induction of Cyp1a1 mRNA, whereas it reversed their inhibitory effects on the Cyp1a1 activity.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	17-20
18079197-7	2008	Furthermore, U0126, an inhibitor of MAPK kinases MEK1 and MEK2, abrogated PGE(2)-induced migration of trophoblasts, and PGE(2) or the other two EP agonists stimulated ERK1/2 activation in trophoblasts, which was not abrogated by pretreatment with C3 transferase, indicating that ERK signaling pathway is an efficient alternate pathway for RhoA in PGE(2)-mediated migration of trophoblasts.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	49-53
18079197-7	2008	Furthermore, U0126, an inhibitor of MAPK kinases MEK1 and MEK2, abrogated PGE(2)-induced migration of trophoblasts, and PGE(2) or the other two EP agonists stimulated ERK1/2 activation in trophoblasts, which was not abrogated by pretreatment with C3 transferase, indicating that ERK signaling pathway is an efficient alternate pathway for RhoA in PGE(2)-mediated migration of trophoblasts.	U 0126	13-18	mitogen-activated protein kinase kinase 2	Homo sapiens	58-62
18079197-7	2008	Furthermore, U0126, an inhibitor of MAPK kinases MEK1 and MEK2, abrogated PGE(2)-induced migration of trophoblasts, and PGE(2) or the other two EP agonists stimulated ERK1/2 activation in trophoblasts, which was not abrogated by pretreatment with C3 transferase, indicating that ERK signaling pathway is an efficient alternate pathway for RhoA in PGE(2)-mediated migration of trophoblasts.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	167-173
18079197-7	2008	Furthermore, U0126, an inhibitor of MAPK kinases MEK1 and MEK2, abrogated PGE(2)-induced migration of trophoblasts, and PGE(2) or the other two EP agonists stimulated ERK1/2 activation in trophoblasts, which was not abrogated by pretreatment with C3 transferase, indicating that ERK signaling pathway is an efficient alternate pathway for RhoA in PGE(2)-mediated migration of trophoblasts.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	167-170
18079197-7	2008	Furthermore, U0126, an inhibitor of MAPK kinases MEK1 and MEK2, abrogated PGE(2)-induced migration of trophoblasts, and PGE(2) or the other two EP agonists stimulated ERK1/2 activation in trophoblasts, which was not abrogated by pretreatment with C3 transferase, indicating that ERK signaling pathway is an efficient alternate pathway for RhoA in PGE(2)-mediated migration of trophoblasts.	U 0126	13-18	ras homolog family member A	Homo sapiens	339-343
18078826-7	2008	In contrast, the ERK inhibitor U0126 further potentiated heavy metal-mediated induction of Cyp1a1 mRNA, whereas it reversed their inhibitory effects on the Cyp1a1 activity.	U 0126	31-36	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	91-97
18078826-7	2008	In contrast, the ERK inhibitor U0126 further potentiated heavy metal-mediated induction of Cyp1a1 mRNA, whereas it reversed their inhibitory effects on the Cyp1a1 activity.	U 0126	31-36	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	156-162
17786963-5	2008	The HNP-induced IL-8 production was blocked by the Src tyrosine kinase inhibitor PP2, MEK1/2 inhibitor U0126, and the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002, but not by the JNK inhibitor SP600125 in both cell types.	U 0126	103-108	kallikrein related peptidase 8	Homo sapiens	4-7
18186080-8	2008	Moreover, inhibition of ERK phosphorylation in the dorsal horn by intrathecal administration of U0126, an inhibitor of ERK activation, produced a striking alleviation of existing, long-term tactile allodynia of diabetic rats.	U 0126	96-101	Eph receptor B1	Rattus norvegicus	24-27
18186080-8	2008	Moreover, inhibition of ERK phosphorylation in the dorsal horn by intrathecal administration of U0126, an inhibitor of ERK activation, produced a striking alleviation of existing, long-term tactile allodynia of diabetic rats.	U 0126	96-101	Eph receptor B1	Rattus norvegicus	119-122
18292945-9	2008	The MEK inhibitor U0126 reduced TAC3 cell growth more effectively in the presence of both laminin-1 and AG73T than in the presence of laminin-1 alone.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
18292945-9	2008	The MEK inhibitor U0126 reduced TAC3 cell growth more effectively in the presence of both laminin-1 and AG73T than in the presence of laminin-1 alone.	U 0126	18-23	tachykinin precursor 3	Homo sapiens	32-36
17786963-5	2008	The HNP-induced IL-8 production was blocked by the Src tyrosine kinase inhibitor PP2, MEK1/2 inhibitor U0126, and the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002, but not by the JNK inhibitor SP600125 in both cell types.	U 0126	103-108	C-X-C motif chemokine ligand 8	Homo sapiens	16-20
18310446-5	2008	To establish whether transient ERK activation via the integrin alpha(V)beta(3) cell surface receptor mediated these effects, MG-63 cells were pretreated for 30 min with the specific MAPK kinase inhibitor, U0126 (1 microM), or an anti-integrin alpha(V)beta(3)-blocking antibody.	U 0126	205-210	mitogen-activated protein kinase 1	Homo sapiens	31-34
18292494-4	2008	Direct treatment with a specific ERK inhibitor, UO126, during CD4+CD25- T cell activation also induced Foxp3 expression and conferred a suppressive function to the induced Foxp3+ T cells.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	33-36
18292494-4	2008	Direct treatment with a specific ERK inhibitor, UO126, during CD4+CD25- T cell activation also induced Foxp3 expression and conferred a suppressive function to the induced Foxp3+ T cells.	U 0126	48-53	forkhead box P3	Homo sapiens	103-108
18292494-4	2008	Direct treatment with a specific ERK inhibitor, UO126, during CD4+CD25- T cell activation also induced Foxp3 expression and conferred a suppressive function to the induced Foxp3+ T cells.	U 0126	48-53	forkhead box P3	Homo sapiens	172-177
18191957-5	2008	RS-induced SRP and ERK 1/2 phosphorylation were both abolished by pretreatment of U0126 (MEK inhibitor).	U 0126	82-87	mitogen activated protein kinase 3	Rattus norvegicus	19-26
18287347-11	2008	SB203580 (p38MAPK inhibitor) and U0126 (MAPK kinase1/2 inhibitor) abrogated the upregulation of Cox-2 and PGI2 release induced by oleanolic acid.	U 0126	33-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	96-101
18079735-0	2008	Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.	U 0126	73-78	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	46-53
18079735-5	2008	Moreover, R18 sensitized BCR-ABL-transformed cells to inhibition with MEK1 inhibitor U0126, Bcl-2 inhibitor GX15-070, or mTOR inhibitor rapamycin.	U 0126	85-90	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	25-32
18079735-5	2008	Moreover, R18 sensitized BCR-ABL-transformed cells to inhibition with MEK1 inhibitor U0126, Bcl-2 inhibitor GX15-070, or mTOR inhibitor rapamycin.	U 0126	85-90	mitogen activated protein kinase kinase 1	Rattus norvegicus	70-74
18347153-6	2008	This feature was associated with reduced sensitivity to the MEK1/2 inhibitor U0126.	U 0126	77-82	mitogen-activated protein kinase kinase 1	Homo sapiens	60-66
18484529-6	2008	In addition, the DBT-induced EPO expression could be abolished by pre-treatment with U0126, a mitogen-activated kinase inhibitor.	U 0126	85-90	erythropoietin	Homo sapiens	29-32
18282182-11	2008	MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression.	U 0126	136-141	mitogen-activated protein kinase kinase 1	Mus musculus	0-6
18282182-11	2008	MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression.	U 0126	136-141	mitogen-activated protein kinase kinase 1	Mus musculus	0-4
18282182-11	2008	MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression.	U 0126	136-141	mitogen-activated protein kinase kinase 1	Mus musculus	119-125
18282182-11	2008	MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression.	U 0126	136-141	prostaglandin-endoperoxide synthase 2	Mus musculus	171-176
18174464-8	2008	Furthermore, blockade of the ERK or JNK pathways by U0126 and SP600125, respectively, abolished ADP- and 2-MeSADP-stimulated HUVEC migration.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	29-32
18442442-9	2008	The protective effects of M1 were significantly inhibited by U0126, an ERK inhibitor.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	71-74
18171671-11	2008	Moreover, we have shown that the mitogen-activated protein kinase (ERK1/2) is persistently activated and blockage of ERK activity with the ERK-specific inhibitor U0126 prevents neuronal differentiation.	U 0126	162-167	mitogen-activated protein kinase 3	Mus musculus	67-73
18171671-11	2008	Moreover, we have shown that the mitogen-activated protein kinase (ERK1/2) is persistently activated and blockage of ERK activity with the ERK-specific inhibitor U0126 prevents neuronal differentiation.	U 0126	162-167	mitogen-activated protein kinase 1	Mus musculus	67-70
18171671-11	2008	Moreover, we have shown that the mitogen-activated protein kinase (ERK1/2) is persistently activated and blockage of ERK activity with the ERK-specific inhibitor U0126 prevents neuronal differentiation.	U 0126	162-167	mitogen-activated protein kinase 1	Mus musculus	117-120
18174464-8	2008	Furthermore, blockade of the ERK or JNK pathways by U0126 and SP600125, respectively, abolished ADP- and 2-MeSADP-stimulated HUVEC migration.	U 0126	52-57	mitogen-activated protein kinase 8	Homo sapiens	36-39
18226471-6	2008	Luciferase activities induced by FGF2 were blocked by tyrosine kinase inhibitor herbimycin A, src-tyrosine kinase inhibitor PP1 and MAP kinase kinase inhibitor U0126.	U 0126	160-165	fibroblast growth factor 2	Rattus norvegicus	33-37
18086564-5	2008	The proliferation of EoL-1 cells and expression of c-Myc were also inhibited by the MEK inhibitor U0126 and JNK inhibitor SP600125.	U 0126	98-103	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
18086564-5	2008	The proliferation of EoL-1 cells and expression of c-Myc were also inhibited by the MEK inhibitor U0126 and JNK inhibitor SP600125.	U 0126	98-103	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
17918745-2	2008	The ebselen-induced MAPK activation was suppressed by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, a selective inhibitor of Trk family tyrosine kinases; AG1478, an antagonist of epidermal growth factor receptor (EGFR); pertussis toxin, an inhibitor of Gi/o; or GP antagonist-2A, an inhibitor of Gq.	U 0126	54-59	mitogen activated protein kinase 3	Rattus norvegicus	20-24
18234163-7	2008	The amitriptyline-induced phosphorylation of CREB was completely blocked by U0126 [a mitogen-activated protein (MAP) kinase kinase 1 inhibitor] and genistein (a PTK inhibitor), but not by inhibitors of protein kinase A, p38 MAP kinase, or Ca(2+)/calmodulin-dependent kinase.	U 0126	76-81	cAMP responsive element binding protein 1	Homo sapiens	45-49
18035481-4	2008	TGFbeta1, a stimulator of PTHrP transcription, abolished the effect of PTHrP and KISS-1 specific siRNAs and increased ERK1/2 phosphorylation, whereas inhibition of ERK1/2 phosphorylation by U0126 reduced colony size.	U 0126	190-195	latent transforming growth factor beta binding protein 1	Homo sapiens	0-8
18035481-4	2008	TGFbeta1, a stimulator of PTHrP transcription, abolished the effect of PTHrP and KISS-1 specific siRNAs and increased ERK1/2 phosphorylation, whereas inhibition of ERK1/2 phosphorylation by U0126 reduced colony size.	U 0126	190-195	parathyroid hormone like hormone	Homo sapiens	26-31
18035481-4	2008	TGFbeta1, a stimulator of PTHrP transcription, abolished the effect of PTHrP and KISS-1 specific siRNAs and increased ERK1/2 phosphorylation, whereas inhibition of ERK1/2 phosphorylation by U0126 reduced colony size.	U 0126	190-195	parathyroid hormone like hormone	Homo sapiens	71-76
18035481-4	2008	TGFbeta1, a stimulator of PTHrP transcription, abolished the effect of PTHrP and KISS-1 specific siRNAs and increased ERK1/2 phosphorylation, whereas inhibition of ERK1/2 phosphorylation by U0126 reduced colony size.	U 0126	190-195	KiSS-1 metastasis suppressor	Homo sapiens	81-87
18036509-5	2008	In contrast, inhibition of MEK1/2 by U0126 resulted in significantly reduced CREB phosphorylation levels after B2 bradykinin, but not M3 mACh receptor activation.	U 0126	37-42	mitogen-activated protein kinase kinase 1	Homo sapiens	27-33
18036509-5	2008	In contrast, inhibition of MEK1/2 by U0126 resulted in significantly reduced CREB phosphorylation levels after B2 bradykinin, but not M3 mACh receptor activation.	U 0126	37-42	cAMP responsive element binding protein 1	Homo sapiens	77-81
18036509-5	2008	In contrast, inhibition of MEK1/2 by U0126 resulted in significantly reduced CREB phosphorylation levels after B2 bradykinin, but not M3 mACh receptor activation.	U 0126	37-42	kininogen 1	Homo sapiens	114-124
18086672-6	2008	IL-18 induces ERK1/2 phosphorylation and enzyme activity, and pretreatment with the MEK inhibitor U0126, ERK1/2 inhibitor PD98059, or small interference RNA targeted to ERK1/2 attenuates ERK1/2 activation and NFATc4 phosphorylation.	U 0126	98-103	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
17706224-9	2008	This is supported by experiments with specific inhibitors for c-Jun-NH(2)-terminal kinase (SP600125), extracellular signal-regulated kinase 1 and 2 (PD98059 and U0126) and p38 (SB203580) that had no inhibitory effect on the up-regulation of TP receptors.	U 0126	161-166	mitogen activated protein kinase 3	Rattus norvegicus	102-147
18240216-5	2008	RESULTS: Inhibiting MEK/ERK with U0126 significantly reduced expression of a cohort of proadhesive and procontractile proteins that normally are overexpressed by scleroderma fibroblasts, including integrin alpha4 and integrin beta1.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	20-23
18240216-5	2008	RESULTS: Inhibiting MEK/ERK with U0126 significantly reduced expression of a cohort of proadhesive and procontractile proteins that normally are overexpressed by scleroderma fibroblasts, including integrin alpha4 and integrin beta1.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	24-27
18240216-5	2008	RESULTS: Inhibiting MEK/ERK with U0126 significantly reduced expression of a cohort of proadhesive and procontractile proteins that normally are overexpressed by scleroderma fibroblasts, including integrin alpha4 and integrin beta1.	U 0126	33-38	integrin subunit alpha 4	Homo sapiens	197-212
18240216-5	2008	RESULTS: Inhibiting MEK/ERK with U0126 significantly reduced expression of a cohort of proadhesive and procontractile proteins that normally are overexpressed by scleroderma fibroblasts, including integrin alpha4 and integrin beta1.	U 0126	33-38	integrin subunit beta 1	Homo sapiens	217-231
17566715-7	2008	Inhibition of BDNF expression with small interfering RNA (siRNA), or blocking the MAPK pathway with U0126 further significantly decreased Bcl-2 protein levels and abrogated the neuroprotective effects of IM against LPS-induced apoptosis in NSCs.	U 0126	100-105	BCL2, apoptosis regulator	Rattus norvegicus	138-143
17981815-9	2008	All three mutants are sensitive to the MEK inhibitor U0126.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
17662043-5	2008	TLR-mediated neutrophil migration was strongly suppressed by pretreatment of cells with U0126 (MAPK/ERK kinase inhibitor) but not with U0124 (an inactive analogue of U0126) or SB203580 (a p38 MAPK inhibitor), and was almost completely abolished by pretreatment of cells with U0126 and SB203580 in combination.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	95-99
17662043-5	2008	TLR-mediated neutrophil migration was strongly suppressed by pretreatment of cells with U0126 (MAPK/ERK kinase inhibitor) but not with U0124 (an inactive analogue of U0126) or SB203580 (a p38 MAPK inhibitor), and was almost completely abolished by pretreatment of cells with U0126 and SB203580 in combination.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	100-103
17893911-10	2008	It was blocked by the MEK inhibitor U0126 or the PI3-K inhibitor LY294002, suggesting that either pathway can prevent NMDA-induced apoptosis.	U 0126	36-41	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
18314480-8	2008	The effect of salvicine on beta(1) integrin function and cell adhesion was reversed by U0126 and SB203580, inhibitors of MAPK/ERK kinase 1/2 and p38 MAPK, respectively.	U 0126	87-92	integrin subunit beta 1	Homo sapiens	27-43
18314480-8	2008	The effect of salvicine on beta(1) integrin function and cell adhesion was reversed by U0126 and SB203580, inhibitors of MAPK/ERK kinase 1/2 and p38 MAPK, respectively.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	121-125
18314480-8	2008	The effect of salvicine on beta(1) integrin function and cell adhesion was reversed by U0126 and SB203580, inhibitors of MAPK/ERK kinase 1/2 and p38 MAPK, respectively.	U 0126	87-92	mitogen-activated protein kinase 1	Homo sapiens	126-129
18054051-8	2008	U0126 blocked the gallic-acid-induced phosphorylation of Cx43 and ERK1/2, indicating that the gallic-acid-induced inhibition of GJIC is mediated by phosphorylation of Cx43 via activation of ERK1/2.	U 0126	0-5	gap junction protein, alpha 1	Rattus norvegicus	57-61
18054051-8	2008	U0126 blocked the gallic-acid-induced phosphorylation of Cx43 and ERK1/2, indicating that the gallic-acid-induced inhibition of GJIC is mediated by phosphorylation of Cx43 via activation of ERK1/2.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	66-72
18054051-8	2008	U0126 blocked the gallic-acid-induced phosphorylation of Cx43 and ERK1/2, indicating that the gallic-acid-induced inhibition of GJIC is mediated by phosphorylation of Cx43 via activation of ERK1/2.	U 0126	0-5	gap junction protein, alpha 1	Rattus norvegicus	167-171
18054051-8	2008	U0126 blocked the gallic-acid-induced phosphorylation of Cx43 and ERK1/2, indicating that the gallic-acid-induced inhibition of GJIC is mediated by phosphorylation of Cx43 via activation of ERK1/2.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	190-196
18202809-4	2008	Two different approaches were used to sensitize the cells to TRAIL-induced apoptosis: inhibition of protein synthesis (cycloheximide, CHX) and inhibition of the pro-survival MEK/ERK pathway (U0126).	U 0126	191-196	TNF superfamily member 10	Homo sapiens	61-66
18202809-4	2008	Two different approaches were used to sensitize the cells to TRAIL-induced apoptosis: inhibition of protein synthesis (cycloheximide, CHX) and inhibition of the pro-survival MEK/ERK pathway (U0126).	U 0126	191-196	mitogen-activated protein kinase 1	Homo sapiens	178-181
18202809-6	2008	TRAIL-induced apoptosis was significantly enhanced by U0126 co-treatment in the HT-29 cells, but not in the FHC cells.	U 0126	54-59	TNF superfamily member 10	Homo sapiens	0-5
18202809-7	2008	The most significant differences between the HT-29 and FHC cells co-treated with TRAIL and U0126 were demonstrated with regard to the involvement of the mitochondrial apoptotic pathway, suggesting its importance in the regulation of cell sensitivity to the TRAIL-induced apoptosis.	U 0126	91-96	low density lipoprotein receptor	Homo sapiens	55-58
18202809-7	2008	The most significant differences between the HT-29 and FHC cells co-treated with TRAIL and U0126 were demonstrated with regard to the involvement of the mitochondrial apoptotic pathway, suggesting its importance in the regulation of cell sensitivity to the TRAIL-induced apoptosis.	U 0126	91-96	TNF superfamily member 10	Homo sapiens	257-262
18154926-6	2008	Blocking ERK1/2 activation with the upstream inhibitor U0126 inhibited NMDA-mediated p53 expression, suggesting that ERK1/2 signals drive the cells to apoptosis under these conditions.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	9-15
18154926-6	2008	Blocking ERK1/2 activation with the upstream inhibitor U0126 inhibited NMDA-mediated p53 expression, suggesting that ERK1/2 signals drive the cells to apoptosis under these conditions.	U 0126	55-60	tumor protein p53	Homo sapiens	85-88
18154926-6	2008	Blocking ERK1/2 activation with the upstream inhibitor U0126 inhibited NMDA-mediated p53 expression, suggesting that ERK1/2 signals drive the cells to apoptosis under these conditions.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	117-123
18023419-10	2008	Additionally, U0126, a specific inhibitor of ERK1/2, also significantly attenuated the TGF-beta1-stimulated VEGF synthesis.	U 0126	14-19	mitogen-activated protein kinase 3	Homo sapiens	45-51
18023419-10	2008	Additionally, U0126, a specific inhibitor of ERK1/2, also significantly attenuated the TGF-beta1-stimulated VEGF synthesis.	U 0126	14-19	transforming growth factor beta 1	Homo sapiens	87-96
18023419-10	2008	Additionally, U0126, a specific inhibitor of ERK1/2, also significantly attenuated the TGF-beta1-stimulated VEGF synthesis.	U 0126	14-19	vascular endothelial growth factor A	Homo sapiens	108-112
17967787-5	2008	Inhibiting hemin-induced ERK-1/2 activation by U0126 (MAPK-inhibitor), the antioxidant N-acetyl cysteine, the NADPH oxidase inhibitors apocynin and diphenyleneiodonium chloride, the superoxide scavenger tiron, or tricarbonyldichlororuthenium(II)-dimer (carbon-monoxide donor; CORM-2) blocked hemin-induced Egr-1 expression.	U 0126	47-52	mitogen-activated protein kinase 3	Homo sapiens	25-32
18037394-3	2008	Microinjection of U0126, a mitogen-activated protein kinase kinase inhibitor, into the RVM decreased phosphorylated ERK at 7 h after complete Freund"s adjuvant (CFA) injection into the hindpaw.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	116-119
18591472-3	2008	The stimulatory effect of E(2) and phytoestrogens was not inhibited by ICI182,780, a nuclear estrogen receptor inhibitor, but abolished by U0126, an inhibitor of extracellular signal-regulated kinase1/2 (ERK1/2) kinase.	U 0126	139-144	mitogen-activated protein kinase 3	Bos taurus	162-202
18591472-3	2008	The stimulatory effect of E(2) and phytoestrogens was not inhibited by ICI182,780, a nuclear estrogen receptor inhibitor, but abolished by U0126, an inhibitor of extracellular signal-regulated kinase1/2 (ERK1/2) kinase.	U 0126	139-144	mitogen-activated protein kinase 3	Bos taurus	204-210
17928626-7	2008	MAPK3/1 phosphorylation was also decreased in the presence of AG 1478, an inhibitor of the epidermal growth factor receptor (EGFR) kinase, and in the presence of MAP2K1/2 inhibitor UO126.	U 0126	181-186	mitogen activated protein kinase 3	Rattus norvegicus	0-5
17928626-7	2008	MAPK3/1 phosphorylation was also decreased in the presence of AG 1478, an inhibitor of the epidermal growth factor receptor (EGFR) kinase, and in the presence of MAP2K1/2 inhibitor UO126.	U 0126	181-186	epidermal growth factor receptor	Rattus norvegicus	91-123
17928626-7	2008	MAPK3/1 phosphorylation was also decreased in the presence of AG 1478, an inhibitor of the epidermal growth factor receptor (EGFR) kinase, and in the presence of MAP2K1/2 inhibitor UO126.	U 0126	181-186	epidermal growth factor receptor	Rattus norvegicus	125-129
17928626-7	2008	MAPK3/1 phosphorylation was also decreased in the presence of AG 1478, an inhibitor of the epidermal growth factor receptor (EGFR) kinase, and in the presence of MAP2K1/2 inhibitor UO126.	U 0126	181-186	mitogen activated protein kinase kinase 1	Rattus norvegicus	162-168
17890452-7	2008	CCL21-driven B-CLL cell migration through Matrigel or human umbilical vein endothelial cells (HUVEC) was blocked by anti-CCR7 antibodies, CCR7-siRNA transfection, or the ERK1/2 inhibitor U0126, as well as by anti-MMP-9 antibodies or tissue inhibitor of metalloproteinase 1 (TIMP-1).	U 0126	187-192	C-C motif chemokine ligand 21	Homo sapiens	0-5
17890452-7	2008	CCL21-driven B-CLL cell migration through Matrigel or human umbilical vein endothelial cells (HUVEC) was blocked by anti-CCR7 antibodies, CCR7-siRNA transfection, or the ERK1/2 inhibitor U0126, as well as by anti-MMP-9 antibodies or tissue inhibitor of metalloproteinase 1 (TIMP-1).	U 0126	187-192	mitogen-activated protein kinase 3	Homo sapiens	170-176
17952111-9	2008	These beneficial effects were prevented by the PI3K inhibitor, LY294002 and the ERK1/2 inhibitor, U0126.	U 0126	98-103	mitogen-activated protein kinase 3	Homo sapiens	80-86
18172275-4	2008	EXPERIMENTAL DESIGN: We recently have shown that growing melanoma cells as three-dimensional collagen-implanted spheroids enhances resistance to the MEK inhibitor U0126.	U 0126	163-168	midkine	Mus musculus	149-152
18047635-8	2008	These effects of 1 micromol/L DADLE were abolished by 10 micromol/L naltrindole, a selective delta-opioid receptor antagonist, 10 nmol/L U0126, a selective ERK antagonist, 1 micromol/L staurosporine, an inhibitor of protein kinase (PK) C, and 100 micromol/L Rp-adenosine 3",5"-cyclic monophosphorothioate triethylammonium salt hydrate (Rp-cAMPS), an inhibitor of PKA.	U 0126	137-142	Eph receptor B1	Rattus norvegicus	156-159
18047635-8	2008	These effects of 1 micromol/L DADLE were abolished by 10 micromol/L naltrindole, a selective delta-opioid receptor antagonist, 10 nmol/L U0126, a selective ERK antagonist, 1 micromol/L staurosporine, an inhibitor of protein kinase (PK) C, and 100 micromol/L Rp-adenosine 3",5"-cyclic monophosphorothioate triethylammonium salt hydrate (Rp-cAMPS), an inhibitor of PKA.	U 0126	137-142	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	216-230
18047635-8	2008	These effects of 1 micromol/L DADLE were abolished by 10 micromol/L naltrindole, a selective delta-opioid receptor antagonist, 10 nmol/L U0126, a selective ERK antagonist, 1 micromol/L staurosporine, an inhibitor of protein kinase (PK) C, and 100 micromol/L Rp-adenosine 3",5"-cyclic monophosphorothioate triethylammonium salt hydrate (Rp-cAMPS), an inhibitor of PKA.	U 0126	137-142	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	232-234
18047635-8	2008	These effects of 1 micromol/L DADLE were abolished by 10 micromol/L naltrindole, a selective delta-opioid receptor antagonist, 10 nmol/L U0126, a selective ERK antagonist, 1 micromol/L staurosporine, an inhibitor of protein kinase (PK) C, and 100 micromol/L Rp-adenosine 3",5"-cyclic monophosphorothioate triethylammonium salt hydrate (Rp-cAMPS), an inhibitor of PKA.	U 0126	137-142	calmodulin 2, pseudogene 1	Rattus norvegicus	339-344
17166687-10	2008	U0126, an inhibitor of the ERK MAPK pathway, completely abolished insulin-induced S6K1 phosphorylation and activity in chicken myoblasts, whereas its effect was only partial in LMH cells.	U 0126	0-5	insulin	Gallus gallus	66-73
17962344-7	2008	Activation of ERbeta by the ERbeta-selective ligand, diarylpropionitrile, led to an increase in phosphorylated extracellular signal-regulated kinase, and subsequent centrosome amplification and hNPC proliferation, which were blocked by the MEKK antagonist, UO126, but not its inactive analog, UO124.	U 0126	257-262	estrogen receptor 2	Homo sapiens	14-20
18357389-9	2008	The transactivation of TNF-alpha-stimulated NF-kappaB, AP-1 and Sp-1 were inhibited by U0126 and SB203580 treatment.	U 0126	87-92	tumor necrosis factor	Homo sapiens	23-32
18357389-9	2008	The transactivation of TNF-alpha-stimulated NF-kappaB, AP-1 and Sp-1 were inhibited by U0126 and SB203580 treatment.	U 0126	87-92	nuclear factor kappa B subunit 1	Homo sapiens	44-53
18256264-6	2008	To examine whether inhibition of ERK in the NAcc prevents cue-induced reward-seeking, we infused an inhibitor of ERK, U0126, into the NAcc before assessing rats" instrumental responding in the presence versus absence of the conditioned cue.	U 0126	118-123	mitogen activated protein kinase 1	Rattus norvegicus	113-116
18156195-7	2008	ANG II induced a transient induction of junB and a delayed induction of PAI-1 and OPN mRNA levels, which were reduced by ERK inhibition with U-0126.	U 0126	141-147	angiotensinogen	Rattus norvegicus	0-6
18156195-7	2008	ANG II induced a transient induction of junB and a delayed induction of PAI-1 and OPN mRNA levels, which were reduced by ERK inhibition with U-0126.	U 0126	141-147	JunB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-44
18156195-7	2008	ANG II induced a transient induction of junB and a delayed induction of PAI-1 and OPN mRNA levels, which were reduced by ERK inhibition with U-0126.	U 0126	141-147	serpin family E member 1	Rattus norvegicus	72-77
18156195-7	2008	ANG II induced a transient induction of junB and a delayed induction of PAI-1 and OPN mRNA levels, which were reduced by ERK inhibition with U-0126.	U 0126	141-147	secreted phosphoprotein 1	Rattus norvegicus	82-85
18156195-7	2008	ANG II induced a transient induction of junB and a delayed induction of PAI-1 and OPN mRNA levels, which were reduced by ERK inhibition with U-0126.	U 0126	141-147	Eph receptor B1	Rattus norvegicus	121-124
17687118-11	2008	Roscovitine, U0126, and metformin inhibited meiotic divisions; they all induced a decrease of CCNB1 and phospho-MAPK3/1 levels and prevented CPEB degradation.	U 0126	13-18	cyclin B1	Bos taurus	94-99
17687118-11	2008	Roscovitine, U0126, and metformin inhibited meiotic divisions; they all induced a decrease of CCNB1 and phospho-MAPK3/1 levels and prevented CPEB degradation.	U 0126	13-18	cytoplasmic polyadenylation element binding protein 1	Mus musculus	141-145
18245228-7	2008	Incubating MSLN-expressing MDA-MB-231 cells in the presence of U0126, an inhibitor of mitogen-activated protein/extracellular-signal-regulated kinase kinase, induced accumulation of Bim and restored susceptibility to anoikis.	U 0126	63-68	mesothelin	Homo sapiens	11-15
18230673-5	2008	We next show that intra-LA infusion of U0126, an inhibitor of ERK/MAPK activation, impairs LTP at thalamo-LA input synapses.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	62-65
17974568-4	2008	Blockade of p38 phosphorylation with SB203580 or SB202190 in turn abolished [Ca(2+)](e)-mediated VDR protein increase, while treatment with PD98059 and U0126, specifically blocked ERK phosphorylation, but had no effect on VDR stimulation by [Ca(2+)](e).	U 0126	152-157	mitogen-activated protein kinase 14	Homo sapiens	12-15
17974568-4	2008	Blockade of p38 phosphorylation with SB203580 or SB202190 in turn abolished [Ca(2+)](e)-mediated VDR protein increase, while treatment with PD98059 and U0126, specifically blocked ERK phosphorylation, but had no effect on VDR stimulation by [Ca(2+)](e).	U 0126	152-157	vitamin D receptor	Homo sapiens	222-225
18024477-6	2008	The treatment of mitogen-activated protein kinase kinase (MEK) inhibitors (PD98059 and U0126) and LAB to HepG(2) cells could result in a synergistic reduction on the MMP-9 expression along with an inhibition on cell invasion.	U 0126	87-92	matrix metallopeptidase 9	Homo sapiens	166-171
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	mitogen-activated protein kinase 1	Mus musculus	50-87
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	mitogen-activated protein kinase 1	Mus musculus	89-92
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	mitogen-activated protein kinase 1	Mus musculus	111-115
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	mitogen-activated protein kinase 1	Mus musculus	116-119
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	fibroblast growth factor 2	Mus musculus	193-197
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	fibroblast growth factor 2	Mus musculus	226-230
18334814-8	2008	Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling.	U 0126	143-148	mitogen-activated protein kinase 1	Mus musculus	116-119
18042150-5	2008	In support of this, pretreatment of oocytes, eggs, or embryos with inhibitors for Src (PP2) and MAPK (U0126) blocked effectively the phosphorylation of hnRNP K.	U 0126	102-107	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	96-100
18042150-5	2008	In support of this, pretreatment of oocytes, eggs, or embryos with inhibitors for Src (PP2) and MAPK (U0126) blocked effectively the phosphorylation of hnRNP K.	U 0126	102-107	heterogeneous nuclear ribonucleoprotein K S homeolog	Xenopus laevis	152-159
17918745-2	2008	The ebselen-induced MAPK activation was suppressed by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, a selective inhibitor of Trk family tyrosine kinases; AG1478, an antagonist of epidermal growth factor receptor (EGFR); pertussis toxin, an inhibitor of Gi/o; or GP antagonist-2A, an inhibitor of Gq.	U 0126	54-59	mitogen activated protein kinase 3	Rattus norvegicus	77-81
17918745-2	2008	The ebselen-induced MAPK activation was suppressed by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, a selective inhibitor of Trk family tyrosine kinases; AG1478, an antagonist of epidermal growth factor receptor (EGFR); pertussis toxin, an inhibitor of Gi/o; or GP antagonist-2A, an inhibitor of Gq.	U 0126	54-59	mitogen activated protein kinase kinase 1	Rattus norvegicus	90-96
17918746-6	2008	This expression was mediated by activation of the ERK1/2 MAPK pathway, as demonstrated by ELISA and Western blot using a specific inhibitor (U0126).	U 0126	141-146	mitogen-activated protein kinase 3	Homo sapiens	50-56
17918746-6	2008	This expression was mediated by activation of the ERK1/2 MAPK pathway, as demonstrated by ELISA and Western blot using a specific inhibitor (U0126).	U 0126	141-146	mitogen-activated protein kinase 3	Homo sapiens	57-61
18275597-4	2008	IEGs exhibited differential temporal and transient regulation, with expression of second phase RNAs within 1 h. Of transcripts upregulated at 30 minutes encoding established proteins, 28 were inhibited &gt;50% by U0126 (which inhibits ERK1/2/5 signaling), with 9 inhibited 25-50%.	U 0126	213-218	mitogen activated protein kinase 3	Rattus norvegicus	235-241
17497701-8	2008	Furthermore, the antiapoptotic effect of lovastatin on mitochondrial apoptotic pathway was effectively abrogated by both PI3K inhibitor, LY294002 and ERK1/2 inhibitor, U0126.	U 0126	168-173	mitogen activated protein kinase 3	Rattus norvegicus	150-156
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	angiotensinogen	Homo sapiens	17-23
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	transforming growth factor beta 1	Homo sapiens	32-41
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	SMAD family member 2	Homo sapiens	106-111
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	mitogen-activated protein kinase kinase 7	Homo sapiens	144-147
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	mitogen-activated protein kinase kinase 7	Homo sapiens	194-197
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	mitogen-activated protein kinase 1	Homo sapiens	198-201
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	angiotensinogen	Homo sapiens	217-223
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	transforming growth factor beta 1	Homo sapiens	246-255
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	SMAD family member 2	Homo sapiens	256-261
17497701-10	2008	The activation of ERK1/2 was inhibited by a PI3K inhibitor, LY294002, but U0126, a ERK1/2 inhibitor did not inhibit phosphorylation of Akt and GSK3 beta.	U 0126	74-79	mitogen activated protein kinase 3	Rattus norvegicus	83-89
18180320-6	2008	The MEK inhibitor UO126 impaired the phosphorylation of CREB and that of C/EBPbeta, suggesting that ERKs mediate the phosphorylation of both proteins.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
18209571-6	2008	IL-6 promoter activity was diminished by U0126 or SB202190, but not by SP600125.	U 0126	41-46	interleukin 6	Homo sapiens	0-4
18180320-6	2008	The MEK inhibitor UO126 impaired the phosphorylation of CREB and that of C/EBPbeta, suggesting that ERKs mediate the phosphorylation of both proteins.	U 0126	18-23	cAMP responsive element binding protein 1	Homo sapiens	56-60
18180320-6	2008	The MEK inhibitor UO126 impaired the phosphorylation of CREB and that of C/EBPbeta, suggesting that ERKs mediate the phosphorylation of both proteins.	U 0126	18-23	CCAAT enhancer binding protein beta	Homo sapiens	73-82
18180320-6	2008	The MEK inhibitor UO126 impaired the phosphorylation of CREB and that of C/EBPbeta, suggesting that ERKs mediate the phosphorylation of both proteins.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	100-104
18180320-7	2008	UO126, but not the protein kinase A inhibitor H89, blocked GH-induced c-fos mRNA expression.	U 0126	0-5	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-75
18480613-9	2008	Inhibition of ERK phosphorylation by U0126 enhanced podocyte apoptosis induced by PA.	U 0126	37-42	mitogen-activated protein kinase 1	Mus musculus	14-17
17847117-6	2008	Inhibition of the early phosphorylated ERK1/2 peak with U0126 increased the generation of reactive oxygen species by 6-OHDA as well as 6-OHDA-induced toxicity, whereas inhibition of the late peak did not affect 6-OHDA-induced cell death.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	39-45
17972959-6	2008	Interestingly, inhibiting SFK with SU6656 or the MAPK kinases MEK with U0126 significantly impaired development of mononuclear phagocytes in cultures of mouse bone marrow cells stimulated with M-CSF.	U 0126	71-76	colony stimulating factor 1 (macrophage)	Mus musculus	193-198
18374181-8	2008	This chapter presents proof-of-principle analyses using the well-characterized MEK inhibitor U0126 to block the Muv phenotype caused by the constitutively activated Ras homolog C. elegans LET-60.	U 0126	93-98	Ras protein let-60	Caenorhabditis elegans	188-194
17980966-7	2007	In contrast, mitogen-activated protein kinase (MAP)/extracellular-signal-regulated kinase (ERK) pathway inhibitor U0126 potentiated insulin-mediated survival.	U 0126	114-119	mitogen-activated protein kinase 1	Mus musculus	91-94
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	kallikrein related peptidase 3	Homo sapiens	18-21
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	kallikrein related peptidase 10	Homo sapiens	23-28
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	kallikrein related peptidase 11	Homo sapiens	33-38
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	mitogen-activated protein kinase kinase 1	Homo sapiens	60-66
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	178-181
18515984-6	2008	The expression of PSA, KLK10 and KLK11 was repressed by the MEK1/2 inhibitor U0126 and the PI3K inhibitor Wortmannin in the presence of the hormone, thus implicating the RAS/MEK/ERK and PI3K/AKT signaling pathways in regulating hormone-dependent KLK gene activation.	U 0126	77-82	kallikrein related peptidase 10	Homo sapiens	23-26
18176067-7	2008	Moreover, we also found that U0126, a MEK1/2 inhibitor, induces apoptosis in HSC-3 cells.	U 0126	29-34	mitogen-activated protein kinase kinase 1	Homo sapiens	38-44
18176067-7	2008	Moreover, we also found that U0126, a MEK1/2 inhibitor, induces apoptosis in HSC-3 cells.	U 0126	29-34	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	77-82
18089824-5	2007	We also showed that inhibition of ERK2 activity by the MEK1/2 inhibitor U0126 or by small interfering RNA silencing decreases MKP-1 induction, leading to an increase in cisplatin-induced cell death, which mimicked the results obtained with cells in which MKP-1 is down-regulated.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	34-38
18089824-5	2007	We also showed that inhibition of ERK2 activity by the MEK1/2 inhibitor U0126 or by small interfering RNA silencing decreases MKP-1 induction, leading to an increase in cisplatin-induced cell death, which mimicked the results obtained with cells in which MKP-1 is down-regulated.	U 0126	72-77	mitogen-activated protein kinase kinase 1	Homo sapiens	55-61
18089824-5	2007	We also showed that inhibition of ERK2 activity by the MEK1/2 inhibitor U0126 or by small interfering RNA silencing decreases MKP-1 induction, leading to an increase in cisplatin-induced cell death, which mimicked the results obtained with cells in which MKP-1 is down-regulated.	U 0126	72-77	dual specificity phosphatase 1	Homo sapiens	126-131
17980351-16	2007	In addition, SSeCKS production was also drastically suppressed by U0126 (ERK inhibitor), SB203580 (p38 inhibitor), or SP600125 (SAPK/JNK inhibitor), which indicated that type-2 astrocytes which regulated SSeCKS expression after LPS stimulation were via ERK, SAPK/JNK, and P38MAP kinase signal pathway.	U 0126	66-71	Eph receptor B1	Rattus norvegicus	73-76
17945434-7	2007	The steady-state levels of full-length APP and cell viability were unaffected by Hup A. Alpha-APPs release induced by Hup A treatment was significantly reduced by muscarinic acetylcholine receptor antagonists (particularly by an M1 antagonist), protein kinase C (PKC) inhibitors, GF109203X and calphostin C, and the mitogen-activated kinase kinase (MEK) inhibitors, U0126 and PD98059.	U 0126	366-371	cathepsin B	Homo sapiens	94-98
17919066-9	2007	Moreover, U0126 and LY294002, which are pharmacologic inhibitors of extracellular signal-regulated kinase1/2 and phosphoinositide 3-kinase, respectively, attenuated HO-1 expression as well as Nrf2-ARE binding activity.	U 0126	10-15	heme oxygenase 1	Rattus norvegicus	165-169
17913840-8	2007	This effect was not mediated by Erk1/2 activation or cell proliferation since U0126, an Erk1/2 inhibitor, did not prevent but ameliorated recovery.	U 0126	78-83	mitogen-activated protein kinase 3	Homo sapiens	88-94
17919066-9	2007	Moreover, U0126 and LY294002, which are pharmacologic inhibitors of extracellular signal-regulated kinase1/2 and phosphoinositide 3-kinase, respectively, attenuated HO-1 expression as well as Nrf2-ARE binding activity.	U 0126	10-15	NFE2 like bZIP transcription factor 2	Rattus norvegicus	192-196
18052977-8	2007	Despite the fact that extracellular signal-regulated kinase/mitogen-activated protein kinases (ERK/MAPK) have been shown to be necessary for amygdala-dependent long-term potentiation and some forms of long-term and STM, inhibition of the ERK/MAPK signaling cascade by U0126 (2.0 or 4.0 microg) in the BLA was not critical for updating the STM of either spatial information or reward expectation.	U 0126	268-273	Eph receptor B1	Rattus norvegicus	95-98
17996850-7	2007	Pretreatment of U-0126 (MEK1/2 inhibitor) completely abolished the GSK-3beta inhibition-induced phosphorylation of ERK1/2.	U 0126	16-22	mitogen activated protein kinase kinase 1	Rattus norvegicus	24-30
17996850-7	2007	Pretreatment of U-0126 (MEK1/2 inhibitor) completely abolished the GSK-3beta inhibition-induced phosphorylation of ERK1/2.	U 0126	16-22	glycogen synthase kinase 3 beta	Rattus norvegicus	67-76
17996850-7	2007	Pretreatment of U-0126 (MEK1/2 inhibitor) completely abolished the GSK-3beta inhibition-induced phosphorylation of ERK1/2.	U 0126	16-22	mitogen activated protein kinase 3	Rattus norvegicus	115-121
17996850-8	2007	U-0126 prevented GSK-3beta inhibition-mediated induction of MMP-9 reporter activity as well as the MMP-9 gene expression.	U 0126	0-6	glycogen synthase kinase 3 beta	Rattus norvegicus	17-26
17996850-8	2007	U-0126 prevented GSK-3beta inhibition-mediated induction of MMP-9 reporter activity as well as the MMP-9 gene expression.	U 0126	0-6	matrix metallopeptidase 9	Rattus norvegicus	60-65
17996850-8	2007	U-0126 prevented GSK-3beta inhibition-mediated induction of MMP-9 reporter activity as well as the MMP-9 gene expression.	U 0126	0-6	matrix metallopeptidase 9	Rattus norvegicus	99-104
18056179-7	2007	Western blotting or reverse transcription-PCR for ERalpha was used to assess the reexpression of ERalpha in cells treated with U0126.	U 0126	127-132	estrogen receptor 1	Homo sapiens	97-104
18053155-6	2007	We found that P42/P44 MAPK inhibitors, PD98059 and U0126, suppressed the induction of cingulate LTP that was induced by presynaptic stimulation with postsynaptic depolarization (the pairing protocol).	U 0126	51-56	cyclin-dependent kinase 20	Mus musculus	14-17
17706640-9	2007	U0126, an inhibitor of the ERK upstream regulator MEK, attenuated the adhesion and spreading of HCT15-KGF cells to type-IV collagen.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	27-30
17706640-9	2007	U0126, an inhibitor of the ERK upstream regulator MEK, attenuated the adhesion and spreading of HCT15-KGF cells to type-IV collagen.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	50-53
17706640-9	2007	U0126, an inhibitor of the ERK upstream regulator MEK, attenuated the adhesion and spreading of HCT15-KGF cells to type-IV collagen.	U 0126	0-5	fibroblast growth factor 7	Homo sapiens	102-105
18075836-8	2007	We found that retinol and retinoic acid induced ERK1/2 phosphorylation, but only retinol-increased MMP-2 activity was inhibited by UO126, an ERK1/2 phosphorylation inhibitor.	U 0126	131-136	matrix metallopeptidase 2	Homo sapiens	99-104
18075836-8	2007	We found that retinol and retinoic acid induced ERK1/2 phosphorylation, but only retinol-increased MMP-2 activity was inhibited by UO126, an ERK1/2 phosphorylation inhibitor.	U 0126	131-136	mitogen-activated protein kinase 3	Homo sapiens	141-147
17868299-8	2007	The MEK inhibitor U0126 applied together with EUK-189 or EUK-207 completely blocked ERK1/2 activation, but had no effect on their protective effects against OGD-induced LDH release.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	84-90
18063082-7	2007	Importantly, blocking of raf-1 pathway by U0126, a potent inhibitor, in the presence of ZM336372 did not reduce the levels of p-GSK-3beta, indicating that GSK-3beta inactivation is independent of raf-1 pathway activation.	U 0126	42-47	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	25-30
17692050-3	2007	In contrast, various approaches, including the use of the MEK (mitogen-activated protein kinase/ERK kinase) inhibitors UO126 and CI-1040 to inhibit ERK1/2 pointed to the involvement of ERK5.	U 0126	119-124	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
17692050-3	2007	In contrast, various approaches, including the use of the MEK (mitogen-activated protein kinase/ERK kinase) inhibitors UO126 and CI-1040 to inhibit ERK1/2 pointed to the involvement of ERK5.	U 0126	119-124	mitogen-activated protein kinase 3	Homo sapiens	148-154
17692050-3	2007	In contrast, various approaches, including the use of the MEK (mitogen-activated protein kinase/ERK kinase) inhibitors UO126 and CI-1040 to inhibit ERK1/2 pointed to the involvement of ERK5.	U 0126	119-124	mitogen-activated protein kinase 7	Homo sapiens	185-189
17910942-5	2007	In addition, it was found that OA inhibited the phosphorylation of ERK1/2, p38 and JNK MAPK, and the treatment of U0126 in LPS-induced raw 264.7 cells showed significant inhibition activity on the NO production and the phosphorylation of IkappaBalpha.	U 0126	114-119	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	238-250
17971416-7	2007	Preventing activation of the classic MAP kinase cascade with the Erk inhibitor UO126 abolished SDF1-induced proliferation and migration of C2C12 cells but not the inhibitory action of SDF1 on myogenic differentiation.	U 0126	79-84	mitogen-activated protein kinase 1	Mus musculus	65-68
17971416-7	2007	Preventing activation of the classic MAP kinase cascade with the Erk inhibitor UO126 abolished SDF1-induced proliferation and migration of C2C12 cells but not the inhibitory action of SDF1 on myogenic differentiation.	U 0126	79-84	chemokine (C-X-C motif) ligand 12	Mus musculus	95-99
17717293-9	2007	The expression of VEGF and NF-kappaB p65 induced by oxLDL was also inhibited by the specific extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580.	U 0126	151-156	vascular endothelial growth factor A	Homo sapiens	18-22
17717293-9	2007	The expression of VEGF and NF-kappaB p65 induced by oxLDL was also inhibited by the specific extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580.	U 0126	151-156	RELA proto-oncogene, NF-kB subunit	Homo sapiens	37-40
17717293-9	2007	The expression of VEGF and NF-kappaB p65 induced by oxLDL was also inhibited by the specific extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580.	U 0126	151-156	mitogen-activated protein kinase 3	Homo sapiens	93-140
17694254-6	2007	LY294002 and UO126, inhibitors of PI3K-Akt and p44/42 phosphorylation respectively, abolished the protective effects of apelin-13 in vitro.Western blot analysis provided further evidence for the involvement of PI3K-Akt and p44/42 in the cardioprotective actions of apelin.	U 0126	13-18	AKT serine/threonine kinase 1	Rattus norvegicus	39-42
17694254-6	2007	LY294002 and UO126, inhibitors of PI3K-Akt and p44/42 phosphorylation respectively, abolished the protective effects of apelin-13 in vitro.Western blot analysis provided further evidence for the involvement of PI3K-Akt and p44/42 in the cardioprotective actions of apelin.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	47-50
17694254-6	2007	LY294002 and UO126, inhibitors of PI3K-Akt and p44/42 phosphorylation respectively, abolished the protective effects of apelin-13 in vitro.Western blot analysis provided further evidence for the involvement of PI3K-Akt and p44/42 in the cardioprotective actions of apelin.	U 0126	13-18	AKT serine/threonine kinase 1	Rattus norvegicus	215-218
17694254-6	2007	LY294002 and UO126, inhibitors of PI3K-Akt and p44/42 phosphorylation respectively, abolished the protective effects of apelin-13 in vitro.Western blot analysis provided further evidence for the involvement of PI3K-Akt and p44/42 in the cardioprotective actions of apelin.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	223-226
18080868-8	2007	Involvement of extracellular signal-regulated kinase (ERK) signaling was assessed using its kinase activity inhibitors PD98059 or U0126.	U 0126	130-135	mitogen-activated protein kinase 1	Mus musculus	15-52
18080868-8	2007	Involvement of extracellular signal-regulated kinase (ERK) signaling was assessed using its kinase activity inhibitors PD98059 or U0126.	U 0126	130-135	mitogen-activated protein kinase 1	Mus musculus	54-57
17893047-6	2007	Pretreatment with MAPK inhibitors SB203580 and U0126, or addition of the exogenous thiol N-acetylcysteine, abrogated both p38(MAPK) and ERK2 activation as well as downstream effects on gene expression.	U 0126	47-52	mitogen-activated protein kinase 14	Mus musculus	122-125
17893047-6	2007	Pretreatment with MAPK inhibitors SB203580 and U0126, or addition of the exogenous thiol N-acetylcysteine, abrogated both p38(MAPK) and ERK2 activation as well as downstream effects on gene expression.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	136-140
17604323-10	2007	Dominant-negative (DN) AKT and LY294002 (PI3K inhibitor) or U0126 (MEK-1/2 inhibitor) blocked chenodeoxycholic acid (CD) and deoxycholic acid (DC) mediated COX-2 induction.	U 0126	60-65	mitogen activated protein kinase kinase 1	Rattus norvegicus	67-74
17604323-10	2007	Dominant-negative (DN) AKT and LY294002 (PI3K inhibitor) or U0126 (MEK-1/2 inhibitor) blocked chenodeoxycholic acid (CD) and deoxycholic acid (DC) mediated COX-2 induction.	U 0126	60-65	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	156-161
18250563-4	2007	The activated ERK level was reduced to the control level by the tyrosine kinase inhibitor genistein, and the MEK inhibitor U0126 markedly reduced the activated ERK level to the control level, whereas the level of activated ERK was unaffected by the angiotensin-converting enzyme inhibitor imidaprilat or the angiotensin II receptor blocker candesartan.	U 0126	123-128	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
18250563-4	2007	The activated ERK level was reduced to the control level by the tyrosine kinase inhibitor genistein, and the MEK inhibitor U0126 markedly reduced the activated ERK level to the control level, whereas the level of activated ERK was unaffected by the angiotensin-converting enzyme inhibitor imidaprilat or the angiotensin II receptor blocker candesartan.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	160-163
18250563-4	2007	The activated ERK level was reduced to the control level by the tyrosine kinase inhibitor genistein, and the MEK inhibitor U0126 markedly reduced the activated ERK level to the control level, whereas the level of activated ERK was unaffected by the angiotensin-converting enzyme inhibitor imidaprilat or the angiotensin II receptor blocker candesartan.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	160-163
17562163-6	2007	The ERK activation was inhibited by U0126, a specific inhibitor of MEK, but not by LY294002, a specific inhibitor of PI3K, whereas the Akt activation was blocked by LY294002, but not by U0126.	U 0126	36-41	mitogen-activated protein kinase 1	Mus musculus	4-7
17562163-6	2007	The ERK activation was inhibited by U0126, a specific inhibitor of MEK, but not by LY294002, a specific inhibitor of PI3K, whereas the Akt activation was blocked by LY294002, but not by U0126.	U 0126	36-41	midkine	Mus musculus	67-70
17548215-12	2007	The ERK1/2 inhibitor U0126 also reduced Egr-1 DNA binding activity to MT1-MMP promoter sequences and subsequent transcription of MT1-MMP.	U 0126	21-26	mitogen-activated protein kinase 3	Bos taurus	4-10
17962344-7	2008	Activation of ERbeta by the ERbeta-selective ligand, diarylpropionitrile, led to an increase in phosphorylated extracellular signal-regulated kinase, and subsequent centrosome amplification and hNPC proliferation, which were blocked by the MEKK antagonist, UO126, but not its inactive analog, UO124.	U 0126	257-262	estrogen receptor 2	Homo sapiens	28-34
17893107-3	2007	METHODS: To address this issue, ERK activity was blocked both in vitro in mesangial cells (MC) and in vivo in experimental glomerulonephritis (GN) by a pharmacological inhibitor (U0126) of the ERK-activating kinase.	U 0126	179-184	Eph receptor B1	Rattus norvegicus	32-35
17893107-3	2007	METHODS: To address this issue, ERK activity was blocked both in vitro in mesangial cells (MC) and in vivo in experimental glomerulonephritis (GN) by a pharmacological inhibitor (U0126) of the ERK-activating kinase.	U 0126	179-184	Eph receptor B1	Rattus norvegicus	193-196
17893107-10	2007	Finally, we noted an increased expression and CDK2-binding of p27(KIP1) protein in the nephritic controls which was decreased in U0126 treated rats.	U 0126	129-134	cyclin dependent kinase 2	Rattus norvegicus	46-50
17893107-10	2007	Finally, we noted an increased expression and CDK2-binding of p27(KIP1) protein in the nephritic controls which was decreased in U0126 treated rats.	U 0126	129-134	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	62-65
17893107-10	2007	Finally, we noted an increased expression and CDK2-binding of p27(KIP1) protein in the nephritic controls which was decreased in U0126 treated rats.	U 0126	129-134	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	66-70
17910942-5	2007	In addition, it was found that OA inhibited the phosphorylation of ERK1/2, p38 and JNK MAPK, and the treatment of U0126 in LPS-induced raw 264.7 cells showed significant inhibition activity on the NO production and the phosphorylation of IkappaBalpha.	U 0126	114-119	mitogen-activated protein kinase 3	Mus musculus	67-73
17910942-5	2007	In addition, it was found that OA inhibited the phosphorylation of ERK1/2, p38 and JNK MAPK, and the treatment of U0126 in LPS-induced raw 264.7 cells showed significant inhibition activity on the NO production and the phosphorylation of IkappaBalpha.	U 0126	114-119	mitogen-activated protein kinase 8	Mus musculus	83-86
17910942-5	2007	In addition, it was found that OA inhibited the phosphorylation of ERK1/2, p38 and JNK MAPK, and the treatment of U0126 in LPS-induced raw 264.7 cells showed significant inhibition activity on the NO production and the phosphorylation of IkappaBalpha.	U 0126	114-119	mitogen-activated protein kinase 1	Mus musculus	87-91
17678888-5	2007	Both PD98059 and U0126, inhibitors of the upstream activator of mitogen-activated protein kinase kinase, inhibited augmentation of endothelin-1 expression stimulated with leptin.	U 0126	17-22	endothelin 1	Rattus norvegicus	131-143
17678888-5	2007	Both PD98059 and U0126, inhibitors of the upstream activator of mitogen-activated protein kinase kinase, inhibited augmentation of endothelin-1 expression stimulated with leptin.	U 0126	17-22	leptin	Rattus norvegicus	171-177
18003837-7	2007	PD98059 or UO126, which selectively block MEK, the upstream kinase of ERK, increased the AHP in neurons from trained rats but not in neurons from naive and pseudo-trained rats.	U 0126	11-16	Eph receptor B1	Rattus norvegicus	70-73
17881458-8	2007	MEK1/2 inhibitor U0126 (10 muM) blocked basal and OSM-induced ERK1/2 phosphorylation but not phosphorylation of either ERK5 or Stat1/3.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
17881458-8	2007	MEK1/2 inhibitor U0126 (10 muM) blocked basal and OSM-induced ERK1/2 phosphorylation but not phosphorylation of either ERK5 or Stat1/3.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	62-68
17881458-9	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at concentrations which inhibit ERK1/2 phosphorylation but not ERK5 phosphorylation, restored N-cadherin expression in the presence of OSM, inhibited basal claudin-2 expression, but did not affect either basal or OSM-inhibited E-cadherin expression or OSM-induced expression of collagen type I and vimentin.	U 0126	33-38	mitogen-activated protein kinase kinase 1	Homo sapiens	15-21
17881458-9	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at concentrations which inhibit ERK1/2 phosphorylation but not ERK5 phosphorylation, restored N-cadherin expression in the presence of OSM, inhibited basal claudin-2 expression, but did not affect either basal or OSM-inhibited E-cadherin expression or OSM-induced expression of collagen type I and vimentin.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	94-100
17881458-9	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at concentrations which inhibit ERK1/2 phosphorylation but not ERK5 phosphorylation, restored N-cadherin expression in the presence of OSM, inhibited basal claudin-2 expression, but did not affect either basal or OSM-inhibited E-cadherin expression or OSM-induced expression of collagen type I and vimentin.	U 0126	33-38	cadherin 2	Homo sapiens	156-166
17881458-9	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at concentrations which inhibit ERK1/2 phosphorylation but not ERK5 phosphorylation, restored N-cadherin expression in the presence of OSM, inhibited basal claudin-2 expression, but did not affect either basal or OSM-inhibited E-cadherin expression or OSM-induced expression of collagen type I and vimentin.	U 0126	33-38	claudin 2	Homo sapiens	218-227
17881458-9	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at concentrations which inhibit ERK1/2 phosphorylation but not ERK5 phosphorylation, restored N-cadherin expression in the presence of OSM, inhibited basal claudin-2 expression, but did not affect either basal or OSM-inhibited E-cadherin expression or OSM-induced expression of collagen type I and vimentin.	U 0126	33-38	cadherin 1	Homo sapiens	289-299
17881458-9	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at concentrations which inhibit ERK1/2 phosphorylation but not ERK5 phosphorylation, restored N-cadherin expression in the presence of OSM, inhibited basal claudin-2 expression, but did not affect either basal or OSM-inhibited E-cadherin expression or OSM-induced expression of collagen type I and vimentin.	U 0126	33-38	vimentin	Homo sapiens	340-368
17964214-6	2007	The epidermal growth factor (EGF) receptor inhibitor, AG1478, completely eliminated the response to bile acid while the mitogen-activated protein extracellular signal-regulated kinase cascade (MEK) inhibitor, U0126, partially inhibited the response to bile acid.	U 0126	209-214	mitogen-activated protein kinase kinase 7	Homo sapiens	120-191
17690170-6	2007	Moreover, this AngII-induced MKP-1 expression is reduced to 250 +/- 35% of controls (n = 3, P &lt; 0.01) in the presence of U0126, an inhibitor of ERK1/2 phosphorylation, suggesting an involvement of the ERK1/2 MAPK pathway in MKP-1 induction.	U 0126	124-129	dual specificity phosphatase 1	Bos taurus	29-34
17690170-6	2007	Moreover, this AngII-induced MKP-1 expression is reduced to 250 +/- 35% of controls (n = 3, P &lt; 0.01) in the presence of U0126, an inhibitor of ERK1/2 phosphorylation, suggesting an involvement of the ERK1/2 MAPK pathway in MKP-1 induction.	U 0126	124-129	mitogen-activated protein kinase 3	Bos taurus	147-153
17690170-6	2007	Moreover, this AngII-induced MKP-1 expression is reduced to 250 +/- 35% of controls (n = 3, P &lt; 0.01) in the presence of U0126, an inhibitor of ERK1/2 phosphorylation, suggesting an involvement of the ERK1/2 MAPK pathway in MKP-1 induction.	U 0126	124-129	mitogen-activated protein kinase 3	Bos taurus	204-210
17690170-6	2007	Moreover, this AngII-induced MKP-1 expression is reduced to 250 +/- 35% of controls (n = 3, P &lt; 0.01) in the presence of U0126, an inhibitor of ERK1/2 phosphorylation, suggesting an involvement of the ERK1/2 MAPK pathway in MKP-1 induction.	U 0126	124-129	mitogen-activated protein kinase 1	Bos taurus	211-215
17690170-6	2007	Moreover, this AngII-induced MKP-1 expression is reduced to 250 +/- 35% of controls (n = 3, P &lt; 0.01) in the presence of U0126, an inhibitor of ERK1/2 phosphorylation, suggesting an involvement of the ERK1/2 MAPK pathway in MKP-1 induction.	U 0126	124-129	dual specificity phosphatase 1	Bos taurus	227-232
17893372-7	2007	Expression of VEGF and capillary formation induced by Ang II were also inhibited by the p44/42 mitogen-activated protein kinase inhibitor U0126 and the p38 mitogen-activated protein kinase inhibitor SB203580.	U 0126	138-143	vascular endothelial growth factor A	Mus musculus	14-18
17893372-7	2007	Expression of VEGF and capillary formation induced by Ang II were also inhibited by the p44/42 mitogen-activated protein kinase inhibitor U0126 and the p38 mitogen-activated protein kinase inhibitor SB203580.	U 0126	138-143	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	54-60
18030065-5	2007	Phosphorylation of the p42/44 and p38 mitogen-activated protein kinases (MAPK) was also induced by PGE2, and U0126 [a mitogen-activated extracellular signal regulated kinase kinase (MEK) 1/2 inhibitor] significantly inhibited the PGE2-induced protein synthesis.	U 0126	109-114	mitogen activated protein kinase 14	Rattus norvegicus	34-37
18030065-5	2007	Phosphorylation of the p42/44 and p38 mitogen-activated protein kinases (MAPK) was also induced by PGE2, and U0126 [a mitogen-activated extracellular signal regulated kinase kinase (MEK) 1/2 inhibitor] significantly inhibited the PGE2-induced protein synthesis.	U 0126	109-114	mitogen activated protein kinase kinase 1	Rattus norvegicus	136-190
17629357-7	2007	U0126 (a selective inhibitor of MEK) also attenuated the enhancement of geniposide on Bcl-2 level by inhibiting the phosphorylation of p90RSK in the hydrogen peroxide treated PC12 cells.	U 0126	0-5	BCL2, apoptosis regulator	Rattus norvegicus	86-91
18053155-6	2007	We found that P42/P44 MAPK inhibitors, PD98059 and U0126, suppressed the induction of cingulate LTP that was induced by presynaptic stimulation with postsynaptic depolarization (the pairing protocol).	U 0126	51-56	mitogen-activated protein kinase 3	Mus musculus	18-21
18053155-6	2007	We found that P42/P44 MAPK inhibitors, PD98059 and U0126, suppressed the induction of cingulate LTP that was induced by presynaptic stimulation with postsynaptic depolarization (the pairing protocol).	U 0126	51-56	mitogen-activated protein kinase 1	Mus musculus	22-26
17890004-4	2007	Inhibition of the ERK pathway for 4h using U0126 (10 microM) also decreased the growth of progenitor cells.	U 0126	43-48	mitogen-activated protein kinase 1	Homo sapiens	18-21
17942905-3	2007	Treatment with the ER stress inducer tunicamycin or thapsigargin did not induce significant apoptosis in the majority of melanoma cell lines, but resistance to these agents was reversed by the MEK inhibitor U0126 or MEK1 small interfering RNA (siRNA).	U 0126	207-212	mitogen-activated protein kinase kinase 7	Homo sapiens	193-196
17596297-5	2007	Furthermore, activity was suppressed by phosphatidylinositol bisphosphate (PIP(2)) chelator (neomycin) or phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002); in contrast, activity, which was partially inhibited by ERK kinase inhibitor (U0126, PD98059), was unaffected by PLC inhibitor (U73122).	U 0126	243-248	heparan sulfate proteoglycan 2	Homo sapiens	278-281
17907155-6	2007	The MAPK inhibitor, U0126, blocked MMP-1 activity and restored HGF-inhibited collagen and CTGF accumulation.	U 0126	20-25	mitogen-activated protein kinase 3	Homo sapiens	4-8
17907155-6	2007	The MAPK inhibitor, U0126, blocked MMP-1 activity and restored HGF-inhibited collagen and CTGF accumulation.	U 0126	20-25	matrix metallopeptidase 1	Homo sapiens	35-40
17907155-6	2007	The MAPK inhibitor, U0126, blocked MMP-1 activity and restored HGF-inhibited collagen and CTGF accumulation.	U 0126	20-25	hepatocyte growth factor	Homo sapiens	63-66
17907155-6	2007	The MAPK inhibitor, U0126, blocked MMP-1 activity and restored HGF-inhibited collagen and CTGF accumulation.	U 0126	20-25	cellular communication network factor 2	Homo sapiens	90-94
17596563-12	2007	ADCYAP1 also increased the activity of the serum response element (Sre) promoter, a target for MAPK3/1, and treatment of the cells with U0126 completely inhibited ADCYAP1-induced Sre promoter activity.	U 0126	136-141	mitogen-activated protein kinase 3	Mus musculus	95-102
17548215-12	2007	The ERK1/2 inhibitor U0126 also reduced Egr-1 DNA binding activity to MT1-MMP promoter sequences and subsequent transcription of MT1-MMP.	U 0126	21-26	early growth response 1	Bos taurus	40-45
17548215-12	2007	The ERK1/2 inhibitor U0126 also reduced Egr-1 DNA binding activity to MT1-MMP promoter sequences and subsequent transcription of MT1-MMP.	U 0126	21-26	matrix metallopeptidase 14	Bos taurus	70-77
17548215-12	2007	The ERK1/2 inhibitor U0126 also reduced Egr-1 DNA binding activity to MT1-MMP promoter sequences and subsequent transcription of MT1-MMP.	U 0126	21-26	matrix metallopeptidase 14	Bos taurus	129-136
17761302-5	2007	Inhibition of ERK activation by U0126 protected against cisplatin/BSO cytotoxicity via inhibiting ROS production but not restoring intracellular glutathione content.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	14-17
17761302-10	2007	Although U0126 failed in restoring intracellular glutathione levels, it restored thioredoxin levels, which maintain the activity of the caspases.	U 0126	9-14	thioredoxin	Homo sapiens	81-92
17596563-9	2007	The MEK inhibitor, U0126, and the PKA inhibitors, H89 and cAMP-dependent protein kinase peptide inhibitor (PKI), completely inhibited MAPK3/1 activation by either ADCYAP1 or CPT-cAMP.	U 0126	19-24	mitogen-activated protein kinase 3	Mus musculus	134-139
17596563-9	2007	The MEK inhibitor, U0126, and the PKA inhibitors, H89 and cAMP-dependent protein kinase peptide inhibitor (PKI), completely inhibited MAPK3/1 activation by either ADCYAP1 or CPT-cAMP.	U 0126	19-24	adenylate cyclase activating polypeptide 1	Mus musculus	163-170
17548901-7	2007	In contrast, inhibition of ERK1/2 with the pharmacologic inhibitors U0126 or PD98059, together with QD, resulted in an important enhancement of apoptosis.	U 0126	68-73	mitogen-activated protein kinase 3	Homo sapiens	27-33
17513150-6	2007	Although IGF-I stimulated the phosphorylation of both Akt (protein kinase B) and extracellular-regulated kinase (ERK), the effect of IGF-I at IL-8 expression was inhibited only by U0126, a pharmacological inhibitor of MAPK/ERK kinase (MEK) and not by inhibition of the upstream activator of Akt, phosphatidylinositol-3 kinase (PI3K).	U 0126	180-185	insulin like growth factor 1	Homo sapiens	133-138
17513150-6	2007	Although IGF-I stimulated the phosphorylation of both Akt (protein kinase B) and extracellular-regulated kinase (ERK), the effect of IGF-I at IL-8 expression was inhibited only by U0126, a pharmacological inhibitor of MAPK/ERK kinase (MEK) and not by inhibition of the upstream activator of Akt, phosphatidylinositol-3 kinase (PI3K).	U 0126	180-185	C-X-C motif chemokine ligand 8	Homo sapiens	142-146
17592496-8	2007	PD98059, U0126 and LY294002 not only abolished IL-12-induced IL-4 release but also inhibited IL-12-induced phosphorylation of extracellular signal-regulated kinase and Akt.	U 0126	9-14	interleukin 4	Mus musculus	61-65
17592496-8	2007	PD98059, U0126 and LY294002 not only abolished IL-12-induced IL-4 release but also inhibited IL-12-induced phosphorylation of extracellular signal-regulated kinase and Akt.	U 0126	9-14	thymoma viral proto-oncogene 1	Mus musculus	168-171
17452987-15	2007	Inhibition of MAP kinase by UO126 abolished adipokine-stimulated aldosterone secretion from primary human adrenocortical and H295R cells, and inhibited StAR gene activity.	U 0126	28-33	steroidogenic acute regulatory protein	Homo sapiens	152-156
17407158-5	2007	Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter activity as well as the MGP mRNA level.	U 0126	30-35	midkine	Mus musculus	37-40
17407158-5	2007	Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter activity as well as the MGP mRNA level.	U 0126	30-35	parathyroid hormone	Mus musculus	64-67
17407158-5	2007	Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter activity as well as the MGP mRNA level.	U 0126	30-35	matrix Gla protein	Mus musculus	81-84
17407158-5	2007	Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter activity as well as the MGP mRNA level.	U 0126	30-35	matrix Gla protein	Mus musculus	118-121
17628025-8	2007	Furthermore, the MCI-186-dependent survival effect in vitro was blocked by U0126, an MEK (an upstream of ERK) inhibitor, and also by LY294002, a PI3 kinase inhibitor.	U 0126	75-80	Eph receptor B1	Rattus norvegicus	105-108
17534697-6	2007	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580.	U 0126	166-171	C1q and tumor necrosis factor related protein 3	Mus musculus	93-98
17534697-6	2007	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580.	U 0126	166-171	C1q and tumor necrosis factor related protein 3	Mus musculus	99-108
17549607-9	2007	U0126 (a MEK1/2 inhibitor) or LY294002 (a PI3K inhibitor) was added to ST2 and MC3T3-E1 cells, and was found to inhibit RANKL mRNA and RANKL protein expression in these cells.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	9-15
17549607-9	2007	U0126 (a MEK1/2 inhibitor) or LY294002 (a PI3K inhibitor) was added to ST2 and MC3T3-E1 cells, and was found to inhibit RANKL mRNA and RANKL protein expression in these cells.	U 0126	0-5	interleukin 1 receptor-like 1	Mus musculus	71-74
17549607-9	2007	U0126 (a MEK1/2 inhibitor) or LY294002 (a PI3K inhibitor) was added to ST2 and MC3T3-E1 cells, and was found to inhibit RANKL mRNA and RANKL protein expression in these cells.	U 0126	0-5	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	120-125
17549607-9	2007	U0126 (a MEK1/2 inhibitor) or LY294002 (a PI3K inhibitor) was added to ST2 and MC3T3-E1 cells, and was found to inhibit RANKL mRNA and RANKL protein expression in these cells.	U 0126	0-5	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	135-140
17596563-12	2007	ADCYAP1 also increased the activity of the serum response element (Sre) promoter, a target for MAPK3/1, and treatment of the cells with U0126 completely inhibited ADCYAP1-induced Sre promoter activity.	U 0126	136-141	adenylate cyclase activating polypeptide 1	Mus musculus	163-170
17596563-13	2007	ADCYAP1-increased Cga promoter activity was inhibited partially by both H89 and U0126.	U 0126	80-85	adenylate cyclase activating polypeptide 1	Mus musculus	0-7
17596563-13	2007	ADCYAP1-increased Cga promoter activity was inhibited partially by both H89 and U0126.	U 0126	80-85	chromogranin A	Mus musculus	18-21
17646391-6	2007	In the presence of ERalpha, U0126 also dramatically reduces (i) ligand-dependent colocalization of SRC-3 and ERalpha, (ii) the formation of ER-SRC-3 complexes in cell lysates, and (iii) SRC-3 targeting to a visible, ERalpha-occupied and -regulated prolactin promoter array.	U 0126	28-33	estrogen receptor 1	Homo sapiens	19-26
17646391-6	2007	In the presence of ERalpha, U0126 also dramatically reduces (i) ligand-dependent colocalization of SRC-3 and ERalpha, (ii) the formation of ER-SRC-3 complexes in cell lysates, and (iii) SRC-3 targeting to a visible, ERalpha-occupied and -regulated prolactin promoter array.	U 0126	28-33	nuclear receptor coactivator 3	Homo sapiens	99-104
17646391-6	2007	In the presence of ERalpha, U0126 also dramatically reduces (i) ligand-dependent colocalization of SRC-3 and ERalpha, (ii) the formation of ER-SRC-3 complexes in cell lysates, and (iii) SRC-3 targeting to a visible, ERalpha-occupied and -regulated prolactin promoter array.	U 0126	28-33	estrogen receptor 1	Homo sapiens	109-116
17646391-6	2007	In the presence of ERalpha, U0126 also dramatically reduces (i) ligand-dependent colocalization of SRC-3 and ERalpha, (ii) the formation of ER-SRC-3 complexes in cell lysates, and (iii) SRC-3 targeting to a visible, ERalpha-occupied and -regulated prolactin promoter array.	U 0126	28-33	nuclear receptor coactivator 3	Homo sapiens	143-148
17646391-6	2007	In the presence of ERalpha, U0126 also dramatically reduces (i) ligand-dependent colocalization of SRC-3 and ERalpha, (ii) the formation of ER-SRC-3 complexes in cell lysates, and (iii) SRC-3 targeting to a visible, ERalpha-occupied and -regulated prolactin promoter array.	U 0126	28-33	nuclear receptor coactivator 3	Homo sapiens	143-148
17646391-6	2007	In the presence of ERalpha, U0126 also dramatically reduces (i) ligand-dependent colocalization of SRC-3 and ERalpha, (ii) the formation of ER-SRC-3 complexes in cell lysates, and (iii) SRC-3 targeting to a visible, ERalpha-occupied and -regulated prolactin promoter array.	U 0126	28-33	estrogen receptor 1	Homo sapiens	109-116
17664275-6	2007	These changes in NHE1 kinetics were absent when MAPK/ERK kinase (MEK) was inhibited by the MEK inhibitor U0126.	U 0126	105-110	solute carrier family 9 member A1	Homo sapiens	17-21
17664275-6	2007	These changes in NHE1 kinetics were absent when MAPK/ERK kinase (MEK) was inhibited by the MEK inhibitor U0126.	U 0126	105-110	mitogen-activated protein kinase kinase 7	Homo sapiens	91-94
17664275-9	2007	U0126 abolished REOX-induced elevation and translocation of p-ERK1/2.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	62-68
17664275-12	2007	Inhibition of MEK activity with U0126 abolished phosphorylation of both NHE1 and p90(RSK).	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
17664275-12	2007	Inhibition of MEK activity with U0126 abolished phosphorylation of both NHE1 and p90(RSK).	U 0126	32-37	solute carrier family 9 member A1	Homo sapiens	72-76
17664275-12	2007	Inhibition of MEK activity with U0126 abolished phosphorylation of both NHE1 and p90(RSK).	U 0126	32-37	cellular inhibitor of PP2A	Homo sapiens	81-84
17664275-12	2007	Inhibition of MEK activity with U0126 abolished phosphorylation of both NHE1 and p90(RSK).	U 0126	32-37	ribosomal protein S6 kinase A1	Homo sapiens	85-88
17616749-10	2007	U0126 blocked the ATV induction of Ser(473) P-Akt and Thr(308) P-Akt while attenuating the induction of P-eNOS.	U 0126	0-5	thymoma viral proto-oncogene 1	Mus musculus	46-49
17616749-10	2007	U0126 blocked the ATV induction of Ser(473) P-Akt and Thr(308) P-Akt while attenuating the induction of P-eNOS.	U 0126	0-5	thymoma viral proto-oncogene 1	Mus musculus	65-68
17616749-10	2007	U0126 blocked the ATV induction of Ser(473) P-Akt and Thr(308) P-Akt while attenuating the induction of P-eNOS.	U 0126	0-5	nitric oxide synthase 3, endothelial cell	Mus musculus	106-110
17636278-7	2007	Furthermore, the CsA treatment increased the MAPK activity, and blocking of the signaling pathway by Mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited CsA-induced titin transcription in trophoblasts.	U 0126	149-154	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	17-20
17636278-7	2007	Furthermore, the CsA treatment increased the MAPK activity, and blocking of the signaling pathway by Mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited CsA-induced titin transcription in trophoblasts.	U 0126	149-154	mitogen-activated protein kinase kinase 7	Homo sapiens	133-136
17636278-7	2007	Furthermore, the CsA treatment increased the MAPK activity, and blocking of the signaling pathway by Mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited CsA-induced titin transcription in trophoblasts.	U 0126	149-154	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	166-169
17636278-7	2007	Furthermore, the CsA treatment increased the MAPK activity, and blocking of the signaling pathway by Mitogen-activated protein MAPK (MEK) inhibitor, U0126, inhibited CsA-induced titin transcription in trophoblasts.	U 0126	149-154	titin	Homo sapiens	178-183
18481199-5	2007	Treatment of PANC-1 cells with the MEK inhibitor U0126 or the Sp1 inhibitor mithramycin reduced CCN2 mRNA and promoter activity.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
18481199-5	2007	Treatment of PANC-1 cells with the MEK inhibitor U0126 or the Sp1 inhibitor mithramycin reduced CCN2 mRNA and promoter activity.	U 0126	49-54	cellular communication network factor 2	Homo sapiens	96-100
18481199-6	2007	Mutation of the BCE-1, but not Sp1 or Ets, site abolished the responsiveness of the CCN2 promoter to U0126.	U 0126	101-106	TLE family member 4, transcriptional corepressor	Homo sapiens	16-21
18481199-6	2007	Mutation of the BCE-1, but not Sp1 or Ets, site abolished the responsiveness of the CCN2 promoter to U0126.	U 0126	101-106	cellular communication network factor 2	Homo sapiens	84-88
17662046-8	2007	Furthermore, U0126, a specific inhibitor of the ERK pathway suppressed the persistent pain by formalin.	U 0126	13-18	mitogen-activated protein kinase 1	Mus musculus	48-51
17660698-7	2007	A specific ERK1/2 inhibitor, U0126, decreased the phosphorylation of ERK1/2 proteins induced by 0.05 Gy of ionizing radiation, and a similar suppressive effect was observed with a p38 inhibitor, PD169316.	U 0126	29-34	mitogen-activated protein kinase 3	Homo sapiens	11-17
17660698-7	2007	A specific ERK1/2 inhibitor, U0126, decreased the phosphorylation of ERK1/2 proteins induced by 0.05 Gy of ionizing radiation, and a similar suppressive effect was observed with a p38 inhibitor, PD169316.	U 0126	29-34	mitogen-activated protein kinase 3	Homo sapiens	69-75
17660698-7	2007	A specific ERK1/2 inhibitor, U0126, decreased the phosphorylation of ERK1/2 proteins induced by 0.05 Gy of ionizing radiation, and a similar suppressive effect was observed with a p38 inhibitor, PD169316.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	180-183
17694057-5	2007	Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Mus musculus	70-123
17694057-5	2007	Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Mus musculus	125-131
17694057-5	2007	Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis.	U 0126	47-52	mitogen-activated protein kinase 3	Mus musculus	179-185
17686496-9	2007	Inhibition of the ERK1/2 activation by U0126 diminished these effects of lithium.	U 0126	39-44	mitogen activated protein kinase 3	Rattus norvegicus	18-24
17644078-8	2007	The MEK 1/2 inhibitor U0126 inhibited both the ERK 1/2 phosphorylation and the migration of the astrocytes across the wound after scratch.	U 0126	22-27	mitogen-activated protein kinase kinase 1	Homo sapiens	4-11
17644078-8	2007	The MEK 1/2 inhibitor U0126 inhibited both the ERK 1/2 phosphorylation and the migration of the astrocytes across the wound after scratch.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	47-54
17353907-7	2007	In turn, MEK inhibitors U0126 and PD98059 and siRNA-mediated depletion of either ERK1 or ERK2 inhibited S6rp phosphorylation much more effectively.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
17652623-2	2007	EXPERIMENTAL DESIGN: A panel of human melanoma cell lines and fresh melanoma isolates was assessed for their sensitivity to apoptosis induced by the MEK inhibitor U0126.	U 0126	163-168	mitogen-activated protein kinase kinase 7	Homo sapiens	149-152
17707437-11	2007	All these effects were blocked by the upstream ERK inhibitor, U0126 (5 microM).	U 0126	62-67	Eph receptor B1	Rattus norvegicus	47-50
17620366-7	2007	The specific mitogen-activated protein kinase kinase 1/2 inhibitor U0126 prevented ERK activation and attenuated focal adhesion kinase, paxillin, and Src phosphorylation, focal adhesion restructuring, and ischemia/reperfusion-induced renal injury.	U 0126	67-72	mitogen-activated protein kinase kinase 1	Homo sapiens	13-54
17620366-7	2007	The specific mitogen-activated protein kinase kinase 1/2 inhibitor U0126 prevented ERK activation and attenuated focal adhesion kinase, paxillin, and Src phosphorylation, focal adhesion restructuring, and ischemia/reperfusion-induced renal injury.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	83-86
17620366-7	2007	The specific mitogen-activated protein kinase kinase 1/2 inhibitor U0126 prevented ERK activation and attenuated focal adhesion kinase, paxillin, and Src phosphorylation, focal adhesion restructuring, and ischemia/reperfusion-induced renal injury.	U 0126	67-72	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	150-153
17709622-11	2007	RESULTS: Using Western blot analysis, we detected the dephosphorylation of ERK1/2 in PTC cells carrying the RET/PTC1 rearrangement or a BRAF mutation after treating the cells with 2 MEK1/2 inhibitors (PD98059 and U0126).	U 0126	213-218	mitogen-activated protein kinase 3	Homo sapiens	75-81
17709622-11	2007	RESULTS: Using Western blot analysis, we detected the dephosphorylation of ERK1/2 in PTC cells carrying the RET/PTC1 rearrangement or a BRAF mutation after treating the cells with 2 MEK1/2 inhibitors (PD98059 and U0126).	U 0126	213-218	ret proto-oncogene	Homo sapiens	108-111
17709622-12	2007	In addition, both PD98059 and U0126 completely inhibited the growth of the PTC cells carrying a BRAF mutation but partially inhibited the growth of the PTC cells carrying the RET/PTC1 rearrangement.	U 0126	30-35	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	96-100
17709622-12	2007	In addition, both PD98059 and U0126 completely inhibited the growth of the PTC cells carrying a BRAF mutation but partially inhibited the growth of the PTC cells carrying the RET/PTC1 rearrangement.	U 0126	30-35	ret proto-oncogene	Homo sapiens	175-178
17709622-12	2007	In addition, both PD98059 and U0126 completely inhibited the growth of the PTC cells carrying a BRAF mutation but partially inhibited the growth of the PTC cells carrying the RET/PTC1 rearrangement.	U 0126	30-35	patched 1	Homo sapiens	179-183
17534697-6	2007	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580.	U 0126	40-45	C1q and tumor necrosis factor related protein 3	Mus musculus	93-98
17534697-6	2007	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580.	U 0126	40-45	C1q and tumor necrosis factor related protein 3	Mus musculus	99-108
17534697-6	2007	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580.	U 0126	166-171	mitogen-activated protein kinase kinase 1	Mus musculus	21-27
17534697-6	2007	MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580.	U 0126	166-171	mitogen-activated protein kinase 14	Mus musculus	51-59
17875706-11	2007	Consistent with this, Erk phosphorylation was transiently induced by irradiation and persisted in irradiated cells treated with TGFbeta, and treatment with U0126, a MAP/Erk kinase (MEK) inhibitor, blocked the EMT phenotype.	U 0126	156-161	mitogen-activated protein kinase 1	Homo sapiens	22-25
17875706-11	2007	Consistent with this, Erk phosphorylation was transiently induced by irradiation and persisted in irradiated cells treated with TGFbeta, and treatment with U0126, a MAP/Erk kinase (MEK) inhibitor, blocked the EMT phenotype.	U 0126	156-161	mitogen-activated protein kinase 1	Homo sapiens	169-172
17613518-5	2007	The effect of DEVA-KSR1 expression was found to correlate with increased levels of active phosphoERK and could be significantly reversed by treating cells with the MEK inhibitor U0126.	U 0126	178-183	kinase suppressor of ras 1	Mus musculus	14-23
17613518-5	2007	The effect of DEVA-KSR1 expression was found to correlate with increased levels of active phosphoERK and could be significantly reversed by treating cells with the MEK inhibitor U0126.	U 0126	178-183	midkine	Mus musculus	164-167
17575006-6	2007	Both U0126, an inhibitor of MEK1/2, and dominant negative ERK1 prevented TNF-alpha-induced MUC1 promoter activation, and anti-TNFR1 antibody blocked TNF-alpha-stimulated ERK1/2 activation.	U 0126	5-10	mitogen-activated protein kinase kinase 1	Homo sapiens	28-34
17575006-6	2007	Both U0126, an inhibitor of MEK1/2, and dominant negative ERK1 prevented TNF-alpha-induced MUC1 promoter activation, and anti-TNFR1 antibody blocked TNF-alpha-stimulated ERK1/2 activation.	U 0126	5-10	tumor necrosis factor	Homo sapiens	73-82
17575006-6	2007	Both U0126, an inhibitor of MEK1/2, and dominant negative ERK1 prevented TNF-alpha-induced MUC1 promoter activation, and anti-TNFR1 antibody blocked TNF-alpha-stimulated ERK1/2 activation.	U 0126	5-10	mucin 1, cell surface associated	Homo sapiens	91-95
17616647-9	2007	MAP kinase pathway inhibitors, RAF1 kinase inhibitor-I and U0126 (MEK), inhibited SPOC1 cell PV-induced secretion by approximately 50%.	U 0126	59-64	PHD finger protein 13	Homo sapiens	82-87
17634416-9	2007	Ouabain-mediated Akt phosphorylation was inhibited by U0126, a MEK/ERK inhibitor, suggesting that ouabain-mediated Akt phosphorylation is dependent on ERK.	U 0126	54-59	AKT serine/threonine kinase 1	Homo sapiens	17-20
17634416-9	2007	Ouabain-mediated Akt phosphorylation was inhibited by U0126, a MEK/ERK inhibitor, suggesting that ouabain-mediated Akt phosphorylation is dependent on ERK.	U 0126	54-59	EPH receptor B2	Homo sapiens	67-70
17634416-9	2007	Ouabain-mediated Akt phosphorylation was inhibited by U0126, a MEK/ERK inhibitor, suggesting that ouabain-mediated Akt phosphorylation is dependent on ERK.	U 0126	54-59	AKT serine/threonine kinase 1	Homo sapiens	115-118
17634416-9	2007	Ouabain-mediated Akt phosphorylation was inhibited by U0126, a MEK/ERK inhibitor, suggesting that ouabain-mediated Akt phosphorylation is dependent on ERK.	U 0126	54-59	EPH receptor B2	Homo sapiens	151-154
18424914-6	2007	Treatment with COX-1 and COX-2 inhibitors in the presence of the selective MEK1/2 inhibitor U0126 effectively suppressed ERK1/2 activation and combinations of either SC-560 or CAY10404 with U0126 resulted in synergistic effects on cell growth inhibition and induction of apoptosis.	U 0126	92-97	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	15-20
18424914-6	2007	Treatment with COX-1 and COX-2 inhibitors in the presence of the selective MEK1/2 inhibitor U0126 effectively suppressed ERK1/2 activation and combinations of either SC-560 or CAY10404 with U0126 resulted in synergistic effects on cell growth inhibition and induction of apoptosis.	U 0126	92-97	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	25-30
18424914-6	2007	Treatment with COX-1 and COX-2 inhibitors in the presence of the selective MEK1/2 inhibitor U0126 effectively suppressed ERK1/2 activation and combinations of either SC-560 or CAY10404 with U0126 resulted in synergistic effects on cell growth inhibition and induction of apoptosis.	U 0126	92-97	mitogen-activated protein kinase kinase 1	Homo sapiens	75-81
18424914-6	2007	Treatment with COX-1 and COX-2 inhibitors in the presence of the selective MEK1/2 inhibitor U0126 effectively suppressed ERK1/2 activation and combinations of either SC-560 or CAY10404 with U0126 resulted in synergistic effects on cell growth inhibition and induction of apoptosis.	U 0126	92-97	mitogen-activated protein kinase 3	Homo sapiens	121-127
18424914-6	2007	Treatment with COX-1 and COX-2 inhibitors in the presence of the selective MEK1/2 inhibitor U0126 effectively suppressed ERK1/2 activation and combinations of either SC-560 or CAY10404 with U0126 resulted in synergistic effects on cell growth inhibition and induction of apoptosis.	U 0126	190-195	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	15-20
18424914-6	2007	Treatment with COX-1 and COX-2 inhibitors in the presence of the selective MEK1/2 inhibitor U0126 effectively suppressed ERK1/2 activation and combinations of either SC-560 or CAY10404 with U0126 resulted in synergistic effects on cell growth inhibition and induction of apoptosis.	U 0126	190-195	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	25-30
17309601-7	2007	Furthermore, inhibiting either FGFR activation with PD173074 or ERK1/2 activation with UO126 blocked all morphogenesis, proliferation, and gene expression changes induced by androgens in the UGS.	U 0126	87-92	mitogen-activated protein kinase 3	Mus musculus	64-70
17825046-6	2007	Treatment of mouse embryonic fibroblasts (MEFs) with Con A induces secretion of matrix metalloproteinase (MMP)-9, a phenomenon that is inhibited in cells expressing YF mutant of SHPS-1, a dominant negative form of Akt or in cells pre-treated with an Akt inhibitor, LY294002 or extracellular-signal regulated kinase (Erk) inhibitor, U0126.	U 0126	332-337	matrix metallopeptidase 9	Mus musculus	80-112
17825046-6	2007	Treatment of mouse embryonic fibroblasts (MEFs) with Con A induces secretion of matrix metalloproteinase (MMP)-9, a phenomenon that is inhibited in cells expressing YF mutant of SHPS-1, a dominant negative form of Akt or in cells pre-treated with an Akt inhibitor, LY294002 or extracellular-signal regulated kinase (Erk) inhibitor, U0126.	U 0126	332-337	signal-regulatory protein alpha	Mus musculus	178-184
17508026-4	2007	The mitogen-activated protein kinase kinase (MEK) inhibitor (U0126) was able to block this effect and reduced cell viability and sensitized cells to cisplatin-induced apoptosis, as shown by PARP cleavage, caspase 3 expression, and annexin-V staining.	U 0126	61-66	collagen type XI alpha 2 chain	Homo sapiens	190-194
17508026-4	2007	The mitogen-activated protein kinase kinase (MEK) inhibitor (U0126) was able to block this effect and reduced cell viability and sensitized cells to cisplatin-induced apoptosis, as shown by PARP cleavage, caspase 3 expression, and annexin-V staining.	U 0126	61-66	caspase 3	Homo sapiens	205-214
17508026-4	2007	The mitogen-activated protein kinase kinase (MEK) inhibitor (U0126) was able to block this effect and reduced cell viability and sensitized cells to cisplatin-induced apoptosis, as shown by PARP cleavage, caspase 3 expression, and annexin-V staining.	U 0126	61-66	annexin A5	Homo sapiens	231-240
17384686-5	2007	Pretreatment with the ERK1/2-specific inhibitor U0126 prevented these galanin-induced effects.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	22-28
17715342-8	2007	Local application of the MAP kinase kinase inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio]butadiene) blocked ERK phosphorylation, and also blocked Arc/Arg3.1 mRNA localization.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	130-133
17715342-8	2007	Local application of the MAP kinase kinase inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio]butadiene) blocked ERK phosphorylation, and also blocked Arc/Arg3.1 mRNA localization.	U 0126	53-58	activity regulated cytoskeleton associated protein	Homo sapiens	168-178
17715342-8	2007	Local application of the MAP kinase kinase inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio]butadiene) blocked ERK phosphorylation, and also blocked Arc/Arg3.1 mRNA localization.	U 0126	60-120	mitogen-activated protein kinase 1	Homo sapiens	130-133
17715342-8	2007	Local application of the MAP kinase kinase inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio]butadiene) blocked ERK phosphorylation, and also blocked Arc/Arg3.1 mRNA localization.	U 0126	60-120	activity regulated cytoskeleton associated protein	Homo sapiens	168-178
17699800-9	2007	Inhibition of MEK1/2 by U0126 inhibited the induction of ER stress response genes.	U 0126	24-29	mitogen-activated protein kinase kinase 1	Homo sapiens	14-20
17549730-6	2007	Furthermore, these protective effects were inhibited by either the MEK1/2 inhibitor UO126 or the PI3-K inhibitor LY294002, supporting the requirement for both the MAPK and PI3-K pathways in progesterone-induced protection.	U 0126	84-89	mitogen-activated protein kinase kinase 1	Homo sapiens	67-73
17549730-6	2007	Furthermore, these protective effects were inhibited by either the MEK1/2 inhibitor UO126 or the PI3-K inhibitor LY294002, supporting the requirement for both the MAPK and PI3-K pathways in progesterone-induced protection.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	163-167
17537430-5	2007	Moreover, 4-AP increased the expressions of p-ERK1/2 in cultured PASMCs s and whole tissues, which were prevented by pretreatment of the cells or tissues with U0126.	U 0126	159-164	mitogen activated protein kinase 3	Rattus norvegicus	46-52
17577579-2	2007	We demonstrated not only that treatment with p44/42 MAPK inhibitor U0126 in intestinal cell line Caco-2 cells reduced the phosphorylation of serine and threonine residues of TRalpha-1, but also that T(3) and U0126 synergistically induced GLUT5 gene expression.	U 0126	67-72	interferon induced protein 44	Homo sapiens	45-48
17577579-2	2007	We demonstrated not only that treatment with p44/42 MAPK inhibitor U0126 in intestinal cell line Caco-2 cells reduced the phosphorylation of serine and threonine residues of TRalpha-1, but also that T(3) and U0126 synergistically induced GLUT5 gene expression.	U 0126	67-72	solute carrier family 2 member 5	Homo sapiens	238-243
17577579-2	2007	We demonstrated not only that treatment with p44/42 MAPK inhibitor U0126 in intestinal cell line Caco-2 cells reduced the phosphorylation of serine and threonine residues of TRalpha-1, but also that T(3) and U0126 synergistically induced GLUT5 gene expression.	U 0126	208-213	interferon induced protein 44	Homo sapiens	45-48
17577579-4	2007	ChIP and transfection assays revealed that co-treatment of T(3) and U0126 induces TRalpha-1-RXR binding to GLUT5-TRE on the human GLUT5 enhancer region, and recruitment of the transcriptional complex in cells.	U 0126	68-73	solute carrier family 2 member 5	Homo sapiens	107-112
17577579-4	2007	ChIP and transfection assays revealed that co-treatment of T(3) and U0126 induces TRalpha-1-RXR binding to GLUT5-TRE on the human GLUT5 enhancer region, and recruitment of the transcriptional complex in cells.	U 0126	68-73	solute carrier family 2 member 5	Homo sapiens	130-135
17490600-3	2007	This ERK-uncoupled ATPase activity is dependent on the phosphorylation status of MEK and is abrogated by the selective MEK kinase inhibitor U0126.	U 0126	140-145	dynein axonemal heavy chain 8	Homo sapiens	19-25
17490600-3	2007	This ERK-uncoupled ATPase activity is dependent on the phosphorylation status of MEK and is abrogated by the selective MEK kinase inhibitor U0126.	U 0126	140-145	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84
17490600-3	2007	This ERK-uncoupled ATPase activity is dependent on the phosphorylation status of MEK and is abrogated by the selective MEK kinase inhibitor U0126.	U 0126	140-145	mitogen-activated protein kinase kinase 7	Homo sapiens	119-122
17664275-6	2007	These changes in NHE1 kinetics were absent when MAPK/ERK kinase (MEK) was inhibited by the MEK inhibitor U0126.	U 0126	105-110	mitogen-activated protein kinase 3	Homo sapiens	48-52
17664275-6	2007	These changes in NHE1 kinetics were absent when MAPK/ERK kinase (MEK) was inhibited by the MEK inhibitor U0126.	U 0126	105-110	mitogen-activated protein kinase kinase 7	Homo sapiens	65-68
17635518-9	2007	E2-induced MAPK/ERK activation was inhibited by the MEK1/2 inhibitor U0126 in a concentration-dependent manner.	U 0126	69-74	mitogen-activated protein kinase kinase 1	Homo sapiens	52-58
17992606-6	2007	Addition of H89 or U0126, both inhibited the testosterone-, FSH-, and forskolin-induced tPA expression.	U 0126	19-24	plasminogen activator, tissue type	Rattus norvegicus	88-91
17265428-7	2007	U0126, a selective inhibitor of ERK1/2, completely blocked Runx2 activation during periods of mechanical stress, but the p38 MAPK-selective inhibitor SB203580 did not alter nuclear phosphorylation of Runx2.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	32-38
17604021-6	2007	Furthermore, U0126, an ERK pathway inhibitor, and SB203580, a p38 MAPK inhibitor, diminished EGF-induced COX-2 expression; whereas, a JNK inhibitor did not suppress COX-2 expression by EGF.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	23-26
17604021-6	2007	Furthermore, U0126, an ERK pathway inhibitor, and SB203580, a p38 MAPK inhibitor, diminished EGF-induced COX-2 expression; whereas, a JNK inhibitor did not suppress COX-2 expression by EGF.	U 0126	13-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	105-110
17415712-4	2007	The synthetic androgen R1881 stimulated ARE-inducible reporter gene activity and prostate-specific antigen expression in LNCaP cells and the MEK/ERK inhibitor U0126 or the anti-androgen bicalutamide (casodex) prevented both of these responses.	U 0126	159-164	mitogen-activated protein kinase kinase 7	Homo sapiens	141-144
17415712-4	2007	The synthetic androgen R1881 stimulated ARE-inducible reporter gene activity and prostate-specific antigen expression in LNCaP cells and the MEK/ERK inhibitor U0126 or the anti-androgen bicalutamide (casodex) prevented both of these responses.	U 0126	159-164	mitogen-activated protein kinase 1	Homo sapiens	145-148
17265428-7	2007	U0126, a selective inhibitor of ERK1/2, completely blocked Runx2 activation during periods of mechanical stress, but the p38 MAPK-selective inhibitor SB203580 did not alter nuclear phosphorylation of Runx2.	U 0126	0-5	RUNX family transcription factor 2	Rattus norvegicus	59-64
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	U 0126	19-24	mitogen-activated protein kinase 3	Homo sapiens	102-109
17320366-7	2007	Fibroblast cells were treated with the compounds homocysteine, methotrexate and the MEK1/2 inhibitor U0126, and relative transcript levels of six genes were determined.	U 0126	101-106	mitogen-activated protein kinase kinase 1	Homo sapiens	84-90
17320366-11	2007	U0126 caused a decrease in DKK1 promoter activity at 50 microM and had no effect on TAGLN promoter activity.	U 0126	0-5	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	27-31
17505473-5	2007	Although IFNalpha treatment no longer protected the RAS- or Raf1-overexpressing cells from VSV infection, responsiveness to IFNalpha was restored following treatment with the mitogen-activated protein kinase kinase (MEK) inhibitor U0126.	U 0126	231-236	interferon alpha 1	Homo sapiens	9-17
17505473-5	2007	Although IFNalpha treatment no longer protected the RAS- or Raf1-overexpressing cells from VSV infection, responsiveness to IFNalpha was restored following treatment with the mitogen-activated protein kinase kinase (MEK) inhibitor U0126.	U 0126	231-236	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	60-64
17505473-5	2007	Although IFNalpha treatment no longer protected the RAS- or Raf1-overexpressing cells from VSV infection, responsiveness to IFNalpha was restored following treatment with the mitogen-activated protein kinase kinase (MEK) inhibitor U0126.	U 0126	231-236	interferon alpha 1	Homo sapiens	124-132
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	U 0126	19-24	mitogen-activated protein kinase 8	Homo sapiens	111-114
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	120-123
17573185-10	2007	The prolactin-induced increase in the formation of SNARE complex and syntaxin 1A phosphorylation was inhibited by PD098059 and U0126, inhibitors of the MAPK pathway.	U 0126	127-132	prolactin	Rattus norvegicus	4-13
17537727-9	2007	Inhibition of ERK1/2 with U0126 potently suppressed gAcrp-stimulated Egr-1 promoter activity, as well as TNF-alpha promoter activity.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	14-20
17537727-9	2007	Inhibition of ERK1/2 with U0126 potently suppressed gAcrp-stimulated Egr-1 promoter activity, as well as TNF-alpha promoter activity.	U 0126	26-31	early growth response 1	Homo sapiens	69-74
17499220-4	2007	The HO-1 inducting effect of LCY-2-CHO was inhibited by SB203580, N(G)-nitro-l-arginine methylester (l-NAME), and wortmannin, but was not affected by U0126 or SP600125.	U 0126	150-155	heme oxygenase 1	Rattus norvegicus	4-8
17573185-10	2007	The prolactin-induced increase in the formation of SNARE complex and syntaxin 1A phosphorylation was inhibited by PD098059 and U0126, inhibitors of the MAPK pathway.	U 0126	127-132	syntaxin 1A	Rattus norvegicus	69-80
17500057-5	2007	U0126 and LY249002, specific inhibitors of MAPK/ERK kinase (MEK) and phosphoinositide 3-kinase, respectively, inhibited IGF-1-induced DNA synthesis and migration in both wild-type and LAR(-/-) VSMC.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	43-47
17500057-5	2007	U0126 and LY249002, specific inhibitors of MAPK/ERK kinase (MEK) and phosphoinositide 3-kinase, respectively, inhibited IGF-1-induced DNA synthesis and migration in both wild-type and LAR(-/-) VSMC.	U 0126	0-5	insulin-like growth factor 1	Mus musculus	120-125
17500057-5	2007	U0126 and LY249002, specific inhibitors of MAPK/ERK kinase (MEK) and phosphoinositide 3-kinase, respectively, inhibited IGF-1-induced DNA synthesis and migration in both wild-type and LAR(-/-) VSMC.	U 0126	0-5	low antibody response	Mus musculus	184-187
17558277-3	2007	The Erk1/2 inhibitor U0126 inhibited both the increase in p-Erk1/2 and the bromodeoxy uridine incorporation.	U 0126	21-26	mitogen activated protein kinase 3	Rattus norvegicus	4-10
17611287-8	2007	In slices, bath-applied NE triggered robust phospho-ERK1/2 immunoreactivity in PVH (including CRH) neurons, which attenuated markedly in the presence of the alpha1 adrenoceptor antagonist, prazosin, or the MAP kinase kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene).	U 0126	241-246	mitogen-activated protein kinase 3	Homo sapiens	52-58
17611287-8	2007	In slices, bath-applied NE triggered robust phospho-ERK1/2 immunoreactivity in PVH (including CRH) neurons, which attenuated markedly in the presence of the alpha1 adrenoceptor antagonist, prazosin, or the MAP kinase kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene).	U 0126	248-307	mitogen-activated protein kinase 3	Homo sapiens	52-58
17558277-3	2007	The Erk1/2 inhibitor U0126 inhibited both the increase in p-Erk1/2 and the bromodeoxy uridine incorporation.	U 0126	21-26	mitogen activated protein kinase 3	Rattus norvegicus	60-66
17919386-15	2007	U0126 and BUD inhibited the phosphorylation of ERK in the cells stimulated by PDGF-BB of the concentration of 25 microg/L.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	47-50
17409261-9	2007	Treatment with the upstream inhibitor of ERK phosphorylation, U0126, significantly (P &lt; or= 0.01) increased bladder capacity in CYP-treated rats (48 h).	U 0126	62-67	Eph receptor B1	Rattus norvegicus	41-44
17588334-4	2007	The effect of specific mitogen-activated protein kinase (MAPK) inhibitors (PD98059 and U0126) on the VEGF-mediated HDFC proliferation was also determined by MTT assay.	U 0126	87-92	vascular endothelial growth factor A	Homo sapiens	101-105
17581316-6	2007	U0126, an inhibitor against extracellular signal-regulated kinase 1/2, however, only inhibited the STI571-induced interleukin-8 accumulation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	28-78
17581316-6	2007	U0126, an inhibitor against extracellular signal-regulated kinase 1/2, however, only inhibited the STI571-induced interleukin-8 accumulation.	U 0126	0-5	C-X-C motif chemokine ligand 8	Homo sapiens	114-127
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	mitogen-activated protein kinase 3	Homo sapiens	10-16
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	basigin (Ok blood group)	Homo sapiens	20-25
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	mitogen-activated protein kinase 3	Homo sapiens	119-125
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	ATP binding cassette subfamily B member 1	Homo sapiens	164-168
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	matrix metallopeptidase 2	Homo sapiens	170-174
17441962-5	2007	Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly.	U 0126	109-114	matrix metallopeptidase 9	Homo sapiens	179-183
17709622-5	2007	The MEK1/2 inhibitors, PD98059 and U0126, have been shown to inhibit cell growth in other cancers.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
17709622-8	2007	INTERVENTION: We treated PTC cells carrying the RET/PTC1 rearrangement or a BRAF mutation with 2 MEK1/2 inhibitors (PD98059 and U0126).	U 0126	128-133	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	76-80
17709622-8	2007	INTERVENTION: We treated PTC cells carrying the RET/PTC1 rearrangement or a BRAF mutation with 2 MEK1/2 inhibitors (PD98059 and U0126).	U 0126	128-133	mitogen-activated protein kinase kinase 1	Homo sapiens	97-103
17363736-8	2007	MM plasma cells stimulated with IFN-gamma or TLR ligands inhibited cytotoxic T lymphocytes (CTLs) generation and this immunosuppressive effect was inhibited by preincubation with an anti-B7-H1 antibody, the UO126 MEK inhibitor, or by transfection of a dominant-negative mutant of MyD88.	U 0126	207-212	interferon gamma	Homo sapiens	32-41
17363736-8	2007	MM plasma cells stimulated with IFN-gamma or TLR ligands inhibited cytotoxic T lymphocytes (CTLs) generation and this immunosuppressive effect was inhibited by preincubation with an anti-B7-H1 antibody, the UO126 MEK inhibitor, or by transfection of a dominant-negative mutant of MyD88.	U 0126	207-212	CD274 antigen	Mus musculus	187-192
17412314-12	2007	Consequently, alpha2M-induced protein synthesis was inhibited upon treatment with the ERK1,2 inhibitor UO126 as well as by LY294002 and wortmannin, which inhibit PI3-kinase, and by rapamycin, which inhibits mammalian target of rapamycin (mTOR) downstream of Akt.	U 0126	103-108	alpha-2-macroglobulin	Homo sapiens	14-21
17412314-12	2007	Consequently, alpha2M-induced protein synthesis was inhibited upon treatment with the ERK1,2 inhibitor UO126 as well as by LY294002 and wortmannin, which inhibit PI3-kinase, and by rapamycin, which inhibits mammalian target of rapamycin (mTOR) downstream of Akt.	U 0126	103-108	mitogen-activated protein kinase 3	Homo sapiens	86-92
17581202-13	2007	These effects of LTB(4) were suppressed by BLT1 antagonist U75302, pertussis toxin, phosphoinositide-3 kinase (PI3K) inhibitor LY294002 and extracellular signal-regulated kinase (ERK) kinase inhibitor U0126, but not by BLT2 antagonist LY255283.	U 0126	201-206	mitogen-activated protein kinase 1	Homo sapiens	140-177
17581202-14	2007	LTB(4) induced phosphorylation of ERK and Akt, downstream kinase of PI3K; LY294002 suppressed phosphorylation of both kinases while U0126 suppressed only the former.	U 0126	132-137	mitogen-activated protein kinase 1	Homo sapiens	34-37
17581202-14	2007	LTB(4) induced phosphorylation of ERK and Akt, downstream kinase of PI3K; LY294002 suppressed phosphorylation of both kinases while U0126 suppressed only the former.	U 0126	132-137	AKT serine/threonine kinase 1	Homo sapiens	42-45
17458879-8	2007	We also show that the calpain inhibitor PD150606 inhibits calpain with a K(i) of 12.5 muM and show that Mek inhibitors PD89059 and U0126 also suppress calpain activity.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
17620438-5	2007	We further found that U0126 down-regulated exogenous P-gp expression in the MDR1-transduced human breast cancer cells, MCF-7/MDR and MDA-MB-231/MDR.	U 0126	22-27	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
17591863-11	2007	Preincubation with U0126 abolished carbachol-induced p42/44 MAPK activation and cell proliferation.	U 0126	19-24	cyclin dependent kinase 20	Homo sapiens	53-56
17620438-3	2007	In our present study, we found that FTI-277 (a farnesyltransferase inhibitor), U0126 [an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)], and 17-allylamino-17-demethoxygeldanamycin (an inhibitor of heat shock protein 90) reduced the endogenous expression levels of P-gp in the human colorectal cancer cells, HCT-15 and SW620-14.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	174-177
17620438-3	2007	In our present study, we found that FTI-277 (a farnesyltransferase inhibitor), U0126 [an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)], and 17-allylamino-17-demethoxygeldanamycin (an inhibitor of heat shock protein 90) reduced the endogenous expression levels of P-gp in the human colorectal cancer cells, HCT-15 and SW620-14.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	187-190
17620438-5	2007	We further found that U0126 down-regulated exogenous P-gp expression in the MDR1-transduced human breast cancer cells, MCF-7/MDR and MDA-MB-231/MDR.	U 0126	22-27	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
17620438-9	2007	Pulse-chase analysis revealed that U0126 promoted P-gp degradation but did not affect the biosynthesis of this gene product.	U 0126	35-40	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
17620438-10	2007	The pretreatment of cells with U0126 enhanced the paclitaxel-induced cleavage of poly(ADP-ribose) polymerase and paclitaxel sensitivity.	U 0126	31-36	poly(ADP-ribose) polymerase 1	Homo sapiens	81-108
17524662-6	2007	These effects of endotoxin were prevented by selective inhibition of ERK1/2 phosphorylation by MAPK kinase (MEK1/2) with U0126 (5 mg kg(-1), i.p.	U 0126	121-126	mitogen activated protein kinase 3	Rattus norvegicus	69-75
17524662-6	2007	These effects of endotoxin were prevented by selective inhibition of ERK1/2 phosphorylation by MAPK kinase (MEK1/2) with U0126 (5 mg kg(-1), i.p.	U 0126	121-126	mitogen activated protein kinase kinase 1	Rattus norvegicus	108-114
17524662-8	2007	Endotoxin also caused an increase in protein levels of phosphorylated ERK1/2 in aorta which was abolished by U0126.	U 0126	109-114	mitogen activated protein kinase 3	Rattus norvegicus	70-76
17524662-11	2007	Myeloperoxidase activity was increased in aorta and decreased in mesenteric artery by endotoxin, which was reversed by U0126.	U 0126	119-124	myeloperoxidase	Rattus norvegicus	0-15
17953842-3	2007	After being treated by the specific ERK/MAPK pathway inhibitor U0126, Western blot technique was used to analyze the alterations of the expression of P-gp, MRP1, LRP and HIF-1alpha at protein level.	U 0126	63-68	mitogen-activated protein kinase 1	Homo sapiens	36-39
17953842-3	2007	After being treated by the specific ERK/MAPK pathway inhibitor U0126, Western blot technique was used to analyze the alterations of the expression of P-gp, MRP1, LRP and HIF-1alpha at protein level.	U 0126	63-68	hypoxia inducible factor 1 subunit alpha	Homo sapiens	170-180
17953842-3	2007	After being treated by the specific ERK/MAPK pathway inhibitor U0126, Western blot technique was used to analyze the alterations of the expression of P-gp, MRP1, LRP and HIF-1alpha at protein level.	U 0126	63-68	phosphoglycolate phosphatase	Homo sapiens	150-154
17953842-5	2007	Cellular location of HIF-1alpha protein was determined by immunocytochemistry after being treated by U0126.	U 0126	101-106	hypoxia inducible factor 1 subunit alpha	Homo sapiens	21-31
17953842-7	2007	After being treated by U0126 for 12 h, the expressions of mdr1, MRP1, LRP genes and protein in those cells were decreased to some extent.	U 0126	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
17953842-3	2007	After being treated by the specific ERK/MAPK pathway inhibitor U0126, Western blot technique was used to analyze the alterations of the expression of P-gp, MRP1, LRP and HIF-1alpha at protein level.	U 0126	63-68	ATP binding cassette subfamily C member 1	Homo sapiens	156-160
17953842-7	2007	After being treated by U0126 for 12 h, the expressions of mdr1, MRP1, LRP genes and protein in those cells were decreased to some extent.	U 0126	23-28	ATP binding cassette subfamily C member 1	Homo sapiens	64-68
17953842-7	2007	After being treated by U0126 for 12 h, the expressions of mdr1, MRP1, LRP genes and protein in those cells were decreased to some extent.	U 0126	23-28	LDL receptor related protein 1	Homo sapiens	70-73
17953842-9	2007	HIF-1alpha protein was reversely translocated into cytoplasm from nucleus after being treated by U0126.	U 0126	97-102	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
17953842-3	2007	After being treated by the specific ERK/MAPK pathway inhibitor U0126, Western blot technique was used to analyze the alterations of the expression of P-gp, MRP1, LRP and HIF-1alpha at protein level.	U 0126	63-68	LDL receptor related protein 1	Homo sapiens	162-165
17467686-6	2007	LY294002 (a specific inhibitor of PI3K) abolished KL-dependent PGC migration or the chemoattractant activity of the conditioned medium and inhibited AKT phosphorylation; Src kinase inhibitors PP2 and SU6656, caused significant reduction of the KL-dependent PGC migration and AKT phosphorylation, while U0126, a selective inhibitor of the MEK/ERK protein kinase cascade, reduced PGC migration and AKT phosphorylation at lesser extent.	U 0126	302-307	kit ligand	Mus musculus	50-52
17451670-0	2007	The MEK inhibitor, U0126, alters fertilization-induced [Ca2+]i oscillation parameters and secretion: differential effects associated with in vivo and in vitro meiotic maturation.	U 0126	19-24	midkine	Mus musculus	4-7
17482227-10	2007	Treatment with PD 98059 or U 0126, inhibitors of the MAP/ERK (MEK) pathway, prevented the 2244-TCB-mediated activation of ERK but had no effect on COX-2 induction or p38 phosphorylation.	U 0126	27-33	mitogen-activated protein kinase kinase 7	Homo sapiens	53-60
17575121-6	2007	This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results.	U 0126	181-186	mitogen-activated protein kinase 1	Homo sapiens	55-92
17575121-6	2007	This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results.	U 0126	181-186	mitogen-activated protein kinase 1	Homo sapiens	94-97
17575121-6	2007	This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results.	U 0126	181-186	mitogen-activated protein kinase kinase 7	Homo sapiens	125-164
17575121-6	2007	This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results.	U 0126	181-186	mitogen-activated protein kinase kinase 7	Homo sapiens	166-169
17482227-10	2007	Treatment with PD 98059 or U 0126, inhibitors of the MAP/ERK (MEK) pathway, prevented the 2244-TCB-mediated activation of ERK but had no effect on COX-2 induction or p38 phosphorylation.	U 0126	27-33	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
17482227-10	2007	Treatment with PD 98059 or U 0126, inhibitors of the MAP/ERK (MEK) pathway, prevented the 2244-TCB-mediated activation of ERK but had no effect on COX-2 induction or p38 phosphorylation.	U 0126	27-33	mitogen-activated protein kinase 1	Homo sapiens	57-60
17308007-8	2007	MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P&lt;0.01), and spontaneous tone (P&lt;0.01) in HT.	U 0126	88-94	mitogen activated protein kinase 3	Rattus norvegicus	5-11
17308007-8	2007	MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P&lt;0.01), and spontaneous tone (P&lt;0.01) in HT.	U 0126	88-94	mitogen activated protein kinase kinase 1	Rattus norvegicus	13-19
17308007-8	2007	MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P&lt;0.01), and spontaneous tone (P&lt;0.01) in HT.	U 0126	88-94	mitogen activated protein kinase 3	Rattus norvegicus	21-27
17308007-8	2007	MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P&lt;0.01), and spontaneous tone (P&lt;0.01) in HT.	U 0126	88-94	mitogen activated protein kinase 3	Rattus norvegicus	21-27
17308007-11	2007	These data suggest that inhibition of ERK1/2 signaling pathway, via PD-98059 or U-0126, may regulate spontaneous tone in an endothelium-dependent manner.	U 0126	80-86	mitogen activated protein kinase 3	Rattus norvegicus	38-44
17329596-5	2007	An inhibitor of phosphoinositide-3-kinase (PIK3), LY 294002, significantly (P &lt; 0.05) reduced the IGF1-enhanced phosphorylation of AKT, and inhibitors of AKT (SH6) and MAPK3/1 (U0126) significantly (P &lt; 0.05) decreased the synthesis and retention of HA stimulated by concomitant exposure of OCCs to both FSH and IGF1.	U 0126	180-185	insulin like growth factor 1	Sus scrofa	101-105
17322281-6	2007	Exposure of C10 lung epithelial cells to crocidolite asbestos led to rapid CREB phosphorylation and apoptosis that was decreased by the inhibition of PKA or ERK1/2 using the specific inhibitors H89 and U0126, respectively.	U 0126	202-207	gene rich cluster, C10 gene	Mus musculus	12-15
17329596-5	2007	An inhibitor of phosphoinositide-3-kinase (PIK3), LY 294002, significantly (P &lt; 0.05) reduced the IGF1-enhanced phosphorylation of AKT, and inhibitors of AKT (SH6) and MAPK3/1 (U0126) significantly (P &lt; 0.05) decreased the synthesis and retention of HA stimulated by concomitant exposure of OCCs to both FSH and IGF1.	U 0126	180-185	AKT serine/threonine kinase 1	Sus scrofa	134-137
17368581-3	2007	Furthermore, cell-cell contacts between RIE1-Sca cells were reformed by treatment with a specific MEK inhibitor (U0126), with translocation of ZO1 and beta-catenin to cell-cell contacts, without changes of their expression levels.	U 0126	113-118	tight junction protein 1	Rattus norvegicus	143-146
17303382-9	2007	We then investigated how these two survival signals, ERK1/2 and Akt, are involved in p38 activation by using MEK inhibitor U0126 and PI3K inhibitor LY294002.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	85-88
17368581-3	2007	Furthermore, cell-cell contacts between RIE1-Sca cells were reformed by treatment with a specific MEK inhibitor (U0126), with translocation of ZO1 and beta-catenin to cell-cell contacts, without changes of their expression levels.	U 0126	113-118	catenin beta 1	Rattus norvegicus	151-163
17368581-4	2007	U0126 treatment also increased EGFR phosphorylation in a ligand-independent manner.	U 0126	0-5	epidermal growth factor receptor	Rattus norvegicus	31-35
17368581-5	2007	Pretreatment with EGFR kinase inhibitor abolished U0126 treatment-mediated EGFR phosphorylation, and expression of dominant negative H-Ras N17 allowed EGFR phosphorylation and cell-cell contacts even without U0126 treatment.	U 0126	50-55	epidermal growth factor receptor	Rattus norvegicus	18-22
17368581-5	2007	Pretreatment with EGFR kinase inhibitor abolished U0126 treatment-mediated EGFR phosphorylation, and expression of dominant negative H-Ras N17 allowed EGFR phosphorylation and cell-cell contacts even without U0126 treatment.	U 0126	50-55	epidermal growth factor receptor	Rattus norvegicus	75-79
17368581-5	2007	Pretreatment with EGFR kinase inhibitor abolished U0126 treatment-mediated EGFR phosphorylation, and expression of dominant negative H-Ras N17 allowed EGFR phosphorylation and cell-cell contacts even without U0126 treatment.	U 0126	50-55	epidermal growth factor receptor	Rattus norvegicus	75-79
17368581-6	2007	Furthermore, the expression of a nonphosphorylatable EGFR Y5F mutant abolished U0126-mediated cell-cell contacts.	U 0126	79-84	epidermal growth factor receptor	Rattus norvegicus	53-57
17368581-8	2007	This U0126-mediated reduction in wound healing was further altered either by pretreatment of EGFR kinase inhibitor or expression of H-Ras N17 or EGFR Y5F.	U 0126	5-10	epidermal growth factor receptor	Rattus norvegicus	93-97
17368581-8	2007	This U0126-mediated reduction in wound healing was further altered either by pretreatment of EGFR kinase inhibitor or expression of H-Ras N17 or EGFR Y5F.	U 0126	5-10	epidermal growth factor receptor	Rattus norvegicus	145-149
17388918-4	2007	METHODS: Using a panel of pharmacological inhibitors (BAY 43-9006, PD98059, U0126, wortmannin, LY294002) we inhibited the MAPK and AKT signalling pathways at different levels and evaluated the effects on growth, survival and invasion of melanoma cells in monolayer and organotypic skin culture.	U 0126	76-81	AKT serine/threonine kinase 1	Homo sapiens	131-134
17303384-7	2007	LPS-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha was blocked by helenalin, U0126, SB202190, or SP600125.	U 0126	118-123	nuclear factor kappa B subunit 1	Homo sapiens	32-41
17303384-7	2007	LPS-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha was blocked by helenalin, U0126, SB202190, or SP600125.	U 0126	118-123	NFKB inhibitor alpha	Homo sapiens	78-91
17303384-8	2007	Moreover, the resultant enhancement of VCAM-1 expression increased the adhesion of polymorphonuclear cells to monolayer of HTSMCs which was blocked by pretreatment with helenalin, U0126, or SP600125 prior to LPS exposure.	U 0126	180-185	vascular cell adhesion molecule 1	Homo sapiens	39-45
17303382-10	2007	When tube-forming HUVECs were treated with U0126 or LY294002 during normoxia, the two inhibitors were able to induce apoptosis and activation of p38 and caspase-3 in a relatively short time.	U 0126	43-48	mitogen-activated protein kinase 1	Homo sapiens	145-148
17303382-10	2007	When tube-forming HUVECs were treated with U0126 or LY294002 during normoxia, the two inhibitors were able to induce apoptosis and activation of p38 and caspase-3 in a relatively short time.	U 0126	43-48	caspase 3	Homo sapiens	153-162
17303382-11	2007	U0126 was able to inhibit ERK1/2 activation, but had almost no effect on Akt activation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	26-32
17303384-3	2007	LPS-induced expression of VCAM-1 protein and mRNA in a time-dependent manner, was significantly inhibited by inhibitors of MEK1/2 (U0126), p38 (SB202190), and c-Jun-N-terminal kinase (JNK; SP600125).	U 0126	131-136	vascular cell adhesion molecule 1	Homo sapiens	26-32
17303384-3	2007	LPS-induced expression of VCAM-1 protein and mRNA in a time-dependent manner, was significantly inhibited by inhibitors of MEK1/2 (U0126), p38 (SB202190), and c-Jun-N-terminal kinase (JNK; SP600125).	U 0126	131-136	mitogen-activated protein kinase kinase 1	Homo sapiens	123-129
17303384-5	2007	Consistently, LPS-stimulated phosphorylation of p42/p44 MAPK and p38 was attenuated by pretreatment with U0126 or SB202190, and transfection with these siRNAs, respectively.	U 0126	105-110	cyclin dependent kinase 20	Homo sapiens	48-51
17303384-5	2007	Consistently, LPS-stimulated phosphorylation of p42/p44 MAPK and p38 was attenuated by pretreatment with U0126 or SB202190, and transfection with these siRNAs, respectively.	U 0126	105-110	interferon induced protein 44	Homo sapiens	52-55
17303384-5	2007	Consistently, LPS-stimulated phosphorylation of p42/p44 MAPK and p38 was attenuated by pretreatment with U0126 or SB202190, and transfection with these siRNAs, respectively.	U 0126	105-110	mitogen-activated protein kinase 3	Homo sapiens	56-60
17303384-5	2007	Consistently, LPS-stimulated phosphorylation of p42/p44 MAPK and p38 was attenuated by pretreatment with U0126 or SB202190, and transfection with these siRNAs, respectively.	U 0126	105-110	mitogen-activated protein kinase 14	Homo sapiens	65-68
17212361-6	2007	Blockade of ERK signaling by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, suppressed both glucose- and insulin-induced ERK 1/2 phosphorylation and PSC proliferation.	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	12-15
17460148-8	2007	Exogenous addition of TGF-beta1 activated ERK1/2 and increased TER across MDCK monolayers, both of which were attenuated by the MEK inhibitor U0126.	U 0126	142-147	transforming growth factor beta-1 proprotein	Canis lupus familiaris	22-31
17460148-8	2007	Exogenous addition of TGF-beta1 activated ERK1/2 and increased TER across MDCK monolayers, both of which were attenuated by the MEK inhibitor U0126.	U 0126	142-147	mitogen-activated protein kinase 1	Canis lupus familiaris	42-48
17212361-6	2007	Blockade of ERK signaling by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, suppressed both glucose- and insulin-induced ERK 1/2 phosphorylation and PSC proliferation.	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	142-147
17311298-5	2007	Specifically, a p38 specific inhibitor, SB203580, significantly inhibited stretching-induced osterix expression as well as ALP activity, whereas a specific inhibitor of ERK1/2, U0126, prevented stretching-induced Runx2 expression.	U 0126	177-182	mitogen-activated protein kinase 3	Homo sapiens	169-175
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	interleukin 1 beta	Homo sapiens	0-8
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	erythrocyte membrane protein band 4.2	Homo sapiens	39-42
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 3	Homo sapiens	43-51
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 14	Homo sapiens	53-56
17311298-5	2007	Specifically, a p38 specific inhibitor, SB203580, significantly inhibited stretching-induced osterix expression as well as ALP activity, whereas a specific inhibitor of ERK1/2, U0126, prevented stretching-induced Runx2 expression.	U 0126	177-182	RUNX family transcription factor 2	Homo sapiens	213-218
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 3	Homo sapiens	47-51
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 8	Homo sapiens	67-70
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase kinase 7	Homo sapiens	190-193
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 3	Homo sapiens	195-198
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 14	Homo sapiens	200-203
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	mitogen-activated protein kinase 8	Homo sapiens	208-211
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	121-126	matrix metallopeptidase 9	Homo sapiens	0-5
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	121-126	interleukin 1 beta	Homo sapiens	40-48
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	121-126	matrix metallopeptidase 9	Homo sapiens	76-81
17409139-6	2007	Specific MEK1/2 inhibitors, flavenoid PD98059 and U0126, decreased the basal and TGF-beta1-stimulated Vp-1 expression by 95% or more.	U 0126	50-55	mitogen-activated protein kinase kinase 1	Homo sapiens	9-15
17451740-3	2007	The ERK phosphorylation inhibitors, PD 98059 and U0126, blocked both basal and PTTH-stimulated ERK phosphorylation and ecdysteroidogenesis.	U 0126	49-54	extracellular regulated MAP kinase	Bombyx mori	4-7
17451740-3	2007	The ERK phosphorylation inhibitors, PD 98059 and U0126, blocked both basal and PTTH-stimulated ERK phosphorylation and ecdysteroidogenesis.	U 0126	49-54	prothoracicotropic hormone	Bombyx mori	79-83
17451740-3	2007	The ERK phosphorylation inhibitors, PD 98059 and U0126, blocked both basal and PTTH-stimulated ERK phosphorylation and ecdysteroidogenesis.	U 0126	49-54	extracellular regulated MAP kinase	Bombyx mori	95-98
17409139-6	2007	Specific MEK1/2 inhibitors, flavenoid PD98059 and U0126, decreased the basal and TGF-beta1-stimulated Vp-1 expression by 95% or more.	U 0126	50-55	transforming growth factor beta 1	Homo sapiens	81-90
17636172-6	2007	Androgen production in response to ACTH and hCG was reduced by UO126 and dexamethasone, which are the inhibitors of ERK1/2 and phospholipase A2 respectively.	U 0126	63-68	pro-opiomelanocortin-alpha	Mus musculus	35-39
17636172-6	2007	Androgen production in response to ACTH and hCG was reduced by UO126 and dexamethasone, which are the inhibitors of ERK1/2 and phospholipase A2 respectively.	U 0126	63-68	chorionic gonadotropin subunit beta 5	Homo sapiens	44-47
17636172-6	2007	Androgen production in response to ACTH and hCG was reduced by UO126 and dexamethasone, which are the inhibitors of ERK1/2 and phospholipase A2 respectively.	U 0126	63-68	mitogen-activated protein kinase 3	Mus musculus	116-122
17636172-6	2007	Androgen production in response to ACTH and hCG was reduced by UO126 and dexamethasone, which are the inhibitors of ERK1/2 and phospholipase A2 respectively.	U 0126	63-68	phospholipase A2, group IB, pancreas	Mus musculus	127-143
17369605-14	2007	In addition, the cytotoxicity of microcystin-LR was attenuated by the inhibitors of MAPK pathways, including U0126, SP600125, and SB203580.	U 0126	109-114	mitogen-activated protein kinase 1	Mus musculus	84-88
17523950-6	2007	Further, inhibition of ERK1,2 by its inhibitor, U0126, in dual APL-induced CD4(+)CD25(+) cells, abrogated their ability to suppress interferon (IFN)-gamma secretion by lymph node (LN) cells of mice that were immunized with the myasthenogenic peptide.	U 0126	48-53	mitogen-activated protein kinase 3	Mus musculus	23-29
17523950-6	2007	Further, inhibition of ERK1,2 by its inhibitor, U0126, in dual APL-induced CD4(+)CD25(+) cells, abrogated their ability to suppress interferon (IFN)-gamma secretion by lymph node (LN) cells of mice that were immunized with the myasthenogenic peptide.	U 0126	48-53	CD4 antigen	Mus musculus	75-78
17523950-6	2007	Further, inhibition of ERK1,2 by its inhibitor, U0126, in dual APL-induced CD4(+)CD25(+) cells, abrogated their ability to suppress interferon (IFN)-gamma secretion by lymph node (LN) cells of mice that were immunized with the myasthenogenic peptide.	U 0126	48-53	interferon gamma	Mus musculus	132-154
17353198-5	2007	Inactivation of KRAS activity by a small interfering RNA specific for oncogenic KRAS inhibits GLI activity and GLI1 expression in PDA cell lines with activating KRAS mutation; the MEK inhibitors U0126 and PD98059 elicit a similar response.	U 0126	195-200	KRAS proto-oncogene, GTPase	Homo sapiens	16-20
17452290-6	2007	Interestingly, the PMA-induced CREB phosphorylation was also blocked by a calcium/calmodulin-dependent protein kinase inhibitor KN93 and the two mitogen-activated protein kinase (MAPK) kinase inhibitors PD98059 and U0126, but not by a p38 MAPK inhibitor SB203580.	U 0126	215-220	cAMP responsive element binding protein 1	Rattus norvegicus	31-35
17452290-6	2007	Interestingly, the PMA-induced CREB phosphorylation was also blocked by a calcium/calmodulin-dependent protein kinase inhibitor KN93 and the two mitogen-activated protein kinase (MAPK) kinase inhibitors PD98059 and U0126, but not by a p38 MAPK inhibitor SB203580.	U 0126	215-220	mitogen activated protein kinase 3	Rattus norvegicus	179-183
17385215-6	2007	The effects of dominant-negative MEK1 (DN-MEK1) and MEK-specific inhibitor U0126 on the ERK signaling pathway and expression of XAF1 and XIAP proteins were determined.	U 0126	75-80	mitogen-activated protein kinase 1	Homo sapiens	88-91
17385215-10	2007	RESULTS: U0126 increased the expression of XAF1 in a time- and dose-dependent manner.	U 0126	9-14	XIAP associated factor 1	Homo sapiens	43-47
17385215-13	2007	Activity of the putative promoter of the XAF1 gene was significantly increased by U0126 treatment and DN-MEK1 transient transfection.	U 0126	82-87	XIAP associated factor 1	Homo sapiens	41-45
17385215-15	2007	Overexpression of XAF1 was more sensitive to U0126-induced apoptosis, whereas down-regulation of XAF1 by antisense reversed U0126-induced inhibition of cell proliferation.	U 0126	45-50	XIAP associated factor 1	Homo sapiens	18-22
17385215-15	2007	Overexpression of XAF1 was more sensitive to U0126-induced apoptosis, whereas down-regulation of XAF1 by antisense reversed U0126-induced inhibition of cell proliferation.	U 0126	124-129	XIAP associated factor 1	Homo sapiens	97-101
17475844-8	2007	Blocking the activation of ERK1/2 with U0126 reduced the enhanced IL-10 production by the TLR4,2-primed DCs upon the TLR4 restimulation.	U 0126	39-44	mitogen-activated protein kinase 3	Mus musculus	27-33
17475844-8	2007	Blocking the activation of ERK1/2 with U0126 reduced the enhanced IL-10 production by the TLR4,2-primed DCs upon the TLR4 restimulation.	U 0126	39-44	interleukin 10	Mus musculus	66-71
17475844-8	2007	Blocking the activation of ERK1/2 with U0126 reduced the enhanced IL-10 production by the TLR4,2-primed DCs upon the TLR4 restimulation.	U 0126	39-44	toll-like receptor 4	Mus musculus	90-94
17475844-8	2007	Blocking the activation of ERK1/2 with U0126 reduced the enhanced IL-10 production by the TLR4,2-primed DCs upon the TLR4 restimulation.	U 0126	39-44	toll-like receptor 4	Mus musculus	117-121
17353198-4	2007	Oncogenic KRAS transformation of human pancreatic ductal epithelial cells increases GLI transcriptional activity, an effect that is inhibited by the MEK-specific inhibitors U0126 and PD98059, but not by the PI3K-specific inhibitor wortmannin.	U 0126	173-178	KRAS proto-oncogene, GTPase	Homo sapiens	10-14
17353198-4	2007	Oncogenic KRAS transformation of human pancreatic ductal epithelial cells increases GLI transcriptional activity, an effect that is inhibited by the MEK-specific inhibitors U0126 and PD98059, but not by the PI3K-specific inhibitor wortmannin.	U 0126	173-178	GLI family zinc finger 1	Homo sapiens	84-87
17353198-4	2007	Oncogenic KRAS transformation of human pancreatic ductal epithelial cells increases GLI transcriptional activity, an effect that is inhibited by the MEK-specific inhibitors U0126 and PD98059, but not by the PI3K-specific inhibitor wortmannin.	U 0126	173-178	mitogen-activated protein kinase kinase 7	Homo sapiens	149-152
17244894-5	2007	MAPK inhibitors including U-0126 and SP-600125, but not SB-203580, suppressed aldosterone-induced cellular DNA synthesis, implying that ERK1/2 and SAPK/JNK pathways play crucial roles in mesangial cell proliferation.	U 0126	26-32	mitogen-activated protein kinase 3	Mus musculus	136-142
17244894-5	2007	MAPK inhibitors including U-0126 and SP-600125, but not SB-203580, suppressed aldosterone-induced cellular DNA synthesis, implying that ERK1/2 and SAPK/JNK pathways play crucial roles in mesangial cell proliferation.	U 0126	26-32	mitogen-activated protein kinase 8	Mus musculus	152-155
17516844-6	2007	The inhibition of this pathway by the MEK inhibitor UO126 led to a strong decrease in EGR1 expression in MCF7/KEPI cells.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
17516844-6	2007	The inhibition of this pathway by the MEK inhibitor UO126 led to a strong decrease in EGR1 expression in MCF7/KEPI cells.	U 0126	52-57	early growth response 1	Homo sapiens	86-90
17516844-6	2007	The inhibition of this pathway by the MEK inhibitor UO126 led to a strong decrease in EGR1 expression in MCF7/KEPI cells.	U 0126	52-57	protein phosphatase 1 regulatory inhibitor subunit 14C	Homo sapiens	110-114
17074386-5	2007	In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	18-21
17074386-5	2007	In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	56-59
17074386-5	2007	In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation.	U 0126	39-44	cAMP responsive element binding protein 1	Mus musculus	109-113
17074386-5	2007	In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation.	U 0126	39-44	cAMP responsive element binding protein 1	Mus musculus	178-182
17074386-5	2007	In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation.	U 0126	39-44	mitogen-activated protein kinase 1	Mus musculus	56-59
17331500-9	2007	Moreover, TGF-beta2-induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen-activated protein (MAP) kinase (MEK) (U0126), p38 (SB202190), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase (PTK) (Genistein), and phosphatidylinositol 3-kinase (PI3K) (Ly294002).	U 0126	136-141	transforming growth factor beta 2	Homo sapiens	10-19
17331500-9	2007	Moreover, TGF-beta2-induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen-activated protein (MAP) kinase (MEK) (U0126), p38 (SB202190), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase (PTK) (Genistein), and phosphatidylinositol 3-kinase (PI3K) (Ly294002).	U 0126	136-141	vascular endothelial growth factor A	Homo sapiens	32-36
17331500-9	2007	Moreover, TGF-beta2-induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen-activated protein (MAP) kinase (MEK) (U0126), p38 (SB202190), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase (PTK) (Genistein), and phosphatidylinositol 3-kinase (PI3K) (Ly294002).	U 0126	136-141	mitogen-activated protein kinase kinase 7	Homo sapiens	130-133
17306348-6	2007	Treatment with MEK inhibitor(U0126) resulted in a reduced MDM2 level, enhanced p53 and p21 levels and inhibited cell growth by the induction of premature senescence.	U 0126	29-34	midkine	Mus musculus	15-18
17306348-6	2007	Treatment with MEK inhibitor(U0126) resulted in a reduced MDM2 level, enhanced p53 and p21 levels and inhibited cell growth by the induction of premature senescence.	U 0126	29-34	transformed mouse 3T3 cell double minute 2	Mus musculus	58-62
17306348-6	2007	Treatment with MEK inhibitor(U0126) resulted in a reduced MDM2 level, enhanced p53 and p21 levels and inhibited cell growth by the induction of premature senescence.	U 0126	29-34	transformation related protein 53, pseudogene	Mus musculus	79-82
17306348-6	2007	Treatment with MEK inhibitor(U0126) resulted in a reduced MDM2 level, enhanced p53 and p21 levels and inhibited cell growth by the induction of premature senescence.	U 0126	29-34	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	87-90
17470518-6	2007	AGE-stimulated 8-isoprostane, cytokine and prostaglandin production was significantly suppressed by the ERK 1/2 inhibitor U0126 and the NF-kappaB inhibitor BAY 11-7082.	U 0126	122-127	mitogen-activated protein kinase 3	Homo sapiens	104-111
17314319-4	2007	On the other hand, inhibition by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) of an HGF downstream kinase mitogen-activated protein kinase kinase (MEK) induced the Cyp2b10 gene and up-regulated the CAR-regulated promoter activity in the absence of TCPOBOP.	U 0126	87-92	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	180-187
17314319-4	2007	On the other hand, inhibition by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) of an HGF downstream kinase mitogen-activated protein kinase kinase (MEK) induced the Cyp2b10 gene and up-regulated the CAR-regulated promoter activity in the absence of TCPOBOP.	U 0126	87-92	nuclear receptor subfamily 1, group I, member 3	Mus musculus	214-217
17314319-6	2007	In contrast, U0126 dephosphorylated ERK1/2 and increased nuclear CAR accumulation in the absence of TCPOBOP.	U 0126	13-18	mitogen-activated protein kinase 3	Mus musculus	36-42
17314319-6	2007	In contrast, U0126 dephosphorylated ERK1/2 and increased nuclear CAR accumulation in the absence of TCPOBOP.	U 0126	13-18	nuclear receptor subfamily 1, group I, member 3	Mus musculus	65-68
17374366-4	2007	Butyrate-stimulated MUC2 production in the LS174T cells was inhibited by the MEK inhibitor, U0126, implicating the involvement of extracellular signal-regulated kinase (ERK) cascades in this process.	U 0126	92-97	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	20-24
17374366-4	2007	Butyrate-stimulated MUC2 production in the LS174T cells was inhibited by the MEK inhibitor, U0126, implicating the involvement of extracellular signal-regulated kinase (ERK) cascades in this process.	U 0126	92-97	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
17374366-4	2007	Butyrate-stimulated MUC2 production in the LS174T cells was inhibited by the MEK inhibitor, U0126, implicating the involvement of extracellular signal-regulated kinase (ERK) cascades in this process.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	130-167
17374366-4	2007	Butyrate-stimulated MUC2 production in the LS174T cells was inhibited by the MEK inhibitor, U0126, implicating the involvement of extracellular signal-regulated kinase (ERK) cascades in this process.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	169-172
17363128-8	2007	Troglitazone-induced cell death was increased by the ERK inhibitor U0126 and prevented by transfection with constitutively active MEK1 and the p38 inhibitor SB203580.	U 0126	67-72	mitogen-activated protein kinase 1	Mus musculus	53-56
17146445-11	2007	Pretreatment of U-1242-PKC-eta cells with inhibitors of PKC or MAPK/ERK kinase (MEK) (bisindolyl maleimide (BIM) or U0126, respectively) blocked both PMA-induced Elk-1 transcriptional activity and PMA-stimulated proliferation.	U 0126	116-121	ETS transcription factor ELK1	Homo sapiens	162-167
17197157-5	2007	Inhibition of mitogen-activated protein kinase kinase-1 (MEK1) with either PD98059 or UO126, however, results in a substantial dose-dependent inhibition of SMAD3 promoter activity.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	14-55
17197157-5	2007	Inhibition of mitogen-activated protein kinase kinase-1 (MEK1) with either PD98059 or UO126, however, results in a substantial dose-dependent inhibition of SMAD3 promoter activity.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	57-61
17197157-5	2007	Inhibition of mitogen-activated protein kinase kinase-1 (MEK1) with either PD98059 or UO126, however, results in a substantial dose-dependent inhibition of SMAD3 promoter activity.	U 0126	86-91	SMAD family member 3	Homo sapiens	156-161
17376416-7	2007	The reduced expressions of MMP-2 and u-PA, as well as inhibition of cell invasion were obtained in the cultures treated with U0126 (ERK 1/2 inhibitor) and SB203580 (p38(MAPK) inhibitor).	U 0126	125-130	matrix metallopeptidase 2	Mus musculus	27-32
17376416-7	2007	The reduced expressions of MMP-2 and u-PA, as well as inhibition of cell invasion were obtained in the cultures treated with U0126 (ERK 1/2 inhibitor) and SB203580 (p38(MAPK) inhibitor).	U 0126	125-130	plasminogen activator, urokinase	Mus musculus	37-41
17376416-7	2007	The reduced expressions of MMP-2 and u-PA, as well as inhibition of cell invasion were obtained in the cultures treated with U0126 (ERK 1/2 inhibitor) and SB203580 (p38(MAPK) inhibitor).	U 0126	125-130	mitogen-activated protein kinase 3	Mus musculus	132-139
17303666-8	2007	Furthermore, only the E2-BSA-induced NOS III phosphorylation on Ser(1179) was totally abolished by UO126.	U 0126	99-104	nitric oxide synthase 3	Rattus norvegicus	37-44
17171644-7	2007	The specific chemical inhibitors LY294002 (PI3K), PP2 (Src), U0126 (MAPK-ERK kinase (MEK)/ERK), and SP600125 (JNK) effectively suppressed cell fusion, although SB203580 (p38) did not.	U 0126	61-66	mitogen-activated protein kinase 14	Mus musculus	170-173
17442973-10	2007	U0126, an inhibitor of p44/42 MAPK, significantly abolished these effects.	U 0126	0-5	interferon-induced protein 44	Mus musculus	23-26
17241117-6	2007	By contrast, glutamate induced a strong phosphorylation of histone H3 that was inhibited by selective inhibitors of the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38 MAPK) pathways, U0126 and SB203580, respectively.	U 0126	226-231	mitogen-activated protein kinase 1	Mus musculus	159-162
17353198-5	2007	Inactivation of KRAS activity by a small interfering RNA specific for oncogenic KRAS inhibits GLI activity and GLI1 expression in PDA cell lines with activating KRAS mutation; the MEK inhibitors U0126 and PD98059 elicit a similar response.	U 0126	195-200	mitogen-activated protein kinase kinase 7	Homo sapiens	180-183
17349975-6	2007	Furthermore, U0126, an inhibitor of MEK1, and DN-MEK partially abrogated the G2 delay, indicating that activation of MEK-ERK pathway is involved.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	36-40
17349975-6	2007	Furthermore, U0126, an inhibitor of MEK1, and DN-MEK partially abrogated the G2 delay, indicating that activation of MEK-ERK pathway is involved.	U 0126	13-18	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
17464189-2	2007	In this study we found that treatment of PMA-induced K562 cells with Go6976, a specific inhibitor of PKC, and U0126, an inhibitor of the extracellular signal-regulated kinase (ERK) reduced expression of GM3 synthase, whereas wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K) did not.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	137-174
17349975-6	2007	Furthermore, U0126, an inhibitor of MEK1, and DN-MEK partially abrogated the G2 delay, indicating that activation of MEK-ERK pathway is involved.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	121-124
17464189-2	2007	In this study we found that treatment of PMA-induced K562 cells with Go6976, a specific inhibitor of PKC, and U0126, an inhibitor of the extracellular signal-regulated kinase (ERK) reduced expression of GM3 synthase, whereas wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K) did not.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	176-179
17464189-2	2007	In this study we found that treatment of PMA-induced K562 cells with Go6976, a specific inhibitor of PKC, and U0126, an inhibitor of the extracellular signal-regulated kinase (ERK) reduced expression of GM3 synthase, whereas wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K) did not.	U 0126	110-115	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	203-215
17209135-4	2007	The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126.	U 0126	306-311	elastin	Homo sapiens	17-24
17464189-3	2007	Moreover, activation of ERK and cAMP response element binding protein (CREB) was prevented by pretreatment with Go6976 and U0126.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	24-27
17464189-3	2007	Moreover, activation of ERK and cAMP response element binding protein (CREB) was prevented by pretreatment with Go6976 and U0126.	U 0126	123-128	cAMP responsive element binding protein 1	Homo sapiens	32-69
17464189-3	2007	Moreover, activation of ERK and cAMP response element binding protein (CREB) was prevented by pretreatment with Go6976 and U0126.	U 0126	123-128	cAMP responsive element binding protein 1	Homo sapiens	71-75
17464189-4	2007	PMA stimulated the promoter activity of the 5"-flanking region from -177 to -83 region of the GM3 synthase gene, and mutation or deletion of a CREB site located around -143 of the promoter reduced PMA-stimulated promoter activity, as did the inhibitors Go6976 and U0126.	U 0126	264-269	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	94-106
17464189-4	2007	PMA stimulated the promoter activity of the 5"-flanking region from -177 to -83 region of the GM3 synthase gene, and mutation or deletion of a CREB site located around -143 of the promoter reduced PMA-stimulated promoter activity, as did the inhibitors Go6976 and U0126.	U 0126	264-269	cAMP responsive element binding protein 1	Homo sapiens	143-147
17317670-10	2007	CDA1 induces phosphorylation of ERK1/2(p44/42), an activity blocked by PD98059 and U0126, inhibitors of the upstream kinase MEK1/2.	U 0126	83-88	TSPY like 2	Homo sapiens	0-4
17317670-10	2007	CDA1 induces phosphorylation of ERK1/2(p44/42), an activity blocked by PD98059 and U0126, inhibitors of the upstream kinase MEK1/2.	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	32-38
17317670-10	2007	CDA1 induces phosphorylation of ERK1/2(p44/42), an activity blocked by PD98059 and U0126, inhibitors of the upstream kinase MEK1/2.	U 0126	83-88	interferon induced protein 44	Homo sapiens	39-42
17317670-10	2007	CDA1 induces phosphorylation of ERK1/2(p44/42), an activity blocked by PD98059 and U0126, inhibitors of the upstream kinase MEK1/2.	U 0126	83-88	mitogen-activated protein kinase kinase 1	Homo sapiens	124-130
17131361-5	2007	Both the SPC-induced cell death and ERK activation were abolished by pretreatment of the cells with the MEK inhibitor U0126 or by overexpression of a dominant negative mutant of MEK1 (DN-MEK1).	U 0126	118-123	mitogen-activated protein kinase 1	Homo sapiens	36-39
17131361-5	2007	Both the SPC-induced cell death and ERK activation were abolished by pretreatment of the cells with the MEK inhibitor U0126 or by overexpression of a dominant negative mutant of MEK1 (DN-MEK1).	U 0126	118-123	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
17460567-8	2007	The MEK inhibitor U0126 and reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor diphenyleneiodonium effectively protected the cells against hypothermia injury.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
16932918-4	2007	U0126, a specific inhibitor of extracellular signal-regulated protein kinase (ERK) kinase, suppressed the elevation of caspase-3 activities as well as that of sub-G(1) population.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	31-76
16932918-4	2007	U0126, a specific inhibitor of extracellular signal-regulated protein kinase (ERK) kinase, suppressed the elevation of caspase-3 activities as well as that of sub-G(1) population.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	78-81
16932918-4	2007	U0126, a specific inhibitor of extracellular signal-regulated protein kinase (ERK) kinase, suppressed the elevation of caspase-3 activities as well as that of sub-G(1) population.	U 0126	0-5	caspase 3	Homo sapiens	119-128
17286604-6	2007	Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126, or by RNA interference, rapidly caused the loss of self-renewal capacity.	U 0126	70-75	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
17286604-6	2007	Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126, or by RNA interference, rapidly caused the loss of self-renewal capacity.	U 0126	70-75	mitogen-activated protein kinase 1	Homo sapiens	18-21
17286604-6	2007	Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126, or by RNA interference, rapidly caused the loss of self-renewal capacity.	U 0126	70-75	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
17393467-7	2007	In ERK1-deficient hepatocytes, silencing ERK2 expression by RNA interference and ERK2 activation by U0126 clearly demonstrate that DNA replication is regulated by an ERK2-dependent mechanism.	U 0126	100-105	mitogen activated protein kinase 1	Rattus norvegicus	81-85
17393467-7	2007	In ERK1-deficient hepatocytes, silencing ERK2 expression by RNA interference and ERK2 activation by U0126 clearly demonstrate that DNA replication is regulated by an ERK2-dependent mechanism.	U 0126	100-105	mitogen activated protein kinase 1	Rattus norvegicus	81-85
17131384-5	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at 10 and 1 microM, respectively, inhibited basal and EGF-induced ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	33-38	mitogen-activated protein kinase kinase 1	Homo sapiens	15-21
17131384-5	2007	Both synthetic MEK1/2 inhibitors U0126 and Cl-1040, when used at 10 and 1 microM, respectively, inhibited basal and EGF-induced ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	128-134
17131384-8	2007	The EGF-mediated time-dependent induction of MKP-3, MKP-1 and DUSP5 mRNA levels was U0126-sensitive at a concentration, which blocked EGF-mediated ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	84-89	dual specificity phosphatase 6	Homo sapiens	45-50
17131384-8	2007	The EGF-mediated time-dependent induction of MKP-3, MKP-1 and DUSP5 mRNA levels was U0126-sensitive at a concentration, which blocked EGF-mediated ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	84-89	dual specificity phosphatase 1	Homo sapiens	52-57
17131384-8	2007	The EGF-mediated time-dependent induction of MKP-3, MKP-1 and DUSP5 mRNA levels was U0126-sensitive at a concentration, which blocked EGF-mediated ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	84-89	dual specificity phosphatase 5	Homo sapiens	62-67
17131384-8	2007	The EGF-mediated time-dependent induction of MKP-3, MKP-1 and DUSP5 mRNA levels was U0126-sensitive at a concentration, which blocked EGF-mediated ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	147-153
17314319-4	2007	On the other hand, inhibition by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) of an HGF downstream kinase mitogen-activated protein kinase kinase (MEK) induced the Cyp2b10 gene and up-regulated the CAR-regulated promoter activity in the absence of TCPOBOP.	U 0126	87-92	hepatocyte growth factor	Mus musculus	100-103
17314319-4	2007	On the other hand, inhibition by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) of an HGF downstream kinase mitogen-activated protein kinase kinase (MEK) induced the Cyp2b10 gene and up-regulated the CAR-regulated promoter activity in the absence of TCPOBOP.	U 0126	87-92	midkine	Mus musculus	122-161
17314319-4	2007	On the other hand, inhibition by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) of an HGF downstream kinase mitogen-activated protein kinase kinase (MEK) induced the Cyp2b10 gene and up-regulated the CAR-regulated promoter activity in the absence of TCPOBOP.	U 0126	87-92	midkine	Mus musculus	163-166
17353005-7	2007	Further study shows that the apoE isoform-dependent variations of TNF-alpha and IL-6 expression/secretion in macrophages are diminished in the presence of ERK1/2 inhibitor U0126.	U 0126	172-177	apolipoprotein E	Homo sapiens	29-33
17353005-7	2007	Further study shows that the apoE isoform-dependent variations of TNF-alpha and IL-6 expression/secretion in macrophages are diminished in the presence of ERK1/2 inhibitor U0126.	U 0126	172-177	tumor necrosis factor	Homo sapiens	66-75
17353005-7	2007	Further study shows that the apoE isoform-dependent variations of TNF-alpha and IL-6 expression/secretion in macrophages are diminished in the presence of ERK1/2 inhibitor U0126.	U 0126	172-177	interleukin 6	Homo sapiens	80-84
17353005-7	2007	Further study shows that the apoE isoform-dependent variations of TNF-alpha and IL-6 expression/secretion in macrophages are diminished in the presence of ERK1/2 inhibitor U0126.	U 0126	172-177	mitogen-activated protein kinase 3	Homo sapiens	155-161
17284251-7	2007	The formation of GFP-SUMO-1 foci was reduced by a MEK inhibitor U0126 or a nuclear export inhibitor leptomycin B, and endogenous SUMO-1 foci were reduced in K562 cells expressing the dominant-negative MEK1 mutant.	U 0126	64-69	small ubiquitin like modifier 1	Homo sapiens	21-27
17284251-7	2007	The formation of GFP-SUMO-1 foci was reduced by a MEK inhibitor U0126 or a nuclear export inhibitor leptomycin B, and endogenous SUMO-1 foci were reduced in K562 cells expressing the dominant-negative MEK1 mutant.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	50-53
17284251-7	2007	The formation of GFP-SUMO-1 foci was reduced by a MEK inhibitor U0126 or a nuclear export inhibitor leptomycin B, and endogenous SUMO-1 foci were reduced in K562 cells expressing the dominant-negative MEK1 mutant.	U 0126	64-69	small ubiquitin like modifier 1	Homo sapiens	129-135
17218409-9	2007	Short-term VP and LP cultures with FgfR antagonist PD173074 and Mek inhibitor U0126 identified epithelial Shh and Hoxb13 up-regulation by androgens to be Fgf10-dependent.	U 0126	78-83	sonic hedgehog signaling molecule	Rattus norvegicus	106-109
17218409-9	2007	Short-term VP and LP cultures with FgfR antagonist PD173074 and Mek inhibitor U0126 identified epithelial Shh and Hoxb13 up-regulation by androgens to be Fgf10-dependent.	U 0126	78-83	fibroblast growth factor 10	Rattus norvegicus	154-159
17091294-5	2007	The animals received 100 mg/kg intraperitoneally of the MEK1/2 inhibitor U0126 or vehicle in conjunction with the occlusion.	U 0126	73-78	mitogen activated protein kinase kinase 1	Rattus norvegicus	56-62
17091294-12	2007	Immunohistochemistry showed that there were lower protein levels of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated transcription factor Elk-1 in the U0126-treated rats compared to control.	U 0126	184-189	mitogen activated protein kinase 3	Rattus norvegicus	83-130
17091294-12	2007	Immunohistochemistry showed that there were lower protein levels of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated transcription factor Elk-1 in the U0126-treated rats compared to control.	U 0126	184-189	ETS transcription factor ELK1	Rattus norvegicus	171-176
17091294-13	2007	The results show that treatment with the MEK1/2 inhibitor U0126 in ischaemic stroke decreases brain damage, neurological symptoms, and ET receptor alteration.	U 0126	58-63	mitogen activated protein kinase kinase 1	Rattus norvegicus	41-47
17091294-14	2007	The vascular effects of U0126 provide new perspective on possible mechanisms of actions of MAPK inhibition in cerebral ischaemia.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	91-95
17591071-8	2007	Treatment with rapamycin resulted in enhanced phosphorylation of AKT, and phosphorylation of AKT was induced by pAxCAHGF plus U0126.	U 0126	126-131	AKT serine/threonine kinase 1	Rattus norvegicus	93-96
17131384-8	2007	The EGF-mediated time-dependent induction of MKP-3, MKP-1 and DUSP5 mRNA levels was U0126-sensitive at a concentration, which blocked EGF-mediated ERK1/2 phosphorylation but not ERK5 phosphorylation.	U 0126	84-89	mitogen-activated protein kinase 7	Homo sapiens	178-182
17131384-9	2007	Furthermore, U0126 inhibited EGF-induced MKP-3 and MKP-1 protein expression.	U 0126	13-18	dual specificity phosphatase 6	Homo sapiens	41-46
17219412-10	2007	Treatment of confluent MDCK cells with PD98059 and UO126, the inhibitors of MEK, enhanced apoptosis as well as activity of caspase-8.	U 0126	51-56	caspase 8	Canis lupus familiaris	123-132
17294242-6	2007	RESULTS: Cyclopamine decreased cell proliferation and arrested the cell cycle at the G1 phase, while U0126 decreased the proliferation of CCA cells with KRAS mutation stronger than with wild-type KRAS.	U 0126	101-106	KRAS proto-oncogene, GTPase	Homo sapiens	153-157
17294242-6	2007	RESULTS: Cyclopamine decreased cell proliferation and arrested the cell cycle at the G1 phase, while U0126 decreased the proliferation of CCA cells with KRAS mutation stronger than with wild-type KRAS.	U 0126	101-106	KRAS proto-oncogene, GTPase	Homo sapiens	196-200
17209135-4	2007	The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126.	U 0126	306-311	transforming growth factor beta 1	Homo sapiens	54-62
17400803-6	2007	Inhibition of ERK1/2 activity by U0126 decreased PMA-treated StAR expression but increased dbcAMP/hCG-mediated StAR and P-StAR; however, progesterone levels were attenuated.	U 0126	33-38	mitogen-activated protein kinase 3	Mus musculus	14-20
17400803-6	2007	Inhibition of ERK1/2 activity by U0126 decreased PMA-treated StAR expression but increased dbcAMP/hCG-mediated StAR and P-StAR; however, progesterone levels were attenuated.	U 0126	33-38	steroidogenic acute regulatory protein	Mus musculus	61-65
17400803-6	2007	Inhibition of ERK1/2 activity by U0126 decreased PMA-treated StAR expression but increased dbcAMP/hCG-mediated StAR and P-StAR; however, progesterone levels were attenuated.	U 0126	33-38	hypertrichosis 2 (generalised, congenital)	Homo sapiens	98-101
17400803-6	2007	Inhibition of ERK1/2 activity by U0126 decreased PMA-treated StAR expression but increased dbcAMP/hCG-mediated StAR and P-StAR; however, progesterone levels were attenuated.	U 0126	33-38	steroidogenic acute regulatory protein	Mus musculus	111-115
17400803-6	2007	Inhibition of ERK1/2 activity by U0126 decreased PMA-treated StAR expression but increased dbcAMP/hCG-mediated StAR and P-StAR; however, progesterone levels were attenuated.	U 0126	33-38	steroidogenic acute regulatory protein	Mus musculus	111-115
17400803-7	2007	U0126 was found to affect StAR expression and steroidogenesis both at the transcriptional and translational levels.	U 0126	0-5	steroidogenic acute regulatory protein	Mus musculus	26-30
17400803-8	2007	Further studies demonstrated that the effect of U0126 on PMA- and dbcAMP/hCG-mediated StAR expression and steroid synthesis was tightly correlated with the expression of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X chromosome, gene 1 (DAX-1) and scavenger receptor class B type 1 (SR-B1).	U 0126	48-53	hypertrichosis 2 (generalised, congenital)	Homo sapiens	73-76
17400803-8	2007	Further studies demonstrated that the effect of U0126 on PMA- and dbcAMP/hCG-mediated StAR expression and steroid synthesis was tightly correlated with the expression of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X chromosome, gene 1 (DAX-1) and scavenger receptor class B type 1 (SR-B1).	U 0126	48-53	steroidogenic acute regulatory protein	Mus musculus	86-90
17400803-8	2007	Further studies demonstrated that the effect of U0126 on PMA- and dbcAMP/hCG-mediated StAR expression and steroid synthesis was tightly correlated with the expression of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X chromosome, gene 1 (DAX-1) and scavenger receptor class B type 1 (SR-B1).	U 0126	48-53	nuclear receptor subfamily 0, group B, member 1	Mus musculus	276-281
17400803-8	2007	Further studies demonstrated that the effect of U0126 on PMA- and dbcAMP/hCG-mediated StAR expression and steroid synthesis was tightly correlated with the expression of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X chromosome, gene 1 (DAX-1) and scavenger receptor class B type 1 (SR-B1).	U 0126	48-53	scavenger receptor class B, member 1	Mus musculus	287-320
17400803-8	2007	Further studies demonstrated that the effect of U0126 on PMA- and dbcAMP/hCG-mediated StAR expression and steroid synthesis was tightly correlated with the expression of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X chromosome, gene 1 (DAX-1) and scavenger receptor class B type 1 (SR-B1).	U 0126	48-53	scavenger receptor class B, member 1	Mus musculus	322-327
17449940-7	2007	Interestingly, the ERK pathway inhibitor, UO126, reversed the apoptotic effects of S1P on B16 melanoma cells.	U 0126	42-47	mitogen-activated protein kinase 1	Mus musculus	19-22
17449940-7	2007	Interestingly, the ERK pathway inhibitor, UO126, reversed the apoptotic effects of S1P on B16 melanoma cells.	U 0126	42-47	sphingosine-1-phosphate receptor 1	Mus musculus	83-86
17446238-4	2007	Pharmacological inhibition of the phosphatidylinositol-3 (PI-3) kinase by LY294002, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)1/2 by U0126, the protein kinase (PK) A pathway by H-89 or KT5720, and the PKC pathway by bisindolylmaleimide suppressed IGF-I-stimulated cell proliferation.	U 0126	172-177	mitogen-activated protein kinase 3	Homo sapiens	156-160
17446238-4	2007	Pharmacological inhibition of the phosphatidylinositol-3 (PI-3) kinase by LY294002, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)1/2 by U0126, the protein kinase (PK) A pathway by H-89 or KT5720, and the PKC pathway by bisindolylmaleimide suppressed IGF-I-stimulated cell proliferation.	U 0126	172-177	mitogen-activated protein kinase 3	Homo sapiens	161-168
17446238-4	2007	Pharmacological inhibition of the phosphatidylinositol-3 (PI-3) kinase by LY294002, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)1/2 by U0126, the protein kinase (PK) A pathway by H-89 or KT5720, and the PKC pathway by bisindolylmaleimide suppressed IGF-I-stimulated cell proliferation.	U 0126	172-177	insulin like growth factor 1	Homo sapiens	286-291
17353023-11	2007	Behavioral experiments showed that U0126 (0.5-2.5nmol), a MAP kinase-ERK inhibitor, dose-dependently attenuated the behavioral response to i.t.	U 0126	35-40	mitogen-activated protein kinase 1	Mus musculus	69-72
17205976-10	2007	The ROS formation was inhibited by the extracellular signal-regulated protein kinase (ERK) inhibitor U0126 (10 microM), the tyrosine kinase inhibitor erbstatin-A (25 microM), eliminating calcium from the buffer and by the superoxide dismutase inhibitor diethyldithio-carbamic acid (DDC, 100 microM).	U 0126	101-106	mitogen-activated protein kinase 3	Homo sapiens	86-89
16815629-4	2007	MEK1/2 inhibitor, U0126, inhibited MMP-2, FAK and actin expression in FHCC-98 cell line.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
16815629-4	2007	MEK1/2 inhibitor, U0126, inhibited MMP-2, FAK and actin expression in FHCC-98 cell line.	U 0126	18-23	matrix metallopeptidase 2	Homo sapiens	35-40
16815629-4	2007	MEK1/2 inhibitor, U0126, inhibited MMP-2, FAK and actin expression in FHCC-98 cell line.	U 0126	18-23	protein tyrosine kinase 2	Homo sapiens	42-45
17188653-6	2007	The release of AA by Na3VO4/A23187 was significantly inhibited by a PKC inhibitor (10 microM GF109203X), in PKC-depleted cells, by a Src inhibitor (2 microM PP2) and by an inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2) kinase (10 microM U0126).	U 0126	254-259	proline rich transmembrane protein 2	Homo sapiens	68-71
17188653-6	2007	The release of AA by Na3VO4/A23187 was significantly inhibited by a PKC inhibitor (10 microM GF109203X), in PKC-depleted cells, by a Src inhibitor (2 microM PP2) and by an inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2) kinase (10 microM U0126).	U 0126	254-259	Rous sarcoma oncogene	Mus musculus	133-136
17188653-6	2007	The release of AA by Na3VO4/A23187 was significantly inhibited by a PKC inhibitor (10 microM GF109203X), in PKC-depleted cells, by a Src inhibitor (2 microM PP2) and by an inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2) kinase (10 microM U0126).	U 0126	254-259	neuropeptide Y receptor Y6	Mus musculus	157-160
17061251-7	2007	U0126 suppressed mechanical stimuli-induced expression of osteocalcin.	U 0126	0-5	bone gamma-carboxyglutamate protein	Homo sapiens	58-69
17239373-4	2007	The interconnected actin-rich columns in U0126-treated, PDBu-stimulated cells contained alpha-actinin, caldesmon, vinculin, and metalloproteinase-2.	U 0126	41-46	vinculin	Rattus norvegicus	114-122
17250809-4	2007	Treatment of cardiomyocytes with inhibitors of phosphatidylinositol 3-kinase (LY294002) or Akt (Akti-1/2) abolished the protective effect of erythropoietin, whereas treatment with MAPK kinase (MEK1) inhibitor U0126 did not.	U 0126	209-214	erythropoietin	Rattus norvegicus	141-155
17209041-5	2007	Sustained intracellular acidosis was used to activate NHE1 via an ERK-dependent pathway that could be blocked with the MEK inhibitor U0126.	U 0126	133-138	solute carrier family 9 member A1	Homo sapiens	54-58
17209041-5	2007	Sustained intracellular acidosis was used to activate NHE1 via an ERK-dependent pathway that could be blocked with the MEK inhibitor U0126.	U 0126	133-138	mitogen-activated protein kinase 1	Homo sapiens	66-69
17131384-9	2007	Furthermore, U0126 inhibited EGF-induced MKP-3 and MKP-1 protein expression.	U 0126	13-18	dual specificity phosphatase 1	Homo sapiens	51-56
17149706-8	2007	Pretreatment of WT monolayers with ERK1/2 inhibitor U0126 (20 microM, 1 h) prevented the LPS-induced decrease in coupling, while inhibition of JNK1/2 with SP600125 (20 microM, 1 h) and p38 with a p38 inhibitor (10 nM, 1 h) had no effect.	U 0126	52-57	mitogen-activated protein kinase 3	Mus musculus	35-41
17149706-8	2007	Pretreatment of WT monolayers with ERK1/2 inhibitor U0126 (20 microM, 1 h) prevented the LPS-induced decrease in coupling, while inhibition of JNK1/2 with SP600125 (20 microM, 1 h) and p38 with a p38 inhibitor (10 nM, 1 h) had no effect.	U 0126	52-57	mitogen-activated protein kinase 14	Mus musculus	185-188
17149706-8	2007	Pretreatment of WT monolayers with ERK1/2 inhibitor U0126 (20 microM, 1 h) prevented the LPS-induced decrease in coupling, while inhibition of JNK1/2 with SP600125 (20 microM, 1 h) and p38 with a p38 inhibitor (10 nM, 1 h) had no effect.	U 0126	52-57	mitogen-activated protein kinase 14	Mus musculus	196-199
17210799-10	2007	20-HETE also increased the phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) in EC, whereas an inhibitor of MAPK [U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] suppressed the proliferative and the VEGF changes but not the pro-oxidant effects of 20-HETE.	U 0126	131-136	erythrocyte membrane protein band 4.2	Homo sapiens	46-49
17210799-10	2007	20-HETE also increased the phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) in EC, whereas an inhibitor of MAPK [U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] suppressed the proliferative and the VEGF changes but not the pro-oxidant effects of 20-HETE.	U 0126	138-197	vascular endothelial growth factor A	Homo sapiens	236-240
17382630-5	2007	In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation.	U 0126	7-12	mitogen activated protein kinase 3	Rattus norvegicus	115-161
17382630-5	2007	In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation.	U 0126	7-12	mitogen activated protein kinase 3	Rattus norvegicus	181-227
17382630-5	2007	In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	115-161
17382630-5	2007	In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	181-227
17382630-9	2007	In the U0126 group, U0126 treatment completely blocked extracellular signal-regulated kinases 1 and 2 phosphorylation.	U 0126	7-12	mitogen activated protein kinase 3	Rattus norvegicus	55-101
17382630-9	2007	In the U0126 group, U0126 treatment completely blocked extracellular signal-regulated kinases 1 and 2 phosphorylation.	U 0126	20-25	mitogen activated protein kinase 3	Rattus norvegicus	55-101
17084586-8	2007	Blocking the activation of p38 MAPK as well as ERK 1/2 with specific inhibitors (SB203580 and U0126, respectively) down-regulated the IL-1beta expression.	U 0126	94-99	mitogen-activated protein kinase 3	Mus musculus	47-54
17084586-8	2007	Blocking the activation of p38 MAPK as well as ERK 1/2 with specific inhibitors (SB203580 and U0126, respectively) down-regulated the IL-1beta expression.	U 0126	94-99	interleukin 1 beta	Mus musculus	134-142
17394769-3	2007	Though no apparent elevation of ERK activity was observed during the apoptosis in NB4 cells caused by 20 microM sodium selenite treatment, PD98059 and U0126, specific chemical inhibitors of the MEK/ERK signaling pathway, were shown to strongly prevent the apoptosis process, while ERK activator TPA enhanced the process.	U 0126	151-156	mitogen-activated protein kinase kinase 7	Homo sapiens	194-197
17394769-3	2007	Though no apparent elevation of ERK activity was observed during the apoptosis in NB4 cells caused by 20 microM sodium selenite treatment, PD98059 and U0126, specific chemical inhibitors of the MEK/ERK signaling pathway, were shown to strongly prevent the apoptosis process, while ERK activator TPA enhanced the process.	U 0126	151-156	mitogen-activated protein kinase 1	Homo sapiens	198-201
17394769-3	2007	Though no apparent elevation of ERK activity was observed during the apoptosis in NB4 cells caused by 20 microM sodium selenite treatment, PD98059 and U0126, specific chemical inhibitors of the MEK/ERK signaling pathway, were shown to strongly prevent the apoptosis process, while ERK activator TPA enhanced the process.	U 0126	151-156	mitogen-activated protein kinase 1	Homo sapiens	198-201
17386088-7	2007	U0126 instillation completely blocked IL-1beta-induced lung fluid absorption as well as IL-1beta-induced/stimulated ERK expression.	U 0126	0-5	interleukin-1 beta	Cavia porcellus	38-46
17386088-7	2007	U0126 instillation completely blocked IL-1beta-induced lung fluid absorption as well as IL-1beta-induced/stimulated ERK expression.	U 0126	0-5	interleukin-1 beta	Cavia porcellus	88-96
17439743-8	2007	Among the above inhibitors, only U0126 (10 micromol/L) completely blocked the effects of FGF9 on Runx2 gene promoter activity.	U 0126	33-38	fibroblast growth factor 9	Mus musculus	89-93
17439743-8	2007	Among the above inhibitors, only U0126 (10 micromol/L) completely blocked the effects of FGF9 on Runx2 gene promoter activity.	U 0126	33-38	runt related transcription factor 2	Mus musculus	97-102
17286987-7	2007	The nicotine-induced VEGF release was inhibited by treatment with U0126, a selective inhibitor of MEK, which attenuated the nicotine-induced ERK phosphorylation.	U 0126	66-71	vascular endothelial growth factor A	Rattus norvegicus	21-25
17286987-7	2007	The nicotine-induced VEGF release was inhibited by treatment with U0126, a selective inhibitor of MEK, which attenuated the nicotine-induced ERK phosphorylation.	U 0126	66-71	Eph receptor B1	Rattus norvegicus	141-144
17344432-6	2007	Using the inhibitors U0126 for mitogen-activated protein kinase (MAPK), and ZM447439 for Aurora kinase A and Aurora kinase B, we found that MAPK is required for phosphorylation of CPEB, whereas Aurora kinases are not.	U 0126	21-26	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	140-144
17344432-6	2007	Using the inhibitors U0126 for mitogen-activated protein kinase (MAPK), and ZM447439 for Aurora kinase A and Aurora kinase B, we found that MAPK is required for phosphorylation of CPEB, whereas Aurora kinases are not.	U 0126	21-26	cytoplasmic polyadenylation element binding protein 1 S homeolog	Xenopus laevis	180-184
17461449-6	2007	Moreover, treatment with MEK1/2 inhibitor (U0126) or PI3K inhibitor (LY294002) also attenuated the effect of CXCL12-induced cholangiocarcinoma cell invasion.	U 0126	43-48	mitogen-activated protein kinase kinase 1	Homo sapiens	25-31
17461449-6	2007	Moreover, treatment with MEK1/2 inhibitor (U0126) or PI3K inhibitor (LY294002) also attenuated the effect of CXCL12-induced cholangiocarcinoma cell invasion.	U 0126	43-48	C-X-C motif chemokine ligand 12	Homo sapiens	109-115
17239853-6	2007	In ccn2+/+ MEFs, the MEK inhibitor U0126 and dominant negative ras reduced expression of IL-6 and lipocalin-2.	U 0126	35-40	cellular communication network factor 2	Mus musculus	3-7
17239853-6	2007	In ccn2+/+ MEFs, the MEK inhibitor U0126 and dominant negative ras reduced expression of IL-6 and lipocalin-2.	U 0126	35-40	midkine	Mus musculus	21-24
17239853-6	2007	In ccn2+/+ MEFs, the MEK inhibitor U0126 and dominant negative ras reduced expression of IL-6 and lipocalin-2.	U 0126	35-40	interleukin 6	Mus musculus	89-93
17239853-6	2007	In ccn2+/+ MEFs, the MEK inhibitor U0126 and dominant negative ras reduced expression of IL-6 and lipocalin-2.	U 0126	35-40	lipocalin 2	Mus musculus	98-109
17239853-9	2007	We found that ccn2+/+ MEFs migrated significantly faster than ccn2-/- MEFs; anti-syndecan 4 antibody and U0126 reduced the migration of ccn2+/+ MEFs to that of ccn2-/- MEFs.	U 0126	105-110	cellular communication network factor 2	Mus musculus	14-18
17239853-9	2007	We found that ccn2+/+ MEFs migrated significantly faster than ccn2-/- MEFs; anti-syndecan 4 antibody and U0126 reduced the migration of ccn2+/+ MEFs to that of ccn2-/- MEFs.	U 0126	105-110	cellular communication network factor 2	Mus musculus	62-66
17239853-9	2007	We found that ccn2+/+ MEFs migrated significantly faster than ccn2-/- MEFs; anti-syndecan 4 antibody and U0126 reduced the migration of ccn2+/+ MEFs to that of ccn2-/- MEFs.	U 0126	105-110	cellular communication network factor 2	Mus musculus	62-66
17239853-9	2007	We found that ccn2+/+ MEFs migrated significantly faster than ccn2-/- MEFs; anti-syndecan 4 antibody and U0126 reduced the migration of ccn2+/+ MEFs to that of ccn2-/- MEFs.	U 0126	105-110	cellular communication network factor 2	Mus musculus	62-66
17209041-5	2007	Sustained intracellular acidosis was used to activate NHE1 via an ERK-dependent pathway that could be blocked with the MEK inhibitor U0126.	U 0126	133-138	mitogen-activated protein kinase kinase 7	Homo sapiens	119-122
17465197-7	2007	In addition to butyrate, several HDAC inhibitors can induce differentiation in colon cancer cells and the responses may be enhanced by U0126, GW5074 and LY294002.	U 0126	135-140	histone deacetylase 9	Homo sapiens	33-37
17465197-5	2007	Unlike the JNK and PKC inhibitors examined, the MEK 1/2 inhibitor U0126 induced alkaline phosphatase activity in Caco-2 as a single agent and caused additive effects with HDAC inhibitors.	U 0126	66-71	mitogen-activated protein kinase kinase 1	Homo sapiens	48-55
17465197-5	2007	Unlike the JNK and PKC inhibitors examined, the MEK 1/2 inhibitor U0126 induced alkaline phosphatase activity in Caco-2 as a single agent and caused additive effects with HDAC inhibitors.	U 0126	66-71	histone deacetylase 9	Homo sapiens	171-175
17096210-8	2007	Pretreatment with U0126, an inhibitor of ERK1/2, significantly enhanced the TGF-beta1-mediated antiproliferative and apoptosis induction effects in BEP2D cells.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	41-47
17096210-8	2007	Pretreatment with U0126, an inhibitor of ERK1/2, significantly enhanced the TGF-beta1-mediated antiproliferative and apoptosis induction effects in BEP2D cells.	U 0126	18-23	transforming growth factor beta 1	Homo sapiens	76-85
17234168-7	2007	In contrast inhibition of insulin"s "mitogenic" Ras-Raf-mitogen-activated protein kinase-kinase pathways with PD98059 (15 micromol/L) or U0126 (2 micromol/L) inhibited insulin-induced MMP-9 gelatinolytic activity in THP-1 cells.	U 0126	137-142	insulin	Homo sapiens	26-33
17234168-7	2007	In contrast inhibition of insulin"s "mitogenic" Ras-Raf-mitogen-activated protein kinase-kinase pathways with PD98059 (15 micromol/L) or U0126 (2 micromol/L) inhibited insulin-induced MMP-9 gelatinolytic activity in THP-1 cells.	U 0126	137-142	insulin	Homo sapiens	168-175
17234168-7	2007	In contrast inhibition of insulin"s "mitogenic" Ras-Raf-mitogen-activated protein kinase-kinase pathways with PD98059 (15 micromol/L) or U0126 (2 micromol/L) inhibited insulin-induced MMP-9 gelatinolytic activity in THP-1 cells.	U 0126	137-142	matrix metallopeptidase 9	Homo sapiens	184-189
17170099-7	2007	LRH-1 expression induced by the heat treatment was completely inhibited by the addition of ERK inhibitor U0126 in the culture, indicating that the heat-induced LRH-1 expression in the Sertoli cells may be regulated via ERK1/2 activation pathway.	U 0126	105-110	nuclear receptor subfamily 5, group A, member 2	Rattus norvegicus	0-5
17170099-7	2007	LRH-1 expression induced by the heat treatment was completely inhibited by the addition of ERK inhibitor U0126 in the culture, indicating that the heat-induced LRH-1 expression in the Sertoli cells may be regulated via ERK1/2 activation pathway.	U 0126	105-110	Eph receptor B1	Rattus norvegicus	91-94
17170099-7	2007	LRH-1 expression induced by the heat treatment was completely inhibited by the addition of ERK inhibitor U0126 in the culture, indicating that the heat-induced LRH-1 expression in the Sertoli cells may be regulated via ERK1/2 activation pathway.	U 0126	105-110	nuclear receptor subfamily 5, group A, member 2	Rattus norvegicus	160-165
17170099-7	2007	LRH-1 expression induced by the heat treatment was completely inhibited by the addition of ERK inhibitor U0126 in the culture, indicating that the heat-induced LRH-1 expression in the Sertoli cells may be regulated via ERK1/2 activation pathway.	U 0126	105-110	mitogen activated protein kinase 3	Rattus norvegicus	219-225
17327470-3	2007	Treatment with PD98059 and U0126 (MEK inhibitors) inhibited not only ET-1-induced cell proliferation but also ET-1-activated phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) in U373MG astrocytoma cells.	U 0126	27-32	endothelin 1	Homo sapiens	69-73
17327470-3	2007	Treatment with PD98059 and U0126 (MEK inhibitors) inhibited not only ET-1-induced cell proliferation but also ET-1-activated phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) in U373MG astrocytoma cells.	U 0126	27-32	endothelin 1	Homo sapiens	110-114
17327470-3	2007	Treatment with PD98059 and U0126 (MEK inhibitors) inhibited not only ET-1-induced cell proliferation but also ET-1-activated phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) in U373MG astrocytoma cells.	U 0126	27-32	mitogen-activated protein kinase 3	Homo sapiens	195-201
17267741-10	2007	Both plasmin-induced ERK activation and EMT were significantly blocked in vitro by the protease-activated receptor-1 (PAR-1) silencing RNA; by pepducin, a specific anti-PAR-1 signaling peptide; and by the ERK kinase inhibitor UO126.	U 0126	226-231	mitogen-activated protein kinase 1	Mus musculus	21-24
17131377-5	2007	ICAM-1 expression in response to TPA was inhibited by pretreatment with GF109203X [a specific inhibitor of protein kinase C (PKC)], or with PD98059 and U0126 (specific inhibitors of MEK), suggesting the importance of PKC, and Erk1/2 signaling cascades in this response.	U 0126	152-157	intercellular adhesion molecule 1	Homo sapiens	0-6
17003101-4	2007	In this connection, the ERK1/2 inhibitor U0126 abrogated the upregulation of AP-1 and COX-2 as well as cell proliferation induced by nicotine.	U 0126	41-46	mitogen-activated protein kinase 3	Homo sapiens	24-30
17003101-4	2007	In this connection, the ERK1/2 inhibitor U0126 abrogated the upregulation of AP-1 and COX-2 as well as cell proliferation induced by nicotine.	U 0126	41-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	86-91
17382186-6	2007	By affecting downstream signaling, the MEK1/2 inhibitors U0126 and PD184352 blocked growth more effectively than did the EGFR inhibitors in selected renal cell carcinoma lines; this effect was enhanced by the addition of rapamycin.	U 0126	57-62	mitogen-activated protein kinase kinase 1	Homo sapiens	39-45
17189253-5	2007	Treatment with U0126, a MEK inhibitor, decreases tyrosine phosphorylation levels at the midbody, leading to abscission failure.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
17276429-6	2007	Moreover, only ERK1/2 inhibition by U0126 suppressed PA-induced TNF-alpha production and MMP-9 expression.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	15-21
17276429-6	2007	Moreover, only ERK1/2 inhibition by U0126 suppressed PA-induced TNF-alpha production and MMP-9 expression.	U 0126	36-41	tumor necrosis factor	Homo sapiens	64-73
17276429-6	2007	Moreover, only ERK1/2 inhibition by U0126 suppressed PA-induced TNF-alpha production and MMP-9 expression.	U 0126	36-41	matrix metallopeptidase 9	Homo sapiens	89-94
17317846-4	2007	RESULTS: MEK inhibitor U0126 or cessation of V600E BRAF expression in PCCL3 cells restored expression of thyroid genes silenced by induced expression of V600E BRAF.	U 0126	23-28	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
17317846-4	2007	RESULTS: MEK inhibitor U0126 or cessation of V600E BRAF expression in PCCL3 cells restored expression of thyroid genes silenced by induced expression of V600E BRAF.	U 0126	23-28	B-Raf proto-oncogene, serine/threonine kinase	Rattus norvegicus	159-163
17317846-5	2007	U0126 also restored the expression of these genes in V600E BRAF-harboring PTC-derived NPA cells.	U 0126	0-5	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	59-63
17329967-10	2007	On the other hand, complete inhibition of ERK2 activation using U0126 had no effect either on MPF activity or on MCM4 phosphorylation either in control or in Ub-K48R-supplemented extracts.	U 0126	64-69	mitogen-activated protein kinase 1 L homeolog	Xenopus laevis	42-46
17157922-6	2007	The pH recovery phenomenon was mediated by an amiloride-sensitive Na+/H+ exchanger and H+ channel, and was inhibited by UO126 (an ERK1/2 MAPK phosphorylation inhibitor), Go6850 (a PKC inhibitor) and calcium chelating.	U 0126	120-125	mitogen-activated protein kinase 3	Bos taurus	130-136
17260965-7	2007	The non-ATP-competitive MEK1 inhibitors, U0126 and PD0325901, showed no preference for npMEK1 and pMEK1 by TdCD.	U 0126	41-46	mitogen-activated protein kinase kinase 1	Homo sapiens	24-28
17137556-5	2007	Interruption of ERK signaling, using the specific MEK inhibitors U-0126 and PD-98059, significantly enhanced CdA cytotoxicity, evaluated by the MTT assay.	U 0126	65-71	mitogen-activated protein kinase 1	Homo sapiens	16-19
17137556-5	2007	Interruption of ERK signaling, using the specific MEK inhibitors U-0126 and PD-98059, significantly enhanced CdA cytotoxicity, evaluated by the MTT assay.	U 0126	65-71	mitogen-activated protein kinase kinase 7	Homo sapiens	50-53
17068135-10	2007	Finally, a specific ERK1/2 inhibitor, UO126, blocks Pi-stimulated MGP expression in ATDC5 cells, indicating that ERK1/2 mediates, mainly, the effects of Pi.	U 0126	38-43	mitogen-activated protein kinase 3	Mus musculus	20-26
17068135-10	2007	Finally, a specific ERK1/2 inhibitor, UO126, blocks Pi-stimulated MGP expression in ATDC5 cells, indicating that ERK1/2 mediates, mainly, the effects of Pi.	U 0126	38-43	matrix Gla protein	Mus musculus	66-69
17068135-10	2007	Finally, a specific ERK1/2 inhibitor, UO126, blocks Pi-stimulated MGP expression in ATDC5 cells, indicating that ERK1/2 mediates, mainly, the effects of Pi.	U 0126	38-43	mitogen-activated protein kinase 3	Mus musculus	113-119
17331200-9	2007	To further confirm the role of ERK activation in the proliferation, we cultured cells in FGF-2 + IGF-I-containing medium in the presence and absence of U0126 (ERK inhibitor), and showed the inhibition of nestin expression in U0126-treated cells.	U 0126	152-157	Eph receptor B1	Rattus norvegicus	159-162
17331200-9	2007	To further confirm the role of ERK activation in the proliferation, we cultured cells in FGF-2 + IGF-I-containing medium in the presence and absence of U0126 (ERK inhibitor), and showed the inhibition of nestin expression in U0126-treated cells.	U 0126	225-230	Eph receptor B1	Rattus norvegicus	31-34
17331200-9	2007	To further confirm the role of ERK activation in the proliferation, we cultured cells in FGF-2 + IGF-I-containing medium in the presence and absence of U0126 (ERK inhibitor), and showed the inhibition of nestin expression in U0126-treated cells.	U 0126	225-230	fibroblast growth factor 2	Rattus norvegicus	89-94
17331200-9	2007	To further confirm the role of ERK activation in the proliferation, we cultured cells in FGF-2 + IGF-I-containing medium in the presence and absence of U0126 (ERK inhibitor), and showed the inhibition of nestin expression in U0126-treated cells.	U 0126	225-230	insulin-like growth factor 1	Rattus norvegicus	97-102
17131424-3	2007	Simultaneous administration of U0126, an ERK inhibitor, with NMDA completely abolished the protective effect of E2.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	41-44
17131424-10	2007	Pretreatment of E2 induced further increases of p-ERK expression 6 hr and 7 days after NMDA injection, and U0126 and ICI182,780 significantly inhibited E2-induced p-ERK expression after 6 hr.	U 0126	107-112	mitogen-activated protein kinase 1	Homo sapiens	165-168
17182854-4	2007	Here, we show that inhibition of MEK1 by RNA interference or by using the MEK1/2-specific inhibitor U0126 delayed the passage of synchronized HeLa cells into M phase.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	33-37
17182854-4	2007	Here, we show that inhibition of MEK1 by RNA interference or by using the MEK1/2-specific inhibitor U0126 delayed the passage of synchronized HeLa cells into M phase.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	74-80
17308073-6	2007	In contrast, simultaneous inactivation of the EGFR downstream targets mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and PI3K by U0126 and wortmannin triggered rapid tumor cell death.	U 0126	159-164	epidermal growth factor receptor	Homo sapiens	46-50
17308073-6	2007	In contrast, simultaneous inactivation of the EGFR downstream targets mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and PI3K by U0126 and wortmannin triggered rapid tumor cell death.	U 0126	159-164	mitogen-activated protein kinase 1	Homo sapiens	135-138
17027076-5	2007	Phosphorylation of MAPK in the SD oocytes was significantly suppressed by MEK inhibitor, U0126 at 60 min; this treatment decreased p34(cdc2) kinase activity via cyclin B1 degradation in a time-dependent manner.	U 0126	89-94	cyclin-dependent kinase 1	Rattus norvegicus	135-139
17027076-5	2007	Phosphorylation of MAPK in the SD oocytes was significantly suppressed by MEK inhibitor, U0126 at 60 min; this treatment decreased p34(cdc2) kinase activity via cyclin B1 degradation in a time-dependent manner.	U 0126	89-94	cyclin B1	Rattus norvegicus	161-170
17209045-5	2007	The transforming activity of RET(Y791F) and RET(S891A) in NIH-3T3 cells was also inhibited by U0126, indicating a role of the ERK1/2 pathway in RET-mediated transformation.	U 0126	94-99	ret proto-oncogene	Mus musculus	29-32
17209045-5	2007	The transforming activity of RET(Y791F) and RET(S891A) in NIH-3T3 cells was also inhibited by U0126, indicating a role of the ERK1/2 pathway in RET-mediated transformation.	U 0126	94-99	ret proto-oncogene	Mus musculus	44-47
17209045-5	2007	The transforming activity of RET(Y791F) and RET(S891A) in NIH-3T3 cells was also inhibited by U0126, indicating a role of the ERK1/2 pathway in RET-mediated transformation.	U 0126	94-99	mitogen-activated protein kinase 3	Mus musculus	126-132
17209045-5	2007	The transforming activity of RET(Y791F) and RET(S891A) in NIH-3T3 cells was also inhibited by U0126, indicating a role of the ERK1/2 pathway in RET-mediated transformation.	U 0126	94-99	ret proto-oncogene	Mus musculus	44-47
17209045-7	2007	These cells displayed elevated levels of activated ERK1/2 and Ser(727)-phosphorylated STAT3, which were inhibited by treatment with U0126.	U 0126	132-137	mitogen-activated protein kinase 3	Homo sapiens	51-57
17209045-7	2007	These cells displayed elevated levels of activated ERK1/2 and Ser(727)-phosphorylated STAT3, which were inhibited by treatment with U0126.	U 0126	132-137	signal transducer and activator of transcription 3	Homo sapiens	86-91
17208315-4	2007	Extracellular signal-regulated kinases (ERK1/2)-MAPK pathway inhibitor, U0126, down-regulated ADAMTS-4 and MMP-13 induction by OSM.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	40-46
17208315-4	2007	Extracellular signal-regulated kinases (ERK1/2)-MAPK pathway inhibitor, U0126, down-regulated ADAMTS-4 and MMP-13 induction by OSM.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	48-52
17208315-4	2007	Extracellular signal-regulated kinases (ERK1/2)-MAPK pathway inhibitor, U0126, down-regulated ADAMTS-4 and MMP-13 induction by OSM.	U 0126	72-77	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	94-102
17208315-4	2007	Extracellular signal-regulated kinases (ERK1/2)-MAPK pathway inhibitor, U0126, down-regulated ADAMTS-4 and MMP-13 induction by OSM.	U 0126	72-77	matrix metallopeptidase 13	Homo sapiens	107-113
17332341-5	2007	Moreover, EGF-mediated activation of ERCC1 was specifically inhibited by either the addition of U0126, a MEK/ERK inhibitor or small interfering RNA-mediated knockdown of ERK2.	U 0126	96-101	epidermal growth factor	Homo sapiens	10-13
17332341-5	2007	Moreover, EGF-mediated activation of ERCC1 was specifically inhibited by either the addition of U0126, a MEK/ERK inhibitor or small interfering RNA-mediated knockdown of ERK2.	U 0126	96-101	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42
17183546-2	2007	In the present study, we demonstrate that MEK activation by EGF increased Rac1 activation, dissociation of intercellular contacts, and migration in both control and polyamine-depleted cells, while U0126, a specific inhibitor of MEK1, prevented disruption of junctions as well as EGF-induced Rac1 activation.	U 0126	197-202	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
17183546-2	2007	In the present study, we demonstrate that MEK activation by EGF increased Rac1 activation, dissociation of intercellular contacts, and migration in both control and polyamine-depleted cells, while U0126, a specific inhibitor of MEK1, prevented disruption of junctions as well as EGF-induced Rac1 activation.	U 0126	197-202	mitogen-activated protein kinase kinase 1	Homo sapiens	228-232
17183546-2	2007	In the present study, we demonstrate that MEK activation by EGF increased Rac1 activation, dissociation of intercellular contacts, and migration in both control and polyamine-depleted cells, while U0126, a specific inhibitor of MEK1, prevented disruption of junctions as well as EGF-induced Rac1 activation.	U 0126	197-202	epidermal growth factor	Homo sapiens	279-282
17183546-2	2007	In the present study, we demonstrate that MEK activation by EGF increased Rac1 activation, dissociation of intercellular contacts, and migration in both control and polyamine-depleted cells, while U0126, a specific inhibitor of MEK1, prevented disruption of junctions as well as EGF-induced Rac1 activation.	U 0126	197-202	Rac family small GTPase 1	Homo sapiens	291-295
17225921-8	2007	A dose-dependent phosphorylation of extracellular signal-regulated-kinases (ERKs)-1 and -2 with a maximum of phosphorylation at 15-20 min was observed and inhibitable by MEK1/2-inhibitor U0126 (5-10 microM).	U 0126	187-192	mitogen-activated protein kinase 1	Homo sapiens	36-90
17225921-8	2007	A dose-dependent phosphorylation of extracellular signal-regulated-kinases (ERKs)-1 and -2 with a maximum of phosphorylation at 15-20 min was observed and inhibitable by MEK1/2-inhibitor U0126 (5-10 microM).	U 0126	187-192	mitogen-activated protein kinase kinase 1	Homo sapiens	170-176
17348861-5	2007	Furthermore, inhibitors of PI3K (LY294002 and Wortmannin), MEK1 (PD98059 and U0126), and Src family tyrosine kinases (PP2) decreased IGF-I-induced proliferation, and blocked ERK1/2 activation.	U 0126	77-82	mitogen-activated protein kinase kinase 1	Homo sapiens	59-63
17348861-5	2007	Furthermore, inhibitors of PI3K (LY294002 and Wortmannin), MEK1 (PD98059 and U0126), and Src family tyrosine kinases (PP2) decreased IGF-I-induced proliferation, and blocked ERK1/2 activation.	U 0126	77-82	insulin like growth factor 1	Homo sapiens	133-138
17197172-5	2007	Hormone-dependent ERK and p38 activation was abolished by MAPK specific inhibitors U0126 and SB203580.	U 0126	83-88	mitogen-activated protein kinase 1	Mus musculus	18-21
17197172-5	2007	Hormone-dependent ERK and p38 activation was abolished by MAPK specific inhibitors U0126 and SB203580.	U 0126	83-88	mitogen-activated protein kinase 14	Mus musculus	26-29
17197172-5	2007	Hormone-dependent ERK and p38 activation was abolished by MAPK specific inhibitors U0126 and SB203580.	U 0126	83-88	mitogen-activated protein kinase 1	Mus musculus	58-62
17045653-8	2007	The classic Ras-mediated pathway of ERK1/2 activation by LPS was confirmed when the specific Raf-1 inhibitor, GW 5074, and the MEK1/2 inhibitor, U0126, both reduced ERK activation by 51-60%.	U 0126	145-150	mitogen-activated protein kinase kinase 2	Gallus gallus	127-133
17045653-15	2007	The FLG induction of the Rap1--&gt;B-Raf--&gt;MEK1/2--&gt;ERK1/2 cascade was confirmed by the reduction of ERK1/2 activation by the specific Rap1 inhibitor (GGTI-298) and U0126.	U 0126	171-176	RAP1 GTPase activating protein 3	Gallus gallus	25-29
17045653-15	2007	The FLG induction of the Rap1--&gt;B-Raf--&gt;MEK1/2--&gt;ERK1/2 cascade was confirmed by the reduction of ERK1/2 activation by the specific Rap1 inhibitor (GGTI-298) and U0126.	U 0126	171-176	B-Raf proto-oncogene, serine/threonine kinase	Gallus gallus	35-40
17045653-15	2007	The FLG induction of the Rap1--&gt;B-Raf--&gt;MEK1/2--&gt;ERK1/2 cascade was confirmed by the reduction of ERK1/2 activation by the specific Rap1 inhibitor (GGTI-298) and U0126.	U 0126	171-176	mitogen-activated protein kinase kinase 2	Gallus gallus	46-52
17021794-8	2007	Aquaporin 5 (AQP5) mRNA and protein levels were upregulated in hyperosmotic conditions and downregulated upon return to isosmotic solutions, but were reduced by the mitogen-activated ERK-activating kinase (MEK) inhibitor U0126.	U 0126	221-226	aquaporin 5	Rattus norvegicus	0-11
17021794-8	2007	Aquaporin 5 (AQP5) mRNA and protein levels were upregulated in hyperosmotic conditions and downregulated upon return to isosmotic solutions, but were reduced by the mitogen-activated ERK-activating kinase (MEK) inhibitor U0126.	U 0126	221-226	aquaporin 5	Rattus norvegicus	13-17
17267111-3	2007	CgA-mediated iNOS expression and NO production were also inhibited by U0126 (MEK inhibitor), but mitochondrial depolarisation and apoptosis were not.	U 0126	70-75	chromogranin A	Rattus norvegicus	0-3
17031853-4	2007	The induction of MMP-1 expression correlates with activation of ERK1/2, MEK, and Raf-1, and is potently prevented by U0126, a selective inhibitor of MEK1/2 activation.	U 0126	117-122	matrix metallopeptidase 1	Homo sapiens	17-22
17031853-4	2007	The induction of MMP-1 expression correlates with activation of ERK1/2, MEK, and Raf-1, and is potently prevented by U0126, a selective inhibitor of MEK1/2 activation.	U 0126	117-122	mitogen-activated protein kinase 3	Homo sapiens	64-70
17031853-4	2007	The induction of MMP-1 expression correlates with activation of ERK1/2, MEK, and Raf-1, and is potently prevented by U0126, a selective inhibitor of MEK1/2 activation.	U 0126	117-122	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
17031853-4	2007	The induction of MMP-1 expression correlates with activation of ERK1/2, MEK, and Raf-1, and is potently prevented by U0126, a selective inhibitor of MEK1/2 activation.	U 0126	117-122	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	81-86
17031853-4	2007	The induction of MMP-1 expression correlates with activation of ERK1/2, MEK, and Raf-1, and is potently prevented by U0126, a selective inhibitor of MEK1/2 activation.	U 0126	117-122	mitogen-activated protein kinase kinase 1	Homo sapiens	149-155
16909118-6	2007	In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126.	U 0126	138-143	mitogen-activated protein kinase 3	Mus musculus	13-19
16909118-6	2007	In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126.	U 0126	138-143	mitogen-activated protein kinase kinase 1	Mus musculus	43-49
16909118-6	2007	In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126.	U 0126	138-143	mitogen-activated protein kinase 3	Mus musculus	91-97
16909118-6	2007	In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126.	U 0126	138-143	mitogen-activated protein kinase kinase 1	Mus musculus	121-127
16909118-7	2007	The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB.	U 0126	4-9	mitogen-activated protein kinase 3	Mus musculus	33-39
16909118-7	2007	The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB.	U 0126	4-9	anaplastic lymphoma kinase	Mus musculus	95-98
16909118-7	2007	The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB.	U 0126	4-9	ras homolog family member J	Mus musculus	100-103
16909118-7	2007	The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB.	U 0126	4-9	BCL2-like 1	Mus musculus	149-155
16909118-7	2007	The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB.	U 0126	4-9	cyclin-dependent kinase 4	Mus musculus	181-185
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	46-51	mitogen activated protein kinase 3	Rattus norvegicus	29-33
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	46-51	Eph receptor B1	Rattus norvegicus	34-37
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	46-51	C-C motif chemokine ligand 2	Rattus norvegicus	105-110
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	46-51	heme oxygenase 1	Rattus norvegicus	140-144
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	96-101	mitogen activated protein kinase 3	Rattus norvegicus	29-33
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	96-101	Eph receptor B1	Rattus norvegicus	34-37
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	96-101	C-C motif chemokine ligand 2	Rattus norvegicus	105-110
16968890-7	2007	Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells.	U 0126	96-101	heme oxygenase 1	Rattus norvegicus	140-144
17384772-7	2007	The MEK1/2 inhibitor, U0126, blocked PSA overexpression in CAsE-PE cells.	U 0126	22-27	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
16888810-5	2007	In addition, pre-exposure to U0126, a specific inhibitor of the ERK1/2 signaling, prevented nicotine-mediated anti-apoptotic effects.	U 0126	29-34	mitogen activated protein kinase 3	Rattus norvegicus	64-70
16824602-7	2007	A specific ERK inhibitor, U0126, as well as PI3K inhibitors, differentially regulated IL-10 and IL-12 p70 productions.	U 0126	26-31	mitogen-activated protein kinase 1	Mus musculus	11-14
16824602-7	2007	A specific ERK inhibitor, U0126, as well as PI3K inhibitors, differentially regulated IL-10 and IL-12 p70 productions.	U 0126	26-31	interleukin 2 receptor, beta chain	Mus musculus	102-105
17090621-7	2007	The ERK1/2 signaling pathway inhibitor, U0126, also significantly decreased the levels of ROS associated with PAT treatment.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	4-10
17113706-7	2007	Inhibition of ERK1/2 activation by U0126 or activation of PKA by cAMP, previously shown to modulate MR and GR activity, did not affect MR(CDEF) activity either.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	14-20
17107963-4	2007	We found that growth factor-induced Ser-166 phosphorylation of Mdm2 was inhibited by the MEK inhibitors U0126 and PD98059 in HepG2 cells and in a rat liver cell line, TRL 1215.	U 0126	104-109	MDM2 proto-oncogene	Homo sapiens	63-67
17107963-4	2007	We found that growth factor-induced Ser-166 phosphorylation of Mdm2 was inhibited by the MEK inhibitors U0126 and PD98059 in HepG2 cells and in a rat liver cell line, TRL 1215.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	89-92
17078024-8	2007	The LPS-induced increase in microglial C/EBPbeta is prevented by coadministration of the MAP kinase inhibitors SB203580 (p38 inhibitor) + SP600125 (JNK inhibitor) or SB203580 + U0126 (ERK inhibitor).	U 0126	177-182	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	39-48
17202371-12	2007	Finally, the administration of U0126, an inhibitor of ERK activation, to infected mice resulted in decreased lesion progression with reduced numbers of parasites in them.	U 0126	31-36	mitogen-activated protein kinase 1	Mus musculus	54-57
17126295-8	2007	The activation of MAPK by CSs 1-3 was suppressed by U0126, a MEK inhibitor, but not by K252a, an inhibitor of TrkA; AG1478, an antagonist of epidermal growth factor receptor (EGFR); or by pertussis toxin.	U 0126	52-57	mitogen activated protein kinase 3	Rattus norvegicus	18-22
17126295-8	2007	The activation of MAPK by CSs 1-3 was suppressed by U0126, a MEK inhibitor, but not by K252a, an inhibitor of TrkA; AG1478, an antagonist of epidermal growth factor receptor (EGFR); or by pertussis toxin.	U 0126	52-57	calpain, small subunit 1	Rattus norvegicus	26-31
16920889-6	2007	Inhibition of JAK1/STAT-3 pathways by piceatannol or ERK1/2 by the MAPK/ERK kinase 1/2 inhibitor U0126 blunted the increase in total protein synthesis.	U 0126	97-102	Janus kinase 1	Homo sapiens	14-18
16920889-6	2007	Inhibition of JAK1/STAT-3 pathways by piceatannol or ERK1/2 by the MAPK/ERK kinase 1/2 inhibitor U0126 blunted the increase in total protein synthesis.	U 0126	97-102	signal transducer and activator of transcription 3	Homo sapiens	19-25
16920889-6	2007	Inhibition of JAK1/STAT-3 pathways by piceatannol or ERK1/2 by the MAPK/ERK kinase 1/2 inhibitor U0126 blunted the increase in total protein synthesis.	U 0126	97-102	mitogen-activated protein kinase 3	Homo sapiens	53-59
16920889-6	2007	Inhibition of JAK1/STAT-3 pathways by piceatannol or ERK1/2 by the MAPK/ERK kinase 1/2 inhibitor U0126 blunted the increase in total protein synthesis.	U 0126	97-102	mitogen-activated protein kinase 3	Homo sapiens	67-71
17404063-8	2007	Pretreatment with U0126 and SB203580, pharmacological inhibitors of ERK and p38 MAPK, respectively, showed that SB203580, but not U0126, attenuated TPA-induced CREB DNA binding in mouse skin.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	68-71
17404063-8	2007	Pretreatment with U0126 and SB203580, pharmacological inhibitors of ERK and p38 MAPK, respectively, showed that SB203580, but not U0126, attenuated TPA-induced CREB DNA binding in mouse skin.	U 0126	18-23	mitogen-activated protein kinase 14	Mus musculus	76-84
17038630-4	2007	Inhibition of ERK1/2 using the MEK1/MEK2 inhibitor, U0126 (but not the inactive analogue) led to a significant increase in apoB secretion.	U 0126	52-57	mitogen-activated protein kinase 3	Homo sapiens	14-20
17038630-4	2007	Inhibition of ERK1/2 using the MEK1/MEK2 inhibitor, U0126 (but not the inactive analogue) led to a significant increase in apoB secretion.	U 0126	52-57	mitogen-activated protein kinase kinase 1	Homo sapiens	31-35
17038630-4	2007	Inhibition of ERK1/2 using the MEK1/MEK2 inhibitor, U0126 (but not the inactive analogue) led to a significant increase in apoB secretion.	U 0126	52-57	mitogen-activated protein kinase kinase 2	Homo sapiens	36-40
17038630-4	2007	Inhibition of ERK1/2 using the MEK1/MEK2 inhibitor, U0126 (but not the inactive analogue) led to a significant increase in apoB secretion.	U 0126	52-57	apolipoprotein B	Homo sapiens	123-127
17636410-9	2007	Moreover, U0126, a MEK1/2 inhibitor, also inhibited B16BL6 cell invasion and metastasis, as well as the mRNA expression and protein activities of MMP-1, -2, -9 and MT1-MMP.	U 0126	10-15	mitogen-activated protein kinase kinase 1	Mus musculus	19-25
17067562-6	2007	We further observed that the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 abolishes PGE2-induced Stat3 activation whereas the p38 MAP kinase blocker SB203580 has no effect.	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	29-70
17067562-6	2007	We further observed that the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 abolishes PGE2-induced Stat3 activation whereas the p38 MAP kinase blocker SB203580 has no effect.	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	72-78
17067562-6	2007	We further observed that the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 abolishes PGE2-induced Stat3 activation whereas the p38 MAP kinase blocker SB203580 has no effect.	U 0126	90-95	signal transducer and activator of transcription 3	Rattus norvegicus	119-124
17636410-9	2007	Moreover, U0126, a MEK1/2 inhibitor, also inhibited B16BL6 cell invasion and metastasis, as well as the mRNA expression and protein activities of MMP-1, -2, -9 and MT1-MMP.	U 0126	10-15	matrix metallopeptidase 13	Mus musculus	146-159
17636410-9	2007	Moreover, U0126, a MEK1/2 inhibitor, also inhibited B16BL6 cell invasion and metastasis, as well as the mRNA expression and protein activities of MMP-1, -2, -9 and MT1-MMP.	U 0126	10-15	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	164-171
17522999-7	2007	The necessity of Erk1/2 activation for keratinocyte survival on collagen gel was confirmed with experiment using U0126, an inhibitor for Erk1/2.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	17-23
17522999-7	2007	The necessity of Erk1/2 activation for keratinocyte survival on collagen gel was confirmed with experiment using U0126, an inhibitor for Erk1/2.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	137-143
17055484-10	2007	Moreover, inhibition of ERK activation by UO126 and PD98059 markedly decreased HGF-stimulated HBMEC migration.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	24-27
17008391-7	2007	A specific ERK inhibitor, U0126, increased estradiol production and decreased FSH- and FSK-induced progesterone production and cAMP synthesis.	U 0126	26-31	Eph receptor B1	Rattus norvegicus	11-14
17241271-9	2007	Remarkably, U0126, an inhibitor of ERK activation, at doses which reduced the hyperactive pERK levels in NF1(+/-) mice to the levels observed in control mice, caused a reduction in the deficits in early-phase LTP and completely rescued the long-term LTP deficits.	U 0126	12-17	mitogen-activated protein kinase 1	Mus musculus	35-38
17241271-9	2007	Remarkably, U0126, an inhibitor of ERK activation, at doses which reduced the hyperactive pERK levels in NF1(+/-) mice to the levels observed in control mice, caused a reduction in the deficits in early-phase LTP and completely rescued the long-term LTP deficits.	U 0126	12-17	neurofibromin 1	Mus musculus	105-108
17055484-10	2007	Moreover, inhibition of ERK activation by UO126 and PD98059 markedly decreased HGF-stimulated HBMEC migration.	U 0126	42-47	hepatocyte growth factor	Homo sapiens	79-82
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	C-X-C motif chemokine ligand 12	Homo sapiens	33-38
17481939-4	2007	Pretreatment of the cells with U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of FN and delayed phosphorylation of Smad2, suggesting that ERK is involved in the SPC induction of FN expression through activation of Smad2.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
17481939-4	2007	Pretreatment of the cells with U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of FN and delayed phosphorylation of Smad2, suggesting that ERK is involved in the SPC induction of FN expression through activation of Smad2.	U 0126	31-36	fibronectin 1	Homo sapiens	106-108
17481939-4	2007	Pretreatment of the cells with U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of FN and delayed phosphorylation of Smad2, suggesting that ERK is involved in the SPC induction of FN expression through activation of Smad2.	U 0126	31-36	SMAD family member 2	Homo sapiens	140-145
17481939-4	2007	Pretreatment of the cells with U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of FN and delayed phosphorylation of Smad2, suggesting that ERK is involved in the SPC induction of FN expression through activation of Smad2.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	163-166
17481939-4	2007	Pretreatment of the cells with U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of FN and delayed phosphorylation of Smad2, suggesting that ERK is involved in the SPC induction of FN expression through activation of Smad2.	U 0126	31-36	fibronectin 1	Homo sapiens	203-205
17481939-4	2007	Pretreatment of the cells with U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of FN and delayed phosphorylation of Smad2, suggesting that ERK is involved in the SPC induction of FN expression through activation of Smad2.	U 0126	31-36	SMAD family member 2	Homo sapiens	239-244
17081797-5	2007	OSM induced phosphorylation of STAT1, and treatment of adipocytes with JAK3 inhibitor WHI-P131 or MEK inhibitor U0126, but not with JAK2 inhibitor AG490, prevented the activation of STAT1.	U 0126	112-117	signal transducer and activator of transcription 1	Homo sapiens	31-36
17081797-5	2007	OSM induced phosphorylation of STAT1, and treatment of adipocytes with JAK3 inhibitor WHI-P131 or MEK inhibitor U0126, but not with JAK2 inhibitor AG490, prevented the activation of STAT1.	U 0126	112-117	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
17081797-5	2007	OSM induced phosphorylation of STAT1, and treatment of adipocytes with JAK3 inhibitor WHI-P131 or MEK inhibitor U0126, but not with JAK2 inhibitor AG490, prevented the activation of STAT1.	U 0126	112-117	signal transducer and activator of transcription 1	Homo sapiens	182-187
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	Janus kinase 3	Homo sapiens	195-199
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	mitogen-activated protein kinase 1	Homo sapiens	227-230
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	Janus kinase 2	Homo sapiens	240-244
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	Janus kinase 3	Homo sapiens	249-253
17169599-3	2007	The OSM-stimulated expression of SDF-1 in hATSCs was completely abrogated by pretreatment of the cells with U0126, an MEK-specific inhibitor, but not with AG490, a JAK2 inhibitor, or WHI-P131, a JAK3 inhibitor, suggesting that ERK, but not JAK2 and JAK3, is involved in the OSM-induced expression of SDF-1.	U 0126	108-113	C-X-C motif chemokine ligand 12	Homo sapiens	300-305
17151336-6	2007	Mitogen-activated protein kinase kinase (MEK) inhibitor U0126 blocked ouabain-induced ERK activation and cell proliferation, suggesting that ouabain effect is mediated through the MEK-ERK pathway.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	0-39
17143555-12	2007	These results provide, for the first time, strong evidence that a combined association implicating a MEK inhibitor (U0126) and diosgenin is the most effective in inducing very strong apoptosis with down-regulation of COX-2 expression and activity in human RA FLS.	U 0126	116-121	mitogen-activated protein kinase kinase 7	Homo sapiens	101-104
17143555-12	2007	These results provide, for the first time, strong evidence that a combined association implicating a MEK inhibitor (U0126) and diosgenin is the most effective in inducing very strong apoptosis with down-regulation of COX-2 expression and activity in human RA FLS.	U 0126	116-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	217-222
17208589-10	2007	The reduction by IFN-gamma was partially restored by U0126, inhibitor for mitogen-activated protein kinase kinase 1/2, suggesting a role for extracellular signal-regulated kinase pathway.	U 0126	53-58	interferon gamma	Homo sapiens	17-26
17208589-10	2007	The reduction by IFN-gamma was partially restored by U0126, inhibitor for mitogen-activated protein kinase kinase 1/2, suggesting a role for extracellular signal-regulated kinase pathway.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	74-117
17151336-6	2007	Mitogen-activated protein kinase kinase (MEK) inhibitor U0126 blocked ouabain-induced ERK activation and cell proliferation, suggesting that ouabain effect is mediated through the MEK-ERK pathway.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
17151336-6	2007	Mitogen-activated protein kinase kinase (MEK) inhibitor U0126 blocked ouabain-induced ERK activation and cell proliferation, suggesting that ouabain effect is mediated through the MEK-ERK pathway.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	86-89
17151336-6	2007	Mitogen-activated protein kinase kinase (MEK) inhibitor U0126 blocked ouabain-induced ERK activation and cell proliferation, suggesting that ouabain effect is mediated through the MEK-ERK pathway.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	180-183
17151336-6	2007	Mitogen-activated protein kinase kinase (MEK) inhibitor U0126 blocked ouabain-induced ERK activation and cell proliferation, suggesting that ouabain effect is mediated through the MEK-ERK pathway.	U 0126	56-61	mitogen-activated protein kinase 1	Homo sapiens	184-187
17189461-6	2007	The mitogenic response to Emdogain depended on Extracellular Regulated Kinase (ERK) activation, which occurred in two waves, peaking after 15 min and 4 to 6 hrs, since it was abolished by U0126, a specific MAPK inhibitor.	U 0126	188-193	mitogen-activated protein kinase 1	Homo sapiens	47-77
17138068-2	2007	In the present study, using the ERK inhibitor U0126, we investigated the role of the ERK pathway in histopathological and behavioral outcomes after TBI.	U 0126	46-51	Eph receptor B1	Rattus norvegicus	85-88
17138068-4	2007	The ERK inhibitor U0126 was injected intravenously before injury at 100, 200 and 400 microg/kg.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	4-7
17138068-8	2007	Pretreatment with U0126 significantly reduced both CA3 neuronal damage and contusional lesion volume after injury.	U 0126	18-23	carbonic anhydrase 3	Rattus norvegicus	51-54
17189461-6	2007	The mitogenic response to Emdogain depended on Extracellular Regulated Kinase (ERK) activation, which occurred in two waves, peaking after 15 min and 4 to 6 hrs, since it was abolished by U0126, a specific MAPK inhibitor.	U 0126	188-193	mitogen-activated protein kinase 1	Homo sapiens	79-82
17189461-6	2007	The mitogenic response to Emdogain depended on Extracellular Regulated Kinase (ERK) activation, which occurred in two waves, peaking after 15 min and 4 to 6 hrs, since it was abolished by U0126, a specific MAPK inhibitor.	U 0126	188-193	mitogen-activated protein kinase 1	Homo sapiens	206-210
17564756-9	2007	Moreover, in FL-RAGE cells, decreased protein levels of the cdk inhibitor p16 were observed, and the p42/44 MAPK inhibitor UO126 prevented AGE and S100B stimulated cyclin D(1) expression and hindered cells to enter the S-phase.	U 0126	123-128	advanced glycosylation end product-specific receptor	Mus musculus	16-20
17564756-9	2007	Moreover, in FL-RAGE cells, decreased protein levels of the cdk inhibitor p16 were observed, and the p42/44 MAPK inhibitor UO126 prevented AGE and S100B stimulated cyclin D(1) expression and hindered cells to enter the S-phase.	U 0126	123-128	cyclin-dependent kinase 20	Mus musculus	101-104
17564756-9	2007	Moreover, in FL-RAGE cells, decreased protein levels of the cdk inhibitor p16 were observed, and the p42/44 MAPK inhibitor UO126 prevented AGE and S100B stimulated cyclin D(1) expression and hindered cells to enter the S-phase.	U 0126	123-128	mitogen-activated protein kinase 1	Mus musculus	108-112
17564756-9	2007	Moreover, in FL-RAGE cells, decreased protein levels of the cdk inhibitor p16 were observed, and the p42/44 MAPK inhibitor UO126 prevented AGE and S100B stimulated cyclin D(1) expression and hindered cells to enter the S-phase.	U 0126	123-128	S100 protein, beta polypeptide, neural	Mus musculus	147-152
17564756-9	2007	Moreover, in FL-RAGE cells, decreased protein levels of the cdk inhibitor p16 were observed, and the p42/44 MAPK inhibitor UO126 prevented AGE and S100B stimulated cyclin D(1) expression and hindered cells to enter the S-phase.	U 0126	123-128	cyclin D1	Mus musculus	164-175
18004277-3	2007	Model analysis and experimental validation show that (i) ErbB2 overexpression, which occurs in approximately 25% of all breast cancers, transforms transient EGF-induced signaling into sustained signaling, (ii) HRG-induced ERK activity is much more robust to the ERK cascade inhibitor U0126 than EGF-induced ERK activity, and (iii) phosphoinositol-3 kinase is a major regulator of post-peak but not pre-peak EGF-induced ERK activity.	U 0126	284-289	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
17259347-8	2007	ERRalpha1-activated transcription in BT-474 cells was inhibited by disruption of ErbB2/epidermal growth factor receptor signaling with trastuzumab or gefitinib or inactivation of downstream components of this signaling, MAPK kinase/MAPK, and phosphatidylinositol-3-OH kinase/Akt, with U0126 or LY294002, respectively.	U 0126	285-290	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-86
18004277-3	2007	Model analysis and experimental validation show that (i) ErbB2 overexpression, which occurs in approximately 25% of all breast cancers, transforms transient EGF-induced signaling into sustained signaling, (ii) HRG-induced ERK activity is much more robust to the ERK cascade inhibitor U0126 than EGF-induced ERK activity, and (iii) phosphoinositol-3 kinase is a major regulator of post-peak but not pre-peak EGF-induced ERK activity.	U 0126	284-289	mitogen-activated protein kinase 1	Homo sapiens	222-225
16979915-10	2007	Dorsohippocampal injections of the Mek inhibitors U0126 (0.5 microg/site) and PD98059 (1.5 microg/site) immediately after the nonreinforced trials prevented Erk-1/2 activation and significantly impaired extinction.	U 0126	50-55	midkine	Mus musculus	35-38
16979915-10	2007	Dorsohippocampal injections of the Mek inhibitors U0126 (0.5 microg/site) and PD98059 (1.5 microg/site) immediately after the nonreinforced trials prevented Erk-1/2 activation and significantly impaired extinction.	U 0126	50-55	mitogen-activated protein kinase 3	Mus musculus	157-164
17198194-9	2007	Mitogen-activated protein kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	45-50	matrix metallopeptidase 3	Homo sapiens	89-94
17202844-8	2006	Furthermore, pretreatment with specific MAPK pathway inhibitors, including the MEK inhibitor U0126, the JNK inhibitor SP600125, and the p38 kinase inhibitor SB202190, completely inhibited ANX-inducible expression of Egr-1.	U 0126	93-98	mitogen-activated protein kinase 3	Homo sapiens	40-44
17202844-8	2006	Furthermore, pretreatment with specific MAPK pathway inhibitors, including the MEK inhibitor U0126, the JNK inhibitor SP600125, and the p38 kinase inhibitor SB202190, completely inhibited ANX-inducible expression of Egr-1.	U 0126	93-98	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
17054908-6	2006	However, we observed that mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors (PD98059 and U0126) significantly sensitized the GC-induced transactivation of anti-inflammatory genes (glucocorticoid-induced leucine zipper (GILZ) and mitogen-activated protein kinase phosphatase (MKP)-1) and FK506 binding protein (FKBP) 51 gene in the presence of TNFalpha.	U 0126	142-147	mitogen-activated protein kinase kinase 1	Homo sapiens	107-112
17054908-6	2006	However, we observed that mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors (PD98059 and U0126) significantly sensitized the GC-induced transactivation of anti-inflammatory genes (glucocorticoid-induced leucine zipper (GILZ) and mitogen-activated protein kinase phosphatase (MKP)-1) and FK506 binding protein (FKBP) 51 gene in the presence of TNFalpha.	U 0126	142-147	mitogen-activated protein kinase 1	Homo sapiens	113-116
17054908-6	2006	However, we observed that mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors (PD98059 and U0126) significantly sensitized the GC-induced transactivation of anti-inflammatory genes (glucocorticoid-induced leucine zipper (GILZ) and mitogen-activated protein kinase phosphatase (MKP)-1) and FK506 binding protein (FKBP) 51 gene in the presence of TNFalpha.	U 0126	142-147	TSC22 domain family member 3	Homo sapiens	233-270
17054908-6	2006	However, we observed that mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors (PD98059 and U0126) significantly sensitized the GC-induced transactivation of anti-inflammatory genes (glucocorticoid-induced leucine zipper (GILZ) and mitogen-activated protein kinase phosphatase (MKP)-1) and FK506 binding protein (FKBP) 51 gene in the presence of TNFalpha.	U 0126	142-147	TSC22 domain family member 3	Homo sapiens	272-276
17054908-6	2006	However, we observed that mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors (PD98059 and U0126) significantly sensitized the GC-induced transactivation of anti-inflammatory genes (glucocorticoid-induced leucine zipper (GILZ) and mitogen-activated protein kinase phosphatase (MKP)-1) and FK506 binding protein (FKBP) 51 gene in the presence of TNFalpha.	U 0126	142-147	dual specificity phosphatase 1	Homo sapiens	328-334
17113582-2	2006	We showed that TRAIL-induced apoptosis may be differentially regulated by inhibitors of MEK ERK (U0126) or PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29) and TRAIL-resistant (SW620) human epithelial colon cancer cells.	U 0126	97-102	TNF superfamily member 10	Homo sapiens	15-20
17054908-6	2006	However, we observed that mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors (PD98059 and U0126) significantly sensitized the GC-induced transactivation of anti-inflammatory genes (glucocorticoid-induced leucine zipper (GILZ) and mitogen-activated protein kinase phosphatase (MKP)-1) and FK506 binding protein (FKBP) 51 gene in the presence of TNFalpha.	U 0126	142-147	tumor necrosis factor	Homo sapiens	396-404
17113582-2	2006	We showed that TRAIL-induced apoptosis may be differentially regulated by inhibitors of MEK ERK (U0126) or PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29) and TRAIL-resistant (SW620) human epithelial colon cancer cells.	U 0126	97-102	mitogen-activated protein kinase kinase 7	Homo sapiens	88-91
17007989-5	2006	The spin-trap s-PBN, the ERK1/2 inhibitor U0126 and the antioxidant Vitamin E inhibited the 2-CPA-induced ROS formation completely, while the mitochondrial transition permeability pore blocker cyclosporine A inhibited the ROS formation partly.	U 0126	42-47	mitogen-activated protein kinase 3	Homo sapiens	25-31
17113582-2	2006	We showed that TRAIL-induced apoptosis may be differentially regulated by inhibitors of MEK ERK (U0126) or PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29) and TRAIL-resistant (SW620) human epithelial colon cancer cells.	U 0126	97-102	mitogen-activated protein kinase 1	Homo sapiens	92-95
17113582-2	2006	We showed that TRAIL-induced apoptosis may be differentially regulated by inhibitors of MEK ERK (U0126) or PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29) and TRAIL-resistant (SW620) human epithelial colon cancer cells.	U 0126	97-102	TNF superfamily member 10	Homo sapiens	138-143
17113582-2	2006	We showed that TRAIL-induced apoptosis may be differentially regulated by inhibitors of MEK ERK (U0126) or PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29) and TRAIL-resistant (SW620) human epithelial colon cancer cells.	U 0126	97-102	TNF superfamily member 10	Homo sapiens	138-143
17113582-3	2006	U0126 or LY294002 significantly enhanced TRAIL-induced apoptosis in HT-29 cells, but not in SW620 cells.	U 0126	0-5	TNF superfamily member 10	Homo sapiens	41-46
17007989-5	2006	The spin-trap s-PBN, the ERK1/2 inhibitor U0126 and the antioxidant Vitamin E inhibited the 2-CPA-induced ROS formation completely, while the mitochondrial transition permeability pore blocker cyclosporine A inhibited the ROS formation partly.	U 0126	42-47	carboxypeptidase A1	Homo sapiens	94-97
16978663-5	2006	The MAP kinase-Erk kinase 1 inhibitor U0126 (0.1-10 microM) suppressed the LPS-induced phosphorylation of p44/42 MAP kinase, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa HDC protein in a concentration-dependent manner.	U 0126	38-43	toll-like receptor 4	Mus musculus	75-78
16978663-5	2006	The MAP kinase-Erk kinase 1 inhibitor U0126 (0.1-10 microM) suppressed the LPS-induced phosphorylation of p44/42 MAP kinase, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa HDC protein in a concentration-dependent manner.	U 0126	38-43	mitogen-activated protein kinase 3	Mus musculus	106-123
16978663-5	2006	The MAP kinase-Erk kinase 1 inhibitor U0126 (0.1-10 microM) suppressed the LPS-induced phosphorylation of p44/42 MAP kinase, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa HDC protein in a concentration-dependent manner.	U 0126	38-43	toll-like receptor 4	Mus musculus	143-146
16978663-5	2006	The MAP kinase-Erk kinase 1 inhibitor U0126 (0.1-10 microM) suppressed the LPS-induced phosphorylation of p44/42 MAP kinase, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa HDC protein in a concentration-dependent manner.	U 0126	38-43	histidine decarboxylase	Mus musculus	201-204
16978663-5	2006	The MAP kinase-Erk kinase 1 inhibitor U0126 (0.1-10 microM) suppressed the LPS-induced phosphorylation of p44/42 MAP kinase, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa HDC protein in a concentration-dependent manner.	U 0126	38-43	histidine decarboxylase	Mus musculus	221-224
16978663-7	2006	Combined treatment with U0126 (0.3 microM) and SP600125 (10 microM) inhibited the LPS-induced production of histamine additively.	U 0126	24-29	toll-like receptor 4	Mus musculus	82-85
16868306-5	2006	COX-2 induction by HGF was preceded by activation of ERK1/2, and an ERK1/2-specific inhibitor, U-0126 (10 microM), completely abolished HGF-induced COX-2 expression.	U 0126	95-101	cytochrome c oxidase subunit II	Canis lupus familiaris	0-5
16798728-8	2006	Inhibition of ERK1/2 and Akt activity by U-0126 and LY-294002, respectively, increased TNF-alpha-induced apoptosis.	U 0126	41-47	mitogen activated protein kinase 3	Rattus norvegicus	14-20
16798728-8	2006	Inhibition of ERK1/2 and Akt activity by U-0126 and LY-294002, respectively, increased TNF-alpha-induced apoptosis.	U 0126	41-47	AKT serine/threonine kinase 1	Rattus norvegicus	25-28
16798728-8	2006	Inhibition of ERK1/2 and Akt activity by U-0126 and LY-294002, respectively, increased TNF-alpha-induced apoptosis.	U 0126	41-47	tumor necrosis factor	Rattus norvegicus	87-96
21171355-0	2007	[Effects of intrathecal injection of U0126 on the expression of phospho-CREB in spinal cord of morphine-induced withdrawal rats].	U 0126	37-42	cAMP responsive element binding protein 1	Rattus norvegicus	72-76
21171355-8	2007	Compared with withdrawal group, level of Phospho-CREB protein detected by Western blot in spinal cord of U0126 group was significantly lower.	U 0126	105-110	cAMP responsive element binding protein 1	Rattus norvegicus	49-53
21171355-9	2007	CONCLUSION: MEK inhibitors U0126 could suppress expression of Phospho-CREB in the spinal cord.	U 0126	27-32	cAMP responsive element binding protein 1	Rattus norvegicus	70-74
16868306-5	2006	COX-2 induction by HGF was preceded by activation of ERK1/2, and an ERK1/2-specific inhibitor, U-0126 (10 microM), completely abolished HGF-induced COX-2 expression.	U 0126	95-101	hepatocyte growth factor	Canis lupus familiaris	19-22
16868306-5	2006	COX-2 induction by HGF was preceded by activation of ERK1/2, and an ERK1/2-specific inhibitor, U-0126 (10 microM), completely abolished HGF-induced COX-2 expression.	U 0126	95-101	mitogen-activated protein kinase 1	Canis lupus familiaris	68-74
16868306-5	2006	COX-2 induction by HGF was preceded by activation of ERK1/2, and an ERK1/2-specific inhibitor, U-0126 (10 microM), completely abolished HGF-induced COX-2 expression.	U 0126	95-101	hepatocyte growth factor	Canis lupus familiaris	136-139
16868306-5	2006	COX-2 induction by HGF was preceded by activation of ERK1/2, and an ERK1/2-specific inhibitor, U-0126 (10 microM), completely abolished HGF-induced COX-2 expression.	U 0126	95-101	cytochrome c oxidase subunit II	Canis lupus familiaris	148-153
17088989-6	2006	When ERK1/2 was inhibited by U0126, apoptosis by VK2 in Hep3B, but not in Huh6, was significantly enhanced.	U 0126	29-34	mitogen-activated protein kinase 3	Homo sapiens	5-11
17384279-6	2006	In contrast, UO126 treatment resulted in only a transient decrease of ERK activity and did not induce cell death.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	70-73
17384282-7	2006	In another experiment, 15d-PGJ2 induced phosphorylation of extracellular signal-regulated kinase (ERK1/2) in 12 h. Treatment of MCF-7 cells with U0126 or transient transfection with dominant negative ERK (DN-ERK) abrogated 15d-PGJ2-induced VEGF expression.	U 0126	145-150	mitogen-activated protein kinase 3	Homo sapiens	98-104
17384282-7	2006	In another experiment, 15d-PGJ2 induced phosphorylation of extracellular signal-regulated kinase (ERK1/2) in 12 h. Treatment of MCF-7 cells with U0126 or transient transfection with dominant negative ERK (DN-ERK) abrogated 15d-PGJ2-induced VEGF expression.	U 0126	145-150	mitogen-activated protein kinase 1	Homo sapiens	98-101
16848764-7	2006	MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK inhibitor U0126 and PI3K (phosphoinositide 3-kinase) inhibitor LY294002 also inhibited EGF-induced AQP3 expression and cell migration.	U 0126	111-116	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
17157164-0	2006	The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.	U 0126	59-64	heat shock protein 90 alpha family class A member 1	Homo sapiens	4-9
16943367-6	2006	In vitro, when MGCs and COCs were treated with U0126 - a specific inhibitor of MAPK3/1 activation - gonadotropin-induced P(4) production, 8-Br-cAMP-induced P(4) production, and expression of Star and Cyp11a1 mRNA were significantly downregulated, whereas the levels of E(2) and Cyp19a1 mRNA in the same samples were significantly upregulated.	U 0126	47-52	mitogen-activated protein kinase 3	Mus musculus	79-84
16943367-6	2006	In vitro, when MGCs and COCs were treated with U0126 - a specific inhibitor of MAPK3/1 activation - gonadotropin-induced P(4) production, 8-Br-cAMP-induced P(4) production, and expression of Star and Cyp11a1 mRNA were significantly downregulated, whereas the levels of E(2) and Cyp19a1 mRNA in the same samples were significantly upregulated.	U 0126	47-52	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	200-207
16943367-6	2006	In vitro, when MGCs and COCs were treated with U0126 - a specific inhibitor of MAPK3/1 activation - gonadotropin-induced P(4) production, 8-Br-cAMP-induced P(4) production, and expression of Star and Cyp11a1 mRNA were significantly downregulated, whereas the levels of E(2) and Cyp19a1 mRNA in the same samples were significantly upregulated.	U 0126	47-52	cytochrome P450, family 19, subfamily a, polypeptide 1	Mus musculus	278-285
17092913-4	2006	Conversely, U0126, a MEK inhibitor, and SAHA or SBHA, 2 histone deacetylase inhibitors, reduced the expression of involucrin during calcium-induced stratification.	U 0126	12-17	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
17105765-5	2006	Pretreatment of the cells with pertussis toxin or U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of beta-SMA and delayed phosphorylation of Smad2, suggesting that the Gi/o-ERK pathway is involved in the increased expression of alpha-SMA through induction of delayed Smad2 activation.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
16972261-2	2006	This effect was potentiated by co-treatment with MEK/ERK (PD98059, U0126) and JNK (SP600125, AS601245) inhibitors, but not with p38 (SB203580, SB220025) inhibitors.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	49-52
16972261-2	2006	This effect was potentiated by co-treatment with MEK/ERK (PD98059, U0126) and JNK (SP600125, AS601245) inhibitors, but not with p38 (SB203580, SB220025) inhibitors.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	53-56
16972261-6	2006	Thus, while it was prevented by N-acetyl-L-cysteine (NAC) in the case of U0126, it behaved as a NAC-insensitive process, regulated at the level of DL-buthionine-(S,R)-sulfoximine (BSO)-sensitive enzyme activity, in the case of SP600125.	U 0126	73-78	X-linked Kx blood group	Homo sapiens	53-56
17105765-5	2006	Pretreatment of the cells with pertussis toxin or U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of beta-SMA and delayed phosphorylation of Smad2, suggesting that the Gi/o-ERK pathway is involved in the increased expression of alpha-SMA through induction of delayed Smad2 activation.	U 0126	50-55	SMAD family member 2	Homo sapiens	165-170
17105765-5	2006	Pretreatment of the cells with pertussis toxin or U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of beta-SMA and delayed phosphorylation of Smad2, suggesting that the Gi/o-ERK pathway is involved in the increased expression of alpha-SMA through induction of delayed Smad2 activation.	U 0126	50-55	EPH receptor B2	Homo sapiens	197-200
17105765-5	2006	Pretreatment of the cells with pertussis toxin or U0126, an MEK inhibitor, markedly attenuated the SPC-induced expression of beta-SMA and delayed phosphorylation of Smad2, suggesting that the Gi/o-ERK pathway is involved in the increased expression of alpha-SMA through induction of delayed Smad2 activation.	U 0126	50-55	SMAD family member 2	Homo sapiens	291-296
17138860-8	2006	The MEK1/2 inhibitors PD098059 and U0126, but not the p38 MAPK inhibitor SB203580, decreased TNF antiapoptotic signaling as measured by caspase 3 activity.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
17138860-8	2006	The MEK1/2 inhibitors PD098059 and U0126, but not the p38 MAPK inhibitor SB203580, decreased TNF antiapoptotic signaling as measured by caspase 3 activity.	U 0126	35-40	tumor necrosis factor	Homo sapiens	93-96
17064361-4	2006	Infusion of the extracellular signal-regulated kinase (ERK) inhibitor U0126 blocked BDNF-LTP and modulation of the translation factor activity and expression.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	16-53
17064361-4	2006	Infusion of the extracellular signal-regulated kinase (ERK) inhibitor U0126 blocked BDNF-LTP and modulation of the translation factor activity and expression.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	55-58
17064361-4	2006	Infusion of the extracellular signal-regulated kinase (ERK) inhibitor U0126 blocked BDNF-LTP and modulation of the translation factor activity and expression.	U 0126	70-75	brain-derived neurotrophic factor	Rattus norvegicus	84-88
17138860-8	2006	The MEK1/2 inhibitors PD098059 and U0126, but not the p38 MAPK inhibitor SB203580, decreased TNF antiapoptotic signaling as measured by caspase 3 activity.	U 0126	35-40	caspase 3	Homo sapiens	136-145
16954213-9	2006	(b) U0126, a specific MEK inhibitor, completely abolished BNIP3 expression and the stimulation of promoter activity by NO and Ras, whereas 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, SB203580, and wortmannin, specific inhibitors of soluble guanylyl cyclase, p38 MAPK, and phosphatidylinositol 3-kinase, respectively, had no effect.	U 0126	4-9	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
17313766-5	2006	RESULTS: (1) the production in 15 and 25 micromol/L U0126 incubated groups was (87 +/- 11) pg/ml and (75 +/- 19) pg/ml respectively, which was significantly decreased compared with that in 10(-7) mol/L ALDO incubated group (P &lt; 0.05), however, the amount of TGF-beta1 in these groups were still significant higher than that in the control group (P &lt; 0.05).	U 0126	52-57	transforming growth factor beta 1	Homo sapiens	261-270
16983661-5	2006	Furthermore, inhibition of ERK activation with the UO126 compound totally prevented OPC differentiation in response to pH(i) shift.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	27-30
16983661-5	2006	Furthermore, inhibition of ERK activation with the UO126 compound totally prevented OPC differentiation in response to pH(i) shift.	U 0126	51-56	glucose-6-phosphate isomerase	Homo sapiens	119-121
17050774-8	2006	Among proline-directed kinases, extracellular signal-regulated kinase 1/2 (ERK1/2) is present in mammalian sperm; nevertheless, U0126 and PD098059, two inhibitors of the ERK pathway, did not block this phosphorylation in mouse sperm.	U 0126	128-133	mitogen-activated protein kinase 3	Homo sapiens	75-78
17253948-5	2006	U0126, an ERK inhibitor, and AMD3100, a CXCR4 antagonist, inhibited the proliferation of CXCR4 overexpression-induced proliferation and ERK phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	10-13
17253948-5	2006	U0126, an ERK inhibitor, and AMD3100, a CXCR4 antagonist, inhibited the proliferation of CXCR4 overexpression-induced proliferation and ERK phosphorylation.	U 0126	0-5	C-X-C motif chemokine receptor 4	Homo sapiens	89-94
17253948-5	2006	U0126, an ERK inhibitor, and AMD3100, a CXCR4 antagonist, inhibited the proliferation of CXCR4 overexpression-induced proliferation and ERK phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	136-139
16963134-10	2006	The MAPK inhibitors U0126 and SB203580 respectively decreased by 63% and 72% PACAP-evoked EM66 release.	U 0126	20-25	adenylate cyclase activating polypeptide 1	Bos taurus	77-82
17020750-7	2006	Neuroprotection was associated with ERK and Akt activation and was abrogated by simultaneous treatment with the MEK (U0126) and PI3-K (LY294002) inhibitors.	U 0126	117-122	mitogen-activated protein kinase 1	Homo sapiens	36-39
17020750-7	2006	Neuroprotection was associated with ERK and Akt activation and was abrogated by simultaneous treatment with the MEK (U0126) and PI3-K (LY294002) inhibitors.	U 0126	117-122	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
16954213-9	2006	(b) U0126, a specific MEK inhibitor, completely abolished BNIP3 expression and the stimulation of promoter activity by NO and Ras, whereas 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, SB203580, and wortmannin, specific inhibitors of soluble guanylyl cyclase, p38 MAPK, and phosphatidylinositol 3-kinase, respectively, had no effect.	U 0126	4-9	BCL2 interacting protein 3	Homo sapiens	58-63
16954213-9	2006	(b) U0126, a specific MEK inhibitor, completely abolished BNIP3 expression and the stimulation of promoter activity by NO and Ras, whereas 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, SB203580, and wortmannin, specific inhibitors of soluble guanylyl cyclase, p38 MAPK, and phosphatidylinositol 3-kinase, respectively, had no effect.	U 0126	4-9	mitogen-activated protein kinase 1	Homo sapiens	259-262
16982618-8	2006	In addition, U0126 (a selective inhibitor of MEK kinase responsible for ERK phosphorylation) blocked ERK1/2 activation by fentanyl.	U 0126	13-18	mitogen-activated protein kinase 3	Mus musculus	101-107
16954213-9	2006	(b) U0126, a specific MEK inhibitor, completely abolished BNIP3 expression and the stimulation of promoter activity by NO and Ras, whereas 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, SB203580, and wortmannin, specific inhibitors of soluble guanylyl cyclase, p38 MAPK, and phosphatidylinositol 3-kinase, respectively, had no effect.	U 0126	4-9	mitogen-activated protein kinase 3	Homo sapiens	263-267
16757729-7	2006	The inhibition of HCO(3)(-) absorption by aldosterone was largely eliminated by the MEK/ERK inhibitors U-0126 and PD-98059.	U 0126	103-109	Eph receptor B1	Rattus norvegicus	88-91
16757729-9	2006	This ERK activation is rapid (&lt;/=5 min) and is blocked by U-0126 or PD-98059 but is unaffected by spironolactone or actinomycin D.	U 0126	61-67	Eph receptor B1	Rattus norvegicus	5-8
16757729-10	2006	Pretreatment with U-0126 to block ERK activation prevented the effect of aldosterone to inhibit apical NHE3.	U 0126	18-24	Eph receptor B1	Rattus norvegicus	34-37
16757729-10	2006	Pretreatment with U-0126 to block ERK activation prevented the effect of aldosterone to inhibit apical NHE3.	U 0126	18-24	solute carrier family 9 member A3	Rattus norvegicus	103-107
16839545-4	2006	UO126, a mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase (MEK) 1 and 2 inhibitor reversed this effect.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	43-47
21783722-8	2006	In human cancer mammary epithelial cell lines, we found that ERK MAPK signaling pathway was deregulated: (1) ERK1/2 was constitutively activated at various levels; (2) ERK1/2 was further significantly activated in response to NNK induction; (3) UO126 partially or totally failed to inhibit ERK1/2 activation induced by NNK; (4) The expression levels of ERK1/2 in the cancer cell lines were much higher than those in the normal mammary epithelial cells.	U 0126	245-250	mitogen-activated protein kinase 3	Homo sapiens	65-69
21783722-8	2006	In human cancer mammary epithelial cell lines, we found that ERK MAPK signaling pathway was deregulated: (1) ERK1/2 was constitutively activated at various levels; (2) ERK1/2 was further significantly activated in response to NNK induction; (3) UO126 partially or totally failed to inhibit ERK1/2 activation induced by NNK; (4) The expression levels of ERK1/2 in the cancer cell lines were much higher than those in the normal mammary epithelial cells.	U 0126	245-250	mitogen-activated protein kinase 3	Homo sapiens	109-115
17079486-4	2006	Whereas the antiandrogen bicalutamide provided no further suppression, treatment with the mitogen-activated protein kinase (MAPK) inhibitor U0126 completely abrogated the residual activity, indicating a MAPK-dependent, AR-independent pathway for regulating the PSA promoter.	U 0126	140-145	androgen receptor	Homo sapiens	219-221
21783722-4	2006	MEK1/2 specific inhibitor UO126 completely blocked NNK-induced ERK1/2 activation and cell proliferation, whereas nicotinic receptor nAchR antagonist mecamylamine partially and the selective alpha(7)-nAchR antagonist alpha-bungarotoxin essentially inhibited the NNK-induced ERK1/2 activation and cell proliferation.	U 0126	26-31	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
21783722-4	2006	MEK1/2 specific inhibitor UO126 completely blocked NNK-induced ERK1/2 activation and cell proliferation, whereas nicotinic receptor nAchR antagonist mecamylamine partially and the selective alpha(7)-nAchR antagonist alpha-bungarotoxin essentially inhibited the NNK-induced ERK1/2 activation and cell proliferation.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	63-69
16839545-4	2006	UO126, a mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase (MEK) 1 and 2 inhibitor reversed this effect.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	49-107
21783722-8	2006	In human cancer mammary epithelial cell lines, we found that ERK MAPK signaling pathway was deregulated: (1) ERK1/2 was constitutively activated at various levels; (2) ERK1/2 was further significantly activated in response to NNK induction; (3) UO126 partially or totally failed to inhibit ERK1/2 activation induced by NNK; (4) The expression levels of ERK1/2 in the cancer cell lines were much higher than those in the normal mammary epithelial cells.	U 0126	245-250	mitogen-activated protein kinase 3	Homo sapiens	168-174
21783722-8	2006	In human cancer mammary epithelial cell lines, we found that ERK MAPK signaling pathway was deregulated: (1) ERK1/2 was constitutively activated at various levels; (2) ERK1/2 was further significantly activated in response to NNK induction; (3) UO126 partially or totally failed to inhibit ERK1/2 activation induced by NNK; (4) The expression levels of ERK1/2 in the cancer cell lines were much higher than those in the normal mammary epithelial cells.	U 0126	245-250	mitogen-activated protein kinase 3	Homo sapiens	168-174
21783722-8	2006	In human cancer mammary epithelial cell lines, we found that ERK MAPK signaling pathway was deregulated: (1) ERK1/2 was constitutively activated at various levels; (2) ERK1/2 was further significantly activated in response to NNK induction; (3) UO126 partially or totally failed to inhibit ERK1/2 activation induced by NNK; (4) The expression levels of ERK1/2 in the cancer cell lines were much higher than those in the normal mammary epithelial cells.	U 0126	245-250	mitogen-activated protein kinase 3	Homo sapiens	168-174
17023264-8	2006	Similar to NAC, the MEK1/2 inhibitor U0126, the p38 inhibitor SB203580, and the protein kinase inhibitor H-89 selectively inhibited ET-1 upregulation without affecting nuclear p65 translocation, suggesting that NAC inhibits ET-1 upregulation via inhibition of mitogen- and stress-activated protein kinase (MSK).	U 0126	37-42	endothelin 1	Homo sapiens	132-136
16903868-6	2006	Enhanced neutrophil motility and morphological change were inhibited by MEK [mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase] inhibitors (PD98059 and U0126), and a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin), but not by a p38 MAPK inhibitor (SB203580).	U 0126	193-198	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
17067316-8	2006	Pertussis toxin and U0126, which, respectively, inhibit Galphai, extracellular signal-regulated kinase (ERK) phosphorylation substantially inhibited Pam3Cys-induced CCL2 generation in LAD 2 mast cells but had little or no effect on chemokine generation in MLMC and BMMC.	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	65-102
17067316-8	2006	Pertussis toxin and U0126, which, respectively, inhibit Galphai, extracellular signal-regulated kinase (ERK) phosphorylation substantially inhibited Pam3Cys-induced CCL2 generation in LAD 2 mast cells but had little or no effect on chemokine generation in MLMC and BMMC.	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	104-107
17067316-8	2006	Pertussis toxin and U0126, which, respectively, inhibit Galphai, extracellular signal-regulated kinase (ERK) phosphorylation substantially inhibited Pam3Cys-induced CCL2 generation in LAD 2 mast cells but had little or no effect on chemokine generation in MLMC and BMMC.	U 0126	20-25	C-C motif chemokine ligand 2	Homo sapiens	165-169
17016644-5	2006	Furthermore, upregulation of vimentin by treatment with SDF-1 was impaired by phosphatidylinositol 3 kinase (PI3K) inhibitor Wortmannin, but not by mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor U0126.	U 0126	229-234	vimentin	Homo sapiens	29-37
17016644-5	2006	Furthermore, upregulation of vimentin by treatment with SDF-1 was impaired by phosphatidylinositol 3 kinase (PI3K) inhibitor Wortmannin, but not by mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor U0126.	U 0126	229-234	C-X-C motif chemokine ligand 12	Homo sapiens	56-61
17080406-6	2006	This effect was inhibited by PD 98059 and U 0126, specific inhibitors of MEK, indicating that MEK, an upstream activator of ERK1/2, was directly involved in ACN-induced ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase kinase 7	Homo sapiens	73-76
17080406-6	2006	This effect was inhibited by PD 98059 and U 0126, specific inhibitors of MEK, indicating that MEK, an upstream activator of ERK1/2, was directly involved in ACN-induced ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase kinase 7	Homo sapiens	94-97
17080406-6	2006	This effect was inhibited by PD 98059 and U 0126, specific inhibitors of MEK, indicating that MEK, an upstream activator of ERK1/2, was directly involved in ACN-induced ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase 3	Homo sapiens	124-130
17080406-6	2006	This effect was inhibited by PD 98059 and U 0126, specific inhibitors of MEK, indicating that MEK, an upstream activator of ERK1/2, was directly involved in ACN-induced ERK1/2 activation.	U 0126	42-48	mitogen-activated protein kinase 3	Homo sapiens	169-175
16911581-4	2006	This effect was mediated through both the MAPK and PI3-kinase signaling pathways, as shown by the ability of the specific inhibitors UO126 and LY294002 to abrogate IGF-I action.	U 0126	133-138	insulin-like growth factor 1	Rattus norvegicus	164-169
17026529-6	2006	The effect of PACAP on c-Fos expression was blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) inhibitor, U0126, while phosphorylation of c-Jun induced by C2-ceramide was abrogated by the protein phosphatase 2A (PP2A) inhibitor, okadaic acid.	U 0126	147-152	adenylate cyclase activating polypeptide 1	Rattus norvegicus	14-19
17026529-6	2006	The effect of PACAP on c-Fos expression was blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) inhibitor, U0126, while phosphorylation of c-Jun induced by C2-ceramide was abrogated by the protein phosphatase 2A (PP2A) inhibitor, okadaic acid.	U 0126	147-152	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	23-28
16950403-8	2006	Furthermore, treatment with siRNA specific for c-Met or MEK inhibitor U0126 inhibited cholangiocarcinoma cell invasion induced by HGF.	U 0126	70-75	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
16950403-8	2006	Furthermore, treatment with siRNA specific for c-Met or MEK inhibitor U0126 inhibited cholangiocarcinoma cell invasion induced by HGF.	U 0126	70-75	hepatocyte growth factor	Homo sapiens	130-133
17079869-7	2006	U0126, a MEK inhibitor, SP600125, a JNK inhibitor, or SB203580, a p38 inhibitor, attenuates the Ang II-induced [3H]thymidine incorporation into the VSMC.	U 0126	0-5	angiotensinogen	Rattus norvegicus	96-102
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	U 0126	118-123	fms related receptor tyrosine kinase 4	Homo sapiens	36-43
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	U 0126	118-123	mitogen-activated protein kinase 1	Homo sapiens	61-64
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	U 0126	118-123	fms related receptor tyrosine kinase 4	Homo sapiens	182-189
16702953-6	2006	Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2.	U 0126	38-43	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
16702953-6	2006	Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2.	U 0126	38-43	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
16702953-6	2006	Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2.	U 0126	38-43	epidermal growth factor receptor	Homo sapiens	101-105
16702953-6	2006	Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2.	U 0126	38-43	fibroblast growth factor receptor substrate 3	Homo sapiens	126-131
16848763-4	2006	Phosphorylation induced by each stimulus was prevented by two structurally distinct inhibitors of MKK1 (PD184352 and U0126), demonstrating that DAZAP1 is a physiological substrate for ERK1/ERK2.	U 0126	117-122	mitogen-activated protein kinase kinase 1	Homo sapiens	98-102
16848763-4	2006	Phosphorylation induced by each stimulus was prevented by two structurally distinct inhibitors of MKK1 (PD184352 and U0126), demonstrating that DAZAP1 is a physiological substrate for ERK1/ERK2.	U 0126	117-122	DAZ associated protein 1	Homo sapiens	144-150
16848763-4	2006	Phosphorylation induced by each stimulus was prevented by two structurally distinct inhibitors of MKK1 (PD184352 and U0126), demonstrating that DAZAP1 is a physiological substrate for ERK1/ERK2.	U 0126	117-122	mitogen-activated protein kinase 3	Homo sapiens	184-188
16848763-4	2006	Phosphorylation induced by each stimulus was prevented by two structurally distinct inhibitors of MKK1 (PD184352 and U0126), demonstrating that DAZAP1 is a physiological substrate for ERK1/ERK2.	U 0126	117-122	mitogen-activated protein kinase 1	Homo sapiens	189-193
16902162-3	2006	HGF-inducible PAI-1 mRNA was attenuated by U0126, a specific inhibitor of mitogen-activated protein kinase (MAPK) kinase, and genistein, an inhibitor of tyrosine kinase.	U 0126	43-48	hepatocyte growth factor	Homo sapiens	0-3
16902162-3	2006	HGF-inducible PAI-1 mRNA was attenuated by U0126, a specific inhibitor of mitogen-activated protein kinase (MAPK) kinase, and genistein, an inhibitor of tyrosine kinase.	U 0126	43-48	serpin family E member 1	Homo sapiens	14-19
17026715-5	2006	Western blot analysis showed a dramatic increase in ERK 1/2 phosphorylation (p-ERK 1/2) 1-5 days after RA induction, which was attenuated in the presence of the p-ERK 1/2-specific inhibitor UO126.	U 0126	190-195	mitogen-activated protein kinase 3	Mus musculus	52-59
17026715-5	2006	Western blot analysis showed a dramatic increase in ERK 1/2 phosphorylation (p-ERK 1/2) 1-5 days after RA induction, which was attenuated in the presence of the p-ERK 1/2-specific inhibitor UO126.	U 0126	190-195	mitogen-activated protein kinase 3	Mus musculus	79-86
17026715-5	2006	Western blot analysis showed a dramatic increase in ERK 1/2 phosphorylation (p-ERK 1/2) 1-5 days after RA induction, which was attenuated in the presence of the p-ERK 1/2-specific inhibitor UO126.	U 0126	190-195	mitogen-activated protein kinase 3	Mus musculus	52-57
17026715-8	2006	STAT3 translocation was attenuated by UO126.	U 0126	38-43	signal transducer and activator of transcription 3	Mus musculus	0-5
17026715-9	2006	Finally, caspase-3 activation was observed in the presence of UO126, suggesting that the ERK pathway also contributes to the survival of differentiating ES cells.	U 0126	62-67	caspase 3	Mus musculus	9-18
17026715-9	2006	Finally, caspase-3 activation was observed in the presence of UO126, suggesting that the ERK pathway also contributes to the survival of differentiating ES cells.	U 0126	62-67	mitogen-activated protein kinase 1	Mus musculus	89-92
16840544-8	2006	Increased expression of phosphatases is associated with the intracellular localization and dephosphorylation of ERK and is inhibited by the selective ERK inhibitor, U0126.	U 0126	165-170	mitogen-activated protein kinase 1	Homo sapiens	112-115
16840544-8	2006	Increased expression of phosphatases is associated with the intracellular localization and dephosphorylation of ERK and is inhibited by the selective ERK inhibitor, U0126.	U 0126	165-170	mitogen-activated protein kinase 1	Homo sapiens	150-153
17003343-7	2006	In addition, pharmacological inhibition of this pathway by coincubation of the palmitate-exposed cells with the MEK1/2 inhibitors PD98059 and U0126 prevented the downregulation of PGC-1alpha.	U 0126	142-147	mitogen-activated protein kinase kinase 1	Mus musculus	112-118
17003343-7	2006	In addition, pharmacological inhibition of this pathway by coincubation of the palmitate-exposed cells with the MEK1/2 inhibitors PD98059 and U0126 prevented the downregulation of PGC-1alpha.	U 0126	142-147	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	180-190
17021402-6	2006	When primary astrocytes were exposed to fibrillar Abeta in vitro, IDE protein level increased as compared with control, and this effect was reduced by the addition of U0126, a specific inhibitor of the ERK1/2 mitogen-activated protein kinase cascade.	U 0126	167-172	amyloid beta precursor protein	Homo sapiens	50-55
17021402-6	2006	When primary astrocytes were exposed to fibrillar Abeta in vitro, IDE protein level increased as compared with control, and this effect was reduced by the addition of U0126, a specific inhibitor of the ERK1/2 mitogen-activated protein kinase cascade.	U 0126	167-172	insulin degrading enzyme	Homo sapiens	66-69
17021402-6	2006	When primary astrocytes were exposed to fibrillar Abeta in vitro, IDE protein level increased as compared with control, and this effect was reduced by the addition of U0126, a specific inhibitor of the ERK1/2 mitogen-activated protein kinase cascade.	U 0126	167-172	mitogen-activated protein kinase 3	Mus musculus	202-208
17029596-7	2006	Prevention of rotenone-induced apoptosis by NGF was attenuated by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor, LY294002, but not MAPK kinase (MEK) inhibitors, PD98059 or U0126.	U 0126	184-189	nerve growth factor	Rattus norvegicus	44-47
16705745-4	2006	Pharmacological inhibition of MEK1 and MEK2 with U0126 drastically increased the levels of alpha(v)beta(3) in Heregulin (HRG)-overexpressing MDA-MB-231 cells (231/WT, 231/VEC) and derivatives transfected with the antisense orientation of the HRG-beta2 full length cDNA (231/ASPOOL, 231/AS31).	U 0126	49-54	mitogen-activated protein kinase kinase 1	Homo sapiens	30-34
16705745-4	2006	Pharmacological inhibition of MEK1 and MEK2 with U0126 drastically increased the levels of alpha(v)beta(3) in Heregulin (HRG)-overexpressing MDA-MB-231 cells (231/WT, 231/VEC) and derivatives transfected with the antisense orientation of the HRG-beta2 full length cDNA (231/ASPOOL, 231/AS31).	U 0126	49-54	mitogen-activated protein kinase kinase 2	Homo sapiens	39-43
16924420-8	2006	In addition, the inhibition of ERK1/2 activity with MEK1/2 inhibitor U0126 increased TGF-beta mediated phosphorylation of Smad3.	U 0126	69-74	mitogen-activated protein kinase 3	Homo sapiens	31-37
16924420-8	2006	In addition, the inhibition of ERK1/2 activity with MEK1/2 inhibitor U0126 increased TGF-beta mediated phosphorylation of Smad3.	U 0126	69-74	mitogen-activated protein kinase kinase 1	Homo sapiens	52-58
16924420-8	2006	In addition, the inhibition of ERK1/2 activity with MEK1/2 inhibitor U0126 increased TGF-beta mediated phosphorylation of Smad3.	U 0126	69-74	SMAD family member 3	Homo sapiens	122-127
16880206-3	2006	Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction.	U 0126	146-151	Fyn proto-oncogene	Mus musculus	21-24
16880206-3	2006	Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction.	U 0126	146-151	mitogen-activated protein kinase 1	Mus musculus	36-39
16880206-3	2006	Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction.	U 0126	146-151	inducible T cell co-stimulator	Mus musculus	60-64
16904070-5	2006	Pretreatment of wild-type cells with U0126, a potent inhibitor of MEK1, significantly inhibited the production of TIMP-2, whereas SB203580, a specific inhibitor for p38, could not.	U 0126	37-42	mitogen-activated protein kinase kinase 1	Homo sapiens	66-70
16904070-5	2006	Pretreatment of wild-type cells with U0126, a potent inhibitor of MEK1, significantly inhibited the production of TIMP-2, whereas SB203580, a specific inhibitor for p38, could not.	U 0126	37-42	TIMP metallopeptidase inhibitor 2	Homo sapiens	114-120
16816403-7	2006	The effects of PGF2alpha were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor.	U 0126	81-86	mitogen-activated protein kinase kinase 1	Homo sapiens	90-94
16716148-5	2006	U0126 pretreatment of HUVEC-CS potentiated ATP-stimulated eNOS activity, independent of changes in intracellular Ca2+ concentration ([Ca2+]i).	U 0126	0-5	nitric oxide synthase 3	Homo sapiens	58-62
16716148-6	2006	In COS-7 cells transiently expressing ovine eNOS, U0126 potentiated A23187-stimulated eNOS activity, but inhibited ATP-stimulated activity.	U 0126	50-55	nitric oxide synthase 3	Homo sapiens	44-48
16716148-6	2006	In COS-7 cells transiently expressing ovine eNOS, U0126 potentiated A23187-stimulated eNOS activity, but inhibited ATP-stimulated activity.	U 0126	50-55	nitric oxide synthase 3	Homo sapiens	86-90
16716148-9	2006	Finally, seven eNOS alanine mutants of putative ERK1/2 targets were generated and the effects of U0126 pretreatment on eNOS activity were gauged with A23187 and ATP treatment.	U 0126	97-102	nitric oxide synthase 3	Homo sapiens	119-123
16716148-10	2006	T97A-eNOS was the only construct significantly different from wild-type after U0126 pretreatment and ATP stimulation of eNOS activation.	U 0126	78-83	nitric oxide synthase 3	Homo sapiens	5-9
16847434-8	2006	Protection was blocked by either LY294002 or UO126, inhibitors of Akt and p44/42 MAPK, respectively.	U 0126	45-50	mitogen activated protein kinase 3	Rattus norvegicus	74-77
16951151-7	2006	The MEK inhibitor U0126 also reversed RAS-induced DNMT3b binding and RECK promoter methylation.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
16951151-7	2006	The MEK inhibitor U0126 also reversed RAS-induced DNMT3b binding and RECK promoter methylation.	U 0126	18-23	DNA methyltransferase 3 beta	Homo sapiens	50-56
16951151-7	2006	The MEK inhibitor U0126 also reversed RAS-induced DNMT3b binding and RECK promoter methylation.	U 0126	18-23	reversion inducing cysteine rich protein with kazal motifs	Homo sapiens	69-73
17004925-6	2006	In addition, U0126, a specific inhibitor of the MAPK kinase-ERK1/2 pathway, abrogated the induction of LTD in cerebellar slices, whereas SB203580 and SP600125, specific inhibitors of p38 MAPK and JNK, respectively, had no effect.	U 0126	13-18	mitogen-activated protein kinase 1	Mus musculus	48-52
17004925-6	2006	In addition, U0126, a specific inhibitor of the MAPK kinase-ERK1/2 pathway, abrogated the induction of LTD in cerebellar slices, whereas SB203580 and SP600125, specific inhibitors of p38 MAPK and JNK, respectively, had no effect.	U 0126	13-18	mitogen-activated protein kinase 3	Mus musculus	60-66
17004925-6	2006	In addition, U0126, a specific inhibitor of the MAPK kinase-ERK1/2 pathway, abrogated the induction of LTD in cerebellar slices, whereas SB203580 and SP600125, specific inhibitors of p38 MAPK and JNK, respectively, had no effect.	U 0126	13-18	mitogen-activated protein kinase 1	Mus musculus	187-191
17004925-6	2006	In addition, U0126, a specific inhibitor of the MAPK kinase-ERK1/2 pathway, abrogated the induction of LTD in cerebellar slices, whereas SB203580 and SP600125, specific inhibitors of p38 MAPK and JNK, respectively, had no effect.	U 0126	13-18	mitogen-activated protein kinase 8	Mus musculus	196-199
16939811-6	2006	However, in 6 of 11 cases pS6 was also suppressed by U0126, indicating that the ERK pathway can significantly input to pS6.	U 0126	53-58	taste 2 receptor member 63 pseudogene	Homo sapiens	26-29
16939811-6	2006	However, in 6 of 11 cases pS6 was also suppressed by U0126, indicating that the ERK pathway can significantly input to pS6.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	80-83
16939811-6	2006	However, in 6 of 11 cases pS6 was also suppressed by U0126, indicating that the ERK pathway can significantly input to pS6.	U 0126	53-58	taste 2 receptor member 63 pseudogene	Homo sapiens	119-122
16809346-4	2006	Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ERalpha expression.	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
16809346-4	2006	Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ERalpha expression.	U 0126	61-66	mitogen-activated protein kinase 3	Homo sapiens	81-87
16809346-4	2006	Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ERalpha expression.	U 0126	61-66	forkhead box M1	Homo sapiens	112-117
16809346-4	2006	Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ERalpha expression.	U 0126	61-66	estrogen receptor 1	Homo sapiens	134-141
16923163-5	2006	1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophynyltio) butadiene (U0126), a specific MEK inhibitor, completely blocked the DHA anti-apoptotic effect.	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
16912315-4	2006	In this virus-host system, the extents of NF-kappaBeta-regulated gene expression and nuclear translocation were reduced in the presence of either PD 98059 or U0126, two compounds capable of blocking ERK1 and ERK2 phosphorylation.	U 0126	158-163	mitogen-activated protein kinase 3	Homo sapiens	199-203
16912315-4	2006	In this virus-host system, the extents of NF-kappaBeta-regulated gene expression and nuclear translocation were reduced in the presence of either PD 98059 or U0126, two compounds capable of blocking ERK1 and ERK2 phosphorylation.	U 0126	158-163	mitogen-activated protein kinase 1	Homo sapiens	208-212
16854387-11	2006	Pre-treatment with the MAPK specific inhibitor (U0126) or the adenylate cyclase inhibitor dideoxyadenosine (ddA) abolished the butyrate-induced: (i) accumulation of TH mRNA, (ii) the phosphorylation of ERK1/2 as well as (iii) CREB phosphorylation.	U 0126	48-53	cAMP responsive element binding protein 1	Rattus norvegicus	226-230
16568090-3	2006	To address this issue, we identified genes suppressed in HRAS-transformed rat fibroblasts but upregulated after treatment with the demethylating agent 5-Aza-2-deoxycytidine and with the MEK1,2 inhibitor U0126.	U 0126	203-208	HRas proto-oncogene, GTPase	Rattus norvegicus	57-61
16568090-3	2006	To address this issue, we identified genes suppressed in HRAS-transformed rat fibroblasts but upregulated after treatment with the demethylating agent 5-Aza-2-deoxycytidine and with the MEK1,2 inhibitor U0126.	U 0126	203-208	mitogen activated protein kinase kinase 1	Rattus norvegicus	186-192
16473861-5	2006	The tropoelastin mRNA downregulation is preceded by release of EGF-like and TGF-alpha-like polypeptides and requires EGFR/MEK/ERK signaling, because it is prevented by the EGFR inhibitor AG1478 and the MEK/ERK uncoupler U0126.	U 0126	220-225	elastin	Rattus norvegicus	4-16
16473861-5	2006	The tropoelastin mRNA downregulation is preceded by release of EGF-like and TGF-alpha-like polypeptides and requires EGFR/MEK/ERK signaling, because it is prevented by the EGFR inhibitor AG1478 and the MEK/ERK uncoupler U0126.	U 0126	220-225	epidermal growth factor receptor	Rattus norvegicus	117-121
16473861-5	2006	The tropoelastin mRNA downregulation is preceded by release of EGF-like and TGF-alpha-like polypeptides and requires EGFR/MEK/ERK signaling, because it is prevented by the EGFR inhibitor AG1478 and the MEK/ERK uncoupler U0126.	U 0126	220-225	epidermal growth factor receptor	Rattus norvegicus	172-176
16825605-8	2006	Caspase 8 activities induced by ANG II were attenuated by U-0126, SP-600125, and CsA.	U 0126	58-64	caspase 8	Rattus norvegicus	0-9
16825605-8	2006	Caspase 8 activities induced by ANG II were attenuated by U-0126, SP-600125, and CsA.	U 0126	58-64	angiotensinogen	Rattus norvegicus	32-38
16356505-7	2006	Pretreatment with the MAPK kinase inhibitor, U0126, completely inhibited chylomicron remnants-induced CD40 protein expression, whereas the p38 MAPK inhibitor, SB203580, had no effect.	U 0126	45-50	mitogen-activated protein kinase 3	Homo sapiens	22-26
16356505-7	2006	Pretreatment with the MAPK kinase inhibitor, U0126, completely inhibited chylomicron remnants-induced CD40 protein expression, whereas the p38 MAPK inhibitor, SB203580, had no effect.	U 0126	45-50	CD40 molecule	Homo sapiens	102-106
16893987-7	2006	When ERK activation was suppressed by an inhibitor (U0126), production of p40 rose from an undetectable to a substantial level and GA-12 activation decreased.	U 0126	52-57	mitogen-activated protein kinase 1	Mus musculus	5-8
16893987-7	2006	When ERK activation was suppressed by an inhibitor (U0126), production of p40 rose from an undetectable to a substantial level and GA-12 activation decreased.	U 0126	52-57	interleukin 12b	Mus musculus	74-77
16644915-3	2006	The MEK inhibitors PD98059 and U0126 were found to repress the expression of proglucagon promoter as well as endogenous proglucagon mRNA in two intestinal proglucagon-producing cell lines and to block the stimulatory effect of forskolin/IBMX on proglucagon mRNA expression.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
17016652-8	2006	The ERK inhibitor U0126 also blocked the cell migration in both parental cells and synuclein-gamma overexpressing cells.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
17016652-8	2006	The ERK inhibitor U0126 also blocked the cell migration in both parental cells and synuclein-gamma overexpressing cells.	U 0126	18-23	synuclein gamma	Homo sapiens	83-98
16883598-6	2006	Both PPARgamma siRNA and U0126, a specific inhibitor of ERK1/2, were able to block these effects of TGZ, suggesting that apoptosis induced by TGZ was PPARgamma and ERK1/2 dependent.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	56-62
16883598-6	2006	Both PPARgamma siRNA and U0126, a specific inhibitor of ERK1/2, were able to block these effects of TGZ, suggesting that apoptosis induced by TGZ was PPARgamma and ERK1/2 dependent.	U 0126	25-30	peroxisome proliferator activated receptor gamma	Homo sapiens	150-159
16883598-6	2006	Both PPARgamma siRNA and U0126, a specific inhibitor of ERK1/2, were able to block these effects of TGZ, suggesting that apoptosis induced by TGZ was PPARgamma and ERK1/2 dependent.	U 0126	25-30	mitogen-activated protein kinase 3	Homo sapiens	164-170
16883598-7	2006	Inhibition of ERK1/2 by U0126 also led to a significant decrease in the level of PPARgamma, indicating a positive cross-talk between PPARgamma and ERK1/2 or an auto-regulatory feedback mechanism to amplify the effect of ERK1/2 on cell growth arrest and apoptosis.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	14-20
16883598-7	2006	Inhibition of ERK1/2 by U0126 also led to a significant decrease in the level of PPARgamma, indicating a positive cross-talk between PPARgamma and ERK1/2 or an auto-regulatory feedback mechanism to amplify the effect of ERK1/2 on cell growth arrest and apoptosis.	U 0126	24-29	peroxisome proliferator activated receptor gamma	Homo sapiens	81-90
16883598-7	2006	Inhibition of ERK1/2 by U0126 also led to a significant decrease in the level of PPARgamma, indicating a positive cross-talk between PPARgamma and ERK1/2 or an auto-regulatory feedback mechanism to amplify the effect of ERK1/2 on cell growth arrest and apoptosis.	U 0126	24-29	peroxisome proliferator activated receptor gamma	Homo sapiens	133-142
16883598-7	2006	Inhibition of ERK1/2 by U0126 also led to a significant decrease in the level of PPARgamma, indicating a positive cross-talk between PPARgamma and ERK1/2 or an auto-regulatory feedback mechanism to amplify the effect of ERK1/2 on cell growth arrest and apoptosis.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	147-153
16883598-7	2006	Inhibition of ERK1/2 by U0126 also led to a significant decrease in the level of PPARgamma, indicating a positive cross-talk between PPARgamma and ERK1/2 or an auto-regulatory feedback mechanism to amplify the effect of ERK1/2 on cell growth arrest and apoptosis.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	147-153
16941494-5	2006	We observed that U0126, an inhibitor of ERK activation, decreased basal survival of these cells.	U 0126	17-22	mitogen-activated protein kinase 1	Mus musculus	40-43
17013930-5	2006	Using HEK293 cells stably transfected with the alpha1beta2gamma2 form of the GABAA receptor, we found that UO126 reduced basal ERK phosphorylation and resulted in an enhancement of GABA-induced peak current amplitudes.	U 0126	107-112	adrenoceptor alpha 1D	Homo sapiens	47-64
17013930-5	2006	Using HEK293 cells stably transfected with the alpha1beta2gamma2 form of the GABAA receptor, we found that UO126 reduced basal ERK phosphorylation and resulted in an enhancement of GABA-induced peak current amplitudes.	U 0126	107-112	mitogen-activated protein kinase 1	Homo sapiens	127-130
17013930-7	2006	Finally, mutation of the ERK phosphorylation site (T375--&gt;A) prevented the UO126-induced enhancement of GABA-gated currents.	U 0126	78-83	mitogen-activated protein kinase 1	Homo sapiens	25-28
17076658-11	2006	Both ERK1/2 phosphorylation and dopaminergic differentiation were inhibited by U0126, a selective ERK kinase inhibitor, as well as by suramin.	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	5-11
17076658-11	2006	Both ERK1/2 phosphorylation and dopaminergic differentiation were inhibited by U0126, a selective ERK kinase inhibitor, as well as by suramin.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	5-8
16702946-4	2006	Growth by this mechanism was sensitive to the Raf-1 inhibitor BAY 43-9006 and the Mek inhibitor U0126.	U 0126	96-101	midkine	Mus musculus	82-85
16969075-10	2006	The ERK inhibitor U0126, added at least 30 min prior to H32, antagonized the growth inhibition induced by H32.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
16969075-10	2006	The ERK inhibitor U0126, added at least 30 min prior to H32, antagonized the growth inhibition induced by H32.	U 0126	18-23	H3 clustered histone 14	Homo sapiens	56-59
16969075-10	2006	The ERK inhibitor U0126, added at least 30 min prior to H32, antagonized the growth inhibition induced by H32.	U 0126	18-23	H3 clustered histone 14	Homo sapiens	106-109
17218971-3	2006	Our data showed that 15-HETE upregulated ERK1/2 phosphorylation in a dose-dependent manner, which could be blocked by ERK pathway inhibitors U0126 and PD98059.	U 0126	141-146	mitogen activated protein kinase 3	Rattus norvegicus	41-47
17218971-3	2006	Our data showed that 15-HETE upregulated ERK1/2 phosphorylation in a dose-dependent manner, which could be blocked by ERK pathway inhibitors U0126 and PD98059.	U 0126	141-146	Eph receptor B1	Rattus norvegicus	41-44
16955211-4	2006	effect of specific inhibitors of PI(3)K (LY294002 and wortmannin) and MAPK (PD98059 and UO126) on the insulin-mediated reduction of ghrelin levels in rats.	U 0126	88-93	ghrelin and obestatin prepropeptide	Rattus norvegicus	132-139
16847309-3	2006	Indeed, inhibition of ERK1/ERK2 phosphorylation by DHA, U0126 [chemical MAPK extracellularly signal-regulated kinase kinase (MEK) inhibitor], and MEK(SA) (cells expressing dominant negative constructs of MEK) resulted in the accumulation of p27(Kip1).	U 0126	56-61	mitogen-activated protein kinase 3	Mus musculus	22-26
16847309-3	2006	Indeed, inhibition of ERK1/ERK2 phosphorylation by DHA, U0126 [chemical MAPK extracellularly signal-regulated kinase kinase (MEK) inhibitor], and MEK(SA) (cells expressing dominant negative constructs of MEK) resulted in the accumulation of p27(Kip1).	U 0126	56-61	mitogen-activated protein kinase 1	Mus musculus	27-31
16953813-3	2006	OBJECTIVES: The purpose of this study was to investigate the caseinolytic activity in human osteosarcoma cell line U2OS cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of p38 inhibitor SB203580, mitogen-activated protein kinase kinase (MEK) inhibitor U0126, and phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002.	U 0126	311-316	interleukin 1 alpha	Homo sapiens	142-160
16953813-3	2006	OBJECTIVES: The purpose of this study was to investigate the caseinolytic activity in human osteosarcoma cell line U2OS cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of p38 inhibitor SB203580, mitogen-activated protein kinase kinase (MEK) inhibitor U0126, and phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002.	U 0126	311-316	interleukin 1 alpha	Homo sapiens	162-171
16953813-8	2006	From the results of casein zymography and ELISA, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated t-PA production, respectively (p &lt; 0.05).	U 0126	59-64	interleukin 1 alpha	Homo sapiens	105-114
16953813-8	2006	From the results of casein zymography and ELISA, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated t-PA production, respectively (p &lt; 0.05).	U 0126	59-64	plasminogen activator, tissue type	Homo sapiens	143-147
16953813-10	2006	SB203580, U0126, and LY294002 suppress t-PA production and/or activity and may therefore be valuable therapeutics in t-PA-mediated periodontal destruction, and might be proved clinically useful agents, in combination with standard treatment modalities, in the treatment of periodontitis.	U 0126	10-15	plasminogen activator, tissue type	Homo sapiens	39-43
16953813-10	2006	SB203580, U0126, and LY294002 suppress t-PA production and/or activity and may therefore be valuable therapeutics in t-PA-mediated periodontal destruction, and might be proved clinically useful agents, in combination with standard treatment modalities, in the treatment of periodontitis.	U 0126	10-15	plasminogen activator, tissue type	Homo sapiens	117-121
17002919-5	2006	Treatment with PD98059 or UO126, mitogen-activated ERK-activating kinase 1/2 inhibitors, significantly inhibited the Ox-LDL-induced increase in PAI-1 mRNA and nuclear Smad3 expression, DNA/protein complex formation, and PAI-1 promoter activity.	U 0126	26-31	mitogen-activated protein kinase 1	Homo sapiens	51-54
17002919-5	2006	Treatment with PD98059 or UO126, mitogen-activated ERK-activating kinase 1/2 inhibitors, significantly inhibited the Ox-LDL-induced increase in PAI-1 mRNA and nuclear Smad3 expression, DNA/protein complex formation, and PAI-1 promoter activity.	U 0126	26-31	serpin family E member 1	Homo sapiens	144-149
17002919-5	2006	Treatment with PD98059 or UO126, mitogen-activated ERK-activating kinase 1/2 inhibitors, significantly inhibited the Ox-LDL-induced increase in PAI-1 mRNA and nuclear Smad3 expression, DNA/protein complex formation, and PAI-1 promoter activity.	U 0126	26-31	SMAD family member 3	Homo sapiens	167-172
17002919-5	2006	Treatment with PD98059 or UO126, mitogen-activated ERK-activating kinase 1/2 inhibitors, significantly inhibited the Ox-LDL-induced increase in PAI-1 mRNA and nuclear Smad3 expression, DNA/protein complex formation, and PAI-1 promoter activity.	U 0126	26-31	serpin family E member 1	Homo sapiens	220-225
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	midkine	Mus musculus	13-16
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	mitogen-activated protein kinase 1	Mus musculus	17-20
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	cannabinoid receptor 1 (brain)	Mus musculus	61-64
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	early growth response 1	Mus musculus	74-81
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	midkine	Mus musculus	107-110
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	cannabinoid receptor 1 (brain)	Mus musculus	153-156
16864584-3	2006	A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24.	U 0126	124-129	early growth response 1	Mus musculus	180-187
16809005-0	2006	The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	22-59
16809005-0	2006	The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells.	U 0126	81-86	glial fibrillary acidic protein	Rattus norvegicus	95-126
16809005-4	2006	Treatment of C6 cells with U0126 caused a significant concentration-dependent reduction in cell proliferation and migration and also induced expression of glial fibrillary acidic protein, a marker of astrocytic differentiation.	U 0126	27-32	glial fibrillary acidic protein	Rattus norvegicus	155-186
16809344-8	2006	MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2-MCP-1 mice.	U 0126	155-160	chemokine (C-C motif) ligand 2	Mus musculus	0-5
16809344-8	2006	MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2-MCP-1 mice.	U 0126	155-160	midkine	Mus musculus	141-144
16809344-8	2006	MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2-MCP-1 mice.	U 0126	155-160	chemokine (C-C motif) ligand 2	Mus musculus	190-195
16809344-8	2006	MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2-MCP-1 mice.	U 0126	155-160	fatty acid binding protein 4, adipocyte	Mus musculus	236-239
16809344-8	2006	MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2-MCP-1 mice.	U 0126	155-160	chemokine (C-C motif) ligand 2	Mus musculus	190-195
16936092-8	2006	It was demonstrated with the use of U0126 and wortmannin that the activation of p42/44 MAP kinase and Akt was responsible for the increased HCF proliferation observed under HNP1 and HBD2 stimulation.	U 0126	36-41	AKT serine/threonine kinase 1	Homo sapiens	102-105
16936092-8	2006	It was demonstrated with the use of U0126 and wortmannin that the activation of p42/44 MAP kinase and Akt was responsible for the increased HCF proliferation observed under HNP1 and HBD2 stimulation.	U 0126	36-41	defensin beta 4A	Homo sapiens	182-186
16920919-8	2006	Treatment with U0126 (a MEK inhibitor) suppressed ATP-induced ERK1/2 phosphorylation without inhibiting cell shrinkage.	U 0126	15-20	mitogen-activated protein kinase 3	Mus musculus	62-68
16800849-5	2006	Interestingly, the survival-promoting effect of tPA was blocked by the phosphatidylinositol-3 (PI-3) kinase inhibitor, LY294002, but not by the mitogen-activated protein (MAP) kinase inhibitor, U0126.	U 0126	194-199	plasminogen activator, tissue type	Homo sapiens	48-51
16942526-8	2006	Neurite measures for BDNF with 25 and 50 microM U0126 (MEK pathway) were reduced to 402.0 and 424.3 microm at 48 hours, respectively (P &lt; 0.05), likely reflecting an accessory molecular pathway.	U 0126	48-53	brain-derived neurotrophic factor	Rattus norvegicus	21-25
16880791-6	2006	Treatment of cells expressing high levels of MAD2 with an MEK inhibitor, U0126, led to cellular protection against cisplatin-induced apoptosis.	U 0126	73-78	mitotic arrest deficient 2 like 1	Homo sapiens	45-49
16880791-6	2006	Treatment of cells expressing high levels of MAD2 with an MEK inhibitor, U0126, led to cellular protection against cisplatin-induced apoptosis.	U 0126	73-78	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
16815303-3	2006	Intraventricular injections of olomoucine and U-0126 (CDK5 and MAP kinase inhibitors, respectively) inhibited hyperphosphorylation.	U 0126	46-52	cyclin dependent kinase 5	Homo sapiens	54-58
16766531-10	2006	15d-PGJ2, PGD2, and partially UO126, down-regulated ERK1/2 phosphorylation, protected cells from BAY 11-7085-induced apoptosis, and reversed both PPAR-gamma dephosphorylation and degradation.	U 0126	30-35	peroxisome proliferator activated receptor gamma	Homo sapiens	146-156
16899113-3	2006	RESULTS: We demonstrate that, in all the tumor cell lines used, the MEK/ERK inhibitor U0126 rapidly induces c-Myc de-phosphorylation, which is followed by a marked reduction in its expression level, by inhibition of proliferation and by reversion of anchorage-independent growth.	U 0126	86-91	mitogen-activated protein kinase kinase 7	Homo sapiens	68-71
16899113-3	2006	RESULTS: We demonstrate that, in all the tumor cell lines used, the MEK/ERK inhibitor U0126 rapidly induces c-Myc de-phosphorylation, which is followed by a marked reduction in its expression level, by inhibition of proliferation and by reversion of anchorage-independent growth.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	72-75
16899113-3	2006	RESULTS: We demonstrate that, in all the tumor cell lines used, the MEK/ERK inhibitor U0126 rapidly induces c-Myc de-phosphorylation, which is followed by a marked reduction in its expression level, by inhibition of proliferation and by reversion of anchorage-independent growth.	U 0126	86-91	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	108-113
16899113-6	2006	Moreover, ectopic MadMyc chimera, a c-Myc function antagonist, causes dramatic growth arrest, CDK and cyclin modulation as well as inhibition of anchorage-independent growth in RD cells, as occurs in U0126-treated cells.	U 0126	200-205	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	36-41
16899113-9	2006	In fact, MEK/ERK inhibitor, U0126, induces growth arrest, anchorage-dependent growth of these cell lines.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
16899113-9	2006	In fact, MEK/ERK inhibitor, U0126, induces growth arrest, anchorage-dependent growth of these cell lines.	U 0126	28-33	mitogen-activated protein kinase 1	Homo sapiens	13-16
16825605-9	2006	DNA fragmentation induced by ANG II was totally blocked by SP-600125, and CsA and was attenuated by U-0126.	U 0126	100-106	angiotensinogen	Rattus norvegicus	29-35
16872362-6	2006	This G(2)-phase arrest was reversed by pre-treatment with bisindolylmaleimide or U0126, which are selective inhibitors of protein kinase C proteins or the extracellular signal-regulated kinase activators, MEK1/2, respectively.	U 0126	81-86	mitogen-activated protein kinase 1	Homo sapiens	155-192
16872362-6	2006	This G(2)-phase arrest was reversed by pre-treatment with bisindolylmaleimide or U0126, which are selective inhibitors of protein kinase C proteins or the extracellular signal-regulated kinase activators, MEK1/2, respectively.	U 0126	81-86	mitogen-activated protein kinase kinase 1	Homo sapiens	205-211
16880823-3	2006	Moreover, both the ERK5 and the ERK1/2 pathways are sensitive to PD98059 and U0126, which are two well-known inhibitors of the ERK pathway.	U 0126	77-82	mitogen-activated protein kinase 7	Homo sapiens	19-23
16880823-3	2006	Moreover, both the ERK5 and the ERK1/2 pathways are sensitive to PD98059 and U0126, which are two well-known inhibitors of the ERK pathway.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	32-38
16880823-3	2006	Moreover, both the ERK5 and the ERK1/2 pathways are sensitive to PD98059 and U0126, which are two well-known inhibitors of the ERK pathway.	U 0126	77-82	mitogen-activated protein kinase 1	Homo sapiens	19-22
16903868-6	2006	Enhanced neutrophil motility and morphological change were inhibited by MEK [mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase] inhibitors (PD98059 and U0126), and a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin), but not by a p38 MAPK inhibitor (SB203580).	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	111-115
16903868-6	2006	Enhanced neutrophil motility and morphological change were inhibited by MEK [mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase] inhibitors (PD98059 and U0126), and a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin), but not by a p38 MAPK inhibitor (SB203580).	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	156-159
16903868-6	2006	Enhanced neutrophil motility and morphological change were inhibited by MEK [mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase] inhibitors (PD98059 and U0126), and a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin), but not by a p38 MAPK inhibitor (SB203580).	U 0126	193-198	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	207-236
16903868-6	2006	Enhanced neutrophil motility and morphological change were inhibited by MEK [mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase] inhibitors (PD98059 and U0126), and a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin), but not by a p38 MAPK inhibitor (SB203580).	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	281-284
16955795-9	2006	The inhibiting effect, moreover, could be blocked by the specific inhibitor of MAPK pathway, U0126.	U 0126	93-98	mitogen-activated protein kinase 1	Mus musculus	79-83
16756989-0	2006	Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes.	U 0126	6-11	endothelin 1	Rattus norvegicus	138-150
16642470-10	2006	The IGF-I effects on the formation of FRE-protein complexes were abolished by tyrosine kinase inhibitor herbimycin A (HA), PI3-kinase/Akt inhibitor LY249002, and MAP kinase kinase inhibitor U0126, while IGF-I effects on HOX-protein complexes were abolished by HA and LY249002.	U 0126	190-195	insulin like growth factor 1	Homo sapiens	4-9
16642470-10	2006	The IGF-I effects on the formation of FRE-protein complexes were abolished by tyrosine kinase inhibitor herbimycin A (HA), PI3-kinase/Akt inhibitor LY249002, and MAP kinase kinase inhibitor U0126, while IGF-I effects on HOX-protein complexes were abolished by HA and LY249002.	U 0126	190-195	insulin like growth factor 1	Homo sapiens	203-208
16861072-9	2006	U0126, an ERK/MAPK inhibitor, inhibited the effects of HGF on DPCs.	U 0126	0-5	EPH receptor B2	Homo sapiens	10-13
16861072-9	2006	U0126, an ERK/MAPK inhibitor, inhibited the effects of HGF on DPCs.	U 0126	0-5	hepatocyte growth factor	Homo sapiens	55-58
16683234-7	2006	The MEK1/2 inhibitor U0126 completely inhibited LPS-induced MMP-9, which was partially inhibited by the p38 MAPK inhibitor SB203580.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
16683234-7	2006	The MEK1/2 inhibitor U0126 completely inhibited LPS-induced MMP-9, which was partially inhibited by the p38 MAPK inhibitor SB203580.	U 0126	21-26	matrix metallopeptidase 9	Homo sapiens	60-65
16683234-7	2006	The MEK1/2 inhibitor U0126 completely inhibited LPS-induced MMP-9, which was partially inhibited by the p38 MAPK inhibitor SB203580.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	104-107
16756989-2	2006	Using Affymetrix rat U34A microarrays, we identified the short-term (2-4 h) changes in gene expression induced in neonatal myocytes by endothelin-1 alone or in combination with the ERK1/2 cascade inhibitor, U0126.	U 0126	207-212	endothelin 1	Rattus norvegicus	135-147
16960431-3	2006	We have also shown that an MEK1/2 inhibitor, U0126, markedly inhibits zinc-induced renal cell injury.	U 0126	45-50	mitogen activated protein kinase kinase 1	Rattus norvegicus	27-33
16756989-4	2006	Of the genes upregulated by U0126, four are classically induced through the aryl hydrocarbon receptor (AhR) by dioxins suggesting that U0126 activates the xenobiotic response element in cardiac myocytes potentially independently of effects on ERK1/2 signalling.	U 0126	28-33	aryl hydrocarbon receptor	Rattus norvegicus	76-101
16756989-4	2006	Of the genes upregulated by U0126, four are classically induced through the aryl hydrocarbon receptor (AhR) by dioxins suggesting that U0126 activates the xenobiotic response element in cardiac myocytes potentially independently of effects on ERK1/2 signalling.	U 0126	28-33	aryl hydrocarbon receptor	Rattus norvegicus	103-106
16756989-4	2006	Of the genes upregulated by U0126, four are classically induced through the aryl hydrocarbon receptor (AhR) by dioxins suggesting that U0126 activates the xenobiotic response element in cardiac myocytes potentially independently of effects on ERK1/2 signalling.	U 0126	135-140	aryl hydrocarbon receptor	Rattus norvegicus	76-101
16756989-4	2006	Of the genes upregulated by U0126, four are classically induced through the aryl hydrocarbon receptor (AhR) by dioxins suggesting that U0126 activates the xenobiotic response element in cardiac myocytes potentially independently of effects on ERK1/2 signalling.	U 0126	135-140	aryl hydrocarbon receptor	Rattus norvegicus	103-106
16756989-6	2006	Thus, U0126 apparently activates the AhR in cardiac myocytes (which must be taken into account in protracted studies), but careful analysis allows identification of genes potentially regulated acutely via the ERK1/2 cascade.	U 0126	6-11	aryl hydrocarbon receptor	Rattus norvegicus	37-40
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	transforming growth factor alpha	Mus musculus	13-21
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	mitogen-activated protein kinase 3	Mus musculus	51-93
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	mitogen-activated protein kinase 3	Mus musculus	95-101
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	cAMP responsive element binding protein 1	Mus musculus	107-144
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	cAMP responsive element binding protein 1	Mus musculus	146-150
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	mitogen-activated protein kinase 1	Mus musculus	95-98
16901926-9	2006	Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively.	U 0126	227-232	cAMP responsive element binding protein 1	Mus musculus	275-279
16960431-9	2006	A Raf-1 kinase inhibitor and an MEK1/2 inhibitor U0126 significantly attenuated zinc-induced decreases PAH accumulation in the slices.	U 0126	49-54	mitogen activated protein kinase kinase 1	Rattus norvegicus	32-38
16601071-6	2006	The induction of ATF2-Thr71 phosphorylation was sensitive to MAPK kinase (MEK) 1/2-inhibition with U0126, and this phosphorylation coincided with nuclear translocation of phosphorylated ERK1/2.	U 0126	99-104	activating transcription factor 2	Homo sapiens	17-21
16601071-6	2006	The induction of ATF2-Thr71 phosphorylation was sensitive to MAPK kinase (MEK) 1/2-inhibition with U0126, and this phosphorylation coincided with nuclear translocation of phosphorylated ERK1/2.	U 0126	99-104	mitogen-activated protein kinase kinase 1	Homo sapiens	61-82
16960431-10	2006	The Raf-1 kinase inhibitor and U0126 also suppressed ERK1/2 activation in nuclear fractions prepared from slices treated with zinc.	U 0126	31-36	mitogen activated protein kinase 3	Rattus norvegicus	53-59
16712881-5	2006	On the other hand, attenuation of the spinal ERK phosphorylation by the MAPK kinase (MEK) inhibitor U0126 also could inhibit the increase of nNOS and iNOS expression in the spinal cord of morphine withdrawal rats.	U 0126	100-105	mitogen activated protein kinase 3	Rattus norvegicus	72-76
16896801-4	2006	U0126 and PD 98059, MEK inhibitors, abolished the effects of UII on motility velocity and stress-fiber formation.	U 0126	0-5	urotensin 2	Homo sapiens	61-64
16712881-5	2006	On the other hand, attenuation of the spinal ERK phosphorylation by the MAPK kinase (MEK) inhibitor U0126 also could inhibit the increase of nNOS and iNOS expression in the spinal cord of morphine withdrawal rats.	U 0126	100-105	nitric oxide synthase 1	Rattus norvegicus	141-145
16712881-5	2006	On the other hand, attenuation of the spinal ERK phosphorylation by the MAPK kinase (MEK) inhibitor U0126 also could inhibit the increase of nNOS and iNOS expression in the spinal cord of morphine withdrawal rats.	U 0126	100-105	nitric oxide synthase 2	Rattus norvegicus	150-154
16712881-8	2006	U0126 in the spinal cord were accompanied by decreased scores of morphine withdrawal and the inhibited spinal Fos protein (a maker for neuronal excitation or activation) expression induced by morphine withdrawal.	U 0126	0-5	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	110-113
16600518-8	2006	The caspase 3 inhibitor DEVD-CHO inhibited valproic acid-induced apoptosis in BV-2 cells whereas the MEK inhibitor U0126 potentiated valproic acid-mediated apoptosis.	U 0126	115-120	midkine	Mus musculus	101-104
16473382-5	2006	Although pretreatment with ERK inhibitors (PD98059 or U0126) abolished ERK phosphorylation in response to NDGA, neither inhibitor had any effect on NDGA-induced apoptosis.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	27-30
16473382-5	2006	Although pretreatment with ERK inhibitors (PD98059 or U0126) abolished ERK phosphorylation in response to NDGA, neither inhibitor had any effect on NDGA-induced apoptosis.	U 0126	54-59	mitogen-activated protein kinase 1	Mus musculus	71-74
17081402-8	2006	U-0126 increased the GATA4 mRNA expression and enhanced the GATA4 binding activity and these effects could be partially attenuated with addition of Parthenolide.	U 0126	0-6	GATA binding protein 4	Rattus norvegicus	21-26
17081402-8	2006	U-0126 increased the GATA4 mRNA expression and enhanced the GATA4 binding activity and these effects could be partially attenuated with addition of Parthenolide.	U 0126	0-6	GATA binding protein 4	Rattus norvegicus	60-65
16728393-6	2006	We found that partial inhibition of the MEK-ERK pathway, one of the mitogen-activated protein kinase phosphorelay modules, by U0126 partially reversed the IFNG-induced cytotoxicity in progenitors.	U 0126	126-131	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
16728393-6	2006	We found that partial inhibition of the MEK-ERK pathway, one of the mitogen-activated protein kinase phosphorelay modules, by U0126 partially reversed the IFNG-induced cytotoxicity in progenitors.	U 0126	126-131	mitogen-activated protein kinase 1	Homo sapiens	44-47
16728393-6	2006	We found that partial inhibition of the MEK-ERK pathway, one of the mitogen-activated protein kinase phosphorelay modules, by U0126 partially reversed the IFNG-induced cytotoxicity in progenitors.	U 0126	126-131	interferon gamma	Homo sapiens	155-159
16787641-6	2006	Manganese-induced up-regulation of caspase-3 mRNA was partially attenuated by the pretreatment with the MEK inhibitor U0126, but not with the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	U 0126	118-123	caspase 3	Rattus norvegicus	35-44
16787641-7	2006	In contrast, the increase in caspase-3 protein was suppressed by both U0126 and SP600125.	U 0126	70-75	caspase 3	Rattus norvegicus	29-38
16678346-7	2006	The effect was completely blocked by a specific MEK inhibitor U0126, suggesting the involvement of ERK dependent CREB signaling.	U 0126	62-67	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
16678346-7	2006	The effect was completely blocked by a specific MEK inhibitor U0126, suggesting the involvement of ERK dependent CREB signaling.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	99-102
16678346-7	2006	The effect was completely blocked by a specific MEK inhibitor U0126, suggesting the involvement of ERK dependent CREB signaling.	U 0126	62-67	cAMP responsive element binding protein 1	Homo sapiens	113-117
16801397-3	2006	MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
16467404-11	2006	In contrast, the ERK1/2 inhibitor U0126 had no effect on chemotaxis.	U 0126	34-39	mitogen-activated protein kinase 3	Homo sapiens	17-23
16801397-3	2006	MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation.	U 0126	14-19	vascular endothelial growth factor A	Homo sapiens	146-150
16801397-3	2006	MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation.	U 0126	14-19	interleukin 6	Homo sapiens	155-159
16801397-3	2006	MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation.	U 0126	14-19	signal transducer and activator of transcription 3	Homo sapiens	216-272
16242916-4	2006	These effects were prominently enhanced by either pretreatment with the MEK inhibitors, PD98059 and U0126 or overexpression of a dominant negative form of MEK, but blocked by a wild type ERK.	U 0126	100-105	mitogen-activated protein kinase 1	Homo sapiens	187-190
16846476-7	2006	Specific MEK [mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) kinase] inhibitors PD98056 and UO126, as well as the use of a dominant-negative form of MEK1 abrogated STAT3 Ser727 phosphorylation, suggesting involvement of MAP-Kinase/Erk pathway.	U 0126	128-133	signal transducer and activator of transcription 3	Homo sapiens	200-205
16846476-7	2006	Specific MEK [mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) kinase] inhibitors PD98056 and UO126, as well as the use of a dominant-negative form of MEK1 abrogated STAT3 Ser727 phosphorylation, suggesting involvement of MAP-Kinase/Erk pathway.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	267-270
16977492-6	2006	Immediate posttraining infusion of U0126 (a selective inhibitor of ERK kinase) into the CA1 region of the dorsal hippocampus blocked STM formation.	U 0126	35-40	carbonic anhydrase 1	Homo sapiens	88-91
16458997-4	2006	Both the cyclooxygenase inhibitor, indomethacin and the ERK inhibitors, UO126 and PD980589 reverse the hypoxia-induced increase in intracellular cAMP levels back to those seen in normoxic hPASM cells.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	56-59
16458997-7	2006	Challenge of hypoxic hPASM cells with indomethacin attenuates total PDE4 activity whilst challenge with UO126 increases total PDE4 activity.	U 0126	104-109	phosphodiesterase 4A	Homo sapiens	126-130
16463383-8	2006	Cotreatment also activated the mitogen-activated protein kinases (MAPKs), such as ERK1/2 and p38 MAPK: Preteatment with PD98059 (ERK1/2 inhibitor) and UO126 (selective MEK inhibitor) abrogated both upregulation of GADD153 and synergistic induction of apoptosis of PC-9 cells, while SB203580 (p38 MAPK inhibitor) did not do so, indicating that GADD153 expression was mediated through the ERK signaling pathway.	U 0126	151-156	mitogen-activated protein kinase 3	Homo sapiens	82-88
16882022-6	2006	Moreover, we found that inhibition of the MAPK/ERK signalling pathway by intrabasolateral amygdala infusion of the MEK inhibitor, U0126, completely blocks acquisition of extinction.	U 0126	130-135	mitogen-activated protein kinase 1	Mus musculus	42-46
16882022-6	2006	Moreover, we found that inhibition of the MAPK/ERK signalling pathway by intrabasolateral amygdala infusion of the MEK inhibitor, U0126, completely blocks acquisition of extinction.	U 0126	130-135	mitogen-activated protein kinase 1	Mus musculus	47-50
16882022-6	2006	Moreover, we found that inhibition of the MAPK/ERK signalling pathway by intrabasolateral amygdala infusion of the MEK inhibitor, U0126, completely blocks acquisition of extinction.	U 0126	130-135	midkine	Mus musculus	115-118
16463383-8	2006	Cotreatment also activated the mitogen-activated protein kinases (MAPKs), such as ERK1/2 and p38 MAPK: Preteatment with PD98059 (ERK1/2 inhibitor) and UO126 (selective MEK inhibitor) abrogated both upregulation of GADD153 and synergistic induction of apoptosis of PC-9 cells, while SB203580 (p38 MAPK inhibitor) did not do so, indicating that GADD153 expression was mediated through the ERK signaling pathway.	U 0126	151-156	mitogen-activated protein kinase kinase 7	Homo sapiens	168-171
16463383-8	2006	Cotreatment also activated the mitogen-activated protein kinases (MAPKs), such as ERK1/2 and p38 MAPK: Preteatment with PD98059 (ERK1/2 inhibitor) and UO126 (selective MEK inhibitor) abrogated both upregulation of GADD153 and synergistic induction of apoptosis of PC-9 cells, while SB203580 (p38 MAPK inhibitor) did not do so, indicating that GADD153 expression was mediated through the ERK signaling pathway.	U 0126	151-156	DNA damage inducible transcript 3	Homo sapiens	214-221
16463383-8	2006	Cotreatment also activated the mitogen-activated protein kinases (MAPKs), such as ERK1/2 and p38 MAPK: Preteatment with PD98059 (ERK1/2 inhibitor) and UO126 (selective MEK inhibitor) abrogated both upregulation of GADD153 and synergistic induction of apoptosis of PC-9 cells, while SB203580 (p38 MAPK inhibitor) did not do so, indicating that GADD153 expression was mediated through the ERK signaling pathway.	U 0126	151-156	DNA damage inducible transcript 3	Homo sapiens	343-350
16463383-8	2006	Cotreatment also activated the mitogen-activated protein kinases (MAPKs), such as ERK1/2 and p38 MAPK: Preteatment with PD98059 (ERK1/2 inhibitor) and UO126 (selective MEK inhibitor) abrogated both upregulation of GADD153 and synergistic induction of apoptosis of PC-9 cells, while SB203580 (p38 MAPK inhibitor) did not do so, indicating that GADD153 expression was mediated through the ERK signaling pathway.	U 0126	151-156	mitogen-activated protein kinase 3	Homo sapiens	82-85
16785500-3	2006	In DC, the inhibitory effect of LPS on CIITA expression was prevented by MyD88 deficiency or pharmacological MAPK inhibitors specific for MEK (U0126) and p38 (SB203580), but not JNK (SP600125).	U 0126	143-148	toll-like receptor 4	Mus musculus	32-35
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	29-34
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	mitogen-activated protein kinase 1	Homo sapiens	124-127
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	mitogen-activated protein kinase kinase 7	Homo sapiens	136-139
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	mitogen-activated protein kinase 1	Homo sapiens	177-180
16596619-4	2006	Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression.	U 0126	151-157	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	216-221
16596619-8	2006	We found that phospho-Myc induced by Cpd 5 had lost its ability to bind to the c-myc promoter, whereas MEK inhibitor U-0126 antagonized this inhibitory effect.	U 0126	117-123	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
16837613-12	2006	Using a specific inhibitor of ERK1/2 (U0126), we also showed that this kinase is a negative regulator of the FSH-induced progesterone secretion in F3/4 and F1 granulosa cells, suggesting that AICAR-mediated AMPK activation modifies FSH-induced progesterone secretion differently through the ERK1/2 signaling pathway in hen F3/4 and F1 granulosa cells.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	30-36
16837613-12	2006	Using a specific inhibitor of ERK1/2 (U0126), we also showed that this kinase is a negative regulator of the FSH-induced progesterone secretion in F3/4 and F1 granulosa cells, suggesting that AICAR-mediated AMPK activation modifies FSH-induced progesterone secretion differently through the ERK1/2 signaling pathway in hen F3/4 and F1 granulosa cells.	U 0126	38-43	mitogen-activated protein kinase 3	Homo sapiens	291-297
16785500-3	2006	In DC, the inhibitory effect of LPS on CIITA expression was prevented by MyD88 deficiency or pharmacological MAPK inhibitors specific for MEK (U0126) and p38 (SB203580), but not JNK (SP600125).	U 0126	143-148	class II transactivator	Mus musculus	39-44
16785500-3	2006	In DC, the inhibitory effect of LPS on CIITA expression was prevented by MyD88 deficiency or pharmacological MAPK inhibitors specific for MEK (U0126) and p38 (SB203580), but not JNK (SP600125).	U 0126	143-148	midkine	Mus musculus	138-141
16639077-6	2006	The increase in inflammatory gene expression coincided with the phosphorylation of the mitogen-activated protein kinase (MAPK) pathway members extracellular signal-regulated kinase (ERK) 1/2, stress-activated protein kinase/c-Jun NH2-terminal kinase, and p38 MAPK and was ameliorated by U0126, an inhibitor of ERK1/2.	U 0126	287-292	mitogen-activated protein kinase 1	Mus musculus	121-125
16614393-5	2006	The activation of MAPK by GLPE was suppressed by AG1478, an antagonist of epidermal growth factor receptor (EGFR), and by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, an inhibitor of TrkA, or by pertussis toxin.	U 0126	122-127	mitogen activated protein kinase 3	Rattus norvegicus	18-22
16614393-5	2006	The activation of MAPK by GLPE was suppressed by AG1478, an antagonist of epidermal growth factor receptor (EGFR), and by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, an inhibitor of TrkA, or by pertussis toxin.	U 0126	122-127	mitogen activated protein kinase 3	Rattus norvegicus	145-149
16805793-5	2006	Nicotine phosphorylated cPKC-alpha, thereby increasing phosphorylation of ERK1/ERK2, as demonstrated by using Go6976, PD98059 or U0126.	U 0126	129-134	mitogen-activated protein kinase 3	Bos taurus	74-78
16805793-5	2006	Nicotine phosphorylated cPKC-alpha, thereby increasing phosphorylation of ERK1/ERK2, as demonstrated by using Go6976, PD98059 or U0126.	U 0126	129-134	mitogen-activated protein kinase 1	Bos taurus	79-83
16809321-7	2006	The treatment of cells with U0126, a specific inhibitor of ERK activation, resulted in a substantial delay in the release of virus from infected cells that was more pronounced with a virus deleted for Us2 than with parental and repaired strains, suggesting that both ERK and Us2 activities are required for efficient virus replication.	U 0126	28-33	mitogen-activated protein kinase 1	Mus musculus	59-62
16650873-5	2006	MATERIALS AND METHODS: SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type) were treated with MEK inhibitor U0126 (10 microM) for 1 and 24 h. Proteins were extracted from untreated and treated cells and analyzed for differential expression by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE).	U 0126	112-117	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
16861876-10	2006	DCA-induced MMP-9 protein expression/activation was inhibited by pretreatment with SB203580, U0126, or PDTC.	U 0126	93-98	matrix metallopeptidase 9	Homo sapiens	12-17
16809321-7	2006	The treatment of cells with U0126, a specific inhibitor of ERK activation, resulted in a substantial delay in the release of virus from infected cells that was more pronounced with a virus deleted for Us2 than with parental and repaired strains, suggesting that both ERK and Us2 activities are required for efficient virus replication.	U 0126	28-33	mitogen-activated protein kinase 1	Mus musculus	267-270
16616417-5	2006	The intrathecal injection of a MEK inhibitor, U0126, reduced the phosphorylation of ERK in DRG neurons and alleviated the struggle behavior elicited by the passive movement of the joint.	U 0126	46-51	Eph receptor B1	Rattus norvegicus	84-87
16632475-8	2006	The protective ability of uPA is prevented by UO126, LY294002, by an MAPK targeting small interference RNA, and by a dominant negative Akt variant.	U 0126	46-51	plasminogen activator, urokinase	Homo sapiens	26-29
16650817-7	2006	Mitogen-activated protein kinase (MAPK) pathway inhibitors U0126 and SB203580 inhibit PAR2-mediated VEGF production.	U 0126	59-64	F2R like trypsin receptor 1	Homo sapiens	86-90
16474847-5	2006	Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference.	U 0126	115-120	nitric oxide synthase 2	Homo sapiens	23-27
16474847-5	2006	Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference.	U 0126	115-120	interferon induced protein 44	Homo sapiens	46-49
16474847-5	2006	Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference.	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	53-57
16650817-7	2006	Mitogen-activated protein kinase (MAPK) pathway inhibitors U0126 and SB203580 inhibit PAR2-mediated VEGF production.	U 0126	59-64	vascular endothelial growth factor A	Homo sapiens	100-104
16778206-7	2006	Finally, PKCzeta inhibition enhanced the effects of both MAPK/ERK kinase (U0126) and broad spectrum PKC inhibitor (chelerythrine chloride) and decreased cell proliferation in SCCHN cell lines.	U 0126	74-79	protein kinase C zeta	Homo sapiens	9-16
16778206-7	2006	Finally, PKCzeta inhibition enhanced the effects of both MAPK/ERK kinase (U0126) and broad spectrum PKC inhibitor (chelerythrine chloride) and decreased cell proliferation in SCCHN cell lines.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	57-61
16778206-7	2006	Finally, PKCzeta inhibition enhanced the effects of both MAPK/ERK kinase (U0126) and broad spectrum PKC inhibitor (chelerythrine chloride) and decreased cell proliferation in SCCHN cell lines.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	62-65
16778206-7	2006	Finally, PKCzeta inhibition enhanced the effects of both MAPK/ERK kinase (U0126) and broad spectrum PKC inhibitor (chelerythrine chloride) and decreased cell proliferation in SCCHN cell lines.	U 0126	74-79	protein kinase C zeta	Homo sapiens	9-12
16616413-8	2006	The phosphorylation of p44/p42 MAP kinase induced by IGF-I was reduced by U0126.	U 0126	74-79	mitogen-activated protein kinase 3	Mus musculus	23-26
16616413-8	2006	The phosphorylation of p44/p42 MAP kinase induced by IGF-I was reduced by U0126.	U 0126	74-79	insulin-like growth factor 1	Mus musculus	53-58
16616413-5	2006	PD98059 and U0126, specific inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly suppressed the IGF-I-induced alkaline phosphatase activity.	U 0126	12-17	mitogen-activated protein kinase 3	Mus musculus	77-80
16616413-5	2006	PD98059 and U0126, specific inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly suppressed the IGF-I-induced alkaline phosphatase activity.	U 0126	12-17	cyclin-dependent kinase 20	Mus musculus	81-84
16616413-5	2006	PD98059 and U0126, specific inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly suppressed the IGF-I-induced alkaline phosphatase activity.	U 0126	12-17	insulin-like growth factor 1	Mus musculus	126-131
16696958-6	2006	U0126, an ERK inhibitor, inhibited the neuroprotective effect of estrogen on axotomized RGC death.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	10-13
16414982-2	2006	Inhibition of the Erk MAPK, MEK, by U0126 produces a marked decrease in NaF-induced caldesmon phosphorylation.	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	18-21
16414982-2	2006	Inhibition of the Erk MAPK, MEK, by U0126 produces a marked decrease in NaF-induced caldesmon phosphorylation.	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	22-26
16414982-2	2006	Inhibition of the Erk MAPK, MEK, by U0126 produces a marked decrease in NaF-induced caldesmon phosphorylation.	U 0126	36-41	mitogen-activated protein kinase kinase 7	Homo sapiens	28-31
16414982-2	2006	Inhibition of the Erk MAPK, MEK, by U0126 produces a marked decrease in NaF-induced caldesmon phosphorylation.	U 0126	36-41	C-X-C motif chemokine ligand 8	Homo sapiens	72-75
16428271-6	2006	The mitogen-activated protein kinase kinase inhibitor U0126 totally reversed the inhibition observed with IFN-gamma, suggesting the involvement of the extracellular signal-regulated kinase pathway in this effect.	U 0126	54-59	interferon gamma	Homo sapiens	106-115
16702812-10	2006	When K101 was treated with MEK inhibitor U0126, the cell death rate was increased.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
16547595-9	2006	However, treatment with U0126 completely blocked SNAP-induced ERK activation and markedly, although not completely, inhibited the cardioprotection exerted by SNAP.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	62-65
16777389-6	2006	Our studies revealed that U0126, an inhibitor of the erk1/2 pathway, markedly suppressed CSM-induced TNF-alpha release.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	53-59
16777389-6	2006	Our studies revealed that U0126, an inhibitor of the erk1/2 pathway, markedly suppressed CSM-induced TNF-alpha release.	U 0126	26-31	tumor necrosis factor	Homo sapiens	101-110
16777389-7	2006	Consistent with this finding, U0126 blocked CSM-stimulated erk1/2 phosphorylation, as well as phosphorylation of the downstream kinase, p90RSK.	U 0126	30-35	mitogen-activated protein kinase 3	Homo sapiens	59-65
16777389-7	2006	Consistent with this finding, U0126 blocked CSM-stimulated erk1/2 phosphorylation, as well as phosphorylation of the downstream kinase, p90RSK.	U 0126	30-35	ribosomal protein S6 kinase A1	Homo sapiens	136-142
16755001-5	2006	Eotaxin-1/CCL11 production was inhibited by a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, but not by the MEK (MAPK/ERK kinase) inhibitors, PD98059 and U0126.	U 0126	172-177	C-C motif chemokine ligand 11	Homo sapiens	0-9
16755001-5	2006	Eotaxin-1/CCL11 production was inhibited by a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, but not by the MEK (MAPK/ERK kinase) inhibitors, PD98059 and U0126.	U 0126	172-177	C-C motif chemokine ligand 11	Homo sapiens	10-15
16755001-6	2006	In contrast, eotaxin-3/CCL26 production was inhibited similarly by PD98059 as well as U0126 and SB203580.	U 0126	86-91	C-C motif chemokine ligand 26	Homo sapiens	13-22
16755001-6	2006	In contrast, eotaxin-3/CCL26 production was inhibited similarly by PD98059 as well as U0126 and SB203580.	U 0126	86-91	C-C motif chemokine ligand 26	Homo sapiens	23-28
16527843-10	2006	The specific inhibitor of ERK activation, U0126, suppressed the activation of CYP11B2 transcription induced by BMP-6 without affecting Smad phosphorylation and Tlx2-Luc activity.	U 0126	42-47	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	78-85
16527843-10	2006	The specific inhibitor of ERK activation, U0126, suppressed the activation of CYP11B2 transcription induced by BMP-6 without affecting Smad phosphorylation and Tlx2-Luc activity.	U 0126	42-47	bone morphogenetic protein 6	Homo sapiens	111-116
16636108-8	2006	Cardiomyogenesis was inhibited by the p38 inhibitor SB203580, the ERK1,2 inhibitor UO126, and the JNK inhibitor SP600125.	U 0126	83-88	mitogen-activated protein kinase 3	Mus musculus	66-72
16488906-7	2006	The expression of Abi-2 in LSMC and MSMC was increased by TGF-beta1 (2.5 ng/ml) and was inhibited by GnRHa (0.1 microM) in a time- and cell-dependent manner, and pretreatment with Smad3 SiRNA and U0126, an MEK-1/2 inhibitor, respectively, reversed their actions.	U 0126	196-201	abl interactor 2	Homo sapiens	18-23
16753025-14	2006	Pretreating MC3T3-E1 cells with the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, or H-89, a PKA inhibitor, significantly inhibited the induction of fgf-2, showing that mechanical induction of fgf-2 is dependent on ERK and PKA signaling pathways.	U 0126	111-116	fibroblast growth factor 2	Mus musculus	185-190
16753025-14	2006	Pretreating MC3T3-E1 cells with the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, or H-89, a PKA inhibitor, significantly inhibited the induction of fgf-2, showing that mechanical induction of fgf-2 is dependent on ERK and PKA signaling pathways.	U 0126	111-116	fibroblast growth factor 2	Mus musculus	229-234
16753025-14	2006	Pretreating MC3T3-E1 cells with the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, or H-89, a PKA inhibitor, significantly inhibited the induction of fgf-2, showing that mechanical induction of fgf-2 is dependent on ERK and PKA signaling pathways.	U 0126	111-116	mitogen-activated protein kinase 1	Mus musculus	251-254
16508949-6	2006	In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt, which was attenuated by U0126, LY294002, or wortmannin, respectively.	U 0126	115-120	mitogen activated protein kinase 3	Rattus norvegicus	73-76
16508949-6	2006	In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt, which was attenuated by U0126, LY294002, or wortmannin, respectively.	U 0126	115-120	mitogen activated protein kinase 3	Rattus norvegicus	77-81
16508949-6	2006	In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt, which was attenuated by U0126, LY294002, or wortmannin, respectively.	U 0126	115-120	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
16720725-5	2006	VP-induced GAGA binding activity was potentiated by the protein kinase C inhibitor, calphostin C, and was prevented by the MEK inhibitor, UO126, and the epidermal growth factor receptor (EGFR) inhibitor, AG1478, suggesting that VP activates GAGA binding through transactivation of the EGFR.	U 0126	138-143	arginine vasopressin	Homo sapiens	0-2
16616413-8	2006	The phosphorylation of p44/p42 MAP kinase induced by IGF-I was reduced by U0126.	U 0126	74-79	cyclin-dependent kinase 20	Mus musculus	27-30
16818510-11	2006	Induction of ERK1/2 phosphorylation correlated with the potency of growth inhibition in tumor cell lines and inhibition of ERK1/2 phosphorylation by the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 inhibitor U0126 or overexpression of the cdc25A gene in Hep3B cells antagonized the growth inhibitory actions of PM-20.	U 0126	218-223	mitogen-activated protein kinase 3	Homo sapiens	13-19
16705159-4	2006	MEK1 inhibitor UO126 suppresses GH-dependent phosphorylation of Ser523, suggesting that extracellular signal-regulated kinases (ERKs) 1 and/or 2 or another kinase downstream of MEK1 phosphorylate Ser523 in response to GH.	U 0126	15-20	mitogen-activated protein kinase kinase 1	Homo sapiens	0-4
16705159-4	2006	MEK1 inhibitor UO126 suppresses GH-dependent phosphorylation of Ser523, suggesting that extracellular signal-regulated kinases (ERKs) 1 and/or 2 or another kinase downstream of MEK1 phosphorylate Ser523 in response to GH.	U 0126	15-20	growth hormone 1	Homo sapiens	32-34
16705159-4	2006	MEK1 inhibitor UO126 suppresses GH-dependent phosphorylation of Ser523, suggesting that extracellular signal-regulated kinases (ERKs) 1 and/or 2 or another kinase downstream of MEK1 phosphorylate Ser523 in response to GH.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	88-144
16705159-4	2006	MEK1 inhibitor UO126 suppresses GH-dependent phosphorylation of Ser523, suggesting that extracellular signal-regulated kinases (ERKs) 1 and/or 2 or another kinase downstream of MEK1 phosphorylate Ser523 in response to GH.	U 0126	15-20	mitogen-activated protein kinase kinase 1	Homo sapiens	177-181
16705159-4	2006	MEK1 inhibitor UO126 suppresses GH-dependent phosphorylation of Ser523, suggesting that extracellular signal-regulated kinases (ERKs) 1 and/or 2 or another kinase downstream of MEK1 phosphorylate Ser523 in response to GH.	U 0126	15-20	growth hormone 1	Homo sapiens	218-220
16818510-11	2006	Induction of ERK1/2 phosphorylation correlated with the potency of growth inhibition in tumor cell lines and inhibition of ERK1/2 phosphorylation by the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 inhibitor U0126 or overexpression of the cdc25A gene in Hep3B cells antagonized the growth inhibitory actions of PM-20.	U 0126	218-223	mitogen-activated protein kinase 3	Homo sapiens	123-129
16818510-11	2006	Induction of ERK1/2 phosphorylation correlated with the potency of growth inhibition in tumor cell lines and inhibition of ERK1/2 phosphorylation by the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 inhibitor U0126 or overexpression of the cdc25A gene in Hep3B cells antagonized the growth inhibitory actions of PM-20.	U 0126	218-223	mitogen-activated protein kinase 3	Homo sapiens	187-191
16818510-11	2006	Induction of ERK1/2 phosphorylation correlated with the potency of growth inhibition in tumor cell lines and inhibition of ERK1/2 phosphorylation by the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 inhibitor U0126 or overexpression of the cdc25A gene in Hep3B cells antagonized the growth inhibitory actions of PM-20.	U 0126	218-223	mitogen-activated protein kinase 1	Homo sapiens	13-16
16690053-4	2006	The chymase-induced IL-8 release was inhibited by pertussis toxin as well as U0126 (an inhibitor for extracellular signal-regulated kinase pathway) and SB203580 (p38 inhibitor), suggesting that the chymase-induced IL-8 production is mediated by G protein-coupled receptor and mitogen-activated protein kinases.	U 0126	77-82	chymase 1	Homo sapiens	4-11
16690053-4	2006	The chymase-induced IL-8 release was inhibited by pertussis toxin as well as U0126 (an inhibitor for extracellular signal-regulated kinase pathway) and SB203580 (p38 inhibitor), suggesting that the chymase-induced IL-8 production is mediated by G protein-coupled receptor and mitogen-activated protein kinases.	U 0126	77-82	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
16443326-5	2006	This was markedly reduced by the ERK pathway inhibitor U0126.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	33-36
16739251-6	2006	Furthermore, activation of the ERK pathway was involved in VPA-mediated CD61/CD41 expression and in cell adhesion, as demonstrated by using the MEK/ERK inhibitor U0126.	U 0126	162-167	mitogen-activated protein kinase 1	Homo sapiens	31-34
16739251-6	2006	Furthermore, activation of the ERK pathway was involved in VPA-mediated CD61/CD41 expression and in cell adhesion, as demonstrated by using the MEK/ERK inhibitor U0126.	U 0126	162-167	integrin subunit beta 3	Homo sapiens	72-76
16739251-6	2006	Furthermore, activation of the ERK pathway was involved in VPA-mediated CD61/CD41 expression and in cell adhesion, as demonstrated by using the MEK/ERK inhibitor U0126.	U 0126	162-167	integrin subunit alpha 2b	Homo sapiens	77-81
16739251-6	2006	Furthermore, activation of the ERK pathway was involved in VPA-mediated CD61/CD41 expression and in cell adhesion, as demonstrated by using the MEK/ERK inhibitor U0126.	U 0126	162-167	mitogen-activated protein kinase kinase 7	Homo sapiens	144-147
16739251-6	2006	Furthermore, activation of the ERK pathway was involved in VPA-mediated CD61/CD41 expression and in cell adhesion, as demonstrated by using the MEK/ERK inhibitor U0126.	U 0126	162-167	mitogen-activated protein kinase 1	Homo sapiens	148-151
16498633-8	2006	Dominant negative Ras or inhibitor of MEK-1/2 (U0126) aborted this activation, and blocked morphologic changes, whereas inhibition of TrkA receptor by K252a had no effects.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Homo sapiens	38-45
16448751-7	2006	The non-competitive NMDA-receptor antagonist, MK-801, and a specific inhibitor of the ERK1/2 pathway, U0126, significantly attenuated the injury-elicited increases in Homer1a mRNA when compared to saline-treated animals.	U 0126	102-107	mitogen activated protein kinase 3	Rattus norvegicus	86-92
16636309-11	2006	Prolactin-induced IDH1 expression was inhibited by the mitogen-activated protein kinase (MAPK) inhibitors PD98059 and U0126, and Janus tyrosine kinase 2 (Jak2) inhibitor AG490, suggesting that both MAPK and Jak2 contribute to regulation of IDH1 expression by prolactin.	U 0126	118-123	isocitrate dehydrogenase [NADP] cytoplasmic	Bos taurus	18-22
16651638-5	2006	Inhibition of ERK activation with MEK inhibitors (PD98059 or U0126) diminished induction of the antioxidant enzyme heme oxygenase-1.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	14-17
16651638-5	2006	Inhibition of ERK activation with MEK inhibitors (PD98059 or U0126) diminished induction of the antioxidant enzyme heme oxygenase-1.	U 0126	61-66	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
16651638-5	2006	Inhibition of ERK activation with MEK inhibitors (PD98059 or U0126) diminished induction of the antioxidant enzyme heme oxygenase-1.	U 0126	61-66	heme oxygenase 1	Homo sapiens	115-131
16455784-0	2006	Pregnancy-enhanced endothelial nitric oxide synthase (eNOS) activation in uterine artery endothelial cells shows altered sensitivity to Ca2+, U0126, and wortmannin but not LY294002--evidence that pregnancy adaptation of eNOS activation occurs at multiple levels of cell signaling.	U 0126	142-147	nitric oxide synthase 3	Homo sapiens	19-52
16455784-0	2006	Pregnancy-enhanced endothelial nitric oxide synthase (eNOS) activation in uterine artery endothelial cells shows altered sensitivity to Ca2+, U0126, and wortmannin but not LY294002--evidence that pregnancy adaptation of eNOS activation occurs at multiple levels of cell signaling.	U 0126	142-147	nitric oxide synthase 3	Homo sapiens	54-58
16455784-5	2006	The MAPK kinase (MEK) 1/2 inhibitor U0126 (10 microM) did not alter ATP-stimulated eNOS activity in P-UAEC, but potentiated the ATP response in NP-UAEC.	U 0126	36-41	mitogen-activated protein kinase kinase 1	Homo sapiens	4-25
16630075-6	2006	Inhibition of mitogen and extracellular signal-regulated kinase (MEK1/2) with U0126 and phosphoinositide 3-OH kinase (PI 3-K) with Wortmannin attenuated Akt activation.	U 0126	78-83	mitogen-activated protein kinase kinase 1	Homo sapiens	65-71
16467309-4	2006	PAR-1 and PAR-2 stimulation rapidly activated both ERK1/2 and p38MAPK, and pharmacological blockade of MEK with either PD98059 or U0126 or of p38MAPK by SB203580 or SB202190 strongly inhibited thrombin- and SLIGKV-induced COX-2 expression and 6-keto-PGF1alpha formation.	U 0126	130-135	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
16650001-8	2006	The MEK1/2 inhibitor, U0126, blocked cartducin-stimulated ERK1/2 phosphorylation and suppressed the DNA synthesis induced by cartducin in N1511 cells.	U 0126	22-27	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
16650001-8	2006	The MEK1/2 inhibitor, U0126, blocked cartducin-stimulated ERK1/2 phosphorylation and suppressed the DNA synthesis induced by cartducin in N1511 cells.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	58-64
16480888-5	2006	ERK1/2-inhibitor, U0126, reduced brain ischemia but not cytokine induction.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	0-6
16632126-6	2006	Our data demonstrated that TNF-alpha-induced upregulation of fibronectin mRNA and protein levels occurs via activation of ROS/ERK, which was prevented by treatment with notoginsenoside R1, DPI, apocynin, NAC, or MAPK/ERK inhibitors PD098059 and U0126.	U 0126	245-250	tumor necrosis factor	Homo sapiens	27-36
16632126-6	2006	Our data demonstrated that TNF-alpha-induced upregulation of fibronectin mRNA and protein levels occurs via activation of ROS/ERK, which was prevented by treatment with notoginsenoside R1, DPI, apocynin, NAC, or MAPK/ERK inhibitors PD098059 and U0126.	U 0126	245-250	fibronectin 1	Homo sapiens	61-72
16632126-6	2006	Our data demonstrated that TNF-alpha-induced upregulation of fibronectin mRNA and protein levels occurs via activation of ROS/ERK, which was prevented by treatment with notoginsenoside R1, DPI, apocynin, NAC, or MAPK/ERK inhibitors PD098059 and U0126.	U 0126	245-250	mitogen-activated protein kinase 1	Homo sapiens	126-129
16632126-6	2006	Our data demonstrated that TNF-alpha-induced upregulation of fibronectin mRNA and protein levels occurs via activation of ROS/ERK, which was prevented by treatment with notoginsenoside R1, DPI, apocynin, NAC, or MAPK/ERK inhibitors PD098059 and U0126.	U 0126	245-250	synuclein alpha	Homo sapiens	204-207
16478922-7	2006	Furthermore the Erk inhibitor U0126 was able to counteract the effect of p38 inhibition on IL-2 production, supporting the conclusion that p38 mediates its effect through Erk.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	16-19
16478922-7	2006	Furthermore the Erk inhibitor U0126 was able to counteract the effect of p38 inhibition on IL-2 production, supporting the conclusion that p38 mediates its effect through Erk.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	73-76
16478922-7	2006	Furthermore the Erk inhibitor U0126 was able to counteract the effect of p38 inhibition on IL-2 production, supporting the conclusion that p38 mediates its effect through Erk.	U 0126	30-35	interleukin 2	Homo sapiens	91-95
16478922-7	2006	Furthermore the Erk inhibitor U0126 was able to counteract the effect of p38 inhibition on IL-2 production, supporting the conclusion that p38 mediates its effect through Erk.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	139-142
16478922-7	2006	Furthermore the Erk inhibitor U0126 was able to counteract the effect of p38 inhibition on IL-2 production, supporting the conclusion that p38 mediates its effect through Erk.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	171-174
16705140-6	2006	Intrahippocampal injection of the MEK inhibitor U0126 prior to each phase prevents the activation of both ERK1/2 and CREB after unpaired conditioning.	U 0126	48-53	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
16705140-6	2006	Intrahippocampal injection of the MEK inhibitor U0126 prior to each phase prevents the activation of both ERK1/2 and CREB after unpaired conditioning.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	106-112
16705140-6	2006	Intrahippocampal injection of the MEK inhibitor U0126 prior to each phase prevents the activation of both ERK1/2 and CREB after unpaired conditioning.	U 0126	48-53	cAMP responsive element binding protein 1	Homo sapiens	117-121
16611730-5	2006	Netrin-1-stimulated NO* production or angiogenesis was inhibited by DCC antibody, DCC small interfering RNA (siRNA), specific inhibitors (PD98059, U0126), or siRNAs for MEK1/2.	U 0126	147-152	netrin 1	Homo sapiens	0-8
16457813-3	2006	In cultures of frontonasal mesenchyme isolated from stage 24/25 embryos, treatment with the MEK inhibitor U0126 increased type II collagen and glycosaminoglycan deposition into cartilage matrix, elevated mRNA levels for three chondrogenic marker genes (col2a1, aggrecan, and sox9), and increased expression of a Sox9-responsive collagen II enhancer-luciferase reporter gene.	U 0126	106-111	collagen type II alpha 1 chain	Gallus gallus	122-138
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	thrombopoietin	Homo sapiens	24-27
16457813-3	2006	In cultures of frontonasal mesenchyme isolated from stage 24/25 embryos, treatment with the MEK inhibitor U0126 increased type II collagen and glycosaminoglycan deposition into cartilage matrix, elevated mRNA levels for three chondrogenic marker genes (col2a1, aggrecan, and sox9), and increased expression of a Sox9-responsive collagen II enhancer-luciferase reporter gene.	U 0126	106-111	collagen type II alpha 1 chain	Gallus gallus	253-259
16457813-3	2006	In cultures of frontonasal mesenchyme isolated from stage 24/25 embryos, treatment with the MEK inhibitor U0126 increased type II collagen and glycosaminoglycan deposition into cartilage matrix, elevated mRNA levels for three chondrogenic marker genes (col2a1, aggrecan, and sox9), and increased expression of a Sox9-responsive collagen II enhancer-luciferase reporter gene.	U 0126	106-111	SRY-box 9	Gallus gallus	275-279
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	immediate early response 3	Homo sapiens	42-47
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	mitogen-activated protein kinase 1	Homo sapiens	116-120
16457813-3	2006	In cultures of frontonasal mesenchyme isolated from stage 24/25 embryos, treatment with the MEK inhibitor U0126 increased type II collagen and glycosaminoglycan deposition into cartilage matrix, elevated mRNA levels for three chondrogenic marker genes (col2a1, aggrecan, and sox9), and increased expression of a Sox9-responsive collagen II enhancer-luciferase reporter gene.	U 0126	106-111	SRY-box 9	Gallus gallus	312-316
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	mitogen-activated protein kinase kinase 7	Homo sapiens	131-134
16457817-8	2006	U0126 titering experiments, furthermore, revealed that the same MEK inhibitor concentration that blocked the TGF-beta1 increase in ERK1/2 phosphorylation (20 microM) also effectively attenuated the PAI-1 inductive response suggesting a requirement for stimulated ERK signaling in TGF-beta1-mediated PAI-1 expression.	U 0126	0-5	transforming growth factor, beta 1	Rattus norvegicus	109-118
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	RUNX family transcription factor 1	Homo sapiens	139-143
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	thrombopoietin	Homo sapiens	198-201
16457817-8	2006	U0126 titering experiments, furthermore, revealed that the same MEK inhibitor concentration that blocked the TGF-beta1 increase in ERK1/2 phosphorylation (20 microM) also effectively attenuated the PAI-1 inductive response suggesting a requirement for stimulated ERK signaling in TGF-beta1-mediated PAI-1 expression.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	131-137
16368886-7	2006	Finally, the ability of TPO to induce the IEX-1 gene expression was inhibited by U0126, a specific inhibitor of the ERKs activator MEK and AML1 transcriptional activity was shown to be modulated by TPO through ERK-dependent phosphorylation.	U 0126	81-86	mitogen-activated protein kinase 1	Homo sapiens	116-119
16457817-8	2006	U0126 titering experiments, furthermore, revealed that the same MEK inhibitor concentration that blocked the TGF-beta1 increase in ERK1/2 phosphorylation (20 microM) also effectively attenuated the PAI-1 inductive response suggesting a requirement for stimulated ERK signaling in TGF-beta1-mediated PAI-1 expression.	U 0126	0-5	serpin family E member 1	Rattus norvegicus	198-203
16457817-8	2006	U0126 titering experiments, furthermore, revealed that the same MEK inhibitor concentration that blocked the TGF-beta1 increase in ERK1/2 phosphorylation (20 microM) also effectively attenuated the PAI-1 inductive response suggesting a requirement for stimulated ERK signaling in TGF-beta1-mediated PAI-1 expression.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	131-134
16452470-5	2006	MEK inhibitor U0126 abolished nicotine-induced rise in P-ERK1/2, but not P-CREB, nor did it inhibit nicotine-evoked elevation in TH promoter activity, indicating that ERK1/2 was not needed for induction of TH gene expression by nicotine.	U 0126	14-19	mitogen activated protein kinase 3	Rattus norvegicus	57-63
16332724-7	2006	While individual Raf reduction by isoform-targeted antisense oligonucleotides (ODNs) produced growth inhibition in some cell lines, similar use of the MEK inhibitor UO126 produced growth inhibition in all cell lines tested.	U 0126	165-170	mitogen-activated protein kinase kinase 7	Homo sapiens	151-154
16443928-7	2006	Treatment of cells with a MEK inhibitor (U0126) or proteasome inhibitor (epoxomicin) also up-regulated Bim accumulation and rendered cells more sensitive to anoikis.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	26-29
16443928-7	2006	Treatment of cells with a MEK inhibitor (U0126) or proteasome inhibitor (epoxomicin) also up-regulated Bim accumulation and rendered cells more sensitive to anoikis.	U 0126	41-46	BCL2 like 11	Homo sapiens	103-106
16284240-4	2006	To study the role of ERK-1/2, veins were incubated with the mitogen-activated protein kinase kinase (MEK-1/2) inhibitor UO126 for 30 min before being grafted.	U 0126	120-125	dual specificity mitogen-activated protein kinase kinase 2	Canis lupus familiaris	101-108
16630308-5	2006	These three parameters, and the phosphorylated ERK-1 protein products of H9c2 cells treated with P. gingivalis medium, were all significantly reduced after pre-administration of U0126.	U 0126	178-183	mitogen activated protein kinase 3	Rattus norvegicus	47-52
16288471-7	2006	VCAM-1 promoter activity was enhanced by TNF-alpha in HTSMCs transfected with VCAM-1-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	124-129	vascular cell adhesion molecule 1	Homo sapiens	78-84
16288471-10	2006	Moreover, the resultant enhancement of VCAM-1 expression increased the adhesion of polymorphonuclear cells (PMNs) to monolayer of HTSMCs, which was blocked by helenalin, U0126, SB202190, or SP600125.	U 0126	170-175	vascular cell adhesion molecule 1	Homo sapiens	39-45
16595703-5	2006	Selective inhibition of these mitogen-activated protein kinases (MAPKs) by UO126 enhanced both the expression and phosphorylation of the StAR protein, but suppressed androgen production by the immature Leydig cells as well as dissipating the mitochondrial electrochemical potential (Psim) in these cells.	U 0126	75-80	steroidogenic acute regulatory protein	Rattus norvegicus	137-141
16515552-10	2006	Moreover, caspase-3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates-induced cytotoxicity.	U 0126	76-81	caspase 3	Homo sapiens	10-19
16515552-10	2006	Moreover, caspase-3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates-induced cytotoxicity.	U 0126	76-81	transthyretin	Rattus norvegicus	44-47
16515552-10	2006	Moreover, caspase-3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates-induced cytotoxicity.	U 0126	76-81	mitogen-activated protein kinase kinase 1	Homo sapiens	85-91
16515552-10	2006	Moreover, caspase-3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates-induced cytotoxicity.	U 0126	76-81	mitogen activated protein kinase 3	Rattus norvegicus	119-125
16515552-10	2006	Moreover, caspase-3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates-induced cytotoxicity.	U 0126	76-81	transthyretin	Rattus norvegicus	154-157
16458614-3	2006	TNF-alpha significantly increased extracellular signal-related kinases (ERK) and protein kinase B (PKB) activation and, which was blocked by notoginsenoside R1, PD098059, U0126 or wortmannin.	U 0126	171-176	tumor necrosis factor	Homo sapiens	0-9
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	epidermal growth factor	Homo sapiens	0-3
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	matrix metallopeptidase 2	Homo sapiens	12-17
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	mitogen-activated protein kinase 1	Homo sapiens	154-157
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	166-195
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	AKT serine/threonine kinase 1	Homo sapiens	203-206
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	epidermal growth factor	Homo sapiens	236-239
16722795-7	2006	EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro.	U 0126	81-86	matrix metallopeptidase 2	Homo sapiens	251-256
16520344-2	2006	TNF-alpha-induced MMP-9 expression, secretion and activity were completely blocked by stress-activated protein kinase/jun kinase (SAPK/JNK) and Erk inhibitors (SP600 125 and U0126 respectively) but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203 580 and SB202 190).	U 0126	174-179	tumor necrosis factor	Homo sapiens	0-9
16520344-5	2006	TNF-alpha-induced transactivation of NF-kappaB was inhibited by U0126, whereas TNF-alpha-induced transactivation of AP-1 was inhibited by SP600 125.	U 0126	64-69	tumor necrosis factor	Homo sapiens	0-9
16520344-5	2006	TNF-alpha-induced transactivation of NF-kappaB was inhibited by U0126, whereas TNF-alpha-induced transactivation of AP-1 was inhibited by SP600 125.	U 0126	64-69	nuclear factor kappa B subunit 1	Homo sapiens	37-46
16458614-3	2006	TNF-alpha significantly increased extracellular signal-related kinases (ERK) and protein kinase B (PKB) activation and, which was blocked by notoginsenoside R1, PD098059, U0126 or wortmannin.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	34-70
16458614-4	2006	Our data demonstrates that TNF-alpha-induced up-regulation of PAI-1 mRNA and protein levels and secretion occur via activation of ERK and PKB, which was prevented by treatment of notoginsenoside R1, PD098059, U0126 or wortmannin.	U 0126	209-214	tumor necrosis factor	Homo sapiens	27-36
16458614-4	2006	Our data demonstrates that TNF-alpha-induced up-regulation of PAI-1 mRNA and protein levels and secretion occur via activation of ERK and PKB, which was prevented by treatment of notoginsenoside R1, PD098059, U0126 or wortmannin.	U 0126	209-214	serpin family E member 1	Homo sapiens	62-67
16458614-4	2006	Our data demonstrates that TNF-alpha-induced up-regulation of PAI-1 mRNA and protein levels and secretion occur via activation of ERK and PKB, which was prevented by treatment of notoginsenoside R1, PD098059, U0126 or wortmannin.	U 0126	209-214	mitogen-activated protein kinase 1	Homo sapiens	130-133
16439367-3	2006	This response maps to the hinge and ligand binding domains of LRH-1 and is blocked by the mitogen-activated protein kinase ERK1/2 inhibitor U0126.	U 0126	140-145	nuclear receptor subfamily 5 group A member 2	Homo sapiens	62-67
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	tumor necrosis factor	Homo sapiens	0-9
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	vascular cell adhesion molecule 1	Homo sapiens	33-39
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	erythrocyte membrane protein band 4.2	Homo sapiens	87-90
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	mitogen-activated protein kinase 3	Homo sapiens	91-99
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	mitogen-activated protein kinase 1	Homo sapiens	101-104
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	mitogen-activated protein kinase 8	Homo sapiens	110-113
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	mitogen-activated protein kinase kinase 1	Homo sapiens	161-167
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	mitogen-activated protein kinase 1	Homo sapiens	177-180
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	U 0126	169-174	mitogen-activated protein kinase 8	Homo sapiens	197-200
16288471-7	2006	VCAM-1 promoter activity was enhanced by TNF-alpha in HTSMCs transfected with VCAM-1-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	124-129	vascular cell adhesion molecule 1	Homo sapiens	0-6
16288471-7	2006	VCAM-1 promoter activity was enhanced by TNF-alpha in HTSMCs transfected with VCAM-1-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	124-129	tumor necrosis factor	Homo sapiens	41-50
16439367-3	2006	This response maps to the hinge and ligand binding domains of LRH-1 and is blocked by the mitogen-activated protein kinase ERK1/2 inhibitor U0126.	U 0126	140-145	mitogen-activated protein kinase 3	Homo sapiens	123-129
16288223-4	2006	We found that cotreatment of drug-resistant HT29RDB colon cancer cells with the topoisomerase inhibitor doxorubicin and the PI3K-inhibitor LY294002 resulted in massive apoptosis, while cotreatment with the Mek inhibitors PD98059 or U0126 had no effect.	U 0126	232-237	mitogen-activated protein kinase kinase 7	Homo sapiens	206-209
16431916-6	2006	Inhibition of p42/p44 mitogen-activated protein kinase activation by U0126 reduced Bim ubiquitination and Bim degradation and blocked rapid ischemic tolerance.	U 0126	69-74	cyclin dependent kinase 20	Homo sapiens	14-17
16431916-6	2006	Inhibition of p42/p44 mitogen-activated protein kinase activation by U0126 reduced Bim ubiquitination and Bim degradation and blocked rapid ischemic tolerance.	U 0126	69-74	interferon induced protein 44	Homo sapiens	18-21
16431916-6	2006	Inhibition of p42/p44 mitogen-activated protein kinase activation by U0126 reduced Bim ubiquitination and Bim degradation and blocked rapid ischemic tolerance.	U 0126	69-74	BCL2 like 11	Homo sapiens	83-86
16431916-6	2006	Inhibition of p42/p44 mitogen-activated protein kinase activation by U0126 reduced Bim ubiquitination and Bim degradation and blocked rapid ischemic tolerance.	U 0126	69-74	BCL2 like 11	Homo sapiens	106-109
16533053-5	2006	Because phosphorylation of cdc2 and upregulation of wee1 by 2-ME(2) can be abolished by both extracellular receptor kinase (ERK) inhibitor (U0126) and c-Jun N-terminal kinase (JNK) inhibitor (SP600125), our studies indicate that the 2-ME(2)-induced upregulation of wee1 and subsequent cdc2 phosphorylation are mediated through mitogen-activated protein kinase (MAPK)-ERK-JNK signaling pathways.	U 0126	140-145	cyclin dependent kinase 1	Homo sapiens	27-31
16533053-5	2006	Because phosphorylation of cdc2 and upregulation of wee1 by 2-ME(2) can be abolished by both extracellular receptor kinase (ERK) inhibitor (U0126) and c-Jun N-terminal kinase (JNK) inhibitor (SP600125), our studies indicate that the 2-ME(2)-induced upregulation of wee1 and subsequent cdc2 phosphorylation are mediated through mitogen-activated protein kinase (MAPK)-ERK-JNK signaling pathways.	U 0126	140-145	WEE1 G2 checkpoint kinase	Homo sapiens	52-56
16533053-5	2006	Because phosphorylation of cdc2 and upregulation of wee1 by 2-ME(2) can be abolished by both extracellular receptor kinase (ERK) inhibitor (U0126) and c-Jun N-terminal kinase (JNK) inhibitor (SP600125), our studies indicate that the 2-ME(2)-induced upregulation of wee1 and subsequent cdc2 phosphorylation are mediated through mitogen-activated protein kinase (MAPK)-ERK-JNK signaling pathways.	U 0126	140-145	WEE1 G2 checkpoint kinase	Homo sapiens	265-269
16533053-5	2006	Because phosphorylation of cdc2 and upregulation of wee1 by 2-ME(2) can be abolished by both extracellular receptor kinase (ERK) inhibitor (U0126) and c-Jun N-terminal kinase (JNK) inhibitor (SP600125), our studies indicate that the 2-ME(2)-induced upregulation of wee1 and subsequent cdc2 phosphorylation are mediated through mitogen-activated protein kinase (MAPK)-ERK-JNK signaling pathways.	U 0126	140-145	cyclin dependent kinase 1	Homo sapiens	285-289
16507596-6	2006	The proxidant- and CoCl2-mediated upregulation of CT-1 was significantly inhibited in the presence of the ERK1,2 antagonist UO126, the JNK antagonist SP600125, the p38 antagonist SKF86002, the PI3-kinase antagonist LY294002, the Jak-2 antagonist AG490 as well as in the presence of free radical scavengers.	U 0126	124-129	cardiotrophin 1	Mus musculus	50-54
16507596-6	2006	The proxidant- and CoCl2-mediated upregulation of CT-1 was significantly inhibited in the presence of the ERK1,2 antagonist UO126, the JNK antagonist SP600125, the p38 antagonist SKF86002, the PI3-kinase antagonist LY294002, the Jak-2 antagonist AG490 as well as in the presence of free radical scavengers.	U 0126	124-129	mitogen-activated protein kinase 3	Mus musculus	106-112
16005925-5	2006	Synthetic inhibitors of ERK1/2 activation (U0126) or p38 kinase activity (SB203580) prevented both apoptosis and induction of p53 phosphorylation by DBalP.	U 0126	43-48	mitogen activated protein kinase 3	Rattus norvegicus	24-30
16527246-8	2006	U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly down-regulated lipopolysaccharide (LPS)-induced iNOS expression and promoter activity.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	27-64
16527246-8	2006	U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly down-regulated lipopolysaccharide (LPS)-induced iNOS expression and promoter activity.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	66-69
16527246-8	2006	U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly down-regulated lipopolysaccharide (LPS)-induced iNOS expression and promoter activity.	U 0126	0-5	nitric oxide synthase 2, inducible	Mus musculus	134-138
16527246-9	2006	Transactivation of LPS-stimulated NF-kappaB was inhibited by U0126.	U 0126	61-66	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	34-43
16005925-5	2006	Synthetic inhibitors of ERK1/2 activation (U0126) or p38 kinase activity (SB203580) prevented both apoptosis and induction of p53 phosphorylation by DBalP.	U 0126	43-48	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	126-129
16219303-6	2006	The neurite outgrowth in PC12D cells induced by panaxynol could be inhibited by the protein kinase A inhibitor RpcAMPS and by MAP kinase kinase 1/2 inhibitor U0126.	U 0126	158-163	mitogen activated protein kinase kinase 1	Rattus norvegicus	126-145
16291739-4	2006	However, LIF and PGF2alpha can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF2alpha treatment.	U 0126	126-131	leukemia inhibitory factor	Mus musculus	9-12
16291739-4	2006	However, LIF and PGF2alpha can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF2alpha treatment.	U 0126	126-131	mitogen-activated protein kinase 3	Mus musculus	52-58
16291739-4	2006	However, LIF and PGF2alpha can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF2alpha treatment.	U 0126	126-131	mitogen-activated protein kinase kinase 1	Mus musculus	135-141
16291739-4	2006	However, LIF and PGF2alpha can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF2alpha treatment.	U 0126	126-131	mitogen-activated protein kinase 3	Mus musculus	167-173
16291739-4	2006	However, LIF and PGF2alpha can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF2alpha treatment.	U 0126	126-131	leukemia inhibitory factor	Mus musculus	219-222
16180010-6	2006	In contrast, a specific inhibitor of ERK kinase (U0126 or PD98059) could abolish the accumulation as well as the phosphorylation of p53 at Ser15.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	37-40
16180010-6	2006	In contrast, a specific inhibitor of ERK kinase (U0126 or PD98059) could abolish the accumulation as well as the phosphorylation of p53 at Ser15.	U 0126	49-54	tumor protein p53	Homo sapiens	132-135
16180010-7	2006	Elevation of MDM2 was also abolished by U0126.	U 0126	40-45	MDM2 proto-oncogene	Homo sapiens	13-17
16272172-7	2006	Pretreatment with MEK1-ERK inhibitor U0126 and JNK inhibitor SP600125 substantially attenuated the decrease in cell viability induced by SFN, PEITC and AITC.	U 0126	37-42	mitogen-activated protein kinase kinase 1	Homo sapiens	18-22
16272172-7	2006	Pretreatment with MEK1-ERK inhibitor U0126 and JNK inhibitor SP600125 substantially attenuated the decrease in cell viability induced by SFN, PEITC and AITC.	U 0126	37-42	mitogen-activated protein kinase 1	Homo sapiens	23-26
16152620-3	2006	This report shows that U0126 inhibits early response (ERK) kinase activation and cyclin A expression in wt p53 C8161 melanoma exposed to either UV radiation or betulinic acid.	U 0126	23-28	tumor protein p53	Homo sapiens	107-110
16152620-5	2006	Protection from the latter drug by joint treatment with U0126 was also evident in wt p53 MelJuso melanoma and mutant p53 WM164 melanoma.	U 0126	56-61	tumor protein p53	Homo sapiens	85-88
16152620-5	2006	Protection from the latter drug by joint treatment with U0126 was also evident in wt p53 MelJuso melanoma and mutant p53 WM164 melanoma.	U 0126	56-61	tumor protein p53	Homo sapiens	117-120
16152620-9	2006	Our data show for the first time that (a) cdk4 protein is an early target of betulinic acid-induced apoptosis and (b) unrestricted ERK signaling favours betulinic acid-induced apoptosis, but this is counteracted by U0126, partly through counteracting chromatin condensation and restoring Akt activation decreased by betulinic acid treatment.	U 0126	215-220	cyclin dependent kinase 4	Homo sapiens	42-46
16152620-9	2006	Our data show for the first time that (a) cdk4 protein is an early target of betulinic acid-induced apoptosis and (b) unrestricted ERK signaling favours betulinic acid-induced apoptosis, but this is counteracted by U0126, partly through counteracting chromatin condensation and restoring Akt activation decreased by betulinic acid treatment.	U 0126	215-220	mitogen-activated protein kinase 1	Homo sapiens	131-134
16407199-8	2006	And the inhibition of ERK1/2 with the MEK1/2 inhibitor U0126 also prevented the differentiation of Sca-1+ cells into endothelial cells.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	22-28
16407199-8	2006	And the inhibition of ERK1/2 with the MEK1/2 inhibitor U0126 also prevented the differentiation of Sca-1+ cells into endothelial cells.	U 0126	55-60	mitogen-activated protein kinase kinase 1	Homo sapiens	38-44
16407199-8	2006	And the inhibition of ERK1/2 with the MEK1/2 inhibitor U0126 also prevented the differentiation of Sca-1+ cells into endothelial cells.	U 0126	55-60	caspase 3	Homo sapiens	99-104
16251475-3	2006	In cultured MVECs, Hcy induced activation of ERK, which was blocked by PD-98059 and U0126 (MEK inhibitors).	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	45-48
16619474-0	2006	Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.	U 0126	138-143	mitogen-activated protein kinase kinase 7	Homo sapiens	124-127
16619474-1	2006	BACKGROUND: This study aimed to evaluate the impact of selective abrogation of either the MEK/ERK1/2 (UO126 or PD98059) or the PI3K/AKT (LY294002) signaling cascade on cell proliferation, motility and invasion and production of VEGF (collectively termed pro-metastasis phenotypes) in cultured malignant pleural mesothelioma (MPM) cells.	U 0126	102-107	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
16571380-7	2006	In mechanistic terms, the transcriptional upregulation of SK-1 is dependent on PKC and the extracellular signal-regulated protein kinase (ERK) cascade since staurosporine and the MEK inhibitor U0126 abolish the TPA-induced SK-1 induction.	U 0126	193-198	sphingosine kinase 1	Homo sapiens	58-62
16571380-7	2006	In mechanistic terms, the transcriptional upregulation of SK-1 is dependent on PKC and the extracellular signal-regulated protein kinase (ERK) cascade since staurosporine and the MEK inhibitor U0126 abolish the TPA-induced SK-1 induction.	U 0126	193-198	protein kinase C alpha	Homo sapiens	79-82
16571380-7	2006	In mechanistic terms, the transcriptional upregulation of SK-1 is dependent on PKC and the extracellular signal-regulated protein kinase (ERK) cascade since staurosporine and the MEK inhibitor U0126 abolish the TPA-induced SK-1 induction.	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	91-136
16571380-7	2006	In mechanistic terms, the transcriptional upregulation of SK-1 is dependent on PKC and the extracellular signal-regulated protein kinase (ERK) cascade since staurosporine and the MEK inhibitor U0126 abolish the TPA-induced SK-1 induction.	U 0126	193-198	mitogen-activated protein kinase 1	Homo sapiens	138-141
16571380-7	2006	In mechanistic terms, the transcriptional upregulation of SK-1 is dependent on PKC and the extracellular signal-regulated protein kinase (ERK) cascade since staurosporine and the MEK inhibitor U0126 abolish the TPA-induced SK-1 induction.	U 0126	193-198	mitogen-activated protein kinase kinase 7	Homo sapiens	179-182
16571380-7	2006	In mechanistic terms, the transcriptional upregulation of SK-1 is dependent on PKC and the extracellular signal-regulated protein kinase (ERK) cascade since staurosporine and the MEK inhibitor U0126 abolish the TPA-induced SK-1 induction.	U 0126	193-198	sphingosine kinase 1	Homo sapiens	223-227
16244358-8	2006	Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE-induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation.	U 0126	97-102	transformation related protein 53, pseudogene	Mus musculus	77-80
16244358-8	2006	Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE-induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation.	U 0126	97-102	mitogen-activated protein kinase kinase 1	Mus musculus	138-144
16244358-8	2006	Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE-induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation.	U 0126	97-102	mitogen-activated protein kinase 14	Mus musculus	148-156
16244358-8	2006	Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE-induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation.	U 0126	97-102	mitogen-activated protein kinase 14	Mus musculus	148-156
16406008-9	2006	Crucially, co-expression of Ca(v)2.2(S447A) with Ca(v)beta1b(S161,348A) had an additive effect, abolishing the action of UO126 on channel current, an effect not seen when Ca(v)beta1b(S161,348A) was co-expressed with Ca(v)2.2(S409A).	U 0126	121-126	calcium voltage-gated channel subunit alpha1 B	Homo sapiens	28-36
16306081-8	2006	MAPK signaling was activated by nAChR-induced calcium influx, and ADP as well as vesicle translocation was suppressed by inhibition of MAPK signaling with MAPK kinase blockers, such as PD 098059 and U0126.	U 0126	199-204	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	32-37
16476053-9	2006	Inhibition of ERK activity, by the inhibitor U0126, reduced LPS-induced iNOS expression in our cell lines.	U 0126	45-50	mitogen-activated protein kinase 1	Mus musculus	14-17
16476053-9	2006	Inhibition of ERK activity, by the inhibitor U0126, reduced LPS-induced iNOS expression in our cell lines.	U 0126	45-50	nitric oxide synthase 2, inducible	Mus musculus	72-76
16152620-0	2006	Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status.	U 0126	97-102	mitogen-activated protein kinase kinase 7	Homo sapiens	83-86
16152620-1	2006	MEK1/2 inhibitors like U0126 can potentiate or antagonize the antitumor activity of cytotoxic agents such as cisplatin, paclitaxel or vinblastine, depending on the drug or the target cells.	U 0126	23-28	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
16152620-3	2006	This report shows that U0126 inhibits early response (ERK) kinase activation and cyclin A expression in wt p53 C8161 melanoma exposed to either UV radiation or betulinic acid.	U 0126	23-28	mitogen-activated protein kinase 1	Homo sapiens	54-57
16152620-3	2006	This report shows that U0126 inhibits early response (ERK) kinase activation and cyclin A expression in wt p53 C8161 melanoma exposed to either UV radiation or betulinic acid.	U 0126	23-28	cyclin A2	Homo sapiens	81-89
16498067-5	2006	Additionally, pre-treatment of SCC-4 cancer cells with 10 and 20 microM of U0126, a specific MEK inhibitor, resulted in a reduced expression of MMP-2 (18.7 and 51.4%) and u-PA (19.2 and 48.9%) concomitantly with a marked inhibition of cell invasion (13.7 and 45.7%).	U 0126	75-80	MAU2 sister chromatid cohesion factor	Homo sapiens	31-36
16498067-5	2006	Additionally, pre-treatment of SCC-4 cancer cells with 10 and 20 microM of U0126, a specific MEK inhibitor, resulted in a reduced expression of MMP-2 (18.7 and 51.4%) and u-PA (19.2 and 48.9%) concomitantly with a marked inhibition of cell invasion (13.7 and 45.7%).	U 0126	75-80	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
16498067-5	2006	Additionally, pre-treatment of SCC-4 cancer cells with 10 and 20 microM of U0126, a specific MEK inhibitor, resulted in a reduced expression of MMP-2 (18.7 and 51.4%) and u-PA (19.2 and 48.9%) concomitantly with a marked inhibition of cell invasion (13.7 and 45.7%).	U 0126	75-80	matrix metallopeptidase 2	Homo sapiens	144-149
16498067-5	2006	Additionally, pre-treatment of SCC-4 cancer cells with 10 and 20 microM of U0126, a specific MEK inhibitor, resulted in a reduced expression of MMP-2 (18.7 and 51.4%) and u-PA (19.2 and 48.9%) concomitantly with a marked inhibition of cell invasion (13.7 and 45.7%).	U 0126	75-80	plasminogen activator, urokinase	Homo sapiens	171-175
16339111-4	2006	In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126.	U 0126	285-290	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
16339111-4	2006	In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126.	U 0126	285-290	mitogen-activated protein kinase 8	Homo sapiens	187-210
16339111-4	2006	In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126.	U 0126	285-290	mitogen-activated protein kinase 8	Homo sapiens	212-215
15959844-3	2006	In the present study, we investigated the effects of ethanol and MEK inhibitor U0126 on the DNA binding activity of NRSF in neural stem cells prepared from rat embryos.	U 0126	79-84	RE1-silencing transcription factor	Rattus norvegicus	116-120
15959844-4	2006	Both ethanol and U0126 enhanced NRSF binding activity measured by the method based on the principal of electrophoretic mobility shift assay (EMSA) and decreased neuronal differentiation in a concentration dependent manner.	U 0126	17-22	RE1-silencing transcription factor	Rattus norvegicus	32-36
16460446-8	2006	Inhibition of extracellular signal-regulated protein kinase 1/2 (Erk 1/2) activation using U0126, an inhibitor of MAP kinase kinase (MEK), suppressed PAR-mediated cPLA2 phosphorylation and TXA2 generation.	U 0126	91-96	mitogen-activated protein kinase 3	Mus musculus	65-72
16460446-8	2006	Inhibition of extracellular signal-regulated protein kinase 1/2 (Erk 1/2) activation using U0126, an inhibitor of MAP kinase kinase (MEK), suppressed PAR-mediated cPLA2 phosphorylation and TXA2 generation.	U 0126	91-96	AFG3-like AAA ATPase 2	Mus musculus	150-153
16460446-8	2006	Inhibition of extracellular signal-regulated protein kinase 1/2 (Erk 1/2) activation using U0126, an inhibitor of MAP kinase kinase (MEK), suppressed PAR-mediated cPLA2 phosphorylation and TXA2 generation.	U 0126	91-96	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	163-168
16546990-7	2006	Inhibition of ERK1/2 with U0126 induces apoptosis but fails to activate JNK phosphorylation or down-regulate beta-catenin protein expression.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	14-20
16546990-8	2006	Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and beta-catenin.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	150-156
16546990-8	2006	Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and beta-catenin.	U 0126	17-22	mitogen-activated protein kinase 8	Homo sapiens	158-161
16546990-8	2006	Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and beta-catenin.	U 0126	17-22	catenin beta 1	Homo sapiens	167-179
16414356-4	2006	MEK inhibition by PD98059 or U0126 not only abrogates sphingosine 1-phosphate-induced Bad phosphorylation, but also its cytoprotective effect.	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
16414356-5	2006	Furthermore, inhibition of both mitochondrial cytochrome c efflux and Bax translocation to the mitochondria by sphingosine 1-phosphate could be overcome by PD98059 or U0126.	U 0126	167-172	cytochrome c, somatic	Homo sapiens	46-58
16414356-5	2006	Furthermore, inhibition of both mitochondrial cytochrome c efflux and Bax translocation to the mitochondria by sphingosine 1-phosphate could be overcome by PD98059 or U0126.	U 0126	167-172	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
16500892-8	2006	Pretreatment with the MAPK inhibitor, U0126, or the LPS antagonist, polymyxin B, resulted in an attenuation of KLF5, p50 and p65 NF-kappaB subunit mRNA levels from LPS treatment.	U 0126	38-43	Kruppel-like factor 5	Rattus norvegicus	111-115
16500892-8	2006	Pretreatment with the MAPK inhibitor, U0126, or the LPS antagonist, polymyxin B, resulted in an attenuation of KLF5, p50 and p65 NF-kappaB subunit mRNA levels from LPS treatment.	U 0126	38-43	synaptotagmin 1	Rattus norvegicus	125-128
16186792-3	2006	While ectopic MEK1Q56P sensitized HU-induced S-phase arrest, inhibition of Erk activation via U0126, PD98059, and MEK1K97M attenuated the arrest, and thereby enhanced cells to HU-induced toxicity.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	75-78
16186792-6	2006	Inhibition of Erk activation with U0126/PD98059 and MEK1K97M substantially reduced HU-induced ATR nuclear foci, leading to a dramatic reduction of gammaH2AX and its nuclear foci.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	14-17
16186792-10	2006	HU treatment caused the redistribution of ATR from the cytosol to the nucleus, a process that is inhibited by U0126.	U 0126	110-115	ATR serine/threonine kinase	Homo sapiens	42-45
16187294-6	2006	Furthermore, inhibition of mitogen-activated protein kinase (Erk-MAPK) in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	112-117	mitogen-activated protein kinase 1	Mus musculus	61-64
16187294-6	2006	Furthermore, inhibition of mitogen-activated protein kinase (Erk-MAPK) in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	112-117	mitogen-activated protein kinase 1	Mus musculus	65-69
16187294-6	2006	Furthermore, inhibition of mitogen-activated protein kinase (Erk-MAPK) in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	112-117	integrin alpha 5 (fibronectin receptor alpha)	Mus musculus	210-225
16187294-6	2006	Furthermore, inhibition of mitogen-activated protein kinase (Erk-MAPK) in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	112-117	glial cell line derived neurotrophic factor	Mus musculus	240-244
16187294-8	2006	Furthermore, inhibition of Erk-MAPK in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	77-82	mitogen-activated protein kinase 1	Mus musculus	27-30
16187294-8	2006	Furthermore, inhibition of Erk-MAPK in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	77-82	mitogen-activated protein kinase 1	Mus musculus	31-35
16187294-8	2006	Furthermore, inhibition of Erk-MAPK in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF.	U 0126	77-82	glial cell line derived neurotrophic factor	Mus musculus	205-209
16332685-10	2006	Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ERK signaling pathway.	U 0126	49-54	mitogen-activated protein kinase kinase 2	Homo sapiens	33-38
16332685-10	2006	Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ERK signaling pathway.	U 0126	49-54	poly(A) binding protein cytoplasmic 1	Homo sapiens	63-67
16332685-10	2006	Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ERK signaling pathway.	U 0126	49-54	poly(A) binding protein cytoplasmic 1	Homo sapiens	124-128
16332685-10	2006	Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ERK signaling pathway.	U 0126	49-54	mitogen-activated protein kinase kinase 2	Homo sapiens	148-153
16332685-10	2006	Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ERK signaling pathway.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	154-157
16251501-6	2006	Exposure of young oocytes to 20 microM roscovitine or 20 microM U0126, specific inhibitors of MPF and MAPK, resulted in the decreased percentage of oocytes showing positive immunostaining for BCL2 and in an increased rate of DNA fragmentation.	U 0126	64-69	mesothelin	Mus musculus	94-97
16251501-6	2006	Exposure of young oocytes to 20 microM roscovitine or 20 microM U0126, specific inhibitors of MPF and MAPK, resulted in the decreased percentage of oocytes showing positive immunostaining for BCL2 and in an increased rate of DNA fragmentation.	U 0126	64-69	B cell leukemia/lymphoma 2	Mus musculus	192-196
16452216-8	2006	Consistently, mitogen-activated protein kinase/ERK kinase inhibitor U0126 could abolish the EFA6A-induced cell invasion.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	47-50
16452216-8	2006	Consistently, mitogen-activated protein kinase/ERK kinase inhibitor U0126 could abolish the EFA6A-induced cell invasion.	U 0126	68-73	pleckstrin and Sec7 domain containing	Homo sapiens	92-97
16336951-5	2006	METHODS AND RESULTS: Human umbilical vascular endothelial cells (HUVECs) were incubated with U0126 (ERK1/2 inhibitor, 10 microM), SB203580 (p38 inhibitor, 20 microM), and SP600125 (JNK inhibitor, 20 microM), as well as the COX-2 selective inhibitor, NS398, for 1 h before treating with VEGF (20 ng/ml).	U 0126	93-98	mitogen-activated protein kinase 3	Homo sapiens	100-106
16303874-6	2006	For this purpose, vein grafts were incubated with the MEK-1/2 inhibitor, UO126, ex vivo for 30 min before grafting.	U 0126	73-78	dual specificity mitogen-activated protein kinase kinase 2	Canis lupus familiaris	54-61
16155909-5	2006	To determine whether age-related activation of ERK1/2-AP-1 signaling is responsible for the up-regulation of GCLC, the MEK inhibitors, PD98059 and U0126, were used to block ERK1/2 in VSMC from old rats.	U 0126	147-152	mitogen activated protein kinase 3	Rattus norvegicus	173-179
16155910-6	2006	Inhibiting the major mechanical signal transduction pathway with the ERK inhibitor, U0126, blocked upregulation of gene expression.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	69-72
16427075-7	2006	The role of extracellular signal-regulated kinase (ERK) 1/2 cascade activated by LIF was highlighted by the use of a MAPK/ERK kinase (MEK) 1/2 inhibitor, U0126, or overexpression of dominant-negative form of MEK1 that abolished sustained phosphorylation of Smad1 and cell survival effect induced by co-stimulation of LIF with BMP2, while BMP2 alone did not activate ERK1/2.	U 0126	154-159	LIF, interleukin 6 family cytokine	Rattus norvegicus	81-84
16420578-5	2006	Preventing ERK2 activation by U0126 prolonged occlusion times in TG (41 +/- 10 min) and WT (51 +/- 17) arterioles more than in TG (46 +/- 5 min) and WT (56 +/- 6 min) venules, uncovering a role for ERK2 in shear controlled thrombosis.	U 0126	30-35	mitogen-activated protein kinase 1	Mus musculus	11-15
16420578-5	2006	Preventing ERK2 activation by U0126 prolonged occlusion times in TG (41 +/- 10 min) and WT (51 +/- 17) arterioles more than in TG (46 +/- 5 min) and WT (56 +/- 6 min) venules, uncovering a role for ERK2 in shear controlled thrombosis.	U 0126	30-35	mitogen-activated protein kinase 1	Mus musculus	198-202
16420578-7	2006	Further inhibition strategies, combining VWF-A1, U0126 and NF449 in WT and TG mice and resulting in occlusion in various time windows, identified that inhibition by VWF-A1 largely abrogated the ERK2 contribution to thrombosis.	U 0126	49-54	Von Willebrand factor	Mus musculus	165-168
16166197-7	2006	IGF-I increased phosphorylation of ERK1/2, an event inhibited by the MAPK/ERK inhibitors, PD98059 and U0126.	U 0126	102-107	insulin-like growth factor 1	Mus musculus	0-5
16166197-7	2006	IGF-I increased phosphorylation of ERK1/2, an event inhibited by the MAPK/ERK inhibitors, PD98059 and U0126.	U 0126	102-107	mitogen-activated protein kinase 3	Mus musculus	35-41
16166197-7	2006	IGF-I increased phosphorylation of ERK1/2, an event inhibited by the MAPK/ERK inhibitors, PD98059 and U0126.	U 0126	102-107	mitogen-activated protein kinase 1	Mus musculus	69-73
16166197-7	2006	IGF-I increased phosphorylation of ERK1/2, an event inhibited by the MAPK/ERK inhibitors, PD98059 and U0126.	U 0126	102-107	mitogen-activated protein kinase 1	Mus musculus	35-38
16314390-5	2006	Treatment of cells with the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 reduces surface expression of MHCI without affecting its rate of endocytosis, suggesting that inactivation of Erk perturbs recycling.	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	28-67
16314390-5	2006	Treatment of cells with the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 reduces surface expression of MHCI without affecting its rate of endocytosis, suggesting that inactivation of Erk perturbs recycling.	U 0126	84-89	mitogen-activated protein kinase kinase 7	Homo sapiens	69-72
16314390-5	2006	Treatment of cells with the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 reduces surface expression of MHCI without affecting its rate of endocytosis, suggesting that inactivation of Erk perturbs recycling.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	200-203
16310170-6	2006	Furthermore, inhibition of ERK1/2 signaling pathway by U-0126 enhances caspase-3 activity and sets up programmed cell death.	U 0126	55-61	mitogen-activated protein kinase 3	Sus scrofa	27-33
16310170-6	2006	Furthermore, inhibition of ERK1/2 signaling pathway by U-0126 enhances caspase-3 activity and sets up programmed cell death.	U 0126	55-61	caspase 3	Sus scrofa	71-80
16310170-7	2006	Both IL-1beta and exogenous C(2)-ceramide effects are reproduced by U-0126 so illustrating the implication of ERK1/2 down-regulation in both caspase-3 activation and apoptosis induction.	U 0126	68-74	interleukin-1 beta	Sus scrofa	5-13
16310170-7	2006	Both IL-1beta and exogenous C(2)-ceramide effects are reproduced by U-0126 so illustrating the implication of ERK1/2 down-regulation in both caspase-3 activation and apoptosis induction.	U 0126	68-74	mitogen-activated protein kinase 3	Sus scrofa	110-116
16310170-7	2006	Both IL-1beta and exogenous C(2)-ceramide effects are reproduced by U-0126 so illustrating the implication of ERK1/2 down-regulation in both caspase-3 activation and apoptosis induction.	U 0126	68-74	caspase 3	Sus scrofa	141-150
16275640-3	2006	Moreover, the group IVA phospholipase A2 inhibitor pyrrophenone and the MEK inhibitor U-0126 inhibited AA release and 5-LO translocation in activated PMN, and these effects were also prevented by exogenous AA, demonstrating a functional link between AA release and 5-LO translocation.	U 0126	86-92	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
16135544-0	2006	Acceleration of K+ channel inactivation by MEK inhibitor U0126.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
16135544-2	2006	In studies of ERK modulation, the organic compound U0126 is often used to suppress the activity of MEK, which is a kinase immediately upstream from ERK.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	14-17
16135544-2	2006	In studies of ERK modulation, the organic compound U0126 is often used to suppress the activity of MEK, which is a kinase immediately upstream from ERK.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
16135544-2	2006	In studies of ERK modulation, the organic compound U0126 is often used to suppress the activity of MEK, which is a kinase immediately upstream from ERK.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	148-151
16155103-8	2006	U-0126, an antagonist of MEK1/2 and therefore of ERK1/2, blocked protection when started 5 min before reperfusion but not when started after only 10 min of reperfusion.	U 0126	0-6	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	25-31
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	U 0126	48-53	thymoma viral proto-oncogene 1	Mus musculus	77-80
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	U 0126	48-53	mitogen-activated protein kinase 3	Mus musculus	85-91
16135544-3	2006	We have observed that the inactivation time constant of heterologously expressed Kv4.2 channels was accelerated by U0126 at 1-20 microM.	U 0126	115-120	potassium voltage-gated channel subfamily D member 2	Homo sapiens	81-86
16135544-4	2006	This effect, however, was not Kv4 family specific, because U0126 also converted noninactivating K+ currents mediated by Kv1.1 subunits into transient ones.	U 0126	59-64	potassium voltage-gated channel subfamily A member 1	Homo sapiens	120-125
16400007-3	2006	The specific ERK1/2 inhibitor PD98059 enhanced the resolution of inflammation, whereas the MEK1/2 inhibitor U0126 had no effect and the flavonoid apigenin, a nonspecific inhibitor of ERK1/2 and COX-2, augmented inflammation.	U 0126	108-113	mitogen activated protein kinase kinase 1	Rattus norvegicus	91-97
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	U 0126	48-53	surfactant associated protein B	Mus musculus	136-140
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	U 0126	48-53	sparse coat	Mus musculus	145-149
16584539-12	2006	Inhibition of PI3K with LY294002 or MEK with UO126 prevented the development of acinar structures from IGFIR-expressing but not control cells.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
16433890-11	2006	In contrast, extracellular signal-regulated kinase (ERK) inhibitors U0126 and PD98059 strongly potentiated the apoptotic effect of trimidox.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	13-50
16433890-11	2006	In contrast, extracellular signal-regulated kinase (ERK) inhibitors U0126 and PD98059 strongly potentiated the apoptotic effect of trimidox.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	52-55
16134968-5	2006	MEK (MAPK/ERK kinase, where ERK stands for extracellular signal related kinase) inhibitors, PD98059 and U0126, completely blocked these protective effects of EGF on TJs.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
16299551-10	2006	4.--However, U0126 only partially inhibited the thrombin-induced GF contraction.	U 0126	13-18	coagulation factor II, thrombin	Homo sapiens	48-56
16584539-12	2006	Inhibition of PI3K with LY294002 or MEK with UO126 prevented the development of acinar structures from IGFIR-expressing but not control cells.	U 0126	45-50	insulin like growth factor 1 receptor	Homo sapiens	103-108
16003751-7	2006	Additive cytotoxicity was observed in A549 cells co-treated with gefitinib and the MEK inhibitor U0126 or the farnesyl transferase inhibitor SCH66336 and in H460 cells treated with gefitinib and the PI3K inhibitor LY294002, but not in H460 cells treated with gefitinib and rapamycin.	U 0126	97-102	mitogen-activated protein kinase kinase 7	Homo sapiens	83-86
16253958-4	2006	ERK1/2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity.	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	0-6
16253958-4	2006	ERK1/2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity.	U 0126	43-48	mitogen-activated protein kinase kinase 1	Homo sapiens	25-31
16253958-4	2006	ERK1/2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity.	U 0126	43-48	formyl peptide receptor 1	Homo sapiens	113-117
16253958-4	2006	ERK1/2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity.	U 0126	43-48	formyl peptide receptor 1	Homo sapiens	138-142
16253958-4	2006	ERK1/2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity.	U 0126	43-48	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	152-155
16374867-3	2006	We found that the type II transcriptional response to IFN-gamma could be suppressed by inhibition of MEK1/2 kinase activity by MEK1/2 inhibitor U0126 in the hepatoma cell line Huh-7.	U 0126	144-149	interferon gamma	Homo sapiens	54-63
16374867-3	2006	We found that the type II transcriptional response to IFN-gamma could be suppressed by inhibition of MEK1/2 kinase activity by MEK1/2 inhibitor U0126 in the hepatoma cell line Huh-7.	U 0126	144-149	mitogen-activated protein kinase kinase 1	Homo sapiens	101-107
16374867-3	2006	We found that the type II transcriptional response to IFN-gamma could be suppressed by inhibition of MEK1/2 kinase activity by MEK1/2 inhibitor U0126 in the hepatoma cell line Huh-7.	U 0126	144-149	mitogen-activated protein kinase kinase 1	Homo sapiens	127-133
16223857-5	2006	PD98059 and U0126, inhibitors of the ERK-MAPK cascade, partially prevented the palmitate-induced TNF-alpha expression.	U 0126	12-17	tumor necrosis factor	Mus musculus	97-106
16410064-8	2006	From the results of casein zymography and ELISA, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha-stimulated t-PA production, respectively (p &lt; 0.05).	U 0126	59-64	interleukin 1 alpha	Homo sapiens	105-114
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	119-156
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	158-161
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	coagulation factor II, thrombin	Homo sapiens	170-178
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	mitogen-activated protein kinase 3	Homo sapiens	206-212
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	C-X-C motif chemokine ligand 8	Homo sapiens	217-221
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	mitogen-activated protein kinase 3	Homo sapiens	263-267
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	mitogen-activated protein kinase 1	Homo sapiens	206-209
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	coagulation factor II, thrombin	Homo sapiens	293-301
16697690-6	2006	It was also found that PD98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor and U0126, an inhibitor of extracellular signal-regulated kinase (ERK) blocks thrombin-induced phosphorylation of ERK1/2 and IL-8 secretion, indicating the involvement of MAPK/ERK signaling pathway in thrombin-induced IL-8 secretion.	U 0126	96-101	C-X-C motif chemokine ligand 8	Homo sapiens	310-314
16384957-9	2006	Western blot analysis showed that phosphorylation of Akt and FKHRL1was abolished by LY294002 and SR13668, but downregulated by U0126, which also abolished phosphorylation of p44/42 mitogen-activated protein kinase (MAPK).	U 0126	127-132	AKT serine/threonine kinase 1	Homo sapiens	53-56
16384957-9	2006	Western blot analysis showed that phosphorylation of Akt and FKHRL1was abolished by LY294002 and SR13668, but downregulated by U0126, which also abolished phosphorylation of p44/42 mitogen-activated protein kinase (MAPK).	U 0126	127-132	forkhead box O3	Homo sapiens	61-67
16384957-9	2006	Western blot analysis showed that phosphorylation of Akt and FKHRL1was abolished by LY294002 and SR13668, but downregulated by U0126, which also abolished phosphorylation of p44/42 mitogen-activated protein kinase (MAPK).	U 0126	127-132	interferon induced protein 44	Homo sapiens	174-177
16270297-2	2006	U0126, a specific inhibitor of MEK1/2, downregulated CAIX expression induced by true hypoxia and cell density.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	31-37
16270297-2	2006	U0126, a specific inhibitor of MEK1/2, downregulated CAIX expression induced by true hypoxia and cell density.	U 0126	0-5	carbonic anhydrase 9	Homo sapiens	53-57
16270297-4	2006	Mapping of the U0126 effect revealed that both critical elements within the CA9 promoter, the hypoxia response element and the juxtaposed SP1-binding PR1, were inhibited.	U 0126	15-20	carbonic anhydrase 9	Homo sapiens	76-79
16270297-6	2006	Further analysis of the U0126 effect on HIF-1-dependent transcription in MCF-7 cells identified p300, a transcriptional co-activator of HIF-1, as the target of ERK.	U 0126	24-29	hypoxia inducible factor 1 subunit alpha	Homo sapiens	40-45
16270297-6	2006	Further analysis of the U0126 effect on HIF-1-dependent transcription in MCF-7 cells identified p300, a transcriptional co-activator of HIF-1, as the target of ERK.	U 0126	24-29	E1A binding protein p300	Homo sapiens	96-100
16270297-6	2006	Further analysis of the U0126 effect on HIF-1-dependent transcription in MCF-7 cells identified p300, a transcriptional co-activator of HIF-1, as the target of ERK.	U 0126	24-29	hypoxia inducible factor 1 subunit alpha	Homo sapiens	136-141
16270297-6	2006	Further analysis of the U0126 effect on HIF-1-dependent transcription in MCF-7 cells identified p300, a transcriptional co-activator of HIF-1, as the target of ERK.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	160-163
16328004-7	2006	BMP-2 induction is dependent on the ERK 1/2 signal transduction pathway, as its expression is abolished in the presence of UO126, a specific synthetic inhibitor of the ERK 1/2 pathway.	U 0126	123-128	bone morphogenetic protein 2	Mus musculus	0-5
16328004-7	2006	BMP-2 induction is dependent on the ERK 1/2 signal transduction pathway, as its expression is abolished in the presence of UO126, a specific synthetic inhibitor of the ERK 1/2 pathway.	U 0126	123-128	mitogen-activated protein kinase 3	Mus musculus	36-43
16328004-7	2006	BMP-2 induction is dependent on the ERK 1/2 signal transduction pathway, as its expression is abolished in the presence of UO126, a specific synthetic inhibitor of the ERK 1/2 pathway.	U 0126	123-128	mitogen-activated protein kinase 3	Mus musculus	168-175
15920755-3	2006	Specificity of this pathway was monitored using MEK inhibitors UO126 and PD98059 in platelet derived growth factor-AB (PDGF-AB)- and fibroblast growth factor-2 (FGF-2)-stimulated SMCs.	U 0126	63-68	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
15920755-3	2006	Specificity of this pathway was monitored using MEK inhibitors UO126 and PD98059 in platelet derived growth factor-AB (PDGF-AB)- and fibroblast growth factor-2 (FGF-2)-stimulated SMCs.	U 0126	63-68	fibroblast growth factor 2	Homo sapiens	133-159
15920755-3	2006	Specificity of this pathway was monitored using MEK inhibitors UO126 and PD98059 in platelet derived growth factor-AB (PDGF-AB)- and fibroblast growth factor-2 (FGF-2)-stimulated SMCs.	U 0126	63-68	fibroblast growth factor 2	Homo sapiens	161-166
15920755-7	2006	However, the reversibility of p27Kip1 down-regulation by UO126 was mainly observed after PDGF-AB stimulation, indicating MEK independent p27Kip1 down-regulation by FGF-2.	U 0126	57-62	cyclin dependent kinase inhibitor 1B	Homo sapiens	30-37
15920755-8	2006	Surprisingly, treatment of SMCs with UO126 or PD98059 increased the level of MEK phosphorylation in a dose dependent manner at serine residues 217/221 in the presence as well as in the absence of both growth factors.	U 0126	37-42	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
16410064-8	2006	From the results of casein zymography and ELISA, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha-stimulated t-PA production, respectively (p &lt; 0.05).	U 0126	59-64	plasminogen activator, tissue type	Homo sapiens	126-130
16410064-10	2006	SB203580, U0126, and LY294002 suppress t-PA activity and may also have important implication for pharmacological intervention.	U 0126	10-15	plasminogen activator, tissue type	Homo sapiens	39-43
16267831-7	2006	Inhibition of MAPK kinase (MEK), an upstream kinase, by U0126, blocked TPA-induced activation of ERK1/2 in wild-type p53 cells and in mutant p53 cells.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
16323212-4	2006	GDNF effects on phosphorylated p42/p44 levels were blocked by the mitogen-activated protein kinase (MAPK) pathway specific inhibitors (PD98059 and U0126).	U 0126	147-152	glial cell derived neurotrophic factor	Homo sapiens	0-4
16323212-4	2006	GDNF effects on phosphorylated p42/p44 levels were blocked by the mitogen-activated protein kinase (MAPK) pathway specific inhibitors (PD98059 and U0126).	U 0126	147-152	cyclin dependent kinase 20	Homo sapiens	31-34
16323212-4	2006	GDNF effects on phosphorylated p42/p44 levels were blocked by the mitogen-activated protein kinase (MAPK) pathway specific inhibitors (PD98059 and U0126).	U 0126	147-152	interferon induced protein 44	Homo sapiens	35-38
16323212-4	2006	GDNF effects on phosphorylated p42/p44 levels were blocked by the mitogen-activated protein kinase (MAPK) pathway specific inhibitors (PD98059 and U0126).	U 0126	147-152	mitogen-activated protein kinase 3	Homo sapiens	100-104
16410143-9	2006	Conversely, p-MEK levels increased with increasing U0126 concentrations at 1 hour in SH-SY5Y (N-type) and at 24 hours in all lines.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
16267831-7	2006	Inhibition of MAPK kinase (MEK), an upstream kinase, by U0126, blocked TPA-induced activation of ERK1/2 in wild-type p53 cells and in mutant p53 cells.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	97-103
16267831-7	2006	Inhibition of MAPK kinase (MEK), an upstream kinase, by U0126, blocked TPA-induced activation of ERK1/2 in wild-type p53 cells and in mutant p53 cells.	U 0126	56-61	tumor protein p53	Homo sapiens	117-120
16267831-7	2006	Inhibition of MAPK kinase (MEK), an upstream kinase, by U0126, blocked TPA-induced activation of ERK1/2 in wild-type p53 cells and in mutant p53 cells.	U 0126	56-61	tumor protein p53	Homo sapiens	141-144
21176443-3	2006	The aim of this study is to investigate the influence of nm23-H1 and exogenous ERK1/2 pathway inhibitor U0126 on the extracellular signal-regulated kinase (ERK1/2) of human high-metastatic large cell lung cancer cell line L9981 and its malignant biological behaviors.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	79-85
16343798-3	2006	In another group, the hyperglycemic ischemic rats were pretreated with ERK inhibitor U0126 (U0126).	U 0126	85-90	Eph receptor B1	Rattus norvegicus	71-74
16343798-3	2006	In another group, the hyperglycemic ischemic rats were pretreated with ERK inhibitor U0126 (U0126).	U 0126	92-97	Eph receptor B1	Rattus norvegicus	71-74
16343798-6	2006	Pretreatment with U0126 in CIH rats significantly decreased ERK1/2 immunoreactive cells.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	60-66
16343798-9	2006	Treatment with U0126 significantly reduced phospho-ERK1/2 in the CIH group.	U 0126	15-20	mitogen activated protein kinase 3	Rattus norvegicus	51-57
16388741-9	2006	Pretreatment of the cells with PD98059 or UO126, inhibitors of phosphorylated p42/44 MAKP, decreased the CTGF-induced expression of phosphorylated p42/44 MAPK and concentration of FLK in supernatants.	U 0126	42-47	CCN family member 2	Ovis aries	105-109
16909037-8	2006	With U0126, an upstream inhibitor of ERK activation, BrdU labeling was markedly reduced immunohistochemically as well as PCNA protein expression, suggesting a role for ERKs in the proliferation response.	U 0126	5-10	proliferating cell nuclear antigen	Rattus norvegicus	121-125
16459022-7	2006	U0126 also blocked the amphetamine-induced increases in phospho-extracellular-regulated kinase and preproenkephalin and preprodynorphin gene expression in the striatum.	U 0126	0-5	prodynorphin	Rattus norvegicus	120-135
21176443-3	2006	The aim of this study is to investigate the influence of nm23-H1 and exogenous ERK1/2 pathway inhibitor U0126 on the extracellular signal-regulated kinase (ERK1/2) of human high-metastatic large cell lung cancer cell line L9981 and its malignant biological behaviors.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	156-162
21176443-6	2006	RESULTS: The phosphorylated ERK1/2 expression level and relative activity in L9981-nm23-H1 lung cancer cell line were remarkably lower than those in L9981 and L9981-PLXSN lung cancer cell lines after being treated with U0126 (P &lt; 0.01), but there was no significant difference between L9981 and L9981-PLXSN lung cancer cell lines.	U 0126	219-224	mitogen-activated protein kinase 3	Homo sapiens	28-34
21176443-6	2006	RESULTS: The phosphorylated ERK1/2 expression level and relative activity in L9981-nm23-H1 lung cancer cell line were remarkably lower than those in L9981 and L9981-PLXSN lung cancer cell lines after being treated with U0126 (P &lt; 0.01), but there was no significant difference between L9981 and L9981-PLXSN lung cancer cell lines.	U 0126	219-224	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	83-90
21208537-3	2005	The aim of this study is to investigate the influence of exogenous MEK1/2 pathway inhibitor U0126 on the expression and activity of extracellular signal-regulated kinase (ERK1/2) of human high-metastatic large cell lung cancer cell line L9981 and its malignant biological behaviors.	U 0126	92-97	mitogen-activated protein kinase kinase 1	Homo sapiens	67-73
16288728-5	2005	Furthermore, the MEK-inhibitor U0126 had similar effects suggesting dual regulatory mechanisms.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
21208537-3	2005	The aim of this study is to investigate the influence of exogenous MEK1/2 pathway inhibitor U0126 on the expression and activity of extracellular signal-regulated kinase (ERK1/2) of human high-metastatic large cell lung cancer cell line L9981 and its malignant biological behaviors.	U 0126	92-97	mitogen-activated protein kinase 3	Homo sapiens	171-177
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	96-101	mitogen-activated protein kinase 3	Homo sapiens	13-19
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	239-244	mitogen-activated protein kinase 3	Homo sapiens	13-19
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	239-244	mitogen-activated protein kinase 3	Homo sapiens	163-169
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	239-244	mitogen-activated protein kinase 3	Homo sapiens	163-169
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	239-244	mitogen-activated protein kinase 3	Homo sapiens	13-19
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	239-244	mitogen-activated protein kinase 3	Homo sapiens	163-169
21208537-6	2005	RESULTS: The ERK1/2 relative activity of L9981 gradually decreased accompanied with increase of U0126 doses, and a highly significant difference of phosphorylated ERK1/2 expression level existed among the different concentration groups of U0126 (P &lt; 0.01), but no significant difference of total ERK1/2 expression was found among the different concentration groups of U0126 (P=0.387).	U 0126	239-244	mitogen-activated protein kinase 3	Homo sapiens	163-169
21208537-7	2005	After treatment with same concentration of U0126 for different time, the ERK1/2 relative activity of L9981 gradually decreased as the treatment time of U0126 prolonging, and a highly significant difference of phosphorylated ERK1/2 expression level was observed among different treatment time groups (P &lt; 0.01).	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	73-79
21208537-7	2005	After treatment with same concentration of U0126 for different time, the ERK1/2 relative activity of L9981 gradually decreased as the treatment time of U0126 prolonging, and a highly significant difference of phosphorylated ERK1/2 expression level was observed among different treatment time groups (P &lt; 0.01).	U 0126	43-48	mitogen-activated protein kinase 3	Homo sapiens	224-230
21208537-7	2005	After treatment with same concentration of U0126 for different time, the ERK1/2 relative activity of L9981 gradually decreased as the treatment time of U0126 prolonging, and a highly significant difference of phosphorylated ERK1/2 expression level was observed among different treatment time groups (P &lt; 0.01).	U 0126	152-157	mitogen-activated protein kinase 3	Homo sapiens	73-79
21208537-9	2005	The inhibition of ERK1/2 pathway by MEK1/2 specific inhibitor U0126 targeting the ERK1/2 pathway of L9981 was dose- and time-dependent.	U 0126	62-67	mitogen-activated protein kinase 3	Homo sapiens	18-24
21208537-9	2005	The inhibition of ERK1/2 pathway by MEK1/2 specific inhibitor U0126 targeting the ERK1/2 pathway of L9981 was dose- and time-dependent.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Homo sapiens	36-42
21208537-9	2005	The inhibition of ERK1/2 pathway by MEK1/2 specific inhibitor U0126 targeting the ERK1/2 pathway of L9981 was dose- and time-dependent.	U 0126	62-67	mitogen-activated protein kinase 3	Homo sapiens	82-88
21208537-14	2005	CONCLUSIONS: The inhibition of Ras-to-MAPK pathway by Ras-to-MAPK specific inhibitor U0126 targeting the Ras-to-MAPK pathway of the human high-metastatic large cell lung cancer cell line L9981 is dose-dependent and time-dependent.	U 0126	85-90	mitogen-activated protein kinase 3	Homo sapiens	38-42
21208537-14	2005	CONCLUSIONS: The inhibition of Ras-to-MAPK pathway by Ras-to-MAPK specific inhibitor U0126 targeting the Ras-to-MAPK pathway of the human high-metastatic large cell lung cancer cell line L9981 is dose-dependent and time-dependent.	U 0126	85-90	mitogen-activated protein kinase 3	Homo sapiens	61-65
21208537-14	2005	CONCLUSIONS: The inhibition of Ras-to-MAPK pathway by Ras-to-MAPK specific inhibitor U0126 targeting the Ras-to-MAPK pathway of the human high-metastatic large cell lung cancer cell line L9981 is dose-dependent and time-dependent.	U 0126	85-90	mitogen-activated protein kinase 3	Homo sapiens	61-65
16170369-9	2005	In addition, co-treatment of RAR-beta(2)-positive cells with BPDE and the MEK1/2 inhibitor U0126 caused little change in c-Jun and COX-2 expression.	U 0126	91-96	mitogen-activated protein kinase kinase 6-like	Nicotiana tabacum	74-80
16351709-4	2005	We have previously demonstrated that the embryonal rhabdomyosarcoma cell line undergoes growth arrest and myogenic differentiation following treatments with TPA and the MEK inhibitor U0126, which respectively activate and inhibit the ERK pathway.	U 0126	183-188	mitogen-activated protein kinase kinase 7	Homo sapiens	169-172
16302187-5	2005	Immunoblot analysis demonstrated that Cx43 and the mitogen-activated protein kinase (MAPK), ERK-1/2, were phosphorylated in response to TrkA activation via NGF and that phosphorylation could be prevented by treatment with the MEK-1/2 inhibitor U0126.	U 0126	244-249	gap junction protein, alpha 1	Rattus norvegicus	38-42
16302187-5	2005	Immunoblot analysis demonstrated that Cx43 and the mitogen-activated protein kinase (MAPK), ERK-1/2, were phosphorylated in response to TrkA activation via NGF and that phosphorylation could be prevented by treatment with the MEK-1/2 inhibitor U0126.	U 0126	244-249	mitogen activated protein kinase 3	Rattus norvegicus	92-99
16302187-5	2005	Immunoblot analysis demonstrated that Cx43 and the mitogen-activated protein kinase (MAPK), ERK-1/2, were phosphorylated in response to TrkA activation via NGF and that phosphorylation could be prevented by treatment with the MEK-1/2 inhibitor U0126.	U 0126	244-249	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	136-140
16302187-5	2005	Immunoblot analysis demonstrated that Cx43 and the mitogen-activated protein kinase (MAPK), ERK-1/2, were phosphorylated in response to TrkA activation via NGF and that phosphorylation could be prevented by treatment with the MEK-1/2 inhibitor U0126.	U 0126	244-249	nerve growth factor	Rattus norvegicus	156-159
16302187-7	2005	Fluorescence recovery in the photobleached area increased after NGF treatment and decreased when pretreated with the MEK-1/2 inhibitor U0126.	U 0126	135-140	mitogen activated protein kinase kinase 1	Rattus norvegicus	117-124
16278666-5	2005	When an inhibitor of ERK activation (10 microM U0126) was included in the Ca2+-supplemented culture medium, ERK-activation did not occur.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	21-24
16278666-5	2005	When an inhibitor of ERK activation (10 microM U0126) was included in the Ca2+-supplemented culture medium, ERK-activation did not occur.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	108-111
16351709-4	2005	We have previously demonstrated that the embryonal rhabdomyosarcoma cell line undergoes growth arrest and myogenic differentiation following treatments with TPA and the MEK inhibitor U0126, which respectively activate and inhibit the ERK pathway.	U 0126	183-188	mitogen-activated protein kinase 1	Homo sapiens	234-237
16351709-6	2005	RESULTS: p21WAF1 expression and growth arrest are induced in both embryonal (RD) and alveolar (RH30) rhabdomyosarcoma cell lines following TPA or MEK/ERK inhibitor (U0126) treatments, whereas myogenic differentiation is induced in RD cells alone.	U 0126	165-170	mitogen-activated protein kinase kinase 7	Homo sapiens	146-149
16351709-6	2005	RESULTS: p21WAF1 expression and growth arrest are induced in both embryonal (RD) and alveolar (RH30) rhabdomyosarcoma cell lines following TPA or MEK/ERK inhibitor (U0126) treatments, whereas myogenic differentiation is induced in RD cells alone.	U 0126	165-170	mitogen-activated protein kinase 1	Homo sapiens	150-153
16351709-8	2005	By contrast, U0126-mediated p21WAF1 expression is controlled transcriptionally by the p38 pathway.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	86-89
16351709-9	2005	Similarly, myogenin and MyoD expression is induced both by U0126 and TPA and is prevented by p38 inhibition.	U 0126	59-64	myogenin	Homo sapiens	11-19
16351709-9	2005	Similarly, myogenin and MyoD expression is induced both by U0126 and TPA and is prevented by p38 inhibition.	U 0126	59-64	myogenic differentiation 1	Homo sapiens	24-28
16351709-10	2005	Although MyoD and myogenin depletion by siRNA prevents U0126-mediated p21WAF1 expression, the over-expression of these two transcription factors is insufficient to induce p21WAF1.	U 0126	55-60	myogenin	Homo sapiens	18-26
16284106-6	2005	Inhibition of the ERK1/2 pathway with U-0126 abolished all effects of temporal gradients.	U 0126	38-44	mitogen-activated protein kinase 3	Homo sapiens	18-24
16289484-6	2005	At 30 min after resuscitation, vehicle (50% saline:50% DMSO) or the ERK kinase inhibitor U0126 (100 microg) was infused into the lateral ventricle.	U 0126	89-94	Eph receptor B1	Rattus norvegicus	68-71
16289484-9	2005	A dose of 100 mug U0126 inhibited ERK bilaterally for 12 to 24 h and decreased phosphorylation of the ERK substrates ATF-2 and CREB.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	34-37
16289484-9	2005	A dose of 100 mug U0126 inhibited ERK bilaterally for 12 to 24 h and decreased phosphorylation of the ERK substrates ATF-2 and CREB.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	102-105
16289484-9	2005	A dose of 100 mug U0126 inhibited ERK bilaterally for 12 to 24 h and decreased phosphorylation of the ERK substrates ATF-2 and CREB.	U 0126	18-23	activating transcription factor 2	Rattus norvegicus	117-122
16289484-9	2005	A dose of 100 mug U0126 inhibited ERK bilaterally for 12 to 24 h and decreased phosphorylation of the ERK substrates ATF-2 and CREB.	U 0126	18-23	cAMP responsive element binding protein 1	Rattus norvegicus	127-131
16289484-12	2005	Therefore, a dose of U0126 sufficient to inhibit biochemical markers of ERK signaling in hippocampus does not alter the beneficial effects of hypothermia induced after resuscitation in rats and did not affect recovery of normothermia-treated rats.	U 0126	21-26	Eph receptor B1	Rattus norvegicus	72-75
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	U 0126	58-63	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	U 0126	58-63	nuclear factor kappa B subunit 1	Homo sapiens	11-33
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	U 0126	58-63	nuclear factor kappa B subunit 1	Homo sapiens	35-44
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	U 0126	58-63	fibroblast growth factor 2	Homo sapiens	111-116
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	U 0126	58-63	neuropilin 1	Homo sapiens	127-132
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	U 0126	58-63	mitogen-activated protein kinase 8	Homo sapiens	168-171
16253760-4	2005	U0126, an inhibitor of MEK1/2, inhibited the TNF-alpha-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and the metastatic properties in vitro without affecting cell proliferation.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	23-29
16253760-4	2005	U0126, an inhibitor of MEK1/2, inhibited the TNF-alpha-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and the metastatic properties in vitro without affecting cell proliferation.	U 0126	0-5	tumor necrosis factor	Mus musculus	45-54
16253760-4	2005	U0126, an inhibitor of MEK1/2, inhibited the TNF-alpha-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and the metastatic properties in vitro without affecting cell proliferation.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	77-118
16253760-4	2005	U0126, an inhibitor of MEK1/2, inhibited the TNF-alpha-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and the metastatic properties in vitro without affecting cell proliferation.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	120-126
16253760-5	2005	In addition, pretreatment with U0126 in vitro completely abrogated the increased lung metastasis of TNF-alpha-treated cells.	U 0126	31-36	tumor necrosis factor	Mus musculus	100-109
16289800-5	2005	Furthermore, attenuation of the spinal ERK phosphorylation by intrathecal a MAPK kinase (MEK) inhibitor U0126 or knockdown of the spinal ERK by antisense oligonucleotides not only decreased the scores of morphine withdrawal, but also attenuated withdrawal-induced allodynia, which were accompanied by decreased ERK phosphorylation in the spinal cord.	U 0126	104-109	Eph receptor B1	Rattus norvegicus	39-42
16322288-9	2005	The MAPK inhibitors PD98059 and U0126 blocked ghrelin-induced MAPK activation, as well as proliferation, in both cell lines.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	4-8
15951157-8	2005	A similar increase of Sp1-DNA binding was observed when phosphorylation of Erk1/2 was inhibited by pretreatment with the MAP kinase inhibitor, U0126.	U 0126	143-148	mitogen-activated protein kinase 3	Homo sapiens	75-81
16322252-9	2005	Inhibition of the MAPK pathway with PD98059 or U0126 blocked the DFMO-induced induction of p21 and the reduction of cdk-2 protein.	U 0126	47-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	91-94
16322252-9	2005	Inhibition of the MAPK pathway with PD98059 or U0126 blocked the DFMO-induced induction of p21 and the reduction of cdk-2 protein.	U 0126	47-52	cyclin dependent kinase 2	Homo sapiens	116-121
16322252-11	2005	MDA-MB-435 cells treated with PD98059 or U0126 in the presence and absence of DFMO exhibited a marked increase in the expression of p27 and its association with cdk-2, a decrease in phosphorylation of cdk-2 on Thr160, and a decrease in cyclin E expression.	U 0126	41-46	interferon alpha inducible protein 27	Homo sapiens	132-135
16322252-11	2005	MDA-MB-435 cells treated with PD98059 or U0126 in the presence and absence of DFMO exhibited a marked increase in the expression of p27 and its association with cdk-2, a decrease in phosphorylation of cdk-2 on Thr160, and a decrease in cyclin E expression.	U 0126	41-46	cyclin dependent kinase 2	Homo sapiens	161-166
16322252-11	2005	MDA-MB-435 cells treated with PD98059 or U0126 in the presence and absence of DFMO exhibited a marked increase in the expression of p27 and its association with cdk-2, a decrease in phosphorylation of cdk-2 on Thr160, and a decrease in cyclin E expression.	U 0126	41-46	cyclin dependent kinase 2	Homo sapiens	201-206
16385238-15	2005	Expression of COX-2 and iNOS was significantly inhibited by U0126 but not by SB203580.	U 0126	60-65	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-19
16385238-15	2005	Expression of COX-2 and iNOS was significantly inhibited by U0126 but not by SB203580.	U 0126	60-65	nitric oxide synthase 2	Rattus norvegicus	24-28
16040022-6	2005	The MEK inhibitor U0126 (10 micromol/l) almost completely prevented the reduction in beta-adrenergic responsiveness and the negative lusitropic effect of ET-1+ISO co-stimulation.	U 0126	18-23	endothelin 1	Rattus norvegicus	154-162
16040022-7	2005	In addition, U0126 completely normalized ANF gene expression, but did not affect or only marginally affected expression of MHC and alpha-actin isoforms.	U 0126	13-18	natriuretic peptide A	Rattus norvegicus	41-44
16322288-9	2005	The MAPK inhibitors PD98059 and U0126 blocked ghrelin-induced MAPK activation, as well as proliferation, in both cell lines.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	62-66
16123166-8	2005	Rapid E(2)-induced increases in pERK immunoreactivity were specific to the ERK1/2 pathway as demonstrated by coinjection of the mitogen-activated, ERK-activating kinase (MEK)1/2 inhibitor U0126.	U 0126	188-193	mitogen activated protein kinase 3	Rattus norvegicus	75-81
16445569-9	2005	Inhibition of MEK/ERK with the pharmacological inhibitors U0126 (10 micromol/L) or PD98059 (20 micromol/L) together with As2O3 (2 and 5 micromol/L) resulted in a significant enhancement of growth inhibition in breast cancer MCF-7 cells as determined by the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide assay and [Methyl-3H]-thymidine incorporation.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
16445569-9	2005	Inhibition of MEK/ERK with the pharmacological inhibitors U0126 (10 micromol/L) or PD98059 (20 micromol/L) together with As2O3 (2 and 5 micromol/L) resulted in a significant enhancement of growth inhibition in breast cancer MCF-7 cells as determined by the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide assay and [Methyl-3H]-thymidine incorporation.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	18-21
16445569-10	2005	Furthermore, the results demonstrated that combined treatment with As2O3 and the MEK1/2 inhibitor U0126 could augment breast cancer MCF-7 cell apoptosis approximately twofold compared with the effects of the two drugs alone, as determined by Hoechst 33258 or annexin V/propidium iodide (PI) staining and flow cytometry.	U 0126	98-103	mitogen-activated protein kinase kinase 1	Homo sapiens	81-87
16123166-8	2005	Rapid E(2)-induced increases in pERK immunoreactivity were specific to the ERK1/2 pathway as demonstrated by coinjection of the mitogen-activated, ERK-activating kinase (MEK)1/2 inhibitor U0126.	U 0126	188-193	mitogen activated protein kinase kinase 1	Rattus norvegicus	147-177
16313280-6	2005	ET-1-stimulated proliferation was inhibited by PD98059 or U0126.	U 0126	58-63	endothelin-1	Oryctolagus cuniculus	0-4
16322329-18	2005	The addition of UO126 caused a decrease in cell number and increased the effects of IGFBP-3.	U 0126	16-21	insulin like growth factor binding protein 3	Homo sapiens	84-91
16263754-5	2005	Moreover, inhibitors of MAPK (U0126 and SB203580) significantly reduced the IL-8 production, while the inhibition of NF-kappaB (pyrrolidinedithiocarbamate and retrovirus containing dominant-negative IkappaB alpha plasmid) did not affect the IL-8 expression increased by CpG ODN.	U 0126	30-35	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
16149052-6	2005	MEK1/2 inhibitors, such as PD98059 and U0126, reduced RA-induced ERK1/2 activity, but could not block the genistein effects.	U 0126	39-44	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
16343111-6	2005	From the results of casein zymography and ELISA, SB203580 and U0126 significantly reduced the P. endodontalis stimulated t-PA production respectively (P &lt; 0.05).	U 0126	62-67	plasminogen activator, tissue type	Homo sapiens	121-125
16149052-6	2005	MEK1/2 inhibitors, such as PD98059 and U0126, reduced RA-induced ERK1/2 activity, but could not block the genistein effects.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	65-71
16149052-9	2005	Failure of inhibition of ERK1/2 activation by the MEK1/2 inhibitors PD98059 and U0126 suggests presence of an unknown activator for ERK1/2 in neuronal cells.	U 0126	80-85	mitogen-activated protein kinase 3	Homo sapiens	25-31
16311341-4	2005	Both intracellular and conditioned medium localised MMP-7 was greatly reduced by treatment with the epidermal growth factor receptor (EGFR) inhibitor AG1478 and the mitogen activated protein kinase kinase (MEK) inhibitor U0126 in pancreatic cancer cells.	U 0126	221-226	matrix metallopeptidase 7	Homo sapiens	52-57
16311341-4	2005	Both intracellular and conditioned medium localised MMP-7 was greatly reduced by treatment with the epidermal growth factor receptor (EGFR) inhibitor AG1478 and the mitogen activated protein kinase kinase (MEK) inhibitor U0126 in pancreatic cancer cells.	U 0126	221-226	mitogen-activated protein kinase kinase 7	Homo sapiens	165-204
16311341-4	2005	Both intracellular and conditioned medium localised MMP-7 was greatly reduced by treatment with the epidermal growth factor receptor (EGFR) inhibitor AG1478 and the mitogen activated protein kinase kinase (MEK) inhibitor U0126 in pancreatic cancer cells.	U 0126	221-226	mitogen-activated protein kinase kinase 7	Homo sapiens	206-209
16219028-7	2005	Unilateral infusions of the MAPK kinase inhibitor U0126 into nucleus accumbens attenuated cocaine-induced ERK and CREB phosphorylation in cocaine-sensitized rats.	U 0126	50-55	Eph receptor B1	Rattus norvegicus	106-109
16139919-4	2005	RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K.	U 0126	120-125	transforming growth factor beta 1	Homo sapiens	141-150
16139919-4	2005	RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K.	U 0126	120-125	ADAM metallopeptidase domain 12	Homo sapiens	161-167
16139919-4	2005	RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K.	U 0126	120-125	ribosomal protein S6 kinase B1	Homo sapiens	216-222
16169554-4	2005	We used dechorionated egg culture as a model system of diapause termination and observed that both yolk cell dissociation and embryonic development are inhibited by MAPK-ERK kinase (MEK) inhibitor U0126.	U 0126	197-202	extracellular regulated MAP kinase	Bombyx mori	170-173
16219028-7	2005	Unilateral infusions of the MAPK kinase inhibitor U0126 into nucleus accumbens attenuated cocaine-induced ERK and CREB phosphorylation in cocaine-sensitized rats.	U 0126	50-55	cAMP responsive element binding protein 1	Rattus norvegicus	114-118
16020504-6	2005	Although VWF fostered the agglutination of platelets regardless of any additional treatment, the inhibition of mitogen-activated protein kinase kinase (MEK) with U0126 abolished VWF-induced platelet aggregation and thromboxane production in non-aspirin-treated washed platelets.	U 0126	162-167	mitogen-activated protein kinase kinase 7	Homo sapiens	111-150
16163708-7	2005	We observed that, without affecting IkappaBalpha phosphorylation, MEK1 inhibitor U0126 treatment inhibited not only p65-S536 phosphorylation but also TNF-alpha-induced polyubiquitination of IkappaBalpha thereby inhibiting IkappaBalpha degradation.	U 0126	81-86	mitogen-activated protein kinase kinase 1	Homo sapiens	66-70
16163708-7	2005	We observed that, without affecting IkappaBalpha phosphorylation, MEK1 inhibitor U0126 treatment inhibited not only p65-S536 phosphorylation but also TNF-alpha-induced polyubiquitination of IkappaBalpha thereby inhibiting IkappaBalpha degradation.	U 0126	81-86	RELA proto-oncogene, NF-kB subunit	Homo sapiens	116-119
16163708-7	2005	We observed that, without affecting IkappaBalpha phosphorylation, MEK1 inhibitor U0126 treatment inhibited not only p65-S536 phosphorylation but also TNF-alpha-induced polyubiquitination of IkappaBalpha thereby inhibiting IkappaBalpha degradation.	U 0126	81-86	tumor necrosis factor	Homo sapiens	150-159
16163708-7	2005	We observed that, without affecting IkappaBalpha phosphorylation, MEK1 inhibitor U0126 treatment inhibited not only p65-S536 phosphorylation but also TNF-alpha-induced polyubiquitination of IkappaBalpha thereby inhibiting IkappaBalpha degradation.	U 0126	81-86	NFKB inhibitor alpha	Homo sapiens	190-202
16163708-7	2005	We observed that, without affecting IkappaBalpha phosphorylation, MEK1 inhibitor U0126 treatment inhibited not only p65-S536 phosphorylation but also TNF-alpha-induced polyubiquitination of IkappaBalpha thereby inhibiting IkappaBalpha degradation.	U 0126	81-86	NFKB inhibitor alpha	Homo sapiens	190-202
16219295-4	2005	Activities of RhoA and ERK were increased by 5-HT, and the increase in cell migration by 5-HT was abolished in the presence of U0126, a MEK1/2 inhibitor, or Y-27632, a Rho-kinase inhibitor.	U 0126	127-132	ras homolog family member A	Homo sapiens	14-18
16219295-4	2005	Activities of RhoA and ERK were increased by 5-HT, and the increase in cell migration by 5-HT was abolished in the presence of U0126, a MEK1/2 inhibitor, or Y-27632, a Rho-kinase inhibitor.	U 0126	127-132	EPH receptor B2	Homo sapiens	23-26
16219295-4	2005	Activities of RhoA and ERK were increased by 5-HT, and the increase in cell migration by 5-HT was abolished in the presence of U0126, a MEK1/2 inhibitor, or Y-27632, a Rho-kinase inhibitor.	U 0126	127-132	mitogen-activated protein kinase kinase 1	Homo sapiens	136-142
16155293-5	2005	Pretreatment with selective NFkappaB inhibitors and the MEK/ERK inhibitor U0126 blocked CLA-mediated IL-6 gene expression.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
16155293-5	2005	Pretreatment with selective NFkappaB inhibitors and the MEK/ERK inhibitor U0126 blocked CLA-mediated IL-6 gene expression.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	60-63
16155293-5	2005	Pretreatment with selective NFkappaB inhibitors and the MEK/ERK inhibitor U0126 blocked CLA-mediated IL-6 gene expression.	U 0126	74-79	interleukin 6	Homo sapiens	101-105
16327214-5	2005	ERK activation, iNOS induction, and NO production following LPS stimulation were all markedly inhibited in the presence of U0126, an ERK inhibitor.	U 0126	123-128	Eph receptor B1	Rattus norvegicus	0-3
16327214-5	2005	ERK activation, iNOS induction, and NO production following LPS stimulation were all markedly inhibited in the presence of U0126, an ERK inhibitor.	U 0126	123-128	nitric oxide synthase 2	Rattus norvegicus	16-20
16327214-5	2005	ERK activation, iNOS induction, and NO production following LPS stimulation were all markedly inhibited in the presence of U0126, an ERK inhibitor.	U 0126	123-128	Eph receptor B1	Rattus norvegicus	133-136
18404517-5	2005	We found that the potentiating effect of ATP on cyclin expression was significantly reduced by U0126, an inhibitor of MEK, the upstream activator of ERK.	U 0126	95-100	proliferating cell nuclear antigen	Rattus norvegicus	48-54
18404517-5	2005	We found that the potentiating effect of ATP on cyclin expression was significantly reduced by U0126, an inhibitor of MEK, the upstream activator of ERK.	U 0126	95-100	Eph receptor B1	Rattus norvegicus	149-152
16020504-6	2005	Although VWF fostered the agglutination of platelets regardless of any additional treatment, the inhibition of mitogen-activated protein kinase kinase (MEK) with U0126 abolished VWF-induced platelet aggregation and thromboxane production in non-aspirin-treated washed platelets.	U 0126	162-167	mitogen-activated protein kinase kinase 7	Homo sapiens	152-155
16020504-6	2005	Although VWF fostered the agglutination of platelets regardless of any additional treatment, the inhibition of mitogen-activated protein kinase kinase (MEK) with U0126 abolished VWF-induced platelet aggregation and thromboxane production in non-aspirin-treated washed platelets.	U 0126	162-167	von Willebrand factor	Homo sapiens	178-181
15951350-7	2005	The alprostadil-induced upregulation of eNOS and VEGF was prevented by inhibition of MAPKs with PD-98056 or U-0126.	U 0126	108-114	nitric oxide synthase 3	Homo sapiens	40-44
15951350-7	2005	The alprostadil-induced upregulation of eNOS and VEGF was prevented by inhibition of MAPKs with PD-98056 or U-0126.	U 0126	108-114	vascular endothelial growth factor A	Homo sapiens	49-53
16267010-14	2005	Additional studies showed that the PI3K/AKT-specific inhibitor LY294002 had a more profound effect than the MAPK-specific inhibitor U0126 in blocking EGF-induced cell proliferation.	U 0126	132-137	epidermal growth factor	Homo sapiens	150-153
16040717-3	2005	Treatment of FGF-2 Tg and wild-type hearts with U-0126, a MEK-ERK pathway inhibitor, significantly reduced recovery of contractile function after global low-flow ischemia-reperfusion injury in FGF-2 Tg (86 +/- 2% vehicle vs. 66 +/- 4% U-0126; P &lt; 0.05) but not wild-type (61 +/- 7% vehicle vs. 67 +/- 7% U-0126) hearts.	U 0126	48-54	fibroblast growth factor 2	Homo sapiens	13-18
16040717-3	2005	Treatment of FGF-2 Tg and wild-type hearts with U-0126, a MEK-ERK pathway inhibitor, significantly reduced recovery of contractile function after global low-flow ischemia-reperfusion injury in FGF-2 Tg (86 +/- 2% vehicle vs. 66 +/- 4% U-0126; P &lt; 0.05) but not wild-type (61 +/- 7% vehicle vs. 67 +/- 7% U-0126) hearts.	U 0126	48-54	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
16040717-3	2005	Treatment of FGF-2 Tg and wild-type hearts with U-0126, a MEK-ERK pathway inhibitor, significantly reduced recovery of contractile function after global low-flow ischemia-reperfusion injury in FGF-2 Tg (86 +/- 2% vehicle vs. 66 +/- 4% U-0126; P &lt; 0.05) but not wild-type (61 +/- 7% vehicle vs. 67 +/- 7% U-0126) hearts.	U 0126	48-54	mitogen-activated protein kinase 1	Homo sapiens	62-65
16040717-3	2005	Treatment of FGF-2 Tg and wild-type hearts with U-0126, a MEK-ERK pathway inhibitor, significantly reduced recovery of contractile function after global low-flow ischemia-reperfusion injury in FGF-2 Tg (86 +/- 2% vehicle vs. 66 +/- 4% U-0126; P &lt; 0.05) but not wild-type (61 +/- 7% vehicle vs. 67 +/- 7% U-0126) hearts.	U 0126	48-54	fibroblast growth factor 2	Homo sapiens	193-198
16040717-3	2005	Treatment of FGF-2 Tg and wild-type hearts with U-0126, a MEK-ERK pathway inhibitor, significantly reduced recovery of contractile function after global low-flow ischemia-reperfusion injury in FGF-2 Tg (86 +/- 2% vehicle vs. 66 +/- 4% U-0126; P &lt; 0.05) but not wild-type (61 +/- 7% vehicle vs. 67 +/- 7% U-0126) hearts.	U 0126	235-241	fibroblast growth factor 2	Homo sapiens	13-18
16040717-4	2005	Similarly, MEK-ERK inhibition significantly increased myocardial infarct size in FGF-2 Tg (12 +/- 3% vehicle vs. 31 +/- 2% U-0126; P &lt; 0.05) but not wild-type (30 +/- 4% vehicle vs. 36 +/- 7% U-0126) hearts.	U 0126	123-129	mitogen-activated protein kinase kinase 7	Homo sapiens	11-14
16040717-4	2005	Similarly, MEK-ERK inhibition significantly increased myocardial infarct size in FGF-2 Tg (12 +/- 3% vehicle vs. 31 +/- 2% U-0126; P &lt; 0.05) but not wild-type (30 +/- 4% vehicle vs. 36 +/- 7% U-0126) hearts.	U 0126	195-201	mitogen-activated protein kinase kinase 7	Homo sapiens	11-14
16356124-7	2005	Treatment of MCF10A cells with U0126, which is a pharmacological inhibitor of ERK1/2, reduced TPA-induced up-regulation of COX-2 and MMP-9.	U 0126	31-36	mitogen-activated protein kinase 3	Homo sapiens	78-84
16356124-7	2005	Treatment of MCF10A cells with U0126, which is a pharmacological inhibitor of ERK1/2, reduced TPA-induced up-regulation of COX-2 and MMP-9.	U 0126	31-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	123-128
16356124-7	2005	Treatment of MCF10A cells with U0126, which is a pharmacological inhibitor of ERK1/2, reduced TPA-induced up-regulation of COX-2 and MMP-9.	U 0126	31-36	matrix metallopeptidase 9	Homo sapiens	133-138
16261339-2	2005	The aim of this study was to investigate the effects of the spin trap agent alpha-phenyl-N-tert-butyl nitrone (PBN), the Src family kinase inhibitor PP2 and the MEK1-inhibitor U0126 on focal hyperglycemic ischemic brain injury.	U 0126	176-181	mitogen activated protein kinase kinase 1	Rattus norvegicus	161-165
16438946-5	2005	Specific inhibitors for the signal proteins, Rp cAMPS, H89, PD98059, and U0126, or SB203580, suppressed the signaling pathway and TNF-alpha expression.	U 0126	73-78	tumor necrosis factor	Mus musculus	130-139
16125055-5	2005	The MEK inhibitor U0126 strongly inhibited both phases of MAPK phosphorylation as well as FD/Fms cell differentiation, indicating that MAPK may relay M-CSF differentiation signaling downstream of M-CSFR.	U 0126	18-23	midkine	Mus musculus	4-7
16125055-5	2005	The MEK inhibitor U0126 strongly inhibited both phases of MAPK phosphorylation as well as FD/Fms cell differentiation, indicating that MAPK may relay M-CSF differentiation signaling downstream of M-CSFR.	U 0126	18-23	colony stimulating factor 1 (macrophage)	Mus musculus	150-155
16125055-6	2005	Treatment of FD/Fms cells with U0126 during the first hour of M-CSF stimulation reversibly blocked the early phase of MAPK phosphorylation but did not affect differentiation.	U 0126	31-36	colony stimulating factor 1 (macrophage)	Mus musculus	62-67
16125055-7	2005	In contrast, U0126 still inhibited FD/Fms cell differentiation when its addition was delayed by 24 h. This demonstrated that late and persistent MEK activity is specifically required for macrophage differentiation to occur.	U 0126	13-18	midkine	Mus musculus	145-148
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	U 0126	102-107	mitogen-activated protein kinase 1	Homo sapiens	19-22
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	U 0126	102-107	AKT serine/threonine kinase 1	Homo sapiens	27-30
15979922-3	2005	OSM treatment induced phosphorylation of ERK, and pretreatment with U0126, a MEK inhibitor, prevented the OSM-stimulated proliferation of hATSCs, suggesting that the MEK/ERK pathway is involved in the OSM-induced proliferation.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	U 0126	102-107	mitogen-activated protein kinase 1	Homo sapiens	87-90
15979922-3	2005	OSM treatment induced phosphorylation of ERK, and pretreatment with U0126, a MEK inhibitor, prevented the OSM-stimulated proliferation of hATSCs, suggesting that the MEK/ERK pathway is involved in the OSM-induced proliferation.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	166-169
15979922-3	2005	OSM treatment induced phosphorylation of ERK, and pretreatment with U0126, a MEK inhibitor, prevented the OSM-stimulated proliferation of hATSCs, suggesting that the MEK/ERK pathway is involved in the OSM-induced proliferation.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	170-173
16248892-5	2005	While mutations of all putative Akt phosphorylation sites in telomerase reverse transcriptase (TERT) has no effect on telomerase activity, inhibition of MAP kinase signalling by PD98059 or U0126 abolishes NGF-induced telomerase down-regulation in a concentration-dependent manner.	U 0126	189-194	nerve growth factor	Rattus norvegicus	205-208
16221210-9	2005	The ERK kinase (MEK1/2) inhibitor U0126 inhibited the fibronectin induction of MCP-1 mRNA suggesting that ERK1/2 was also involved in this inflammatory pathway.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Homo sapiens	16-22
16222076-7	2005	Metastin-induced synaptic potentiation was abolished by 50 microM PD98059 and 20 microM U0126, two inhibitors of the MAP kinases ERK1 and ERK2.	U 0126	88-93	KiSS-1 metastasis suppressor	Homo sapiens	0-8
16222076-7	2005	Metastin-induced synaptic potentiation was abolished by 50 microM PD98059 and 20 microM U0126, two inhibitors of the MAP kinases ERK1 and ERK2.	U 0126	88-93	mitogen-activated protein kinase 3	Homo sapiens	129-133
16222076-7	2005	Metastin-induced synaptic potentiation was abolished by 50 microM PD98059 and 20 microM U0126, two inhibitors of the MAP kinases ERK1 and ERK2.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	138-142
16296925-3	2005	The MAPK/ERK kinase (MEK) inhibitor U0126 was used to examine the involvement of mitogen-activated protein kinase (MAPK) signaling pathway in this differentiation inducing effect.	U 0126	36-41	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
16296925-5	2005	This phenomenon was accompanied by the phosphorylation of extracellular-signal-regulated kinase (ERK) and could be inhibited by the MEK inhibitor, U0126.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	58-95
16296925-5	2005	This phenomenon was accompanied by the phosphorylation of extracellular-signal-regulated kinase (ERK) and could be inhibited by the MEK inhibitor, U0126.	U 0126	147-152	mitogen-activated protein kinase 1	Homo sapiens	97-100
16296925-5	2005	This phenomenon was accompanied by the phosphorylation of extracellular-signal-regulated kinase (ERK) and could be inhibited by the MEK inhibitor, U0126.	U 0126	147-152	mitogen-activated protein kinase kinase 7	Homo sapiens	132-135
16081599-5	2005	Pretreatment with specific inhibitors of the mitogen-activated protein kinases (MAPK) extracellular signal-regulated kinase 1/2 (ERK-1/2; PD98059, U0126) and p38 (SB202190, PD169316) inhibited the secretion of TNF-alpha.	U 0126	147-152	mitogen-activated protein kinase 3	Homo sapiens	80-84
16190874-5	2005	The activity of GCH was increased up to 5-fold after the NGF treatment, and the increase was repressed by pretreatment with U0126, an MEK1/2 inhibitor, but not with protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and c-Jun NH2-terminal kinase (JNK) inhibitors.	U 0126	124-129	GTP cyclohydrolase 1	Rattus norvegicus	16-19
16190874-5	2005	The activity of GCH was increased up to 5-fold after the NGF treatment, and the increase was repressed by pretreatment with U0126, an MEK1/2 inhibitor, but not with protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and c-Jun NH2-terminal kinase (JNK) inhibitors.	U 0126	124-129	mitogen activated protein kinase kinase 1	Rattus norvegicus	134-140
16190874-5	2005	The activity of GCH was increased up to 5-fold after the NGF treatment, and the increase was repressed by pretreatment with U0126, an MEK1/2 inhibitor, but not with protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and c-Jun NH2-terminal kinase (JNK) inhibitors.	U 0126	124-129	mitogen activated protein kinase 14	Rattus norvegicus	223-259
16190874-5	2005	The activity of GCH was increased up to 5-fold after the NGF treatment, and the increase was repressed by pretreatment with U0126, an MEK1/2 inhibitor, but not with protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and c-Jun NH2-terminal kinase (JNK) inhibitors.	U 0126	124-129	mitogen-activated protein kinase 8	Rattus norvegicus	272-297
16190874-5	2005	The activity of GCH was increased up to 5-fold after the NGF treatment, and the increase was repressed by pretreatment with U0126, an MEK1/2 inhibitor, but not with protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and c-Jun NH2-terminal kinase (JNK) inhibitors.	U 0126	124-129	mitogen-activated protein kinase 8	Rattus norvegicus	299-302
16190874-6	2005	Induction of GCH mRNA by NGF was also abolished by pretreatment with U0126.	U 0126	69-74	GTP cyclohydrolase 1	Rattus norvegicus	13-16
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	U 0126	101-106	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	U 0126	101-106	Eph receptor B1	Rattus norvegicus	21-24
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	U 0126	101-106	mitogen activated protein kinase 3	Rattus norvegicus	112-118
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	U 0126	101-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	130-137
16052566-6	2005	Moreover, the potentiation of ATP responses by Ap(5)A and EGF was completely abolished by the MAP kinase (MEK) inhibitor U-0126, indicating that ERK activation is a required step for the potentiation event.	U 0126	121-127	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
16052566-6	2005	Moreover, the potentiation of ATP responses by Ap(5)A and EGF was completely abolished by the MAP kinase (MEK) inhibitor U-0126, indicating that ERK activation is a required step for the potentiation event.	U 0126	121-127	mitogen-activated protein kinase 1	Homo sapiens	145-148
15994315-9	2005	Inhibition of MEK1 by U0126 prevented phosphorylation of Bad at Ser112.	U 0126	22-27	mitogen-activated protein kinase kinase 1	Homo sapiens	14-18
16129978-8	2005	Preconditioning protection was eliminated by the mitogen-activated extracellular kinase inhibitor U0126, which prevented phosphorylation of p44 during preconditioning, and by calmidazolium, which antagonizes the effects of Ca2+-bound calmodulin.	U 0126	98-103	mitogen activated protein kinase 3	Rattus norvegicus	140-143
16129978-8	2005	Preconditioning protection was eliminated by the mitogen-activated extracellular kinase inhibitor U0126, which prevented phosphorylation of p44 during preconditioning, and by calmidazolium, which antagonizes the effects of Ca2+-bound calmodulin.	U 0126	98-103	carbonic anhydrase 2	Rattus norvegicus	223-226
16129978-8	2005	Preconditioning protection was eliminated by the mitogen-activated extracellular kinase inhibitor U0126, which prevented phosphorylation of p44 during preconditioning, and by calmidazolium, which antagonizes the effects of Ca2+-bound calmodulin.	U 0126	98-103	calmodulin 1	Rattus norvegicus	234-244
15993752-10	2005	Using gel shift analysis, we found that forskolin activation of T-cells resulted in activation of AP1 sites; this increase in nuclear extract AP1 was significantly blocked by MEK1 inhibitor U0126.	U 0126	190-195	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-101
15993752-10	2005	Using gel shift analysis, we found that forskolin activation of T-cells resulted in activation of AP1 sites; this increase in nuclear extract AP1 was significantly blocked by MEK1 inhibitor U0126.	U 0126	190-195	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	142-145
15961554-7	2005	Prior administration of the MAPK kinase inhibitor U0126 abolished the capacity of MTII to suppress 2-h food intake and significantly decreased MTII-induced ERK phosphorylation in the NTS.	U 0126	50-55	mitogen activated protein kinase 3	Rattus norvegicus	28-32
15961554-7	2005	Prior administration of the MAPK kinase inhibitor U0126 abolished the capacity of MTII to suppress 2-h food intake and significantly decreased MTII-induced ERK phosphorylation in the NTS.	U 0126	50-55	mitogen activated protein kinase 3	Rattus norvegicus	156-159
16128807-8	2005	In a biological assay comparing these two pathways, the ability of LY294002 and the MEK inhibitor, U0126, to induce apoptosis were tested.	U 0126	99-104	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
16043662-8	2005	U0126 (10 micromol/L), an MEK1/2 inhibitor, abolished the aldosterone-induced increase in MMP activities.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	26-32
16164983-4	2005	Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation.	U 0126	73-79	midkine	Mus musculus	18-21
16164983-4	2005	Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation.	U 0126	73-79	mitogen-activated protein kinase 1	Mus musculus	22-25
16164983-4	2005	Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation.	U 0126	73-79	midkine	Mus musculus	59-62
16164983-4	2005	Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation.	U 0126	73-79	colony stimulating factor 3 (granulocyte)	Mus musculus	104-109
16164983-4	2005	Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation.	U 0126	73-79	interleukin 6	Mus musculus	151-155
16081525-17	2005	Immunoblotting studies showed that MAP kinases ERK and JNK are not activated by PCB 126 in H4IIE cells and the ERK inhibitor U0126 did not impair CYP1A1 induction.	U 0126	125-130	Eph receptor B1	Rattus norvegicus	111-114
16535835-6	2005	RESULTS: The results showed that the apoptosis induced by CdCl2 inclined to enhance with dose dependent manner, Further more, U0126 and SB203580, the specific inhibitor of ERK1/2 and p38 MAPK respectively, could decrease the expression of TUNEL-positive cells significantly and lower apoptotic rate of primary cultured anterior pituitary cells.	U 0126	126-131	mitogen activated protein kinase 3	Rattus norvegicus	172-178
16535835-6	2005	RESULTS: The results showed that the apoptosis induced by CdCl2 inclined to enhance with dose dependent manner, Further more, U0126 and SB203580, the specific inhibitor of ERK1/2 and p38 MAPK respectively, could decrease the expression of TUNEL-positive cells significantly and lower apoptotic rate of primary cultured anterior pituitary cells.	U 0126	126-131	mitogen activated protein kinase 14	Rattus norvegicus	183-186
16535835-6	2005	RESULTS: The results showed that the apoptosis induced by CdCl2 inclined to enhance with dose dependent manner, Further more, U0126 and SB203580, the specific inhibitor of ERK1/2 and p38 MAPK respectively, could decrease the expression of TUNEL-positive cells significantly and lower apoptotic rate of primary cultured anterior pituitary cells.	U 0126	126-131	mitogen activated protein kinase 3	Rattus norvegicus	187-191
16313723-14	2005	U0126 markedly reduced AP-1 DNA binding activity induced by Aldo; NAC partly decreased AP-1 activity induced by Aldo.	U 0126	0-5	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	23-27
16044162-6	2005	The MEK inhibitor, U0126, abrogated GEP production in response to ET-1 and 8-CPT, confirming involvement of MAPK.	U 0126	19-24	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
16044162-6	2005	The MEK inhibitor, U0126, abrogated GEP production in response to ET-1 and 8-CPT, confirming involvement of MAPK.	U 0126	19-24	granulin precursor	Homo sapiens	36-39
16139244-3	2005	Treatment with TGFalpha or BTC increases levels of TGFbeta1 mRNA in undifferentiated granulosa cells, while the selective inhibitor of mitogen activated protein kinase signaling, U0126, reverses these effects.	U 0126	179-184	transforming growth factor alpha	Homo sapiens	15-23
16220193-14	2005	Intrathecal administration of U0126 or antisense ODN against ERK decreased the scores of morphine withdrawal, attenuated morphine withdrawal-induced allodynia and also inhibited the increase of pERK expression in the spinal cord of morphine withdrawal rats.	U 0126	30-35	Eph receptor B1	Rattus norvegicus	61-64
16223495-5	2005	A second mGSTA4 induction occurred 2 days after cell seeding concomitantly to DNA replication and was prevented by treatment with mitogen-activated protein kinase (MEK) inhibitor U0126.	U 0126	179-184	glutathione S-transferase, alpha 4	Mus musculus	9-15
16139249-7	2005	Cellular signaling analysis using MAPK-(U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) and Jak2-specific (AG490) inhibitors demonstrated that LPS stimulated iNOS expression via activating Jak2-mediated JNK, but not ERK and p38, pathway.	U 0126	40-45	toll-like receptor 4	Mus musculus	159-162
16007158-4	2005	Hypoxia further caused transcriptional downregulation of ERalpha via activation of ERK1/2 in cell lines and, importantly, MEK1/2 inhibitors (U0126 or PD184352) or ERK1/2 suppression by siRNA partially restored the ERalpha expression.	U 0126	141-146	estrogen receptor 1	Homo sapiens	57-64
16007158-4	2005	Hypoxia further caused transcriptional downregulation of ERalpha via activation of ERK1/2 in cell lines and, importantly, MEK1/2 inhibitors (U0126 or PD184352) or ERK1/2 suppression by siRNA partially restored the ERalpha expression.	U 0126	141-146	mitogen-activated protein kinase kinase 1	Homo sapiens	122-128
16198345-7	2005	The p38 MAPK inhibitor, SB203580, or MEK1/2 inhibitor, U0126, inhibited hypertonic induction of COX-2 expression.	U 0126	55-60	mitogen-activated protein kinase kinase 1	Homo sapiens	37-43
16198345-7	2005	The p38 MAPK inhibitor, SB203580, or MEK1/2 inhibitor, U0126, inhibited hypertonic induction of COX-2 expression.	U 0126	55-60	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
16174443-5	2005	The phosphorylation level of Akt decreased after serum withdrawal and treatment with the MEK inhibitor Uo126, but increased after treatment with H(2)O(2) at low concentration, whereas none of these treatments changed PRAS40 activity.	U 0126	103-108	AKT serine/threonine kinase 1	Homo sapiens	29-32
16174443-5	2005	The phosphorylation level of Akt decreased after serum withdrawal and treatment with the MEK inhibitor Uo126, but increased after treatment with H(2)O(2) at low concentration, whereas none of these treatments changed PRAS40 activity.	U 0126	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	89-92
15888549-8	2005	Inhibitors of p38 (SB-203580) and ERK (U-0126) blunted contraction-mediated IKK phosphorylation by 39 +/- 4% (P = 0.06) and 35 +/- 10% (P = 0.09), respectively, and in combination by 76 +/- 5% (P &lt; 0.05), suggesting that these kinases might influence the activation of IKK and NF-kappaB during exercise.	U 0126	39-45	Eph receptor B1	Rattus norvegicus	34-37
16093451-7	2005	Increased YB-1 expression and subcellular shuttling was dependent on PDGF-B signaling via the mitogen-activated protein kinase pathway because these alterations were prevented by specific PDGF aptamers and the mitogen-activated protein kinase pathway inhibitor U0126.	U 0126	261-266	Y-box binding protein 1	Homo sapiens	10-14
16093451-7	2005	Increased YB-1 expression and subcellular shuttling was dependent on PDGF-B signaling via the mitogen-activated protein kinase pathway because these alterations were prevented by specific PDGF aptamers and the mitogen-activated protein kinase pathway inhibitor U0126.	U 0126	261-266	platelet derived growth factor subunit B	Homo sapiens	69-75
16093451-7	2005	Increased YB-1 expression and subcellular shuttling was dependent on PDGF-B signaling via the mitogen-activated protein kinase pathway because these alterations were prevented by specific PDGF aptamers and the mitogen-activated protein kinase pathway inhibitor U0126.	U 0126	261-266	platelet derived growth factor subunit B	Homo sapiens	69-73
16341587-5	2005	In DHA-supplemented cells U0126, a MEK inhibitor, prevented ERK activation and EPG translocation and protected from cell death.	U 0126	26-31	Eph receptor B1	Rattus norvegicus	60-63
16105664-6	2005	The MEK inhibitors, PD98059 and U0126, blocked LTB4-stimulated ERK1/2 activation and cell proliferation.	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
16105664-6	2005	The MEK inhibitors, PD98059 and U0126, blocked LTB4-stimulated ERK1/2 activation and cell proliferation.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	63-69
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	U 0126	109-114	mitogen-activated protein kinase 1	Homo sapiens	60-63
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	U 0126	109-114	mitogen-activated protein kinase 8	Homo sapiens	65-68
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	U 0126	109-114	AKT serine/threonine kinase 1	Homo sapiens	74-77
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	U 0126	109-114	mitogen-activated protein kinase 8	Homo sapiens	188-191
16157281-4	2005	Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	51-54
16157281-4	2005	Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP.	U 0126	24-29	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
16157281-4	2005	Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	98-101
16157281-4	2005	Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP.	U 0126	24-29	cAMP responsive element binding protein 1	Homo sapiens	103-107
16157281-4	2005	Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP.	U 0126	24-29	ETS transcription factor ELK1	Homo sapiens	109-114
16157281-4	2005	Intra-AcbC infusions of U0126, an inhibitor of the ERK kinase MEK, prevent both the activation of ERK, CREB, Elk-1, and Fos and retrieval of COC-CPP.	U 0126	24-29	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	120-123
16157281-5	2005	When tested again 24 hr or 14 days after intra-AcbC infusions of U0126 or another MEK inhibitor, PD98059, CPP retrieval and concomitant protein activation were significantly attenuated.	U 0126	65-70	mitogen-activated protein kinase kinase 7	Homo sapiens	82-85
16159392-8	2005	Pharmacological manipulation of MEK 1/2, PKA and PKC with their inhibitors (U0126, H89 and NPC 15473, respectively) significantly blocked this increment of CREB phosphorylation.	U 0126	76-81	mitogen activated protein kinase kinase 1	Rattus norvegicus	32-39
16159392-8	2005	Pharmacological manipulation of MEK 1/2, PKA and PKC with their inhibitors (U0126, H89 and NPC 15473, respectively) significantly blocked this increment of CREB phosphorylation.	U 0126	76-81	protein kinase C, gamma	Rattus norvegicus	49-52
16159392-8	2005	Pharmacological manipulation of MEK 1/2, PKA and PKC with their inhibitors (U0126, H89 and NPC 15473, respectively) significantly blocked this increment of CREB phosphorylation.	U 0126	76-81	cAMP responsive element binding protein 1	Rattus norvegicus	156-160
16039614-3	2005	PKC activator PDBu induced ERK1/2 phosphorylation which was inhibited by general PKC inhibitor bisindolylmaleimide and Go 6983 as well as the MEK inhibitor U0126 but not by the PKCdelta inhibitor rottlerin.	U 0126	156-161	protein kinase C delta	Homo sapiens	0-3
16039614-3	2005	PKC activator PDBu induced ERK1/2 phosphorylation which was inhibited by general PKC inhibitor bisindolylmaleimide and Go 6983 as well as the MEK inhibitor U0126 but not by the PKCdelta inhibitor rottlerin.	U 0126	156-161	mitogen-activated protein kinase 3	Homo sapiens	27-33
16039614-3	2005	PKC activator PDBu induced ERK1/2 phosphorylation which was inhibited by general PKC inhibitor bisindolylmaleimide and Go 6983 as well as the MEK inhibitor U0126 but not by the PKCdelta inhibitor rottlerin.	U 0126	156-161	mitogen-activated protein kinase kinase 7	Homo sapiens	142-145
16039614-6	2005	The MEK inhibitor U0126 inhibited cisplatin-induced ERK activation and attenuated cisplatin-induced cell death.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
16039614-6	2005	The MEK inhibitor U0126 inhibited cisplatin-induced ERK activation and attenuated cisplatin-induced cell death.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	52-55
16171557-0	2005	Erk pathway inhibitor U0126 induces gamma-globin expression in erythroid cells.	U 0126	22-27	mitogen-activated protein kinase 1	Homo sapiens	0-3
16171557-4	2005	Therefore, we determined the ability of U0126, a selective inhibitor of MEK1/2 the upstream activators of ERK, to re-activate gamma-globin expression.	U 0126	40-45	mitogen-activated protein kinase kinase 1	Homo sapiens	72-78
16171557-4	2005	Therefore, we determined the ability of U0126, a selective inhibitor of MEK1/2 the upstream activators of ERK, to re-activate gamma-globin expression.	U 0126	40-45	mitogen-activated protein kinase 1	Homo sapiens	106-109
16171557-6	2005	A significant increase in ERK phosphorylation was observed and gamma-gene expression was silenced concomitantly, however U0126 attenuated this effect.	U 0126	121-126	mitogen-activated protein kinase 1	Homo sapiens	26-29
15944807-8	2005	U0126, wortmannin and LY294002 all abrogated EPO-mediated protection (% I/R 49.2% +/- 5.6, 46.1% +/- 5.5 and 49.9% +/- 6.1 respectively, p &lt; 0.05).	U 0126	0-5	erythropoietin	Rattus norvegicus	45-48
16141544-5	2005	ERK inhibitor, U0126 completely prevented TGF-beta production.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	0-3
16141544-5	2005	ERK inhibitor, U0126 completely prevented TGF-beta production.	U 0126	15-20	transforming growth factor beta 1	Homo sapiens	42-50
16187238-7	2005	In contrast, incubation with the MEK inhibitor U0126 not only arrested growth, but also killed all the cell lines within 2-4 days in the absence of serum; the presence of serum only slighted extended viability, except in MCF10A and MDA-MB-468 cells, in which serum provided significantly greater protection.	U 0126	47-52	mitogen-activated protein kinase kinase 7	Homo sapiens	33-36
15993752-10	2005	Using gel shift analysis, we found that forskolin activation of T-cells resulted in activation of AP1 sites; this increase in nuclear extract AP1 was significantly blocked by MEK1 inhibitor U0126.	U 0126	190-195	mitogen-activated protein kinase kinase 1	Homo sapiens	175-179
16140948-8	2005	U0126, a MEK inhibitor, had a moderate antiproliferative effect only on the EBV+/III cells.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
16266864-7	2005	Experiments using inhibitors of metabolic pathways (U0126, LY294002 and SN50) revealed that the secretion of MMP-9 was mediated through PI3/MEK1 kinases.	U 0126	52-57	matrix metallopeptidase 9	Homo sapiens	109-114
16221210-9	2005	The ERK kinase (MEK1/2) inhibitor U0126 inhibited the fibronectin induction of MCP-1 mRNA suggesting that ERK1/2 was also involved in this inflammatory pathway.	U 0126	34-39	fibronectin 1	Homo sapiens	54-65
15815581-4	2005	However, U0126 (an inhibitor of mitogen-activated protein kinase kinase1/2, MEK1/2) protected against this effect.	U 0126	9-14	mitogen-activated protein kinase kinase 1	Homo sapiens	32-74
15815581-4	2005	However, U0126 (an inhibitor of mitogen-activated protein kinase kinase1/2, MEK1/2) protected against this effect.	U 0126	9-14	mitogen-activated protein kinase kinase 1	Homo sapiens	76-82
16221210-9	2005	The ERK kinase (MEK1/2) inhibitor U0126 inhibited the fibronectin induction of MCP-1 mRNA suggesting that ERK1/2 was also involved in this inflammatory pathway.	U 0126	34-39	C-C motif chemokine ligand 2	Homo sapiens	79-84
16221210-9	2005	The ERK kinase (MEK1/2) inhibitor U0126 inhibited the fibronectin induction of MCP-1 mRNA suggesting that ERK1/2 was also involved in this inflammatory pathway.	U 0126	34-39	mitogen-activated protein kinase 3	Homo sapiens	106-112
16103080-5	2005	Specific inhibitors for Ras or mitogen-activated protein/ERK kinase (farnesylthiosalicylic acid and UO126, respectively) inhibited Gal-3-mediated apoptotic resistance and anchorage-independent growth functions.	U 0126	100-105	galectin 3	Homo sapiens	131-136
16156742-4	2005	The phosphorylation level of Arix in cultured SH-SY5Y neuroblastoma cells is reduced when cells are treated with the mitogen activated protein kinase kinase 1 (MEK1) inhibitor UO126.	U 0126	176-181	paired like homeobox 2A	Homo sapiens	29-33
16156742-4	2005	The phosphorylation level of Arix in cultured SH-SY5Y neuroblastoma cells is reduced when cells are treated with the mitogen activated protein kinase kinase 1 (MEK1) inhibitor UO126.	U 0126	176-181	mitogen-activated protein kinase kinase 1	Homo sapiens	117-158
16156742-4	2005	The phosphorylation level of Arix in cultured SH-SY5Y neuroblastoma cells is reduced when cells are treated with the mitogen activated protein kinase kinase 1 (MEK1) inhibitor UO126.	U 0126	176-181	mitogen-activated protein kinase kinase 1	Homo sapiens	160-164
16006144-4	2005	Surprisingly, the MEK1 inhibitors PD 98059 and U 0126 blocked both ERK1/2 and JNK phosphorylation, indicating a novel form of balancing MAPK cascade cross-talk.	U 0126	47-53	mitogen activated protein kinase kinase 1	Rattus norvegicus	18-22
16006144-4	2005	Surprisingly, the MEK1 inhibitors PD 98059 and U 0126 blocked both ERK1/2 and JNK phosphorylation, indicating a novel form of balancing MAPK cascade cross-talk.	U 0126	47-53	mitogen activated protein kinase 3	Rattus norvegicus	67-73
16006144-4	2005	Surprisingly, the MEK1 inhibitors PD 98059 and U 0126 blocked both ERK1/2 and JNK phosphorylation, indicating a novel form of balancing MAPK cascade cross-talk.	U 0126	47-53	mitogen-activated protein kinase 8	Rattus norvegicus	78-81
16103078-6	2005	Similar results were obtained with U0126 and ursolic acid, specific and nonspecific inhibitors of ERK1/2, respectively.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	98-104
16099910-9	2005	When cells were treated with the ERK inhibitor U0126, DHEA lost its antiviral effect.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	33-36
15996482-5	2005	The MAPK, PI3K and PLCgamma pathways were blocked by U0126, LY249002 and U73122, respectively.	U 0126	53-58	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	4-8
16102563-5	2005	Both MEK1/2 inhibitors, U0126 and PD98059, suppressed ERK1/2 activation in either HEK293 or MDCK cells.	U 0126	24-29	mitogen-activated protein kinase kinase 1	Homo sapiens	5-11
16102563-5	2005	Both MEK1/2 inhibitors, U0126 and PD98059, suppressed ERK1/2 activation in either HEK293 or MDCK cells.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	54-60
16102563-6	2005	In HEK293 cells, U0126-mediated inhibition of PAT-induced ERK1/2 phosphorylation resulted in a significant decrease in levels of DNA damage, expressed as tail moment values, in the single cell gel electrophoresis assay.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	58-64
16103080-5	2005	Specific inhibitors for Ras or mitogen-activated protein/ERK kinase (farnesylthiosalicylic acid and UO126, respectively) inhibited Gal-3-mediated apoptotic resistance and anchorage-independent growth functions.	U 0126	100-105	mitogen-activated protein kinase 1	Homo sapiens	57-60
16103085-6	2005	Inhibiting both MAPK kinase (MEK)/ERK and PKA pathways by a combination of U0126 (10 micromol/L) and H-89 (5 micromol/L) reduced most of BAD phosphorylation at Ser112 and induced apoptosis to a level comparable with that induced by FLT3 inhibitor AG1296 (5 micromol/L) in BaF3/FLT3/ITD cells.	U 0126	75-80	midkine	Mus musculus	29-32
16103085-6	2005	Inhibiting both MAPK kinase (MEK)/ERK and PKA pathways by a combination of U0126 (10 micromol/L) and H-89 (5 micromol/L) reduced most of BAD phosphorylation at Ser112 and induced apoptosis to a level comparable with that induced by FLT3 inhibitor AG1296 (5 micromol/L) in BaF3/FLT3/ITD cells.	U 0126	75-80	mitogen-activated protein kinase 1	Mus musculus	34-37
16103085-6	2005	Inhibiting both MAPK kinase (MEK)/ERK and PKA pathways by a combination of U0126 (10 micromol/L) and H-89 (5 micromol/L) reduced most of BAD phosphorylation at Ser112 and induced apoptosis to a level comparable with that induced by FLT3 inhibitor AG1296 (5 micromol/L) in BaF3/FLT3/ITD cells.	U 0126	75-80	FMS-like tyrosine kinase 3	Mus musculus	232-236
16103085-6	2005	Inhibiting both MAPK kinase (MEK)/ERK and PKA pathways by a combination of U0126 (10 micromol/L) and H-89 (5 micromol/L) reduced most of BAD phosphorylation at Ser112 and induced apoptosis to a level comparable with that induced by FLT3 inhibitor AG1296 (5 micromol/L) in BaF3/FLT3/ITD cells.	U 0126	75-80	FMS-like tyrosine kinase 3	Mus musculus	277-281
15962287-4	2005	However, it was not prevented by a pretreatment with a p38 MAP kinase inhibitor, SB202190, and a specific inhibitor of the upstream kinase of extracellular signal-regulated kinase (ERK1/2), U0126.	U 0126	190-195	mitogen-activated protein kinase 3	Homo sapiens	181-187
16103085-8	2005	The MEK inhibitor U0126 and/or the PKA inhibitor H-89 greatly enhanced the efficacy of the FLT3 inhibitor AG1296, suggesting that combining FLT3/ITD downstream pathway inhibition with FLT3 inhibitors may be a viable therapeutic strategy for AML caused by a FLT3/ITD mutation.	U 0126	18-23	midkine	Mus musculus	4-7
16103085-8	2005	The MEK inhibitor U0126 and/or the PKA inhibitor H-89 greatly enhanced the efficacy of the FLT3 inhibitor AG1296, suggesting that combining FLT3/ITD downstream pathway inhibition with FLT3 inhibitors may be a viable therapeutic strategy for AML caused by a FLT3/ITD mutation.	U 0126	18-23	FMS-like tyrosine kinase 3	Mus musculus	91-95
16103085-8	2005	The MEK inhibitor U0126 and/or the PKA inhibitor H-89 greatly enhanced the efficacy of the FLT3 inhibitor AG1296, suggesting that combining FLT3/ITD downstream pathway inhibition with FLT3 inhibitors may be a viable therapeutic strategy for AML caused by a FLT3/ITD mutation.	U 0126	18-23	FMS-like tyrosine kinase 3	Mus musculus	140-144
16103085-8	2005	The MEK inhibitor U0126 and/or the PKA inhibitor H-89 greatly enhanced the efficacy of the FLT3 inhibitor AG1296, suggesting that combining FLT3/ITD downstream pathway inhibition with FLT3 inhibitors may be a viable therapeutic strategy for AML caused by a FLT3/ITD mutation.	U 0126	18-23	FMS-like tyrosine kinase 3	Mus musculus	140-144
16103085-8	2005	The MEK inhibitor U0126 and/or the PKA inhibitor H-89 greatly enhanced the efficacy of the FLT3 inhibitor AG1296, suggesting that combining FLT3/ITD downstream pathway inhibition with FLT3 inhibitors may be a viable therapeutic strategy for AML caused by a FLT3/ITD mutation.	U 0126	18-23	FMS-like tyrosine kinase 3	Mus musculus	140-144
16003000-8	2005	Furthermore, in the presence of U0126 and PD-98059, selective inhibitors of MEK1/2, IL-17-induced IL-6 production was significantly attenuated.	U 0126	32-37	mitogen-activated protein kinase kinase 1	Homo sapiens	76-82
16081820-10	2005	Moreover, IFN-gamma-induced gammaIP-10 expression was completely abolished by the protein kinase C inhibitor staurosporine, and partially reduced by U0126, a specific inhibitor for ERKs.	U 0126	149-154	interferon gamma	Rattus norvegicus	10-19
15908120-5	2005	U0126, an inhibitor of the MEK kinases, blocked the CART-stimulated activation of ERKs.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	27-30
15908120-5	2005	U0126, an inhibitor of the MEK kinases, blocked the CART-stimulated activation of ERKs.	U 0126	0-5	CART prepropeptide	Mus musculus	52-56
15908120-5	2005	U0126, an inhibitor of the MEK kinases, blocked the CART-stimulated activation of ERKs.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	82-86
15772123-6	2005	Immunoblotting studies have shown that leptin fails to activate Akt but increases p42/p44 MAPK phosphorylation, an effect that is prevented by U0126 but not by H-89.	U 0126	143-148	cyclin dependent kinase 20	Homo sapiens	82-85
15772123-6	2005	Immunoblotting studies have shown that leptin fails to activate Akt but increases p42/p44 MAPK phosphorylation, an effect that is prevented by U0126 but not by H-89.	U 0126	143-148	general transcription factor IIH subunit 2	Homo sapiens	86-89
15772123-6	2005	Immunoblotting studies have shown that leptin fails to activate Akt but increases p42/p44 MAPK phosphorylation, an effect that is prevented by U0126 but not by H-89.	U 0126	143-148	mitogen-activated protein kinase 3	Homo sapiens	90-94
16083499-8	2005	Moreover, the induction of COX-2 by PANC-1 CM was prevented by U0126, an extracellular signal-regulated kinase (ERK) 1/2 inhibitor suggesting that activation of ERK 1/2 is needed for stimulation of COX-2.	U 0126	63-68	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-32
16083499-8	2005	Moreover, the induction of COX-2 by PANC-1 CM was prevented by U0126, an extracellular signal-regulated kinase (ERK) 1/2 inhibitor suggesting that activation of ERK 1/2 is needed for stimulation of COX-2.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	73-120
16083499-8	2005	Moreover, the induction of COX-2 by PANC-1 CM was prevented by U0126, an extracellular signal-regulated kinase (ERK) 1/2 inhibitor suggesting that activation of ERK 1/2 is needed for stimulation of COX-2.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	161-168
16083499-8	2005	Moreover, the induction of COX-2 by PANC-1 CM was prevented by U0126, an extracellular signal-regulated kinase (ERK) 1/2 inhibitor suggesting that activation of ERK 1/2 is needed for stimulation of COX-2.	U 0126	63-68	prostaglandin-endoperoxide synthase 2	Homo sapiens	198-203
16003000-8	2005	Furthermore, in the presence of U0126 and PD-98059, selective inhibitors of MEK1/2, IL-17-induced IL-6 production was significantly attenuated.	U 0126	32-37	interleukin 17A	Homo sapiens	84-89
16003000-8	2005	Furthermore, in the presence of U0126 and PD-98059, selective inhibitors of MEK1/2, IL-17-induced IL-6 production was significantly attenuated.	U 0126	32-37	interleukin 6	Homo sapiens	98-102
15946993-2	2005	Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	27-64
15963474-7	2005	MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression.	U 0126	17-22	mitogen-activated protein kinase 1	Mus musculus	0-4
15963474-7	2005	MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Mus musculus	27-33
15963474-7	2005	MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression.	U 0126	17-22	prostaglandin-endoperoxide synthase 2	Mus musculus	114-119
16110828-7	2005	In contrast, U0126 (a MEK1/2 inhibitor) treatment significantly induced the peripheral distribution of ZO-1 as well as cell aggregation in PC-1.0 and AsPC-1 cells, which usually grew as single cells, but seriously suppressed ERK2 and p-ERK1/2 expression.	U 0126	13-18	tight junction protein 1	Homo sapiens	103-107
16110828-7	2005	In contrast, U0126 (a MEK1/2 inhibitor) treatment significantly induced the peripheral distribution of ZO-1 as well as cell aggregation in PC-1.0 and AsPC-1 cells, which usually grew as single cells, but seriously suppressed ERK2 and p-ERK1/2 expression.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	225-229
16110828-7	2005	In contrast, U0126 (a MEK1/2 inhibitor) treatment significantly induced the peripheral distribution of ZO-1 as well as cell aggregation in PC-1.0 and AsPC-1 cells, which usually grew as single cells, but seriously suppressed ERK2 and p-ERK1/2 expression.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	236-242
16115207-8	2005	Holotransferrin transcytosis as well as p42-44 MAPK activation are inhibited after addition of a p42-44 MAPK pathway inhibitor (UO126) during TNF-alpha challenge.	U 0126	128-133	cyclin dependent kinase 20	Homo sapiens	40-43
16115207-8	2005	Holotransferrin transcytosis as well as p42-44 MAPK activation are inhibited after addition of a p42-44 MAPK pathway inhibitor (UO126) during TNF-alpha challenge.	U 0126	128-133	cyclin dependent kinase 20	Homo sapiens	97-100
16115207-8	2005	Holotransferrin transcytosis as well as p42-44 MAPK activation are inhibited after addition of a p42-44 MAPK pathway inhibitor (UO126) during TNF-alpha challenge.	U 0126	128-133	tumor necrosis factor	Homo sapiens	142-151
15801908-6	2005	The MEK (MAPK/ERK kinase) inhibitors PD98059 and U0126 blocked IGF-I-stimulated ERK phosphorylation but did not block the phosphorylation of Akt and did not decrease proteoglycan synthesis.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
15801908-6	2005	The MEK (MAPK/ERK kinase) inhibitors PD98059 and U0126 blocked IGF-I-stimulated ERK phosphorylation but did not block the phosphorylation of Akt and did not decrease proteoglycan synthesis.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	9-24
15801908-6	2005	The MEK (MAPK/ERK kinase) inhibitors PD98059 and U0126 blocked IGF-I-stimulated ERK phosphorylation but did not block the phosphorylation of Akt and did not decrease proteoglycan synthesis.	U 0126	49-54	insulin like growth factor 1	Homo sapiens	63-68
15801908-6	2005	The MEK (MAPK/ERK kinase) inhibitors PD98059 and U0126 blocked IGF-I-stimulated ERK phosphorylation but did not block the phosphorylation of Akt and did not decrease proteoglycan synthesis.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	14-17
16036214-6	2005	While pretreatment of cells with the MAPKK inhibitors PD98059 and U0126 blocked phosphorylation of Ser782 prior to LIF stimulation, these inhibitors did not block Ser782 phosphorylation by LIF-stimulated 3T3-L1 cell extracts in vitro.	U 0126	66-71	leukemia inhibitory factor	Mus musculus	115-118
15894174-5	2005	Furthermore, PD98059 or U0126 hardly blocked the heat-induced activation of ERK.	U 0126	24-29	mitogen-activated protein kinase 1	Mus musculus	76-79
15905315-9	2005	Furthermore, this leptin- and adiponectin-induced proinflammatory response could be abrogated by treatment with the antiinflammatory ERK1/2 MAPK inhibitor U0126, the peroxisomal proliferator-activated receptor-gamma ligand troglitazone, and the nuclear factor-kappaB inhibitor BAY 11-7082.	U 0126	155-160	leptin	Homo sapiens	18-24
15905315-9	2005	Furthermore, this leptin- and adiponectin-induced proinflammatory response could be abrogated by treatment with the antiinflammatory ERK1/2 MAPK inhibitor U0126, the peroxisomal proliferator-activated receptor-gamma ligand troglitazone, and the nuclear factor-kappaB inhibitor BAY 11-7082.	U 0126	155-160	adiponectin, C1Q and collagen domain containing	Homo sapiens	30-41
15905315-9	2005	Furthermore, this leptin- and adiponectin-induced proinflammatory response could be abrogated by treatment with the antiinflammatory ERK1/2 MAPK inhibitor U0126, the peroxisomal proliferator-activated receptor-gamma ligand troglitazone, and the nuclear factor-kappaB inhibitor BAY 11-7082.	U 0126	155-160	mitogen-activated protein kinase 3	Homo sapiens	133-139
15905315-9	2005	Furthermore, this leptin- and adiponectin-induced proinflammatory response could be abrogated by treatment with the antiinflammatory ERK1/2 MAPK inhibitor U0126, the peroxisomal proliferator-activated receptor-gamma ligand troglitazone, and the nuclear factor-kappaB inhibitor BAY 11-7082.	U 0126	155-160	mitogen-activated protein kinase 3	Homo sapiens	140-144
15896771-12	2005	U0126, an inhibitor of MEK1 protein, significantly reduced the phosphorylated forms of ERK1/2 and MB formation in vitro.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	23-27
15896771-12	2005	U0126, an inhibitor of MEK1 protein, significantly reduced the phosphorylated forms of ERK1/2 and MB formation in vitro.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	87-93
16051071-5	2005	U0126 was found to definitely inhibit phosphorylation of extracellular signal-regulated kinase (Erk) 1/2 and augment the levels of inducible type of NO synthase.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	57-104
16051071-7	2005	Inactivation of Erk1/2 by U0126 furthermore inhibited LPS-induced activating protein-1 activation, but not nuclear factor-kappaB activation.	U 0126	26-31	mitogen-activated protein kinase 3	Mus musculus	16-22
15946993-2	2005	Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection.	U 0126	81-86	erythropoietin	Rattus norvegicus	120-123
15946993-2	2005	Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection.	U 0126	81-86	erythropoietin	Rattus norvegicus	144-147
15946993-2	2005	Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	193-230
15946993-2	2005	Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	232-235
15946993-2	2005	Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection.	U 0126	81-86	erythropoietin	Rattus norvegicus	144-147
15969741-7	2005	ERK1/2 but not JNK and p38 were activated by GTS-21, and the ERK phosphorylation inhibitors PD98059 and U0126 blocked protection.	U 0126	104-109	mitogen activated protein kinase 3	Rattus norvegicus	0-6
15754340-8	2005	Conversely, the inhibition of Erk activity induced by 12 h exposure to 10 mM Mek-1 inhibitor U0126 antagonized the effects induced by HSP90 transfection on apoptosis caused by MW-EMF.	U 0126	93-98	mitogen-activated protein kinase 1	Homo sapiens	30-33
15754340-8	2005	Conversely, the inhibition of Erk activity induced by 12 h exposure to 10 mM Mek-1 inhibitor U0126 antagonized the effects induced by HSP90 transfection on apoptosis caused by MW-EMF.	U 0126	93-98	mitogen-activated protein kinase kinase 1	Homo sapiens	77-82
15754340-8	2005	Conversely, the inhibition of Erk activity induced by 12 h exposure to 10 mM Mek-1 inhibitor U0126 antagonized the effects induced by HSP90 transfection on apoptosis caused by MW-EMF.	U 0126	93-98	heat shock protein 90 alpha family class A member 1	Homo sapiens	134-139
16050986-6	2005	UO126 treatment attenuated ERK1/2 phosphorylation irrespective of whether estradiol was administered.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	27-33
16046706-7	2005	Disrupting mitogen-activated protein kinase/Erk kinase (MEK) and protein kinase C (PKC) activity with U0126 and Bisindolylmaleimide (Bis), respectively, suppressed palmitate-induced IL-6 expression (P &lt; 0.05), but had no effect on NF-kappaB reporter gene activity (P &gt; 0.05).	U 0126	102-107	mitogen-activated protein kinase kinase 7	Homo sapiens	11-54
16046706-7	2005	Disrupting mitogen-activated protein kinase/Erk kinase (MEK) and protein kinase C (PKC) activity with U0126 and Bisindolylmaleimide (Bis), respectively, suppressed palmitate-induced IL-6 expression (P &lt; 0.05), but had no effect on NF-kappaB reporter gene activity (P &gt; 0.05).	U 0126	102-107	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
16046706-7	2005	Disrupting mitogen-activated protein kinase/Erk kinase (MEK) and protein kinase C (PKC) activity with U0126 and Bisindolylmaleimide (Bis), respectively, suppressed palmitate-induced IL-6 expression (P &lt; 0.05), but had no effect on NF-kappaB reporter gene activity (P &gt; 0.05).	U 0126	102-107	interleukin 6	Homo sapiens	182-186
16046706-7	2005	Disrupting mitogen-activated protein kinase/Erk kinase (MEK) and protein kinase C (PKC) activity with U0126 and Bisindolylmaleimide (Bis), respectively, suppressed palmitate-induced IL-6 expression (P &lt; 0.05), but had no effect on NF-kappaB reporter gene activity (P &gt; 0.05).	U 0126	102-107	nuclear factor kappa B subunit 1	Homo sapiens	234-243
16051824-13	2005	U0126, a selective inhibitor for MEK/ERK blocked the gpK8.1A- and KSHV-induced ERK activation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	37-40
16051824-13	2005	U0126, a selective inhibitor for MEK/ERK blocked the gpK8.1A- and KSHV-induced ERK activation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	79-82
16051824-15	2005	Analyses of viral gene expression by quantitative real-time reverse transcriptase PCR revealed that pretreatment of cells with U0126 for 1 h and during the 2-h infection with KSHV significantly inhibited the expression of ORF 73, ORF 50 (RTA), and the IE-K8 and v-IRF2 genes.	U 0126	127-132	LANA	Human gammaherpesvirus 8	222-228
16051824-15	2005	Analyses of viral gene expression by quantitative real-time reverse transcriptase PCR revealed that pretreatment of cells with U0126 for 1 h and during the 2-h infection with KSHV significantly inhibited the expression of ORF 73, ORF 50 (RTA), and the IE-K8 and v-IRF2 genes.	U 0126	127-132	ORF50	Human gammaherpesvirus 8	230-236
16051824-15	2005	Analyses of viral gene expression by quantitative real-time reverse transcriptase PCR revealed that pretreatment of cells with U0126 for 1 h and during the 2-h infection with KSHV significantly inhibited the expression of ORF 73, ORF 50 (RTA), and the IE-K8 and v-IRF2 genes.	U 0126	127-132	ORF50	Human gammaherpesvirus 8	238-241
16051824-17	2005	Expression of ORF 73 in BCBL-1 cells was also significantly inhibited by preincubation with U0126.	U 0126	92-97	LANA	Human gammaherpesvirus 8	14-20
15888667-4	2005	Moreover, blockade of Raf, MEK1/2, or PKC activation with geldanamycin, U0126, or calphostin C inhibited ERK1/2 phosphorylation, demonstrating a PKC-Raf-MEK1/2 pathway.	U 0126	72-77	zinc fingers and homeoboxes 2	Homo sapiens	22-25
15888667-4	2005	Moreover, blockade of Raf, MEK1/2, or PKC activation with geldanamycin, U0126, or calphostin C inhibited ERK1/2 phosphorylation, demonstrating a PKC-Raf-MEK1/2 pathway.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	105-111
15888667-4	2005	Moreover, blockade of Raf, MEK1/2, or PKC activation with geldanamycin, U0126, or calphostin C inhibited ERK1/2 phosphorylation, demonstrating a PKC-Raf-MEK1/2 pathway.	U 0126	72-77	zinc fingers and homeoboxes 2	Homo sapiens	149-152
15888667-4	2005	Moreover, blockade of Raf, MEK1/2, or PKC activation with geldanamycin, U0126, or calphostin C inhibited ERK1/2 phosphorylation, demonstrating a PKC-Raf-MEK1/2 pathway.	U 0126	72-77	mitogen-activated protein kinase kinase 1	Homo sapiens	153-159
16092976-6	2005	In addition, HSC-T6 were preincubated for 1 h or not at all with U0126 (an inhibitor of the MAPK/ERK kinase), and antioxidant-N-acetylcysteine (NAC) prior to exposure to Aldo for the indicated times.	U 0126	65-70	mitogen-activated protein kinase 3	Homo sapiens	97-100
15919053-6	2005	U0126 (the inhibitor for MAP/ERK kinase) suppressed chymase-induced migration of EoL-1 cells and mouse eosinophils.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	29-32
15919053-6	2005	U0126 (the inhibitor for MAP/ERK kinase) suppressed chymase-induced migration of EoL-1 cells and mouse eosinophils.	U 0126	0-5	chymase 1	Homo sapiens	52-59
15701816-10	2005	Inhibition of MAPK activity by MEK inhibitor U-0126 abolished EGF-induced DNA synthesis.	U 0126	45-51	mitogen-activated protein kinase 3	Homo sapiens	14-18
16253189-4	2005	In addition, HSC-T6 cells were preincubated for 60 min with U0126, an inhibitor of MAPK/ERK kinase, irbesartan, an AT-1 receptor blocker, N-acetylcysteine (NAC), antioxidant, angiotensin converting enzyme inhibitor (ACEI), or tumor necrosis factor alpha (TNFalpha) prior to exposure to Ang II or Aldo.	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	83-87
16253189-4	2005	In addition, HSC-T6 cells were preincubated for 60 min with U0126, an inhibitor of MAPK/ERK kinase, irbesartan, an AT-1 receptor blocker, N-acetylcysteine (NAC), antioxidant, angiotensin converting enzyme inhibitor (ACEI), or tumor necrosis factor alpha (TNFalpha) prior to exposure to Ang II or Aldo.	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	88-91
16253189-9	2005	The levels of phopho-ERK1/2 protein of the irbesartan + Ang II and U0126 + Ang II groups were significantly lower than that of the Ang II group (both P &lt; 0.01).	U 0126	67-72	mitogen activated protein kinase 3	Rattus norvegicus	21-27
16253189-9	2005	The levels of phopho-ERK1/2 protein of the irbesartan + Ang II and U0126 + Ang II groups were significantly lower than that of the Ang II group (both P &lt; 0.01).	U 0126	67-72	angiotensinogen	Rattus norvegicus	75-81
16253189-9	2005	The levels of phopho-ERK1/2 protein of the irbesartan + Ang II and U0126 + Ang II groups were significantly lower than that of the Ang II group (both P &lt; 0.01).	U 0126	67-72	angiotensinogen	Rattus norvegicus	75-81
16253189-11	2005	The level of phopho-ERK1/2 protein of the U0126 + Aldo group was significantly lower than that of the Aldo group (P &lt; 0.01).	U 0126	42-47	mitogen activated protein kinase 3	Rattus norvegicus	20-26
15960884-12	2005	Intrathecal injection of U0126 or ERK antisense ODN markedly suppressed the increase of CCI-induced pERK, pCREB and c-Fos expression in the spinal cord.	U 0126	25-30	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	116-121
15701816-10	2005	Inhibition of MAPK activity by MEK inhibitor U-0126 abolished EGF-induced DNA synthesis.	U 0126	45-51	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
15701816-10	2005	Inhibition of MAPK activity by MEK inhibitor U-0126 abolished EGF-induced DNA synthesis.	U 0126	45-51	epidermal growth factor	Homo sapiens	62-65
15778245-7	2005	Importantly, only pharmacological inhibition of p38 MAPK by SB-203580 (20 microM, 1 h) attenuated nocodazole-induced MT depolymerization, actin remodeling, and EC barrier dysfunction, whereas the MEK/ERK1/2 inhibitor U0126 (5 microM, 1 h) exhibited no effect.	U 0126	217-222	mitogen-activated protein kinase 1	Homo sapiens	48-51
15746213-5	2005	Inhibitors of EGFR (AG1478) and p44/p42 MAPK (U0126) phosphorylation blocked redox-dependent p44/p42 phosphorylation, indicating that signaling occurred by EGFR.	U 0126	46-51	interferon induced protein 44	Homo sapiens	32-35
15746213-5	2005	Inhibitors of EGFR (AG1478) and p44/p42 MAPK (U0126) phosphorylation blocked redox-dependent p44/p42 phosphorylation, indicating that signaling occurred by EGFR.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	36-44
15746213-5	2005	Inhibitors of EGFR (AG1478) and p44/p42 MAPK (U0126) phosphorylation blocked redox-dependent p44/p42 phosphorylation, indicating that signaling occurred by EGFR.	U 0126	46-51	interferon induced protein 44	Homo sapiens	93-96
15746213-5	2005	Inhibitors of EGFR (AG1478) and p44/p42 MAPK (U0126) phosphorylation blocked redox-dependent p44/p42 phosphorylation, indicating that signaling occurred by EGFR.	U 0126	46-51	cyclin dependent kinase 20	Homo sapiens	36-39
15746213-5	2005	Inhibitors of EGFR (AG1478) and p44/p42 MAPK (U0126) phosphorylation blocked redox-dependent p44/p42 phosphorylation, indicating that signaling occurred by EGFR.	U 0126	46-51	epidermal growth factor receptor	Homo sapiens	156-160
16253189-15	2005	U0126, irbesartan, and NAC, as well as ACEUI, significantly inhibited the increased AP-1 DNA binding activity induced by Ang II.	U 0126	0-5	angiotensinogen	Rattus norvegicus	121-127
15845624-5	2005	Coincubation of IGF-I with specific inhibitors of the p42/44 MAPK pathway (PD098059 or U0126) completely abolished the stimulatory effect of IGF-I on IGFBP-3 mRNA expression but did not affect increased IGFBP-5 mRNA levels.	U 0126	87-92	insulin-like growth factor binding protein 5	Rattus norvegicus	203-210
15956760-6	2005	PDBu also increased phosphorylated ERK1/2 levels, a response blocked by U-0126.	U 0126	72-78	mitogen-activated protein kinase 3	Homo sapiens	35-41
15763431-7	2005	Treatment with the p38 inhibitor, SB202190, or either of the ERK1/2 inhibitors, PD98059 and U0126, partially blocked Stx1-induced eIF4E phosphorylation.	U 0126	92-97	syntaxin 1A	Homo sapiens	117-121
15763431-7	2005	Treatment with the p38 inhibitor, SB202190, or either of the ERK1/2 inhibitors, PD98059 and U0126, partially blocked Stx1-induced eIF4E phosphorylation.	U 0126	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
15622520-2	2005	Pharmacologic agents that target MEK (PD98059, U0126) or src family (PP1) kinases attenuated TGF-beta1-dependent PAI-1 transcription in R22 aortic smooth muscle cells.	U 0126	47-52	transforming growth factor, beta 1	Rattus norvegicus	93-102
16113101-8	2005	Similarly the MEK inhibitor U0126 decreased basal ERalpha-mediated transcription and proliferation in the LTED cells by 50% and reduced their sensitivity to the proliferative effects of E2 10-fold, whilst having no effect on the wild type (wt).	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
16113101-8	2005	Similarly the MEK inhibitor U0126 decreased basal ERalpha-mediated transcription and proliferation in the LTED cells by 50% and reduced their sensitivity to the proliferative effects of E2 10-fold, whilst having no effect on the wild type (wt).	U 0126	28-33	estrogen receptor 1	Homo sapiens	50-57
15963850-6	2005	The farnesyl transferase inhibitor L744832 and the MEK inhibitor U0126 both restored p27 levels and cell-cycle arrest in response to TGF-beta.	U 0126	65-70	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
15963850-6	2005	The farnesyl transferase inhibitor L744832 and the MEK inhibitor U0126 both restored p27 levels and cell-cycle arrest in response to TGF-beta.	U 0126	65-70	interferon alpha inducible protein 27	Homo sapiens	85-88
15963850-6	2005	The farnesyl transferase inhibitor L744832 and the MEK inhibitor U0126 both restored p27 levels and cell-cycle arrest in response to TGF-beta.	U 0126	65-70	transforming growth factor beta 1	Homo sapiens	133-141
15962331-9	2005	The activation was abolished when ERK was inhibited with U0126.	U 0126	57-62	Eph receptor B1	Rattus norvegicus	34-37
16164824-10	2005	On the other hand, immune complex-stimulated monocytes displayed a reduced expression of CD95, which is prevented by dexamethasone, as well as by MEK inhibitor U0126.	U 0126	160-165	mitogen-activated protein kinase kinase 7	Homo sapiens	146-149
15622520-12	2005	PP1, PD98059, and U0126 also inhibited TGF-beta1-dependent cell motility at concentrations that significantly attenuated PAI-1 expression.	U 0126	18-23	transforming growth factor, beta 1	Rattus norvegicus	39-48
15622520-12	2005	PP1, PD98059, and U0126 also inhibited TGF-beta1-dependent cell motility at concentrations that significantly attenuated PAI-1 expression.	U 0126	18-23	serpin family E member 2	Rattus norvegicus	121-126
15622520-2	2005	Pharmacologic agents that target MEK (PD98059, U0126) or src family (PP1) kinases attenuated TGF-beta1-dependent PAI-1 transcription in R22 aortic smooth muscle cells.	U 0126	47-52	serpin family E member 2	Rattus norvegicus	113-118
15905098-5	2005	Inhibitors of the p38 MAP kinase pathway (SB-202190 or SB-203580) and an inhibitor of the ERK1/2 pathway (U0126) reduced ceramide-induced neuronal death.	U 0126	106-111	mitogen-activated protein kinase 3	Homo sapiens	90-96
15838870-4	2005	Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	44-50
15838870-4	2005	Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor.	U 0126	21-26	mitogen-activated protein kinase 3	Homo sapiens	113-119
15838870-4	2005	Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor.	U 0126	21-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	123-128
15982617-10	2005	U0126, a specific inhibitor of p42/p44 ERK, induced a maximal decrease of 84+/-5% (n=8, p&lt;0.001).	U 0126	0-5	cyclin dependent kinase 20	Homo sapiens	31-34
15731170-5	2005	Dopamine inhibited histone H4 acetylation by 2-fold in 30 min, an effect mimicked by the MAPK kinase (MEK1) inhibitor U0126.	U 0126	118-123	mitogen activated protein kinase 3	Rattus norvegicus	89-93
15731170-5	2005	Dopamine inhibited histone H4 acetylation by 2-fold in 30 min, an effect mimicked by the MAPK kinase (MEK1) inhibitor U0126.	U 0126	118-123	mitogen activated protein kinase kinase 1	Rattus norvegicus	102-106
16123076-6	2005	The effect of TGF-beta and GnRHa on FMOD expression was reversed following pretreatment of LSMC and MSMC with Smad3 SiRNA and U0126 (MEK1/2 inhibitor), respectively.	U 0126	126-131	transforming growth factor beta 1	Homo sapiens	14-22
16123076-6	2005	The effect of TGF-beta and GnRHa on FMOD expression was reversed following pretreatment of LSMC and MSMC with Smad3 SiRNA and U0126 (MEK1/2 inhibitor), respectively.	U 0126	126-131	fibromodulin	Homo sapiens	36-40
16123076-6	2005	The effect of TGF-beta and GnRHa on FMOD expression was reversed following pretreatment of LSMC and MSMC with Smad3 SiRNA and U0126 (MEK1/2 inhibitor), respectively.	U 0126	126-131	mitogen-activated protein kinase kinase 1	Homo sapiens	133-139
15802625-4	2005	In contrast, mitogen-activated protein kinase kinase-1 (MEK1) inhibition (dominant-negative MEK1 adenovirus or inhibitor U0126) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA-binding activity, p65 phosphorylation, and led to 70% reduction in IL-6 transcription/production.	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	13-54
15896303-4	2005	Treatment of human pancreatic cancer cells with specific MEK inhibitor, PD98059 or U0126, inhibited ERK1/2 phosphorylation and cell growth.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
15896303-4	2005	Treatment of human pancreatic cancer cells with specific MEK inhibitor, PD98059 or U0126, inhibited ERK1/2 phosphorylation and cell growth.	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	100-106
15831492-4	2005	However, treatment of Ras-transformed RIE-1 or ROSE cells with the MEK inhibitors U0126 and PD98059 increased Par-4 protein expression.	U 0126	82-87	pro-apoptotic WT1 regulator	Rattus norvegicus	110-115
15767248-11	2005	Furthermore, studies with the inhibitory antibody and U0126, the MAPK inhibitor, show that GALR1 inhibits proliferation in immortalized and malignant keratinocytes by inactivating the MAPK pathway.	U 0126	54-59	galanin receptor 1	Homo sapiens	91-96
15797857-6	2005	Sodium orthovanadate, chondroitin sulfate-C, PP1, wortmannin, LY294002, and U0126 inhibit HARP-mediated signaling and HUVEC migration and tube formation.	U 0126	76-81	pleiotrophin	Homo sapiens	90-94
15695555-10	2005	Treatment of serum-starved cells with the selective inhibitors of MAPK/ERK, PD-98059 (40 microM) and U-0126 (10 microM), abolished the effect of d-glucose on ENT-1.	U 0126	101-107	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	158-163
15845624-5	2005	Coincubation of IGF-I with specific inhibitors of the p42/44 MAPK pathway (PD098059 or U0126) completely abolished the stimulatory effect of IGF-I on IGFBP-3 mRNA expression but did not affect increased IGFBP-5 mRNA levels.	U 0126	87-92	insulin-like growth factor 1	Rattus norvegicus	16-21
15845624-5	2005	Coincubation of IGF-I with specific inhibitors of the p42/44 MAPK pathway (PD098059 or U0126) completely abolished the stimulatory effect of IGF-I on IGFBP-3 mRNA expression but did not affect increased IGFBP-5 mRNA levels.	U 0126	87-92	insulin-like growth factor 1	Rattus norvegicus	141-146
15845624-5	2005	Coincubation of IGF-I with specific inhibitors of the p42/44 MAPK pathway (PD098059 or U0126) completely abolished the stimulatory effect of IGF-I on IGFBP-3 mRNA expression but did not affect increased IGFBP-5 mRNA levels.	U 0126	87-92	insulin-like growth factor binding protein 3	Rattus norvegicus	150-157
15882976-6	2005	LY294002 and U0126, pharmacological inhibitors of phosphatidylinositol 3-kinase and MEK1/2 which are upstream of Akt and ERK1/2, respectively, attenuated resveratrol-induced HO-1 expression and exhibited antioxidant effects.	U 0126	13-18	mitogen activated protein kinase kinase 1	Rattus norvegicus	84-90
15882976-6	2005	LY294002 and U0126, pharmacological inhibitors of phosphatidylinositol 3-kinase and MEK1/2 which are upstream of Akt and ERK1/2, respectively, attenuated resveratrol-induced HO-1 expression and exhibited antioxidant effects.	U 0126	13-18	AKT serine/threonine kinase 1	Rattus norvegicus	113-116
15882976-6	2005	LY294002 and U0126, pharmacological inhibitors of phosphatidylinositol 3-kinase and MEK1/2 which are upstream of Akt and ERK1/2, respectively, attenuated resveratrol-induced HO-1 expression and exhibited antioxidant effects.	U 0126	13-18	mitogen activated protein kinase 3	Rattus norvegicus	121-127
15882976-6	2005	LY294002 and U0126, pharmacological inhibitors of phosphatidylinositol 3-kinase and MEK1/2 which are upstream of Akt and ERK1/2, respectively, attenuated resveratrol-induced HO-1 expression and exhibited antioxidant effects.	U 0126	13-18	heme oxygenase 1	Rattus norvegicus	174-178
15894121-5	2005	In addition, the expression of AIRE gene was inhibited by specific p38 MAPK inhibitor (SB203580), whereas the expression was rather enhanced by the MEK1/2 inhibitor (U0126), suggesting that AIRE gene expression is regulated by mitogen-activated protein kinase pathway.	U 0126	166-171	autoimmune regulator	Homo sapiens	31-35
15894121-5	2005	In addition, the expression of AIRE gene was inhibited by specific p38 MAPK inhibitor (SB203580), whereas the expression was rather enhanced by the MEK1/2 inhibitor (U0126), suggesting that AIRE gene expression is regulated by mitogen-activated protein kinase pathway.	U 0126	166-171	mitogen-activated protein kinase kinase 1	Homo sapiens	148-154
15894121-5	2005	In addition, the expression of AIRE gene was inhibited by specific p38 MAPK inhibitor (SB203580), whereas the expression was rather enhanced by the MEK1/2 inhibitor (U0126), suggesting that AIRE gene expression is regulated by mitogen-activated protein kinase pathway.	U 0126	166-171	autoimmune regulator	Homo sapiens	190-194
15802625-4	2005	In contrast, mitogen-activated protein kinase kinase-1 (MEK1) inhibition (dominant-negative MEK1 adenovirus or inhibitor U0126) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA-binding activity, p65 phosphorylation, and led to 70% reduction in IL-6 transcription/production.	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	56-60
15802625-4	2005	In contrast, mitogen-activated protein kinase kinase-1 (MEK1) inhibition (dominant-negative MEK1 adenovirus or inhibitor U0126) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA-binding activity, p65 phosphorylation, and led to 70% reduction in IL-6 transcription/production.	U 0126	121-126	angiotensinogen	Homo sapiens	139-145
15802625-4	2005	In contrast, mitogen-activated protein kinase kinase-1 (MEK1) inhibition (dominant-negative MEK1 adenovirus or inhibitor U0126) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA-binding activity, p65 phosphorylation, and led to 70% reduction in IL-6 transcription/production.	U 0126	121-126	nuclear factor kappa B subunit 1	Homo sapiens	154-163
15802625-4	2005	In contrast, mitogen-activated protein kinase kinase-1 (MEK1) inhibition (dominant-negative MEK1 adenovirus or inhibitor U0126) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA-binding activity, p65 phosphorylation, and led to 70% reduction in IL-6 transcription/production.	U 0126	121-126	nuclear factor kappa B subunit 1	Homo sapiens	183-192
15573401-7	2005	Pretreatment with U0126 (a MEK1/2 inhibitor) attenuated the p42/p44 MAPK phosphorylation and [3H]thymidine incorporation stimulated by BK, but had no effect on Akt activation.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Homo sapiens	27-33
15821757-6	2005	5 eEF2K phosphorylation was abolished by U0126 (1 microM), a selective inhibitor of MEK1, and was significantly reduced by GF109203X at &gt; or =3 microM and by Ro31-8220 at &gt; or =1 microM.	U 0126	41-46	eukaryotic elongation factor-2 kinase	Rattus norvegicus	2-7
15821757-6	2005	5 eEF2K phosphorylation was abolished by U0126 (1 microM), a selective inhibitor of MEK1, and was significantly reduced by GF109203X at &gt; or =3 microM and by Ro31-8220 at &gt; or =1 microM.	U 0126	41-46	mitogen activated protein kinase kinase 1	Rattus norvegicus	84-88
15955068-7	2005	The activation of the MEK--&gt;ERK pathway by the calcium-dependent tyrosine kinase PYK 2, a survival pathway which delays apoptosis as shown by the use of the MEK inhibitor U0126, and a pathway involving another pro-apoptotic BH3 only protein, Bim.	U 0126	174-179	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
15955068-7	2005	The activation of the MEK--&gt;ERK pathway by the calcium-dependent tyrosine kinase PYK 2, a survival pathway which delays apoptosis as shown by the use of the MEK inhibitor U0126, and a pathway involving another pro-apoptotic BH3 only protein, Bim.	U 0126	174-179	EPH receptor B2	Homo sapiens	31-34
15955068-7	2005	The activation of the MEK--&gt;ERK pathway by the calcium-dependent tyrosine kinase PYK 2, a survival pathway which delays apoptosis as shown by the use of the MEK inhibitor U0126, and a pathway involving another pro-apoptotic BH3 only protein, Bim.	U 0126	174-179	protein tyrosine kinase 2 beta	Homo sapiens	84-89
15870880-5	2005	To confirm these findings, the MAPK signal transduction cascade was activated with EGF and response to doxorubicin or paclitaxel was measured in the presence/absence of the MEK-specific inhibitor, U0126.	U 0126	197-202	mitogen-activated protein kinase 1	Homo sapiens	31-35
15883646-14	2005	U0126, a MAPK inhibitor, alone decreased cyclin D1 protein, suggesting that the basal cyclin D1 protein is MAPK dependent.	U 0126	0-5	cyclin D1	Mus musculus	41-50
15883646-14	2005	U0126, a MAPK inhibitor, alone decreased cyclin D1 protein, suggesting that the basal cyclin D1 protein is MAPK dependent.	U 0126	0-5	cyclin D1	Mus musculus	86-95
15930308-7	2005	Inhibition of p27Kip1 expression in Mia PaCa-2 cells restored the activity of cyclin/cdk2, phosphorylation of pRb, and E2F activity and partially relieved the effects of U0126 on pancreatic cancer cell cycle arrest.	U 0126	170-175	cyclin dependent kinase inhibitor 1B	Homo sapiens	14-21
16019439-8	2005	VEGF production was significantly decreased following pretreatment with U0126 or wortmannin for two hours before treatment with EGF (p &lt; 0.01, p &lt; 0.01).	U 0126	72-77	vascular endothelial growth factor A	Homo sapiens	0-4
16019439-8	2005	VEGF production was significantly decreased following pretreatment with U0126 or wortmannin for two hours before treatment with EGF (p &lt; 0.01, p &lt; 0.01).	U 0126	72-77	epidermal growth factor	Homo sapiens	1-4
15573401-7	2005	Pretreatment with U0126 (a MEK1/2 inhibitor) attenuated the p42/p44 MAPK phosphorylation and [3H]thymidine incorporation stimulated by BK, but had no effect on Akt activation.	U 0126	18-23	cyclin dependent kinase 20	Homo sapiens	60-63
15573401-7	2005	Pretreatment with U0126 (a MEK1/2 inhibitor) attenuated the p42/p44 MAPK phosphorylation and [3H]thymidine incorporation stimulated by BK, but had no effect on Akt activation.	U 0126	18-23	interferon induced protein 44	Homo sapiens	64-67
15573401-7	2005	Pretreatment with U0126 (a MEK1/2 inhibitor) attenuated the p42/p44 MAPK phosphorylation and [3H]thymidine incorporation stimulated by BK, but had no effect on Akt activation.	U 0126	18-23	kininogen 1	Homo sapiens	135-137
15930378-6	2005	The in vivo administration of the MAP kinase kinase 1/2 inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto) butadiene] attenuated MSK1 phosphorylation.	U 0126	66-71	ribosomal protein S6 kinase A5	Homo sapiens	150-154
15894894-9	2005	The p38 MAP-kinase inhibitor SB202190 or the MEK-ERK pathway inhibitor UO126 totally inhibited the activation of both NADPH oxidase and cPLA2 as well as the translocation of cytosolic oxidase components and of cPLA2 to the membrane fractions.	U 0126	71-76	mitogen-activated protein kinase kinase 7	Homo sapiens	45-48
15894894-9	2005	The p38 MAP-kinase inhibitor SB202190 or the MEK-ERK pathway inhibitor UO126 totally inhibited the activation of both NADPH oxidase and cPLA2 as well as the translocation of cytosolic oxidase components and of cPLA2 to the membrane fractions.	U 0126	71-76	phospholipase A2 group IVA	Homo sapiens	136-141
15894894-9	2005	The p38 MAP-kinase inhibitor SB202190 or the MEK-ERK pathway inhibitor UO126 totally inhibited the activation of both NADPH oxidase and cPLA2 as well as the translocation of cytosolic oxidase components and of cPLA2 to the membrane fractions.	U 0126	71-76	phospholipase A2 group IVA	Homo sapiens	210-215
15956343-16	2005	However, TGF-beta even in MCC-DNTbetaRII cells induced ERK1/2 phosphorylation, and treatment with MEK inhibitor, UO126, inhibited the antagonistic effects of TGF-beta on IGFBP-3.	U 0126	113-118	mitogen-activated protein kinase 3	Homo sapiens	55-61
15956343-16	2005	However, TGF-beta even in MCC-DNTbetaRII cells induced ERK1/2 phosphorylation, and treatment with MEK inhibitor, UO126, inhibited the antagonistic effects of TGF-beta on IGFBP-3.	U 0126	113-118	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
15956343-16	2005	However, TGF-beta even in MCC-DNTbetaRII cells induced ERK1/2 phosphorylation, and treatment with MEK inhibitor, UO126, inhibited the antagonistic effects of TGF-beta on IGFBP-3.	U 0126	113-118	transforming growth factor beta 1	Homo sapiens	158-166
15956343-16	2005	However, TGF-beta even in MCC-DNTbetaRII cells induced ERK1/2 phosphorylation, and treatment with MEK inhibitor, UO126, inhibited the antagonistic effects of TGF-beta on IGFBP-3.	U 0126	113-118	insulin like growth factor binding protein 3	Homo sapiens	170-177
15956343-17	2005	Furthermore, UO126 blocked the TGF-beta inhibition of STAT-1 phosphorylation induced by IGFBP-3.	U 0126	13-18	transforming growth factor beta 1	Homo sapiens	31-39
15956343-17	2005	Furthermore, UO126 blocked the TGF-beta inhibition of STAT-1 phosphorylation induced by IGFBP-3.	U 0126	13-18	signal transducer and activator of transcription 1	Homo sapiens	54-60
15956343-17	2005	Furthermore, UO126 blocked the TGF-beta inhibition of STAT-1 phosphorylation induced by IGFBP-3.	U 0126	13-18	insulin like growth factor binding protein 3	Homo sapiens	88-95
15976138-9	2005	Preincubation of fat cells with candesartan, an angiotensin II type 1 receptor antagonist, or the extracellular-signal-regulated kinases 1 and 2 inhibitor UO126 completely abolished the effect of Ang II on leptin production.	U 0126	155-160	mitogen-activated protein kinase 1	Homo sapiens	98-144
15935058-7	2005	The pro-apoptotic Bax was increased by axotomy; FGF-2 treatment greatly decreased Bax levels, an effect that was inhibited by U0126.	U 0126	126-131	BCL2 associated X, apoptosis regulator	Canis lupus familiaris	18-21
15935058-7	2005	The pro-apoptotic Bax was increased by axotomy; FGF-2 treatment greatly decreased Bax levels, an effect that was inhibited by U0126.	U 0126	126-131	fibroblast growth factor 2	Canis lupus familiaris	48-53
15935058-7	2005	The pro-apoptotic Bax was increased by axotomy; FGF-2 treatment greatly decreased Bax levels, an effect that was inhibited by U0126.	U 0126	126-131	BCL2 associated X, apoptosis regulator	Canis lupus familiaris	82-85
15934945-4	2005	U0126, a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, both inhibited FGF2-induced BrdU incorporation, suggesting that the extracellular signal-regulated kinase1/2 (ERK1/2) and PI3K pathways are required for FGF2-induced NP cell proliferation.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	9-52
15934945-4	2005	U0126, a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, both inhibited FGF2-induced BrdU incorporation, suggesting that the extracellular signal-regulated kinase1/2 (ERK1/2) and PI3K pathways are required for FGF2-induced NP cell proliferation.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	54-60
15934945-4	2005	U0126, a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, both inhibited FGF2-induced BrdU incorporation, suggesting that the extracellular signal-regulated kinase1/2 (ERK1/2) and PI3K pathways are required for FGF2-induced NP cell proliferation.	U 0126	0-5	fibroblast growth factor 2	Homo sapiens	152-156
15934945-4	2005	U0126, a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, both inhibited FGF2-induced BrdU incorporation, suggesting that the extracellular signal-regulated kinase1/2 (ERK1/2) and PI3K pathways are required for FGF2-induced NP cell proliferation.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	205-245
15934945-4	2005	U0126, a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, both inhibited FGF2-induced BrdU incorporation, suggesting that the extracellular signal-regulated kinase1/2 (ERK1/2) and PI3K pathways are required for FGF2-induced NP cell proliferation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	247-253
15934945-4	2005	U0126, a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, both inhibited FGF2-induced BrdU incorporation, suggesting that the extracellular signal-regulated kinase1/2 (ERK1/2) and PI3K pathways are required for FGF2-induced NP cell proliferation.	U 0126	0-5	fibroblast growth factor 2	Homo sapiens	290-294
15968405-8	2005	Inhibition of either the PI3K by LY294002 or ERK1/2 by U0126 reduced HIF-1alpha protein levels while both inhibitors together completely abolished the IGF-1 effect on HIF-1alpha.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	45-51
16044913-4	2005	U0126, a MEK inhibitor, inhibited the transcription of titin in dosage-dependent manner.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
16044913-4	2005	U0126, a MEK inhibitor, inhibited the transcription of titin in dosage-dependent manner.	U 0126	0-5	titin	Homo sapiens	55-60
15833446-3	2005	Inhibition of MAPK signaling by U0126 in HeLa cells led to reduced activity of the PR1-HRE-luc CA9 promoter construct and decreased CA IX protein levels in dense culture as well as in hypoxia.	U 0126	32-37	transmembrane protein 37	Homo sapiens	83-86
15833446-3	2005	Inhibition of MAPK signaling by U0126 in HeLa cells led to reduced activity of the PR1-HRE-luc CA9 promoter construct and decreased CA IX protein levels in dense culture as well as in hypoxia.	U 0126	32-37	carbonic anhydrase 9	Homo sapiens	95-98
15833446-3	2005	Inhibition of MAPK signaling by U0126 in HeLa cells led to reduced activity of the PR1-HRE-luc CA9 promoter construct and decreased CA IX protein levels in dense culture as well as in hypoxia.	U 0126	32-37	carbonic anhydrase 9	Homo sapiens	132-137
15833446-4	2005	Similar reduction was obtained by expression of a dominant-negative ERK1 mutant and was also observed in U0126-treated HIF-1alpha-deficient Ka13 cells.	U 0126	105-110	mitogen-activated protein kinase 3	Homo sapiens	68-72
15899786-7	2005	In addition, inhibition of ERK activation by exposing MEFs to the MEK1/2-specific inhibitors PD98059 and U0126 protected both KSR+/+ and KSR-/- MEFs cells from CDDP-induced apoptosis.	U 0126	105-110	mitogen-activated protein kinase 1	Mus musculus	27-30
15899786-7	2005	In addition, inhibition of ERK activation by exposing MEFs to the MEK1/2-specific inhibitors PD98059 and U0126 protected both KSR+/+ and KSR-/- MEFs cells from CDDP-induced apoptosis.	U 0126	105-110	mitogen-activated protein kinase kinase 1	Mus musculus	66-72
15899786-7	2005	In addition, inhibition of ERK activation by exposing MEFs to the MEK1/2-specific inhibitors PD98059 and U0126 protected both KSR+/+ and KSR-/- MEFs cells from CDDP-induced apoptosis.	U 0126	105-110	kinase suppressor of ras 1	Mus musculus	126-129
15899786-7	2005	In addition, inhibition of ERK activation by exposing MEFs to the MEK1/2-specific inhibitors PD98059 and U0126 protected both KSR+/+ and KSR-/- MEFs cells from CDDP-induced apoptosis.	U 0126	105-110	kinase suppressor of ras 1	Mus musculus	137-140
15866480-6	2005	Pretreatment with U0126 attenuated the D-erythro-SPC-induced release of cytochrome c.	U 0126	18-23	cytochrome c, somatic	Homo sapiens	72-84
15683736-5	2005	Furthermore, that the MAPK kinase (MEK) 1/2 inhibitor, U0126, blocked proliferation and induced death of B9 cells indicate that IL-6 may not exert its survival effect primarily through bcl-XL and emphasizes the key role of Ras-MAPK cascade elements in the regulation of myeloma growth/viability.	U 0126	55-60	mitogen-activated protein kinase kinase 1	Mus musculus	22-43
15683736-5	2005	Furthermore, that the MAPK kinase (MEK) 1/2 inhibitor, U0126, blocked proliferation and induced death of B9 cells indicate that IL-6 may not exert its survival effect primarily through bcl-XL and emphasizes the key role of Ras-MAPK cascade elements in the regulation of myeloma growth/viability.	U 0126	55-60	interleukin 6	Mus musculus	128-132
15683736-5	2005	Furthermore, that the MAPK kinase (MEK) 1/2 inhibitor, U0126, blocked proliferation and induced death of B9 cells indicate that IL-6 may not exert its survival effect primarily through bcl-XL and emphasizes the key role of Ras-MAPK cascade elements in the regulation of myeloma growth/viability.	U 0126	55-60	BCL2-like 1	Mus musculus	185-191
15836771-7	2005	This up-regulation of Sox9 expression disappeared when the cells were treated with a specific MEK inhibitor, U0126.	U 0126	109-114	SRY (sex determining region Y)-box 9	Mus musculus	22-26
15836771-7	2005	This up-regulation of Sox9 expression disappeared when the cells were treated with a specific MEK inhibitor, U0126.	U 0126	109-114	midkine	Mus musculus	94-97
15809719-4	2005	Intracellular MMP-7 protein presented as pre-proenzyme and its expression was decreased by AG1478 (EGFR inhibitor) or U0126 (MEK inhibitor) treatment in pancreatic cancer cells.	U 0126	118-123	matrix metallopeptidase 7	Homo sapiens	14-19
15809719-4	2005	Intracellular MMP-7 protein presented as pre-proenzyme and its expression was decreased by AG1478 (EGFR inhibitor) or U0126 (MEK inhibitor) treatment in pancreatic cancer cells.	U 0126	118-123	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
15829704-10	2005	Finally, pretreatment with AG-1478, the MEK inhibitor UO126, and NAC prevented the albumin-induced increase in IL-8 expression.	U 0126	54-59	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
15829704-10	2005	Finally, pretreatment with AG-1478, the MEK inhibitor UO126, and NAC prevented the albumin-induced increase in IL-8 expression.	U 0126	54-59	C-X-C motif chemokine ligand 8	Homo sapiens	111-115
15468069-5	2005	Inhibitors of this pathway, PD98059 and U0126, downregulated TGF-beta-induced expression of TIMP-3 RNA and protein.	U 0126	40-45	transforming growth factor beta 1	Homo sapiens	61-69
15468069-5	2005	Inhibitors of this pathway, PD98059 and U0126, downregulated TGF-beta-induced expression of TIMP-3 RNA and protein.	U 0126	40-45	TIMP metallopeptidase inhibitor 3	Homo sapiens	92-98
15843518-7	2005	In contrast, H4R stimulation did not affect cAMP production but induced the transcription factor AP-1, and U0126, an inhibitor of AP-1 transactivation and MEK, rescued H4R mediated IL-12p70 suppression.	U 0126	107-112	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	130-134
15843518-7	2005	In contrast, H4R stimulation did not affect cAMP production but induced the transcription factor AP-1, and U0126, an inhibitor of AP-1 transactivation and MEK, rescued H4R mediated IL-12p70 suppression.	U 0126	107-112	mitogen-activated protein kinase kinase 7	Homo sapiens	155-158
15879678-8	2005	On the other hand, the MEK1 inhibitors PD98059 or U0126 showed no effect on repression of cell death, but rather an increase.	U 0126	50-55	mitogen-activated protein kinase kinase 1	Homo sapiens	23-27
15931581-6	2005	The inhibition of ERK1/2 phosphorylation was associated to a decrease in the IFN-gamma production, due that UO126, a specific ERK1/2 inhibitor, also reduced the IFN-gamma production in murine T-cells induced by CON-A.	U 0126	108-113	mitogen-activated protein kinase 3	Mus musculus	18-24
15931581-6	2005	The inhibition of ERK1/2 phosphorylation was associated to a decrease in the IFN-gamma production, due that UO126, a specific ERK1/2 inhibitor, also reduced the IFN-gamma production in murine T-cells induced by CON-A.	U 0126	108-113	interferon gamma	Mus musculus	77-86
15931581-6	2005	The inhibition of ERK1/2 phosphorylation was associated to a decrease in the IFN-gamma production, due that UO126, a specific ERK1/2 inhibitor, also reduced the IFN-gamma production in murine T-cells induced by CON-A.	U 0126	108-113	mitogen-activated protein kinase 3	Mus musculus	126-132
15931581-6	2005	The inhibition of ERK1/2 phosphorylation was associated to a decrease in the IFN-gamma production, due that UO126, a specific ERK1/2 inhibitor, also reduced the IFN-gamma production in murine T-cells induced by CON-A.	U 0126	108-113	interferon gamma	Mus musculus	161-170
15723837-8	2005	The amounts of both transcripts that are associated with polyribosomes and are, hence, being actively translated are reduced by &gt;80% by the MEK inhibitor, U0126.	U 0126	158-163	mitogen-activated protein kinase kinase 7	Homo sapiens	143-146
15843032-6	2005	Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1.	U 0126	149-154	leukemia inhibitory factor	Mus musculus	28-31
15843032-6	2005	Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1.	U 0126	149-154	mitogen-activated protein kinase 1	Mus musculus	59-62
15843032-6	2005	Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1.	U 0126	149-154	leukemia inhibitory factor	Mus musculus	72-75
15843032-6	2005	Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1.	U 0126	149-154	midkine	Mus musculus	167-170
15843032-6	2005	Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1.	U 0126	149-154	mitogen-activated protein kinase kinase 1	Mus musculus	237-241
15591095-7	2005	Inhibition of ERK MAPK pathway using U0126 prevented CRP-induced IL-8 upregulation, and Western blot analysis revealed a rapid activation of ERK1/2 after CRP stimulation.	U 0126	37-42	C-reactive protein	Homo sapiens	53-56
15591095-7	2005	Inhibition of ERK MAPK pathway using U0126 prevented CRP-induced IL-8 upregulation, and Western blot analysis revealed a rapid activation of ERK1/2 after CRP stimulation.	U 0126	37-42	C-X-C motif chemokine ligand 8	Homo sapiens	65-69
15777538-5	2005	The MEK1/2 inhibitor U0126 strongly diminished TNF expression, indicating that MEK1/2 plays a central role in the regulation of TNF expression.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	4-10
15777538-5	2005	The MEK1/2 inhibitor U0126 strongly diminished TNF expression, indicating that MEK1/2 plays a central role in the regulation of TNF expression.	U 0126	21-26	tumor necrosis factor	Homo sapiens	47-50
15777538-5	2005	The MEK1/2 inhibitor U0126 strongly diminished TNF expression, indicating that MEK1/2 plays a central role in the regulation of TNF expression.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	79-85
15777538-5	2005	The MEK1/2 inhibitor U0126 strongly diminished TNF expression, indicating that MEK1/2 plays a central role in the regulation of TNF expression.	U 0126	21-26	tumor necrosis factor	Homo sapiens	128-131
15637287-5	2005	U0126, an inhibitor of MAPK p44/42, blocked the bFGF-induced activation of MAPK p44/42 as well as the bFGF-induced cell proliferation of enriched lactotropes and PR1 cells.	U 0126	0-5	fibroblast growth factor 2	Gallus gallus	48-52
15637287-5	2005	U0126, an inhibitor of MAPK p44/42, blocked the bFGF-induced activation of MAPK p44/42 as well as the bFGF-induced cell proliferation of enriched lactotropes and PR1 cells.	U 0126	0-5	fibroblast growth factor 2	Gallus gallus	102-106
15735687-6	2005	Since U0126, a specific inhibitor for MEK1/2, also induced a partial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibition of ERK1/2.	U 0126	6-11	mitogen-activated protein kinase kinase 1	Homo sapiens	38-44
15735687-6	2005	Since U0126, a specific inhibitor for MEK1/2, also induced a partial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibition of ERK1/2.	U 0126	6-11	mitogen-activated protein kinase 3	Homo sapiens	172-178
15843040-3	2005	Cisplatin stimulated ERK1/2 phosphorylation and caused apoptosis in U-937 promonocytic cells, an effect which was attenuated by the MEK/ERK inhibitors PD98059 and U0126.	U 0126	163-168	mitogen-activated protein kinase 3	Homo sapiens	21-27
15843040-3	2005	Cisplatin stimulated ERK1/2 phosphorylation and caused apoptosis in U-937 promonocytic cells, an effect which was attenuated by the MEK/ERK inhibitors PD98059 and U0126.	U 0126	163-168	mitogen-activated protein kinase kinase 7	Homo sapiens	132-135
15863357-5	2005	Pretreatment of HL60 cells with the MEK inhibitor, U0126, but not the p38 MAPK inhibitor, SB203580, completely suppressed dbcAMP-induced ERK1/2 activation and granulocytic differentiation, but did not affect the increase in SPHK activity.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
15863357-5	2005	Pretreatment of HL60 cells with the MEK inhibitor, U0126, but not the p38 MAPK inhibitor, SB203580, completely suppressed dbcAMP-induced ERK1/2 activation and granulocytic differentiation, but did not affect the increase in SPHK activity.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	137-143
15863357-5	2005	Pretreatment of HL60 cells with the MEK inhibitor, U0126, but not the p38 MAPK inhibitor, SB203580, completely suppressed dbcAMP-induced ERK1/2 activation and granulocytic differentiation, but did not affect the increase in SPHK activity.	U 0126	51-56	sphingosine kinase 1	Homo sapiens	224-228
15777784-8	2005	Furthermore, pretreatment with an upstream kinase MEK1/2 inhibitor U0126 also impaired the MAPK/ERK activation and cell proliferation induced by E2.	U 0126	67-72	mitogen-activated protein kinase kinase 1	Homo sapiens	50-56
15777784-8	2005	Furthermore, pretreatment with an upstream kinase MEK1/2 inhibitor U0126 also impaired the MAPK/ERK activation and cell proliferation induced by E2.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	91-95
15777784-8	2005	Furthermore, pretreatment with an upstream kinase MEK1/2 inhibitor U0126 also impaired the MAPK/ERK activation and cell proliferation induced by E2.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	96-99
15833869-4	2005	Treatment of MDA-MB-231 cells with 50 micromol/L U0126 for 2, 4, 8, 16, 24, 32, and 40 hours caused inhibition of extracellular signal-regulated kinases (ERK1/2) phosphorylation from 2 hours onwards.	U 0126	49-54	mitogen-activated protein kinase 3	Homo sapiens	154-160
15833869-7	2005	Depletion of P-ERK1/2 in MCF-7 and Hs578T cells with 50 micromol/L U0126 also produced a drop in phosphocholine levels to 51 +/- 17% at 40 hours and 23 +/- 12% at 48 hours, respectively.	U 0126	67-72	mitogen-activated protein kinase 3	Homo sapiens	15-21
15833869-8	2005	Similarly, in HCT116 cells, inhibition with 30 micromol/L U0126 caused depletion of P-ERK1/2 and a decrease in phosphocholine levels to 80 +/- 9% at 16 hours and 61 +/- 4% at 24 hours post-treatment.	U 0126	58-63	mitogen-activated protein kinase 3	Homo sapiens	86-92
15833869-10	2005	Our results show that MAPK signaling inhibition with U0126 is associated with a time-dependent decrease in cellular phosphocholine levels.	U 0126	53-58	mitogen-activated protein kinase 3	Homo sapiens	22-26
15833106-14	2005	Using a murine asthma model of late phase eosinophilia, we demonstrated that the ERK inhibitor U0126 and the JNK inhibitor SP600125 inhibited lung inflammation in vivo.	U 0126	95-100	mitogen-activated protein kinase 1	Mus musculus	81-84
15833106-17	2005	In contrast, we found that the p38 inhibitor SB203580 antagonizes the action of the ERK inhibitor U0126 in vitro and in vivo.	U 0126	98-103	mitogen-activated protein kinase 14	Mus musculus	31-34
15833106-17	2005	In contrast, we found that the p38 inhibitor SB203580 antagonizes the action of the ERK inhibitor U0126 in vitro and in vivo.	U 0126	98-103	mitogen-activated protein kinase 1	Mus musculus	84-87
15563540-11	2005	Administration of the selective MAPK inhibitor PD-98059 (10 nM) and the specific MEK1/2 inhibitor U-0126 (10 microM) also inhibited ME-induced cardioprotection.	U 0126	98-104	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	81-87
15653932-6	2005	Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein.	U 0126	191-196	mitogen-activated protein kinase 1	Mus musculus	58-95
15653932-6	2005	Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein.	U 0126	191-196	mitogen-activated protein kinase 1	Mus musculus	97-100
15653932-6	2005	Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein.	U 0126	191-196	mitogen-activated protein kinase 1	Mus musculus	125-128
15653932-6	2005	Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein.	U 0126	191-196	tumor necrosis factor	Mus musculus	206-215
15653932-6	2005	Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein.	U 0126	191-196	transforming growth factor, beta 1	Mus musculus	229-240
15805287-2	2005	We have previously shown additivity between Taxol and the MEK inhibitor, U0126 in human cancer cell lines.	U 0126	73-78	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
15968405-8	2005	Inhibition of either the PI3K by LY294002 or ERK1/2 by U0126 reduced HIF-1alpha protein levels while both inhibitors together completely abolished the IGF-1 effect on HIF-1alpha.	U 0126	55-60	hypoxia inducible factor 1 subunit alpha	Homo sapiens	69-79
15831279-11	2005	In addition, pretreatment with U0126 restored the IL-6-induced suppression of aromatase activity.	U 0126	31-36	interleukin 6	Homo sapiens	50-54
15748885-7	2005	By contrast, the ERK1,2 antagonist UO126 inhibited electrical field-induced angiogenesis, whereas angiogenesis under control conditions was unimpaired.	U 0126	35-40	mitogen-activated protein kinase 3	Mus musculus	17-23
15831279-13	2005	U0126 markedly reduced the level of the IL-6-induced phosphorylation of ERK1/2.	U 0126	0-5	interleukin 6	Homo sapiens	40-44
15831279-13	2005	U0126 markedly reduced the level of the IL-6-induced phosphorylation of ERK1/2.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	72-78
15669079-9	2005	Moreover, U0126-induced inhibition of MAPK activity completely abolished C75-induced up-regulation of HIF-1alpha expression and VEGF secretion, whereas it did not modulate C75-induced down-regulation of Her-2/neu oncogene.	U 0126	10-15	hypoxia inducible factor 1 subunit alpha	Homo sapiens	102-112
15695523-6	2005	IFN-gamma-induced neurite outgrowth was abolished by the treatment of MEK1/2 kinase inhibitors, such as U0126 and PD98059, which inhibit the ERK1/2 activation and subsequently prevent the up-regulation of p35 expression and Cdk5 activity.	U 0126	104-109	interferon gamma	Homo sapiens	0-9
15695523-6	2005	IFN-gamma-induced neurite outgrowth was abolished by the treatment of MEK1/2 kinase inhibitors, such as U0126 and PD98059, which inhibit the ERK1/2 activation and subsequently prevent the up-regulation of p35 expression and Cdk5 activity.	U 0126	104-109	mitogen-activated protein kinase kinase 1	Homo sapiens	70-76
15695523-6	2005	IFN-gamma-induced neurite outgrowth was abolished by the treatment of MEK1/2 kinase inhibitors, such as U0126 and PD98059, which inhibit the ERK1/2 activation and subsequently prevent the up-regulation of p35 expression and Cdk5 activity.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	141-147
15695523-6	2005	IFN-gamma-induced neurite outgrowth was abolished by the treatment of MEK1/2 kinase inhibitors, such as U0126 and PD98059, which inhibit the ERK1/2 activation and subsequently prevent the up-regulation of p35 expression and Cdk5 activity.	U 0126	104-109	cyclin dependent kinase 5 regulatory subunit 1	Homo sapiens	205-208
15695523-6	2005	IFN-gamma-induced neurite outgrowth was abolished by the treatment of MEK1/2 kinase inhibitors, such as U0126 and PD98059, which inhibit the ERK1/2 activation and subsequently prevent the up-regulation of p35 expression and Cdk5 activity.	U 0126	104-109	cyclin dependent kinase 5	Homo sapiens	224-228
15389630-5	2005	Ihh mRNA levels were also inhibited by U0126, a specific MEK1/2 inhibitor, or SB203580, a specific p38 MAPK inhibitor.	U 0126	39-44	Indian hedgehog signaling molecule	Rattus norvegicus	0-3
15389630-5	2005	Ihh mRNA levels were also inhibited by U0126, a specific MEK1/2 inhibitor, or SB203580, a specific p38 MAPK inhibitor.	U 0126	39-44	mitogen activated protein kinase kinase 1	Rattus norvegicus	57-63
15669079-9	2005	Moreover, U0126-induced inhibition of MAPK activity completely abolished C75-induced up-regulation of HIF-1alpha expression and VEGF secretion, whereas it did not modulate C75-induced down-regulation of Her-2/neu oncogene.	U 0126	10-15	vascular endothelial growth factor A	Homo sapiens	128-132
15626719-5	2005	Here, we investigated the effect of OTA in the absence or presence of the ERK1/2 inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4bis(2-aminophenylthio)-butadiene] to test whether OTA then will exert increased toxicity.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	74-80
15744743-7	2005	The MAPK kinase (MEK) inhibitor U0126 (10 microM) partially blocked NMDA neuroprotection, whereas LY294002, a selective inhibitor of the PI3-K pathway, did not affect the neuroprotective activity of NMDA.	U 0126	32-37	mitogen activated protein kinase 3	Rattus norvegicus	4-8
15626723-7	2005	U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] or SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole], specific inhibitors of mitogen-activated protein kinase kinase and p38 kinase activities, significantly decreased or delayed apoptosis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	223-226
15722441-10	2005	PRL promoter activity was inhibited by both H-89 and U0126 indicating multiple signalling pathways are activated by RLX in endometrial cells for different target gene activation.	U 0126	53-58	prolactin	Homo sapiens	0-3
15626723-9	2005	Moreover, U0126 and ERK siRNA inhibition completely suppressed asiatic acid-induced Bcl-2 phosphorylation and Bax up-regulation, and caspase-9 activation.	U 0126	10-15	BCL2 apoptosis regulator	Homo sapiens	84-89
15626723-9	2005	Moreover, U0126 and ERK siRNA inhibition completely suppressed asiatic acid-induced Bcl-2 phosphorylation and Bax up-regulation, and caspase-9 activation.	U 0126	10-15	BCL2 associated X, apoptosis regulator	Homo sapiens	110-113
15767444-11	2005	We also found that H/N-Ras inhibitor FTI-277 and MEK1/2 inhibitors PD98059 and U0126 strongly inhibited JSRV transformation of NIH 3T3 fibroblasts, suggesting that the H/N-Ras-MEK-mitogen-activated protein kinase (MAPK) p44/42 pathway is necessary for the transformation.	U 0126	79-84	mitogen-activated protein kinase kinase 1	Homo sapiens	49-55
15767444-11	2005	We also found that H/N-Ras inhibitor FTI-277 and MEK1/2 inhibitors PD98059 and U0126 strongly inhibited JSRV transformation of NIH 3T3 fibroblasts, suggesting that the H/N-Ras-MEK-mitogen-activated protein kinase (MAPK) p44/42 pathway is necessary for the transformation.	U 0126	79-84	interferon induced protein 44	Homo sapiens	220-223
15753041-5	2005	Inhibition of ERK signaling by the MEK (MAPK/ERK kinase) inhibitor U0126 blocks bidirectional melanosome transport along microtubules, and stimulation of ERK by constitutively active MEK1/2 stimulates transport.	U 0126	67-72	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	14-17
15797724-6	2005	Process extension was completely blocked by the specific MEK inhibitor U0126.	U 0126	71-76	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
15615697-8	2005	The ErbB inhibitor PD158780 and the mitogen-activated protein kinase kinase inhibitor U0126 also markedly inhibited NHK proliferation, migration, and amphiregulin production.	U 0126	86-91	amphiregulin	Homo sapiens	150-162
15637050-7	2005	A subset of these SFK-dependent genes was induced by PDGF even in the presence of the MEK1/2 inhibitor U0126 or the PI3K inhibitor LY294002.	U 0126	103-108	Rous sarcoma oncogene	Mus musculus	18-21
15637050-7	2005	A subset of these SFK-dependent genes was induced by PDGF even in the presence of the MEK1/2 inhibitor U0126 or the PI3K inhibitor LY294002.	U 0126	103-108	mitogen-activated protein kinase kinase 1	Mus musculus	86-92
15780848-8	2005	Prior administration of MEK1/2 inhibitors U0126 or Sl327, or ERK inhibitor 5-iodotubercidin, reversed suppression of CAR induced by clozapine, whereas administration of vehicle, JNK or p38 inhibitors (L-JNK-1 and SB203580, respectively) had no effect.	U 0126	42-47	mitogen activated protein kinase kinase 1	Rattus norvegicus	24-30
15780848-8	2005	Prior administration of MEK1/2 inhibitors U0126 or Sl327, or ERK inhibitor 5-iodotubercidin, reversed suppression of CAR induced by clozapine, whereas administration of vehicle, JNK or p38 inhibitors (L-JNK-1 and SB203580, respectively) had no effect.	U 0126	42-47	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	117-120
15728252-5	2005	Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter.	U 0126	88-93	midkine	Mus musculus	14-17
15728252-5	2005	Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	18-21
15728252-5	2005	Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	107-110
15728252-5	2005	Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter.	U 0126	88-93	matrix metallopeptidase 9	Mus musculus	166-171
15728252-5	2005	Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter.	U 0126	88-93	matrix metallopeptidase 9	Mus musculus	218-223
15753041-5	2005	Inhibition of ERK signaling by the MEK (MAPK/ERK kinase) inhibitor U0126 blocks bidirectional melanosome transport along microtubules, and stimulation of ERK by constitutively active MEK1/2 stimulates transport.	U 0126	67-72	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	45-48
15753041-5	2005	Inhibition of ERK signaling by the MEK (MAPK/ERK kinase) inhibitor U0126 blocks bidirectional melanosome transport along microtubules, and stimulation of ERK by constitutively active MEK1/2 stimulates transport.	U 0126	67-72	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	45-48
15670755-8	2005	Furthermore, YM529/ONO-5920 reduced phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and similarly, U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, inhibited RANKL expression.	U 0126	118-123	mitogen-activated protein kinase kinase 1	Homo sapiens	127-170
15670755-8	2005	Furthermore, YM529/ONO-5920 reduced phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and similarly, U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, inhibited RANKL expression.	U 0126	118-123	TNF superfamily member 11	Homo sapiens	192-197
15618436-4	2005	MAPK/ERK kinase (MEK) inhibitors, U0126 or PD98059, each blocked the protective effect of FGF-10 against asbestos-induced DNA damage and apoptosis, whereas a p38-MAPK inhibitor had a negligible effect, suggesting a crucial role for MEK/ERK activation in mediating the protective effects of FGF-10.	U 0126	34-39	fibroblast growth factor 10	Homo sapiens	90-96
15618223-10	2005	The effects of PMA on MAPK phosphorylation and glioblastoma cell proliferation were reduced by BIM, rottlerin, the MEK inhibitor U0126, and PKCdelta and c-Src siRNAs.	U 0126	129-134	mitogen-activated protein kinase kinase 7	Homo sapiens	115-118
15618436-5	2005	Further, we show that FGF-10 attenuates asbestos-induced change in AEC mitochondrial membrane potential and caspase 9 activation, both of which are blocked by U0126.	U 0126	159-164	fibroblast growth factor 10	Homo sapiens	22-28
15618436-5	2005	Further, we show that FGF-10 attenuates asbestos-induced change in AEC mitochondrial membrane potential and caspase 9 activation, both of which are blocked by U0126.	U 0126	159-164	caspase 9	Homo sapiens	108-117
15537865-7	2005	Finally, inhibition of MAP kinase signaling, using the selective inhibitor U0126, promoted FSH-R expression and further enhanced TGF beta1-induced FSH-R expression in vitro.	U 0126	75-80	follicle stimulating hormone receptor	Homo sapiens	147-152
15567065-7	2005	Blocking the MEK-ERK1/2 signaling pathway with the MEK inhibitors U0126, or PD98059 led to the abrogation of ERK1/2 activity in hypoxic cells, an effect that was counteracted by Fer.	U 0126	66-71	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
15537865-7	2005	Finally, inhibition of MAP kinase signaling, using the selective inhibitor U0126, promoted FSH-R expression and further enhanced TGF beta1-induced FSH-R expression in vitro.	U 0126	75-80	follicle stimulating hormone receptor	Homo sapiens	91-96
15537865-7	2005	Finally, inhibition of MAP kinase signaling, using the selective inhibitor U0126, promoted FSH-R expression and further enhanced TGF beta1-induced FSH-R expression in vitro.	U 0126	75-80	transforming growth factor beta 1	Homo sapiens	129-138
15567065-7	2005	Blocking the MEK-ERK1/2 signaling pathway with the MEK inhibitors U0126, or PD98059 led to the abrogation of ERK1/2 activity in hypoxic cells, an effect that was counteracted by Fer.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	17-23
15567065-7	2005	Blocking the MEK-ERK1/2 signaling pathway with the MEK inhibitors U0126, or PD98059 led to the abrogation of ERK1/2 activity in hypoxic cells, an effect that was counteracted by Fer.	U 0126	66-71	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
15567065-7	2005	Blocking the MEK-ERK1/2 signaling pathway with the MEK inhibitors U0126, or PD98059 led to the abrogation of ERK1/2 activity in hypoxic cells, an effect that was counteracted by Fer.	U 0126	66-71	mitogen-activated protein kinase 3	Homo sapiens	109-115
15703831-0	2005	Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.	U 0126	153-158	mitogen-activated protein kinase kinase 7	Homo sapiens	139-142
15576461-8	2005	In addition, the appearance of the two phosphorylated forms of the gap junction protein, connexin 43, in response to LH, was avoided by UO126.	U 0126	136-141	gap junction protein, alpha 1	Rattus norvegicus	89-100
15683716-4	2005	Inhibition of the upstream ERK1,2 activator MEK1,2 with U0126 prevented IL-1beta-stimulated iNOS expression, while the p38MAPK inhibitor SB03580 potentiated iNOS expression.	U 0126	56-61	mitogen activated protein kinase 3	Rattus norvegicus	27-33
15683716-4	2005	Inhibition of the upstream ERK1,2 activator MEK1,2 with U0126 prevented IL-1beta-stimulated iNOS expression, while the p38MAPK inhibitor SB03580 potentiated iNOS expression.	U 0126	56-61	mitogen activated protein kinase kinase 1	Rattus norvegicus	44-48
15683716-4	2005	Inhibition of the upstream ERK1,2 activator MEK1,2 with U0126 prevented IL-1beta-stimulated iNOS expression, while the p38MAPK inhibitor SB03580 potentiated iNOS expression.	U 0126	56-61	interleukin 1 beta	Rattus norvegicus	72-80
15683716-4	2005	Inhibition of the upstream ERK1,2 activator MEK1,2 with U0126 prevented IL-1beta-stimulated iNOS expression, while the p38MAPK inhibitor SB03580 potentiated iNOS expression.	U 0126	56-61	nitric oxide synthase 2	Rattus norvegicus	92-96
15894298-4	2005	In addition, we found that a second and more potent MEK inhibitor (U0126) significantly blocked CXCL8 release in epithelial cells by M. bovis BCG.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
15739119-6	2005	Insulin-stimulated cyclic GMP production was significantly reduced by pertussis toxin and by the inhibitors of ERK1/2, PD098059 and U0126.	U 0126	132-137	insulin	Homo sapiens	0-7
15739119-6	2005	Insulin-stimulated cyclic GMP production was significantly reduced by pertussis toxin and by the inhibitors of ERK1/2, PD098059 and U0126.	U 0126	132-137	5'-nucleotidase, cytosolic II	Homo sapiens	26-29
15703831-3	2005	We determined the effect of NS398 on ERK signaling and the synergistic effect of combined treatment with NS398 and a specific MEK inhibitor U0126 on three human endometrial cancer cell lines: Ishikawa, HEC-1A and AN3CA cells.	U 0126	140-145	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
15703831-6	2005	However, both phosphorylated ERK1/2 and COX-2 protein expression were concentration-dependently decreased in all three cell types by combined treatment with NS398 and U0126 assessed by western blot analysis.	U 0126	167-172	mitogen-activated protein kinase 3	Homo sapiens	29-35
15703831-6	2005	However, both phosphorylated ERK1/2 and COX-2 protein expression were concentration-dependently decreased in all three cell types by combined treatment with NS398 and U0126 assessed by western blot analysis.	U 0126	167-172	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-45
15703831-8	2005	The synergistic and complementary effects of combining NS398 and U0126 were found to be associated with activation of caspase-3, alterations of Bcl-2 family proteins and cell cycle regulatory proteins detected by western blot analysis.	U 0126	65-70	caspase 3	Homo sapiens	118-127
15703831-9	2005	Taken together, these findings correlate with blocking MEK-ERK signaling cascade and down-regulating COX-2 protein expression in endometrial cancer cells with combination treatment of NS398 and U0126, suggesting that the combinatory use of NS398 and specific MEK inhibitors may be valuable for chemotherapy or chemoprevention of human endometrial cancer.	U 0126	194-199	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
15389644-5	2005	Addition of the MEK inhibitor U0126, either prior to stimulation with NT + EGF or 2 h after stimulation with NT + EGF prevented the synergistic increase in DNA synthesis and suppressed the sustained phase of ERK activation.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19
15703831-9	2005	Taken together, these findings correlate with blocking MEK-ERK signaling cascade and down-regulating COX-2 protein expression in endometrial cancer cells with combination treatment of NS398 and U0126, suggesting that the combinatory use of NS398 and specific MEK inhibitors may be valuable for chemotherapy or chemoprevention of human endometrial cancer.	U 0126	194-199	prostaglandin-endoperoxide synthase 2	Homo sapiens	101-106
15389644-5	2005	Addition of the MEK inhibitor U0126, either prior to stimulation with NT + EGF or 2 h after stimulation with NT + EGF prevented the synergistic increase in DNA synthesis and suppressed the sustained phase of ERK activation.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	208-211
15703831-9	2005	Taken together, these findings correlate with blocking MEK-ERK signaling cascade and down-regulating COX-2 protein expression in endometrial cancer cells with combination treatment of NS398 and U0126, suggesting that the combinatory use of NS398 and specific MEK inhibitors may be valuable for chemotherapy or chemoprevention of human endometrial cancer.	U 0126	194-199	mitogen-activated protein kinase kinase 7	Homo sapiens	259-262
15607817-9	2005	Thus, U0126, which blocked C3a-induced RANTES/CCL5 production by 50.6+/-2.3%, inhibited MCP-1/CCL2 generation by 85.2+/-0.6%.	U 0126	6-11	complement C3	Homo sapiens	27-30
15749808-5	2005	Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells.	U 0126	45-50	midkine	Mus musculus	40-43
15749808-5	2005	Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells.	U 0126	45-50	tyrosine hydroxylase	Mus musculus	89-91
15749808-5	2005	Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells.	U 0126	45-50	fibroblast growth factor 2	Mus musculus	127-131
15749808-5	2005	Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells.	U 0126	45-50	fibroblast growth factor 2	Mus musculus	177-181
15749808-5	2005	Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells.	U 0126	45-50	tyrosine hydroxylase	Mus musculus	206-208
15749808-5	2005	Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells.	U 0126	45-50	mitogen-activated protein kinase 1	Mus musculus	246-249
15565652-5	2005	The complete blockage of active NOS-2 production by the brief exposure to U0126 was bypassed by simply adding BH(4) to the culture medium.	U 0126	74-79	nitric oxide synthase 2	Homo sapiens	32-37
15728479-5	2005	Microglial proliferation was also inhibited by PP2 (Src inhibitor), LY294002 (PI3K inhibitor), and U0126 (MEK inhibitor).	U 0126	99-104	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	U 0126	83-88	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	U 0126	83-88	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	U 0126	83-88	mitogen-activated protein kinase 3	Homo sapiens	215-219
15563545-7	2005	In contrast, P44/p42 MAPK (Erk) appeared to provide protection from Fas-mediated apoptosis because an MAPK kinase inhibitor (U0126) sensitized thyroid cells to anti-Fas antibody.	U 0126	125-130	interferon induced protein 44	Homo sapiens	13-16
15563545-7	2005	In contrast, P44/p42 MAPK (Erk) appeared to provide protection from Fas-mediated apoptosis because an MAPK kinase inhibitor (U0126) sensitized thyroid cells to anti-Fas antibody.	U 0126	125-130	mitogen-activated protein kinase 1	Homo sapiens	17-25
15563545-7	2005	In contrast, P44/p42 MAPK (Erk) appeared to provide protection from Fas-mediated apoptosis because an MAPK kinase inhibitor (U0126) sensitized thyroid cells to anti-Fas antibody.	U 0126	125-130	mitogen-activated protein kinase 1	Homo sapiens	27-30
15607817-9	2005	Thus, U0126, which blocked C3a-induced RANTES/CCL5 production by 50.6+/-2.3%, inhibited MCP-1/CCL2 generation by 85.2+/-0.6%.	U 0126	6-11	C-C motif chemokine ligand 5	Homo sapiens	39-45
15607817-9	2005	Thus, U0126, which blocked C3a-induced RANTES/CCL5 production by 50.6+/-2.3%, inhibited MCP-1/CCL2 generation by 85.2+/-0.6%.	U 0126	6-11	C-C motif chemokine ligand 5	Homo sapiens	46-50
15607817-9	2005	Thus, U0126, which blocked C3a-induced RANTES/CCL5 production by 50.6+/-2.3%, inhibited MCP-1/CCL2 generation by 85.2+/-0.6%.	U 0126	6-11	C-C motif chemokine ligand 2	Homo sapiens	88-93
15607817-9	2005	Thus, U0126, which blocked C3a-induced RANTES/CCL5 production by 50.6+/-2.3%, inhibited MCP-1/CCL2 generation by 85.2+/-0.6%.	U 0126	6-11	C-C motif chemokine ligand 2	Homo sapiens	94-98
15649404-4	2005	This PKCepsilon-induced IL-6 expression could be completely inhibited by U0126, an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase.	U 0126	73-78	protein kinase C, epsilon	Mus musculus	5-15
15649404-4	2005	This PKCepsilon-induced IL-6 expression could be completely inhibited by U0126, an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase.	U 0126	73-78	interleukin 6	Mus musculus	24-28
15608673-4	2005	Inhibition of B-RAF/MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF.	U 0126	75-80	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	14-19
15608673-4	2005	Inhibition of B-RAF/MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF.	U 0126	75-80	hepatocyte growth factor	Homo sapiens	91-94
15608673-4	2005	Inhibition of B-RAF/MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF.	U 0126	75-80	early growth response 1	Homo sapiens	103-108
15608673-4	2005	Inhibition of B-RAF/MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF.	U 0126	75-80	early growth response 1	Homo sapiens	156-161
15626475-6	2005	In contrast, U0126 decreased p19 and increased TMEV-induced p40 and IFN-beta expression.	U 0126	13-18	interleukin 12b	Mus musculus	60-63
15664394-9	2005	In contrast, both U0126 and LY294002 abolished SMC [(3)H]thymidine incorporation induced by either TNF, PDGF, or both agonists.	U 0126	18-23	tumor necrosis factor	Oryctolagus cuniculus	99-102
15539400-4	2005	Application of VEGF induced a rapid increase in venular permeability, and the effect was blocked by PD98059 and UO126, selective inhibitors of the mitogen-activated protein kinase kinase MEK1/2, in a dose-dependent pattern.	U 0126	112-117	vascular endothelial growth factor A	Homo sapiens	15-19
15539400-4	2005	Application of VEGF induced a rapid increase in venular permeability, and the effect was blocked by PD98059 and UO126, selective inhibitors of the mitogen-activated protein kinase kinase MEK1/2, in a dose-dependent pattern.	U 0126	112-117	mitogen-activated protein kinase kinase 1	Homo sapiens	187-193
15626475-6	2005	In contrast, U0126 decreased p19 and increased TMEV-induced p40 and IFN-beta expression.	U 0126	13-18	interferon beta 1, fibroblast	Mus musculus	68-76
15626475-8	2005	Thus ERK MAPKs regulate expression of TMEV-induced p19 differently than p40 and IFN-beta suggesting the benefits of U0126 in treatment of DD.	U 0126	116-121	mitogen-activated protein kinase 1	Mus musculus	5-8
15572374-3	2005	Cotreatment of hepa1c1c7 cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Erk kinase inhibitor PD98059, U0126, or SL327 led to enhanced nuclear accumulation of Ah receptor but with a reduced capacity to complement TCDD induction of Cyp1a1.	U 0126	113-118	mitogen-activated protein kinase 1	Mus musculus	83-86
15671063-7	2005	This activating effect was suppressed by the MEK1/2 inhibitor U0126.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Homo sapiens	45-51
15671063-11	2005	Importantly, inhibition of Raf/MEK/MAPK signaling by U0126 led to suppression of FOXM1 target gene expression and delayed progression through G2/M, verifying the functional relevance of FOXM1 activation by MEK1.	U 0126	53-58	zinc fingers and homeoboxes 2	Homo sapiens	27-30
15671063-11	2005	Importantly, inhibition of Raf/MEK/MAPK signaling by U0126 led to suppression of FOXM1 target gene expression and delayed progression through G2/M, verifying the functional relevance of FOXM1 activation by MEK1.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
15671063-11	2005	Importantly, inhibition of Raf/MEK/MAPK signaling by U0126 led to suppression of FOXM1 target gene expression and delayed progression through G2/M, verifying the functional relevance of FOXM1 activation by MEK1.	U 0126	53-58	forkhead box M1	Homo sapiens	81-86
15671063-11	2005	Importantly, inhibition of Raf/MEK/MAPK signaling by U0126 led to suppression of FOXM1 target gene expression and delayed progression through G2/M, verifying the functional relevance of FOXM1 activation by MEK1.	U 0126	53-58	forkhead box M1	Homo sapiens	186-191
15671063-11	2005	Importantly, inhibition of Raf/MEK/MAPK signaling by U0126 led to suppression of FOXM1 target gene expression and delayed progression through G2/M, verifying the functional relevance of FOXM1 activation by MEK1.	U 0126	53-58	mitogen-activated protein kinase kinase 1	Homo sapiens	206-210
15569684-6	2005	This process was blocked by the ERK 1/2 inhibitor U0126.	U 0126	50-55	mitogen-activated protein kinase 1	Canis lupus familiaris	32-39
15613280-4	2005	These changes are blocked by the MEK1/2 specific inhibitor U0126, indicating that MEK1/2 is essential for IL-1beta signaling in TT cells.	U 0126	59-64	mitogen-activated protein kinase kinase 1	Homo sapiens	33-39
15613280-4	2005	These changes are blocked by the MEK1/2 specific inhibitor U0126, indicating that MEK1/2 is essential for IL-1beta signaling in TT cells.	U 0126	59-64	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
15613280-4	2005	These changes are blocked by the MEK1/2 specific inhibitor U0126, indicating that MEK1/2 is essential for IL-1beta signaling in TT cells.	U 0126	59-64	interleukin 1 beta	Homo sapiens	106-114
15607817-8	2005	Furthermore, U0126 and LY294002, which respectively inhibit MEK-induced ERK phosphorylation and PI3 kinase-mediated Akt phosphorylation had distinct effects on C3a-induced responses.	U 0126	13-18	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
15607817-8	2005	Furthermore, U0126 and LY294002, which respectively inhibit MEK-induced ERK phosphorylation and PI3 kinase-mediated Akt phosphorylation had distinct effects on C3a-induced responses.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	72-75
15607817-8	2005	Furthermore, U0126 and LY294002, which respectively inhibit MEK-induced ERK phosphorylation and PI3 kinase-mediated Akt phosphorylation had distinct effects on C3a-induced responses.	U 0126	13-18	complement C3	Homo sapiens	160-163
15569684-9	2005	U0126 treatment of MDCK strain I cells decreased active ERK 1/2 levels, induced expression of claudin-2 protein, and decreased TER by approximately 20-fold.	U 0126	0-5	mitogen-activated protein kinase 1	Canis lupus familiaris	56-63
15569684-9	2005	U0126 treatment of MDCK strain I cells decreased active ERK 1/2 levels, induced expression of claudin-2 protein, and decreased TER by approximately 20-fold.	U 0126	0-5	claudin 2	Canis lupus familiaris	94-103
15569684-10	2005	U0126 treatment also induced claudin-2 expression and decreased TER in a high resistance mouse cortical collecting duct cell line (94D).	U 0126	0-5	claudin 2	Mus musculus	29-38
15647742-6	2005	The protein kinase A inhibitor H89, the calcium/calmodulin kinase inhibitor KN62, and the MEK inhibitor U0126 blocked ischemic tolerance, but not the phosphatidylinositol 3-kinase inhibitor LY294002.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	90-93
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	U 0126	142-147	interleukin 1 beta	Homo sapiens	0-8
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	U 0126	142-147	vascular cell adhesion molecule 1	Homo sapiens	31-37
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	U 0126	142-147	mitogen-activated protein kinase kinase 1	Homo sapiens	134-140
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	U 0126	116-121	interleukin 1 beta	Homo sapiens	14-22
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	U 0126	116-121	cyclin dependent kinase 20	Homo sapiens	53-56
15572029-6	2005	LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells.	U 0126	119-124	leukemia inhibitory factor	Mus musculus	41-44
15572029-6	2005	LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells.	U 0126	119-124	mitogen-activated protein kinase kinase 1	Mus musculus	93-99
15572029-6	2005	LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells.	U 0126	119-124	mitogen-activated protein kinase 1	Mus musculus	150-153
15572029-6	2005	LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells.	U 0126	119-124	leukemia inhibitory factor	Mus musculus	41-44
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	U 0126	78-83	interleukin 1 beta	Homo sapiens	4-12
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	U 0126	78-83	intercellular adhesion molecule 1	Homo sapiens	26-32
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	U 0126	78-83	mitogen-activated protein kinase kinase 1	Homo sapiens	120-126
15389584-6	2005	U0126 was more potent than other inhibitors to attenuate IL-1beta-induced ICAM-1 expression.	U 0126	0-5	interleukin 1 beta	Homo sapiens	57-65
15389584-6	2005	U0126 was more potent than other inhibitors to attenuate IL-1beta-induced ICAM-1 expression.	U 0126	0-5	intercellular adhesion molecule 1	Homo sapiens	74-80
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	U 0126	116-121	interleukin 1 beta	Homo sapiens	14-22
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	U 0126	116-121	cyclin dependent kinase 20	Homo sapiens	53-56
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	U 0126	116-121	interferon induced protein 44	Homo sapiens	57-60
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	U 0126	116-121	mitogen-activated protein kinase 1	Homo sapiens	61-65
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	U 0126	116-121	mitogen-activated protein kinase 8	Homo sapiens	70-73
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	U 0126	143-148	interleukin 1 beta	Homo sapiens	14-22
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	U 0126	143-148	nuclear factor kappa B subunit 1	Homo sapiens	51-60
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	U 0126	143-148	NFKB inhibitor alpha	Homo sapiens	97-110
15647742-7	2005	H89, KN62, and U0126 reduced CREB activation and Bcl-2 expression.	U 0126	15-20	cAMP responsive element binding protein 1	Homo sapiens	29-33
15647742-7	2005	H89, KN62, and U0126 reduced CREB activation and Bcl-2 expression.	U 0126	15-20	BCL2 apoptosis regulator	Homo sapiens	49-54
15678124-6	2005	Indeed, the protective effect of OPN was reduced by inhibiting the activation of Akt and p42/p44 MAPK using LY294002 and U0126, respectively.	U 0126	121-126	secreted phosphoprotein 1	Mus musculus	33-36
15860276-5	2005	UO126 (specific inhibitor of MEK 1/2) blocked E2 induced axonal elongation and ERK phosphorylation, confirming the involvement of ERK in the neuritogenic effect of E2.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	29-36
15678124-6	2005	Indeed, the protective effect of OPN was reduced by inhibiting the activation of Akt and p42/p44 MAPK using LY294002 and U0126, respectively.	U 0126	121-126	thymoma viral proto-oncogene 1	Mus musculus	81-84
15678124-6	2005	Indeed, the protective effect of OPN was reduced by inhibiting the activation of Akt and p42/p44 MAPK using LY294002 and U0126, respectively.	U 0126	121-126	cyclin-dependent kinase 20	Mus musculus	89-92
15678124-6	2005	Indeed, the protective effect of OPN was reduced by inhibiting the activation of Akt and p42/p44 MAPK using LY294002 and U0126, respectively.	U 0126	121-126	mitogen-activated protein kinase 3	Mus musculus	93-101
15673293-4	2005	RESULTS: Pretreatment of MEK inhibitor, U0126, decreased ERK1/2 phosphorylation following cisplatin administration with significant functional and histologic protection.	U 0126	40-45	mitogen-activated protein kinase 3	Mus musculus	57-63
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	U 0126	116-121	mitogen-activated protein kinase 3	Homo sapiens	57-65
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	U 0126	116-121	mitogen-activated protein kinase 14	Homo sapiens	67-70
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	U 0126	116-121	mitogen-activated protein kinase 8	Homo sapiens	76-79
15489374-7	2005	Moreover, the resultant enhancement of VCAM-1 expression increased the adhesion of polymorphonuclear cells to a monolayer of HTSMC, which was blocked by pretreatment with helenalin, U0126, SB-202190, or SP-600125 before IL-1beta exposure or by anti-VCAM-1 antibody.	U 0126	182-187	vascular cell adhesion molecule 1	Homo sapiens	39-45
15860276-5	2005	UO126 (specific inhibitor of MEK 1/2) blocked E2 induced axonal elongation and ERK phosphorylation, confirming the involvement of ERK in the neuritogenic effect of E2.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	79-82
15860276-5	2005	UO126 (specific inhibitor of MEK 1/2) blocked E2 induced axonal elongation and ERK phosphorylation, confirming the involvement of ERK in the neuritogenic effect of E2.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	130-133
15796067-4	2005	The amitriptyline-induced GDNF release was completely inhibited by U0126, a mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor, but was not inhibited by H-89, a protein kinase A inhibitor or calphostin C, a protein kinase C inhibitor.	U 0126	67-72	glial cell derived neurotrophic factor	Rattus norvegicus	26-30
15895830-7	2005	The ERK activation and cell death induced by H2O2 was prevented by catalase, the hydrogen peroxide scavenger, and U0126, an inhibitor of ERK upstream kinase MEK1/2.	U 0126	114-119	mitogen-activated protein kinase 1	Homo sapiens	4-7
15895830-7	2005	The ERK activation and cell death induced by H2O2 was prevented by catalase, the hydrogen peroxide scavenger, and U0126, an inhibitor of ERK upstream kinase MEK1/2.	U 0126	114-119	mitogen-activated protein kinase 1	Homo sapiens	137-140
15895830-7	2005	The ERK activation and cell death induced by H2O2 was prevented by catalase, the hydrogen peroxide scavenger, and U0126, an inhibitor of ERK upstream kinase MEK1/2.	U 0126	114-119	mitogen-activated protein kinase kinase 1	Homo sapiens	157-163
15592521-9	2005	Indeed, functional blockade of alphavbeta3, similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G2 phase of the cell cycle and the appearance of sub-G1 hypodiploid (apoptotic) cells caused by Taxol.	U 0126	92-97	cellular communication network factor 1	Homo sapiens	148-153
15680252-6	2005	Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK.	U 0126	59-118	mitogen activated protein kinase 3	Rattus norvegicus	14-25
15680252-6	2005	Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK.	U 0126	59-118	mitogen activated protein kinase 3	Rattus norvegicus	21-25
15680252-6	2005	Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK.	U 0126	59-118	mitogen activated protein kinase 3	Rattus norvegicus	212-223
15680252-6	2005	Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK.	U 0126	120-125	mitogen activated protein kinase 3	Rattus norvegicus	14-25
15680252-6	2005	Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK.	U 0126	120-125	mitogen activated protein kinase 3	Rattus norvegicus	21-25
15525649-11	2005	Inhibition of ERK activation by U0126 or PD98059 significantly decreased EGF-dependent COX-2 expression, but did not affect Ang II-dependent COX-2 expression.	U 0126	32-37	Eph receptor B1	Rattus norvegicus	14-17
15611796-4	2005	The inhibition of Ras-mediated signalling with protein kinase inhibitors, such as PD58059 and U0126 which inhibited MEK and ERK, in T24 cells also rendered the identical phenotypic reversion.	U 0126	94-99	mitogen-activated protein kinase kinase 7	Homo sapiens	116-119
15611796-4	2005	The inhibition of Ras-mediated signalling with protein kinase inhibitors, such as PD58059 and U0126 which inhibited MEK and ERK, in T24 cells also rendered the identical phenotypic reversion.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	124-127
15796067-9	2005	The 5-HT-induced GDNF release was completely inhibited by U0126, but was not inhibited by H-89 or calphostin C.	U 0126	58-63	glial cell derived neurotrophic factor	Rattus norvegicus	17-21
15525649-11	2005	Inhibition of ERK activation by U0126 or PD98059 significantly decreased EGF-dependent COX-2 expression, but did not affect Ang II-dependent COX-2 expression.	U 0126	32-37	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	87-92
16082415-9	2005	Inhibitors of extracellular signal regulated kinases (ERKs), PD98059 or U0126, prevented Na(+),K(+)-ATPase stimulation by leptin and H(2)O(2).	U 0126	72-77	leptin	Rattus norvegicus	122-128
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	mitogen-activated protein kinase 3	Homo sapiens	47-53
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	hypoxia inducible factor 1 subunit alpha	Homo sapiens	94-104
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	ATP binding cassette subfamily B member 1	Homo sapiens	109-123
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	hypoxia inducible factor 1 subunit alpha	Homo sapiens	228-238
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	ATP binding cassette subfamily B member 1	Homo sapiens	243-257
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	mitogen-activated protein kinase 3	Homo sapiens	272-278
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	U 0126	64-69	mitogen-activated protein kinase 8	Homo sapiens	283-286
16302024-4	2005	To shed light on this process, a specific inhibitor of ERK1/2 phosphorylation, U0126, was used.	U 0126	79-84	mitogen-activated protein kinase 3	Homo sapiens	55-61
15589965-4	2005	A specific inhibitor for ERK1/2 activation, U0126, inhibited phenylephrine- and U46619-induced contraction, shifting both concentration-response curves rightward.	U 0126	44-49	mitogen activated protein kinase 3	Rattus norvegicus	25-31
15589965-6	2005	Both phenylephrine and U46619 induced a transient activation of ERK1/2 which was abolished by U0126 but unaffected by a general tyrosine kinase inhibitor genistein or Rho kinase inhibitor Y27632 at concentrations inhibiting more than 50% force.	U 0126	94-99	mitogen activated protein kinase 3	Rattus norvegicus	64-70
15631999-7	2005	By contrast, treatment with PD98059 and U0126, inhibitors for MEK1/2, was less effective.	U 0126	40-45	mitogen activated protein kinase kinase 1	Rattus norvegicus	62-68
15513932-9	2005	Furthermore, the phosphorylation of p90RSK and histone H3 were both antagonized by the MEK inhibitor U0126, implying that SeMet-induced phosphorylation of p90RSK and histone H3 are at least in part ERK pathway dependent.	U 0126	101-106	mitogen-activated protein kinase 1	Homo sapiens	198-201
15664007-11	2005	U0126, a specific inhibitor of the ERK pathway, completely blocked both TGF(beta)- and PGE2-induced cell proliferation whereas SB203580 and SP600125, which are selective inhibitors of, respectively, p38 and JNK pathways, had no effect.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	35-38
15513932-9	2005	Furthermore, the phosphorylation of p90RSK and histone H3 were both antagonized by the MEK inhibitor U0126, implying that SeMet-induced phosphorylation of p90RSK and histone H3 are at least in part ERK pathway dependent.	U 0126	101-106	ribosomal protein S6 kinase A1	Homo sapiens	36-42
15513932-9	2005	Furthermore, the phosphorylation of p90RSK and histone H3 were both antagonized by the MEK inhibitor U0126, implying that SeMet-induced phosphorylation of p90RSK and histone H3 are at least in part ERK pathway dependent.	U 0126	101-106	mitogen-activated protein kinase kinase 7	Homo sapiens	87-90
15513932-9	2005	Furthermore, the phosphorylation of p90RSK and histone H3 were both antagonized by the MEK inhibitor U0126, implying that SeMet-induced phosphorylation of p90RSK and histone H3 are at least in part ERK pathway dependent.	U 0126	101-106	ribosomal protein S6 kinase A1	Homo sapiens	155-161
15355882-5	2005	The ET-1-mediated cell proliferation was inhibited in the presence of U0126, a specific inhibitor of (mitogen-activated protein kinase ERK kinase), indicating that extracellular signal-regulated kinase (ERK) activation is involved.	U 0126	70-75	endothelin 1	Rattus norvegicus	4-8
15355882-5	2005	The ET-1-mediated cell proliferation was inhibited in the presence of U0126, a specific inhibitor of (mitogen-activated protein kinase ERK kinase), indicating that extracellular signal-regulated kinase (ERK) activation is involved.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	135-138
15355882-5	2005	The ET-1-mediated cell proliferation was inhibited in the presence of U0126, a specific inhibitor of (mitogen-activated protein kinase ERK kinase), indicating that extracellular signal-regulated kinase (ERK) activation is involved.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	164-201
15355882-5	2005	The ET-1-mediated cell proliferation was inhibited in the presence of U0126, a specific inhibitor of (mitogen-activated protein kinase ERK kinase), indicating that extracellular signal-regulated kinase (ERK) activation is involved.	U 0126	70-75	Eph receptor B1	Rattus norvegicus	203-206
15654867-6	2005	We show that intra-LA infusions of the MAPK kinase (MEK) inhibitor U0126, a manipulation which inhibits activation of ERK-MAPK, impairs postreactivation long-term memory (PR-LTM) but leaves the postreactivation short-term memory (PR-STM) intact.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
16036314-12	2005	Phosphorylation of eNOS Ser1177 under shear stress was elevated by 20 min, a response that was blocked by PI-3K (phosphatidylinositol 3-kinase) inhibitors wortmannin and LY294002, but not the MEK (MAPK kinase) inhibitor UO126.	U 0126	220-225	nitric oxide synthase 3	Homo sapiens	19-23
15654867-6	2005	We show that intra-LA infusions of the MAPK kinase (MEK) inhibitor U0126, a manipulation which inhibits activation of ERK-MAPK, impairs postreactivation long-term memory (PR-LTM) but leaves the postreactivation short-term memory (PR-STM) intact.	U 0126	67-72	mitogen-activated protein kinase 1	Homo sapiens	118-121
15654867-6	2005	We show that intra-LA infusions of the MAPK kinase (MEK) inhibitor U0126, a manipulation which inhibits activation of ERK-MAPK, impairs postreactivation long-term memory (PR-LTM) but leaves the postreactivation short-term memory (PR-STM) intact.	U 0126	67-72	sulfotransferase family 1A member 3	Homo sapiens	233-236
15569628-7	2005	FSH induced PCNA expression in a time dependent manner, with a maximum stimulation at 2 h. Similarly, StAR and steroid levels increased as FSH treatment time extended, with a maximum progesterone and StAR production at 48 h. ERK1/2 inactivation by UO126 inhibited the stimulatory effects of FSH on both PCNA and StAR expression and steroid synthesis in the GCs (p less than 0.01).	U 0126	248-253	proliferating cell nuclear antigen	Rattus norvegicus	12-16
15569628-7	2005	FSH induced PCNA expression in a time dependent manner, with a maximum stimulation at 2 h. Similarly, StAR and steroid levels increased as FSH treatment time extended, with a maximum progesterone and StAR production at 48 h. ERK1/2 inactivation by UO126 inhibited the stimulatory effects of FSH on both PCNA and StAR expression and steroid synthesis in the GCs (p less than 0.01).	U 0126	248-253	steroidogenic acute regulatory protein	Rattus norvegicus	102-106
15917991-9	2005	ERK 1/2 activation was increased for at least 30 min in cells incubated with MCP-1, and this effect was abolished by U0126 or DPI pretreatment.	U 0126	117-122	mitogen activated protein kinase 3	Rattus norvegicus	0-7
15569628-7	2005	FSH induced PCNA expression in a time dependent manner, with a maximum stimulation at 2 h. Similarly, StAR and steroid levels increased as FSH treatment time extended, with a maximum progesterone and StAR production at 48 h. ERK1/2 inactivation by UO126 inhibited the stimulatory effects of FSH on both PCNA and StAR expression and steroid synthesis in the GCs (p less than 0.01).	U 0126	248-253	mitogen activated protein kinase 3	Rattus norvegicus	225-231
15917991-7	2005	Interestingly, U0126 and PD98059, which inhibit activation of extracellular signal-regulated kinases 1/2 (ERK 1/2), significantly inhibited MCP-1-activated ROS generation.	U 0126	15-20	mitogen activated protein kinase 3	Rattus norvegicus	62-104
15917991-7	2005	Interestingly, U0126 and PD98059, which inhibit activation of extracellular signal-regulated kinases 1/2 (ERK 1/2), significantly inhibited MCP-1-activated ROS generation.	U 0126	15-20	mitogen activated protein kinase 3	Rattus norvegicus	106-113
15917991-9	2005	ERK 1/2 activation was increased for at least 30 min in cells incubated with MCP-1, and this effect was abolished by U0126 or DPI pretreatment.	U 0126	117-122	C-C motif chemokine ligand 2	Rattus norvegicus	77-82
15917991-7	2005	Interestingly, U0126 and PD98059, which inhibit activation of extracellular signal-regulated kinases 1/2 (ERK 1/2), significantly inhibited MCP-1-activated ROS generation.	U 0126	15-20	C-C motif chemokine ligand 2	Rattus norvegicus	140-145
15784961-5	2005	A selective MAPK kinase inhibitor, U0126, blocked the H2O2-induced phosphorylation of Erk1/2 (extracellular signal-regulated kinase) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment.	U 0126	35-40	mitogen activated protein kinase 3	Rattus norvegicus	12-16
15654950-6	2005	Using the MAPK/extracellular signal-regulated kinase kinase 1-specific inhibitor U0126 we could exclude a stimulatory effect of MAPK on MRP gene expression.	U 0126	81-86	mitogen-activated protein kinase 3	Homo sapiens	10-14
16025880-9	2005	This effect peaked at 5 minutes, dissipated by 20 minutes, and was abolished by the inhibitor of ERK phosphorylation, compound U0126, in a dose-dependent manner.	U 0126	127-132	mitogen-activated protein kinase 1	Homo sapiens	97-100
15784961-5	2005	A selective MAPK kinase inhibitor, U0126, blocked the H2O2-induced phosphorylation of Erk1/2 (extracellular signal-regulated kinase) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment.	U 0126	35-40	mitogen activated protein kinase 3	Rattus norvegicus	86-92
15784961-5	2005	A selective MAPK kinase inhibitor, U0126, blocked the H2O2-induced phosphorylation of Erk1/2 (extracellular signal-regulated kinase) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment.	U 0126	35-40	caspase 3	Rattus norvegicus	182-191
15567516-9	2005	BDNF neuroprotection was also preceded by activation of mitogen activated protein kinase (MAPK) and suppressed by two MAPK/ERK (MEK)-selective inhibitors, PD 98059 and U-0126.	U 0126	168-174	brain-derived neurotrophic factor	Rattus norvegicus	0-4
16501318-6	2005	Neuroprotective effect of FBP 3.5 mM against Abeta induced neurotoxicity in hippocampal slices was attenuated by addition of phospholipase C (PLC) inhibitor, U73122, mitogen activated extracellular signal protein kinase (MEK) inhibitor, U0126, or extracellular signal activated protein kinase (ERK) inhibitor, PD98059 at 24 h, 48 h and 72 h. However, co-treatment with these three kinds of inhibitors did not change the FBP"s effect on ATP levels.	U 0126	237-242	far upstream element binding protein 1	Rattus norvegicus	26-29
15786722-10	2005	It was also observed that apoptosis was induced when U0126, an MEK inhibitor, was added to the cells to inhibit ERK.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
15786722-10	2005	It was also observed that apoptosis was induced when U0126, an MEK inhibitor, was added to the cells to inhibit ERK.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	112-115
15627804-7	2005	Also the MEK1/2 inhibitors PD98059 and U0126, and the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 decreased 3H-taurocholate uptake.	U 0126	39-44	mitogen activated protein kinase kinase 1	Rattus norvegicus	9-15
15585341-6	2005	By contrast, inhibition of the ERK pathway with U0126 did not appreciably affect either outcome measure.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	31-34
15623602-8	2004	Additional analyses using LY294002 and U0126 indicated that the increase in hypoxia-inducible factor 1 (HIF-1)alpha protein level was highly dependent on phosphatidylinositol 3"-kinase and p42/p44 mitogen-activated protein kinase activities in hypoxic MDA-MB-468 cells.	U 0126	39-44	hypoxia inducible factor 1 subunit alpha	Homo sapiens	104-115
15868656-4	2005	Pre-incubation of both cell types with the mitogen-activated protein kinase kinase (MEK) inhibitors U0126 and PD98059 reduced LH-induced steroidogenesis, and tonically enhanced the expression of the StAR protein.	U 0126	100-105	midkine	Mus musculus	43-82
15868656-4	2005	Pre-incubation of both cell types with the mitogen-activated protein kinase kinase (MEK) inhibitors U0126 and PD98059 reduced LH-induced steroidogenesis, and tonically enhanced the expression of the StAR protein.	U 0126	100-105	midkine	Mus musculus	84-87
15868656-4	2005	Pre-incubation of both cell types with the mitogen-activated protein kinase kinase (MEK) inhibitors U0126 and PD98059 reduced LH-induced steroidogenesis, and tonically enhanced the expression of the StAR protein.	U 0126	100-105	steroidogenic acute regulatory protein	Mus musculus	199-203
20021069-8	2005	MAP Kinase Kinase (MEK) inhibitor U0126 prevented Egr-1 induction by silica.	U 0126	34-39	early growth response 1	Mus musculus	50-55
15456914-4	2005	TBBPA induced activation of respiratory burst was also inhibited by the MEK 1/2 inhibitor U0126 (10 microM), the PKC inhibitor BIM (0.25 microM), and the tyrosine kinase inhibitor erbstatin-A (25 microM).	U 0126	90-95	mitogen-activated protein kinase kinase 1	Homo sapiens	72-79
15837125-4	2005	Pretreatment of cells with protein kinase A (PKA) inhibitor or U0126 substantially suppressed the sargachromenol-enhanced neurite outgrowth from PC12D cells, suggesting that the activation of cyclic AMP-mediated protein kinase and mitogen-activated protein (MAP) kinase 1/2 was apparently required for the action of sargachromenol.	U 0126	63-68	mitogen activated protein kinase 1	Rattus norvegicus	231-273
15590919-6	2004	Furthermore, the stress effects were obviated by the intrahippocampal injection of specific inhibitors of MEK1/2 (U0126), protein kinase C (bisindolylmaleimide I), tyrosine kinase (K252a), and BDNF antisense oligonucleotides.	U 0126	114-119	mitogen activated protein kinase kinase 1	Rattus norvegicus	106-112
15355987-9	2004	Activation of NHE1 by zinc was totally blocked by the ERK1/2 inhibitor, U0126.	U 0126	72-77	solute carrier family 9 member A1	Homo sapiens	14-18
15355987-9	2004	Activation of NHE1 by zinc was totally blocked by the ERK1/2 inhibitor, U0126.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	54-60
15308507-8	2004	Inhibition of ERK with the MAP kinase kinase 1/2 inhibitor, U0126, shortens the survival time of cells in hyperoxia, suggesting that increased ERK activity partially compensates for the hyperoxia-induced Akt downregulation.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	14-17
15375172-8	2004	Pretreatment by U0126 (30 microM), a MEK inhibitor, markedly inhibited the c-Fos, cyclooxygenase-2 (COX-2), and IL-6 mRNA expression of the KB epithelial cells.	U 0126	16-21	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
15317664-9	2004	U0126 (10 muM) completely inhibited carbachol-induced ERK1/2 MAPK phosphorylation but did not significantly affect carbachol-induced upregulation of GAPDH and SMA expression, suggesting that the ERK1/2 MAPK pathway was not the underlying mechanism.	U 0126	0-5	mitogen-activated protein kinase 3	Bos taurus	54-60
15317664-9	2004	U0126 (10 muM) completely inhibited carbachol-induced ERK1/2 MAPK phosphorylation but did not significantly affect carbachol-induced upregulation of GAPDH and SMA expression, suggesting that the ERK1/2 MAPK pathway was not the underlying mechanism.	U 0126	0-5	mitogen-activated protein kinase 1	Bos taurus	61-65
15317664-9	2004	U0126 (10 muM) completely inhibited carbachol-induced ERK1/2 MAPK phosphorylation but did not significantly affect carbachol-induced upregulation of GAPDH and SMA expression, suggesting that the ERK1/2 MAPK pathway was not the underlying mechanism.	U 0126	0-5	mitogen-activated protein kinase 3	Bos taurus	195-201
15317664-9	2004	U0126 (10 muM) completely inhibited carbachol-induced ERK1/2 MAPK phosphorylation but did not significantly affect carbachol-induced upregulation of GAPDH and SMA expression, suggesting that the ERK1/2 MAPK pathway was not the underlying mechanism.	U 0126	0-5	mitogen-activated protein kinase 1	Bos taurus	202-206
15308507-8	2004	Inhibition of ERK with the MAP kinase kinase 1/2 inhibitor, U0126, shortens the survival time of cells in hyperoxia, suggesting that increased ERK activity partially compensates for the hyperoxia-induced Akt downregulation.	U 0126	60-65	mitogen-activated protein kinase kinase 2	Homo sapiens	27-48
15308507-8	2004	Inhibition of ERK with the MAP kinase kinase 1/2 inhibitor, U0126, shortens the survival time of cells in hyperoxia, suggesting that increased ERK activity partially compensates for the hyperoxia-induced Akt downregulation.	U 0126	60-65	mitogen-activated protein kinase 1	Homo sapiens	143-146
15308507-8	2004	Inhibition of ERK with the MAP kinase kinase 1/2 inhibitor, U0126, shortens the survival time of cells in hyperoxia, suggesting that increased ERK activity partially compensates for the hyperoxia-induced Akt downregulation.	U 0126	60-65	AKT serine/threonine kinase 1	Homo sapiens	204-207
15477222-4	2004	We examined the effect of selective MAPK inhibitors, SB239063 (a p38 MAPK inhibitor), U0126 (a mitogen-activated and extracellular regulated kinase kinase, MEK-1, inhibitor which inhibits downstream extracellular regulated kinase, ERK, activity), and SP600125 (a c-jun N-terminal kinase, JNK, inhibitor) on IL-1beta-induced proliferation.	U 0126	86-91	mitogen activated protein kinase kinase 1	Rattus norvegicus	156-161
15498512-6	2004	Moreover, the EGFR receptor-selective tyrosine kinase inhibitor AG1478 and mitogen activated kinase kinase inhibitor U0126 blocked growth factor-mediated Cdc25B induction.	U 0126	117-122	cell division cycle 25B	Homo sapiens	154-160
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	U 0126	10-15	interleukin 1 beta	Rattus norvegicus	56-64
15319299-9	2004	Pre-treatment with specific mitogen-activated protein kinase kinase (MEK) inhibitors (U0126 or PD98059) attenuated COX-2 expression and subsequent PGE(2) release by nicotine.	U 0126	86-91	prostaglandin-endoperoxide synthase 2	Mus musculus	115-120
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	U 0126	10-15	mitogen activated protein kinase 14	Rattus norvegicus	129-132
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	U 0126	10-15	Eph receptor B1	Rattus norvegicus	134-137
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	U 0126	10-15	mitogen-activated protein kinase 8	Rattus norvegicus	142-145
15319299-10	2004	Furthermore, the stimulatory action of nicotine on cancer cell growth and angiogenic factor VEGF production was suppressed by inhibitors of MEK (U0126) and COX-2 (SC-236).	U 0126	145-150	vascular endothelial growth factor A	Mus musculus	92-96
15669185-0	2004	U0126 prevents ERK pathway phosphorylation and interleukin-1beta mRNA production after cerebral ischemia.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	15-18
15669185-0	2004	U0126 prevents ERK pathway phosphorylation and interleukin-1beta mRNA production after cerebral ischemia.	U 0126	0-5	interleukin 1 beta	Mus musculus	47-64
15669185-6	2004	RESULTS: Phosphorylated ERK1/2 in 2 hours MCAO mice was down-regulated after intravenous injection of U0126.	U 0126	102-107	mitogen-activated protein kinase 3	Mus musculus	24-30
15669185-11	2004	CONCLUSION: Intravenous administration of the MEK inhibitor U0126 inhibits pMEK, pERK1/2, and pElk-1 up-regulation induced by cerebral ischemia.	U 0126	60-65	midkine	Mus musculus	46-49
15669185-12	2004	The protective effect of U0126 against ischemic injury is probably resulted from the reduction of IL-1beta mRNA via the inhibition of ERK pathway.	U 0126	25-30	interleukin 1 beta	Mus musculus	98-106
15669185-12	2004	The protective effect of U0126 against ischemic injury is probably resulted from the reduction of IL-1beta mRNA via the inhibition of ERK pathway.	U 0126	25-30	mitogen-activated protein kinase 1	Mus musculus	134-137
15579142-3	2004	Treatment with the MAPK kinase 1/2 inhibitor, U0126, suppressed CCI-induced mechanical allodynia and partially reversed the increase in neuropeptide Y (NPY) expression in damaged DRG neurons.	U 0126	46-51	neuropeptide Y	Rattus norvegicus	136-150
15579142-3	2004	Treatment with the MAPK kinase 1/2 inhibitor, U0126, suppressed CCI-induced mechanical allodynia and partially reversed the increase in neuropeptide Y (NPY) expression in damaged DRG neurons.	U 0126	46-51	neuropeptide Y	Rattus norvegicus	152-155
15579142-6	2004	On the other hand, the nerve growth factor (NGF)-induced increase in BDNF expression in small-to-medium-diameter neurons was reversed by SB203580, whereas the anti-NGF-induced increase in NPY in medium-sized and large-sized neurons was partially blocked by U0126.	U 0126	257-262	brain-derived neurotrophic factor	Rattus norvegicus	69-73
15547692-5	2004	However, U0126 (a MEK1/2 inhibitor) treatment apparently induced the plasma membrane distribution of claudin-1 and aggregation of single cells in PC-1.0 and AsPC-1 cells, synchronously seriously suppressed MEK2 and p-MEK1/2 expression.	U 0126	9-14	mitogen-activated protein kinase kinase 1	Homo sapiens	18-24
15547692-5	2004	However, U0126 (a MEK1/2 inhibitor) treatment apparently induced the plasma membrane distribution of claudin-1 and aggregation of single cells in PC-1.0 and AsPC-1 cells, synchronously seriously suppressed MEK2 and p-MEK1/2 expression.	U 0126	9-14	claudin 1	Homo sapiens	101-110
15547725-8	2004	Treatment of HepG2 cells with MEK1/2 inhibitor U0126 resulted in cell cycle arrest, downregulation of cyclin D1 and Cdk-2 expression and inhibition of pRB phosphorylation at Ser780 and Ser795.	U 0126	47-52	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
15547725-8	2004	Treatment of HepG2 cells with MEK1/2 inhibitor U0126 resulted in cell cycle arrest, downregulation of cyclin D1 and Cdk-2 expression and inhibition of pRB phosphorylation at Ser780 and Ser795.	U 0126	47-52	cyclin D1	Homo sapiens	102-111
15547692-5	2004	However, U0126 (a MEK1/2 inhibitor) treatment apparently induced the plasma membrane distribution of claudin-1 and aggregation of single cells in PC-1.0 and AsPC-1 cells, synchronously seriously suppressed MEK2 and p-MEK1/2 expression.	U 0126	9-14	mitogen-activated protein kinase kinase 2	Homo sapiens	206-210
15547725-8	2004	Treatment of HepG2 cells with MEK1/2 inhibitor U0126 resulted in cell cycle arrest, downregulation of cyclin D1 and Cdk-2 expression and inhibition of pRB phosphorylation at Ser780 and Ser795.	U 0126	47-52	cyclin dependent kinase 2	Homo sapiens	116-121
15547692-5	2004	However, U0126 (a MEK1/2 inhibitor) treatment apparently induced the plasma membrane distribution of claudin-1 and aggregation of single cells in PC-1.0 and AsPC-1 cells, synchronously seriously suppressed MEK2 and p-MEK1/2 expression.	U 0126	9-14	mitogen-activated protein kinase kinase 1	Homo sapiens	217-223
15547725-8	2004	Treatment of HepG2 cells with MEK1/2 inhibitor U0126 resulted in cell cycle arrest, downregulation of cyclin D1 and Cdk-2 expression and inhibition of pRB phosphorylation at Ser780 and Ser795.	U 0126	47-52	RB transcriptional corepressor 1	Homo sapiens	151-154
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	midkine	Mus musculus	0-3
15322069-6	2004	The effect of TNF-alpha was completely blocked by pretreatment with U-0126 or cycloheximide, but not with SB-203580.	U 0126	68-74	tumor necrosis factor	Rattus norvegicus	14-23
15322069-8	2004	Furthermore, the TNF-alpha-induced upregulation of RhoA protein was abolished by U-0126 pretreatment.	U 0126	81-87	tumor necrosis factor	Rattus norvegicus	17-26
15322069-8	2004	Furthermore, the TNF-alpha-induced upregulation of RhoA protein was abolished by U-0126 pretreatment.	U 0126	81-87	ras homolog family member A	Rattus norvegicus	51-55
15743030-0	2004	A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.	U 0126	17-22	mitogen-activated protein kinase kinase 7	Homo sapiens	2-5
15569266-5	2004	The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126.	U 0126	133-138	adenylate cyclase activating polypeptide 1	Homo sapiens	31-36
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	matrix metallopeptidase 2	Mus musculus	63-68
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	matrix metallopeptidase 9	Mus musculus	70-75
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	plasminogen activator, urokinase	Mus musculus	88-91
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	tissue inhibitor of metalloproteinase 1	Mus musculus	116-122
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	tissue inhibitor of metalloproteinase 2	Mus musculus	124-130
15743030-4	2004	MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3).	U 0126	28-33	tissue inhibitor of metalloproteinase 3	Mus musculus	135-141
15743030-11	2004	The present results suggest that a MEK inhibitor, U0126, prolonged the survival of the mice with NOZ tumor by inhibiting direct liver invasion and vessel invasion of the cancer cells via down-regulation of the matrix degrading ability of the cancer cells.	U 0126	50-55	midkine	Mus musculus	35-38
15569266-5	2004	The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126.	U 0126	133-138	BCL2 associated X, apoptosis regulator	Homo sapiens	40-43
15569266-5	2004	The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126.	U 0126	133-138	BCL2 apoptosis regulator	Homo sapiens	48-53
15569266-5	2004	The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126.	U 0126	133-138	mitogen-activated protein kinase kinase 7	Homo sapiens	119-122
15584918-8	2004	The effect of CGRP on gene transcription was inhibited by H89, myristoylated-protein kinase A inhibitor(14-22)-amide and U0126, indicating that protein kinase A and mitogen-activated protein kinase/extracellular receptor kinase kinase are enzymes that mediate effects of CGRP on gene transcription.	U 0126	121-126	calcitonin related polypeptide alpha	Homo sapiens	14-18
15569266-6	2004	L-JNKI1 prevented the alteration of mitochondria induced by C2-ceramide while U0126 suppressed the protective effect of PACAP against the deleterious action of C2-ceramide on mitochondrial potential.	U 0126	78-83	adenylate cyclase activating polypeptide 1	Homo sapiens	120-125
15569266-8	2004	U0126 blocked PACAP-induced Bcl-2 expression, abrogated the inhibitory effect of PACAP on ceramide-induced caspase-9 activity, and promoted granule cell death.	U 0126	0-5	adenylate cyclase activating polypeptide 1	Homo sapiens	14-19
15569266-8	2004	U0126 blocked PACAP-induced Bcl-2 expression, abrogated the inhibitory effect of PACAP on ceramide-induced caspase-9 activity, and promoted granule cell death.	U 0126	0-5	BCL2 apoptosis regulator	Homo sapiens	28-33
15569266-8	2004	U0126 blocked PACAP-induced Bcl-2 expression, abrogated the inhibitory effect of PACAP on ceramide-induced caspase-9 activity, and promoted granule cell death.	U 0126	0-5	adenylate cyclase activating polypeptide 1	Homo sapiens	81-86
15569266-8	2004	U0126 blocked PACAP-induced Bcl-2 expression, abrogated the inhibitory effect of PACAP on ceramide-induced caspase-9 activity, and promoted granule cell death.	U 0126	0-5	caspase 9	Homo sapiens	107-116
15663199-7	2004	Downstream signaling routes involve mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK) and p38 MAPK, as Gal-1 expression was prevented by U0126 and SB202190.	U 0126	185-190	mitogen-activated protein kinase 1	Homo sapiens	70-74
15555922-7	2004	Preventing Akt activation with the phosphatidylinositol-3 (PI-3) kinase inhibitor LY294002 blocked the HGF survival response, and inhibition of ERK activation with the MEK inhibitors PD98059 or U0126 reduced the HGF survival response and the neurite growth-promoting effects of HGF.	U 0126	194-199	thymoma viral proto-oncogene 1	Mus musculus	11-14
15663199-7	2004	Downstream signaling routes involve mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK) and p38 MAPK, as Gal-1 expression was prevented by U0126 and SB202190.	U 0126	185-190	mitogen-activated protein kinase kinase 1	Homo sapiens	84-89
15663199-7	2004	Downstream signaling routes involve mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK) and p38 MAPK, as Gal-1 expression was prevented by U0126 and SB202190.	U 0126	185-190	galectin 1	Homo sapiens	151-156
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	ATP binding cassette subfamily B member 1	Homo sapiens	322-327
15474610-5	2004	Western blot analysis demonstrated that cisplatin treatment induced time-dependent activation of ERK, which was inhibited by chemical inhibitors of the MEK signaling pathway (PD98059 and U0126) and N-acetylcysteine.	U 0126	187-192	mitogen-activated protein kinase 1	Homo sapiens	97-100
15474610-5	2004	Western blot analysis demonstrated that cisplatin treatment induced time-dependent activation of ERK, which was inhibited by chemical inhibitors of the MEK signaling pathway (PD98059 and U0126) and N-acetylcysteine.	U 0126	187-192	mitogen-activated protein kinase kinase 1	Homo sapiens	152-155
15672554-6	2004	NT-4 stimulated the phosphorylation of ERK1/2 and this phosphorylation was attenuated by U0126 and PD098059.	U 0126	89-94	neurotrophin 4	Homo sapiens	0-4
15672554-6	2004	NT-4 stimulated the phosphorylation of ERK1/2 and this phosphorylation was attenuated by U0126 and PD098059.	U 0126	89-94	mitogen-activated protein kinase 3	Homo sapiens	39-45
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	ATP binding cassette subfamily B member 1	Homo sapiens	50-55
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	ATP binding cassette subfamily C member 1	Homo sapiens	335-340
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	ATP binding cassette subfamily C member 1	Homo sapiens	70-75
15504369-9	2004	TGF-beta production was completely inhibited by U0126, a specific inhibitor for ERK.	U 0126	48-53	transforming growth factor, beta 1	Mus musculus	0-8
15526378-14	2004	Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%).	U 0126	137-142	major vault protein	Homo sapiens	100-103
15504369-9	2004	TGF-beta production was completely inhibited by U0126, a specific inhibitor for ERK.	U 0126	48-53	mitogen-activated protein kinase 1	Mus musculus	80-83
15548677-3	2004	We previously reported that sulindac metabolites inhibit the mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling cascade in colorectal cancer cell lines at doses that induce apoptosis, and inhibition of MEK/ERK activity with U0126 is sufficient to induce apoptotic cell death.	U 0126	302-307	mitogen-activated protein kinase kinase 7	Homo sapiens	171-174
15545519-9	2004	U0126, a specific inhibitor of ERK phosphorylation, significantly inhibited ERK 1/2 phosphorylation and reduced resistin-simulated proliferation of HASMCs.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	31-34
15545519-9	2004	U0126, a specific inhibitor of ERK phosphorylation, significantly inhibited ERK 1/2 phosphorylation and reduced resistin-simulated proliferation of HASMCs.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	76-83
15347670-7	2004	Blocking the action of ERK with U0126 inhibited the induction of p21Cip/WAK-1, suggesting that ERK activation functions upstream of p21Cip/WAK-1 activation to initiate the CSE overexpression-induced cell growth inhibition.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	23-26
15347670-7	2004	Blocking the action of ERK with U0126 inhibited the induction of p21Cip/WAK-1, suggesting that ERK activation functions upstream of p21Cip/WAK-1 activation to initiate the CSE overexpression-induced cell growth inhibition.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	95-98
15347670-7	2004	Blocking the action of ERK with U0126 inhibited the induction of p21Cip/WAK-1, suggesting that ERK activation functions upstream of p21Cip/WAK-1 activation to initiate the CSE overexpression-induced cell growth inhibition.	U 0126	32-37	cystathionine gamma-lyase	Homo sapiens	172-175
15548677-3	2004	We previously reported that sulindac metabolites inhibit the mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling cascade in colorectal cancer cell lines at doses that induce apoptosis, and inhibition of MEK/ERK activity with U0126 is sufficient to induce apoptotic cell death.	U 0126	302-307	mitogen-activated protein kinase 1	Homo sapiens	175-178
15389877-5	2004	Moreover, inhibition of Akt or ERK activity with respectively a PI-3K inhibitor (LY294002) or MEK inhibitors (PD98059, UO126), partially or totally suppressed the anti-apoptotic capacity of 1,25(OH)2D3.	U 0126	119-124	AKT serine/threonine kinase 1	Homo sapiens	24-27
15389877-5	2004	Moreover, inhibition of Akt or ERK activity with respectively a PI-3K inhibitor (LY294002) or MEK inhibitors (PD98059, UO126), partially or totally suppressed the anti-apoptotic capacity of 1,25(OH)2D3.	U 0126	119-124	mitogen-activated protein kinase 1	Homo sapiens	31-34
15389877-5	2004	Moreover, inhibition of Akt or ERK activity with respectively a PI-3K inhibitor (LY294002) or MEK inhibitors (PD98059, UO126), partially or totally suppressed the anti-apoptotic capacity of 1,25(OH)2D3.	U 0126	119-124	mitogen-activated protein kinase kinase 7	Homo sapiens	94-97
15486316-5	2004	Antagonists of EGFR phosphotyrosine activity (AG-1478) and ERK phosphorylation (PD-98059, U-0126) abolished phenylephrine-induced protein synthesis, whereas antagonists of p38 or JNK phosphorylation had no specific effect.	U 0126	90-96	epidermal growth factor receptor	Rattus norvegicus	15-19
15528359-2	2004	Suppression of MAPK kinase (MEK1) by the reagent UO126 in activated T cells maintained in the cytokine IL-2 disrupts cytoplasmic localization of Bax and cell survival.	U 0126	49-54	mitogen-activated protein kinase kinase 1	Homo sapiens	28-32
15528359-2	2004	Suppression of MAPK kinase (MEK1) by the reagent UO126 in activated T cells maintained in the cytokine IL-2 disrupts cytoplasmic localization of Bax and cell survival.	U 0126	49-54	interleukin 2	Homo sapiens	103-107
15528359-2	2004	Suppression of MAPK kinase (MEK1) by the reagent UO126 in activated T cells maintained in the cytokine IL-2 disrupts cytoplasmic localization of Bax and cell survival.	U 0126	49-54	BCL2 associated X, apoptosis regulator	Homo sapiens	145-148
15528359-3	2004	UO126 triggers mitochondrial translocation of ectopically expressed Bax-GFP, and both UO126 and dominant negative MEK-1 (DN-MEK1) trigger increased apoptosis in Bax-GFP-expressing T cell lines.	U 0126	0-5	BCL2 associated X, apoptosis regulator	Homo sapiens	68-71
15269004-6	2004	U0126 (10 microM) completely inhibited carbachol-induced ERK1/2 phosphorylation but did not significantly affect the correlation between alpha-actinin P/S and carbachol concentration.	U 0126	0-5	mitogen-activated protein kinase 3	Bos taurus	57-63
15537881-5	2004	Post-training intra-EC infusion of ERK cascade inhibitors (PD098059, UO126) at 40 min, but not at 10 min, resulted in increased freezing to the context, but not to the tone, during a 48 hr retention test.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	35-38
15331595-5	2004	Inhibition of ERK activation by the MEK inhibitor, U0126, stimulated VDR activity in MC3T3-E1 cells, but inhibited the activity in MG-63 cells as well as in HeLa cells.	U 0126	51-56	mitogen-activated protein kinase 1	Mus musculus	14-17
15331595-5	2004	Inhibition of ERK activation by the MEK inhibitor, U0126, stimulated VDR activity in MC3T3-E1 cells, but inhibited the activity in MG-63 cells as well as in HeLa cells.	U 0126	51-56	midkine	Mus musculus	36-39
15331595-5	2004	Inhibition of ERK activation by the MEK inhibitor, U0126, stimulated VDR activity in MC3T3-E1 cells, but inhibited the activity in MG-63 cells as well as in HeLa cells.	U 0126	51-56	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	69-72
15265761-8	2004	Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression.	U 0126	18-24	mitogen-activated protein kinase kinase 1	Homo sapiens	28-34
15265761-8	2004	Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression.	U 0126	18-24	transforming growth factor beta 1	Homo sapiens	83-92
15265761-8	2004	Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression.	U 0126	18-24	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	146-151
15265761-8	2004	Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression.	U 0126	18-24	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	153-158
15519527-4	2004	Treatment with the mitogen-activated protein kinase/extracellular signal-related kinase (MEK) inhibitor U0126 reduced expression of VEGF and IL-8 in MDA-MB-231 cells, partially inhibited expression in MDA-MB-468 and Hs578T cells, with minimal effects in GI101A cells.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	19-87
15265761-8	2004	Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression.	U 0126	18-24	fibronectin 1	Homo sapiens	164-175
15546477-6	2004	Cyclooxygenase-2 expression was significantly inhibited by U0126 but was not affected by SB203580.	U 0126	59-64	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	0-16
15284194-7	2004	During oocyte maturation, leptin increased phosphorylated MAPK content by 2.8-fold (P &lt; 0.05), and leptin-stimulated oocyte maturation was blocked when leptin-induced MAPK phosphorylation was suppressed by a specific MAPK activation inhibitor, U0126 (P &lt; 0.01), demonstrating that leptin enhances nuclear maturation via activation of the MAPK pathway.	U 0126	247-252	leptin	Homo sapiens	26-32
15284194-7	2004	During oocyte maturation, leptin increased phosphorylated MAPK content by 2.8-fold (P &lt; 0.05), and leptin-stimulated oocyte maturation was blocked when leptin-induced MAPK phosphorylation was suppressed by a specific MAPK activation inhibitor, U0126 (P &lt; 0.01), demonstrating that leptin enhances nuclear maturation via activation of the MAPK pathway.	U 0126	247-252	leptin	Homo sapiens	102-108
15284194-7	2004	During oocyte maturation, leptin increased phosphorylated MAPK content by 2.8-fold (P &lt; 0.05), and leptin-stimulated oocyte maturation was blocked when leptin-induced MAPK phosphorylation was suppressed by a specific MAPK activation inhibitor, U0126 (P &lt; 0.01), demonstrating that leptin enhances nuclear maturation via activation of the MAPK pathway.	U 0126	247-252	leptin	Homo sapiens	102-108
15284194-7	2004	During oocyte maturation, leptin increased phosphorylated MAPK content by 2.8-fold (P &lt; 0.05), and leptin-stimulated oocyte maturation was blocked when leptin-induced MAPK phosphorylation was suppressed by a specific MAPK activation inhibitor, U0126 (P &lt; 0.01), demonstrating that leptin enhances nuclear maturation via activation of the MAPK pathway.	U 0126	247-252	leptin	Homo sapiens	102-108
15519527-4	2004	Treatment with the mitogen-activated protein kinase/extracellular signal-related kinase (MEK) inhibitor U0126 reduced expression of VEGF and IL-8 in MDA-MB-231 cells, partially inhibited expression in MDA-MB-468 and Hs578T cells, with minimal effects in GI101A cells.	U 0126	104-109	mitogen-activated protein kinase kinase 7	Homo sapiens	89-92
15519527-4	2004	Treatment with the mitogen-activated protein kinase/extracellular signal-related kinase (MEK) inhibitor U0126 reduced expression of VEGF and IL-8 in MDA-MB-231 cells, partially inhibited expression in MDA-MB-468 and Hs578T cells, with minimal effects in GI101A cells.	U 0126	104-109	vascular endothelial growth factor A	Homo sapiens	132-136
15519527-4	2004	Treatment with the mitogen-activated protein kinase/extracellular signal-related kinase (MEK) inhibitor U0126 reduced expression of VEGF and IL-8 in MDA-MB-231 cells, partially inhibited expression in MDA-MB-468 and Hs578T cells, with minimal effects in GI101A cells.	U 0126	104-109	C-X-C motif chemokine ligand 8	Homo sapiens	141-145
15522841-5	2004	Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor, U0126, could abolish the LDL-mediated inhibition of PLTP secretion.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
15371330-9	2004	Inhibition of ERK by U0126 decreased caspase-3 activity, whereas AC-DEVD-CHO did not alter ERK activity.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	14-17
15371330-9	2004	Inhibition of ERK by U0126 decreased caspase-3 activity, whereas AC-DEVD-CHO did not alter ERK activity.	U 0126	21-26	caspase 3	Homo sapiens	37-46
15522841-5	2004	Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor, U0126, could abolish the LDL-mediated inhibition of PLTP secretion.	U 0126	64-69	phospholipid transfer protein	Homo sapiens	116-120
15824471-7	2004	HGF also stimulated Akt phosphorylation (Ser-473), which was completely suppressed by LY294002 and was partially suppressed by U0126.	U 0126	127-132	hepatocyte growth factor	Bos taurus	0-3
15501794-3	2004	Subsequent interleukin-8 (IL-8) expression was dependent on p38-MAPK and ERK1/2 activation as demonstrated by preincubation of endothelial cells with specific inhibitors for the p38-MAPK (SB202190) or ERK (U0126) pathway.	U 0126	206-211	mitogen-activated protein kinase 1	Homo sapiens	60-63
15501794-3	2004	Subsequent interleukin-8 (IL-8) expression was dependent on p38-MAPK and ERK1/2 activation as demonstrated by preincubation of endothelial cells with specific inhibitors for the p38-MAPK (SB202190) or ERK (U0126) pathway.	U 0126	206-211	mitogen-activated protein kinase 1	Homo sapiens	178-181
15824471-7	2004	HGF also stimulated Akt phosphorylation (Ser-473), which was completely suppressed by LY294002 and was partially suppressed by U0126.	U 0126	127-132	AKT serine/threonine kinase 1	Bos taurus	20-23
15824471-8	2004	Moreover, HGF stimulated extracellular signal-regulated kinase 1/2 phosphorylation (Thr-202/Tyr-204), which was completely suppressed by U0126 and was partially suppressed by LY294002.	U 0126	137-142	hepatocyte growth factor	Bos taurus	10-13
15824471-8	2004	Moreover, HGF stimulated extracellular signal-regulated kinase 1/2 phosphorylation (Thr-202/Tyr-204), which was completely suppressed by U0126 and was partially suppressed by LY294002.	U 0126	137-142	mitogen-activated protein kinase 3	Bos taurus	25-64
15331624-4	2004	Pharmacological suppression of p38 or ERK1/2 MAPK with specific inhibitors (SB203580, SB202190, U0126, or PD98059) significantly attenuated LPS-induced TNF production but failed to inhibit LPS-induced HMGB1 release.	U 0126	96-101	mitogen-activated protein kinase 14	Mus musculus	31-34
15536411-12	2004	Treatment with PD98059 and UO126 (specific mitogen-activated protein kinase kinase [MEK]/ERK inhibitors), but not a p38 inhibitor or a c-Jun N-terminal kinase inhibitor, restored the response to steroids, as indicated by proliferation assays.	U 0126	27-32	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
15536411-12	2004	Treatment with PD98059 and UO126 (specific mitogen-activated protein kinase kinase [MEK]/ERK inhibitors), but not a p38 inhibitor or a c-Jun N-terminal kinase inhibitor, restored the response to steroids, as indicated by proliferation assays.	U 0126	27-32	mitogen-activated protein kinase 1	Homo sapiens	89-92
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	transforming growth factor beta 1	Homo sapiens	10-18
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	mitogen-activated protein kinase 3	Homo sapiens	29-35
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-112
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	mitogen-activated protein kinase kinase 1	Homo sapiens	159-179
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	mitogen-activated protein kinase kinase 1	Homo sapiens	239-245
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	transforming growth factor beta 1	Homo sapiens	278-286
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	325-330
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	335-340
15660418-9	2004	Inhibition of the ERK pathway by PD98059 and U0126 inhibited proliferation but did not inhibit migration.	U 0126	45-50	mitogen-activated protein kinase 1	Mus musculus	18-21
15331624-4	2004	Pharmacological suppression of p38 or ERK1/2 MAPK with specific inhibitors (SB203580, SB202190, U0126, or PD98059) significantly attenuated LPS-induced TNF production but failed to inhibit LPS-induced HMGB1 release.	U 0126	96-101	mitogen-activated protein kinase 3	Mus musculus	38-44
15331624-4	2004	Pharmacological suppression of p38 or ERK1/2 MAPK with specific inhibitors (SB203580, SB202190, U0126, or PD98059) significantly attenuated LPS-induced TNF production but failed to inhibit LPS-induced HMGB1 release.	U 0126	96-101	mitogen-activated protein kinase 1	Mus musculus	45-49
15331624-4	2004	Pharmacological suppression of p38 or ERK1/2 MAPK with specific inhibitors (SB203580, SB202190, U0126, or PD98059) significantly attenuated LPS-induced TNF production but failed to inhibit LPS-induced HMGB1 release.	U 0126	96-101	tumor necrosis factor	Mus musculus	152-155
15451430-8	2004	Inhibition of ERK 1/2 phosphorylation (U0126) prevented the increases in growth and TIMP-1 expression.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	14-21
15292274-8	2004	However, U0126, which prevented the phosphorylation of Erk1/2, ribosomal protein S6, TSC2, and 4E-BP1, attenuated de novo protein synthesis in recovering cells.	U 0126	9-14	mitogen-activated protein kinase 3	Homo sapiens	55-61
15292274-8	2004	However, U0126, which prevented the phosphorylation of Erk1/2, ribosomal protein S6, TSC2, and 4E-BP1, attenuated de novo protein synthesis in recovering cells.	U 0126	9-14	ribosomal protein S6	Homo sapiens	63-83
15292274-8	2004	However, U0126, which prevented the phosphorylation of Erk1/2, ribosomal protein S6, TSC2, and 4E-BP1, attenuated de novo protein synthesis in recovering cells.	U 0126	9-14	TSC complex subunit 2	Homo sapiens	85-89
15292274-8	2004	However, U0126, which prevented the phosphorylation of Erk1/2, ribosomal protein S6, TSC2, and 4E-BP1, attenuated de novo protein synthesis in recovering cells.	U 0126	9-14	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	95-101
15566970-10	2004	Furthermore, the MEK1/2 inhibitor U0126 could reduce detectable iNOS mRNA levels suggesting that MAP kinases were upstream regulators of iNOS transcription.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Homo sapiens	17-23
15566970-10	2004	Furthermore, the MEK1/2 inhibitor U0126 could reduce detectable iNOS mRNA levels suggesting that MAP kinases were upstream regulators of iNOS transcription.	U 0126	34-39	nitric oxide synthase 2	Homo sapiens	64-68
15566970-10	2004	Furthermore, the MEK1/2 inhibitor U0126 could reduce detectable iNOS mRNA levels suggesting that MAP kinases were upstream regulators of iNOS transcription.	U 0126	34-39	nitric oxide synthase 2	Homo sapiens	137-141
15322124-8	2004	Both PKCbeta promoter activity and PKCbetaII mRNA levels are inhibited by the MEK1 and -2 inhibitor U0126, but not the Cox-2 inhibitor celecoxib in RIE/PKCbetaII cells.	U 0126	100-105	protein kinase C beta	Homo sapiens	5-12
15322124-8	2004	Both PKCbeta promoter activity and PKCbetaII mRNA levels are inhibited by the MEK1 and -2 inhibitor U0126, but not the Cox-2 inhibitor celecoxib in RIE/PKCbetaII cells.	U 0126	100-105	phospholipase C, beta 2	Rattus norvegicus	35-44
15322124-8	2004	Both PKCbeta promoter activity and PKCbetaII mRNA levels are inhibited by the MEK1 and -2 inhibitor U0126, but not the Cox-2 inhibitor celecoxib in RIE/PKCbetaII cells.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	78-89
15322124-8	2004	Both PKCbeta promoter activity and PKCbetaII mRNA levels are inhibited by the MEK1 and -2 inhibitor U0126, but not the Cox-2 inhibitor celecoxib in RIE/PKCbetaII cells.	U 0126	100-105	phospholipase C, beta 2	Rattus norvegicus	152-161
15322124-10	2004	PKCbeta promoter activity and PKCbetaII mRNA expression in HCT116 cells are inhibited by the selective PKCbeta inhibitor LY317615 and by U0126, demonstrating autoregulation of PKCbetaII expression.	U 0126	137-142	protein kinase C beta	Homo sapiens	0-7
15322124-10	2004	PKCbeta promoter activity and PKCbetaII mRNA expression in HCT116 cells are inhibited by the selective PKCbeta inhibitor LY317615 and by U0126, demonstrating autoregulation of PKCbetaII expression.	U 0126	137-142	phospholipase C, beta 2	Rattus norvegicus	30-39
15322124-10	2004	PKCbeta promoter activity and PKCbetaII mRNA expression in HCT116 cells are inhibited by the selective PKCbeta inhibitor LY317615 and by U0126, demonstrating autoregulation of PKCbetaII expression.	U 0126	137-142	protein kinase C beta	Homo sapiens	30-37
15322124-10	2004	PKCbeta promoter activity and PKCbetaII mRNA expression in HCT116 cells are inhibited by the selective PKCbeta inhibitor LY317615 and by U0126, demonstrating autoregulation of PKCbetaII expression.	U 0126	137-142	phospholipase C, beta 2	Rattus norvegicus	176-185
15451430-8	2004	Inhibition of ERK 1/2 phosphorylation (U0126) prevented the increases in growth and TIMP-1 expression.	U 0126	39-44	TIMP metallopeptidase inhibitor 1	Homo sapiens	84-90
15371228-2	2004	The mitogen-activated protein kinase (MAPK) inhibitors UO126 and SB203850 decreased TF expression in both naive and crocidolite-treated Beas-2B cells to the same extent.	U 0126	55-60	coagulation factor III, tissue factor	Homo sapiens	84-86
15322121-9	2004	Phosphorylation of Erk and tau was reduced by preincubation with the Erk pathway inhibitor U0126.	U 0126	91-96	mitogen-activated protein kinase 1	Mus musculus	19-22
15322121-9	2004	Phosphorylation of Erk and tau was reduced by preincubation with the Erk pathway inhibitor U0126.	U 0126	91-96	mitogen-activated protein kinase 1	Mus musculus	69-72
15292266-11	2004	This effect was not attenuated by Y-27632 but could be inhibited by the MEK inhibitor, UO126.	U 0126	87-92	midkine	Mus musculus	72-75
15304489-6	2004	Treatment with U0126, which inhibits ERK1/2 activation, reduced IGF-1-stimulated RUNX2 DNA binding without affecting RUNX2 protein levels.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	37-43
15304489-6	2004	Treatment with U0126, which inhibits ERK1/2 activation, reduced IGF-1-stimulated RUNX2 DNA binding without affecting RUNX2 protein levels.	U 0126	15-20	insulin like growth factor 1	Homo sapiens	64-69
15172888-6	2004	Inhibition of MEK with U-0126 did not prevent GLUT4 from translocating to the plasma membrane, nor did it inhibit the subsequent docking and fusion of GLUT4-myc with the plasma membrane.	U 0126	23-29	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
15304489-6	2004	Treatment with U0126, which inhibits ERK1/2 activation, reduced IGF-1-stimulated RUNX2 DNA binding without affecting RUNX2 protein levels.	U 0126	15-20	RUNX family transcription factor 2	Homo sapiens	81-86
15304489-6	2004	Treatment with U0126, which inhibits ERK1/2 activation, reduced IGF-1-stimulated RUNX2 DNA binding without affecting RUNX2 protein levels.	U 0126	15-20	RUNX family transcription factor 2	Homo sapiens	117-122
15380445-3	2004	Ox-LDL-induced proliferation of mouse peritoneal macrophages assessed by [3H]thymidine incorporation and cell counting assays was significantly inhibited by MEK1/2 inhibitors, PD98059 or U0126, and p38 MAPK inhibitors, SB203580 or SB202190, respectively.	U 0126	187-192	mitogen-activated protein kinase kinase 1	Mus musculus	157-163
15231484-8	2004	Both U-0126 and SB-203580 attenuated the acid-induced increase in COX-2 mRNA.	U 0126	5-11	prostaglandin-endoperoxide synthase 2	Homo sapiens	66-71
15231484-9	2004	Acid significantly increased COX-2 protein expression and promoter activity, and both of these effects were abolished by treatment with U-0126 and SB-203580.	U 0126	136-142	prostaglandin-endoperoxide synthase 2	Homo sapiens	29-34
15231484-10	2004	Acid exposure also stabilized COX-2 mRNA levels, an effect that was abolished by U-0126 but not by SB-203580.	U 0126	81-87	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-35
15380445-3	2004	Ox-LDL-induced proliferation of mouse peritoneal macrophages assessed by [3H]thymidine incorporation and cell counting assays was significantly inhibited by MEK1/2 inhibitors, PD98059 or U0126, and p38 MAPK inhibitors, SB203580 or SB202190, respectively.	U 0126	187-192	mitogen-activated protein kinase 14	Mus musculus	198-201
15380445-3	2004	Ox-LDL-induced proliferation of mouse peritoneal macrophages assessed by [3H]thymidine incorporation and cell counting assays was significantly inhibited by MEK1/2 inhibitors, PD98059 or U0126, and p38 MAPK inhibitors, SB203580 or SB202190, respectively.	U 0126	187-192	mitogen-activated protein kinase 1	Mus musculus	202-206
15380002-11	2004	U0126 inhibited D3, LIF and to a lesser extent NGF mRNA induction, but did not affect significantly the induction of D2 and IL-6 mRNAs.	U 0126	0-5	LIF, interleukin 6 family cytokine	Rattus norvegicus	20-23
15242988-4	2004	Specific inhibition of ERK1/2 by Uo126 suppressed all of these cellular responses to hCG.	U 0126	33-38	mitogen-activated protein kinase 3	Homo sapiens	23-29
15242988-4	2004	Specific inhibition of ERK1/2 by Uo126 suppressed all of these cellular responses to hCG.	U 0126	33-38	chorionic gonadotropin subunit beta 5	Homo sapiens	85-88
15380002-11	2004	U0126 inhibited D3, LIF and to a lesser extent NGF mRNA induction, but did not affect significantly the induction of D2 and IL-6 mRNAs.	U 0126	0-5	nerve growth factor	Rattus norvegicus	47-50
15480997-8	2004	NGF proliferation in vitro was partially blocked by the MEK inhibitor (UO126) and completely ablated by the phosphatidylinositol 3-kinase inhibitor (wortmannin).	U 0126	71-76	nerve growth factor	Rattus norvegicus	0-3
15474068-10	2004	The NF-kappaB inhibitor (TPCK) and MAPK inhibitor (U0126) blocked the TNF-alpha-induced IL-6 expression.	U 0126	51-56	tumor necrosis factor	Homo sapiens	70-79
15474068-10	2004	The NF-kappaB inhibitor (TPCK) and MAPK inhibitor (U0126) blocked the TNF-alpha-induced IL-6 expression.	U 0126	51-56	interleukin 6	Homo sapiens	88-92
15474068-11	2004	Electrophoretic mobility shift assay revealed that U0126 attenuated activator protein-1 (AP-1) activation induced by TNF-alpha.	U 0126	51-56	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	68-87
15474068-11	2004	Electrophoretic mobility shift assay revealed that U0126 attenuated activator protein-1 (AP-1) activation induced by TNF-alpha.	U 0126	51-56	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	89-93
15474068-11	2004	Electrophoretic mobility shift assay revealed that U0126 attenuated activator protein-1 (AP-1) activation induced by TNF-alpha.	U 0126	51-56	tumor necrosis factor	Homo sapiens	117-126
15336230-7	2004	The MAP kinase and akt activities were recognized by treatment with IGF-I and suppressed by U0126 and wortmannin, respectively.	U 0126	92-97	AKT serine/threonine kinase 1	Homo sapiens	19-22
15336230-7	2004	The MAP kinase and akt activities were recognized by treatment with IGF-I and suppressed by U0126 and wortmannin, respectively.	U 0126	92-97	insulin like growth factor 1	Homo sapiens	68-73
15336230-8	2004	When WISH cells were pretreated for 2 h with U0126 and wortmannin and then treated with IGF-I for 16 h, the production of VEGF was significantly decreased in a dose-dependent manner (p &lt; 0.01, p &lt; 0.01, respectively).	U 0126	45-50	NCK interacting protein with SH3 domain	Homo sapiens	5-9
15336230-8	2004	When WISH cells were pretreated for 2 h with U0126 and wortmannin and then treated with IGF-I for 16 h, the production of VEGF was significantly decreased in a dose-dependent manner (p &lt; 0.01, p &lt; 0.01, respectively).	U 0126	45-50	vascular endothelial growth factor A	Homo sapiens	122-126
15375559-5	2004	Interestingly, this transactivation by LPS was eliminated with the treatment of U0126, specific inhibitor of mitogen-activated protein kinase (MAPK) kinases (MEKs) 1/2 which has little effect on NF-kappaB activation.	U 0126	80-85	mitogen-activated protein kinase 1	Homo sapiens	143-147
15375559-5	2004	Interestingly, this transactivation by LPS was eliminated with the treatment of U0126, specific inhibitor of mitogen-activated protein kinase (MAPK) kinases (MEKs) 1/2 which has little effect on NF-kappaB activation.	U 0126	80-85	nuclear factor kappa B subunit 1	Homo sapiens	195-204
15379891-4	2004	ERK1/2 phosphorylation was abolished by ERK1/2 kinase (MEK) inhibitors PD98059 and U0126.	U 0126	83-88	mitogen-activated protein kinase 3	Mus musculus	0-6
15379891-4	2004	ERK1/2 phosphorylation was abolished by ERK1/2 kinase (MEK) inhibitors PD98059 and U0126.	U 0126	83-88	mitogen-activated protein kinase 3	Mus musculus	40-46
15379891-4	2004	ERK1/2 phosphorylation was abolished by ERK1/2 kinase (MEK) inhibitors PD98059 and U0126.	U 0126	83-88	midkine	Mus musculus	55-58
15367685-4	2004	Pretreating the cells with a MEK1-specific inhibitor (U0126) significantly attenuates this activity.	U 0126	54-59	mitogen-activated protein kinase kinase 1	Mus musculus	29-33
15325273-3	2004	In a panel of colorectal cancer cell lines that carry Ras mutations and have constitutively active MEK/MAPK, we found that inhibition of the MAPK upstream kinase MEK by the small molecular MEK inhibitor U0126 induced cell death only in p53 wild-type cells.	U 0126	203-208	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
15325273-3	2004	In a panel of colorectal cancer cell lines that carry Ras mutations and have constitutively active MEK/MAPK, we found that inhibition of the MAPK upstream kinase MEK by the small molecular MEK inhibitor U0126 induced cell death only in p53 wild-type cells.	U 0126	203-208	mitogen-activated protein kinase kinase 7	Homo sapiens	162-165
15328027-8	2004	With U0126, an inhibitor of ERK activation, BrdU labeling was strikingly reduced implicating ERKs in the proliferation response.	U 0126	5-10	Eph receptor B1	Rattus norvegicus	28-31
15325273-3	2004	In a panel of colorectal cancer cell lines that carry Ras mutations and have constitutively active MEK/MAPK, we found that inhibition of the MAPK upstream kinase MEK by the small molecular MEK inhibitor U0126 induced cell death only in p53 wild-type cells.	U 0126	203-208	mitogen-activated protein kinase kinase 7	Homo sapiens	162-165
15328027-8	2004	With U0126, an inhibitor of ERK activation, BrdU labeling was strikingly reduced implicating ERKs in the proliferation response.	U 0126	5-10	mitogen activated protein kinase 3	Rattus norvegicus	93-97
15325273-3	2004	In a panel of colorectal cancer cell lines that carry Ras mutations and have constitutively active MEK/MAPK, we found that inhibition of the MAPK upstream kinase MEK by the small molecular MEK inhibitor U0126 induced cell death only in p53 wild-type cells.	U 0126	203-208	tumor protein p53	Homo sapiens	236-239
15325273-5	2004	Using isogenic colon cancer cell lines and RNA interference, we show that loss of p53 significantly reduces MAPK phosphorylation and renders cells resistant to U0126 treatment.	U 0126	160-165	tumor protein p53	Homo sapiens	82-85
15356145-3	2004	This migration shift was strongly diminished by treating cells with the MEK inhibitor U0126, indicating a possible role for ERK in Gab2 phosphorylation.	U 0126	86-91	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
15166036-7	2004	Moreover, the effects of oncogenic H-ras expression on primary erythroid cells are blocked by the addition of U0126, a specific inhibitor of MEK1 and MEK2, allowing normal terminal erythroid proliferation and differentiation.	U 0126	110-115	HRas proto-oncogene, GTPase	Homo sapiens	35-40
15166036-7	2004	Moreover, the effects of oncogenic H-ras expression on primary erythroid cells are blocked by the addition of U0126, a specific inhibitor of MEK1 and MEK2, allowing normal terminal erythroid proliferation and differentiation.	U 0126	110-115	mitogen-activated protein kinase kinase 1	Homo sapiens	141-145
15166036-7	2004	Moreover, the effects of oncogenic H-ras expression on primary erythroid cells are blocked by the addition of U0126, a specific inhibitor of MEK1 and MEK2, allowing normal terminal erythroid proliferation and differentiation.	U 0126	110-115	mitogen-activated protein kinase kinase 2	Homo sapiens	150-154
15356145-3	2004	This migration shift was strongly diminished by treating cells with the MEK inhibitor U0126, indicating a possible role for ERK in Gab2 phosphorylation.	U 0126	86-91	EPH receptor B2	Homo sapiens	124-127
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	GRB2 associated binding protein 2	Homo sapiens	66-70
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	71-76
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	121-126
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	interleukin 2	Homo sapiens	142-146
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	EPH receptor B2	Homo sapiens	164-167
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	GRB2 associated binding protein 2	Homo sapiens	232-236
15356145-3	2004	This migration shift was strongly diminished by treating cells with the MEK inhibitor U0126, indicating a possible role for ERK in Gab2 phosphorylation.	U 0126	86-91	GRB2 associated binding protein 2	Homo sapiens	131-135
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	121-126
15353548-8	2004	In vitro kinase assays demonstrate that extracellular signal-regulated protein kinase phosphorylates actopaxin, and treatment of U2OS cells with the MEK1 inhibitor UO126 inhibited adhesion-induced phosphorylation of actopaxin and also inhibited cell migration.	U 0126	164-169	parvin alpha	Homo sapiens	101-110
15356145-5	2004	We report that pretreatment of Kit 225 cells with U0126 increased Gab2/SHP-2 association and tyrosine phosphorylation of SHP-2 in response to IL-2, suggesting that ERK phosphorylation of serine 623 regulates the interaction between Gab2 and SHP-2, and consequently the activity of SHP-2.	U 0126	50-55	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	121-126
15353548-8	2004	In vitro kinase assays demonstrate that extracellular signal-regulated protein kinase phosphorylates actopaxin, and treatment of U2OS cells with the MEK1 inhibitor UO126 inhibited adhesion-induced phosphorylation of actopaxin and also inhibited cell migration.	U 0126	164-169	mitogen-activated protein kinase kinase 1	Homo sapiens	149-153
15353548-8	2004	In vitro kinase assays demonstrate that extracellular signal-regulated protein kinase phosphorylates actopaxin, and treatment of U2OS cells with the MEK1 inhibitor UO126 inhibited adhesion-induced phosphorylation of actopaxin and also inhibited cell migration.	U 0126	164-169	parvin alpha	Homo sapiens	216-225
15331404-6	2004	By contrast, inhibiting Erk1,2 with U-0126, a specific inhibitor of Mek1,2, had no appreciable effect on ionomycin-induced calpain activation.	U 0126	36-42	mitogen-activated protein kinase 3	Homo sapiens	24-30
15213065-5	2004	Inhibition of PI3K with LY-294002 blocked Akt phosphorylation and proliferation, whereas U-0126 blocked ERK1/2 phosphorylation but had no effect on proliferation.	U 0126	89-95	mitogen-activated protein kinase 3	Homo sapiens	104-110
15302569-6	2004	MEK inhibitors (PD098059 or U0126) blocked ERK1/2 phosphorylation induced by apigenin and conferred partial protection against this flavonoid.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
15302569-6	2004	MEK inhibitors (PD098059 or U0126) blocked ERK1/2 phosphorylation induced by apigenin and conferred partial protection against this flavonoid.	U 0126	28-33	mitogen-activated protein kinase 3	Homo sapiens	43-49
15302580-9	2004	We further determined potential signaling pathways through which PTHrP inhibits Runx2 expression using protein kinase inhibitors, H89 (PKA inhibitor): Go-6976 (PKC inhibitor): SB203850 (p38 MAPK inhibitor), and U0126 (MEK inhibitor).	U 0126	211-216	parathyroid hormone like hormone	Gallus gallus	65-70
15339391-7	2004	U0126, an MEK1/2 inhibitor, increased CT-1-induced the phosphorylation of STAT3 in a dose-dependent manner and, consistently, augmented CT-1-induced increase in [3H]leucine incorporation and cellular protein-to-DNA ratio by 17.6 % and 16.3 %, respectively.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	10-16
15339391-7	2004	U0126, an MEK1/2 inhibitor, increased CT-1-induced the phosphorylation of STAT3 in a dose-dependent manner and, consistently, augmented CT-1-induced increase in [3H]leucine incorporation and cellular protein-to-DNA ratio by 17.6 % and 16.3 %, respectively.	U 0126	0-5	cardiotrophin 1	Rattus norvegicus	38-42
15339391-7	2004	U0126, an MEK1/2 inhibitor, increased CT-1-induced the phosphorylation of STAT3 in a dose-dependent manner and, consistently, augmented CT-1-induced increase in [3H]leucine incorporation and cellular protein-to-DNA ratio by 17.6 % and 16.3 %, respectively.	U 0126	0-5	signal transducer and activator of transcription 3	Rattus norvegicus	74-79
15339391-7	2004	U0126, an MEK1/2 inhibitor, increased CT-1-induced the phosphorylation of STAT3 in a dose-dependent manner and, consistently, augmented CT-1-induced increase in [3H]leucine incorporation and cellular protein-to-DNA ratio by 17.6 % and 16.3 %, respectively.	U 0126	0-5	cardiotrophin 1	Rattus norvegicus	136-140
15331404-6	2004	By contrast, inhibiting Erk1,2 with U-0126, a specific inhibitor of Mek1,2, had no appreciable effect on ionomycin-induced calpain activation.	U 0126	36-42	mitogen-activated protein kinase kinase 1	Homo sapiens	68-74
15289288-8	2004	An inhibitor of the NF-kappaB pathway, pyrrolidine dithiocarbamate (PDTC), as well as inhibitors of JAK2/STAT and ERK, AG490 and U0126, respectively, significantly reduced albumin-induced iNOS expression and NO production, while an inhibitor of the p38 pathway, SB203580, did not significantly affect NO production induced by albumin.	U 0126	129-134	Janus kinase 2	Homo sapiens	100-104
15192040-9	2004	Similarly, MAPK kinase-1 inhibitors PD98059 and U0126 each abolished TGFalpha-stimulated increases in IGFBP-3 mRNA levels.	U 0126	48-53	mitogen-activated protein kinase 1	Bos taurus	11-15
15166121-8	2004	Leptin"s antiapoptotic activity required Janus kinase/STAT, MAPK, and phosphatidylinositol-3-kinase activation because the antiapoptotic effects of leptin were abolished, and caspase-3 immunoreactivity increased in the presence of the specific blockers AG490, U0126, or LY294002.	U 0126	260-265	leptin	Homo sapiens	0-6
15342404-5	2004	The inhibition of erk, p38, jnk, and akt with U0126, SB203580, SP600125, and Akt inhibitor, respectively, document that normal cells require simultaneous erk and jnk signaling for survival, plus akt signaling for proliferation.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	18-21
15342404-5	2004	The inhibition of erk, p38, jnk, and akt with U0126, SB203580, SP600125, and Akt inhibitor, respectively, document that normal cells require simultaneous erk and jnk signaling for survival, plus akt signaling for proliferation.	U 0126	46-51	AKT serine/threonine kinase 1	Homo sapiens	37-40
15192040-9	2004	Similarly, MAPK kinase-1 inhibitors PD98059 and U0126 each abolished TGFalpha-stimulated increases in IGFBP-3 mRNA levels.	U 0126	48-53	transforming growth factor alpha	Bos taurus	69-77
15192040-9	2004	Similarly, MAPK kinase-1 inhibitors PD98059 and U0126 each abolished TGFalpha-stimulated increases in IGFBP-3 mRNA levels.	U 0126	48-53	insulin like growth factor binding protein 3	Bos taurus	102-109
15341531-6	2004	Consistently, IL-1beta-stimulated translocation of NF-kappaB into the nucleus and degradation of inhibitory kappa B-alpha (IkappaB-alpha) was revealed by western blotting and immunofluorescence staining, which was blocked by helenalin, but not by U0126, SB202190, or SP600125.	U 0126	247-252	interleukin 1 beta	Rattus norvegicus	14-22
15341531-6	2004	Consistently, IL-1beta-stimulated translocation of NF-kappaB into the nucleus and degradation of inhibitory kappa B-alpha (IkappaB-alpha) was revealed by western blotting and immunofluorescence staining, which was blocked by helenalin, but not by U0126, SB202190, or SP600125.	U 0126	247-252	NFKB inhibitor alpha	Rattus norvegicus	123-136
15341518-5	2004	Application of U0126, a specific inhibitor of MEK1/2 which are upstream to Erk1/2, blocked the phosphorylation of Erk1/2, suppressed the expression of Olig-1 and prevented NSC differentiation into OLPs in response to NT3 stimulation.	U 0126	15-20	mitogen-activated protein kinase kinase 1	Homo sapiens	46-52
15235105-4	2004	The MAPK inhibitor U0126 decreased cell migration and ERK phosphorylation, but it did not influence p70S6K phosphorylation in response to EGF.	U 0126	19-24	mitogen-activated protein kinase 3	Homo sapiens	4-8
15341518-5	2004	Application of U0126, a specific inhibitor of MEK1/2 which are upstream to Erk1/2, blocked the phosphorylation of Erk1/2, suppressed the expression of Olig-1 and prevented NSC differentiation into OLPs in response to NT3 stimulation.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	75-81
15341518-5	2004	Application of U0126, a specific inhibitor of MEK1/2 which are upstream to Erk1/2, blocked the phosphorylation of Erk1/2, suppressed the expression of Olig-1 and prevented NSC differentiation into OLPs in response to NT3 stimulation.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	114-120
15341518-5	2004	Application of U0126, a specific inhibitor of MEK1/2 which are upstream to Erk1/2, blocked the phosphorylation of Erk1/2, suppressed the expression of Olig-1 and prevented NSC differentiation into OLPs in response to NT3 stimulation.	U 0126	15-20	oligodendrocyte transcription factor 1	Homo sapiens	151-157
15341518-5	2004	Application of U0126, a specific inhibitor of MEK1/2 which are upstream to Erk1/2, blocked the phosphorylation of Erk1/2, suppressed the expression of Olig-1 and prevented NSC differentiation into OLPs in response to NT3 stimulation.	U 0126	15-20	neurotrophin 3	Homo sapiens	217-220
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	U 0126	152-157	interleukin 1 beta	Rattus norvegicus	35-43
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	U 0126	152-157	mitogen activated protein kinase 3	Rattus norvegicus	78-86
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	U 0126	152-157	mitogen activated protein kinase 14	Rattus norvegicus	88-91
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	U 0126	152-157	mitogen-activated protein kinase 8	Rattus norvegicus	97-120
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	U 0126	152-157	mitogen-activated protein kinase 8	Rattus norvegicus	122-125
15453987-6	2004	Treatment with the MEK inhibitor U0126 or the free radical scavenger S-PBN, both with neuroprotective properties in TBI, attenuated the early activation of ERK and resulted in less activation of caspase-3 and subsequent DNA fragmentation.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
15453987-6	2004	Treatment with the MEK inhibitor U0126 or the free radical scavenger S-PBN, both with neuroprotective properties in TBI, attenuated the early activation of ERK and resulted in less activation of caspase-3 and subsequent DNA fragmentation.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	156-159
15453987-6	2004	Treatment with the MEK inhibitor U0126 or the free radical scavenger S-PBN, both with neuroprotective properties in TBI, attenuated the early activation of ERK and resulted in less activation of caspase-3 and subsequent DNA fragmentation.	U 0126	33-38	caspase 3	Homo sapiens	195-204
15548370-9	2004	Treatment with an MEK inhibitor, U0126, inhibited increased Erk phosphorylation and kinase activity, and blocked TGF-beta1-induced EMT in both cell lines.	U 0126	33-38	midkine	Mus musculus	18-21
15548370-9	2004	Treatment with an MEK inhibitor, U0126, inhibited increased Erk phosphorylation and kinase activity, and blocked TGF-beta1-induced EMT in both cell lines.	U 0126	33-38	mitogen-activated protein kinase 1	Mus musculus	60-63
15548370-9	2004	Treatment with an MEK inhibitor, U0126, inhibited increased Erk phosphorylation and kinase activity, and blocked TGF-beta1-induced EMT in both cell lines.	U 0126	33-38	transforming growth factor, beta 1	Mus musculus	113-122
15333786-9	2004	Interfering with either signalling pathway via PI3K inhibitor LY294002 or MEK inhibitor U0126 in EGF-stimulated HTR8/SVneo cells blocked the induction of MMP-9 and TIMP-1.	U 0126	88-93	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
15327816-7	2004	However, inhibiting ERK activation using a MEK inhibitor, U0126, following inflammation attenuates the intrathecal DHPG-induced behavioral responses to a greater extent than in control animals.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	20-23
15327816-7	2004	However, inhibiting ERK activation using a MEK inhibitor, U0126, following inflammation attenuates the intrathecal DHPG-induced behavioral responses to a greater extent than in control animals.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	43-46
15333786-9	2004	Interfering with either signalling pathway via PI3K inhibitor LY294002 or MEK inhibitor U0126 in EGF-stimulated HTR8/SVneo cells blocked the induction of MMP-9 and TIMP-1.	U 0126	88-93	epidermal growth factor	Homo sapiens	97-100
15333786-9	2004	Interfering with either signalling pathway via PI3K inhibitor LY294002 or MEK inhibitor U0126 in EGF-stimulated HTR8/SVneo cells blocked the induction of MMP-9 and TIMP-1.	U 0126	88-93	matrix metallopeptidase 9	Homo sapiens	154-159
15333786-9	2004	Interfering with either signalling pathway via PI3K inhibitor LY294002 or MEK inhibitor U0126 in EGF-stimulated HTR8/SVneo cells blocked the induction of MMP-9 and TIMP-1.	U 0126	88-93	TIMP metallopeptidase inhibitor 1	Homo sapiens	164-170
15333786-10	2004	LY294002 inhibited Akt phosphorylation, but had no effect on ERK phosphorylation; U0126 suppressed ERK phosphorylation without interfering with the phosphorylation of Akt.	U 0126	82-87	mitogen-activated protein kinase 1	Homo sapiens	99-102
15313931-4	2004	Blocking STAT3 phosphorylation with a specific inhibitor, AG490, abolished leptin-induced proliferation of MCF-7 cells, whereas blocking ERK1/2 activation by a specific ERK1/2 kinase inhibitor, U0126, did not result in any significant changes in leptin-induced cell proliferation.	U 0126	194-199	mitogen-activated protein kinase 3	Homo sapiens	137-143
15192088-10	2004	When an inhibitor of MAPK (U0126) was used, the TGF-beta-mediated proliferative response in HeLa cells was completely abolished.	U 0126	27-32	transforming growth factor beta 1	Homo sapiens	48-56
15197768-9	2004	Selective inhibition of ERK/MAPK (by PD98059 or U0126) and PI3K (by LY294002 or wortmannin) led to marked reduction of both basal and BTC-induced MMP-9 activity and invasive ability of HNSCC cells.	U 0126	48-53	mitogen-activated protein kinase 1	Homo sapiens	24-27
15197768-9	2004	Selective inhibition of ERK/MAPK (by PD98059 or U0126) and PI3K (by LY294002 or wortmannin) led to marked reduction of both basal and BTC-induced MMP-9 activity and invasive ability of HNSCC cells.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	28-32
15197768-9	2004	Selective inhibition of ERK/MAPK (by PD98059 or U0126) and PI3K (by LY294002 or wortmannin) led to marked reduction of both basal and BTC-induced MMP-9 activity and invasive ability of HNSCC cells.	U 0126	48-53	matrix metallopeptidase 9	Homo sapiens	146-151
15249198-3	2004	Insulin-induced accumulation of glycosaminoglycan and expression of chondrogenic differentiation markers, type II collagen, type X collagen, and aggrecan mRNA were inhibited by the MEK1/2 inhibitor (U0126) and the p38 MAP kinase inhibitor (SB203580).	U 0126	199-204	mitogen-activated protein kinase kinase 1	Mus musculus	181-187
15177934-8	2004	The effects of NT on EGFR/ERK/Akt activation and DNA synthesis were attenuated by PLC-inhibitor (U73122), PKC-inhibitors (bisindolylmaleimide, staurosporine, rottlerin), MEK inhibitor (U0126) and PI3 kinase inhibitors (wortmannin, LY 294002).	U 0126	185-190	epidermal growth factor receptor	Homo sapiens	21-25
15177934-8	2004	The effects of NT on EGFR/ERK/Akt activation and DNA synthesis were attenuated by PLC-inhibitor (U73122), PKC-inhibitors (bisindolylmaleimide, staurosporine, rottlerin), MEK inhibitor (U0126) and PI3 kinase inhibitors (wortmannin, LY 294002).	U 0126	185-190	mitogen-activated protein kinase 1	Homo sapiens	26-29
15249198-3	2004	Insulin-induced accumulation of glycosaminoglycan and expression of chondrogenic differentiation markers, type II collagen, type X collagen, and aggrecan mRNA were inhibited by the MEK1/2 inhibitor (U0126) and the p38 MAP kinase inhibitor (SB203580).	U 0126	199-204	mitogen-activated protein kinase 14	Mus musculus	214-217
15249198-8	2004	Insulin-induced accumulation of p21 mRNA and protein was inhibited by the addition of U0126 and SB203580.	U 0126	86-91	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	32-35
15279887-7	2004	The inhibitory effects of IL-1alpha were blocked by pretreatments with herbimycin A, U0126 and PD 98054, but not with SB202190, SP 600125 or pertussis toxin (PTX).	U 0126	85-90	interleukin 1 alpha	Bos taurus	26-35
15070810-4	2004	MEK inhibitors PD-98059 and U0126 inhibited these HGF-dependent changes, indicating the dependence on phosphorylation of ERK1/2 during HGF-induced loss of contact inhibition.	U 0126	28-33	hepatocyte growth factor	Canis lupus familiaris	50-53
15070810-4	2004	MEK inhibitors PD-98059 and U0126 inhibited these HGF-dependent changes, indicating the dependence on phosphorylation of ERK1/2 during HGF-induced loss of contact inhibition.	U 0126	28-33	mitogen-activated protein kinase 1	Canis lupus familiaris	121-127
15070810-4	2004	MEK inhibitors PD-98059 and U0126 inhibited these HGF-dependent changes, indicating the dependence on phosphorylation of ERK1/2 during HGF-induced loss of contact inhibition.	U 0126	28-33	hepatocyte growth factor	Canis lupus familiaris	135-138
15072963-9	2004	Chronic in vivo treatment with U-0126 also significantly inhibited the RU-486-induced increase in in vitro contractility and ERK and caldesmon phosphorylation but did not alter the RU-486-induced increase in 20-kDa myosin light chain phosphorylation.	U 0126	31-37	Eph receptor B1	Rattus norvegicus	125-128
15262180-8	2004	The retinoic acid-stimulated release of VEGF was significantly reduced by PD98059 and U0126, specific MEK inhibitors, which attenuated the retinoic acid-induced phosphorylation of p44/p42 MAP kinase.	U 0126	86-91	vascular endothelial growth factor A	Homo sapiens	40-44
15262180-8	2004	The retinoic acid-stimulated release of VEGF was significantly reduced by PD98059 and U0126, specific MEK inhibitors, which attenuated the retinoic acid-induced phosphorylation of p44/p42 MAP kinase.	U 0126	86-91	interferon induced protein 44	Homo sapiens	180-183
15262180-8	2004	The retinoic acid-stimulated release of VEGF was significantly reduced by PD98059 and U0126, specific MEK inhibitors, which attenuated the retinoic acid-induced phosphorylation of p44/p42 MAP kinase.	U 0126	86-91	cyclin dependent kinase 20	Homo sapiens	184-187
15237095-7	2004	Incubation with the MEK/ERK inhibitors U0126 and SB386023 diminished the contractile response to S6c.	U 0126	39-44	mitogen activated protein kinase 3	Rattus norvegicus	24-27
15237095-10	2004	The ETB receptor mRNA levels were diminished by SB386023 and U0126.	U 0126	61-66	endothelin receptor type B	Rattus norvegicus	4-7
15361284-9	2004	Inhibition of ERK1/2 by U0126 resulted in an increase of CT-1-induced tyrosine phosphorylation of STAT3 and, consequently, the protein-to-DNA ratio and [(3)H]-leucine incorporation.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	14-20
15361284-9	2004	Inhibition of ERK1/2 by U0126 resulted in an increase of CT-1-induced tyrosine phosphorylation of STAT3 and, consequently, the protein-to-DNA ratio and [(3)H]-leucine incorporation.	U 0126	24-29	cardiotrophin 1	Rattus norvegicus	57-61
15361284-9	2004	Inhibition of ERK1/2 by U0126 resulted in an increase of CT-1-induced tyrosine phosphorylation of STAT3 and, consequently, the protein-to-DNA ratio and [(3)H]-leucine incorporation.	U 0126	24-29	signal transducer and activator of transcription 3	Rattus norvegicus	98-103
15296479-14	2004	The positive effect of ghrelin and desoctanoyl ghrelin on [(3)H]thymidine incorporation was abolished by the MAPK kinase inhibitor U0126, the PKC inhibitor GF109203X and the tyrosine kinase inhibitor tyrphostin 23, suggesting that the ghrelin-induced cell proliferation of GH3 cells is mediated both via a PKC-MAPK-dependent pathway and via a tyrosine kinase-dependent pathway.	U 0126	131-136	ghrelin and obestatin prepropeptide	Rattus norvegicus	23-30
15296479-14	2004	The positive effect of ghrelin and desoctanoyl ghrelin on [(3)H]thymidine incorporation was abolished by the MAPK kinase inhibitor U0126, the PKC inhibitor GF109203X and the tyrosine kinase inhibitor tyrphostin 23, suggesting that the ghrelin-induced cell proliferation of GH3 cells is mediated both via a PKC-MAPK-dependent pathway and via a tyrosine kinase-dependent pathway.	U 0126	131-136	mitogen activated protein kinase 3	Rattus norvegicus	109-113
15277479-8	2004	Inhibition of EGFR, ERK1/2, and PI3K activities with kinase-specific inhibitors (AG1478, U0126, and LY294002, respectively) resulted in an increase in the number of apoptotic cells, in elevated cellular caspase-3 activity, and/or in increased cleaved PARP in P. aeruginosa-infected HUCL cells or primary culture of HCECs.	U 0126	89-94	epidermal growth factor receptor	Homo sapiens	14-18
15316530-7	2004	Selective MEK inhibitors, PD98059 and U0126, and Raf1 kinase inhibitor I significantly inhibited ML-1-induced GM-CSF production.	U 0126	38-43	interleukin 17F	Homo sapiens	97-101
15174100-6	2004	Indeed, MEK blockade with PD98059 or U0126 attenuated keratinocyte migration (by &gt; or =60%), as did transient transfection of a dominant-negative ERK1 construct (40% decrease in monolayer repair), and completely inhibited PAI-1 transcript expression.	U 0126	37-42	midkine	Mus musculus	8-11
15174091-5	2004	Conversely, treatment with U0126, a potent inhibitor of MEK-mediated ERK activation, prevented FAK phosphorylation at Ser-910 induced by PDGF but did not interfere with PDGF-induced FAK phosphorylation at Tyr-397.	U 0126	27-32	midkine	Mus musculus	56-59
15174091-5	2004	Conversely, treatment with U0126, a potent inhibitor of MEK-mediated ERK activation, prevented FAK phosphorylation at Ser-910 induced by PDGF but did not interfere with PDGF-induced FAK phosphorylation at Tyr-397.	U 0126	27-32	mitogen-activated protein kinase 1	Mus musculus	69-72
15631696-5	2004	Hypoxia-induced cell death was increased by treatment with ERK1/2 inhibitor U0126 (10 microM), but attenuated by p38 MAPK inhibitor SB202190 (10 microM).	U 0126	76-81	mitogen activated protein kinase 3	Rattus norvegicus	59-65
15174091-5	2004	Conversely, treatment with U0126, a potent inhibitor of MEK-mediated ERK activation, prevented FAK phosphorylation at Ser-910 induced by PDGF but did not interfere with PDGF-induced FAK phosphorylation at Tyr-397.	U 0126	27-32	PTK2 protein tyrosine kinase 2	Mus musculus	95-98
15255937-6	2004	PD98059 and U0126, two distinct inhibitors of MEK, block the activation of ERK by GW5074 but have no effect on its ability to prevent cell death.	U 0126	12-17	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
15255937-6	2004	PD98059 and U0126, two distinct inhibitors of MEK, block the activation of ERK by GW5074 but have no effect on its ability to prevent cell death.	U 0126	12-17	mitogen-activated protein kinase 1	Homo sapiens	75-78
15287886-8	2004	AMPA-mediated neuroprotection is blocked by PP1, an inhibitor of src family kinases, LY294002, a PI3-K inhibitor, or U0126, a MAPK kinase (MEK) inhibitor.	U 0126	117-122	mitogen-activated protein kinase kinase 7	Homo sapiens	139-142
15114341-0	2004	Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.	U 0126	119-124	carbonic anhydrase 1	Rattus norvegicus	134-137
15114341-3	2004	It was found that rolipram, a PDE4-selective inhibitor, reversed the amnesic effect in the radial-arm maze test of the MEK inhibitor U0126 administered into the CA1 subregion of the rat hippocampus.	U 0126	133-138	carbonic anhydrase 1	Rattus norvegicus	161-164
15141098-6	2004	Furthermore, the ROS formation was inhibited by the Erk1/2 pathway inhibitor U0126.	U 0126	77-82	mitogen activated protein kinase 3	Rattus norvegicus	52-58
15363324-6	2004	PI3K pathway inhibitor LY294002 and MEK inhibitor U0126 were used to block the two pathways.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
15363324-11	2004	When treated with LY294002 or U0126 for 24 hours, the amount of wild p53 protein in MCF7-neu3 cells was 1.7 or 1.5 times higher than those in DMSO treated cells.	U 0126	30-35	tumor protein p53	Homo sapiens	69-72
15363324-12	2004	There were 4.7 or 5.3 times increase in the p53 protein when MCF7-neu3 cells were treated with LY294002 or U0126 for 48 hours (P &lt; 0.01).	U 0126	107-112	tumor protein p53	Homo sapiens	44-47
15145928-7	2004	Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants.	U 0126	21-26	mitogen activated protein kinase 3	Rattus norvegicus	31-37
15145928-7	2004	Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants.	U 0126	21-26	major intrinsic protein of lens fiber	Rattus norvegicus	70-73
15145928-7	2004	Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants.	U 0126	21-26	fibroblast growth factor 2	Rattus norvegicus	100-105
15184882-9	2004	DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126.	U 0126	132-137	BCL2 apoptosis regulator	Homo sapiens	13-18
15184882-9	2004	DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126.	U 0126	132-137	mitogen-activated protein kinase 3	Homo sapiens	108-114
15194004-4	2004	Inhibition of activated/phosphorylated mitogen-activated protein kinase (MAPK) with phospho-p38 or phospho-p42/44 specific inhibitors, SB203580 or U0126, induces apoptosis without DADS treatment, indicating that at least the endogenous activated forms of p38 MAPK and p42/p44 MAPK markedly exert cytoprotective roles from cell apoptosis in the HepG2 hepatoma cells.	U 0126	147-152	mitogen-activated protein kinase 3	Homo sapiens	73-77
15194004-4	2004	Inhibition of activated/phosphorylated mitogen-activated protein kinase (MAPK) with phospho-p38 or phospho-p42/44 specific inhibitors, SB203580 or U0126, induces apoptosis without DADS treatment, indicating that at least the endogenous activated forms of p38 MAPK and p42/p44 MAPK markedly exert cytoprotective roles from cell apoptosis in the HepG2 hepatoma cells.	U 0126	147-152	cyclin dependent kinase 20	Homo sapiens	107-110
15194004-4	2004	Inhibition of activated/phosphorylated mitogen-activated protein kinase (MAPK) with phospho-p38 or phospho-p42/44 specific inhibitors, SB203580 or U0126, induces apoptosis without DADS treatment, indicating that at least the endogenous activated forms of p38 MAPK and p42/p44 MAPK markedly exert cytoprotective roles from cell apoptosis in the HepG2 hepatoma cells.	U 0126	147-152	mitogen-activated protein kinase 14	Homo sapiens	255-258
15194004-4	2004	Inhibition of activated/phosphorylated mitogen-activated protein kinase (MAPK) with phospho-p38 or phospho-p42/44 specific inhibitors, SB203580 or U0126, induces apoptosis without DADS treatment, indicating that at least the endogenous activated forms of p38 MAPK and p42/p44 MAPK markedly exert cytoprotective roles from cell apoptosis in the HepG2 hepatoma cells.	U 0126	147-152	cyclin dependent kinase 20	Homo sapiens	268-271
15194004-4	2004	Inhibition of activated/phosphorylated mitogen-activated protein kinase (MAPK) with phospho-p38 or phospho-p42/44 specific inhibitors, SB203580 or U0126, induces apoptosis without DADS treatment, indicating that at least the endogenous activated forms of p38 MAPK and p42/p44 MAPK markedly exert cytoprotective roles from cell apoptosis in the HepG2 hepatoma cells.	U 0126	147-152	mitogen-activated protein kinase 3	Homo sapiens	272-280
15194007-0	2004	Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP.	U 0126	79-84	mitogen-activated protein kinase kinase 1	Homo sapiens	63-67
15194007-2	2004	ERKs are activated by the dual phosphorylation kinase MEK1 and MEK1 inhibitors PD98059, U0126 and CI-1040 are now widely used to inhibit ERKs in cell and animal studies.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	0-4
15194007-2	2004	ERKs are activated by the dual phosphorylation kinase MEK1 and MEK1 inhibitors PD98059, U0126 and CI-1040 are now widely used to inhibit ERKs in cell and animal studies.	U 0126	88-93	mitogen-activated protein kinase kinase 1	Homo sapiens	54-58
15194007-2	2004	ERKs are activated by the dual phosphorylation kinase MEK1 and MEK1 inhibitors PD98059, U0126 and CI-1040 are now widely used to inhibit ERKs in cell and animal studies.	U 0126	88-93	mitogen-activated protein kinase kinase 1	Homo sapiens	63-67
15194007-2	2004	ERKs are activated by the dual phosphorylation kinase MEK1 and MEK1 inhibitors PD98059, U0126 and CI-1040 are now widely used to inhibit ERKs in cell and animal studies.	U 0126	88-93	mitogen-activated protein kinase 1	Homo sapiens	137-141
15194007-3	2004	In an analysis of ERK functions in astrocytes we found that PD98059 (100microM) failed to inhibit ERK phosphorylation but U0126 (50microM) inhibited ERK phosphorylation to approximately 80%.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	18-21
15212942-5	2004	The survival effect of NGF was inhibited by inhibitors of protein kinase C (PKC), phosphatidylinositol-3-kinase (PI 3-kinase), and the mitogen-activated protein kinase kinase (MEK) inhibitors GF109203X, LY294002, and U0126.	U 0126	217-222	nerve growth factor	Rattus norvegicus	23-26
15114341-4	2004	Consistent with this, rolipram, either by peripheral administration or direct intra-CA1 infusion, enhanced the retrieval of long-term memory impaired by intra-CA1 infusion of U0126 using the step-through inhibitory avoidance test.	U 0126	175-180	carbonic anhydrase 1	Rattus norvegicus	84-87
15114341-4	2004	Consistent with this, rolipram, either by peripheral administration or direct intra-CA1 infusion, enhanced the retrieval of long-term memory impaired by intra-CA1 infusion of U0126 using the step-through inhibitory avoidance test.	U 0126	175-180	carbonic anhydrase 1	Rattus norvegicus	159-162
15487702-6	2004	Similar experiments were performed using LY294002 and U0126, specific inhibitors of PI3 kinase and MEK, respectively.	U 0126	54-59	midkine	Mus musculus	99-102
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	19-22
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	tumor protein p53	Homo sapiens	128-131
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	tumor protein p53	Homo sapiens	140-143
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	cyclin dependent kinase inhibitor 1A	Homo sapiens	149-152
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	cyclin dependent kinase inhibitor 1A	Homo sapiens	153-157
15212949-3	2004	Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks.	U 0126	72-77	cyclin D1	Homo sapiens	221-230
15210577-7	2004	3 6MNA stimulation of MMP-1 secretion was inhibited approximately 30% by PGE1 (1 microm) and approximately 80% by the Erk pathway inhibitor UO126 (10 microm), confirming that PGE depletion and Erk activation mediate MMP-1 secretion by 6MNA.	U 0126	140-145	interstitial collagenase	Oryctolagus cuniculus	22-27
15183121-6	2004	Two specific inhibitors of the MAPK/ERK pathway, PD-98059 and U-0126, also enhanced dCK activity.	U 0126	62-68	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	84-87
14963018-4	2004	Our experimental results show that UVA-induced Ser727 phosphorylation of STAT1 was, to different degrees, diminished by PD98059 and U0126, two specific inhibitors of MEKs, and SB202190 and PD169316, inhibitors of p38 kinase and c-Jun N-terminal kinases (JNKs), respectively.	U 0126	132-137	signal transducer and activator of transcription 1	Homo sapiens	73-78
14963018-4	2004	Our experimental results show that UVA-induced Ser727 phosphorylation of STAT1 was, to different degrees, diminished by PD98059 and U0126, two specific inhibitors of MEKs, and SB202190 and PD169316, inhibitors of p38 kinase and c-Jun N-terminal kinases (JNKs), respectively.	U 0126	132-137	mitogen-activated protein kinase 1	Homo sapiens	213-216
15231676-3	2004	We investigated the ability of the MEK activation inhibitor U0126 to block the increased growth of estrogen receptor-positive MCF-7 breast cancer cells caused by fibroblast growth factor 1 (FGF-1), heregulin beta1 (HRGbeta1), and epidermal growth factor (EGF) in the presence of the pure antiestrogen ICI 182780 (Faslodex; fulvestrant).	U 0126	60-65	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
15231676-3	2004	We investigated the ability of the MEK activation inhibitor U0126 to block the increased growth of estrogen receptor-positive MCF-7 breast cancer cells caused by fibroblast growth factor 1 (FGF-1), heregulin beta1 (HRGbeta1), and epidermal growth factor (EGF) in the presence of the pure antiestrogen ICI 182780 (Faslodex; fulvestrant).	U 0126	60-65	fibroblast growth factor 1	Homo sapiens	162-188
15231676-3	2004	We investigated the ability of the MEK activation inhibitor U0126 to block the increased growth of estrogen receptor-positive MCF-7 breast cancer cells caused by fibroblast growth factor 1 (FGF-1), heregulin beta1 (HRGbeta1), and epidermal growth factor (EGF) in the presence of the pure antiestrogen ICI 182780 (Faslodex; fulvestrant).	U 0126	60-65	fibroblast growth factor 1	Homo sapiens	190-195
15231676-4	2004	We found that either FGF-1 or HRGbeta1 but not EGF substantially reduced the inhibitory effects of U0126 on growth and ERK1/2 activation, including the combined inhibitory effects of U0126 and ICI 182780.	U 0126	99-104	fibroblast growth factor 1	Homo sapiens	21-26
15231676-4	2004	We found that either FGF-1 or HRGbeta1 but not EGF substantially reduced the inhibitory effects of U0126 on growth and ERK1/2 activation, including the combined inhibitory effects of U0126 and ICI 182780.	U 0126	183-188	fibroblast growth factor 1	Homo sapiens	21-26
15231676-9	2004	We also demonstrate that the cytosolic phospholipase A2 inhibitor arachidonyl trifluoro methyl ketone and the pan PKC inhibitor bisindolymaleimide abrogated U0126-resistant phosphorylation of ERK1/2 induced by HRGbeta1 but not by FGF-1.	U 0126	157-162	phospholipase A2 group IVA	Homo sapiens	29-55
15231676-9	2004	We also demonstrate that the cytosolic phospholipase A2 inhibitor arachidonyl trifluoro methyl ketone and the pan PKC inhibitor bisindolymaleimide abrogated U0126-resistant phosphorylation of ERK1/2 induced by HRGbeta1 but not by FGF-1.	U 0126	157-162	mitogen-activated protein kinase 3	Homo sapiens	192-198
15231676-9	2004	We also demonstrate that the cytosolic phospholipase A2 inhibitor arachidonyl trifluoro methyl ketone and the pan PKC inhibitor bisindolymaleimide abrogated U0126-resistant phosphorylation of ERK1/2 induced by HRGbeta1 but not by FGF-1.	U 0126	157-162	fibroblast growth factor 1	Homo sapiens	230-235
15231676-10	2004	Phosphorylation of ERK5 by all three of the factors was also resistant to U0126 suggesting that its activation is not sufficient to overturn growth inhibition due to diminished ERK1/2 activation.	U 0126	74-79	mitogen-activated protein kinase 7	Homo sapiens	19-23
15183100-7	2004	Furthermore, EGF-induced protection was substantially reduced by either the PI3K inhibitor LY294002 (25 microm) or the MEK inhibitor U0126 (10 microm), under conditions in which phosphorylation of Akt and ERK1/2, respectively, was blocked.	U 0126	133-138	epidermal growth factor	Homo sapiens	13-16
15183100-7	2004	Furthermore, EGF-induced protection was substantially reduced by either the PI3K inhibitor LY294002 (25 microm) or the MEK inhibitor U0126 (10 microm), under conditions in which phosphorylation of Akt and ERK1/2, respectively, was blocked.	U 0126	133-138	mitogen-activated protein kinase kinase 7	Homo sapiens	119-122
15132991-9	2004	However, treatment with U0126 (known as the ERKs inhibitor) or wortmannin (known as the PI-3K inhibitor), but not SB203580 (known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells.	U 0126	24-29	mitogen-activated protein kinase 3	Homo sapiens	44-48
15183100-7	2004	Furthermore, EGF-induced protection was substantially reduced by either the PI3K inhibitor LY294002 (25 microm) or the MEK inhibitor U0126 (10 microm), under conditions in which phosphorylation of Akt and ERK1/2, respectively, was blocked.	U 0126	133-138	AKT serine/threonine kinase 1	Homo sapiens	197-200
15132991-9	2004	However, treatment with U0126 (known as the ERKs inhibitor) or wortmannin (known as the PI-3K inhibitor), but not SB203580 (known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells.	U 0126	24-29	matrix metallopeptidase 9	Homo sapiens	195-200
15183100-7	2004	Furthermore, EGF-induced protection was substantially reduced by either the PI3K inhibitor LY294002 (25 microm) or the MEK inhibitor U0126 (10 microm), under conditions in which phosphorylation of Akt and ERK1/2, respectively, was blocked.	U 0126	133-138	mitogen-activated protein kinase 3	Homo sapiens	205-211
15132991-9	2004	However, treatment with U0126 (known as the ERKs inhibitor) or wortmannin (known as the PI-3K inhibitor), but not SB203580 (known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells.	U 0126	24-29	X protein	Hepatitis B virus	212-215
15132991-9	2004	However, treatment with U0126 (known as the ERKs inhibitor) or wortmannin (known as the PI-3K inhibitor), but not SB203580 (known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells.	U 0126	24-29	X protein	Hepatitis B virus	219-222
15112327-10	2004	U0126, a MEK1/2 inhibitor, completely abrogated the phosphorylation of ERK1/2 and the cell proliferation in response to HGF.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	9-15
15132991-10	2004	Seemingly, the invasiveness of HBx-transfected cells was decreased by treating with U0126 or wortmannin, but not SB203580.	U 0126	84-89	X protein	Hepatitis B virus	31-34
15249224-7	2004	SB203580 inhibition of p38 activity eliminated activin A-mediated growth inhibition and Hb synthesis, whereas U0126 inhibition of ERK1/2 activity augmented the effects of activin A on K562 cells.	U 0126	110-115	mitogen-activated protein kinase 3	Homo sapiens	130-136
15239099-7	2004	Accordingly, leading postnatal day 2-isolated hepatocytes to embryo or adult redox conditions with H(2)O(2) or NO-H(2)O(2) scavengers, or with ERK inhibitor U0126, p38 inhibitor SB202190 or p38 activator anisomycin resulted in correlative changes of ERK/p38 activity ratio, cyclin D1 expression, and [(3)H] thymidine incorporation in the cells.	U 0126	157-162	Eph receptor B1	Rattus norvegicus	143-146
15153785-5	2004	Treatment of BHV-4-infected BAE cells with either U0126, a potent inhibitor of MAPK/ERK kinase, or arsenite dose-dependently blocked ERK activation and inhibited viral DNA synthesis and viral replication in the culture.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	79-83
15153785-5	2004	Treatment of BHV-4-infected BAE cells with either U0126, a potent inhibitor of MAPK/ERK kinase, or arsenite dose-dependently blocked ERK activation and inhibited viral DNA synthesis and viral replication in the culture.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	84-87
15153785-5	2004	Treatment of BHV-4-infected BAE cells with either U0126, a potent inhibitor of MAPK/ERK kinase, or arsenite dose-dependently blocked ERK activation and inhibited viral DNA synthesis and viral replication in the culture.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	133-136
15112327-10	2004	U0126, a MEK1/2 inhibitor, completely abrogated the phosphorylation of ERK1/2 and the cell proliferation in response to HGF.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	71-77
15112327-10	2004	U0126, a MEK1/2 inhibitor, completely abrogated the phosphorylation of ERK1/2 and the cell proliferation in response to HGF.	U 0126	0-5	hepatocyte growth factor	Homo sapiens	120-123
15250049-7	2004	Type II collagen mRNA expression was expressed strongly during chondrogenesis and MEK inhibition (U0126) resulted in complete down-regulation of type II collagen.	U 0126	98-103	mitogen-activated protein kinase kinase 7	Homo sapiens	82-85
15252145-5	2004	Moreover, a MEK1/2 inhibitor, U0126, mimicked nobiletin"s ability to decrease the production of proMMPs-1 and 9 in human fibrosarcoma HT-1080 cells stimulated by 12-O-tetradecanoyl phorbol-13-acetate (TPA).	U 0126	30-35	mitogen-activated protein kinase kinase 1	Homo sapiens	12-18
15283151-8	2004	New agents which inhibit the signaling pathway related to BCR-ABL, such as adaphostin (NSC680410), farnesyltransferase inhibitor SCH66336, MAP kinase inhibitor PD184352, PD98059, U0126, and antibiotic geldanamycin, have shown excellent activity combined with imatinib in vitro.	U 0126	179-184	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	58-65
15212964-5	2004	When cultured astrocytes were incubated during 8 h simulated ischemia with [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] (U0126), an extracellular regulated kinase 1 and 2 (Erk1/2) inhibitor or wortmannin, a phosphatidylinositol 3-kinase (PI3 kinase)/Akt inhibitor, the cell apoptosis was accelerated.	U 0126	138-143	mitogen activated protein kinase 3	Rattus norvegicus	189-195
15212964-5	2004	When cultured astrocytes were incubated during 8 h simulated ischemia with [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] (U0126), an extracellular regulated kinase 1 and 2 (Erk1/2) inhibitor or wortmannin, a phosphatidylinositol 3-kinase (PI3 kinase)/Akt inhibitor, the cell apoptosis was accelerated.	U 0126	138-143	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	224-253
15212964-5	2004	When cultured astrocytes were incubated during 8 h simulated ischemia with [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] (U0126), an extracellular regulated kinase 1 and 2 (Erk1/2) inhibitor or wortmannin, a phosphatidylinositol 3-kinase (PI3 kinase)/Akt inhibitor, the cell apoptosis was accelerated.	U 0126	138-143	AKT serine/threonine kinase 1	Rattus norvegicus	267-270
15173027-6	2004	Activation of the p44/42 mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinases 1 and 2 [ERK 1/2]) pathway on binding of FVIIa to TF was demonstrated by transient ERK phosphorylation in Western blots and by suppression of proliferation with the specific MEK (MAP kinase/ERK kinase) inhibitor UO126.	U 0126	316-321	mitogen-activated protein kinase 1	Homo sapiens	65-111
15122344-5	2004	Moreover, p21 induction was dramatically attenuated by ERK inhibitors PD98059 and U0126.	U 0126	82-87	H3 histone pseudogene 16	Homo sapiens	10-13
15122344-5	2004	Moreover, p21 induction was dramatically attenuated by ERK inhibitors PD98059 and U0126.	U 0126	82-87	mitogen-activated protein kinase 1	Homo sapiens	55-58
15067015-5	2004	Furthermore, the trans-10, cis-12 CLA-mediated activation of MEK/ERK could be attenuated by pretreatment with U0126 and pertussis toxin.	U 0126	110-115	mitogen-activated protein kinase kinase 7	Homo sapiens	61-64
15067015-5	2004	Furthermore, the trans-10, cis-12 CLA-mediated activation of MEK/ERK could be attenuated by pretreatment with U0126 and pertussis toxin.	U 0126	110-115	mitogen-activated protein kinase 1	Homo sapiens	65-68
15018608-7	2004	Furthermore, treatment of mIMCD3 cells with MAPK (mitogen-activated protein kinase) inhibitors (SB203580, PD98059, U0126 and SP600125) and a proteasome inhibitor (MG132) suppressed the increase in Osp94 gene expression caused by hypertonic NaCl.	U 0126	115-120	heat shock protein 4 like	Mus musculus	197-202
15173027-6	2004	Activation of the p44/42 mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinases 1 and 2 [ERK 1/2]) pathway on binding of FVIIa to TF was demonstrated by transient ERK phosphorylation in Western blots and by suppression of proliferation with the specific MEK (MAP kinase/ERK kinase) inhibitor UO126.	U 0126	316-321	mitogen-activated protein kinase 3	Homo sapiens	113-120
15173027-6	2004	Activation of the p44/42 mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinases 1 and 2 [ERK 1/2]) pathway on binding of FVIIa to TF was demonstrated by transient ERK phosphorylation in Western blots and by suppression of proliferation with the specific MEK (MAP kinase/ERK kinase) inhibitor UO126.	U 0126	316-321	coagulation factor III, tissue factor	Homo sapiens	154-156
15147830-3	2004	The MEK inhibitor U0126 (0.1 to 10 microM) enhanced the TPA-induced ICAM-1 expression but not the IFN-gamma-induced one.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
15196329-4	2004	17beta-estradiol-induced activation of the coll-73-luc reporter correlated with cytoplasmic localization of various ERalpha and ERbeta mutant receptors, and was inhibited in the presence of the full estrogen antagonist ICI 182,780 and the MAP-kinase inhibitor UO126.	U 0126	260-265	estrogen receptor 2	Homo sapiens	128-134
15069060-7	2004	Dominant negative MEK1 (a kinase that activates ERK1/2) blocked flagellin-stimulated IL-8 and MIP3alpha transcriptional activity, while the MEK-specific inhibitors PD98059 and U0126 reduced protein production of these cytokines.	U 0126	176-181	mitogen-activated protein kinase kinase 1	Homo sapiens	18-22
15069060-7	2004	Dominant negative MEK1 (a kinase that activates ERK1/2) blocked flagellin-stimulated IL-8 and MIP3alpha transcriptional activity, while the MEK-specific inhibitors PD98059 and U0126 reduced protein production of these cytokines.	U 0126	176-181	C-C motif chemokine ligand 20	Homo sapiens	94-103
15147830-3	2004	The MEK inhibitor U0126 (0.1 to 10 microM) enhanced the TPA-induced ICAM-1 expression but not the IFN-gamma-induced one.	U 0126	18-23	intercellular adhesion molecule 1	Homo sapiens	68-74
15147830-4	2004	U0126 also enhanced the ICAM-1 expression induced by two other PKC activators teleocidin (22.5 nM) and aplysiatoxin (14.9 nM).	U 0126	0-5	intercellular adhesion molecule 1	Homo sapiens	24-30
15147830-8	2004	TPA partially decreased the level of IkappaB-alpha and the reduction was further augmented by U0126 in a concentration-dependent manner.	U 0126	94-99	NFKB inhibitor alpha	Homo sapiens	37-50
15044465-7	2004	TGF-beta-induced motility was blocked by coincubation with either the phosphatidylinositol 3-kinase inhibitor LY294002, the mitogen-activated protein kinase (MAPK) inhibitor U0126, the p38 MAPK inhibitor SB202190, and an integrin beta(1) blocking antibody.	U 0126	174-179	transforming growth factor beta 1	Homo sapiens	0-8
15144886-6	2004	Also, U0126 (10 microM; an upstream ERK1/2 inhibitor) completely blocked agonist-induced hONA proliferation in normoxia and partially blocked the same in hypoxia.	U 0126	6-11	mitogen-activated protein kinase 3	Homo sapiens	36-42
14749211-7	2004	We found that peroxynitrite-induced arachidonic acid release was completely abrogated by the mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 and by calcium chelators.	U 0126	146-151	Eph receptor B1	Rattus norvegicus	119-122
14749211-8	2004	With the p38 inhibitor SB-20219, we demonstrated that peroxynitrite-induced p38 phosphorylation led to minor arachidonic acid release, whereas U0126 completely blocked p38 phosphorylation.	U 0126	143-148	mitogen activated protein kinase 14	Rattus norvegicus	9-12
14749256-9	2004	Inhibition of ERK1/2 phosphorylation with U-0126 (10 micromol/l) stimulated I(sc), indicating constitutive ENaC inhibition.	U 0126	42-48	mitogen-activated protein kinase 1	Canis lupus familiaris	14-20
15151916-5	2004	In contrast, inhibition of mitogen-activated protein (MAP) kinase with PD-98059 or U0126 abolished the stimulatory effect of IGF-I.	U 0126	83-88	insulin-like growth factor 1	Rattus norvegicus	125-130
14963412-4	2004	ZBP-89-induced apoptosis was markedly enhanced by ERK inhibition with U0126.	U 0126	70-75	zinc finger protein 148	Homo sapiens	0-6
14963412-4	2004	ZBP-89-induced apoptosis was markedly enhanced by ERK inhibition with U0126.	U 0126	70-75	mitogen-activated protein kinase 1	Homo sapiens	50-53
15172989-3	2004	MAP/extracellular signal-regulated kinase 1/2 inhibition by U0126 caused G(1) cyclins down-regulation and p27Kip1 up-regulation as well.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	4-45
15172989-3	2004	MAP/extracellular signal-regulated kinase 1/2 inhibition by U0126 caused G(1) cyclins down-regulation and p27Kip1 up-regulation as well.	U 0126	60-65	cyclin dependent kinase inhibitor 1B	Homo sapiens	106-113
15529758-5	2004	Inhibition of ERK-pathway with UO126 did not prevent the accumulation of heat shock protein 70.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	14-17
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	U 0126	20-25	mitogen-activated protein kinase 14	Homo sapiens	84-87
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	U 0126	20-25	mitogen-activated protein kinase 8	Homo sapiens	93-96
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	U 0126	20-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	139-144
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	U 0126	20-25	mitogen-activated protein kinase 14	Homo sapiens	208-211
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	U 0126	20-25	mitogen-activated protein kinase 8	Homo sapiens	216-219
15095291-2	2004	Specific pharmacological inhibitors, like PD98059 and U0126, are often used to inhibit p42/p44 MAPK signaling.	U 0126	54-59	cyclin-dependent kinase 20	Mus musculus	87-90
15095291-2	2004	Specific pharmacological inhibitors, like PD98059 and U0126, are often used to inhibit p42/p44 MAPK signaling.	U 0126	54-59	mitogen-activated protein kinase 3	Mus musculus	91-94
15156564-1	2004	PD98059 and U0126 are considered as specific inhibitors of the p42/44 mitogen-activated protein kinases (MAPK) pathway, which affects osteogenesis and adipogenesis.	U 0126	12-17	cyclin dependent kinase 20	Homo sapiens	63-66
15156564-4	2004	In contrast, U0126 slightly decreased osteogenesis but had no effects on adipogenesis, although it inhibited p42/44 MAPK more potently than PD98059.	U 0126	13-18	cyclin dependent kinase 20	Homo sapiens	109-112
15153516-8	2004	Mitogen-activated protein/ERK kinase inhibitor U0126 caused approximately 30% inhibition of NGF-induced MIP-1beta production but had no effect on priming by C3a.	U 0126	47-52	mitogen-activated protein kinase 1	Homo sapiens	26-29
15051723-7	2004	The wall stress-induced increase in the DNA-binding activity of GATA-4 was abolished both in the presence of the p38 inhibitor SB239063 and MEK1/2 inhibitor U0126.	U 0126	157-162	GATA binding protein 4	Rattus norvegicus	64-70
15051723-7	2004	The wall stress-induced increase in the DNA-binding activity of GATA-4 was abolished both in the presence of the p38 inhibitor SB239063 and MEK1/2 inhibitor U0126.	U 0126	157-162	mitogen activated protein kinase kinase 1	Rattus norvegicus	140-146
15075366-9	2004	Second, the p38 inhibitors SB202190 and SB203580 reduced nucleotide-induced blebbing and actin reorganization, whereas the MAPK kinase-1/2 inhibitor U0126, which blocks ERK1/ERK2 activation, had no discernable effect.	U 0126	149-154	mitogen-activated protein kinase 3	Homo sapiens	123-127
15075366-9	2004	Second, the p38 inhibitors SB202190 and SB203580 reduced nucleotide-induced blebbing and actin reorganization, whereas the MAPK kinase-1/2 inhibitor U0126, which blocks ERK1/ERK2 activation, had no discernable effect.	U 0126	149-154	mitogen-activated protein kinase 3	Homo sapiens	169-173
15075366-9	2004	Second, the p38 inhibitors SB202190 and SB203580 reduced nucleotide-induced blebbing and actin reorganization, whereas the MAPK kinase-1/2 inhibitor U0126, which blocks ERK1/ERK2 activation, had no discernable effect.	U 0126	149-154	mitogen-activated protein kinase 1	Homo sapiens	174-178
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p &lt; 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	mitogen-activated protein kinase 1	Mus musculus	52-56
15153516-8	2004	Mitogen-activated protein/ERK kinase inhibitor U0126 caused approximately 30% inhibition of NGF-induced MIP-1beta production but had no effect on priming by C3a.	U 0126	47-52	C-C motif chemokine ligand 4	Homo sapiens	104-113
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p &lt; 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	mitogen-activated protein kinase 1	Mus musculus	57-60
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p &lt; 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	interleukin 4	Mus musculus	184-188
15147515-5	2004	Ser9-GSK3beta phosphorylation induced by HNE was abolished by treatment with LY294002 or U0126, two inhibitors of PI3K/AKT and ERK pathways, respectively.	U 0126	89-94	glycogen synthase kinase 3 beta	Homo sapiens	5-13
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p &lt; 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	interleukin 5	Mus musculus	190-194
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p &lt; 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	interleukin 13	Mus musculus	196-201
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p &lt; 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	chemokine (C-C motif) ligand 11	Mus musculus	207-214
15153527-6	2004	U0126 also substantially (p &lt; 0.05) reduced the serum levels of total IgE and OVA-specific IgE and IgG1.	U 0126	0-5	LOC105243590	Mus musculus	102-106
15153527-7	2004	Histological studies show that U0126 dramatically inhibited OVA-induced lung tissue eosinophilia, airway mucus production, and expression of VCAM-1 in lung tissues.	U 0126	31-36	vascular cell adhesion molecule 1	Mus musculus	141-147
15153527-9	2004	Western blot analysis of whole lung lysates shows that U0126 markedly attenuated OVA-induced tyrosine phosphorylation of ERK1/2.	U 0126	55-60	mitogen-activated protein kinase 3	Mus musculus	121-127
15147515-5	2004	Ser9-GSK3beta phosphorylation induced by HNE was abolished by treatment with LY294002 or U0126, two inhibitors of PI3K/AKT and ERK pathways, respectively.	U 0126	89-94	AKT serine/threonine kinase 1	Homo sapiens	119-122
15147515-5	2004	Ser9-GSK3beta phosphorylation induced by HNE was abolished by treatment with LY294002 or U0126, two inhibitors of PI3K/AKT and ERK pathways, respectively.	U 0126	89-94	mitogen-activated protein kinase 1	Homo sapiens	127-130
15102045-3	2004	OBJECTIVES: The purpose of this study was to investigate the gelatinolytic activity in human osteosarcoma cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of SB203580 (p38 inhibitor), U0126 [mitogen-activated protein kinase kinase (MEK) inhibitor], and LY294002 [phosphatidylinositaol 3-kinase (PI3K) inhibitor].	U 0126	243-248	interleukin 1 alpha	Homo sapiens	128-146
15102045-8	2004	In addition, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated MMP-9 production, respectively (p &lt; 0.05).	U 0126	23-28	interleukin 1 alpha	Homo sapiens	69-78
15102045-3	2004	OBJECTIVES: The purpose of this study was to investigate the gelatinolytic activity in human osteosarcoma cells stimulated with interleukin-1alpha (IL-1alpha) or Porphyromonas gingivalis in the absence or presence of SB203580 (p38 inhibitor), U0126 [mitogen-activated protein kinase kinase (MEK) inhibitor], and LY294002 [phosphatidylinositaol 3-kinase (PI3K) inhibitor].	U 0126	243-248	interleukin 1 alpha	Homo sapiens	148-157
15102045-8	2004	In addition, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated MMP-9 production, respectively (p &lt; 0.05).	U 0126	23-28	matrix metallopeptidase 9	Homo sapiens	107-112
15102045-11	2004	SB203580, U0126, and LY294002 suppress MMP-9 production and/or activity and may therefore be valuable therapeutics in MMP-mediated periodontal destruction, and might be proved clinically useful agents, in combination with standard treatment modalities, in the treatment of periodontitis.	U 0126	10-15	matrix metallopeptidase 9	Homo sapiens	39-44
15047712-7	2004	Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	18-22
15102045-11	2004	SB203580, U0126, and LY294002 suppress MMP-9 production and/or activity and may therefore be valuable therapeutics in MMP-mediated periodontal destruction, and might be proved clinically useful agents, in combination with standard treatment modalities, in the treatment of periodontitis.	U 0126	10-15	matrix metallopeptidase 2	Homo sapiens	39-42
15161349-8	2004	The survival-enhancing effect of bFGF was partly inhibited by U0126 and PD98059.	U 0126	62-67	fibroblast growth factor 2	Homo sapiens	33-37
15044479-5	2004	Blockade of the MEK/ERK kinase pathway with U0126 abrogates the ability of ET-1 to induce expression of matrix and matrix-associated mRNAs and the CCN2 protein.	U 0126	44-49	mitogen-activated protein kinase kinase 7	Homo sapiens	16-19
15044479-5	2004	Blockade of the MEK/ERK kinase pathway with U0126 abrogates the ability of ET-1 to induce expression of matrix and matrix-associated mRNAs and the CCN2 protein.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	20-23
15044479-5	2004	Blockade of the MEK/ERK kinase pathway with U0126 abrogates the ability of ET-1 to induce expression of matrix and matrix-associated mRNAs and the CCN2 protein.	U 0126	44-49	endothelin 1	Homo sapiens	75-79
15044479-5	2004	Blockade of the MEK/ERK kinase pathway with U0126 abrogates the ability of ET-1 to induce expression of matrix and matrix-associated mRNAs and the CCN2 protein.	U 0126	44-49	cellular communication network factor 2	Homo sapiens	147-151
15047712-7	2004	Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner.	U 0126	77-82	leucine rich glioma inactivated 1	Homo sapiens	105-109
15047712-7	2004	Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner.	U 0126	77-82	matrix metallopeptidase 1	Homo sapiens	130-134
15047712-7	2004	Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner.	U 0126	77-82	matrix metallopeptidase 3	Homo sapiens	139-143
15047712-7	2004	Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner.	U 0126	77-82	mitogen-activated protein kinase 3	Homo sapiens	161-167
15123736-4	2004	Inhibition of ERK activation either by U0126 or by dominant-negative mitogen-activated protein kinase/ERK kinase (MEK) overexpression results in a dramatic reduction of PM damaged neurons and nuclear condensation.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	14-17
15037605-7	2004	PKCbetaII-mediated invasion is blocked by the Mek inhibitor, U0126, and by expression of either dominant negative Rac1 or kinase-deficient atypical PKCiota.	U 0126	61-66	phospholipase C, beta 2	Rattus norvegicus	0-9
15064145-6	2004	Addition of either the PI3K inhibitor wortmannin or the MAPK inhibitor U0126 blocked 50-100% BDNF-induced neurite elongation; U0126 also significantly reduced neurite regeneration below untreated control levels.	U 0126	71-76	brain derived neurotrophic factor	Sus scrofa	93-97
15274354-13	2004	Pre-incubating cells with ERK inhibitors (U0126 and PD98059) attenuated the HMJ-38-induced ERK activation and apoptosis.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	26-29
15021912-6	2004	Nocodazole activated Plk3 and its activation was blocked by MEK-specific inhibitors (PD98059 or U0126).	U 0126	96-101	polo like kinase 3	Homo sapiens	21-25
15021912-6	2004	Nocodazole activated Plk3 and its activation was blocked by MEK-specific inhibitors (PD98059 or U0126).	U 0126	96-101	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
15111329-4	2004	The VEGF-induced mRNA increase of Ets-1 was suppressed by a tyrosine kinase inhibitor (genistein), by inhibitors of MEK (mitogen-activated protein and extracellular signal-regulated kinase kinase) (PD98059 and UO126), and by inhibitors of protein kinase C (GF109203X, staurosporine, and Go6976).	U 0126	210-215	vascular endothelial growth factor A	Mus musculus	4-8
15111329-4	2004	The VEGF-induced mRNA increase of Ets-1 was suppressed by a tyrosine kinase inhibitor (genistein), by inhibitors of MEK (mitogen-activated protein and extracellular signal-regulated kinase kinase) (PD98059 and UO126), and by inhibitors of protein kinase C (GF109203X, staurosporine, and Go6976).	U 0126	210-215	E26 avian leukemia oncogene 1, 5' domain	Mus musculus	34-39
15274354-13	2004	Pre-incubating cells with ERK inhibitors (U0126 and PD98059) attenuated the HMJ-38-induced ERK activation and apoptosis.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	91-94
15113601-12	2004	U0126 and Bis I significantly decreased GAP-43, but not synapsin I expression.	U 0126	0-5	growth associated protein 43	Rattus norvegicus	40-46
14639470-7	2004	Furthermore, U0126, a specific inhibitor of MAPK kinase (MEK), suppressed the stretch-induced mRNA expressions of Cbfa1, ALP and type I collagen in OPLL cells.	U 0126	13-18	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
14639470-7	2004	Furthermore, U0126, a specific inhibitor of MAPK kinase (MEK), suppressed the stretch-induced mRNA expressions of Cbfa1, ALP and type I collagen in OPLL cells.	U 0126	13-18	RUNX family transcription factor 2	Homo sapiens	114-119
14639470-7	2004	Furthermore, U0126, a specific inhibitor of MAPK kinase (MEK), suppressed the stretch-induced mRNA expressions of Cbfa1, ALP and type I collagen in OPLL cells.	U 0126	13-18	alkaline phosphatase, placental	Homo sapiens	121-124
14639470-7	2004	Furthermore, U0126, a specific inhibitor of MAPK kinase (MEK), suppressed the stretch-induced mRNA expressions of Cbfa1, ALP and type I collagen in OPLL cells.	U 0126	13-18	OPLL	Homo sapiens	148-152
14729583-8	2004	The p38 inhibitor SB203580 blocked TPA-mediated AP-1 activation, while the MEK1/2 inhibitor U0126 was not inhibitory despite suppression of c-Fos expression in mouse skin.	U 0126	92-97	mitogen-activated protein kinase kinase 1	Mus musculus	75-81
15086522-6	2004	We also found that application of the ERK pathway inhibitors U0126 (50 micro m) or PD98059 (100 micro m) markedly reduced 4AP-induced epileptiform synchronization, thus abolishing ictal discharges in the CA3 area.	U 0126	61-66	Eph receptor B1	Rattus norvegicus	38-41
15086522-6	2004	We also found that application of the ERK pathway inhibitors U0126 (50 micro m) or PD98059 (100 micro m) markedly reduced 4AP-induced epileptiform synchronization, thus abolishing ictal discharges in the CA3 area.	U 0126	61-66	carbonic anhydrase 3	Rattus norvegicus	204-207
14742747-8	2004	This activation of ERK1/2 was blocked by pretreatment with the mitogen-activated protein kinase kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene (U-0126) or the protein kinase C inhibitor chelerythrine chloride, but not by MRS-2179.	U 0126	113-176	mitogen-activated protein kinase 3	Homo sapiens	19-25
14742747-8	2004	This activation of ERK1/2 was blocked by pretreatment with the mitogen-activated protein kinase kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene (U-0126) or the protein kinase C inhibitor chelerythrine chloride, but not by MRS-2179.	U 0126	178-184	mitogen-activated protein kinase 3	Homo sapiens	19-25
15069537-5	2004	MEK1/2 inhibitor U0126 significantly induced the expression of occludin at the cell-cell junction and substantially suppressed the p-MEK1/2 and p-ERK1/2 expressions in PC-1.0 and AsPC-1 cells.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
15069537-5	2004	MEK1/2 inhibitor U0126 significantly induced the expression of occludin at the cell-cell junction and substantially suppressed the p-MEK1/2 and p-ERK1/2 expressions in PC-1.0 and AsPC-1 cells.	U 0126	17-22	occludin	Mesocricetus auratus	63-71
15069537-5	2004	MEK1/2 inhibitor U0126 significantly induced the expression of occludin at the cell-cell junction and substantially suppressed the p-MEK1/2 and p-ERK1/2 expressions in PC-1.0 and AsPC-1 cells.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	133-139
15069537-5	2004	MEK1/2 inhibitor U0126 significantly induced the expression of occludin at the cell-cell junction and substantially suppressed the p-MEK1/2 and p-ERK1/2 expressions in PC-1.0 and AsPC-1 cells.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	146-152
15069537-7	2004	In addition, occludin expressions at cell-cell junction were restored and p-MEK1/2 and p-ERK1/2 expressions were suppressed by subsequent U0126-treatment in DF treated PC-1 and CAPAN-2 cells.	U 0126	138-143	mitogen-activated protein kinase kinase 1	Homo sapiens	76-82
15069537-7	2004	In addition, occludin expressions at cell-cell junction were restored and p-MEK1/2 and p-ERK1/2 expressions were suppressed by subsequent U0126-treatment in DF treated PC-1 and CAPAN-2 cells.	U 0126	138-143	mitogen-activated protein kinase 3	Homo sapiens	89-95
15063796-3	2004	Use of a pharmacological inhibitor (U0126) demonstrated that extracellular signal regulated kinase (ERK) plays a major role in TPA-induced MMP-13 gene expression.	U 0126	36-41	mitogen-activated protein kinase 1	Mus musculus	61-98
15086914-8	2004	MAP kinase/ERK kinase (MEK) inhibitors, U0126 and PD98059, both inhibited BMK1 activation by high glucose in a concentration-dependent manner.	U 0126	40-45	mitogen-activated protein kinase 7	Rattus norvegicus	74-78
14985367-4	2004	When the MAPK pathway was blocked by MEK inhibitor U0126, degradation of polyubiquitinated cyclin B occurred even at pH 7.0 without an increase of the peptidase activity of the proteasome.	U 0126	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	37-40
15063796-3	2004	Use of a pharmacological inhibitor (U0126) demonstrated that extracellular signal regulated kinase (ERK) plays a major role in TPA-induced MMP-13 gene expression.	U 0126	36-41	mitogen-activated protein kinase 1	Mus musculus	100-103
15063796-3	2004	Use of a pharmacological inhibitor (U0126) demonstrated that extracellular signal regulated kinase (ERK) plays a major role in TPA-induced MMP-13 gene expression.	U 0126	36-41	matrix metallopeptidase 13	Mus musculus	139-145
14747473-5	2004	The pathway through which EGFR activates PKCdelta is suggested by the fact that the MEK-1 inhibitor U0126 and the phosphatidylinositol 3-kinase inhibitor LY294002 had no effect on PKCdelta activation, whereas lack of PLCgamma signaling resulted in delayed PKCdelta activation.	U 0126	100-105	protein kinase C delta	Homo sapiens	41-49
15116093-4	2004	Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55.	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	35-39
15116093-4	2004	Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55.	U 0126	71-76	tumor protein p53	Homo sapiens	106-109
15116093-4	2004	Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55.	U 0126	71-76	tumor protein p53	Homo sapiens	155-158
14747473-5	2004	The pathway through which EGFR activates PKCdelta is suggested by the fact that the MEK-1 inhibitor U0126 and the phosphatidylinositol 3-kinase inhibitor LY294002 had no effect on PKCdelta activation, whereas lack of PLCgamma signaling resulted in delayed PKCdelta activation.	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	84-89
15033458-6	2004	MEK inhibitor U0126 inhibited the down-regulation of Smad6 mRNA expression but not the up-regulation of Smad7 mRNA expression.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
15033458-6	2004	MEK inhibitor U0126 inhibited the down-regulation of Smad6 mRNA expression but not the up-regulation of Smad7 mRNA expression.	U 0126	14-19	SMAD family member 6	Homo sapiens	53-58
15033490-6	2004	Either adiponectin or inhibition of ERK1/2 with U0126 diminished the induction of IL6 by LPS (P&lt;0.05), but the combination of adiponectin and the inhibitor did not further reduce IL6 production.	U 0126	48-53	mitogen-activated protein kinase 3	Homo sapiens	36-42
15033490-6	2004	Either adiponectin or inhibition of ERK1/2 with U0126 diminished the induction of IL6 by LPS (P&lt;0.05), but the combination of adiponectin and the inhibitor did not further reduce IL6 production.	U 0126	48-53	interleukin 6	Homo sapiens	82-85
14742443-4	2004	This effect is blocked almost entirely by PD98059 and UO126, implying involvement of the MEK/ERK signal transduction cascade in the activation.	U 0126	54-59	Eph receptor B1	Rattus norvegicus	93-96
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	9-15
14963006-6	2004	Endothelin-1 or bFGF significantly increased the number of VSMCs counted 24 hours later compared with basal, and both responses were blocked by the MEK inhibitor, U0126, or iloprost.	U 0126	163-168	endothelin 1	Rattus norvegicus	0-12
14963006-6	2004	Endothelin-1 or bFGF significantly increased the number of VSMCs counted 24 hours later compared with basal, and both responses were blocked by the MEK inhibitor, U0126, or iloprost.	U 0126	163-168	fibroblast growth factor 2	Rattus norvegicus	16-20
14963006-7	2004	Under basal conditions, U0126 or iloprost reduced the number of viable cells and increased caspase-3 activity, which could be reversed by coapplication with endothelin-1, bFGF, or the adenylate cyclase inhibitor, SQ22536.	U 0126	24-29	caspase 3	Rattus norvegicus	91-100
14963006-7	2004	Under basal conditions, U0126 or iloprost reduced the number of viable cells and increased caspase-3 activity, which could be reversed by coapplication with endothelin-1, bFGF, or the adenylate cyclase inhibitor, SQ22536.	U 0126	24-29	endothelin 1	Rattus norvegicus	157-169
14963006-7	2004	Under basal conditions, U0126 or iloprost reduced the number of viable cells and increased caspase-3 activity, which could be reversed by coapplication with endothelin-1, bFGF, or the adenylate cyclase inhibitor, SQ22536.	U 0126	24-29	fibroblast growth factor 2	Rattus norvegicus	171-175
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	U 0126	0-5	glycogen synthase kinase 3 beta	Homo sapiens	65-74
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	92-98
15020233-5	2004	Further, the pretreatment of fibroblasts with U0126 inhibited serum-induced nuclear translocation of GSK-3beta.	U 0126	46-51	glycogen synthase kinase 3 beta	Homo sapiens	101-110
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	U 0126	0-5	glycogen synthase kinase 3 beta	Homo sapiens	150-159
14684387-5	2004	Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover.	U 0126	107-112	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	41-56
14644751-4	2004	EGF activated ERK1/2 in S2 tubules and IHKE-hOAT1, and, in both cases, inhibition of ERK activation (by U-0126) abolished this stimulation.	U 0126	104-110	pro-epidermal growth factor	Oryctolagus cuniculus	0-3
14644751-5	2004	In S2 tubules and IHKE-hOAT1, EGF led to an increase of organic anion uptake, which again was inhibited by U-0126.	U 0126	107-113	pro-epidermal growth factor	Oryctolagus cuniculus	30-33
14684387-5	2004	Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover.	U 0126	107-112	mitogen-activated protein kinase 1	Mus musculus	179-182
14684387-5	2004	Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover.	U 0126	107-112	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	218-233
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	U 0126	21-26	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	104-119
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	U 0126	21-26	midkine	Mus musculus	197-200
14684387-5	2004	Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover.	U 0126	107-112	mitogen-activated protein kinase kinase 1	Mus musculus	90-96
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	U 0126	21-26	mitogen-activated protein kinase 1	Mus musculus	201-204
14684387-5	2004	Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover.	U 0126	107-112	midkine	Mus musculus	90-93
15037119-6	2004	Intravitreal injection of IL-1 receptor antagonist (IL-1Ra) or MAP kinase inhibitor U0126 significantly decreased both ERK1/2 phosphorylation and MMP-9 induction suggesting that interruption of this cascade might attenuate retinal damage.	U 0126	84-89	mitogen-activated protein kinase 3	Homo sapiens	119-125
15001425-5	2004	ATP (10 microM) increased ERK2 phosphorylation from basal 17 +/- 3 to 53 +/- 4%, an effect suppressed in the presence of the MEK inhibitors PD-98059 (20 microM) or U0126 (10 microM).	U 0126	164-169	mitogen-activated protein kinase 1	Homo sapiens	26-30
15001425-5	2004	ATP (10 microM) increased ERK2 phosphorylation from basal 17 +/- 3 to 53 +/- 4%, an effect suppressed in the presence of the MEK inhibitors PD-98059 (20 microM) or U0126 (10 microM).	U 0126	164-169	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
15003938-7	2004	Finally, the specific ERK1/2 inhibitor U-0126 abolishes PDGF-induced expression of EGR-1 in these cells.	U 0126	39-45	mitogen-activated protein kinase 3	Homo sapiens	22-28
15003938-7	2004	Finally, the specific ERK1/2 inhibitor U-0126 abolishes PDGF-induced expression of EGR-1 in these cells.	U 0126	39-45	early growth response 1	Homo sapiens	83-88
15059911-3	2004	Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, reduced invasion, which correlated with reduction of the metalloproteinase matrix metalloproteinase 2.	U 0126	18-23	mitogen-activated protein kinase kinase 1	Mus musculus	27-70
15073105-6	2004	The activation of Akt and NF-kappa B was prevented by LY294002, whereas the activity of MAPK(Erk), but not NF-kappa B, was inhibited by U0126.	U 0126	136-141	mitogen-activated protein kinase 1	Homo sapiens	93-96
14747473-5	2004	The pathway through which EGFR activates PKCdelta is suggested by the fact that the MEK-1 inhibitor U0126 and the phosphatidylinositol 3-kinase inhibitor LY294002 had no effect on PKCdelta activation, whereas lack of PLCgamma signaling resulted in delayed PKCdelta activation.	U 0126	100-105	epidermal growth factor receptor	Homo sapiens	26-30
14709335-4	2004	ERK pathway inhibitors, PD98059 and U0126, down-regulated IL-17-induced MMP and ADAM-TS4 gene expression.	U 0126	36-41	interleukin 17A	Bos taurus	58-63
14709335-4	2004	ERK pathway inhibitors, PD98059 and U0126, down-regulated IL-17-induced MMP and ADAM-TS4 gene expression.	U 0126	36-41	ADAM metallopeptidase with thrombospondin type 1 motif 4	Bos taurus	80-88
15037119-6	2004	Intravitreal injection of IL-1 receptor antagonist (IL-1Ra) or MAP kinase inhibitor U0126 significantly decreased both ERK1/2 phosphorylation and MMP-9 induction suggesting that interruption of this cascade might attenuate retinal damage.	U 0126	84-89	matrix metallopeptidase 9	Homo sapiens	146-151
15010817-3	2004	U0126 (a MEK1/2 inhibitor) significantly suppressed ERK2 and p-ERK1/2 expressions in PC-1.0 and AsPC-1 cells (P&lt;0.05).	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	52-56
15010817-3	2004	U0126 (a MEK1/2 inhibitor) significantly suppressed ERK2 and p-ERK1/2 expressions in PC-1.0 and AsPC-1 cells (P&lt;0.05).	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	63-69
15030400-7	2004	Inhibition of hypoxia-induced ERK1/2 pathway with intracerebral administration of U0126 significantly attenuated the neuroprotection afforded by HP against HI injury.	U 0126	82-87	mitogen activated protein kinase 3	Rattus norvegicus	30-36
15030407-7	2004	An early and transient phosphorylation of ERK1/2 occurred after thapsigargin-induced ER stress, and targeting this pathway with the MEK inhibitors U0126 or PD98059 significantly reduced cell death.	U 0126	147-152	mitogen-activated protein kinase 3	Homo sapiens	42-48
15052200-3	2004	We evaluated the ability of a mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-specific inhibitor (U0126) to block extracellular signal-regulated kinase activation and mitigate ischemic neuronal damage in a model of deep hypothermic circulatory arrest.	U 0126	125-130	mitogen-activated protein kinase 3	Homo sapiens	63-102
15044623-0	2004	Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes.	U 0126	120-125	aryl hydrocarbon receptor	Homo sapiens	0-25
15107577-7	2004	Pretreatment with Go6983 (PKC inhibitor), U0126 (MEK inhibitor), or SB203580 (p38MARK inhibitor) partially inhibited the urotensin II-induced contraction with no effects on the high K(+)-induced contractions.	U 0126	42-47	urotensin 2	Rattus norvegicus	121-133
15044623-9	2004	We conclude that the widely used specific inhibitor of MEK/ERK, U0126, also acts as a potent AhR activator and an inducer of related genes.	U 0126	64-69	mitogen-activated protein kinase 1	Homo sapiens	59-62
15044623-9	2004	We conclude that the widely used specific inhibitor of MEK/ERK, U0126, also acts as a potent AhR activator and an inducer of related genes.	U 0126	64-69	aryl hydrocarbon receptor	Homo sapiens	93-96
15024089-7	2004	Strikingly, EGF-induced, FLNa-dependent migration of human melanoma cells is significantly reduced by UO126 treatment.	U 0126	102-107	epidermal growth factor	Homo sapiens	12-15
15024089-7	2004	Strikingly, EGF-induced, FLNa-dependent migration of human melanoma cells is significantly reduced by UO126 treatment.	U 0126	102-107	filamin A	Homo sapiens	25-29
15044623-4	2004	We now report that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a specific inhibitor of MAPK kinase (MEK) MEK1/2, elicits a marked increase in CYP1A1 expression at both mRNA and protein levels associated with a significant increase of enzyme activity in primary rat hepatocytes and a human hepatoma cell line.	U 0126	19-78	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
15044623-4	2004	We now report that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a specific inhibitor of MAPK kinase (MEK) MEK1/2, elicits a marked increase in CYP1A1 expression at both mRNA and protein levels associated with a significant increase of enzyme activity in primary rat hepatocytes and a human hepatoma cell line.	U 0126	19-78	mitogen activated protein kinase kinase 1	Rattus norvegicus	130-136
15044623-4	2004	We now report that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a specific inhibitor of MAPK kinase (MEK) MEK1/2, elicits a marked increase in CYP1A1 expression at both mRNA and protein levels associated with a significant increase of enzyme activity in primary rat hepatocytes and a human hepatoma cell line.	U 0126	19-78	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	167-173
15044623-4	2004	We now report that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a specific inhibitor of MAPK kinase (MEK) MEK1/2, elicits a marked increase in CYP1A1 expression at both mRNA and protein levels associated with a significant increase of enzyme activity in primary rat hepatocytes and a human hepatoma cell line.	U 0126	80-85	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
15044623-4	2004	We now report that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a specific inhibitor of MAPK kinase (MEK) MEK1/2, elicits a marked increase in CYP1A1 expression at both mRNA and protein levels associated with a significant increase of enzyme activity in primary rat hepatocytes and a human hepatoma cell line.	U 0126	80-85	mitogen activated protein kinase kinase 1	Rattus norvegicus	130-136
15044623-4	2004	We now report that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a specific inhibitor of MAPK kinase (MEK) MEK1/2, elicits a marked increase in CYP1A1 expression at both mRNA and protein levels associated with a significant increase of enzyme activity in primary rat hepatocytes and a human hepatoma cell line.	U 0126	80-85	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	167-173
15044623-7	2004	CYP1A1 modulation was abolished by a cotreatment with resveratrol, an established AhR antagonist, arguing for AhR activation by U0126.	U 0126	128-133	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	0-6
15044623-7	2004	CYP1A1 modulation was abolished by a cotreatment with resveratrol, an established AhR antagonist, arguing for AhR activation by U0126.	U 0126	128-133	aryl hydrocarbon receptor	Homo sapiens	82-85
15044623-7	2004	CYP1A1 modulation was abolished by a cotreatment with resveratrol, an established AhR antagonist, arguing for AhR activation by U0126.	U 0126	128-133	aryl hydrocarbon receptor	Homo sapiens	110-113
15044623-8	2004	Such an effect was demonstrated by direct in vitro ligand binding competition assays using rabbit liver cytosol, showing that this compound binds AhR with an EC(50) = 25 x 10(-6) M. Moreover, we demonstrated that U0126 is a substrate for several P450s including human CYP1A2, -1A1, and -1B1.	U 0126	213-218	aryl hydrocarbon receptor	Oryctolagus cuniculus	146-149
15044623-8	2004	Such an effect was demonstrated by direct in vitro ligand binding competition assays using rabbit liver cytosol, showing that this compound binds AhR with an EC(50) = 25 x 10(-6) M. Moreover, we demonstrated that U0126 is a substrate for several P450s including human CYP1A2, -1A1, and -1B1.	U 0126	213-218	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	268-274
15044623-8	2004	Such an effect was demonstrated by direct in vitro ligand binding competition assays using rabbit liver cytosol, showing that this compound binds AhR with an EC(50) = 25 x 10(-6) M. Moreover, we demonstrated that U0126 is a substrate for several P450s including human CYP1A2, -1A1, and -1B1.	U 0126	213-218	solute carrier family 45 member 2	Homo sapiens	276-290
15044623-9	2004	We conclude that the widely used specific inhibitor of MEK/ERK, U0126, also acts as a potent AhR activator and an inducer of related genes.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
15003539-5	2004	Pretreatment with SB203580 or U0126 revealed that p38 enhances or maintains migration rates while ERK retarded migration.	U 0126	30-35	mitogen-activated protein kinase 14	Homo sapiens	50-53
15013748-3	2004	Expression of dominant-negative Raf and ERK mutants or treatment with a MEK inhibitor (U0126) strongly impaired viral propagation, while selective activation of the pathway resulted in increased virus titers.	U 0126	87-92	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
15056710-5	2004	Unexpectedly, two MEK (MAP kinase kinase) inhibitors (PD 98059 and U 0126) enhanced dendritic growth, and a ligand, basic FGF, that activates the ERK pathway inhibited the growth of these processes.	U 0126	67-73	mitogen activated protein kinase 3	Rattus norvegicus	146-149
14722101-10	2004	The involvement of ERK1/2 and p38 MAP kinase in acetaldehyde-induced apoptosis was confirmed by selective kinase inhibitors U0126, SB203580, and SB202190.	U 0126	124-129	mitogen-activated protein kinase 3	Homo sapiens	19-25
14722101-10	2004	The involvement of ERK1/2 and p38 MAP kinase in acetaldehyde-induced apoptosis was confirmed by selective kinase inhibitors U0126, SB203580, and SB202190.	U 0126	124-129	mitogen-activated protein kinase 1	Homo sapiens	30-33
14980516-6	2004	Data using the MEK inhibitor UO126 showed MAP kinase activity is not only needed for cellular proliferation but is also necessary for both the initiation and the progression of primary human myoblast differentiation.	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	15-18
14766220-4	2004	Induction of TH mRNA by NGF was abolished by pretreatment of the cells with U0126, an inhibitor for MEK1/2, but not with inhibitors for p38 MAPK, PI3K, and PKA.	U 0126	76-81	tyrosine hydroxylase	Rattus norvegicus	13-15
14981539-6	2004	In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
14981539-6	2004	In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	21-24
14981539-6	2004	In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction.	U 0126	49-54	TNF receptor associated factor 1	Homo sapiens	82-87
14981539-6	2004	In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	128-131
14981539-6	2004	In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction.	U 0126	49-54	TNF receptor associated factor 1	Homo sapiens	135-140
14726474-8	2004	Lastly, BNP stimulated the extracellular signal-related kinase pathway via cyclic guanosine monophosphate-dependent protein kinase signaling, and two mitogen-activated protein kinase kinase inhibitors, U0126 and PD98059, reversed BNP inhibition of TGF-beta-induced collagen-1 expression.	U 0126	202-207	natriuretic peptide B	Homo sapiens	230-233
14726474-8	2004	Lastly, BNP stimulated the extracellular signal-related kinase pathway via cyclic guanosine monophosphate-dependent protein kinase signaling, and two mitogen-activated protein kinase kinase inhibitors, U0126 and PD98059, reversed BNP inhibition of TGF-beta-induced collagen-1 expression.	U 0126	202-207	transforming growth factor beta 1	Homo sapiens	248-256
14766220-4	2004	Induction of TH mRNA by NGF was abolished by pretreatment of the cells with U0126, an inhibitor for MEK1/2, but not with inhibitors for p38 MAPK, PI3K, and PKA.	U 0126	76-81	mitogen activated protein kinase kinase 1	Rattus norvegicus	100-106
14766220-5	2004	U0126 inhibited TH promoter activity at the same concentration as it acted on ERK1/2 phosphorylation.	U 0126	0-5	tyrosine hydroxylase	Rattus norvegicus	16-18
14766220-5	2004	U0126 inhibited TH promoter activity at the same concentration as it acted on ERK1/2 phosphorylation.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	78-84
14563673-5	2004	Pretreatment of polyamine-depleted IEC-6 cells with a cell membrane-permeable MEK1/2 inhibitor, U-0126, significantly inhibited TNF-alpha/CHX-induced ERK phosphorylation and significantly increased DNA fragmentation, JNK activity, and caspase-3 activity in response to TNF-alpha/CHX.	U 0126	96-102	mitogen activated protein kinase kinase 1	Rattus norvegicus	78-84
14563673-5	2004	Pretreatment of polyamine-depleted IEC-6 cells with a cell membrane-permeable MEK1/2 inhibitor, U-0126, significantly inhibited TNF-alpha/CHX-induced ERK phosphorylation and significantly increased DNA fragmentation, JNK activity, and caspase-3 activity in response to TNF-alpha/CHX.	U 0126	96-102	tumor necrosis factor	Rattus norvegicus	128-137
14563673-5	2004	Pretreatment of polyamine-depleted IEC-6 cells with a cell membrane-permeable MEK1/2 inhibitor, U-0126, significantly inhibited TNF-alpha/CHX-induced ERK phosphorylation and significantly increased DNA fragmentation, JNK activity, and caspase-3 activity in response to TNF-alpha/CHX.	U 0126	96-102	Eph receptor B1	Rattus norvegicus	150-153
14563673-5	2004	Pretreatment of polyamine-depleted IEC-6 cells with a cell membrane-permeable MEK1/2 inhibitor, U-0126, significantly inhibited TNF-alpha/CHX-induced ERK phosphorylation and significantly increased DNA fragmentation, JNK activity, and caspase-3 activity in response to TNF-alpha/CHX.	U 0126	96-102	mitogen-activated protein kinase 8	Rattus norvegicus	217-220
14563673-5	2004	Pretreatment of polyamine-depleted IEC-6 cells with a cell membrane-permeable MEK1/2 inhibitor, U-0126, significantly inhibited TNF-alpha/CHX-induced ERK phosphorylation and significantly increased DNA fragmentation, JNK activity, and caspase-3 activity in response to TNF-alpha/CHX.	U 0126	96-102	caspase 3	Rattus norvegicus	235-244
14563673-5	2004	Pretreatment of polyamine-depleted IEC-6 cells with a cell membrane-permeable MEK1/2 inhibitor, U-0126, significantly inhibited TNF-alpha/CHX-induced ERK phosphorylation and significantly increased DNA fragmentation, JNK activity, and caspase-3 activity in response to TNF-alpha/CHX.	U 0126	96-102	tumor necrosis factor	Rattus norvegicus	269-278
14563673-6	2004	Moreover, the dose dependency of U-0126-mediated inhibition of TNF-alpha/ CHX-induced ERK phosphorylation correlated with the reversal of the antiapoptotic effect of DFMO.	U 0126	33-39	tumor necrosis factor	Rattus norvegicus	63-72
14656772-6	2004	Inhibition of either ERK1/2, PKC, or the inhibitory G protein (Gi) with U-0126, bisindolylmaleimide HCl, and pertussis toxin, respectively, blocked (P &lt; 0.05) the increase in IL-6 expression caused by LPS.	U 0126	72-78	mitogen-activated protein kinase 3	Sus scrofa	21-27
14563673-6	2004	Moreover, the dose dependency of U-0126-mediated inhibition of TNF-alpha/ CHX-induced ERK phosphorylation correlated with the reversal of the antiapoptotic effect of DFMO.	U 0126	33-39	Eph receptor B1	Rattus norvegicus	86-89
14630723-18	2004	Furthermore, pretreatment of cells with the PI3K inhibitors wortmannin and LY29404 or the MAPK inhibitors U0126 and PD 98059 were all observed to inhibit Ang II-stimulated Na(+) pump activity.	U 0126	106-111	angiogenin	Rattus norvegicus	154-157
14670803-7	2004	Finally, IL-13- or IL-4-dependent eotaxin release was abolished when inhibitors of both p42/p44 ERK (U0126, 10 microM) and p38 (SB202190, 10 microM) mitogen-activated protein kinase pathways were combined in STAT6 antisense ODN-transfected cells.	U 0126	101-106	interleukin 13	Homo sapiens	9-14
14670803-7	2004	Finally, IL-13- or IL-4-dependent eotaxin release was abolished when inhibitors of both p42/p44 ERK (U0126, 10 microM) and p38 (SB202190, 10 microM) mitogen-activated protein kinase pathways were combined in STAT6 antisense ODN-transfected cells.	U 0126	101-106	interleukin 4	Homo sapiens	19-23
14670803-7	2004	Finally, IL-13- or IL-4-dependent eotaxin release was abolished when inhibitors of both p42/p44 ERK (U0126, 10 microM) and p38 (SB202190, 10 microM) mitogen-activated protein kinase pathways were combined in STAT6 antisense ODN-transfected cells.	U 0126	101-106	C-C motif chemokine ligand 11	Homo sapiens	34-41
14670803-7	2004	Finally, IL-13- or IL-4-dependent eotaxin release was abolished when inhibitors of both p42/p44 ERK (U0126, 10 microM) and p38 (SB202190, 10 microM) mitogen-activated protein kinase pathways were combined in STAT6 antisense ODN-transfected cells.	U 0126	101-106	cyclin dependent kinase 20	Homo sapiens	88-91
14627544-5	2004	On the other hand, treatments of a high concentration of Ca2+ ionophore or a low concentration of Ca2+ ionophore plus MEK inhibitor, U0126, linearly decreased MAP kinase activity following the decrease of p34cdc2 kinase activity; most of these oocytes formed pronuclei.	U 0126	133-138	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
14627544-5	2004	On the other hand, treatments of a high concentration of Ca2+ ionophore or a low concentration of Ca2+ ionophore plus MEK inhibitor, U0126, linearly decreased MAP kinase activity following the decrease of p34cdc2 kinase activity; most of these oocytes formed pronuclei.	U 0126	133-138	cyclin dependent kinase 1	Homo sapiens	205-212
14627548-7	2004	Phosphorylation of eNOS Ser1177 under shear stress was elevated by 20 min, a response that was blocked by the phosphatidyl inositol-3-kinase (PI-3K)-inhibitors wortmannin and LY294002 but not by the mitogen activated protein kinase kinase (MEK)-inhibitor UO126.	U 0126	255-260	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	110-140
14985070-5	2004	Mechanical load significantly increased procollagen alpha1(I) mRNA levels up to twofold above static controls after 24 h. This increase was completely abolished by the MEK 1/2 inhibitor U0126, with no effect on basal levels.	U 0126	186-191	mitogen activated protein kinase kinase 1	Rattus norvegicus	168-175
14755547-6	2004	Treatment with U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly downregulated TNF-alpha-induced MMP-9 expression and promoter activity, whereas the inactive analog U0124 had no effect.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	42-79
14992744-9	2004	U0126 exhibited more potent inhibition of ERK1,2 phosphorylation and had more pronounced anticancer effects in both cell lines.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	42-48
15016079-8	2004	The ERK1/2 phosphorylation induced by these agents was also sensitive to the MAPK kinase 1 (MEK1) inhibitor PD98059 and the MEK1/2 inhibitor U0126.	U 0126	141-146	mitogen activated protein kinase 3	Rattus norvegicus	4-10
15016079-8	2004	The ERK1/2 phosphorylation induced by these agents was also sensitive to the MAPK kinase 1 (MEK1) inhibitor PD98059 and the MEK1/2 inhibitor U0126.	U 0126	141-146	mitogen activated protein kinase kinase 1	Rattus norvegicus	124-130
15016079-10	2004	The NMDA- and AMPA/kainate-induced CREB phosphorylation was completely and partially blocked by U0126, respectively.	U 0126	96-101	cAMP responsive element binding protein 1	Rattus norvegicus	35-39
14755547-6	2004	Treatment with U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly downregulated TNF-alpha-induced MMP-9 expression and promoter activity, whereas the inactive analog U0124 had no effect.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	81-84
14755547-6	2004	Treatment with U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly downregulated TNF-alpha-induced MMP-9 expression and promoter activity, whereas the inactive analog U0124 had no effect.	U 0126	15-20	tumor necrosis factor	Homo sapiens	115-124
14755547-6	2004	Treatment with U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly downregulated TNF-alpha-induced MMP-9 expression and promoter activity, whereas the inactive analog U0124 had no effect.	U 0126	15-20	matrix metallopeptidase 9	Homo sapiens	133-138
14755547-7	2004	Furthermore, the transactivation of TNF-alpha-stimulated NF-kappaB and AP-1 was inhibited by U0126 treatment.	U 0126	93-98	tumor necrosis factor	Homo sapiens	36-45
14755547-7	2004	Furthermore, the transactivation of TNF-alpha-stimulated NF-kappaB and AP-1 was inhibited by U0126 treatment.	U 0126	93-98	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-75
14755552-6	2004	Marked inhibitory effects on PDGF-BB-induced gel contraction and ERK/AP-1 activity were observed in the presence of either function blocking anti-alpha1- or anti-beta1-integrin antibody or U0126.	U 0126	189-194	Eph receptor B1	Rattus norvegicus	65-68
14699071-7	2004	Surprisingly, when MAPK was inhibited by U0126 after the MAPK-dependent period, activation of caspase-3 occurred earlier than in the control eggs.	U 0126	41-46	caspase 3	Homo sapiens	94-103
15086566-5	2004	Inhibition of mitogen and ERK with U0126 and phosphoinositide 3-OH kinase attenuated BrdU incorporation and ERK1/2 activation.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	108-114
15086566-7	2004	Twenty-four hours of stretching stimulated reporter activity driven by activator protein 1 (AP-1), induction of K6, and suppression of K10, which were inhibited by U0126.	U 0126	164-169	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-90
15086566-7	2004	Twenty-four hours of stretching stimulated reporter activity driven by activator protein 1 (AP-1), induction of K6, and suppression of K10, which were inhibited by U0126.	U 0126	164-169	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	92-96
15086566-7	2004	Twenty-four hours of stretching stimulated reporter activity driven by activator protein 1 (AP-1), induction of K6, and suppression of K10, which were inhibited by U0126.	U 0126	164-169	keratin 10	Homo sapiens	135-138
15054132-6	2004	The MEK (ERK kinase) inhibitors PD98059 and U0126 completely prevented the increase in spine density induced by BDNF, without having an effect on spine density by themselves.	U 0126	44-49	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
15054132-6	2004	The MEK (ERK kinase) inhibitors PD98059 and U0126 completely prevented the increase in spine density induced by BDNF, without having an effect on spine density by themselves.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	9-12
15054132-6	2004	The MEK (ERK kinase) inhibitors PD98059 and U0126 completely prevented the increase in spine density induced by BDNF, without having an effect on spine density by themselves.	U 0126	44-49	brain derived neurotrophic factor	Homo sapiens	112-116
15033174-3	2004	This effect was specifically blocked by inhibitors of phosphatidylinositol 3-kinase (PI3-K) pathways (LY294002 and wortmannin) or p42/p44 mitogen-activated protein (MAP) kinase (PD98059 and U0126).	U 0126	190-195	cyclin dependent kinase 20	Homo sapiens	130-133
15030175-9	2004	Similarly, inhibition of the MEK/ERK pathway with either PD98059 or U0126 decreased beta-AR mRNA stability substantially.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	29-32
15030175-9	2004	Similarly, inhibition of the MEK/ERK pathway with either PD98059 or U0126 decreased beta-AR mRNA stability substantially.	U 0126	68-73	mitogen-activated protein kinase 1	Homo sapiens	33-36
14983053-7	2004	Inhibition of ERK1/2 by U0126 mimicked the effects of PGE2.	U 0126	24-29	mitogen-activated protein kinase 3	Mus musculus	14-20
14681216-4	2004	ERK5 activation was blocked by the MEK5 inhibitor U0126 and expression of a dominant negative MEK5 mutant.	U 0126	50-55	mitogen-activated protein kinase 7	Homo sapiens	0-4
14681216-4	2004	ERK5 activation was blocked by the MEK5 inhibitor U0126 and expression of a dominant negative MEK5 mutant.	U 0126	50-55	mitogen-activated protein kinase kinase 5	Homo sapiens	35-39
14983015-8	2004	Exposure to the U0126 mitogen-activated protein kinase kinase inhibitor inhibited head but not foot regeneration, abolished CREB phosphorylation and activation of the early gene HyBra1 in head-regenerating tips.	U 0126	16-21	cAMP responsive element binding protein 1	Homo sapiens	124-128
14660675-7	2004	In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	9-12
14660675-7	2004	In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity.	U 0126	122-127	BCL2 apoptosis regulator	Homo sapiens	46-51
14696090-8	2004	The EGFR tyrosine kinase inhibitor, AG1478, and the MEK inhibitor, U0126, blocked these cellular effects of EGFRvIII.	U 0126	67-72	midkine	Mus musculus	52-55
14660675-7	2004	In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	101-104
14613890-9	2004	In addition, the inhibitors of the MAPK pathway, SB-203580 and U-0126, inhibited nucleotide-induced elastase release.	U 0126	63-69	mitogen-activated protein kinase 3	Homo sapiens	35-39
14973246-9	2004	A single intra-VTA infusion of BDNF, but not NGF, induced long-lasting enhancement of cocaine seeking for up to 30 d, an effect reversed by U0126.	U 0126	140-145	brain-derived neurotrophic factor	Rattus norvegicus	31-35
14617631-4	2004	We found that the MEK inhibitors, U0126 and PD98059, promote increased accumulation of cartilage-characteristic mRNA transcripts for type II collagen, aggrecan, and the transcription factor, Sox9.	U 0126	34-39	collagen type II alpha 1 chain	Gallus gallus	133-149
14617631-4	2004	We found that the MEK inhibitors, U0126 and PD98059, promote increased accumulation of cartilage-characteristic mRNA transcripts for type II collagen, aggrecan, and the transcription factor, Sox9.	U 0126	34-39	SRY-box 9	Gallus gallus	191-195
14757120-6	2004	The MEK (MAPK kinase) inhibitor, U0126, which has been shown to induce growth arrest, inactivated ERK and down-regulated cyclins D and E. Although DIF-1 activated the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway, neither wortmannin nor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; PI-3K inhibitors) cancelled DIF-1-induced growth arrest.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
14757120-6	2004	The MEK (MAPK kinase) inhibitor, U0126, which has been shown to induce growth arrest, inactivated ERK and down-regulated cyclins D and E. Although DIF-1 activated the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway, neither wortmannin nor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; PI-3K inhibitors) cancelled DIF-1-induced growth arrest.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	98-101
14757120-6	2004	The MEK (MAPK kinase) inhibitor, U0126, which has been shown to induce growth arrest, inactivated ERK and down-regulated cyclins D and E. Although DIF-1 activated the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway, neither wortmannin nor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; PI-3K inhibitors) cancelled DIF-1-induced growth arrest.	U 0126	33-38	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	167-196
14757120-6	2004	The MEK (MAPK kinase) inhibitor, U0126, which has been shown to induce growth arrest, inactivated ERK and down-regulated cyclins D and E. Although DIF-1 activated the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway, neither wortmannin nor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; PI-3K inhibitors) cancelled DIF-1-induced growth arrest.	U 0126	33-38	AKT serine/threonine kinase 1	Homo sapiens	205-208
14592950-6	2004	Activation of protein kinase C (PKC) and ERK1/2 was required for the UCN II-induced activation of MLC(20), because treatment of myometrial cells with inhibitors of MAPK kinase 1 (U0126) and PKC (bisindolylmaleimide) inhibited the UCN II-induced phosphorylation of MLC(20).	U 0126	179-184	urocortin 2	Homo sapiens	69-75
14636892-3	2004	The induction of egr-1 correlated with a rapid ERK1/2 phosphorylation and was prevented with MEK1/2 inhibitors PD 98059 and UO126.	U 0126	124-129	early growth response 1	Mus musculus	17-22
14636892-3	2004	The induction of egr-1 correlated with a rapid ERK1/2 phosphorylation and was prevented with MEK1/2 inhibitors PD 98059 and UO126.	U 0126	124-129	mitogen-activated protein kinase 3	Mus musculus	47-53
14636892-3	2004	The induction of egr-1 correlated with a rapid ERK1/2 phosphorylation and was prevented with MEK1/2 inhibitors PD 98059 and UO126.	U 0126	124-129	mitogen-activated protein kinase kinase 1	Mus musculus	93-99
14592955-8	2004	Furthermore, MAPK signaling appeared to be involved in aldosterone production induced by Ang II and BMP-6 because an inhibitor of MAPK activation, U0126, reduced the level of aldosterone synthesis stimulated by Ang II and BMP-6 but not activin.	U 0126	147-152	angiotensinogen	Homo sapiens	89-95
14592955-8	2004	Furthermore, MAPK signaling appeared to be involved in aldosterone production induced by Ang II and BMP-6 because an inhibitor of MAPK activation, U0126, reduced the level of aldosterone synthesis stimulated by Ang II and BMP-6 but not activin.	U 0126	147-152	bone morphogenetic protein 6	Homo sapiens	100-105
14605001-5	2004	Both PACAP-38 and VIP also rapidly induced ERK1/2 phosphorylation and their stimulatory effect on NNT-1/BSF-3 mRNA expression was reduced by the MAPK kinase/ERK kinase (MEK) inhibitor U0126 (10 microm).	U 0126	184-189	adenylate cyclase activating polypeptide 1	Mus musculus	5-10
14605001-5	2004	Both PACAP-38 and VIP also rapidly induced ERK1/2 phosphorylation and their stimulatory effect on NNT-1/BSF-3 mRNA expression was reduced by the MAPK kinase/ERK kinase (MEK) inhibitor U0126 (10 microm).	U 0126	184-189	vasoactive intestinal polypeptide	Mus musculus	18-21
14605001-5	2004	Both PACAP-38 and VIP also rapidly induced ERK1/2 phosphorylation and their stimulatory effect on NNT-1/BSF-3 mRNA expression was reduced by the MAPK kinase/ERK kinase (MEK) inhibitor U0126 (10 microm).	U 0126	184-189	mitogen-activated protein kinase 3	Mus musculus	43-49
14592955-8	2004	Furthermore, MAPK signaling appeared to be involved in aldosterone production induced by Ang II and BMP-6 because an inhibitor of MAPK activation, U0126, reduced the level of aldosterone synthesis stimulated by Ang II and BMP-6 but not activin.	U 0126	147-152	angiotensinogen	Homo sapiens	211-217
14592950-6	2004	Activation of protein kinase C (PKC) and ERK1/2 was required for the UCN II-induced activation of MLC(20), because treatment of myometrial cells with inhibitors of MAPK kinase 1 (U0126) and PKC (bisindolylmaleimide) inhibited the UCN II-induced phosphorylation of MLC(20).	U 0126	179-184	myosin light chain 12B	Homo sapiens	98-104
14592955-8	2004	Furthermore, MAPK signaling appeared to be involved in aldosterone production induced by Ang II and BMP-6 because an inhibitor of MAPK activation, U0126, reduced the level of aldosterone synthesis stimulated by Ang II and BMP-6 but not activin.	U 0126	147-152	bone morphogenetic protein 6	Homo sapiens	222-227
14592955-8	2004	Furthermore, MAPK signaling appeared to be involved in aldosterone production induced by Ang II and BMP-6 because an inhibitor of MAPK activation, U0126, reduced the level of aldosterone synthesis stimulated by Ang II and BMP-6 but not activin.	U 0126	147-152	inhibin subunit beta E	Homo sapiens	236-243
14605001-5	2004	Both PACAP-38 and VIP also rapidly induced ERK1/2 phosphorylation and their stimulatory effect on NNT-1/BSF-3 mRNA expression was reduced by the MAPK kinase/ERK kinase (MEK) inhibitor U0126 (10 microm).	U 0126	184-189	cardiotrophin-like cytokine factor 1	Mus musculus	98-109
14605001-5	2004	Both PACAP-38 and VIP also rapidly induced ERK1/2 phosphorylation and their stimulatory effect on NNT-1/BSF-3 mRNA expression was reduced by the MAPK kinase/ERK kinase (MEK) inhibitor U0126 (10 microm).	U 0126	184-189	mitogen-activated protein kinase 1	Mus musculus	145-149
14592950-6	2004	Activation of protein kinase C (PKC) and ERK1/2 was required for the UCN II-induced activation of MLC(20), because treatment of myometrial cells with inhibitors of MAPK kinase 1 (U0126) and PKC (bisindolylmaleimide) inhibited the UCN II-induced phosphorylation of MLC(20).	U 0126	179-184	mitogen-activated protein kinase 3	Homo sapiens	164-168
14756825-7	2004	These effects were prevented by the ERK signaling inhibitor U0126.	U 0126	60-65	Eph receptor B1	Rattus norvegicus	36-39
14765977-18	2004	In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels.	U 0126	174-179	insulin-like growth factor 1	Rattus norvegicus	68-73
14765977-18	2004	In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels.	U 0126	174-179	insulin-like growth factor 1	Rattus norvegicus	191-196
14765977-18	2004	In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels.	U 0126	174-179	transferrin	Rattus norvegicus	208-219
14765977-18	2004	In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels.	U 0126	174-179	insulin-like growth factor 1	Rattus norvegicus	191-196
14585838-7	2004	The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells.	U 0126	92-97	apolipoprotein E	Mus musculus	28-32
15019950-1	2004	Bone morphogenetic proteins (BMPs) 4 and 6 as well as MEK inhibitors PD98059 and U0126 potentiate neurotrophin 3 (NT3)- and neurturin (NTN)-induced neurite outgrowth and survival of peripheral neurons from the E9 chicken embryo.	U 0126	81-86	neurotrophin 3	Gallus gallus	98-112
15019950-1	2004	Bone morphogenetic proteins (BMPs) 4 and 6 as well as MEK inhibitors PD98059 and U0126 potentiate neurotrophin 3 (NT3)- and neurturin (NTN)-induced neurite outgrowth and survival of peripheral neurons from the E9 chicken embryo.	U 0126	81-86	neurotrophin 3	Gallus gallus	114-117
15019950-1	2004	Bone morphogenetic proteins (BMPs) 4 and 6 as well as MEK inhibitors PD98059 and U0126 potentiate neurotrophin 3 (NT3)- and neurturin (NTN)-induced neurite outgrowth and survival of peripheral neurons from the E9 chicken embryo.	U 0126	81-86	neurturin	Gallus gallus	124-133
15019950-1	2004	Bone morphogenetic proteins (BMPs) 4 and 6 as well as MEK inhibitors PD98059 and U0126 potentiate neurotrophin 3 (NT3)- and neurturin (NTN)-induced neurite outgrowth and survival of peripheral neurons from the E9 chicken embryo.	U 0126	81-86	neurturin	Gallus gallus	135-138
15084344-3	2004	Inhibition of the MAPK activity by PD98059 or U0126 suppressed not only insulin-induced proliferation but also forskolin- and estradiol-induced proliferation.	U 0126	46-51	insulin	Homo sapiens	72-79
14719071-7	2004	U0126, an inhibitor for MEK and LY294002, an inhibitor for phosphatidylinositol 3-kinase (PI3K), sensitized resistant UM-SCC-23 to cisplatin-induced cell death.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
14719071-7	2004	U0126, an inhibitor for MEK and LY294002, an inhibitor for phosphatidylinositol 3-kinase (PI3K), sensitized resistant UM-SCC-23 to cisplatin-induced cell death.	U 0126	0-5	serpin family B member 3	Homo sapiens	121-124
14585838-7	2004	The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells.	U 0126	92-97	mitogen-activated protein kinase 1	Mus musculus	115-152
14610070-5	2004	The addition of N-acetyl-L-cysteine, the PKC inhibitor GF109203X, and the MEK/ERK inhibitors PD98059 and U0126 attenuated both apoptosis induction and GSH decrease, whereas the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were ineffective.	U 0126	105-110	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
14585838-7	2004	The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells.	U 0126	92-97	mitogen-activated protein kinase 1	Mus musculus	154-157
14610070-5	2004	The addition of N-acetyl-L-cysteine, the PKC inhibitor GF109203X, and the MEK/ERK inhibitors PD98059 and U0126 attenuated both apoptosis induction and GSH decrease, whereas the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were ineffective.	U 0126	105-110	mitogen-activated protein kinase 1	Homo sapiens	78-81
14585838-7	2004	The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells.	U 0126	92-97	mitogen-activated protein kinase 1	Mus musculus	180-183
14610070-5	2004	The addition of N-acetyl-L-cysteine, the PKC inhibitor GF109203X, and the MEK/ERK inhibitors PD98059 and U0126 attenuated both apoptosis induction and GSH decrease, whereas the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were ineffective.	U 0126	105-110	mitogen-activated protein kinase 14	Homo sapiens	177-180
14585838-7	2004	The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells.	U 0126	92-97	apolipoprotein E	Mus musculus	226-230
14610070-5	2004	The addition of N-acetyl-L-cysteine, the PKC inhibitor GF109203X, and the MEK/ERK inhibitors PD98059 and U0126 attenuated both apoptosis induction and GSH decrease, whereas the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were ineffective.	U 0126	105-110	mitogen-activated protein kinase 8	Homo sapiens	208-211
14735194-11	2004	Inhibitors of extracellular regulated kinase (U0126) and p38 (SB203580), and to a lesser extent the phosphatidylinositol-3-kinase inhibitor LY294002, suppressed the action of TIMP-1.	U 0126	46-51	TIMP metallopeptidase inhibitor 1	Homo sapiens	175-181
14647427-7	2004	Subsequent co-culture with either the MEK inhibitor U0126 or the GM-CSF antagonist E21R negated this induced resistance to cytotoxic chemotherapy, confirming the importance of the GF receptor as well as MAPK in mediating these effects.	U 0126	52-57	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
14706638-4	2004	We found that annexin V was induced 13.3-fold by anisomycin and that this superinduction was attenuated by pretreatment with the MEK inhibitors, U0126 and PD98059, but not with the p38 MAPK inhibitor, SB203580.	U 0126	145-150	annexin A5	Homo sapiens	14-23
14705145-3	2004	From immunoblotting experiments, we observed that RA induced delayed but persistent ERK1 and ERK2 phosphorylation (until 96 hr) that was reduced significantly by the specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126.	U 0126	242-247	mitogen-activated protein kinase 3	Homo sapiens	84-88
14602717-7	2004	Inhibition of the MEK1,2/ERK1,2 pathway by either serum starvation or treatment with selective MEK1,2 inhibitors PD98059 and U0126 or expression of a dominant-negative mutant form of MEK1 decreased the amplitude of the G17-stimulated Ca2+ release response.	U 0126	125-130	mitogen activated protein kinase kinase 1	Rattus norvegicus	18-24
14602717-7	2004	Inhibition of the MEK1,2/ERK1,2 pathway by either serum starvation or treatment with selective MEK1,2 inhibitors PD98059 and U0126 or expression of a dominant-negative mutant form of MEK1 decreased the amplitude of the G17-stimulated Ca2+ release response.	U 0126	125-130	mitogen activated protein kinase 3	Rattus norvegicus	25-31
14602717-7	2004	Inhibition of the MEK1,2/ERK1,2 pathway by either serum starvation or treatment with selective MEK1,2 inhibitors PD98059 and U0126 or expression of a dominant-negative mutant form of MEK1 decreased the amplitude of the G17-stimulated Ca2+ release response.	U 0126	125-130	mitogen activated protein kinase kinase 1	Rattus norvegicus	18-22
14602717-7	2004	Inhibition of the MEK1,2/ERK1,2 pathway by either serum starvation or treatment with selective MEK1,2 inhibitors PD98059 and U0126 or expression of a dominant-negative mutant form of MEK1 decreased the amplitude of the G17-stimulated Ca2+ release response.	U 0126	125-130	mitogen activated protein kinase kinase 1	Rattus norvegicus	95-99
14698040-9	2004	Furthermore, the inhibition of PI-3 kinase (PI-3K) by wortmannin or LY294002 as well as the inhibition of MEK by PD098059 or U0126 prevented the protective effect of VEGF and EGF.	U 0126	125-130	vascular endothelial growth factor A	Homo sapiens	166-170
14705145-3	2004	From immunoblotting experiments, we observed that RA induced delayed but persistent ERK1 and ERK2 phosphorylation (until 96 hr) that was reduced significantly by the specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126.	U 0126	242-247	mitogen-activated protein kinase 1	Homo sapiens	93-97
14705145-3	2004	From immunoblotting experiments, we observed that RA induced delayed but persistent ERK1 and ERK2 phosphorylation (until 96 hr) that was reduced significantly by the specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126.	U 0126	242-247	mitogen-activated protein kinase 3	Homo sapiens	209-213
14705145-3	2004	From immunoblotting experiments, we observed that RA induced delayed but persistent ERK1 and ERK2 phosphorylation (until 96 hr) that was reduced significantly by the specific mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126.	U 0126	242-247	mitogen-activated protein kinase 1	Homo sapiens	84-87
15366258-6	2004	The induction of both TEA-LTP and Ca-LTP, could be prevented by inhibitors of the extracellular signal regulated kinase (ERK) cascade U0126 and PD98059.	U 0126	134-139	Eph receptor B1	Rattus norvegicus	82-119
14581482-5	2004	Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD.	U 0126	18-23	interleukin 1 beta	Rattus norvegicus	111-128
14581482-5	2004	Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	138-141
14581482-5	2004	Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD.	U 0126	18-23	nitric oxide synthase 2	Rattus norvegicus	175-179
14581482-5	2004	Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD.	U 0126	18-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	184-189
14581482-5	2004	Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD.	U 0126	18-23	vascular cell adhesion molecule 1	Rattus norvegicus	241-247
14581482-5	2004	Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD.	U 0126	18-23	superoxide dismutase 2	Rattus norvegicus	252-258
14715940-6	2004	PD98059 or another MEK inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (10 microm), also prevented the induction of the prolonged epileptiform discharges by DHPG.	U 0126	34-93	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
15366258-6	2004	The induction of both TEA-LTP and Ca-LTP, could be prevented by inhibitors of the extracellular signal regulated kinase (ERK) cascade U0126 and PD98059.	U 0126	134-139	Eph receptor B1	Rattus norvegicus	121-124
12829451-5	2004	Blockage of the ERK pathway with U0126 (a selective MEK1/2 inhibitor) significantly decreased stretch-inducible surfactant protein-C (SP-C) mRNA expression.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	16-19
12829451-5	2004	Blockage of the ERK pathway with U0126 (a selective MEK1/2 inhibitor) significantly decreased stretch-inducible surfactant protein-C (SP-C) mRNA expression.	U 0126	33-38	mitogen-activated protein kinase kinase 1	Homo sapiens	52-58
12829451-5	2004	Blockage of the ERK pathway with U0126 (a selective MEK1/2 inhibitor) significantly decreased stretch-inducible surfactant protein-C (SP-C) mRNA expression.	U 0126	33-38	surfactant protein C	Homo sapiens	134-138
13679314-6	2004	The activation of the LHbeta promoter by GnRH was inhibited by PD098059 and U0126, MAP kinase kinase (MEK) inhibitors.	U 0126	76-81	luteinizing hormone beta	Mus musculus	22-28
13679314-6	2004	The activation of the LHbeta promoter by GnRH was inhibited by PD098059 and U0126, MAP kinase kinase (MEK) inhibitors.	U 0126	76-81	gonadotropin releasing hormone 1	Mus musculus	41-45
14977049-6	2004	Incubation of cells with the MEK1/2 inhibitor U0126 or the p38 inhibitor SB202190 abolished the UVA and UVB mediated induction of MMP-1 and MMP-10.	U 0126	46-51	mitogen-activated protein kinase kinase 1	Homo sapiens	29-35
14977049-6	2004	Incubation of cells with the MEK1/2 inhibitor U0126 or the p38 inhibitor SB202190 abolished the UVA and UVB mediated induction of MMP-1 and MMP-10.	U 0126	46-51	matrix metallopeptidase 1	Homo sapiens	130-135
14977049-6	2004	Incubation of cells with the MEK1/2 inhibitor U0126 or the p38 inhibitor SB202190 abolished the UVA and UVB mediated induction of MMP-1 and MMP-10.	U 0126	46-51	matrix metallopeptidase 10	Homo sapiens	140-146
14691048-12	2004	PAF MAPK activation was also inhibited by WEB2086, pertussis toxin (PTX), genistein, wortmannin, LY294002, PD98059 and UO126 in bovine neutrophils.	U 0126	119-124	PCNA-associated factor	Bos taurus	0-3
14691048-12	2004	PAF MAPK activation was also inhibited by WEB2086, pertussis toxin (PTX), genistein, wortmannin, LY294002, PD98059 and UO126 in bovine neutrophils.	U 0126	119-124	mitogen-activated protein kinase 1	Bos taurus	4-8
14732213-10	2004	An ERK inhibitor U0126 fully inhibited Ang II-induced ET-1 expression.	U 0126	17-22	Eph receptor B1	Rattus norvegicus	3-6
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	U 0126	99-104	mitogen-activated protein kinase 1	Homo sapiens	51-55
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	U 0126	99-104	mitogen-activated protein kinase 1	Homo sapiens	109-112
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	U 0126	99-104	mitogen-activated protein kinase 8	Homo sapiens	157-160
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	U 0126	99-104	mitogen-activated protein kinase 1	Homo sapiens	165-168
14732213-10	2004	An ERK inhibitor U0126 fully inhibited Ang II-induced ET-1 expression.	U 0126	17-22	angiotensinogen	Rattus norvegicus	39-45
14732213-10	2004	An ERK inhibitor U0126 fully inhibited Ang II-induced ET-1 expression.	U 0126	17-22	endothelin 1	Rattus norvegicus	54-58
15193284-7	2004	The MEK-1 inhibitors UO126 or PD98059 induced erythroid differentiation in K562 cells and acted additively with butyrate.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Homo sapiens	4-9
15371627-6	2004	HIV-1, gp120, or Tat induced Erk 1/2 phosphorylation, activation of caspase-3, and apoptosis of NRVMs and CAECs; all of these were inhibited by a MAPK/ERK-kinase (MEK) inhibitor U0126.	U 0126	178-183	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	7-12
14724072-5	2004	Since mitogen-activated protein kinase ERK1/2 induce MMP-9 expression, we examined whether U0126, an ERK1/2 inhibitor, influenced MMP-9 expression in aged SMC.	U 0126	91-96	matrix metallopeptidase 9	Mus musculus	130-135
14755151-9	2004	Mitogen-activated protein (MAP) kinase inhibitors (U0126 and PD098059) also blocked the MMP-1, -3 and TIMP-1 secretion.	U 0126	51-56	matrix metallopeptidase 13	Homo sapiens	88-97
14755151-9	2004	Mitogen-activated protein (MAP) kinase inhibitors (U0126 and PD098059) also blocked the MMP-1, -3 and TIMP-1 secretion.	U 0126	51-56	TIMP metallopeptidase inhibitor 1	Homo sapiens	102-108
14724072-6	2004	Treatment with U0126 successfully inhibited MMP-9 expression in both young and aged SMC.	U 0126	15-20	matrix metallopeptidase 9	Mus musculus	44-49
14667793-5	2004	The inhibitor PD98059 significantly reduced M. bovis BCG-induced TNF-alpha production and almost completely abrogated phosphorylation of ERK1/2; in addition the potent MEK inhibitor U0126 also abrogated phosphorylation.	U 0126	182-187	tumor necrosis factor	Homo sapiens	65-74
14723708-6	2004	In support of this, the MEK1/2 specific inhibitor U0126 enhanced the expression of ATF3 induced by TNFalpha.	U 0126	50-55	mitogen-activated protein kinase kinase 1	Homo sapiens	24-30
14723708-6	2004	In support of this, the MEK1/2 specific inhibitor U0126 enhanced the expression of ATF3 induced by TNFalpha.	U 0126	50-55	activating transcription factor 3	Homo sapiens	83-87
14723708-6	2004	In support of this, the MEK1/2 specific inhibitor U0126 enhanced the expression of ATF3 induced by TNFalpha.	U 0126	50-55	tumor necrosis factor	Homo sapiens	99-107
14738765-5	2004	Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Mus musculus	110-114
14738765-5	2004	Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity.	U 0126	61-66	mitogen-activated protein kinase 3	Mus musculus	115-121
14654942-5	2004	The expression of MEK2 and p-MEK were reduced and the cell aggregation was found in PC-1.0 and ASPC-1 cells after U0126 (a MEK inhibitor) treatment.	U 0126	114-119	mitogen-activated protein kinase kinase 2	Homo sapiens	18-22
14654942-5	2004	The expression of MEK2 and p-MEK were reduced and the cell aggregation was found in PC-1.0 and ASPC-1 cells after U0126 (a MEK inhibitor) treatment.	U 0126	114-119	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
14654942-5	2004	The expression of MEK2 and p-MEK were reduced and the cell aggregation was found in PC-1.0 and ASPC-1 cells after U0126 (a MEK inhibitor) treatment.	U 0126	114-119	mitogen-activated protein kinase kinase 7	Homo sapiens	29-32
14715858-6	2004	A MAPK kinase inhibitor (U0126) could enhance the cytokine-induced sensitization of thyroid cells to TRAIL, reinforcing the inhibitory role of Erk on TRAIL signaling.	U 0126	25-30	TNF superfamily member 10	Homo sapiens	101-106
14715858-6	2004	A MAPK kinase inhibitor (U0126) could enhance the cytokine-induced sensitization of thyroid cells to TRAIL, reinforcing the inhibitory role of Erk on TRAIL signaling.	U 0126	25-30	mitogen-activated protein kinase 1	Homo sapiens	143-146
14715858-6	2004	A MAPK kinase inhibitor (U0126) could enhance the cytokine-induced sensitization of thyroid cells to TRAIL, reinforcing the inhibitory role of Erk on TRAIL signaling.	U 0126	25-30	TNF superfamily member 10	Homo sapiens	150-155
15456934-6	2004	Glial-derived nerve factor (GDNF) induction by fluoxetine is prevented by U0126, suggesting that Erk is implicated.	U 0126	74-79	glial cell derived neurotrophic factor	Rattus norvegicus	0-26
15456934-6	2004	Glial-derived nerve factor (GDNF) induction by fluoxetine is prevented by U0126, suggesting that Erk is implicated.	U 0126	74-79	glial cell derived neurotrophic factor	Rattus norvegicus	28-32
15456934-6	2004	Glial-derived nerve factor (GDNF) induction by fluoxetine is prevented by U0126, suggesting that Erk is implicated.	U 0126	74-79	Eph receptor B1	Rattus norvegicus	97-100
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	transforming growth factor beta 1	Homo sapiens	0-9
14730203-9	2004	An ERK inhibitor, U0126, inhibited Ang II-induced ET-1 expression completely.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	3-6
14730203-9	2004	An ERK inhibitor, U0126, inhibited Ang II-induced ET-1 expression completely.	U 0126	18-23	angiotensinogen	Homo sapiens	35-41
14730203-9	2004	An ERK inhibitor, U0126, inhibited Ang II-induced ET-1 expression completely.	U 0126	18-23	endothelin 1	Homo sapiens	50-54
14667449-7	2004	These effects were reversed by U0126, a MEK kinase inhibitor.	U 0126	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	40-43
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	nuclear factor kappa B subunit 1	Homo sapiens	19-31
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	115-147
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	AKT serine/threonine kinase 1	Homo sapiens	155-158
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	mitogen-activated protein kinase 3	Homo sapiens	203-249
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	transforming growth factor beta 1	Homo sapiens	276-285
14751283-10	2004	Of note, wortmannin and U0126, as well as kappabeta-decoy DNA, abolished the anti-apoptotic effect of TGF-beta1, corroborating the notion that both PI3k/Akt and MAPK/Erk1,2 pathways, and NF-kappabeta activity are necessary for the anti-apoptotic activity of TGF-beta1.	U 0126	24-29	transforming growth factor beta 1	Homo sapiens	102-111
14673957-6	2004	The MAPK kinase (MEK) inhibitor U0126 completely inhibited Erk activation by NSC 95397 and NSC 672121.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	4-8
15207334-6	2004	Furthermore, we found that nerve growth factor (NGF) injection directly into the L4/5 nerve roots and DRG produced mechanical allodynia, and an increase in the phosphorylation of ERK and BDNF expression in the DRG, but the mitogen-activated protein kinase (MAPK) kinase1/2 inhibitor, U0126, inhibited the effects induced by NGF.	U 0126	284-289	nerve growth factor	Homo sapiens	27-46
15207334-6	2004	Furthermore, we found that nerve growth factor (NGF) injection directly into the L4/5 nerve roots and DRG produced mechanical allodynia, and an increase in the phosphorylation of ERK and BDNF expression in the DRG, but the mitogen-activated protein kinase (MAPK) kinase1/2 inhibitor, U0126, inhibited the effects induced by NGF.	U 0126	284-289	nerve growth factor	Homo sapiens	48-51
15557793-3	2004	U0126, SB202190 and JNKI-1, inhibitors for MAPK kinase, (MEK) 1/2, p38 MAP kinase and SAPK/JNK, respectively, specifically and clearly inhibited their corresponding kinases.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	43-65
15557793-3	2004	U0126, SB202190 and JNKI-1, inhibitors for MAPK kinase, (MEK) 1/2, p38 MAP kinase and SAPK/JNK, respectively, specifically and clearly inhibited their corresponding kinases.	U 0126	0-5	mitogen-activated protein kinase 14	Homo sapiens	67-81
15557793-4	2004	U0126 and SB202190, but not JNKI-1, almost completely inhibited the doxorubicin-induced uPA expression in both RC-K8 and H69 cells.	U 0126	0-5	plasminogen activator, urokinase	Homo sapiens	88-91
15557793-5	2004	However, U0126 rather enhanced the doxorubicin-induced activation of caspase-3 and poly ADP-ribose polymerase (PARP), and U0126 itself activated caspase-3 and PARP.	U 0126	9-14	caspase 3	Homo sapiens	69-78
15557793-5	2004	However, U0126 rather enhanced the doxorubicin-induced activation of caspase-3 and poly ADP-ribose polymerase (PARP), and U0126 itself activated caspase-3 and PARP.	U 0126	9-14	poly(ADP-ribose) polymerase 1	Homo sapiens	83-109
15557793-5	2004	However, U0126 rather enhanced the doxorubicin-induced activation of caspase-3 and poly ADP-ribose polymerase (PARP), and U0126 itself activated caspase-3 and PARP.	U 0126	9-14	poly(ADP-ribose) polymerase 1	Homo sapiens	111-115
15557793-5	2004	However, U0126 rather enhanced the doxorubicin-induced activation of caspase-3 and poly ADP-ribose polymerase (PARP), and U0126 itself activated caspase-3 and PARP.	U 0126	122-127	caspase 3	Homo sapiens	145-154
15557793-5	2004	However, U0126 rather enhanced the doxorubicin-induced activation of caspase-3 and poly ADP-ribose polymerase (PARP), and U0126 itself activated caspase-3 and PARP.	U 0126	122-127	poly(ADP-ribose) polymerase 1	Homo sapiens	159-163
14673957-6	2004	The MAPK kinase (MEK) inhibitor U0126 completely inhibited Erk activation by NSC 95397 and NSC 672121.	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
14673957-6	2004	The MAPK kinase (MEK) inhibitor U0126 completely inhibited Erk activation by NSC 95397 and NSC 672121.	U 0126	32-37	mitogen-activated protein kinase 1	Homo sapiens	59-62
14551213-4	2003	Galpha16QL-induced STAT3 activation was enhanced by overexpression of extracellular signal-regulated kinase 1 (ERK1), but was inhibited by U0126, a Raf-1 inhibitor, and coexpression of the dominant negative mutants of Ras and Rac1.	U 0126	139-144	signal transducer and activator of transcription 3	Homo sapiens	19-24
14551213-4	2003	Galpha16QL-induced STAT3 activation was enhanced by overexpression of extracellular signal-regulated kinase 1 (ERK1), but was inhibited by U0126, a Raf-1 inhibitor, and coexpression of the dominant negative mutants of Ras and Rac1.	U 0126	139-144	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	148-153
14654170-7	2003	However, after the inhibition of MAPK/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) with U0126, apoptosis was observed when TNF-alpha was added.	U 0126	101-106	mitogen-activated protein kinase kinase 1	Mus musculus	88-94
14654170-7	2003	However, after the inhibition of MAPK/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) with U0126, apoptosis was observed when TNF-alpha was added.	U 0126	101-106	tumor necrosis factor	Mus musculus	136-145
14530261-8	2003	Expression of COX-2 was partially blocked by U0126, a MEK inhibitor, and SB 203580, a p38 MAPK inhibitor.	U 0126	45-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-19
14530261-8	2003	Expression of COX-2 was partially blocked by U0126, a MEK inhibitor, and SB 203580, a p38 MAPK inhibitor.	U 0126	45-50	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
14551200-6	2003	The use of U0126, a selective inhibitor of MAPKinase kinase, provides evidence that MAPKinase contributes to the regulation of the PRL gene.	U 0126	11-16	prolactin	Rattus norvegicus	131-134
14507918-7	2003	Similarly, oocytes treated with the MEK inhibitor U0126, stimulated by insulin exhibited delayed germinal vesicle breakdown, absence of Xp42(Mpk1) activation, and partial phosphorylation of Raf.	U 0126	50-55	insulin S homeolog	Xenopus laevis	71-78
14507918-7	2003	Similarly, oocytes treated with the MEK inhibitor U0126, stimulated by insulin exhibited delayed germinal vesicle breakdown, absence of Xp42(Mpk1) activation, and partial phosphorylation of Raf.	U 0126	50-55	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	136-140
14507918-7	2003	Similarly, oocytes treated with the MEK inhibitor U0126, stimulated by insulin exhibited delayed germinal vesicle breakdown, absence of Xp42(Mpk1) activation, and partial phosphorylation of Raf.	U 0126	50-55	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	141-145
14507918-7	2003	Similarly, oocytes treated with the MEK inhibitor U0126, stimulated by insulin exhibited delayed germinal vesicle breakdown, absence of Xp42(Mpk1) activation, and partial phosphorylation of Raf.	U 0126	50-55	Raf-1 proto-oncogene, serine/threonine kinase S homeolog	Xenopus laevis	190-193
14615287-8	2003	UO126, a mitogen-activated protein kinase kinase-1/2 (MEK1/2) inhibitor, reduced Ang II-increased ICaT density and CaV3.1 mRNA amount.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	9-52
14615287-8	2003	UO126, a mitogen-activated protein kinase kinase-1/2 (MEK1/2) inhibitor, reduced Ang II-increased ICaT density and CaV3.1 mRNA amount.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	54-60
14615287-8	2003	UO126, a mitogen-activated protein kinase kinase-1/2 (MEK1/2) inhibitor, reduced Ang II-increased ICaT density and CaV3.1 mRNA amount.	U 0126	0-5	angiotensinogen	Rattus norvegicus	81-87
14615287-10	2003	Finally, cotreatment with bosentan and UO126 abolished the Ang II-increased ICaT density.	U 0126	39-44	angiotensinogen	Rattus norvegicus	59-65
14673008-7	2003	Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 (aSvg-30) prevented stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Mus musculus	44-51
14673008-7	2003	Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 (aSvg-30) prevented stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Mus musculus	162-169
14673008-7	2003	Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 (aSvg-30) prevented stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1.	U 0126	62-67	mitogen-activated protein kinase 3	Mus musculus	194-201
14673008-7	2003	Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 (aSvg-30) prevented stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1.	U 0126	62-67	ribosomal protein S6 kinase polypeptide 1	Mus musculus	206-214
14517212-5	2003	The MEK inhibitors PD 98059 and U0126 blocked ERK phosphorylation, as did the adenylate cyclase activator forskolin.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	46-49
14654779-4	2003	This shift correlates with ERK activation and is prevented by the MEK inhibitor U0126.	U 0126	80-85	Eph receptor B1	Rattus norvegicus	27-30
14712780-7	2003	U0126 (20 microM), the MEK1/2 inhibitor, could completely block the VEGF-D induced phospholylation of Erk1/2 signaling pathway.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	23-29
15033699-0	2003	An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia.	U 0126	42-47	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
15033699-0	2003	An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia.	U 0126	42-47	mitogen-activated protein kinase 1	Homo sapiens	28-31
15033699-2	2003	This investigation examined the effect of the potent MEK/ERK inhibitor U0126 on apoptosis in acute myeloblastic leukemia (AML) cell lines, and acute leukemic and non-leukemic patient samples.	U 0126	71-76	mitogen-activated protein kinase kinase 7	Homo sapiens	53-56
15033699-2	2003	This investigation examined the effect of the potent MEK/ERK inhibitor U0126 on apoptosis in acute myeloblastic leukemia (AML) cell lines, and acute leukemic and non-leukemic patient samples.	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	57-60
15033699-4	2003	The pro-apoptotic effect of U0126 in the most sensitive cell line, KG1a, appeared to be related to its CD34 positivity.	U 0126	28-33	CD34 molecule	Homo sapiens	103-107
14575869-5	2003	Further, treatment with a MEK (a MAPK kinase) inhibitor, PD 098059 or U0126, suppressed 1,10-phenanthroline-stimulated MAPK phosphorylation, indicating that 1,10-phenanthroline can phosphorylate MAPK in a MEK-dependent fashion.	U 0126	70-75	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	33-37
14575869-5	2003	Further, treatment with a MEK (a MAPK kinase) inhibitor, PD 098059 or U0126, suppressed 1,10-phenanthroline-stimulated MAPK phosphorylation, indicating that 1,10-phenanthroline can phosphorylate MAPK in a MEK-dependent fashion.	U 0126	70-75	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	119-123
14575869-5	2003	Further, treatment with a MEK (a MAPK kinase) inhibitor, PD 098059 or U0126, suppressed 1,10-phenanthroline-stimulated MAPK phosphorylation, indicating that 1,10-phenanthroline can phosphorylate MAPK in a MEK-dependent fashion.	U 0126	70-75	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	119-123
14712780-7	2003	U0126 (20 microM), the MEK1/2 inhibitor, could completely block the VEGF-D induced phospholylation of Erk1/2 signaling pathway.	U 0126	0-5	vascular endothelial growth factor D	Homo sapiens	68-74
14712780-7	2003	U0126 (20 microM), the MEK1/2 inhibitor, could completely block the VEGF-D induced phospholylation of Erk1/2 signaling pathway.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	102-108
14612941-7	2003	Pharmacologic MEK inhibitor U0126 inhibited the growth of TAC3; it was more effective with non-adherent cells than with adherent cells.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
14612941-7	2003	Pharmacologic MEK inhibitor U0126 inhibited the growth of TAC3; it was more effective with non-adherent cells than with adherent cells.	U 0126	28-33	tachykinin precursor 3	Homo sapiens	58-62
14711387-7	2003	The authors show that this reporter system is able to detect inhibition of upstream MAP kinase signaling proteins by the MEK inhibitor U0126.	U 0126	135-140	mitogen-activated protein kinase kinase 7	Homo sapiens	121-124
14566975-8	2003	VEGF mRNA levels and protein secretion induced by TGF-beta were significantly inhibited by SB203580 and U0126, inhibitors of MAP kinases, but not by staurosporine and PDTC, protein kinase C and NF-kappaB pathway inhibitors, respectively.	U 0126	104-109	vascular endothelial growth factor A	Homo sapiens	0-4
14566975-8	2003	VEGF mRNA levels and protein secretion induced by TGF-beta were significantly inhibited by SB203580 and U0126, inhibitors of MAP kinases, but not by staurosporine and PDTC, protein kinase C and NF-kappaB pathway inhibitors, respectively.	U 0126	104-109	transforming growth factor beta 1	Homo sapiens	50-58
12923227-4	2003	Arachidonic acid treatment led to a prolonged activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 activity by the addition of U0126 rescued differentiation.	U 0126	171-176	mitogen-activated protein kinase 3	Mus musculus	136-142
14675712-11	2003	Treatment with the COX-2 inhibitor NS398 in the presence of U0126 (MEK inhibitor) effectively suppressed ERK1/2 phosphorylation as determined by phosphospecific ERK1/2 immunoblot.	U 0126	60-65	prostaglandin-endoperoxide synthase 2	Homo sapiens	19-24
14675712-11	2003	Treatment with the COX-2 inhibitor NS398 in the presence of U0126 (MEK inhibitor) effectively suppressed ERK1/2 phosphorylation as determined by phosphospecific ERK1/2 immunoblot.	U 0126	60-65	mitogen-activated protein kinase kinase 7	Homo sapiens	67-70
14675712-11	2003	Treatment with the COX-2 inhibitor NS398 in the presence of U0126 (MEK inhibitor) effectively suppressed ERK1/2 phosphorylation as determined by phosphospecific ERK1/2 immunoblot.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	105-111
14675712-11	2003	Treatment with the COX-2 inhibitor NS398 in the presence of U0126 (MEK inhibitor) effectively suppressed ERK1/2 phosphorylation as determined by phosphospecific ERK1/2 immunoblot.	U 0126	60-65	mitogen-activated protein kinase 3	Homo sapiens	161-167
14675712-22	2003	Despite differential signaling in HepG2 and Hep3B cells, the sum effect of combining the COX-2 inhibitor NS398 and the MEK inhibitor U0126 results in enhanced antitumor actions.	U 0126	133-138	mitogen-activated protein kinase kinase 7	Homo sapiens	119-122
12923227-7	2003	Omission of a cAMP-elevating agent or addition of H-89 or U0126 prevented sustained expression of COX-2.	U 0126	58-63	prostaglandin-endoperoxide synthase 2	Mus musculus	98-103
12928431-9	2003	The increase in both CTbeta2 mRNA and CT activity was inhibited by U0126, an inhibitor of mitogen-activated kinase/extracellular signal-regulated kinase kinase 1/2 (MEK1/2).	U 0126	67-72	mitogen activated protein kinase kinase 1	Rattus norvegicus	165-171
14645669-8	2003	MOR-mediated EGFR down-regulation seems to be MAP kinase-dependent, because it was inhibited by the ERK kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126), and tyrphostin AG1478.	U 0126	121-181	epidermal growth factor receptor	Rattus norvegicus	13-17
14645669-8	2003	MOR-mediated EGFR down-regulation seems to be MAP kinase-dependent, because it was inhibited by the ERK kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126), and tyrphostin AG1478.	U 0126	121-181	Eph receptor B1	Rattus norvegicus	100-103
14645669-8	2003	MOR-mediated EGFR down-regulation seems to be MAP kinase-dependent, because it was inhibited by the ERK kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126), and tyrphostin AG1478.	U 0126	183-188	epidermal growth factor receptor	Rattus norvegicus	13-17
14645669-8	2003	MOR-mediated EGFR down-regulation seems to be MAP kinase-dependent, because it was inhibited by the ERK kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126), and tyrphostin AG1478.	U 0126	183-188	Eph receptor B1	Rattus norvegicus	100-103
14645670-5	2003	Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted.	U 0126	161-166	TNF superfamily member 10	Homo sapiens	83-88
14645670-5	2003	Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted.	U 0126	161-166	tumor necrosis factor	Homo sapiens	93-102
14645670-5	2003	Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted.	U 0126	161-166	mitogen-activated protein kinase kinase 7	Homo sapiens	127-130
14645670-5	2003	Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted.	U 0126	161-166	urocortin	Homo sapiens	168-171
14645670-5	2003	Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted.	U 0126	161-166	BCL2 apoptosis regulator	Homo sapiens	263-268
14645670-5	2003	Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted.	U 0126	161-166	BCL2 like 1	Homo sapiens	274-280
14500714-7	2003	The secreted ATP-mediated P2X1-dependent ERK2 activation induced by low collagen concentrations contributes to MLC kinase activation since P2X1 desensitization or blockade of ERK2 phosphorylation by U0126 strongly attenuated MLC phosphorylation, degranulation, and aggregation.	U 0126	199-204	purinergic receptor P2X 1	Homo sapiens	26-30
14500714-7	2003	The secreted ATP-mediated P2X1-dependent ERK2 activation induced by low collagen concentrations contributes to MLC kinase activation since P2X1 desensitization or blockade of ERK2 phosphorylation by U0126 strongly attenuated MLC phosphorylation, degranulation, and aggregation.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	41-45
14500714-7	2003	The secreted ATP-mediated P2X1-dependent ERK2 activation induced by low collagen concentrations contributes to MLC kinase activation since P2X1 desensitization or blockade of ERK2 phosphorylation by U0126 strongly attenuated MLC phosphorylation, degranulation, and aggregation.	U 0126	199-204	modulator of VRAC current 1	Homo sapiens	111-114
14500714-7	2003	The secreted ATP-mediated P2X1-dependent ERK2 activation induced by low collagen concentrations contributes to MLC kinase activation since P2X1 desensitization or blockade of ERK2 phosphorylation by U0126 strongly attenuated MLC phosphorylation, degranulation, and aggregation.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	175-179
14500714-7	2003	The secreted ATP-mediated P2X1-dependent ERK2 activation induced by low collagen concentrations contributes to MLC kinase activation since P2X1 desensitization or blockade of ERK2 phosphorylation by U0126 strongly attenuated MLC phosphorylation, degranulation, and aggregation.	U 0126	199-204	modulator of VRAC current 1	Homo sapiens	225-228
14575691-10	2003	On the other hand, they were inhibited only partially by a MAPK/ERK 1/2 inhibitor, U-0126.	U 0126	83-89	mitogen-activated protein kinase 3	Homo sapiens	59-63
14575691-10	2003	On the other hand, they were inhibited only partially by a MAPK/ERK 1/2 inhibitor, U-0126.	U 0126	83-89	mitogen-activated protein kinase 3	Homo sapiens	64-71
14613582-8	2003	In addition, the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125 up-regulates expression of p8.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Homo sapiens	17-23
12839832-9	2003	The effect of aldosterone to potentiate inhibition by 1,25(OH)2D3 was not affected by spironolactone but was eliminated by the MAPK kinase/ERK inhibitor U-0126.	U 0126	153-159	Eph receptor B1	Rattus norvegicus	139-142
12882762-7	2003	Blocking ERK1/2 activation by MEK1/2 inhibitors (PD-98059 or U-0126) diminishes HB-EGF-induced Fra-1 accumulation and subsequent downregulation of elastin mRNA.	U 0126	61-67	mitogen activated protein kinase 3	Rattus norvegicus	9-15
12882762-7	2003	Blocking ERK1/2 activation by MEK1/2 inhibitors (PD-98059 or U-0126) diminishes HB-EGF-induced Fra-1 accumulation and subsequent downregulation of elastin mRNA.	U 0126	61-67	mitogen activated protein kinase kinase 1	Rattus norvegicus	30-36
12882762-7	2003	Blocking ERK1/2 activation by MEK1/2 inhibitors (PD-98059 or U-0126) diminishes HB-EGF-induced Fra-1 accumulation and subsequent downregulation of elastin mRNA.	U 0126	61-67	heparin-binding EGF-like growth factor	Rattus norvegicus	80-86
12882762-7	2003	Blocking ERK1/2 activation by MEK1/2 inhibitors (PD-98059 or U-0126) diminishes HB-EGF-induced Fra-1 accumulation and subsequent downregulation of elastin mRNA.	U 0126	61-67	FOS like 1, AP-1 transcription factor subunit	Rattus norvegicus	95-100
12882762-7	2003	Blocking ERK1/2 activation by MEK1/2 inhibitors (PD-98059 or U-0126) diminishes HB-EGF-induced Fra-1 accumulation and subsequent downregulation of elastin mRNA.	U 0126	61-67	elastin	Rattus norvegicus	147-154
14688474-0	2003	Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro.	U 0126	92-97	mitogen-activated protein kinase kinase 1	Homo sapiens	75-81
14688474-11	2003	The enhancement in Taxotere anti-proliferative effects by U0126 correlated with increased cell killing, 48-72h after treatment of cells that was blocked by inhibition of caspase 9, but not caspase 8, function.	U 0126	58-63	caspase 9	Homo sapiens	170-179
14563359-6	2003	Experiments based on inhibitors of specific signaling pathways, such as manumycin A, toxin A, U0126, PD98059 and wortmannin revealed that Ras, MEK and PI-3K are involved in the activation of ERK.	U 0126	94-99	mitogen-activated protein kinase 1	Homo sapiens	191-194
14622133-4	2003	Blockade of ERK activation with U0126, of PKC with Go6976 and of SAPK with SP600125 decreased basal P-gp but did not abolish the H2O2-induced increase.	U 0126	32-37	Eph receptor B1	Rattus norvegicus	12-15
14631113-5	2003	We found that the MEK inhibitors, PD98059 and U0126, inhibited the induction of PAI-1 gene and protein expression during cell adhesion, PD98059 also inhibited the adhesion of cells to the culture plate, and cell adhesion elicited the kinase activities of MEK and ERK.	U 0126	46-51	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
14631113-5	2003	We found that the MEK inhibitors, PD98059 and U0126, inhibited the induction of PAI-1 gene and protein expression during cell adhesion, PD98059 also inhibited the adhesion of cells to the culture plate, and cell adhesion elicited the kinase activities of MEK and ERK.	U 0126	46-51	serpin family E member 1	Homo sapiens	80-85
14631113-5	2003	We found that the MEK inhibitors, PD98059 and U0126, inhibited the induction of PAI-1 gene and protein expression during cell adhesion, PD98059 also inhibited the adhesion of cells to the culture plate, and cell adhesion elicited the kinase activities of MEK and ERK.	U 0126	46-51	mitogen-activated protein kinase kinase 7	Homo sapiens	255-258
14631113-5	2003	We found that the MEK inhibitors, PD98059 and U0126, inhibited the induction of PAI-1 gene and protein expression during cell adhesion, PD98059 also inhibited the adhesion of cells to the culture plate, and cell adhesion elicited the kinase activities of MEK and ERK.	U 0126	46-51	mitogen-activated protein kinase 1	Homo sapiens	263-266
12907681-9	2003	Addition of the MEK1/2-specific inhibitor U0126 or the PI3K-specific inhibitor LY294002 (but not p38 kinase and JNK inhibitors) completely nullified collagen I-III production and significantly decreased laminin beta2 and fibronectin secretion.	U 0126	42-47	mitogen-activated protein kinase kinase 1	Homo sapiens	16-22
14646244-3	2003	The A beta-induced increase in tyrosine phosphorylation of 44-kDa protein was blocked by U0126, a specific inhibitor of the extracellular signal-regulated kinase (ERK) kinase MEK.	U 0126	89-94	amyloid beta precursor protein	Rattus norvegicus	4-10
14646244-3	2003	The A beta-induced increase in tyrosine phosphorylation of 44-kDa protein was blocked by U0126, a specific inhibitor of the extracellular signal-regulated kinase (ERK) kinase MEK.	U 0126	89-94	Eph receptor B1	Rattus norvegicus	124-161
14646244-3	2003	The A beta-induced increase in tyrosine phosphorylation of 44-kDa protein was blocked by U0126, a specific inhibitor of the extracellular signal-regulated kinase (ERK) kinase MEK.	U 0126	89-94	Eph receptor B1	Rattus norvegicus	163-166
14576498-0	2003	MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.	U 0126	48-53	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
14576498-2	2003	In the current study, we examined the effect of inhibiting the MEK-ERK pathway in pancreatic tumor cells with the MEK-specific inhibitor U0126.	U 0126	137-142	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
14576498-2	2003	In the current study, we examined the effect of inhibiting the MEK-ERK pathway in pancreatic tumor cells with the MEK-specific inhibitor U0126.	U 0126	137-142	mitogen-activated protein kinase kinase 7	Homo sapiens	114-117
14576498-13	2003	The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment.	U 0126	130-135	cyclin dependent kinase inhibitor 1A	Homo sapiens	38-41
14576498-13	2003	The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment.	U 0126	130-135	interferon alpha inducible protein 27	Homo sapiens	43-46
14576498-13	2003	The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment.	U 0126	130-135	cyclin D1	Homo sapiens	48-57
14576498-13	2003	The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment.	U 0126	130-135	BCL2 like 1	Homo sapiens	84-90
14506750-9	2003	Docetaxel plus U0126 had only 20% added effect on Bcl-2 phosphorylation compared to docetaxel alone.	U 0126	15-20	BCL2 apoptosis regulator	Homo sapiens	50-55
12920232-8	2003	PACAP quickly activated MAPK (within 5 min) and also resulted in elevated levels of phospho-cAMP response element-binding protein and phospho-SF-1, as judged by a specific antiphospho-S203 antibody; this effect was blocked by the MAPK kinase inhibitor, UO126.	U 0126	253-258	adenylate cyclase activating polypeptide 1	Homo sapiens	0-5
14551401-8	2003	U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	57-60
14551401-8	2003	U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively.	U 0126	0-5	mitogen-activated protein kinase 14	Homo sapiens	62-65
14551401-8	2003	U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively.	U 0126	0-5	mitogen-activated protein kinase 8	Homo sapiens	71-74
12780343-6	2003	PD98059 and U0126 also blocked HIF-1alpha gene expression induced by cyclical stretch.	U 0126	12-17	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	31-41
13679234-11	2003	It was also observed that apoptosis was induced when U0126, an MEK inhibitor, was added to the cells to inhibit ERK.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
13679234-11	2003	It was also observed that apoptosis was induced when U0126, an MEK inhibitor, was added to the cells to inhibit ERK.	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	112-115
12704019-2	2003	Here we report that isoproterenol phosphorylated the protein S6 kinase (p70S6k) in alveolar epithelial cells, which was inhibited by both rapamycin and the MEK1/2 inhibitor U-0126.	U 0126	173-179	ribosomal protein S6 kinase B1	Homo sapiens	72-78
12704019-2	2003	Here we report that isoproterenol phosphorylated the protein S6 kinase (p70S6k) in alveolar epithelial cells, which was inhibited by both rapamycin and the MEK1/2 inhibitor U-0126.	U 0126	173-179	mitogen-activated protein kinase kinase 1	Homo sapiens	156-162
12730073-9	2003	The protective effects of both IL-6 and IL-11 were not associated with any changes in antioxidants and were decreased by approximately 80% in the presence of U0126, a specific inhibitor of MEK-1-dependent pathways.	U 0126	158-163	interleukin 6	Homo sapiens	31-35
12730073-9	2003	The protective effects of both IL-6 and IL-11 were not associated with any changes in antioxidants and were decreased by approximately 80% in the presence of U0126, a specific inhibitor of MEK-1-dependent pathways.	U 0126	158-163	interleukin 11	Homo sapiens	40-45
12730073-9	2003	The protective effects of both IL-6 and IL-11 were not associated with any changes in antioxidants and were decreased by approximately 80% in the presence of U0126, a specific inhibitor of MEK-1-dependent pathways.	U 0126	158-163	mitogen-activated protein kinase kinase 1	Homo sapiens	189-194
14672561-1	2003	In this study we used U0126, a potent and specific inhibitor of MEK, to study the roles of MEK/ERK/p90rsk signaling pathway in the meiotic cell cycle of mouse oocytes.	U 0126	22-27	midkine	Mus musculus	64-67
14672561-2	2003	The phosphorylation of MAP kinase and p90rsk in the oocytes treated with 1.5 microM U0126 was the same as that in oocytes cultured in drug-free medium.	U 0126	84-89	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	38-44
14672561-8	2003	When the concentration of U0126 was increased to 15 mM, the phosphorylation of both MAPK and p90rsk were inhibited, while symmetric division was decreased.	U 0126	26-31	mitogen-activated protein kinase 1	Mus musculus	84-88
14672561-8	2003	When the concentration of U0126 was increased to 15 mM, the phosphorylation of both MAPK and p90rsk were inhibited, while symmetric division was decreased.	U 0126	26-31	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	93-99
14672561-10	2003	MII oocytes were also activated by 15 microM U0126, at the same time the dephosphorylation of MAP kinase and p90rsk was observed.	U 0126	45-50	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	109-115
14516792-7	2003	Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes.	U 0126	142-147	matrix metallopeptidase 1	Homo sapiens	37-41
14516792-7	2003	Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes.	U 0126	142-147	matrix metallopeptidase 9	Homo sapiens	56-61
14516792-7	2003	Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes.	U 0126	142-147	matrix metallopeptidase 1	Homo sapiens	71-76
14516792-7	2003	Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes.	U 0126	142-147	matrix metallopeptidase 13	Homo sapiens	81-87
14516792-7	2003	Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes.	U 0126	142-147	matrix metallopeptidase 9	Homo sapiens	236-241
14534235-4	2003	Local administration of U0126, a selective inhibitor of ERK kinase, prevents memory improvements exerted by the agonists, without causing any behavioral effect per se.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	56-59
12832284-10	2003	The specific p44/42 MAP kinase inhibitor UO126 completely blocked p44/42 phosphorylation and, subsequently, PGE2 production.	U 0126	41-46	interferon induced protein 44	Homo sapiens	13-16
12832284-10	2003	The specific p44/42 MAP kinase inhibitor UO126 completely blocked p44/42 phosphorylation and, subsequently, PGE2 production.	U 0126	41-46	interferon induced protein 44	Homo sapiens	66-69
12970086-9	2003	The inhibitor of ERK pathway (U0126 or PD98059) or JNK pathway (SP600125) markedly prevented kinase activation, and also greatly reduced NCTD-induced apoptotic cell death.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	17-20
14559821-5	2003	In addition, pretreatment of wild-type cells with U0126, a potent inhibitor for mitogen-activated protein/ERK kinase 1, or with SB203580, a specific inhibitor for p38, significantly inhibited the Con A-dependent secretion and activation of MMP-2.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	106-109
14559821-5	2003	In addition, pretreatment of wild-type cells with U0126, a potent inhibitor for mitogen-activated protein/ERK kinase 1, or with SB203580, a specific inhibitor for p38, significantly inhibited the Con A-dependent secretion and activation of MMP-2.	U 0126	50-55	matrix metallopeptidase 2	Homo sapiens	240-245
14570609-4	2003	An ERK pathway inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio] butadiene (U0126), was administered intravenously 20 minutes before MCAO, and the neurological deficit levels and the infarct volumes were measured 24 hours after MCAO.	U 0126	26-87	mitogen-activated protein kinase 1	Mus musculus	3-6
14570609-4	2003	An ERK pathway inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio] butadiene (U0126), was administered intravenously 20 minutes before MCAO, and the neurological deficit levels and the infarct volumes were measured 24 hours after MCAO.	U 0126	89-94	mitogen-activated protein kinase 1	Mus musculus	3-6
14499638-7	2003	More importantly, modulation of ERK activity by the MEK inhibitor U0126 or the gene transduction of a constitutively active form of MEK resulted in a suppression and increment, respectively, of integrin beta3 induction by RANKL.	U 0126	66-71	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	222-227
14499638-7	2003	More importantly, modulation of ERK activity by the MEK inhibitor U0126 or the gene transduction of a constitutively active form of MEK resulted in a suppression and increment, respectively, of integrin beta3 induction by RANKL.	U 0126	66-71	Eph receptor B2	Mus musculus	32-35
14511121-8	2003	The induction by CNTF was inhibited by the protein kinase C inhibitor, BIM, and the MAPK-kinase inhibitor, U0126.	U 0126	107-112	ciliary neurotrophic factor	Homo sapiens	17-21
14499638-7	2003	More importantly, modulation of ERK activity by the MEK inhibitor U0126 or the gene transduction of a constitutively active form of MEK resulted in a suppression and increment, respectively, of integrin beta3 induction by RANKL.	U 0126	66-71	midkine	Mus musculus	52-55
14499638-7	2003	More importantly, modulation of ERK activity by the MEK inhibitor U0126 or the gene transduction of a constitutively active form of MEK resulted in a suppression and increment, respectively, of integrin beta3 induction by RANKL.	U 0126	66-71	integrin beta 3	Mus musculus	194-208
12963974-0	2003	A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model.	U 0126	17-22	midkine	Mus musculus	2-5
12963974-0	2003	A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model.	U 0126	17-22	KRAS proto-oncogene, GTPase	Homo sapiens	99-104
14584892-14	2003	Inhibition of ERK phosphorylation with the specific inhibitors, PD-98059 and U-0126, decreased the [Ca2+]e induction of both COX-2 mRNA and luciferase activity by 70-80%.	U 0126	77-83	mitogen-activated protein kinase 1	Mus musculus	14-17
14511112-5	2003	U0126, an antagonist for MEK1/2, a kinase that phosphorylates the extracellular signal-regulated kinases ERK1/2, decreased IFN gamma-induced NO production.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	25-31
14511112-5	2003	U0126, an antagonist for MEK1/2, a kinase that phosphorylates the extracellular signal-regulated kinases ERK1/2, decreased IFN gamma-induced NO production.	U 0126	0-5	mitogen-activated protein kinase 3	Mus musculus	105-111
14511112-5	2003	U0126, an antagonist for MEK1/2, a kinase that phosphorylates the extracellular signal-regulated kinases ERK1/2, decreased IFN gamma-induced NO production.	U 0126	0-5	interferon gamma	Mus musculus	123-132
14515181-7	2003	Moreover, the MEK (ERK kinase) inhibitors, PD98059 and UO126, completely prevented PAI-1 induction by Wy-14,643 without inhibiting the activation of a reporter gene carrying the PPRE element.	U 0126	55-60	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
14519096-5	2003	MAPK kinase inhibitors U0126 (U) and PD98059 (PD) and a PI3K inhibitor wortmannin (W) were able to block the stimulatory effects of bFGF on phosphorylated MAPK and PKB levels respectively.	U 0126	23-28	fibroblast growth factor 2	Rattus norvegicus	132-136
14515181-7	2003	Moreover, the MEK (ERK kinase) inhibitors, PD98059 and UO126, completely prevented PAI-1 induction by Wy-14,643 without inhibiting the activation of a reporter gene carrying the PPRE element.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	19-22
14515181-7	2003	Moreover, the MEK (ERK kinase) inhibitors, PD98059 and UO126, completely prevented PAI-1 induction by Wy-14,643 without inhibiting the activation of a reporter gene carrying the PPRE element.	U 0126	55-60	serpin family E member 1	Homo sapiens	83-88
12824190-8	2003	Strikingly, the MEK1/2 inhibitor, U0126, which selectively inhibits the p44/42 MAP kinase pathway, reduces AR112-stimulated cell death.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Homo sapiens	16-22
12867426-7	2003	Phosphorylation of tuberin by phorbol 12-myristate 13-acetate was reduced by treatment of cells with either bisindolylmaleimide I or UO126, inhibitors of PKC and MAPK/MEK (MAPK/ERK kinase), respectively, but not by wortmannin (an inhibitor of PI3K).	U 0126	133-138	TSC complex subunit 2	Homo sapiens	19-26
12867426-7	2003	Phosphorylation of tuberin by phorbol 12-myristate 13-acetate was reduced by treatment of cells with either bisindolylmaleimide I or UO126, inhibitors of PKC and MAPK/MEK (MAPK/ERK kinase), respectively, but not by wortmannin (an inhibitor of PI3K).	U 0126	133-138	mitogen-activated protein kinase kinase 7	Homo sapiens	167-170
12867429-4	2003	Preincubation with the ERK1/2 inhibitor U0126 significantly reduced the IGF-1 effect on the amount of p21CIP/WAF protein in MCF-7 cells.	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	23-29
12867429-4	2003	Preincubation with the ERK1/2 inhibitor U0126 significantly reduced the IGF-1 effect on the amount of p21CIP/WAF protein in MCF-7 cells.	U 0126	40-45	insulin like growth factor 1	Homo sapiens	72-77
12951049-9	2003	The activation of AKT, p70(s6k), and ERK1/2 induced by HGF was abolished by pre-treatment with LY294002, a phosphoinositide 3-OH kinase (PI3K) inhibitor, and U0126, a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, respectively.	U 0126	158-163	AKT serine/threonine kinase 1	Rattus norvegicus	18-21
12951049-9	2003	The activation of AKT, p70(s6k), and ERK1/2 induced by HGF was abolished by pre-treatment with LY294002, a phosphoinositide 3-OH kinase (PI3K) inhibitor, and U0126, a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, respectively.	U 0126	158-163	mitogen activated protein kinase 3	Rattus norvegicus	37-43
12951049-9	2003	The activation of AKT, p70(s6k), and ERK1/2 induced by HGF was abolished by pre-treatment with LY294002, a phosphoinositide 3-OH kinase (PI3K) inhibitor, and U0126, a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, respectively.	U 0126	158-163	hepatocyte growth factor	Rattus norvegicus	55-58
12951049-9	2003	The activation of AKT, p70(s6k), and ERK1/2 induced by HGF was abolished by pre-treatment with LY294002, a phosphoinositide 3-OH kinase (PI3K) inhibitor, and U0126, a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, respectively.	U 0126	158-163	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	107-135
12821655-18	2003	Further, the GH-promoted nuclear relocalization of C/EBP beta to pericentromeric heterochromatin was prevented by the MEK inhibitor U0126.	U 0126	132-137	growth hormone	Mus musculus	13-15
12821655-18	2003	Further, the GH-promoted nuclear relocalization of C/EBP beta to pericentromeric heterochromatin was prevented by the MEK inhibitor U0126.	U 0126	132-137	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	51-61
12821655-18	2003	Further, the GH-promoted nuclear relocalization of C/EBP beta to pericentromeric heterochromatin was prevented by the MEK inhibitor U0126.	U 0126	132-137	midkine	Mus musculus	118-121
12824190-8	2003	Strikingly, the MEK1/2 inhibitor, U0126, which selectively inhibits the p44/42 MAP kinase pathway, reduces AR112-stimulated cell death.	U 0126	34-39	androgen receptor	Homo sapiens	107-112
12810818-7	2003	Furthermore, treatment with U0126, an inhibitor of MAPK kinase (MEK)1/2, attenuated the p42/p44 MAPK phosphorylation, but had no effect on Akt activation in response to OxLDL and EGF.	U 0126	28-33	mitogen-activated protein kinase kinase 1	Homo sapiens	51-71
12845643-5	2003	Mitogen-activated protein kinase kinase (MAPKK; MEK) inhibitor, UO126, blocked migration, demonstrating MEK involvement in C3L5 cell migration.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
12845643-5	2003	Mitogen-activated protein kinase kinase (MAPKK; MEK) inhibitor, UO126, blocked migration, demonstrating MEK involvement in C3L5 cell migration.	U 0126	64-69	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
12893744-10	2003	Accordingly, inhibitors of FGFR signaling, including the FGFR1 tyrosine kinase inhibitor SU 5402, the MEK1/2 inhibitor U0126, and the protein kinase C inhibitor GF109 all prevented cardiomyocyte differentiation in fgfr1+/- EBs without affecting the expression of the hematopoietic/endothelial marker flk-1.	U 0126	119-124	mitogen-activated protein kinase kinase 1	Mus musculus	102-108
12911620-9	2003	In fact, inhibition of activation of MAPK with U0126 resulted in increased neuritic branching, possibly as a result of the concomitant increase observed in phospho-Akt.	U 0126	47-52	AKT serine/threonine kinase 1	Rattus norvegicus	164-167
12960088-4	2003	This effect was mediated through the MAPK signaling pathway, as shown by the ability of the specific inhibitor UO126 to abrogate IGF-I action.	U 0126	111-116	insulin like growth factor 1	Homo sapiens	129-134
12845643-9	2003	Finally, both ODQ and UO126 blocked the capacity of L-arginine to restore ERK(1/2) phosphorylation in L-NAME-treated cells, demonstrating that GC and MEK are both required for endogenous NO-mediated MAPK activation.	U 0126	22-27	mitogen-activated protein kinase 3	Homo sapiens	74-81
12845643-9	2003	Finally, both ODQ and UO126 blocked the capacity of L-arginine to restore ERK(1/2) phosphorylation in L-NAME-treated cells, demonstrating that GC and MEK are both required for endogenous NO-mediated MAPK activation.	U 0126	22-27	mitogen-activated protein kinase kinase 7	Homo sapiens	150-153
12844482-10	2003	The MEK1/2 inhibitor U0126 strongly inhibited NF-kappaB activation, while p38 inhibitor SB203580 failed to block TPA-induced NF-kappaB activation in mouse skin.	U 0126	21-26	mitogen-activated protein kinase kinase 1	Mus musculus	4-10
12844482-10	2003	The MEK1/2 inhibitor U0126 strongly inhibited NF-kappaB activation, while p38 inhibitor SB203580 failed to block TPA-induced NF-kappaB activation in mouse skin.	U 0126	21-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	46-55
12844482-11	2003	Furthermore, U0126 blocked the IkappaBalpha phosphorylation by TPA, thereby blocking the nuclear translocation of NF-kappaB.	U 0126	13-18	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	31-43
12844482-11	2003	Furthermore, U0126 blocked the IkappaBalpha phosphorylation by TPA, thereby blocking the nuclear translocation of NF-kappaB.	U 0126	13-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	114-123
14614324-3	2003	HDI-mediated apoptosis was attenuated by pharmacologic JNK inhibitors and enhanced by the MEK1/2 inhibitor U0126 as well as by the JNK activator anisomycin.	U 0126	107-112	mitogen-activated protein kinase kinase 1	Homo sapiens	90-96
12898704-5	2003	Although PMA increased phosphorylation in all three major MAP kinase pathways (ERK, p38 MAP kinase, and JNK), only inhibition of the ERK pathway by the MEK/ERK inhibitor U0126 (0.1-10 microM) significantly reduced MMP-9 upregulation, even when treatment was delayed for 4 h after PMA exposure.	U 0126	170-175	Eph receptor B1	Rattus norvegicus	133-136
12898704-5	2003	Although PMA increased phosphorylation in all three major MAP kinase pathways (ERK, p38 MAP kinase, and JNK), only inhibition of the ERK pathway by the MEK/ERK inhibitor U0126 (0.1-10 microM) significantly reduced MMP-9 upregulation, even when treatment was delayed for 4 h after PMA exposure.	U 0126	170-175	Eph receptor B1	Rattus norvegicus	133-136
12898704-5	2003	Although PMA increased phosphorylation in all three major MAP kinase pathways (ERK, p38 MAP kinase, and JNK), only inhibition of the ERK pathway by the MEK/ERK inhibitor U0126 (0.1-10 microM) significantly reduced MMP-9 upregulation, even when treatment was delayed for 4 h after PMA exposure.	U 0126	170-175	matrix metallopeptidase 9	Rattus norvegicus	214-219
12898704-8	2003	But in this case, all three MAP kinase inhibitors (U0126, SB203580, and SP600125) reduced TNFalpha-induced MMP-9 upregulation.	U 0126	51-56	tumor necrosis factor	Rattus norvegicus	90-98
12898704-8	2003	But in this case, all three MAP kinase inhibitors (U0126, SB203580, and SP600125) reduced TNFalpha-induced MMP-9 upregulation.	U 0126	51-56	matrix metallopeptidase 9	Rattus norvegicus	107-112
12970315-6	2003	BRAF mutation-associated enhanced cell growth was suppressed by MAPK kinase inhibitor, U0126.	U 0126	87-92	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	0-4
12950464-6	2003	Incubation of cells with mitogen-activated protein kinase kinase (MEK) inhibitors (PD98059 or U0126) attenuated the ability of NGF to increase HO-1 expression and to protect PC12 cells against SD-induced apoptosis.	U 0126	94-99	heme oxygenase 1	Rattus norvegicus	143-147
12810818-7	2003	Furthermore, treatment with U0126, an inhibitor of MAPK kinase (MEK)1/2, attenuated the p42/p44 MAPK phosphorylation, but had no effect on Akt activation in response to OxLDL and EGF.	U 0126	28-33	cyclin dependent kinase 20	Homo sapiens	88-91
12929133-6	2003	The inhibitors of NF-kappaB (pyrrolidine dithiocarbamate, PDTC) and ERK (1,4-diamino-2,3-dicyano-1,4 bis[2-aminophenylthio]butadiene; U0126) markedly decreased synergistic NO production in BV2 cells treated with IFN-gamma and PMA in combination.	U 0126	73-132	mitogen-activated protein kinase 1	Mus musculus	68-71
12810818-7	2003	Furthermore, treatment with U0126, an inhibitor of MAPK kinase (MEK)1/2, attenuated the p42/p44 MAPK phosphorylation, but had no effect on Akt activation in response to OxLDL and EGF.	U 0126	28-33	interferon induced protein 44	Homo sapiens	92-95
12929133-6	2003	The inhibitors of NF-kappaB (pyrrolidine dithiocarbamate, PDTC) and ERK (1,4-diamino-2,3-dicyano-1,4 bis[2-aminophenylthio]butadiene; U0126) markedly decreased synergistic NO production in BV2 cells treated with IFN-gamma and PMA in combination.	U 0126	73-132	interferon gamma	Mus musculus	212-221
12934102-8	2003	Furthermore, sensitization could be blocked by the ERK inhibitor U0126 but not the p38 inhibitor SB203580, suggesting that activation of ERK2 is required for this effect.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	51-54
12816972-6	2003	In turn in the adult, but not fetus, protein kinase C (PKC) inhibition by staurosporine (3 x 10(-8) M) prior to ERK1/2 inhibition by U-0126 (10(-5) M) prevented this elimination of [Ca2+]i increase.	U 0126	133-139	mitogen-activated protein kinase 3	Homo sapiens	112-118
12816972-10	2003	The ERK1/2 inhibitor U-0126, but not the MEK inhibitor PD-98059, lowered basal activated ERK1/2 levels in vessels of both age groups.	U 0126	21-27	mitogen-activated protein kinase 3	Homo sapiens	4-10
12816972-10	2003	The ERK1/2 inhibitor U-0126, but not the MEK inhibitor PD-98059, lowered basal activated ERK1/2 levels in vessels of both age groups.	U 0126	21-27	mitogen-activated protein kinase 3	Homo sapiens	89-95
12943991-7	2003	Specific inhibition of the MAPK activation by PD98059 or U0126, two selective MEK inhibitors, significantly inhibited IGF-I-stimulated cell proliferation, and reduced the number of cells that migrated towards IGF-I.	U 0126	57-62	insulin like growth factor 1	Homo sapiens	118-123
12943991-7	2003	Specific inhibition of the MAPK activation by PD98059 or U0126, two selective MEK inhibitors, significantly inhibited IGF-I-stimulated cell proliferation, and reduced the number of cells that migrated towards IGF-I.	U 0126	57-62	insulin like growth factor 1	Homo sapiens	209-214
12791686-10	2003	Furthermore, inhibition of MEK1/2 by pretreatment of NRVM with two structurally distinct inhibitors, PD98059 (30 microM) or UO126 (3 microM), inhibited the activation of ERK and p90RSK and abolished the stimulation of NHE activity by sustained (3 min) intracellular acidosis.	U 0126	124-129	mitogen activated protein kinase kinase 1	Rattus norvegicus	27-33
12791686-10	2003	Furthermore, inhibition of MEK1/2 by pretreatment of NRVM with two structurally distinct inhibitors, PD98059 (30 microM) or UO126 (3 microM), inhibited the activation of ERK and p90RSK and abolished the stimulation of NHE activity by sustained (3 min) intracellular acidosis.	U 0126	124-129	Eph receptor B1	Rattus norvegicus	170-173
12801933-7	2003	Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression.	U 0126	59-64	midkine	Mus musculus	34-37
12801933-7	2003	Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression.	U 0126	59-64	mitogen-activated protein kinase 3	Mus musculus	112-116
12801933-7	2003	Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression.	U 0126	59-64	mitogen-activated protein kinase 1	Mus musculus	121-125
12801933-7	2003	Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression.	U 0126	59-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	149-152
12801933-7	2003	Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression.	U 0126	59-64	B cell leukemia/lymphoma 2	Mus musculus	194-199
12934102-8	2003	Furthermore, sensitization could be blocked by the ERK inhibitor U0126 but not the p38 inhibitor SB203580, suggesting that activation of ERK2 is required for this effect.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	137-141
12941468-7	2003	The upstream inhibitor of ERK phosphorylation, U0126 (100-400 microg/kg, i.v., 10 min pre-capsaicin), dose-dependently inhibited referred hyperalgesia 3-6 h after capsaicin.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	26-29
12775708-4	2003	Similarly the MEK inhibitor U0126 decreased transcription and proliferation in the LTED cells and reduced their sensitivity to the proliferative effects of E2, while having no effect on the wt.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
12921749-7	2003	Subsequent inhibition assays using U0126, a specific inhibitor of ERK1/2 phosphorylation, were conducted.	U 0126	35-40	mitogen-activated protein kinase 3	Homo sapiens	66-72
12921749-8	2003	U0126 inhibited EGF-induced ERK1/2 phosphorylation in a dose-dependent manner and consequently MEE cells stopped proliferation.	U 0126	0-5	epidermal growth factor	Homo sapiens	16-19
12921749-8	2003	U0126 inhibited EGF-induced ERK1/2 phosphorylation in a dose-dependent manner and consequently MEE cells stopped proliferation.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	28-34
12689928-3	2003	Inhibition of the upstream MAPK kinase (also called MEK) by the small molecule UO126 inhibited the phosphorylation of ERK and demonstrated a dose- and time-dependent antiproliferative activity in HD cell lines.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
12898507-4	2003	We demonstrated that U0126 or PD98059 blocked TNF-alpha-induced ERK activity and decreased TNF-alpha-induced lipolysis by 65 or 76% respectively.	U 0126	21-26	tumor necrosis factor	Homo sapiens	46-55
12906713-12	2003	In vitro, treatment of human HepG2 and Hep3B cells with MEK1/2 specific inhibitors U0126 and PD98059 led to growth inhibition and apoptosis.	U 0126	83-88	mitogen-activated protein kinase kinase 1	Homo sapiens	56-62
12906713-13	2003	U0126 induced the release of cytochrome c and increased the cleavage of caspase-3, caspase-7, and poly ADP-ribose polymerase (PARP).	U 0126	0-5	cytochrome c, somatic	Homo sapiens	29-41
12906713-13	2003	U0126 induced the release of cytochrome c and increased the cleavage of caspase-3, caspase-7, and poly ADP-ribose polymerase (PARP).	U 0126	0-5	caspase 3	Homo sapiens	72-81
12906713-13	2003	U0126 induced the release of cytochrome c and increased the cleavage of caspase-3, caspase-7, and poly ADP-ribose polymerase (PARP).	U 0126	0-5	caspase 7	Homo sapiens	83-92
12906713-13	2003	U0126 induced the release of cytochrome c and increased the cleavage of caspase-3, caspase-7, and poly ADP-ribose polymerase (PARP).	U 0126	0-5	poly(ADP-ribose) polymerase 1	Homo sapiens	98-124
12906713-13	2003	U0126 induced the release of cytochrome c and increased the cleavage of caspase-3, caspase-7, and poly ADP-ribose polymerase (PARP).	U 0126	0-5	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
12906713-15	2003	Activated MEK1-transfected cells were more resistant to UO126-induced apoptosis in vitro and formed larger tumors in SCID mice than mock-transfected cells.	U 0126	56-61	mitogen-activated protein kinase kinase 1	Mus musculus	10-14
12904462-7	2003	Visual stimulation triggered a prolonged episode of CRE-mediated gene expression in the visual cortex that was suppressed by infusion with the ERK inhibitor U0126.	U 0126	157-162	mitogen-activated protein kinase 1	Mus musculus	143-146
12851216-7	2003	Furthermore, treatment of BON-raf cells with MEK inhibitors PD-98059 and U-0126 blocked raf-1-mediated morphological changes and hormone suppression but not ERK1/2 phosphorylation.	U 0126	73-79	mitogen-activated protein kinase kinase 7	Homo sapiens	45-48
12851216-7	2003	Furthermore, treatment of BON-raf cells with MEK inhibitors PD-98059 and U-0126 blocked raf-1-mediated morphological changes and hormone suppression but not ERK1/2 phosphorylation.	U 0126	73-79	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	88-93
12893270-9	2003	Addition of the MEK inhibitor U0126 to PC12 cells expressing Gal4-Smad5/wt did not increase background transcriptional activity.	U 0126	30-35	galectin 4	Rattus norvegicus	61-65
12893270-9	2003	Addition of the MEK inhibitor U0126 to PC12 cells expressing Gal4-Smad5/wt did not increase background transcriptional activity.	U 0126	30-35	SMAD family member 5	Rattus norvegicus	66-71
12907245-8	2003	Inhibition of ERK signaling by the MEK inhibitor, U0126, potentiated the cytotoxic effects of vinblastine and doxorubicin, but not that of VP-16.	U 0126	50-55	mitogen-activated protein kinase 1	Homo sapiens	14-17
12907245-8	2003	Inhibition of ERK signaling by the MEK inhibitor, U0126, potentiated the cytotoxic effects of vinblastine and doxorubicin, but not that of VP-16.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
12974390-5	2003	This migration shift of FRS2 is completely abrogated by U0126, a specific MAPK kinase 1 (MEK1) inhibitor, suggesting that ERK1/2 acts as serine/threonine kinase upstream of FRS2.	U 0126	56-61	fibroblast growth factor receptor substrate 2	Homo sapiens	24-28
12974390-5	2003	This migration shift of FRS2 is completely abrogated by U0126, a specific MAPK kinase 1 (MEK1) inhibitor, suggesting that ERK1/2 acts as serine/threonine kinase upstream of FRS2.	U 0126	56-61	mitogen-activated protein kinase kinase 1	Homo sapiens	89-93
12974390-5	2003	This migration shift of FRS2 is completely abrogated by U0126, a specific MAPK kinase 1 (MEK1) inhibitor, suggesting that ERK1/2 acts as serine/threonine kinase upstream of FRS2.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	122-128
12974390-5	2003	This migration shift of FRS2 is completely abrogated by U0126, a specific MAPK kinase 1 (MEK1) inhibitor, suggesting that ERK1/2 acts as serine/threonine kinase upstream of FRS2.	U 0126	56-61	fibroblast growth factor receptor substrate 2	Homo sapiens	173-177
12689928-3	2003	Inhibition of the upstream MAPK kinase (also called MEK) by the small molecule UO126 inhibited the phosphorylation of ERK and demonstrated a dose- and time-dependent antiproliferative activity in HD cell lines.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	118-121
12851419-4	2003	FGF-1-induced ET-AR expression was inhibited by FGF-receptor inhibitor PD-166866, MEK inhibitor U-0126, transcription inhibitor actinomycin D, and translation inhibitor cycloheximide.	U 0126	96-102	fibroblast growth factor 1	Rattus norvegicus	0-5
12898507-4	2003	We demonstrated that U0126 or PD98059 blocked TNF-alpha-induced ERK activity and decreased TNF-alpha-induced lipolysis by 65 or 76% respectively.	U 0126	21-26	mitogen-activated protein kinase 1	Homo sapiens	64-67
12898507-4	2003	We demonstrated that U0126 or PD98059 blocked TNF-alpha-induced ERK activity and decreased TNF-alpha-induced lipolysis by 65 or 76% respectively.	U 0126	21-26	tumor necrosis factor	Homo sapiens	91-100
14513837-6	2003	Thrombin-inducedVEGF release was blocked by anti-thrombin, heparin, a synthetic thrombin receptor inhibitor E5510, the calcium chelator BAPTA, the protein kinase C inhibitor calphostin C, and the MEK1/2 inhibitor U0126.	U 0126	213-218	coagulation factor II, thrombin	Homo sapiens	0-8
12824291-4	2003	Total serine phosphorylation of Smad2/3, but not phosphorylation of the C-terminal SS(P)XS(P) motif, was decreased by pretreatment with the MEK/ERK inhibitors, PD98059 (10 microM) or U0126 (25 microM).	U 0126	183-188	SMAD family member 2	Homo sapiens	32-39
12824291-4	2003	Total serine phosphorylation of Smad2/3, but not phosphorylation of the C-terminal SS(P)XS(P) motif, was decreased by pretreatment with the MEK/ERK inhibitors, PD98059 (10 microM) or U0126 (25 microM).	U 0126	183-188	mitogen-activated protein kinase kinase 7	Homo sapiens	140-143
12848848-6	2003	A specific inhibitor of mitogen-activated protein kinase pathway, U0126, totally inhibited the increase of MUC2 mRNA by IL-4 or IL-13 in those cells.	U 0126	66-71	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	107-111
12848848-6	2003	A specific inhibitor of mitogen-activated protein kinase pathway, U0126, totally inhibited the increase of MUC2 mRNA by IL-4 or IL-13 in those cells.	U 0126	66-71	interleukin 4	Homo sapiens	120-124
12848848-6	2003	A specific inhibitor of mitogen-activated protein kinase pathway, U0126, totally inhibited the increase of MUC2 mRNA by IL-4 or IL-13 in those cells.	U 0126	66-71	interleukin 13	Homo sapiens	128-133
12851419-4	2003	FGF-1-induced ET-AR expression was inhibited by FGF-receptor inhibitor PD-166866, MEK inhibitor U-0126, transcription inhibitor actinomycin D, and translation inhibitor cycloheximide.	U 0126	96-102	endothelin receptor type A	Rattus norvegicus	14-19
12929934-11	2003	PTH activated p42/p44 MAP kinase, and the effects of PTH, PDBu, and ionomycin on PLD, but not on calcium influx, were prevented by the MEK inhibitors PD98059 and U0126.	U 0126	162-167	parathyroid hormone	Rattus norvegicus	0-3
12929934-11	2003	PTH activated p42/p44 MAP kinase, and the effects of PTH, PDBu, and ionomycin on PLD, but not on calcium influx, were prevented by the MEK inhibitors PD98059 and U0126.	U 0126	162-167	mitogen activated protein kinase 3	Rattus norvegicus	18-21
12929934-11	2003	PTH activated p42/p44 MAP kinase, and the effects of PTH, PDBu, and ionomycin on PLD, but not on calcium influx, were prevented by the MEK inhibitors PD98059 and U0126.	U 0126	162-167	parathyroid hormone	Rattus norvegicus	53-56
12834262-2	2003	The MEK 1 and 2 inhibitors, U0126 and PD98059, significantly suppressed cell viability mediated by bFGF in a dose-dependent manner, and to a greater extent compared with EGF and NGF.	U 0126	28-33	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-15
12794177-6	2003	The contraction-induced activation of HSL was abolished by the protein kinase C (PKC) inhibitors bisindolylmaleimide I and calphostin C and reduced 50% by the mitogen-activated protein kinase kinase (MEK) inhibitor U0126, which also completely blocked extracellular signal-regulated kinase (ERK) 1 and 2 phosphorylation.	U 0126	215-220	lipase E, hormone sensitive type	Rattus norvegicus	38-41
12834262-2	2003	The MEK 1 and 2 inhibitors, U0126 and PD98059, significantly suppressed cell viability mediated by bFGF in a dose-dependent manner, and to a greater extent compared with EGF and NGF.	U 0126	28-33	fibroblast growth factor 2	Rattus norvegicus	99-103
12834262-2	2003	The MEK 1 and 2 inhibitors, U0126 and PD98059, significantly suppressed cell viability mediated by bFGF in a dose-dependent manner, and to a greater extent compared with EGF and NGF.	U 0126	28-33	epidermal growth factor like 1	Rattus norvegicus	170-173
12749822-7	2003	PD98059 and U0126, MEK1/2 inhibitors, significantly attenuated CER-induced increases in lipid peroxidation and LDH leakage in the slices.	U 0126	12-17	mitogen activated protein kinase kinase 1	Rattus norvegicus	19-25
12736249-5	2003	We observed that growth stimulation was associated with stimulation of ERK1/2 phosphorylation (ERK-P), and both growth and ERK-P could be blocked by the MEK inhibitor (U0126, 100 nm).	U 0126	168-173	mitogen activated protein kinase 3	Rattus norvegicus	71-77
12689928-4	2003	UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis.	U 0126	0-5	BCL2 apoptosis regulator	Homo sapiens	71-96
12689928-4	2003	UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis.	U 0126	0-5	BCL2 apoptosis regulator	Homo sapiens	98-103
12689928-4	2003	UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis.	U 0126	0-5	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	106-129
12689928-4	2003	UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis.	U 0126	0-5	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	131-136
12689928-4	2003	UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis.	U 0126	0-5	caspase 8	Homo sapiens	142-151
12689928-4	2003	UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis.	U 0126	0-5	caspase 8	Homo sapiens	160-165
12689928-5	2003	Furthermore, UO126 potentiated the activity of apoliprotein 2/tumor necrosis factor-related apoptosis-inducing ligand (APO2L/TRAIL) and chemotherapy-induced cell death.	U 0126	13-18	TNF superfamily member 10	Homo sapiens	119-124
12689928-5	2003	Furthermore, UO126 potentiated the activity of apoliprotein 2/tumor necrosis factor-related apoptosis-inducing ligand (APO2L/TRAIL) and chemotherapy-induced cell death.	U 0126	13-18	TNF superfamily member 10	Homo sapiens	125-130
12689928-7	2003	UO126 inhibited basal and ligand-induced ERK phosphorylation, and inhibited ligand-induced cell survival of HD cell lines.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	41-44
12860392-1	2003	Exposure of PC12 cells to 100 microM peroxynitrite promotes phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) sensitive to PD98059 or U0126.	U 0126	159-164	mitogen activated protein kinase 3	Rattus norvegicus	79-125
12837293-5	2003	Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	61-64
12860392-1	2003	Exposure of PC12 cells to 100 microM peroxynitrite promotes phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) sensitive to PD98059 or U0126.	U 0126	159-164	mitogen activated protein kinase 3	Rattus norvegicus	127-133
12860392-2	2003	At higher concentrations, however, ERK1/2 phosphorylation was prevented by U0126 and increased by PD98059 via a U0126-sensitive mechanism.	U 0126	75-80	mitogen activated protein kinase 3	Rattus norvegicus	35-41
12860392-2	2003	At higher concentrations, however, ERK1/2 phosphorylation was prevented by U0126 and increased by PD98059 via a U0126-sensitive mechanism.	U 0126	112-117	mitogen activated protein kinase 3	Rattus norvegicus	35-41
12837293-5	2003	Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	89-95
12837293-5	2003	Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	107-113
12837293-5	2003	Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion.	U 0126	39-44	hepatocyte growth factor	Homo sapiens	135-138
12837293-5	2003	Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion.	U 0126	39-44	hepatocyte growth factor	Homo sapiens	154-157
12878040-5	2003	ROS formation was inhibited by the MEK1/2 inhibitor U0126, the tyrosine kinase inhibitor erbstatin-A, and the phosphatidylinositol-3 kinase inhibitor wortmannin.	U 0126	52-57	mitogen-activated protein kinase kinase 1	Homo sapiens	35-41
12854631-6	2003	U0126, an inhibitor of p42/p44 ERK, also produced a significant decrease in chemokine production (46.3 +/- 9%, P &lt; 0.01 n = 10 and 67.8 +/- 12%, P &lt; 0.01, n = 12).	U 0126	0-5	cyclin dependent kinase 20	Homo sapiens	23-26
12788788-4	2003	Thrombin-induced ERK-dependent caldesmon phosphorylation (Ser789) was inhibited by either KN-93, a specific CaM kinase II inhibitor, or U0126, an inhibitor of MEK activation.	U 0126	136-141	coagulation factor II, thrombin	Bos taurus	0-8
12788788-6	2003	Pretreatment with either U0126 or KN-93 attenuated thrombin-mediated cytoskeletal rearrangement and evoked declines in transendothelial electrical resistance while reversing thrombin-induced dissociation of myosin from nondenaturing caldesmon immunoprecipitates.	U 0126	25-30	coagulation factor II, thrombin	Bos taurus	51-59
12788788-6	2003	Pretreatment with either U0126 or KN-93 attenuated thrombin-mediated cytoskeletal rearrangement and evoked declines in transendothelial electrical resistance while reversing thrombin-induced dissociation of myosin from nondenaturing caldesmon immunoprecipitates.	U 0126	25-30	coagulation factor II, thrombin	Bos taurus	174-182
12801520-4	2003	PD98059 and U-0126, specific inhibitors of MEK, suppressed the VEGF synthesis induced by TGF-beta.	U 0126	12-18	vascular endothelial growth factor A	Mus musculus	63-67
12801520-4	2003	PD98059 and U-0126, specific inhibitors of MEK, suppressed the VEGF synthesis induced by TGF-beta.	U 0126	12-18	transforming growth factor, beta 1	Mus musculus	89-97
12801520-5	2003	U-0126 inhibited the TGF-beta-induced p44/p42 MAP kinase phosphorylation.	U 0126	0-6	transforming growth factor, beta 1	Mus musculus	21-29
12801520-5	2003	U-0126 inhibited the TGF-beta-induced p44/p42 MAP kinase phosphorylation.	U 0126	0-6	mitogen-activated protein kinase 3	Mus musculus	38-41
12801520-5	2003	U-0126 inhibited the TGF-beta-induced p44/p42 MAP kinase phosphorylation.	U 0126	0-6	cyclin-dependent kinase 20	Mus musculus	42-45
12815714-7	2003	The PI3K specific inhibitor LY294002 (10-50 microM) blocked GDNF-mediated protection against nuclear condensation, as did the MAPK kinase (MEK) inhibitor U0126 (5- 20 microM).	U 0126	154-159	midkine	Mus musculus	139-142
12832293-6	2003	Exposure to E. coli DNA resulted in phosphorylation of ERK 1/2 MAPK and inhibitors of ERK activity (PD98059, UO126) significantly reduced the evoked IL-8 production.	U 0126	109-114	C-X-C motif chemokine ligand 8	Bos taurus	149-153
12807421-6	2003	Neuronal death and phosphorylation of components in this cascade were inhibited by the Raf inhibitor SB-386023, by the MEK inhibitor U0126, or by the MSK1 inhibitors H89 and Ro318220.	U 0126	133-138	midkine	Mus musculus	119-122
12883037-6	2003	The MEK-specific inhibitor U0126 or PKC inhibitor staurosporine (STP) also down-regulated XIAP expression and induced apoptosis.	U 0126	27-32	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
12883037-6	2003	The MEK-specific inhibitor U0126 or PKC inhibitor staurosporine (STP) also down-regulated XIAP expression and induced apoptosis.	U 0126	27-32	X-linked inhibitor of apoptosis	Homo sapiens	90-94
12854631-6	2003	U0126, an inhibitor of p42/p44 ERK, also produced a significant decrease in chemokine production (46.3 +/- 9%, P &lt; 0.01 n = 10 and 67.8 +/- 12%, P &lt; 0.01, n = 12).	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	31-34
12692126-6	2003	Treatment with the ERK inhibitors U0126 and PD98059 prevented FAK phosphorylation at Ser-910 in response to all of the stimuli tested.	U 0126	34-39	mitogen-activated protein kinase 1	Mus musculus	19-22
12676927-11	2003	Inhibition of the ERK and protein kinase C signaling pathways with the MEK-1 inhibitor, U0126, and protein kinase C inhibitor, GF 1092030x, respectively, and chelating intracellular free calcium with 1,2-bis(2-aminophenoyl)ethane-N,N,N",N"-tetraacetic acid-AM, which also reduced ERK1/2 activation, significantly reduced H2O2-induced AA release in MC+/+ expressing either group IIa or V PLA2s.	U 0126	88-93	mitogen-activated protein kinase 1	Mus musculus	18-21
12692126-6	2003	Treatment with the ERK inhibitors U0126 and PD98059 prevented FAK phosphorylation at Ser-910 in response to all of the stimuli tested.	U 0126	34-39	PTK2 protein tyrosine kinase 2	Mus musculus	62-65
12665505-8	2003	Leptin activated ERK, but not p38 and JNK, and up-regulated cPLA2 activity; the latter was abolished by pre-treatment of cells with the MEK inhibitor (PD98059 or U0126) or cPLA2 inhibitor (AACOCF3).	U 0126	162-167	leptin	Homo sapiens	0-6
12788473-6	2003	However, complete inhibition of cPLA(2) phosphorylation by U0126, an inhibitor for mitogen-activated protein kinase kinase (MEK) and GF109203x, a nonselective PKC inhibitor preferring the conventional and novel isoforms, only reduced H(2)O(2)-stimulated AA release by 50%.	U 0126	59-64	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	32-39
12832561-4	2003	We show that inhibition of the MAPK pathway by intracerebroventricular injection of the MEK [MAPK/extracellular signal-regulated kinase (ERK)] inhibitor UO126 blocks consolidation of object recognition memory but does not affect short-term memory.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	31-35
12832561-4	2003	We show that inhibition of the MAPK pathway by intracerebroventricular injection of the MEK [MAPK/extracellular signal-regulated kinase (ERK)] inhibitor UO126 blocks consolidation of object recognition memory but does not affect short-term memory.	U 0126	153-158	mitogen-activated protein kinase kinase 7	Homo sapiens	88-91
12832561-4	2003	We show that inhibition of the MAPK pathway by intracerebroventricular injection of the MEK [MAPK/extracellular signal-regulated kinase (ERK)] inhibitor UO126 blocks consolidation of object recognition memory but does not affect short-term memory.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	93-97
12832561-4	2003	We show that inhibition of the MAPK pathway by intracerebroventricular injection of the MEK [MAPK/extracellular signal-regulated kinase (ERK)] inhibitor UO126 blocks consolidation of object recognition memory but does not affect short-term memory.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	137-140
12665505-8	2003	Leptin activated ERK, but not p38 and JNK, and up-regulated cPLA2 activity; the latter was abolished by pre-treatment of cells with the MEK inhibitor (PD98059 or U0126) or cPLA2 inhibitor (AACOCF3).	U 0126	162-167	phospholipase A2 group IVA	Homo sapiens	60-65
12665505-9	2003	PD98059, U0126, and AACOCF3 also diminished the leptin-induced cytochrome c release into cytosol, cell death, and caspase-3 activation.	U 0126	9-14	leptin	Homo sapiens	48-54
12665505-9	2003	PD98059, U0126, and AACOCF3 also diminished the leptin-induced cytochrome c release into cytosol, cell death, and caspase-3 activation.	U 0126	9-14	cytochrome c, somatic	Homo sapiens	63-75
12665505-9	2003	PD98059, U0126, and AACOCF3 also diminished the leptin-induced cytochrome c release into cytosol, cell death, and caspase-3 activation.	U 0126	9-14	caspase 3	Homo sapiens	114-123
12588703-6	2003	U-0126 blocked the synergism between IL-9 and IL-13 on eotaxin release.	U 0126	0-6	interleukin 9	Homo sapiens	37-41
12832521-4	2003	The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2).	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	50-56
12832521-4	2003	The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2).	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	57-61
12832521-4	2003	The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2).	U 0126	90-95	mitogen activated protein kinase 3	Rattus norvegicus	117-123
12832521-4	2003	The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2).	U 0126	90-95	mitogen activated protein kinase kinase 1	Rattus norvegicus	137-143
12576295-5	2003	PDGF chemotaxis was blocked by the phosphatidyl 3"-kinase inhibitor LY-294002, the MEK inhibitor U-0126, PGE(2), formoterol, pertussis toxin, and the Rho kinase inhibitor Y-27632.	U 0126	97-103	mitogen-activated protein kinase kinase 7	Homo sapiens	83-86
12588703-6	2003	U-0126 blocked the synergism between IL-9 and IL-13 on eotaxin release.	U 0126	0-6	interleukin 13	Homo sapiens	46-51
12588703-6	2003	U-0126 blocked the synergism between IL-9 and IL-13 on eotaxin release.	U 0126	0-6	C-C motif chemokine ligand 11	Homo sapiens	55-62
12868493-4	2003	U0126, an ERK1/2 kinase inhibitor, inhibited both the production of O2- and the translocation of p47(phox) elicited by fMLP.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	10-16
12786942-8	2003	Pretreatment of cells with a MEK1 inhibitor, U0126, also strongly inhibited IL-1beta-dependent secretion of MMP-9.	U 0126	45-50	mitogen-activated protein kinase kinase 1	Mus musculus	29-33
12786942-8	2003	Pretreatment of cells with a MEK1 inhibitor, U0126, also strongly inhibited IL-1beta-dependent secretion of MMP-9.	U 0126	45-50	interleukin 1 beta	Mus musculus	76-84
12786942-8	2003	Pretreatment of cells with a MEK1 inhibitor, U0126, also strongly inhibited IL-1beta-dependent secretion of MMP-9.	U 0126	45-50	matrix metallopeptidase 9	Mus musculus	108-113
12730952-10	2003	The induction of 14-3-3gamma proteins was neither suppressed by an MAP kinase inhibitor (U0126) nor a PI-3 kinase inhibitor (LY294002).	U 0126	89-94	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	Homo sapiens	17-28
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	34-37
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	38-42
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	47-53
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	interleukin 1 beta	Homo sapiens	88-96
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	121-126
12868493-4	2003	U0126, an ERK1/2 kinase inhibitor, inhibited both the production of O2- and the translocation of p47(phox) elicited by fMLP.	U 0126	0-5	NSFL1 cofactor	Rattus norvegicus	97-100
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	161-165
12868493-6	2003	In this case, U0126 showed no inhibition against the production of O2- and slight inhibition against the translocation of p47(phox).	U 0126	14-19	NSFL1 cofactor	Rattus norvegicus	122-125
12787125-9	2003	Furthermore, a specific MEK1/2 inhibitor, U0126, mimicked the effect of CX-659S.	U 0126	42-47	mitogen-activated protein kinase kinase 1	Mus musculus	24-30
12743010-6	2003	Inhibition of p38 (with SB 203580), ERK 44/42 (with UO126 or PD 98059), or COX-2 (with NS398) each significantly suppressed uric acid-induced MCP-1 expression at 24 hours, implicating these pathways in the response to uric acid.	U 0126	52-57	mitogen-activated protein kinase 1	Homo sapiens	36-39
12773514-5	2003	Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	71-75
12773514-5	2003	Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506.	U 0126	199-204	mitogen-activated protein kinase kinase 1	Homo sapiens	85-90
12773514-5	2003	Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	136-139
12773514-5	2003	Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506.	U 0126	199-204	MHC class I polypeptide-related sequence A	Homo sapiens	166-170
23604762-6	2003	U0126 (25 microM) completely abolished ERK1/2 activation induced by OTA.	U 0126	0-5	mitogen activated protein kinase 3	Rattus norvegicus	39-45
12788379-9	2003	The MEK1/2 inhibitor U0126 prevented the hypertrophic effect of 10 microM H(2)O(2).	U 0126	21-26	mitogen activated protein kinase kinase 1	Rattus norvegicus	4-10
12657625-5	2003	Treatment of cells with selective mitogen-activated protein kinase kinase (MEK) inhibitors PD098059 and U0126 showed that integrin alpha2 expression, cell adhesion, and activation of ERK are inhibited in a parallel concentration-dependent fashion.	U 0126	104-109	integrin subunit alpha 2	Homo sapiens	122-137
12745093-3	2003	The PMA-induced MMP-9 secretion was abolished by treatment of a pan-protein kinase C (PKC) inhibitor, GF109203X, and an inhibitor of NF-kappaB activation, sulfasalazine, and partly inhibited by treatment of inhibitors of ERK pathway, PD98059 and U0126.	U 0126	246-251	matrix metallopeptidase 9	Homo sapiens	16-21
12637510-10	2003	ECs treated with MEK inhibitor (U0126 or PD98059) consistently and significantly reduced the shear-induced ERK1/2 and Ser-727 phosphorylation, indicating that ERK1/2 is upstream of Ser-727 phosphorylation.	U 0126	32-37	mitogen-activated protein kinase 3	Bos taurus	107-113
12637510-10	2003	ECs treated with MEK inhibitor (U0126 or PD98059) consistently and significantly reduced the shear-induced ERK1/2 and Ser-727 phosphorylation, indicating that ERK1/2 is upstream of Ser-727 phosphorylation.	U 0126	32-37	mitogen-activated protein kinase 3	Bos taurus	159-165
12657625-5	2003	Treatment of cells with selective mitogen-activated protein kinase kinase (MEK) inhibitors PD098059 and U0126 showed that integrin alpha2 expression, cell adhesion, and activation of ERK are inhibited in a parallel concentration-dependent fashion.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	183-186
12732214-9	2003	Elevated ERK activity that contributed to apoptosis by EGCG plus vanadate was supported by PD98059 and U0126, chemical inhibitor of MEK/ERK signaling pathway, prevented apoptosis.	U 0126	103-108	mitogen-activated protein kinase 1	Homo sapiens	9-12
12646577-12	2003	PD98059 or U0126, inhibitors of MEK, suppressed the VEGF synthesis induced by PGF2 alpha.	U 0126	11-16	mitogen-activated protein kinase kinase 1	Mus musculus	32-35
12646577-12	2003	PD98059 or U0126, inhibitors of MEK, suppressed the VEGF synthesis induced by PGF2 alpha.	U 0126	11-16	vascular endothelial growth factor A	Mus musculus	52-56
12732214-9	2003	Elevated ERK activity that contributed to apoptosis by EGCG plus vanadate was supported by PD98059 and U0126, chemical inhibitor of MEK/ERK signaling pathway, prevented apoptosis.	U 0126	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	132-135
12732214-9	2003	Elevated ERK activity that contributed to apoptosis by EGCG plus vanadate was supported by PD98059 and U0126, chemical inhibitor of MEK/ERK signaling pathway, prevented apoptosis.	U 0126	103-108	mitogen-activated protein kinase 1	Homo sapiens	136-139
12750255-7	2003	Finally, we demonstrate that NT stimulated clonal growth of PANC-1 cells in semisolid medium, which is abrogated by both GF-1 and the MEK-1/2 inhibitor, U0126.	U 0126	153-158	mitogen-activated protein kinase kinase 1	Homo sapiens	134-141
12521992-7	2003	Accordingly, the MEK1/2 inhibitor U0126 potently inhibited the collagen-induced aggregation of transgenic platelets when stirred or when perfused over a collagen surface.	U 0126	34-39	mitogen-activated protein kinase kinase 1	Mus musculus	17-23
12729801-7	2003	IGF-I-stimulated activation of MAPK/ERK signaling in WM1341D cells was inhibited by U0126, but a 33-fold higher dose of U0126 was needed to inhibit IGF-I-stimulated cellular migration.	U 0126	120-125	insulin like growth factor 1	Homo sapiens	0-5
12729801-7	2003	IGF-I-stimulated activation of MAPK/ERK signaling in WM1341D cells was inhibited by U0126, but a 33-fold higher dose of U0126 was needed to inhibit IGF-I-stimulated cellular migration.	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	36-39
12729801-7	2003	IGF-I-stimulated activation of MAPK/ERK signaling in WM1341D cells was inhibited by U0126, but a 33-fold higher dose of U0126 was needed to inhibit IGF-I-stimulated cellular migration.	U 0126	120-125	insulin like growth factor 1	Homo sapiens	148-153
12729802-9	2003	Both basal and ATF-mediated migratory responses were suppressed in the presence of selective pharmacological inhibitors LY294002, U73122, and U0126, implicating the respective roles of phosphatidinylinositol 3-kinase (PI 3-K), phospholipase C (PLC), and MEK1/2 in basal and ATF-stimulated migratory capacity.	U 0126	142-147	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	185-216
12729802-9	2003	Both basal and ATF-mediated migratory responses were suppressed in the presence of selective pharmacological inhibitors LY294002, U73122, and U0126, implicating the respective roles of phosphatidinylinositol 3-kinase (PI 3-K), phospholipase C (PLC), and MEK1/2 in basal and ATF-stimulated migratory capacity.	U 0126	142-147	mitogen-activated protein kinase kinase 1	Homo sapiens	254-260
12704791-5	2003	The MEK-specific inhibitors PD98059 and U0126 blocked MAP kinase phosphorylation; furthermore, PD98059 inhibited the increase in integrin expression induced by uPAR clustering.	U 0126	40-45	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
12704791-5	2003	The MEK-specific inhibitors PD98059 and U0126 blocked MAP kinase phosphorylation; furthermore, PD98059 inhibited the increase in integrin expression induced by uPAR clustering.	U 0126	40-45	plasminogen activator, urokinase receptor	Homo sapiens	160-164
12764099-3	2003	The treatment of the mitogen-activated protein kinase (MAPK) kinase 1/2 inhibitor U0126 reversed the pain hypersensitivity and the increase in phosphorylated-ERK (p-ERK) and BDNF in DRG neurons induced by complete Freund"s adjuvant.	U 0126	82-87	mitogen-activated protein kinase 1	Homo sapiens	55-59
12764099-3	2003	The treatment of the mitogen-activated protein kinase (MAPK) kinase 1/2 inhibitor U0126 reversed the pain hypersensitivity and the increase in phosphorylated-ERK (p-ERK) and BDNF in DRG neurons induced by complete Freund"s adjuvant.	U 0126	82-87	mitogen-activated protein kinase 1	Homo sapiens	158-161
12764099-3	2003	The treatment of the mitogen-activated protein kinase (MAPK) kinase 1/2 inhibitor U0126 reversed the pain hypersensitivity and the increase in phosphorylated-ERK (p-ERK) and BDNF in DRG neurons induced by complete Freund"s adjuvant.	U 0126	82-87	mitogen-activated protein kinase 1	Homo sapiens	165-168
12764099-3	2003	The treatment of the mitogen-activated protein kinase (MAPK) kinase 1/2 inhibitor U0126 reversed the pain hypersensitivity and the increase in phosphorylated-ERK (p-ERK) and BDNF in DRG neurons induced by complete Freund"s adjuvant.	U 0126	82-87	brain derived neurotrophic factor	Homo sapiens	174-178
12764099-5	2003	U0126 suppressed the axotomy-induced autotomy behavior and reversed the increase in p-ERK and BDNF.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	86-89
12764099-5	2003	U0126 suppressed the axotomy-induced autotomy behavior and reversed the increase in p-ERK and BDNF.	U 0126	0-5	brain derived neurotrophic factor	Homo sapiens	94-98
12771938-3	2003	Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis.	U 0126	59-64	mitogen-activated protein kinase 3	Homo sapiens	14-20
12771938-3	2003	Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis.	U 0126	59-64	mitogen-activated protein kinase kinase 7	Homo sapiens	45-48
12771938-3	2003	Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis.	U 0126	59-64	TNF superfamily member 10	Homo sapiens	141-146
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	46-51	caspase 8	Homo sapiens	81-90
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	46-51	BH3 interacting domain death agonist	Homo sapiens	95-98
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	46-51	caspase 3	Homo sapiens	115-124
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	46-51	caspase 8	Homo sapiens	171-180
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	46-51	BH3 interacting domain death agonist	Homo sapiens	185-188
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	46-51	TNF superfamily member 10	Homo sapiens	192-197
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	248-253	caspase 3	Homo sapiens	115-124
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	248-253	caspase 8	Homo sapiens	171-180
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	248-253	BH3 interacting domain death agonist	Homo sapiens	185-188
12771938-4	2003	The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126.	U 0126	248-253	TNF superfamily member 10	Homo sapiens	192-197
12771938-5	2003	Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126.	U 0126	117-122	caspase 3	Homo sapiens	0-9
12771938-5	2003	Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126.	U 0126	117-122	collagen type XI alpha 2 chain	Homo sapiens	53-57
12771938-5	2003	Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126.	U 0126	117-122	DNA fragmentation factor subunit alpha	Homo sapiens	59-63
12771938-5	2003	Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126.	U 0126	117-122	X-linked inhibitor of apoptosis	Homo sapiens	68-72
12771938-7	2003	Exploration of events leading to the changes in MMP revealed an increased translocation of Bax from the cytosol to mitochondria in the presence of U0126.	U 0126	147-152	BCL2 associated X, apoptosis regulator	Homo sapiens	91-94
12771938-10	2003	Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126.	U 0126	76-81	BCL2 apoptosis regulator	Homo sapiens	19-24
12771938-10	2003	Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126.	U 0126	76-81	TNF superfamily member 10	Homo sapiens	33-38
12729908-5	2003	Clock gene mRNA induction by PE was inhibited by U0126, a MEK inhibitor, suggesting involvement of the mitogen-activated protein kinase signaling pathway.	U 0126	49-54	midkine	Mus musculus	58-61
12600999-7	2003	The treatments with MEK inhibitor U0126, p38 kinase inhibitor SB203580, and JNK inhibitor SP600125 significantly attenuated hypertonicity-induced AQP1 expression in mIMCD-3 cells.	U 0126	34-39	midkine	Mus musculus	20-23
12600999-7	2003	The treatments with MEK inhibitor U0126, p38 kinase inhibitor SB203580, and JNK inhibitor SP600125 significantly attenuated hypertonicity-induced AQP1 expression in mIMCD-3 cells.	U 0126	34-39	aquaporin 1	Mus musculus	146-150
12600999-9	2003	NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2.	U 0126	125-130	aquaporin 1	Mus musculus	27-31
12600999-9	2003	NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2.	U 0126	125-130	mitogen-activated protein kinase 8	Mus musculus	253-257
12600999-9	2003	NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2.	U 0126	125-130	mitogen-activated protein kinase 9	Mus musculus	262-266
12711332-5	2003	PD098059 and U0126 (two MEK inhibitors), and LY294002 (a PI3K inhibitor) inhibited GM-CSF/IL-10-induced CCR1 gene and protein expression.	U 0126	13-18	colony stimulating factor 2	Homo sapiens	83-89
12711332-5	2003	PD098059 and U0126 (two MEK inhibitors), and LY294002 (a PI3K inhibitor) inhibited GM-CSF/IL-10-induced CCR1 gene and protein expression.	U 0126	13-18	interleukin 10	Homo sapiens	90-95
12711332-5	2003	PD098059 and U0126 (two MEK inhibitors), and LY294002 (a PI3K inhibitor) inhibited GM-CSF/IL-10-induced CCR1 gene and protein expression.	U 0126	13-18	C-C motif chemokine receptor 1	Homo sapiens	104-108
12711332-6	2003	PD098059, U0126, and LY294002 also attenuated chemotaxis of GM-CSF/IL-10-primed U937 cells in response to MIP-1alpha.	U 0126	10-15	colony stimulating factor 2	Homo sapiens	60-66
12711332-6	2003	PD098059, U0126, and LY294002 also attenuated chemotaxis of GM-CSF/IL-10-primed U937 cells in response to MIP-1alpha.	U 0126	10-15	interleukin 10	Homo sapiens	67-72
12711332-6	2003	PD098059, U0126, and LY294002 also attenuated chemotaxis of GM-CSF/IL-10-primed U937 cells in response to MIP-1alpha.	U 0126	10-15	C-C motif chemokine ligand 3	Homo sapiens	106-116
12711332-10	2003	PD098059 and U0126 completely abrogated ERK2 phosphorylation; whereas, LY294002 completely blocked PKB/Akt and p70(S6k) phosphorylation.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	40-44
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	U 0126	72-78	mitogen-activated protein kinase kinase 2	Homo sapiens	57-61
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	U 0126	72-78	CCAAT enhancer binding protein beta	Homo sapiens	152-162
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	U 0126	72-78	interleukin 6	Homo sapiens	167-171
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	U 0126	72-78	interferon gamma	Homo sapiens	175-184
12517735-7	2003	The MEK inhibitor U-0126 partially suppressed BSA-induced MCP-1 expression and MCP-1 promoter/luciferase reporter activity.	U 0126	18-24	midkine	Mus musculus	4-7
12517735-7	2003	The MEK inhibitor U-0126 partially suppressed BSA-induced MCP-1 expression and MCP-1 promoter/luciferase reporter activity.	U 0126	18-24	chemokine (C-C motif) ligand 2	Mus musculus	58-63
12517735-7	2003	The MEK inhibitor U-0126 partially suppressed BSA-induced MCP-1 expression and MCP-1 promoter/luciferase reporter activity.	U 0126	18-24	chemokine (C-C motif) ligand 2	Mus musculus	79-84
12517735-8	2003	U-0126 also inhibited an increase in nuclear factor-kappaB and activator protein-1 DNA-binding activity of MCP-1 promoter by protein overload in mProx cells.	U 0126	0-6	chemokine (C-C motif) ligand 2	Mus musculus	107-112
12540365-4	2003	The PKC-mediated decreases in beta- and gamma-ENaC were significantly reversed by simultaneous addition of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase-1/2 inhibitors U-0126 and PD-98059.	U 0126	204-210	sodium channel epithelial 1 subunit gamma	Homo sapiens	40-50
12540365-4	2003	The PKC-mediated decreases in beta- and gamma-ENaC were significantly reversed by simultaneous addition of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase-1/2 inhibitors U-0126 and PD-98059.	U 0126	204-210	mitogen-activated protein kinase 3	Homo sapiens	145-149
12540365-4	2003	The PKC-mediated decreases in beta- and gamma-ENaC were significantly reversed by simultaneous addition of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase-1/2 inhibitors U-0126 and PD-98059.	U 0126	204-210	mitogen-activated protein kinase 1	Homo sapiens	151-190
12717136-11	2003	PD98059 and U0126, specific inhibitors of MAP kinase kinase, significantly reduced the midazolam-stimulated release of VEGF.	U 0126	12-17	vascular endothelial growth factor A	Rattus norvegicus	119-123
12606350-8	2003	Third, and perhaps the most important of all, this TGFbeta3-mediated inhibitory effect on the TJ barrier and the TGFbeta3-induced p-p38 MAP kinase production could be blocked by SB202190, a specific p38 MAP kinase inhibitor, but not U0126, a specific MEK1/2 kinase inhibitor.	U 0126	233-238	transforming growth factor beta 3	Homo sapiens	51-59
12853332-7	2003	In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126.	U 0126	173-178	interferon induced protein 44	Homo sapiens	64-67
12853332-7	2003	In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126.	U 0126	173-178	cyclin dependent kinase 20	Homo sapiens	72-75
12606350-8	2003	Third, and perhaps the most important of all, this TGFbeta3-mediated inhibitory effect on the TJ barrier and the TGFbeta3-induced p-p38 MAP kinase production could be blocked by SB202190, a specific p38 MAP kinase inhibitor, but not U0126, a specific MEK1/2 kinase inhibitor.	U 0126	233-238	transforming growth factor beta 3	Homo sapiens	113-121
12606479-8	2003	Furthermore, addition of U0126, an inhibitor of MEK 1/2, abolished the increase in VEGF production stimulated by both hCG and 8Br-cAMP.	U 0126	25-30	mitogen-activated protein kinase kinase 1	Mus musculus	48-55
12606479-8	2003	Furthermore, addition of U0126, an inhibitor of MEK 1/2, abolished the increase in VEGF production stimulated by both hCG and 8Br-cAMP.	U 0126	25-30	vascular endothelial growth factor A	Mus musculus	83-87
12606479-8	2003	Furthermore, addition of U0126, an inhibitor of MEK 1/2, abolished the increase in VEGF production stimulated by both hCG and 8Br-cAMP.	U 0126	25-30	hypertrichosis 2 (generalised, congenital)	Homo sapiens	118-121
12784909-4	2003	Thus, these investigations were conducted to delineate signal transduction mechanisms of CCL11, CCL24 and CCL26-induced eosinophil peroxidase (EPO) degranulation following pretreatment of cells with or without a specific inhibitor of MEK1/MEK2 (U0126), inhibitor of p38 MAP kinase (SB203580) or a specific inhibitor of PI 3-kinase (LY294002).	U 0126	245-250	C-C motif chemokine ligand 11	Homo sapiens	89-94
12697421-5	2003	The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor.	U 0126	74-79	C-X-C motif chemokine ligand 8	Homo sapiens	12-16
12697421-5	2003	The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor.	U 0126	74-79	C-C motif chemokine ligand 2	Homo sapiens	21-26
12697421-5	2003	The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	92-131
12697421-5	2003	The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	133-136
12763138-8	2003	RESULTS: Western blotting of extracts of cells exposed to various chemical inhibitors revealed that the MEK inhibitors PD98059 and U0126 abrogated the EPO-mediated STAT3 serine 727 phosphorylation without an effect on tyrosine phosphorylation.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
12763138-8	2003	RESULTS: Western blotting of extracts of cells exposed to various chemical inhibitors revealed that the MEK inhibitors PD98059 and U0126 abrogated the EPO-mediated STAT3 serine 727 phosphorylation without an effect on tyrosine phosphorylation.	U 0126	131-136	erythropoietin	Homo sapiens	151-154
12763138-8	2003	RESULTS: Western blotting of extracts of cells exposed to various chemical inhibitors revealed that the MEK inhibitors PD98059 and U0126 abrogated the EPO-mediated STAT3 serine 727 phosphorylation without an effect on tyrosine phosphorylation.	U 0126	131-136	signal transducer and activator of transcription 3	Homo sapiens	164-169
12763138-10	2003	Furthermore, the STAT3-mediated transactivation was reduced by blocking the STAT3 serine phosphorylation with the MEK inhibitor U0126 or by expression of kinase-inactive MSK1.	U 0126	128-133	signal transducer and activator of transcription 3	Homo sapiens	17-22
12763138-10	2003	Furthermore, the STAT3-mediated transactivation was reduced by blocking the STAT3 serine phosphorylation with the MEK inhibitor U0126 or by expression of kinase-inactive MSK1.	U 0126	128-133	signal transducer and activator of transcription 3	Homo sapiens	76-81
12763138-10	2003	Furthermore, the STAT3-mediated transactivation was reduced by blocking the STAT3 serine phosphorylation with the MEK inhibitor U0126 or by expression of kinase-inactive MSK1.	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	114-117
12717386-7	2003	The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities.	U 0126	92-97	mitogen-activated protein kinase kinase 7	Homo sapiens	36-75
12717386-7	2003	The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities.	U 0126	92-97	mitogen-activated protein kinase kinase 7	Homo sapiens	77-80
12717386-7	2003	The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities.	U 0126	92-97	ADAM metallopeptidase domain 12	Homo sapiens	108-114
12717386-7	2003	The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities.	U 0126	92-97	transforming growth factor beta 1	Homo sapiens	128-136
12717386-7	2003	The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities.	U 0126	92-97	mitogen-activated protein kinase kinase 7	Homo sapiens	177-180
12784909-4	2003	Thus, these investigations were conducted to delineate signal transduction mechanisms of CCL11, CCL24 and CCL26-induced eosinophil peroxidase (EPO) degranulation following pretreatment of cells with or without a specific inhibitor of MEK1/MEK2 (U0126), inhibitor of p38 MAP kinase (SB203580) or a specific inhibitor of PI 3-kinase (LY294002).	U 0126	245-250	C-C motif chemokine ligand 26	Homo sapiens	106-111
12784909-4	2003	Thus, these investigations were conducted to delineate signal transduction mechanisms of CCL11, CCL24 and CCL26-induced eosinophil peroxidase (EPO) degranulation following pretreatment of cells with or without a specific inhibitor of MEK1/MEK2 (U0126), inhibitor of p38 MAP kinase (SB203580) or a specific inhibitor of PI 3-kinase (LY294002).	U 0126	245-250	eosinophil peroxidase	Homo sapiens	120-141
12784909-4	2003	Thus, these investigations were conducted to delineate signal transduction mechanisms of CCL11, CCL24 and CCL26-induced eosinophil peroxidase (EPO) degranulation following pretreatment of cells with or without a specific inhibitor of MEK1/MEK2 (U0126), inhibitor of p38 MAP kinase (SB203580) or a specific inhibitor of PI 3-kinase (LY294002).	U 0126	245-250	eosinophil peroxidase	Homo sapiens	143-146
12784909-6	2003	However, the rank order of U0126 with respect to inhibition of chemokine-induced degranulation was CCL11 = CCL24 &gt; CCL26.	U 0126	27-32	C-C motif chemokine ligand 11	Homo sapiens	99-104
12784909-6	2003	However, the rank order of U0126 with respect to inhibition of chemokine-induced degranulation was CCL11 = CCL24 &gt; CCL26.	U 0126	27-32	C-C motif chemokine ligand 24	Homo sapiens	107-112
12784909-6	2003	However, the rank order of U0126 with respect to inhibition of chemokine-induced degranulation was CCL11 = CCL24 &gt; CCL26.	U 0126	27-32	C-C motif chemokine ligand 26	Homo sapiens	118-123
12652655-7	2003	When an MEK 1/2 inhibitor U0126 inhibited activities of extracellular signal-regulated kinases (ERKs), the expression of Bcl-xL protein was down-regulated and subsequently apoptosis was induced.	U 0126	26-31	mitogen-activated protein kinase kinase 1	Homo sapiens	8-15
12652655-7	2003	When an MEK 1/2 inhibitor U0126 inhibited activities of extracellular signal-regulated kinases (ERKs), the expression of Bcl-xL protein was down-regulated and subsequently apoptosis was induced.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	96-100
12652655-7	2003	When an MEK 1/2 inhibitor U0126 inhibited activities of extracellular signal-regulated kinases (ERKs), the expression of Bcl-xL protein was down-regulated and subsequently apoptosis was induced.	U 0126	26-31	BCL2 like 1	Homo sapiens	121-127
12727988-3	2003	Moreover, the potent MAPK inhibitors, PD98059 and UO126, augment progesterone production in these cell cultures concomitantly with specific elevation of intracellular steroidogenic acute regulatory protein (StAR).	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	21-25
12727988-3	2003	Moreover, the potent MAPK inhibitors, PD98059 and UO126, augment progesterone production in these cell cultures concomitantly with specific elevation of intracellular steroidogenic acute regulatory protein (StAR).	U 0126	50-55	steroidogenic acute regulatory protein	Homo sapiens	207-211
12652655-8	2003	Interestingly, Z-VAD-FMK blocked U0126-induced down-regulation of Bcl-xL protein and apoptosis, strongly suggesting that Bcl-xL expression is regulated by caspases which lies downstream of ERK activation pathway in EPO signaling.	U 0126	33-38	BCL2 like 1	Homo sapiens	66-72
12727988-9	2003	Intracellular levels of DAX-1 decreased significantly during 24 h of incubation of cells with or without LH in the presence of PD98059 or UO126 compared with those in cultures incubated in the absence of the MAPK inhibitors.	U 0126	138-143	nuclear receptor subfamily 0 group B member 1	Homo sapiens	24-29
12652655-8	2003	Interestingly, Z-VAD-FMK blocked U0126-induced down-regulation of Bcl-xL protein and apoptosis, strongly suggesting that Bcl-xL expression is regulated by caspases which lies downstream of ERK activation pathway in EPO signaling.	U 0126	33-38	BCL2 like 1	Homo sapiens	121-127
12652655-8	2003	Interestingly, Z-VAD-FMK blocked U0126-induced down-regulation of Bcl-xL protein and apoptosis, strongly suggesting that Bcl-xL expression is regulated by caspases which lies downstream of ERK activation pathway in EPO signaling.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	189-192
12652655-8	2003	Interestingly, Z-VAD-FMK blocked U0126-induced down-regulation of Bcl-xL protein and apoptosis, strongly suggesting that Bcl-xL expression is regulated by caspases which lies downstream of ERK activation pathway in EPO signaling.	U 0126	33-38	erythropoietin	Homo sapiens	215-218
12692897-5	2003	The effect of PACAP on cell survival was mimicked by dibutyryl-cAMP (dbcAMP) and forskolin and prevented by the MEK inhibitor U0126, indicating that both the adenylyl-cyclase and MAP-kinase pathways contribute to the neuroprotective action of the peptide.	U 0126	126-131	adenylate cyclase activating polypeptide 1	Homo sapiens	14-19
12797541-3	2003	Using highly specific inhibitors of p38 (SB203580) and of MAPK kinase-1 (U0126 and PD98059), we found that both p38 and ERK were essential for M. tuberculosis H37Rv-induced TNF-alpha production, whereas activation of the p38 pathway, but not that of ERK, was essential for M. tuberculosis H37Rv-induced IL-10 production.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	58-62
12797541-3	2003	Using highly specific inhibitors of p38 (SB203580) and of MAPK kinase-1 (U0126 and PD98059), we found that both p38 and ERK were essential for M. tuberculosis H37Rv-induced TNF-alpha production, whereas activation of the p38 pathway, but not that of ERK, was essential for M. tuberculosis H37Rv-induced IL-10 production.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	112-115
12797541-3	2003	Using highly specific inhibitors of p38 (SB203580) and of MAPK kinase-1 (U0126 and PD98059), we found that both p38 and ERK were essential for M. tuberculosis H37Rv-induced TNF-alpha production, whereas activation of the p38 pathway, but not that of ERK, was essential for M. tuberculosis H37Rv-induced IL-10 production.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	120-123
12797541-3	2003	Using highly specific inhibitors of p38 (SB203580) and of MAPK kinase-1 (U0126 and PD98059), we found that both p38 and ERK were essential for M. tuberculosis H37Rv-induced TNF-alpha production, whereas activation of the p38 pathway, but not that of ERK, was essential for M. tuberculosis H37Rv-induced IL-10 production.	U 0126	73-78	tumor necrosis factor	Homo sapiens	173-182
12797541-3	2003	Using highly specific inhibitors of p38 (SB203580) and of MAPK kinase-1 (U0126 and PD98059), we found that both p38 and ERK were essential for M. tuberculosis H37Rv-induced TNF-alpha production, whereas activation of the p38 pathway, but not that of ERK, was essential for M. tuberculosis H37Rv-induced IL-10 production.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	112-115
12692897-5	2003	The effect of PACAP on cell survival was mimicked by dibutyryl-cAMP (dbcAMP) and forskolin and prevented by the MEK inhibitor U0126, indicating that both the adenylyl-cyclase and MAP-kinase pathways contribute to the neuroprotective action of the peptide.	U 0126	126-131	mitogen-activated protein kinase kinase 7	Homo sapiens	112-115
12692897-7	2003	The effect of PACAP on ERK phosphorylation was blocked by U0126, but was not affected by H89 or chelerythrine indicating that PACAP activates ERK through a PKA- and PKC-independent mechanism.	U 0126	58-63	adenylate cyclase activating polypeptide 1	Homo sapiens	14-19
12692897-7	2003	The effect of PACAP on ERK phosphorylation was blocked by U0126, but was not affected by H89 or chelerythrine indicating that PACAP activates ERK through a PKA- and PKC-independent mechanism.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	23-26
12692897-7	2003	The effect of PACAP on ERK phosphorylation was blocked by U0126, but was not affected by H89 or chelerythrine indicating that PACAP activates ERK through a PKA- and PKC-independent mechanism.	U 0126	58-63	adenylate cyclase activating polypeptide 1	Homo sapiens	126-131
12692897-7	2003	The effect of PACAP on ERK phosphorylation was blocked by U0126, but was not affected by H89 or chelerythrine indicating that PACAP activates ERK through a PKA- and PKC-independent mechanism.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	142-145
12695541-3	2003	The increase of [(3)H]STX binding and the attenuated phosphorylation of ERK1 and ERK2 returned to the control nontreated levels after the addition of serum or the washout of PD98059- or U0126-treated cells.	U 0126	186-191	mitogen-activated protein kinase 3	Bos taurus	72-76
12554763-10	2003	We confirmed that the up-regulation of synaptophysin was blocked by the MAPK pathway inhibitor, U0126.	U 0126	96-101	synaptophysin	Homo sapiens	39-52
12695528-9	2003	Only ERK inhibitor U0126 could inhibit ET-1-induced transcription of the ET-1 gene.	U 0126	19-24	Eph receptor B1	Rattus norvegicus	5-8
12695528-9	2003	Only ERK inhibitor U0126 could inhibit ET-1-induced transcription of the ET-1 gene.	U 0126	19-24	endothelin 1	Rattus norvegicus	39-43
12695528-9	2003	Only ERK inhibitor U0126 could inhibit ET-1-induced transcription of the ET-1 gene.	U 0126	19-24	endothelin 1	Rattus norvegicus	73-77
12711247-11	2003	On the contrary, U0126, which inhibits an upstream kinase of Erk (MEK), did not affect PGF(2alpha)-induced enhancement of Pi transport.	U 0126	17-22	mitogen-activated protein kinase 1	Mus musculus	61-64
12717425-12	2003	This effect could be synergistically increased by addition of the MEK inhibitor UO126.	U 0126	80-85	midkine	Mus musculus	66-69
12694865-3	2003	Studies on ERKs in platelets have relied on pharmacological tools, including an inhibitor of ERK activation, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene].	U 0126	116-175	mitogen-activated protein kinase 1	Homo sapiens	11-15
12694865-3	2003	Studies on ERKs in platelets have relied on pharmacological tools, including an inhibitor of ERK activation, U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene].	U 0126	116-175	mitogen-activated protein kinase 1	Homo sapiens	11-14
12694865-6	2003	U0126, at concentrations consistent with inhibition of the isolated enzyme, inhibited ERK phosphorylation, and therefore MEK activation, in response to each agonist.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	86-89
12694865-6	2003	U0126, at concentrations consistent with inhibition of the isolated enzyme, inhibited ERK phosphorylation, and therefore MEK activation, in response to each agonist.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	121-124
12547826-5	2003	We found that induction of both c-fos and c-jun by arsenite can be substantially inhibited by the MEK- selective inhibitor U0126, suggesting that the ERK pathway is critically involved in their up-regulation.	U 0126	123-128	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-37
12547826-5	2003	We found that induction of both c-fos and c-jun by arsenite can be substantially inhibited by the MEK- selective inhibitor U0126, suggesting that the ERK pathway is critically involved in their up-regulation.	U 0126	123-128	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	42-47
12547826-5	2003	We found that induction of both c-fos and c-jun by arsenite can be substantially inhibited by the MEK- selective inhibitor U0126, suggesting that the ERK pathway is critically involved in their up-regulation.	U 0126	123-128	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
12547826-5	2003	We found that induction of both c-fos and c-jun by arsenite can be substantially inhibited by the MEK- selective inhibitor U0126, suggesting that the ERK pathway is critically involved in their up-regulation.	U 0126	123-128	mitogen-activated protein kinase 1	Homo sapiens	150-153
12588860-6	2003	We find that Ca(2+) oscillations continue after Cdk1-cyclin B1 activity falls at the time of polar body extrusion and after MAP kinase has been inhibited with UO126.	U 0126	159-164	cyclin-dependent kinase 1	Mus musculus	48-52
12729801-7	2003	IGF-I-stimulated activation of MAPK/ERK signaling in WM1341D cells was inhibited by U0126, but a 33-fold higher dose of U0126 was needed to inhibit IGF-I-stimulated cellular migration.	U 0126	84-89	insulin like growth factor 1	Homo sapiens	0-5
12729801-7	2003	IGF-I-stimulated activation of MAPK/ERK signaling in WM1341D cells was inhibited by U0126, but a 33-fold higher dose of U0126 was needed to inhibit IGF-I-stimulated cellular migration.	U 0126	84-89	mitogen-activated protein kinase 1	Homo sapiens	36-39
12641726-4	2003	A selective p38 MAPK inhibitor, SB203580, or dn-JNK, JNK1(A-F) or SAPKbeta(K-R), blocked anandamide-induced cell death, whereas a specific inhibitor of MEK-1/2, U0126, had no effect, indicating that activation of p38 MAPK and JNK is critical in anandamide-induced cell death.	U 0126	161-166	mitogen-activated protein kinase 8	Rattus norvegicus	48-51
12684495-4	2003	Application of the ERK pathway inhibitor U0126 attenuates photic induction of both P-ERK and P-Elk-1 and phase advances of wheel-running behavior.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	19-22
12684495-4	2003	Application of the ERK pathway inhibitor U0126 attenuates photic induction of both P-ERK and P-Elk-1 and phase advances of wheel-running behavior.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	85-88
12684495-4	2003	Application of the ERK pathway inhibitor U0126 attenuates photic induction of both P-ERK and P-Elk-1 and phase advances of wheel-running behavior.	U 0126	41-46	ETS transcription factor ELK1	Homo sapiens	95-100
12608905-9	2003	Furthermore, MMP-3 expression induced by bFGF was abrogated by U0126, a specific inhibitor of MEK1/2 and ERK1/2 in mitogen-activated protein (MAP) kinase pathway, not by PD98059, a specific inhibitor of MEK1.	U 0126	63-68	matrix metallopeptidase 3	Homo sapiens	13-18
12608905-9	2003	Furthermore, MMP-3 expression induced by bFGF was abrogated by U0126, a specific inhibitor of MEK1/2 and ERK1/2 in mitogen-activated protein (MAP) kinase pathway, not by PD98059, a specific inhibitor of MEK1.	U 0126	63-68	fibroblast growth factor 2	Homo sapiens	41-45
12608905-9	2003	Furthermore, MMP-3 expression induced by bFGF was abrogated by U0126, a specific inhibitor of MEK1/2 and ERK1/2 in mitogen-activated protein (MAP) kinase pathway, not by PD98059, a specific inhibitor of MEK1.	U 0126	63-68	mitogen-activated protein kinase kinase 1	Homo sapiens	94-100
12608905-9	2003	Furthermore, MMP-3 expression induced by bFGF was abrogated by U0126, a specific inhibitor of MEK1/2 and ERK1/2 in mitogen-activated protein (MAP) kinase pathway, not by PD98059, a specific inhibitor of MEK1.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	105-111
12608905-9	2003	Furthermore, MMP-3 expression induced by bFGF was abrogated by U0126, a specific inhibitor of MEK1/2 and ERK1/2 in mitogen-activated protein (MAP) kinase pathway, not by PD98059, a specific inhibitor of MEK1.	U 0126	63-68	mitogen-activated protein kinase kinase 1	Homo sapiens	94-98
12608905-10	2003	In addition, bFGF up-regulated the phosphorylated ERK1/2 in 5 min with the maximal at 20 min as examined by Western blotting, and U0126 inhibited the ERK1/2 phosphorylation induced by bFGF.	U 0126	130-135	fibroblast growth factor 2	Homo sapiens	13-17
12608905-10	2003	In addition, bFGF up-regulated the phosphorylated ERK1/2 in 5 min with the maximal at 20 min as examined by Western blotting, and U0126 inhibited the ERK1/2 phosphorylation induced by bFGF.	U 0126	130-135	mitogen-activated protein kinase 3	Homo sapiens	150-156
12608905-10	2003	In addition, bFGF up-regulated the phosphorylated ERK1/2 in 5 min with the maximal at 20 min as examined by Western blotting, and U0126 inhibited the ERK1/2 phosphorylation induced by bFGF.	U 0126	130-135	fibroblast growth factor 2	Homo sapiens	184-188
12554776-6	2003	The MAPK kinase inhibitor, U0126, blocked epidermal growth factor but not progestin-induced Ser294 phosphorylation and translocation of wt PR, indicating a novel mechanism for nuclear localization.	U 0126	27-32	epidermal growth factor	Homo sapiens	42-65
12554776-8	2003	Prolonged treatment with U0126 or the nuclear export inhibitor, leptomycin B, promoted nuclear accumulation of wt PR-B and blocked ligand-dependent PR down-regulation, suggesting that PR degradation occurs in the cytoplasm and requires MAPK-dependent nuclear export.	U 0126	25-30	RB transcriptional corepressor 1	Homo sapiens	114-118
12692261-8	2003	In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk).	U 0126	114-120	matrix metallopeptidase 1	Homo sapiens	44-49
12692261-8	2003	In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk).	U 0126	114-120	matrix metallopeptidase 2	Homo sapiens	51-56
12692261-8	2003	In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk).	U 0126	114-120	matrix metallopeptidase 9	Homo sapiens	62-67
12692261-8	2003	In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk).	U 0126	114-120	mitogen-activated protein kinase 1	Homo sapiens	210-214
12692261-8	2003	In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk).	U 0126	114-120	mitogen-activated protein kinase 1	Homo sapiens	215-218
12540838-4	2003	Cpd 5-mediated suppression of CREB phosphorylation and transcriptional activity was antagonized by mitogen-activated protein kinase kinase inhibitors PD 98059 and U-0126, implying that this inhibition of CREB activity was regulated at least in part by the ERK pathway.	U 0126	163-169	cAMP responsive element binding protein 1	Homo sapiens	30-34
12540838-4	2003	Cpd 5-mediated suppression of CREB phosphorylation and transcriptional activity was antagonized by mitogen-activated protein kinase kinase inhibitors PD 98059 and U-0126, implying that this inhibition of CREB activity was regulated at least in part by the ERK pathway.	U 0126	163-169	cAMP responsive element binding protein 1	Homo sapiens	204-208
12540838-4	2003	Cpd 5-mediated suppression of CREB phosphorylation and transcriptional activity was antagonized by mitogen-activated protein kinase kinase inhibitors PD 98059 and U-0126, implying that this inhibition of CREB activity was regulated at least in part by the ERK pathway.	U 0126	163-169	mitogen-activated protein kinase 1	Homo sapiens	256-259
12551910-3	2003	First, we showed that two specific mitogen-activated protein kinase/ERK kinase-inhibitors, PD98059 and U0126, both counteracted TPA-mediated suppression of Fas-induced apoptosis.	U 0126	103-108	mitogen-activated protein kinase 1	Homo sapiens	68-71
12650969-7	2003	The number of Fos-LI neurons observed when the MEK inhibitor, U0126, was administered was significantly suppressed compared to the DMSO- (vehicle control) administered group.	U 0126	62-67	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	14-17
12551910-4	2003	Moreover, the dose-dependence of U0126-mediated inhibition of ERK phosphorylation correlated with that of reversion of the anti-apoptotic effect of TPA.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	62-65
12514175-6	2003	In contrast, mitogen-activated protein kinase (MEK)/extracellular-signal-regulated kinase (ERK) pathway inhibitors U0126 and PD98059 potentiated GDF-15 mediated survival and prevented cell death in low K(+) even without factor treatment.	U 0126	115-120	mitogen-activated protein kinase kinase 7	Homo sapiens	13-45
12628924-4	2003	We show that the mitogen-activated protein kinase inhibitors SB203580 and PD98059 or U0126, as well as a potent mitogen- and stress- activated protein kinase-1 (MSK1) inhibitor H89, counteract tumor necrosis factor (TNF)-mediated stimulation of p65 transactivation capacity.	U 0126	85-90	tumor necrosis factor	Homo sapiens	193-214
12628924-4	2003	We show that the mitogen-activated protein kinase inhibitors SB203580 and PD98059 or U0126, as well as a potent mitogen- and stress- activated protein kinase-1 (MSK1) inhibitor H89, counteract tumor necrosis factor (TNF)-mediated stimulation of p65 transactivation capacity.	U 0126	85-90	tumor necrosis factor	Homo sapiens	216-219
12628924-4	2003	We show that the mitogen-activated protein kinase inhibitors SB203580 and PD98059 or U0126, as well as a potent mitogen- and stress- activated protein kinase-1 (MSK1) inhibitor H89, counteract tumor necrosis factor (TNF)-mediated stimulation of p65 transactivation capacity.	U 0126	85-90	RELA proto-oncogene, NF-kB subunit	Homo sapiens	245-248
12514175-6	2003	In contrast, mitogen-activated protein kinase (MEK)/extracellular-signal-regulated kinase (ERK) pathway inhibitors U0126 and PD98059 potentiated GDF-15 mediated survival and prevented cell death in low K(+) even without factor treatment.	U 0126	115-120	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
12514175-6	2003	In contrast, mitogen-activated protein kinase (MEK)/extracellular-signal-regulated kinase (ERK) pathway inhibitors U0126 and PD98059 potentiated GDF-15 mediated survival and prevented cell death in low K(+) even without factor treatment.	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	91-94
12514175-6	2003	In contrast, mitogen-activated protein kinase (MEK)/extracellular-signal-regulated kinase (ERK) pathway inhibitors U0126 and PD98059 potentiated GDF-15 mediated survival and prevented cell death in low K(+) even without factor treatment.	U 0126	115-120	growth differentiation factor 15	Homo sapiens	145-151
12514175-11	2003	GDF-15 or U0126 prevented c-Jun activation.	U 0126	10-15	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-31
12618753-6	2003	Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL).	U 0126	53-58	mitogen-activated protein kinase 1	Homo sapiens	35-38
12604650-7	2003	MAPK kinase (MAPKK or MEK) inhibitor U0126 inhibited the activation of MAPK and p90rsk in both cumulus-enclosed and denuded pig oocytes, but prevented GV breakdown (GVBD) only in cumulus-enclosed oocytes.	U 0126	37-42	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	0-4
12604650-7	2003	MAPK kinase (MAPKK or MEK) inhibitor U0126 inhibited the activation of MAPK and p90rsk in both cumulus-enclosed and denuded pig oocytes, but prevented GV breakdown (GVBD) only in cumulus-enclosed oocytes.	U 0126	37-42	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	13-17
12604650-7	2003	MAPK kinase (MAPKK or MEK) inhibitor U0126 inhibited the activation of MAPK and p90rsk in both cumulus-enclosed and denuded pig oocytes, but prevented GV breakdown (GVBD) only in cumulus-enclosed oocytes.	U 0126	37-42	ribosomal protein S6 kinase A6 S homeolog	Xenopus laevis	80-86
12604650-9	2003	In meiosis II arrested eggs, U0126 led to the inactivation of MAPK and p90rsk, as well as the interphase transition of the eggs.	U 0126	29-34	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	62-66
12604650-9	2003	In meiosis II arrested eggs, U0126 led to the inactivation of MAPK and p90rsk, as well as the interphase transition of the eggs.	U 0126	29-34	ribosomal protein S6 kinase A6 S homeolog	Xenopus laevis	71-77
12667551-4	2003	PD98059, U0126, and N(omega)-nitro-L-arginine methyl ester completely blocked the shear stress-induced increases in ERK phosphorylation, [(3)H]thymidine incorporation, and alkaline phosphatase, but without an effect on integrin beta1 expression, indicating that the ERK and nitric oxide synthase pathways are essential for the shear stress-induced proliferation and differentiation of normal human osteoblasts and that each involves ERK activation but not integrin beta1 upregulation.	U 0126	9-14	mitogen-activated protein kinase 1	Homo sapiens	116-119
12688422-11	2003	The DCF fluorescence was inhibited with U0126 (an extracellular signal regulated protein kinase (ERK) inhibitor).	U 0126	40-45	mitogen-activated protein kinase 3	Homo sapiens	97-100
12601032-7	2003	RESULTS: EGF-stimulated peroxidase secretion in a concentration-dependent manner with a significant increase at 10(-7) M. EGF-stimulated secretion was inhibited by the EGF receptor (EGFR) inhibitor AG1478, but not by the phosphoinositide-3 kinase inhibitor LY292004 or the mitogen-activated kinase kinase (MEK) inhibitor U0126.	U 0126	321-326	epidermal growth factor receptor	Rattus norvegicus	168-180
12601032-7	2003	RESULTS: EGF-stimulated peroxidase secretion in a concentration-dependent manner with a significant increase at 10(-7) M. EGF-stimulated secretion was inhibited by the EGF receptor (EGFR) inhibitor AG1478, but not by the phosphoinositide-3 kinase inhibitor LY292004 or the mitogen-activated kinase kinase (MEK) inhibitor U0126.	U 0126	321-326	epidermal growth factor receptor	Rattus norvegicus	182-186
12631071-9	2003	Similar results were found with the U0126 inhibitor of ERK 1/2.	U 0126	36-41	mitogen-activated protein kinase 1	Canis lupus familiaris	55-62
12406867-9	2003	Interestingly, full rescue of G-CSF-induced neutrophilic differentiation was observed when cells were cultured with the mitogen-induced extracellular kinase (MEK) inhibitors, PD98059 or U0126, and partial recovery was detected with the phosphoinositide 3-kinase (PI3-K) inhibitor LY-294002.	U 0126	186-191	colony stimulating factor 3 (granulocyte)	Mus musculus	30-35
12589789-4	2003	This was blocked by MEK inhibitor U0126 or PI 3-K inhibitor LY294002.	U 0126	34-39	mitogen-activated protein kinase kinase 7	Homo sapiens	20-23
12589789-6	2003	U0126 and LY294002 abolished ERK1/2 and Akt phosphorylation, respectively.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	29-35
12589789-6	2003	U0126 and LY294002 abolished ERK1/2 and Akt phosphorylation, respectively.	U 0126	0-5	AKT serine/threonine kinase 1	Homo sapiens	40-43
12527329-7	2003	The MAPK kinase (MKK) inhibitor U0126 (10 microM), while preventing ERK phosphorylation in MDA-MB-468 cells, did not induce apoptosis.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	68-71
12598729-3	2003	Co-administration either of the protein tyrosine kinase inhibitor genistein or the mitogen activated protein kinase inhibitor U0126 with nociceptin/orphanin FQ partially prevented the inhibition of NMDA dilation compared to that observed in their absence.	U 0126	126-131	prepronociceptin	Sus scrofa	137-147
12598729-3	2003	Co-administration either of the protein tyrosine kinase inhibitor genistein or the mitogen activated protein kinase inhibitor U0126 with nociceptin/orphanin FQ partially prevented the inhibition of NMDA dilation compared to that observed in their absence.	U 0126	126-131	prepronociceptin	Sus scrofa	148-159
12388158-5	2003	PD-098059 and U-0126, inhibitors of the mitogen-activated protein kinase kinase MEK1/2, abolished CaR-stimulated secretion but had no effect on basal secretion.	U 0126	14-20	mitogen-activated protein kinase kinase 1	Homo sapiens	80-86
12388158-5	2003	PD-098059 and U-0126, inhibitors of the mitogen-activated protein kinase kinase MEK1/2, abolished CaR-stimulated secretion but had no effect on basal secretion.	U 0126	14-20	calcium sensing receptor	Homo sapiens	98-101
12529294-6	2003	In contrast, ROS production induced by fMLP stimulation of GM-CSF-primed cells was inhibited by LY294002 and U0126.	U 0126	109-114	formyl peptide receptor 1	Homo sapiens	39-43
12588763-7	2003	MEK inhibitors U0126 and PD98059 blocked both ERK activation and the increase in TF mRNA.	U 0126	15-20	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
12588763-7	2003	MEK inhibitors U0126 and PD98059 blocked both ERK activation and the increase in TF mRNA.	U 0126	15-20	mitogen-activated protein kinase 1	Homo sapiens	46-49
12588763-7	2003	MEK inhibitors U0126 and PD98059 blocked both ERK activation and the increase in TF mRNA.	U 0126	15-20	coagulation factor III, tissue factor	Homo sapiens	81-83
12529294-5	2003	We subsequently investigated the signal transduction pathways involved in ROS generation and demonstrated that fMLP-stimulated ROS production was inhibited by the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002, but not by the MAPK/ERK kinase (MEK) inhibitor U0126.	U 0126	267-272	formyl peptide receptor 1	Homo sapiens	111-115
12529294-6	2003	In contrast, ROS production induced by fMLP stimulation of GM-CSF-primed cells was inhibited by LY294002 and U0126.	U 0126	109-114	colony stimulating factor 2	Homo sapiens	59-65
12566304-9	2003	EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126, a selective MAP kinase kinase (MKK)1/2 inhibitor.	U 0126	78-83	epidermal growth factor	Homo sapiens	0-3
12566304-9	2003	EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126, a selective MAP kinase kinase (MKK)1/2 inhibitor.	U 0126	78-83	mitogen-activated protein kinase 1	Homo sapiens	34-37
12566304-9	2003	EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126, a selective MAP kinase kinase (MKK)1/2 inhibitor.	U 0126	78-83	mitogen-activated protein kinase kinase 1	Homo sapiens	116-123
12574212-10	2003	Blocking the MAPK pathway with the specific methyl ethyl ketone 1/2 inhibitor (U0126) completely neutralized the enhancement of cell proliferation induced by KGF and FGF-10.	U 0126	79-84	fibroblast growth factor 7	Homo sapiens	158-161
12538600-2	2003	We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines.	U 0126	141-146	mitogen-activated protein kinase 1	Mus musculus	13-16
12538600-2	2003	We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines.	U 0126	141-146	mitogen-activated protein kinase 1	Homo sapiens	113-117
12538600-2	2003	We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines.	U 0126	141-146	mitogen-activated protein kinase 1	Mus musculus	118-121
12538600-2	2003	We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines.	U 0126	141-146	mitogen-activated protein kinase 1	Mus musculus	118-121
12574212-10	2003	Blocking the MAPK pathway with the specific methyl ethyl ketone 1/2 inhibitor (U0126) completely neutralized the enhancement of cell proliferation induced by KGF and FGF-10.	U 0126	79-84	fibroblast growth factor 10	Homo sapiens	166-172
12535662-6	2003	PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner.	U 0126	12-18	mitogen activated protein kinase 3	Rattus norvegicus	69-72
12558965-4	2003	This increase in TH activity was partially blocked by the MEK1/2 inhibitor U0126 but was unaffected by the p38 antagonist SB203580 or the JNK blocker JNKI1.	U 0126	75-80	tyrosine hydroxylase	Bos taurus	17-19
12558965-6	2003	Treatment with U0126 totally inhibited the histamine-induced phosphorylation of TH at Ser31, without affecting the phosphorylation of either Ser40 or Ser19.	U 0126	15-20	tyrosine hydroxylase	Bos taurus	80-82
12535662-6	2003	PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner.	U 0126	12-18	vascular endothelial growth factor A	Rattus norvegicus	135-139
12535662-7	2003	The phosphorylation of p44/p42 MAP kinase induced by simvastatin was reduced by PD98059 or U-0126.	U 0126	91-97	mitogen activated protein kinase 3	Rattus norvegicus	23-26
12471618-11	2003	The importance of these proteins was further demonstrated by induction of apoptosis in SH-SY5Y cells by a combination of U0126 (MEK1/2 inhibitor) and LY294002 (an inhibitor of PI3K).	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	128-134
12507511-7	2003	Moreover the MAPkinase pERK seems to be involved since a specific pERK inhibitor, e.g., U0126, but not a p38Kinase inhibitor, e.g., SB203580 prevented sPLA(2)-induced chemokine upregulation.	U 0126	88-93	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	23-27
12507511-7	2003	Moreover the MAPkinase pERK seems to be involved since a specific pERK inhibitor, e.g., U0126, but not a p38Kinase inhibitor, e.g., SB203580 prevented sPLA(2)-induced chemokine upregulation.	U 0126	88-93	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	66-70
12507511-7	2003	Moreover the MAPkinase pERK seems to be involved since a specific pERK inhibitor, e.g., U0126, but not a p38Kinase inhibitor, e.g., SB203580 prevented sPLA(2)-induced chemokine upregulation.	U 0126	88-93	phospholipase A2 group IIA	Homo sapiens	151-158
12502791-5	2003	The more potent and specific MEK inhibitor UO126 and the cyclin-dependent kinase inhibitor roscovitine, which inhibit the cell cycle at different points, block MCE, expression of cell cycle and adipocyte markers, as well as adipogenesis.	U 0126	43-48	mitogen-activated protein kinase kinase 7	Homo sapiens	29-32
12419820-8	2003	We also investigated whether activation of the MAPK pathway is necessary for BMP-15 biological activity and found that the addition of U0126, an inhibitor of ERK1/2 phosphorylation, suppresses BMP-15 activity on GC mitotsis but not on FSH-induced progesterone production, suggesting a selective signaling cascade in GC proliferation and differentiation.	U 0126	135-140	mitogen-activated protein kinase 3	Homo sapiens	47-51
12419820-8	2003	We also investigated whether activation of the MAPK pathway is necessary for BMP-15 biological activity and found that the addition of U0126, an inhibitor of ERK1/2 phosphorylation, suppresses BMP-15 activity on GC mitotsis but not on FSH-induced progesterone production, suggesting a selective signaling cascade in GC proliferation and differentiation.	U 0126	135-140	bone morphogenetic protein 15	Homo sapiens	77-83
12419820-8	2003	We also investigated whether activation of the MAPK pathway is necessary for BMP-15 biological activity and found that the addition of U0126, an inhibitor of ERK1/2 phosphorylation, suppresses BMP-15 activity on GC mitotsis but not on FSH-induced progesterone production, suggesting a selective signaling cascade in GC proliferation and differentiation.	U 0126	135-140	mitogen-activated protein kinase 3	Homo sapiens	158-164
12419820-8	2003	We also investigated whether activation of the MAPK pathway is necessary for BMP-15 biological activity and found that the addition of U0126, an inhibitor of ERK1/2 phosphorylation, suppresses BMP-15 activity on GC mitotsis but not on FSH-induced progesterone production, suggesting a selective signaling cascade in GC proliferation and differentiation.	U 0126	135-140	bone morphogenetic protein 15	Homo sapiens	193-199
12508271-4	2003	p38 inhibitor (SB203580) prevented CsA-induced hemoglobin synthesis in K562 cells, although MEK/ERK inhibitor (U0126) enhanced it by 3.3 times in K562 cells.	U 0126	111-116	mitogen-activated protein kinase kinase 7	Homo sapiens	92-95
12508271-4	2003	p38 inhibitor (SB203580) prevented CsA-induced hemoglobin synthesis in K562 cells, although MEK/ERK inhibitor (U0126) enhanced it by 3.3 times in K562 cells.	U 0126	111-116	mitogen-activated protein kinase 1	Homo sapiens	96-99
12485817-3	2003	Coadministration of either of the PTK inhibitors genistein or tyrphostin A23 or the MAPK inhibitors U-0126 or PD-98059 with NOC/oFQ (10(-10) M) partially prevented the inhibition of hypercapnic PAD compared with that observed in their absence (21 +/- 2% vs. 17 +/- 1% for genistein).	U 0126	100-106	nocturnin	Homo sapiens	124-127
12485817-3	2003	Coadministration of either of the PTK inhibitors genistein or tyrphostin A23 or the MAPK inhibitors U-0126 or PD-98059 with NOC/oFQ (10(-10) M) partially prevented the inhibition of hypercapnic PAD compared with that observed in their absence (21 +/- 2% vs. 17 +/- 1% for genistein).	U 0126	100-106	prepronociceptin	Homo sapiens	128-131
12784042-3	2003	The induction of Egr2 was confirmed by transient transfection assays using an Egr2 promoter/luciferase reporter construct and could be inhibited by the p44/42 mitogen-activated protein kinase (MAPK)-specific inhibitor U0126, or by calcium chelator TMB-8, but not by the SAPK2/p38 MAPK inhibitor SB202190 or by the protein kinase C inhibitor bisindolylmaleimide I (Bis-I).	U 0126	218-223	early growth response 2	Homo sapiens	17-21
12683942-9	2003	The acute response of egr-1 to an oestrogenic stimulus is attenuated by the MEK (MAPK kinase) inhibitor U0126, and is accompanied by increased levels of phospho-p44/42 MAPK protein, suggesting regulation of egr-1 through a MAPK-linked pathway in the pituitary.	U 0126	104-109	early growth response 1	Rattus norvegicus	22-27
12784042-3	2003	The induction of Egr2 was confirmed by transient transfection assays using an Egr2 promoter/luciferase reporter construct and could be inhibited by the p44/42 mitogen-activated protein kinase (MAPK)-specific inhibitor U0126, or by calcium chelator TMB-8, but not by the SAPK2/p38 MAPK inhibitor SB202190 or by the protein kinase C inhibitor bisindolylmaleimide I (Bis-I).	U 0126	218-223	early growth response 2	Homo sapiens	78-82
12784042-3	2003	The induction of Egr2 was confirmed by transient transfection assays using an Egr2 promoter/luciferase reporter construct and could be inhibited by the p44/42 mitogen-activated protein kinase (MAPK)-specific inhibitor U0126, or by calcium chelator TMB-8, but not by the SAPK2/p38 MAPK inhibitor SB202190 or by the protein kinase C inhibitor bisindolylmaleimide I (Bis-I).	U 0126	218-223	interferon induced protein 44	Homo sapiens	152-155
14671615-0	2003	An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia.	U 0126	53-58	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
12589773-13	2003	The MAP kinase inhibitor U0126 prevented activation of ERK1/2 in LECs and inhibited EF-directed migration, implicating MAP kinase signaling in directing the migration of LECs in a physiological EF.	U 0126	25-30	mitogen-activated protein kinase 3	Bos taurus	55-61
14671615-3	2003	This investigation examined the effect of the potent MEK inhibitor U0126 alone and in combination with Ara-C on apoptosis in acute myeloblastic leukemia (AML) cell lines, patient acute leukemic and nonleukemic samples.	U 0126	67-72	mitogen-activated protein kinase kinase 7	Homo sapiens	53-56
14671615-7	2003	The proapoptotic effect of U0126 in the most sensitive cell line appeared to be related to CD34 positivity.	U 0126	27-32	CD34 molecule	Homo sapiens	91-95
12414794-6	2002	Use of the MEK1 inhibitor U0126 and dominant negative MEK1 further showed that MSK1 activation and c-jun induction require the ERK pathway.	U 0126	26-31	mitogen-activated protein kinase kinase 1	Homo sapiens	11-15
12892532-11	2003	On the other hand, they were inhibited only partially by a MAPK kinase inhibitor, U-0126.	U 0126	82-88	mitogen-activated protein kinase 14	Homo sapiens	59-63
12506081-7	2003	U0126, an inhibitor of mitogen-activated protein kinase (MAPK) signaling, inhibited wound healing, with or without exposure to an EF.	U 0126	0-5	mitogen-activated protein kinase 1	Bos taurus	57-61
12506081-8	2003	Western blot analysis showed that both wounding and application of an EF enhanced the activation of ERK 1/2 independently and that U0126 completely inhibited these activations of ERK 1/2 in monolayers.	U 0126	131-136	mitogen-activated protein kinase 3	Bos taurus	179-186
12510806-9	2003	The induction of c-fos was inhibited 74% by the MEK1/2 inhibitor U0126 (p &lt; 0.001) but was not affected by MEK1 or p38 MAPK-specific inhibitors.	U 0126	65-70	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	17-22
12510806-9	2003	The induction of c-fos was inhibited 74% by the MEK1/2 inhibitor U0126 (p &lt; 0.001) but was not affected by MEK1 or p38 MAPK-specific inhibitors.	U 0126	65-70	mitogen-activated protein kinase kinase 1	Homo sapiens	48-54
12510806-9	2003	The induction of c-fos was inhibited 74% by the MEK1/2 inhibitor U0126 (p &lt; 0.001) but was not affected by MEK1 or p38 MAPK-specific inhibitors.	U 0126	65-70	mitogen-activated protein kinase kinase 1	Homo sapiens	48-52
16233487-3	2003	Treatment with U0126 (20 microM, 60 min), a specific inhibitor of extracellular signal-related kinase (ERK1/2), decreased the expression level of hGM-CSF mRNA at 0.1 MPa to 80% of that without U0126 treatment.	U 0126	15-20	colony stimulating factor 2	Homo sapiens	146-153
16233487-4	2003	Similarly, treatment with U0126 decreased the pressure-induced (0.9 MPa) expression level of hGM-CSF mRNA to 79% of the control expression level at 0.1 MPa without treatment.	U 0126	26-31	colony stimulating factor 2	Homo sapiens	93-100
12525252-9	2003	In SK-BR3 cells, treatment with the MEK inhibitor UO126 resulted in a profound suppression of endogenous COUP-TFII expression.	U 0126	50-55	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
12525252-9	2003	In SK-BR3 cells, treatment with the MEK inhibitor UO126 resulted in a profound suppression of endogenous COUP-TFII expression.	U 0126	50-55	nuclear receptor subfamily 2 group F member 2	Homo sapiens	105-114
12525252-10	2003	Furthermore, cotreatment with UO126 prevented induction of COUP-TFII expression by EGF in MCF-7 cells.	U 0126	30-35	nuclear receptor subfamily 2 group F member 2	Homo sapiens	59-68
12525252-10	2003	Furthermore, cotreatment with UO126 prevented induction of COUP-TFII expression by EGF in MCF-7 cells.	U 0126	30-35	epidermal growth factor	Homo sapiens	83-86
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	2-28
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-34
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	interleukin 17A	Homo sapiens	69-74
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	interleukin 1 beta	Homo sapiens	77-85
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	tumor necrosis factor	Homo sapiens	92-101
12414794-6	2002	Use of the MEK1 inhibitor U0126 and dominant negative MEK1 further showed that MSK1 activation and c-jun induction require the ERK pathway.	U 0126	26-31	ribosomal protein S6 kinase A5	Homo sapiens	79-83
12414794-6	2002	Use of the MEK1 inhibitor U0126 and dominant negative MEK1 further showed that MSK1 activation and c-jun induction require the ERK pathway.	U 0126	26-31	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	99-104
12414794-6	2002	Use of the MEK1 inhibitor U0126 and dominant negative MEK1 further showed that MSK1 activation and c-jun induction require the ERK pathway.	U 0126	26-31	mitogen-activated protein kinase 3	Homo sapiens	127-130
12237315-0	2002	U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells.	U 0126	0-5	midkine	Mus musculus	42-45
12499846-3	2002	Pretreatment of untransfected cells with 20 microM UO126 for 2 h, shown to down-regulate the basic level and to completely inhibit cholinergic activation of mitoge-activated kinase (MAPK; erk1/erk2), had no effect neither on spontaneous nor on induced lamellar protrusions.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	182-186
12499846-3	2002	Pretreatment of untransfected cells with 20 microM UO126 for 2 h, shown to down-regulate the basic level and to completely inhibit cholinergic activation of mitoge-activated kinase (MAPK; erk1/erk2), had no effect neither on spontaneous nor on induced lamellar protrusions.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	188-192
12499846-3	2002	Pretreatment of untransfected cells with 20 microM UO126 for 2 h, shown to down-regulate the basic level and to completely inhibit cholinergic activation of mitoge-activated kinase (MAPK; erk1/erk2), had no effect neither on spontaneous nor on induced lamellar protrusions.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	193-197
12468029-3	2002	The phospholipase-C inhibitor U73122 and the MEK1/2 inhibitor U0126 prevented this protection.	U 0126	62-67	mitogen-activated protein kinase kinase 1	Homo sapiens	45-51
12622936-5	2002	In the presence of insulin signaling pathway inhibitors wortmannin and UO126, metformin reduced PEPCK mRNA levels, but wortmannin blocked inhibitory regulation of insulin on PEPCK gene expression.	U 0126	71-76	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	96-101
12359725-4	2002	Surprisingly, nuclear localized CDK2-NLS and CDK2-NLS(A14,F15), which lacks the inhibitory phosphorylation sites, require serum to become active, despite complexing with expressed cyclin E. We show that inhibition of mitogen-mediated ERK activation by treatment with U0126, a selective MEK inhibitor, or expression of dominant-negative ERK markedly reduces the phosphorylation of Thr-160 and enzymatic activity of both CDK2-NLS constructs.	U 0126	267-272	cyclin dependent kinase 2	Homo sapiens	32-36
12359725-4	2002	Surprisingly, nuclear localized CDK2-NLS and CDK2-NLS(A14,F15), which lacks the inhibitory phosphorylation sites, require serum to become active, despite complexing with expressed cyclin E. We show that inhibition of mitogen-mediated ERK activation by treatment with U0126, a selective MEK inhibitor, or expression of dominant-negative ERK markedly reduces the phosphorylation of Thr-160 and enzymatic activity of both CDK2-NLS constructs.	U 0126	267-272	cyclin dependent kinase 2	Homo sapiens	45-49
12359725-4	2002	Surprisingly, nuclear localized CDK2-NLS and CDK2-NLS(A14,F15), which lacks the inhibitory phosphorylation sites, require serum to become active, despite complexing with expressed cyclin E. We show that inhibition of mitogen-mediated ERK activation by treatment with U0126, a selective MEK inhibitor, or expression of dominant-negative ERK markedly reduces the phosphorylation of Thr-160 and enzymatic activity of both CDK2-NLS constructs.	U 0126	267-272	cyclin dependent kinase 2	Homo sapiens	45-49
12359725-5	2002	Consistent with a role for ERK in Thr-160 phosphorylation, expression of constitutively active Raf-1 induces Thr-160 phosphorylation of CDK2-NLS in serum-arrested cells, an effect that is blocked by treatment with U0126.	U 0126	214-219	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	95-100
12359725-5	2002	Consistent with a role for ERK in Thr-160 phosphorylation, expression of constitutively active Raf-1 induces Thr-160 phosphorylation of CDK2-NLS in serum-arrested cells, an effect that is blocked by treatment with U0126.	U 0126	214-219	cyclin dependent kinase 2	Homo sapiens	136-140
12388341-9	2002	Indomethacin, the MEK and p38 inhibitors U-0126 and SB-203580, the protein kinase A inhibitor H-89, and dexamethasone each completely abolished the ability of IL-1beta to induce CRE-driven gene expression but only slightly increased the ability of ISO to induce CRE-driven gene expression in IL-1beta-treated cells.	U 0126	41-47	mitogen-activated protein kinase 14	Homo sapiens	26-29
12388341-9	2002	Indomethacin, the MEK and p38 inhibitors U-0126 and SB-203580, the protein kinase A inhibitor H-89, and dexamethasone each completely abolished the ability of IL-1beta to induce CRE-driven gene expression but only slightly increased the ability of ISO to induce CRE-driven gene expression in IL-1beta-treated cells.	U 0126	41-47	interleukin 1 beta	Homo sapiens	159-167
12444029-6	2002	Human bronchial smooth muscle cells and fibroblasts do not constitutively express ESE-3; however, after stimulation with interleukin-1beta or tumor necrosis factor-alpha, levels of ESE-3 mRNA and protein increase dramatically by 24 h. This cytokine induction is dose-dependent and abrogated by specific inhibitors of the MEK1/2 (U0126) and p38 (SB03580) signal transduction pathways.	U 0126	329-334	interleukin 1 beta	Homo sapiens	121-169
12444029-6	2002	Human bronchial smooth muscle cells and fibroblasts do not constitutively express ESE-3; however, after stimulation with interleukin-1beta or tumor necrosis factor-alpha, levels of ESE-3 mRNA and protein increase dramatically by 24 h. This cytokine induction is dose-dependent and abrogated by specific inhibitors of the MEK1/2 (U0126) and p38 (SB03580) signal transduction pathways.	U 0126	329-334	ETS homologous factor	Homo sapiens	181-186
12622936-5	2002	In the presence of insulin signaling pathway inhibitors wortmannin and UO126, metformin reduced PEPCK mRNA levels, but wortmannin blocked inhibitory regulation of insulin on PEPCK gene expression.	U 0126	71-76	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	174-179
12446589-7	2002	The antisense-expressing cells were able to significantly resist the growth-inhibitory effect of the MAPK kinase inhibitors PD98059 and U0126 but not that of other factors tested.	U 0126	136-141	mitogen-activated protein kinase 3	Homo sapiens	101-105
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	mitogen-activated protein kinase 3	Homo sapiens	0-4
12415005-3	2002	We have adopted a genetic approach in combination with U0126, an inhibitor of Mek activation to study the role of Mek in cell cycle progression.	U 0126	55-60	midkine	Mus musculus	78-81
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	5-9
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	interleukin 1 beta	Homo sapiens	82-90
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	tumor necrosis factor	Homo sapiens	122-130
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	141-144
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	interleukin 1 beta	Homo sapiens	185-193
12466948-2	2002	We investigated the effect of calcineurin blockade with cyclosporin A and mitogen-activated protein kinase kinase (MEK1/2) blockade with U0126 upon myosin heavy chain (MHC) isoform mRNA levels and activities of metabolic enzymes after 1 day, 3 days and 7 days of treatment in primary cultures of spontaneously twitching rat skeletal muscle.	U 0126	137-142	mitogen activated protein kinase kinase 1	Rattus norvegicus	115-121
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	tumor necrosis factor	Homo sapiens	199-208
12466948-10	2002	The effect of U0126 on the percentage of pyruvate dehydrogenase in the active form suggests that the ERK1/2 pathway may also be involved in regulation of the phosphorylation state of this enzyme.	U 0126	14-19	mitogen activated protein kinase 3	Rattus norvegicus	101-107
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	mitogen-activated protein kinase 1	Homo sapiens	282-285
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	mitogen-activated protein kinase kinase 1	Homo sapiens	57-61
12244120-12	2002	The EGFR kinase inhibitor tyrphostin AG1478 or the MEK1/2 inhibitor U0126 completely prevented the effect.	U 0126	68-73	mitogen-activated protein kinase kinase 1	Homo sapiens	51-57
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	peroxisome proliferator activated receptor alpha	Homo sapiens	185-227
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	peroxisome proliferator activated receptor alpha	Homo sapiens	229-233
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	CCAAT enhancer binding protein alpha	Homo sapiens	274-286
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	perilipin 1	Homo sapiens	288-297
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	transcription factor AP-2 alpha	Homo sapiens	350-353
12270934-3	2002	Treating the preadipocytes with troglitazone, a potent PPARgamma ligand, could circumvent the inhibition of adipogenic gene expression by U0126.	U 0126	138-143	peroxisome proliferator activated receptor gamma	Homo sapiens	55-64
12270934-5	2002	Consequently, preadipocytes treated with U0126 in the presence of fibroblast growth factor-2 (FGF-2) express normal post-induction levels of MEK activity, and, in so doing, are capable of undergoing adipogenesis.	U 0126	41-46	fibroblast growth factor 2	Homo sapiens	66-92
12270934-5	2002	Consequently, preadipocytes treated with U0126 in the presence of fibroblast growth factor-2 (FGF-2) express normal post-induction levels of MEK activity, and, in so doing, are capable of undergoing adipogenesis.	U 0126	41-46	fibroblast growth factor 2	Homo sapiens	94-99
12270934-5	2002	Consequently, preadipocytes treated with U0126 in the presence of fibroblast growth factor-2 (FGF-2) express normal post-induction levels of MEK activity, and, in so doing, are capable of undergoing adipogenesis.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	141-144
12435395-4	2002	A significant increase in LRP expression was detected after serum deprivation and this increase was blocked by treatment of U0126, an inhibitor of MAP kinase.	U 0126	124-129	protein tyrosine phosphatase, receptor type, A	Rattus norvegicus	26-29
12169099-5	2002	Up-regulation of c- jun mRNA by endothelin-1 was attenuated by inhibitors of protein kinase C (GF109203X) and the extracellular signal-regulated kinase (ERK) cascade (PD98059 or U0126), but not by inhibitors of the JNK (SP600125) or p38-MAPK (SB203580) cascades.	U 0126	178-183	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	17-23
12169099-5	2002	Up-regulation of c- jun mRNA by endothelin-1 was attenuated by inhibitors of protein kinase C (GF109203X) and the extracellular signal-regulated kinase (ERK) cascade (PD98059 or U0126), but not by inhibitors of the JNK (SP600125) or p38-MAPK (SB203580) cascades.	U 0126	178-183	endothelin 1	Homo sapiens	32-44
12376555-9	2002	The MEK inhibitor U0126 prevented residual Erk phosphorylation and abrogated the synergistic responses to TGF-beta1 and EGF.	U 0126	18-23	transforming growth factor beta 1	Sus scrofa	106-115
12376555-9	2002	The MEK inhibitor U0126 prevented residual Erk phosphorylation and abrogated the synergistic responses to TGF-beta1 and EGF.	U 0126	18-23	epidermal growth factor	Sus scrofa	120-123
12384488-5	2002	NBC activation was significantly decreased with the ERK inhibitors PD-98059 and U-0126.	U 0126	80-86	Eph receptor B1	Rattus norvegicus	52-55
12384488-8	2002	ERK phosphorylation (measured by immunoblot analysis) during intracellular acidification was increased by ANG II, an effect that was abolished by losartan and U-0126.	U 0126	159-165	Eph receptor B1	Rattus norvegicus	0-3
12384488-8	2002	ERK phosphorylation (measured by immunoblot analysis) during intracellular acidification was increased by ANG II, an effect that was abolished by losartan and U-0126.	U 0126	159-165	angiotensinogen	Rattus norvegicus	106-112
12502566-4	2002	Inhibition of ERK with the MEK inhibitor UO126, the ERK protein phosphatase MKP-3, inhibited ERK activation, but only inhibited alpha-adrenergic-induced NCX1 upregulation by 30%.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	14-17
12502566-4	2002	Inhibition of ERK with the MEK inhibitor UO126, the ERK protein phosphatase MKP-3, inhibited ERK activation, but only inhibited alpha-adrenergic-induced NCX1 upregulation by 30%.	U 0126	41-46	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
12502566-4	2002	Inhibition of ERK with the MEK inhibitor UO126, the ERK protein phosphatase MKP-3, inhibited ERK activation, but only inhibited alpha-adrenergic-induced NCX1 upregulation by 30%.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	52-55
12502566-4	2002	Inhibition of ERK with the MEK inhibitor UO126, the ERK protein phosphatase MKP-3, inhibited ERK activation, but only inhibited alpha-adrenergic-induced NCX1 upregulation by 30%.	U 0126	41-46	dual specificity phosphatase 6	Homo sapiens	76-81
12502566-4	2002	Inhibition of ERK with the MEK inhibitor UO126, the ERK protein phosphatase MKP-3, inhibited ERK activation, but only inhibited alpha-adrenergic-induced NCX1 upregulation by 30%.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	52-55
12502566-4	2002	Inhibition of ERK with the MEK inhibitor UO126, the ERK protein phosphatase MKP-3, inhibited ERK activation, but only inhibited alpha-adrenergic-induced NCX1 upregulation by 30%.	U 0126	41-46	solute carrier family 8 member A1	Homo sapiens	153-157
12137564-5	2002	Inhibition of ERK activation during reoxygenation with U0126, an inhibitor of the ERK activator, MAPK/ERK kinase 1/2, prevented both barrier restoration and stress-fibre formation, but did not prevent recruitment of FAK to focal contacts.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	14-17
12137564-5	2002	Inhibition of ERK activation during reoxygenation with U0126, an inhibitor of the ERK activator, MAPK/ERK kinase 1/2, prevented both barrier restoration and stress-fibre formation, but did not prevent recruitment of FAK to focal contacts.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	82-85
12137564-5	2002	Inhibition of ERK activation during reoxygenation with U0126, an inhibitor of the ERK activator, MAPK/ERK kinase 1/2, prevented both barrier restoration and stress-fibre formation, but did not prevent recruitment of FAK to focal contacts.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	97-101
12137564-5	2002	Inhibition of ERK activation during reoxygenation with U0126, an inhibitor of the ERK activator, MAPK/ERK kinase 1/2, prevented both barrier restoration and stress-fibre formation, but did not prevent recruitment of FAK to focal contacts.	U 0126	55-60	mitogen-activated protein kinase 1	Homo sapiens	82-85
12439598-6	2002	Incubation of cell lines with the MEK1 inhibitors PD98059 or UO126 after, but not during, cisplatin treatment completely inhibited cisplatin-induced activation of ERK.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Homo sapiens	34-38
12169099-5	2002	Up-regulation of c- jun mRNA by endothelin-1 was attenuated by inhibitors of protein kinase C (GF109203X) and the extracellular signal-regulated kinase (ERK) cascade (PD98059 or U0126), but not by inhibitors of the JNK (SP600125) or p38-MAPK (SB203580) cascades.	U 0126	178-183	mitogen-activated protein kinase 1	Homo sapiens	153-156
12150710-5	2002	The specific inhibitors, U0126 (for ERK1/2 signalling) and SB203580 (for p38 MAPK signalling), both abrogated IL-8 secretion from HPE-treated THP-1.	U 0126	25-30	GLI family zinc finger 2	Homo sapiens	142-147
12426209-6	2002	Inhibition of ERK phosphorylation with selective inhibitors (PD98059 or U0126) attenuated interleukin-1beta-induced persistent NF-kappaB activation and iNOS expression in either the absence or presence of the growth factors.	U 0126	72-77	Eph receptor B1	Rattus norvegicus	14-17
12426209-6	2002	Inhibition of ERK phosphorylation with selective inhibitors (PD98059 or U0126) attenuated interleukin-1beta-induced persistent NF-kappaB activation and iNOS expression in either the absence or presence of the growth factors.	U 0126	72-77	interleukin 1 beta	Rattus norvegicus	90-107
12426209-6	2002	Inhibition of ERK phosphorylation with selective inhibitors (PD98059 or U0126) attenuated interleukin-1beta-induced persistent NF-kappaB activation and iNOS expression in either the absence or presence of the growth factors.	U 0126	72-77	nitric oxide synthase 2	Rattus norvegicus	152-156
12642693-2	2002	Coexposure of K562 cells to UCN-01 (e.g., 100 nM) or U0126 (30 microM) resulted in a marked increase in mitochondrial injury (e.g., release of cytochrome c; loss of deltapsi(m)) and apoptosis.	U 0126	53-58	cytochrome c, somatic	Homo sapiens	143-155
12642693-5	2002	Coadminstration of UCN-01 with U0126 produced multiple perturbations in signal transduction/cell cycle regulatory pathways, including diminished expression of Bcr/Abl, Mcl-1, cylin D(1), and activation of JNK and p34(cdc2).	U 0126	31-36	urocortin	Homo sapiens	19-22
12439598-6	2002	Incubation of cell lines with the MEK1 inhibitors PD98059 or UO126 after, but not during, cisplatin treatment completely inhibited cisplatin-induced activation of ERK.	U 0126	61-66	mitogen-activated protein kinase 1	Homo sapiens	163-166
12642693-5	2002	Coadminstration of UCN-01 with U0126 produced multiple perturbations in signal transduction/cell cycle regulatory pathways, including diminished expression of Bcr/Abl, Mcl-1, cylin D(1), and activation of JNK and p34(cdc2).	U 0126	31-36	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	159-166
12642693-5	2002	Coadminstration of UCN-01 with U0126 produced multiple perturbations in signal transduction/cell cycle regulatory pathways, including diminished expression of Bcr/Abl, Mcl-1, cylin D(1), and activation of JNK and p34(cdc2).	U 0126	31-36	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	168-173
12439598-8	2002	Treatment of cells with PD98059 or UO126 after cisplatin incubation or inhibition of signaling through ERK by tetracycline-regulated expression of dominant-inhibitory ERK enhanced resistance to cisplatin in p53-negative osteosarcoma cells and reduced cisplatin-induced apoptosis.	U 0126	35-40	mitogen-activated protein kinase 1	Homo sapiens	167-170
12642693-5	2002	Coadminstration of UCN-01 with U0126 produced multiple perturbations in signal transduction/cell cycle regulatory pathways, including diminished expression of Bcr/Abl, Mcl-1, cylin D(1), and activation of JNK and p34(cdc2).	U 0126	31-36	mitogen-activated protein kinase 8	Homo sapiens	205-208
12439598-8	2002	Treatment of cells with PD98059 or UO126 after cisplatin incubation or inhibition of signaling through ERK by tetracycline-regulated expression of dominant-inhibitory ERK enhanced resistance to cisplatin in p53-negative osteosarcoma cells and reduced cisplatin-induced apoptosis.	U 0126	35-40	tumor protein p53	Homo sapiens	207-210
12642693-5	2002	Coadminstration of UCN-01 with U0126 produced multiple perturbations in signal transduction/cell cycle regulatory pathways, including diminished expression of Bcr/Abl, Mcl-1, cylin D(1), and activation of JNK and p34(cdc2).	U 0126	31-36	alpha and gamma adaptin binding protein	Homo sapiens	213-216
12460740-4	2002	HNE-induced secretion of fibronectin was inhibited by U-0126, an inhibitor of the Erk1/2 pathway, while no significant inhibition by SB-203580, an inhibitor of p38MAPK pathway, was observed.	U 0126	54-60	fibronectin 1	Homo sapiens	25-36
12642693-5	2002	Coadminstration of UCN-01 with U0126 produced multiple perturbations in signal transduction/cell cycle regulatory pathways, including diminished expression of Bcr/Abl, Mcl-1, cylin D(1), and activation of JNK and p34(cdc2).	U 0126	31-36	cyclin dependent kinase 1	Homo sapiens	217-221
12270548-4	2002	Treatment of RON-expressing cells with PD98059 or U0126, inhibitors of mitogen-activated protein kinase kinase activity, blocked both IL-3- and MSP-induced morphological changes.	U 0126	50-55	macrophage stimulating 1 receptor (c-met-related tyrosine kinase)	Mus musculus	13-16
12270548-4	2002	Treatment of RON-expressing cells with PD98059 or U0126, inhibitors of mitogen-activated protein kinase kinase activity, blocked both IL-3- and MSP-induced morphological changes.	U 0126	50-55	interleukin 3	Mus musculus	134-138
12270548-4	2002	Treatment of RON-expressing cells with PD98059 or U0126, inhibitors of mitogen-activated protein kinase kinase activity, blocked both IL-3- and MSP-induced morphological changes.	U 0126	50-55	macrophage stimulating 1 (hepatocyte growth factor-like)	Mus musculus	144-147
12270548-7	2002	Tyrosine phosphorylation of ERK was detected after stimulation with IL-3 or MSP, whereas treatment with U0126 specifically inhibited IL-3- or MSP-induced ERK phosphorylation but not tyrosine phosphorylation of betac.	U 0126	104-109	interleukin 3	Mus musculus	133-137
12270548-7	2002	Tyrosine phosphorylation of ERK was detected after stimulation with IL-3 or MSP, whereas treatment with U0126 specifically inhibited IL-3- or MSP-induced ERK phosphorylation but not tyrosine phosphorylation of betac.	U 0126	104-109	macrophage stimulating 1 (hepatocyte growth factor-like)	Mus musculus	142-145
12270548-7	2002	Tyrosine phosphorylation of ERK was detected after stimulation with IL-3 or MSP, whereas treatment with U0126 specifically inhibited IL-3- or MSP-induced ERK phosphorylation but not tyrosine phosphorylation of betac.	U 0126	104-109	mitogen-activated protein kinase 1	Mus musculus	154-157
12429728-3	2002	Preincubation of eosinophils with U0126, a mitogen-activated protein kinase/ERK kinase inhibitor, suppressed IL-5-induced activation of cytosolic phospholipase A(2) (cPLA(2)) and eosinophil adhesion, and p38 inhibition by SB203580 had neither effect.	U 0126	34-39	interleukin 5	Homo sapiens	109-113
12429728-3	2002	Preincubation of eosinophils with U0126, a mitogen-activated protein kinase/ERK kinase inhibitor, suppressed IL-5-induced activation of cytosolic phospholipase A(2) (cPLA(2)) and eosinophil adhesion, and p38 inhibition by SB203580 had neither effect.	U 0126	34-39	phospholipase A2 group IVA	Homo sapiens	136-173
12429728-3	2002	Preincubation of eosinophils with U0126, a mitogen-activated protein kinase/ERK kinase inhibitor, suppressed IL-5-induced activation of cytosolic phospholipase A(2) (cPLA(2)) and eosinophil adhesion, and p38 inhibition by SB203580 had neither effect.	U 0126	34-39	mitogen-activated protein kinase 1	Homo sapiens	204-207
12588051-8	2002	Blockade of protein synthesis with cycloheximide as well as abrogation of mitogen-activated protein kinase (MAPK) activity with PD98059 or U0126 also prevented the TZD-induced increase in UCP2 mRNA.	U 0126	139-144	uncoupling protein 2	Homo sapiens	188-192
12395317-7	2002	No interference between the MEK/ERK pathway and 4E-BP1 phosphorylation was detected, whereas p70S6K phosphorylation induced by EGF was under a U0126-sensitive regulation.	U 0126	143-148	ribosomal protein S6 kinase B1	Homo sapiens	93-99
12395317-7	2002	No interference between the MEK/ERK pathway and 4E-BP1 phosphorylation was detected, whereas p70S6K phosphorylation induced by EGF was under a U0126-sensitive regulation.	U 0126	143-148	epidermal growth factor	Homo sapiens	127-130
12490006-6	2002	Treatment with U0126, which inhibits MEK, the kinase upstream of ERK, effectively prevented the activation of ERK.	U 0126	15-20	mitogen-activated protein kinase 1	Mus musculus	65-68
12490006-6	2002	Treatment with U0126, which inhibits MEK, the kinase upstream of ERK, effectively prevented the activation of ERK.	U 0126	15-20	mitogen-activated protein kinase 1	Mus musculus	110-113
12490006-8	2002	U0126 significantly reduced trauma-induced MMP-9 levels.	U 0126	0-5	matrix metallopeptidase 9	Mus musculus	43-48
12490006-9	2002	Correspondingly, U0126 ameliorated the degradation of the tight junction protein ZO-1, which is an MMP-9 substrate, and significantly attenuated tissue edema.	U 0126	17-22	tight junction protein 1	Mus musculus	81-85
12490006-9	2002	Correspondingly, U0126 ameliorated the degradation of the tight junction protein ZO-1, which is an MMP-9 substrate, and significantly attenuated tissue edema.	U 0126	17-22	matrix metallopeptidase 9	Mus musculus	99-104
12460740-4	2002	HNE-induced secretion of fibronectin was inhibited by U-0126, an inhibitor of the Erk1/2 pathway, while no significant inhibition by SB-203580, an inhibitor of p38MAPK pathway, was observed.	U 0126	54-60	mitogen-activated protein kinase 3	Homo sapiens	82-88
12370392-15	2002	Adhesion was partially inhibited by the mitogen-activated protein kinase kinase 1/2 inhibitor U0126 (24.5 +/- 3.3%; n = 3) and the p38 inhibitor SB203580 (25.1 +/- 10.4%; n = 3).	U 0126	94-99	mitogen-activated protein kinase kinase 1	Mus musculus	40-81
12441075-6	2002	U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
12441075-6	2002	U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	47-57
12441075-6	2002	U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	67-74
12441075-6	2002	U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells.	U 0126	0-5	H3 histone pseudogene 16	Homo sapiens	95-98
12441075-6	2002	U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	142-149
12149272-11	2002	Cells were treated with U0126, a specific inhibitor of the ERK-activating kinases MEK1 and MEK2.	U 0126	24-29	mitogen-activated protein kinase 1	Homo sapiens	59-62
12388598-6	2002	D1- and D2-induced phospho-Thr(308) Akt is decreased by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, as well as by overexpression of a dominant-negative version of MEK, thus implicating the Ras/ERK signaling cascade in this process.	U 0126	117-122	AKT serine/threonine kinase 1	Homo sapiens	36-39
12388598-6	2002	D1- and D2-induced phospho-Thr(308) Akt is decreased by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, as well as by overexpression of a dominant-negative version of MEK, thus implicating the Ras/ERK signaling cascade in this process.	U 0126	117-122	mitogen-activated protein kinase kinase 7	Homo sapiens	101-104
12388598-6	2002	D1- and D2-induced phospho-Thr(308) Akt is decreased by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, as well as by overexpression of a dominant-negative version of MEK, thus implicating the Ras/ERK signaling cascade in this process.	U 0126	117-122	mitogen-activated protein kinase 1	Homo sapiens	217-220
12149272-11	2002	Cells were treated with U0126, a specific inhibitor of the ERK-activating kinases MEK1 and MEK2.	U 0126	24-29	mitogen-activated protein kinase kinase 1	Homo sapiens	82-86
12149272-11	2002	Cells were treated with U0126, a specific inhibitor of the ERK-activating kinases MEK1 and MEK2.	U 0126	24-29	mitogen-activated protein kinase kinase 2	Homo sapiens	91-95
12149272-12	2002	Although U0126 inhibited ERK1 and ERK2 phosphorylation, U0126 had no effect on LPL activity, indicating that MEK/ERK pathways were not involved in this mechanism of LPL regulation.	U 0126	9-14	mitogen-activated protein kinase 3	Homo sapiens	25-29
12149272-12	2002	Although U0126 inhibited ERK1 and ERK2 phosphorylation, U0126 had no effect on LPL activity, indicating that MEK/ERK pathways were not involved in this mechanism of LPL regulation.	U 0126	9-14	mitogen-activated protein kinase 1	Homo sapiens	34-38
12239162-7	2002	Selective MEK1/2 inhibition by U-0126 and Ca(++) chelation with EGTA (ethyleneglycoltetraacetic acid) behaved similarly, whereas the PKC inhibitor GF109203-X totally prevented collagen-induced secretion and ERK2 activation.	U 0126	31-37	mitogen-activated protein kinase kinase 1	Homo sapiens	10-16
12438173-9	2002	U0126, an inhibitor of MAPK kinase, abolished the effect of leptin on (14)C-catecholamine synthesis.	U 0126	0-5	leptin	Bos taurus	60-66
12370087-5	2002	Inhibition of AA release by U0126 was still observed when stoichiometric phosphorylation of cPLA2 on Ser505 was maintained by activating p38 with anisomycin.	U 0126	28-33	phospholipase A2 group IVA	Canis lupus familiaris	92-97
12360405-7	2002	STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases.	U 0126	93-98	signal transducer and activator of transcription 3	Homo sapiens	0-5
12360405-7	2002	STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases.	U 0126	93-98	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
12438155-5	2002	The MAP kinase kinase inhibitor U0126 inhibits both baseline proliferation and stimulated process outgrowth, consistent with a model in which sustained low-level ERK activation drives proliferation, and more intense activation drives neuronal differentiation.	U 0126	32-37	mitogen-activated protein kinase 1	Mus musculus	162-165
12359775-6	2002	In ASPC-1, PANC-1, and T3M4 cells, PD98059 and U0126 inhibited MAPK kinase activation but not EGF-stimulated mitogenesis, whereas SB203580 inhibited EGF-stimulated mitogenesis, p38 MAPK activation, and MAPK-activated protein kinase 2 activation, without attenuating the mitogenic effect of insulin-like growth factor 1.	U 0126	47-52	mitogen-activated protein kinase 14	Homo sapiens	177-180
12359775-6	2002	In ASPC-1, PANC-1, and T3M4 cells, PD98059 and U0126 inhibited MAPK kinase activation but not EGF-stimulated mitogenesis, whereas SB203580 inhibited EGF-stimulated mitogenesis, p38 MAPK activation, and MAPK-activated protein kinase 2 activation, without attenuating the mitogenic effect of insulin-like growth factor 1.	U 0126	47-52	insulin like growth factor 1	Homo sapiens	290-318
12359775-7	2002	In contrast, in COLO-357 cells, PD98059, and U0126, but not SB203580, inhibited EGF-stimulated mitogenesis, whereas SP600125 did not alter the mitogenic actions of EGF in any of the cell lines.	U 0126	45-50	epidermal growth factor	Homo sapiens	80-83
12206996-7	2002	In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126.	U 0126	173-178	interferon induced protein 44	Homo sapiens	64-67
12351429-4	2002	TNF-alpha activated ERK and increased lipolysis; these effects were inhibited by two specific MEK inhibitors, PD98059 and U0126.	U 0126	122-127	tumor necrosis factor	Homo sapiens	0-9
12351429-4	2002	TNF-alpha activated ERK and increased lipolysis; these effects were inhibited by two specific MEK inhibitors, PD98059 and U0126.	U 0126	122-127	mitogen-activated protein kinase 1	Homo sapiens	20-23
12351429-4	2002	TNF-alpha activated ERK and increased lipolysis; these effects were inhibited by two specific MEK inhibitors, PD98059 and U0126.	U 0126	122-127	mitogen-activated protein kinase kinase 7	Homo sapiens	94-97
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	mitogen-activated protein kinase 3	Homo sapiens	170-176
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	coagulation factor II thrombin receptor	Homo sapiens	205-210
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	coagulation factor II thrombin receptor	Homo sapiens	0-5
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	phospholipase A2 group IVA	Homo sapiens	219-224
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	phospholipase A2 group IVA	Homo sapiens	28-33
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
12356841-10	2002	Moreover, administration of U0126 and LY294002 decreased significantly, but only partially, the neuroprotective effect of BDNF on the axotomized RGCs.	U 0126	28-33	brain-derived neurotrophic factor	Rattus norvegicus	122-126
12374774-6	2002	PAR-1-induced activation of cPLA2, as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation.	U 0126	139-144	mitogen-activated protein kinase kinase 7	Homo sapiens	166-169
12370536-0	2002	Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059.	U 0126	112-117	mitogen activated protein kinase kinase 1	Rattus norvegicus	94-100
12209879-3	2002	Surprisingly, the addition of the MEK1/2 inhibitors PD98059 or U0126 to 8226 cultures at doses that block virtually all ERK1/2 activity had minimal effects on the rapid proliferation of this cell line.	U 0126	63-68	mitogen-activated protein kinase kinase 1	Homo sapiens	34-40
12209879-3	2002	Surprisingly, the addition of the MEK1/2 inhibitors PD98059 or U0126 to 8226 cultures at doses that block virtually all ERK1/2 activity had minimal effects on the rapid proliferation of this cell line.	U 0126	63-68	mitogen-activated protein kinase 3	Homo sapiens	120-126
12423237-3	2002	However, complete inhibition of phospho-ERK by U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), did not completely inhibit PMA-stimulated cPLA2 and AA release.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	40-43
12423237-3	2002	However, complete inhibition of phospho-ERK by U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), did not completely inhibit PMA-stimulated cPLA2 and AA release.	U 0126	47-52	midkine	Mus musculus	70-109
12423237-3	2002	However, complete inhibition of phospho-ERK by U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), did not completely inhibit PMA-stimulated cPLA2 and AA release.	U 0126	47-52	midkine	Mus musculus	111-114
12423237-6	2002	However, complete inhibition of ATP-induced cPLA2 phosphorylation and AA release was observed when astrocytes were treated with GF109203x, a general PKC inhibitor, together with U0126, indicating the important role for both PKC and ERK in mediating the ATP-induced AA response.	U 0126	178-183	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	44-49
12370536-9	2002	The phosphorylation of pancreatic ERK1/2 was attenuated in PD98059- and U0126-treated animals at both 30 minutes and 3 hours after cerulein injection.	U 0126	72-77	mitogen activated protein kinase 3	Rattus norvegicus	34-40
12370536-10	2002	Rats rendered neutropenic with vinblastine and pretreated with U0126 still showed attenuated manifestations of cerulein-induced acute pancreatitis, a finding suggesting that pancreatic ERK1/2 is mostly responsible for the effect, rather than infiltrating neutrophils.	U 0126	63-68	mitogen activated protein kinase 3	Rattus norvegicus	185-191
12407196-4	2002	U0126, a specific inhibitor of mammalian MAPK kinases (MEKs), significantly reduced ODC enzyme activity, but not the ODC transcript level.	U 0126	0-5	ornithine decarboxylase 1	Homo sapiens	84-87
12107166-7	2002	Both MAP kinase and phosphatidylinositol (PI) 3-kinase cascades in NIH3T3 cells were activated by PTN, and this effect persisted for up to 3 h. Surprisingly, the anti-apoptotic effect of PTN was completely blocked by the MAP kinase inhibitor UO126, but was not affected by the PI 3-kinase inhibitor LY294002.	U 0126	242-247	pleiotrophin	Mus musculus	98-101
12121979-8	2002	At the nuclear level, the MEK1 inhibitor U0126 mimics the D2-agonist bromocryptine in suppressing levels of endogenous prolactin transcripts.	U 0126	41-46	mitogen activated protein kinase kinase 1	Rattus norvegicus	26-30
12110689-12	2002	Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway.	U 0126	58-63	mitogen-activated protein kinase 3	Mus musculus	24-30
12121979-8	2002	At the nuclear level, the MEK1 inhibitor U0126 mimics the D2-agonist bromocryptine in suppressing levels of endogenous prolactin transcripts.	U 0126	41-46	prolactin	Rattus norvegicus	119-128
12110689-12	2002	Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway.	U 0126	58-63	fibroblast growth factor 2	Mus musculus	89-94
12121979-10	2002	Both dopamine and U0126 enhance the nuclear localization of ERF, a MAPK-sensitive ETS repressor that inhibits prolactin promoter activity.	U 0126	18-23	Ets2 repressor factor	Rattus norvegicus	60-63
12121979-10	2002	Both dopamine and U0126 enhance the nuclear localization of ERF, a MAPK-sensitive ETS repressor that inhibits prolactin promoter activity.	U 0126	18-23	prolactin	Rattus norvegicus	110-119
12110689-12	2002	Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway.	U 0126	58-63	runt related transcription factor 2	Mus musculus	106-111
12130649-9	2002	Specific inhibitors of ERK1/2 activation (PD98059 and U0126), as well as JNK inhibitors (curcumin and dicumarol) antagonized the inhibitory effects of TGF-beta on ALP activity and mineralization, whereas the specific inhibitor of p38 MAPK (SB203580) did not affect them.	U 0126	54-59	transforming growth factor, beta 1	Mus musculus	151-159
12110689-12	2002	Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway.	U 0126	58-63	bone gamma-carboxyglutamate protein 2	Mus musculus	132-143
12110689-12	2002	Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway.	U 0126	58-63	mitogen-activated protein kinase 1	Mus musculus	208-212
12232764-11	2002	In contrast to geldanamycin and U0126, which act upstream of extracellular signal-regulated kinase 1 and 2, roscovitine and LY294002 failed to suppress phosphocholine production.	U 0126	32-37	mitogen-activated protein kinase 3	Homo sapiens	61-106
12077118-4	2002	Protein kinase C inhibitors (bisindolylmaleimide, calphostin C) and inhibitors of mitogen-activated protein/extracellular signal regulated kinase kinase (MEK) (PD98059 and U0126) suppressed up-regulation of MUC2.	U 0126	172-177	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	207-211
12186945-7	2002	Notably, sarcomeric myosin expression is induced by both TPA and UO126 but is abrogated by the p38 inhibitor.	U 0126	65-70	myosin heavy chain 14	Homo sapiens	20-26
12186945-10	2002	In accordance with this negative role, reactivation of JNKs by anisomycin, in UO126-pre-treated cells, also prevents myosin expression.	U 0126	78-83	myosin heavy chain 14	Homo sapiens	117-123
12412688-7	2002	In isolated perfused mouse lungs, the MAPK/ERK kinase inhibitor U0126 prevented ventilation-induced activation of ERK-1/2 and Elk-1, but had no effect on ventilation-induced cytokine release.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	38-42
12394272-8	2002	Consistent with this possibility, inhibition of ERK activation by the MEK inhibitor, U0126, reversed the EBPC-mediated enhancement of cell death.	U 0126	85-90	mitogen-activated protein kinase 1	Homo sapiens	48-51
12412688-7	2002	In isolated perfused mouse lungs, the MAPK/ERK kinase inhibitor U0126 prevented ventilation-induced activation of ERK-1/2 and Elk-1, but had no effect on ventilation-induced cytokine release.	U 0126	64-69	mitogen-activated protein kinase 1	Mus musculus	43-46
12412688-7	2002	In isolated perfused mouse lungs, the MAPK/ERK kinase inhibitor U0126 prevented ventilation-induced activation of ERK-1/2 and Elk-1, but had no effect on ventilation-induced cytokine release.	U 0126	64-69	mitogen-activated protein kinase 3	Mus musculus	114-121
12412688-7	2002	In isolated perfused mouse lungs, the MAPK/ERK kinase inhibitor U0126 prevented ventilation-induced activation of ERK-1/2 and Elk-1, but had no effect on ventilation-induced cytokine release.	U 0126	64-69	ELK1, member of ETS oncogene family	Mus musculus	126-131
12093796-5	2002	Plasmin-induced DNA binding of STAT1 and STAT3 was blocked by SB203580 and AG490, inhibitors of p38 MAPK and JAK, respectively, but not by U0126, an inhibitor of MKK1/2.	U 0126	139-144	plasminogen	Homo sapiens	0-7
12394272-8	2002	Consistent with this possibility, inhibition of ERK activation by the MEK inhibitor, U0126, reversed the EBPC-mediated enhancement of cell death.	U 0126	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
12205041-6	2002	Inhibition of PKC by GF109203x or MEK1/2 by U0126 (or PD98059) abolished the 5-LO up-regulation effects of PMA.	U 0126	44-49	mitogen-activated protein kinase kinase 1	Homo sapiens	34-40
12193378-7	2002	Pretreatment of LbetaT2 cells with a mitogen-activated protein kinase kinase-specific inhibitor, U0126, abolished the PMA-stimulated increase in MAPK activity and significantly reduced basal and PMA-stimulated promoter activity.	U 0126	97-102	mitogen-activated protein kinase 3	Homo sapiens	145-149
12193378-8	2002	Electrophoretic mobility shift assays for SF-1 and GATA revealed that PMA failed to affect SF-1 binding but enhanced GATA binding to a consensus GATA oligonucleotide, an effect that was blocked with U0126 pretreatment, suggesting that GATA may mediate ERK activation of alphaGSU transcription.	U 0126	199-204	splicing factor 1	Homo sapiens	42-46
12193378-8	2002	Electrophoretic mobility shift assays for SF-1 and GATA revealed that PMA failed to affect SF-1 binding but enhanced GATA binding to a consensus GATA oligonucleotide, an effect that was blocked with U0126 pretreatment, suggesting that GATA may mediate ERK activation of alphaGSU transcription.	U 0126	199-204	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	51-55
12193378-8	2002	Electrophoretic mobility shift assays for SF-1 and GATA revealed that PMA failed to affect SF-1 binding but enhanced GATA binding to a consensus GATA oligonucleotide, an effect that was blocked with U0126 pretreatment, suggesting that GATA may mediate ERK activation of alphaGSU transcription.	U 0126	199-204	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	117-121
12193378-8	2002	Electrophoretic mobility shift assays for SF-1 and GATA revealed that PMA failed to affect SF-1 binding but enhanced GATA binding to a consensus GATA oligonucleotide, an effect that was blocked with U0126 pretreatment, suggesting that GATA may mediate ERK activation of alphaGSU transcription.	U 0126	199-204	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	117-121
12193378-8	2002	Electrophoretic mobility shift assays for SF-1 and GATA revealed that PMA failed to affect SF-1 binding but enhanced GATA binding to a consensus GATA oligonucleotide, an effect that was blocked with U0126 pretreatment, suggesting that GATA may mediate ERK activation of alphaGSU transcription.	U 0126	199-204	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	117-121
12193378-8	2002	Electrophoretic mobility shift assays for SF-1 and GATA revealed that PMA failed to affect SF-1 binding but enhanced GATA binding to a consensus GATA oligonucleotide, an effect that was blocked with U0126 pretreatment, suggesting that GATA may mediate ERK activation of alphaGSU transcription.	U 0126	199-204	mitogen-activated protein kinase 1	Homo sapiens	252-255
12176126-10	2002	Additionally, injection of the ERK-1/2 inhibitor UO126 decreased the cardioprotective effect of FGF-1.	U 0126	49-54	mitogen-activated protein kinase 3	Mus musculus	31-38
12176126-10	2002	Additionally, injection of the ERK-1/2 inhibitor UO126 decreased the cardioprotective effect of FGF-1.	U 0126	49-54	fibroblast growth factor 1	Mus musculus	96-101
12181740-4	2002	With serum deprivation, the MEK inhibitors, PD98059 and U0126, inhibited ERK1/2 activity but did not increase apoptosis.	U 0126	56-61	mitogen-activated protein kinase kinase 7	Homo sapiens	28-31
12181740-4	2002	With serum deprivation, the MEK inhibitors, PD98059 and U0126, inhibited ERK1/2 activity but did not increase apoptosis.	U 0126	56-61	mitogen-activated protein kinase 3	Homo sapiens	73-79
12181740-5	2002	PD98059 and U0126 induced cell cycle arrest in G(0)/G(i) in cells with the highest levels of ERK1/2 activity, which correlated with induction of p27 but not p21.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	93-99
12181740-5	2002	PD98059 and U0126 induced cell cycle arrest in G(0)/G(i) in cells with the highest levels of ERK1/2 activity, which correlated with induction of p27 but not p21.	U 0126	12-17	interferon alpha inducible protein 27	Homo sapiens	145-148
12181740-5	2002	PD98059 and U0126 induced cell cycle arrest in G(0)/G(i) in cells with the highest levels of ERK1/2 activity, which correlated with induction of p27 but not p21.	U 0126	12-17	H3 histone pseudogene 16	Homo sapiens	157-160
12202524-6	2002	This CHA-induced secretion of MMP-2 was inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine (CPT) and by the ERK1/2 pathway inhibitor U0126.	U 0126	169-174	matrix metallopeptidase 2	Homo sapiens	30-35
12225365-6	2002	U0126, a MAPK/extracellular signal-regulated protein kinase kinase (MEK) inhibitor, at the concentrations that blocked PMA-induced ERK phosphorylation, had no effect on PMA stimulated AML cell adhesion.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	9-13
12225365-6	2002	U0126, a MAPK/extracellular signal-regulated protein kinase kinase (MEK) inhibitor, at the concentrations that blocked PMA-induced ERK phosphorylation, had no effect on PMA stimulated AML cell adhesion.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	68-71
12202524-6	2002	This CHA-induced secretion of MMP-2 was inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine (CPT) and by the ERK1/2 pathway inhibitor U0126.	U 0126	169-174	mitogen-activated protein kinase 3	Homo sapiens	144-150
12202524-8	2002	The CHA-induced activation of ERK1/2 was inhibited by pretreatment with the adenosine A(1) antagonist CPT and by the ERK pathway inhibitor U0126.	U 0126	139-144	mitogen-activated protein kinase 3	Homo sapiens	30-36
12202524-8	2002	The CHA-induced activation of ERK1/2 was inhibited by pretreatment with the adenosine A(1) antagonist CPT and by the ERK pathway inhibitor U0126.	U 0126	139-144	mitogen-activated protein kinase 3	Homo sapiens	30-33
12217403-4	2002	The kinase inhibitors PP1 (src family), GF109203X (PKC), PD98059 (MEK1/2), and U0126 (MEK1/2) substantially inhibited ionomycin-mediated granule release, while the p38 kinase inhibitor SB203580 did not.	U 0126	79-84	mitogen activated protein kinase kinase 1	Rattus norvegicus	86-92
12217403-4	2002	The kinase inhibitors PP1 (src family), GF109203X (PKC), PD98059 (MEK1/2), and U0126 (MEK1/2) substantially inhibited ionomycin-mediated granule release, while the p38 kinase inhibitor SB203580 did not.	U 0126	79-84	mitogen activated protein kinase 14	Rattus norvegicus	164-167
12498315-13	2002	IL-1beta-induced monocyte chemoattractant protein-1 was partially inhibited by specific inhibitors of MAP kinase kinase (U0126) and of p38 MAP kinase (SB203580) whereas intercellular adhesion molecule-1 expression was not altered by the inhibitors.	U 0126	121-126	interleukin 1 beta	Rattus norvegicus	0-8
12498315-13	2002	IL-1beta-induced monocyte chemoattractant protein-1 was partially inhibited by specific inhibitors of MAP kinase kinase (U0126) and of p38 MAP kinase (SB203580) whereas intercellular adhesion molecule-1 expression was not altered by the inhibitors.	U 0126	121-126	C-C motif chemokine ligand 2	Rattus norvegicus	17-51
12110546-10	2002	Inhibition of mitogen-activated protein (MAP)/ERK kinase (MEK)1/2 by U0126 (a specific MEK1/2 inhibitor) reduced shear-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	69-74	mitogen activated protein kinase kinase 1	Rattus norvegicus	46-65
12023956-5	2002	Inhibition of p44/42 MAPK signaling by use of the MAPK kinase inhibitors PD 98059 or U0126, or by use of a dominant negative MAPK construct, enhanced proteasome inhibitor-mediated apoptosis.	U 0126	85-90	interferon induced protein 44	Homo sapiens	14-17
12069688-2	2002	Pharmacological inhibition of the ERK1/2 pathway using PD98059 and U0126 prevents cyclin D1 expression and inhibits cell proliferation, arguing that the ERK1/2 pathway is rate limiting for cell-cycle re-entry.	U 0126	67-72	G1/S-specific cyclin-D1	Cricetulus griseus	82-91
12177784-8	2002	An inhibitor of extracellular signal-related kinase pathway signalling (U0126) blocked induction of matrix metalloproteinase-1 production induced by keratinocyte-conditioned medium (as well as by epidermal growth factor or interleukin-1beta), and also inhibited proliferation.	U 0126	72-77	matrix metallopeptidase 1	Homo sapiens	100-126
12177784-8	2002	An inhibitor of extracellular signal-related kinase pathway signalling (U0126) blocked induction of matrix metalloproteinase-1 production induced by keratinocyte-conditioned medium (as well as by epidermal growth factor or interleukin-1beta), and also inhibited proliferation.	U 0126	72-77	epidermal growth factor	Homo sapiens	196-219
12177784-8	2002	An inhibitor of extracellular signal-related kinase pathway signalling (U0126) blocked induction of matrix metalloproteinase-1 production induced by keratinocyte-conditioned medium (as well as by epidermal growth factor or interleukin-1beta), and also inhibited proliferation.	U 0126	72-77	interleukin 1 beta	Homo sapiens	223-240
12110546-10	2002	Inhibition of mitogen-activated protein (MAP)/ERK kinase (MEK)1/2 by U0126 (a specific MEK1/2 inhibitor) reduced shear-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	69-74	mitogen activated protein kinase kinase 1	Rattus norvegicus	87-93
12110546-10	2002	Inhibition of mitogen-activated protein (MAP)/ERK kinase (MEK)1/2 by U0126 (a specific MEK1/2 inhibitor) reduced shear-induced ERK1/2 phosphorylation and cell proliferation.	U 0126	69-74	mitogen activated protein kinase 3	Rattus norvegicus	127-133
12124207-7	2002	Increased NHE activity was associated with phosphorylation of the NHE-1 carboxyl tail that was blocked by U-0126.	U 0126	106-112	solute carrier family 9 member A1	Rattus norvegicus	66-71
12162498-8	2002	U0126, a specific inhibitor of MEK-1/2 members of the MAPK family, abolished BMP-2-mediated expression of BSP and OCN.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	31-38
12210141-0	2002	MEK inhibitor U0126 interferes with immunofluorescence analysis of apoptotic cell death.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
12210141-5	2002	We investigated the limitations of detection of apoptotic cell death and cytofluorometry in cells cultured in the presence of the MEK inhibitor U0126.	U 0126	144-149	mitogen-activated protein kinase kinase 7	Homo sapiens	130-133
12115721-7	2002	The MEK inhibitors PD098056 and U0126 abrogated both the induction by Cpd 5 of phospho-ERK, its nuclear translocation and phospho-Elk-1 and also antagonized its growth inhibitory effects.	U 0126	32-37	EPH receptor B2	Homo sapiens	87-90
12115721-7	2002	The MEK inhibitors PD098056 and U0126 abrogated both the induction by Cpd 5 of phospho-ERK, its nuclear translocation and phospho-Elk-1 and also antagonized its growth inhibitory effects.	U 0126	32-37	ETS transcription factor ELK1	Homo sapiens	130-135
12230870-6	2002	UO126, a MEK1/2 inhibitor, enhanced HO-1 expression in PAEC under normoxia, but not hypoxia.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	9-15
12230870-6	2002	UO126, a MEK1/2 inhibitor, enhanced HO-1 expression in PAEC under normoxia, but not hypoxia.	U 0126	0-5	heme oxygenase 1	Rattus norvegicus	36-40
12230870-10	2002	Pretreatment with SB203580 and PD98059 enhanced AP-1 binding activity under hypoxia in PAEC; UO126 stimulated AP-1 binding under normoxia, whereas diphenylene iodonium stimulated AP-1 binding under normoxia and hypoxia.	U 0126	93-98	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	110-114
12230870-10	2002	Pretreatment with SB203580 and PD98059 enhanced AP-1 binding activity under hypoxia in PAEC; UO126 stimulated AP-1 binding under normoxia, whereas diphenylene iodonium stimulated AP-1 binding under normoxia and hypoxia.	U 0126	93-98	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	110-114
12162498-8	2002	U0126, a specific inhibitor of MEK-1/2 members of the MAPK family, abolished BMP-2-mediated expression of BSP and OCN.	U 0126	0-5	bone morphogenetic protein 2	Homo sapiens	77-82
12162498-8	2002	U0126, a specific inhibitor of MEK-1/2 members of the MAPK family, abolished BMP-2-mediated expression of BSP and OCN.	U 0126	0-5	integrin binding sialoprotein	Homo sapiens	106-109
12162498-8	2002	U0126, a specific inhibitor of MEK-1/2 members of the MAPK family, abolished BMP-2-mediated expression of BSP and OCN.	U 0126	0-5	bone gamma-carboxyglutamate protein	Homo sapiens	114-117
12122507-4	2002	The MAPK kinase (MKK(mek)) inhibitors PD98059 (100 microM) and U0126 (10 microM) significantly inhibited the inotropic responses to the alpha(1)-adrenoceptor agonist methoxamine (300 microM) and endothelin-1 (50 nM), but not the chronotropic responses to these agonists.	U 0126	63-68	endothelin 1	Rattus norvegicus	195-207
12163549-9	2002	Pretreatment with the MAPK/ERK kinase (MEK) inhibitor U0126 (10 microM) attenuated CREB phosphorylation, indicating that the MAPK pathway regulates that activation state of CREB.	U 0126	54-59	cAMP responsive element binding protein 1	Homo sapiens	83-87
12163549-9	2002	Pretreatment with the MAPK/ERK kinase (MEK) inhibitor U0126 (10 microM) attenuated CREB phosphorylation, indicating that the MAPK pathway regulates that activation state of CREB.	U 0126	54-59	cAMP responsive element binding protein 1	Homo sapiens	173-177
12163549-13	2002	Both GABA and muscimol stimulated BDNF expression, and pretreatment with U0126 attenuated GABA-induced BDNF expression.	U 0126	73-78	brain derived neurotrophic factor	Homo sapiens	103-107
12122507-7	2002	We conclude that activation of the PD98059/U0126-sensitive MAPK pathway is essential for the inotropic but not chronotropic actions of adrenoceptor agonists and endothelin-1.	U 0126	43-48	endothelin 1	Rattus norvegicus	161-173
12055096-8	2002	The MEK inhibitors PD-98059 and U-0126 blocked ERK activation mediated by diazoxide.	U 0126	32-38	mitogen-activated protein kinase 1	Homo sapiens	47-50
12000769-7	2002	Suppression of ERK1/2 activation by the MEK inhibitor UO126 restored the ability of pRB-deficient MEFs to undergo adipocyte differentiation, as manifested by expression of adipocyte marker genes and lipid accumulation.	U 0126	54-59	mitogen-activated protein kinase 3	Mus musculus	15-21
12000769-7	2002	Suppression of ERK1/2 activation by the MEK inhibitor UO126 restored the ability of pRB-deficient MEFs to undergo adipocyte differentiation, as manifested by expression of adipocyte marker genes and lipid accumulation.	U 0126	54-59	midkine	Mus musculus	40-43
12000769-7	2002	Suppression of ERK1/2 activation by the MEK inhibitor UO126 restored the ability of pRB-deficient MEFs to undergo adipocyte differentiation, as manifested by expression of adipocyte marker genes and lipid accumulation.	U 0126	54-59	RB transcriptional corepressor 1	Mus musculus	84-87
12055088-7	2002	Inhibition of ERK activation with the MEK inhibitors PD-98059 and U-0126 as well as the Src family kinase inhibitor PP2 completely blocked the effect of DABK to increase p27Kip1 and partially reversed the DABK-mediated inhibition of PDGF-stimulated proliferation.	U 0126	66-72	Eph receptor B1	Rattus norvegicus	14-17
12055088-7	2002	Inhibition of ERK activation with the MEK inhibitors PD-98059 and U-0126 as well as the Src family kinase inhibitor PP2 completely blocked the effect of DABK to increase p27Kip1 and partially reversed the DABK-mediated inhibition of PDGF-stimulated proliferation.	U 0126	66-72	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	170-177
12086980-7	2002	Delta(9)-THC elicited a pronounced increase in the phosphorylation of connexin 43, which was sensitive to PD98059 and U0126, two inhibitors of ERK1/2 activation.	U 0126	118-123	gap junction protein alpha 1	Homo sapiens	70-81
12086980-7	2002	Delta(9)-THC elicited a pronounced increase in the phosphorylation of connexin 43, which was sensitive to PD98059 and U0126, two inhibitors of ERK1/2 activation.	U 0126	118-123	mitogen-activated protein kinase 3	Homo sapiens	143-149
12086980-14	2002	Moreover, PD98059 and U0126 prolonged the bradykinin-induced hyperpolarization of porcine coronary arteries, without affecting the magnitude of the response.	U 0126	22-27	kininogen 1	Homo sapiens	42-52
12074563-3	2002	Inhibition of MEK1/2 with a specific inhibitor, U0126, parthenogenetically activated mouse eggs, producing phenotypes similar to Mos(-/-) parthenogenotes (premature, unequal cleavages and large polar bodies).	U 0126	48-53	mitogen-activated protein kinase kinase 1	Mus musculus	14-20
12124440-5	2002	As has been described elsewhere, EGR1 induction was dependent on activation of p42/44 MAP kinase, as it was blocked by the MEK inhibitor U0126.	U 0126	137-142	early growth response 1	Homo sapiens	33-37
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	4-40
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	mitogen-activated protein kinase 1	Homo sapiens	30-33
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	caspase 3	Homo sapiens	79-88
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	mitogen-activated protein kinase 1	Homo sapiens	71-74
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	mitogen-activated protein kinase 1	Homo sapiens	71-74
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	amyloid beta precursor protein	Homo sapiens	233-239
12153530-8	2002	The mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 blocked ERK and caspase 3 activation, suppressed ERK translocation and reduced the number of apoptotic cells, suggesting a central role for the ERK signalling cascade in A beta(1-40) plus Fe(2+) (A beta(1-40)/Fe(2+)) -induced apoptotic death.	U 0126	57-62	amyloid beta precursor protein	Homo sapiens	259-265
12101277-5	2002	Whereas defensin-induced cell proliferation was not inhibited by the EGF receptor tyrosine kinase inhibitor AG1478, it was completely inhibited by the mitogen-activated protein (MAP) kinase kinase (MEK) inhibitor U0126, suggesting that defensins mediate cell proliferation via an EGF receptor-independent, MAP kinase signaling pathway.	U 0126	213-218	mitogen-activated protein kinase kinase 7	Homo sapiens	198-201
12011049-5	2002	Inhibition of MEK using U0126 prevented v-Src-induced disruption of the cytoskeleton as well as dephosphorylation of cofilin, whereas treatment with a phosphatidylinositol 3-kinase inhibitor had no protective effect.	U 0126	24-29	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	42-45
12124422-6	2002	Neuroprotection by l-AP4 was attenuated by MSOP and abrogated by the compounds PD98059 and UO126, which inhibit the MAPK pathway, or by the compound LY294002, which inhibits the PI-3-K pathway.	U 0126	91-96	transcription factor AP-4	Homo sapiens	21-24
12124422-6	2002	Neuroprotection by l-AP4 was attenuated by MSOP and abrogated by the compounds PD98059 and UO126, which inhibit the MAPK pathway, or by the compound LY294002, which inhibits the PI-3-K pathway.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	116-120
12124440-5	2002	As has been described elsewhere, EGR1 induction was dependent on activation of p42/44 MAP kinase, as it was blocked by the MEK inhibitor U0126.	U 0126	137-142	mitogen-activated protein kinase kinase 7	Homo sapiens	123-126
12191496-5	2002	Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells.	U 0126	128-133	protein kinase C alpha	Homo sapiens	46-49
11934880-6	2002	Pertussis toxin and U0126, which inhibit G(i) and p44/42 mitogen-activated protein kinase (ERK) activation, respectively, caused very little inhibition of PAF-induced CCL2 production (approximately 20% inhibition).	U 0126	20-25	Eph receptor B1	Rattus norvegicus	91-94
12191496-5	2002	Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells.	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
12191496-5	2002	Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells.	U 0126	128-133	protein kinase C alpha	Homo sapiens	84-87
12191496-5	2002	Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells.	U 0126	128-133	mitogen-activated protein kinase kinase 7	Homo sapiens	100-103
12191496-5	2002	Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells.	U 0126	128-133	hepatocyte growth factor	Homo sapiens	157-160
12191496-5	2002	Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells.	U 0126	128-133	small nucleolar RNA, C/D box 87	Homo sapiens	174-177
12079690-7	2002	The angiotensin II- and endothelin-1-induced phosphorylations of p44/42 MAP kinases were inhibited by PD98059 as well as U0126 in the intact aorta.	U 0126	121-126	angiotensinogen	Rattus norvegicus	4-18
12056831-5	2002	Lactate dehydrogenase (LDH) assay and Hoechst nucleic staining indicated that U0126, which inhibits Erk1/2 phosphorylation, enhanced ischemia-induced cell death, whereas LY294002, which inhibits Akt phosphorylation, delayed cell death.	U 0126	78-83	mitogen-activated protein kinase 3	Homo sapiens	100-106
12056831-5	2002	Lactate dehydrogenase (LDH) assay and Hoechst nucleic staining indicated that U0126, which inhibits Erk1/2 phosphorylation, enhanced ischemia-induced cell death, whereas LY294002, which inhibits Akt phosphorylation, delayed cell death.	U 0126	78-83	AKT serine/threonine kinase 1	Homo sapiens	195-198
12056831-7	2002	At 4 and 6 h ischemia, U0126-treated astrocytes expressed a lower level of Bcl-2 than controls.	U 0126	23-28	BCL2 apoptosis regulator	Homo sapiens	75-80
12063170-7	2002	The MEK-inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these processes were MEK-dependent, quite different from that which was observed in A549 cells.	U 0126	19-24	midkine	Mus musculus	4-7
12063170-7	2002	The MEK-inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these processes were MEK-dependent, quite different from that which was observed in A549 cells.	U 0126	19-24	mitogen-activated protein kinase 1	Mus musculus	71-74
12063170-7	2002	The MEK-inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these processes were MEK-dependent, quite different from that which was observed in A549 cells.	U 0126	19-24	src homology 2 domain-containing transforming protein C1	Mus musculus	111-117
12063170-7	2002	The MEK-inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these processes were MEK-dependent, quite different from that which was observed in A549 cells.	U 0126	19-24	v-raf-leukemia viral oncogene 1	Mus musculus	122-127
12063170-7	2002	The MEK-inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these processes were MEK-dependent, quite different from that which was observed in A549 cells.	U 0126	19-24	midkine	Mus musculus	166-169
12063170-10	2002	The time course of Taxol-induced TNF-alpha expression coincides with that of Taxol-induced p66shc phosphorylation, and U0126 inhibits significantly Taxol-induced TNF-alpha expression in RAW 264.7 cells.	U 0126	119-124	tumor necrosis factor	Mus musculus	162-171
12003792-7	2002	In contrast, NF-kappaB activation by bleomycin is inhibited by U-0126, but not by NAC.	U 0126	63-69	nuclear factor kappa B subunit 1	Homo sapiens	13-22
12079690-7	2002	The angiotensin II- and endothelin-1-induced phosphorylations of p44/42 MAP kinases were inhibited by PD98059 as well as U0126 in the intact aorta.	U 0126	121-126	endothelin 1	Rattus norvegicus	24-36
12079690-7	2002	The angiotensin II- and endothelin-1-induced phosphorylations of p44/42 MAP kinases were inhibited by PD98059 as well as U0126 in the intact aorta.	U 0126	121-126	mitogen activated protein kinase 3	Rattus norvegicus	65-68
11997322-5	2002	The selective MAP kinase kinase (MEK1/2) inhibitors U0126 and PD-98059 abolished the NGF-induced ERK activation and largely eliminated (&gt; or = 60%) the effects of NGF to inhibit basolateral Na(+)/H(+) exchange activity and transepithelial HCO absorption in perfused MTALs.	U 0126	52-57	mitogen activated protein kinase kinase 1	Rattus norvegicus	33-39
11997322-5	2002	The selective MAP kinase kinase (MEK1/2) inhibitors U0126 and PD-98059 abolished the NGF-induced ERK activation and largely eliminated (&gt; or = 60%) the effects of NGF to inhibit basolateral Na(+)/H(+) exchange activity and transepithelial HCO absorption in perfused MTALs.	U 0126	52-57	Eph receptor B1	Rattus norvegicus	97-100
12021186-6	2002	A specific inhibitor (U0126) of MEK, a MAPKK required for MAPK activity, inhibited gonadotropin-induced GVB in OCC of both Mos(+/+) and Mos(-/-) mice.	U 0126	22-27	midkine	Mus musculus	32-35
12016129-9	2002	MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion.	U 0126	42-48	interleukin 17A	Homo sapiens	76-81
12016129-9	2002	MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion.	U 0126	42-48	interleukin 6	Homo sapiens	90-94
12021186-6	2002	A specific inhibitor (U0126) of MEK, a MAPKK required for MAPK activity, inhibited gonadotropin-induced GVB in OCC of both Mos(+/+) and Mos(-/-) mice.	U 0126	22-27	Moloney sarcoma oncogene	Mus musculus	123-126
12021186-6	2002	A specific inhibitor (U0126) of MEK, a MAPKK required for MAPK activity, inhibited gonadotropin-induced GVB in OCC of both Mos(+/+) and Mos(-/-) mice.	U 0126	22-27	Moloney sarcoma oncogene	Mus musculus	136-139
12021186-8	2002	U0126 also inhibited cumulus expansion stimulated by FSH, epidermal growth factor, 8-bromo-cAMP, and recombinant growth differentiation factor-9.	U 0126	0-5	growth differentiation factor 9	Mus musculus	113-144
12067409-4	2002	MG-132 increased the expression of IL-6 mRNA and protein;and this effect was abolished by the pretreatment of the cells with U0126, an inhibitor of MAP or ERK kinases (MEK 1/2).	U 0126	125-130	interleukin 6	Homo sapiens	35-39
12067409-4	2002	MG-132 increased the expression of IL-6 mRNA and protein;and this effect was abolished by the pretreatment of the cells with U0126, an inhibitor of MAP or ERK kinases (MEK 1/2).	U 0126	125-130	mitogen-activated protein kinase kinase 1	Homo sapiens	168-175
12039976-2	2002	In this study, in vivo ERK activity was blocked, with a pharmacologic inhibitor (U0126) of the ERK-activating kinase, in rats with mesangioproliferative GN.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	23-26
11992543-8	2002	MEK inhibitor U0126 preferentially blocked AP-1 activity and expression of both IL-8 and VEGF, while PI3K inhibitor LY-294002 or a dominant negative inhibitor-kappaB preferentially blocked NF-kappaB activation and expression of IL-8 but not VEGF.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
11992543-8	2002	MEK inhibitor U0126 preferentially blocked AP-1 activity and expression of both IL-8 and VEGF, while PI3K inhibitor LY-294002 or a dominant negative inhibitor-kappaB preferentially blocked NF-kappaB activation and expression of IL-8 but not VEGF.	U 0126	14-19	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-47
11992543-8	2002	MEK inhibitor U0126 preferentially blocked AP-1 activity and expression of both IL-8 and VEGF, while PI3K inhibitor LY-294002 or a dominant negative inhibitor-kappaB preferentially blocked NF-kappaB activation and expression of IL-8 but not VEGF.	U 0126	14-19	C-X-C motif chemokine ligand 8	Homo sapiens	80-84
11992543-8	2002	MEK inhibitor U0126 preferentially blocked AP-1 activity and expression of both IL-8 and VEGF, while PI3K inhibitor LY-294002 or a dominant negative inhibitor-kappaB preferentially blocked NF-kappaB activation and expression of IL-8 but not VEGF.	U 0126	14-19	vascular endothelial growth factor A	Homo sapiens	89-93
12039976-2	2002	In this study, in vivo ERK activity was blocked, with a pharmacologic inhibitor (U0126) of the ERK-activating kinase, in rats with mesangioproliferative GN.	U 0126	81-86	Eph receptor B1	Rattus norvegicus	95-98
12039976-5	2002	Treatment with U0126 significantly reduced glomerular stimulation of ERK in anti-Thy1 GN.	U 0126	15-20	Eph receptor B1	Rattus norvegicus	69-72
11888667-1	2002	The anti-invasive ability of the mitogen-activated protein kinase (MAPK) kinase inhibitor, U0126, was examined in human A375 melanoma cells in vitro.	U 0126	91-96	mitogen-activated protein kinase 3	Homo sapiens	67-71
12070303-6	2002	Inhibition of ERK-1/2 with UO126 reduced CVB3 titers in Jurkat cells, but not in JCaM cells.	U 0126	27-32	mitogen-activated protein kinase 1	Mus musculus	14-21
11896055-2	2002	Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells.	U 0126	49-54	mitogen-activated protein kinase 1	Homo sapiens	11-14
11896055-2	2002	Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
11896055-2	2002	Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells.	U 0126	49-54	epidermal growth factor	Homo sapiens	69-72
11896055-2	2002	Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells.	U 0126	49-54	GRB2 associated binding protein 1	Homo sapiens	99-103
11896055-2	2002	Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells.	U 0126	49-54	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	154-157
11896055-2	2002	Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells.	U 0126	49-54	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	165-168
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	hepatocyte growth factor	Homo sapiens	78-81
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	epidermal growth factor	Homo sapiens	86-89
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	hepatocyte growth factor	Homo sapiens	123-126
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	153-156
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	GRB2 associated binding protein 1	Homo sapiens	165-169
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	epidermal growth factor	Homo sapiens	213-216
11896055-5	2002	In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain.	U 0126	103-108	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	243-246
11896055-6	2002	An examination of the mechanism of this effect revealed that the treatment of cells with EGF + U0126 increased the tyrosine phosphorylation of Gab1 as well as its association with another SH2-containing protein, SHP2.	U 0126	95-100	epidermal growth factor	Homo sapiens	89-92
11896055-6	2002	An examination of the mechanism of this effect revealed that the treatment of cells with EGF + U0126 increased the tyrosine phosphorylation of Gab1 as well as its association with another SH2-containing protein, SHP2.	U 0126	95-100	GRB2 associated binding protein 1	Homo sapiens	143-147
11896055-6	2002	An examination of the mechanism of this effect revealed that the treatment of cells with EGF + U0126 increased the tyrosine phosphorylation of Gab1 as well as its association with another SH2-containing protein, SHP2.	U 0126	95-100	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	212-216
11888667-6	2002	At 5 microM, U0126 inhibited phosphorylation of the MEK 1/2 to a non-detectable level within 24 h. The phosphorylation of extracellular signal-related kinase 1/2 was also dramatically suppressed by the treatment with 10 microM U0126 or 40 microM PD98059.	U 0126	13-18	mitogen-activated protein kinase kinase 1	Homo sapiens	52-59
11888667-6	2002	At 5 microM, U0126 inhibited phosphorylation of the MEK 1/2 to a non-detectable level within 24 h. The phosphorylation of extracellular signal-related kinase 1/2 was also dramatically suppressed by the treatment with 10 microM U0126 or 40 microM PD98059.	U 0126	13-18	mitogen-activated protein kinase 3	Homo sapiens	122-161
11888667-6	2002	At 5 microM, U0126 inhibited phosphorylation of the MEK 1/2 to a non-detectable level within 24 h. The phosphorylation of extracellular signal-related kinase 1/2 was also dramatically suppressed by the treatment with 10 microM U0126 or 40 microM PD98059.	U 0126	227-232	mitogen-activated protein kinase kinase 1	Homo sapiens	52-59
11888667-6	2002	At 5 microM, U0126 inhibited phosphorylation of the MEK 1/2 to a non-detectable level within 24 h. The phosphorylation of extracellular signal-related kinase 1/2 was also dramatically suppressed by the treatment with 10 microM U0126 or 40 microM PD98059.	U 0126	227-232	mitogen-activated protein kinase 3	Homo sapiens	122-161
11888667-9	2002	Our data suggest that U0126 is an effective agent in inhibiting human A375 melanoma cell invasion and that the effect is partially due to the decreased production of uPA and MMP-9.	U 0126	22-27	plasminogen activator, urokinase	Homo sapiens	166-169
11888667-9	2002	Our data suggest that U0126 is an effective agent in inhibiting human A375 melanoma cell invasion and that the effect is partially due to the decreased production of uPA and MMP-9.	U 0126	22-27	matrix metallopeptidase 9	Homo sapiens	174-179
11893739-4	2002	U0126, a pharmacological inhibitor of MEK, blocked the phosphorylation of the downstream elements ERK, RSK, and CREB, inhibited chemokine synthesis, and reduced transcription from a KC promoter construct.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
11893739-4	2002	U0126, a pharmacological inhibitor of MEK, blocked the phosphorylation of the downstream elements ERK, RSK, and CREB, inhibited chemokine synthesis, and reduced transcription from a KC promoter construct.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	98-101
11893739-4	2002	U0126, a pharmacological inhibitor of MEK, blocked the phosphorylation of the downstream elements ERK, RSK, and CREB, inhibited chemokine synthesis, and reduced transcription from a KC promoter construct.	U 0126	0-5	ribosomal protein S6 kinase A2	Homo sapiens	103-106
11893739-4	2002	U0126, a pharmacological inhibitor of MEK, blocked the phosphorylation of the downstream elements ERK, RSK, and CREB, inhibited chemokine synthesis, and reduced transcription from a KC promoter construct.	U 0126	0-5	cAMP responsive element binding protein 1	Homo sapiens	112-116
11992399-7	2002	U0126, a specific inhibitor of the ERK-activating kinases MEK-1/-2, prevented the activation of ERK induced by NS-398 and blocked the increase in COX-2 protein expression seen when HT29 cells were treated with NS-398 alone.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	35-38
11992399-9	2002	U0126 dose-dependently protected HT29 cells from these antiproliferative effects of NS-398, indicating an antiproliferative role for sustained ERK-1/-2 activation in response to this NSAID.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	143-151
11992399-7	2002	U0126, a specific inhibitor of the ERK-activating kinases MEK-1/-2, prevented the activation of ERK induced by NS-398 and blocked the increase in COX-2 protein expression seen when HT29 cells were treated with NS-398 alone.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	58-66
11992399-7	2002	U0126, a specific inhibitor of the ERK-activating kinases MEK-1/-2, prevented the activation of ERK induced by NS-398 and blocked the increase in COX-2 protein expression seen when HT29 cells were treated with NS-398 alone.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	96-99
11992399-7	2002	U0126, a specific inhibitor of the ERK-activating kinases MEK-1/-2, prevented the activation of ERK induced by NS-398 and blocked the increase in COX-2 protein expression seen when HT29 cells were treated with NS-398 alone.	U 0126	0-5	prostaglandin-endoperoxide synthase 2	Homo sapiens	146-151
12008100-4	2002	The sIL-6R-induced GRO-alpha expression was inhibited by the pretreatment of the cells with AG490, a janus kinase 2 (JAK2) inhibitor, or with U0126, a MAP kinase-ERK kinase (MEK) inhibitor.	U 0126	142-147	C-X-C motif chemokine ligand 1	Homo sapiens	19-28
12008100-4	2002	The sIL-6R-induced GRO-alpha expression was inhibited by the pretreatment of the cells with AG490, a janus kinase 2 (JAK2) inhibitor, or with U0126, a MAP kinase-ERK kinase (MEK) inhibitor.	U 0126	142-147	mitogen-activated protein kinase kinase 7	Homo sapiens	174-177
12019309-9	2002	These effects were blocked by U0126, a mitogen-activated protein kinase/Erk kinase 1/2 inhibitor, suggesting an association between Bad phosphorylation and MAPK activation.	U 0126	30-35	Eph receptor B1	Rattus norvegicus	72-75
12019309-9	2002	These effects were blocked by U0126, a mitogen-activated protein kinase/Erk kinase 1/2 inhibitor, suggesting an association between Bad phosphorylation and MAPK activation.	U 0126	30-35	mitogen-activated protein kinase 1	Mus musculus	156-160
12019309-10	2002	Notably, U0126 and a Rsk1 inhibitor (Ro318220) abolished the neuroprotective activity of TGF-beta1 in staurosporine-induced apoptosis, indicating that activation of MAPK is necessary for the antiapoptotic effect of TGF-beta1 in cultured hippocampal cells.	U 0126	9-14	transforming growth factor, beta 1	Rattus norvegicus	89-98
12019309-10	2002	Notably, U0126 and a Rsk1 inhibitor (Ro318220) abolished the neuroprotective activity of TGF-beta1 in staurosporine-induced apoptosis, indicating that activation of MAPK is necessary for the antiapoptotic effect of TGF-beta1 in cultured hippocampal cells.	U 0126	9-14	mitogen-activated protein kinase 1	Mus musculus	165-169
12019309-10	2002	Notably, U0126 and a Rsk1 inhibitor (Ro318220) abolished the neuroprotective activity of TGF-beta1 in staurosporine-induced apoptosis, indicating that activation of MAPK is necessary for the antiapoptotic effect of TGF-beta1 in cultured hippocampal cells.	U 0126	9-14	transforming growth factor, beta 1	Rattus norvegicus	215-224
11872747-5	2002	Activation was inhibited by wortmannin, rapamycin, and the ERK inhibitors PD98059 and UO126, as well as by a dominant negative mutant of AKT.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	59-62
12008100-4	2002	The sIL-6R-induced GRO-alpha expression was inhibited by the pretreatment of the cells with AG490, a janus kinase 2 (JAK2) inhibitor, or with U0126, a MAP kinase-ERK kinase (MEK) inhibitor.	U 0126	142-147	STIL centriolar assembly protein	Homo sapiens	4-7
12062470-6	2002	The inhibition of the ERK/MAPK pathway with U0126, however, did not affect the increase in alpha-synuclein.	U 0126	44-49	mitogen-activated protein kinase 1	Homo sapiens	22-25
11872750-8	2002	UO126, a pharmacologic inhibitor of MEK1, also blocks UbC transcriptional activation by dexamethasone; L6 cells transfected to express constitutively active MEK1 exhibit increased UbC promoter activity.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	36-40
11872750-8	2002	UO126, a pharmacologic inhibitor of MEK1, also blocks UbC transcriptional activation by dexamethasone; L6 cells transfected to express constitutively active MEK1 exhibit increased UbC promoter activity.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	157-161
11978861-6	2002	TGF-beta1-treated sensory neurons showed a significant reduction in the number of these puncta, an effect that was blocked by the MAP/ERK kinase inhibitor U0126.	U 0126	155-160	transforming growth factor beta 1	Homo sapiens	0-9
11891214-6	2002	Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126, inhibited, in a dose-dependent manner, ML-1-induced expression of IL-6 and IL-8.	U 0126	61-66	mitogen-activated protein kinase kinase 1	Homo sapiens	29-36
11891214-6	2002	Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126, inhibited, in a dose-dependent manner, ML-1-induced expression of IL-6 and IL-8.	U 0126	61-66	interleukin 17F	Homo sapiens	107-111
11891214-6	2002	Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126, inhibited, in a dose-dependent manner, ML-1-induced expression of IL-6 and IL-8.	U 0126	61-66	interleukin 6	Homo sapiens	134-138
11891214-6	2002	Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126, inhibited, in a dose-dependent manner, ML-1-induced expression of IL-6 and IL-8.	U 0126	61-66	C-X-C motif chemokine ligand 8	Homo sapiens	143-147
12028355-5	2002	The protective action of PACAP upon hydrogen peroxide-induced neuronal cell death was abolished by the MAP-kinase kinase (MEK) inhibitor U0126 and mimicked by the caspase-3 inhibitor Z-DEVD-FMK.	U 0126	137-142	adenylate cyclase activating polypeptide 1	Homo sapiens	25-30
12028355-5	2002	The protective action of PACAP upon hydrogen peroxide-induced neuronal cell death was abolished by the MAP-kinase kinase (MEK) inhibitor U0126 and mimicked by the caspase-3 inhibitor Z-DEVD-FMK.	U 0126	137-142	mitogen-activated protein kinase kinase 7	Homo sapiens	103-120
12028355-5	2002	The protective action of PACAP upon hydrogen peroxide-induced neuronal cell death was abolished by the MAP-kinase kinase (MEK) inhibitor U0126 and mimicked by the caspase-3 inhibitor Z-DEVD-FMK.	U 0126	137-142	mitogen-activated protein kinase kinase 7	Homo sapiens	122-125
11953364-7	2002	Pretreatment of cells with the highly specific MEK1/2 inhibitor U0126, the p38 inhibitor SB203580, and/or the proteasome inhibitor ALLN led to inhibition of the IL-8 secretion induced in EHEC-infected T84 cells.	U 0126	64-69	mitogen-activated protein kinase kinase 1	Homo sapiens	47-53
11953364-7	2002	Pretreatment of cells with the highly specific MEK1/2 inhibitor U0126, the p38 inhibitor SB203580, and/or the proteasome inhibitor ALLN led to inhibition of the IL-8 secretion induced in EHEC-infected T84 cells.	U 0126	64-69	C-X-C motif chemokine ligand 8	Homo sapiens	161-165
12054565-7	2002	PD098059 and U0126, two MAPK kinase inhibitors, and LY294002, a PI3K inhibitor, significantly blocked thrombin-induced [(3)H]thymidine incorporation and cyclin D(1) expression in ASM cells.	U 0126	13-18	G1/S-specific cyclin-D1	Cavia porcellus	153-164
11821415-7	2002	Inhibition of ERK activation by PD98059 or U0126 attenuated p21(CIP1) induction, resulting in partial release of the G(2)/M cell cycle arrest induced by ETOP.	U 0126	43-48	H3 histone pseudogene 16	Homo sapiens	60-63
11821415-7	2002	Inhibition of ERK activation by PD98059 or U0126 attenuated p21(CIP1) induction, resulting in partial release of the G(2)/M cell cycle arrest induced by ETOP.	U 0126	43-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	64-68
11948414-7	2002	The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RAS-dependent transcriptional responses, cell scattering and morphogenesis.	U 0126	83-88	hepatocyte growth factor	Homo sapiens	46-52
11948414-7	2002	The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RAS-dependent transcriptional responses, cell scattering and morphogenesis.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	121-124
11948414-7	2002	The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RAS-dependent transcriptional responses, cell scattering and morphogenesis.	U 0126	83-88	ETS proto-oncogene 1, transcription factor	Homo sapiens	174-178
11880312-8	2002	Pretreatment with either U-0126 (10 microM) or PD-98059 (30 microM), both inhibitors of MAP/ERK kinase, the enzyme upstream of ERK, inhibited IL-13- or IL-4-induced eotaxin release (P &lt; 0.05).	U 0126	25-31	mitogen-activated protein kinase 1	Homo sapiens	127-130
11880312-8	2002	Pretreatment with either U-0126 (10 microM) or PD-98059 (30 microM), both inhibitors of MAP/ERK kinase, the enzyme upstream of ERK, inhibited IL-13- or IL-4-induced eotaxin release (P &lt; 0.05).	U 0126	25-31	interleukin 13	Homo sapiens	142-147
11880312-8	2002	Pretreatment with either U-0126 (10 microM) or PD-98059 (30 microM), both inhibitors of MAP/ERK kinase, the enzyme upstream of ERK, inhibited IL-13- or IL-4-induced eotaxin release (P &lt; 0.05).	U 0126	25-31	interleukin 4	Homo sapiens	152-156
11880312-8	2002	Pretreatment with either U-0126 (10 microM) or PD-98059 (30 microM), both inhibitors of MAP/ERK kinase, the enzyme upstream of ERK, inhibited IL-13- or IL-4-induced eotaxin release (P &lt; 0.05).	U 0126	25-31	C-C motif chemokine ligand 11	Homo sapiens	165-172
11880312-9	2002	U-0126 also inhibited IL-13, and TNF-alpha induced mRNA expression.	U 0126	0-6	interleukin 13	Homo sapiens	22-27
11959794-15	2002	MEK inhibitor U0126 inhibited TPA/ionomycin induced IL-13 synthesis very effectively, whereas alpha-CD3/alpha-CD28 stimulated IL-13 induction was resistant to this drug.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
11959794-15	2002	MEK inhibitor U0126 inhibited TPA/ionomycin induced IL-13 synthesis very effectively, whereas alpha-CD3/alpha-CD28 stimulated IL-13 induction was resistant to this drug.	U 0126	14-19	interleukin 13	Homo sapiens	52-57
11959794-18	2002	In difference to PBMCs alpha-CD3/alpha-CD28 stimulated IL-13 synthesis was effectively inhibited by CsA, FK-506 and U0126.	U 0126	116-121	interleukin 13	Homo sapiens	55-60
11900461-8	2002	When in vitro-grown oocytes were treated with UO126, a specific MEK inhibitor that prevents activation of mitogen-activated protein kinases (ERK-1 and ERK-2), for 1 h before, during, and following OA treatment, only 22% of oocytes underwent germinal vesicle breakdown after 24 h from the OA treatment.	U 0126	46-51	midkine	Mus musculus	64-67
11900461-8	2002	When in vitro-grown oocytes were treated with UO126, a specific MEK inhibitor that prevents activation of mitogen-activated protein kinases (ERK-1 and ERK-2), for 1 h before, during, and following OA treatment, only 22% of oocytes underwent germinal vesicle breakdown after 24 h from the OA treatment.	U 0126	46-51	mitogen-activated protein kinase 3	Mus musculus	141-146
11900461-8	2002	When in vitro-grown oocytes were treated with UO126, a specific MEK inhibitor that prevents activation of mitogen-activated protein kinases (ERK-1 and ERK-2), for 1 h before, during, and following OA treatment, only 22% of oocytes underwent germinal vesicle breakdown after 24 h from the OA treatment.	U 0126	46-51	mitogen-activated protein kinase 1	Mus musculus	151-156
11923207-4	2002	By using the MEK inhibitor U0126, we have demonstrated that activation of p90Rsk2 during meiotic progression requires activation of the MAPK pathway.	U 0126	27-32	midkine	Mus musculus	13-16
11923207-4	2002	By using the MEK inhibitor U0126, we have demonstrated that activation of p90Rsk2 during meiotic progression requires activation of the MAPK pathway.	U 0126	27-32	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	74-81
11923207-4	2002	By using the MEK inhibitor U0126, we have demonstrated that activation of p90Rsk2 during meiotic progression requires activation of the MAPK pathway.	U 0126	27-32	mitogen-activated protein kinase 1	Mus musculus	136-140
11923207-10	2002	We show that inhibition of the MAPK pathway by preincubation of spermatocytes with U0126 suppresses Nek2 activation, and that incubation of spermatocyte cell extracts with activated p90Rsk2 causes stimulation of Nek2 kinase activity.	U 0126	83-88	mitogen-activated protein kinase 1	Mus musculus	31-35
11923207-10	2002	We show that inhibition of the MAPK pathway by preincubation of spermatocytes with U0126 suppresses Nek2 activation, and that incubation of spermatocyte cell extracts with activated p90Rsk2 causes stimulation of Nek2 kinase activity.	U 0126	83-88	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	100-104
11918738-9	2002	ERK was activated during apoptosis and blocking ERK activation with U0126 or PD98059 partially rescued MC from apoptosis.	U 0126	68-73	mitogen-activated protein kinase 1	Mus musculus	0-3
11918738-9	2002	ERK was activated during apoptosis and blocking ERK activation with U0126 or PD98059 partially rescued MC from apoptosis.	U 0126	68-73	mitogen-activated protein kinase 1	Mus musculus	48-51
11960350-6	2002	Pretreatment of cells with 5 microM of the MEK-1/-2-specific inhibitor U0126 abrogated PMA- or RA-induced activation of ERK-1/MAPK and ERK-2/MAPK.	U 0126	71-76	mitogen-activated protein kinase kinase 1	Homo sapiens	43-51
11960350-6	2002	Pretreatment of cells with 5 microM of the MEK-1/-2-specific inhibitor U0126 abrogated PMA- or RA-induced activation of ERK-1/MAPK and ERK-2/MAPK.	U 0126	71-76	mitogen-activated protein kinase 3	Homo sapiens	120-125
11960350-6	2002	Pretreatment of cells with 5 microM of the MEK-1/-2-specific inhibitor U0126 abrogated PMA- or RA-induced activation of ERK-1/MAPK and ERK-2/MAPK.	U 0126	71-76	mitogen-activated protein kinase 1	Homo sapiens	135-140
11960350-7	2002	Importantly, pretreatment of HL-60 cells with U0126 was found to potently inhibit both monocytic and granulocytic differentiation, as assessed by cytochemical staining for non-specific esterase or nitroblue tetrazolium reduction, flow cytometric analysis of myeloid surface markers, and immunoblotting for the cell cycle inhibitor p21 WAF1/Cip1.	U 0126	46-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	331-334
11960350-7	2002	Importantly, pretreatment of HL-60 cells with U0126 was found to potently inhibit both monocytic and granulocytic differentiation, as assessed by cytochemical staining for non-specific esterase or nitroblue tetrazolium reduction, flow cytometric analysis of myeloid surface markers, and immunoblotting for the cell cycle inhibitor p21 WAF1/Cip1.	U 0126	46-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	335-339
11960350-7	2002	Importantly, pretreatment of HL-60 cells with U0126 was found to potently inhibit both monocytic and granulocytic differentiation, as assessed by cytochemical staining for non-specific esterase or nitroblue tetrazolium reduction, flow cytometric analysis of myeloid surface markers, and immunoblotting for the cell cycle inhibitor p21 WAF1/Cip1.	U 0126	46-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	340-344
11960350-8	2002	Similar results were seen in U937 cells, where U0126 inhibited PMA-induced monocytic differentiation, and in 32D cells, where G-CSF-induced granulocytic differentiation was inhibited by U0126 pretreatment.	U 0126	186-191	peripheral blood stem cell response to granulocyte colony stimulating factor 1	Mus musculus	126-131
11940578-6	2002	Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR.	U 0126	58-63	mitogen-activated protein kinase kinase 1	Homo sapiens	40-46
11784715-4	2002	In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126.	U 0126	157-162	hepatocyte growth factor	Mus musculus	13-16
11940578-6	2002	Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR.	U 0126	58-63	ribosomal protein S6 kinase B1	Homo sapiens	155-159
11940578-6	2002	Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR.	U 0126	58-63	mechanistic target of rapamycin kinase	Homo sapiens	164-168
12009331-5	2002	U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes.	U 0126	0-5	matrix metallopeptidase 3	Homo sapiens	24-29
12009331-5	2002	U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes.	U 0126	0-5	matrix metallopeptidase 13	Homo sapiens	43-49
12009331-5	2002	U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes.	U 0126	0-5	matrix metallopeptidase 3	Homo sapiens	85-90
12009331-5	2002	U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes.	U 0126	0-5	matrix metallopeptidase 13	Homo sapiens	105-111
11784715-8	2002	The prevention of the FAK-paxillin association with U0126 correlated with an inhibition of the HGF-mediated FAK tyrosine phosphorylation and inhibition of HGF-dependent cell spreading and adhesion.	U 0126	52-57	PTK2 protein tyrosine kinase 2	Mus musculus	22-25
11784715-8	2002	The prevention of the FAK-paxillin association with U0126 correlated with an inhibition of the HGF-mediated FAK tyrosine phosphorylation and inhibition of HGF-dependent cell spreading and adhesion.	U 0126	52-57	paxillin	Mus musculus	26-34
11784715-8	2002	The prevention of the FAK-paxillin association with U0126 correlated with an inhibition of the HGF-mediated FAK tyrosine phosphorylation and inhibition of HGF-dependent cell spreading and adhesion.	U 0126	52-57	hepatocyte growth factor	Mus musculus	95-98
11784715-8	2002	The prevention of the FAK-paxillin association with U0126 correlated with an inhibition of the HGF-mediated FAK tyrosine phosphorylation and inhibition of HGF-dependent cell spreading and adhesion.	U 0126	52-57	PTK2 protein tyrosine kinase 2	Mus musculus	108-111
11784715-8	2002	The prevention of the FAK-paxillin association with U0126 correlated with an inhibition of the HGF-mediated FAK tyrosine phosphorylation and inhibition of HGF-dependent cell spreading and adhesion.	U 0126	52-57	hepatocyte growth factor	Mus musculus	155-158
11784715-4	2002	In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126.	U 0126	157-162	paxillin	Mus musculus	40-48
11784715-4	2002	In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126.	U 0126	157-162	mitogen-activated protein kinase 1	Mus musculus	63-66
11784715-4	2002	In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126.	U 0126	157-162	paxillin	Mus musculus	106-114
11784715-4	2002	In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126.	U 0126	157-162	mitogen-activated protein kinase 1	Mus musculus	143-146
11784715-7	2002	HGF induced an increase in paxillin-FAK association that was inhibited by pretreatment with U0126 and reproduced by in vitro phosphorylation of paxillin with ERK.	U 0126	92-97	hepatocyte growth factor	Mus musculus	0-3
11784715-7	2002	HGF induced an increase in paxillin-FAK association that was inhibited by pretreatment with U0126 and reproduced by in vitro phosphorylation of paxillin with ERK.	U 0126	92-97	paxillin	Mus musculus	27-35
11880312-8	2002	Pretreatment with either U-0126 (10 microM) or PD-98059 (30 microM), both inhibitors of MAP/ERK kinase, the enzyme upstream of ERK, inhibited IL-13- or IL-4-induced eotaxin release (P &lt; 0.05).	U 0126	25-31	mitogen-activated protein kinase 1	Homo sapiens	92-95
11784715-7	2002	HGF induced an increase in paxillin-FAK association that was inhibited by pretreatment with U0126 and reproduced by in vitro phosphorylation of paxillin with ERK.	U 0126	92-97	PTK2 protein tyrosine kinase 2	Mus musculus	36-39
11839529-4	2002	At the same time, U-0126 treatment reduced ERK-1/2, slightly increased p38 kinase, but did not change c-Jun NH(2)-terminal kinase activities, indicating that U-0126 specifically inhibited the ERK-1/2 enzymes.	U 0126	18-24	mitogen activated protein kinase 3	Rattus norvegicus	192-199
11782488-6	2002	BMK1 activation by H(2)O(2) was inhibited by both PD98059 and U0126, which were reported to inhibit MEK5 as well as MEK1/2.	U 0126	62-67	mitogen-activated protein kinase 7	Rattus norvegicus	0-4
11782488-6	2002	BMK1 activation by H(2)O(2) was inhibited by both PD98059 and U0126, which were reported to inhibit MEK5 as well as MEK1/2.	U 0126	62-67	mitogen activated protein kinase kinase 5	Rattus norvegicus	100-104
11782488-6	2002	BMK1 activation by H(2)O(2) was inhibited by both PD98059 and U0126, which were reported to inhibit MEK5 as well as MEK1/2.	U 0126	62-67	mitogen activated protein kinase kinase 1	Rattus norvegicus	116-122
11782488-10	2002	Finally, pretreatment of cells with PD98059 and U0126 resulted in an increase in cell death including apoptosis by H(2)O(2) in ERK1/2 down-regulated cells as well as in intact PC12 cells.	U 0126	48-53	mitogen activated protein kinase 3	Rattus norvegicus	127-133
11866445-6	2002	H. pylori-mediated c-fos promoter activation was inhibited by MEK1/2 inhibitor (U0126).	U 0126	80-85	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	19-24
11839529-2	2002	To determine if ERK-1/2 signaling plays a role in fetal lung branching morphogenesis, U-0126, an inhibitor of the upstream kinase MAP ERK kinase (MEK), was added to fetal lung explants in vitro.	U 0126	86-92	mitogen activated protein kinase 3	Rattus norvegicus	16-23
11839529-2	2002	To determine if ERK-1/2 signaling plays a role in fetal lung branching morphogenesis, U-0126, an inhibitor of the upstream kinase MAP ERK kinase (MEK), was added to fetal lung explants in vitro.	U 0126	86-92	mitogen activated protein kinase kinase 1	Rattus norvegicus	146-149
11777913-5	2002	UVB-induced phosphorylation of 4E-BP1 was blocked by p38 kinase inhibitors, PD169316 and SB202190, and MSK1 inhibitor, H89, but not by mitogen-activated protein kinase kinase inhibitors, PD98059 or U0126.	U 0126	198-203	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	31-37
11756441-2	2002	Whereas small molecule inhibitors PD098095 and U0126 have been used to study MAPK/ERK kinase (MEK), their target selectivity has been questioned recently.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	77-81
11756441-2	2002	Whereas small molecule inhibitors PD098095 and U0126 have been used to study MAPK/ERK kinase (MEK), their target selectivity has been questioned recently.	U 0126	47-52	Eph receptor B1	Rattus norvegicus	82-85
11756441-2	2002	Whereas small molecule inhibitors PD098095 and U0126 have been used to study MAPK/ERK kinase (MEK), their target selectivity has been questioned recently.	U 0126	47-52	mitogen activated protein kinase kinase 1	Rattus norvegicus	94-97
11839529-4	2002	At the same time, U-0126 treatment reduced ERK-1/2, slightly increased p38 kinase, but did not change c-Jun NH(2)-terminal kinase activities, indicating that U-0126 specifically inhibited the ERK-1/2 enzymes.	U 0126	18-24	mitogen activated protein kinase 3	Rattus norvegicus	43-50
11839529-4	2002	At the same time, U-0126 treatment reduced ERK-1/2, slightly increased p38 kinase, but did not change c-Jun NH(2)-terminal kinase activities, indicating that U-0126 specifically inhibited the ERK-1/2 enzymes.	U 0126	158-164	mitogen activated protein kinase 3	Rattus norvegicus	192-199
11839529-7	2002	Thus U-0126 causes specific inhibition of ERK-1/2 signaling, diminished branching morphogenesis, characterized by increased mesenchymal apoptosis, and decreased epithelial proliferation in fetal lung explants.	U 0126	5-11	mitogen activated protein kinase 3	Rattus norvegicus	42-49
11884280-4	2002	The MAPK kinase inhibitor (MEKI), U0126 (1 micromol/L), blocked ERK1/2 phosphorylation and at higher doses (5 micromol/L) blocked BMK1 phosphorylation.	U 0126	34-39	mitogen activated protein kinase 3	Rattus norvegicus	4-8
11884280-4	2002	The MAPK kinase inhibitor (MEKI), U0126 (1 micromol/L), blocked ERK1/2 phosphorylation and at higher doses (5 micromol/L) blocked BMK1 phosphorylation.	U 0126	34-39	mitogen activated protein kinase 3	Rattus norvegicus	64-70
11884280-4	2002	The MAPK kinase inhibitor (MEKI), U0126 (1 micromol/L), blocked ERK1/2 phosphorylation and at higher doses (5 micromol/L) blocked BMK1 phosphorylation.	U 0126	34-39	mitogen-activated protein kinase 7	Rattus norvegicus	130-134
11966759-7	2002	U0126, an inhibitor of MAPK-kinase (MEK) activation, not only prevented extracellular signal-regulated kinase 1/2 (ERK1/2) activation but also significantly inhibited the MCP-mediated chemotaxis.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
11966759-7	2002	U0126, an inhibitor of MAPK-kinase (MEK) activation, not only prevented extracellular signal-regulated kinase 1/2 (ERK1/2) activation but also significantly inhibited the MCP-mediated chemotaxis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	72-113
11966759-7	2002	U0126, an inhibitor of MAPK-kinase (MEK) activation, not only prevented extracellular signal-regulated kinase 1/2 (ERK1/2) activation but also significantly inhibited the MCP-mediated chemotaxis.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	115-121
11966759-7	2002	U0126, an inhibitor of MAPK-kinase (MEK) activation, not only prevented extracellular signal-regulated kinase 1/2 (ERK1/2) activation but also significantly inhibited the MCP-mediated chemotaxis.	U 0126	0-5	capping actin protein, gelsolin like	Homo sapiens	171-174
11857451-6	2002	U0126 and PD 098059, specific inhibitors of MEK1/2, the ERK1/2 kinases, antagonized both cell growth inhibition and ERK1/2 phosphorylation mediated by Cpd5.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	44-50
11857451-6	2002	U0126 and PD 098059, specific inhibitors of MEK1/2, the ERK1/2 kinases, antagonized both cell growth inhibition and ERK1/2 phosphorylation mediated by Cpd5.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	56-62
11857451-6	2002	U0126 and PD 098059, specific inhibitors of MEK1/2, the ERK1/2 kinases, antagonized both cell growth inhibition and ERK1/2 phosphorylation mediated by Cpd5.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	116-122
11880483-5	2002	Local infusion of MEK (MAP kinase kinase) inhibitors (PD98059 and U0126) during BDNF delivery abolished BDNF-LTP and the associated ERK activation.	U 0126	66-71	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
11880483-5	2002	Local infusion of MEK (MAP kinase kinase) inhibitors (PD98059 and U0126) during BDNF delivery abolished BDNF-LTP and the associated ERK activation.	U 0126	66-71	mitogen-activated protein kinase kinase 7	Homo sapiens	23-40
11880483-5	2002	Local infusion of MEK (MAP kinase kinase) inhibitors (PD98059 and U0126) during BDNF delivery abolished BDNF-LTP and the associated ERK activation.	U 0126	66-71	brain derived neurotrophic factor	Homo sapiens	80-84
11880483-5	2002	Local infusion of MEK (MAP kinase kinase) inhibitors (PD98059 and U0126) during BDNF delivery abolished BDNF-LTP and the associated ERK activation.	U 0126	66-71	brain derived neurotrophic factor	Homo sapiens	104-108
11880483-5	2002	Local infusion of MEK (MAP kinase kinase) inhibitors (PD98059 and U0126) during BDNF delivery abolished BDNF-LTP and the associated ERK activation.	U 0126	66-71	mitogen-activated protein kinase 1	Homo sapiens	132-135
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	Eph receptor B1	Rattus norvegicus	47-84
11861786-6	2002	Two MEK inhibitors, 2-(2"-amino-3"-methoxyphenol)-oxanaphthalen-4-one (PD98059) and 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (UO126), blocked lead-induced MAPK activation and inhibited lead-induced DNA synthesis, as measured by incorporation of [methyl-3H]thymidine into cell DNA.	U 0126	84-143	mitogen-activated protein kinase kinase 1	Homo sapiens	4-7
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	Eph receptor B1	Rattus norvegicus	223-260
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	Eph receptor B1	Rattus norvegicus	262-265
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	mechanistic target of rapamycin kinase	Homo sapiens	271-300
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	mechanistic target of rapamycin kinase	Homo sapiens	302-306
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	ribosomal protein S6 kinase B1	Homo sapiens	308-315
12489846-4	2002	U0126 selectively repressed anchorage-independent growth of MDA-MB231 and HBC4 cells, two lines with constitutively activated ERK.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	126-129
12489846-10	2002	As in Ki-ras-transformed rat fibroblasts, U0126 reduced activation of both ERK and p70(S6K) in MDA-MB231 and HBC4 cells, irrespective of anchorage.	U 0126	42-47	Eph receptor B1	Rattus norvegicus	75-78
12489846-10	2002	As in Ki-ras-transformed rat fibroblasts, U0126 reduced activation of both ERK and p70(S6K) in MDA-MB231 and HBC4 cells, irrespective of anchorage.	U 0126	42-47	ribosomal protein S6 kinase B1	Rattus norvegicus	83-86
12489846-13	2002	U0126 was either without effect or less inhibitory on p70(S6K) in MDA-MB453 and SKBR3, two cell lines in which anoikis sensitivity was not induced.	U 0126	0-5	ribosomal protein S6 kinase B1	Homo sapiens	54-57
11890736-5	2002	Western blot analysis indicated that p53 accumulation caused by SIN-1 did not require p53 phosphorylation, whereas SIN-1 treatment triggered MAP kinase (MAPK) phosphorylation and pretreatment with the MAP kinase kinase (MEK) inhibitor U0126 inhibited p53 accumulation.	U 0126	235-240	mitogen-activated protein kinase associated protein 1	Mus musculus	115-120
11846418-6	2002	Insulin (1 nM)-stimulated NOS activity was also abolished by U0126, an inhibitor of p42/p44 MAPK activation, and by 1 microM okadaic acid (OA), which inhibits both PP-1 and PP-2A but not by 1 nM OA which inhibits only PP-2A.	U 0126	61-66	mitogen activated protein kinase 3	Rattus norvegicus	88-91
11822870-8	2002	Although SB203580 had no effect on the telomerase activity of regenerating hepatocytes, treatment with MEK inhibitors (PD 98059, U0126) significantly repressed the telomerase activity.	U 0126	129-134	midkine	Mus musculus	103-106
11812003-5	2002	The MEK inhibitors, U0126 and PD-98059, dose-dependently inhibited the ERK activity stimulated by EGF.	U 0126	20-25	epidermal growth factor	Canis lupus familiaris	98-101
11799150-3	2002	Inhibition of ERK and p38 with U0126 and SB203580, respectively, reduced the expression of IP-10 mRNA following transduction with AdCMV beta gal.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	14-17
11836141-5	2002	TCHQ-induced apoptosis was markedly suppressed by treatment with a p38 inhibitor (SB203580) and mildly (but significantly) suppressed by treatment with a MAPK/ERK kinase inhibitor (U0126).	U 0126	181-186	mitogen-activated protein kinase 1	Homo sapiens	154-158
11836141-5	2002	TCHQ-induced apoptosis was markedly suppressed by treatment with a p38 inhibitor (SB203580) and mildly (but significantly) suppressed by treatment with a MAPK/ERK kinase inhibitor (U0126).	U 0126	181-186	mitogen-activated protein kinase 1	Homo sapiens	159-162
11834445-10	2002	PD98059 and U-0126, inhibitors of the upstream kinase of p44/p42 MAP kinase, reduced the accumulation of HSP27 induced by PGE2.	U 0126	12-18	mitogen-activated protein kinase 3	Mus musculus	57-60
11834445-10	2002	PD98059 and U-0126, inhibitors of the upstream kinase of p44/p42 MAP kinase, reduced the accumulation of HSP27 induced by PGE2.	U 0126	12-18	cyclin-dependent kinase 20	Mus musculus	61-64
11834445-10	2002	PD98059 and U-0126, inhibitors of the upstream kinase of p44/p42 MAP kinase, reduced the accumulation of HSP27 induced by PGE2.	U 0126	12-18	heat shock protein 1	Mus musculus	105-110
11799150-3	2002	Inhibition of ERK and p38 with U0126 and SB203580, respectively, reduced the expression of IP-10 mRNA following transduction with AdCMV beta gal.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	22-25
11799150-3	2002	Inhibition of ERK and p38 with U0126 and SB203580, respectively, reduced the expression of IP-10 mRNA following transduction with AdCMV beta gal.	U 0126	31-36	C-X-C motif chemokine ligand 10	Homo sapiens	91-96
11784793-4	2002	CFA also induced an upregulation of prodynorphin and neurokinin-1 (NK-1) in dorsal horn neurons, which was suppressed by intrathecal delivery of the MEK (MAP kinase kinase) inhibitor U0126.	U 0126	183-188	tachykinin precursor 1	Homo sapiens	53-65
11964089-7	2002	Furthermore, full phosphorylation of RSK was inhibited when oocytes were treated with U0126, a specific MAP kinase kinase inhibitor, in dose-dependent manner, indicating that RSK is one of the substrates of MAP kinase.	U 0126	86-91	ribosomal protein S6 kinase A2	Homo sapiens	37-40
11964089-7	2002	Furthermore, full phosphorylation of RSK was inhibited when oocytes were treated with U0126, a specific MAP kinase kinase inhibitor, in dose-dependent manner, indicating that RSK is one of the substrates of MAP kinase.	U 0126	86-91	ribosomal protein S6 kinase A2	Homo sapiens	175-178
11698409-7	2002	Activation of the Shc/mitogen-activated protein kinase pathway mediates the induction of MMP-9 in response to NGF, as this response is abrogated in cells expressing a mutant TrkA receptor that does not bind Shc and by pretreatment of cells with the MEK-1 inhibitor, U0126.	U 0126	266-271	matrix metallopeptidase 9	Rattus norvegicus	89-94
11698409-7	2002	Activation of the Shc/mitogen-activated protein kinase pathway mediates the induction of MMP-9 in response to NGF, as this response is abrogated in cells expressing a mutant TrkA receptor that does not bind Shc and by pretreatment of cells with the MEK-1 inhibitor, U0126.	U 0126	266-271	nerve growth factor	Rattus norvegicus	110-113
11698409-7	2002	Activation of the Shc/mitogen-activated protein kinase pathway mediates the induction of MMP-9 in response to NGF, as this response is abrogated in cells expressing a mutant TrkA receptor that does not bind Shc and by pretreatment of cells with the MEK-1 inhibitor, U0126.	U 0126	266-271	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	174-178
11777344-6	2002	Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2.	U 0126	49-54	mitogen-activated protein kinase kinase 7	Homo sapiens	33-36
11777344-6	2002	Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2.	U 0126	49-54	X-linked inhibitor of apoptosis	Homo sapiens	124-128
11777344-6	2002	Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2.	U 0126	49-54	colony stimulating factor 1 receptor	Homo sapiens	137-142
11777344-6	2002	Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2.	U 0126	49-54	BCL2 apoptosis regulator	Homo sapiens	218-223
11784793-4	2002	CFA also induced an upregulation of prodynorphin and neurokinin-1 (NK-1) in dorsal horn neurons, which was suppressed by intrathecal delivery of the MEK (MAP kinase kinase) inhibitor U0126.	U 0126	183-188	tachykinin precursor 1	Homo sapiens	67-71
11694531-9	2002	UV-induced cell apoptosis measured by DNA fragmentation and caspase 3 activation was enhanced by AG1478 and an ERK kinase inhibitor (U0126) but inhibited by EGF receptor stimulation by the agonist.	U 0126	133-138	caspase 3	Homo sapiens	60-69
11682465-9	2002	In addition, dominant negative Ras, Raf, and MEK1/2 could block the induction of hMMP1, and a MEK1/2-specific inhibitor (UO126) could block the induction of hMMP1 and c-Fos by BCP crystals.	U 0126	121-126	mitogen-activated protein kinase kinase 1	Homo sapiens	94-100
11682465-9	2002	In addition, dominant negative Ras, Raf, and MEK1/2 could block the induction of hMMP1, and a MEK1/2-specific inhibitor (UO126) could block the induction of hMMP1 and c-Fos by BCP crystals.	U 0126	121-126	matrix metallopeptidase 1	Homo sapiens	157-162
11682465-9	2002	In addition, dominant negative Ras, Raf, and MEK1/2 could block the induction of hMMP1, and a MEK1/2-specific inhibitor (UO126) could block the induction of hMMP1 and c-Fos by BCP crystals.	U 0126	121-126	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
11694531-9	2002	UV-induced cell apoptosis measured by DNA fragmentation and caspase 3 activation was enhanced by AG1478 and an ERK kinase inhibitor (U0126) but inhibited by EGF receptor stimulation by the agonist.	U 0126	133-138	mitogen-activated protein kinase 1	Homo sapiens	111-114
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	mitogen-activated protein kinase 3	Homo sapiens	0-6
11860736-11	2002	Both the VEGF-induced up-regulation of phospho-p42/p44 CCDPK and its anti-apoptotic action were prevented by the specific p42/p44 CCDPK inhibitor U0126.	U 0126	146-151	vascular endothelial growth factor A	Bos taurus	9-13
11860736-11	2002	Both the VEGF-induced up-regulation of phospho-p42/p44 CCDPK and its anti-apoptotic action were prevented by the specific p42/p44 CCDPK inhibitor U0126.	U 0126	146-151	erythrocyte membrane protein band 4.2	Bos taurus	47-50
11860736-11	2002	Both the VEGF-induced up-regulation of phospho-p42/p44 CCDPK and its anti-apoptotic action were prevented by the specific p42/p44 CCDPK inhibitor U0126.	U 0126	146-151	erythrocyte membrane protein band 4.2	Bos taurus	122-125
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	mitogen-activated protein kinase 3	Homo sapiens	153-159
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	mitogen-activated protein kinase 3	Homo sapiens	185-189
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	mitogen-activated protein kinase 1	Homo sapiens	286-289
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	mitogen-activated protein kinase 3	Homo sapiens	290-294
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	mitogen-activated protein kinase 3	Homo sapiens	153-159
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	transforming growth factor beta 1	Homo sapiens	415-424
12142035-5	2002	Delayed addition of 20microM U0126, an Mek (Erk kinase) inhibitor, also induced the switch.	U 0126	29-34	mitogen-activated protein kinase kinase 7	Homo sapiens	39-42
12142035-5	2002	Delayed addition of 20microM U0126, an Mek (Erk kinase) inhibitor, also induced the switch.	U 0126	29-34	mitogen-activated protein kinase 1	Homo sapiens	44-47
12794242-7	2002	In addition, treatment with the MEK inhibitors PD98059 or UO126 reduced PMA-mediated induction of Bad gene expression.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	32-35
12794242-8	2002	PMA also increased the expression of TRAIL receptors DR4 and DR5; this expression was inhibited by the PKC inhibitors GF109203x, Go6983, and Ro-31-8220 and the MEK inhibitor UO126, suggesting a role for conventional PKC isoforms and MEK in the regulation of TRAIL receptor expression.	U 0126	174-179	major histocompatibility complex, class II, DR beta 4	Homo sapiens	53-56
12794242-8	2002	PMA also increased the expression of TRAIL receptors DR4 and DR5; this expression was inhibited by the PKC inhibitors GF109203x, Go6983, and Ro-31-8220 and the MEK inhibitor UO126, suggesting a role for conventional PKC isoforms and MEK in the regulation of TRAIL receptor expression.	U 0126	174-179	TNF receptor superfamily member 10b	Homo sapiens	61-64
12794242-8	2002	PMA also increased the expression of TRAIL receptors DR4 and DR5; this expression was inhibited by the PKC inhibitors GF109203x, Go6983, and Ro-31-8220 and the MEK inhibitor UO126, suggesting a role for conventional PKC isoforms and MEK in the regulation of TRAIL receptor expression.	U 0126	174-179	mitogen-activated protein kinase kinase 7	Homo sapiens	160-163
11771655-10	2002	U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	36-73
11771655-10	2002	U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.	U 0126	0-5	bone morphogenetic protein 7	Mus musculus	96-101
11771655-10	2002	U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	215-252
11771655-10	2002	U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.	U 0126	0-5	mitogen-activated protein kinase 1	Mus musculus	254-257
11813263-5	2002	In contrast, PD98059 and U0126, inhibitors of upstream kinase of p44/p42 MAP kinase, markedly enhanced the BMP-4-stimulated osteocalcin synthesis.	U 0126	25-30	mitogen-activated protein kinase 3	Mus musculus	65-68
11813263-5	2002	In contrast, PD98059 and U0126, inhibitors of upstream kinase of p44/p42 MAP kinase, markedly enhanced the BMP-4-stimulated osteocalcin synthesis.	U 0126	25-30	erythrocyte membrane protein band 4.2	Mus musculus	69-72
11813263-5	2002	In contrast, PD98059 and U0126, inhibitors of upstream kinase of p44/p42 MAP kinase, markedly enhanced the BMP-4-stimulated osteocalcin synthesis.	U 0126	25-30	bone morphogenetic protein 4	Mus musculus	107-112
11813263-5	2002	In contrast, PD98059 and U0126, inhibitors of upstream kinase of p44/p42 MAP kinase, markedly enhanced the BMP-4-stimulated osteocalcin synthesis.	U 0126	25-30	bone gamma-carboxyglutamate protein 2	Mus musculus	124-135
11835393-6	2002	The alphavbeta6 correlated increase in HMW-uPA and pro-MMP secretion could be inhibited by tyrosine kinase inhibitor genistein or the MEK 1 inhibitor U0126, consistent with a role of active p42/44 MAPK in the elevation of uPA, MMP-9, and MMP-2 secretion.	U 0126	150-155	cilia and flagella associated protein 97	Homo sapiens	39-42
11835393-6	2002	The alphavbeta6 correlated increase in HMW-uPA and pro-MMP secretion could be inhibited by tyrosine kinase inhibitor genistein or the MEK 1 inhibitor U0126, consistent with a role of active p42/44 MAPK in the elevation of uPA, MMP-9, and MMP-2 secretion.	U 0126	150-155	plasminogen activator, urokinase	Homo sapiens	43-46
11835393-6	2002	The alphavbeta6 correlated increase in HMW-uPA and pro-MMP secretion could be inhibited by tyrosine kinase inhibitor genistein or the MEK 1 inhibitor U0126, consistent with a role of active p42/44 MAPK in the elevation of uPA, MMP-9, and MMP-2 secretion.	U 0126	150-155	mitogen-activated protein kinase kinase 1	Homo sapiens	134-139
11754081-3	2002	Surprisingly, the present results showed that outgrowth stimulation by neurotrophin-3 (NT-3), interacting with another neuronal subgroup, was markedly enhanced by PD98059 and also by U0126, another inhibitor of MAPK activation.	U 0126	183-188	neurotrophin 3	Mus musculus	71-85
11902114-7	2002	Treatment of striatal neurones with glutamate induced a rapid Ca2+-dependent and PI 3-kinase-dependent phosphorylation of Akt (Ser473), which was not blocked by the Mek inhibitors PD98059 or U0126.	U 0126	191-196	AKT serine/threonine kinase 1	Homo sapiens	122-125
11796740-5	2002	Blocking ERK1/2 activation with the upstream inhibitor U0126 (10 microm) enhanced H(2)O(2)-induced (100-300 microm range) neurotoxicity and inhibited H(2)O(2)-mediated phosphorylation of the cyclic AMP regulatory binding protein (CREB), suggesting that ERK1/2 signals to survival under these conditions.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	9-15
11796740-5	2002	Blocking ERK1/2 activation with the upstream inhibitor U0126 (10 microm) enhanced H(2)O(2)-induced (100-300 microm range) neurotoxicity and inhibited H(2)O(2)-mediated phosphorylation of the cyclic AMP regulatory binding protein (CREB), suggesting that ERK1/2 signals to survival under these conditions.	U 0126	55-60	cAMP responsive element binding protein 1	Homo sapiens	191-228
11796740-5	2002	Blocking ERK1/2 activation with the upstream inhibitor U0126 (10 microm) enhanced H(2)O(2)-induced (100-300 microm range) neurotoxicity and inhibited H(2)O(2)-mediated phosphorylation of the cyclic AMP regulatory binding protein (CREB), suggesting that ERK1/2 signals to survival under these conditions.	U 0126	55-60	cAMP responsive element binding protein 1	Homo sapiens	230-234
11902114-9	2002	Glutamate-induced phosphorylation of cAMP response element binding protein (CREB; Ser133) was partially blocked with either PD98059, U0126, LY294002 or wortmannin but was very strongly inhibited on co-application of LY294002 and PD98059.	U 0126	133-138	cAMP responsive element binding protein 1	Homo sapiens	37-74
11796740-5	2002	Blocking ERK1/2 activation with the upstream inhibitor U0126 (10 microm) enhanced H(2)O(2)-induced (100-300 microm range) neurotoxicity and inhibited H(2)O(2)-mediated phosphorylation of the cyclic AMP regulatory binding protein (CREB), suggesting that ERK1/2 signals to survival under these conditions.	U 0126	55-60	mitogen-activated protein kinase 3	Homo sapiens	253-259
11902114-9	2002	Glutamate-induced phosphorylation of cAMP response element binding protein (CREB; Ser133) was partially blocked with either PD98059, U0126, LY294002 or wortmannin but was very strongly inhibited on co-application of LY294002 and PD98059.	U 0126	133-138	cAMP responsive element binding protein 1	Homo sapiens	76-80
11750912-8	2002	PD098,029 and U0126 showed a small dose-dependent inhibitory effect on ionomycin-induced glutamate release, at concentrations shown to inhibit ionomycin-stimulated ERK phosphorylation.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	164-167
11687581-6	2001	15-d-PGJ2-induced expression of c-fos mRNA was blocked by PD98059 or U0126, two ERK kinase inhibitors, suggesting that the MEK/ERK pathway mediates 15-d-PGJ2-induced c-fos gene expression.	U 0126	69-74	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-37
11687581-6	2001	15-d-PGJ2-induced expression of c-fos mRNA was blocked by PD98059 or U0126, two ERK kinase inhibitors, suggesting that the MEK/ERK pathway mediates 15-d-PGJ2-induced c-fos gene expression.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	80-83
11687581-6	2001	15-d-PGJ2-induced expression of c-fos mRNA was blocked by PD98059 or U0126, two ERK kinase inhibitors, suggesting that the MEK/ERK pathway mediates 15-d-PGJ2-induced c-fos gene expression.	U 0126	69-74	mitogen-activated protein kinase kinase 7	Homo sapiens	123-126
11687581-6	2001	15-d-PGJ2-induced expression of c-fos mRNA was blocked by PD98059 or U0126, two ERK kinase inhibitors, suggesting that the MEK/ERK pathway mediates 15-d-PGJ2-induced c-fos gene expression.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	127-130
11687581-6	2001	15-d-PGJ2-induced expression of c-fos mRNA was blocked by PD98059 or U0126, two ERK kinase inhibitors, suggesting that the MEK/ERK pathway mediates 15-d-PGJ2-induced c-fos gene expression.	U 0126	69-74	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	166-171
11735115-4	2001	Using primary rat GCs from early antral follicles cultured in serum-free medium for 48 h, we found that the addition of a specific inhibitor of ERK1/2 activation, U0126, caused the attenuation or enhancement of FSH-induced progesterone or estradiol production, respectively, in a dose-dependent manner.	U 0126	163-168	mitogen activated protein kinase 3	Rattus norvegicus	144-150
11735115-6	2001	The addition of U0126 caused a decrease in the levels of phosphorylated but not unphosphorylated ERK1/2 which was maintained throughout the 48-h culture, suggesting that U0126 was continuously active to inhibit the phosphorylation of ERK1/2.	U 0126	16-21	mitogen-activated protein kinase 3	Homo sapiens	97-103
11735115-6	2001	The addition of U0126 caused a decrease in the levels of phosphorylated but not unphosphorylated ERK1/2 which was maintained throughout the 48-h culture, suggesting that U0126 was continuously active to inhibit the phosphorylation of ERK1/2.	U 0126	16-21	mitogen-activated protein kinase 3	Homo sapiens	234-240
11735115-6	2001	The addition of U0126 caused a decrease in the levels of phosphorylated but not unphosphorylated ERK1/2 which was maintained throughout the 48-h culture, suggesting that U0126 was continuously active to inhibit the phosphorylation of ERK1/2.	U 0126	170-175	mitogen-activated protein kinase 3	Homo sapiens	234-240
11641391-7	2001	In eight independent experiments approximately 45% of oocytes expressing FA-Rsk underwent germinal vesicle breakdown (GVBD, the G(2)/M transition) in the absence of progesterone, and this effect could be observed even in the presence of the MAPK kinase inhibitor U0126.	U 0126	263-268	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	76-79
11641391-9	2001	In oocytes that did not undergo GVBD with FA-Rsk expression, subsequent treatment with progesterone resulted in a very rapid rate of GVBD even in the presence of U0126 to inhibit the endogenous MAPK/Rsk pathway.	U 0126	162-167	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	199-202
11502738-10	2001	Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II.	U 0126	5-10	mitogen-activated protein kinase 1	Homo sapiens	32-36
11591711-7	2001	This activity was only partially reduced upon treatment of cells with the MKK1/2 inhibitor, U0126, indicating that in vivo the mechanism of ERK2 activation occurs substantially through autophosphorylation and partially through phosphorylation by MKK1/2.	U 0126	92-97	mitogen-activated protein kinase kinase 1	Homo sapiens	74-80
11591711-7	2001	This activity was only partially reduced upon treatment of cells with the MKK1/2 inhibitor, U0126, indicating that in vivo the mechanism of ERK2 activation occurs substantially through autophosphorylation and partially through phosphorylation by MKK1/2.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	140-144
11591711-7	2001	This activity was only partially reduced upon treatment of cells with the MKK1/2 inhibitor, U0126, indicating that in vivo the mechanism of ERK2 activation occurs substantially through autophosphorylation and partially through phosphorylation by MKK1/2.	U 0126	92-97	mitogen-activated protein kinase kinase 1	Homo sapiens	246-252
11742864-3	2001	Either PD98059 or U0126, selective inhibitors of ERK activation, did not influence IL-1beta-induced early activation but effectively reduced the prolonged activation of NF-kappaB and significantly reduced IL-1beta induction of iNOS.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	49-52
11742864-3	2001	Either PD98059 or U0126, selective inhibitors of ERK activation, did not influence IL-1beta-induced early activation but effectively reduced the prolonged activation of NF-kappaB and significantly reduced IL-1beta induction of iNOS.	U 0126	18-23	interleukin 1 beta	Rattus norvegicus	205-213
11742864-3	2001	Either PD98059 or U0126, selective inhibitors of ERK activation, did not influence IL-1beta-induced early activation but effectively reduced the prolonged activation of NF-kappaB and significantly reduced IL-1beta induction of iNOS.	U 0126	18-23	nitric oxide synthase 2	Rattus norvegicus	227-231
11746976-8	2001	Transcription regulation of BACH2 in BCR/ABL-positive cells was exerted via the MEK pathways, as shown by their responses to the U0126-specific inhibitor.	U 0126	129-134	BTB domain and CNC homolog 2	Homo sapiens	28-33
11746976-8	2001	Transcription regulation of BACH2 in BCR/ABL-positive cells was exerted via the MEK pathways, as shown by their responses to the U0126-specific inhibitor.	U 0126	129-134	BCR activator of RhoGEF and GTPase	Homo sapiens	37-40
11746976-8	2001	Transcription regulation of BACH2 in BCR/ABL-positive cells was exerted via the MEK pathways, as shown by their responses to the U0126-specific inhibitor.	U 0126	129-134	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	41-44
11746976-8	2001	Transcription regulation of BACH2 in BCR/ABL-positive cells was exerted via the MEK pathways, as shown by their responses to the U0126-specific inhibitor.	U 0126	129-134	mitogen-activated protein kinase kinase 7	Homo sapiens	80-83
11745456-9	2001	The specific MEK inhibitors PD098059 and U0126, which in turn suppress ERK, abolished 12(S)-HETE-stimulated proliferation.	U 0126	41-46	mitogen-activated protein kinase 1	Homo sapiens	71-74
12030372-4	2002	We observed that U0126, an inhibitor of MAPK kinase-ERK kinase 1/2 (MEK1/2), abolished the actions of these two agents on MAPK activation, suggesting that they act upstream of MEK1/2.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	68-74
12030372-4	2002	We observed that U0126, an inhibitor of MAPK kinase-ERK kinase 1/2 (MEK1/2), abolished the actions of these two agents on MAPK activation, suggesting that they act upstream of MEK1/2.	U 0126	17-22	mitogen-activated protein kinase 3	Homo sapiens	40-44
12030372-4	2002	We observed that U0126, an inhibitor of MAPK kinase-ERK kinase 1/2 (MEK1/2), abolished the actions of these two agents on MAPK activation, suggesting that they act upstream of MEK1/2.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	176-182
11720767-4	2001	Acute opioid treatment of HEK 293 cells expressing mu-opioid receptors resulted in the activation of ERK1/2, and this response was abolished in the presence of U0126, a MEK1/2 inhibitor.	U 0126	160-165	mitogen-activated protein kinase 3	Homo sapiens	101-107
11720767-4	2001	Acute opioid treatment of HEK 293 cells expressing mu-opioid receptors resulted in the activation of ERK1/2, and this response was abolished in the presence of U0126, a MEK1/2 inhibitor.	U 0126	160-165	mitogen-activated protein kinase kinase 1	Homo sapiens	169-175
11748143-4	2001	Subsequent blocking experiments using UO126 (a specific inhibitor of ERK activation) showed that activation of ERK is required for FGF-induced lens cell proliferation and fibre differentiation.	U 0126	38-43	mitogen-activated protein kinase 1	Homo sapiens	69-72
11748143-4	2001	Subsequent blocking experiments using UO126 (a specific inhibitor of ERK activation) showed that activation of ERK is required for FGF-induced lens cell proliferation and fibre differentiation.	U 0126	38-43	mitogen-activated protein kinase 1	Homo sapiens	111-114
11989653-1	2001	Effect of specific inhibitors of extracellular-signal regulated protein kinase (ERK) pathway, PD98059 and U0126, on P-glycoprotein (Pgp)-mediated vincristine resistance of L1210/VCR cells was investigated.	U 0126	106-111	phosphoglycolate phosphatase	Mus musculus	116-130
11989653-1	2001	Effect of specific inhibitors of extracellular-signal regulated protein kinase (ERK) pathway, PD98059 and U0126, on P-glycoprotein (Pgp)-mediated vincristine resistance of L1210/VCR cells was investigated.	U 0126	106-111	phosphoglycolate phosphatase	Mus musculus	132-135
11739023-5	2001	Pre-treatment of alpha T3-1 cells with the specific MAPK kinase (MEK) inhibitor, U0126, blocked PACAP and EGF-induced activation of ERK.	U 0126	81-86	midkine	Mus musculus	65-68
11739023-5	2001	Pre-treatment of alpha T3-1 cells with the specific MAPK kinase (MEK) inhibitor, U0126, blocked PACAP and EGF-induced activation of ERK.	U 0126	81-86	adenylate cyclase activating polypeptide 1	Mus musculus	96-101
11739023-5	2001	Pre-treatment of alpha T3-1 cells with the specific MAPK kinase (MEK) inhibitor, U0126, blocked PACAP and EGF-induced activation of ERK.	U 0126	81-86	mitogen-activated protein kinase 1	Mus musculus	132-135
11734574-3	2001	We stimulated the MAP kinase pathway with anti-CD3 antibodies and phorbol 12-myristate 13-acetate (PMA), which act upstream of the MAP kinase (MAPK)/ERK kinase (MEK) as U0126, an MEK inhibitor, abolished the actions of these two agents on MAP kinase activation.	U 0126	169-174	mitogen-activated protein kinase kinase 7	Homo sapiens	161-164
11746428-4	2001	The elevation of ROS was inhibited after incubation of the cells with the ERK-type of MAP kinases inhibitor U0126, the mitochondrial permeability transition pore inhibitor cyclosporin A (CSA), the antioxidant vitamin E, and the spin trap N-tert-butyl-alpha-(2-sulfophenyl)-nitrone (S-PBN).	U 0126	108-113	Eph receptor B1	Rattus norvegicus	74-77
11560921-6	2001	Under normal serum conditions, the addition of the MAPK inhibitor U0126 also caused cell death in alpha-synuclein-expressing cells.	U 0126	66-71	synuclein, alpha	Mus musculus	98-113
11571286-4	2001	Whereas U0126, a specific inhibitor of ERK kinase (MEK), completely abolished FGF2-induced ERK1/2 tyrosine phosphorylation and survival in cultured photoreceptors, persistent ERK1/2 phosphorylation was observed in cultured inner retinal cells and MGC.	U 0126	8-13	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
11571286-4	2001	Whereas U0126, a specific inhibitor of ERK kinase (MEK), completely abolished FGF2-induced ERK1/2 tyrosine phosphorylation and survival in cultured photoreceptors, persistent ERK1/2 phosphorylation was observed in cultured inner retinal cells and MGC.	U 0126	8-13	fibroblast growth factor 2	Homo sapiens	78-82
11571286-4	2001	Whereas U0126, a specific inhibitor of ERK kinase (MEK), completely abolished FGF2-induced ERK1/2 tyrosine phosphorylation and survival in cultured photoreceptors, persistent ERK1/2 phosphorylation was observed in cultured inner retinal cells and MGC.	U 0126	8-13	mitogen-activated protein kinase 3	Homo sapiens	91-97
11571286-5	2001	Furthermore U0126 treatment entirely blocked nerve growth factor-induced ERK1/2 activation in MGC, as well as FGF2-induced ERK1/2 activation in cerebral glial cells.	U 0126	12-17	mitogen-activated protein kinase 3	Homo sapiens	73-79
11571295-6	2001	However, using an inhibitor of ERK activation, U0126, we show that Alb-AGE stimulates VEGF expression through an ERK-dependent pathway.	U 0126	47-52	albumin	Mus musculus	67-70
11571295-6	2001	However, using an inhibitor of ERK activation, U0126, we show that Alb-AGE stimulates VEGF expression through an ERK-dependent pathway.	U 0126	47-52	vascular endothelial growth factor A	Mus musculus	86-90
11571295-6	2001	However, using an inhibitor of ERK activation, U0126, we show that Alb-AGE stimulates VEGF expression through an ERK-dependent pathway.	U 0126	47-52	mitogen-activated protein kinase 1	Mus musculus	113-116
11717164-6	2001	This was abolished by preincubation of HASMCs with a PI3-kinase inhibitor (LY294002, 50 micromol/L), and partially inhibited by a MEK1 inhibitor (U0126, 10 micromol/L), but not affected by a p38 kinase inhibitor (SB202190, 10 micromol/L).	U 0126	146-151	mitogen-activated protein kinase kinase 1	Homo sapiens	130-134
11717166-6	2001	Downstream of Ras, MEK1/2 and ERK1/2 are important in this pathway, as 2 inhibitors of MEK1/2, PD98059 and UO126, completely prevented this early increase in eNOS mRNA.	U 0126	107-112	mitogen-activated protein kinase kinase 1	Homo sapiens	19-25
11717166-6	2001	Downstream of Ras, MEK1/2 and ERK1/2 are important in this pathway, as 2 inhibitors of MEK1/2, PD98059 and UO126, completely prevented this early increase in eNOS mRNA.	U 0126	107-112	mitogen-activated protein kinase 3	Homo sapiens	30-36
11717166-6	2001	Downstream of Ras, MEK1/2 and ERK1/2 are important in this pathway, as 2 inhibitors of MEK1/2, PD98059 and UO126, completely prevented this early increase in eNOS mRNA.	U 0126	107-112	mitogen-activated protein kinase kinase 1	Homo sapiens	87-93
11717166-6	2001	Downstream of Ras, MEK1/2 and ERK1/2 are important in this pathway, as 2 inhibitors of MEK1/2, PD98059 and UO126, completely prevented this early increase in eNOS mRNA.	U 0126	107-112	nitric oxide synthase 3	Homo sapiens	158-162
11700037-5	2001	These changes were inhibited by U0126, an inhibitor of the extracellular signal-regulated kinase kinase (ERKK/MEK).	U 0126	32-37	mitogen-activated protein kinase kinase 7	Homo sapiens	110-113
11709198-1	2001	Complete inhibition of the potentiated toxicity by U0126 an ERK1/2 and p38 kinase inhibitor.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	60-66
11709198-1	2001	Complete inhibition of the potentiated toxicity by U0126 an ERK1/2 and p38 kinase inhibitor.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	71-74
11709198-9	2001	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), which inhibited activation of extracellular signal-regulated kinase1/2 and p38 kinase in cells under sulfur amino acid deprivation, completely prevented potentiation in Cd-induced cytotoxicity and apoptosis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	99-139
11709198-9	2001	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), which inhibited activation of extracellular signal-regulated kinase1/2 and p38 kinase in cells under sulfur amino acid deprivation, completely prevented potentiation in Cd-induced cytotoxicity and apoptosis.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	144-147
11709198-9	2001	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), which inhibited activation of extracellular signal-regulated kinase1/2 and p38 kinase in cells under sulfur amino acid deprivation, completely prevented potentiation in Cd-induced cytotoxicity and apoptosis.	U 0126	7-66	mitogen-activated protein kinase 1	Homo sapiens	99-139
11709198-9	2001	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), which inhibited activation of extracellular signal-regulated kinase1/2 and p38 kinase in cells under sulfur amino acid deprivation, completely prevented potentiation in Cd-induced cytotoxicity and apoptosis.	U 0126	7-66	mitogen-activated protein kinase 1	Homo sapiens	144-147
11522789-2	2001	Here we show that GPIb-IX-mediated activation of integrin alpha(IIb)beta(3) is inhibited by dominant negative mutants of Raf-1 and MEK1 in a reconstituted integrin activation model in Chinese hamster ovary (CHO) cells and that the integrin-dependent platelet aggregation induced by either vWF or low dose thrombin is inhibited by MEK inhibitors PD98059 and U0126.	U 0126	357-362	RAF proto-oncogene serine/threonine-protein kinase	Cricetulus griseus	121-126
11522789-2	2001	Here we show that GPIb-IX-mediated activation of integrin alpha(IIb)beta(3) is inhibited by dominant negative mutants of Raf-1 and MEK1 in a reconstituted integrin activation model in Chinese hamster ovary (CHO) cells and that the integrin-dependent platelet aggregation induced by either vWF or low dose thrombin is inhibited by MEK inhibitors PD98059 and U0126.	U 0126	357-362	dual specificity mitogen-activated protein kinase kinase 1	Cricetulus griseus	131-135
11527971-4	2001	In two antiestrogen-resistant cell lines that showed increased MAPK activation, inhibition of the MAPK kinase (MEK) by addition of U0126 changed p27 phosphorylation and restored p27 inhibitory function and sensitivity to antiestrogens.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
11527971-4	2001	In two antiestrogen-resistant cell lines that showed increased MAPK activation, inhibition of the MAPK kinase (MEK) by addition of U0126 changed p27 phosphorylation and restored p27 inhibitory function and sensitivity to antiestrogens.	U 0126	131-136	interferon alpha inducible protein 27	Homo sapiens	145-148
11527971-4	2001	In two antiestrogen-resistant cell lines that showed increased MAPK activation, inhibition of the MAPK kinase (MEK) by addition of U0126 changed p27 phosphorylation and restored p27 inhibitory function and sensitivity to antiestrogens.	U 0126	131-136	interferon alpha inducible protein 27	Homo sapiens	178-181
11640901-11	2001	Similarly, FBP"s protection was eliminated in the presence of the mitogen/extracellular signal protein kinase (MEK) inhibitor U0126.	U 0126	126-131	fructose-bisphosphatase 1	Homo sapiens	11-14
11668087-7	2001	Ischemia resulted in a 1.8-fold increase in NO generation that was suppressed by inhibitors of ERK1/2 activation (PD-98059 or U-0126).	U 0126	126-132	mitogen-activated protein kinase 3	Bos taurus	95-101
11713104-8	2001	The MAPK kinase1/2 (MEK1/2) inhibitor U0126 blocked MAPK and Egr-1 activation by bleomycin, suggesting that Egr-1 activation is MAPK dependent.	U 0126	38-43	mitogen-activated protein kinase kinase 1	Homo sapiens	20-26
11713104-8	2001	The MAPK kinase1/2 (MEK1/2) inhibitor U0126 blocked MAPK and Egr-1 activation by bleomycin, suggesting that Egr-1 activation is MAPK dependent.	U 0126	38-43	early growth response 1	Homo sapiens	61-66
11713104-8	2001	The MAPK kinase1/2 (MEK1/2) inhibitor U0126 blocked MAPK and Egr-1 activation by bleomycin, suggesting that Egr-1 activation is MAPK dependent.	U 0126	38-43	early growth response 1	Homo sapiens	108-113
11767000-6	2001	The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
11767000-6	2001	The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest.	U 0126	18-23	BCL2 apoptosis regulator	Homo sapiens	39-44
11767000-6	2001	The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest.	U 0126	18-20	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
11767000-6	2001	The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest.	U 0126	18-20	BCL2 apoptosis regulator	Homo sapiens	39-44
11640885-7	2001	The MEK selective inhibitor U0126 and the phosphatidyl-inositol-3 kinase (PI3K) inhibitor LY294002 inhibited migrating neo cells and were able to further inhibit residual dnPKA cell migration.	U 0126	28-33	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
11697801-5	2001	Osteoblast proliferation induced by all BPs diminished to control levels in the presence of U0126, a specific inhibitor of the upstream kinase MEK 1 responsible for ERK phosphorylation.	U 0126	92-97	mitogen activated protein kinase kinase 1	Rattus norvegicus	143-148
11697801-5	2001	Osteoblast proliferation induced by all BPs diminished to control levels in the presence of U0126, a specific inhibitor of the upstream kinase MEK 1 responsible for ERK phosphorylation.	U 0126	92-97	Eph receptor B1	Rattus norvegicus	165-168
11701758-9	2001	Cytotoxicity was also attenuated by MEK inhibition with PD98059 or U0126 at concentrations that were sufficient to prevent ERK activation.	U 0126	67-72	midkine	Mus musculus	36-39
11701758-9	2001	Cytotoxicity was also attenuated by MEK inhibition with PD98059 or U0126 at concentrations that were sufficient to prevent ERK activation.	U 0126	67-72	mitogen-activated protein kinase 1	Mus musculus	123-126
11585926-6	2001	Phosphorylation of serine 105 enhanced the transcriptional potency of GATA4, which was sensitive to U0126 (MEK1 inhibitor) but not SB202190 (p38 inhibitor).	U 0126	100-105	GATA binding protein 4	Homo sapiens	70-75
11585926-6	2001	Phosphorylation of serine 105 enhanced the transcriptional potency of GATA4, which was sensitive to U0126 (MEK1 inhibitor) but not SB202190 (p38 inhibitor).	U 0126	100-105	mitogen-activated protein kinase kinase 1	Homo sapiens	107-111
11710832-5	2001	Inhibition of the ERK1/2 MAP kinase pathway using UO126 or PD098059 re-sensitised the Taxol resistant cells at least 20-fold.	U 0126	50-55	mitogen-activated protein kinase 3	Homo sapiens	18-24
11739023-7	2001	However, pre-treatment with U0126 significantly inhibited PACAP stimulation of [(3)H]-thymidine incorporation in alpha T3-1 cells.	U 0126	28-33	adenylate cyclase activating polypeptide 1	Mus musculus	58-63
11502738-10	2001	Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II.	U 0126	5-10	mitogen-activated protein kinase 1	Homo sapiens	37-40
11502738-10	2001	Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II.	U 0126	5-10	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
11502738-10	2001	Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II.	U 0126	5-10	early growth response 1	Homo sapiens	101-106
11502738-10	2001	Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II.	U 0126	5-10	early growth response 1	Homo sapiens	133-138
11502738-10	2001	Both U0126 (an inhibitor of the MAPK/ERK kinase MEK) and wortmannin (an inhibitor of PI3K) abrogated Egr-1 endogenous expression and Egr-1 promoter activity induced by Ang II.	U 0126	5-10	angiotensinogen	Homo sapiens	168-174
11546664-4	2001	The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation.	U 0126	82-88	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
11489882-9	2001	An indication of the possible involvement of the mitogen-activated protein kinase (MAPK) pathway in Rac1-mediated myoblast proliferation was obtained by the use of MAPK kinase inhibitors U0126 and PD098059.	U 0126	187-192	Rac family small GTPase 1	Homo sapiens	100-104
11709700-6	2001	We show that IL-4 or IL-13-induced IL-13Ralpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580.	U 0126	99-104	interleukin 4	Homo sapiens	13-17
11709700-6	2001	We show that IL-4 or IL-13-induced IL-13Ralpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580.	U 0126	99-104	interleukin 13	Homo sapiens	21-26
11709700-6	2001	We show that IL-4 or IL-13-induced IL-13Ralpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580.	U 0126	99-104	interleukin 13 receptor subunit alpha 2	Homo sapiens	35-47
11709700-6	2001	We show that IL-4 or IL-13-induced IL-13Ralpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580.	U 0126	99-104	mitogen-activated protein kinase 1	Homo sapiens	85-88
11546664-4	2001	The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation.	U 0126	82-88	interleukin 1 alpha	Homo sapiens	98-108
11546664-4	2001	The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation.	U 0126	82-88	mitogen-activated protein kinase 3	Homo sapiens	117-120
11546664-4	2001	The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation.	U 0126	82-88	phospholipase A2 group IVA	Homo sapiens	157-169
11546664-4	2001	The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation.	U 0126	82-88	mitogen-activated protein kinase 1	Homo sapiens	222-225
11546664-4	2001	The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation.	U 0126	82-88	phospholipase A2 group IVA	Homo sapiens	271-283
11567984-3	2001	Evidence is provided, using a dominant-negative N17 H-Ras protein (dn-H-Ras) and MEK inhibitor U0126, that activation of the Ras-Raf-MEK-ERK pathway plays a determining role in the prolongation of eosinophil survival by IL-5.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84
11566022-9	2001	Exposure to HOCl caused a loss of viability in HUVEC that was markedly enhanced when ERK1/2 activation was inhibited by U0126.	U 0126	120-125	mitogen-activated protein kinase 3	Homo sapiens	85-91
11567984-3	2001	Evidence is provided, using a dominant-negative N17 H-Ras protein (dn-H-Ras) and MEK inhibitor U0126, that activation of the Ras-Raf-MEK-ERK pathway plays a determining role in the prolongation of eosinophil survival by IL-5.	U 0126	95-100	zinc fingers and homeoboxes 2	Homo sapiens	129-132
11567984-3	2001	Evidence is provided, using a dominant-negative N17 H-Ras protein (dn-H-Ras) and MEK inhibitor U0126, that activation of the Ras-Raf-MEK-ERK pathway plays a determining role in the prolongation of eosinophil survival by IL-5.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	133-136
11567984-3	2001	Evidence is provided, using a dominant-negative N17 H-Ras protein (dn-H-Ras) and MEK inhibitor U0126, that activation of the Ras-Raf-MEK-ERK pathway plays a determining role in the prolongation of eosinophil survival by IL-5.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	137-140
11568005-4	2001	This study found that in the presence of the mitogen-activated protein kinase kinase 1-extracellular signal-regulated kinase (ERK) inhibitors PD98059 or U0126, TNF-alpha- and LPS-induced phenotypic and functional maturation is enhanced.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	126-129
11568005-4	2001	This study found that in the presence of the mitogen-activated protein kinase kinase 1-extracellular signal-regulated kinase (ERK) inhibitors PD98059 or U0126, TNF-alpha- and LPS-induced phenotypic and functional maturation is enhanced.	U 0126	153-158	tumor necrosis factor	Homo sapiens	160-169
11568005-7	2001	In agreement with the effect of ERK inhibitors, maturation of MDDC was delayed in the presence of serum, an effect that was reversed by U0126.	U 0126	136-141	mitogen-activated protein kinase 1	Homo sapiens	32-35
11562428-9	2001	Furthermore, PD-98059 and U0126, two MAPK inhibitors, blocked PLC-gamma 1-induced expression of MDR1.	U 0126	26-31	phospholipase C gamma 1	Homo sapiens	62-73
11576169-4	2001	The increase in ERK activity was reduced by treatment with an FGF receptor 1 inhibitor, SU5402, and a MEK (ERK kinase/MAPKK) inhibitor, U0126.	U 0126	136-141	mitogen-activated protein kinase 1	Homo sapiens	16-19
11576169-4	2001	The increase in ERK activity was reduced by treatment with an FGF receptor 1 inhibitor, SU5402, and a MEK (ERK kinase/MAPKK) inhibitor, U0126.	U 0126	136-141	mitogen-activated protein kinase kinase 7	Homo sapiens	102-105
11576169-4	2001	The increase in ERK activity was reduced by treatment with an FGF receptor 1 inhibitor, SU5402, and a MEK (ERK kinase/MAPKK) inhibitor, U0126.	U 0126	136-141	mitogen-activated protein kinase 1	Homo sapiens	107-110
11595754-7	2001	Amitriptyline-induced GDNF release was inhibited by U0126 (10 microM), a mitogen-activated protein kinase (MAPK)-extracellular signal-related kinase (ERK) kinase (MEK) inhibitor, but was not inhibited by H-89 (1 microM), a protein kinase A inhibitor, calphostin C (100 nM), a protein kinase C inhibitor and PD 169316 (10 microM), a p38 mitogen-activated protein kinase inhibitor.	U 0126	52-57	glial cell derived neurotrophic factor	Rattus norvegicus	22-26
11595754-7	2001	Amitriptyline-induced GDNF release was inhibited by U0126 (10 microM), a mitogen-activated protein kinase (MAPK)-extracellular signal-related kinase (ERK) kinase (MEK) inhibitor, but was not inhibited by H-89 (1 microM), a protein kinase A inhibitor, calphostin C (100 nM), a protein kinase C inhibitor and PD 169316 (10 microM), a p38 mitogen-activated protein kinase inhibitor.	U 0126	52-57	mitogen activated protein kinase 14	Rattus norvegicus	332-368
11544480-8	2001	Neutralizing antibodies to PDGFRA blocks MAP2K1, MAP2K2 and MAPK1/3 phosphorylation, whereas U0126, a highly specific inhibitor of MAP2K1 and MAP2K2, also blocks MAPK1/3.	U 0126	93-98	mitogen-activated protein kinase kinase 1	Homo sapiens	131-137
11544480-8	2001	Neutralizing antibodies to PDGFRA blocks MAP2K1, MAP2K2 and MAPK1/3 phosphorylation, whereas U0126, a highly specific inhibitor of MAP2K1 and MAP2K2, also blocks MAPK1/3.	U 0126	93-98	mitogen-activated protein kinase kinase 2	Homo sapiens	142-148
11562428-9	2001	Furthermore, PD-98059 and U0126, two MAPK inhibitors, blocked PLC-gamma 1-induced expression of MDR1.	U 0126	26-31	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
11549284-3	2001	When cells expressing H-Ras(V12) were treated with mitogen activated protein kinase (MAPK) kinase inhibitors (U0126, PD98059), suppression of rNLRR-3 mRNA correlated well with a reduction in MAPK activity.	U 0126	110-115	leucine rich repeat neuronal 3	Rattus norvegicus	142-149
11504919-7	2001	administration of U0126 (100-200 mg/kg), a specific inhibitor of MEK (MAPK/ERK kinase), protects the hippocampus against forebrain ischemia.	U 0126	18-23	mitogen-activated protein kinase 1	Mus musculus	75-78
11549284-5	2001	U0126 completely suppressed the induction by EGF of rNLRR-3 mRNA with abrogation of MAPK phosphorylation.	U 0126	0-5	epidermal growth factor like 1	Rattus norvegicus	45-48
11549284-5	2001	U0126 completely suppressed the induction by EGF of rNLRR-3 mRNA with abrogation of MAPK phosphorylation.	U 0126	0-5	leucine rich repeat neuronal 3	Rattus norvegicus	52-59
11549284-6	2001	U0126 inhibited the basal transcription of rNLRR-3.	U 0126	0-5	leucine rich repeat neuronal 3	Rattus norvegicus	43-50
11527418-4	2001	PD98059 and U0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly enhanced the T(3)-induced alkaline phosphatase activity in a dose-dependent manner.	U 0126	12-17	mitogen-activated protein kinase 3	Mus musculus	68-71
11527401-2	2001	Coadministration of subtoxic concentrations of the MEK1/2 inhibitors U0126 (20 microM), PD98059 (40 microM), or PD184352 (10 microM) with 10-100 microM ara-C (6 h) potentiated apoptosis (i.e., by approx twofold), and pro-caspase 3, pro-caspase 8, Bid, and PARP cleavage.	U 0126	69-74	mitogen-activated protein kinase kinase 1	Homo sapiens	51-57
11593397-5	2001	Moreover, both expression of dominant-negative MEK1 and treatment of cells with U0126, a MEK1 inhibitor, restored the cell spreading of v-Crk3Y1.	U 0126	80-85	mitogen-activated protein kinase kinase 1	Homo sapiens	47-51
11593397-5	2001	Moreover, both expression of dominant-negative MEK1 and treatment of cells with U0126, a MEK1 inhibitor, restored the cell spreading of v-Crk3Y1.	U 0126	80-85	mitogen-activated protein kinase kinase 1	Homo sapiens	89-93
11504687-6	2001	Pretreatment of cells with the extracellular signal-regulated kinase inhibitor U-0126 partially blocked HIF-1 alpha protein and PAI-1 mRNA levels induced by nickel, whereas antioxidants and NADPH oxidase inhibitors had no effect.	U 0126	79-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	104-115
11504687-6	2001	Pretreatment of cells with the extracellular signal-regulated kinase inhibitor U-0126 partially blocked HIF-1 alpha protein and PAI-1 mRNA levels induced by nickel, whereas antioxidants and NADPH oxidase inhibitors had no effect.	U 0126	79-85	serpin family E member 1	Homo sapiens	128-133
11531942-8	2001	Secretion of IL-8 by C1q-IC stimulated HUVEC was completely blocked by the PTK inhibitor, genistein or the MAPK inhibitor, UO126.	U 0126	123-128	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
11531942-8	2001	Secretion of IL-8 by C1q-IC stimulated HUVEC was completely blocked by the PTK inhibitor, genistein or the MAPK inhibitor, UO126.	U 0126	123-128	complement C1q A chain	Homo sapiens	21-24
11527418-4	2001	PD98059 and U0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly enhanced the T(3)-induced alkaline phosphatase activity in a dose-dependent manner.	U 0126	12-17	cyclin-dependent kinase 20	Mus musculus	72-75
11527418-5	2001	The phosphorylation of p44/p42 MAP kinase induced by T(3) was reduced by U0126.	U 0126	73-78	mitogen-activated protein kinase 3	Mus musculus	23-26
11527418-5	2001	The phosphorylation of p44/p42 MAP kinase induced by T(3) was reduced by U0126.	U 0126	73-78	cyclin-dependent kinase 20	Mus musculus	27-30
11323435-5	2001	Pre-incubation with the ERK1/2 inhibitor U0126 or expression of a dominant negative MEK-1 abolished the effect of IGF-1 on Twist mRNA expression in NWTb3 cells, suggesting that Twist induction by IGF-1 occurs via the mitogen-activated protein kinase signaling pathway.	U 0126	41-46	mitogen-activated protein kinase 3	Homo sapiens	24-30
11511524-8	2001	The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor.	U 0126	231-236	early growth response 1	Mus musculus	34-39
11511524-8	2001	The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor.	U 0126	231-236	mitogen-activated protein kinase kinase 1	Mus musculus	53-94
11511524-8	2001	The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor.	U 0126	231-236	mitogen-activated protein kinase 3	Mus musculus	106-152
11511524-8	2001	The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor.	U 0126	231-236	mitogen-activated protein kinase 3	Mus musculus	154-160
11564986-8	2001	PI3-kinase activity, IRS-1-associated tyrosine phosphorylation and p85 subunit of PI3-kinase in VSMC from WKY rats decreased in response to treatment with Ang II and returned to control levels upon co-treatment with U0126.	U 0126	216-221	angiotensinogen	Rattus norvegicus	155-161
11410588-3	2001	Compared with cells in attached matrices, cells in floating or released matrices showed down-regulation of cyclin D1 and up-regulation of p27(Kip1) cyclin-dependent kinase inhibitor, and similar changes occurred after the ERK signaling pathway was blocked by UO126 in cells in attached matrices.	U 0126	259-264	cyclin dependent kinase inhibitor 1B	Homo sapiens	142-146
11410588-3	2001	Compared with cells in attached matrices, cells in floating or released matrices showed down-regulation of cyclin D1 and up-regulation of p27(Kip1) cyclin-dependent kinase inhibitor, and similar changes occurred after the ERK signaling pathway was blocked by UO126 in cells in attached matrices.	U 0126	259-264	mitogen-activated protein kinase 1	Homo sapiens	222-225
11485974-9	2001	In addition, PD98059 and U0126, which are two distinct inhibitors of upstream MAPK kinase 1/2 (MEK1/2), abolished the mitogenic effect of C pneumoniae and chlamydial hsp60.	U 0126	25-30	mitogen-activated protein kinase kinase 1	Homo sapiens	95-101
11485974-9	2001	In addition, PD98059 and U0126, which are two distinct inhibitors of upstream MAPK kinase 1/2 (MEK1/2), abolished the mitogenic effect of C pneumoniae and chlamydial hsp60.	U 0126	25-30	heat shock protein family D (Hsp60) member 1	Homo sapiens	166-171
11434901-3	2001	In the present study, we have demonstrated that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a potent and selective inhibitor of the p44/42 MAP kinase signaling pathway, prevents glutamate-induced death in neuronally differentiated P19 cells.	U 0126	48-107	interferon induced protein 44	Homo sapiens	157-160
11434901-3	2001	In the present study, we have demonstrated that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a potent and selective inhibitor of the p44/42 MAP kinase signaling pathway, prevents glutamate-induced death in neuronally differentiated P19 cells.	U 0126	48-107	cyclin dependent kinase inhibitor 2D	Homo sapiens	256-259
11434901-3	2001	In the present study, we have demonstrated that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a potent and selective inhibitor of the p44/42 MAP kinase signaling pathway, prevents glutamate-induced death in neuronally differentiated P19 cells.	U 0126	109-114	interferon induced protein 44	Homo sapiens	157-160
11434901-3	2001	In the present study, we have demonstrated that 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), a potent and selective inhibitor of the p44/42 MAP kinase signaling pathway, prevents glutamate-induced death in neuronally differentiated P19 cells.	U 0126	109-114	cyclin dependent kinase inhibitor 2D	Homo sapiens	256-259
11434901-5	2001	Differentiated P19 cells exhibited specific NMDA receptor binding and intracellular calcium responses to glutamate that were blocked by the selective NMDA receptor antagonist [5R,10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), but not U0126.	U 0126	267-272	cyclin dependent kinase inhibitor 2D	Homo sapiens	15-18
11434901-6	2001	Glutamate treatment of differentiated P19 cells triggered a rapid and sustained induction in p42 MAP kinase phosphorylation that was blocked by U0126.	U 0126	144-149	cyclin dependent kinase inhibitor 2D	Homo sapiens	38-41
11434901-6	2001	Glutamate treatment of differentiated P19 cells triggered a rapid and sustained induction in p42 MAP kinase phosphorylation that was blocked by U0126.	U 0126	144-149	cyclin dependent kinase 20	Homo sapiens	93-96
11434901-7	2001	Pretreatment of differentiated P19 cells with U0126, but not other classes of protein kinase inhibitors, protected against glutamate-induced cell death.	U 0126	46-51	cyclin dependent kinase inhibitor 2D	Homo sapiens	31-34
11683414-9	2001	Treatment with PD98059 or U0126 also abrogated the inhibitory action of the AhR on adipogenesis.	U 0126	26-31	aryl-hydrocarbon receptor	Mus musculus	76-79
11483651-3	2001	The inhibitors of mitogen-activated protein kinase kinase 1/2 (MEK1/2) activation, PD98059 (0.1-50 microM) and UO126 (0.1-10 microM), dose-dependently inhibited both ERK2 and Ser31 phosphorylation on TOH in response to AII, suggesting MEK1/2 involvement.	U 0126	111-116	mitogen-activated protein kinase kinase 1	Bos taurus	18-61
11483651-3	2001	The inhibitors of mitogen-activated protein kinase kinase 1/2 (MEK1/2) activation, PD98059 (0.1-50 microM) and UO126 (0.1-10 microM), dose-dependently inhibited both ERK2 and Ser31 phosphorylation on TOH in response to AII, suggesting MEK1/2 involvement.	U 0126	111-116	mitogen-activated protein kinase 1	Bos taurus	166-170
11592732-4	2001	PMA acts upstream of MEK and via activation of protein kinase C (PKC), as GF109203X, a potent PKC inhibitor, and U0126, a MEK inhibitor, abolished its actions on ERK1/ERK2 phosphorylation.	U 0126	113-118	midkine	Mus musculus	21-24
11592732-4	2001	PMA acts upstream of MEK and via activation of protein kinase C (PKC), as GF109203X, a potent PKC inhibitor, and U0126, a MEK inhibitor, abolished its actions on ERK1/ERK2 phosphorylation.	U 0126	113-118	midkine	Mus musculus	122-125
11592732-4	2001	PMA acts upstream of MEK and via activation of protein kinase C (PKC), as GF109203X, a potent PKC inhibitor, and U0126, a MEK inhibitor, abolished its actions on ERK1/ERK2 phosphorylation.	U 0126	113-118	mitogen-activated protein kinase 3	Mus musculus	162-166
11592732-4	2001	PMA acts upstream of MEK and via activation of protein kinase C (PKC), as GF109203X, a potent PKC inhibitor, and U0126, a MEK inhibitor, abolished its actions on ERK1/ERK2 phosphorylation.	U 0126	113-118	mitogen-activated protein kinase 1	Mus musculus	167-171
11518769-9	2001	The MEK inhibitors PD 98059 and U0126 blocked ERK1/2 activation but did not diminish survival.	U 0126	32-37	mitogen-activated protein kinase 3	Mus musculus	46-52
11564986-10	2001	U0126 treatment of VSMC from SHR significantly increased levels of PI3-kinase activity, IRS-1-associated tyrosine phosphorylation, and p85 subunit of PI3-kinase.	U 0126	0-5	insulin receptor substrate 1	Rattus norvegicus	88-93
11485567-9	2001	With the use of UO126, a specific inhibitor of the mitogen-activated protein kinase (MAPK) pathway, we show that the PMA-induced IL-6Ralpha shedding is mediated in part by the MAPK pathway.	U 0126	16-21	mitogen-activated protein kinase 3	Homo sapiens	85-89
11485567-9	2001	With the use of UO126, a specific inhibitor of the mitogen-activated protein kinase (MAPK) pathway, we show that the PMA-induced IL-6Ralpha shedding is mediated in part by the MAPK pathway.	U 0126	16-21	interleukin 6 receptor	Homo sapiens	129-139
11485567-9	2001	With the use of UO126, a specific inhibitor of the mitogen-activated protein kinase (MAPK) pathway, we show that the PMA-induced IL-6Ralpha shedding is mediated in part by the MAPK pathway.	U 0126	16-21	mitogen-activated protein kinase 3	Homo sapiens	176-180
11478855-0	2001	Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by "MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells.	U 0126	109-114	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	19-24
11478855-0	2001	Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by "MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells.	U 0126	109-114	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
11443060-7	2001	Basal APLP2 shedding as well as that induced by PMA and EGF was blocked by a mitogen-activated protein kinase (MAPK) kinase inhibitor, U-0126.	U 0126	135-141	amyloid beta precursor like protein 2	Homo sapiens	6-11
11443060-7	2001	Basal APLP2 shedding as well as that induced by PMA and EGF was blocked by a mitogen-activated protein kinase (MAPK) kinase inhibitor, U-0126.	U 0126	135-141	epidermal growth factor	Homo sapiens	56-59
11466201-4	2001	MAP kinase kinase (MAPKK, MEK) inhibitor, PD98059 or U0126, produced a dose-dependent inhibitory effect on both FSH-induced oocyte meiotic resumption and MAP kinase activation in the oocytes.	U 0126	53-58	midkine	Mus musculus	26-29
11466212-1	2001	In this study, the effects of U0126 that inhibits the activity of mitogen-activated protein (MAP) kinase kinase (MEK), and LY294002, which is a phosphatidylinositol (PI) 3-kinase inhibitor, on meiotic progression beyond the metaphase I (MI) stage in porcine oocytes were examined.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	113-116
11466212-4	2001	In the denuded oocytes, U0126 suppressed MAP kinase activity, p34(cdc2) kinase activity, and meiotic progression to the MII stage; however, LY294002 did not significantly affect the activity of these kinases and meiotic progression.	U 0126	24-29	leucine rich repeat containing 59	Homo sapiens	62-65
11466212-4	2001	In the denuded oocytes, U0126 suppressed MAP kinase activity, p34(cdc2) kinase activity, and meiotic progression to the MII stage; however, LY294002 did not significantly affect the activity of these kinases and meiotic progression.	U 0126	24-29	cyclin dependent kinase 1	Homo sapiens	66-70
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	cyclin dependent kinase 20	Homo sapiens	54-57
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	interferon induced protein 44	Homo sapiens	58-61
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	mitogen-activated protein kinase 1	Homo sapiens	62-65
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	AKT serine/threonine kinase 1	Homo sapiens	71-74
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	hepatocyte growth factor	Homo sapiens	112-115
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	C-X-C motif chemokine ligand 8	Homo sapiens	138-142
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	vascular endothelial growth factor A	Homo sapiens	147-151
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	C-X-C motif chemokine ligand 8	Homo sapiens	234-238
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	19-24	vascular endothelial growth factor A	Homo sapiens	243-247
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	180-185	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
11479233-9	2001	Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A.	U 0126	180-185	hepatocyte growth factor	Homo sapiens	112-115
11483666-5	2001	Even though U0126 and PD98059 are both MEK inhibitors, we find that U0126, but not PD98059, blocks induction of nNOS protein and NOS activity in NGF-treated PC12 cells.	U 0126	68-73	nitric oxide synthase 1	Rattus norvegicus	112-116
11483666-8	2001	We find that U0126 is much more effective than PD98059 in blocking the Ras-ERK pathway, thereby explaining the discrepancy in nNOS inhibition.	U 0126	13-18	nitric oxide synthase 1	Rattus norvegicus	126-130
11454948-3	2001	In the present study, we examined the effects of PD098059 and U0126, two structurally dissimilar inhibitors of MAP kinase kinase (MEK1/2), on the activation of ERK and Akt stimulated by human 5-hydroxytryptamine(1B) (serotonin) (5-HT1B) receptors.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	160-163
11454948-3	2001	In the present study, we examined the effects of PD098059 and U0126, two structurally dissimilar inhibitors of MAP kinase kinase (MEK1/2), on the activation of ERK and Akt stimulated by human 5-hydroxytryptamine(1B) (serotonin) (5-HT1B) receptors.	U 0126	62-67	AKT serine/threonine kinase 1	Homo sapiens	168-171
11454948-9	2001	Nevertheless, our findings that PD098059 and U0126 inhibit activation of Akt at commonly used concentrations demonstrate that in at least some systems, these compounds inhibit activation of both ERK and Akt, and cannot be used to discern the relative roles of each pathway in mediating cellular responses.	U 0126	45-50	AKT serine/threonine kinase 1	Homo sapiens	73-76
11454948-9	2001	Nevertheless, our findings that PD098059 and U0126 inhibit activation of Akt at commonly used concentrations demonstrate that in at least some systems, these compounds inhibit activation of both ERK and Akt, and cannot be used to discern the relative roles of each pathway in mediating cellular responses.	U 0126	45-50	mitogen-activated protein kinase 1	Homo sapiens	195-198
11454948-9	2001	Nevertheless, our findings that PD098059 and U0126 inhibit activation of Akt at commonly used concentrations demonstrate that in at least some systems, these compounds inhibit activation of both ERK and Akt, and cannot be used to discern the relative roles of each pathway in mediating cellular responses.	U 0126	45-50	AKT serine/threonine kinase 1	Homo sapiens	203-206
11455016-8	2001	We evaluated the nature of the interaction between paclitaxel and the MAPK kinase inhibitor U0126 in three cell lines, on the basis of a potential chemotherapeutic advantage of paclitaxel plus ERK inhibition.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	70-74
11455016-8	2001	We evaluated the nature of the interaction between paclitaxel and the MAPK kinase inhibitor U0126 in three cell lines, on the basis of a potential chemotherapeutic advantage of paclitaxel plus ERK inhibition.	U 0126	92-97	mitogen-activated protein kinase 1	Homo sapiens	193-196
11463858-8	2001	Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERalpha.	U 0126	79-84	zinc fingers and homeoboxes 2	Homo sapiens	14-17
11463858-8	2001	Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERalpha.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
11463858-8	2001	Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERalpha.	U 0126	79-84	estrogen receptor 1	Homo sapiens	113-120
11478941-2	2001	The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required.	U 0126	10-15	mitogen-activated protein kinase kinase 1	Homo sapiens	62-66
11478941-2	2001	The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required.	U 0126	10-15	mitogen-activated protein kinase 3	Homo sapiens	96-100
11478941-2	2001	The drugs U0126 and PD184352, which prevent the activation of MKK1 (and hence the activation of ERK1/ERK2), also prevent the activation of MKK5, although higher concentrations are required.	U 0126	10-15	mitogen-activated protein kinase 1	Homo sapiens	101-105
11337508-8	2001	Inhibition of the MEK-ERK pathway with U0126 or reduction in the expression of endogenous ERK with an antisense oligonucleotide to ERK significantly inhibited sodium butyrate- and HC toxin-induced transcription but had no effect on trichostatin A-induced transcription.	U 0126	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
11337508-8	2001	Inhibition of the MEK-ERK pathway with U0126 or reduction in the expression of endogenous ERK with an antisense oligonucleotide to ERK significantly inhibited sodium butyrate- and HC toxin-induced transcription but had no effect on trichostatin A-induced transcription.	U 0126	39-44	mitogen-activated protein kinase 1	Homo sapiens	22-25
11337508-10	2001	In cells in which sodium butyrate induction of promoter activation had been inhibited by various concentrations of U0126, constitutively activated ERK2 reversed this inhibition.	U 0126	115-120	mitogen-activated protein kinase 1	Homo sapiens	147-151
11323435-5	2001	Pre-incubation with the ERK1/2 inhibitor U0126 or expression of a dominant negative MEK-1 abolished the effect of IGF-1 on Twist mRNA expression in NWTb3 cells, suggesting that Twist induction by IGF-1 occurs via the mitogen-activated protein kinase signaling pathway.	U 0126	41-46	insulin like growth factor 1	Homo sapiens	114-119
11399647-7	2001	Inhibition of ERK activation with U0126 completely blocked the HGF-dependent reversal of ATP-depleted cell adhesion.	U 0126	34-39	mitogen-activated protein kinase 1	Mus musculus	14-17
11399647-7	2001	Inhibition of ERK activation with U0126 completely blocked the HGF-dependent reversal of ATP-depleted cell adhesion.	U 0126	34-39	hepatocyte growth factor	Mus musculus	63-66
11404249-4	2001	Analysis of total RNA and protein showed a 1.5-fold increase in the Na-K-ATPase beta1-subunit mRNA levels and up to a fivefold increase in beta1-subunit protein abundance after DA stimulation, which was blocked by the MAPK kinase (MEK) inhibitors PD-98059 and U-0126.	U 0126	260-266	mitogen-activated protein kinase 1	Homo sapiens	218-222
11404258-6	2001	Downregulation of NPR-C expression by FGF-1, FGF-2, and PDGF-BB was inhibited by the selective FGF-1 receptor tyrosine kinase inhibitor PD-166866 and mitogen-activated protein/extracellular signal-regulated kinase inhibitors U-0126 and PD-98059.	U 0126	225-231	natriuretic peptide receptor 3	Rattus norvegicus	18-23
11404258-6	2001	Downregulation of NPR-C expression by FGF-1, FGF-2, and PDGF-BB was inhibited by the selective FGF-1 receptor tyrosine kinase inhibitor PD-166866 and mitogen-activated protein/extracellular signal-regulated kinase inhibitors U-0126 and PD-98059.	U 0126	225-231	fibroblast growth factor 1	Rattus norvegicus	38-43
11404258-6	2001	Downregulation of NPR-C expression by FGF-1, FGF-2, and PDGF-BB was inhibited by the selective FGF-1 receptor tyrosine kinase inhibitor PD-166866 and mitogen-activated protein/extracellular signal-regulated kinase inhibitors U-0126 and PD-98059.	U 0126	225-231	fibroblast growth factor 1	Rattus norvegicus	95-100
11435252-10	2001	IL-13 (50 ng/ml for 24 h), but not IL-4, significantly reduced beta-adrenergic responsiveness of HASM cells, and the MEK inhibitor U0126 significantly reduced the effects of IL-13 on ISO-induced changes in cell stiffness.	U 0126	131-136	mitogen-activated protein kinase kinase 7	Homo sapiens	117-120
11435252-10	2001	IL-13 (50 ng/ml for 24 h), but not IL-4, significantly reduced beta-adrenergic responsiveness of HASM cells, and the MEK inhibitor U0126 significantly reduced the effects of IL-13 on ISO-induced changes in cell stiffness.	U 0126	131-136	interleukin 13	Homo sapiens	174-179
11377403-11	2001	Addition of the extracellular signal-regulated protein kinase (MEK)-1 and -2 inhibitor U0126 reduced the fluorescence stimulated by MeHg and TMCH by 62% and 63%.	U 0126	87-92	mitogen activated protein kinase kinase 1	Rattus norvegicus	16-76
11454659-4	2001	Contractions to the alpha(2) adrenoceptor agonist UK14304 in the porcine palmar lateral vein in vitro were reduced 70 - 80% by the MEK inhibitors PD98059 (10 - 50 microM) and U0126 (10 - 50 microM), indicating the involvement of the Erk signal transduction cascade.	U 0126	175-180	mitogen-activated protein kinase 1	Homo sapiens	233-236
11454659-5	2001	Immunoblots also demonstrated an increase in the phosphorylated (activated) form of Erk in palmar lateral vein segments after contraction with UK14304, which was inhibited by PD98059 and U0126.	U 0126	187-192	mitogen-activated protein kinase 1	Homo sapiens	84-87
11416034-4	2001	On the other hand, inhibition of mitogen-activated protein (MAP) kinase signaling, using the MAP kinase kinase inhibitors U0126 and PD98059, in the presence of FSH further increased StAR mRNA and protein levels, LH-R mRNA levels, and progesterone synthesis compared with those in cells cultured with FSH alone.	U 0126	122-127	steroidogenic acute regulatory protein	Homo sapiens	182-186
11416034-4	2001	On the other hand, inhibition of mitogen-activated protein (MAP) kinase signaling, using the MAP kinase kinase inhibitors U0126 and PD98059, in the presence of FSH further increased StAR mRNA and protein levels, LH-R mRNA levels, and progesterone synthesis compared with those in cells cultured with FSH alone.	U 0126	122-127	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	212-216
11428860-7	2001	Pretreatment with U0126 or chelerythrine significantly reduced ERK 1/2 activation induced by PDGF-BB or PMA.	U 0126	18-23	mitogen-activated protein kinase 3	Homo sapiens	63-70
11428860-9	2001	This secretory response was inhibited by pretreatment with the MEK inhibitor U0126.	U 0126	77-82	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
11428868-5	2001	The induced IL-8 and MCP-1 mRNA and proteins were partially suppressed by U0126, a specific MEK inhibitor, and by SB202190, a selective p38 inhibitor.	U 0126	74-79	C-X-C motif chemokine ligand 8	Homo sapiens	12-16
11428868-5	2001	The induced IL-8 and MCP-1 mRNA and proteins were partially suppressed by U0126, a specific MEK inhibitor, and by SB202190, a selective p38 inhibitor.	U 0126	74-79	C-C motif chemokine ligand 2	Homo sapiens	21-26
11428868-5	2001	The induced IL-8 and MCP-1 mRNA and proteins were partially suppressed by U0126, a specific MEK inhibitor, and by SB202190, a selective p38 inhibitor.	U 0126	74-79	mitogen-activated protein kinase kinase 7	Homo sapiens	92-95
11450699-9	2001	In addition, wortmannin and U0126 inhibited TGF-beta-induced chemotaxis, suggesting involvement of the phosphatidylinositol 3 (PI 3) kinase and mitogen-activated protein (MAP) kinase signaling pathways.	U 0126	28-33	transforming growth factor, beta 1	Rattus norvegicus	44-52
11418683-7	2001	Preincubation of eosinophils with U0126 or SB203580 blocked fMLP-enhanced cPLA(2) activity.	U 0126	34-39	formyl peptide receptor 1	Homo sapiens	60-64
11418683-7	2001	Preincubation of eosinophils with U0126 or SB203580 blocked fMLP-enhanced cPLA(2) activity.	U 0126	34-39	phospholipase A2 group IVA	Homo sapiens	74-81
11461971-6	2001	TPA-dependent ERK phosphorylation was also blocked by the MEK1 inhibitors PD098059 or U0126.	U 0126	86-91	mitogen-activated protein kinase 1	Homo sapiens	14-17
11461971-6	2001	TPA-dependent ERK phosphorylation was also blocked by the MEK1 inhibitors PD098059 or U0126.	U 0126	86-91	mitogen-activated protein kinase kinase 1	Homo sapiens	58-62
11408609-3	2001	Similar results were obtained with other MEK/MAPK inhibitors (e.g., U0126 and PD184352).	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	41-44
11500965-5	2001	These effects were completely prevented by inhibitors of PKC (bis-indolylmaleimide I; 2 microM) and ERK activation (U-0126; 10 microM).	U 0126	116-122	Eph receptor B1	Rattus norvegicus	100-103
11274178-5	2001	Pretreatment of cells with the MEK inhibitor U-0126 prevented the induction by Compound 5 of phospho-Erk (but not phospho-p38) nuclear accumulation and protected cells from the antiproliferative effects of Compound 5.	U 0126	45-51	mitogen-activated protein kinase kinase 7	Homo sapiens	31-34
11274178-5	2001	Pretreatment of cells with the MEK inhibitor U-0126 prevented the induction by Compound 5 of phospho-Erk (but not phospho-p38) nuclear accumulation and protected cells from the antiproliferative effects of Compound 5.	U 0126	45-51	mitogen-activated protein kinase 1	Homo sapiens	101-104
11360301-7	2001	By 30 min, the entire monolayer showed activation, which persisted for 4 to 8 h. ERK/MAPK activation was specifically blocked by application of the MEK inhibitors, PD98059 and U0126.	U 0126	176-181	mitogen-activated protein kinase 1	Homo sapiens	81-84
11381075-8	2001	Moreover, GHSA-stimulated IL-8 secretion was more sensitive to U0126 (50% inhibitory concentration [IC(50)] = 0.5 microM) than MCP-1 (IC(50) = 10 microM).	U 0126	63-68	C-X-C motif chemokine ligand 8	Homo sapiens	26-30
11393781-6	2001	Activation of ERK-1 and the phosphorylation of ER-alpha, by both estrogen and strain, were prevented by the MAP kinase kinase (MEK) inhibitor U0126 and the protein kinase A (PKA) inhibitor (PKI).	U 0126	142-147	mitogen activated protein kinase 3	Rattus norvegicus	14-19
11393781-6	2001	Activation of ERK-1 and the phosphorylation of ER-alpha, by both estrogen and strain, were prevented by the MAP kinase kinase (MEK) inhibitor U0126 and the protein kinase A (PKA) inhibitor (PKI).	U 0126	142-147	estrogen receptor 1	Rattus norvegicus	47-55
11389170-5	2001	These changes are accompanied by increased activation of one member of the family of mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) and the data indicate that these events play a role in modulating release of glutamate from perforant path-granule cell synapses, because the Trk inhibitor K252a and the ERK inhibitor, UO126, both inhibited the BDNF-induced enhancement of release.	U 0126	349-354	Eph receptor B1	Rattus norvegicus	120-157
11389170-5	2001	These changes are accompanied by increased activation of one member of the family of mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) and the data indicate that these events play a role in modulating release of glutamate from perforant path-granule cell synapses, because the Trk inhibitor K252a and the ERK inhibitor, UO126, both inhibited the BDNF-induced enhancement of release.	U 0126	349-354	Eph receptor B1	Rattus norvegicus	159-162
11389170-5	2001	These changes are accompanied by increased activation of one member of the family of mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) and the data indicate that these events play a role in modulating release of glutamate from perforant path-granule cell synapses, because the Trk inhibitor K252a and the ERK inhibitor, UO126, both inhibited the BDNF-induced enhancement of release.	U 0126	349-354	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	306-309
11389170-5	2001	These changes are accompanied by increased activation of one member of the family of mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) and the data indicate that these events play a role in modulating release of glutamate from perforant path-granule cell synapses, because the Trk inhibitor K252a and the ERK inhibitor, UO126, both inhibited the BDNF-induced enhancement of release.	U 0126	349-354	Eph receptor B1	Rattus norvegicus	334-337
11389170-5	2001	These changes are accompanied by increased activation of one member of the family of mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) and the data indicate that these events play a role in modulating release of glutamate from perforant path-granule cell synapses, because the Trk inhibitor K252a and the ERK inhibitor, UO126, both inhibited the BDNF-induced enhancement of release.	U 0126	349-354	brain-derived neurotrophic factor	Rattus norvegicus	375-379
11408585-5	2001	Inhibition of the MAPK pathway in the extract by the MEK1 inhibitor U0126 delayed, but did not prevent, activation of the Plx1 pathway, and inhibition of Mos synthesis by cycloheximide had a similar effect, suggesting that MAPK activation is the only relevant function of Mos.	U 0126	68-73	mitogen-activated protein kinase kinase 1 S homeolog	Xenopus laevis	53-57
11408587-4	2001	GRASP55 mitotic phosphorylation was significantly reduced, both in vitro and in vivo, by treatment with U0126, a potent and specific inhibitor of MKK and thus ERK activation.	U 0126	104-109	golgi reassembly stacking protein 2	Homo sapiens	0-7
11408587-4	2001	GRASP55 mitotic phosphorylation was significantly reduced, both in vitro and in vivo, by treatment with U0126, a potent and specific inhibitor of MKK and thus ERK activation.	U 0126	104-109	mitogen-activated protein kinase 1	Homo sapiens	159-162
11278479-6	2001	Furthermore, U0126 and PD 184352 reduced Ca(2+) entry stimulated by thapsigargin or thrombin, in a concentration-dependent manner.	U 0126	13-18	coagulation factor II, thrombin	Homo sapiens	84-92
11157486-9	2001	Inhibition of MEK activity by U0126 prevented OSM-induced TF expression by suppressing NF-kappaB DNA binding activity as determined by gel-shift analysis.	U 0126	30-35	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
11743886-9	2001	Interestingly, TNF-alpha-stimulated activation of p44/42 CCDPK was completely blocked, TNF-alpha-induced apoptosis was markedly increased by preincubation with U0126, a specific p44/42 CCDPK inhibitor.	U 0126	160-165	tumor necrosis factor	Bos taurus	15-24
11743886-9	2001	Interestingly, TNF-alpha-stimulated activation of p44/42 CCDPK was completely blocked, TNF-alpha-induced apoptosis was markedly increased by preincubation with U0126, a specific p44/42 CCDPK inhibitor.	U 0126	160-165	tumor necrosis factor	Bos taurus	87-96
11290527-4	2001	Inhibition of MAP kinase kinases 1 and 2 (MEK1 and MEK2, respectively), which are upstream from ERK, with the specific MEK inhibitor U-0126 blocked both cell proliferation and ERK activation.	U 0126	133-139	mitogen-activated protein kinase kinase 2	Homo sapiens	14-40
11290527-4	2001	Inhibition of MAP kinase kinases 1 and 2 (MEK1 and MEK2, respectively), which are upstream from ERK, with the specific MEK inhibitor U-0126 blocked both cell proliferation and ERK activation.	U 0126	133-139	mitogen-activated protein kinase kinase 1	Homo sapiens	42-46
11290527-4	2001	Inhibition of MAP kinase kinases 1 and 2 (MEK1 and MEK2, respectively), which are upstream from ERK, with the specific MEK inhibitor U-0126 blocked both cell proliferation and ERK activation.	U 0126	133-139	mitogen-activated protein kinase kinase 2	Homo sapiens	51-55
11290527-4	2001	Inhibition of MAP kinase kinases 1 and 2 (MEK1 and MEK2, respectively), which are upstream from ERK, with the specific MEK inhibitor U-0126 blocked both cell proliferation and ERK activation.	U 0126	133-139	mitogen-activated protein kinase 1	Homo sapiens	96-99
11290527-4	2001	Inhibition of MAP kinase kinases 1 and 2 (MEK1 and MEK2, respectively), which are upstream from ERK, with the specific MEK inhibitor U-0126 blocked both cell proliferation and ERK activation.	U 0126	133-139	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
11290527-4	2001	Inhibition of MAP kinase kinases 1 and 2 (MEK1 and MEK2, respectively), which are upstream from ERK, with the specific MEK inhibitor U-0126 blocked both cell proliferation and ERK activation.	U 0126	133-139	mitogen-activated protein kinase 1	Homo sapiens	176-179
11290527-5	2001	In addition, U-0126 inhibited mitogen-induced activation of p90 ribosomal S6 kinase and expression of c-Fos and cyclin D1, all of which are downstream from ERK in the signaling cascade that leads to cell proliferation.	U 0126	13-19	cellular inhibitor of PP2A	Homo sapiens	60-63
11290527-5	2001	In addition, U-0126 inhibited mitogen-induced activation of p90 ribosomal S6 kinase and expression of c-Fos and cyclin D1, all of which are downstream from ERK in the signaling cascade that leads to cell proliferation.	U 0126	13-19	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-107
11290527-5	2001	In addition, U-0126 inhibited mitogen-induced activation of p90 ribosomal S6 kinase and expression of c-Fos and cyclin D1, all of which are downstream from ERK in the signaling cascade that leads to cell proliferation.	U 0126	13-19	cyclin D1	Homo sapiens	112-121
11290527-5	2001	In addition, U-0126 inhibited mitogen-induced activation of p90 ribosomal S6 kinase and expression of c-Fos and cyclin D1, all of which are downstream from ERK in the signaling cascade that leads to cell proliferation.	U 0126	13-19	mitogen-activated protein kinase 1	Homo sapiens	156-159
11278290-6	2001	Furthermore, an inhibitor of the ERK1/2 pathway, U0126, or inhibitors of the p38 MAPK pathway, SB203580 and SKF86002, repressed TGF-beta-induced Agc expression in a dose-dependent manner, indicating that ERK1/2 or p38 MAPK activation is also required for TGF-beta-induced Agc expression in confluent ATDC5 cells.	U 0126	49-54	transforming growth factor, beta 1	Mus musculus	128-136
11278290-6	2001	Furthermore, an inhibitor of the ERK1/2 pathway, U0126, or inhibitors of the p38 MAPK pathway, SB203580 and SKF86002, repressed TGF-beta-induced Agc expression in a dose-dependent manner, indicating that ERK1/2 or p38 MAPK activation is also required for TGF-beta-induced Agc expression in confluent ATDC5 cells.	U 0126	49-54	aggrecan	Mus musculus	145-148
11336792-6	2001	Sp1 binding to its consensus sequence, as well as promoter activity and mRNA expression, were found to be inhibited by an inhibitor of MAP kinase kinase 1 and 2, U0126, in the androgen-independent cell lines.	U 0126	162-167	mitogen-activated protein kinase kinase 2	Homo sapiens	135-160
11302731-4	2001	While phosphorylation of extracellular signal-regulated protein kinase, c-Jun NH2-terminal kinase and p38 was found in cells treated with CdCl(2), treatment with U0126, LL-Z1640-2, or SB203580 did not suppress Ser 15 phosphorylation.	U 0126	162-167	mitogen-activated protein kinase 14	Homo sapiens	102-105
11262176-6	2001	Incubation with the MEK1 inhibitor UO126 inhibited cell growth and induced apoptosis in K562 cells in a dose-dependent manner as well.	U 0126	35-40	mitogen-activated protein kinase kinase 1	Homo sapiens	20-24
11267961-11	2001	In addition, U0126, which is a potent inhibitor for ERK phosphorylation, antagonized increase of cyclin D1, thus suggesting that EGF- or HGF-mediated ERK phosphorylation might have played an essential role for cell growth.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	52-55
11267961-11	2001	In addition, U0126, which is a potent inhibitor for ERK phosphorylation, antagonized increase of cyclin D1, thus suggesting that EGF- or HGF-mediated ERK phosphorylation might have played an essential role for cell growth.	U 0126	13-18	cyclin D1	Homo sapiens	97-106
11267961-11	2001	In addition, U0126, which is a potent inhibitor for ERK phosphorylation, antagonized increase of cyclin D1, thus suggesting that EGF- or HGF-mediated ERK phosphorylation might have played an essential role for cell growth.	U 0126	13-18	hepatocyte growth factor	Homo sapiens	137-140
11267961-11	2001	In addition, U0126, which is a potent inhibitor for ERK phosphorylation, antagonized increase of cyclin D1, thus suggesting that EGF- or HGF-mediated ERK phosphorylation might have played an essential role for cell growth.	U 0126	13-18	mitogen-activated protein kinase 1	Homo sapiens	150-153
11267961-13	2001	U0126 reduced ERK phosphorylation and prevented growth inhibition by VK3.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	14-17
11423913-4	2001	Pretreatment with either the MEK1 inhibitor U0126 or PI3-kinase inhibitor LY294002 sensitized BAE cells to TNF-induced apoptosis.	U 0126	44-49	tumor necrosis factor	Bos taurus	107-110
11434613-8	2001	Two-dimensional electrophoresis showed extra phospho ERK spot, which was indicated to have close association with CPD 5-induced growth inhibition, since U0126 antagonized growth inhibition and appearance of this spot.	U 0126	153-158	mitogen-activated protein kinase 1	Homo sapiens	53-56
11278768-3	2001	To investigate whether this pathway plays an essential role for the differentiation, phenotype, and survival of chondrocytes, we blocked mitogen-activated protein kinase/extracellular signal-regulated kinase (Erk) (MEK), a kinase upstream of the kinase Erk by using U0126.	U 0126	266-271	mitogen-activated protein kinase 1	Homo sapiens	209-212
11278768-3	2001	To investigate whether this pathway plays an essential role for the differentiation, phenotype, and survival of chondrocytes, we blocked mitogen-activated protein kinase/extracellular signal-regulated kinase (Erk) (MEK), a kinase upstream of the kinase Erk by using U0126.	U 0126	266-271	mitogen-activated protein kinase kinase 7	Homo sapiens	215-218
11278768-4	2001	Exposure of chondrocytes to U0126 caused activation of caspase-3 in a dose-dependent manner.	U 0126	28-33	caspase 3	Homo sapiens	55-64
11278768-5	2001	Western blot analysis with an antibody specific for dually phosphorylated Erk shows that collagen type II induced phosphorylation of Erk1/2 was specifically blocked by U0126 in a dose-dependent manner.	U 0126	168-173	mitogen-activated protein kinase 1	Homo sapiens	74-77
11278768-5	2001	Western blot analysis with an antibody specific for dually phosphorylated Erk shows that collagen type II induced phosphorylation of Erk1/2 was specifically blocked by U0126 in a dose-dependent manner.	U 0126	168-173	mitogen-activated protein kinase 3	Homo sapiens	133-139
11312036-9	2001	Treatment of cells with U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] an ERK1/2 inhibitor or SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole] a p38 kinase inhibitor effectively prevented SAAD-potentiated arsenic toxicity.	U 0126	24-29	mitogen activated protein kinase 3	Rattus norvegicus	95-101
11413001-7	2001	Full synthesis and accumulation can be restored in the presence of U0126 by the expression of a constitutively active form of the MAPK target, p90(Rsk).	U 0126	67-72	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	143-146
11413001-7	2001	Full synthesis and accumulation can be restored in the presence of U0126 by the expression of a constitutively active form of the MAPK target, p90(Rsk).	U 0126	67-72	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	147-150
11137625-4	2001	The phosphorylation of p44/42 MAPK occurred rapidly within 5 min after addition of bFGF, and lasted for 48 h. The bFGF-induced phosphorylation of p44/42 MAPK and axonal branch formation were both blocked by simultaneous addition of U0126 and PD98059, specific inhibitors of MAPK kinases.	U 0126	232-237	mitogen activated protein kinase 3	Rattus norvegicus	23-26
11137625-4	2001	The phosphorylation of p44/42 MAPK occurred rapidly within 5 min after addition of bFGF, and lasted for 48 h. The bFGF-induced phosphorylation of p44/42 MAPK and axonal branch formation were both blocked by simultaneous addition of U0126 and PD98059, specific inhibitors of MAPK kinases.	U 0126	232-237	fibroblast growth factor 2	Rattus norvegicus	83-87
11137625-4	2001	The phosphorylation of p44/42 MAPK occurred rapidly within 5 min after addition of bFGF, and lasted for 48 h. The bFGF-induced phosphorylation of p44/42 MAPK and axonal branch formation were both blocked by simultaneous addition of U0126 and PD98059, specific inhibitors of MAPK kinases.	U 0126	232-237	fibroblast growth factor 2	Rattus norvegicus	114-118
11137625-4	2001	The phosphorylation of p44/42 MAPK occurred rapidly within 5 min after addition of bFGF, and lasted for 48 h. The bFGF-induced phosphorylation of p44/42 MAPK and axonal branch formation were both blocked by simultaneous addition of U0126 and PD98059, specific inhibitors of MAPK kinases.	U 0126	232-237	mitogen activated protein kinase 3	Rattus norvegicus	146-149
11137625-5	2001	Furthermore, when U0126 and PD98059 were added 24 h after bFGF, phosphorylation of p44/42 m MAPK was decreased, and axonal branch formation was stopped.	U 0126	18-23	fibroblast growth factor 2	Rattus norvegicus	58-62
11137625-5	2001	Furthermore, when U0126 and PD98059 were added 24 h after bFGF, phosphorylation of p44/42 m MAPK was decreased, and axonal branch formation was stopped.	U 0126	18-23	mitogen activated protein kinase 3	Rattus norvegicus	83-86
11118451-7	2001	In contrast, the MKK inhibitor U0126 markedly inhibited both ERK1/2 and ERK5 activation and completely prevented HGF- and EGF-dependent migration and branching process formation.	U 0126	31-36	mitogen-activated protein kinase 3	Mus musculus	61-67
11118451-7	2001	In contrast, the MKK inhibitor U0126 markedly inhibited both ERK1/2 and ERK5 activation and completely prevented HGF- and EGF-dependent migration and branching process formation.	U 0126	31-36	mitogen-activated protein kinase 7	Mus musculus	72-76
11118451-7	2001	In contrast, the MKK inhibitor U0126 markedly inhibited both ERK1/2 and ERK5 activation and completely prevented HGF- and EGF-dependent migration and branching process formation.	U 0126	31-36	hepatocyte growth factor	Mus musculus	113-116
11118451-7	2001	In contrast, the MKK inhibitor U0126 markedly inhibited both ERK1/2 and ERK5 activation and completely prevented HGF- and EGF-dependent migration and branching process formation.	U 0126	31-36	epidermal growth factor	Mus musculus	122-125
11108720-8	2001	Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1.	U 0126	118-123	mitogen-activated protein kinase kinase 7	Homo sapiens	31-101
11108720-8	2001	Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1.	U 0126	118-123	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
11108720-8	2001	Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1.	U 0126	118-123	ribosomal protein S6 kinase B2	Homo sapiens	134-138
11108720-8	2001	Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1.	U 0126	118-123	ribosomal protein S6 kinase B1	Homo sapiens	175-179
11108720-9	2001	Furthermore, S6K2 mutants with C-terminal deletion or acidic phosphorylation site mutations displayed greatly reduced U0126 sensitivity.	U 0126	118-123	ribosomal protein S6 kinase B2	Homo sapiens	13-17
11289135-6	2001	Coexposure to FP also resulted in a more pronounced and sustained activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinase cascade after PMA treatment, although disruption of this pathway by the mitogen-activated protein kinase kinase 1 inhibitor U0126 did not prevent potentiation of apoptosis.	U 0126	294-299	mitogen-activated protein kinase kinase 1	Homo sapiens	242-283
11238629-4	2001	PD98059 or U0126 treatment substantially inhibited the BCR-induced activation of the extracellular signal-regulated kinase (ERK) forms of mitogen-activated protein kinase in the immature B cell line WEHI-231, in immature splenic B cells, and in mature splenic B cells.	U 0126	11-16	mitogen-activated protein kinase 1	Mus musculus	85-122
11238629-4	2001	PD98059 or U0126 treatment substantially inhibited the BCR-induced activation of the extracellular signal-regulated kinase (ERK) forms of mitogen-activated protein kinase in the immature B cell line WEHI-231, in immature splenic B cells, and in mature splenic B cells.	U 0126	11-16	mitogen-activated protein kinase 1	Mus musculus	124-127
11258898-7	2001	T(4)-induced nuclear complexing of p53 and MAPK was inhibited by PD 98059 (PD) and U0126, two MAPK kinase (MEK) inhibitors, and was absent in cells treated with MEK antisense oligonucleotide and in dominant negative Ras cells.	U 0126	83-88	tumor protein p53	Homo sapiens	35-38
11258898-7	2001	T(4)-induced nuclear complexing of p53 and MAPK was inhibited by PD 98059 (PD) and U0126, two MAPK kinase (MEK) inhibitors, and was absent in cells treated with MEK antisense oligonucleotide and in dominant negative Ras cells.	U 0126	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	107-110
11231289-3	2001	Pharmacologic inhibition of either the ERK or the p38 MAPK pathway, using U0126 and SB203580, respectively, reduced interleukin-6 protein induction by at least 70%, and combined inhibition of both pathways fully blocked interleukin-6 protein expression and reduced interleukin-6 mRNA induction by more than 80%.	U 0126	74-79	mitogen-activated protein kinase 1	Homo sapiens	39-42
11231289-3	2001	Pharmacologic inhibition of either the ERK or the p38 MAPK pathway, using U0126 and SB203580, respectively, reduced interleukin-6 protein induction by at least 70%, and combined inhibition of both pathways fully blocked interleukin-6 protein expression and reduced interleukin-6 mRNA induction by more than 80%.	U 0126	74-79	mitogen-activated protein kinase 14	Homo sapiens	50-53
11231289-3	2001	Pharmacologic inhibition of either the ERK or the p38 MAPK pathway, using U0126 and SB203580, respectively, reduced interleukin-6 protein induction by at least 70%, and combined inhibition of both pathways fully blocked interleukin-6 protein expression and reduced interleukin-6 mRNA induction by more than 80%.	U 0126	74-79	interleukin 6	Homo sapiens	116-129
11231289-5	2001	Induction of interferon-regulatory factor-1 (IRF-1) by pI:C in IFN alpha primed cells was profoundly inhibited by U0126 but not by SB203580.	U 0126	114-119	interferon regulatory factor 1	Homo sapiens	13-43
11231289-5	2001	Induction of interferon-regulatory factor-1 (IRF-1) by pI:C in IFN alpha primed cells was profoundly inhibited by U0126 but not by SB203580.	U 0126	114-119	interferon regulatory factor 1	Homo sapiens	45-50
11231289-5	2001	Induction of interferon-regulatory factor-1 (IRF-1) by pI:C in IFN alpha primed cells was profoundly inhibited by U0126 but not by SB203580.	U 0126	114-119	interferon alpha 1	Homo sapiens	63-72
11260269-6	2001	The induction of SGK was blocked by pre-treatment with a specific MEK inhibitor U0126, and expression of constitutively active MEK was able to induce SGK.	U 0126	80-85	serum/glucocorticoid regulated kinase 1	Mus musculus	17-20
11260269-6	2001	The induction of SGK was blocked by pre-treatment with a specific MEK inhibitor U0126, and expression of constitutively active MEK was able to induce SGK.	U 0126	80-85	midkine	Mus musculus	66-69
11172089-2	2001	Treatment of infected fibroblasts with U0126, a potent and specific inhibitor of MKK1/2 kinase activity, completely blocked ERK1/2 activation following HCMV infection without affecting cell viability.	U 0126	39-44	mitogen-activated protein kinase kinase 1	Homo sapiens	81-85
11172089-2	2001	Treatment of infected fibroblasts with U0126, a potent and specific inhibitor of MKK1/2 kinase activity, completely blocked ERK1/2 activation following HCMV infection without affecting cell viability.	U 0126	39-44	mitogen-activated protein kinase 3	Homo sapiens	124-130
11181896-7	2001	Blocking ERK activity with the specific mitogen-activated protein kinase kinase inhibitors PD98059 (50 microM for 45 min) and UO126 (30 microM for 30 min) inhibited PX-induced exocytosis in the presence but not in the absence of extracellular Ca(2+).	U 0126	126-131	Eph receptor B1	Rattus norvegicus	9-12
11231581-5	2001	Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	168-172
11231581-5	2001	Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).	U 0126	120-125	mitogen-activated protein kinase 1	Homo sapiens	173-176
11231581-5	2001	Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).	U 0126	120-125	mitogen-activated protein kinase kinase 7	Homo sapiens	185-188
11160334-11	2001	SDF-1alpha-induced chemokine expression was abrogated upon inclusion of U0126, a pharmacological inhibitor of ERK1/2, indicating that the ERK signaling cascade is involved in this response.	U 0126	72-77	mitogen-activated protein kinase 3	Homo sapiens	110-116
11160334-11	2001	SDF-1alpha-induced chemokine expression was abrogated upon inclusion of U0126, a pharmacological inhibitor of ERK1/2, indicating that the ERK signaling cascade is involved in this response.	U 0126	72-77	mitogen-activated protein kinase 1	Homo sapiens	110-113
11171084-5	2001	Moreover, the induction of HB-EGF mRNA was blocked by PD098059 and U0126, inhibitors that prevent the activation of p42/p44 MAPKs and extracellular signal-regulated protein kinase 5 (ERK5).	U 0126	67-72	heparin-binding EGF-like growth factor	Rattus norvegicus	27-33
11171084-5	2001	Moreover, the induction of HB-EGF mRNA was blocked by PD098059 and U0126, inhibitors that prevent the activation of p42/p44 MAPKs and extracellular signal-regulated protein kinase 5 (ERK5).	U 0126	67-72	mitogen activated protein kinase 3	Rattus norvegicus	120-123
11171084-5	2001	Moreover, the induction of HB-EGF mRNA was blocked by PD098059 and U0126, inhibitors that prevent the activation of p42/p44 MAPKs and extracellular signal-regulated protein kinase 5 (ERK5).	U 0126	67-72	mitogen-activated protein kinase 7	Rattus norvegicus	134-181
11171084-5	2001	Moreover, the induction of HB-EGF mRNA was blocked by PD098059 and U0126, inhibitors that prevent the activation of p42/p44 MAPKs and extracellular signal-regulated protein kinase 5 (ERK5).	U 0126	67-72	mitogen-activated protein kinase 7	Rattus norvegicus	183-187
11245463-6	2001	Treatment of HCT116 human colon cancer cells with the specific mitogen-activated protein kinase kinase, U0126 (5-50 microM) resulted in a time- and dose-dependent inhibition of ERK1/2 phosphorylation, and induction of apoptosis.	U 0126	104-109	mitogen-activated protein kinase 3	Homo sapiens	177-183
11368346-6	2001	Likewise, inhibition of protein kinase C with chelerythrin, farnesyl transferase with manumycin A, MEK kinase with U0126, Erk1/2 kinases with PD98059, p38MAPK with SB203580, PI 3-kinase with wortmannin or LY294002, p70s6k with rapamycin, or depletion of [Ca2+]i with either BAPTA/AM or EGTA drastically reduced alpha2M* induction of cPLA2.	U 0126	115-120	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
11231148-11	2001	In oocytes treated with the MEK1 inhibitor U0126, the MAPK pathway does not become activated, and Bub1 remains in its low-activity, unshifted form.	U 0126	43-48	mitogen-activated protein kinase kinase 1 S homeolog	Xenopus laevis	28-32
11231148-11	2001	In oocytes treated with the MEK1 inhibitor U0126, the MAPK pathway does not become activated, and Bub1 remains in its low-activity, unshifted form.	U 0126	43-48	BUB1 mitotic checkpoint serine/threonine kinase L homeolog	Xenopus laevis	98-102
11231148-12	2001	Injection of a constitutively active target of MAPK, the protein kinase p90(Rsk), restores the activation of Bub1 in the presence of U0126.	U 0126	133-138	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	72-75
11231148-12	2001	Injection of a constitutively active target of MAPK, the protein kinase p90(Rsk), restores the activation of Bub1 in the presence of U0126.	U 0126	133-138	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	76-79
11231148-12	2001	Injection of a constitutively active target of MAPK, the protein kinase p90(Rsk), restores the activation of Bub1 in the presence of U0126.	U 0126	133-138	BUB1 mitotic checkpoint serine/threonine kinase L homeolog	Xenopus laevis	109-113
11238629-6	2001	In contrast, PD98059 and U0126 treatment did inhibit the up-regulation of specific BCR-induced proteins, including the transcription factor Egr-1 in WEHI-231 and mature splenic B cells, and the CD44 adhesion molecule and CD69 activation marker in mature splenic B cells.	U 0126	25-30	early growth response 1	Mus musculus	140-145
11238629-6	2001	In contrast, PD98059 and U0126 treatment did inhibit the up-regulation of specific BCR-induced proteins, including the transcription factor Egr-1 in WEHI-231 and mature splenic B cells, and the CD44 adhesion molecule and CD69 activation marker in mature splenic B cells.	U 0126	25-30	CD44 antigen	Mus musculus	194-198
11157486-9	2001	Inhibition of MEK activity by U0126 prevented OSM-induced TF expression by suppressing NF-kappaB DNA binding activity as determined by gel-shift analysis.	U 0126	30-35	nuclear factor kappa B subunit 1	Homo sapiens	87-96
11042220-3	2001	The up-regulation of nucleolin mRNA was substantially repressed by U0126, a specific inhibitor that blocks phosphorylation of extracellular-regulated kinase (ERK).	U 0126	67-72	LOW QUALITY PROTEIN: nucleolin	Oryctolagus cuniculus	21-30
11238629-6	2001	In contrast, PD98059 and U0126 treatment did inhibit the up-regulation of specific BCR-induced proteins, including the transcription factor Egr-1 in WEHI-231 and mature splenic B cells, and the CD44 adhesion molecule and CD69 activation marker in mature splenic B cells.	U 0126	25-30	CD69 antigen	Mus musculus	221-225
11234901-7	2001	Basal and tumor necrosis factor-alpha-inducible phosphorylation of ERK1/2 and secretion of IL-8 and VEGF could be specifically inhibited by a MEK inhibitor, U0126.	U 0126	157-162	tumor necrosis factor	Homo sapiens	10-37
11234901-7	2001	Basal and tumor necrosis factor-alpha-inducible phosphorylation of ERK1/2 and secretion of IL-8 and VEGF could be specifically inhibited by a MEK inhibitor, U0126.	U 0126	157-162	mitogen-activated protein kinase 3	Homo sapiens	67-73
11234901-7	2001	Basal and tumor necrosis factor-alpha-inducible phosphorylation of ERK1/2 and secretion of IL-8 and VEGF could be specifically inhibited by a MEK inhibitor, U0126.	U 0126	157-162	C-X-C motif chemokine ligand 8	Homo sapiens	91-95
11234901-7	2001	Basal and tumor necrosis factor-alpha-inducible phosphorylation of ERK1/2 and secretion of IL-8 and VEGF could be specifically inhibited by a MEK inhibitor, U0126.	U 0126	157-162	vascular endothelial growth factor A	Homo sapiens	100-104
11234901-7	2001	Basal and tumor necrosis factor-alpha-inducible phosphorylation of ERK1/2 and secretion of IL-8 and VEGF could be specifically inhibited by a MEK inhibitor, U0126.	U 0126	157-162	mitogen-activated protein kinase kinase 7	Homo sapiens	142-145
11234901-8	2001	Expression of IL-8 and VEGF in the cell lines was associated with coactivation of both NF-kappaB and AP-1, and U0126 inhibited both NF-kappaB and AP-1 reporter activity in UM-SCC-9 and UM-SCC-11B cells.	U 0126	111-116	nuclear factor kappa B subunit 1	Homo sapiens	132-141
11168553-6	2001	Pretreatment with U0126, an inhibitor of MAPK/ERK kinase, inhibited the rapid activation of ERK by 17 beta-estradiol in the rat hippocampus.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	46-49
11168553-6	2001	Pretreatment with U0126, an inhibitor of MAPK/ERK kinase, inhibited the rapid activation of ERK by 17 beta-estradiol in the rat hippocampus.	U 0126	18-23	Eph receptor B1	Rattus norvegicus	92-95
11160424-3	2001	Like ERK1 and ERK2, ERK5 is expressed in neurons, and ERK5 stimulation by epidermal growth factor is blocked by the MAP kinase/ERK kinase 1 (MEK1) inhibitors PD98059 and U0126.	U 0126	170-175	mitogen-activated protein kinase 7	Rattus norvegicus	20-24
11160424-3	2001	Like ERK1 and ERK2, ERK5 is expressed in neurons, and ERK5 stimulation by epidermal growth factor is blocked by the MAP kinase/ERK kinase 1 (MEK1) inhibitors PD98059 and U0126.	U 0126	170-175	mitogen-activated protein kinase 7	Rattus norvegicus	54-58
11160424-3	2001	Like ERK1 and ERK2, ERK5 is expressed in neurons, and ERK5 stimulation by epidermal growth factor is blocked by the MAP kinase/ERK kinase 1 (MEK1) inhibitors PD98059 and U0126.	U 0126	170-175	mitogen activated protein kinase kinase 1	Rattus norvegicus	116-139
11160424-3	2001	Like ERK1 and ERK2, ERK5 is expressed in neurons, and ERK5 stimulation by epidermal growth factor is blocked by the MAP kinase/ERK kinase 1 (MEK1) inhibitors PD98059 and U0126.	U 0126	170-175	mitogen activated protein kinase kinase 1	Rattus norvegicus	141-145
11029471-8	2001	However, the MEK inhibitor U0126 blocked progesterone-induced p42 MAPK activation but not progesterone-induced JNK activation.	U 0126	27-32	cyclin-dependent kinase 20 S homeolog	Xenopus laevis	62-65
11409852-6	2001	MAPK kinase inhibitors PD098059 and U0126 prevent ERK(1/2) phosphorylation by Tat.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	0-4
11137705-4	2001	U0126 and PD98059, two specific p44/42 MAPK kinase inhibitors, prevented the induction of ODC elicited by any stimulus employed, whereas SB203580 and SB202190, which are widely used as p38 MAPK inhibitors, enhanced ODC induction in a way that appeared dependent on p44/42 MAPK activation.	U 0126	0-5	interferon induced protein 44	Homo sapiens	32-35
11137705-4	2001	U0126 and PD98059, two specific p44/42 MAPK kinase inhibitors, prevented the induction of ODC elicited by any stimulus employed, whereas SB203580 and SB202190, which are widely used as p38 MAPK inhibitors, enhanced ODC induction in a way that appeared dependent on p44/42 MAPK activation.	U 0126	0-5	ornithine decarboxylase 1	Homo sapiens	90-93
11137705-4	2001	U0126 and PD98059, two specific p44/42 MAPK kinase inhibitors, prevented the induction of ODC elicited by any stimulus employed, whereas SB203580 and SB202190, which are widely used as p38 MAPK inhibitors, enhanced ODC induction in a way that appeared dependent on p44/42 MAPK activation.	U 0126	0-5	mitogen-activated protein kinase 14	Homo sapiens	185-188
11137705-4	2001	U0126 and PD98059, two specific p44/42 MAPK kinase inhibitors, prevented the induction of ODC elicited by any stimulus employed, whereas SB203580 and SB202190, which are widely used as p38 MAPK inhibitors, enhanced ODC induction in a way that appeared dependent on p44/42 MAPK activation.	U 0126	0-5	ornithine decarboxylase 1	Homo sapiens	215-218
11137705-4	2001	U0126 and PD98059, two specific p44/42 MAPK kinase inhibitors, prevented the induction of ODC elicited by any stimulus employed, whereas SB203580 and SB202190, which are widely used as p38 MAPK inhibitors, enhanced ODC induction in a way that appeared dependent on p44/42 MAPK activation.	U 0126	0-5	interferon induced protein 44	Homo sapiens	265-268
11409852-6	2001	MAPK kinase inhibitors PD098059 and U0126 prevent ERK(1/2) phosphorylation by Tat.	U 0126	36-41	mitogen-activated protein kinase 3	Homo sapiens	50-57
11409852-6	2001	MAPK kinase inhibitors PD098059 and U0126 prevent ERK(1/2) phosphorylation by Tat.	U 0126	36-41	tyrosine aminotransferase	Homo sapiens	78-81
11444050-3	2001	Use of U0126, a new potent inhibitor of MAPK kinase (MEK), shows that MAPK activation is essential to inhibit the anaphase-promoting complex and cyclin B degradation at the MI/MII transition.	U 0126	7-12	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	40-44
11280707-9	2001	The MAP-kinase-1-specific inhibitor U0126 blocked the leptin-induced cell proliferation in a dose-dependent fashion.	U 0126	36-41	mitogen-activated protein kinase 1	Homo sapiens	4-16
11280707-9	2001	The MAP-kinase-1-specific inhibitor U0126 blocked the leptin-induced cell proliferation in a dose-dependent fashion.	U 0126	36-41	leptin	Homo sapiens	54-60
11500937-5	2001	We confirmed that PD98059 or U0126 did actually suppress the phosphorylation of p42/p44 MAP kinase by TGF-beta in our preparations.	U 0126	29-34	cyclin dependent kinase 20	Homo sapiens	80-83
11500937-5	2001	We confirmed that PD98059 or U0126 did actually suppress the phosphorylation of p42/p44 MAP kinase by TGF-beta in our preparations.	U 0126	29-34	interferon induced protein 44	Homo sapiens	84-87
11500937-5	2001	We confirmed that PD98059 or U0126 did actually suppress the phosphorylation of p42/p44 MAP kinase by TGF-beta in our preparations.	U 0126	29-34	transforming growth factor beta 1	Homo sapiens	102-110
11145995-4	2001	The glutamate-induced ERK1/2 phosphorylation was blocked by U0126 and PD98059, specific inhibitors of the MAPK-activating enzyme MEK.	U 0126	60-65	mitogen activated protein kinase 3	Rattus norvegicus	22-28
11444050-3	2001	Use of U0126, a new potent inhibitor of MAPK kinase (MEK), shows that MAPK activation is essential to inhibit the anaphase-promoting complex and cyclin B degradation at the MI/MII transition.	U 0126	7-12	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	70-74
11444050-5	2001	These events are restored in U0126-treated oocytes by a constitutively active form of the protein kinase p90Rsk.	U 0126	29-34	ribosomal protein S6 kinase A1 L homeolog	Xenopus laevis	105-111
11108803-7	2000	On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene ), suppressed CdCl(2)-induced ERK activation and the apoptosis as well.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	36-40
11108803-7	2000	On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene ), suppressed CdCl(2)-induced ERK activation and the apoptosis as well.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	41-44
11108803-7	2000	On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene ), suppressed CdCl(2)-induced ERK activation and the apoptosis as well.	U 0126	69-74	mitogen-activated protein kinase 1	Homo sapiens	166-169
11108803-7	2000	On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene ), suppressed CdCl(2)-induced ERK activation and the apoptosis as well.	U 0126	76-135	mitogen-activated protein kinase 1	Homo sapiens	36-40
11108803-7	2000	On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene ), suppressed CdCl(2)-induced ERK activation and the apoptosis as well.	U 0126	76-135	mitogen-activated protein kinase 1	Homo sapiens	41-44
11108803-7	2000	On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene ), suppressed CdCl(2)-induced ERK activation and the apoptosis as well.	U 0126	76-135	mitogen-activated protein kinase 1	Homo sapiens	166-169
11110685-5	2000	It was also found that though inhibition of phosphatidyl-inositol 3-kinase (PI-3K) by LY294002 in alpha(IIb)beta(3)(+) cells induced apoptosis and inhibited chemotaxis adhesion and the secretion of MMP-9 and VEGF, the inhibition of MAPK p42/44 (by the MEK inhibitor U0126) had no effect on the survival, proliferation, and migration of these cells.	U 0126	266-271	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	44-74
11038347-5	2000	The inhibition of MEK/ERK with a pharmacologic inhibitor, U0126, together with paclitaxel resulted in a dramatic enhancement of apoptosis that is four times more than the additive value of the two drugs alone.	U 0126	58-63	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
11116048-5	2000	Treatment with either SB203580 (inhibitor of p38 MAPK) or U0126 (inhibitor of the ERK pathway) downregulated the TNF-alpha-induced MMP-9 expression in a dose-dependent manner.	U 0126	58-63	Eph receptor B1	Rattus norvegicus	82-85
11038347-5	2000	The inhibition of MEK/ERK with a pharmacologic inhibitor, U0126, together with paclitaxel resulted in a dramatic enhancement of apoptosis that is four times more than the additive value of the two drugs alone.	U 0126	58-63	mitogen-activated protein kinase 1	Homo sapiens	22-25
11116048-5	2000	Treatment with either SB203580 (inhibitor of p38 MAPK) or U0126 (inhibitor of the ERK pathway) downregulated the TNF-alpha-induced MMP-9 expression in a dose-dependent manner.	U 0126	58-63	tumor necrosis factor	Rattus norvegicus	113-122
11116048-5	2000	Treatment with either SB203580 (inhibitor of p38 MAPK) or U0126 (inhibitor of the ERK pathway) downregulated the TNF-alpha-induced MMP-9 expression in a dose-dependent manner.	U 0126	58-63	matrix metallopeptidase 9	Rattus norvegicus	131-136
11116048-7	2000	Furthermore, suboptimal inhibitory concentrations of SB203580 and U0126 together almost completely inhibited the MMP-9 expression.	U 0126	66-71	matrix metallopeptidase 9	Rattus norvegicus	113-118
11152962-3	2000	In agreement with our previous finding that p90(rsk1) is essential for TPA-induced activation of NF-kappaB in Adenovirus 5E1-transformed Baby Rat Kidney cells, we now report that the MEK/ERK/p90(rsk1) inhibitor U0126 efficiently blocks TPA-induced IkappaBalpha processing in these cells.	U 0126	211-216	ribosomal protein S6 kinase A1	Rattus norvegicus	44-52
11133806-6	2000	Nevertheless, the ERK pathway does not fully account for this synergy, since fos induction was differentially sensitive to the MEK inhibitor U0126, indicating that these two agonists signal differently to this immediate early gene.	U 0126	141-146	mitogen-activated protein kinase kinase 7	Homo sapiens	127-130
11152962-3	2000	In agreement with our previous finding that p90(rsk1) is essential for TPA-induced activation of NF-kappaB in Adenovirus 5E1-transformed Baby Rat Kidney cells, we now report that the MEK/ERK/p90(rsk1) inhibitor U0126 efficiently blocks TPA-induced IkappaBalpha processing in these cells.	U 0126	211-216	Eph receptor B1	Rattus norvegicus	187-190
11152962-3	2000	In agreement with our previous finding that p90(rsk1) is essential for TPA-induced activation of NF-kappaB in Adenovirus 5E1-transformed Baby Rat Kidney cells, we now report that the MEK/ERK/p90(rsk1) inhibitor U0126 efficiently blocks TPA-induced IkappaBalpha processing in these cells.	U 0126	211-216	ribosomal protein S6 kinase A1	Rattus norvegicus	191-199
11097748-2	2000	Stimulation with phorbol ester led to expression of TNF-alpha protein without significant changes in mRNA, a response that was sensitive to the MEK-1/2 inhibitors PD98059 and U0126.	U 0126	175-180	tumor necrosis factor	Homo sapiens	52-61
11097748-2	2000	Stimulation with phorbol ester led to expression of TNF-alpha protein without significant changes in mRNA, a response that was sensitive to the MEK-1/2 inhibitors PD98059 and U0126.	U 0126	175-180	mitogen-activated protein kinase kinase 1	Homo sapiens	144-151
11154849-5	2000	Inhibition of the activation of extracellular signal regulated kinases (ERK1/2) by U0126, prevented neuritogenesis of Neuro-2a by all the three agents.	U 0126	83-88	mitogen-activated protein kinase 3	Mus musculus	72-78
10984495-4	2000	U0126 and SB-386023 blocked ET-1 and PE-induced ERK but not p38 and JNK activation in cardiomyocytes.	U 0126	0-5	endothelin 1	Rattus norvegicus	28-32
11123423-5	2000	EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF.	U 0126	66-71	epidermal growth factor	Homo sapiens	0-3
11095644-9	2000	Formin IV was found to be a phosphorylation substrate for activated extracellular signal-regulated kinase in vitro, and pretreatment of cells with the mitogen-activated protein kinase inhibitor U0126 prevented the translocation of formin IV and inhibited HGF-dependent phosphorylation of formin IV in intact cells.	U 0126	194-199	hepatocyte growth factor	Mus musculus	255-258
11086108-6	2000	When exposed to the anergy protocol, lupus T cells, in marked contrast to normal T cells, did not phosphorylate Cbl/Cbl-b but continued to express strongly phosphorylated extracellular signal-regulated kinase (ERK); U0126, a specific inhibitor of mitogen-activated protein kinase kinase --&gt; ERK, could block both the early and the prolonged hyperexpression of CD40L.	U 0126	216-221	mitogen-activated protein kinase 1	Homo sapiens	210-213
11113870-6	2000	Up-regulation of CD44 by EGF is also prevented by the transcriptional inhibitor actinomycin D (5 microg/ml) and by blocking the MAP kinase (MAPK) pathway using the MEK inibitor U0126 (100 microM).	U 0126	177-182	CD44 molecule (Indian blood group)	Homo sapiens	17-21
11113870-6	2000	Up-regulation of CD44 by EGF is also prevented by the transcriptional inhibitor actinomycin D (5 microg/ml) and by blocking the MAP kinase (MAPK) pathway using the MEK inibitor U0126 (100 microM).	U 0126	177-182	epidermal growth factor	Homo sapiens	25-28
11113870-6	2000	Up-regulation of CD44 by EGF is also prevented by the transcriptional inhibitor actinomycin D (5 microg/ml) and by blocking the MAP kinase (MAPK) pathway using the MEK inibitor U0126 (100 microM).	U 0126	177-182	mitogen-activated protein kinase kinase 7	Homo sapiens	164-167
11123423-5	2000	EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF.	U 0126	66-71	mitogen-activated protein kinase 1	Homo sapiens	39-42
11123423-5	2000	EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF.	U 0126	66-71	mitogen-activated protein kinase 1	Homo sapiens	98-101
11123423-5	2000	EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF.	U 0126	66-71	cyclin D1	Homo sapiens	145-154
11123423-5	2000	EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF.	U 0126	66-71	epidermal growth factor	Homo sapiens	158-161
11123423-8	2000	On two-dimensional electrophoresis, we found an extra type of phospho-ERK, and this was completely and selectively abolished by U0126.	U 0126	128-133	mitogen-activated protein kinase 1	Homo sapiens	70-73
10896671-8	2000	The ERK inhibitor U0126 blocked the neurite- but not the survival-promoting activity of both NGF and active peptide.	U 0126	18-23	mitogen-activated protein kinase 1	Homo sapiens	4-7
10982368-9	2000	Tat(72aa)-mediated MCP-1 and IL-8 mRNA induction was susceptible to inhibition by the MEK1/2 inhibitor UO126 but was only modestly decreased by the inclusion of the p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190.	U 0126	103-108	C-C motif chemokine ligand 2	Homo sapiens	19-24
10982368-9	2000	Tat(72aa)-mediated MCP-1 and IL-8 mRNA induction was susceptible to inhibition by the MEK1/2 inhibitor UO126 but was only modestly decreased by the inclusion of the p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190.	U 0126	103-108	C-X-C motif chemokine ligand 8	Homo sapiens	29-33
10982368-9	2000	Tat(72aa)-mediated MCP-1 and IL-8 mRNA induction was susceptible to inhibition by the MEK1/2 inhibitor UO126 but was only modestly decreased by the inclusion of the p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190.	U 0126	103-108	mitogen-activated protein kinase kinase 1	Homo sapiens	86-92
11062070-4	2000	Both growth factors strongly activated mitogen-activated protein (MAP) kinases, but blockade of signalling through this pathway, either by the expression of dominant-negative Ras or by treatment with the MAP kinase/ERK kinase (MEK) inhibitor U0126, partially inhibited only bFGF, but not NGF, anti-apoptotic signalling.	U 0126	242-247	fibroblast growth factor 2	Rattus norvegicus	274-278
11501067-8	2000	Interestingly, H2O2-induced apoptosis was markedly increased by preincubation with U0126, a specific p42/p44 CCDPK inhibitor.	U 0126	83-88	erythrocyte membrane protein band 4.2	Bos taurus	101-104
11029295-7	2000	The MEK inhibitor U-0126 inhibited extracellular signal-regulated kinase phosphorylation and cyclin D expression in C7caMEK1 cells and almost abolished their already reduced cell proliferation rate.	U 0126	18-24	complement C7	Canis lupus familiaris	116-124
11095246-3	2000	Inhibition of the mitogen-activated protein kinase pathway by the specific inhibitors PD98059 and U0126 and of phosphatidylinositol 3-kinase by LY294002, strongly inhibited Epo-induced TIMP-1 expression and secretion.	U 0126	98-103	erythropoietin	Homo sapiens	173-176
11095246-3	2000	Inhibition of the mitogen-activated protein kinase pathway by the specific inhibitors PD98059 and U0126 and of phosphatidylinositol 3-kinase by LY294002, strongly inhibited Epo-induced TIMP-1 expression and secretion.	U 0126	98-103	TIMP metallopeptidase inhibitor 1	Homo sapiens	185-191
11095246-6	2000	The addition of PD98059, U0126, and LY294002 in the presence of Epo restored MMP-9 production in UT-7 and CD36+ cells.	U 0126	25-30	erythropoietin	Homo sapiens	64-67
11095246-6	2000	The addition of PD98059, U0126, and LY294002 in the presence of Epo restored MMP-9 production in UT-7 and CD36+ cells.	U 0126	25-30	matrix metallopeptidase 9	Homo sapiens	77-82
11050141-4	2000	We next show that infusions of U0126, an inhibitor of ERK/MAPK activation, aimed at the LA, dose-dependently impair long-term memory of Pavlovian fear conditioning but leaves short-term memory intact.	U 0126	31-36	mitogen-activated protein kinase 1	Homo sapiens	54-57
11146399-8	2000	In intact arteries, contraction through 5-HT(1B)/5-HT(1D) receptors was significantly attenuated by inhibitors of phosphatidylinositol 3-kinase (wortmannin) and activated mitogen-activated protein kinase (MAPK), MEK (U0126).	U 0126	217-222	5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus	40-47
11146399-8	2000	In intact arteries, contraction through 5-HT(1B)/5-HT(1D) receptors was significantly attenuated by inhibitors of phosphatidylinositol 3-kinase (wortmannin) and activated mitogen-activated protein kinase (MAPK), MEK (U0126).	U 0126	217-222	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	49-56
11059787-3	2000	Inhibition of HER2 and MAPKs with AG1478 and U0126, respectively, as well as dominant-negative MEK-1/2 constructs restored the inhibitory effect of tamoxifen on estrogen receptor (ER)-mediated transcription and cell proliferation.	U 0126	45-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
11059787-4	2000	Both AG1478 and U0126 also restored the tamoxifen-mediated association of ER with nuclear receptor corepressor (N-CoR) in the antiestrogen-resistant MCF-7 cells.	U 0126	16-21	nuclear receptor corepressor 1	Homo sapiens	112-117
10918063-10	2000	However, MKK1 inhibitors UO126 and PD98095 suppressed gene expression.	U 0126	25-30	mitogen-activated protein kinase kinase 1	Homo sapiens	9-13
10998351-6	2000	U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	174-178
10998351-6	2000	U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	203-207
11091139-4	2000	The fMLP-mediated 5-LO product formation was also sensitive to MEK inhibition by U0126 and to p38 inhibition by SB203580.	U 0126	81-86	formyl peptide receptor 1	Homo sapiens	4-8
11091139-4	2000	The fMLP-mediated 5-LO product formation was also sensitive to MEK inhibition by U0126 and to p38 inhibition by SB203580.	U 0126	81-86	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
11281730-6	2000	This and UO126, another MEK inhibitor were ably to reproducibly inhibit p45-JNK activation induced by hydrogen peroxide.	U 0126	9-14	mitogen-activated protein kinase kinase 7	Homo sapiens	24-27
11022134-9	2000	This ERK activation can be blocked by pertussis toxin and by the MEK inhibitor U0126.	U 0126	79-84	mitogen-activated protein kinase 1	Homo sapiens	5-8
11022134-9	2000	This ERK activation can be blocked by pertussis toxin and by the MEK inhibitor U0126.	U 0126	79-84	mitogen-activated protein kinase kinase 7	Homo sapiens	65-68
11022134-10	2000	Most importantly, SDF-1-dependent HIV-1 expression is abolished by pretreating the cells with pertussis toxin or with U0126.	U 0126	118-123	C-X-C motif chemokine ligand 12	Homo sapiens	18-23
11281730-6	2000	This and UO126, another MEK inhibitor were ably to reproducibly inhibit p45-JNK activation induced by hydrogen peroxide.	U 0126	9-14	mitogen-activated protein kinase 8	Homo sapiens	76-79
11281730-9	2000	It is concluded that JNK mediates H(2)O(2)-induced cellular injury in the HT29 cell line, and additionally, we report for the first time that JNK activation can be inhibited by both PD98059 and UO126 at conventional doses used to inhibit MEK.	U 0126	194-199	mitogen-activated protein kinase 8	Homo sapiens	21-24
11281730-9	2000	It is concluded that JNK mediates H(2)O(2)-induced cellular injury in the HT29 cell line, and additionally, we report for the first time that JNK activation can be inhibited by both PD98059 and UO126 at conventional doses used to inhibit MEK.	U 0126	194-199	mitogen-activated protein kinase 8	Homo sapiens	142-145
11281730-9	2000	It is concluded that JNK mediates H(2)O(2)-induced cellular injury in the HT29 cell line, and additionally, we report for the first time that JNK activation can be inhibited by both PD98059 and UO126 at conventional doses used to inhibit MEK.	U 0126	194-199	mitogen-activated protein kinase kinase 7	Homo sapiens	238-241
10952721-8	2000	IL-12-induced IFN-gamma production in IL-12Rbeta1-deficient T cells could be inhibited by the p38 mitogen-activated protein kinase (MAP) kinase inhibitor SB203580 and the MAP kinase kinase (MEK) 1/2 inhibitor U0126, suggesting involvement of MAP kinases in this alternative, Stat4-independent, IL-12 signaling pathway.Collectively, these results indicate that IL-12 acts as a partial agonist in the absence of IL-12Rbeta1.	U 0126	209-214	interferon gamma	Homo sapiens	14-23
10942601-8	2000	The MEK inhibitor U0126 had an even more pronounced effect compared to AG 1478, indicating a Ras/MAPK-mediated signal in the regulation of Met expression and activation.	U 0126	18-23	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
10952721-8	2000	IL-12-induced IFN-gamma production in IL-12Rbeta1-deficient T cells could be inhibited by the p38 mitogen-activated protein kinase (MAP) kinase inhibitor SB203580 and the MAP kinase kinase (MEK) 1/2 inhibitor U0126, suggesting involvement of MAP kinases in this alternative, Stat4-independent, IL-12 signaling pathway.Collectively, these results indicate that IL-12 acts as a partial agonist in the absence of IL-12Rbeta1.	U 0126	209-214	mitogen-activated protein kinase kinase 2	Homo sapiens	171-198
10952721-8	2000	IL-12-induced IFN-gamma production in IL-12Rbeta1-deficient T cells could be inhibited by the p38 mitogen-activated protein kinase (MAP) kinase inhibitor SB203580 and the MAP kinase kinase (MEK) 1/2 inhibitor U0126, suggesting involvement of MAP kinases in this alternative, Stat4-independent, IL-12 signaling pathway.Collectively, these results indicate that IL-12 acts as a partial agonist in the absence of IL-12Rbeta1.	U 0126	209-214	interleukin 12 receptor subunit beta 1	Homo sapiens	38-49
10931950-7	2000	Proteasome depletion of the tumor lysates, addition of the specific MEK1/2 inhibitor U-0126, or a T187A mutation in recombinant p27 all prevented p27 degradation.	U 0126	85-91	mitogen-activated protein kinase kinase 1	Homo sapiens	68-74
10874134-4	2000	U0126 inhibited ERK activation, LT and PGD(2) release, and granulocyte macrophage-colony stimulating factor (GM-CSF) production after stimulation of HCMC.	U 0126	0-5	colony stimulating factor 2	Homo sapiens	59-107
10874134-4	2000	U0126 inhibited ERK activation, LT and PGD(2) release, and granulocyte macrophage-colony stimulating factor (GM-CSF) production after stimulation of HCMC.	U 0126	0-5	colony stimulating factor 2	Homo sapiens	109-115
10931950-7	2000	Proteasome depletion of the tumor lysates, addition of the specific MEK1/2 inhibitor U-0126, or a T187A mutation in recombinant p27 all prevented p27 degradation.	U 0126	85-91	interferon alpha inducible protein 27	Homo sapiens	146-149
10915907-4	2000	bFGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK.	U 0126	92-97	fibroblast growth factor 2	Homo sapiens	0-4
10899931-11	2000	OSM-induced IL-6 mRNA and protein expression is inhibited by the mitogen-activated protein kinase (MAPK) inhibitors U0126 and SB202190, suggesting a requirement for the MAPKs ERK1/2 and p38 in this response.	U 0126	116-121	interleukin 6	Homo sapiens	12-16
10899931-11	2000	OSM-induced IL-6 mRNA and protein expression is inhibited by the mitogen-activated protein kinase (MAPK) inhibitors U0126 and SB202190, suggesting a requirement for the MAPKs ERK1/2 and p38 in this response.	U 0126	116-121	mitogen-activated protein kinase 3	Homo sapiens	99-103
10915907-4	2000	bFGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK.	U 0126	92-97	mitogen-activated protein kinase 3	Homo sapiens	13-19
10915907-4	2000	bFGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK.	U 0126	92-97	mitogen-activated protein kinase kinase 7	Homo sapiens	152-155
10915910-6	2000	A novel MAPK kinase (MEK1) inhibitor U0126 blocked the activation of MAPK and the proliferation of primary cells more effectively than the same concentration of PD98059.	U 0126	37-42	mitogen-activated protein kinase kinase 1	Homo sapiens	21-25
10876086-0	2000	Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons.	U 0126	51-56	mitogen-activated protein kinase 1	Mus musculus	24-27
10876086-4	2000	Here, we show that a novel MAPK/ERK kinase (MEK) specific inhibitor U0126 profoundly protected HT22 cells against oxidative stress induced by glutamate, which was accompanied by an inhibition of phosphorylation of ERK1/2.	U 0126	68-73	mitogen-activated protein kinase 1	Mus musculus	32-35
10876086-4	2000	Here, we show that a novel MAPK/ERK kinase (MEK) specific inhibitor U0126 profoundly protected HT22 cells against oxidative stress induced by glutamate, which was accompanied by an inhibition of phosphorylation of ERK1/2.	U 0126	68-73	mitogen-activated protein kinase 3	Mus musculus	214-220
10903976-0	2000	The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.	U 0126	37-42	interleukin 1 beta	Homo sapiens	65-73
10940738-8	2000	ERK activation by VIP or PACAP38 and TRH were additive and both sensitive to the MEK inhibitors PD98059 and U0126.	U 0126	108-113	Eph receptor B1	Rattus norvegicus	0-3
10940738-8	2000	ERK activation by VIP or PACAP38 and TRH were additive and both sensitive to the MEK inhibitors PD98059 and U0126.	U 0126	108-113	vasoactive intestinal peptide	Rattus norvegicus	18-21
10940738-8	2000	ERK activation by VIP or PACAP38 and TRH were additive and both sensitive to the MEK inhibitors PD98059 and U0126.	U 0126	108-113	thyrotropin releasing hormone	Rattus norvegicus	37-40
10940738-9	2000	In parallel, U0126 reduced prolactin (PRL) mRNA levels induced by VIP.	U 0126	13-18	prolactin	Rattus norvegicus	38-41
10940738-9	2000	In parallel, U0126 reduced prolactin (PRL) mRNA levels induced by VIP.	U 0126	13-18	vasoactive intestinal peptide	Rattus norvegicus	66-69
10856236-3	2000	UO126, an inhibitor of MAP kinase kinase 1 (MEK1), suppressed focal adhesion targeting of active ERK and cell spreading.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	23-42
10903976-13	2000	In contrast, UO126 was highly effective at inhibiting IL-1beta-dependent arachidonate release, implicating MEK2 in the activation of the PLA(2) that is involved in IL-1beta-dependent PGE(2) release.	U 0126	13-18	interleukin 1 beta	Homo sapiens	54-62
10903976-13	2000	In contrast, UO126 was highly effective at inhibiting IL-1beta-dependent arachidonate release, implicating MEK2 in the activation of the PLA(2) that is involved in IL-1beta-dependent PGE(2) release.	U 0126	13-18	mitogen-activated protein kinase kinase 2	Homo sapiens	107-111
10903976-13	2000	In contrast, UO126 was highly effective at inhibiting IL-1beta-dependent arachidonate release, implicating MEK2 in the activation of the PLA(2) that is involved in IL-1beta-dependent PGE(2) release.	U 0126	13-18	interleukin 1 beta	Homo sapiens	164-172
10903976-15	2000	We conclude that the MEK1, MEK2 and p38 MAP kinase inhibitors, PD098059, UO126 and SB203580, are highly potent in respect of inflammatory PG release.	U 0126	73-78	mitogen-activated protein kinase kinase 1	Homo sapiens	21-25
10903976-15	2000	We conclude that the MEK1, MEK2 and p38 MAP kinase inhibitors, PD098059, UO126 and SB203580, are highly potent in respect of inflammatory PG release.	U 0126	73-78	mitogen-activated protein kinase kinase 2	Homo sapiens	27-31
10903976-15	2000	We conclude that the MEK1, MEK2 and p38 MAP kinase inhibitors, PD098059, UO126 and SB203580, are highly potent in respect of inflammatory PG release.	U 0126	73-78	mitogen-activated protein kinase 14	Homo sapiens	36-39
10845922-5	2000	U0126, a potent inhibitor of the upstream activator of ERK1/2, ie, MEK1/2, suppresses IL-1beta messenger RNA (mRNA) expression in a dose-dependent fashion, showing the implication of this pathway in the transcriptional control of IL-1beta production.	U 0126	0-5	mitogen-activated protein kinase 3	Homo sapiens	55-61
10845922-5	2000	U0126, a potent inhibitor of the upstream activator of ERK1/2, ie, MEK1/2, suppresses IL-1beta messenger RNA (mRNA) expression in a dose-dependent fashion, showing the implication of this pathway in the transcriptional control of IL-1beta production.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Homo sapiens	67-73
10845922-5	2000	U0126, a potent inhibitor of the upstream activator of ERK1/2, ie, MEK1/2, suppresses IL-1beta messenger RNA (mRNA) expression in a dose-dependent fashion, showing the implication of this pathway in the transcriptional control of IL-1beta production.	U 0126	0-5	interleukin 1 beta	Homo sapiens	86-94
10845922-5	2000	U0126, a potent inhibitor of the upstream activator of ERK1/2, ie, MEK1/2, suppresses IL-1beta messenger RNA (mRNA) expression in a dose-dependent fashion, showing the implication of this pathway in the transcriptional control of IL-1beta production.	U 0126	0-5	interleukin 1 beta	Homo sapiens	230-238
10856236-3	2000	UO126, an inhibitor of MAP kinase kinase 1 (MEK1), suppressed focal adhesion targeting of active ERK and cell spreading.	U 0126	0-5	mitogen activated protein kinase kinase 1	Rattus norvegicus	44-48
10856236-3	2000	UO126, an inhibitor of MAP kinase kinase 1 (MEK1), suppressed focal adhesion targeting of active ERK and cell spreading.	U 0126	0-5	Eph receptor B1	Rattus norvegicus	97-100
10880840-3	2000	ERK is phosphorylated by MEK-1 and PD098059 and U0126 are specific inhibitors for this kinase.	U 0126	48-53	Eph receptor B1	Rattus norvegicus	0-3
10655493-5	2000	The increase in Sox9 levels induced by FGF2 was inhibited by a specific mitogen-activated protein kinase kinase (MAPKK)/mitogen-activated protein kinase/ERK kinase (MEK) inhibitor U0126 in primary chondrocytes.	U 0126	180-185	SRY (sex determining region Y)-box 9	Mus musculus	16-20
10823417-10	2000	Similar results were obtained upon the inhibition of AP-1 activation with the MEK1/2 inhibitor, U0126.	U 0126	96-101	mitogen-activated protein kinase kinase 1	Homo sapiens	78-84
10766856-6	2000	Furthermore, we find that U0126, a specific inhibitor of the ERK-activating kinase, MEK-1/2, protects both HT22 cells and immature primary cortical neuron cultures from glutamate toxicity.	U 0126	26-31	mitogen-activated protein kinase 1	Mus musculus	61-64
10766856-6	2000	Furthermore, we find that U0126, a specific inhibitor of the ERK-activating kinase, MEK-1/2, protects both HT22 cells and immature primary cortical neuron cultures from glutamate toxicity.	U 0126	26-31	mitogen-activated protein kinase kinase 1	Mus musculus	84-91
10751432-10	2000	Finally, BDNF caused phosphorylation of mitogen-activated protein kinase (MAPK), and because the treatment with the MAPK inhibitor U0126 completely abolished CREB activation and c-fos upregulation, it is likely that both processes depend mainly on the MAP kinase pathway.	U 0126	131-136	brain-derived neurotrophic factor	Rattus norvegicus	9-13
10751432-10	2000	Finally, BDNF caused phosphorylation of mitogen-activated protein kinase (MAPK), and because the treatment with the MAPK inhibitor U0126 completely abolished CREB activation and c-fos upregulation, it is likely that both processes depend mainly on the MAP kinase pathway.	U 0126	131-136	cAMP responsive element binding protein 1	Rattus norvegicus	158-162
10751432-10	2000	Finally, BDNF caused phosphorylation of mitogen-activated protein kinase (MAPK), and because the treatment with the MAPK inhibitor U0126 completely abolished CREB activation and c-fos upregulation, it is likely that both processes depend mainly on the MAP kinase pathway.	U 0126	131-136	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	178-183
10734171-4	2000	Moreover, U0126 inhibited staurosporine-induced arachidonic acid release at 1 h. Although PD98059 and U0126 at 30 microM partially inhibited staurosporine-induced COX-2 protein expression, they completely inhibited staurosporine-induced PGE(2) production.	U 0126	10-15	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	163-168
10734171-4	2000	Moreover, U0126 inhibited staurosporine-induced arachidonic acid release at 1 h. Although PD98059 and U0126 at 30 microM partially inhibited staurosporine-induced COX-2 protein expression, they completely inhibited staurosporine-induced PGE(2) production.	U 0126	102-107	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	163-168
10722758-6	2000	ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERK activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, blocked AQP5 induction.	U 0126	193-198	mitogen-activated protein kinase 1	Mus musculus	0-3
10722758-6	2000	ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERK activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, blocked AQP5 induction.	U 0126	193-198	mitogen-activated protein kinase 1	Mus musculus	86-89
10722758-6	2000	ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERK activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, blocked AQP5 induction.	U 0126	193-198	aquaporin 5	Mus musculus	220-224
10713051-9	2000	Conversely, the MEK inhibitors PD98059 and UO126 could attenuate EGF-induced mitogen-activated protein kinase activation, they do not affect the EGF-induced mobility shift of caveolin-1.	U 0126	43-48	epidermal growth factor	Mus musculus	65-68
10713403-4	2000	EGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK.	U 0126	91-96	epidermal growth factor like 1	Rattus norvegicus	0-3
10713403-4	2000	EGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK.	U 0126	91-96	mitogen activated protein kinase 3	Rattus norvegicus	12-18
10811109-3	2000	Similarly, a Ras farnesyltransferase inhibitor, manumycin A, and a MEK1 inhibitor, U0126, suppressed MMP secretion in a dose-dependent manner, whereas a PI3 kinase inhibitor, wortmannin, could not.	U 0126	83-88	mitogen-activated protein kinase kinase 1	Homo sapiens	67-71
10737896-3	2000	Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin.	U 0126	129-134	mitogen-activated protein kinase 1	Mus musculus	88-91
10737896-3	2000	Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin.	U 0126	129-134	mitogen-activated protein kinase 1	Mus musculus	157-160
10737896-3	2000	Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin.	U 0126	129-134	Sec23 interacting protein	Mus musculus	220-224
10737896-3	2000	Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin.	U 0126	129-134	PTK2 protein tyrosine kinase 2	Mus musculus	225-228
10737896-3	2000	Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin.	U 0126	129-134	nucleolar and coiled-body phosphoprotein 1	Mus musculus	231-235
10737896-3	2000	Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin.	U 0126	129-134	breast cancer anti-estrogen resistance 1	Mus musculus	236-239
10777769-4	2000	Inhibition of the ERK signaling cascade with either PD 098059 or U0126 prevented the induction of both 200 Hz-LTP and TEA-LTP in area CA1.	U 0126	65-70	mitogen-activated protein kinase 1	Homo sapiens	18-21
10777769-4	2000	Inhibition of the ERK signaling cascade with either PD 098059 or U0126 prevented the induction of both 200 Hz-LTP and TEA-LTP in area CA1.	U 0126	65-70	carbonic anhydrase 1	Homo sapiens	134-137
10777769-8	2000	The forskolin-induced increase in active ERK was inhibited by U0126, whereas the increase in CREB phosphorylation was not, which suggests that in area CA3 the PKA cascade is not coupled to CREB phosphorylation via ERK.	U 0126	62-67	mitogen-activated protein kinase 1	Homo sapiens	41-44
10757809-8	2000	Transient transfection of a constitutively active Mek1, a specific upstream activator of ERKs, maintained myoblast viability in the absence of growth factors, while inhibition of Mek1 by the drug UO126 blocked PDGF-mediated but not IGF-stimulated survival.	U 0126	196-201	mitogen-activated protein kinase kinase 1	Homo sapiens	50-54
10757809-8	2000	Transient transfection of a constitutively active Mek1, a specific upstream activator of ERKs, maintained myoblast viability in the absence of growth factors, while inhibition of Mek1 by the drug UO126 blocked PDGF-mediated but not IGF-stimulated survival.	U 0126	196-201	mitogen-activated protein kinase 3	Homo sapiens	89-93
10757809-8	2000	Transient transfection of a constitutively active Mek1, a specific upstream activator of ERKs, maintained myoblast viability in the absence of growth factors, while inhibition of Mek1 by the drug UO126 blocked PDGF-mediated but not IGF-stimulated survival.	U 0126	196-201	mitogen-activated protein kinase kinase 1	Homo sapiens	179-183
10801413-7	2000	U0126-treated oocytes expressing a constitutively active form of p90(Rsk) were able to reaccumulate cyclin B, hyperphosphorylate Cdc27 and form metaphase spindles in the absence of detectable MAP kinase activity.	U 0126	0-5	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	65-68
10801413-7	2000	U0126-treated oocytes expressing a constitutively active form of p90(Rsk) were able to reaccumulate cyclin B, hyperphosphorylate Cdc27 and form metaphase spindles in the absence of detectable MAP kinase activity.	U 0126	0-5	ribosomal protein S6 kinase A3 L homeolog	Xenopus laevis	69-72
10801413-7	2000	U0126-treated oocytes expressing a constitutively active form of p90(Rsk) were able to reaccumulate cyclin B, hyperphosphorylate Cdc27 and form metaphase spindles in the absence of detectable MAP kinase activity.	U 0126	0-5	cell division cycle 27 S homeolog	Xenopus laevis	129-134
10786668-2	2000	Immunoblot analyses with phosphospecific antibodies indicated that in addition to MAPK, U0126 suppressed activation of p70(S6K), but not Akt, at concentrations at which it normalized the transformed phenotypes.	U 0126	88-93	ribosomal protein S6 kinase B1	Rattus norvegicus	123-126
10786668-6	2000	The results suggest that normalization of Ki-ras-induced transformed phenotypes by U0126 is a consequence of concurrent inhibition of the MAPK and p70S6K pathways.	U 0126	83-88	ribosomal protein S6 kinase B1	Rattus norvegicus	147-153
10753897-7	2000	The biological relevance of ERK activation to IL-5 priming is supported by the observation that inhibition of ERK activity by treatment with the MEK inhibitors PD98059 or U0126 inhibited the release of leukotriene C(4) stimulated by fMet-Leu-Phe in IL-5-primed eosinophils.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	28-31
10753897-7	2000	The biological relevance of ERK activation to IL-5 priming is supported by the observation that inhibition of ERK activity by treatment with the MEK inhibitors PD98059 or U0126 inhibited the release of leukotriene C(4) stimulated by fMet-Leu-Phe in IL-5-primed eosinophils.	U 0126	171-176	interleukin 5	Homo sapiens	46-50
10753897-7	2000	The biological relevance of ERK activation to IL-5 priming is supported by the observation that inhibition of ERK activity by treatment with the MEK inhibitors PD98059 or U0126 inhibited the release of leukotriene C(4) stimulated by fMet-Leu-Phe in IL-5-primed eosinophils.	U 0126	171-176	mitogen-activated protein kinase 1	Homo sapiens	110-113
10753897-7	2000	The biological relevance of ERK activation to IL-5 priming is supported by the observation that inhibition of ERK activity by treatment with the MEK inhibitors PD98059 or U0126 inhibited the release of leukotriene C(4) stimulated by fMet-Leu-Phe in IL-5-primed eosinophils.	U 0126	171-176	interleukin 5	Homo sapiens	249-253
10733512-5	2000	Inhibition of ERK activity by UO126 induces erythroid differentiation and acts synergistically with butyrate on hemoglobin synthesis and inhibition of cell proliferation, whereas inhibition of p38 activity by SB203580 completely abolished induction of hemoglobin expression by butyrate.	U 0126	30-35	mitogen-activated protein kinase 1	Homo sapiens	14-17
10733581-4	2000	Expression of an activated form of Raf (Raf-BXB) also inhibits TTF-1 function to a similar extent, while the MEK inhibitors U0126 and PD98059 partially relieve Ras-mediated inactivation of TTF-1, suggesting that the extracellular signal-regulated kinase (ERK) pathway is involved in this process.	U 0126	124-129	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
10722699-7	2000	Consistent with our hypothesis, exogenous H(2)O(2)-mediated repression of alpha-ENaC GRE activity is partially blocked by either a specific inhibitor for extracellular signal-regulated kinase (ERK) pathway activation, U0126, or dominant negative ERK, suggesting that, in part, activated ERK may mediate the repressive effects of H(2)O(2) on alpha-ENaC expression.	U 0126	218-223	sodium channel epithelial 1 subunit alpha	Homo sapiens	74-84
10679258-5	2000	Topical treatment of ears with the MEK inhibitor, U0126, prevents ERK phosphorylation and ear swelling in a dose-dependent manner in this model.	U 0126	50-55	mitogen-activated protein kinase 1	Mus musculus	66-69
10711350-12	2000	The other MEK-1 inhibitor, U-0126, also inhibited both the thapsigargin- and TPA-induced histamine production in a concentration-dependent manner.	U 0126	27-33	mitogen-activated protein kinase kinase 1	Mus musculus	10-15
10655493-5	2000	The increase in Sox9 levels induced by FGF2 was inhibited by a specific mitogen-activated protein kinase kinase (MAPKK)/mitogen-activated protein kinase/ERK kinase (MEK) inhibitor U0126 in primary chondrocytes.	U 0126	180-185	fibroblast growth factor 2	Mus musculus	39-43
10655493-5	2000	The increase in Sox9 levels induced by FGF2 was inhibited by a specific mitogen-activated protein kinase kinase (MAPKK)/mitogen-activated protein kinase/ERK kinase (MEK) inhibitor U0126 in primary chondrocytes.	U 0126	180-185	mitogen-activated protein kinase kinase 1	Mus musculus	165-168
10657432-7	2000	(2) MAPK inhibitors PD-98059 and U-0126 produced dose-dependent inhibition of ET-1-induced contraction.	U 0126	33-39	endothelin-1	Oryctolagus cuniculus	78-82
10657432-10	2000	(5) In arteries precontracted by ET-1, PD-98059, U-0126, wortmannin, AG-490, genistein, and staurosporine produced concentration-dependent relaxation.	U 0126	49-55	endothelin-1	Oryctolagus cuniculus	33-37
10657432-12	2000	(7) PD-98059, U-0126, genistein, AG-490, and damnacanthal, but not staurosporine or wortmannin, abolished the effect of ET-1 on MAPK immunoreactivity.	U 0126	14-20	endothelin-1	Oryctolagus cuniculus	120-124
10648867-5	2000	This BDNF-dependent expression of GABA(A) receptor subunit mRNAs could be effectively blocked by treatment with the mitogen-activated protein kinase kinase (MEK) inhibitors, PD98059 or U0126.	U 0126	185-190	brain derived neurotrophic factor	Mus musculus	5-9
11467775-4	2000	Treatment of cells with MEK1 inhibitors, U0126 and PD98059, dramatically suppressed the secretion of MMP-9 activated by FN.	U 0126	41-46	mitogen-activated protein kinase kinase 1	Homo sapiens	24-28
11467775-4	2000	Treatment of cells with MEK1 inhibitors, U0126 and PD98059, dramatically suppressed the secretion of MMP-9 activated by FN.	U 0126	41-46	matrix metallopeptidase 9	Homo sapiens	101-106
11467775-4	2000	Treatment of cells with MEK1 inhibitors, U0126 and PD98059, dramatically suppressed the secretion of MMP-9 activated by FN.	U 0126	41-46	fibronectin 1	Homo sapiens	120-122
10649432-5	2000	This observation was further confirmed by experiments using inhibitors of the ERK pathway (i.e., PD and U0126), which increased type I collagen mRNA in MC3T3-E1 cells, indicating that the inhibition of ERK pathway upregulates type I collagen gene expression.	U 0126	104-109	mitogen-activated protein kinase 1	Mus musculus	78-81
10649432-5	2000	This observation was further confirmed by experiments using inhibitors of the ERK pathway (i.e., PD and U0126), which increased type I collagen mRNA in MC3T3-E1 cells, indicating that the inhibition of ERK pathway upregulates type I collagen gene expression.	U 0126	104-109	mitogen-activated protein kinase 1	Mus musculus	202-205
10617147-9	2000	U0126, another chemically unrelated inhibitor of the MAPK cascade, mimicked the effect of PD98059 on mu-receptor phosphorylation and desensitization.	U 0126	0-5	mitogen-activated protein kinase 1	Homo sapiens	53-57
10393094-5	1999	U0126, a novel and more potent inhibitor of MEK1/2, provoked a dose-dependent inhibition of ODC induction at lower concentrations with respect to PD98059.	U 0126	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	44-50
10576211-4	1999	The IL-8-guided migration through an imitation of inflammatory matrix, a fibrin gel, was impaired by 90% after treatment with 7 microM U0126, a specific inhibitor of the kinase of p44/42 kinase.	U 0126	135-140	C-X-C motif chemokine ligand 8	Homo sapiens	4-8
10576211-4	1999	The IL-8-guided migration through an imitation of inflammatory matrix, a fibrin gel, was impaired by 90% after treatment with 7 microM U0126, a specific inhibitor of the kinase of p44/42 kinase.	U 0126	135-140	interferon induced protein 44	Homo sapiens	180-183
10473620-5	1999	The epidermal growth factor-induced activation of ERK5 was found to be inhibited by PD98059 and U0126 inhibitors, which were previously thought to act specifically on classical MAPK kinase (also known as MEK1) and readily reversed by CL100 and MKP-3 dual-specificity phosphatases for which classical MAPKs were previously shown to serve as preferred substrates.	U 0126	96-101	mitogen-activated protein kinase 7	Rattus norvegicus	50-54
10473620-5	1999	The epidermal growth factor-induced activation of ERK5 was found to be inhibited by PD98059 and U0126 inhibitors, which were previously thought to act specifically on classical MAPK kinase (also known as MEK1) and readily reversed by CL100 and MKP-3 dual-specificity phosphatases for which classical MAPKs were previously shown to serve as preferred substrates.	U 0126	96-101	mitogen activated protein kinase kinase 1	Rattus norvegicus	204-208
10473620-5	1999	The epidermal growth factor-induced activation of ERK5 was found to be inhibited by PD98059 and U0126 inhibitors, which were previously thought to act specifically on classical MAPK kinase (also known as MEK1) and readily reversed by CL100 and MKP-3 dual-specificity phosphatases for which classical MAPKs were previously shown to serve as preferred substrates.	U 0126	96-101	dual specificity phosphatase 1	Rattus norvegicus	234-239
10473620-5	1999	The epidermal growth factor-induced activation of ERK5 was found to be inhibited by PD98059 and U0126 inhibitors, which were previously thought to act specifically on classical MAPK kinase (also known as MEK1) and readily reversed by CL100 and MKP-3 dual-specificity phosphatases for which classical MAPKs were previously shown to serve as preferred substrates.	U 0126	96-101	dual specificity phosphatase 6	Rattus norvegicus	244-249
10484455-6	1999	Two different inhibitors of MAPK/extracellular signal-regulated kinase kinase (MEK), PD-98059 and U-0126, inhibited mitogen-induced [3H]thymidine incorporation in a manner consistent with their ability to inhibit p42/p44 activation.	U 0126	98-104	mitogen-activated protein kinase 3	Homo sapiens	28-32
10484455-6	1999	Two different inhibitors of MAPK/extracellular signal-regulated kinase kinase (MEK), PD-98059 and U-0126, inhibited mitogen-induced [3H]thymidine incorporation in a manner consistent with their ability to inhibit p42/p44 activation.	U 0126	98-104	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
10484455-6	1999	Two different inhibitors of MAPK/extracellular signal-regulated kinase kinase (MEK), PD-98059 and U-0126, inhibited mitogen-induced [3H]thymidine incorporation in a manner consistent with their ability to inhibit p42/p44 activation.	U 0126	98-104	cyclin dependent kinase 20	Homo sapiens	213-216
10484455-6	1999	Two different inhibitors of MAPK/extracellular signal-regulated kinase kinase (MEK), PD-98059 and U-0126, inhibited mitogen-induced [3H]thymidine incorporation in a manner consistent with their ability to inhibit p42/p44 activation.	U 0126	98-104	interferon induced protein 44	Homo sapiens	217-220
10544002-9	1999	Further, the MEK inhibitor U0126 markedly inhibited S1P-induced tube formation but S1P-induced migration was not affected by inhibition of ERK and p38 MAPK.	U 0126	27-32	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
10544002-9	1999	Further, the MEK inhibitor U0126 markedly inhibited S1P-induced tube formation but S1P-induced migration was not affected by inhibition of ERK and p38 MAPK.	U 0126	27-32	sphingosine-1-phosphate receptor 1	Mus musculus	52-55
10455174-8	1999	The selective inhibitors of mitogen-activated protein kinase kinase, i.e. PD98059 and U0126, inhibit LIF-induced C/EBP gene expression and prevent adipocyte differentiation induced by LIF.	U 0126	86-91	leukemia inhibitory factor	Mus musculus	101-104
10455174-8	1999	The selective inhibitors of mitogen-activated protein kinase kinase, i.e. PD98059 and U0126, inhibit LIF-induced C/EBP gene expression and prevent adipocyte differentiation induced by LIF.	U 0126	86-91	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	113-118
10455174-8	1999	The selective inhibitors of mitogen-activated protein kinase kinase, i.e. PD98059 and U0126, inhibit LIF-induced C/EBP gene expression and prevent adipocyte differentiation induced by LIF.	U 0126	86-91	leukemia inhibitory factor	Mus musculus	184-187
10393815-3	1999	This is prevented by the MEK inhibitors PD 098059 and U0126, which also inhibit FGF2-mediated upregulation of urokinase-type plasminogen activator (uPA) and in vitro formation of capillary-like structures in three-dimensional type I collagen gel.	U 0126	54-59	fibroblast growth factor 2	Bos taurus	80-84
10393815-3	1999	This is prevented by the MEK inhibitors PD 098059 and U0126, which also inhibit FGF2-mediated upregulation of urokinase-type plasminogen activator (uPA) and in vitro formation of capillary-like structures in three-dimensional type I collagen gel.	U 0126	54-59	plasminogen activator, urokinase	Bos taurus	110-146
10393815-3	1999	This is prevented by the MEK inhibitors PD 098059 and U0126, which also inhibit FGF2-mediated upregulation of urokinase-type plasminogen activator (uPA) and in vitro formation of capillary-like structures in three-dimensional type I collagen gel.	U 0126	54-59	plasminogen activator, urokinase	Bos taurus	148-151
10436007-13	1999	Neutralization of TGFalpha function by an anti-TGFalpha antibody or inhibition of MAPK function by MEK1/2 inhibitors (PD98059 and U0126) radiosensitized A431 and MDA-MB-231 cells after irradiation in apoptosis, 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), and clonogenic assays.	U 0126	130-135	mitogen-activated protein kinase kinase 1	Homo sapiens	99-105
10393094-5	1999	U0126, a novel and more potent inhibitor of MEK1/2, provoked a dose-dependent inhibition of ODC induction at lower concentrations with respect to PD98059.	U 0126	0-5	ornithine decarboxylase, structural 1	Mus musculus	92-95
10102471-11	1999	PD 098059 and U0126, both highly specific MEK inhibitors, efficiently prevented PMA-induced PAI-1 synthesis (mRNA and protein levels) and cell adhesion whereas SB203580, a specific inhibitor of stress-activated MAPK p38, did not.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
10080949-4	1999	The inhibition by alpha-thrombin was attenuated if cells were pretreated with U0126, a specific inhibitor of the mitogen-activated protein (MAP) kinase kinase 1 (MAPKK1).	U 0126	78-83	coagulation factor II, thrombin	Homo sapiens	24-32
10080949-4	1999	The inhibition by alpha-thrombin was attenuated if cells were pretreated with U0126, a specific inhibitor of the mitogen-activated protein (MAP) kinase kinase 1 (MAPKK1).	U 0126	78-83	mitogen-activated protein kinase kinase 1	Homo sapiens	162-168
10395291-7	1999	We demonstrate suppression of crystal-induced MMPs via the utilization of two different MEK inhibitors: PD98059 and the recently described U0126, a novel inhibitor of MEK1 and MEK2.	U 0126	139-144	matrix metallopeptidase 1	Homo sapiens	46-50
10395291-7	1999	We demonstrate suppression of crystal-induced MMPs via the utilization of two different MEK inhibitors: PD98059 and the recently described U0126, a novel inhibitor of MEK1 and MEK2.	U 0126	139-144	mitogen-activated protein kinase kinase 1	Homo sapiens	167-171
10395291-7	1999	We demonstrate suppression of crystal-induced MMPs via the utilization of two different MEK inhibitors: PD98059 and the recently described U0126, a novel inhibitor of MEK1 and MEK2.	U 0126	139-144	mitogen-activated protein kinase kinase 2	Homo sapiens	176-180
10395291-11	1999	Treatment of HF with U0126 inhibits EGF-induced phosphorylation of p42/44 MAPK as well as crystal- and EGF-induced upregulation of MMP-1 mRNA.	U 0126	21-26	cyclin dependent kinase 20	Homo sapiens	67-70
10395291-11	1999	Treatment of HF with U0126 inhibits EGF-induced phosphorylation of p42/44 MAPK as well as crystal- and EGF-induced upregulation of MMP-1 mRNA.	U 0126	21-26	matrix metallopeptidase 1	Homo sapiens	131-136
10102471-11	1999	PD 098059 and U0126, both highly specific MEK inhibitors, efficiently prevented PMA-induced PAI-1 synthesis (mRNA and protein levels) and cell adhesion whereas SB203580, a specific inhibitor of stress-activated MAPK p38, did not.	U 0126	14-19	serpin family E member 1	Homo sapiens	92-97
10102471-11	1999	PD 098059 and U0126, both highly specific MEK inhibitors, efficiently prevented PMA-induced PAI-1 synthesis (mRNA and protein levels) and cell adhesion whereas SB203580, a specific inhibitor of stress-activated MAPK p38, did not.	U 0126	14-19	mitogen-activated protein kinase 14	Homo sapiens	216-219
9917510-9	1999	In brief, we have demonstrated that the PKC activator 12-O-tetradecanoyl phorbol 13-acetate (TPA)-induced luciferase activity in this cell system is mediated via the MAP kinase pathway and can be blocked in the presence of MEK1 selective inhibitors (PD 098059 or U0126).	U 0126	263-268	mitogen-activated protein kinase kinase 1	Homo sapiens	223-227
9873633-0	1998	MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.	U 0126	57-62	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
9820549-3	1998	To address this issue, we used the novel MAP/ERK kinase (MEK) inhibitor, U0126.	U 0126	73-78	mitogen-activated protein kinase 1	Homo sapiens	45-48
9820549-3	1998	To address this issue, we used the novel MAP/ERK kinase (MEK) inhibitor, U0126.	U 0126	73-78	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
9820549-5	1998	Treatment of monocytes with LPS in the presence of U0126 blocked the activation of ERK1 and ERK2.	U 0126	51-56	mitogen-activated protein kinase 3	Homo sapiens	83-87
9820549-5	1998	Treatment of monocytes with LPS in the presence of U0126 blocked the activation of ERK1 and ERK2.	U 0126	51-56	mitogen-activated protein kinase 1	Homo sapiens	92-96
9873633-1	1998	In search of antiinflammatory drugs with a new mechanism of action, U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with an IC50 of 0.07 microM for MEK 1 and 0.06 microM for MEK 2.	U 0126	68-73	mitogen-activated protein kinase kinase 7	Homo sapiens	202-205
9873633-1	1998	In search of antiinflammatory drugs with a new mechanism of action, U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with an IC50 of 0.07 microM for MEK 1 and 0.06 microM for MEK 2.	U 0126	68-73	mitogen-activated protein kinase kinase 1	Homo sapiens	238-243
9873633-1	1998	In search of antiinflammatory drugs with a new mechanism of action, U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with an IC50 of 0.07 microM for MEK 1 and 0.06 microM for MEK 2.	U 0126	68-73	mitogen-activated protein kinase kinase 2	Homo sapiens	264-269
9873633-2	1998	U0126 can undergo isomerization and cyclization reactions to form a variety of products, both chemically and in vivo, all of which exhibit less affinity for MEK and lower inhibition of AP-1 activity than parent, U0126.	U 0126	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	157-160
33771483-7	2021	In this study, we found that PD-L1 induces the upregulation of CD206 expression, which is inhibited by nivolumab, LY294002, U0126, and rapamycin.	U 0126	124-129	CD274 molecule	Homo sapiens	29-34
9660836-1	1998	The compound U0126 (1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene) was identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay.	U 0126	13-18	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-120
9660836-1	1998	The compound U0126 (1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene) was identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay.	U 0126	20-80	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-120
9660836-2	1998	U0126 was also shown to inhibit endogenous promoters containing AP-1 response elements but did not affect genes lacking an AP-1 response element in their promoters.	U 0126	0-5	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-68
9660836-3	1998	These effects of U0126 result from direct inhibition of the mitogen-activated protein kinase kinase family members, MEK-1 and MEK-2.	U 0126	17-22	mitogen-activated protein kinase kinase 1	Homo sapiens	116-121
9660836-3	1998	These effects of U0126 result from direct inhibition of the mitogen-activated protein kinase kinase family members, MEK-1 and MEK-2.	U 0126	17-22	mitogen-activated protein kinase kinase 2	Homo sapiens	126-131
9660836-9	1998	92, 7686-7689) demonstrates that U0126 and PD098059 are noncompetitive inhibitors with respect to both MEK substrates, ATP and ERK.	U 0126	33-38	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
9660836-9	1998	92, 7686-7689) demonstrates that U0126 and PD098059 are noncompetitive inhibitors with respect to both MEK substrates, ATP and ERK.	U 0126	33-38	mitogen-activated protein kinase 1	Homo sapiens	127-130
9660836-11	1998	Quantitative evaluation of the steady state kinetics of MEK inhibition by these compounds reveals that U0126 has approximately 100-fold higher affinity for deltaN3-S218E/S222D MEK than does PD098059.	U 0126	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
9660836-11	1998	Quantitative evaluation of the steady state kinetics of MEK inhibition by these compounds reveals that U0126 has approximately 100-fold higher affinity for deltaN3-S218E/S222D MEK than does PD098059.	U 0126	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	176-179
9660836-15	1998	The MEK affinity of U0126, its selectivity for MEK over other kinases, and its cellular efficacy suggest that this compound will serve as a powerful tool for in vitro and cellular investigations of mitogen-activated protein kinase-mediated signal transduction.	U 0126	20-25	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
9660836-15	1998	The MEK affinity of U0126, its selectivity for MEK over other kinases, and its cellular efficacy suggest that this compound will serve as a powerful tool for in vitro and cellular investigations of mitogen-activated protein kinase-mediated signal transduction.	U 0126	20-25	mitogen-activated protein kinase kinase 7	Homo sapiens	47-50
9574517-2	1998	To examine the effects of blocking the ERK pathway on T cell activation, we used the inhibitor U0126, which has been shown to specifically block mitogen-activated protein kinase/ERK kinase (MEK), the kinase upstream of ERK.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	39-42
9574517-2	1998	To examine the effects of blocking the ERK pathway on T cell activation, we used the inhibitor U0126, which has been shown to specifically block mitogen-activated protein kinase/ERK kinase (MEK), the kinase upstream of ERK.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	178-181
9574517-2	1998	To examine the effects of blocking the ERK pathway on T cell activation, we used the inhibitor U0126, which has been shown to specifically block mitogen-activated protein kinase/ERK kinase (MEK), the kinase upstream of ERK.	U 0126	95-100	mitogen-activated protein kinase kinase 7	Homo sapiens	190-193
9574517-2	1998	To examine the effects of blocking the ERK pathway on T cell activation, we used the inhibitor U0126, which has been shown to specifically block mitogen-activated protein kinase/ERK kinase (MEK), the kinase upstream of ERK.	U 0126	95-100	mitogen-activated protein kinase 1	Homo sapiens	178-181
33771483-7	2021	In this study, we found that PD-L1 induces the upregulation of CD206 expression, which is inhibited by nivolumab, LY294002, U0126, and rapamycin.	U 0126	124-129	mannose receptor C-type 1	Homo sapiens	63-68
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	76-79
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	MAPK interacting serine/threonine kinase 1	Homo sapiens	91-95
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	MAPK interacting serine/threonine kinase 1	Homo sapiens	123-127
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	166-169
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	mitogen-activated protein kinase 1	Homo sapiens	166-169
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	ATPase copper transporting alpha	Homo sapiens	215-218
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	230-233
28766096-10	2018	MEK inhibitor U0126 also significantly enhances chemotherapeutic agents" inhibitory effects.	U 0126	14-19	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
26384551-6	2015	Dual inhibition of BRAF(V600E) and MEK reduced but did not prevent SW1736 invasion although rebound phosphorylation of ERK in response to PLX4720 was blocked by U0126.	U 0126	161-166	mitogen-activated protein kinase 1	Homo sapiens	119-122
32502508-8	2020	Treatment with alpha7nAChR agonist PNU282987 or ERK inhibitor U0126 reversed Abeta-induced 5-HT1A and 5-HT2C receptor changes.	U 0126	62-67	mitogen-activated protein kinase 1	Mus musculus	48-51
32502508-8	2020	Treatment with alpha7nAChR agonist PNU282987 or ERK inhibitor U0126 reversed Abeta-induced 5-HT1A and 5-HT2C receptor changes.	U 0126	62-67	amyloid beta (A4) precursor protein	Mus musculus	77-82
32502508-8	2020	Treatment with alpha7nAChR agonist PNU282987 or ERK inhibitor U0126 reversed Abeta-induced 5-HT1A and 5-HT2C receptor changes.	U 0126	62-67	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	91-97
32502508-8	2020	Treatment with alpha7nAChR agonist PNU282987 or ERK inhibitor U0126 reversed Abeta-induced 5-HT1A and 5-HT2C receptor changes.	U 0126	62-67	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	102-117
27025961-7	2016	Treatment with U0126 inhibited migration in both conditions, demonstrating that ERK1/2 activity was necessary but not responsible for the observed differences.	U 0126	15-20	mitogen-activated protein kinase 3	Homo sapiens	80-86
26820827-6	2016	5-HT-induced elevation of IL-8 at both mRNA and protein levels was observed, which was inhibited by TEMPOL (a free radical scavenger), and inhibitors for p38 MAPK (SB203580) and ERK (U0126), in line with the time-dependent phosphorylation of p38 MAPK and ERK.	U 0126	183-188	C-X-C motif chemokine ligand 8	Homo sapiens	26-30